<SEC-DOCUMENT>0001599298-24-000031.txt : 20240220
<SEC-HEADER>0001599298-24-000031.hdr.sgml : 20240220
<ACCEPTANCE-DATETIME>20240220073256
ACCESSION NUMBER:		0001599298-24-000031
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		113
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240220
DATE AS OF CHANGE:		20240220

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Summit Therapeutics Inc.
		CENTRAL INDEX KEY:			0001599298
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36866
		FILM NUMBER:		24650721

	BUSINESS ADDRESS:	
		STREET 1:		2882 SAND HILL ROAD
		STREET 2:		SUITE 106
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		650-460-8308

	MAIL ADDRESS:	
		STREET 1:		2882 SAND HILL ROAD
		STREET 2:		SUITE 106
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Summit Therapeutics plc
		DATE OF NAME CHANGE:	20150219

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Summit Corp plc
		DATE OF NAME CHANGE:	20140205
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>smmt-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:smmt="http://www.summitplc.com/20231231" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>smmt-20231231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-31">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-32">0001599298</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-33">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-34">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="us-gaap:NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration" id="f-76">http://fasb.org/us-gaap/2023#RelatedPartyMember</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration" id="f-77">http://fasb.org/us-gaap/2023#RelatedPartyMember</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:NotesPayableNoncurrentRelatedPartyTypeExtensibleEnumeration" id="f-86">http://fasb.org/us-gaap/2023#RelatedPartyMember</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="us-gaap:NotesPayableNoncurrentRelatedPartyTypeExtensibleEnumeration" id="f-87">http://fasb.org/us-gaap/2023#RelatedPartyMember</ix:nonNumeric><ix:nonNumeric contextRef="c-59" name="us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" id="f-377">http://fasb.org/us-gaap/2023#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember</ix:nonNumeric><ix:nonNumeric contextRef="c-6" name="us-gaap:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-630">http://fasb.org/us-gaap/2023#ImpairmentOfIntangibleAssetsExcludingGoodwill</ix:nonNumeric><ix:nonNumeric contextRef="c-148" name="smmt:NotesPayableRelatedPartiesPotentialPrepaymentPeriodPostReceiptOfCashProceedsFromPublicOffering" id="f-764">P5D</ix:nonNumeric><ix:nonNumeric contextRef="c-185" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="f-862">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="c-148" name="smmt:NotesPayableRelatedPartiesPotentialPrepaymentPeriodPostReceiptOfCashProceedsFromPublicOffering" id="f-967">P5D</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="smmt-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-02-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">smmt:RightsOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">smmt:RightsOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">smmt:RightsOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">smmt:RightsOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">smmt:AkesoLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">smmt:AkesoLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">smmt:ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:NotePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-19</xbrli:startDate><xbrli:endDate>2023-01-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-01-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-01-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">smmt:RightsOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">smmt:RightsOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:DugganFebruaryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">smmt:ChiefExecutiveOfficerAndPresidentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:ZanganehNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-15</xbrli:startDate><xbrli:endDate>2023-02-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">smmt:S3RegistrationStatementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">smmt:S3RegistrationStatementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">smmt:S3RegistrationStatementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">smmt:ChiefExecutiveOfficerAndPresidentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">smmt:A2020StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-12</xbrli:startDate><xbrli:endDate>2023-10-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-13</xbrli:startDate><xbrli:endDate>2023-10-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-13</xbrli:startDate><xbrli:endDate>2023-10-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:DugganFebruaryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-17</xbrli:startDate><xbrli:endDate>2024-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:DugganFebruaryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-17</xbrli:startDate><xbrli:endDate>2024-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">smmt:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">smmt:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">smmt:FurnitureAndFixturesOfficeEquipmentAndSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">smmt:FurnitureAndFixturesOfficeEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">smmt:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-17</xbrli:startDate><xbrli:endDate>2023-01-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">smmt:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">smmt:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-06</xbrli:startDate><xbrli:endDate>2023-03-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>smmt:segment</xbrli:measure></xbrli:unit><xbrli:unit id="country"><xbrli:measure>smmt:country</xbrli:measure></xbrli:unit><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-17</xbrli:startDate><xbrli:endDate>2023-01-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="gbp"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">smmt:UtrophinProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">smmt:UtrophinProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">smmt:DiscuvaPlatformMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">smmt:DiscuvaPlatformMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">smmt:OptionOverNonFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">smmt:OptionOverNonFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">smmt:OtherPatentsAndLicensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">smmt:OtherPatentsAndLicensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">smmt:DiscuvaPlatformMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">smmt:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">smmt:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">smmt:FurnitureAndFixturesOfficeEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">smmt:FurnitureAndFixturesOfficeEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">smmt:MenloParkCaliforniaExpirationMay2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">smmt:MenloParkCaliforniaExpirationMay2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">smmt:CambridgeUKLaboratoryAndOfficeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">smmt:MenloParkCaliforniaExpirationMay2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:PromissoryNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:PromissoryNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:March2022NoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-10</xbrli:startDate><xbrli:endDate>2022-03-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:March2022NoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:March2022NoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-10</xbrli:startDate><xbrli:endDate>2022-08-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">smmt:RightsOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-08</xbrli:startDate><xbrli:endDate>2022-08-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:March2022NoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">smmt:ChiefExecutiveOfficerAndPresidentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:ZanganehNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:DugganSeptemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:DugganFebruaryNoteAndZanganehNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">smmt:ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-06</xbrli:startDate><xbrli:endDate>2022-12-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:DugganPromissoryNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-19</xbrli:startDate><xbrli:endDate>2023-01-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="promissory_note"><xbrli:measure>smmt:promissory_note</xbrli:measure></xbrli:unit><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:DugganFebruaryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">smmt:ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:NotePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-06</xbrli:startDate><xbrli:endDate>2022-12-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">smmt:ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:NotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="smmt:VariableRatePeriodAxis">smmt:VariableRatePeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-06</xbrli:startDate><xbrli:endDate>2022-12-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="smmt:VariableRatePeriodAxis">smmt:VariableRatePeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">smmt:ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:NotePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-06</xbrli:startDate><xbrli:endDate>2022-12-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">smmt:ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:NotePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">smmt:ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:NotePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">smmt:ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:NotePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">smmt:ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:NotePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:DugganFebruaryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">smmt:ChiefExecutiveOfficerAndPresidentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:ZanganehNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:DugganSeptemberNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">smmt:RightsOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">smmt:RightsOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-24</xbrli:startDate><xbrli:endDate>2019-12-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:ConsultingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:ConsultingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-24</xbrli:startDate><xbrli:endDate>2019-12-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:ConsultingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-30</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:ConsultingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">smmt:A2020StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">smmt:A2020StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-21</xbrli:startDate><xbrli:endDate>2020-09-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-27</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-07-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">smmt:A2020StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-27</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">smmt:A2020StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-19</xbrli:startDate><xbrli:endDate>2020-08-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-02</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-19</xbrli:startDate><xbrli:endDate>2020-08-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">smmt:EmployeeStockOptionTimeBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">smmt:EmployeeStockOptionTimeBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">smmt:EmployeeStockOptionTimeBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">smmt:EmployeeStockOptionTimeBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">smmt:EmployeeStockOptionTimeBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">smmt:EmployeeStockOptionTimeBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">smmt:EmployeeStockOptionPerformanceAndMarketBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">smmt:EmployeeStockOptionPerformanceAndMarketBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">smmt:EmployeeStockOptionPerformanceAndMarketBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">smmt:EmployeeStockOptionPerformanceAndMarketBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-02-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:SubleaseAgreementFirstAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:SubleaseAgreementFirstAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:SubleaseAgreementSecondAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:SubleaseAgreementSecondAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:March2022NoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-30</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:AkesoSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:AkesoSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:ConsultingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="if355807d1b914743a4dab03fe6913e8f_1"></div><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_____________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_____________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Mark One)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric>&#160;&#160;&#160;&#160;ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-4">December 31</ix:nonNumeric>, 2023</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">or</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the transition period from                      to                     </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commission file number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-36866</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.637%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">Summit Therapeutics Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.637%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.602%"><tr><td style="width:1.0%"/><td style="width:20.669%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.298%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.661%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.972%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">37-1979717</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or Other Jurisdiction of Incorporation or Organization)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">601 Brickell Key Drive, Suite 1000</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Miami</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-12">FL</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">33131</ix:nonNumeric></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">650</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">460-8308</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.625%"><tr><td style="width:1.0%"/><td style="width:34.039%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.489%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">SMMT</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(g) of the Act: None</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes &#9744;    <ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-19">No</ix:nonNumeric>  &#9746;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.   Yes  &#9744;    <ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-20">No</ix:nonNumeric>  &#9746;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-21">Yes</ix:nonNumeric> &#9746;    No &#9744;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-22">Yes</ix:nonNumeric>  &#9746;    No  &#9744;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"/><td style="width:18.658%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:51.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.675%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.728%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-23">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-24">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-25">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  <ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="f-26">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-27"></ix:nonNumeric>Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive o&#64259;cers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes     No  <ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-28">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate market value of the voting common stock held by non-affiliates based on the closing stock price on June 30, 2023, was $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="6" id="f-29">108.4</ix:nonFraction>&#160;million. For purposes of this computation only, all executive officers and directors have been deemed affiliates.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of outstanding shares of the registrant&#8217;s common stock, par value $0.01 per share, as of February 9, 2024 was <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-30">701,697,179</ix:nonFraction>.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:3pt"><span><br/></span></div><div id="if355807d1b914743a4dab03fe6913e8f_7"></div><div style="text-align:right"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:80.005%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cautionary Note Regarding Forward-Looking Statements</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_10">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_13">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if355807d1b914743a4dab03fe6913e8f_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_16">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if355807d1b914743a4dab03fe6913e8f_16">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_19">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if355807d1b914743a4dab03fe6913e8f_19">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1C.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_1553">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_1553">ybersecurity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if355807d1b914743a4dab03fe6913e8f_1553">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_22">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if355807d1b914743a4dab03fe6913e8f_22">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_25">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if355807d1b914743a4dab03fe6913e8f_25">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_28">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if355807d1b914743a4dab03fe6913e8f_28">58</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_31">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_34">Market for Registrant</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8217;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_34">s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if355807d1b914743a4dab03fe6913e8f_34">59</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_37">Selected Financial Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if355807d1b914743a4dab03fe6913e8f_37">60</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_40">Management</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8217;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_40">s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if355807d1b914743a4dab03fe6913e8f_40">60</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_43">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if355807d1b914743a4dab03fe6913e8f_43">74</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_46">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if355807d1b914743a4dab03fe6913e8f_46">75</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_49">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if355807d1b914743a4dab03fe6913e8f_49">75</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_52">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if355807d1b914743a4dab03fe6913e8f_52">75</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_55">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if355807d1b914743a4dab03fe6913e8f_55">76</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_58">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if355807d1b914743a4dab03fe6913e8f_58">76</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_61">PART III</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_64">Directors, Executive Officers, and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if355807d1b914743a4dab03fe6913e8f_64">76</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_67">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if355807d1b914743a4dab03fe6913e8f_67">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_70">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if355807d1b914743a4dab03fe6913e8f_70">90</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_73">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if355807d1b914743a4dab03fe6913e8f_73">92</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_76">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if355807d1b914743a4dab03fe6913e8f_76">96</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_79">PART IV</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_82">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if355807d1b914743a4dab03fe6913e8f_82">97</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;16</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_88">Report Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if355807d1b914743a4dab03fe6913e8f_88">102</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_91">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if355807d1b914743a4dab03fe6913e8f_91">103</a></span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 regarding the future financial performance, business prospects and growth of Summit Therapeutics Inc., that involve substantial risks and uncertainties. All statements contained in this Annual Report on Form 10-K, other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue,&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements in this Annual Report on Form 10-K include, among other things, statements about:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to develop a successful product candidate under the License Agreement (as defined in Item I Business, Overview);</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to raise sufficient additional funds to make payments under the License Agreement;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of and the ability to effectively execute clinical development of ivonescimab;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and conduct of clinical trials for any product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans with respect to possible future collaborations and partnering arrangements;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential benefits of possible future acquisitions or investments in other businesses, products or technologies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to pursue research and development of other future product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding the potential market opportunity for our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our sales, marketing and distribution capabilities and strategy;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain arrangements for manufacture of our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our intellectual property position;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding expenses, future revenues, capital requirements and needs for additional financing;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of government laws and regulations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitive position;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the need to raise additional capital to fund ongoing operations and capital needs; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of public health epidemics, such as the novel coronavirus pandemic (&#8220;COVID-19&#8221;), the response to such epidemics and the potential effects of such epidemics on our business, financial results, supply chain and market.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Report, particularly in the &#8220;Risk Factors&#8221; in Part 1, Item 1A of this Annual Report on Form 10-K, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read this Annual Report on Form 10-K and the documents that we have filed as exhibits to this Annual Report on Form 10-K completely and with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">SUMMARY OF RISK FACTORS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Summary</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the principal factors that make an investment in Summit Therapeutics Inc. speculative or risky. The following summary does not contain all of the information that may be important to you, and you should read the below summary in conjunction with the more detailed discussion of risks set forth under the heading &#8220;Risk Factors&#8221; in Part I, Item IA of this Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We presently do not have sufficient working capital to fund our operations for the next twelve months, which raises substantial doubt of our ability to continue as a going concern. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will need to obtain additional funding to finance our operations and complete the development and any commercialization of our investigational products. If we do not receive substantial capital when needed, we may be forced to restrict our operations or delay, reduce or eliminate our product development programs. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend heavily on the success of ivonescimab. If we are unable to successfully develop and commercialize ivonescimab, or experience significant delays in doing so, we may extend the period in which we will incur significant financial losses as an organization.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are a development-stage company and have incurred significant losses since our inception. We anticipate that we will continue to incur losses for at least the next several years and may never generate profits from operations or maintain profitability.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will need substantial additional capital to fund our operations and to make payments under the License Agreement and the Note Purchase Agreement and if we fail to obtain necessary financing, we could be forced to delay, reduce or eliminate the development and commercialization of our product candidates. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will need to raise additional capital which may result in further dilution to our investors and additional indebtedness. The servicing of debt may impair our liquidity position. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to the Development and Commercialization of our Product Candidates</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We can provide no assurance that our clinical product candidates, including our lead product candidate, ivonescimab, will obtain regulatory approval or that the results of clinical studies will be favorable.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Drug discovery and development is a complex, time-consuming and expensive process that is fraught with risk and a high rate of failure.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we experience delays or difficulties in the enrollment of patients in our clinical trials, our receipt of necessary marketing approvals could be delayed or prevented.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Regulatory requirements and timelines may affect the scope and timeline of our trials and the potential market for our product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we experience any number of possible unforeseen events in connection with our clinical trials, potential marketing approval or commercialization of our product candidates could be delayed or prevented.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If serious adverse or inappropriate side effects are identified during the development of ivonescimab or any other product candidate, we may need to abandon or limit our development of that product candidate.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If clinical trials of our product candidates fail to demonstrate safety and efficacy to the satisfaction of the U.S. Food and Drug Administration, or the FDA, or the European Medicines Agency, or the EMA, or do not otherwise produce favorable results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of ivonescimab or any other product candidate.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Biologics, such as ivonescimab, carry unique risks and uncertainties, which could have a negative impact on our business.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Use of third parties, including Akeso, to manufacture our product candidates may increase the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable time and cost, which could delay, prevent or impair our development or commercialization efforts, </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our manufacturing partners for the supply of ivonescimab or other product candidates divert their supply of materials needed for our product candidates to larger pharmaceutical companies, our ability to complete our clinical trials or eventually bring our product candidates to market may be compromised. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have not yet developed, and may never successfully develop, any marketed drugs.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulatory requirements and timelines may affect the scope and timeline of our trials and the potential market for our product candidates.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to our Financial and Intellectual Property Dependencies on Third Parties</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend on our relationship with, and the comprehensiveness of the intellectual property licensed from Akeso, and termination of the License Agreement, any of the licenses under the License Agreement, or issues as to intellectual property could have a material adverse effect on our business.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend on collaborations with third parties for the development and commercialization of some of our product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Our Industry and Market</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face substantial competition, which may result in others discovering, developing or commercializing products before us or more successfully than we do.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may pursue business development opportunities to expand or enhance our pipeline of drug candidates, including without limitation, through potential acquisitions of and/or collaborations with other entities, that may not achieve intended results or could increase the number of our outstanding shares or amount of outstanding debt or result in a change of control.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Legal, Tax, Regulatory and Compliance Risks</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to commercialize any of our product candidates is subject to substantial regulatory and legislative uncertainty, including as to pricing, reimbursement practices or other healthcare initiatives which could harm our business.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business is subject to the risks associated with doing business in China. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may face costly legal claims, in particular related to product liability and intellectual property infringement.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to certain United States (&#8220;U.S.&#8221;), United Kingdom (&#8220;U.K.&#8221;) and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations. We can face serious consequences for violations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Our Intellectual Property, Cybersecurity and Data Privacy</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely upon patents to protect our technology. We may be unable to protect our intellectual property rights and we may be liable for infringing the intellectual property rights of others.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our actual or perceived failure to comply with stringent and changing obligations related to data privacy and security could lead to regulatory investigations and actions, litigation, fines and penalties, disruptions to our business operations, reputational harm, loss of revenue and profits and other adverse business impacts.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are exposed to risks related to cybersecurity and data privacy threats and incidents and we are subject to restrictions and changes in laws and regulations governing our data privacy and data protection, any of which could have a material adverse affect on our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Corporate Governance and Employee Relations</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our future success depends on our ability to retain our Chairman and Chief Executive Officer, our Chief Executive Officer, President and member of the Board, our Chief Operating Officer and a member of the Board, and other key executives and to attract, retain and motivate qualified personnel.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our Chairman and Chief Executive Officer owns more than a majority of the voting power of the outstanding shares of our common stock, and as a result investors may have limited ability to affect either the corporate governance of the Company or the taking of certain major decisions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Owning Our Common Stock</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Substantial future sales of our shares of common stock in the public market, or the perception that these sales could occur, could cause the price of the shares to decline significantly, even if our business is doing well.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The prices of our shares of common stock may be volatile and fluctuate substantially, which could result in substantial losses for our stockholders. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Widespread Health Concerns</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Widespread health concerns, including COVID-19 and their enduring impact on our business remains uncertain. Our business has and could continue to be adversely affected, directly or indirectly, by any pandemic and other health concerns that may arise.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii</span></div></div></div><div id="if355807d1b914743a4dab03fe6913e8f_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:24pt;text-align:center"><span><br/></span></div><div id="if355807d1b914743a4dab03fe6913e8f_13"></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:156%">PART I</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Business </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summit Therapeutics Inc. (&#8220;we&#8221;, &#8220;Summit&#8221; or the &#8220;Company&#8221;) is a biopharmaceutical company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The Company&#8217;s pipeline of product candidates is designed with the goal to become the patient-friendly, new-era standard-of-care medicines, in the therapeutic area of oncology.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s current lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. On December 5, 2022, the Company entered into a Collaboration and License Agreement (the &#8220;License Agreement&#8221;) with Akeso, Inc. and its affiliates (&#8220;Akeso&#8221;) pursuant to which the Company has in-licensed ivonescimab. Through the License Agreement, the Company obtained the rights to develop and commercialize ivonescimab in the United States, Canada, Europe, and Japan (the &#8220;Licensed Territory&#8221;). The License Agreement and transaction closed in January 2023 following customary waiting periods. The Company&#8217;s operations will be focused on the development of ivonescimab and other future activities, as the Company determines.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has begun its development for ivonescimab in non-small cell lung cancer (&#8220;NSCLC&#8221;), specifically launching Phase III clinical trials in the following indications:</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)  ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (&#8220;EGFR&#8221;)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (&#8220;TKI&#8221;) (&#8220;HARMONi&#8221;); and</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)  ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (&#8220;HARMONi-3&#8221;)</span></div><div style="padding-left:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of these financial statements, both studies are enrolling patients.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The entry into the License Agreement with Akeso represents a significant change in the Company&#8217;s strategy and its future operations will be focused on the development of ivonescimab and other future activities as the Company determines. The Company&#8217;s portfolio includes ridinilazole, a product candidate for treating patients suffering from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clostridioides difficile </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">infection, also known as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C. difficile </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">infection, or CDI. All prior development and marketing activities related to ridinilazole have been terminated. The Company&#8217;s anti-infectives portfolio includes SMT-738, the first of a novel class of precision antibiotics for combating multidrug resistant infections, specifically carbapenem-resistant Enterobacteriaceae (&#8220;CRE&#8221;) infections. The Company will continue to pursue partnerships for further development of SMT-738. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Akeso Collaboration and License Agreement</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the License Agreement with Akeso, the Company received the rights to develop and commercialize ivonescimab in the Licensed Territory. Akeso will retain development and commercialization rights for the rest of the world excluding the Licensed Territory. In exchange for these rights, Summit made an upfront payment during the first quarter of 2023 comprising of $474.9 million cash and the issuance of 10 million shares of Company common stock in lieu of $25.1 million cash pursuant to a share transfer agreement. In addition, the Company will potentially owe Akeso (a) milestone payments tied to achievement of regulatory approval of ivonescimab with various regulatory authorities in Licensed Territory (b) milestone payments tied to achievement of annual revenue from ivonescimab in Licensed Territory and (c ) Royalty payments equal to low-double-digit percentage of annual revenues from ivonescimab in Licensed Territory. In connection with the License Agreement, the Company has also agreed to enter into a Supply Agreement with Akeso; pursuant to the License Agreement, Summit agreed to purchase a certain portion of drug substance for clinical and commercial supply (the &#8220;Supply Agreement&#8221;). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the License Agreement, Summit will have final decision-making authority with respect to commercial strategy, pricing and reimbursement and other commercialization matters in the Licensed Territory. Summit has not assumed any liabilities (including contingent liabilities), nor acquired any physical assets or trade names, or hired or acquired any employees from Akeso in connection with the License Agreement.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ivonescimab</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ivonescimab is a novel potential first-in-class PD-1 / VEGF bispecific antibody, believed to be the most advanced in clinical development in the Licensed Territories. Engineered with Akeso&#8217;s unique Tetrabody technology, ivonescimab, as a single molecule, blocks programmed cell death protein 1 (&#8220;PD-1&#8221;) from binding to PD-L1 and PD-L2, and blocks vascular endothelial growth factor (&#8220;VEGF&#8221;) from binding to VEGF receptors. Ivonescimab is designed to potentially allow cooperative binding of the intended targets, such that the finding of PD-1 increases the binding affinity of VEGF and the binding of VEGF increases the affinity towards PD-1. In view of the co-expression of VEGF and PD-1 in the tumor micro-environment (&#8220;TME&#8221;), ivonescimab, may block these two pathways more effectively and enhance the antitumor activity, as compared to combination therapy through what is believed to be a unique cooperative binding mechanism.</span></div><div style="text-align:center"><img src="smmt-20231231_g1.jpg" alt="SMT112 without shaded background.jpg" style="height:317px;margin-bottom:5pt;vertical-align:text-bottom;width:400px"/></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This could differentiate ivonescimab as there is potentially higher expression (presence) of both PD-1 and VEGF in tumor tissue and the TME as compared to normal tissue in the body. As shown in Akeso&#8217;s in-vitro studies, ivonescimab&#8217;s tetravalent structure (four binding sites) enables higher avidity (accumulated strength of multiple binding interactions) in the tumor microenvironment with over 18 fold increased binding affinity to PD-1 in the presence of VEGF </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and over 4 times increased binding affinity to VEGF in the presence of PD-1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This tetravalent structure, the intentional novel design of the molecule, and bringing these two targets into a single bispecific antibody with cooperative binding qualities have the potential to direct ivonescimab to the tumor tissue versus healthy tissue. The intent of this design is to improve upon previously established efficacy thresholds, in addition to side effects and safety profiles associated with these targets.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the two Phase III clinical trials sponsored by the Company, ivonescimab is also being developed in China and Australia by Akeso in multiple solid tumors and has been dosed in more than 1,600 patients globally. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on data published by Akeso with a cut-off date of October 2023, ivonescimab treatment after a median follow-up time of approximately 25.8 months, was associated with an overall response rate (ORR) in a Phase II study in patients with NSCLC who have failed EGFR-TKI&#8217;s of 68.4%, a median Progression-Free Survival (&#8220;mPFS&#8221;) time period of 8.5 months, and a median Overall Survival (&#8220;mOS&#8221;) of 22.5 months when combined with combination chemotherapy (pemetrexed and carboplatin). The Phase II study, AK112-201, Cohort 2, was considered to have demonstrated a tolerable safety profile and a low discontinuation rate for adverse events.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a separate group in the same Phase II study, AK112-301 (Cohort 1) for NSCLC patients with squamous histology, ivonescimab, combined with carboplatin and paclitaxel, in first-line advanced or metastatic patients demonstrated a mPFS of 11.1 months. Median overall survival was not reached after a median follow-up period of 21.0 months. Phase II study was considered to have demonstrated a tolerable safety profile and a low discontinuation rate for adverse events.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summit plans to conduct its current clinical trials, as well as design and conduct additional clinical trial activities for ivonescimab in its Licensed Territory, to support and submit relevant regulatory filings. Summit also plans to support additional study activities through its Investigator Initiated Study program.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Product Pipeline</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Sponsored Ivonescimab Trials:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Ivonescimab is currently being investigated in global Phase III clinical trials. Phase I and II trials were completed by our partner Akeso. This pipeline reflects clinical trials that have been initiated by Summit in its Licensed Territory.</span></div><div><span><br/></span></div><div><img src="smmt-20231231_g2.jpg" alt="Screenshot 2024-02-16 145418.jpg" style="height:103px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">HARMONi study (NCT05184712) is a  multi-regional, registration-enabling clinical trial that we joined with Akeso, and for which we started initiating and activating sites in North America and Europe during 2023. The first patient in our Licensed Territory was enrolled during the second quarter of 2023. We plan to initiate additional sites in North America and Europe over the next few quarters. We expect to complete enrollment during second half of 2024. The co-primary endpoints for this study are Progression free survival (PFS) and Overall survival (OS). We expect to combine data across all regions, including China, for assessing the results. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">HARMONi-3 study (NCT05899608) is a phase III, is multi-regional, registration-enabling clinical trial for which we initiated activating sites in North Americas and China during fourth quarter of 2023. We plan to initiate additional sites in North America, China, European countries, Japan and several other countries through early 2025. Our plan to initiate in new countries and sites is dependent upon the timing and requirements for getting the regulatory approval of the clinical trial applications with the respective regulatory authorities and approvals from central or local independent review boards. We may decide to modify our plans to go in certain regions or countries based on the timelines and requirements from the respective regulatory regions. We commenced patient enrollment in the HARMONi-3 study during fourth quarter of 2023. The primary endpoint for this study is Overall survival (OS). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Q4 2023 we began collaborating with multiple institutions globally and opened our investigator initiated study program across several disease areas.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our partners at Akeso are sponsoring multiple, ongoing Phase II and III clinical trials in NSCLC and other cancers outside of our Licensed Territory. We plan to review the data generated from these clinical trials as a part of our consideration for advancing our clinical development pipeline for ivonescimab in our Licensed Territory.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Status of Anti-Infectives Pipeline</span></div><div><span><br/></span></div><div style="margin-top:0.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discuva Platform</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we acquired Discuva Limited, a privately held United Kingdom-based company. Through this acquisition, we obtained a bacterial genetics platform and a suite of software-based technologies (collectively termed our &#8220;Discuva Platform&#8221;), which facilitate the discovery and development of new mechanism antibiotics. Our Discuva Platform can be used to identify new bacterial targets for drug discovery, understand the mechanism of action of small molecules targeting varying types of bacteria and select the most optimal preclinical candidates, including those with the least propensity to develop bacterial resistance. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 20, 2023, we announced that, given the License Agreement that we entered into in December 2022 and the shift in Company&#8217;s focus to oncology, we will cease further investment in the Discuva platform and evaluate further options for the use of the Discuva Platform.  See Note 13 to our consolidated financial statements contained in this Annual Report on Form 10-K for further details.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The markets for oncology pharmaceuticals, in which we compete, are characterized by significant scientific innovation, regulatory oversight and intense competition. The key competitive factors affecting the success of our product candidates are </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">likely to be their efficacy, safety, convenience, price and availability of coverage and reimbursement from government and other third-party payors. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors may have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop. Our competitors also may obtain marketing approvals for their products more rapidly than we obtain approval for ours. This may have the effect of making branded products less attractive from a cost perspective to buyers. Our commercial opportunity could also be reduced or eliminated if the results of our clinical trials, both safety and efficacy, combined with other factors, do not lead to significant adoption of our product. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Competition for ivonescimab (SMT112) </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ivonescimab is currently being investigated in Phase III clinical trials in Summit&#8217;s Licensed Territory in two metastatic NSCLC indications:</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)  ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (&#8220;EGFR&#8221;)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (&#8220;TKI&#8221;) (&#8220;HARMONi&#8221;); and</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)  ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (&#8220;HARMONi-3&#8221;)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ivonescimab is also being investigated in multiple Phase II and Phase III clinical trials in China. We plan to review the data generated from these clinical trials as a part of our consideration for advancing our clinical development pipeline for ivonescimab in our Licensed Territory.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no known approved PD-1/VEGF bispecific antibodies that are further advanced in clinical trial development or approved in the territories in which we have licensed ivonescimab. There are also no known PD-1-based bispecific antibodies approved by the US Food and Drug Administration (&#8220;FDA&#8221;), the European Medicines Agency (&#8220;EMA&#8221;), or Japan&#8217;s Pharmaceuticals and Medical Devices Agency (&#8220;PMDA&#8221;).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several pharmaceutical and biotechnology companies have established themselves in the market for the treatment of NSCLC, and several additional companies are developing products for the treatment of NSCLC. Currently, the most commonly used treatments for NSCLC are several immuno-oncology drugs and chemotherapies, administered either individually as monotherapy, in combination with each other, or in combination with other approved therapeutics. NSCLC treatment regimens vary due to several factors, including genetic mutations and progression of disease. In addition to various chemotherapies, several immunotherapies have been approved by the FDA for these treatments, including, but not limited to pembrolizumab, atezolizumab, nivolumab, durvalumab, and ipilimumab. There are anti-angiogenic therapies which are approved for the treatment of certain lung cancers, including bevacizumab and ramucirumab. In addition, there are several targeted therapies that have also been approved, including, but not limited to, osimertinib, adagrasib, and alectinib. Beyond currently approved therapies, several potential therapeutics are in various stages of development and clinical trials for the treatment of NSCLC, including late-stage candidates which have recently released Phase III clinical trial data in NSCLC in 2023, such as Daiichi Sankyo and AstraZeneca&#8217;s datopotamab deruxetecan and Johnson &amp; Johnson&#8217;s amivantamab and lazertinib. Finally, there are candidates in various stages of ongoing clinical trials for NSCLC, including Daiichi Sankyo and Merck with patritumab deruxtecan and AstraZeneca&#8217;s volrustomig, each currently enrolling in Phase III clinical trials.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate, and currently have no plans to establish, manufacturing facilities for the production of clinical or commercial quantities of ivonescimab, ridinilazole or SMT-738. We currently rely, and expect to continue to rely, on third parties for the manufacture of our product candidates and any products that we may develop.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ivonescimab</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the License Agreement, we have also agreed to enter into the Supply Agreement with Akeso, pursuant to which we agree to purchase a certain portion of drug substance for clinical and commercial. Until such time that we are able to establish second source suppliers or are able to manufacture the drug substance independently, Akeso shall initially be solely responsible for the manufacture of our requirements of clinical and commercial drug substance for use in the Licensed Territory. We have engaged with third-parties to initiate transfer of relevant know-how and potentially establish them as second source supplier of ivonescimab. We are using a different third-party supplier for clinical packaging, labeling and distribution of the clinical drug product.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained and maintain proprietary protection for our antibiotic product candidates, technology and know-how, to operate without infringing the proprietary rights of others and to prevent others from infringing our proprietary rights. We strive to protect the proprietary technology by, among other methods, seeking and maintaining patents, where available, that are intended to cover our product candidates, compositions and formulations, their methods of use and processes for their manufacture and any other inventions that are commercially important to the development of our business. We also rely on trade secrets, know-how, continuing technological innovation and in-licensing opportunities to develop and maintain our proprietary and competitive position.  </span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ivonescimab Program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Following the completion of the License and Collaboration Agreement with Akeso, Summit has in-licensed the rights to various Akeso patent applications directed to ivonescimab in specific countries and has rights to control prosecution of such in-licensed intellectual property in these specific countries in collaboration with Akeso. The collaboration has 1 patent issued with 14 pending and we expect that these patent applications (assuming the applications proceed to grant) will provide patent coverage for the program until 2042.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discuva Platform Technology.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Our Discuva Platform technology is currently protected by 14 granted U.S. and foreign patents. We expect patent protection for this portfolio to expire in 2032.  </span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ridinilazole Program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our ridinilazole program is currently protected by 96 granted U.S. and foreign patents, with 34 pending patent applications. Our patent portfolio for ridinilazole includes patents and patent applications directed to composition of matter, polymorphic forms, methods of manufacture and use and formulation subject matter. We expect that our existing patents and patent applications (assuming the applications proceed to grant) will provide patent coverage for our ridinilazole program until 2043. </span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SMT-738 Program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our SMT-738 program currently has 14 granted patents and 29 patent applications pending worldwide, directed to the composition of matter. We anticipate that our existing portfolio (assuming the applications proceed to grant) will provide patent coverage for our SMT-738 program until 2042.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade Secrets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition to patents, we rely on trade secrets and know-how to develop and maintain our competitive position. Trade secrets and know-how can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors and commercial partners. These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed through a relationship with a third-party. We also seek to preserve the integrity and confidentiality of our data, trade secrets and know-how by maintaining physical security of our premises and physical and electronic security of our information technology systems.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trademarks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Summit, in working with Akeso, is in the process of selecting a name for ivonescimab, which we will pursue protection for as a trademark in licensed Summit countries. In connection with the development of our product pipeline, we will seek protection for marks we currently use and future marks when appropriate.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to obtain, maintain or protect the intellectual property rights necessary to conduct our business, and we may be subject to claims that we infringe or otherwise violate the intellectual property rights of third parties. For more information, please see the section on &#8220;Risk Factors &#8211; Risks Related to Intellectual Property&#8221;.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Material Agreements</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following material agreements relate to our commitments and obligations with respect to ridinilazole and SMT-738 only. The entry into the License Agreement represents a significant change in the Company&#8217;s strategy. All prior development and marketing activities relating to ridinilazole have been terminated and all business activities related to anti-infectives are being reviewed for partnership opportunities for potential further development.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BARDA</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, we were awarded a contract from the Biomedical Advanced Research and Development Authority (&#8220;BARDA&#8221;), part of the Office of the Assistant Secretary for Preparedness and Response at the United States Department of Health and Human Services, to fund, in part, the clinical and regulatory development of ridinilazole for the treatment of infections caused by</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> C. difficile</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The contract provides for a cost-sharing arrangement under which BARDA funded a specified portion of estimated costs for the continued clinical and regulatory development of ridinilazole for CDI. Under this cost sharing arrangement, we were responsible for a portion of the costs associated with each segment of work, including any costs in excess of the estimated amounts. The awarded contract, as amended in 2019 and 2020, provided for total award up to $72.5M, and total amount of committed funding to $62.4 million. As of December 31, 2023, based on translation of historical foreign currency amounts in the period, the Company has recognized $59.2 million of cumulative income since contract inception.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Company&#8217;s decision to not pursue further internal clinical development of ridinilazole and seek partners or a divestiture related to ridinilazole as a path forward for the clinical development of the asset, the Company recorded expenses for the remaining clinical trial costs associated with the close out activities of ridinilazole and recognized the remainder of the deferred income that had been received from BARDA prior to the expenses being recognized during the third quarter of 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Wellcome Trust</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2012, we entered into a translation award funding agreement with the Wellcome Trust Limited, as trustee of the Wellcome Trust, in order to support a Phase I and a Phase II clinical trial of ridinilazole for the treatment of CDI, for which we received $6.3 million. The translation award funding agreement followed an initial funding agreement we and the Wellcome Trust entered into in October 2009, under which we received $3.7 million for preclinical development of CDI antibiotics. </span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, we entered into a revenue sharing agreement with the Wellcome Trust. Under the terms of the revenue sharing agreement upon commercialization of ridinilazole the Wellcome Trust is eligible to receive a share of the net revenues that we, our affiliates, licensees or third-party collaborators receive from commercial sales, and a one-time milestone payment of a specified amount if cumulative net revenues that we our affiliates, licensees or third-party collaborators receive exceed a specified amount. In addition, if a third party commercializes ridinilazole following the first commercial sale by such third party, the Wellcome Trust is eligible to receive a one-time milestone payment of a share of the aggregate amount of any pre-commercial payments we receive from third-party licensees prior to such commercial sale and in the event of an assignment or sale of the assets or intellectual property pertaining to ridinilazole, the net proceeds we receive from such assignment or sale would be treated as net revenue under the revenue sharing agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eurofarma Laborat&#243;rios S.A.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we entered into an exclusive license and commercialization agreement with Eurofarma, pursuant to which we granted Eurofarma the exclusive right to commercialize ridinilazole in specified countries in South America, Central America and the Caribbean (the licensed territory). We have retained commercialization rights in the rest of the world.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the license agreement, we received an upfront payment of $2.5 million. In 2020 and 2021, we achieved the first and second enrollment targets and earned $2.25 million We are also entitled to receive additional development, commercial and sales milestones and have a provision to enter into commercial supply agreement. With the closeout of ridinilazole clinical trials, at this time, we are not anticipating any future payments from Eurofarma under this agreement.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the license agreement, Eurofarma is responsible for all costs related to obtaining regulatory approval of ridinilazole in the licensed territory and is obligated to use commercially reasonable efforts to file applications for regulatory approval in specified countries in the licensed territory within a specified time period after we have filed an application for regulatory approval, or obtained regulatory approval, for ridinilazole in a jurisdiction where we retain commercial rights. We retain sole responsibility for the clinical development of ridinilazole in all countries and are responsible for all costs related to obtaining regulatory approval for ridinilazole outside of the licensed territory.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">University College London</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2010, we entered into a collaborative research agreement with the School of Pharmacy, University of London which was later novated on November 28, 2011, by the School of Pharmacy to University College London. As part of this agreement, and in consideration of their role in the development of the initial compound series from which ridinilazole was later identified, we agreed to pay the School of Pharmacy (now University College London) a low single-digit share of all revenue received by us with respect to ridinilazole, including any pre-commercial licensing revenue, up to a maximum of $1.2 million. To date, we have paid $0.1 million under this agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CARB-X</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we announced the selection of a new preclinical candidate, SMT-738, which originated from the DDS-04 series. SMT-738 has been under development to combat multi-drug resistant infections, specifically Carbapenem-resistant Enterobacteriaceae (&#8220;CRE&#8221;) infections. Simultaneously, Summit has received a sub-award from CARB-X to progress SMT-738 through preclinical development and an option to continue into Phase Ia clinical studies. The award commits initial non-dilutive funding of up to $4.1 million for the preclinical phase, with the potential for a further $3.7 million available for the Phase Ia clinical phase upon successfully achieving key preclinical development milestones. During the quarter ended September 30, 2022, CARB-X announced changes to its funding arrangements and terms and conditions. As a result, the current arrangement concluded as of June 30, 2022 however, we have the ability to recognize revenue for any milestone payments related to work incurred subsequent to this date in accordance with this agreement. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for serious diseases, we are subject to extensive and ongoing regulation by the FDA under the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;) and its implementing regulations, as well as other regulatory bodies in the United States, Europe and other countries. Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions, including the European Union, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, packaging, storage, record keeping, labeling, pricing, reimbursement, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and import and export of pharmaceutical products. The processes for obtaining regulatory approvals in the United States and in foreign countries and jurisdictions, along with compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Review and Approval of Drugs in the United States</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the FDA regulates drugs under the FDCA, and implementing regulations. The failure to comply with the FDCA and applicable U.S. requirements at any time during the product development process, approval process or after approval may subject an applicant or sponsor to a variety of administrative or judicial sanctions, including refusal by the FDA to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters and other types of letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal investigations and penalties brought by the FDA and the Department of Justice (&#8220;DOJ&#8221;), or other federal and state governmental entities.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An applicant seeking approval to market and distribute a new drug product in the United States must typically undertake the following:</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA&#8217;s good laboratory practice (&#8220;GLP regulations&#8221;);</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">submission to the FDA of an Investigational New Drug (&#8220;IND&#8221;), which must take effect before human clinical trials may begin;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">approval by an independent institutional review board, or IRB, approving each clinical study before each clinical trial may be initiated;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">performance of adequate and well-controlled human clinical trials in accordance with current good clinical practices (&#8220;GCP&#8221;), to establish the safety and efficacy of the proposed drug product for each indication;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">preparation and submission to the FDA of a new drug application (&#8220;NDA&#8221;) or Biologic Licensing Application (&#8220;BLA&#8221;);</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">review of the product candidate by an FDA advisory committee, where appropriate or if applicable;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the product, or components thereof, are produced to assess compliance with current Good Manufacturing Practices (&#8220;cGMP&#8221;), requirements and to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, strength, quality and purity;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the clinical data;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">payment of user fees and securing FDA approval of the NDA/BLA; and</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">compliance with any post-approval requirements, including Risk Evaluation and Mitigation Strategies (&#8220;REMS&#8221;), where applicable, and any post-approval studies required by the FDA.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical Studies</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before an applicant begins testing a compound with potential therapeutic value in humans, the product candidate enters the preclinical testing stage. Preclinical studies include laboratory evaluation of the purity and stability of the API, and the formulated drug or drug product, as well as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and animal studies to assess the safety and activity of the drug for initial testing in humans and to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations. The results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among other things, are submitted to the FDA as part of an IND. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies usually must complete some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, and must also develop additional information about the synthesis and physical characteristics of the investigational product and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the candidate product and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested. Stability studies must be conducted to demonstrate that the candidate product does not undergo unacceptable deterioration over its shelf-life.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The IND and Institutional Review Board (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IRB</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">) Processes</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An IND is an exemption from the FDCA that allows an unapproved drug to be shipped in interstate commerce for use in an investigational clinical trial and a request for FDA authorization to administer an investigational drug to humans. Such authorization must be secured prior to interstate shipment and administration of any new drug that is not the subject of an approved NDA/BLA. In support of a request for an IND, applicants must submit a protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among other things, are submitted to the FDA as part of an IND. The FDA requires a 30-day waiting period after the filing of each new IND before clinical trials may begin. This waiting period is designed to allow the FDA to review the IND to determine whether human research subjects will be exposed to unreasonable health risks. At any time during this 30-day period, the FDA may raise concerns or questions about the conduct of the trials as outlined in the IND and impose a clinical hold. In this case, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials can begin.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following commencement of a clinical trial under an IND, the FDA may also place a clinical hold or partial clinical hold on that trial. Clinical holds are imposed by the FDA whenever there is concern for patient safety and may be a result of new data, findings, or developments in clinical, nonclinical, and/or chemistry, manufacturing, and controls, or CMC. A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. For example, a specific protocol or part of a protocol or new patient enrollment is not allowed to proceed, while other protocols or already enrolled patients may continue. </span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following issuance of a clinical hold or partial clinical hold, an investigation may only resume after the FDA has notified the sponsor that the investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the investigation can proceed.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sponsor may choose, but is not required, to conduct a foreign clinical study under an IND. When a foreign clinical study is conducted under an IND, all FDA IND requirements must be met unless waived. When the foreign clinical study is not </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conducted under an IND, the sponsor must ensure that the study complies with certain regulatory requirements of the FDA in order to use the study as support for an IND or application for marketing approval. Specifically, on April 28, 2008, the FDA amended its regulations governing the acceptance of foreign clinical studies not conducted under an investigational new drug application as support for an IND or a new drug application. The final rule provides that such studies must be conducted in accordance with good clinical practice, or GCP, including review and approval by an independent ethics committee, or IEC, and informed consent from subjects. The GCP requirements in the final rule encompass both ethical and data integrity standards for clinical studies. The FDA&#8217;s regulations are intended to help ensure the protection of human subjects enrolled in non-IND foreign clinical studies, as well as the quality and integrity of the resulting data. They further help ensure that non-IND foreign studies are conducted in a manner comparable to that required for IND studies.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the foregoing IND requirements, an IRB/Ethics Committee (&#8220;EC&#8221;) representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review and reapprove the study at least annually. The IRB/EC must review and approve, among other things, the study protocol and informed consent information to be provided to study subjects. An IRB/EC must operate in compliance with FDA/HA (&#8220;Health Authority&#8221;) regulations. An IRB/EC can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#8217;s/EC&#8217;s requirements or if the product candidate has been associated with unexpected serious harm to patients.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether or not a trial may move forward at designated check points based on access that only the group maintains to available data from the study. Suspension or termination of development during any phase of clinical trials can occur if it is determined that the participants or patients are being exposed to an unacceptable health risk. Other reasons for suspension or termination may be made by us based on evolving business objectives and/or competitive climate.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about clinical trials must be submitted within specific timeframes to the National Institutes of Health (&#8220;NIH&#8221;), for public dissemination on its ClinicalTrials.gov website. Similar requirements for posting clinical trial information are present in the European Union (EudraCT) website: https://eudract.ema.europa.eu/ and other countries, as well.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expanded Access to an Investigational Drug for Treatment Use</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expanded access, sometimes called &#8220;compassionate use,&#8221; is the use of investigational new drug products outside of clinical trials to treat patients with serious or immediately life-threatening diseases or conditions when there are no comparable or satisfactory alternative treatment options. The rules and regulations related to expanded access are intended to improve access to investigational drugs for patients who may benefit from investigational therapies. FDA regulations allow access to investigational drugs under an IND by the company or the treating physician for treatment purposes on a case-by-case basis for: individual patients (single-patient IND applications for treatment in emergency settings and non-emergency settings); intermediate-size patient populations; and larger populations for use of the drug under a treatment protocol or Treatment IND Application.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When considering an IND application for expanded access to an investigational product with the purpose of treating a patient or a group of patients, the sponsor and treating physicians or investigators will determine suitability when all of the following criteria apply: patient(s) have a serious or immediately life-threatening disease or condition, and there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition; the potential patient benefit justifies the potential risks of the treatment and the potential risks are not unreasonable in the context or condition to be treated; and the expanded use of the investigational drug for the requested treatment will not interfere with initiation, conduct, or completion of clinical investigations that could support marketing approval of the product or otherwise compromise the potential development of the product.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 13, 2016, the 21st Century Cures Act established (and the 2017 Food and Drug Administration Reauthorization Act later amended) a requirement that sponsors of one or more investigational drugs for the treatment of a serious disease(s) or condition(s) make publicly available their policy for evaluating and responding to requests for expanded access for individual patients. Although these requirements were rolled out over time, they have now come into full effect. This provision requires drug and biologic companies to make publicly available their policies for expanded access for individual patient access to products intended for serious diseases. Sponsors are required to make such policies publicly available upon the earlier of initiation of a Phase II or Phase III study; or 15 days after the drug or biologic receives designation as a breakthrough therapy, fast track product, or regenerative medicine advanced therapy. Running clinical trials that can support regulatory approvals is </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the best way to ultimately ensure wide access for patients to our product candidates. At this point in the development, we cannot support any use of our product candidates outside of clinical trials.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, on May 30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase I clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a drug manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act, but the manufacturer must develop an internal policy and respond to patient requests according to that policy.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Human Clinical Trials in Support of an NDA/BLA</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include, among other things, the requirement that all research subjects provide their informed consent in writing before their participation in any clinical trial. Clinical trials are conducted under written study protocols detailing, among other things, the inclusion and exclusion criteria, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined:</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The investigational drug is initially introduced into healthy human subjects or, in certain indications such as cancer, patients with the target disease or condition, and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness and to determine optimal dosage.</span></div><div style="text-align:justify;text-indent:32.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase II</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The investigational drug is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase III</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The investigational drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product. These clinical trials are commonly referred to as &#8220;pivotal&#8221; studies, which denotes a study that presents the data that the FDA or other relevant regulatory agency will use to determine the primary basis of whether or not to approve a product candidate.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Progress reports of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. In addition, IND safety reports must be submitted to the FDA for any of the following: serious and unexpected suspected adverse reactions; findings from other studies or animal or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">testing that suggest a significant risk in humans exposed to the drug; and any clinically important increase in the case of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. Phase I, Phase II and Phase III clinical trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA/HA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB/EC can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#8217;s/EC&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. The FDA/HA will typically inspect one or more clinical sites to assure compliance with GCP and the integrity of the clinical data submitted.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pediatric Research Equity Act (&#8220;PREA&#8221;) of 2003, an NDA or supplement thereto must contain data that are adequate to assess the safety and effectiveness of the drug product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. With enactment of the Food and Drug Administration Safety and Innovation Act (&#8220;FDASIA&#8221;), in 2012, sponsors must also submit pediatric</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">study</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prior</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assessment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">data.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Those</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">must</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contain</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outline</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proposed</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pediatric</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">study</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">studies the applicant plans to conduct, including study objectives and design, any deferral or waiver requests and other information required by regulation. The applicant, the FDA, and the FDA&#8217;s internal review committee must then review the information submitted, consult with each other, and agree upon a final plan. The FDA or the applicant may request an amendment to the plan at any</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">time.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sponsor must submit an initial pediatric study plan, if required under PREA, no later than either 60 calendar days after the date of the end-of-phase II meeting or such other time as agreed upon between FDA and the sponsor. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. Additional requirements and procedures relating to deferral requests and requests for extension of deferrals are contained in FDASIA. </span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA Reauthorization Act of 2017 established new requirements to govern certain molecularly targeted cancer indications. Any company that submits an NDA/BLA three years after the date of enactment of that statute must submit pediatric assessments with the NDA/BLA if the drug is intended for the treatment of an adult cancer and is directed at a molecular target that the FDA determines to be substantially relevant to the growth or progression of a pediatric cancer. The investigation must be designed to yield clinically meaningful pediatric study data regarding the dosing, safety and preliminary efficacy to inform pediatric labeling for the product.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Submission of an NDA/BLA to the FDA</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful completion of required clinical testing and other requirements, the results of the preclinical studies and clinical trials, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA/BLA requesting approval to market the drug product for one or more indications. Under federal law, the submission of most NDAs/BLAs is subject to an application user fee, which for federal fiscal year 2023 is $3,242,026 for an application requiring clinical data. The sponsor of the approved NDA/BLA is also subject to an annual program fee, which for the fiscal year 2023 is $393,933. Certain exceptions and waivers are available for some of these fees, such as an exception from the application fee for products with orphan designation and a waiver for certain small businesses.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following submission of an application, the FDA conducts a filing review of an NDA/BLA within 60 calendar days of its receipt and strives to inform the sponsor by the 74th day after the FDA&#8217;s receipt of the submission whether the application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA/BLA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has agreed to certain performance goals in the review process of NDAs/BLAs. Under that agreement, 90% of applications seeking approval of new molecular entities (&#8220;NMEs&#8221;), are meant to be reviewed within ten months from the date on which FDA accepts the NDA for filing, and 90% of applications for NMEs that have been designated for &#8220;priority review&#8221; are meant to be reviewed within six months of the acceptance date. The review process may be extended by the FDA for three additional months to consider new information or clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving an NDA/BLA, the FDA typically will inspect the facility or facilities where the product is or will be manufactured. These pre-approval inspections cover all or selected facilities associated with an NDA/BLA submission, including drug component manufacturing (such as API), finished drug product manufacturing, and control testing laboratories. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA/BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Under the FDA Reauthorization Act of 2017, the FDA must implement a protocol to expedite review of responses to inspection reports pertaining to certain applications, including applications for products in shortage or those for which approval is dependent on remediation of conditions identified in the inspection report.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as a condition of approval, the FDA may require an applicant to develop a REMS. REMS use risk minimization strategies beyond the professional labeling to ensure that the benefits of the product outweigh the potential risks. To determine whether a REMS is needed, the FDA will consider the size of the population likely to use the product, seriousness of the disease, expected benefit of the product, expected duration of treatment, seriousness of known or potential adverse events, and whether the product is a new molecular entity. REMS can include medication guides, physician communication plans for healthcare professionals, and elements to assure safe use (&#8220;ETASU&#8221;). ETASU may include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. The FDA may require a REMS before approval or post-approval if it becomes aware of a serious risk associated with use of the product. The requirement for a REMS can materially affect the potential market and profitability of a product.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may refer an application for a drug to an advisory committee or explain why such referral was not made. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fast Track, Breakthrough Therapy, Priority Review and Regenerative Advanced Therapy Designations</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA is authorized to designate certain products for expedited review if they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. These programs are referred to as fast-track designation, breakthrough therapy designation, priority review designation and regenerative advanced therapy designation.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, the FDA may designate a product for fast-track review if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. For fast-track products, sponsors may have greater interactions with the FDA, and the FDA may initiate review of sections of a fast-track product&#8217;s application before the NDA/BLA is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a fast-track product may be effective. The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information and the sponsor must pay applicable user fees. However, the FDA&#8217;s time period goal for reviewing a fast-track application does not begin until the last section of the NDA/BLA is submitted. In addition, the fast-track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Second, a product may be designated as a breakthrough therapy if it is intended, either alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The FDA may take certain actions with respect to breakthrough therapies, including holding meetings with the sponsor throughout the development process; providing timely advice to the product sponsor regarding development and approval; involving more senior staff in the review process; assigning a cross-disciplinary project lead for the review team; and taking other steps to design the clinical trials in an efficient manner.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third, the FDA may designate a product for priority review if it is a product that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA determines, on a case-by-case basis, whether the proposed product represents a significant improvement when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new subpopulation. A priority designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&#8217;s goal for taking action on a marketing application from ten months to six months.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, with passage of the 21st Century Cures Act, or Cures Act, in December 2016, Congress authorized the FDA to accelerate review and approval of antibacterial products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">via</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the limited-population antibacterial drug (&#8220;LPAD&#8221;) pathway. The LPAD pathway provides a unique mechanism for the Food and Drug Administration to review and approve new antibacterial drugs that address unmet medical needs for specific, limited populations of patients - those with serious and life-threatening bacterial infections that are resistant to current treatments. This targeted approach would make antibiotic development more feasible by allowing for smaller clinical development programs that are focused on the limited, high-risk populations that would use these new antibiotics, instead of on more general populations that can be treated with existing medicines. LPAD would also make antibiotic development more feasible by enabling FDA to assess these drugs based on the unique balance of benefits they offer versus risks they present to the limited number of patients they are intended to treat - specifically, patients who have few or no other treatment options. Product candidates that qualify for LPAD review may simultaneously qualify for one or more of FDA&#8217;s expedited review programs.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accelerated Approval Pathway</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may grant accelerated approval to a drug for a serious or life-threatening condition that provides meaningful therapeutic advantage to patients over existing treatments based upon a determination that the drug has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may also grant accelerated approval for such a drug when </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality (&#8220;IMM&#8221;), and that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. Drugs granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An intermediate clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a drug, such as an effect on IMM. The FDA has limited experience with accelerated approvals based on intermediate clinical endpoints, but has indicated that such endpoints generally may support accelerated approval where the therapeutic effect measured by the endpoint is not itself a clinical benefit and basis for traditional approval, if there is a basis for concluding that the therapeutic effect is reasonably likely to predict the ultimate clinical benefit of a drug.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accelerated approval pathway is most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a drug, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. For example, accelerated approval has been used extensively in the development and approval of drugs for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large clinical trials to demonstrate a clinical or survival benefit.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accelerated approval pathway is usually contingent on a sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug&#8217;s clinical benefit. As a result, a product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase IV or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or confirm a clinical benefit during post-marketing studies, would allow the FDA to withdraw the drug from the market on an expedited basis. All promotional materials for product candidates approved under accelerated regulations are subject to prior review by the FDA.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The FDA&#8217;s Decision on an NDA/BLA</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the basis of the FDA&#8217;s evaluation of the NDA/BLA and accompanying information, including the results of the inspection of the manufacturing facilities, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the NDA/BLA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA approves a product, it may limit the approved indications for use for the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase IV clinical trials, be conducted to further assess the drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. After approval, many types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Post-Approval Requirements</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record keeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual program fee requirements for any marketed products, as well as new application fees for supplemental applications with clinical data.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing testing, including clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies. The drug manufacturers are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of the product, suspension of the approval, complete withdrawal of the product from the market or product recalls;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning letters or holds on post-approval clinical trials;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of products; or</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA strictly regulates the marketing, labeling, advertising and promotion of prescription drug products placed on the market. Regulation includes, among other things, standards and regulations for direct-to-consumer advertising, communications regarding unapproved uses, industry-sponsored scientific and educational activities, and promotional activities involving the Internet and social media. Promotional claims about a drug&#8217;s safety or effectiveness are prohibited before the drug is approved. After approval, a drug product generally may not be promoted for uses that are not approved by the FDA, as reflected in the product&#8217;s prescribing information. In the United States, health care professionals are generally permitted to prescribe drugs for such uses not described in the drug&#8217;s labeling, known as off-label uses, because the FDA does not regulate the practice of medicine. However, FDA regulations impose rigorous restrictions on manufacturers&#8217; communications, prohibiting the promotion of off-label uses. It may be permissible, under very specific, narrow conditions, for a manufacturer to engage in non-promotional, non-misleading communication regarding off-label information, such as distributing scientific or medical journal information.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a company is found to have promoted off-label uses, it may become subject to adverse public relations and administrative and judicial enforcement by the FDA, the DOJ, or the Office of the Inspector General of the Department of Health and Human Services, as well as state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes drug products. The federal government has levied large civil and criminal fines against companies for alleged improper promotion, and has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act (&#8220;PDMA&#8221;), and its implementing regulations, as well as the Drug Supply Chain Security Act (&#8220;DSCSA&#8221;), which regulate the distribution and tracing of prescription drug samples at the federal level, and set minimum standards for the regulation of distributors by the states. The PDMA, its implementing regulations and state laws limit the distribution of prescription pharmaceutical product samples, and the DSCSA imposes requirements to ensure accountability in distribution and to identify and remove counterfeit and other illegitimate products from the market.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pediatric Exclusivity</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pediatric exclusivity is another type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity, including the non-patent and orphan exclusivity. This six-month exclusivity may be granted if an NDA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve another application.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Term Restoration and Extension</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of a U.S. patent that covers a drug, biological product or medical device approved pursuant to a premarket approval may also be eligible for patent term extension when FDA approval is granted, provided that certain statutory and regulatory requirements are met. The length of the patent term extension is related to the length of time the drug is under regulatory review while the patent is in force. The Hatch-Waxman Act permits a patent term extension of up to five years beyond the expiration date set for the patent. Patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent applicable to each regulatory review period may be granted an extension and only those claims reading on the approved drug may be extended. Similar provisions are available in Europe and certain other foreign jurisdictions to extend the term of a patent that covers an approved drug, provided that statutory and regulatory requirements are met. The U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) reviews and approves the application for any patent term extension or restoration in consultation with the FDA.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulation Outside the United States</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of drug products. Whether or not it obtains FDA approval for a product, the company would need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can commence clinical trials or marketing of the product in those countries or jurisdictions. The approval process ultimately varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulation and Marketing Authorization in the European Union (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">E.U.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">)</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Trial Approval</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Clinical Trials Directive 2001/20/EC, the Directive 2005/28/EC on Good Clinical Practice (&#8220;GCP&#8221;), and the related national implementing provisions of the individual E.U. Member States govern the system for the approval of clinical trials in the European Union. Under this system, an applicant must obtain prior approval from the competent national authority of the</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">E.U. Member States in which the clinical trial is to be conducted. Furthermore, the applicant may only start a clinical trial at a specific study site after the competent ethics committee has issued a favorable opinion. The clinical trial application must be accompanied by, among other documents, an investigational medicinal product dossier (the Common Technical Document) with supporting information prescribed by Directive 2001/20/EC, Directive 2005/28/EC, where relevant the implementing national provisions of the individual E.U. Member States and further detailed in applicable guidance documents.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2014, the new Clinical Trials Regulation, (E.U.) No 536/2014 (Clinical Trials Regulation) was adopted. The Regulation was published on June 16, 2014, but has not yet become effective. The Clinical Trials Regulation will be directly applicable in all the E.U. Member States, repealing the current Clinical Trials Directive 2001/20/EC and replacing any national legislation that was put in place to implement the Directive. Conduct of all clinical trials performed in the European Union will continue to be bound by currently applicable provisions until the new Clinical Trials Regulation becomes applicable. The extent to which ongoing clinical trials will be governed by the Clinical Trials Regulation will depend on when the Clinical Trials Regulation becomes applicable and on the duration of the individual clinical trial. If a clinical trial continues for more than three </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years from the day on which the Clinical Trials Regulation becomes applicable, the Clinical Trials Regulation will at that time begin to apply to the clinical trial.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The new Clinical Trials Regulation aims to simplify and streamline the approval of clinical trials in the European Union. The main characteristics of the regulation include: a streamlined application procedure </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">via </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a single entry point, the &#8220;E.U. Portal and Database;&#8221; a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts. Part I is assessed by the appointed reporting Member State, whose assessment report is submitted for review by the sponsor and all other competent authorities of all E.U. Member States in which an application for authorization of a clinical trial has been submitted (Concerned Member States). Part II is assessed separately by each Concerned Member State. Strict deadlines have been established for the assessment of clinical trial applications. The role of the relevant ethics committees in the assessment procedure will continue to be governed by the national law of the Concerned Member State. However, overall related timelines will be defined by the Clinical Trials Regulation.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As in the United States, similar requirements for posting clinical trial information are present in the European Union (EudraCT) website: https://eudract.ema.europa.eu/ and in other countries.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketing Authorization</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain a marketing authorization for a product under E.U. regulatory systems, an applicant must submit a marketing authorization application (&#8220;MAA&#8221;) either under a centralized procedure administered by the EMA, or one of the procedures administered by competent authorities in the E.U. Member States (decentralized procedure, national procedure or mutual recognition procedure). A marketing authorization may be granted only to an applicant established in the E.U. Regulation (EC) No 1901/2006 provides that prior to obtaining a marketing authorization in the European Union, applicants have to demonstrate compliance with all measures included in an EMA-approved Paediatric Investigation Plan (&#8220;PIP&#8221;), covering all subsets of the pediatric population, unless the EMA has granted (1) a product-specific waiver, (2) a class waiver or (3) a deferral for one or more of the measures included in the PIP.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid across the European Economic Area (i.e., the European Union as well as Iceland, Liechtenstein and Norway). Pursuant to Regulation (EC) No 726/2004, the centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological processes, products designated as orphan medicinal products and products with a new active substance indicated for the treatment of certain diseases, including products for the treatment of cancer. For products with a new active substance indicated for the treatment of other diseases and products that are highly innovative or for which a centralized process is in the interest of patients, the centralized procedure may be optional. The centralized procedure may at the request of the applicant also be used in certain other cases. We anticipate that the centralized procedure will be mandatory for the product candidates we are developing.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the centralized procedure, the Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;) is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing marketing authorization. Under the centralized procedure in the European Union, the maximum timeframe for the evaluation of an MAA is 210 days, excluding clock stops, when additional information or written or oral explanation is to be provided by the applicant in response to questions of the CHMP. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation. If the CHMP accepts such request, the time limit of 210 days will be reduced to 150 days, but it is possible that the CHMP can revert to the standard time limit for the centralized procedure if it considers that it is no longer appropriate to conduct an accelerated assessment. At the end of this period, the CHMP provides a scientific opinion on whether or not a marketing authorization should be granted in relation to a medicinal product. Within 15 calendar days of receipt of a final opinion from the CHMP, the European Commission must prepare a draft decision concerning an application for marketing authorization. This draft decision must take the opinion and any relevant provisions of E.U. law into account. Before arriving at a final decision on an application for centralized authorization of a medicinal product, the European Commission must consult the Standing Committee on Medicinal Products for Human Use. The Standing Committee is composed of representatives of the E.U. Member States and chaired by a non- voting European Commission representative. The European Parliament also has a related &#8220;droit de regard&#8221;. The European Parliament&#8217;s role is to ensure that the European Commission has not exceeded its powers in deciding to grant or refuse to grant a marketing authorization.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The European Commission may grant a so-called &#8220;marketing authorization under exceptional circumstances&#8221;. Such authorization is intended for products for which the applicant can demonstrate that it is unable to provide comprehensive data </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the efficacy and safety under normal conditions of use, because the indications for which the product in question is intended are encountered so rarely that the applicant cannot reasonably be expected to provide comprehensive evidence, or in the present state of scientific knowledge, comprehensive information cannot be provided, or it would be contrary to generally accepted principles of medical ethics to collect such information. Consequently, marketing authorization under exceptional circumstances may be granted subject to certain specific obligations, which may include the following:</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the applicant must complete an identified program of studies within a time period specified by the competent authority, the results of which form the basis of a reassessment of the benefit/risk profile;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the medicinal product in question may be supplied on medical prescription only and may in certain cases be administered only under strict medical supervision, possibly in a hospital and in the case of a radiopharmaceutical, by an authorized person; and</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the package leaflet and any medical information must draw the attention of the medical practitioner to the fact that the particulars available concerning the medicinal product in question are as yet inadequate in certain specified respects.</span></div><div style="padding-left:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A marketing authorization under exceptional circumstances is subject to annual review to reassess the risk-benefit balance in an annual reassessment procedure. Continuation of the authorization is linked to the annual reassessment and a negative assessment could potentially result in the marketing authorization being suspended or revoked. The renewal of a marketing authorization of a medicinal product under exceptional circumstances, however, follows the same rules as a &#8220;normal&#8221; marketing authorization. Thus, a marketing authorization under exceptional circumstances is granted for an initial five years, after which the authorization will become valid indefinitely, unless the EMA decides that safety grounds merit one additional five-year renewal.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The European Commission may also grant a so-called &#8220;conditional marketing authorization&#8221; prior to obtaining the comprehensive clinical data required for an application for a full marketing authorization. Such conditional marketing authorizations may be granted for product candidates (including medicines designated as orphan medicinal products), if (i) the risk-benefit balance of the product candidate is positive, (ii) it is likely that the applicant will be in a position to provide the required comprehensive clinical trial data, (iii) the product fulfills an unmet medical need and (iv) the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required. A conditional marketing authorization may contain specific obligations to be fulfilled by the marketing authorization holder, including obligations with respect to the completion of ongoing or new studies, and with respect to the collection of pharmacovigilance data. Conditional marketing authorizations are valid for one year, and may be renewed annually, if the risk-benefit balance remains positive, and after an assessment of the need for additional or modified conditions and/or specific obligations. The timelines for the centralized procedure described above also apply with respect to the review by the CHMP of applications for a conditional marketing authorization.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The E.U. medicines rules expressly permit the E.U. Member States to adopt national legislation prohibiting or restricting the sale, supply or use of any medicinal product containing, consisting of or derived from a specific type of human or animal cell, such as embryonic stem cells. While the products we have in development do not make use of embryonic stem cells, it is possible that the national laws in certain E.U. Member States may prohibit or restrict us from commercializing our products, even if they have been granted an E.U. marketing authorization.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unlike the centralized authorization procedure, the decentralized marketing authorization procedure requires a separate application to, and leads to separate approval by, the competent authorities of each E.U. Member State in which the product is to be marketed. This application is identical to the application that would be submitted to the EMA for authorization through the centralized procedure. The referenced E.U. Member State prepares a draft assessment and drafts of the related materials within 120 days after receipt of a valid application. The resulting assessment report is submitted to the concerned E.U. Member States who, within 90 days of receipt, must decide whether to approve the assessment report and related materials. If a concerned E.U. Member State cannot approve the assessment report and related materials due to concerns relating to a potential serious risk to public health, disputed elements may be referred to the European Commission, whose decision is binding on all E.U. Member States.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The mutual recognition procedure similarly is based on the acceptance by the competent authorities of the E.U. Member States of the marketing authorization of a medicinal product by the competent authorities of other E.U. Member States. The holder of a national marketing authorization may submit an application to the competent authority of an E.U. Member State requesting that this authority recognize the marketing authorization delivered by the competent authority of another E.U. Member State.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Data Protection in the European Union</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, innovative medicinal products approved on the basis of a complete independent data package qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity pursuant to Directive 2001/83/EC. Regulation (EC) No 726/2004 repeats this entitlement for medicinal products authorized in accordance to the centralized authorization procedure. Data exclusivity prevents applicants for authorization of generics of these innovative products from referencing the innovator&#8217;s data to assess a generic (abridged) application for a period of eight years. During an additional two-year period of market exclusivity, a generic marketing authorization application can be submitted and authorized, and the innovator&#8217;s data may be referenced, but no generic medicinal product can be placed on the E.U. market until the expiration of the market exclusivity. The overall ten-year period will be extended to a maximum of 11 years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. Even if a compound is considered to be a new chemical entity so that the innovator gains the prescribed period of data exclusivity, another company nevertheless could also market another version of the product if such company obtained marketing authorization based on an MAA with a complete independent data package of pharmaceutical tests, preclinical tests and clinical trials.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Periods of Authorization and Renewals</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A marketing authorization has an initial validity for five years in principle. The marketing authorization may be renewed after five years on the basis of a re-evaluation of the risk-benefit balance by the EMA or by the competent authority of the E.U. Member State. To this end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least six months before the marketing authorization ceases to be valid. The European Commission or the competent authorities of the E.U. Member States decide on justified grounds relating to pharmacovigilance, to proceed with one further five-year period of marketing authorization. Once subsequently definitively renewed, the marketing authorization shall be valid for an unlimited period. Any authorization which is not followed by the actual placing of the medicinal product on the E.U. market (in case of centralized procedure) or on the market of the authorizing E.U. Member State within three years after authorization ceases to be valid (the so-called sunset clause).</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span id="if179e545b9494232be9e6a27c29f7ed3_149685"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pediatric Studies</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to obtaining a marketing authorization in the European Union, applicants have to demonstrate compliance with all measures included in an EMA-approved Paediatric Investigation Plan, covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, a class waiver, or a deferral for one or more of the measures included in the PIP. The respective requirements for all marketing authorization procedures are set forth in Regulation (EC) No 1901/2006, which is referred to as the Paediatric Regulation. This requirement also applies when a company wants to add a new indication, pharmaceutical form or route of administration for a medicine that is already authorized. The Paediatric Committee of the EMA (&#8220;PDCO&#8221;) may grant deferrals for some medicines, allowing a company to delay development of the medicine in children until there is enough information to demonstrate its effectiveness and safety in adults. The PDCO may also grant waivers when development of a medicine in children is not needed or is not appropriate, such as for diseases that only affect the elderly population.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before a marketing authorization application can be filed, or an existing marketing authorization can be amended, the EMA determines that companies actually comply with the agreed studies and measures listed in each relevant PIP.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Requirements after a Marketing Authorization has been Obtained</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In case an authorization for a medicinal product in the European Union is obtained, the holder of the marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products. These include:</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div style="margin-bottom:4pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Compliance with the European Union&#8217;s stringent pharmacovigilance or safety reporting rules must be ensured. These rules can impose post-authorization studies and additional monitoring obligations;</span></div><div style="margin-bottom:4pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The manufacturing of authorized medicinal products, for which a separate manufacturer&#8217;s license is mandatory, must also be conducted in strict compliance with the applicable E.U. laws, regulations and guidance, including Directive 2001/83/EC, Directive 2003/94/EC, Regulation (EC) No 726/2004 and the European Commission Guidelines for Good Manufacturing Practice. These requirements include compliance with E.U. cGMP standards when manufacturing medicinal products and active pharmaceutical ingredients, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:4pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including the manufacture of active pharmaceutical ingredients outside of the European Union with the intention to import the active pharmaceutical ingredients into the European Union;</span></div><div style="margin-bottom:4pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The marketing and promotion of authorized drugs, including industry-sponsored continuing medical education and advertising directed toward the prescribers of drugs and/or the general public, are strictly regulated in the European Union notably under Directive 2001/83EC, as amended, and E.U. Member State laws. Direct-to- consumer advertising of prescription medicines is prohibited across the European Union.</span></div><div style="padding-left:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General Data Protection Regulation</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collection, use, disclosure, transfer, or other processing of personal data regarding individuals in the European Union, including personal health data, is subject to the E.U. General Data Protection Regulation (&#8220;GDPR&#8221;), which became effective on May 25, 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the European Union, including the U.S., and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#8364;20 million or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. Compliance with the GDPR will be a rigorous and time-intensive process that may increase the cost of doing business or require companies to change their business practices to ensure full compliance.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pricing Decisions for Approved Products</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies or so- called health technology assessments in order to obtain reimbursement or pricing approval. For example, the European Union provides options for its Member States to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. Member States may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other Member States allow companies to fix their own prices for products, but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the European Union have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage health care expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the European Union. The downward pressure on health care costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various Member States, and parallel trade, i.e., arbitrage between low-priced and high- priced Member States, can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any products, if approved in those countries.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Term Extension</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to compensate the patentee for delays in obtaining a marketing authorization for a patented product, a supplementary certificate (&#8220;SPC&#8221;) may be granted extending the exclusivity period for that specific product by up to five years. Applications for SPCs must be made to the relevant patent office in each E.U. member state and the granted certificates are valid only in the member state of grant. An application has to be made by the patent owner within six months of the first marketing authorization being granted in the European Union (assuming the patent in question has not expired, lapsed or been revoked) or within six months of the grant of the patent (if the marketing authorization is granted first). In the context of SPCs, the term &#8220;product&#8221; means the active ingredient or combination of active ingredients for a medicinal product and the term &#8220;patent&#8221; means a patent protecting such a product or a new manufacturing process or application for it. The duration of an SPC is calculated as the difference between the patent&#8217;s filing date and the date of the first marketing authorization, minus five years, subject to a maximum term of five years.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A six month pediatric extension of an SPC may be obtained where the patentee has carried out an agreed pediatric investigation plan, the authorized product information includes information on the results of the studies and the product is authorized in all member states of the European Union.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare Law and Regulation</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health care providers and third-party payors play a primary role in the recommendation and prescription of drug products that are granted marketing approval. Arrangements with providers, consultants, third-party payors and customers are subject to broadly applicable fraud and abuse, anti-kickback, false claims laws, patient privacy laws and regulations and other healthcare laws and regulations that may constrain business and/or financial arrangements. Restrictions under applicable federal and state healthcare laws and regulations, include the following:</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, paying, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalties laws, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false, fictitious or fraudulent or knowingly making, using or causing to be made or used a false record or statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal laws that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or making false statements relating to health care matters;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their respective implementing regulations, including the Final Omnibus Rule published in January 2013, which impose obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Foreign Corrupt Practices Act, or FCPA, which prohibits companies and their intermediaries from making, or offering or promising to make improper payments to non-U.S. officials for the purpose of obtaining or retaining business or otherwise seeking favorable treatment;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal false statements statute, which prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal transparency requirements known as the federal Physician Payments Sunshine Act, under the Patient Protection and Affordable Care Act, as amended by the Health Care Education Reconciliation Act, or the Affordable Care Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, within the United States Department of Health and Human Services, information related to payments and other transfers of value made by that entity to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; and</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to healthcare items or services that are reimbursed by non-government third-party payors, including private insurers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharmaceutical Coverage and Reimbursement </span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Significant uncertainty exists as to the coverage and reimbursement status of products approved by the FDA and other </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">government authorities. Thus, even if a product candidate is approved, sales of the product will depend, in part, on the extent to which third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care organizations, provide coverage and establish adequate reimbursement levels for, the product. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity and reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable marketing approvals. Nonetheless, product candidates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover a product could reduce physician utilization once the product is approved and have a material adverse effect on sales, results of operations and financial condition. Additionally, a payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor to payor.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The containment of health care costs also has become a priority of federal, state and foreign governments and the prices of products have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#8217;s revenue generated from the sale of any approved products. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive marketing approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been a number of federal and state proposals during the last few years regarding the pricing of pharmaceutical and biopharmaceutical products, limiting coverage and reimbursement for drugs and other medical products, government control and other changes to the healthcare system in the United States. In March 2010, the United States Congress enacted the Affordable Care Act, or ACA, which, among other things, includes changes to the coverage and payment for drug products under government health care programs. Among the provisions of the ACA of importance to our potential product candidates are:</span></div><div style="text-indent:32.5pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expanded manufacturers&#8217; rebate liability under the Medicaid Drug Rebate Program by increasing the minimum rebate for both branded and generic drugs and revising the definition of &#8220;average manufacturer price,&#8221; or AMP, for calculating and reporting Medicaid drug rebates on outpatient prescription drug prices;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expanded the types of entities eligible for the 340B drug discount program;</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">established the Medicare Part D coverage gap discount program by requiring manufacturers to provide a 70% as of January 1, 2019 point-of-sale-discount off the negotiated price of applicable brand drugs to eligible beneficiaries during their coverage gap period as a condition for the manufacturers&#8217; outpatient drugs to be covered under Medicare Part D; and</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers up to 2% per fiscal year, which went into effect in April 2013 and, due to subsequent legislative amendments, will remain in effect through 2027 unless additional Congressional action is taken. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in additional pricing pressures. The demand for our products is predicated on our clinical trial strategy of attempting to achieve superiority against the standard-of-care. If there are not adequate reimbursement levels, our business and results of operations could be adversely affected.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to be a competitive, innovative and successful Company, we believe it is critical to attract, engage, motivate and retain a dedicated, talented and innovative team of employees. As part of these efforts, we strive to foster a diverse, equitable and inclusive community, invest in continuous learning and development, offer a competitive compensation and benefits program and provide a safe and healthy workplace. Our success starts and ends with having the best talent and, as a result, we are focused on attracting, developing, and engaging our employees. In 2022, we continued to strengthen the team by attracting a number of world class leaders with successful track records into the Company, all of our executive positions are now filled with proven leaders.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, we had 105 total employees. Of our total workforce, approximately 72% work in research and development, and 28% work in finance, legal, information technology, general management and other administrative functions. Approximately 90% and 10% of our workforce is located in the U.S. and the U.K., respectively.</span></div><div style="text-indent:31.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we once again made challenging demands of our employees and they have responded with dedication and enthusiasm. In August 2023, Summit launched an engagement survey, in which 91% of employees responded. The results of this survey showed our employees to be well engaged, with a strong team spirit and strongly aligned to the Company&#8217;s mission.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation and Benefits </span></div><div style="text-indent:31.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide competitive compensation and benefits programs to attract, motivate and retain our employees. We regularly review our compensation practices and analyze the equity of compensation decisions for individual employees and our workforce as a whole. In addition to competitive compensation, we provide generous benefits including employer contributions to pension/401k plans, an employee stock purchase plan, health and welfare programs and benefits, and paid vacation. We are committed to ensuring that our total compensation packages are competitive while supporting our business plans and strategies.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Diversity, Equity and Inclusion</span></div><div style="text-indent:31.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to embedding a culture of diversity, equity and inclusion across our Company. We believe that diversity of gender, age, ethnicity, sexual orientation, culture, education, background and experience fuels innovation and enables our employees to succeed. This includes ensuring opportunity for all and embraces the positive effect that our diverse workforce brings. We do not tolerate any form of discrimination and our employment policies and practices focus on ensuring that all our employment processes are free from discrimination or harassment on any grounds. Approximately 57% of our employees are female and 47% of our executive team is female.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Learning and Development</span></div><div style="text-indent:31.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to investing in learning and development for our employees. Our employees have access to online training courses which cover a wide range of technical and business topics to help them develop their professional skills and explore other areas as they plan for their career and personal growth. Our performance management process includes timely performance feedback and career development discussions which are critical to each employee&#8217;s continued growth and development within the organization.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Workplace Health and Safety</span></div><div style="text-indent:31.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to the health and safety of all of our employees. We accomplish this through strict compliance with applicable workplace safety laws and regulations, continuous risk assessment and expeditious action. We have again had no reportable health and safety issues in 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Corporate Information</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summit Therapeutics Inc. was incorporated in Delaware on July 17, 2020. Our principal executive office is located at 601 Brickell Key Drive, Suite 1000, Miami, Florida 33131 and our phone number is (650) 460-8308. Our website is https://www.smmttx.com. The information contained on, or that can be accessed through, our website is not incorporated by reference into this Report or in any other report or document we file with the SEC, and any reference to our website address is intended to be an inactive textual reference only.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own or have rights to trademarks, service marks, and trade names that we use in connection with the operation of our business, including our corporate name, logos and website names. Other trademarks, service marks, and trade names appearing in this Report are the property of their respective owners. Solely for convenience, some of the trademarks, service marks, and trade names referred to in this Report are listed without the &#174; and &#8482; symbols.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a website with the address https://www.smmttx.com/. We are not including the information contained on our website as part of, or incorporating it by reference into, this Form 10-K. Through our website, we make available free of charge our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to these reports in a timely manner after we provide them to the Securities and Exchange Commission (&#8220;SEC&#8221;).</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="if355807d1b914743a4dab03fe6913e8f_16"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.  Risk Factors</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This section describes certain risks we face in our business. Additional risks we do not yet know of or that we currently believe are immaterial may also impair our business. If any of the events or circumstances described in this section actually occurs, our business, financial condition or operating results could suffer, and the market price of our common stock could decline. In assessing these risks, investors should also refer to the other information contained or incorporated by reference in this report and our other filings with the Securities and Exchange Commission.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Financial Position and Need for Additional Capital</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not currently have sufficient working capital to fund our planned operations, including fulfilling our debt obligations, for the next twelve months. There is uncertainty regarding our ability to raise additional capital and as such, there is substantial doubt regarding our ability  to continue as a going concern.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial statements have been prepared under the assumption that we would continue as a going concern. However, we have concluded that there is substantial doubt about our ability to continue as a going concern, because without additional sources of funding, our cash and cash equivalents at December 31, 2023 is not sufficient for  us to fund our working capital needs for the next twelve months after the date that the financial statements included in this Annual Report on Form 10-K are issued. Management&#8217;s plans concerning these matters, including raising additional capital, are described in Item 2 &#8211; Liquidity and Capital Resources &#8211; Sources of Liquidity of our financial statements included within this Annual Report on Form 10-K. However, we cannot guarantee that we will be able to obtain any or sufficient additional funding or that such funding, if available, will be obtainable on terms satisfactory to us. If we cannot continue as a going concern, our stockholders would likely lose most or all of their investment in us.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Worldwide economic social, and geopolitical instability could adversely affect our operations, revenue, financial condition, or results of operations.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, worldwide economic conditions remain uncertain, particularly due to the effects of the conflict between Russia and Ukraine and the conflicts in the Middle East, including those in Gaza and Yemen, and disruptions in the banking system and financial markets, lingering COVID-19 pandemic, increased inflation and rising interest rates. The general economic and capital market conditions, both in the U.S. and worldwide, have been volatile in the past and at times have adversely affected the Company&#8217;s access to capital and increased the cost of capital. The capital and credit markets may not be available to support future capital raising activity on favorable terms. If economic conditions decline, the Company&#8217;s future cost of equity or debt capital and access to the capital markets could be adversely affected.  In addition, adverse economic conditions, such as recent supply chain disruptions and labor shortages and persistent inflation, may negatively impact our business. These economic conditions make it more difficult for us to accurately forecast and plan our future business activities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend heavily on the success of ivonescimab. If we are unable to successfully develop or commercialize ivonescimab, or experience significant delays in doing so, we may extend the period in which we will incur significant financial losses as an organization.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to invest a significant portion of our efforts and financial resources in the development of ivonescimab, which is still in clinical development. Our ability to generate product revenues, which may not occur for several years, if ever, will depend heavily on the successful development and commercialization of ivonescimab. The success of this product candidate will depend on a number of factors, including the following:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ability to use preclinical data and data of patients from Akeso&#8217;s clinical trials in China supporting registration studies and regulatory approval;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful completion of global clinical development;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receipt of clinical trial approvals and future marketing approvals from applicable regulatory authorities in all the countries where we intend to conduct clinical trials and/or seek marketing approval;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing supply chain and commercial manufacturing arrangements with third-party manufacturers;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">protecting our rights in our intellectual property portfolio;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing sales, marketing and distribution capabilities;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">launching commercial sales of ivonescimab if and when approved, whether alone or in collaboration with others;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of ivonescimab, if and when approved, by patients, the medical community and third-party payors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining adequate pricing and a reimbursement profile;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ensuring no disruption in supply or lack of sufficient quantities of ivonescimab;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effectively competing with other therapies; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining an acceptable safety profile of ivonescimab during development and following approval.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize ivonescimab, which would materially harm our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a development-stage company and have incurred significant losses since our inception. We expect to incur losses for at least the next several years and may never generate profits from operations or maintain profitability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a development-stage company and we cannot assure profitability. We expect to continue to generate operating losses for the foreseeable future. Until we can generate substantial revenue and achieve profitability, we will need to raise additional capital to fund ongoing operations and capital needs. Since inception, we have incurred significant operating losses. During the year ended December 31, 2023, we incurred a net loss of $614.9 million, and cash flows used in operating activities was $76.8&#160;million. As of December 31, 2023 we had an accumulated deficit of $993.3 million, cash and cash equivalents of $71.4&#160;million, short-term investments in U.S. treasury securities of $114.8 million, and current and long-term research and development tax credits receivable of $1.8&#160;million. These losses could continue for the next several years as we invest in clinical development of ivonescimab. We expect to continue to generate operating losses for the foreseeable future. Until we can generate substantial revenue and achieve profitability, we will need to raise additional capital to fund ongoing operations and capital needs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To become and remain profitable, we must succeed in developing and eventually either commercializing or partnering with other organizations to commercialize products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing preclinical testing and clinical trials of our product candidates, discovering additional product candidates, obtaining regulatory approval for these product candidates and manufacturing, marketing, and selling any products for which we may obtain regulatory approval. We are in the preliminary stages of many of these activities. We may never succeed in these activities and, even if we do, may never generate revenue that is significant enough to achieve profitability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with pharmaceutical products and biological development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress our value and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product offerings or even continue our operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have not yet demonstrated our ability to successfully complete development of any product candidates which may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not yet demonstrated our ability to successfully complete development of any product candidates, obtain marketing approvals, manufacture a commercial scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities or otherwise obtain a partner to do so as is necessary for successful product commercialization. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming we obtain marketing approval for any of our product candidates, we will need to transition from a company with a research and development focus to a company capable of supporting commercial activities or seek an appropriate partner or partners to maximize the commercial opportunity of our products with a deal structure that maximizes our opportunities for profitability. We may encounter unforeseen expenses, difficulties, complications and delays and may not be successful in such a transition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need substantial additional capital to fund our operations and to make payments under the License Agreement and the Note Purchase Agreement and if we fail to obtain necessary financing, we could be forced to delay, reduce or eliminate the development and commercialization of our product candidates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval  achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we are not planning to have commercially available for several years, if at all. Accordingly, </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we will need to continue to rely on additional financing to achieve our business objectives. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. Additional financing may not be available to us on acceptable terms, or at all.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our research and development expenses to increase substantially in connection with our ongoing activities, particularly in connection with the License Agreement. In addition, if we obtain marketing approval for our potential future product candidates where we retain commercial rights or any other product candidates we develop, we expect to incur significant commercialization expenses related to product sales, marketing, distribution and manufacturing. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary future capital requirements will be related to our obligations under the License Agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to generate operating losses for the foreseeable future. The License Agreement calls for initial consideration payments of $500 million (which have been paid), as well as total contingent payments by the Company of up to $5.0 billion, as Akeso will be eligible to receive regulatory milestones of up to $1.05 billion and commercial milestones of up to $3.45 billion, many of which will be due before the Company anticipates generating any revenue from the License Agreement. We entered into the Note Purchase Agreement to fund the initial consideration payments and we will need additional capital to fund our operations and payments under the License Agreement and the Note Purchase Agreement. We may anticipate the need for further capital raises to repay the remaining $100 million principal balance under the Note Purchase Agreement. We therefore expect to raise additional capital via issuances of equity or debt.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our investors, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, collaborations, strategic alliances, grants and clinical trial support from government entities, philanthropic, non-government and not-for-profit organizations and patient advocacy groups, debt financings, and marketing, distribution or licensing arrangements. We do not have any committed external source of funds. We will need to seek additional funding in the future to fund operations. Additional capital, when needed, may not be available to us on acceptable terms, or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our existing stockholders may be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our existing stockholders. Additional debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends or other distributions. If we raise additional funds through collaborations, strategic alliances or marketing, distribution, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to raise additional funds through equity or debt financings, or other arrangements when needed based on our liquidity needs, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have substantial indebtedness and may require additional indebtedness in the future, which may require us to use a substantial portion of our cash flow to service debt and limit our financial and operating flexibility.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have substantial indebtedness and may require additional indebtedness in the future. As of February 19, 2024, we had a total of $100 million of indebtedness outstanding under the Note Purchase Agreement. Further, the License Agreement calls for certain additional future payment obligations and we may require additional indebtedness to fund those obligations. Our existing and future indebtedness will require interest payments and need to be repaid or refinanced and could require us to divert funds identified for other purposes to service our debt. Our debt obligations could also result in cash demands and impair our liquidity position, causing financial risk for us. Diverting funds identified for other purposes for debt service may adversely affect our growth prospects. If we cannot generate sufficient cash flow from operations to service our debt, we will need to refinance our debt, dispose of assets, or issue equity to obtain necessary funds. We do not know whether we would be able to take any of these actions on a timely basis, on terms satisfactory to us, or at all.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company&#8217;s failure to comply with the terms and obligations of the Note Purchase Agreement, including as a result of events beyond our control, may result in an event of default.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Note Purchase Agreement requires us to comply with certain repayment obligations, representations and covenants. A breach of any of these obligations, representations or covenants or the occurrence of certain other specified events could result in an event of default under the Note Purchase Agreement. Upon the occurrence of any event of default under the Note Purchase Agreement, the outstanding balance on the corresponding Note will, at the option of such lender, become immediately and automatically due and payable in cash and a default interest rate of an additional 2% per annum will apply on all outstanding obligations during the occurrence and continuance of an event of default.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to maintain compliance with these repayment obligations and covenants in the future and, if we fail to do so, we may not be able to obtain waivers from the lender and/or amend the covenants. Our failure to comply with the repayment obligations and covenants described above could result in an event of default, which, if not cured or waived, and if the lender accelerates, would result in us being required to repay these borrowings before their due date. If we are forced to refinance these borrowings on less favorable terms or if we are unable to refinance these borrowings, our business, financial condition, and results of operations could be materially adversely affected.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Development and Commercialization of our Product Candidates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials, as well any interim results, may not be predictive of future trial results. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical development can take several years to complete and is an expensive process with inherent uncertainty in outcomes. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of ivonescimab may not be predictive of the results of our later-stage clinical trials. Similarly, initial or interim results of a clinical trial may not be predictive of the final results and results for one indication may not be predictive of the success in additional indications. Drug candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. Several factors can lead to significant variability in safety and/or efficacy results between different trials of the same drug candidate, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, including genetic differences, patient adherence to the dosing regimen and other trial protocol elements and the rate of dropout among clinical trial participants. In the case of any trials we conduct, results may differ from earlier trials due to the larger number of clinical trial sites and additional countries involved in such later trials. In multi-regional trials results may differ across regions and countries, Our future clinical trial results may not be favorable. If future clinical trial results prove unfavorable, we may incur additional product development costs, experience delays and/or become unable to obtain regulatory approval of ivonescimab, thereby adversely affecting our business. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we experience delays or difficulties in the enrollment of patients in our clinical trials, our receipt of necessary marketing approvals could be delayed or prevented.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to initiate or continue clinical trials for our product candidates for several factors including inability to get required regulatory approvals to initiate clinical trials in all the planned countries, as well as inability to locate and enroll a sufficient number of eligible patients to participate in these clinical trials. For our clinical trials of ivonescimab, we need to identify potential patients, potentially test them for specific diagnoses and enroll them. In addition, our competitors in NSCLC have ongoing clinical trials for product candidates that could be competitive with our product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates or choose not to enroll in any clinical trials for various reasons, including due to fears of contagious diseases, illnesses or side effects.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient enrollment is affected by several factors, including, but not limited to, :</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">severity of the disease under investigation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">eligibility criteria for the clinical trial in question;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">perceived risks and benefits of the product candidate under study;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition for patients, time and resources at clinical trials sites from other investigational therapies in clinical trials that target the same patient population;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the standard of care, including new clinical trial data;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval of other therapies to treat the indication that is being investigated in the clinical trial;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">efforts to facilitate timely enrollment in clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patient referral practices of physicians;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to monitor patients adequately during and after treatment; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">proximity and availability of clinical trial sites for prospective patients.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing. Our inability to enroll a sufficient number of patients in our planned clinical trials of ivonescimab or any other planned clinical trials would result in significant delays, may generate a limited data set from which no meaningful conclusions could be made, or may require us to abandon one or more clinical trials altogether.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If clinical trials of our product candidates fail to demonstrate safety and efficacy to the satisfaction of the U.S. Food and Drug Administration, or the FDA, or the European Medicines Agency, or the EMA, or do not otherwise produce favorable results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of ivonescimab or any other product candidate. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with obtaining marketing approval from regulatory authorities for the sale of ivonescimab, or any other product candidate, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is inherently uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. In particular, due to the small number of patients in our early clinical trials, results from such trials may not be predictive of the outcome of later clinical trials. The design of a clinical trial can determine whether its results will support approval of a product, and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced or completed. We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing approval. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. To date, we have not conducted a clinical trial for ivonescimab and cannot predict the results of such trials.</span></div><div><span><br/></span></div><div><span id="ie3783745aab24a698ceea5ae72eb578a_305123"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory requirements and timelines may affect the scope and timeline of our trials and the potential market for our product candidates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we expand into additional countries and sites for our current and/or additional clinical trials, we are required to obtain the regulatory approval of the applicable clinical trial applications with the respective regulatory authorities and approvals from central or local institutional review boards. We may decide to modify our plans to enter certain regions or countries based on the timelines and requirements from the respective regulatory regions. If the process to obtain regulatory approvals in a given region or country places onerous requirements on the Company or if the Company cannot reasonably obtain such approvals without material delays to its plans, we may choose not to enter certain regions or countries for our clinical trials, which may delay the development of our product in those countries and/or impact the scope of our dataset and market for our products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we experience any number of possible unforeseen events in connection with our clinical trials, potential marketing approval or commercialization of our product candidates could be delayed or prevented.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to complete the clinical trials and receive marketing approval for or commercialize our product candidates, including:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate for various reasons, including due to contagious diseases or illnesses;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to combine data from different regions and countries may be limited due to lack of consistency in data in these regions and/or countries, potentially delaying or preventing marketing approval for our product</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In our multi-regional trials, we may experience delays in enrollment across one or more countries and/or regions, which may lead to variability in data and/or trial missing the required endpoints resulting in lack of approval from regulatory authorities</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to enroll a sufficient number of patients in our clinical trials to ensure adequate statistical power to detect any statistically significant treatment effects;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators, institutional review boards or independent ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may have delays in reaching or fail to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may have to suspend or terminate clinical trials of our product candidates for various reasons, including a finding that the participants are being exposed to unacceptable health risks;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators, institutional review boards or independent ethics committees may require that we or our investigators materially modify the terms of our clinical research in order to meet additional requirements for receiving marketing approval, including by requiring that we enlarge our trials, broaden the scope of our research, or perform studies in addition to those we currently anticipate, which may delay our ability to obtain marketing approval or impose additional costs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators, institutional review boards or independent ethics committees may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of clinical trials of our product candidates may be greater than we anticipate;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the supply or quality of our product candidates, comparator drugs or other materials necessary to conduct clinical trials of our product candidates in adolescent patients may be insufficient or inadequate, which may occur if, for example, enrollment for our clinical trial programs are delayed and the clinical supply of ivonescimab or related comparator drug manufactured for such trials was not utilized prior to its expiration and needed to be replaced, or if there were disruptions in our supply chain due to weather conditions, natural disasters or contagious diseases or illnesses, such as the novel coronavirus; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators, institutional review boards or independent ethics committees to suspend or terminate the clinical trials.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product development costs will increase as we experience delays in testing or marketing approvals. We do not know whether any preclinical tests or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant preclinical or clinical trial delays also could shorten any periods during which we may have the</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Global economic uncertainty, changes in geopolitical conditions and political instability, changes in trade agreements and disputes, such as the conflict between Russia and Ukraine, conflict in the Middle East and other macroeconomic factors, could adversely affect our business and results of operations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations and performance depend on ongoing stability of global, regional and U.S. economic and geopolitical conditions. General worldwide economic conditions have experienced significant instability in recent years, including due to recent global economic uncertainty and turbulent financial market conditions. The ongoing geopolitical conflicts in various parts of the world, including but not limited to Russia, Ukraine and Middle East, are difficult to predict and could adversely affect our business in our licensed territories as well as our ability to enroll patients and supply ivonescimab to various clinical sites in the world, resulting in adverse effects on our business and financial condition. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If serious adverse or inappropriate side effects are identified during the development of ivonescimab or any other product candidate, we may need to abandon or limit our development of that product candidate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our product candidates are in clinical or early-stage development and their risk of failure is high. It is impossible to predict when or if any of our product candidates will prove effective or safe in humans or will receive marketing approval. If our product candidates are associated with undesirable side effects or have characteristics that are unexpected, we may need to abandon their development or limit development to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many compounds that initially showed promise in clinical or earlier stage testing have later been found to cause side effects or other safety issues that prevented further development of the compound. If we elect or are forced to suspend or terminate any clinical trial of our product candidates, the commercial prospects of such product candidate will be harmed and our ability to generate product revenues from such product candidate will be delayed or eliminated. Any of these occurrences could materially harm our business.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if ivonescimab or any other product candidate receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If ivonescimab or any of our other product candidates receive marketing approval, such products may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. If these products do not achieve an adequate level of acceptance, it could make it more difficult to enter into third-party partnership arrangements, and we may not generate significant product revenues or revenue from collaboration agreements or any income from operations. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efficacy and potential advantages compared to alternative treatments or competitive products;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any side effects;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to offer our product candidates for sale at competitive prices;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">convenience and ease of administration compared to alternative treatments;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the strength of marketing and distribution support;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of third-party coverage and adequate reimbursement;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of any such marketing approval in relation to other product approvals;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">support from patient advocacy groups; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any restrictions on concomitant use of other medications.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability to negotiate, secure and maintain third-party coverage and reimbursement may be affected by political, economic and regulatory developments in the United States, the European Union and other jurisdictions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Governments continue to impose cost containment measures, and third-party payors are increasingly challenging prices charged for medicines and examining their cost effectiveness, in addition to their safety and efficacy. These and other similar developments could significantly limit the degree of market acceptance of ivonescimab or any of our other product candidates that receive marketing approval.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be successful in commercializing a product candidate if and when such product candidates are approved.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have a sales or marketing infrastructure and have no experience as a company in the sale or marketing of pharmaceutical products, although certain employees do have experience in the sale and marketing of pharmaceutical products. To achieve commercial success for any approved product, we must either develop a sales and marketing organization or outsource these functions to third parties. If ivonescimab receives marketing approval, we may seek commercialization partners in some parts of the Licensed Territory. There are risks involved with establishing our own sales and marketing capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time-consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may inhibit our efforts to commercialize our products on our own include:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability of sales personnel to obtain access to or persuade adequate numbers of physicians to prescribe any future products;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen costs and expenses associated with creating an independent sales and marketing organization.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we enter into arrangements with third parties to perform sales and marketing services, our product revenues or the profitability of these product revenues to us are likely to be lower than if we were to market and sell any products that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and market our product candidates or may be unable to do so on terms that are acceptable to us. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biologics, such as ivonescimab, carry unique risks and uncertainties, which could have a negative impact on our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful development, manufacturing and sale of biologics is a long, expensive and uncertain process. There are unique risks and uncertainties with biologics. For example, access to and supply of necessary biological materials, such as cell lines, may be limited and governmental regulations restrict access to and regulate the transport and use of such materials. In addition, the development, manufacturing and sale of biologics is subject to regulations that are often more complex and extensive than the regulations applicable to other pharmaceutical products. Manufacturing biologic, especially in large quantities, is often complex and may require the use of innovative technologies. Such manufacturing also requires facilities specifically designed and validated for this purpose and sophisticated quality assurance and quality control procedures. Biologics are also frequently costly to manufacture. Failure to successfully, develop, manufacture and sell ivonescimab could adversely affect our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources to pursue a particular product candidate and fail to capitalize on product candidates that may be more profitable or for which there is a greater likelihood of success.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding our large investment to date and anticipated future expenditures in proprietary technologies, we have not yet developed, and may never successfully develop, any marketed drugs. As a result of pursuing the development of product candidates using our proprietary technologies, we may fail to develop product candidates or address indications based on other scientific approaches that may offer greater commercial potential or for which there is a greater likelihood of success. Research programs to identify new product candidates require substantial technical, financial and human resources. These research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Financial and Intellectual Property Dependencies on Third Parties</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on our relationship with, and the comprehensiveness of the intellectual property licensed from, Akeso, and termination of the License Agreement, or issues related to intellectual property could have a material adverse effect on our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on the know-how and other intellectual property licensed from Akeso through the License Agreement for the development and, if approved, commercialization of the bispecific antibody, ivonescimab. If the License Agreement is terminated, or found to be unenforceable, it could result in the loss of significant rights and could harm our ability to commercialize ivonescimab.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The License Agreement imposes certain obligations on us, including obligations to use diligent efforts to meet development thresholds, funding requirements, payment obligations, and commercialization. If we are unable to meet our obligations, some or all of our rights under the License Agreement may be restricted or terminated.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary product candidate, ivonescimab, is subject to the License Agreement from Akeso, which is revocable in certain circumstances, including in the event we do not achieve certain payment deadlines. Without the patents under the License Agreement, we will not be able to continue to develop ivonescimab.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The License Agreement may be terminated by Akeso in the event of a material breach by Summit or if we default in the performance of any of our material obligations under the License Agreement, and such default continues for 90 days, or with respect to any breach of any undisputed payment obligations, for 60 days, or with respect to any breach of a supply requirement, for 30 days after written notice thereof. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the ability of Summit to realize the full potential of the License Agreement may be severely limited by factors involving intellectual property rights including:  </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether and to what extent our technology and processes infringe on intellectual property rights of other third parties that are not subject to the License Agreement;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether third parties are entitled to compensation or equitable relief, such as an injunction, for our use of intellectual property without their authorization;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our right to sublicense patent and other rights to third parties under collaborative development relationships;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our compliance with our obligations with respect to the use of the licensed technology in relation to our development and commercialization of product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ownership of specific intellectual property; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact on payments and costs associated with commercialization if there is blocking intellectual property in or costs associated with prosecution, maintenance and enforcement under the Akeso License Agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These issues, if they arise, could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, increase what we believe to be our financial or other obligations under the relevant agreement, or increase our costs to develop, manufacture and commercialize products under the License Agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will be reliant on Akeso for knowledge transfer relating to manufacturing of our product candidate. The loss of any of the knowledge transferred relating to ivonescimab from Akeso may cause us to incur additional transition costs or result in delays in the manufacturing and delivery of the ivonescimab product candidate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into the License Agreement and will enter into a Supply Agreement with Akeso for manufacturing of drug substance and or drug product that we will rely on to be used in our product candidate, and the termination or Akeso&#8217;s breach of these agreements could have a material adverse effect on our business. Akeso&#8217;s drug substance and/or drug product may not comply with FDA quality requirements and/or have sufficient stability for commercialization which may require additional investment  and delay our development, approval and commercialization plans</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, failure of Akeso to adequately transfer knowledge to Summit to produce ivonescimab could have a material adverse effect on our business. Manufacturing of biological compounds is inherently complex and establishing new manufacturing relationships with a third party manufacturer may take longer, resulting in higher costs and potential inventory issues. Manufacturing processes may use materials which Summit may not be able to secure, requiring Summit to have to develop alternative processes and delay manufacturing. The product may not comply with the FDA quality requirements and/or have sufficient stability for commercialization, which may require additional manufacturing development and delays. As Summit is relying initially on supply from Akeso, any delays in obtaining import or export licenses may delay development.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on collaborations with third parties for the development and commercialization of some of our product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may enter into third-party collaborations for the development and commercialization of ivonescimab. Additionally, we may seek third-party collaborators for development and commercialization of any other product candidates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our likely future collaborators for any marketing, distribution, development, licensing or broader collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. Under our license and commercialization agreements we have, and under any such arrangements we enter into with any third parties in the future we will likely have, limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities and efforts to successfully perform the functions assigned to them in these arrangements.</span></div><div><span><br/></span></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current collaborations pose, and any future collaboration likely will pose, numerous risks to us, including the following:</span></div><div style="margin-bottom:2pt"><span><br/></span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations and may not perform their obligations as expected;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may de-emphasize or not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#8217; strategic focus, including as a result of a sale or disposition of a business unit or development function, or available funding, or external factors such as an acquisition that diverts resources or creates competing priorities;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a collaborator with marketing and distribution rights to multiple products may not commit sufficient resources to the marketing and distribution of our product relative to other products;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes may arise between the collaborator and us as to the ownership of intellectual property arising during the collaboration;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may grant exclusive rights to our collaborators, which would prevent us from collaborating with others;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our products or product candidates or that result in costly litigation or arbitration that diverts management attention and resources; and</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If a collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program could be delayed, diminished or terminated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of third parties, including Akeso, to manufacture our product candidates may increase the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable time and cost, which could delay, prevent or impair our development or commercialization efforts.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate manufacturing facilities for the production of clinical or commercial supplies of our product candidates. We have limited personnel with experience in drug manufacturing and lack the resources and the capabilities to manufacture any of our product candidates on a clinical or commercial scale. We currently rely on third parties for supply of the active pharmaceutical ingredients (API), drug substance or drug product, in our product candidates. Our strategy is to outsource all manufacturing of our product candidates and products to third parties.</span></div><div><span><br/></span></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have supply agreements with Akeso for supply of ivonescimab for use in clinical trials as well as for commercial supply. We have agreements with third-party manufacturers for development, validation and manufacturing of ivonescimab to secure the long-term clinical or commercial supply of our product candidates. We are in the process of setting up agreements with third party manufacturers for the long-term clinical and commercial supply of ivonescimab.  We may be unable to conclude agreements for commercial supply with third-party manufacturers, or may be unable to do so on acceptable terms The third-party manufacturers may not successfully carry out their contractual duties or obligations, the occurrence of which could substantially increase our costs and limit our supply of such product candidates. The demand for third-party manufacturer&#8217;s services is very high, and such manufacturers could be subject to market transactions including mergers, acquisitions and other market consolidation transactions that limit their ability to provide products and services to us thereby increasing the time and cost it could take us to manufacture our product. </span></div><div style="margin-bottom:2pt"><span><br/></span></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are able to establish and maintain arrangements with third-party manufacturers, reliance on third-party manufacturers, including Akeso, entails additional risks, including:</span></div><div style="margin-bottom:2pt"><span><br/></span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reliance on the third party for regulatory compliance and quality assurance;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the possible breach of the manufacturing agreement by the third party;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the possible diversion of manufacturing capacity to other customers by the third party;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the possible misappropriation of our proprietary information, including our trade secrets and know-how; and</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the possible termination or non-renewal of the agreement by the third party at a time that is costly or inconvenient for us.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party manufacturers, including Akeso, may not be able to comply with current good manufacturing practice (cGMP), regulations or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, including Akeso,, to comply with applicable regulations could result in sanctions being imposed on us, </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in order to conduct late-stage clinical trials of our product candidates, we will need to have them manufactured in large quantities. Our third-party manufacturers, including Akeso, may be unable to successfully increase the manufacturing capacity for any of our product candidates in a timely or cost-effective manner, or at all.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, if our third-party manufacturers, including Akeso, are unable to successfully scale up the manufacture of our product candidates in sufficient quality and quantity, the development, testing and clinical trials of that product candidate may be delayed or infeasible, and regulatory approval or commercial launch of that product candidate may be delayed or not obtained, which could significantly harm our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the third parties, including Akeso, that we engage to manufacture product for our preclinical tests and clinical trials should cease to continue to do so for any reason, including due to the novel coronavirus or another outbreak, we likely would experience delays in advancing these clinical trials while we identify and qualify replacement suppliers, and we may be unable to obtain replacement supplies on terms that are favorable to us. In addition, if we are not able to obtain adequate supplies of our product candidates or the drug substances used to manufacture them, it will be more difficult for us to develop our product candidates and compete effectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to manufacture our product candidates. If our third party manufacturers divert their capacity and/or supply of materials needed for our product candidates, our ability to complete our clinical trials or eventually bring our product candidates to market may be compromised. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party manufacturers for the capability to manufacture ivonescimab and/or other product candidates. Large pharmaceutical companies with greater resources, either through acquisitions, market consolidation or otherwise, may be able to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obtain privileged access to manufacturing capacity and/or supply of material needed for the manufacture of ivonescimab or other similar competing drugs.  If our competitors are able to use their resources to secure preferential access to the supply capacity of third party manufacturers, or if third party manufacturers elect to terminate their contracts with us in favor of exclusive contracts with other larger pharmaceutical companies, our ability to obtain a supply of ivonescimab or any other future product candidates may be impacted resulting in significant delays and higher costs for development and commercialization of our products. We may not be able to complete our clinical trials or market our products at scale without stable partnerships with third party manufacturers who produce ivonescimab or other drug compounds necessary for our product candidates. Shifting manufacturing relationship to another third-party manufacturer takes significant time and resources, and could delay development and commercialization of our product.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to conduct our clinical trials and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such clinical trials.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not independently conduct clinical trials for our product candidates. We rely on third parties, such as contract research organizations, clinical data management organizations, medical institutions and clinical investigators, to perform this function. Any of these third parties may terminate their engagements with us at any time. If we need to enter into alternative arrangements, it would delay our product development activities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on these third parties for clinical development activities reduces our control over these activities but does not relieve us of our responsibilities. For example, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the clinical trial. Moreover, the FDA requires us to comply with standards, commonly referred to as Good Clinical Practice (GCP), for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity of data and confidentiality of clinical trial participants are protected. The European Medicines Agency (EMA) and Pharmaceutical and Medical Devices agency (PDMA) impose similar requirements on us for products that are the subject of clinical trials in the European Union, including the United Kingdom, and Japan.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, third parties that we rely on for our clinical development activities may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. Our product development costs will increase if we experience delays in testing or obtaining marketing approvals.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or marketing approval of our product candidates or commercialization of our products, producing additional losses and depriving us of potential product revenue.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are not able to establish additional collaborations, we may have to alter our development and commercialization plans.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. For some of our product candidates, we may decide to collaborate further with pharmaceutical and biotechnology companies for the development and potential commercialization of those product candidates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge; and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. We may also be restricted under future license agreements from entering into agreements on certain terms with potential collaborators. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators and changes to the strategies of the combined company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Industry and Market</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, which may result in others discovering, developing or commercializing products before us or more successfully than we do.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and commercialization of new drug products is highly competitive. We face competition with respect to our current product candidates and any products we may seek to develop or commercialize whether ourselves or through third-party partners, in the future from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several pharmaceutical and biotechnology companies have established themselves in the market for the treatment of non-small cell lung cancer (&#8220;NSCLC&#8221;), and several additional companies are developing products for the treatment of NSCLC. Currently, the most commonly used treatments for NSCLC are several immuno-oncology drugs and chemotherapies, administered either as monotherapy or in combination with other approved therapeutics. NSCLC treatment regimens vary due to several factors, including genetic mutations and progression of disease. Several medications have been approved by FDA for these treatments, including, but not limited to pembrolizumab, atezolizumab, nivolumab, durvalumab and ipilmumab. There are anti-angiogenic therapies which are approved for the treatment of certain lung cancers, including bevacizumab and ramucirumab. In addition, there are several targeted therapies that have also been approved, including, but not limited to, osimertinib, adagrasib, and alectinib. Beyond currently approved therapies, several potential therapeutics are in various stages of development and clinical trials for the treatment of NSCLC, including late-stage candidates which have recently released Phase III clinical trial data in </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NSCLC in 2023, such as Daiichi Sankyo and AstraZeneca&#8217;s datopotamab deruxetecan and Johnson &amp; Johnson&#8217;s amivantamab and lazertinib. Finally, there are candidates in various stages of ongoing clinical trials for NSCLC, including Daiichi Sankyo and Merck with patritumab deruxtecan and AstraZeneca&#8217;s volrustomig, each currently enrolling in Phase III clinical trials.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are more effective, safer, have fewer or less severe side effects, are approved for broader indications or patient populations, or are more convenient or less expensive than any products that we develop and commercialize. Our competitors may also obtain marketing approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that many competitors are attempting to develop therapeutics for the target indications of our product candidates, including academic institutions, government agencies, public and private research organizations, large pharmaceutical companies and smaller more focused companies.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors may have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining approvals from regulatory authorities and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to or necessary for our programs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inadequate funding for the FDA, the SEC, and other government agencies, including from government shutdowns, or other disruptions to these agencies&#8217; operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, the ability to hire and retain key personnel and the acceptance of user fees payments, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. If a prolonged government shutdown occurs, if the FDA is required to furlough review staff or necessary employees, or if the agency operations are otherwise impacted, it could significantly affect the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our ability to successfully develop and commercialize ivonescimab or any other product candidate in our pipeline. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may complete a future acquisition that may not achieve intended results or could increase the number of our outstanding shares or amount of outstanding debt or result in a change of control. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the License Agreement and the transactions contemplated thereby, we may pursue business development opportunities to expand or enhance our pipeline of drug candidates, including without limitation, through potential acquisitions of and/or collaborations with other entities. Any such transaction could happen at any time, could be material to our business and could take any number of forms, including, for example, an acquisition, merger or a collaboration with other entities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evaluating potential transactions and integrating completed ones may divert the attention of our management from ordinary operating matters. The success of these potential transactions will depend, in part, on our ability to realize the anticipated growth opportunities through the successful integration of the businesses we acquire with our existing business, as well as the success of the underlying business or intellectual property that we acquire or otherwise obtain rights to. Even if we are successful in integrating the acquired businesses, these integrations may not result in the realization of the full benefit of any anticipated growth opportunities or these benefits may not be realized within the expected time frames. In addition, acquired businesses may have unanticipated liabilities or contingencies.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we complete an acquisition, investment or other strategic transaction, we may require additional financing that could result in an increase in the number of our outstanding shares or the aggregate amount of our debt.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal, Tax, Regulatory, and Compliance Risks</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we are able to commercialize ivonescimab or any other product candidate that we develop, the product may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which would harm our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug products vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to commercialize ivonescimab or any other product candidate successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. and E.U. healthcare industries and elsewhere is cost containment.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be sure that coverage and reimbursement will be available for ivonescimab or any other product that we commercialize and, if coverage and reimbursement are available, the level of reimbursement. Reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. In addition, third-party payors are likely to impose strict requirements for reimbursement of a higher priced drug. If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the applicable regulatory authority. Moreover, eligibility for coverage and reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, intellectual property, manufacture, sale and distribution expenses. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs, and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. In the United States, third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. In the European Union, reference pricing systems and other measures may lead to cost containment and reduced prices. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governments outside the United States tend to impose strict price controls, which may adversely affect our revenues, if any.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some countries, particularly the member states of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states and parallel distribution, </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries, we may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our product candidate to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on prices or reimbursement levels within the country of publication and other countries. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be adversely affected.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is subject to the risks associated with doing business in China. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our reliance on Akeso, located in China, our results of operations, financial condition, and prospects are subject to a significant degree to economic, political, and legal developments in China including government control over capital investments or changes in tax regulations that are applicable to us. China&#8217;s economy differs from the economies of most developed countries in many respects, including with respect to the amount of government involvement, level of development, growth rate and control of foreign exchange, and allocation of resources. Since we rely on an entity located in China, our business is subject to the risks associated with doing business in China, including:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse political and economic conditions, particularly those potentially negatively affecting the trade relationship between the United States and China;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trade protection measures, such as tariff increases, and import and export licensing and control requirements;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potentially negative consequences from changes in tax laws;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties associated with the Chinese legal system, including increased costs and uncertainties associated with enforcing contractual obligations in China;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">historically lower protection of intellectual property rights;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requirements relating to China&#8217;s data security rules and regulations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requirements relating to China personal information protection laws; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes and volatility in currency exchange rates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unexpected or unfavorable changes in regulatory requirements; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties in managing foreign relationships and operations generally</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S.-China trade relations may adversely impact our supply chain operations and business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. and Chinese governments have taken certain actions that change trade policies, including tariffs that affect certain products which are manufactured in China and mutual exchange of certain types of data. Due to our collaboration with Akeso, we are reliant on collaborating with a company with significant operations in China. It is unknown whether and to what extent new tariffs, laws or regulations will be adopted that increase the cost or feasibility of importing and/or exporting products, components and information from China to the United States and vice versa. Further, the effect of any such new tariffs or actions on our industry and customers is unknown and difficult to predict. As additional new tariffs, legislation and/or regulations are implemented, or if existing trade agreements are renegotiated or if China or other affected countries take retaliatory trade actions, such changes could have a material adverse effect on our clinical development plans, business, financial condition, results of operations or cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk if we commercially sell any products that we may develop. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></div><div><span><br/></span></div><div style="margin-top:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced resources of our management to pursue our business strategy;</span></div><div style="margin-top:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for any product candidates or products that we may develop;</span></div><div style="margin-top:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injury to our reputation and significant negative media attention;</span></div><div style="margin-top:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants;</span></div><div style="margin-top:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant costs to defend the related litigation;</span></div><div style="margin-top:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to clinical trial participants or patients;</span></div><div style="margin-top:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue;</span></div><div style="margin-top:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased insurance costs; and</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to commercialize any products that we may develop.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The insurance policies covering our clinical trials are subject to a per claim deductible. The amount of insurance that we currently hold may not be adequate to cover all liabilities that we may incur. We will need to increase our insurance coverage when and if we begin commercializing ivonescimab or any other product candidate that receives marketing approval. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations currently, and may in the future, involve the use of hazardous and flammable materials, including chemicals and medical and biological materials, and produce hazardous waste products. Even if we contract with third parties for the disposal of these materials and wastes, we cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials or disposal of hazardous wastes, we could be held liable for any resulting damages, and any liability could exceed our resources.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent and potential future changes to U.S. and non-U.S. tax laws could materially adversely affect our company and holders of our shares of common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to predict what tax changes may be enacted in the future or what effect such changes would have on our business, but such changes could affect our effective tax rates in countries where we have operations and could have an adverse effect on our overall tax position in the future, along with increasing the complexity, burden and cost of tax compliance.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recent changes in tax law may adversely affect our business or financial condition. On December 22, 2017, the U.S. government enacted the Tax Cuts and Jobs Act, or the TCJA, which significantly reformed the U.S. Internal Revenue Code of 1986, as amended, or the Code. The TCJA, among other things, contained significant changes to corporate taxation, including the limitation of the tax deduction for net interest expense to 30% of adjusted taxable income (except for certain small businesses), the limitation of the deduction for net operating losses arising in taxable years beginning after December 31, 2017 to 80% of current year taxable income, the allowance of net operating losses arising in taxable years beginning after December 31, 2017 to be carried forward indefinitely, the allowance of immediate deductions for certain new investments instead of deductions for depreciation expense over time, and the modification or repeal of many business deductions and credits. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning with costs incurred in 2022, the TCJA also eliminated the option to deduct research and development expenditures currently and requires taxpayers to capitalize and amortize them over five or fifteen years pursuant to Internal Revenue Code Section 174. This does not increase our effective tax rate or our cash tax payable in 2022 or 2023. However, if the requirement to capitalize Section 174 expenditures is not modified, it may also impact our effective tax rate and our cash tax liability in future years. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United Kingdom</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recent announcements of changes in the UK R&amp;D regime are likely to impact the level of cash benefit that the Company will be able to receive in respect of the R&amp;D activity. As a result of a reduction in rates applied in the SME regime, the cash credit that the Company will be able to obtain is likely to reduce if the qualified spending remains consistent. This will be partly offset by an increase in the RDEC regime. In addition, there is a refocus of relief towards UK activity and therefore costs outside the </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UK are expected to be restricted going forward with further changes anticipated following a government consultation being launched with the intention of merging the SME and RDEC schemes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our U.S. federal, U.S. state and foreign net operating losses and other tax attributes may be limited. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to use our U.S. federal, U.S. state and foreign net operating losses to offset potential future taxable income and related income taxes that would otherwise be due is dependent upon our generation of future taxable income, and we cannot predict with certainty when, or whether, we will generate sufficient taxable income to use all of our net operating losses. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unused U.S. federal tax losses for tax years beginning before January 1, 2018 and prior tax years will carry forward to offset future taxable income, if any, until such unused losses expire. Unused U.S. federal tax losses generated for tax year beginning after December 31, 2017 will not expire and may be carried forward indefinitely, and generally may not be carried back to prior taxable years, except that, under the CARES Act, net operating losses generated in 2018, 2019 and 2020 may be carried back to each of the five tax years preceding the tax years of such losses. Additionally, for taxable years beginning after December 31, 2020, the deductibility of such U.S. federal net operating losses is limited to 80% of our taxable income in any future taxable year. In addition, both our current and our future unused U.S. federal and state tax losses and unused U.S. federal and state research and development tax credits may be subject to limitation under Sections 382 and 383 of the Internal Revenue Code (&#8220;IRC&#8221; or &#8220;the Code&#8221;) of 1986, as amended, if we undergo an &#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a rolling three-year period. We may have experienced such ownership changes in the past, and we may experience ownership changes in the future as a result of shifts in our stock ownership, some of which are outside our control. As of December 31, 2023 and 2022, we reported U.S. federal and state gross operating loss carryforwards of approximately $53.4 million and $18.9 million, respectively, and federal research and development tax credit carryforwards of $5.3 million and $1.7 million, respectively. Our ability to utilize those net operating loss carryforwards could be limited by an &#8220;ownership change&#8221; as described above, which could result in increased tax liability to us. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, we reported foreign gross operating loss carryforwards of $194.5 million. Our ability to utilize those net operating loss carryforwards are dependent upon our generation of future taxable income.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Laws and regulations affecting government contracts, such as BARDA and CARB-X , make it more costly and difficult for us to successfully conduct our business. Failure to comply with these laws and regulations could result in significant civil and criminal penalties and adversely affect our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">W</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e must comply during the term of such government contracts and upon expiration/termination of such contracts, as to continuing obligations, with numerous laws and regulations. These laws, regulations and obligations include, for example, the Federal Acquisition Regulation, compliance regulations, business ethics and public integrity obligations, export and import laws and regulations, etc. Additionally, government agencies routinely audit and investigate government contractors for compliance with the applicable laws and standards. If an audit uncovers improper or illegal activities, we may be subject to civil and criminal penalties including fines, debarment and exclusion from government funding and administrative sanctions, such as long-term monitoring arrangements and exclusion from regulatory approvals. In addition, we could suffer serious reputational harm if allegations of impropriety were made against us, which could jeopardize our other research programs, deter research institutions from engaging with us, and cause our stock price to decrease.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we complete the necessary clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization of some or all of our product candidates. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize our product candidates, and our ability to generate revenue will be materially impaired.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates, including ivonescimab, and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA and by comparable authorities in other countries. Failure to obtain marketing approval for a product candidate will prevent us or our collaborators from commercializing the product candidate. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have only limited experience in filing and supporting the applications necessary to obtain marketing approvals for product candidates and expect to rely on third-party contract research organizations to assist us in this process. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by, the regulatory authorities. Regulatory authorities may determine that ivonescimab or any of our other product candidates are not effective or only moderately effective, or have undesirable or unintended side effects, toxicities, safety profiles or other characteristics that preclude us from obtaining marketing approval or that prevent or limit commercial use.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of obtaining marketing approvals is expensive, may take many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable. If we experience delays in obtaining approval or if we fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenues will be materially impaired.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also are required to register ongoing clinical trials and post the results of completed clinical trials on a U.S. government-sponsored database, www.ClinicalTrials.gov, within certain timeframes. Failure to comply would violate federal requirements and could result in fines and/or civil and criminal sanctions, which would delay the regulatory approval process and result in adverse publicity. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to obtain marketing approval in foreign jurisdictions would prevent our product candidates from being marketed in these other jurisdictions, and any approval we are granted for our product candidates in the United States and Europe would not assure approval of our product candidates in other jurisdictions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market and sell ivonescimab and our other product candidates in foreign jurisdictions, we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements in those jurisdictions. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ from that required to obtain FDA or EMA approval. The regulatory approval process outside the United States and Europe generally includes all of the risks associated with obtaining FDA and EMA approval. In addition, some countries outside the United States and Europe require approval of the sales price of a drug before it can be marketed. In many countries, separate procedures must be followed to obtain reimbursement. We may not obtain marketing, pricing or reimbursement approvals outside the United States and Europe on a timely basis, if at all. Approval by the FDA or the EMA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States and Europe does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA or the EMA. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our products in any market. Marketing approvals in countries outside the United States and Europe do not ensure pricing approvals in those countries or in any other countries, and marketing approvals and pricing approvals do not ensure that reimbursement will be obtained.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to obtain and maintain conditional marketing authorizations in the European Union is limited to specific circumstances and subject to several conditions and obligations. A failure to renew any conditional approval that we obtain prior to full approval for the applicable indication would prevent us from continuing to market our products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conditional marketing authorizations based on incomplete clinical data may be granted for a limited number of listed medicinal products for human use, including products designated as orphan medicinal products under E.U. law, if (1) the risk-benefit balance of the product is positive, (2) it is likely that the applicant will be in a position to provide the required comprehensive clinical trial data, (3) unmet medical needs will be fulfilled and (4) the benefit to public health of the immediate availability on the market of the medicinal product outweighs the risk inherent in the fact that additional data are still required. Specific obligations, including with respect to the completion of ongoing or new studies, and with respect to the collection of pharmacovigilance data, may be specified in the conditional marketing authorization. Conditional marketing authorizations are valid for one year and may be renewed annually, if the risk-benefit balance remains positive, and after an assessment of the need for additional or modified conditions. Even if we, or a third-party collaborator, obtain conditional approval for ivonescimab, or any other product candidate, we or they may not be able to renew such conditional approval.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain marketing approvals for our product candidates, the terms of approvals and ongoing regulation of our products may limit how we manufacture and market our products and compliance with such requirements may involve substantial resources, which could materially impair our ability to generate revenue.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if marketing approval of a product candidate is granted, an approved product and its manufacturer and marketer are subject to ongoing review and extensive regulation, including the requirement to implement a risk evaluation and mitigation strategy or to conduct costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the product. We and our collaborators must also comply with requirements concerning advertising and promotion for any of our product candidates for which we obtain marketing approval. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved labeling. Thus, neither we nor our collaborators will be able to promote any products we develop for indications or uses for which they are not approved. In addition, manufacturers of approved products and those manufacturers&#8217; facilities are required to ensure that quality control and manufacturing procedures conform to cGMP, which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation and reporting requirements. We and our contract manufacturers could be subject to periodic unannounced inspections by the FDA to monitor and ensure compliance with cGMP.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, assuming we receive marketing approval for one or more of our product candidates, we and our contract manufacturers will continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance and quality control. If we are not able to comply with post-approval regulatory requirements, we could have the marketing approvals for our products withdrawn by regulatory authorities and our ability to market any future products could be limited, which could adversely affect our ability to achieve or sustain profitability. Thus, the cost of compliance with post-approval regulations may have a negative effect on our operating results and financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any product candidate for which we obtain marketing approval will be subject to strict enforcement of post-marketing requirements and we could be subject to substantial penalties, including withdrawal of our product from the market, if we fail to comply with all regulatory requirements or if we experience unanticipated problems with our products, when and if any of them are approved.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such product, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include, but are not limited to, restrictions governing promotion of an approved product, submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, and requirements regarding the distribution of samples to physicians and recordkeeping.</span></div><div><span><br/></span></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other federal and state agencies, including the Department of Justice, or DOJ, closely regulate compliance with all requirements governing prescription drug products, including requirements pertaining to marketing and promotion of drugs in accordance with the provisions of the approved labeling and manufacturing of products in accordance with cGMP requirements. The FDA and DOJ impose stringent restrictions on manufacturers&#8217; communications regarding off-label use, and if we do not market our products for their approved indications, we may be subject to enforcement action for off-label marketing. Violations of such requirements may lead to investigations alleging violations of the Food, Drug and Cosmetic Act and other statutes, including the False Claims Act and other federal and state health care fraud and abuse laws as well as state consumer protection laws. Our failure to comply with all regulatory requirements, and later discovery of previously unknown adverse events or other problems with our products, manufacturers or manufacturing processes, may yield various results, including:</span></div><div style="margin-bottom:2pt"><span><br/></span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">litigation involving patients taking our products;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on such products, manufacturers or manufacturing processes;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the labeling or marketing of a product;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on product distribution or use;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requirements to conduct post-marketing studies or clinical trials;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">warning or untitled letters;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of the products from the market;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal to approve pending applications or supplements to approved applications that we submit;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recall of products;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, restitution or disgorgement of profits or revenues;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension or withdrawal of marketing approvals;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">damage to relationships with any potential collaborators;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unfavorable press coverage and damage to our reputation;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal to permit the import or export of our products;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure; or</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-compliance by us or any future collaborator with regulatory requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with regulatory requirements regarding the protection of personal information can also lead to significant penalties and sanctions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-compliance with E.U. requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with the European Union&#8217;s requirements regarding the protection of personal information can also lead to significant penalties and sanctions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with customers, healthcare providers and professionals and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers, physicians and third-party payors play a primary role in the recommendation and prescription of any product candidates, including ivonescimab, for which we obtain marketing approval. Our future arrangements with customers, healthcare providers and professionals and third-party payors may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our products for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations, include, and are not limited to, the following:</span></div><div style="margin-bottom:2pt"><span><br/></span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The federal healthcare anti-kickback statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federally funded healthcare programs such as Medicare and Medicaid. This statute has been broadly interpreted to apply to manufacturer arrangements with prescribers, purchasers and formulary managers, among others. Several other countries, including the United Kingdom, have enacted similar anti-kickback, fraud and abuse, and healthcare laws and regulations.</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The federal False Claims Act imposes civil penalties, including civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. The government and qui tam relators have brought False Claims Act actions against pharmaceutical companies on the theory that their practices have caused false claims to be submitted to the government. There is also a separate false claims provision imposing criminal penalties.</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program and also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information.</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA also imposes criminal liability for knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services.</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The federal Physician Sunshine Act requirements under the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, referred to together as the Affordable Care Act, require manufacturers of drugs, devices, biologics and medical supplies to report to the Department of Health and Human Services information related to payments and other transfers of value made to or at the request of covered recipients, such as physicians and teaching hospitals, and physician ownership and investment interests in such manufacturers. Payments made to physicians and research institutions for clinical trials are included within the ambit of this law. Failure to submit timely, accurate and required information for all payments, transfers of value and ownership or investment interests may result in civil monetary penalties.</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Analogous state laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, and some state laws require pharmaceutical companies to comply with the </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:2pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures. Additionally, some state and local laws require the registration of pharmaceutical sales representatives in the jurisdiction.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. Exclusion, suspension and debarment from government funded healthcare programs would significantly impact our ability to commercialize, sell or distribute any drug. If any of the physicians or other providers or entities with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current and future legislation may increase the difficulty and cost for us and any future collaborators to obtain marketing approval of and commercialize our product candidates and affect the prices we, or they, may obtain.</span></div><div><span><br/></span></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and some foreign jurisdictions, there have been and continue to be a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability, or the ability of any future collaborators, to profitably sell any products for which we, or they, obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or any future collaborators, may receive for any approved products.</span></div><div style="margin-bottom:2pt"><span><br/></span></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that recently enacted healthcare reforms, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product and/or the level of reimbursement physicians receive for administering any approved product we might bring to market. Reductions in reimbursement levels may negatively impact the prices we receive or the frequency with which our products are prescribed or administered. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The costs of prescription pharmaceuticals has also been the subject of considerable discussion in the United States. To date, there have been several U.S. congressional inquiries and proposed and enacted state and federal legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More recently, in August 2022, President Biden signed into law the Inflation Reduction Act of 2022 (the &#8220;IRA&#8221;). Among other things, the IRA has multiple provisions that may impact the prices of drug products that are both sold into the Medicare program and throughout the United States. Starting in 2023, a manufacturer of a drug or biological product covered by Medicare Parts B or D must pay a rebate to the federal government if the drug product&#8217;s price increases faster than the rate of inflation. This calculation is made on a drug product by drug product basis and the amount of the rebate owed to the federal government is directly dependent on the volume of a drug product that is paid for by Medicare Parts B or D. Additionally, starting in payment year 2026, the U.S. Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;), will negotiate drug prices annually for a select number of single source Part D drugs without generic or biosimilar competition. CMS will also negotiate drug prices for a select number of Part B drugs starting for payment year 2028. If a drug product is selected by CMS for negotiation, it is expected that the revenue generated from such drug will decrease. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislative and regulatory proposals have also been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us and any future collaborators to more stringent product labeling and post-marketing testing and other requirements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, similar political, economic and regulatory developments may affect our ability to profitably commercialize our products. In addition to continuing pressure on prices and cost containment measures, legislative developments at the European Union or member state level may result in significant additional requirements or obstacles that may increase our operating costs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures and legal expenses, which could adversely affect our business, results of operations and financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are subject to anti-corruption laws, including the U.S. Foreign Corrupt Practices Act, or FCPA, the U.K. Bribery Act 2010, or Bribery Act, and other anti-corruption laws that apply in countries where we do business and may do business in the future. The FCPA, Bribery Act and these other laws generally prohibit us, our officers, and our employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. We may in the future operate in jurisdictions that pose a high risk of potential FCPA or Bribery Act violations, and we may participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under the FCPA, Bribery Act or local anti-corruption laws. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the United States and the United Kingdom, and authorities in the European Union, including applicable export control regulations, economic sanctions on countries and persons, customs requirements and currency exchange regulations, collectively referred to as the Trade Control laws.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the FCPA, the Bribery Act or other legal requirements, including Trade Control laws. If we are not in compliance with the FCPA, the Bribery Act and other anti-corruption laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and liquidity. Likewise, any investigation of any potential violations of the FCPA, the Bribery Act, other anti-corruption laws or Trade Control laws by U.S., U.K. or other authorities could also have an adverse impact on our reputation, our business, results of operations and financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Committee on Foreign Investment in the United States (&#8220;CFIUS&#8221;) or other regulatory agencies may modify, delay or prevent the transactions contemplated by the License Agreement. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee on Foreign Investment in the United States (&#8220;CFIUS&#8221;) has authority to review direct or indirect foreign investments in U.S. companies. Among other things, CFIUS is empowered to require certain foreign investors to make mandatory filings, to charge filing fees related to such filings and to self-initiate national security reviews of foreign direct and indirect investments in U.S. companies if the parties to that investment choose not to file voluntarily. In the case that CFIUS determines an investment to be a threat to national security, CFIUS has the power to unwind or place restrictions on the investment. Whether CFIUS has jurisdiction to review an acquisition or investment transaction depends on, among other factors, the nature and structure of the transaction, including the level of beneficial ownership interest and the nature of any information or governance rights involved. For example, investments that result in &#8220;control&#8221; of a U.S. business by a foreign person always are subject to CFIUS jurisdiction. CFIUS&#8217;s expanded jurisdiction under the Foreign Investment Risk Review Modernization Act of 2018 and implementing regulations that became effective on February 13, 2020 further includes investments that do not result in control of a U.S. business by a foreign person but afford certain foreign investors certain </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">information or governance rights in a U.S. business that has a nexus to &#8220;critical technologies,&#8221; &#8220;critical infrastructure&#8221; and/or &#8220;sensitive personal data&#8221;.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that no mandatory filing was required in connection with the License Agreement but we have not yet determined whether we will make a voluntary filing. CFIUS may decide to modify or delay our proposed business combination, impose conditions with respect to such business combination, request the President of the United States to order us to divest all or a portion of the assets we acquired without first obtaining CFIUS approval or prohibit the License Agreement entirely. If it is determined that a mandatory filing was required to be made, it is possible that a material penalty could be assessed against the Company.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Environmental, social and governance matters may impact our business and reputation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Governmental authorities, non-governmental organizations, customers, investors, external stakeholders and employees are increasingly sensitive to environmental, social and governance, or ESG, concerns, such as diversity and inclusion, climate change, water use, recyclability or recoverability of packaging, and plastic waste. This focus on ESG concerns may lead to new requirements that could result in increased costs associated with developing, manufacturing and distributing our products. Our ability to compete could also be affected by changing customer preferences and requirements, such as growing demand for more environmentally friendly products, packaging or supplier practices, or by failure to meet such customer expectations or demand. We risk negative stockholder reaction, including from proxy advisory services, as well as damage to our brand and reputation, if we do not act responsibly, or if we are perceived to not be acting responsibly in key ESG areas, including equitable access to medicines, product quality and safety, diversity and inclusion, environmental stewardship, support for local communities, corporate governance and transparency, and addressing human capital factors in our operations. If we do not meet the ESG expectations of our investors, customers and other stakeholders, we could experience reduced demand for our products, loss of customers, and other negative impacts on our business and results of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property, Cybersecurity and Data Privacy</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and maintain patent protection for our technology and product candidates, or if the scope of our patent protection is not sufficiently broad, our competitors could develop and commercialize technology and drug products similar or identical to ours, and our ability to successfully commercialize our technology and drug product candidates may be impaired.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our proprietary technology and products. We seek to protect our proprietary position by filing patent applications in the United States, in Europe and in certain additional foreign jurisdictions related to our novel technologies and product candidates that are important to our business. This process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, if we license technology or product candidates from third parties in the future, these license agreements may not permit us to control the preparation, filing and prosecution of patent applications, or to maintain or enforce the patents, covering the licensed technology or product candidates. These agreements could also give our licensors the right to enforce the licensed patents without our involvement, or to decide not to enforce the patents at all. Therefore, in these circumstances, these patents and applications may not be prosecuted or enforced in a manner consistent with the best interests of our business. For example, while  under the collaboration and license agreement with Akeso for  ivonescimab, we have the right, after a set period of time,  to take control of the  prosecution,  maintenance and enforcement of certain patent applications licensed under the agreement  in the Licensed Territory,  prosecution is subject to consultation and cooperation with Akeso, except with regard to patent extension. If the parties cannot align this could impact patentability of the licensed intellectual property. Additionally, as actions or statements during prosecution in other territories (i.e., the non-Licensed Territory) can impact the validity of any patent obtained in the Licensed Territory, Akeso prosecution of  its patent applications in the non-Licensed Territory, can have an impact on patent prosecution and validity of applications/patents that we are prosecuting, maintaining or enforcing in the Licensed Territory. Additionally, Akeso owned  patents and patent applications, non-exclusively licensed to Summit under the agreement, are under the control of Akeso, Akeso&#8217;s prosecution and/or licensing strategies with regard to these patents and/or patent  application  may impact our business. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patent laws in the United States and other countries may diminish the value of our patents, narrow the scope of our patent protection or make enforcement more difficult or uncertain.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws of foreign countries may not protect our patent rights to the same extent as the laws of the United States. For example, European patent law restricts the patentability of methods of treatment of the human body more than U.S. law does. In addition, for the foregoing reasons, we may not pursue or obtain patent protection in all major markets or may not obtain protection that enables us to prevent the entry of third parties into the market.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming the other requirements for patentability are met, currently, the first to file a patent application is generally entitled to the patent. However, prior to March 16, 2013, in the United States, the first to invent was entitled to the patent. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our U.S. patents or pending U.S. patent applications, or that we were the first to file for patent protection of such inventions outside the United States or, since March 16, 2013, within the United States.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we may be subject to a third party pre-issuance submission of prior art to the USPTO or become involved in opposition, derivation, reexamination, reissue, inter parties review, post grant review, interference proceedings or other patent office proceedings, court litigation or International Trade Commission proceedings, in the United States or elsewhere, challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation concerning our patent rights could reduce the scope of or prevent the enforceability of, or invalidate, our patent rights, allowing third parties to commercialize our technology or products, or equivalent or similar technology or products, and so to compete directly with us, without payment to us, or, where such proceedings involve third-party patents, result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened or narrowed by operation of any of the foregoing, such an event could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may have filed patent applications or received patents and may obtain additional patents and proprietary rights that block or compete with our patents. Resolving an intellectual property infringement claim can be costly and time consuming and may require Summit to design around the claims of patents covering our products that may have been issued by third parties or to obtain a license, either of which could cause us to incur additional expenses. Summit cannot guarantee that it would be able to obtain license agreements on commercially reasonable terms. A successful claim of patent or other intellectual property infringement could subject Summit to significant damages or an injunction preventing the manufacture, sale, or use of the affected product. We may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property. Even if our patent applications issue as patents, they may not issue in a form that will provide us with adequate protection to prevent competitors from competing with us or otherwise to provide us with any competitive advantage. Our competitors may be able to circumvent our owned or licensed patents by developing similar, improved or alternative technologies or products in a non-infringing manner.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other companies may attempt to circumvent any regulatory data protection or market exclusivity, such as orphan drug exclusivity in the United States, which we obtain under applicable legislation, which may require us to allocate significant resources to preventing such circumvention. Legal and regulatory developments in the European Union and elsewhere may also result in clinical trial data submitted as part of a marketing authorization application becoming publicly available. Such developments could enable other companies to use our clinical trial data to assist in their own product development and to obtain marketing authorizations in the European Union and in other jurisdictions. Such developments may also require us to allocate significant resources to prevent other companies from circumventing or violating our intellectual property rights. Our attempts to prevent third parties from circumventing our intellectual property and other rights may ultimately be unsuccessful. We may also fail to take the required actions or pay the necessary fees to maintain our patents. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Future changes in U.S. statutory or case law beyond our control could affect some or all of the foregoing possibilities. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. This could be the case even after giving effect to patent term extensions and data exclusivity provisions preventing third parties from relying on clinical trial data filed by us for regulatory approval in support of their own applications </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for such approval. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in lawsuits or other enforcement proceedings to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and potentially unsuccessful.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our patents, trademarks, copyrights or other intellectual property. To counter infringement or unauthorized use, we may be required to file claims, which can be expensive and time-consuming. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their intellectual property or that our patent and other intellectual property rights are invalid or unenforceable, including for anti-trust reasons. As a result, in a patent infringement proceeding, a court or administrative body may decide that a patent of ours is invalid or unenforceable, in whole or in part, or may construe the patent&#8217;s claims narrowly and so refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the competitor technology in question. Even if we are successful in a patent infringement action, the unsuccessful party may subsequently raise antitrust issues and bring a follow-on action thereon. Antitrust issues may also provide a bar to settlement or constrain the permissible settlement terms. Further, settlement agreements in the pharmaceutical sector are the subject of ongoing review by the antitrust authorities in the European Union.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell our product candidates and use our proprietary technologies, including our in-licensed drug candidate ivonescimab, without infringing the intellectual property and other proprietary rights of third parties. There is considerable intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our products and technology, including interference, derivation, inter parties review, reexamination, reissue or post-grant review proceedings before the USPTO. The risks of being involved in such litigation and office proceedings may also increase as our product candidates approach commercialization, and as we gain greater visibility as a publicly traded company in the United States. Third parties may assert infringement claims against us based on existing or future intellectual property rights and so restrict our freedom to operate. Third parties may also seek injunctive relief against us, whereby they would attempt to prevent us from practicing our technologies altogether pending outcome of any litigation against us. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are found to infringe a third party&#8217;s intellectual property rights, or in order to avoid or settle litigation, we could be required to obtain a license to enable us to continue developing and marketing our products and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies as are licensed to us, and could require us to make substantial payments. Absent a license, we could be forced, including by court order, to cease commercializing the infringing technology or product. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent or other intellectual property right. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties, or claims that we derived our inventions from another, could have a similar negative impact on our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims by third parties asserting that we or our employees have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our employees were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees do not use the proprietary or otherwise confidential information or know-how of others in their work for us, we may be subject to claims that we or these employees have without authorization used or disclosed intellectual property, including trade secrets or other proprietary or confidential information, of any such employee&#8217;s former employer. Litigation may be necessary to defend against these claims.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, while we typically require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us and agreeing to cooperate and assist us with securing and defending our intellectual property, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our and their assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to management.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property litigation could cause us to spend substantial resources and could distract our personnel from their normal responsibilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our shares of common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development, sales, marketing or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Accordingly, costs and lost management time, as well as uncertainties resulting from the initiation and continuation of patent litigation or other proceedings, could have a material adverse effect on our ability to compete in the marketplace.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patents for some of our technology and products, we also rely on trade secrets, including unpatented know-how, technology and other proprietary and confidential information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. However, we cannot guarantee that we have executed these agreements with each party that may have or have had access to our trade secrets or that the agreements we have executed will provide adequate protection. Any party with whom we have executed such an agreement may breach that agreement and disclose our proprietary or confidential information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets, particularly unpatented know-how, were to be obtained or independently developed by a competitor, our competitive position would be harmed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We operate in the biotechnology sector and rely heavily on information technology. Any interruption or lapse related to that technology, including any cyber security incidents, could harm our ability to operate our business effectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite our security measures, our information technology and infrastructure are subject to attacks or breaches. Any such breach could result in a material compromise of our systems or these systems of our third party vendors, and the information stored there could be accessed, publicly disclosed, lost, stolen, or rendered, permanently or temporarily, inaccessible. Furthermore, we may not promptly discover a system intrusion. Attacks could have a material impact on our business, operations or financial results. Any such access, disclosure or other loss of information, including our data being breached at third party providers, could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, disrupt our operations and damage our reputation, which could adversely affect our business. We also may need to pay &#8220;ransomware&#8221; to re-access our systems. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our information technology systems or data, or those of third parties upon whom we rely, are or were compromised, we could experience adverse consequences resulting from such compromise, including, but not limited to, regulatory investigations and actions; litigation (including class claims); fines and penalties; a disruption of our business operations such as our clinical trials; reputational harm; loss of revenue and profits; and other adverse consequences.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we (and third parties upon whom we rely) may collect, receive, store, use, transfer, make accessible, protect, secure, dispose of, transmit, disclose or otherwise process proprietary, confidential and sensitive information (including personal data (such as health-related data and participant study related data), intellectual property, and trade secrets (collectively, sensitive data). In addition, we rely on service providers to establish and maintain appropriate information technology and data security protections over the information technology systems they provide to us to operate our critical business systems (such as cloud-based infrastructure and systems, personnel email, as well as data storage and management systems). However, except for contractual protections, we have limited ability to control their safeguards and actions related to </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such matters and these service providers may not maintain adequate information security measures. We may share or receive sensitive data with or from third parties whose information security measures may not be adequate. In particular, the COVID-19 pandemic has caused us to modify our information technology practices including that our employees may work remotely which increases the risk of data breaches. Additionally, the prevalent use of mobile devices that access our sensitive data increases the risk of data breaches.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our information technology systems, including in our remote work environment, and those of parties upon which we rely, are vulnerable to evolving threats. These threats are prevalent, continue to increase and come from a variety of sources such as &#8220;hackers;&#8221; external or internal bad actors; personnel (such as through theft, error and/or misuse); sophisticated nation states and nation-state-supported actors; and others. These threats include, but are not limited to, social-engineering attacks, malicious code or intrusions, malware, denial-of-service attacks, personnel misconduct or errors, ransomware attacks, supply-chain attacks, software bugs, computer viruses, server malfunctions, software and hardware failures, theft or loss of data and other information technology assets, adware, natural disasters, terrorism, war, as well as telecommunication and electrical failures. In particular, ransomware attacks are becoming increasingly prevalent and severe and can lead to significant disruptions to operations, loss of data and income, reputational harm and diversion of funds. If we were to experience such an attack, extortion payments might alleviate some of the negative impacts of a ransomware attack but we might be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments. Any of these threats may result in unauthorized, unlawful or accidental loss, corruption, access, modification, destruction, alteration, acquisition or disclosure of sensitive data (such as clinical trial data). The costs to us to attempt to protect against such breaches is significant and could potentially require us to modify our business (including non-clinical and clinical trial activities). While we have implemented security measures designed to protect our information technology systems and to identify and remediate potential vulnerabilities, such measures may not be successful. We may not be able to detect vulnerabilities in our information technology systems because such threats and techniques used by threat actors change frequently, are sophisticated in nature and may not be detected until after a security incident has occurred. In addition, we may not have adequate insurance coverage to provide compensation for any losses associated with such events.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or others upon whom we rely experience or are perceived to have experienced a breach, we may experience adverse consequences. These consequences may include: government enforcement actions (for example, investigations, fines, penalties, audits and inspections), interruptions in our operations (including disruptions to our clinical trials), interruptions or restrictions on processing sensitive data (which could result in delays in obtaining, or our inability to obtain, regulatory approvals and significantly increase our costs to recover or reproduce the sensitive data), reputational harm, litigation (including class-action claims), indemnification obligations, monetary fund diversions, financial loss and other harms. In addition, such a breach may require notification of the breach to relevant stakeholders. Such disclosures are costly and the disclosure or the failure to comply with such requirements could lead to adverse consequences.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our contracts with relevant stakeholders include obligations relating to the safeguarding of sensitive data and a breach could lead to claims against us by such stakeholders. There can be no assurance that the limitations of liability in our contracts would be enforceable or adequate or would otherwise protect us from liabilities, damages or claims relating to our data privacy and security obligations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, failure to maintain effective internal accounting controls related to data security breaches and cybersecurity in general could impact our ability to produce timely and accurate financial statements and could subject us to regulatory and private party scrutiny.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to stringent and changing obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations and actions; litigation; fines and penalties; disruptions to our business operations; reputational harm; loss of revenue and profits; and other adverse business impacts.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we process personal data and other sensitive data (including proprietary and confidential business information, trade secrets, intellectual property, clinical trial data, and other sensitive third-party data). We are subject to or affected by numerous data privacy and security obligations such as various federal, state, local and foreign laws, regulations, and guidances; industry standards; external and internal privacy and security notices and policies; contracts; and other obligations governing the processing of personal data by us and on our behalf. These obligations may change, are subject to differing interpretations and may be inconsistent among jurisdictions. The global data protection landscape is rapidly evolving and implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future. This evolution may create uncertainty in our business, affect us or our collaborators&#8217;, service providers&#8217; and others&#8217; ability to operate in certain jurisdictions or to collect, store, transfer, use, share, and otherwise process personal data, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these obligations is high and is likely to increase in the future. These obligations may necessitate changes to our information </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">technologies, systems and practices and to those of any service providers that process personal data on our behalf. In addition, these obligations may require us to change our business plans.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., an increasing number of laws, regulations and industry standards apply to data privacy and security. For example, the European Union&#8217;s General Data Protection Regulation (GDPR) (EU) 2016/679, or the EU GDPR, imposes strict requirements on the processing of personal data. Under the EU GDPR, government regulators may impose temporary or definitive bans on personal data processing as well as fines of up to 20 million Euros or 4% of the annual global revenues of the noncompliant company, whichever is greater. Additionally, the Personal Information Protection Law (&#8220;PIPL&#8221;) of the People&#8217;s Republic of China may apply to certain personal data processed by us, our collaborators or others on our behalf. Similar to the EU GDPR, PIPL imposes strict requirements on the processing of personal data and allows for statutory fines and penalties.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain jurisdictions, including the United Kingdom, EU, and China have enacted data localization laws and cross-border personal data transfer laws which make it more difficult to transfer information across jurisdictions (such as transferring or receiving personal data that originates in the UK or in other foreign jurisdictions). Existing mechanisms that facilitate cross-border personal data transfers may change or be invalidated. The processing of sensitive personal data, such as physical health conditions, is a topic of active interest among regulators. As we expand into countries and jurisdictions outside the U.S., we may be subject to additional laws and regulations that may affect how we conduct business in relation to the personal data we process. For example, in relation to these cross-border personal data laws, if we cannot maintain a valid compliance mechanism for cross-border personal data transfers, we may face increased exposure to regulatory actions, fines and injunctions against the transferring of personal data from the UK, Europe, China and elsewhere. We may have to increase our personal data processing capabilities and infrastructure in foreign jurisdictions at significant expense.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Likewise, we expect that there will continue to be new proposed laws, regulations and industry standards relating to data privacy and security in the U.S. For example, the California Consumer Privacy Act, as amended, imposes obligations on business to which it applies. These obligations include, but are not limited to, providing specific disclosures in privacy notices and affording California residents certain rights related to their personal data. The CCPA allows for statutory fines for noncompliance (up to $7,500 per violation). While the CCPA contains limited exceptions for clinical trial data, the CCPA&#8217;s implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future. In addition, the CCPA, as amended, establishes a new California Privacy Protection Agency to implement and enforce the CCPA which could increase the risk of an enforcement action. Other states (such as Colorado and Virginia) have also enacted data privacy laws. If we become subject to new data privacy laws, at the state level, the risk of enforcement action against us could increase because we may become subject to additional obligations and the number of individuals or entities that can initiate actions against us may increase (including individuals, via a private right of action, and state actors).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we endeavor to comply with all applicable data privacy and security obligations, we may at times fail to do so or may be perceived to have failed to do so. Moreover, despite our efforts, we may not be successful in achieving compliance if our personnel or third parties upon whom we rely fail to comply with such obligations, which could negatively impact our business operations and compliance posture. For example, any failure by a service provider to comply with applicable data privacy and security obligations could result in adverse effects, including inability to operate our business and proceedings against us by governmental entities or others. If we fail, or are perceived to have failed, to address or comply with data privacy and security obligations, we could face significant consequences. These consequences may include, but are not limited to, government enforcement actions (e.g., investigations, fines, penalties, audits, inspections and similar activities); litigation (including class-related claims); additional reporting requirements and/or oversight; bans on processing personal data; orders to destroy or not use personal data; and imprisonment of company officials. Any of these events could have a material adverse effect on our reputation, business or financial condition, including but not limited to: interruptions or stoppages in our business operations (including, as relevant, our clinical trials); inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to comply as well as to defend any claim or inquiry; adverse publicity; or revision or restructuring of our operations. Moreover, trial participants or research subjects as well as the providers who share their information with us, may contractually limit our ability to use and disclose the information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We or the third parties upon whom we depend may be adversely affected by natural disasters and/or terrorism attacks, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Natural disasters could severely disrupt our operations, and have a material adverse effect on our business, results of operations, financial condition and prospects. If a natural disaster, power outage, terrorism attack or other event occurred that prevented us from using all or a significant portion of our office, manufacturing and/or lab spaces, that damaged critical infrastructure, such as the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The Company may incur </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Corporate Governance and Employee Relations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends on our ability to retain our Chief Executive Offices and other key executives and to attract, retain and motivate qualified personnel.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on the principal members of our executive and scientific teams, including Mr. Robert W. Duggan and and Dr. Mahkam Zanganeh, our Chief Executive Officers,, and Mr. Manmeet Soni, our Chief Operating Officer, all of whom are at-will employees. They may terminate their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance on any of our executive officers. The unplanned loss of the services of any of these persons could materially impact the achievement of our research, development and commercialization objectives.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel, including in the United States where we plan to continue to expand our physical presence, will also be critical to our success. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous biotechnology and pharmaceutical companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our principal stockholder and Chief Executive Officer maintains the ability to control or significantly influence all matters submitted to stockholders for approval.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, Mr. Duggan beneficially owned, in the aggregate, shares of common stock representing approximately 78.3% of our outstanding capital stock. Mr. Duggan is able to control or significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, Mr. Duggan is able to control or influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of voting power could delay or prevent an acquisition of our company on terms that other stockholders may desire. As a member of the board of directors, Mr. Duggan will adhere to the corporate governance standards adopted by the company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As a &#8220;controlled company&#8221; under the listing requirements of the Nasdaq Stock Market, we have an exemption from certain corporate governance requirements, which could adversely affect our stockholders by denying them certain rights and protections.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Duggan owns more than a majority of the voting power of our outstanding shares of common stock. Under the Nasdaq Stock Market listing requirements, a company of which more than 50% of the voting power is held by an individual, group, or another company is a &#8220;controlled company&#8221;. We have in the past, and we expect in the future, to rely on the &#8220;controlled company&#8221; exemptions under the Nasdaq Stock Market listing requirements. For example, in the past, a majority of the members of our board of directors were not independent directors, and our compensation and nominating and corporate governance committees did not consist entirely of independent directors. Accordingly, during the period we remain a controlled company and during any transition period following a time when we are no longer a controlled company, you may not have the same protections afforded to stockholders of companies that are subject to all of the corporate governance requirements of the Nasdaq Stock Market.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of employee fraud or other misconduct, including intentional failures to comply with FDA or Office of Inspector General regulations or similar regulations of comparable non-U.S. regulatory authorities, provide accurate information to the FDA or comparable non-U.S. regulatory authorities, comply with manufacturing standards we have established, comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable non-U.S. regulatory authorities, report financial information or data accurately or disclose unauthorized activities to us. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation, or a request for the reimbursement of expenses that were not incurred. It is not always possible to identify and deter employee misconduct, and the </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, standards or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Key personnel have been, and may continue to be, difficult to attract and retain.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to maintain and grow our business is directly related to the service of our employees in each area of our business, as we consider talent to be a significant asset. Our performance is directly tied to our ability to hire, train, motivate and retain qualified personnel, including highly skilled technical, operational and program managerial, clinical, medical, analytical and legal or financial personnel. There is significant competition for personnel in the clinical sciences marketplace, particularly in certain geographies where we are located, including but not limited to Miami, the San Francisco Bay area and Europe. Also, employees in our industry are increasingly able to work remotely, which could increase employee mobility and turnover, making it more difficult for us to attract and retain employees. In addition, many of our clinical development, operational and program management positions, require deep technical expertise, and it can be particularly challenging to identify and attract candidates and retain employees possessing such expertise. We have experienced, and may continue to experience, attrition in certain key positions. If we are unable to hire sufficient numbers of qualified employees or retain and motivate existing employees, our business and operating results would be harmed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Owning Our Common Stock</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The prices of our shares of common stock may be volatile and fluctuate substantially, which could result in substantial losses for our stockholders.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market prices of our shares of common stock on the Nasdaq Global Market may be volatile and fluctuate substantially. The stock market in general and the market for smaller pharmaceutical and biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, stockholders may not be able to sell their shares of common stock at or above the price at which they were purchased.</span></div><div style="margin-bottom:2pt"><span><br/></span></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price for our shares of common stock may be influenced by many factors, including:</span></div><div style="margin-bottom:2pt"><span><br/></span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of competitive products or technologies;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of clinical trials of ivonescimab and any other product candidate that we develop;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of clinical trials of product candidates of our competitors;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes or developments in laws or regulations applicable to ivonescimab and any other product candidates that we develop;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our entry into, and the success of, any collaboration agreements with third parties;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the recruitment or departure of key personnel;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of expenses related to any of our product candidates or clinical development programs;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of our efforts to discover, develop, acquire or in-license additional product candidates, products or technologies;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in our financial results or those of companies that are perceived to be similar to us;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market conditions in the biotechnology and pharmaceutical sectors;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory or legal developments in the United States and other countries;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the societal and economic impact of public health epidemics, such as the ongoing COVID-19 pandemic, and government efforts to slow their spread;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic, industry and market conditions;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the trading volume of the shares on the Nasdaq Global Market; and</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the other factors described in this &#8220;Risk Factors&#8221; section.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the stock market historically has experienced significant price and volume fluctuations. These fluctuations are often unrelated to the operating performance of particular companies. These broad market fluctuations, such as those caused by the COVID-19 pandemic, may cause declines in the trading price and market value of our common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Substantial future sales of our shares of common stock in the public market, or the perception that these sales could occur, could cause the price of the shares to decline significantly, even if our business is doing well.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of our shares of common stock in the public market could occur at any time. These sales, or the perception in the market that these sales could occur, could cause the market price of the shares to decline. Following the domestication, all of our outstanding shares of common stock were freely tradeable in the public market without restriction, unless held by our affiliates. Our principal stockholder and chief executive officer, Mr. Duggan, holds a substantial number of shares. Mr. Duggan&#8217;s shares have been registered for resale pursuant to an effective registration statement on Form S-3. If he sells, or indicates an intention to sell, substantial amounts of shares in the public market, the trading price of our shares could decline.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a &#8220;smaller reporting company&#8221; and the reduced disclosure requirements applicable to smaller reporting companies may make our shares of common stock less attractive to investors.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a &#8220;smaller reporting company&#8221;, as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended. We would cease to be a smaller reporting company if we have a public float in excess of $250 million or have annual revenues in excess of $100 million and a public float in excess of $700 million, determined on an annual basis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to take advantage of some or all of the exemptions available to us as a smaller reporting company. We cannot predict whether investors will find our shares of common stock less attractive if we rely on these exemptions. If some investors find our shares of common stock less attractive as a result, there may be a less active trading market for the shares and the market price of the shares may be more volatile.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incur increased costs as a result of operating as a company with shares of common stock that are publicly traded in the United States, and our management is required to devote substantial time to compliance initiatives.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a company with shares of common stock that are publicly traded in the United States, and particularly after we are no longer a &#8220;smaller reporting company&#8221;, we have incurred and will continue to incur significant legal, accounting and other expenses that we did not previously incur. In addition, the Sarbanes-Oxley Act, the Dodd-Frank Act, the listing requirements of the Nasdaq Stock Market and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations increase our legal and financial compliance costs and make some activities more time-consuming and costly.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, for as long as we remain a smaller reporting company, we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not smaller reporting companies as described in the preceding risk factor.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our shares of common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section 404 of the Sarbanes-Oxley Act, or Section 404, or any subsequent testing by our independent registered public accounting firm, as and when required, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our shares of common stock.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to disclose changes made in our internal controls and procedures on a quarterly basis, and our management is required to assess the effectiveness of these controls annually. However, for as long as we are a &#8220;smaller reporting company&#8221;, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal control over </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial reporting pursuant to Section 404. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section 404(a) of the Sarbanes-Oxley Act, we are required to furnish a report by our management on our internal controls over financial reporting. In order to comply with Section 404(a) of the Sarbanes-Oxley Act, we expect to incur additional expenses and devote increased management effort including documenting and evaluating our internal controls over financial reporting. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude that our internal control over financial reporting is effective as required by Section 404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our restated certificate of incorporation designates the Court of Chancery of the State of Delaware and the federal district courts of the United States of America as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers and employees.</span></div><div><span><br/></span></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery of the State of Delaware does not have jurisdiction, the federal district court for the District of Delaware) will be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any derivative action or proceeding brought on our behalf;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, employees or stockholders to our company or our stockholders;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action asserting a claim arising pursuant to any provision of the DGCL or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware; or</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action asserting a claim arising pursuant to any provision of our certificate of incorporation or bylaws (in each case, as they may be amended from time to time) or governed by the internal affairs doctrine.</span></div><div style="margin-bottom:2pt"><span><br/></span></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These choice of forum provisions will not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any claims arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These exclusive forum provisions may limit the ability of our stockholders to bring a claim in a judicial forum that such stockholders find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees. If a court were to find the either exclusive forum provision contained in our restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving such action in other jurisdictions, all of which could materially adversely affect our business, financial condition and operating results.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we do not anticipate paying any cash dividends on our shares of common stock in the foreseeable future, capital appreciation, if any, will be the sole source of gain for our stockholders.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our shares of common stock or on Summit Therapeutics plc&#8217;s ordinary shares. We currently intend to retain all of our future earnings to fund the development and expansion of our business. Any determination to pay dividends in the future will be at the discretion of our board of directors. As a result, capital appreciation of our shares of common stock, if any, will be the sole source of gain for our stockholders for the foreseeable future.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If equity research analysts stop publishing research or reports about our business or if they issue unfavorable commentary or downgrade our shares of common stock, the price of the shares could decline.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our shares of common stock relies in part on the research and reports that equity research analysts publish about us and our business. We do not control these analysts. The price of our shares of common stock could decline if one or more equity research analysts downgrades such securities or if analysts issue other unfavorable commentary about us or our business. In addition, if one or more of these analysts cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause the trading prices and trading volumes of our shares of common stock to decline.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are exposed to risks related to currency exchange rates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct a portion of our operations in the United Kingdom. Because our financial statements are presented in U.S. dollars, changes in currency exchange rates have had and could have a significant effect on our operating results when our operating results are translated into pounds sterling. Exchange rate fluctuations between local currencies and the U.S. dollar create risk in several ways, including the following: weakening of the U.S. dollar may increase the U.S. dollar cost of overseas research and development expenses and the cost of sourced product components outside the United Kingdom; strengthening of the U.S. dollar may decrease the value of our revenues denominated in other currencies; the exchange rates on non-dollar transactions and cash deposits can distort our financial results; and commercial pricing and profit margins are affected by currency fluctuations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have broad discretion in the use of our cash and cash equivalents and may not use them effectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management has broad discretion in the use of our cash and cash equivalents and could spend our cash in ways that do not improve our results of operations or enhance the value of our shares of common stock. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the market price of our shares of common stock to decline and delay the development of our product candidates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Widespread Health Concerns</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Widespread health concerns, pandemics or epidemics, and other outbreaks of illness may negatively affect the Company&#8217;s ability to maintain operations and execute its business plan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Widespread health concerns, pandemics, epidemics and other outbreaks of illness, particularly in North America but also globally, can have evolving and uncertain impacts on our business. We continue to monitor our operations and applicable government recommendations, and we have made modifications to our normal operations because of the COVID-19 pandemic, including flexible working arrangements. Changes in flexible working arrangements could impact employee retention, employees&#8217; productivity and morale, strain our technology resources and introduce operational risks. Additionally, the risk of cyber-attacks or other privacy or data security incidents may be heightened as a result of our moving increasingly towards a remote working environment, which may be less secure and more susceptible to hacking attacks. As a result of any widespread health concern, pandemic, or other outbreaks of illness, including the COVID-19 pandemic, the Company may experience disruptions that severely impact our business, commercialization, third party vendor operations, including foreign and domestic supply chains, or delays in clinical trial activities, including:</span></div><div><span><br/></span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">delays or difficulties in initiating clinical trial sites;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">disruption to and delays in preclinical research and analysis activities due to an extended temporary closure of contract lab facilities;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">disruptions in supply, logistics or other activities related to the procurement of materials, which could have a negative impact on the Company&#8217;s ability to conduct preclinical studies, initiate or complete clinical trials or commercialize product candidates;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">diversion of healthcare resources away from conducting clinical trials;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">interruption of key preclinical studies and clinical trial activities, due to limitations on travel imposed or recommended by federal, state, provincial or municipal governments, employers and others;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">limitations in resources that would otherwise be focused on the conduct of the Company&#8217;s business or current or planned preclinical studies or clinical trials, including due to sickness, restrictions on travel, prolonged stay-at-home or shelter-in-place orders and other pandemic related concerns; and</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">changes in regulations as part of a response to the future pandemic and/or epidemic may require the Company to change the ways in which the preclinical studies and clinical trials are conducted and incur unexpected costs, or requires the Company to discontinue our preclinical research or clinical trials altogether.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="if355807d1b914743a4dab03fe6913e8f_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1B. Unresolved Staff Comments </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:18pt"><span><br/></span></div><div id="if355807d1b914743a4dab03fe6913e8f_1553"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1C. <span id="iac465fd2c09840709e30476656ca838e_7063"></span>Cybersecurity</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have implemented a risk-based approach to identify and assess the cybersecurity threats that could affect our business and information systems. We use recognized commercially reasonable measures, tools and methodologies to manage cybersecurity risk that are tested on a regular cadence. We also monitor and evaluate our cybersecurity posture on an ongoing basis through regular vulnerability scans, penetration tests and third party reviews. We rely on industry leading third party service providers to provide the systems required to effectively run our clinical trials and require these third-party service providers with access to personal, confidential or proprietary information to implement and maintain cybersecurity practices. Specific controls that are used to some extent include endpoint threat detection and response (EDR), identity and access management (IAM), privileged access management (PAM), logging and monitoring involving the use of security information and event management (SIEM), multi-factor authentication (MFA), firewalls and intrusion detection and prevention, and vulnerability and patch management.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To manage our material risks from cybersecurity threats and to protect against, detect, and prepare to respond to cybersecurity incidents, we undertake the below listed activities:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Monitor emerging data protection laws and implement changes to our processes to comply;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Conduct annual cybersecurity management and incident training for employees involved in our systems and processes that handle sensitive data;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Conduct on boarding and cyber security training for all employees on an ongoing basis;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Conduct regular phishing email simulations for all employees; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Carry cybersecurity risk insurance that provides protection against the potential losses arising from a cybersecurity incident.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our incident response plan coordinates the activities that we and our third-party cybersecurity provider take to prepare to respond and recover from cybersecurity incidents, which include processes to triage, assess severity, investigate, escalate, contain, and remediate an incident, as well as to comply with potentially applicable legal obligations and mitigate brand and reputational damage. We have business continuity plans that we continuously review and update in line with our evolving applications architecture.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors provides oversight to our Cybersecurity efforts to ensure effective governance in managing risks associated with cybersecurity threats. Our Head of Information Technology, provides periodic updates to the Board of Directors regarding our cybersecurity program, including information about cyber risk management governance and status updates on various projects intended to enhance the overall cybersecurity posture of the Company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We describe whether and how risks from cybersecurity threats have or that are reasonably likely to affect our financial position, results of operations and cash flows, under the heading &#8220;Information technology failures and cybersecurity breaches could harm our business&#8221; included as part of our Item 1A. Risk Factors of this Annual Report on Form 10-K, which disclosures are incorporated by reference herein.</span></div><div><span><br/></span></div><div><span><br/></span></div><div id="if355807d1b914743a4dab03fe6913e8f_22"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Properties</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information concerning Summit&#8217;s principal leased facilities as of December 31, 2023:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain the following leased properties: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:17.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.472%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.472%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.472%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.339%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Type/Uses</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Size</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Lease&#160;Expiration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Executive office</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Oxfordshire,&#160;United&#160;Kingdom</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,781 square feet</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February&#160;2027</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Executive office</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Menlo Park, California, United States</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,760 square feet</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2026</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We signed a lease agreement on January&#160;8, 2024 for executive office space for our new headquarters in Miami, Florida. The office space is approximately 9,000 square feet. The term of the lease is 64 months. Total payments for this office space is approximately $5,100 over the term of the lease. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our facilities are suitable and adequate to meet our needs.</span></div><div id="if355807d1b914743a4dab03fe6913e8f_25"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3. Legal Proceedings </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We are not currently subject to any material legal proceedings.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="if355807d1b914743a4dab03fe6913e8f_28"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="if355807d1b914743a4dab03fe6913e8f_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:24pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div style="margin-top:24pt;text-align:center"><span><br/></span></div><div id="if355807d1b914743a4dab03fe6913e8f_34"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock has been publicly traded on the Nasdaq Global Market under the symbol &#8220;SMMT&#8221; since September 21, 2020. Prior to that date, there was no public market for our common stock. On September 21, 2020, Summit Therapeutics plc became our wholly-owned subsidiary and we became the holding company and successor issuer to Summit Therapeutics plc (the predecessor registrant and former holding company) and its subsidiaries. Such succession occurred pursuant to a statutory scheme of arrangement under U.K. law pursuant to which all Summit Therapeutics plc&#8217;s outstanding ordinary shares were exchanged on a five-for-one basis for newly issued shares of our common stock. Summit Therapeutics plc&#8217;s American Depositary Shares (&#8220;ADSs&#8221;) had traded on the Nasdaq Global Market under the symbol &#8220;SMMT&#8221; since March 2015 and its ordinary shares previously traded on AIM, a sub-market of the London Stock Exchange plc, under the symbol &#8220;SUMM&#8221;. Each ADS represented five ordinary shares of Summit Therapeutics plc. We canceled the admission of the ordinary shares to trading on AIM on February 24, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders of Record</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 9, 2024, there were approximately 178 holders of record of our common stock. The actual number of stockholders is greater than this number of holders of record and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our common stock or ordinary shares. We currently intend to retain all available funds and any future earnings to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination to declare and pay dividends will be made at the discretion of our Board of Directors and will depend on then-existing conditions, including our results of operations, financial condition, contractual restrictions, capital requirements, business prospects, and other factors our Board of Directors may deem relevant.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 10, 2022, the Company&#8217;s Chairman and Chief Executive Officer, Mr. Duggan, entered into a Note Purchase Agreement (the &#8220;2022 Note&#8221;), pursuant to which he has loaned the Company $25.0 million in exchange for the issuance by the Company of an unsecured promissory note in the amount of $25.0 million. The 2022 Note is to accrue interest at a rate per annum equal to the prime rate as reported in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wall Street Journal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is 3.25% as of the effective date. The 2022 Note becomes due upon the earlier of (i) the consummation of a registered public offering with net proceeds of no less than $25.0 million or (ii) 18 months from the date of issuance of the 2022 Note and was repaid on August 10, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 5, 2022, the Company entered into the License Agreement with Akeso. The License Agreement closed on January 17, 2023, and both Akeso and Summit entered into the Common Stock Issuance Agreement (&#8220;Issuance Agreement&#8221;). Pursuant to the License Agreement and Issuance Agreement, Akeso elected to receive 10&#160;million shares of Company common stock in lieu of cash and was paid $274.9 million in cash as the initial upfront payment. The remaining $200 million of the upfront payment was paid on March 6, 2023. As regulatory approval for ivonescimab has not yet been granted, the Company will record in-process research and development expenses in the first quarter of 2023 for the cash payments of $474.9 million and for the fair market value of the 10 million shares issued to Akeso.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 6, 2022, the Company entered into a Note Purchase Agreement (the &#8220;Note Purchase Agreement&#8221;), with Mr. Robert Duggan and Dr. Maky Zanganeh, pursuant to which the Company agreed to sell to each of Mr. Duggan and Dr. Zanganeh unsecured promissory notes in the aggregate amount of $520 million. Pursuant to the Note Purchase Agreement, the Company issued to Mr. Duggan and Dr. Zanganeh unsecured promissory notes in the amount of $400 million (the &#8220;Duggan February Note&#8221;) and $20 million (the &#8220;Zanganeh Note&#8221;), respectively, which matured and became due on February 15, 2023 </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and an unsecured promissory note to Mr. Duggan in the amount of $100 million (the &#8220;Duggan September Note&#8221; and together with the Duggan February Note and the Zanganeh Note, the &#8220;December 2022 Notes&#8221;), which was originally due on September 15, 2023. The maturity dates of the December 2022 Notes could have been extended one or more times at the Company&#8217;s election, but in no event to a date later than September 6, 2024. In addition, if the Company consummates a public offering, then upon the later to occur of (i) five business days after the Company receives the net cash proceeds therefrom or (ii) May 15, 2023, the Duggan February Note and the Zanganeh Note shall be prepaid by an amount equal to the lesser of (a) 100% of the amount of the net proceeds of such offering and (b) the outstanding principal amount on such Notes. On January 19, 2023, the Company provided notice to extend the term of the Duggan February Note and Duggan September Note to a maturity date of September 6, 2024. Furthermore, on January 19, 2023, the Company and Mr. Duggan rectified the Duggan February Note and Duggan September Note in order to correctly reflect the parties&#8217; intent that the Company may only prepay (i) the Duggan February Note following the completion of a public rights offering to be conducted by Summit in the approximate amount of $500 million (the &#8220;Rights Offering&#8221;), or a similar capital raise, in an amount equal to the lesser of (x) the net proceeds of the Rights Offering or such capital raise or (y) the full amount outstanding of the Duggan February Note, and (ii) the Duggan September Note following the completion of a capital raising transaction subsequent to the Rights Offering in an amount equal to the lesser of (A) the net proceeds of such capital raise or (B) the full amount outstanding of the Duggan September Note. Following the issuance of the two new Promissory Notes (the &#8220;Duggan Promissory Notes&#8221;), the Duggan February Note and Duggan September Note were marked as &#8220;cancelled&#8221; on their face and replaced in their entirety by the Duggan Promissory Notes (together with the Zanganeh Note, the &#8220;Notes&#8221;). The Notes accrued interest at an initial rate of 7.5%. All interest on the Notes was to be paid on the date of signing for the period through February 15, 2023. Such prepaid interest was to be paid in a number of shares of the Company&#8217;s common stock, par value $0.01 (&#8220;Common Stock&#8221;) equal to the dollar amount of such prepaid interest, divided by $0.7913 (the consolidated closing bid price immediately preceding the time the Company entered into the Note Purchase Agreement, plus $.01), which was 9,720,291 shares. For all applicable periods following February 15, 2023, interest shall accrue on the outstanding principal balance of the Notes at the US prime interest rate, as reported in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wall Street Journal,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plus 50 basis points, as adjusted monthly, for three months immediately following February 15, 2023, and thereafter at the US prime rate plus 300 basis points, as adjusted monthly. On February 15, 2023, the $20 million Zanganeh Note matured and the Company repaid the outstanding principal balance. In connection with the closing of the Rights Offering, the $400 million Duggan Promissory Note matured and became due, and the Company repaid all principal and accrued interest thereunder using a portion of the proceeds from the Rights Offering.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2024 the Duggan February Note was amended to extend the maturity date from September 6, 2024 to April 1, 2025. For all applicable periods commencing  February 17, 2024, interest shall accrue on the outstanding principal balance at the greater of 12% or the US prime interest rate, as reported in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wall Street Journal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plus 350 basis points, as adjusted monthly, compounded quarterly. Interest shall be paid upon maturity of the loan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intended use of proceeds generated from the transactions described above includes funding the Company&#8217;s activities to support clinical and regulatory development of its assets and general corporate purposes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 13, 2023, the Company entered into a Securities Purchase Agreement with Manmeet S. Soni pursuant to which Mr. Soni invested $5.0 million in the Company in exchange for 2,976,190 shares (the &#8220;Shares&#8221;) of the Company&#8217;s common stock at a purchase price of $1.68 per share. The Shares were offered and sold to Mr. Soni in a private placement pursuant to an exception from the registration requirements under Section 4(a)(2) of the Securities Act of 1933 and Rule 506 of Regulation D promulgated thereunder. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>Not applicable.</span></div><div><span><br/></span></div><div id="if355807d1b914743a4dab03fe6913e8f_37"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. [RESERVED]</span></div><div><span><br/></span></div><div id="if355807d1b914743a4dab03fe6913e8f_40"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes appearing elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in &#8220;Item 1A. Risk Factors&#8221; of this Annual Report on Form 10-K, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, or MD&amp;A, describes principal factors affecting the results of our operations, financial condition and liquidity, as well as our critical accounting policies and estimates that require significant judgment and thus have the most significant potential impact on our Consolidated Financial Statements. This section provides an analysis of our financial results for the year ended December 31, 2023 compared to the same period in the prior year. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company Overview</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Our pipeline of product candidates is designed with the goal to become the patient-friendly, new-era standard-of-care medicines, in the therapeutic area of oncology.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. On December 5, 2022, we entered into a Collaboration and License Agreement (the &#8220;License Agreement&#8221;) with Akeso, Inc. and its affiliates (&#8220;Akeso&#8221;) pursuant to which the Company has in-licensed ivonescimab. Through the License Agreement, we obtained the rights to develop and commercialize ivonescimab in the United States, Canada, Europe, and Japan (the &#8220;Licensed Territory&#8221;). The License Agreement and transaction closed in January 2023 following customary waiting periods. Our operations will be focused on the development of ivonescimab and other future activities, as the Company determines.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have begun our development for ivonescimab in non-small cell lung cancer (&#8220;NSCLC&#8221;), specifically launching Phase III clinical trials in the following indications:</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)  ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (&#8220;EGFR&#8221;)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (&#8220;TKI&#8221;) (&#8220;HARMONi&#8221;); and</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)  ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (&#8220;HARMONi-3&#8221;)</span></div><div style="padding-left:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of these financial statements, both studies are enrolling patients.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The entry into the License Agreement with Akeso represents a significant change in our strategy and its future operations will be focused on the development of ivonescimab and other future activities as the Company determines. Our portfolio includes ridinilazole, a product candidate for treating patients suffering from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clostridioides difficile </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">infection, also known as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C. difficile </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">infection, or CDI. All prior development and marketing activities related to ridinilazole have been terminated. Our anti-infectives portfolio includes SMT-738, the first of a novel class of precision antibiotics for combating multidrug resistant infections, specifically carbapenem-resistant Enterobacteriaceae (&#8220;CRE&#8221;) infections. We will continue to pursue partnerships for further development of SMT-738. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key Components of our Results of Operations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue consists of amounts received from the license and commercialization agreement with Eurofarma Laborat&#243;rios S.A. (&#8220;Eurofarma&#8221;). We have not generated any revenue from product sales.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the license and commercialization agreement with Eurofarma, we received an upfront payment of $2.5 million in December 2017. In February 2020, we achieved the first enrollment milestone and received $1.0 million. In September 2021, we achieved the second enrollment milestone and received $1.3 million. The terms of the contract have been assessed under ASC 606 and currently only the upfront payment and the first two milestone payments are included in the transaction price. These payments were initially reported as deferred revenue in the balance sheet and were recognized as revenue ratably over the determined performance period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no revenue recognized for the year ended December 31, 2023. Revenue recognized during the year ended December 31, 2022 related to the upfront payment and the first two enrollment milestones earned in accordance with our revenue </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognition policy. The revenue was recognized ratably over the determined performance period to reflect the transfer of control to the customer occurring over the time period that the research and development services were provided. This output method is, in management&#8217;s judgment, the best measure of progress towards satisfying the performance period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Operating Income</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating income includes income received and recognized from grants and clinical trial support from government entities, philanthropic, non-government and not-for-profit organizations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, we were awarded a contract from the Biomedical Advanced Research and Development Authority (&#8220;BARDA&#8221;), part of the Office of the Assistant Secretary for Preparedness and Response at the United States Department of Health and Human Services, to fund, in part, the clinical and regulatory development of ridinilazole for the treatment of infections caused by</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> C. difficile</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The contract provides for a cost-sharing arrangement under which BARDA funded a specified portion of estimated costs for the continued clinical and regulatory development of ridinilazole for CDI. Under this cost sharing arrangement, we were responsible for a portion of the costs associated with each segment of work, including any costs in excess of the estimated amounts. The awarded contract, as amended in 2019 and 2020, provided for total award up to $72.5&#160;million, and total amount of committed funding to $62.4 million. As of December 31, 2023, based on translation of historical foreign currency amounts in the period, the Company has recognized $59.2 million of cumulative income since contract inception.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining federal government funding is dependent on BARDA in its sole discretion exercising the final independent option work segment, upon the achievement by the Company of certain agreed-upon milestones for ridinilazole. This option work segment was never exercised by BARDA. The contract ran through April 2022 and was extended through December 2022 as a no cost contract, solely to close out open activities. As of December 31, 2023, based on translation of historical foreign currency amounts in the period, an aggregate of $59.2&#160;million of cumulative income has been recognized since contract inception. As a result of our decision to not pursue further internal clinical development of ridinilazole and seek partners or a divestiture related to ridinilazole as a path forward for the clinical development of the asset, we recognized the remainder of the deferred income for BARDA during the third quarter of 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also received income from research and development (&#8220;R&amp;D&#8221;) tax credits, which consist of the R&amp;D tax credit received in the United Kingdom (&#8220;U.K.&#8221;). We benefit from two U.K. research and development tax credit cash rebate regimes: Small and Medium Enterprise Program (&#8220;SME Program&#8221;) and the Research and Development Expenditure Credit Program (&#8220;RDEC Program&#8221;). Qualifying expenditures largely comprise employment costs for research staff, consumables, a proportion of relevant, permitted sub-contract costs and certain internal overhead costs incurred as part of research projects for which we do not receive income. Tax credits related to the SME Program and RDEC Program are recorded as other operating income in the consolidated statements of operations and other comprehensive loss. Under both schemes, we receive cash payments that are not dependent on our pre-tax net income levels.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on criteria established by His Majesty&#8217;s Revenue and Customs (&#8220;HMRC&#8221;), a portion of expenditures being carried out in relation to our pipeline research and development, clinical trials management and third-party manufacturing development activities are eligible for the SME regime and we expect such elements of research and development expenditure incurred in our UK entities will also continue to be eligible for the SME regime for future periods.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we started development of  a new preclinical candidate, SMT-738, for development in the fight against multi-drug resistant infections, specifically Carbapenem-resistant Enterobacteriaceae (&#8220;CRE&#8221;) infections. Simultaneously, we received an award from the Trustees of Boston University under the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator program (&#8220;CARB-X&#8221;) to progress this candidate through preclinical development and Phase Ia clinical trials. The award committed initial funding of up to $4.1&#160;million with the possibility of up to another $3.7&#160;million based on the achievement of future milestones. As of December 31, 2023, based on translation of historical foreign currency amounts in the period, $2.9&#160;million of cumulative income has been recognized since contract inception. During the quarter ended September 30, 2022, CARB-X announced changes to its funding arrangements and terms and conditions. As a result, the current arrangement concluded as of June 30, 2022, however we have the ability to recognize reimbursements for any milestone payments related to work incurred subsequent to this date in accordance with this agreement. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Expenses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our operating expenses since inception have consisted of research and development activities and general and administrative costs.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of all costs associated with our research and development activities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These include:&#160;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs incurred in conducting our preclinical studies and clinical trials through contract research and development organizations, including, but not limited to, preclinical toxicology, pharmacology, formulation and manufacturing work, as well as regulatory, operational, drug supply and treatment costs related to conducting the study; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">laboratory and vendor expenses incurred in relation to our preclinical, non-clinical and clinical studies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs incurred in supply chain development and scale up activities to support product registration; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee related expenses, which include salary, benefits and stock-based compensation, for our research and development staff; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs incurred in development and conduct of training and education related our development candidates; and  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance and other supplies.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize our employee and infrastructure resources across multiple research projects. We track expenses related to our clinical programs and certain preclinical programs on a per project basis. We expect our research and development expenses to continue to be significant as we initiate our planned clinical trials of ivonescimab, and continue our activities to initiate preclinical programs for future product candidates. The timing and amount of these expenses will depend upon the outcome of our clinical trials and the associated costs. The timing and amount of these expenses will also depend on the costs associated with potential future clinical trials of our product candidates and the related expansion of our research and development organization, regulatory requirements, advancement of our preclinical programs and product candidate manufacturing costs. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and benefits related to our executive, finance, business development, human resources and other support functions. Other general and administrative expenses include stock-based compensation expenses, market research costs, facility-related costs, consulting costs and expenses associated with the requirements of being a publicly traded company in the United States, including insurance, legal, audit and taxation services fees.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our general and administrative expenses will continue to increase in the future as we increase our headcount to support our planned clinical trials of ivonescimab, continued research and development and potential commercialization of our product candidates. We also anticipate continued accounting, audit, regulatory, compliance, insurance and investor and public relations expenses associated with being a publicly traded company in the United States.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other expense, net </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net primarily consists of foreign currency net gains and losses, cash and imputed interest expense incurred related to our promissory notes to related parties and investment income related to investments in money market funds and U.S. treasury securities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Imputed interest is calculated as the difference between the expected interest payable and the deemed market rate of interest and is recorded as a debt discount at inception of the note payable with a credit to additional paid-in capital for notes payable to related parties. The debt discount is amortized to interest expense using an effective interest rate method. All highly liquid investments with a maturity date of 90 days or less at the date of purchase are considered to be cash equivalents and the related investment income is recognized in net loss. The appropriate classification of investments in securities is determined by the Company at the time of purchase.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Taxation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a U.S. tax resident trading entity, we are subject to U.S. corporate taxation. Our U.K. resident trading subsidiaries are individually subject to U.K. corporate taxation. Due to the nature of our business, we have generated losses since inception. We have recorded a full valuation allowance against the deferred tax assets with respect to these tax losses in excess of our deferred tax liabilities in each jurisdiction because we do not consider it more likely than not that there will be suitable taxable profits in the foreseeable future based on the evidence available against which to offset these losses.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the Year Ended December 31, 2023 to the Year Ended December 31, 2022 </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.847%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$ Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(609.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(537.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(614.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(536.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(614.9)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(536.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for the year ended December 31, 2022 relates to revenue from our license and commercialization agreement with Eurofarma Laborat&#243;rios S.A. for ridinilazole, the Company&#8217;s product candidate for treating patients suffering from Clostridioides difficile infection, also known as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C. difficile infection</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This revenue was recognized ratably over the determined performance period that the research and development services were provided. The decrease for the year ended December 31, 2023 compared to the same period in the prior year is attributed to the total milestones received of $4.8 million being fully recognized ratably over the determined performance period, which ended during 2022. We are currently not anticipating receipt of additional milestone payments under this agreement given Company&#8217;s determination that it would seek partners or a divestiture of ridinilazole as the path forward for the clinical development of the asset.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes our research and development expenses by category for the year ended December 31, 2023 and 2022, respectively.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.993%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$ Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-infectives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation related costs, excluding stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other research and development costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The entry into the License Agreement with Akeso, Inc., effective in January 2023, represents a significant change in our strategy from anti-infectives to the therapeutic area of oncology. We have invested our resources in the clinical development of ivonescimab during the year ended December 31, 2023. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncology expenses represent our investment in the clinical development of ivonescimab, known as SMT112 in the United States, Canada, Europe, and Japan. On May 3, 2023 we announced plans to initiate Phase III clinical studies for ivonescimab in non-small cell lung cancer (&#8220;NSCLC&#8221;) and on May 9, 2023, we announced that the first United States-based patient had been enrolled in the Phase III HARMONi study. We have commenced enrollment in our second Phase III HARMONi-3 clinical trial. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are continuing to focus our efforts on patient enrollment in both the Phase III HARMONi and Phase III HARMONi-3 studies. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With this shift in focus from anti-infectives to oncology, total research and development expenses increased by $7.4 million during the year ended December 31, 2023, compared to the same period in the prior year, primarily due to our investment in oncology expenses of $31.0 million, and an increase in compensation related expenses of $5.0 million to support the clinical development of ivonescimab as we hire experts in the oncology field, partially offset by a decrease of $30.1 million related to discontinuing the development activities related to ridinilazole and SMT-738. We expect oncology-related research and development costs to continue to increase as we progress with the development of  ivonescimab. The Company recorded a net benefit related to its anti-infectives programs during the year ended December 31, 2023 due to completing financial close-out activities with the lead contract research organization for our ridinilazole clinical trials, thus resulting in a true-up of the estimated anti-infectives research and development expenses during the second quarter of 2023. </span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In-process research and development</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes our in-process research and development expenses by category for the year ended December 31, 2023 and 2022, respectively.</span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.531%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.856%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront milestone payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct transaction costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment in ivonescimab totaled $520.9 million for the year ended December 31, 2023 and primarily relates to our upfront milestone payments pursuant to the License Agreement with Akeso. The License Agreement was executed in January 2023, and both Akeso and Summit entered into the Common Stock Issuance Agreement (&#8220;Issuance Agreement&#8221;). Pursuant to the License Agreement and Issuance Agreement, Akeso elected to receive 10 million shares of our common stock in lieu of $25.1 million cash and was paid $274.9 million in cash as the initial upfront payment. The remaining $200.0 million upfront payment was paid on March 6, 2023. In-process research and development expense comprised of the $474.9 million paid in cash, the fair value of the 10&#160;million shares of common stock on the date of closing the transaction of $45.9 million, and $0.1 million of direct transactions costs incurred. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes our general and administrative expenses by category for the year ended December 31, 2023 and 2022, respectively. </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.993%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$ Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation related costs, excluding stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal fees and professional services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased by $3.6 million for the year ended December 31, 2023, compared to the same period in the prior year, primarily due to an increase of $2.1 million in stock-based compensation as the Company is focused on building its executive management team to continue supporting the growth of the Company, and an increase of $1.4 million in legal and professional services related to corporate projects and transactions. We expect general and administrative expenses to continue to increase in the coming quarters as we scale our infrastructure and management to support development of ivonescimab.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Note management has updated this category to include general and administrative consulting expenses and has reclassified these expenses in the prior period for consistency. Expenses of $1.8 million for the year ended December 31, 2022, were previously recorded in compensation related costs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Intangible Assets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we expanded our activities in the field of infectious diseases with the acquisition of Discuva Limited, a privately held United Kingdom-based company. Through this acquisition, we obtained a bacterial genetics platform and a suite of software-based technologies (collectively termed our &#8220;Discuva Platform&#8221;), which facilitates the discovery and development of new mechanism antibiotics. In conjunction with the significant change in the Company&#8217;s strategy and shift in focus to the therapeutic area of oncology, the Company determined that it will cease further investment in the Discuva Platform and evaluate further options for the use of the Discuva Platform. Management also concluded that this indicated the carrying amount of the acquired Discuva Platform intangible asset may not be recoverable and performed an assessment to calculate the fair value of the asset using a probability-weighted approach which was compared to the carrying value of the asset. An impairment charge of $8.5&#160;million which represented the carrying value of the Discuva Platform was recognized for the year ended December 31, 2022. This impairment charge is presented as impairment of intangible assets in the consolidated statements of operations and comprehensive loss.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Operating Income</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes our other operating income by category for the year ended December 31, 2023 and 2022, respectively:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.847%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$ Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funding income from BARDA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant income from CARB-X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Funding income from BARDA decreased by $8.1 million for the year ended December 31, 2023, compared to the same periods in the prior year, due to management&#8217;s decision to terminate all prior development and marketing activities related to ridinilazole. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.K. research and development tax credits decreased by $3.5 million for the year ended December 31, 2023, compared to the same period in the prior year, due to a decrease in clinical and manufacturing activity spend associated with the ridinilazole Phase III clinical program, which resulted in a decrease in tax credits claimed in the U.K., coupled with a decrease in eligible expenses claimed due to recent changes in U.K. tax legislation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant income received from CARB-X decreased by $1.8 million for the year ended December 31, 2023, compared to the same period in the prior year due to the CARB-X arrangement for our preclinical candidate SMT-738 concluding in 2022. We do not expect further income under this arrangement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other (Expense) Income, Net</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes our other income (expense), net by category for the year ended December 31, 2023 and 2022, respectively.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.847%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$ Change</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency gains (losses)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense on promissory notes payable to related parties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of cumulative currency translation gain</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense) income, net primarily decreased by $1.4&#160;million for the year ended December 31, 2023, compared to the same period in the prior year, primarily due to favorable changes in foreign currency gains of $4.7 million, an increase of $9.0 million in interest income related to investments in money market funds and U.S. government securities, and an increase of $0.4 million related to the reclassification of cumulative foreign currency translation gains from accumulated other comprehensive loss due to the dissolution of certain dormant entities, partially offset by an increase of $12.1 million in interest expense on promissory notes to related parties, where amounts recognized in 2023 related to the $520 million promissory notes issued to our Chief Executive Officers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have financed our operations primarily through issuances of our common stock, issuance of debt, receipt of payments to us under license, collaboration, and commercialization arrangements, for example, our license and commercialization agreement with Eurofarma Laborat&#243;rios SA, or Eurofarma, development funding and other assistance from government entities, philanthropic, non-government and not-for-profit organizations for our product candidates. In particular, we have received funding from BARDA, CARB-X, Innovate UK, Wellcome Trust and a number of not-for-profit organizations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have devoted substantially all of our efforts to research and development, including clinical trials. We have not completed the development of any drugs. We expect to continue to incur significant expenses and increasing operating losses for at least the next few years. The net losses we incur may fluctuate significantly from quarter to quarter and year to year, due to the nature and timing of our research and development activities. We expect that our research and development and general and administrative expenses will continue to be significant in connection with our ongoing research and development efforts. In addition, if we obtain marketing approval for any of our product candidates in the United States or other jurisdictions where we retain commercial rights, and if we choose to retain those rights, we would expect to incur significant sales, marketing, distribution and outsourced manufacturing expenses, as well as ongoing research and development expenses. In addition, our expenses will increase if and as we:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Invest in clinical development of ivonescimab in our Licensed Territory;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conduct research and continue development of additional product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain and augment our intellectual property portfolio and opportunistically acquire complimentary intellectual property;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek further regulatory advancement for ivonescimab;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">invest in our manufacturing capabilities for ivonescimab and any other products for which we may obtain regulatory approval;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek marketing approvals for any product candidates that successfully complete clinical development;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ultimately establish a sales, marketing and distribution infrastructure in jurisdictions where we have retained commercialization rights and scale up external manufacturing capabilities to commercialize any product candidates for which we receive marketing approval;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">perform our obligations under our collaboration agreements;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pursue business development opportunities, including investing in other businesses, products and technologies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">experience any delays or encounter any issues with any of the above, including but not limited to failed studies, complex results, safety issues or other regulatory challenges;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire additional clinical, regulatory, scientific and administrative personnel;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expand our physical presence;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">borrow capital to fund our resources and have to pay interest expenses on such borrowings.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, we incurred a net loss of $614.9&#160;million, and cash flows used in operating activities was $76.8&#160;million. As of December 31, 2023 we had an accumulated deficit of $993.3&#160;million, cash and cash equivalents and short-term investments in U.S. treasury securities of $186.2&#160;million. We expect to continue to generate operating losses for the foreseeable future. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have evaluated whether our cash, cash equivalents, short-term investments and U.K. research and development tax credits provide sufficient cash to fund our operating cash needs for the next twelve months from the date of issuance of these annual financials. We are investing in the clinical development of ivonescimab, including our ongoing clinical trials. In addition, we have a $100 million promissory note payable to a related party (refer to Note 18 in the consolidated financials included in this Annual Report further details) that matures on April 1, 2025.  Based upon our cash and cash equivalents and short-term investments as of December 31, 2023, we expect to be able to operate into the first quarter of 2025. In order to further fund our operating cash needs and repay this promissory note, we intend to raise additional capital. As of the date of the issuance of these financial statements the additional capital has not been secured. As a result, these conditions raise substantial doubt about our ability to continue as a going concern.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the payments already made to Akeso, under the License Agreement there are additional potential milestone payments of $4.5 billion, as Akeso will be eligible to receive regulatory milestones of up to $1.05 billion and commercial milestones of up to $3.45 billion. In addition, Akeso will be eligible to receive low double-digit royalties on net sales. Until we can generate substantial revenue and achieve profitability, we will need to raise additional capital to fund ongoing operations and capital needs, including the payment of the milestone payments referenced above. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have based the foregoing estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. This estimate assumes, among other things, that we do not obtain any additional funding through grants and clinical trial support or through new collaboration arrangements. Our future capital requirements will depend on many factors, including:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the costs, timing and outcome of clinical trials required for clinical development of ivonescimab;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the costs, timing and outcome of activities related to development, validation, manufacturing and establishment of supply chain for ivonescimab;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and development requirements of other future product candidates that we pursue;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs, timing and outcome of regulatory review of ivonescimab and/or our other product candidates we develop;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of commercialization activities, including product sales, marketing, distribution and manufacturing, for any of our product candidates that receive marketing approval;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we become liable for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">milestone payments under our Licensing Agreement for ivonescimab;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">subject to receipt of marketing approval, revenue received from commercial sales of any product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and defending against any intellectual property-related claims;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain collaborations, licensing or other arrangements and the financial terms of such arrangements;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or invest in other businesses, products and technologies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate of the expansion of our physical presence; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we change our physical presence.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of some, or all, of the following: equity and debt offerings, collaborations, strategic alliances, grants and clinical trial support from government entities, philanthropic, non-government and not-for-profit organizations, and marketing, distribution or licensing arrangements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need to seek additional funding in the future to fund operations. Additional capital, when needed, may not be available to us on acceptable terms, or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our existing stockholders may be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our existing stockholders. Additional debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incurring additional debt, making capital expenditures or declaring dividends or other distributions. If we raise additional funds through collaborations, strategic alliances or marketing, distribution, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves, which could materially adversely affect our business prospects or our ability to continue operations. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of our cash flows for the years ended December 31, 2023 and 2022.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"/><td style="width:66.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(587.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the year ended December 31, 2023 was $76.8&#160;million and resulted from a net loss of $614.9&#160;million, which included an adjustment of $475.0&#160;million in cash payments related to investing activities for the purchase of in-process research and development from Akeso under the terms of the License Agreement and the associated direct transaction costs and non-cash charges of $65.5&#160;million and a net increase in working capital of $2.4&#160;million. Non-cash charges primarily include a $45.9&#160;million expense for the issuance of shares in lieu of cash for the Akeso upfront payment, $14.1&#160;million of stock-based compensation, $6.3&#160;million related to non-cash interest expense, $1.9 million related to amortization of right-of-use assets, and a $0.5&#160;million impairment charge, partially offset by $1.9&#160;million related to amortization of discount on short-term investments and $0.8&#160;million in a net unrealized foreign exchange gain. The net increase in working capital is primarily due to a $3.7&#160;million increase in other long-term assets, a $2.4 million decrease in accrued liabilities, and a $2.2&#160;million decrease in lease liabilities , partially offset by a $4.2&#160;million decrease in the research and development tax credit receivable and a $2.3&#160;million increase in accounts payable.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the year ended December 31, 2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was $41.6&#160;million and resulted from a net loss of $78.8&#160;million, which included non-cash charges of $28.6 million and a $8.6&#160;million net decrease in working capital. Non-cash charges primarily include $11.9&#160;million of stock-based compensation, a $8.5&#160;million impairment charge, $4.3&#160;million related to non-cash interest expense, a $2.6&#160;million unrealized foreign currency exchange loss, and $1.3 million in amortization of right-of-use assets, partially offset by a $1.3&#160;million gain on remeasurement of an assumed contingent liability. The net decrease in working capital primarily includes an $8.4&#160;million decrease in research and development tax credit receivable, a $5.1&#160;million decrease in prepaid expenses, a $4.8&#160;million increase in accrued liabilities, and a $1.6&#160;million increase in accrued compensation, partially offset by a $7.3&#160;million decrease in deferred revenue and income, a $4.1&#160;million decrease in accounts payable, and a $1.1&#160;million decrease in lease liabilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the years ended December 31, 2023 was $587.8&#160;million and was primarily due to $475.0&#160;million of cash payments made to Akeso pursuant to the License Agreement and $112.9&#160;million of net purchases of short-term investments. Net cash used in investing activities for the year ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2022 was for the purchase of property and equipment.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the year ended December 31, 2023 was $86.5&#160;million  and was primarily due to net proceeds received of $104.1 million (net of paid issuance costs) related to the issuance of common stock from the 2023 Rights Offering and net of the extinguishment of $395.3 million of principal and accrued interest due and payable by us under </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the $400 million Duggan Promissory Note in satisfaction of the subscription price for the shares subscribed by Mr. Duggan in the 2023 Rights Offering, $5.0 million received for the issuance of common stock via a private placement to a related party, and $1.2 million received for the exercise of stock option warrants, partially offset by the repayment of $24.7 million related to promissory notes from related parties.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the year ended December 31, 2022 was $620.2 million and primarily resulted from net proceeds of $99.9 million from the rights offering in August 2022, proceeds from promissory notes from related parties of $545.0 million, partially offset by the repayment of a promissory note from a related party of $25.0 million and $0.4 million of net proceeds from the exercise of stock options.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Commitments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fixed asset purchase commitments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2023 and 2022, we had no capital commitments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease commitments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our lease contractual obligations as of December 31, 2023. </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"/><td style="width:36.624%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.880%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Payment due by period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less than 1 year</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Between 1 and 3 years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Between 3 and 5 years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">More than 5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table above does not include the lease agreement signed by the Company on January&#160;8, 2024 for executive office space for its new headquarters in Miami, Florida. The office space is approximately 9,000 square feet. The term of the lease is 64 months. Total payments for this office space is approximately $5.1&#160;million over the term of the lease. The table above excludes payments related to the lease signed in January 2024. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt commitments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 6, 2022, we entered into a Note Purchase Agreement (the &#8220;Note Purchase Agreement&#8221;), with Mr. Robert Duggan and Dr. Maky Zanganeh, pursuant to which the Company agreed to sell to each of Mr. Duggan and Dr. Zanganeh unsecured promissory notes in the aggregate amount of $520 million. Pursuant to the Note Purchase Agreement, the Company issued to Mr. Duggan and Dr. Zanganeh unsecured promissory notes in the amount of $400 million (the &#8220;Duggan February Note&#8221;) and $20 million (the &#8220;Zanganeh Note&#8221;), respectively, which matured and became due on February 15, 2023 and an unsecured promissory note to Mr. Duggan in the amount of $100 million (the &#8220;Duggan September Note&#8221; and together with the Duggan February Note and the Zanganeh Note, the &#8220;December 2022 Notes&#8221;), which was originally due on September 15, 2023. The maturity dates of the December 2022 Notes could have been extended one or more times at the Company&#8217;s election, but in no event to a date later than September 6, 2024. In addition, if the Company consummates a public offering, then upon the later to occur of (i) five business days after the Company receives the net cash proceeds therefrom or (ii) May 15, 2023, the Duggan February Note and the Zanganeh Note shall be prepaid by an amount equal to the lesser of (a) 100% of the amount of the net proceeds of such offering and (b) the outstanding principal amount on such Notes. On January 19, 2023, the Company provided notice to extend the term of the Duggan February Note and Duggan September Note to a maturity date of September 6, 2024. Furthermore, on January 19, 2023, the Company and Mr. Duggan rectified the Duggan February Note and Duggan September Note in order to correctly reflect the parties&#8217; intent that the Company may only prepay (i) the Duggan February Note following the completion of a public rights offering to be conducted by Summit in the approximate amount of $500 million (the &#8220;Rights Offering&#8221;), or a similar capital raise, in an amount equal to the lesser of (x) the net proceeds of the Rights Offering or such capital raise or (y) the full amount outstanding of the Duggan February Note, and (ii) the Duggan September Note following the completion of a capital raising transaction subsequent to the Rights Offering in an amount equal to the lesser of (A) the net proceeds of such capital raise or (B) the full amount outstanding of the Duggan September Note. Following the issuance of the two new Promissory Notes (the &#8220;Duggan Promissory Notes&#8221;), the Duggan February Note and Duggan September Note were marked as &#8220;cancelled&#8221; on their face and replaced in their entirety by the Duggan Promissory Notes (together with the Zanganeh Note, the &#8220;Notes&#8221;). The Notes accrue interest at an initial rate of 7.5%. All interest on the Notes shall be paid on the date of signing for the period through February 15, 2023. Such prepaid interest shall be paid in a number of shares of the Company&#8217;s common stock, par value $0.01 (&#8220;Common Stock&#8221;) equal to the dollar amount of such prepaid interest, divided by $0.7913 (the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated closing bid price immediately preceding the time the Company entered into the Note Purchase Agreement, plus $.01), which was 9,720,291 shares. For all applicable periods following February 15, 2023, interest shall accrue on the outstanding principal balance of the Notes at the US prime interest rate, as reported in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wall Street Journal,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plus 50 basis points, as adjusted monthly, for three months immediately following February 15, 2023, and thereafter at the US prime rate plus 300 basis points, as adjusted monthly. On February 15, 2023, the $20 million Zanganeh Note matured and we repaid the outstanding principal balance. In connection with the closing of the Rights Offering, the $400 million Duggan Promissory Note matured and became due, and we repaid all principal and accrued interest thereunder using a portion of the proceeds from the Rights Offering. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2024 the Duggan February Note was amended to extend the maturity date from September 6, 2024 to April 1, 2025. For all applicable periods commencing  February 17, 2024, interest shall accrue on the outstanding principal balance at the greater of 12% or the US prime interest rate, as reported in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wall Street Journal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plus 350 basis points, as adjusted monthly, compounded quarterly. Interest shall be paid upon maturity of the loan.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future principal payments are $0 and $100,000,000 for 2024 and 2025, respectively, as the note matures on April 1, 2025.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other commitments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into contracts in the normal course of business with various third parties for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes. Most contracts provide for termination upon notice, and therefore are cancellable contracts. As of December 31, 2023, total contractual commitments, excluding leases commitments and debt commitments, are estimated to be approximately $37.7 million and the majority of these commitments are due within one year.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to December 31, 2023 through February 9, 2024, the Company entered into additional contractual commitments of approximately $23.0 million with various third parties related to our clinical trials.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have certain commitments under our agreements with Akeso, Wellcome Trust, the University College London and certain employees, former employees and former directors of Discuva, pursuant to which we will be required to pay royalties or make milestone payments. The License Agreement with Akeso also contains certain manufacturing and purchase commitments. As of December 31, 2023, we are unable to estimate the amount, timing or likelihood of achieving the milestones, making future product sales or assessing estimated forecasts for manufacturing and supplied materials which these contingent payment obligations relate to. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indemnifications</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation provides that it will indemnify the directors and officers to the fullest extent permitted by Delaware law. In addition, we have entered into indemnification agreements with all of the directors and executive officers. These indemnification agreements may require us, among other things, to indemnify each such director or executive officer for some expenses, including attorneys&#8217; fees, judgments, fines, and settlement amounts incurred by him or her in any action or proceeding arising out of his or her service as one of our directors or executive officers. We believe the fair value for these indemnification obligations is minimal. Accordingly, we have not recognized any liabilities relating to these obligations as of December 31, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently subject to any material legal proceedings.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with United States generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to accrued research and development expenses, stock-based compensation and income taxes. We base our estimates on historical experience, known trends and events, and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the following critical accounting policies affect the most significant judgments, assumptions and estimates we use in preparing the consolidated financial statements:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquired In-Process Research and Development</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company  may enter into agreements with collaboration partners for the development and commercialization of its products. These arrangements may include payments contingent on the occurrence of certain events such as development, regulatory or sales-based milestones. The Company considers the unique nature, terms and facts and circumstances of each transaction. The Company considers whether or not the assets acquired have a future alternative use. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value associated with acquired in-process research and development which does not have an alternative future use is expensed and is recorded as research and development expense. Any development or commercial milestone payments are recognized when the achievement of the associated milestone becomes probable and will either be expensed or capitalized depending upon whether or not regulatory approval has been obtained. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Costs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred to discover, research and develop product candidates, including personnel expenses, stock-based compensation expense, allocated facility-related and depreciation expenses, third-party license fees and external costs of outside vendors engaged to conduct preclinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials. Non - refundable prepayments for goods or services that will be used or rendered for future research and development activities are recorded as prepaid expenses. Such amounts are recognized as an expense as the goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered. The significant estimates in our accrued research and development expenses include the costs incurred for services performed by our vendors in connection with research and development activities for which we have not yet been invoiced. Milestone and other payments made to third-parties with respect to in-process research and development, in accordance with the Company&#8217;s license, acquisition and other similar agreements are expensed when determined to be probable and estimable.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various research and development contracts with other companies. These agreements are generally cancellable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research and development costs or prepaid expenses where the payments made exceeds the estimated costs. When evaluating the adequacy of these balances, the Company analyzes progress of the studies, including the estimated costs to complete each study or activity, the estimation of the current stage of completion and the invoices received, as well as predetermined milestones which are not reflective of the current stage of development for prepaid expenses. Actual results could differ from the Company&#8217;s estimates. In all cases, the full cost of each study or activity is expensed by the time the final report or where applicable, product, has been received. The Company&#8217;s historical estimates have not been materially different from the actual costs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and recognizes compensation expense for all stock option and restricted stock unit awards based on the estimated fair value of the award on the grant date. The Company uses the Black-Scholes option pricing model to estimate the fair value of stock option awards. Additionally, the Company uses a Monte Carlo simulation model to calculate the estimated fair value on the date of grant related to awards with market-based service conditions. The fair value is recognized as expense, over the requisite service period, which is generally the vesting period of the respective award, on a straight-line basis for each separately vesting portion of the award when the only condition to vesting is continued service.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If vesting is subject to a market or performance condition, recognition is based on the derived service period of the award. Expense for awards with performance conditions is estimated and adjusted on a quarterly basis based upon the assessment of the probability that the performance condition will be met. Use of the Black-Scholes option-pricing model requires management to apply judgment under highly subjective assumptions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These assumptions include:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expected term&#8212;The expected term of stock options represents the weighted-average period the stock options are expected to be outstanding. The Company uses the simplified method for estimating the expected term as provided by the Securities and Exchange Commission. The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life of the options.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.85pt">Expected volatility&#8212;The expected volatility is calculated based on historical volatility of the Company&#8217;s share price.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk-free interest rate&#8212;The risk-free rate assumption is based on the U.S. Treasury instruments, the terms of which were consistent with the expected term of the Company&#8217;s stock options.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expected dividend&#8212;The expected dividend assumption is based on the Company&#8217;s history and expectation of dividend payouts. The Company has not paid and does not intend to pay dividends. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates expected forfeitures at the time of grant instead of accounting for forfeitures as they occur. Stock option and restricted stock unit awards have been granted at fair value to non-employees, in connection with research and consulting services provided to the Company, to non-employees in connection with corporate activities, and to employees, in connection with Stock Purchase and Restriction Agreements. Equity awards generally vest over terms of 3 or 4 years. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies stock-based compensation expense in the consolidated statements of operations in the same manner in which the award recipient&#8217;s payroll costs are classified.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is determined using the asset and liability approach. Tax laws may require items to be included in tax filings at different times than the items are reflected in the financial statements. A current asset or liability is recognized for the estimated taxes receivable or payable for the current year. Deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. Deferred taxes are initially recognized at enacted tax rates in force at the time of initial recognition and are subsequently adjusted for any enacted changes in tax rates and tax laws. Subsequent changes to deferred taxes originally recognized in equity are recognized in income. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The Company has recorded a full valuation allowance against the deferred tax assets in excess of its deferred tax liabilities, as the deferred tax liability represents future reversals of existing taxable temporary differences. The Company records interest and penalties related to income tax matters as part of income tax expense.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertainty in income taxes by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed as the amount of benefit to recognize in the consolidated financial statements. The amount of benefits that may be used is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate, as well as the related net interest and penalties. At December 31, 2023 and 2022, the Company had unrecognized tax positions of $1.1 million and nil, respectively.  Due to the Company&#8217;s full valuation allowance, the unrecognized tax benefits would not materially impact the Company&#8217;s effective tax rate when recognized. The Company does not anticipate the total amount of unrecognized tax benefits to significantly increase or decrease in the next 12 months. The Company&#8217;s policy is to recognize interest and penalties related to uncertain tax positions as part of its income tax provision. For the years ended December 31, 2023 and 2022, the Company had no interest or penalties related to unrecognized tax benefits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of recent accounting pronouncements, please see Note 5 to our consolidated financial statements contained in this Annual Report on Form 10-K. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><div id="if355807d1b914743a4dab03fe6913e8f_43"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7A. Quantitative and Qualitative Disclosures About Market Risk </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary exposures to market risk are liquidity risk and foreign currency risk.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity Risk</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have funded our operations since inception primarily through the issuance of equity and debt securities. We have also received funding from our license, collaboration, and commercialization arrangements, for example, our license and commercialization agreement with Eurofarma, as well as philanthropic, non-government and not-for-profit organizations and grant funding from government entities, including BARDA, CARB-X, Innovate UK, Wellcome Trust and a number of not-for-profit organizations. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity or debt financings or other sources. Adequate additional financing may not be available to us on acceptable terms, or at all. Our inability to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Exchange Rate Risk</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency exchange rate risk refers to the risk that the value of a financial commitment or recognized asset or liability will fluctuate due to changes in foreign currency rates. Our net loss and financial position, as expressed in U.S. dollars, are exposed to movements in foreign exchange rates against the pound sterling and the euro. The main trading currencies are the pound sterling, the U.S. dollar, and the euro. We are exposed to foreign currency exchange rate risk as a result of entering into operating transactions denominated in currencies other than the functional currency of our subsidiaries, particularly in relation to our monetary assets and liabilities relating to intercompany transactions, supplier liabilities and the translation of foreign cash balances. Operating transaction foreign currency gains and losses are included in the determination of net loss in our statements of operations. We monitor our exposure to foreign currency exchange rate risk. Exposures are generally managed through natural hedging via the currency denomination of cash balances and any impact currently is not material to us.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hold our cash, cash equivalents and short-term investments for working capital purposes. Some of the securities we invest in are subject to market risk. This means that a change in prevailing interest rates may cause the principal amount of such investments to fluctuate. To minimize this risk, we maintain our portfolio of cash, cash equivalents and short-term investments which are invested in a variety of short term securities, including money market funds and investments in U.S. treasury securities. Due to the short-term nature of these instruments, we believe that we do not have any material exposure to changes in the fair value of our investment portfolio as a result of changes in interest rates. Declines in interest rates, however, would reduce future interest income. The effect of a hypothetical 10% increase or decrease in overall interest rates would not have had a material impact on our operating results or the total fair value of our portfolio.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We are exposed to market risks related to fluctuations in interest rates related to our promissory notes payable to related parties. As of December 31, 2022, the principal balance payable was $520&#160;million, the outstanding principal balance is subject to a variable interest rate from February 15, 2023. As of December 31, 2023, the principal balance outstanding was $100.0 million. For all applicable periods following February 15, 2023, interest accrued on the outstanding principal balance at the United States prime interest rate, as reported in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Wall Street Journal,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> plus 50 basis points, as adjusted monthly, for three months immediately following February 15, 2023, and thereafter at the United States prime rate plus 300 basis points, as adjusted monthly. On February 17, 2024 the Duggan February Note was amended to extend the maturity date from September 6, 2024 to April 1, 2025. For all applicable periods commencing  February 17, 2024, interest shall accrue on the outstanding principal balance at the greater of 12% or the US prime interest rate, as reported in the Wall Street Journal plus 350 basis points, as adjusted monthly, compounded quarterly. Interest shall be paid upon maturity of the loan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit Risk</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all of our material counterparties to be creditworthy. We consider the credit risk for each of our counterparties to be low and do not have a significant concentration of credit risk at any of our counterparties. We have $1.8&#160;million of research and development tax credits outstanding at December 31, 2023. Given that these receivables relate to U.K. research and development tax credit cash rebate regimes and given our history of collection, it is highly unlikely that these amounts will not be collected.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt"><span><br/></span></div><div id="if355807d1b914743a4dab03fe6913e8f_46"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;8. Financial Statements and Supplementary Data</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements required to be filed pursuant to this Item 8 are included in this Annual Report on Form 10-K. An index of those financial statements is found in Item 15. </span></div><div><span><br/></span></div><div id="if355807d1b914743a4dab03fe6913e8f_49"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div><span><br/></span></div><div id="if355807d1b914743a4dab03fe6913e8f_52"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9A. Controls and Procedures</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules&#160;13a-15(e) and 15d-15(e) under the Exchange Act) under the supervision and the participation of the company&#8217;s management, which is responsible for the management of the internal controls, and which includes our Chief Executive Officers (our Principal Executive Officers) and our Chief Financial Officer (our Principal Financial Officer). The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Securities Exchange Act of 1934 is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives. Based upon our evaluation of our disclosure controls and procedures as o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f December 31, 2023,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> our Chief Executive Officer and Executive Chairman and Chief Executive Officer, President and Director (our Principal Executive Officers), and our Chief Financial Officer (our Principal Financial Officer) concluded that, as of such date, our disclosure controls and procedures were effective at a reasonable level of assurance.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting is a process designed, under the supervision of the Chief Executive Officers (our Principal Executive Officers), and our Chief Financial Officer (our Principal Financial Officer), to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external reporting purposes in accordance with Generally Accepted Accounting Principles.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect all misstatements. Moreover, projections of any evaluation of the effectiveness of internal control to future periods are subject to a risk that controls may become inadequate because of changes in conditions and that the degree of compliance with the policies or procedures may deteriorate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management has assessed the effectiveness of internal control over financial reporting as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, based on the Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) 2013. Based on this assessment, our management has concluded that our internal control over financial reporting as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was effective. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report does not include an attestation report of our registered public accounting firm as we are a non-accelerated filer and a smaller reporting company.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting (as defined in Rules 13a&#8209;15(f) and 15d&#8209;15(f) under the Exchange Act) during the quarter ended December 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div><span><br/></span></div><div id="if355807d1b914743a4dab03fe6913e8f_55"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. Other Information</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2024 the Duggan February Note was amended to extend the maturity date from September 6, 2024 to April 1, 2025. For all applicable periods commencing  February 17, 2024, interest shall accrue on the outstanding principal balance at the greater of 12% or the US prime interest rate, as reported in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wall Street Journal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plus 350 basis points, as adjusted monthly, compounded quarterly. Interest shall be paid upon maturity of the loan.</span></div><div><span><br/></span></div><div><span><br/></span></div><div id="if355807d1b914743a4dab03fe6913e8f_58"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="if355807d1b914743a4dab03fe6913e8f_61"></div><div style="margin-top:24pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:120%">s</span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div id="if355807d1b914743a4dab03fe6913e8f_64"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. Directors, Executive Officers and Corporate Governance</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CORPORATE GOVERNANCE</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors oversees our Chief Executive Officers, and other senior management in the competent and ethical operation of our business and affairs and assures that the long-term interests of the stockholders are being served. Our Board of Directors has adopted Corporate Governance Guidelines that address items such as the qualifications and responsibilities of our directors and director candidates and corporate governance policies and standards applicable to us in general. We believe that good governance leads to high board effectiveness, promotes the long-term interests of our stockholders, strengthens the accountability of our Board of Directors and management and improves our standing in our industry.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board Leadership Structure</span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors believes that the roles of Chairman and Chief Executive Officer may be filled by the same or different individuals. This allows our Board of Directors to have the flexibility to determine whether the two roles should be combined or separated based upon the needs of the Company and our Board of Directors&#8217; assessment of our leadership from time to time. Our Board of Directors also believes that combining the role of Chairman and Chief Executive Officer facilitates the strategic development of the Company and the flow of information between the Board and management. In our Board&#8217;s view, Mr. Duggan is best situated to serve as Chairman because of his familiarity with the Company&#8217;s business and industry and his insight into the strategies and policies to be discussed by the Board of Directors. At this time, our Board of Directors believes it is in the best interests of our Company and our stockholders for Robert W. Duggan to serve as our Chief Executive Officer and Chairman of the Board of Directors. The Chairman of the Board of Directors presides over all Board meetings and approves the agenda for meetings of the Board of Directors. He also works with the Board of Directors to drive decisions about particular strategies and policies. </span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Appointment of the Lead Independent Director</span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors has determined that it is advisable, in light of having the same person, Robert W. Duggan, serve as both Chief Executive Officer and Chairman of the Board of Directors, to appoint a lead independent director (&#8220;LID&#8221;). The Board of Directors has approved the appointment of Kenneth Clark as LID. The LID shall be responsible for the following duties: (i) to chair any meeting of the independent directors in executive sessions; (ii) to meet with any director who is not adequately performing his or her duties as a member of the Board of Directors; (iii) to facilitate communications between other members of the Board of Directors and the Chairman of the Board and Chief Executive Officer; (iv) to monitor, with the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assistance of the Company&#8217;s legal advisors, communications from stockholders and other interested parties; (v) to work with the Chairman of the Board in the preparation of the agenda for each Board of Directors meeting; and (vi) to otherwise consult with the Chairman of the Board and Chief Executive Officer on corporate governance matters and the Board of Directors&#8217; performance. </span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Board of Director&#8217;s Role in Risk Oversight</span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management has day-to-day responsibility for identifying risks facing us, including implementing suitable mitigating processes and controls, assessing risks in relation to Company strategies and objectives, and appropriately managing risks in a manner that serves the best interests of the Company, our stockholders, and other stakeholders. Our Board of Directors is responsible for ensuring that an appropriate culture of risk management exists within the Company and for setting the right &#8220;tone at the top,&#8221; overseeing our aggregate risk profile, and assisting management in addressing specific risks.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, various committees of our Board of Directors oversee risks associated with their respective areas of responsibility and expertise. For example, our Audit Committee oversees, reviews and discusses with management and the independent auditor risks associated with our internal controls and procedures for financial reporting and the steps management has taken to monitor and mitigate those exposures; our Audit Committee also oversees the manage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ment of other risks, including those associated with credit risk. Our Compensation Committee oversees the management of risks associated with our compensation policies, plans and practices. Our Nominating and Corporate Governance Committee oversees the management of risks associated with director independence and the composition and organization of the Board of Directors. Our Board of Directors provides direct oversight over cybersecurity risks. Management and other employees report to the Board of Directors and/or relevant committee from time to time on risk-related issues.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Diversity of the Board</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Nominating and Corporate Governance Committee does not maintain a specific policy with respect to board diversity, the Board of Directors believes that the Board of Directors should be a diverse body. Diversity in experiences, perspectives, and backgrounds is just one of many factors considered by the Nominating and Corporate Governance Committee in considering director nominees. In August 2021, the SEC adopted Nasdaq&#8217;s proposal that requires listed companies to provide statistical information about their boards of directors, in the form of a matrix chart. The below Diversity Matrix reports self-identified diversity statistics for the Board in the format required by Nasdaq&#8217;s rules.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"><tr><td style="width:1.0%"/><td style="width:41.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.646%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Board Diversity Matrix (as of February 13, 2024)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Number of Directors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Female</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Male</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Binary</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Did Not Disclose </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gender</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gender Identity</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Directors</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Demographic Background</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">African American or Black</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alaskan Native or Native American</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asian</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hispanic or Latinx</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Native Hawaiian or Pacific Islander</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">White</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Two or More Races or Ethnicities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LGBTQ+</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Did Not Disclose Demographic Background</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Director Independence</span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under applicable Nasdaq rules, a director will only qualify as an &#8220;independent director&#8221; if, in the opinion of the listed company&#8217;s board of directors, that person does not have a relationship that would interfere with the exercise of independent </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">judgment in carrying out the responsibilities of a director. In order to be considered independent for purposes of Rule 10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee, accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries or otherwise be an affiliated person of the listed company or any of its subsidiaries. In order to be considered independent for purposes of Rule 10C-1, the board must consider, for each member of a compensation committee of a listed company, all factors specifically relevant to determining whether a director has a relationship to such company which is material to that director&#8217;s ability to be independent from management in connection with the duties of a compensation committee member, including, but not limited to: (1) the source of compensation of the director, including any consulting advisory or other compensatory fee paid by such company to the director; and (2) whether the director is affiliated with the company or any of its subsidiaries or affiliates.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon information requested from and provided by each director concerning his or her background, employment and affiliations, including family relationships, our Board of Directors has determined that each of Mr. Clark, Ms. Mahatme, Mr. Booth and Ms. Cesano, representing four of our eight directors, is &#8220;independent&#8221; as that term is defined under the rules of The Nasdaq Stock Market and none of these directors has or has had a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors also determined that Mr. Clark, Ms. Mahatme, Mr. Booth, and Ms. Cesano, who comprise our Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee, satisfy the independence standards for those committees established by applicable SEC rules, including Rule 10A-3 of the Exchange Act, and the rules of The Nasdaq Stock Market. In making this determination, our Board of Directors considered the relationships that each non-employee director has or has had with our Company and all other facts and circumstances that our Board of Directors deemed relevant in determining their independence, including the beneficial ownership of our capital stock by each non-employee director.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under The Nasdaq Stock Market listing requirements, a company of which more than 50% of the voting power is held by an individual, group, or another company is a &#8220;controlled company.&#8221;&#160;Because Mr. Duggan owns more than a majority of the voting power of our outstanding shares of common stock, we are a &#8220;controlled company&#8221; under the corporate governance rules for Nasdaq-listed companies. A &#8220;controlled company&#8221; may elect not to comply with certain Nasdaq corporate governance requirements, including the requirements that:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a majority of the board of directors consist of independent directors;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.85pt">the compensation committee be composed entirely of directors meeting Nasdaq independence standards applicable to compensation committee members with a written charter addressing the committee&#8217;s purpose and responsibilities;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the compensation committee be responsible for the hiring and overseeing of persons acting as compensation consultants and be required to consider certain independence factors when engaging such persons; and</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.53pt">director nominees either be selected, or recommended for board of directors&#8217; selection, either by &#8220;independent directors&#8221; as defined under the rules of Nasdaq constituting a majority of the board of director&#8217;s &#8220;independent directors&#8221; in a vote in which only &#8220;independent directors&#8221; participate, or by a nominations committee comprised solely of &#8220;independent directors.&#8221;</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to take advantage of these exemptions. As a result, our stockholders may not have the same protections afforded to stockholders of companies that are subject to all of the Nasdaq corporate governance rules.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Director Nominations</span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Candidates for nomination to our Board of Directors are selected by the Nominating and Corporate Governance Committee in accordance with the committee&#8217;s charter, and our Certificate of Incorporation and Bylaws. The Nominating and Corporate Governance Committee evaluates all candidates in the same manner and using the same criteria, regardless of the source of the recommendation.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Nominating and Corporate Governance Committee may retain recruiting professionals to assist in identifying and evaluating candidates for director nominees. Our Board of Directors has adopted Corporate Governance Guidelines and the Nominating and Corporate Governance Committee has adopted Policies and Procedures for Director Candidates which sets out, among other things, that the Nominating and Corporate Governance Committee considers factors such as character, integrity, judgment, diversity of experience (including age, gender, international background, race and professional experience), independence, area of expertise, length of service, potential conflicts of interest, other commitments and the like. The </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nominating and Corporate Governance Committee considers the following minimum qualifications to be satisfied by any nominee to the Board of Directors: a reputation for integrity, honesty and adherence to high ethical standards; a demonstrated business acumen, experience and ability to exercise sound judgments in matters that relate to the current and long-term objectives of the Company; a commitment to understanding the Company and its industry; a commitment to regularly attend and participate in meetings of the Board and its committees; an interest and ability to understand the sometimes conflicting interests of the various constituencies of the Company, including stockholders, employees, customers, governmental units, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">credito</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rs and the general public, and to act in the interests of all stockholders. Based on the Nominating and Corporate Governance Committee&#8217;s recommendation, the Board of Directors selects director nominees and recommends them for election by our stockholders, and also fills any vacancies that may arise between annual meetings of stockholders.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Nominating and Corporate Governance Committee will consider director candidates who are proposed by our stockholders in accordance with our Bylaws, our Nominating and Corporate Governance Committee&#8217;s Policies and Procedures for Director Candidates and other procedures established from time to time by the Nominating and Corporate Governance Committee. If you would like the Nominating and Corporate Governance Committee to consider a prospective director candidate, please follow the procedures in our Bylaws and submit the candidate&#8217;s name and qualifications to: Corporate Secretary, Summit Therapeutics Inc., 601 Brickell Key Drive, Suite 1000, Miami, FL 33131.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Code of Business Conduct and Ethics</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officers, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A copy of the code is filed herewith as Exhibit 14.1 and posted on the &#8220;Investor Center/Corporate Governance&#8221; section of our website, which is located at https://www.smmttx.com/. If we make any substantive amendments to, or grant any waivers from, the code of business conduct and ethics for any officer or director, we will disclose the nature of such amendment or waiver on our website or in a current report on Form 8-K to be filed with the SEC.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Policy on Short Sales, Derivative Transactions and Hedging Transactions</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Insider Trading Policy prohibits any director or employee from engaging in any of the following types of transactions with respect to the Company&#8217;s securities: (i) short sales, including short sales &#8220;against the box&#8221;, (ii) purchases or sales of puts, calls, or other derivative securities or (iii) purchases of financial instruments (including prepaid variable forward contracts, equity swaps, collars and exchange funds) or other similar transactions that directly hedge or offset, or are designed to directly hedge or offset, any decrease in the market value of Company securities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Communication with the Board of Directors</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any stockholder communication with our Board of Directors or individual directors should be directed to Summit Therapeutics Inc., c/o Corporate Secretary, 601 Brickell Key Drive, Suite 1000, Miami, FL 33131. The Corporate Secretary will forward these communications, as appropriate, directly to the director(s). The independent directors of the Board of Directors review and approve the stockholder communication process periodically in an effort to enable an effective method by which stockholders can communicate with the Board of Directors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BOARD OF DIRECTORS AND COMMITTEES OF THE BOARD</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board and Committee Meetings</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors and its committees meet throughout the year on a set schedule, hold special meetings as needed, and act by written consent from time to time. During fiscal year 2023, our Board of Directors held 3 meetings, and each director attended at least 75% of the aggregate of (i) the total number of meetings of our Board of Directors held during the period for which he or she has been a director and (ii) the total number of meetings held by all committees of our Board of Directors on which he or she served during the periods that he or she served.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The names of our director nominees and directors, their ages and certain other information about them are set forth below:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"/><td style="width:32.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.980%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:55.540%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Age</span></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Position</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert W. Duggan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Executive Chairman</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mahkam Zanganeh</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer, President, and Director</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manmeet S. Soni</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Operating Officer and Director</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kenneth A. Clark</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65</span></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lead Independent Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert Booth</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70</span></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alessandra Cesano</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63</span></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ujwala Mahatme</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59</span></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yu Xia</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57</span></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal occupations and positions and directorships for at least the past five years of our directors and director nominees, as well as certain information regarding their individual experience, qualifications, attributes and skills that led our Board of Directors to conclude that they should serve on the Board of Directors, are described below. There are no family relationships among any of our directors or executive officers, however, Mr. Duggan and Dr. Zanganeh have a personal relationship with each other.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Robert W. Duggan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 79,&#160;has served as a member of our Board of Directors since December 2019, Executive Chairman since February 2020, and Chief Executive Officer since April 2020. Since 2016, Mr. Duggan has been Chief Executive Officer of Duggan Investments, Inc., a family office of Mr. Duggan dedicated to research and administration of his personal investments primarily in the field of biotech focused on patient-friendly breakthrough solutions to complex diseases of aging. From September 2007 through the acquisition by AbbVie Inc. in May 2015, Mr. Duggan was a member of the board of directors of Pharmacyclics, Inc., a patient-friendly, science-based, employee-driven developer of small-molecule medicines for the treatment of cancers. Mr. Duggan was also the Chairman and Chief Executive Officer of Pharmacyclics from September 2008 to May 2015 as well as its largest investor. From 1990 to 2003, Mr. Duggan was chairman of the board of directors of Computer Motion, Inc. From 1997 to 2003, Mr. Duggan also served as Chief Executive Officer of Computer Motion. In June 2003, Computer Motion merged with Intuitive Surgical Inc. Mr. Duggan has been a director and the chairman of the board of directors of Pulse Biosciences, Inc. since November 2017. From 2003 to 2011, Mr. Duggan served on the board of directors of Intuitive Surgical.  Mr. Duggan received a U.S. Congressman&#8217;s Medal of Merit from Ron Paul in 1985 and in 2000 he was named a Knight of the Legion of Honor by President Jacques Chirac of France.  He is a member of the University of California at Santa Barbara Foundation board of trustees.</span></div><div style="margin-bottom:0.1pt;text-indent:0.35pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Duggan was appointed as a director because of his significant combined service as Chief Executive Officer of an innovative biopharmaceutical company and career spanning over 30 years as a venture investor and advisor for a broad range of companies, and extensive expertise in vision, strategic development, planning, finance and management.</span></div><div style="margin-bottom:0.1pt;text-indent:0.35pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> &#160;&#160;&#160;&#160;Mahkam (Maky) Zanganeh</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 53, has served as a member of our Board of Directors since November 2020 and as Chief Executive Officer and President since July 2022. Dr. Zanganeh has previously served as the Company&#8217;s Chief Operations Officer from November 2020 to July 2022. Dr. Zanganeh is Founder, Chief Executive Officer and Director of Maky Zanganeh and Associates, an executive management and consulting firm founded in 2015. Previously, from August 2012 to September 2015, she served as the Chief Operating Officer of Pharmacyclics Inc. She also served as Chief of Staff and Chief Business Officer of Pharmacyclics from December 2011 to July 2012 and Vice President, Business Development from August 2008 to November 2011. Prior to joining Pharmacyclics Inc., Dr. Zanganeh served as President Director General (2007-2008) for the French government bio-cluster project initiative in France, establishing alliances and developing small life science businesses regionally. From September 2003 to August 2008, Dr. Zanganeh served as Vice President of Business Development for Robert W. Duggan &amp; Associates. Dr. Zanganeh also served as worldwide Vice President of Training &amp; Education (2002-2003) and President Director General for Europe, Middle East and Africa (1998-2002) for Computer Motion Inc. Dr. Zanganeh has been a member  of the Board of Directors of Pulse Biosciences, Inc. since February 2017. Dr. Zanganeh received a DDS degree from Louis Pasteur University in Strasbourg, France and MBA from Schiller International University in France.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Zanganeh was appointed as a director because of her years of executive and operational experience in the life sciences industry.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manmeet S. Soni</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 46, has served as a member of our Board of Directors since December 2019 and as Chief Operating Officer since October 2023. From February 2022 to October 2023, Mr. Soni was the President, Chief Operating Officer and Chief Financial Officer of Reata Pharmaceuticals, Inc., a pharmaceutical company focused on developing and commercializing novel therapeutics for the treatment of severe or life-threatening diseases, until its acquisition by Biogen in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">October 2023. Mr. Soni joined Reata in August 2019 as Chief Financial Officer, Executive Vice President and was promoted in June 2020 to Chief Operating Officer and Chief Financial Officer, Executive Vice President of Reata.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to joining Reata Pharmaceuticals, Mr. Soni was the Senior Vice President and Chief Financial Officer of Alnylam Pharmaceuticals Inc. from May 2017 to August 2019.  From March 2016 to February 2017, Mr. Soni served as Executive Vice President, Chief Financial Officer and Treasurer of ARIAD Pharmaceuticals, Inc., a biopharmaceutical company, when ARIAD was acquired by Takeda Pharmaceutical Company Limited. Previously, he served as Chief Financial Officer of Pharmacyclics, Inc., a biopharmaceutical company, until its acquisition by AbbVie in 2015.  Prior to joining Pharmacyclics, Mr. Soni worked at Zeltiq Aesthetics Inc., a publicly held medical technology company which was acquired by Allergan Inc. (acquired by Abbvie).  Prior to Zeltiq, Mr. Soni worked at PricewaterhouseCoopers in the life science and venture capital group. Mr. Soni currently serves as a member of the board of directors of Pulse Biosciences, Inc. since November 2017 and previously served as a member of the board of directors of Arena Pharmaceuticals, Inc. (acquired by Pfizer, Inc.). Mr. Soni is a Certified Public Accountant and Chartered Accountant (India).</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Soni was appointed as a director because of his extensive experience in the life sciences industry and his financial and accounting expertise.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Kenneth A. Clark</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 65, has served on our Board of Directors since October 2021. Mr. Clark is a partner of Wilson Sonsini Goodrich &amp; Rosati, where he advises biotech companies on strategic partnerships, mergers and acquisitions, financing transactions and operational matters.  He is also a partner of TCG Labs, a venture capital fund affiliated with The Column Group.   Mr. Clark has previously served as a member of the boards of directors for multiple publicly traded companies, including Pulse BioSciences, Inc. and Pharmacyclics, Inc, and is currently a director of Acurex Biosciences.  Mr. Clark received his undergraduate degree from Vanderbilt University and a juris doctorate from the University of Texas School of Law.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe Mr. Clark is qualified to serve on our Board of Directors because of his expertise in business consulting, deal transactions, financing, and corporate law in the biotechnology sector.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Robert Booth</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 70, has served on our Board of Directors since September 2022 and also serves as a member of the Audit Committee and the Nominating and Corporate Governance Committee. Dr. Booth has spent more than 30 years in the biopharmaceutical industry, most recently as founder and chief executive officer of Virobay Inc. Additionally, he has served as operating partner and senior advisor at TPG Biotech. Prior to Virobay, Dr. Booth was the chief scientific officer at Celera Genomics, where he was responsible for all discovery and development activities. At Celera, Dr. Booth conceived and initiated the BTK inhibitor program that was ultimately licensed to Pharmacyclics and from which IMBRUVICA&#174; (ibrutinib) was developed and approved. Dr. Booth served on the board of directors of Pharmacyclics until its acquisition by AbbVie. Prior to Celera, Dr. Booth was senior vice president for Roche in Palo Alto, California, where he was a member of the global research management team and the business development committee, which oversaw licensing opportunities. Dr. Booth additionally currently serves on the boards of Acurex Biosciences and Thryv Therapeutics, private companies that are focused on neurodegenerative diseases and cardiovascular diseases, respectively. Dr. Booth received his BSc and PhD in biochemistry from the University of London. The Board has determined that Dr. Booth qualifies as an independent director under applicable Nasdaq listing rules.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe Dr. Booth is qualified to serve on our Board of Directors because of his expertise in the life sciences industry.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ujwala Mahatme</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 59, has served as a member of our Board of Directors since July 2020. Currently, Ms. Mahatme serves as the Founder and Managing Partner of Mahatme Bitterman PLLC, a role she has held since 2002. Previously, Ms. Mahatme served as Counsel at Gibson, Dunn &amp; Crutcher and Counsel and Associate at Pillsbury Winthrop Shaw Pittman LLP. She received her Bachelor of Commerce from Brihan Maharashtra College of Commerce, University of Poona, her Bachelor of Laws from ILS Law School, University of Poona, Master of Laws from the University of Cambridge and Master of Laws in Corporation Law from New York University.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe Ms. Mahatme is qualified to serve on our Board of Directors because of her expertise in corporate law and financing in the biotechnology sector.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Alessandra Cesano</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 63,&#160;has served as a member of our Board of Directors and the Nominating and Corporate Governance Committee since November 2022. Dr. Cesano has 26 years of experience in research and development in both drug and diagnostic companies ranging from large, global biopharma to private, venture-backed companies, and currently serves as </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Medical Officer of ESSA Pharma. Prior to ESSA, Dr. Cesano was the Chief Medical Officer at NanoString Inc., where she built and led the Immuno-Oncology program and the diagnostic pipeline. Prior to NanoString, she was Chief Medical Officer for Cleave Biosciences. There, Dr. Cesano led the successful filing of two INDs for a clinical candidate and led two Phase I trials in Multiple Myeloma and solid tumors. Dr. Cesano has global full-phase development and regulatory experience with large and small molecules and had a substantive and lead role in two approved drugs &#8211; Kepivance&#174; (palifermin) and Vectibix&#174; (panitumumab). Dr. Cesano serves on the board of directors at Puma Biotechnology. She received her PhD in tumor immunology and her MD from the University of Turin. The Board has determined that Dr. Cesano qualifies as an independent director under applicable Nasdaq listing rules.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe Dr. Cesano is qualified to serve on our Board of Directors because of her expertise in the biopharmaceutical industry focused on oncology. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Yu (Michelle) Xi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a, age 57, has served as a member of our Board of Directors since January 2023. Dr. Xia is the founder of Akeso, Inc., and has been the chairwoman, president and CEO of the Company since its inception in 2012.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Xia has over 27 years of experience in the pharmaceutical industry and academic research. Prior to founding Akeso Biosciences, Dr. Xia held senior leadership roles at Crown Bioscience Inc., where she played a decisive role in constructing Crown Bioscience&#8217;s platform, building its team, setting and implementing its strategies, and forging its joint venture with Pfizer (the Pfizer-Crown Asian Cancer Research Centre). From 2006 to 2008, Dr. Xia served as a senior scientist and group leader at PDL BioPharma, Inc. (later acquired by AbbVie). In 2006, Dr. Xia served as a senior process development scientist at Bayer Corporation in the U.S. At both PDL BioPharma and Bayer, Dr. Xia oversaw CMC, process development and manufacturing of therapeutic protein and antibody drugs. Dr. Xia began her pharmaceutical career at Axys Pharmaceuticals, Inc. (later acquired by Celera Genomics), where she held both scientific and managerial roles in drug discovery programs from December 2000 to December 2005, overseeing a broad range of activities from target validation through IND-enabling studies. Dr. Xia earned her Ph.D. degree in molecular biology and microbiology from Newcastle University in the U.K. in 1994. Dr. Xia completed her postdoctoral research training at the University of Glasgow in the U.K. from 1993 to 1996, and she also conducted the cancer immune therapy research at the University of Louisville School of Medicine in the U.S. from 1996 to 2000.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the years, Dr. Xia has served important roles in numerous influential organizations, including a member of the Special Committee for Monoclonal Antibody of the China Medicinal Biotech Association, a committee member of the Special Committee for Science and Technology Innovation of China Overseas Returnee Entrepreneur Investment Association, an advisory committee member of the Chinese Antibody Society, and a director of Tongxieyi Antibody Talent Club. Dr. Xia has also received numerous awards and recognitions for her contributions to both the pharmaceutical industry and commercial enterprises. Most recently, Dr. Xia was selected into Forbes&#8217; Powerful Women in Technology in 2020 and in 2023 was named by Forbes China as a Top 100 Women in Business in China.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe Dr. Xia is qualified to serve on our Board of Directors because of her extensive experience in the biopharmaceutical industry, including in oncology.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board Committees</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors has the following standing committees: Audit Committee,  Compensation Committee, and Nominating and Corporate Governance Committee, each of which has the composition and the responsibilities described below. The Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee all operate under charters approved by our Board of Directors, which charters are available on the Investor Center of our website at https://www.smmttx.com under &#8220;Corporate Governance.&#8221; Our Board of Directors from time to time establishes additional committees to address specific needs.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth (i) the three standing committees of the Board of Directors, (ii) the members of each committee as of December 31, 2023, and (iii) the number of meetings held by each committee in fiscal year 2023:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.935%"><tr><td style="width:1.0%"/><td style="width:34.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.282%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.282%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.284%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Audit</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compensation</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nominating and Corporate Governance</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert W. Duggan</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mahkam Zanganeh</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manmeet S. Soni</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kenneth A. Clark</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X (Chair)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X (Chair)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X (Chair)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert Booth</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alessandra Cesano</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ujwala Mahatme</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of Meetings Held During 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_______________</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">On October 13, 2023, the Company appointed Manmeet Soni as Chief Operating Officer. In connection with his employment as Chief Operating Officer, Mr. Soni resigned from his seat on the Board&#8217;s Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee, as well as from his position as lead independent director. To fill the vacancies left by Mr. Soni, Robert Booth was appointed to the Audit Committee and Kenneth A. Clark was appointed as the lead independent director on the Board.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">On February 16, 2024, Mr. Clark was appointed to serve as Compensation Committee Chair.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Corporate Governance Guidelines set out that all directors are expected to attend our annual meeting of stockholders. All of the current Board members who were members of the Board at our 2023 annual stockholder meeting attended such meeting.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Audit Committee</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Audit Committee oversees our corporate accounting and financial reporting process and assists the Board of Directors in monitoring our financial systems and our legal and regulatory compliance. Our Audit Committee is responsible for, among other things:</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">appointing, approving the compensation of, and assessing the independence of our registered public accounting firm;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">overseeing the work of our registered public accounting firm, including through the receipt and consideration of reports from such firm;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing and discussing with management and the registered public accounting firm our annual and quarterly financial statements and related disclosures;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">monitoring our internal control over financial reporting, disclosure controls and procedures and code of business conduct and ethics; </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing policies regarding the receipt and retention of accounting related complaints and concerns;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">meeting independently with our internal auditing staff, if any, our registered public accounting firm and management;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing and approving or ratifying any related person transactions; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preparing the Audit Committee report required by SEC rules.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The members of our Audit Committee are Mr. Clark, Mr. Booth and Ms. Mahatme. Mr. Clark serves as our Audit Committee Chair. Our Board of Directors has determined that each member of our Audit Committee is independent within the meaning of the independent director guidelines of The Nasdaq Stock Market. We believe that the composition of our Audit Committee meets the requirements for independence under, and the functioning of our Audit Committee complies with, all applicable requirements of The Nasdaq Stock Market and SEC rules and regulations. In addition, our Board of Directors has determined that Mr. Clark meets the financial literacy requirements under the rules of The Nasdaq Stock Market and the SEC and that he qualifies as Audit Committee financial expert as defined under SEC rules and regulations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation Committee</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Compensation Committee oversees our corporate compensation policies, plans and programs. Our Compensation Committee is responsible for, among other things:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing and approving, or making recommendations to our Board of Directors with respect to, the compensation of our chief executive officers and our other executive officers;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">overseeing an evaluation of our senior executives;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">overseeing and administering our cash and equity incentive plans;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing and making recommendations to our Board of Directors with respect to director compensation;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing and discussing annually with management our &#8220;Compensation Discussion and Analysis&#8221; disclosure if and to the extent then required by SEC rules; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preparing the Compensation Committee report required by SEC rules.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The members of our Compensation Committee are Mr. Clark and Ms. Mahatme. Mr Clark serves as our Compensation Committee Chair. Our Board of Directors has determined that each member of our Compensation Committee is independent within the meaning of the independent director guidelines of The Nasdaq Stock Market. We believe that the composition of our Compensation Committee meets the requirements for independence under, and the functioning of our Compensation Committee complies with, all applicable requirements of The Nasdaq Stock Market and SEC rules and regulations.</span></div><div style="margin-bottom:12pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nominating and Corporate Governance Committee</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Nominating and Corporate Governance Committee oversees and assists our Board of Directors in reviewing and recommending corporate governance policies and nominees for election to our Board of Directors. Our Nominating and Corporate Governance Committee is responsible for, among other things:</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identifying individuals qualified to become members of our Board of Directors;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recommending to our Board of Directors the persons to be nominated for election as directors and to each of our Board of Directors&#8217; committees;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing and making recommendations to our Board of Directors with respect to our Board of Directors leadership structure;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing and making recommendations to our Board of Directors with respect to management succession planning;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing and recommending to our Board of Directors corporate governance principles; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">overseeing an annual evaluation of our Board of Directors.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023 the members of our Nominating and Corporate Governance Committee are Mr. Clark, Dr. Booth, Ms. Mahatme and Dr. Cesano. Mr. Clark serves as our Nominating and Corporate Governance Committee Chair. Our Board of Directors has determined that each member of our Nominating and Corporate Governance Committee is independent within the meaning of the independent director guidelines of The Nasdaq Stock Market.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Director Compensation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee directors are not compensated for Board of Directors services in addition to their regular employee compensation. </span></div><div style="margin-bottom:0.1pt;text-align:justify;text-indent:0.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For 2023, the non-employee members of the Board of Directors were compensated as follows:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cash compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">: Each non-employee member of the Board received the following cash compensation (the &#8220;Retainer Cash Payments&#8221;):</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an annual retainer for each member of the Board of $48,000 paid in equal quarterly installments;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the members of our Audit, Compensation and Nominating and Corporate Governance Committees were eligible to receive an additional annual retainer of $6,500 for their service on each committee; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Chairs of the Audit, Compensation and Nominating and Corporate Governance Committees were eligible to receive annual retainers of $36,700, $13,000, and $13,000, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We reimbursed our non-employee directors for all reasonable out-of-pocket expenses incurred in the performance of their duties as directors.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Equity Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">: Each non-employee director received a stock option annual grant to purchase 35,000 shares of the Company&#8217;s common stock, par value $0.01, at a strike price equal to the fair market value of the common stock on the grant date, which shall vest in four equal quarterly installments, with the first such installment occurring on March 31 in the year of grant.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each new non-employee director appointed during 2023 received a stock option grant to purchase 200,000 shares of the Company&#8217;s common stock, par value $0.01, at a strike price equal to the fair market value of the common stock on the grant </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">date, which shall vest in four equal annual installments, with the first such installment occurring on the one-year anniversary of the grant date. Each new non-employee director appointed during 2023 was also granted a prorated annual grant for their service in the fourth quarter of 2023, at a strike price equal to the fair market value of the common stock on the grant date, which vested in full on December 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2023, each non-employee director may elect to convert all or a portion of his or her Retainer Cash Payments into a number of options (the &#8220;Retainer Option,&#8221; and such election, a &#8220;Retainer Option Election&#8221;) into a set number of options. The number of shares subject to a Retainer Option will be equal to (i) the product of (A) the dollar value of the aggregate Retainer Cash Payments that the non-employee director elects to forego over the course of a specified period covered by a Retainer Option Election in favor of receiving a Retainer Option multiplied by (B) 3.0 (the &#8220;Retainer Option Multiplier&#8221;), divided by (ii) the fair market value of a share on the date of grant of the Retainer Option, provided that the number of shares covered by such Retainer Option shall be rounded to the nearest whole share. The Retainer Options shall be awarded annually and vest in four equal quarterly installments on March 31, June 30, September 30 and December 31 following the Retainer Option Election, subject to the director remaining as a non-employee director on each such vesting date. The election must have been made by December 31 of the preceding year. </span></div><div style="margin-bottom:0.1pt;text-align:justify;text-indent:0.35pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information concerning compensation paid or earned for services rendered to us by the non-employee members of our Board of Directors for the fiscal year ended December 31, 2023. Compensation paid to Mr. Duggan, Dr. Zanganeh and Mr. Soni is included in the section entitled, &#8220;Executive Compensation&#8221; and excluded from the table below:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"><tr><td style="width:1.0%"/><td style="width:35.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.053%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.053%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.056%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fees Earned or Paid in Cash ($)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Option Awards ($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total ($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kenneth A. Clark</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,792&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308,855&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334,647&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert Booth</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ujwala Mahatme</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alessandra Cesano</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michelle Xia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_______________</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Amounts shown represent the aggregate grant date fair value of the option awards computed in accordance with FASB ASC Topic 718. These amounts do not correspond to the actual value that will be realized by our directors. The assumptions used in the valuation of these awards are consistent with the valuation methodologies specified in the notes to our financial statements.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Fees earned or paid in cash for Mr. Clark and Mr. Booth were a result of these individuals filling the vacancies left by Mr. Soni as described above.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Dr. Xia did not receive any compensation for her role as a member of the Company's Board of Directors in 2023.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The aggregate number of shares subject to stock options outstanding and exercisable on December 31, 2023 for each non-employee director is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"/><td style="width:41.620%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.540%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Number of Stock Options Outstanding as of December 31, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Number of Stock Options Exercisable as of December 31, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert Booth</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alessandra Cesano</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kenneth A. Clark</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369,160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269,160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ujwala Mahatme</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Michelle Xia</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">DELINQUENT SECTION 16(a) REPORTS</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Section 16(a) of the Exchange Act requires that our executive officers and directors and other persons who beneficially own more than 10% of a registered class of our equity securities file with the SEC reports of ownership and reports of changes in ownership of shares and other equity securities. Such executive officers and directors and other persons who beneficially </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">own more than 10% of a registered class of our equity securities are required by the SEC to furnish us with copies of all Section 16(a) reports filed by such reporting persons.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Based solely on our review of such forms furnished to us or written representations provided to us by the reporting person, we are aware of no late Section 16(a) reports required to be filed by our executive officers, directors and other persons who beneficially own more than 10% of a registered class of our equity securities in the year ended December 31, 2023, other than: (i) a late Form 4 to report the acquisition by Akeso of 10,000,000 shares of common stock on January 17, 2023 in connection with the entry into the License Agreement; and (ii) a late Form 4 to report the acquisition by Akeso of 21,523,530 shares of common stock on March 7, 2023 in the Company&#8217;s 2023 Rights Offering. Dr. Xia is a stockholder and exercises the right to vote approximately 28.9% of Akeso's ordinary shares, and serves as chairwoman, president and chief executive officer of Akeso. Dr. Xia disclaims beneficial ownership of the shares of Issuer's Common Stock beneficially owned by Akeso, except to the extent of her pecuniary interest therein. Dr. Xia filed a Form 5 on February 14, 2024 to report each of the transactions described in clauses (i) and (ii) of this paragraph.</span></div><div><span><br/></span></div><div id="if355807d1b914743a4dab03fe6913e8f_67"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;11. Executive Compensation</span></div><div style="text-align:center"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXECUTIVE COMPENSATION</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation Committee Report</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The information contained in the following report of the Compensation Committee shall not be deemed to be &#8220;soliciting material&#8221; or to otherwise be considered &#8220;filed&#8221; with the SEC, nor shall such information be incorporated by reference into any future filing under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or the Exchange Act except to the extent that the Company specifically incorporates it by reference into such filing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee has reviewed and discussed the following &#8220;Executive Compensation&#8221; section of this Annual Report with management. Based on this review and discussion, the Compensation Committee recommended to our Board of Directors that such information be included in this Annual Report.</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Members of the Compensation Committee:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kenneth A. Clark (Chair)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ujwala Mahatme</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Compensation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a discussion and analysis of compensation arrangements of our named executive officers (NEOs). This discussion contains forward looking statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs. Actual compensation programs that we adopt may differ materially from currently planned programs as summarized in this discussion. As a smaller reporting company, we are not required to include a Compensation Discussion and Analysis section and have elected to comply with the scaled disclosure requirements applicable to smaller reporting companies.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to ensure that the total compensation paid to our executive officers is reasonable and competitive. Compensation of our executives is structured around the achievement of individual performance and near-term corporate targets as well as long-term business objectives.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our NEOs for fiscal year 2023 were as follows, who are comprised of (1) our principal executive officers in fiscal year 2023 and (2) our next most highly compensated executive officers who were serving as executive officers as of December 31, 2023:</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Robert W. Duggan, our Chief Executive Officer and Executive Chairman;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Mahkam Zanganeh, our Chief Executive Officer, President and Director;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Manmeet Soni, our Chief Operating Officer and Director</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ankur Dhingra, our Chief Financial Officer;</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary Compensation Table</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding the compensation of our principal executive officers and our next two most highly compensated executive officers, who were serving as executive officers as of December 31, 2023:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"><tr><td style="width:1.0%"/><td style="width:24.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.801%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name and Principal Position</span></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Salary ($)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bonus ($)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.37pt;padding-right:1.37pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Option Awards ($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.37pt;padding-right:1.37pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">All Other Compensation ($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></div><div style="margin-bottom:1.5pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">($)</span></div></td></tr><tr style="height:14pt"><td colspan="3" rowspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.65pt;padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Robert W. Duggan,</span></div><div style="margin-bottom:1.5pt;padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer and Executive Chairman</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:18pt"><td colspan="3" rowspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mahkam Zanganeh, Director, Chief Executive Officer, and President</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,905,115</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,562,924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:18pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452,500</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,200</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,349</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,242,049</span></td></tr><tr style="height:18pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,250</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,987,768</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,196</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,639,214</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manmeet Soni, Chief Operating Officer</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,381,640</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(9)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,699</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,613,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ankur Dhingra, Chief Financial Officer</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,231</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381,918</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694,464</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(10)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,237</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,362,850</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_______________</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) &#160;&#160;&#160;&#160;Final bonus amounts for 2023 have not yet been approved by the Compensation Committee and will be paid in April 2024.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Amounts shown represent the aggregate grant date fair value of the option awards computed in accordance with FASB ASC Topic 718. These amounts do not correspond to the actual value that will be realized by our named executive officers. The assumptions used in the valuation of these awards are consistent with the valuation methodologies specified in the notes to our financial statements. </span></div><div style="padding-left:0.35pt;text-align:justify;text-indent:-0.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;The amounts paid for all other compensation consisted of the following:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"><tr><td style="width:1.0%"/><td style="width:28.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.156%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name and Principal Position</span></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.4pt;padding-right:1.4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Health, Life and Disability Benefits ($)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">401(k) Match/Pension Scheme ($)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.4pt;padding-right:1.4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Director Fees</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></div><div style="margin-bottom:1.5pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">($)</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Robert W. Duggan,</span></div><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer and Executive Chairman</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mahkam Zanganeh, Director, co- Chief Executive Officer, and President</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manmeet Soni</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ankur Dhingra, Chief Financial Officer </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;Mr.&#160;Duggan has declined any compensation from the Company.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;Dr. Zanganeh&#8217;s salary was increased to from $450,000 per annum to $600,000 per annum effective January 1, 2023.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)  &#160;&#160;&#160;&#160;Mr. Dhingra&#8217;s salary was increased from $450,000 per annum to $500,000 per annum effective January 1, 2023.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)&#160;&#160;&#160;&#160;Dr. Zanganeh was awarded 11,988,198 of options which vest in four equal annual installments, with an aggregate fair value associated at the date of grant date of $16,524,442. Dr. Zanganeh was also awarded 11,988,198 of stock options with performance-based criteria and market service conditions with an aggregate fair value at the grant date of $16,903,359, assuming 100% of the performance conditions are achieved. Only 20% of these awards were estimated to be probable at December 31, 2023 and these awards have a fair value associated with the awards at the date of grant of $3,380,673.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8)      Dr. Zanganeh was awarded stock options with performance-based criteria and market service conditions with an aggregate fair value at the grant date of $1,384,400, assuming 100% of the performance conditions are achieved. Only </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20% of the awards were estimated to be probable at December 31, 2023 and these awards have a fair value associated with the awards at grant date of $307,200. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9)        Mr. Soni was awarded 14,000,000 stock options which vest in four equal annual installments, with an aggregate fair value associated at the date of grant date of $19,297,495. Mr Soni was also awarded 14,000,000 stock options with performance-based criteria and market service conditions with an aggregate fair value at the grant date of $19,740,000, assuming 100% of the performance conditions are achieved. Only 20% of these awards were estimated to be probable at December 31, 2023 and these awards have a fair value associated with the awards at the date of grant of $3,948,000. Prior to joining the Company as Chief Operating Officer, Mr. Soni was granted options for serving on the Company's Board of Directors with a fair value of $136,145. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10)       Mr. Dhingra was awarded 600,000 of options which vest in four equal annual installments, with an aggregate fair value associated at the date of grant date of $563,064. Mr Soni was also awarded 750,000 of stock options with performance-based criteria and market service conditions with an aggregate fair value at the grant date of $587,600, assuming 100% of the performance conditions are achieved. Only 20% of these awards were estimated to be probable at December 31, 2023 and these awards have a fair value associated with the awards at the date of grant of $131,400. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span><br/></span></div><div style="margin-bottom:0.1pt"><span><br/></span></div><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outstanding Equity Awards at Fiscal Year-End</span></div><div style="margin-bottom:0.1pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents certain information concerning equity awards held by our principal executive officer and our next most highly compensated executive officer, who were serving as executive officers as of December 31, 2023:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"><tr><td style="width:1.0%"/><td style="width:33.515%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.521%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.124%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Option Awards</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of securities underlying outstanding options</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Option exercise price ($/sh)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Option expiration date</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant date</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercisable</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unexercisable</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert W. Duggan, Chief Executive Officer and Executive Chairman</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" rowspan="8" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mahkam Zanganeh, Director, Chief Executive Officer, and President</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11/11/2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/11/2030</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/11/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,323</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/11/2030</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11/22/2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600,000</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/22/2030</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12/15/2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/15/2031</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/28/2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,300,000</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/28/2032</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/9/2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,000</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/9/2032</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/13/2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,988,198</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/13/2033</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/13/2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,988,198</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/13/2033</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" rowspan="8" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manmeet Soni, Director, Chief Operating Officer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/23/2019</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/23/2029</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/1/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,273</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/1/2030</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/19/2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/19/2031</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/3/2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/3/2032</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/3/2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,446</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/3/2032</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/3/2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/3/2033</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/13/2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/13/2033</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/13/2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/13/2033</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ankur Dhingra, Chief Financial Officer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/31/2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,000</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/31/2032</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/28/2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,000</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/28/2032</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/9/2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,000</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/9/2032</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">_______________</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Option award was originally a performance-based award. In September 2021, this award was modified to a time-based award, which vest in four equal annual installments beginning on November 22, 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Options vest in three years on December 15, 2024.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3) &#160;&#160;&#160;&#160;Option award is a performance-based award with market service conditions. As of December 31, 2023, none of the conditions had been met. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)           Options vest in four equal quarterly installments. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)           Options vest in four equal annual installments beginning May 31, 2023.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)           On October 13, 2023, the Company appointed Manmeet Soni as Chief Operating Officer. Awards granted prior to October 13, 2023 were for Mr. Soni&#8217;s service on the Company&#8217;s Board of Directors.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Narrative to Summary Compensation Table and Outstanding Equity Awards at Fiscal Year End</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employment Agreement with Mahkam Zanganeh</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We entered into an employment agreement with Dr. Zanganeh, our current Chief Executive Officer and President, on November 22, 2020. The employment relationship between the Company and Dr. Zanganeh is &#8220;at-will&#8221;, and the employment agreement has no specific term.  Dr. Zanganeh&#8217;s annual base salary as of December 31, 2022 was $450,000. Pursuant to her employment agreement, upon her appointment she received a grant of options to purchase 2,400,000 shares of our common stock, vesting in four equal annual installments, subject to the satisfaction of certain performance conditions. During fiscal year ended December 31, 2021, the Compensation Committee of the Board of Directors determined to eliminate the requirements for satisfying performance-based stock option awards and deemed all performance-based vesting requirements satisfied. Following this determination, the option awards are subject only to previous existing time-based vesting conditions. Dr. Zanganeh was eligible for an annual target bonus equal to 45% of her salary in 2021 and 2022 and 60% of her annual base salary for 2023, subject to achievement of performance objectives. Dr. Zanganeh was paid a discretionary cash bonus of $182,250 relating to 2021 and this bonus was paid in March of 2022. Dr. Zanganeh was paid a discretionary cash bonus of $202,500 and an extraordinary bonus of $250,000 relating to 2022 and this bonus was paid in January 2023. Dr. Zanganeh&#8217;s salary was increased to from $450,000 per annum to $600,000 per annum effective January 1, 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Zanganeh is eligible to participate in employee benefit plans maintained from time to time by us of general applicability to other senior executives. During her term of service as an executive officer, Dr. Zanganeh will not receive compensation that would otherwise be owed to her in her capacity as a member of our Board of Directors.  </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employment Agreement with Manmeet Soni</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into an employment agreement with Mr. Soni, our Chief Operating Officer on October 13, 2023. The employment relationship between the Company and Mr. Soni is &#8220;at-will&#8221;, and the employment agreement has no specific term. Mr. Soni&#8217;s annual base salary as of December 31, 2023 was $600,000. Pursuant to his employment agreement upon his appointment he received a grant of options to purchase 14,000,000 shares of our common stock, vesting in four equal annual installments. In addition, Mr. Soni received a performance-based grant of options to purchase 14,000,000 shares of our common stock, vesting annually over four years, subject to the satisfaction of certain performance and market service conditions. Mr. Soni will be eligible for a yearly discretionary cash bonus in an amount solely determined by the Company of up to 60% of annual base salary.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employment Agreement with Ankur Dhingra</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into an employment letter with Mr. Dhingra, our Chief Financial Officer, on April 15, 2022. The employment relationship between the Company and Mr. Dhingra is &#8220;at-will&#8221;, and the employment agreement has no specific term.  Mr. Dhingra&#8217;s annual base salary as of December 31, 2023 was $500,000. Pursuant to his employment agreement, upon his appointment he received a grant of options to purchase 600,000 shares of our common stock, vesting in four equal annual installments on the date approved by the Compensation Committee, and then on the next three anniversaries of such date. Mr. Dhingra was eligible in 2022 for an annual target bonus equal to 50% of his annual base salary, payable in accordance with the Company&#8217;s normal payroll practices. Mr. Dhingra was paid a discretionary cash bonus of $131,918 and an extraordinary bonus of $250,000 relating to 2022 and this bonus was paid in January 2023. Mr. Dhingra&#8217;s salary was increased from $450,000 per annum to $500,000 per annum effective January 1, 2023.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Dhingra is eligible to participate in employee benefit plans maintained from time to time by us of general applicability to other senior executives.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PAY VERSUS PERFORMANCE</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Item&#160;402(v)&#160;of&#160;Regulation&#160;S-K,&#160;we are providing the following information about the relationship between executive </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compensation and certain financial performance of our Company. The disclosure included in this section is prescribed by SEC rules and does not necessarily align with how the Company or the compensation committee view the link between the Company&#8217;s performance and its NEOs pay.</span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div id="if355807d1b914743a4dab03fe6913e8f_70"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="text-align:center"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain information as of February 9, 2024 with respect to the beneficial ownership of our common stock by (i) each person we believe beneficially holds more than 5% of the outstanding shares of our common stock based solely on our review of SEC filings or information provided to us by such person; (ii) each director and nominee; (iii) each named executive officer listed in the table entitled, &#8220;Summary Compensation Table&#8221; under the section entitled, &#8220;Executive Compensation&#8221;; and (iv) all directors and executive officers as a group. As of February 9, 2023, 701,697,179 shares of our common stock were issued and outstanding. Unless otherwise indicated, all persons named as beneficial owners of our common stock have sole voting power and sole investment power with respect to the shares indicated as beneficially owned. Unless otherwise noted below, the address of each stockholder listed on the table is c/o Summit Therapeutics Inc., 601 Brickell Key Drive, Suite 1000, Miami, FL 33131.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Name and Address of Beneficial Owner</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Number of Shares Owned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Right to Acquire Shares </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Total Beneficial Ownership</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Percent of Class </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">5% Stockholders:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert W. Duggan </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,369,106</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,003,691</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552,372,797</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.3%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mahkam Zanganeh</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,268,388</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,269,004</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,537,392</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yu Xia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,523,530</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,750</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,532,280</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5%</span></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Named executive officers and directors:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert W. Duggan </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,369,106</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,003,691</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552,372,797</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.3%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Mahkam Zanganeh</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,268,388</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,269,004</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,537,392</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yu Xia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,523,530</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,750</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,532,280</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manmeet S. Soni</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,976,190</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394,719</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,370,909</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ankur Dhingra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294,485</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444,485</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kenneth A. Clark</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,533</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,533</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert Booth</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,613</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,613</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ujwala Mahatme</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358,606</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358,606</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alessandra Cesano</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,607</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,607</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.569%"/><td style="width:0.1%"/></tr><tr style="height:26pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All named executive officers and directors as a group (9 people)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618,431,699</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,744,523</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">626,176,222</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">_______________</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(*)&#160;&#160;&#160;&#160;Represents beneficial ownership of less than 1% of the outstanding shares of our common stock.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Excludes shares that may be acquired through the exercise of outstanding stock options or other equity awards.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Represents shares issuable within 60 days after February 9, 2024 upon exercise of exercisable options and warrants; however, unless otherwise indicated, these shares do not include any equity awards awarded after February 9, 2024.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;For purposes of calculating the Percent of Class, shares that the person or entity had a right to acquire within 60 days after February 9, 2024 are deemed to be outstanding when calculating the Percent of Class of such person or entity.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;This information is based upon a Schedule 13D/A filed by Mr. Duggan with the Securities and Exchange Commission on February 16, 2023, updated by a Form 4 filed by Mr. Duggan on January 4, 2024, and information known to the Company. The 552,372,797 shares of common stock beneficially owned by Mr. Duggan includes (i) 548,369,106 shares of common stock, 9,346,434 shares of common stock, representing the number of shares of common stock issued to Mr. Duggan as payment of interest in connection with the Note Purchase Agreement, (ii) warrants to purchase 3,985,055 shares of common stock, which are exercisable until December 24, 2029 and (iii) options to purchase 18,636 shares of Common Stock, comprised of 18,636 options (exercisable beginning on March 31, 2024 and exercisable until January 2, 2034).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;This information is based upon a Schedule 13D/A filed by Dr. Zanganeh with the Securities and Exchange Commission on March 13, 2023, updated by a Form 4 filed by and information known to the Company. The 37,537,392 shares of Common Stock beneficially owned consist of (i) 35,268,388 shares of Common Stock owned in the aggregate by the Mahkam Zanganeh Revocable Trust and the Shaun Zanganeh Irrevocable Trust, (ii) warrants to purchase 315,681 shares of Common Stock (exercisable until December 24, 2029), and (iii) options to purchase 1,953,323 shares of Common Stock, comprising of 153,323 options (exercisable beginning on December 31, 2020 and exercisable until November 11, 2030) and 1,800,000 options (exercisable beginning on November 22, 2021 and exercisable until November 22, 2030). Of the warrants to purchase 315,681 shares of Common Stock, 315,681 are held by the Shaun Zanganeh Irrevocable Trust. The options to purchase 1,953,323 shares of Common Stock are held individually by Dr. Zanganeh.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)&#160;&#160;&#160;&#160;The shares beneficially owned by Dr. Xia include (i) 31,520,000 shares of Common Stock owned by Akeso, a company in which Dr. Xia is a stockholder and exercises the right to vote approximately 28.9% of Akeso&#8217;s ordinary shares, and in which Dr. Xia serves as chairwoman, president and chief executive officer, and (ii) options to purchase 8,750 shares of Common Stock held individually by Dr. Xia. Dr. Xia disclaims beneficial ownership of all shares of Common Stock held by Akeso, except to the extent of her pecuniary interest therein.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)&#160;&#160;&#160;&#160;This information is based upon a Form 4 filed by Mr. Soni with the securities and Exchange Commission on October 16, 2023 and information known to the Company. The 3,370,909 shares of common stock beneficially owned by Mr. Soni includes 2,976,190 shares acquired in the private placement on October 13, 2023.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8)&#160;&#160;&#160;&#160;This information is based upon a Form 4 filed by Mr. Dhingra with the Securities and Exchange Commission on December 13, 2023 and information known to the Company. The 444,485 shares of common stock beneficially owned by includes (i) 39,527 shares of common stock directly owned and (ii) 254,958 shares of common stock indirectly held by the Dhingra Family Revocable Trust.</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXECUTIVE OFFICERS</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biographical data for our current executive officers, including their ages as of December 31, 2023 is set forth below, except Mr. Duggan&#8217;s, Dr. Zanganeh and Mr. Soni&#8217;s biography, each of which are included under the heading, &#8220;Board of Directors and Committees of the Board&#8221; above.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ankur Dhingra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 48, has served as Chief Financial Officer since May 2022. Mr. Dhingra served as Chief Financial Officer at CareDx, a company focused on transplant patient journey, from March 25, 2021 through May 25, 2022. In his role at CareDx, Mr. Dhingra was responsible for finance, information technology and market access functions. Prior to CareDx, Mr. Dhingra spent 18 years at Agilent Technologies (&#8220;Agilent&#8221;) in various finance and business management roles. From January 2019 through March 2021, he was Vice President of Investor Relations and prior to that, Mr. Dhingra served as Group CFO for Agilent&#8217;s Life Sciences and Applied Markets business. Mr. Dhingra has demonstrated a track record of success scaling businesses by executing and influencing growth-oriented business strategies, expanding margins and deploying M&amp;A policies. He has extensive experience managing global teams of finance and accounting professionals. Mr. Dhingra is a qualified Chartered Accountant (India).</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Equity Compensation Plan Information</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about our equity compensation plans as of December 31, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.520%"><tr><td style="width:1.0%"/><td style="width:35.002%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.666%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.666%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.266%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Plan category</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of securities to be issued upon exercise of outstanding options, warrants and rights (a)</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price of outstanding options, warrants and rights ($)</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of securities remaining available for future issuance under equity compensation plans excluding securities reflected in column (a)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.15pt;padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans approved by security holders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,809,178</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.95</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,261,496</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans not approved by security holders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,973</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.44</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_______________</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Includes the following plans: the 2020 Stock Incentive Plan (the &#8220;Stock Incentive Plan&#8221;), the 2016 Long Term Incentive Plan (the &#8220;LTIP&#8221;) and the 2005 EMI Scheme Rules (the &#8220;EMI Plan&#8221; and together with the LTIP, the &#8220;Legacy Plans&#8221;). Our Stock Incentive Plan provides that the number of shares available for issuance thereunder will be increased on the first day of each fiscal year beginning with the 2021 fiscal year in an amount equal to the least of (i) 6,400,000 shares, (ii) 4% of the outstanding shares of our common stock as of such date, or (iii) such number of shares as determined by our Board of Directors. On January 1, 2024, the number of shares available for issuance under the Stock Incentive Plan increased by 6,400,000 shares pursuant to these provisions.  This increase is not reflected in the table above. On September 18, 2020, the Company became the successor issuer to Summit Therapeutics plc (&#8220;Old Summit&#8221;), at which point the Company assumed Old Summit&#8217;s obligations under our Legacy Plans and replaced all equity awards granted under the Legacy Plans with equivalent equity awards for our common stock. Excludes shares issued under the 2020 Employee Stock Purchase Plan.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Includes outstanding warrants granted to Elaine Stracker for consultancy services provided to the Company pursuant to the Company&#8217;s consultancy agreement that was terminated by mutual agreement in June 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div id="if355807d1b914743a4dab03fe6913e8f_73"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. Certain Relationships and Related Party Transactions</span></div><div style="text-align:center"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors has adopted written policies and procedures for the review of any transaction, arrangement or relationship in which the Company is a participant, the amount involved exceeds $120,000, and one of our executive officers, directors, director nominees or 5% stockholders (or their immediate family members), each of whom we refer to as a &#8220;related person,&#8221; has a direct or indirect material interest. If a related person proposes to enter into such a transaction, arrangement or relationship, which we refer to as a &#8220;related person transaction,&#8221; the related person must report the proposed related person transaction to our Chief Executive Officers or principal financial officer. The policy calls for the proposed related person transaction to be reviewed and, if deemed appropriate, approved by our Audit Committee. Whenever practicable, the reporting, review and approval will occur prior to entry into the transaction. If advance review and approval is not practicable, the Audit Committee will review, and, in its discretion, may ratify the related person transaction. The policy also permits the Chair of the Audit Committee to review and, if deemed appropriate, approve proposed related person transactions that arise between Audit Committee meetings, subject to ratification by the Audit Committee at its next meeting. Any related person transactions that are ongoing in nature will be reviewed annually.</span></div><div><span><br/></span></div><div><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A related person transaction reviewed under the policy will be considered approved or ratified if it is authorized by the Audit Committee after full disclosure of the related person&#8217;s interest in the transaction. As appropriate for the circumstances, the Audit Committee will review and consider:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the related person&#8217;s interest in the related person transaction;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the approximate dollar value of the amount involved in the related person transaction;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the approximate dollar value of the amount of the related person&#8217;s interest in the transaction without regard to the amount of any profit or loss;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether the transaction was undertaken in the ordinary course of our business;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether the terms of the transaction are no less favorable to us than terms that could have been reached with an unrelated third party;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the purpose of, and the potential benefits to us of, the transaction; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any other information regarding the related person transaction or the related person in the context of the proposed transaction that would be material to investors in light of the circumstances of the particular transaction.</span></div><div><span><br/></span></div><div><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee may approve or ratify the transaction only if the Audit Committee determines that, under all of the circumstances, the transaction is in the best interests of the Company and its stockholders. The Audit Committee may impose any conditions on the related person transaction that it deems appropriate.</span></div><div><span><br/></span></div><div><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the transactions that are excluded by the instructions to the SEC&#8217;s related person transaction disclosure rule, our Board of Directors has determined that the following transactions do not create a material direct or indirect interest on behalf of related persons and, therefore, are presumed not to be related person transactions for purposes of this policy:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interests arising solely from the related person&#8217;s position as an executive officer of another entity (whether or not the person is also a director of such entity), that is a participant in the transaction, where (a) the related person and all other related persons own in the aggregate less than a 10% equity interest in such entity, (b) the related person and his or her immediate family members are not involved in the negotiation of the terms of the transaction and do not receive any special benefits as a result of the transaction, and (c) the amount involved in the transaction equals less than the greater of $200,000 or 5% of the annual gross revenues of the entity receiving payment under the transaction; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a transaction that is specifically contemplated by provisions of our charter or Bylaws.</span></div><div><span><br/></span></div><div><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The policy provides that transactions involving compensation of executive officers shall be reviewed and approved by our Compensation Committee in the manner specified in its charter.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Related Party Transactions</span></div><div><span><br/></span></div><div><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the compensation arrangements, including employment, termination of employment and change in control arrangements discussed above in the sections titled &#8220;Director Compensation&#8221; and &#8220;Executive Compensation,&#8221; we describe below transactions and series of similar transactions, since the beginning of our last fiscal year, to which we were a party or will be a party, in which:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amounts involved exceeded or will exceed $120,000; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any of our directors, nominees for director, executive officers or holders of more than 5% of our outstanding capital stock, or any immediate family member of, or person sharing the household with, any of these individuals or entities, had or will have a direct or indirect material interest.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transactions with Robert W. Duggan</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 6, 2022, the Company entered into a Note Purchase Agreement (the &#8220;Note Purchase Agreement&#8221;), with Mr. Duggan and Dr. Zanganeh, pursuant to which the Company agreed to sell to each of Mr. Duggan and Dr. Zanganeh unsecured promissory notes in the aggregate amount of $520 million. Pursuant to the Note Purchase Agreement, the Company issued to Mr. Duggan and Dr. Zanganeh unsecured promissory notes in the amount of $400 million (the &#8220;Duggan February Note&#8221;) and $20 million (the &#8220;Zanganeh Note&#8221;), respectively, which matured and became due on February 15, 2023 and an unsecured promissory note to Mr. Duggan in the amount of $100 million (the &#8220;Duggan September Note&#8221; and together with the Duggan February Note and the Zanganeh Note, the &#8220;December 2022 Notes&#8221;), which was originally due on September 15, 2023. The maturity dates of the December 2022 Notes could have been extended one or more times at the Company&#8217;s election, but in no event to a date later than September 6, 2024. In addition, if the Company consummates a public offering, then upon the later to occur of (i) five business days after the Company receives the net cash proceeds therefrom or (ii) May 15, 2023, the Duggan February Note and the Zanganeh Note shall be prepaid by an amount equal to the lesser of (a) 100% of the amount of the net proceeds of such offering and (b) the outstanding principal amount on such notes.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 19, 2023, the Company provided notice to extend the term of the Duggan February Note and Duggan September Note to a maturity date of September 6, 2024. Furthermore, on January 19, 2023, the Company and Mr. Duggan rectified the Duggan February Note and Duggan September Note in order to correctly reflect the parties&#8217; intent that the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company may only prepay (i) the Duggan February Note following the completion of a public rights offering to be conducted by Summit in the approximate amount of $500 million (the &#8220;2023 Rights Offering&#8221;), or a similar capital raise, in an amount equal to the lesser of (x) the net proceeds of the Rights Offering or such capital raise or (y) the full amount outstanding of the Duggan February Note, and (ii) the Duggan September Note following the completion of a capital raising transaction subsequent to the 2023 Rights Offering in an amount equal to the lesser of (A) the net proceeds of such capital raise or (B) the full amount outstanding of the Duggan September Note. Following the issuance of the two new Promissory Notes (the &#8220;Duggan Promissory Notes&#8221;), the Duggan February Note and Duggan September Note were marked as &#8220;cancelled&#8221; on their faces and replaced in their entirety by the Duggan Promissory Notes (together with the Zanganeh Note, the &#8220;Notes&#8221;). The Notes accrue interest at an initial rate of 7.5%. All interest on the Notes were paid on the date of signing for the period through February 15, 2023. Such prepaid interest was paid in a number of shares of the Company&#8217;s common stock, par value $0.01 equal to the dollar amount of such prepaid interest, divided by $0.7913 (the consolidated closing bid price immediately preceding the time the Company entered into the Note Purchase Agreement, plus $0.01), which was 9,346,434 shares to Mr. Duggan and 373,857 shares to Dr. Zanganeh. For all applicable periods following February 15, 2023, interest shall accrue on the outstanding principal balance of the Notes at the US prime interest rate, as reported in the Wall Street Journal, plus 50 basis points, as adjusted monthly, for three months immediately following February 15, 2023, and thereafter at the US prime rate plus 300 basis points, as adjusted monthly. In connection with the closing of the 2023 Rights Offering, the $400 million Duggan February Note matured and became due, and the Company repaid all principal and accrued interest thereunder using a portion of the proceeds from the 2023 Rights Offering. During the year ended December 31, 2023, the Company made payments for interest of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$10.7 million</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2024 the Duggan February Note was amended to extend the maturity date from September 6, 2024 to April 1, 2025. For all applicable periods commencing  February 17, 2024, interest shall accrue on the outstanding principal balance at the greater of 12% or the US prime interest rate, as reported in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wall Street Journal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plus 350 basis points, as adjusted monthly, compounded quarterly. Interest shall be paid upon maturity of the loan.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 10, 2022, the Company entered into a note purchase agreement with Mr. Duggan, pursuant to which Mr. Duggan loaned the Company $25.0 million in exchange for the issuance by the Company of an unsecured promissory note in the amount of $25.0 million (the &#8220;2022 Note&#8221;). The 2022 Note accrued interest at a rate per annum equal to the prime rate as reported in the Wall Street Journal, which was 3.25% as of the effective date. The 2022 Note became due upon the earlier of (i) the consummation of a registered public offering with net proceeds of no less than $25.0 million or (ii) 18 months from the date of issuance of the 2022 Note, and was repaid on August 10, 2022.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2022, 94,849,203 shares were purchased by Mr. Duggan in connection with the July 2022 rights offering (&#8220;2022 Rights Offering&#8221;).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transactions with Dr. Mahkam Zanganeh</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, Dr. Zanganeh exercised warrants to purchase 805,495 shares. Refer to Note 20 in our consolidated financial statements contained in this Annual Report on Form 10-K for the warrants exercise activity for the year ended December 31, 2023.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described above, on December 6, 2022, the Company entered into the Note Purchase Agreement with Mr. Duggan and Dr. Zanganeh, pursuant to which the Company agreed to sell to Mr. Duggan and Dr. Zanganeh the Notes in the aggregate amount of $520 million. Pursuant to the Note Purchase Agreement, the Company issued Dr. Zanganeh the Zanganeh Note in the amount of $20 million, which matured and became due on February 15, 2023. All interest on the Notes shall be paid on the date of signing for the period through February 15, 2023. Such prepaid interest was paid in a number of shares of the Company&#8217;s common stock equal to the dollar amount of such prepaid interest, which was 373,857 shares to Dr. Zanganeh. On February 15, 2023, the $20 million Zanganeh Note matured and the Company repaid the outstanding principal balance.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2022, (i) 184,430 shares were purchased by Dr. Zanganeh (ii) 4,593,777 shares were purchased by the Mahkam Zanganeh Revocable Trust, of which Dr. Zanganeh is a trustee, and (iii) 1,030,925 shares were purchased by the Shaun Zanganeh Irrevocable Trust, of which Dr. Zanganeh is a trustee in connection with the 2022 Rights Offering.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 12, 2021, 389,977 shares were purchased by the Mahkam Zanganeh Revocable Trust in connection with the 2021 Rights Offering.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 26, 2021, the Company entered into the Sublease with Dr. Zanganeh and Associates, Inc. (&#8220;MZA&#8221;) consisting of 4,500 square feet of space at 2882 Sand Hill Road, Menlo Park, CA (the &#8220;Sublease&#8221;). The Sublease runs until </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 2022. The rent payable under the terms of the Sublease is equivalent to the proportionate share of the rent payable by MZA to the third party landlord, based on the square footage of office space sublet by the Company, and no mark-up has been applied. During the year ended December 31, 2021, payments of $556 thousand were made pursuant to the sublease. During the year ended December 31, 2022, payments of $537 thousand were made pursuant to the sublease.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 25, 2022, the Company entered into the First Amendment, dated July 19, 2022 to the Sublease with MZA. The existing Sublease term, which was set to expire on September 30, 2022, was extended for a period of thirty-nine months from October 1, 2022 through December 31, 2025. The rent payable under the terms of the Sublease is equivalent to the proportionate share of the net payable by MZA to the third-party landlord, based on the square footage of office space sublet by the Company, and no mark-up has been applied. During the year ended December 31, 2023, payments of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.8&#160;million</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, were made pursuant to the first amendment to the Sublease Agreement.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 29, 2022, the Company entered into the Second Amendment, dated August 1, 2022, to the Sublease with MZA. The Second Amendment was effective as of August 1, 2022 and expires on December 31, 2025. The Second Amendment includes an additional 1,277 square feet (the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expansion Premises&#8221;) of office space at 2882 Sand Hill Road, Menlo Park, California. The rent payable under the terms of the Sublease is equivalent to the proportionate share of the net payable by MZA to the third-party landlord, based on the square footage of office space sublet by the Company, and no mark-up has been applied. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the year ended December 31, 2023 payments of $218 thousand, were made pursuant to the Secondment Amendment to the Sublease.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transactions with Dr. Yu (Michelle) Xia</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 5, 2022, the Company entered into a Collaboration and License Agreement (the &#8220;License Agreement&#8221;) with Akeso, Inc. and its affiliates (&#8220;Akeso&#8221;) and certain ancillary transaction documents as set forth in the License Agreement. The License Agreement closed on January 17, 2023 following customary waiting periods, and both Akeso and Summit entered into the Common Stock Issuance Agreement (&#8220;Issuance Agreement&#8221;). Pursuant to the License Agreement and Issuance Agreement, Akeso elected to receive 10 million shares of Company common stock in lieu of cash and was paid $274.9 million in cash as the initial upfront payment. The $200 million remaining amount of the $500 million upfront payment was paid on March 5, 2023. The Company and Akeso also entered into Amendment No. 1 to the License Agreement, dated January 16, 2023 (the &#8220;License Agreement Amendment&#8221;), to modify the Akeso party receiving payments under the License Agreement from Akeso Biopharma Co., Ltd. to Akeso, Inc. Upon the closing of the License Agreement, the Board of Directors of the Company appointed Dr. Yu (Michelle) Xia, current Chief Executive Officer and Chairwoman of Akeso, to serve as a member of the Board of Directors pursuant to the terms of the License Agreement.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid approximately $2.5 million to Akeso during year ended December 31, 2023. As of December 31, 2023, the Company included in accrued expenses approximately $3.6 million due to Akeso.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transactions with Mr. Manmeet Soni</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 16, 2023, the Company announced the appointment of Mr. Manmeet Soni as its Chief Operating Officer, effective immediately. Mr. Soni has been a part of the Company&#8217;s Board of Directors since 2019. He will remain a member of the Board of Directors. In conjunction with his appointment, Mr. Soni entered into a share purchase agreement with the Company to purchase $5.0 million of its common stock via a private placement. The transaction was effective October 13, 2023 with a closing price of $1.68, resulting in the purchase of 2,976,190 shares of the Company&#8217;s common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnification Agreements</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation provides that we will indemnify our directors and officers to the fullest extent permitted by Delaware law. In addition, we have entered into indemnification agreements with all of our directors and named executive officers. These indemnification agreements may require us, among other things, to indemnify each such director or executive officer for some expenses, including attorneys&#8217; fees, judgments, fines, and settlement amounts incurred by him or her in any action or proceeding arising out of his or her service as one of our directors or executive officers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employment Arrangements</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into employment agreements with certain of our executive officers. For more information regarding the agreements with our named executive officers, see &#8220;Executive Compensation.&#8221;</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt"><span><br/></span></div><div id="if355807d1b914743a4dab03fe6913e8f_76"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;14. Principal Accounting Fees and Services </span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Auditor Services and Fees</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Policy on Audit Committee&#8217;s Pre-Approval of Audit and Permissible Non-Audit Services of Independent Registered Public Accounting Firm</span></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee reviews and pre-approves all audit and permissible non-audit services provided by the independent registered public accounting firm. These services may include audit services, audit-related services and tax services, as well as specifically designated non-audit services which, in the opinion of the Audit Committee, will not impair the independence of the independent registered public accounting firm. Pre-approval generally is provided for up to one year, and any pre-approval is detailed as to the particular service or category of services and generally is subject to a specific budget. The independent registered public accounting firm and the Company&#8217;s management are required to periodically report to the Audit Committee regarding the extent of services provided by the independent registered public accounting firm in accordance with this pre-approval, including the fees for the services performed to date. In addition, the Audit Committee also may pre-approve particular services on a case-by-case basis, as necessary or appropriate.</span></div><div><span><br/></span></div><div><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Auditor Fees</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the approximate aggregate fees billed to the Company by PricewaterhouseCoopers LLP for the years ending December 31, 2023 and 2022, respectively (in thousands):</span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:69.653%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.080%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.344%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fee Category</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit Fees</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,175&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,234&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit-Related Fees</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax Fees</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Other Fees</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,179&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,238&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Audit Fees: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Audit fees for both years consisted of professional services rendered for: (i) the audit of our annual consolidated financial statements, (ii) statutory audits, (iii) the review of our consolidated financial statements included in our quarterly reports on Form 10-Q and (iv) audit services associated with other reports filed with the Securities and Exchange Commission.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Audit-Related Fees: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consists of fees for professional services that are reasonably related to the performance of the audit or review of the Corporation&#8217;s financial statements and which are not reported under &#8220;Audit Fees&#8221; above. There were no audit-related fees for the year ended December 31, 2023 and 2022, respectively.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Fees: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consists of fees for professional services for tax compliance, tax advice and tax planning. There were no tax fees for the year ended December 31, 2023 and 2022, respectively.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">All Other Fees:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> All other fees for the year ended December 31, 2023 and 2022, respectively, related to a subscription to a global research and disclosure software platform.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee has concluded that the provision of the non-audit services listed above was compatible with maintaining the independence of PricewaterhouseCoopers LLP.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt"><span><br/></span></div><div id="if355807d1b914743a4dab03fe6913e8f_79"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="if355807d1b914743a4dab03fe6913e8f_82"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;15. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibits, Financial Statement Schedules</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.982%"><tr><td style="width:1.0%"/><td style="width:25.770%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.770%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:45.160%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial Statements</span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of this Report, the consolidated financial statements are listed in the accompanying index to financial statements on page 106.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.409%"><tr><td style="width:1.0%"/><td style="width:19.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:57.212%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial Statement Schedules</span></div></td></tr></table></div><div style="text-indent:32.05pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All financial statement schedules have been omitted because they are not applicable, not required, or the information required is shown in the consolidated financial statements or the notes thereto.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><div id="if355807d1b914743a4dab03fe6913e8f_85"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span><br/></span></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.982%"><tr><td style="width:1.0%"/><td style="width:25.770%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.770%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:45.160%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibits</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The exhibits filed as part of this Report are listed below.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312520199664/d78408dex991.htm">Scheme of Arrangement, dated September 18, 2020 (incorporated by reference to Exhibit 99.1 to the Company&#8217;s Report on Form 6-K (File No. 001-36866), filed with the Securities and Exchange Commission on July 27, 2020)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312520248702/d76627dex31.htm">Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K (File No. 001-36866), filed with the Securities and Exchange Commission on September 18, 2020</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312520248702/d76627dex32.htm">Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K (File No. 001-36866), filed with the Securities and Exchange Commission on September 18, 2020)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929822000086/summittherapeuticsinc-de.htm">Amendment to Restated Certificate of Incorporation of Summit Therapeutics Inc., as filed with the Delaware Secretary of State on July 27, 2022 (incorporated by reference to Exhibit 3.1 of Form 8-K filed by the Company on July 29, 2022, File No. 001-36866)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929823000012/exhibit51summittherapeut.htm">Amendment No. 2 to Restated Certificate of Incorporation, dated January 19, 2023 (incorporated by reference to Exhibit 5.1 of Form 8-K filed by the Company on January 20, 2023, File No. 001-36866)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312519005734/d683406dex21.htm">Registration Rights Agreement, dated January 9, 2019, by and among Summit Therapeutics plc and Robert W. Duggan (incorporated by reference to Exhibit 2.1 to the Company&#8217;s Report on Form 6-K (File No. 001-36866), filed with the Securities and Exchange Commission on January 10, 2019)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1599298/000159929820000039/smmt-20200929.htm#i5f970bbb3fbc499788e0a3a1c28008bd_2832">Form of Specimen Stock Certificate (incorporated by reference to Exhibit 4.2 to the Company</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8217;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1599298/000159929820000039/smmt-20200929.htm#i5f970bbb3fbc499788e0a3a1c28008bd_2832">s Current Report on Form 8-K (File No. 001-36866), filed with the Securities and Exchange Commission on September 29, 2020)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312520248702/d76627dex42.htm">Form of Consultant Warrant (incorporated by reference to Exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K (File No. 001-36866), filed with the Securities and Exchange Commission on September 18, 2020)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312520248702/d76627dex41.htm">Form of Investor Warrant (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K (File No. 001-36866), filed with the Securities and Exchange Commission on September 18, 2020)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1599298/000159929820000039/smmt-20200929.htm#i5f970bbb3fbc499788e0a3a1c28008bd_2771">Description of Securities Registered Under Section 12 of the Exchange Act (incorporated by reference to the description of securities contained in the Company</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8217;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1599298/000159929820000039/smmt-20200929.htm#i5f970bbb3fbc499788e0a3a1c28008bd_2771">s Current Report on Form 8-K (File No. 001-36866), filed with the Securities and Exchange Commission on September 18, 2020)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000092189520002819/ex103to8k12566007_11052020.htm">Registration Rights Agreement, dated November 6, 2020, by and among Summit Therapeutics Inc., Polar Capital Funds plc - Biotechnology Fund and the Mahkam Zanganeh Revocable Trust (incorporated by reference to Exhibit 10.3 to the Company</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8217;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000092189520002819/ex103to8k12566007_11052020.htm">s Current Report on Form 8-K (File No. 001-36866), filed with the Securities and Exchange Commission on November 6, 2020)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001599298/000119380521000519/ex41to8k12566001_04162021.htm">Form of Subscription Rights Certificate (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K (File No. 001-36866), filed with the Securities and Exchange Commission on April 21, 2021)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312515070214/d822352dex103.htm">Translation Award Funding Agreement, entered into as of October 19, 2012, by and between the Wellcome Trust Limited and Summit Therapeutics plc (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Registration Statement on Form F-1 (File No. 333-201807), as amended, filed with the Securities and Exchange Commission on February 27, 2015)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312515056561/d822352dex1010.htm">Service Agreement, effective as of January 14, 2015, by and between Cambridge Innovation Center and Summit Therapeutics Inc. (incorporated by reference to Exhibit 10.10 to the Company&#8217;s Registration Statement on Form F-1 (File No. 333-201807), as amended, filed with the Securities and Exchange Commission on February 20, 2015)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929820000005/sum-ex43_20191231x20f.htm">2005 Enterprise Management Incentive Scheme </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929820000005/sum-ex43_20191231x20f.htm">(incorporated by reference to Exhibit 4.3 to the Company&#8217;s Transition Report on 20-F (File No. 333-36866), as amended, filed with the Securities and Exchange Commission on April 30, 2020)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312516587491/d185299dex422.htm">2016 Long Term Incentive Plan (incorporated by reference to Exhibit 4.22 to the Company&#8217;s Annual Report on Form 20-F (File No. 001-36866), filed with the Securities and Exchange Commission on May 12, 2016)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312517104086/d365559dex423.htm">License and Collaboration Agreement, dated October 3, 2016, by and between Summit (Oxford) Ltd. and Sarepta Therapeutics, Inc. (incorporated by reference to Exhibit 4.23 to the Company&#8217;s Annual Report on Form 20-F (File No. 001-36866), filed with the Securities and Exchange Commission on March 30, 2017)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312517104086/d365559dex425.htm">Lease, dated February 17, 2017, by and among MEPC Milton Park No. 1 Limited, MEPC Milton Park No. 2 Limited and Summit Therapeutics plc (incorporated by reference to Exhibit 4.25 to the Company&#8217;s Annual Report on Form 20-F (File No. 001-36866), filed with the Securities and Exchange Commission on March 30, 2017)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000162828018004229/sum-ex426_20180131x20f.htm">Agreement, dated September 5, 2017, by and between Summit (Oxford) Limited and the U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority&#160;(BARDA) (incorporated by reference to Exhibit 4.26 to the Company&#8217;s Annual Report on Form 20-F (File No. 001-36866), filed with the Securities and Exchange Commission on April 13, 2018)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929819000008/sum-ex413_20190131x20f.htm">Amendment of Solicitation/Modification of Contract (0001), dated June 19, 2018, to Agreement, dated September 5, 2017, by and between Summit (Oxford) Limited and the U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority&#160;(BARDA) </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929819000008/sum-ex413_20190131x20f.htm">(incorporated by reference to Exhibit 4.13 to the Company&#8217;s Transition Report on 20-F (File No. 333-36866) filed with the Securities and Exchange Commission on March 29, 2019)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929819000008/sum-ex414_20190131x20f.htm">Amendment of Solicitation/Modification of Contract (0002), dated August 14, 2018, to Agreement, dated September 5, 2017, by and between Summit (Oxford) Limited and the U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority&#160;(BARDA) </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929819000008/sum-ex414_20190131x20f.htm">(incorporated by reference to Exhibit 4.14 to the Company&#8217;s Transition Report on 20-F(File No. 333-36866) filed with the Securities and Exchange Commission on March 29, 2019)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929819000008/sum-ex415_20190131x20f.htm">Amendment of Solicitation/Modification of Contract (0003), dated February 14, 2019, to Agreement, dated September 5, 2017, by and between Summit (Oxford) Limited and the U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority&#160;(BARDA) </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929819000008/sum-ex415_20190131x20f.htm">(incorporated by reference to Exhibit 4.15 to the Company&#8217;s Transition Report on 20-F (File No. 333-36866), filed with the Securities and Exchange Commission on March 29, 2019)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000162828018004229/sum-ex427_20180131x20f.htm">License and Commercialization Agreement, dated December 18, 2017, by and between Summit (Oxford) Ltd. and Eurofarma Laborat&#243;rios S.A. (incorporated by reference to Exhibit 4.27 to the Company&#8217;s Annual Report on Form 20-F (File No. 001-36866), filed with the Securities and Exchange Commission on April 13, 2018)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12&#8224;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000162828018004229/sum-ex428_20180131x20f.htm">Share Purchase Agreement, dated December 23, 2017, by and among Summit Therapeutics plc and the shareholders of Discuva Limited (incorporated by reference to Exhibit 4.28 to the Company&#8217;s Annual Report on Form 20-F (File No. 001-36866), filed with the Securities and Exchange Commission on April 13, 2018)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000162828018004229/sum-ex429_20180131x20f.htm">Transfer Incentive Agreement, dated December 23, 2017, by and among Discuva Limited and certain of its managers (incorporated by reference to Exhibit 4.29 to the Company&#8217;s Annual Report on Form 20-F (File No. 001-36866), filed with the Securities and Exchange Commission on April 13, 2018)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000162828018004229/sum-ex431_20180131x20f.htm">Lease, dated December 22, 2017, by and between Merrifield Centre Ltd and Discuva Limited (incorporated by reference to Exhibit 4.31 to the Company&#8217;s Annual Report on Form 20-F (File No. 001-36866), filed with the Securities and Exchange Commission on April 13, 2018)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000162828018004229/sum-ex432_20180131x20f.htm">Equity and Revenue Sharing Agreement, dated October 16, 2017, by and between Summit (Oxford) Limited and the Wellcome Trust Limited (incorporated by reference to Exhibit 4.32 to the Company&#8217;s Annual Report on Form 20-F (File No. 001-36866), filed with the Securities and Exchange Commission on April 13, 2018)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000162828018004229/sum-ex433_20180131x20f.htm">Form of Non-Executive Director Restricted Stock Unit (RSU) Agreement (incorporated by reference to Exhibit 4.33 to the Company&#8217;s Annual Report on Form 20-F (File No. 001-36866), filed with the Securities and Exchange Commission on April 13, 2018)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312518350442/d639714dex101.htm">Securities Purchase Agreement, dated December 14, 2018, by and among Summit Therapeutics plc and Robert W. Duggan (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Report on Form 6-K (File No. 001-36866), filed with the Securities and Exchange Commission on December 17, 2018)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929820000005/sum-ex424_20190131x20f1.htm">Amendment of Solicitation/Modification of Contract (0004), dated June 17, 2019, to Agreement, dated September 5, 2017, by and between Summit (Oxford) Limited and the U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority&#160;(BARDA) </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929820000005/sum-ex424_20190131x20f1.htm">(incorporated by reference to Exhibit 4.24 to the Company&#8217;s Transition Report on 20-f (File No. 333-36866) filed with the Securities and Exchange Commission on April 30, 2020)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312519307884/d824147dex41.htm">Securities Purchase Agreement, dated December 6, 2019, by and among Summit Therapeutics plc and Robert W. Duggan (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Report on Form 6-K (File No. 001-36866), filed with the Securities and Exchange Commission on December 6, 2019)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312519307884/d824147dex42.htm">Placing Agreement, December 6, 2019, by and between Summit Therapeutics plc and Nplus1 Singer Advisory LLP (incorporated by reference to Exhibit 4.2 to the Company&#8217;s Report on Form 6-K (File No. 001-36866), filed with the Securities and Exchange Commission on December 6, 2019)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312519307884/d824147dex44.htm">Consulting Agreement, dated December 6, 2019, by and between Summit Therapeutics plc and Maky Zanganeh &amp; Associates, Inc. (incorporated by reference to Exhibit 4.4 to the Company</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8217;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312519307884/d824147dex44.htm">s Report on Form 6-K (File No. 001-36866), filed with the Securities and Exchange Commission on December 6, 2019)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312518350442/d639714dex102.htm">Relationship Agreement, dated December 14, 2018, by and among Summit Therapeutics plc, Robert W. Duggan and Cairn Financial Advisers LLP (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Report on Form 6-K (File No. 001-36866), filed with the Securities and Exchange Commission on December 17, 2018)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312519307884/d824147dex43.htm">Deed of Termination, dated December 6, 2019, by and among Summit Therapeutics plc, Robert Duggan and Cairn Financial Advisers LLP (incorporated by reference to Exhibit 4.3 to the Company&#8217;s Report on Form 6-K (File No. 001-36866), filed with the Securities and Exchange Commission on December 6, 2019)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929820000005/sumex436_20191231-20f.htm">Amendment of Solicitation/Modification of Contract (0005), dated January 21, 2020, to Agreement, dated September 5, 2017, by and between Summit (Oxford) Limited and the U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority&#160;(BARDA) </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929820000005/sumex436_20191231-20f.htm">(incorporated by reference to Exhibit 4.36 to the Company&#8217;s Transition Report on 20-F (File No. 333-36866)  filed with the Securities and Exchange Commission on April 30, 2020)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119380520001233/ex101to8k12566001_10052020.htm">Securities Purchase Agreement, dated October 2, 2020, by and between Summit Therapeutics Inc. and Robert W. Duggan (incorporated by reference to Exhibit 10.1 to the Company</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8217;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119380520001233/ex101to8k12566001_10052020.htm">s Current Report on Form 8-K (File No. 001-36866) filed with the Securities and Exchange Commission on October 5, 2020)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000092189520002819/ex101to8k12566007_11052020.htm">Securities Purchase Agreement, dated November 6, 2020, by and between Summit Therapeutics Inc. and Polar Capital Fund plc - Biotechnology Fund (incorporated by reference to Exhibit 10.1 to the Company</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8217;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000092189520002819/ex101to8k12566007_11052020.htm">s Current Report on Form 8-K (File No. 001-36866) filed with the Securities and Exchange Commission on November 6, 2020)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000092189520002819/ex102to8k12566007_11052020.htm">Securities Purchase Agreement, dated November 6, 2020, by and between Summit Therapeutics Inc. and Mahkam Zanganeh Revocable Trust (incorporated by reference to Exhibit 10.2 to the Company</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8217;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000092189520002819/ex102to8k12566007_11052020.htm">s Current Report on Form 8-K (File No. 001-36866) filed with the Securities and Exchange Commission on November 6, 2020)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312520248702/d76627dex101.htm">Form of Indemnification Agreement between Summit Therapeutics Inc. and each of its Executive Officers and Directors (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K (File No. 001-36866), filed with the Securities and Exchange Commission on September 18, 2020)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1599298/000159929820000039/smmt-20200929.htm#i5f970bbb3fbc499788e0a3a1c28008bd_3229">Offer of Employment, dated May 21, 2020, by and between Summit Therapeutics Inc. and Michael Donaldson (incorporated by reference to Exhibit 10.25 to the Company</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8217;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1599298/000159929820000039/smmt-20200929.htm#i5f970bbb3fbc499788e0a3a1c28008bd_3229">s Current Report on Form 8-K (File No. 001-36866), filed with the Securities and Exchange Commission on September 29, 2020)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1599298/000159929820000039/smmt-20200929.htm#i5f970bbb3fbc499788e0a3a1c28008bd_3237">Contract of Employment, dated May 29, 2020, by and between Summit Therapeutics Inc. and Ventzislav Stefanov (incorporated by reference to Exhibit 10.26 to the Company</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8217;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1599298/000159929820000039/smmt-20200929.htm#i5f970bbb3fbc499788e0a3a1c28008bd_3237">s Current Report on Form 8-K (File No. 001-36866), filed with the Securities and Exchange Commission on September 29, 2020)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312520248702/d76627dex102.htm">2020 Stock Incentive Plan (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K (File No. 001-36866), filed with the Securities and Exchange Commission on September 18, 2020)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1599298/000159929820000039/smmt-20200929.htm#i5f970bbb3fbc499788e0a3a1c28008bd_2807">Form of Option Award under 2020 Stock Incentive Plan (incorporated by reference to Exhibit 10.28 to the Company</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8217;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1599298/000159929820000039/smmt-20200929.htm#i5f970bbb3fbc499788e0a3a1c28008bd_2807">s Current Report on Form 8-K (File No. 001-36866), filed with the Securities and Exchange Commission on September 29, 2020)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.33#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1599298/000159929820000039/smmt-20200929.htm#i5f970bbb3fbc499788e0a3a1c28008bd_2812">Form of Restricted Stock Unit Agreement under 2020 Stock Incentive Plan (incorporated by reference to Exhibit 10.29 to the Company</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8217;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1599298/000159929820000039/smmt-20200929.htm#i5f970bbb3fbc499788e0a3a1c28008bd_2812">s Current Report on Form 8-K (File No. 001-36866), filed with the Securities and Exchange Commission on September 29, 2020)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.34#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312520248702/d76627dex103.htm">2020 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K (File No. 001-36866), filed with the Securities and Exchange Commission on September 18, 2020)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.35#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001599298/000159929821000011/sum-ex1035_20201231x10k.htm">Contract of Employment, dated November 22, 2020, by and between Summit Therapeutics Inc. and Mahkam Zanganeh (incorporated by reference to Exhibit 10.35 to the Company</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8217;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001599298/000159929821000011/sum-ex1035_20201231x10k.htm">s Annual Report on Form 10-K (File No. 001-36866), filed with the Securities and Exchange Commission on March 31, 2021)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.36</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001599298/000159929821000011/sum-ex1036_20201231x10k.htm">Sublease Agreement, dated March 26, 2021, by and between Maky Zanganeh &amp; Associates Inc. and Summit Therapeutics Sub Inc. (incorporated by reference to Exhibit 10.36 to the Company</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8217;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001599298/000159929821000011/sum-ex1036_20201231x10k.htm">s Annual Report on Form 10-K (File No. 001-36866), filed with the Securities and Exchange Commission on March 31, 2021)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.37</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001599298/000092189521001523/ex101to8k12566003_05282021.htm">Exit Agreement, dated May 28, 2021, by and between Summit Therapeutics Inc. and Michael Donaldson (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K (File No. 001-36866), filed with the Securities and Exchange Commission on May 28, 2021)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.38</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001599298/000159929822000022/summit-notepurchaseagreeme.htm">Note Purchase Agreement, dated March 10, 2022, by and between Summit Therapeutics Inc. and Robert W. Duggan (incorporated by reference to Exhibit 10.1 to the Company</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8217;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001599298/000159929822000022/summit-notepurchaseagreeme.htm">s Current Report on Form 8-K (File. No. 001-36866), filed with the Securities and Exchange Commission on March 11, 2022)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001599298/000159929822000022/summit-promissorynote4867x.htm">Promissory Note, dated March 10, 2022, in the name of Robert W. Duggan (incorporated by reference to Exhibit 10.2 to the Company</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8217;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001599298/000159929822000022/summit-promissorynote4867x.htm">s Current Report on Form 8-K (File. No. 001-36866), filed with the Securities and Exchange Commission on March 11, 2022)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.40</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929822000136/notepurchaseagreementpre.htm">Note Purchase Agreement, dated December 6, 2022, by and among Summit Therapeutics Inc., Robert W. Duggan, and Dr. Mahkam Zanganeh (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K (File No. 001-36866), filed with the Securities and Exchange Commission on December 6, 2022)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.41&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000138713122012619/ex-10_1.htm">Collaboration and License Agreement ,dated December 5, 2022, by and between Akeso, Inc. and its affiliates and Summit Therapeutics Sub Inc. (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form S-3 (File No. 333-268932) filed with the Securities and Exchange Commission on December 21, 2022)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.42</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929823000012/exhibit101amendment1toak.htm">Amendment No. 1 to Collaboration and License Agreement Amendment, dated January 16, 2023, by and among Summit Therapeutics Inc. and Akeso, Inc. (incorporated by reference to Exhibit 10.1 of Form 8-K filed by the Company on January 20, 2023, File No. 001-36866)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.43</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929823000012/redactedakeso-summitcomm.htm">Common Stock Issuance Agreement, dated January 17, 2023, by and among Summit Therapeutics Inc. and Akeso, Inc. (incorporated by reference to Exhibit 10.2 of Form 8-K filed by the Company on January 20, 2023, File No. 001-36866)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.44</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929823000012/exhibit103promissorynote.htm">Promissory Notes, dated January 19, 2023, by and among Summit Therapeutics Inc. and Robert W. Duggan (incorporated by reference to Exhibit 10.3 of Form 8-K filed by the Company on January 20, 2023, File No. 001-36866)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.45#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929823000034/amendedandrestated2020st.htm">Amended and Restated 2020 Stock Incentive Plan, dated July 27, 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.46&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929823000034/amd1tosublease.htm">First Amendment to Sublease Agreement, dated July 25, 2022, by and among Summit Therapeutics Inc. and Maky Zanganeh and Associates, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.47&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929823000034/amd2tosublease.htm">Second Amendment to Sublease Agreement, dated July 29, 2022, by and among Summit Therapeutics Inc. and Maky Zanganeh and Associates, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.48#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929823000034/executedofferdocuments-a.htm">Contract of Employment, dated April 15, 2022, by and between Summit Therapeutics Inc. and Ankur Dhingra</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> </span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929823000098/sum-ex101xmsoniemploymenta.htm">Employment Agreement, dated October 13, 2023, by and between Summit Therapeutics</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929823000098/sum-ex101xmsoniemploymenta.htm"> Inc. and Manmeet Soni</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.50</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929823000098/sum-ex102xsharepurchaseagr.htm">Securities </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929823000098/sum-ex102xsharepurchaseagr.htm">P</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929823000098/sum-ex102xsharepurchaseagr.htm">urchase Agreement, dated October 13, 2023, by and between Summit Therapeutics</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000159929823000098/sum-ex102xsharepurchaseagr.htm"> Inc. and Manmeet Soni</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.51*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="exhibit1051loanagreement.htm">Amended and Restated Promissory Note, dated February 17, 2024, by and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="exhibit1051loanagreement.htm">between Summit </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="exhibit1051loanagreement.htm">Therapeutics</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="exhibit1051loanagreement.htm"> Inc. and Robert W. Duggan</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="exhibit1051loanagreement.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312520248702/d76627dex141.htm">Code of Business Conduct and Ethics of Summit Therapeutics Inc. Restated Certificate of Incorporation (incorporated by reference to Exhibit 14.1 to the Company&#8217;s Current Report on Form 8-K (File No. 001-36866), filed with the Securities and Exchange Commission on September 18, 2020</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1599298/000119312520248702/d76627dex141.htm">)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sum-ex211_20231231xxsubsid.htm">List of Significant Subsidiaries</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sum-ex231_20231231xxuscons.htm">Consent of PricewaterhouseCoopers LLP</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, an independent registered public accounting firm</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sum-ex311_20231231xduggan.htm">Certification of Chief Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to &#167;302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sum-ex312_20231231xzanganeh.htm">Certification of Co-Chief Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to &#167;302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.3*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sum-ex313_20231231xdhingra.htm">Certification of Chief Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to &#167;302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sum-ex321_20231231xx404906.htm">Certification pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.1*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex971summitclawbackpolicy.htm">S</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex971summitclawbackpolicy.htm">um</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex971summitclawbackpolicy.htm">mit Ther</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex971summitclawbackpolicy.htm">apeutics</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex971summitclawbackpolicy.htm">, Inc. Incentive-bas</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex971summitclawbackpolicy.htm">ed Compensation Clawback Policy</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portions of this exhibit have been omitted in compliance with Regulation S-K Item 601(b)(10)(iv) because the Registrant has determined that the information is not material and is the type that the Registrant treats as private or confidential. </span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain portions of this exhibit have been omitted because they are not material and would likely cause competitive harm to the registrant if disclosed. </span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The schedules and exhibits have been omitted. A copy of any omitted schedule or exhibit will be furnished to the Securities and Exchange Commission upon request. </span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicates management contract or compensatory plan or arrangement.</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div id="if355807d1b914743a4dab03fe6913e8f_88"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16. Report Summary</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span><br/></span></div><div id="if355807d1b914743a4dab03fe6913e8f_91"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SIGNATURES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:right;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.497%"><tr><td style="width:1.0%"/><td style="width:18.766%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:74.793%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SUMMIT THERAPEUTICS INC.</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Robert W. Duggan</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:<br/>Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert W. Duggan<br/>Chief Executive Officer and Executive Chairman; Principal Executive Officer</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mahkam Zanganeh</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:<br/>Title:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Mahkam Zanganeh</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer, President and member of the Board; Principal Executive Officer</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Ankur Dhingra</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:<br/>Title:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ankur Dhingra<br/>Chief Financial Officer; Principal Financial Officer</span></td></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: February 20, 2024</span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:23.323%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:55.428%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.493%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Robert W. Duggan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Executive Chairman (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Principal Executive Officer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 18, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert W. Duggan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mahkam Zanganeh</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer, President and Director</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Principal Executive Officer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 18, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Mahkam Zanganeh</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Manmeet Soni</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Operating Officer and Director</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 18, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manmeet Soni</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Ankur Dhingra</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 18, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ankur Dhingra</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Robert F. Booth</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 16, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Robert F. Booth</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Alessandra Cesano</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 16, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Alessandra Cesano</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Kenneth Clark</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 16, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kenneth Clark</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Ujwala Mahatme</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 18, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ujwala Mahatme</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Yu Xia</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 18, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Yu Xia</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><div id="if355807d1b914743a4dab03fe6913e8f_94"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.818%"><tr><td style="width:1.0%"/><td style="width:88.848%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.952%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Summit Therapeutics Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Index to the Financial Statements</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_100">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> (PCAOB ID <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-35">238</ix:nonNumeric>)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_100">106</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_106">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_106">108</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_109">Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_109">109</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_112">Consolidated Statements of Stockholders</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8217;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_112"> Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_112">110</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_115">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_115">111</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_118">Notes to the Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if355807d1b914743a4dab03fe6913e8f_118">112</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><div id="if355807d1b914743a4dab03fe6913e8f_100"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:12pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and Stockholders of Summit Therapeutics Inc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Summit Therapeutics Inc. and its subsidiaries (the &#8220;Company&#8221;) as of December 31, 2023 and 2022, and the related consolidated statements of operations and comprehensive loss, of stockholders&#8217; equity and of cash flows for the years then ended, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Substantial Doubt About the Company&#8217;s Ability to Continue as a Going Concern</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the consolidated financial statements, the Company has incurred losses and cash outflows from operations and has a note payable with a principal amount of $100 million maturing on April 1, 2025 that raise substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 3. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis for Opinion</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued and Prepaid Research and Development Costs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Notes 4 and 16 to the consolidated financial statements, included within prepaid expenses as of December 31, 2023 is $1.5 million of prepayments relating to research and development expenditures. Included within accrued liabilities as of December 31, 2023 is $7.3 million relating to research and development expenditures. The Company records accruals for </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">estimated ongoing research and development costs or prepaid expenses where the payments made exceed the estimated costs. These amounts are determined by management based on the estimated costs to complete each study or activity, the estimation of the current stage of completion and the invoices received, as well as predetermined milestones which are not reflective of the current stage of development for prepaid expenses. However, prepaid expenses decrease, and accrued liabilities increase as the activities progress, and if actual costs incurred exceed the prepaid expense, an accrual will be recorded for the liability. The key sensitivity is the estimated current stage of completion of each study or activity, which is based on information received from the supplier and management&#8217;s operational knowledge of the work completed under those contracts.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal considerations for our determination that performing procedures relating to accrued and prepaid research and development costs is a critical audit matter are the significant judgment by management when determining the estimated research and development costs, which in turn led to significant auditor judgment, subjectivity, and effort in performing procedures and evaluating audit evidence related to estimated current stage of completion of each study or activity.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included, among others, (i) evaluating management&#8217;s process on a sample basis for determining the current stage of completion of each study or activity; (ii) reading a sample of research and development contracts; (iii) evaluating the reasonableness of progress towards completion for a sample of research and development activities and the associated incurred cost based on invoices, external confirmations or other information received from the supplier; and (iv) testing the completeness and accuracy of the underlying data including total costs included within contracts and actual billed amounts for a sample of contracts.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-36">PricewaterhouseCoopers LLP</ix:nonNumeric> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-37">Boston, Massachusetts</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 20, 2024</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2021.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><div id="if355807d1b914743a4dab03fe6913e8f_106"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.471%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-38">71,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-39">348,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:fixed-zero" scale="3" id="f-40">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="3" id="f-41">300,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="3" id="f-42">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="f-43">349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-44">114,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:fixed-zero" scale="3" id="f-45">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Prepaid expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-46">2,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-47">1,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="f-48">181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="f-49">486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Research and development tax credit receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="smmt:ResearchAndDevelopmentTaxCreditReceivableCurrent" scale="3" id="f-50">848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="smmt:ResearchAndDevelopmentTaxCreditReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-51">5,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-52">189,712</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-53">656,712</ix:nonFraction></span></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-54">204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-55">906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-56">5,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-57">4,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-58">1,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-59">1,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Research and development tax credit receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="smmt:ResearchAndDevelopmentTaxCreditReceivableNoncurrent" scale="3" id="f-60">959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="smmt:ResearchAndDevelopmentTaxCreditReceivableNoncurrent" format="ixt:fixed-zero" scale="3" id="f-61">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">4,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-63">577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-64">202,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-65">664,168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities and stockholders&#8217; equity</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-66">2,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="f-67">355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-68">8,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-69">10,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accrued compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-70">5,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-71">5,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-72">2,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-73">1,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="f-74">717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="f-75">662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden:f-76"><span style="-sec-ix-hidden:f-77">Promissory note payable to related parties</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:NotesPayableCurrent" format="ixt:fixed-zero" scale="3" id="f-78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NotesPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-79">19,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-80">20,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-81">38,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Lease liabilities, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-82">3,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-83">2,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-84">1,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-85">1,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden:f-86"><span style="-sec-ix-hidden:f-87">Promissory notes payable to related parties</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-88">100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-89">494,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-90">125,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-91">537,514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 22)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-92"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-93"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-94"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-95">0.01</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-96"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-97">20,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-98"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-99"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-100"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-101">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> issued and outstanding at December 31, 2023 and 2022, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-102">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-103">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-104"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-105">0.01</ix:nonFraction></ix:nonFraction> par value: <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-106"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-107">1,000,000,000</ix:nonFraction></ix:nonFraction> shares authorized;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;<ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-108"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-109">701,660,053</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-110"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-111">211,091,425</ix:nonFraction></ix:nonFraction> shares issued and outstanding at</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;December 31, 2023 and 2022, respectively</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="f-112">7,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="f-113">2,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Additional paid-in capital</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-114">1,066,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-115">504,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-116">2,448</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-117">1,893</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accumulated deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-118">993,258</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-119">378,330</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-120">77,692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-121">126,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-122">202,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-123">664,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the consolidated financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><div id="if355807d1b914743a4dab03fe6913e8f_109"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations and Comprehensive Loss </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-124">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-125">705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-126">59,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-127">51,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-128">30,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-129">26,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="smmt:InProcessResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-130">520,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="smmt:InProcessResearchAndDevelopmentExpense" format="ixt:fixed-zero" scale="3" id="f-131">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Impairment of intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="3" id="f-132">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-133">8,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-134">610,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-135">87,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="f-136">1,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="f-137">14,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-138">609,650</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-139">72,089</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-140">5,278</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-141">6,693</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-142">614,928</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-143">78,782</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-144">614,928</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-145">78,782</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-146"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-147">0.99</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-148"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-149">0.41</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-150"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-151">619,646,180</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-152"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-153">193,336,063</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Foreign currency translation adjustments </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="f-154">172</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="f-155">304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Reclassification of cumulative currency translation gain to other expense, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" scale="3" id="f-156">419</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" format="ixt:fixed-zero" scale="3" id="f-157">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Unrealized gain on short-term investments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-158">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:fixed-zero" scale="3" id="f-159">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-160">615,483</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-161">78,478</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><div id="if355807d1b914743a4dab03fe6913e8f_112"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share data)</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.132%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.461%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.461%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.497%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.461%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.461%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.461%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.407%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.461%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.531%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity</span></div></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-162">98,039,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-163">980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-164">384,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-165">2,197</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-166">299,548</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-167">83,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Rights Offering of common stock, net of offering costs of $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="f-168">111</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-169">103,092,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-170">1,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-171">98,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-172">99,889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock in lieu of interest to related parties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="smmt:StockIssuedDuringPeriodSharesIssuedForRelatedPartyInterest" format="ixt:num-dot-decimal" scale="0" id="f-173">9,720,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="smmt:StockIssuedDuringPeriodValueIssuedForRelatedPartyInterest" scale="3" id="f-174">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="smmt:StockIssuedDuringPeriodValueIssuedForRelatedPartyInterest" format="ixt:num-dot-decimal" scale="3" id="f-175">7,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="smmt:StockIssuedDuringPeriodValueIssuedForRelatedPartyInterest" format="ixt:num-dot-decimal" scale="3" id="f-176">7,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under stock purchase plans and exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-177">238,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-178">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-179">397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-180">399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-181">11,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-182">11,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imputed interest expense on promissory note payable to a related party</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="smmt:AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty" format="ixt:num-dot-decimal" scale="3" id="f-183">2,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="smmt:AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty" format="ixt:num-dot-decimal" scale="3" id="f-184">2,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="f-185">304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="f-186">304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-187">78,782</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-188">78,782</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-189">211,091,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-190">2,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-191">504,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-192">1,893</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-193">378,330</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-194">126,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 Rights Offering of common stock, net of offering costs of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="f-195">619</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-196">476,190,471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-197">4,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-198">494,619</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-199">499,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock purchase plans and exercise of stock options</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-200">596,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-201">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-202">922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-203">929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock in lieu of cash for Akeso upfront payment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="INF" name="smmt:StockIssuedDuringPeriodSharesInLieuOfCashForCollaborativeArrangement" format="ixt:num-dot-decimal" scale="0" id="f-204">10,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="smmt:StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement" scale="3" id="f-205">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="smmt:StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement" format="ixt:num-dot-decimal" scale="3" id="f-206">45,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="smmt:StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement" format="ixt:num-dot-decimal" scale="3" id="f-207">45,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private placement of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-208">2,976,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-209">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-210">4,970</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-211">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="INF" name="smmt:StockIssuedDuringPeriodSharesWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="f-212">805,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="smmt:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="f-213">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="smmt:StockIssuedDuringPeriodValueWarrantsExercised" format="ixt:num-dot-decimal" scale="3" id="f-214">1,195</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="smmt:StockIssuedDuringPeriodValueWarrantsExercised" format="ixt:num-dot-decimal" scale="3" id="f-215">1,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-216">14,108</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-217">14,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on short-term investments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-218">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-219">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of cumulative translation gain (Note 10)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" scale="3" id="f-220">419</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" scale="3" id="f-221">419</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="f-222">172</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="f-223">172</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-224">614,928</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-225">614,928</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-226">701,660,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-227">7,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-228">1,066,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-229">2,448</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-230">993,258</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-231">77,692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the consolidated financial statements. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><div id="if355807d1b914743a4dab03fe6913e8f_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> Summit Therapeutics Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.476%"><tr><td style="width:1.0%"/><td style="width:73.022%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-232">614,928</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-233">78,782</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Gain on remeasurement of liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="smmt:BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss" format="ixt:fixed-zero" scale="3" id="f-234">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="smmt:BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-235">1,265</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Non-cash interest expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="smmt:InterestExpenseIncomeNoncash" format="ixt:num-dot-decimal" scale="3" id="f-236">6,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="smmt:InterestExpenseIncomeNoncash" format="ixt:num-dot-decimal" scale="3" id="f-237">4,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Amortization of discount on short-term investments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-238">1,924</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:fixed-zero" scale="3" id="f-239">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Unrealized foreign currency (gain) loss</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="f-240">812</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" format="ixt:num-dot-decimal" scale="3" id="f-241">2,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Reclassification of currency translation gain   </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="smmt:CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome" scale="3" id="f-242">419</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="smmt:CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome" format="ixt:fixed-zero" scale="3" id="f-243">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Impairment of fixed assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:TangibleAssetImpairmentCharges" scale="3" id="f-244">474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="f-245">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Amortization of operating right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="f-246">1,852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="f-247">1,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-248">198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-249">349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Amortization of intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="3" id="f-250">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="f-251">914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Impairment of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="3" id="f-252">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-253">8,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-254">14,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-255">11,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;Loss on disposal of assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="f-256">109</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:fixed-zero" scale="3" id="f-257">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;In-process research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="smmt:InProcessResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-258">520,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="smmt:InProcessResearchAndDevelopmentExpense" format="ixt:fixed-zero" scale="3" id="f-259">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="f-260">359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="f-261">975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Prepaid expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="f-262">914</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="f-263">5,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other current and long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="f-264">3,421</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="f-265">215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Research and development tax credit receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="smmt:IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable" format="ixt:num-dot-decimal" scale="3" id="f-266">4,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="smmt:IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable" format="ixt:num-dot-decimal" scale="3" id="f-267">8,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Deferred revenue and other income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="f-268">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-269">7,278</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-270">2,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-271">4,132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-272">2,377</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-273">4,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Accrued compensation </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="f-274">235</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-275">1,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-276">2,211</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-277">1,099</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-278">76,760</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-279">41,582</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows used in investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Purchase of property and equipment</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-280">128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-281">624</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale of property. plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="f-282">226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-283">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-284">321,022</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:fixed-zero" scale="3" id="f-285">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Maturities and sales of short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-286">208,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" format="ixt:fixed-zero" scale="3" id="f-287">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments to Akeso for upfront milestone payments and associated direct transaction costs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="smmt:PaymentsForCollaborativeArrangement" format="ixt:num-dot-decimal" scale="3" id="f-288">475,015</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="smmt:PaymentsForCollaborativeArrangement" format="ixt:fixed-zero" scale="3" id="f-289">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-290">587,774</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-291">624</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows provided by financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Proceeds from the issuance of common stock for rights offering</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-292">104,686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-293">100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Transaction costs from the issuance of common stock for rights offering</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="f-294">619</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="f-295">111</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Proceeds from the issuance of common stock via private placement</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="3" id="f-296">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:fixed-zero" scale="3" id="f-297">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net receipts related to the exercise of warrants</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="3" id="f-298">1,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:fixed-zero" scale="3" id="f-299">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;Proceeds received related to employee stock purchase plan and exercise of stock options</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="f-300">929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="f-301">399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Proceeds from related party promissory notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromRelatedPartyDebt" format="ixt:fixed-zero" scale="3" id="f-302">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ProceedsFromRelatedPartyDebt" format="ixt:num-dot-decimal" scale="3" id="f-303">545,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Re-payment of related party promissory notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfRelatedPartyDebt" format="ixt:num-dot-decimal" scale="3" id="f-304">24,686</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RepaymentsOfRelatedPartyDebt" format="ixt:num-dot-decimal" scale="3" id="f-305">25,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Payments of related party promissory notes issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-306">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="f-307">44</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-308">86,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-309">620,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange rates on cash and cash equivalents</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="f-310">839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-311">1,222</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Decrease) Increase in cash, cash equivalents and restricted cash</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-312">577,182</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-313">576,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-314">648,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-315">71,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-316">71,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-317">648,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental Disclosure of Cash Flow Information</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for interest on related party promissory note</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-318">10,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="f-319">434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="f-320">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:fixed-zero" scale="3" id="f-321">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt issuance costs in accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="smmt:DebtIssuanceCostsIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-322">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="smmt:DebtIssuanceCostsIncurredButNotYetPaid" scale="3" id="f-323">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consideration for the issuance of common stock for rights offering used to satisfy a portion of a related party promissory note (Note 18)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="3" id="f-324">395,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="f-325">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred transaction costs included in other non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="smmt:DeferredTransactionCostsIncurredDuringNoncashOrPartialNoncashTransaction" format="ixt:fixed-zero" scale="3" id="f-326">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="smmt:DeferredTransactionCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="3" id="f-327">425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased assets obtained in exchange for operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-328">4,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-329">2,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock pursuant to the Akeso License Agreement (Note 6)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="3" id="f-330">45,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="f-331">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="height:37.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the consolidated financial statements.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><div id="if355807d1b914743a4dab03fe6913e8f_118"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div><span><br/></span></div><div id="if355807d1b914743a4dab03fe6913e8f_121"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:NatureOfOperations" id="f-332" continuedAt="f-332-1" escape="true">Nature of Business and Operations and Recent Events</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-332-1" continuedAt="f-332-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Nature of Business and Operations</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summit Therapeutics Inc. (</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we&#8221;, </span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summit&#8221; or the </span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company&#8221;) is a biopharmaceutical company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s pipeline of product candidates is designed with the goal to become the patient-friendly, new-era standard-of-care medicines, in the therapeutic area of oncology.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s current lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. On December 5, 2022, the Company entered into a Collaboration and License Agreement (the &#8220;License Agreement&#8221;) with Akeso, Inc. and its affiliates (&#8220;Akeso&#8221;) pursuant to which the Company has in-licensed ivonescimab. Through the License Agreement (as defined in Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company obtained the rights to develop and commercialize ivonescimab in the United States, Canada, Europe, and Japan (the &#8220;Licensed Territory&#8221;). The License Agreement and transaction closed in January 2023 following customary waiting periods. The Company&#8217;s operations will be focused on the development of ivonescimab and other future activities, as the Company determines.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has begun its development for ivonescimab in non-small cell lung cancer (</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NSCLC&#8221;), specifically launching Phase III clinical trials in the following indications:</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)  ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EGFR&#8221;)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TKI&#8221;) (&#8220;HARMONi&#8221;); and</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)  ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (&#8220;HARMONi-3&#8221;)</span></div><div style="padding-left:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of these financial statements, both studies are enrolling patients.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The entry into the License Agreement with Akeso represents a significant change in the Company&#8217;s strategy and its future operations will be focused on the development of ivonescimab and other future activities as the Company determines. The Company&#8217;s portfolio includes ridinilazole, a product candidate for treating patients suffering from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clostridioides difficile </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">infection, also known as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C. difficile </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">infection, or CDI. All prior development and marketing activities related to ridinilazole have been terminated. The Company&#8217;s anti-infectives portfolio includes SMT-738, the first of a novel class of precision antibiotics for combating multidrug resistant infections, specifically carbapenem-resistant Enterobacteriaceae (&#8220;CRE&#8221;) infections. The Company will continue to pursue partnerships for further development of SMT-738. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Recent Events</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the events detailed in the Company Overview section above, the following other recent developments have occurred. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, on December 5, 2022, the Company entered into a Collaboration and License Agreement (the &#8220;License Agreement&#8221;) with Akeso  pursuant to which the Company is in-licensing breakthrough bispecific antibody, ivonescimab (Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;6, 2022, the Company entered into a Note Purchase Agreement (the &#8220;Note Purchase Agreement&#8221;), with Mr. Robert Duggan and Dr. Maky Zanganeh, pursuant to which the Company agreed to sell to each of Mr. Duggan and Dr. Zanganeh unsecured promissory notes in the aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-333">520,000</ix:nonFraction> (Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-332-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January&#160;19, 2023, the Company filed Amendment No. 2 to the Restated Certificate of Incorporation (the &#8220;Amendment No. 2&#8221;) with the Secretary of State of the State of Delaware to increase the number of authorized shares of its common stock by <ix:nonFraction unitRef="shares" contextRef="c-38" decimals="INF" name="smmt:CommonStockSharesAuthorizedIncreaseDecrease" format="ixt:num-dot-decimal" scale="0" id="f-334">650,000,000</ix:nonFraction> (from <ix:nonFraction unitRef="shares" contextRef="c-39" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-335">350,000,000</ix:nonFraction> to <ix:nonFraction unitRef="shares" contextRef="c-40" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-336">1,000,000,000</ix:nonFraction>), which became effective on such date. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;7, 2023, the Company commenced its previously announced rights offering (&#8220;2023 Rights Offering&#8221;). On March 1, 2023, the Company closed the 2023 Rights Offering, which was fully subscribed. The Company received aggregate gross proceeds from the 2023 Rights Offering of $<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-337">500,000</ix:nonFraction> from the sale of&#8239;<ix:nonFraction unitRef="shares" contextRef="c-41" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-338">476,190,471</ix:nonFraction>&#8239;shares of its common stock at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-42" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-339">1.05</ix:nonFraction>. Issuance costs associated with the 2023 Rights Offering were approximately $<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="f-340">619</ix:nonFraction>. In connection with the closing of the 2023 Rights Offering, $<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-341">400,000</ix:nonFraction> of the unsecured promissory notes, issued by the Company to Mr. Duggan,&#8239;matured and became due and the Company repaid the principal amount and all outstanding accrued interest thereunder using a portion of the proceeds from this 2023 Rights Offering (Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;15, 2023, $<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:RepaymentsOfRelatedPartyDebt" format="ixt:num-dot-decimal" scale="3" id="f-342">20,000</ix:nonFraction> of the unsecured promissory notes, issued by us to Dr. Zanganeh, matured and the Company repaid the outstanding principal balance.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2023, the Company filed a registration statement on Form S-3 to register for resale the following shares of its common stock at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-45" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-343">0.01</ix:nonFraction> par value: (i) <ix:nonFraction unitRef="shares" contextRef="c-46" decimals="INF" name="smmt:SaleOfStockNumberOfSharesRegisteredForResale" format="ixt:num-dot-decimal" scale="0" id="f-344">10,000,000</ix:nonFraction> shares of Common Stock issued on January 17, 2023 in connection with the License Agreement with Akeso pursuant to which the Company issued Akeso such shares; and (ii) the <ix:nonFraction unitRef="shares" contextRef="c-47" decimals="INF" name="smmt:SaleOfStockNumberOfSharesRegisteredForResale" format="ixt:num-dot-decimal" scale="0" id="f-345">9,346,434</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-48" decimals="INF" name="smmt:SaleOfStockNumberOfSharesRegisteredForResale" format="ixt:num-dot-decimal" scale="0" id="f-346">373,857</ix:nonFraction> shares of common stock issued in December 2022 to its Chief Executive Officers, Mr. Robert Duggan and Dr. Mahkam Zanganeh, respectively, as payment of prepaid interest in connection with the Note Purchase Agreement dated December 6, 2022 between Mr. Duggan, Dr. Zanganeh and the Company (Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). On April 27, 2023, the SEC issued a Notice of Effectiveness for the registration statement on Form S-3 filed with the SEC.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 12, 2023, the Company held a Special Meeting of Stockholders (the &#8220;October Special Meeting&#8221;) whereby an amendment to the Summit Therapeutics Inc. 2020 Stock Incentive Plan (the &#8220;Plan&#8221;) to increase the number of shares of the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s common stock issuable under the Plan by <ix:nonFraction unitRef="shares" contextRef="c-49" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-347">70,000,000</ix:nonFraction> shares was approved by a vote of the Company&#8217;s stockholders at the Special Meeting and subsequently ratified by the Board of Directors.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 16, 2023, the Company announced the appointment of Mr. Manmeet Soni as its Chief Operating Officer, effective immediately. Mr. Soni has been a part of the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s Board of Directors since 2019. He will remain a member of the Board of Directors. In conjunction with his appointment, Mr. Soni entered into a share purchase agreement with the Company to purchase $<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="3" id="f-348">5,000</ix:nonFraction> of its common stock via a private placement. The transaction was effective October 13, 2023 with a closing price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-51" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-349">1.68</ix:nonFraction>, resulting in the purchase of <ix:nonFraction unitRef="shares" contextRef="c-52" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-350">2,976,190</ix:nonFraction> shares of the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2024 the Duggan February Note was amended to extend the maturity date from September 6, 2024 to April 1, 2025. For all applicable periods commencing  February 17, 2024, interest shall accrue on the outstanding principal balance at the greater of <ix:nonFraction unitRef="number" contextRef="c-53" decimals="2" name="us-gaap:RelatedPartyTransactionRate" scale="-2" id="f-351">12</ix:nonFraction>% or the US prime interest rate, as reported in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wall Street Journal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plus <ix:nonFraction unitRef="number" contextRef="c-54" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-4" id="f-352">350</ix:nonFraction> basis points, as adjusted monthly, compounded quarterly (Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Interest shall be paid upon maturity of the loan.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div id="if355807d1b914743a4dab03fe6913e8f_127"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccounting" id="f-353" continuedAt="f-353-1" escape="true">Basis of Presentation, Use of Estimates, and Risks and Uncertainties </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-353-1" continuedAt="f-353-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-354" escape="true">The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission.</ix:nonNumeric> Any reference in these notes to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and as amended by Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). <ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-355" continuedAt="f-355-1" escape="true">The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments, including those related to revenue recognition, accrued research and development expenses, stock-based compensation, intangible assets, goodwill, other long-lived assets and income taxes. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of </ix:nonNumeric></span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-355-1"><ix:continuation id="f-353-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div id="if355807d1b914743a4dab03fe6913e8f_130"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="smmt:LiquidityAndCapitalResourcesTextBlock" id="f-356" continuedAt="f-356-1" escape="true">Liquidity and Capital Resources</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-356-1"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company incurred a net loss of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-357">614,928</ix:nonFraction> and cash flows used in operating activities was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-358">76,760</ix:nonFraction>. As of December 31, 2023, the Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-359">993,258</ix:nonFraction>, and cash and cash equivalents and short term investments in U.S. treasury securities of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-360">186,242</ix:nonFraction>. The Company expects to continue to generate operating losses for the foreseeable future. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated whether its cash, cash equivalents, short-term investments and U.K. research and development tax credits provide sufficient cash to fund its operating cash needs for the next twelve months from the date of issuance of these annual financials. The Company is investing in the clinical development of ivonescimab, including its ongoing clinical trials. In addition, the Company has a $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-361">100,000</ix:nonFraction> promissory note payable to a related party (refer to Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details) that matures on April 1, 2025. Based upon the Company's cash and cash equivalents and short-term investments as of December 31, 2023, the Company expects to be able to operate into the first quarter of 2025. In order to further fund the Company's operating cash needs and repay this promissory note, the Company intends to raise additional capital. As of the date of the issuance of these financial statements the additional capital has not been secured. As a result, these conditions raise substantial doubt about the Company's ability to continue as a going concern.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until the Company can generate substantial revenue and achieve profitability, the Company will need to raise additional capital to fund its ongoing operations and capital needs. The Company continues to evaluate options to further finance its operating cash needs for its product candidates through a combination of some, or all, of the following: equity and debt offerings, collaborations, strategic alliances, grants and clinical trial support from government entities, philanthropic, non-government and not-for-profit organizations, and marketing, distribution or licensing arrangements. There is no assurance, however, that additional financing will be available when needed or that management of the Company will be able to obtain financing on terms acceptable to the Company. If the Company is unable to obtain funding when required in the future, the Company could be required to delay, reduce, or eliminate research and development programs, product portfolio expansion, or future commercialization efforts, which could adversely affect its business prospects.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements are prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of the business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classifications of liabilities that might result from the outcome of this uncertainty.</span></div></ix:continuation><div id="if355807d1b914743a4dab03fe6913e8f_133"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-362" continuedAt="f-362-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-362-1" continuedAt="f-362-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant accounting policies adopted by the Company in the preparation of these consolidated financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-363" continuedAt="f-363-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation </span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-363-1">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. The consolidated financial statements reflect the accounts of Summit Therapeutics Inc. and its wholly owned subsidiaries. Intercompany balances and transactions are eliminated in consolidation.</ix:continuation> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="f-364" continuedAt="f-364-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements of the Company&#8217;s subsidiaries with functional currencies other than the United States (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) dollar are translated into U.S. dollars using period-end exchange rates for assets and liabilities, historical exchange rates for stockholders&#8217; equity and weighted average exchange rates for operating results. Translation gains and losses are included in </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-362-2" continuedAt="f-362-3"><ix:continuation id="f-364-1"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accumulated other comprehensive (loss) income in shareholders&#8217; equity. Foreign currency transaction gains and losses are included in other expen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">se, net in the results of operations. The Company recorded realized and unrealized foreign currency transaction gains (losses) of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="f-365">613</ix:nonFraction> and ($<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-366">4,109</ix:nonFraction>) for the years ended December 31, 2023 and 2022, respectively, which is included in other expense, net in the statements of operations and comprehensive loss.</span></div></ix:continuation><div><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="smmt:OtherOperatingIncomePolicyPolicyTextBlock" id="f-367" continuedAt="f-367-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Operating Income</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates income from government contracts that reimburse the Company for certain allowable costs for funded projects. For contracts with government agencies where the funding arrangement is considered central to the Company&#8217;s ongoing operations, the Company classifies the recognized funding received as other operating income.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income from government grants is recognized as the qualifying expenses related to the contracts are incurred, provided that there is reasonable assurance of recoverability. If the government agency approves the project proposed by the Company, the government agency funds the project upon receipt of the support for the costs incurred up to the contract limit. Income recognized upon incurring qualifying expenses in advance of billing is recorded as unbilled receivable, a component of other current assets, in the consolidated balance sheet.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant income is not recognized as deductions of research and development costs because the Company acts as the principal in conducting the research and development activities and these contracts are central to its ongoing operations. The funds received through these means are held as deferred income in the consolidated balance sheets and are released to the consolidated statement of operations and comprehensive loss, classified as other operating income, as the underlying expenditure is incurred and to the extent the conditions of the grant are met. The related costs incurred by the Company are included in research and development expense in the Company&#8217;s consolidated statements of operations and comprehensive loss.</span></div></ix:nonNumeric><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-367-1">The Company benefits from two U.K. research and development (&#8220;R&amp;D&#8221;) tax credit cash rebate regimes: Small and Medium Enterprise (&#8220;SME&#8221;) Program and the Research and Development Expenditure Credit (&#8220;RDEC&#8221;) Program. Each reporting period, management evaluates which tax relief programs the Company is expected to be eligible for and records as other operating income the portion of the expense that it expects to qualify under the programs, that it plans to submit a claim for, and it has reasonable assurance that the amount will ultimately be realized. Based on criteria established by HM Revenue and Customs (&#8220;HMRC&#8221;), management of the Company expects a proportion of expenditures being undertaken in relation to its pipeline research, clinical trials management and manufacturing development activities to be eligible for the research and development tax relief programs for the year ended December 31, 2023. Qualifying expenditures largely comprise of employment costs for research staff, consumables, a proportion of relevant, permitted sub-contract costs and certain internal overhead costs incurred as part of research projects for which the Company does not receive commercial or other funding income. Credits related to the SME and RDEC Programs are recorded as other operating income in the consolidated statements of operations and other comprehensive (loss)/income. Under the SME scheme, the Company receives cash rebate payments of up to 33.3% up to March 31, 2023 and 18.6% from April 1, 2023 of eligible research and development expenditures, and under the RDEC scheme the Company receives cash rebate payments of up to 10.53% up to March 31, 2023 and 15% from April 1, 2023 of eligible research and development expenditure, and these payments are not dependent on the Company&#8217;s pre-tax net income levels.</ix:continuation> The Company has qualified under the more favorable SME regime and expects such elements of expenditures will also continue to be eligible for the SME regime for future periods.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-368" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the diluted net loss by the weighted-average number of common shares outstanding for the period, including potentially dilutive common shares. The dilutive effect of share options and warrants are determined under the treasury stock method using the average market price for the period.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the assumed proceeds under the treasury stock method include the average unrecognized compensation expense of stock options and warrants that are in-the-money.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-362-3" continuedAt="f-362-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationsPolicy" id="f-369" continuedAt="f-369-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Combinations </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for under the acquisition method. Acquired assets and assumed liabilities are measured at their fair values at the acquisition date. The excess of the consideration transferred over the net fair value of assets acquired and liabilities assumed is recorded as goodwill. The accounting for an acquisition involves a considerable amount of judgement and estimation. Cost, income, market or a combination of approaches may be used to establish the fair value of consideration exchanged, assets acquired, and liabilities assumed, depending on the nature of those items. The valuation approach is determined in accordance with generally accepted valuation methods. Key areas of estimation and judgment may include the selection of valuation approaches, cost of capital, market characteristics, cost structure, impacts of synergies, and estimates of terminal value, among other factors.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-369-1">While the Company uses estimates and assumptions as part of the purchase price allocation process to estimate the value of assets acquired and liabilities assumed, estimates are inherently uncertain and subject to refinement. During the measurement period, which maybe up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with a corresponding offset to goodwill, to the extent that adjustments are identified to the preliminary purchase price allocation. Upon conclusion of the measurement period, or final determination of the value of the assets acquired and liabilities assumed, whichever comes first, any subsequent adjustments are recorded to results of operations. Results of operations related to business combinations are included prospectively beginning with the date of acquisition and transaction costs related to business combinations are recorded within general and administrative expenses.</ix:continuation> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="f-370" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the consideration transferred over the fair value of net assets acquired. Goodwill is assigned to reporting units at the time of acquisition or when there is a change in the reporting structure and bases that allocation on which reporting units will benefit from the acquired assets and liabilities. Reporting units are defined as operating segments or one level below an operating segment, referred to as a component. Typically acquisitions related to a single reporting unit do not require the allocation of goodwill to multiple reporting units. If the products obtained in an acquisition are assigned to multiple reporting units, the goodwill is distributed to the respective reporting units as part of the purchase price allocation process.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses goodwill for impairment on an annual basis or more frequently when events and circumstances occur indicating that the recorded goodwill may be impaired. The Company regularly monitors current business conditions and other factors including, but not limited to, adverse industry or economic trends and lower projections of profitability that may impact future operating results. The process of evaluating the potential impairment of goodwill requires significant judgment. In performing the Company&#8217;s annual goodwill impairment test, the Company is permitted to first assess qualitative factors to determine whether it is more likely than not that the fair value of the Company&#8217;s reporting unit is less than its carrying amount, including goodwill. In performing the qualitative assessment, the Company considers certain events and circumstances specific to the reporting unit and to the entity as a whole, such as macroeconomic conditions, industry and market considerations, overall financial performance and cost factors when evaluating whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. The Company is also permitted to bypass the qualitative assessment and proceed directly to the quantitative test. If the Company chooses to undertake the qualitative assessment and concludes that it is more likely than not that the fair value of the reporting unit is less than its carrying amount, the Company would then proceed to the quantitative impairment test. In the quantitative assessment, the Company compares the fair value of the reporting unit to its carrying amount, which includes goodwill. If the fair value exceeds the carrying value, no impairment loss exists. If the fair value is less than the carrying amount, a goodwill impairment loss is measured and recorded.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses goodwill for impairment on an annual basis as of December 31 or more frequently when events and circumstances occur indicating that recorded goodwill may be impaired.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-371" continuedAt="f-371-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment </span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation. Cost is comprised of the purchase price plus any incidental costs of acquisition and commissioning. </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-362-4" continuedAt="f-362-5"><ix:continuation id="f-371-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-372" continuedAt="f-372-1" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is calculated based on cost, less residual value, in equal annual installments over the estimated useful lives of the assets. The residual value, if significant, is reassessed annually.</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:56.064%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-55" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-373">2</ix:nonNumeric> - <ix:nonNumeric contextRef="c-56" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-374">10</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures, office equipment and software</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-57" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-375">3</ix:nonNumeric> - <ix:nonNumeric contextRef="c-58" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-376">5</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="-sec-ix-hidden:f-377"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Over the shorter of the asset</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">s useful life or the remaining lease term</span></span></div></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is recognized as part of the general and administrative and research and development expense lines shown on the face of the consolidated statement of operations and comprehensive loss depending on the nature of the underlying assets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenditures for repairs and maintenance are expensed as incurred. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in loss from operations.</span></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-378" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for real estate. The Company does not have any finance leases. Under ASC 842, a contract is or contains a lease when the lessee has the right to control the use of an identified asset. The Company determines if an arrangement is a lease at inception of the contract, which is the date on which the terms of the contract are agreed to and the agreement creates enforceable rights and obligations. The lease term used to calculate the lease liability include options to extend or terminate the lease when it is reasonably certain that the option will be exercised.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the lease commencement date, the Company measures and recognizes a lease liability and a right-of-use asset in the financial statements. Lease liabilities are recognized based on the present value of the future lease payments over the lease term at commencement date. The right-of use asset is measured by taking the present value of future lease payments, plus any incremental direct costs incurred, less any lease incentives received. As most of the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s leases do not provide an implicit rate, the Company uses an estimated incremental borrowing rate based on the lease term and the economic environment of the lease at the lease commencement date, which is then utilized to determine the present value of future lease payments. Lease expense for minimum lease payments are recognized on a straight-line basis over the lease term, with variable lease payments recognized in the periods in which they are incurred.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has existing lease agreements with lease and non-lease components, has elected to account for the lease and non-lease components as a single lease component, and has allocated all of the contract consideration to the lease component only. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial lease term of 12 months or less are not recorded on the balance sheet. The Company recognizes lease expense for its short-term leases on a straight-line basis over the lease term.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InProcessResearchAndDevelopmentPolicy" id="f-379" continuedAt="f-379-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquired In-Process Research and Development</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company  may enter into agreements with collaboration partners for the development and commercialization of its products. These arrangements may include payments contingent on the occurrence of certain events such as development, regulatory or sales-based milestones. The Company considers the unique nature, terms and facts and circumstances of each transaction. The Company considers whether or not the assets acquired have a future alternative use. </span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-379-1">The fair value associated with acquired in-process research and development which does not have an alternative future use is expensed and is recorded as research and development expense. Any development or commercial milestone payments are recognized when the achievement of the associated milestone becomes probable and will either be expensed or capitalized depending upon whether or not regulatory approval has been obtained.</ix:continuation> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-380" continuedAt="f-380-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Costs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred to discover, research and develop product candidates, including personnel expenses, stock-based compensation expense, allocated facility-related and depreciation expenses, third-party license fees and external costs of outside vendors engaged to conduct </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-362-5" continuedAt="f-362-6"><ix:continuation id="f-380-1"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preclinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are recorded as prepaid expenses. Such amounts are recognized as an expense as the goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered. Milestone and other payments made to third-parties with respect to in-process research and development, in accordance with the Company&#8217;s license, acquisition and other similar agreements are expensed when determined to be probable and estimable.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various research and development contracts with other companies. These agreements are generally cancellable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research and development costs or prepaid expenses where the payments made exceeds the estimated costs. When evaluating the adequacy of these balances, the Company analyzes progress of the studies, including the estimated costs to complete each study or activity, the estimation of the current stage of completion and the invoices received, as well as predetermined milestones which are not reflective of the current stage of development for prepaid expenses. Actual results could differ from the Company&#8217;s estimates. In all cases, the full cost of each study or activity is expensed by the time the final report or where applicable, product, has been received. The Company&#8217;s historical estimates have not been materially different from the actual costs.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-381" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and recognizes compensation expense for all stock option and restricted stock unit awards based on the estimated fair value of the award on the grant date. The Company uses the Black-Scholes option pricing model to estimate the fair value of stock option awards. Additionally, the Company uses a Monte Carlo simulation model to calculate the estimated fair value on the date of grant related to awards with market-based service conditions. The fair value is recognized as expense, over the requisite service period, which is generally the vesting period of the respective award, on a straight-line basis for each separately vesting portion of the award when the only condition to vesting is continued service.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If vesting is subject to a market or performance condition, recognition is based on the derived service period of the award. Expense for awards with performance conditions is estimated and adjusted on a quarterly basis based upon the assessment of the probability that the performance condition will be met. Use of the Black-Scholes option-pricing model requires management to apply judgment under highly subjective assumptions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These assumptions include:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expected term&#8212;The expected term of stock options represents the weighted-average period the stock options are expected to be outstanding. The Company uses the simplified method for estimating the expected term as provided by the Securities and Exchange Commission. The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life of the options.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expected volatility&#8212;The expected volatility is calculated based on historical volatility of the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s share price.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk-free interest rate&#8212;The risk-free rate assumption is based on the U.S. Treasury instruments, the terms of which were consistent with the expected term of the Company&#8217;s stock options.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expected dividend&#8212;The expected dividend assumption is based on the Company&#8217;s history and expectation of dividend payouts. The Company has not paid and does not intend to pay dividends. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates expected forfeitures at the time of grant instead of accounting for forfeitures as they occur. Stock option and restricted stock unit awards have been granted at fair value to non-employees in connection with research and consulting services provided to the Company. Equity awards generally vest over terms of <ix:nonNumeric contextRef="c-60" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="f-382">3</ix:nonNumeric> or <ix:nonNumeric contextRef="c-61" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="f-383">4</ix:nonNumeric> years. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies stock-based compensation expense in the consolidated statements of operations in the same manner in which the award recipient&#8217;s payroll costs are classified.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-384" continuedAt="f-384-1" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is determined using the asset and liability approach. Tax laws may require items to be included in tax filings at different times than the items are reflected in the financial statements. A current asset or liability is recognized for the estimated taxes receivable or payable for the current year. Deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. Deferred taxes are initially recognized at enacted tax rates in force at the time of initial recognition and are subsequently adjusted for any enacted changes in tax rates </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-362-6" continuedAt="f-362-7"><ix:continuation id="f-384-1" continuedAt="f-384-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and tax laws. Subsequent changes to deferred taxes originally recognized in equity are recognized in income. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The Company has recorded a full valuation allowance against the deferred tax assets in excess of its deferred tax liabilities, as the deferred tax liability represents future reversals of existing taxable temporary differences. The Company records interest and penalties related to income tax matters as part of income tax expense.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-384-2" continuedAt="f-384-3">The Company accounts for uncertainty in income taxes by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed as the amount of benefit to recognize in the consolidated financial statements. The amount of benefits that may be used is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate, as well as the related net interest and penalties. </ix:continuation>At December 31, 2023 and 2022, the Company had unrecognized tax positions of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-385">1,064</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="f-386">0</ix:nonFraction>, respectively. Due to the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s full valuation allowance, the unrecognized tax benefits would not materially impact the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s effective tax rate when recognized.  The Company does not anticipate the total amount of unrecognized tax benefits to significantly increase or decrease in the next 12 months. <ix:continuation id="f-384-3">The Company&#8217;s policy is to recognize interest and penalties related to uncertain tax positions as part of its income tax provision.</ix:continuation> For the years ended December 31, 2023and 2022, the Company had <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt-sec:numwordsen" id="f-387"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt-sec:numwordsen" id="f-388">no</ix:nonFraction></ix:nonFraction> interest or penalties related to unrecognized tax benefits.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-389" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk and of Significant Supplier</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of short-term cash deposits and accounts and other receivables. The Company&#8217;s cash is comprised of short-term cash deposits at a variety of financial institutions with strong credit ratings in amounts that may exceed federally insured limits and has not experienced any losses on such accounts. Cash balances maintained during the year have been principally held with reputable U.K.-based and U.S.-based banks. The Company does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The credit risk with respect to customers and funding bodies is limited as the Company has only a small number of these arrangements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies, and expects to continue to rely, on a number of vendors to conduct its clinical trials and preclinical studies, manufacture drug product and supply clinical trial and preclinical study materials for its development programs. These programs could be adversely affected by a significant interruption in these services or the availability of materials.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-390" continuedAt="f-390-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the provisions of fair value accounting, a fair value measurement assumes that the transaction to sell an asset or transfer a liability occurs in the principal market for the asset or liability or, in the absence of a principal market, the most advantageous market for the asset or liability and defines fair value based on the exit price model.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurement guidance establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The guidance describes three levels of inputs that may be used to measure fair value:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-362-7" continuedAt="f-362-8"><ix:continuation id="f-390-1"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quoted prices in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 2 assets and liabilities include debt securities with quoted prices that are traded less frequently than exchange-traded instruments or securities or derivative contracts that are valued using a pricing model with inputs that are observable in the market or can be derived principally from or corroborated by observable market data.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the Company categorizes such assets and liabilities based on the lowest level input that is significant to the fair value measurement in its entirety. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset.</span></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" id="f-391" continuedAt="f-391-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-391-1">The Company considers only those investments that are highly liquid, readily convertible to cash and that mature within 90 days or less from date of purchase to be cash equivalents.</ix:continuation> As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2023 and 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, cash equivalents were comprised of a money market funds and U.S. treasury securities with maturities less than 90 days from the date of purchase. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="f-392" continuedAt="f-392-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Cash</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-392-1">Restricted cash of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="3" id="f-393">300,000</ix:nonFraction> as of December 31, 2022, represents amounts which are legally restricted to withdrawal or usage and is presented in the Consolidated Balance Sheet as restricted cash.</ix:continuation> On December 15, 2022, the Company transferred $<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="3" id="f-394">300,000</ix:nonFraction> into an escrow fund reserved for the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s initial upfront payment to Akeso in connection with the License Agreement, as described further in Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Following the Antitrust Clearance Date, on January 17, 2023, the License Agreement closed and Akeso was issued <ix:nonFraction unitRef="shares" contextRef="c-63" decimals="INF" name="smmt:CollaborativeArrangementRightsAndObligationsUpfrontPaymentSharesOfCommonStockIssuedInLieuOfCash" format="ixt:num-dot-decimal" scale="0" id="f-395">10,000,000</ix:nonFraction> shares of Company common stock pursuant to the Common Stock Issuance Agreement and was paid $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="smmt:CashPaymentForCollaborativeArrangementUpfrontPayment" format="ixt:num-dot-decimal" scale="3" id="f-396">274,900</ix:nonFraction> in cash as initial upfront payment. The remaining amounts in escrow were returned to the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s operating cash accounts. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="smmt:AssumedContingentLiabilitiesPolicyPolicyTextBlock" id="f-397" continuedAt="f-397-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assumed Contingent Liabilities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the acquisition of Discuva Limited in December 2017, the Company assumed certain contingent liabilities as certain employees, former employees and former directors of Discuva Limited are eligible for payments from Discuva Limited based on specified development and clinical milestones related to proprietary product candidates developed under the Discuva Platform. The timing of these potential payments is uncertain. The fair value of the assumed contingent liability was estimated using the expected value of the payments. The assumed contingent liabilities are subsequently measured at amortized cost using discounted cash flow models which calculate the risk adjusted net present values of estimated potential future cash flows of the payments. The assumed contingent liabilities are remeasured when there is a specific significant event that provides evidence of a significant change in the probability of successful development and clinical milestones being achieved. The models will be updated for changes in the probability of successful development and clinical milestones being achieved and other associated assumptions with the discount factor remaining unchanged within the model. A discount factor of <ix:nonFraction unitRef="number" contextRef="c-64" decimals="2" name="smmt:BusinessCombinationAssumedContingentLiabilityMeasurementInput" scale="-2" id="f-398">13</ix:nonFraction>% has been used to discount the contingent liabilities back to net present value. This discount factor has been calculated using appropriate measures and rates which could have been obtained in the period that the contingent liabilities were assumed. Accretion of the discount </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-362-8" continuedAt="f-362-9"><ix:continuation id="f-397-1"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">factor and gains or losses upon remeasurement are recognized as part of operating expenses in the consolidated statements of operations and comprehensive loss.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="smmt:WarrantsPolicyPolicyTextBlock" id="f-399" continuedAt="f-399-1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants issued by the Company are recognized and classified as equity when, upon exercise, the Company would issue a fixed amount of its own equity instruments (common stock) in exchange for a fixed amount of cash or another financial asset.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration received, net of incremental costs directly attributable to the issue of such new warrants, is shown in equity. Such warrants are not remeasured at fair value in subsequent reporting periods.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants issued in which external services are received as consideration for equity instruments of the company should be measured at the fair value of the goods or services received. Only if the fair value of the services cannot be measured reliably would the fair value of the equity instruments granted be used. The fair value for the warrants is calculated using the Black-Scholes formula and recorded in the consolidated statement of operations and comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on a straight-line basis over the period of the consulting services. If the services are terminated prior to the end of the consultancy agreement, the warrants cease vesting and any unvested portion of the warrants will lapse immediately.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><ix:continuation id="f-399-1" continuedAt="f-399-2"><ix:continuation id="f-362-9" continuedAt="f-362-10"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The warrants in issue are classified within stockholders&#8217; equity as they are indexed to the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-399-2"><ix:continuation id="f-362-10">s own shares of common stock and require settlement in its shares of common stocks with no provision for any cash settlement.</ix:continuation></ix:continuation> </span></div><div style="margin-bottom:9pt"><span><br/></span></div><div id="if355807d1b914743a4dab03fe6913e8f_136"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="f-401" continuedAt="f-401-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-400" continuedAt="f-400-1" escape="true">Recently Issued or Adopted Accounting Pronouncements </ix:nonNumeric></ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-401-1"><ix:continuation id="f-400-1"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards update &#8220;ASU&#8221; No. 2023-09, &#8220;Improvements to Income Tax Disclosures&#8221;, which requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. ASU No. 2023-09 is effective for fiscal years beginning after December 15, 2024 and allows for adoption on a prospective basis, with a retrospective option. Early adoption is permitted. The Company is currently evaluating the impact of the ASU on the income tax disclosures within the consolidated financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU No. 2023-07, &#8220;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&#8221;, which provides updates to qualitative and quantitative reportable segment disclosure requirements, including enhanced disclosures about significant segment expenses and increased interim disclosure requirements, among others. ASU No. 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. Early adoption is permitted, and the amendments should be applied retrospectively. The Company is currently evaluating the impact of the ASU on the consolidated financial statement disclosures. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, &#8220;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#8221;, which has subsequently been amended by ASU 2019-04 and ASU 2019-10 (collectively &#8220;ASU 2016-03&#8221;). ASU 2016-13 amends the guidance on the impairment of financial instruments. This update adds an impairment model (known as the current expected credit losses model) that is based on expected losses rather than incurred losses. Under the new guidance, an entity recognizes, as an allowance, its estimate of expected credit losses. The Company adopted this standard on January 1, 2023, and it did not have a material impact on the consolidated financial statements or related disclosures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other recent authoritative guidance issued by the FASB (including technical corrections to the FASB ASC), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not expected to have a material impact on the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s consolidated financial statements.</span></div></ix:continuation></ix:continuation><div id="if355807d1b914743a4dab03fe6913e8f_1452"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.  <ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-402" continuedAt="f-402-1" escape="true">Akeso License and Collaboration Agreement</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-402-1" continuedAt="f-402-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 5, 2022, the Company entered into a Collaboration and License Agreement (the &#8220;License Agreement&#8221;) with Akeso pursuant to which the Company is in-licensing its breakthrough bispecific antibody, ivonescimab. The License Agreement and transaction closed in January 2023 following customary waiting periods.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><div><span><br/></span></div><ix:continuation id="f-402-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ivonescimab, known as AK112 in China and Australia, and also as SMT112 in the United States, Canada, Europe, and Japan, is a novel, potential first-in-class bispecific antibody intending to combine the benefits of immunotherapy via a blockade of PD-1 with the anti-angiogenesis benefits of an anti-VEGF into a single molecule. Ivonescimab was engineered to bring two well established oncology targeted mechanisms together. Ivonescimab is currently in clinical development and, pursuant to the terms of the License Agreement, Summit will design and conduct the clinical trial activities to support regulatory filings in the Licensed Territory that Summit will submit. Pursuant to the terms of the License Agreement, Summit will have final decision making authority with respect to commercial strategy, pricing and reimbursement and other commercialization matters in the Licensed Territory. In connection with the License Agreement, the Company has also entered into a Supply Agreement with Akeso, pursuant to which Summit agrees to purchase a certain portion of drug substance for clinical and commercial supply. Summit is not assuming any liabilities (including contingent liabilities), acquiring any physical assets or trade names, or hiring or acquiring any employees from Akeso in connection with the License Agreement. Through the License Agreement, the Company obtained the rights to develop and commercialize SMT112 in the United States, Canada, Europe, and Japan (the &#8220;Licensed Territory&#8221;).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In exchange for the rights obtained, an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="smmt:CollaborativeArrangementRightsAndObligationsUpfrontPayment" format="ixt:num-dot-decimal" scale="3" id="f-403">500,000</ix:nonFraction> was made to Akeso, of which $<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="smmt:CashPaymentForCollaborativeArrangementUpfrontPayment" format="ixt:num-dot-decimal" scale="3" id="f-404">274,900</ix:nonFraction> was paid in cash and, pursuant to the License Agreement and Issuance Agreement, Akeso elected to receive <ix:nonFraction unitRef="shares" contextRef="c-66" decimals="INF" name="smmt:CollaborativeArrangementRightsAndObligationsUpfrontPaymentSharesOfCommonStockIssuedInLieuOfCash" format="ixt:num-dot-decimal" scale="0" id="f-405">10,000,000</ix:nonFraction> shares of our common stock in lieu of $<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="smmt:CollaborativeArrangementRightsAndObligationsUpfrontPaymentPaidInShares" format="ixt:num-dot-decimal" scale="3" id="f-406">25,100</ix:nonFraction> cash. The remaining $<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="smmt:CashPaymentForCollaborativeArrangementUpfrontPayment" format="ixt:num-dot-decimal" scale="3" id="f-407">200,000</ix:nonFraction> amount of the upfront payment was paid on March 6, 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has accounted for the License Agreement to acquire the rights to develop and commercialize SMT112 as the acquisition of an asset. All of the consideration relates to SMT112 and technological feasibility of the asset has not yet been established since SMT112 is in clinical development. As such, the Company has expensed the consideration as in-process research and development upon closing of the transaction in the consolidated statement of comprehensive loss. In-process research and development expense for the year ended December 31, 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="smmt:InProcessResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-408">520,915</ix:nonFraction>, which is comprised of the $<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="smmt:CashPaymentForCollaborativeArrangementUpfrontPayment" format="ixt:num-dot-decimal" scale="3" id="f-409">474,900</ix:nonFraction> paid in cash, the fair value of the <ix:nonFraction unitRef="shares" contextRef="c-66" decimals="INF" name="smmt:CollaborativeArrangementRightsAndObligationsUpfrontPaymentSharesOfCommonStockIssuedInLieuOfCash" format="ixt:num-dot-decimal" scale="0" id="f-410">10,000,000</ix:nonFraction> shares of common stock on the date of closing the transaction of $<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="smmt:StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement" format="ixt:num-dot-decimal" scale="3" id="f-411">45,900</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="smmt:CollaborativeArrangementRightsAndObligationsDirectTransactionCosts" scale="3" id="f-412">115</ix:nonFraction> of direct transactions costs incurred.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the payments already made to Akeso, under the License Agreement, there are additional potential milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="smmt:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" format="ixt:num-dot-decimal" scale="3" id="f-413">4,500,000</ix:nonFraction>, as Akeso will be eligible to receive regulatory milestones of up to $<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="smmt:CollaborativeArrangementRightsAndObligationsPotentialRegulatoryMilestonePayments" format="ixt:num-dot-decimal" scale="3" id="f-414">1,050,000</ix:nonFraction> and commercial milestones of up to $<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="smmt:CollaborativeArrangementRightsAndObligationsPotentialCommercialMilestonePayments" format="ixt:num-dot-decimal" scale="3" id="f-415">3,450,000</ix:nonFraction>. In addition, Akeso will be eligible to receive low double-digit royalties on net sales.</span></div></ix:continuation><div><span><br/></span></div><div id="if355807d1b914743a4dab03fe6913e8f_139"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-416" continuedAt="f-416-1" escape="true">Segment Reporting </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-416-1" continuedAt="f-416-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s chief operating decision makers (the &#8220;CODM function&#8221;), which are the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s Chief Executive Officers, Mr. Duggan and Dr. Zanganeh, utilize consolidated financial information to make decisions about allocating resources and assessing performance for the entire Company. The CODM function approves of key operating and strategic decisions, including key decisions in clinical development and clinical operating activities, entering into significant contracts, such as revenue contracts and collaboration agreements and approves the Company&#8217;s consolidated operating budget. The CODM function views the Company&#8217;s operations and manages its business as a single reportable operating segment. The Company&#8217;s single operating segment covers the Company&#8217;s research and development activities, primarily comprising of oncology product research activities (including ivonescimab), antibiotic pipeline research activities, and CDI program activities. As the Company operates in <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-417">one</ix:nonFraction> operating segment, all required financial segment information can be found in the consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in <ix:nonFraction unitRef="country" contextRef="c-4" decimals="INF" name="us-gaap:NumberOfCountriesInWhichEntityOperates" format="ixt-sec:numwordsen" scale="0" id="f-418">two</ix:nonFraction> geographic regions: the U.K. and the U.S. <ix:nonNumeric contextRef="c-1" name="us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock" id="f-419" continuedAt="f-419-1" escape="true">The following table summarizes the Company&#8217;s long-lived assets, which include the Company&#8217;s property and equipment, net and right-of-use assets by geography: </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-419-1" continuedAt="f-419-2"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:NoncurrentAssets" scale="3" id="f-420">808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-421">2,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-422">5,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-423">2,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-424">6,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-425">5,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><div><span><br/></span></div><ix:continuation id="f-416-2"><ix:continuation id="f-419-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The decrease of long-lived assets in the United Kingdom is primarily attributed to the Company exiting its lease for its Sawston, United Kingdom location.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The increase of long-lived assets in the United States is primarily attributed to additional right-of-use assets recorded related to the Company&#8217;s amendment to its sublease agreement during the period for its Menlo Park, California, U.S. location.</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For details of revenue from external customers by geography refer to Note 8.</span></div></ix:continuation><div><span><br/></span></div><div id="if355807d1b914743a4dab03fe6913e8f_142"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-426" continuedAt="f-426-1" escape="true">Revenue</ix:nonNumeric></span></div><ix:continuation id="f-426-1"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-427">no</ix:nonFraction> revenue and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-428">705</ix:nonFraction> during the year ended December 31, 2023 and 2022, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized during the year ended December 31, 2022 consists of amounts received from the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s license and commercialization agreement with Eurofarma Laborat&#243;rios S.A. Revenue recognized during the year ended December 31, 2022 was from Latin America. The analysis of revenue by geography has been identified on the basis of the geographical location of each collaboration partner.</span></div><div style="margin-top:5pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="f-429" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the deferred revenue relating to Eurofarma Laborat&#243;rios S.A. and deferred other income relating to BARDA (as defined in Note 9):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:69.653%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.080%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.344%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning deferred revenue and other income, January 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="f-430">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-431">7,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="smmt:ContractWithCustomerLiabilityAdditions" format="ixt:fixed-zero" scale="3" id="f-432">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="smmt:ContractWithCustomerLiabilityAdditions" format="ixt:num-dot-decimal" scale="3" id="f-433">1,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of deferred revenue and other income recognized in the statement of operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="smmt:ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance" format="ixt:fixed-zero" scale="3" id="f-434">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="smmt:ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance" format="ixt:num-dot-decimal" scale="3" id="f-435">8,790</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="smmt:ContractWithCustomerLiabilityForeignCurrencyTranslation" format="ixt:fixed-zero" scale="3" id="f-436">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="smmt:ContractWithCustomerLiabilityForeignCurrencyTranslation" scale="3" id="f-437">546</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending deferred revenue and other income, December 31</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="f-438">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="f-439">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 9 below for further details regarding other income recognized under the BARDA contract.</span></div></ix:continuation><div style="margin-bottom:9pt"><span><br/></span></div><div id="if355807d1b914743a4dab03fe6913e8f_145"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="c-1" name="us-gaap:OtherOperatingIncomeAndExpenseTextBlock" id="f-440" continuedAt="f-440-1" escape="true">Other Operating Income, net</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-440-1" continuedAt="f-440-2"><ix:nonNumeric contextRef="c-1" name="smmt:ScheduleOfOtherOperatingIncomeExpenseNetTableTextBlock" id="f-441" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of other operating income by category:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Funding income from BARDA (as defined below)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="smmt:GrantFundingArrangementIncomeEarned" format="ixt:fixed-zero" scale="3" id="f-442">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="smmt:GrantFundingArrangementIncomeEarned" format="ixt:num-dot-decimal" scale="3" id="f-443">8,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="smmt:ResearchAndDevelopmentTaxCredit" scale="3" id="f-444">946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="smmt:ResearchAndDevelopmentTaxCredit" format="ixt:num-dot-decimal" scale="3" id="f-445">4,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grant income from CARB-X (as defined below)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="smmt:GrantFundingArrangementIncomeEarned" scale="3" id="f-446">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="smmt:GrantFundingArrangementIncomeEarned" format="ixt:num-dot-decimal" scale="3" id="f-447">1,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="smmt:OtherOperatingIncomeOther" scale="3" id="f-448">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="smmt:OtherOperatingIncomeOther" format="ixt:fixed-zero" scale="3" id="f-449">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherOperatingIncome" format="ixt:num-dot-decimal" scale="3" id="f-450">1,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherOperatingIncome" format="ixt:num-dot-decimal" scale="3" id="f-451">14,416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BARDA (as defined below)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, the Company was awarded a funding contract from the Biomedical Advanced Research and Development Authority (&#8220;BARDA&#8221;), part of the Office of the Assistant Secretary for Preparedness and Response at the United States Department of Health and Human Services, in support of the Company&#8217;s Ri-CoDIFy clinical trials and clinical development of ridinilazole. The awarded contract was originally worth up to $<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="smmt:GrantFundingArrangementMaximumFundingValue" format="ixt:num-dot-decimal" scale="3" id="f-452">62,000</ix:nonFraction>. In June 2019 and again in January 2020, BARDA increased the value of the contract such that it is now worth up to $<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="smmt:GrantFundingArrangementMaximumFundingValue" format="ixt:num-dot-decimal" scale="3" id="f-453">72,500</ix:nonFraction> and brought the total amount of committed funding to $<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="smmt:GrantFundingArrangementCommittedFundingTotal" format="ixt:num-dot-decimal" scale="3" id="f-454">62,400</ix:nonFraction>. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining federal government funding is dependent on BARDA in its sole discretion exercising the final independent option work segment, upon the achievement by the Company of certain agreed-upon milestones for ridinilazole. This option work segment was never exercised by BARDA. The contract ran through April 2022 and was extended through December 2022 </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-440-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as a no cost contract, solely to close out open activities. As of December 31, 2022, based on translation of historical foreign currency amounts in the period of recognition, the Company has recognized $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="smmt:GrantFundingArrangementIncomeEarned" format="ixt:num-dot-decimal" scale="3" id="f-455">59,203</ix:nonFraction> of cumulative income since contract inception. As a result of the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s decision, on September 28, 2022, to not pursue further internal clinical development of ridinilazole and seek partners or a divestiture related to ridinilazole as a path forward for the clinical development of the asset, the Company recorded expenses for the remaining clinical trial costs associated with the close out activities of ridinilazole and recognized the remainder of the deferred income that had been received from BARDA prior to the expenses being recognized during the third quarter of 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and development credits</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income from tax credits, consist of R&amp;D tax credits received in the U.K. The Company benefits from two U.K. research and development tax credit cash rebate regimes: Small and Medium Enterprise Program (&#8220;SME, Program&#8221;) and the Research and Development Expenditure Credit Program (&#8220;RDEC Program&#8221;). Qualifying expenditures largely comprise of employment costs for research staff, consumables, a proportion of relevant, permitted sub-contract costs and certain internal overhead costs incurred as part of research projects for which the Company does not receive income. Tax credits related to the SME Program and RDEC Program are recorded as other operating income in the consolidated statements of operations and other comprehensive loss. Under both schemes, the Company receives cash payments that are not dependent on the Company&#8217;s pre-tax net income levels.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on criteria established by His Majesty&#8217;s Revenue and Customs (&#8220;HMRC&#8221;), a portion of expenditures being carried out in relation to the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s pipeline research and development, clinical trials management and third-party manufacturing development activities are eligible for the SME regime and the Company expects such elements of research and development expenditure incurred in its UK entities will also continue to be eligible for the SME regime for future periods.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023 and 2022, the current and long-term research and development tax credit receivable was $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="smmt:ResearchAndDevelopmentTaxCreditReceivable" format="ixt:num-dot-decimal" scale="3" id="f-456">1,807</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="smmt:ResearchAndDevelopmentTaxCreditReceivable" format="ixt:num-dot-decimal" scale="3" id="f-457">5,766</ix:nonFraction>, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARB-X (as defined below)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company announced the selection of a new preclinical candidate, SMT-738, from the DDS-04 series for development in the fight against multi-drug resistant infections, specifically Carbapenem-resistant Enterobacteriaceae (&#8220;CRE&#8221;) infections. Simultaneously, the Company announced it had received an award from the Trustees of Boston University under the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator program (&#8220;CARB-X&#8221;) to progress this candidate through preclinical development and Phase Ia clinical trials. The award commits initial funding of up to $<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="smmt:GrantFundingArrangementMaximumFundingValue" format="ixt:num-dot-decimal" scale="3" id="f-458">4,100</ix:nonFraction>, with the possibility of up to another $<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="smmt:GrantFundingArrangementMilestoneFundingIncrease" format="ixt:num-dot-decimal" scale="3" id="f-459">3,700</ix:nonFraction> based on the achievement of future milestones. As of December 31, 2023, based on translation of historical foreign currency amounts in the period that the amounts were recognized, the Company has recognized $<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="smmt:GrantFundingArrangementIncomeEarned" format="ixt:num-dot-decimal" scale="3" id="f-460">2,920</ix:nonFraction> of cumulative income since contract inception. During the quarter ended September 30, 2022, CARB-X announced changes to its funding arrangements and terms and conditions. As a result, the current arrangement concluded as of June 30, 2022, however the Company has the ability to recognize reimbursements for any milestone payments related to work incurred subsequent to this date in accordance with this agreement.</span></div></ix:continuation><div style="margin-bottom:9pt"><span><br/></span></div><div id="if355807d1b914743a4dab03fe6913e8f_148"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="c-1" name="us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock" id="f-461" continuedAt="f-461-1" escape="true">Other (Expense) Income, net</ix:nonNumeric></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="f-462" continuedAt="f-462-1" escape="true"><ix:continuation id="f-461-1" continuedAt="f-461-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of other (expense) income:</span></div></ix:continuation></ix:nonNumeric><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-461-2" continuedAt="f-461-3"><ix:continuation id="f-462-1"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency gains (losses)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="f-463">613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-464">4,109</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense on promissory notes payable to related parties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-465">16,461</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-466">4,401</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-467">10,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InvestmentIncomeNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-468">1,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of cumulative currency translation gain</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="smmt:CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome" scale="3" id="f-469">419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="smmt:CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome" format="ixt:fixed-zero" scale="3" id="f-470">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-471">252</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-472">304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-473">5,278</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-474">6,693</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 17, 2023, the Company dissolved the following dormant entities; Summit (Cambridge) Limited, Summit (Wales) Limited, Summit Corporation Employee Benefit Trust Company Limited, Summit Corporation Limited, Summit Discovery 1 Limited and Summit Infectious Diseases Limited. As a result, the Company reclassified $<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="smmt:CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome" scale="3" id="f-475">419</ix:nonFraction> of cumulative foreign currency translation adjustments from accumulated other comprehensive loss relating to these entities.</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2023, other expense, net primarily consisted of loan interest expense incurred related to the promissory notes described in Note 18. These amounts are partially offset in the year ended December 31, 2023 by interest income related to the Company&#8217;s money market funds and the Company&#8217;s short-term investments in U.S. treasury securities and favorable changes in foreign currency.</span></div></ix:continuation><div><span><br/></span></div><div><ix:continuation id="f-461-3"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2022, other expense, net primarily consisted of unfavorable changes in foreign currency, loan interest expense incurred related to the promissory notes described in Note 18, partially offset by investment income related to the Company&#8217;s money market funds and investments in highly liquid U.S. treasury securities, which are classified as cash equivalents as of December&#160;31, 2022.</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div><span><br/></span></div><div id="if355807d1b914743a4dab03fe6913e8f_151"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-476" continuedAt="f-476-1" escape="true">Income Tax&#160;</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-476-1" continuedAt="f-476-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is primarily subject to corporation taxes in the U.S. and the U.K.. The calculation of the Company&#8217;s tax provision involves the application of both U.S. and U.K. tax law and requires judgment and estimates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is determined using the asset and liability approach. Tax laws may require items to be included in tax filings at different times than the items are reflected in the financial statements. A current asset or liability is recognized for the estimated taxes receivable or payable for the current year. Deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. Deferred taxes are initially recognized at enacted tax rates in force at the time of initial recognition and are subsequently adjusted for any enacted changes in tax rates and tax laws. Subsequent changes to deferred taxes originally recognized in equity are recognized in income. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The Company has recorded a full valuation allowance against the deferred tax assets in excess of its deferred tax liabilities, as the deferred tax liability represents future reversals of existing taxable temporary differences. The Company records interest and penalties related to income tax matters as part of income tax expense.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertainty in income taxes by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed as the amount of benefit to recognize in the consolidated financial statements. The amount of benefits that may be used is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-476-2" continuedAt="f-476-3"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate, as well as the related net interest and penalties. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="f-477" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company&#8217;s loss before income taxes are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-478">499,810</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-479">46,868</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-480">115,118</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-481">31,914</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-482">614,928</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-483">78,782</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-484"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-485"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="INF" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-486"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-487"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="INF" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-488"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="INF" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-489"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="INF" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-490"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="INF" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-491"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="INF" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-492"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="INF" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-493"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-494"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="INF" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-495">not</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> recognized a current or deferred provision for federal, state or non-United States income taxes in either of the years ending December 31, 2023 or 2022, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-496" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of deferred tax assets and liabilities are as follows:</span></div><div style="padding-left:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.468%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss carryforward</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-497">58,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-498">52,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development credit carryforward</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-499">4,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-500">1,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-501">4,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-502">3,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Section 174 Research and Development Capitalization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="smmt:DeferredTaxAssetsCapitalizedResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-503">15,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="smmt:DeferredTaxAssetsCapitalizedResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-504">3,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liability</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="smmt:DeferredTaxAssetsLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-505">1,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="smmt:DeferredTaxAssetsLeasingArrangements" scale="3" id="f-506">737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-507">1,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-508">2,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-509">86,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-510">64,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-511">1,085</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="f-512">651</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="f-513">174</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="f-514">226</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-515">1,259</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="f-516">877</ix:nonFraction>)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax assets before valuation allowance </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="smmt:DeferredTaxAssetsLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-517">84,751</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="smmt:DeferredTaxAssetsLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-518">64,016</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-519">84,751</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-520">64,016</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-521">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-522">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated the positive and negative evidence bearing upon its ability to realize its deferred tax assets, which are comprised primarily of net operating loss carryforwards and research and development costs capitalized for tax purposes. Management has considered the Company&#8217;s history of cumulative net losses in the United States (&#8220;U.S.&#8221;) and the United Kingdom (&#8220;U.K.&#8221;), estimated future taxable income, as well as prudent and feasible tax planning strategies, and has concluded that it is more likely than not that the Company will not realize the benefits of its U.S. federal and state deferred tax assets and U.K. deferred tax assets. Accordingly, a full valuation allowance has been established against these net deferred tax assets as of December 31, 2023 and 2022, respectively. The Company reevaluates the positive and negative evidence at each reporting period. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><div><span><br/></span></div><ix:continuation id="f-476-3" continuedAt="f-476-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="f-523" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the valuation allowance was as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.468%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance as of beginning of year</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-524">64,016</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-525">51,746</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase recorded to the income tax provision</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="3" id="f-526">20,735</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="3" id="f-527">12,270</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance as of end of year</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-528">84,751</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-529">64,016</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023 and 2022, the Company had U.S. Federal gross operating loss carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-530">48,184</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-531">11,620</ix:nonFraction>, respectively, which may be available to offset future income tax liabilities. The 2017 Tax Cuts and Jobs Act (&#8220;TCJA&#8221;) will generally allow losses incurred after 2017 to be carried over indefinitely, but will generally limit the net operating loss deduction to the lesser of the net operating loss carryover or 80% of a corporation&#8217;s taxable income (subject to Section 382 of the Internal Revenue Code of 1986, as amended). In addition, the Company has approximately $<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-532">3,705</ix:nonFraction> in U.S. State gross loss carryforwards which expire through various dates through 2043 and as of December 31, 2023, the Company had an estimated U.S. federal and state research and development tax credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="3" id="f-533">2,900</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:TaxCreditCarryforwardAmount" scale="3" id="f-534">900</ix:nonFraction>, respectively, which may be available to offset future tax liabilities, and each begin to expire in 2041 and 2037, respectively. The Company also had approximately $<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-535">194,454</ix:nonFraction> in U.K. gross loss carryforwards available to use against future taxable profits on a year-by-year basis. To the extent that U.K. taxable profits exceed &#163;5,000 in each year, the loss available to utilize against profits in excess of &#163;5,000 will be restricted to 50%. The U.K. loss carryforwards do not lapse and therefore, the full amount will be relieved over time provided there are sufficient profits against which the losses can be utilized. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilization of the U.S. net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986 due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has not completed a study to assess whether a change of ownership has occurred, or whether there have been multiple ownership changes since its formation. Any limitation may result in the loss of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.K. tax losses are subject to additional restrictions where there is a change in ownership in the business and certain other conditions are met. An ownership change of a UK tax resident company would occur where (directly or indirectly) a single person acquires more than half of the ordinary share capital of a company, or two or more persons each acquire a holding of at least 5% of the ordinary share capital of a company and these holdings together amount to more than half the ordinary share capital of a company. Where a change in ownership has occurred, and within three years prior to that change in ownership and five years afterwards, there is a major change in the nature and conduct of trade of that company or the trade of that business becomes small or negligible, any losses carried forward will be extinguished from the point of the change in ownership. In addition, losses accrued subsequent to April 1, 2017 will be extinguished on a change of ownership when there is a major change in the nature or conduct of a company&#8217;s business, or where there is a major change in the scale of that business, or a company ceases to carry on a particular trade or business. The Company has not completed a study to assess whether a change of ownership has occurred since its formation, or whether there has been a major change in the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s business that would restrict the U.K. tax losses. Any limitation may result in the loss of a portion of the net operating loss carryforwards before utilization.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2017 Tax Cuts and Jobs Act (&#8220;TCJA&#8221;) created a requirement that US corporations include in income earnings of certain controlled foreign corporations (&#8220;CFC&#8221;) under the global intangible low taxed income (&#8220;GILTI&#8221;) regime. The Company is allowed to make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as period expense only. The Company has elected to account for GILTI in the year the tax is incurred and include the current tax impact of GILTI in the effective tax rate. Given the Company&#8217;s loss position in the U.S. and the valuation allowance recorded against </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-476-4" continuedAt="f-476-5"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">its U.S. net deferred tax assets, these provisions have not had a material impact on the Company&#8217;s consolidated financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IRC Section 174 generally permitted taxpayers that incurred research expenses to deduct them in the current year. For tax years beginning before January 1, 2022, taxpayers were able to make an election with respect to research and experimental (&#8220;R&amp;E&#8221;) expenditures incurred in connection with a trade or business to either currently deduct or defer and amortize such expenditures.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The TCJA amended this provision to require that R&amp;E expenditures be capitalized and amortized, but delayed the effective date of this amendment, which applies to tax years beginning January 1, 2022 or later. As such, the changes to IRC Section 174 pursuant to the TCJA are currently applicable to the Company for the 2022 tax year. R&amp;E expenditures attributable to U.S. based research must be amortized over a period of five years and R&amp;E expenditures attributable to research conducted outside of the U.S. must be amortized over a period of 15 years. As such, the Company is capitalizing $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="smmt:ResearchAndDevelopmentExpenseCapitalizedAmount" format="ixt:num-dot-decimal" scale="3" id="f-536">73,129</ix:nonFraction> R&amp;E expenditures with a net adjustment of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="smmt:ResearchAndDevelopmentExpenseAmortizableAmount" format="ixt:num-dot-decimal" scale="3" id="f-537">65,816</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to account for the capitalization and amortization of R&amp;D expenses incurred in the U.S.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-538" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the Company&#8217;s effective tax rate to the U.S. federal statutory rate is as follows: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. federal income tax statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-539">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-540">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-541">3.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-542">16.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Refundable research and development tax credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="smmt:EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent" scale="-2" id="f-543">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="smmt:EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent" scale="-2" id="f-544">3.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of foreign operations taxed at various rates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-545">17.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-546">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="f-547">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="f-548">2.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-549">0.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-550">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="f-551">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="f-552">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.K., the Company is entitled to a research and development tax relief for small and medium-sized enterprises which allows the Company an enhanced deduction rate of 230% (up to March 31, 2023) and 186% (from April 1, 2023) on qualifying research and development expenditure (the tax relief). If the Company incurs tax losses, it is entitled to surrender the lesser of unrelieved tax loss sustained and the tax relief. As the realization of the tax relief does not depend on generation of future taxable income or the Company&#8217;s ongoing tax status or tax position, the Company does not consider the tax relief as an element of income tax accounting under ASC 740. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2023 and 2022, the Company recognized research and development tax relief of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="smmt:ResearchAndDevelopmentTaxCredit" scale="3" id="f-553">946</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="smmt:ResearchAndDevelopmentTaxCredit" format="ixt:num-dot-decimal" scale="3" id="f-554">4,523</ix:nonFraction> respectively, which is included in other operating income in the consolidated statements of operations and other comprehensive loss.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the intention of the Company to reinvest the earnings of its non-U.S. subsidiaries in those operations and not to repatriate the earnings to the U.S. Accordingly, the Company does not provide for deferred taxes on differences between financial reporting and tax basis in its investments in foreign subsidiaries as they are considered permanent in duration or are not expected to reverse in the foreseeable future. As of December 31, 2023, there are no unremitted earnings of the Company&#8217;s foreign subsidiaries.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records unrecognized tax benefits in accordance with ASC 740-10, Income Taxes. ASC 740-10 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in the Company&#8217;s income tax return and also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. As of December 31, 2023 and 2022, the Company had total unrecognized tax benefits of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-555">1,064</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="f-556">0</ix:nonFraction>, respectively.</span></div></ix:continuation><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-476-5" continuedAt="f-476-6"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Company&#8217;s full valuation allowance, the unrecognized tax benefits would not materially impact the Company&#8217;s effective tax rate when recognized.  The Company does not anticipate the total amounts of unrecognized tax benefits will significantly increase or decrease in the next 12 months. The Company&#8217;s policy is to recognize interest and penalties related to uncertain tax positions as part of its income tax provision. For the years ended December 31, 2023 and 2022, the Company had <ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="3" id="f-557"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="3" id="f-558">no</ix:nonFraction></ix:nonFraction> interest or penalties related to unrecognized tax benefits.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="f-559" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of unrecognized tax benefits from continuing operations is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:67.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.627%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.629%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized tax benefits, beginning of year</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="3" id="f-560">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="3" id="f-561">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases related to prior year tax positions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="f-562">610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-563">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decreases related to prior year tax positions</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-564">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-565">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases related to current year tax positions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="f-566">454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-567">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized tax benefits, end of year</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-568">1,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="3" id="f-569">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-476-6">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal, state, and foreign jurisdictions, where applicable. the U.S. In the U.S., tax years from 2020 remain subject to examination by the U.S. Internal Revenue Service and state tax authorities. The Company is not currently under examination by the Internal Revenue Service or any other jurisdiction for years 2020 through present. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may be adjusted upon examination by the Internal Revenue Service or state tax authorities to the extent utilized in a future period. In the U.K., tax returns for the year ended December 31, 2022 remains subject to examination by HMRC.</ix:continuation> </span></div><div><span><br/></span></div><div id="if355807d1b914743a4dab03fe6913e8f_154"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-570" continuedAt="f-570-1" escape="true">Net Loss per Share </ix:nonNumeric></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-571" escape="true"><ix:continuation id="f-570-1" continuedAt="f-570-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net loss per share: </span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.198%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-572">614,928</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-573">78,782</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average number of shares of common stock outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-574">619,646,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-575">193,336,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average number of shares of common stock outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-576">619,646,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-577">193,336,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net loss per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-578">0.99</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-579">0.41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net loss per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-580">0.99</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-581">0.41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="margin-top:1pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-570-2"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the diluted net loss by the weighted-average number of common shares outstanding for the period, including potentially dilutive common shares. Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share for all periods, as the inclusion of all potential common share equivalents outstanding would have been anti-dilutive. </span></div><div style="margin-top:1pt"><span><br/></span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because the 2023 Rights Offering (as defined in Note 20) exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-42" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-582">1.05</ix:nonFraction> per share was less than the closing price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-86" decimals="2" name="us-gaap:SharePrice" scale="0" id="f-583">1.82</ix:nonFraction> per share on March 1, 2023, the expiration of the , the Company has retroactively adjusted earnings per share and weighted average number of shares outstanding for the bonus element for all periods presented.</span></div><div style="margin-top:1pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-584" escape="true"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities were excluded from the computation of the diluted net loss per share of common stock for the periods presented because their effect would have been anti-dilutive: </span></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-87" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-585">54,209,289</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-88" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-586">19,476,359</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-89" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-587">5,015,642</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-90" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-588">5,821,137</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares expected to be purchased under employee stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-91" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-589">155,163</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-92" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-590">229,475</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-591">59,380,094</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-592">25,526,971</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:1pt"><span><br/></span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options that are outstanding and contain performance-based or market-based vesting criteria for which the performance or market conditions have not been met are excluded from the presentation of common stock equivalents outstanding in the chart above. Refer to Note 21 for further information on market-based awards.</span></div></ix:continuation><div style="margin-top:1pt"><span><br/></span></div><div id="if355807d1b914743a4dab03fe6913e8f_157"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="f-593" continuedAt="f-593-1" escape="true">Goodwill and Intangible Assets</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-593-1" continuedAt="f-593-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Company expanded its activities in the field of infectious diseases with the acquisition of Discuva Limited, a privately held United Kingdom-based company. Through this acquisition, the Company obtained a bacterial genetics platform and a suite of software-based technologies (the &#8220;Discuva Platform&#8221;), which facilitates the discovery and development of new mechanism antibiotics. This resulted in the recognition of goodwill of &#163;<ix:nonFraction unitRef="gbp" contextRef="c-93" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="f-594">1.5</ix:nonFraction>&#160;million, which is translated into U.S. dollars at each reporting period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses goodwill for impairment on an annual basis as of December 31 or more frequently when events and circumstances occur indicating that recorded goodwill may be impaired.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the Company performed its annual impairment assessment of goodwill and determined that it is more likely than not that the fair value of the reporting unit exceeds its carrying amount. There have been <ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:fixed-zero" scale="3" id="f-595">no</ix:nonFraction> cumulative goodwill impairment charges recognized to date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023 and 2022, goodwill was $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-596">1,893</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-597">1,798</ix:nonFraction>, respectively. Changes year over year are the result of changes in foreign currency.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Intangible Assets</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="f-598" continuedAt="f-598-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of the Company&#8217;s acquired intangible assets are comprised of the following:</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-598-1"><ix:continuation id="f-593-2" continuedAt="f-593-3"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:25.301%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.961%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.681%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.717%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.961%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.681%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.724%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated amortization and impairment charges</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated amortization and impairment charges</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Utrophin program acquired</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:fixed-zero" scale="3" id="f-599">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment" format="ixt:fixed-zero" scale="3" id="f-600">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="3" id="f-601">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-602">4,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment" format="ixt:num-dot-decimal" scale="3" id="f-603">4,015</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="3" id="f-604">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discuva platform acquired</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-605">13,583</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment" format="ixt:num-dot-decimal" scale="3" id="f-606">13,583</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="3" id="f-607">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-608">12,900</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment" format="ixt:num-dot-decimal" scale="3" id="f-609">12,900</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="3" id="f-610">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Option over non-financial asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="f-611">859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment" scale="3" id="f-612">859</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="3" id="f-613">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="f-614">816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment" scale="3" id="f-615">816</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="3" id="f-616">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other intangibles</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="f-617">140</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment" scale="3" id="f-618">140</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="3" id="f-619">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="f-620">133</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment" scale="3" id="f-621">133</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="3" id="f-622">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-623">14,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment" format="ixt:num-dot-decimal" scale="3" id="f-624">14,582</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="3" id="f-625">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-626">17,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment" format="ixt:num-dot-decimal" scale="3" id="f-627">17,864</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="3" id="f-628">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company dissolved the wholly-owned subsidiary, Muox Limited, a dormant entity. The Utrophin program intangible assets, which arose from the Muox Limited acquisition were fully impaired and have been removed from the Company&#8217;s accounting records.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the significant change in the Company&#8217;s strategy and shift in focus to the therapeutic area of oncology, the Company determined that it would cease further investment in the Discuva Platform. Management concluded that the carrying amount of the acquired Discuva Platform intangible asset may not be recoverable and performed an assessment to calculate the fair value of the asset using a probability-weighted approach which was compared to the carrying value of the asset. An impairment charge of $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="3" id="f-629">8,468</ix:nonFraction> which represented the carrying value of the Discuva Platform was recognized during the year ended December 31, 2022. This impairment charge is presented as <span style="-sec-ix-hidden:f-630">impairment of intangible assets</span> in the consolidated statements of operations and comprehensive loss.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-593-3">Changes year over year in the gross and accumulation amortization amounts of intangible assets are the result of changes in foreign currency. Amortization expense was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="f-631">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="f-632">914</ix:nonFraction> for the years ended December 31, 2023 and 2022, respectively.</ix:continuation> </span></div><div><span><br/></span></div><div><span><br/></span></div><div id="if355807d1b914743a4dab03fe6913e8f_160"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="c-1" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="f-633" continuedAt="f-633-1" escape="true">Fair Value Measurements and Short-Term Investments</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-633-1" continuedAt="f-633-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Fair Value Measurements</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="f-634" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables sets forth the Company&#8217;s fair value hierarchy for its assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2023 and 2022: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:37.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.486%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements as of December 31, 2023</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="smmt:CashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-635">21,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="smmt:CashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-636">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="smmt:CashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-637">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="smmt:CashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-638">21,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government treasury bills</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="smmt:CashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-639">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="smmt:CashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-640">39,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="smmt:CashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-641">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="smmt:CashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-642">39,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government treasury bills</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-643">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-644">114,817</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-645">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-646">114,817</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-647">21,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-648">154,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-649">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-650">175,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:37.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.486%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements as of December 31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="smmt:CashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-651">60,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="smmt:CashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-652">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="smmt:CashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-653">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="smmt:CashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-654">60,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government treasury bills</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="smmt:CashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-655">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="smmt:CashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-656">225,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="smmt:CashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-657">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="smmt:CashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-658">225,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-659">60,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-660">225,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-661">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-662">286,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><div><span><br/></span></div><ix:continuation id="f-633-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table above does not include cash at December 31, 2023 and 2022 of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="3" id="f-663">11,068</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="3" id="f-664">62,094</ix:nonFraction>, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that the carrying amounts of prepaid expenses, other current assets, accounts payable, and accrued expenses approximates their fair values due to the short-term nature of those instruments. The carrying value of the Company&#8217;s promissory note approximates its fair value due to the recent issuance of the notes in December 2022 and the current interest rate of the note outstanding when compared to market interest rates (which represents a Level 2 measurement). Refer to Note 18 for further details.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Short-Term Investments</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="f-665" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Company&#8217;s short-term investments as of December 31, 2023, which have a contractual maturity of less than one year:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:35.655%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Credit Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-666">114,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-667">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-668">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-669">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-670">114,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-671">114,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-672">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-673">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-674">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-675">114,817</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:fixed-zero" scale="0" id="f-676">not</ix:nonFraction> have any short-term investments as of December 31, 2022.</span></div></ix:continuation><div><span><br/></span></div><div id="if355807d1b914743a4dab03fe6913e8f_163"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-677" continuedAt="f-677-1" escape="true">Property and Equipment </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-677-1"><ix:continuation id="f-372-1"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:60.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.826%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.829%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-678">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-679">505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures, office equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-680">896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-681">889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-682">328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-683">809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-684">1,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-685">2,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-686">1,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-687">1,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-688">204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-689">906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:1pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the years ended December 31, 2023 and 2022 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-690">198</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-691">349</ix:nonFraction>, respectively. The Company recognized a fixed asset impairment charge of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:TangibleAssetImpairmentCharges" scale="3" id="f-692">474</ix:nonFraction> for the year ended December 31, 2023. There were <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="f-693">no</ix:nonFraction> impairment charges related to fixed assets for the year ended December 31, 2022.</span></div></ix:continuation><div><span><br/></span></div><div id="if355807d1b914743a4dab03fe6913e8f_169"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" id="f-694" continuedAt="f-694-1" escape="true">Research and Development Prepaid Expenses and Accrued Liabilities</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-694-1" continuedAt="f-694-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included within prepaid expenses at December 31, 2023 and 2022 is $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="smmt:ResearchAndDevelopmentPrepaidExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-695">1,466</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="smmt:ResearchAndDevelopmentPrepaidExpensesCurrent" scale="3" id="f-696">442</ix:nonFraction>, respectively, of prepayments relating to research and development expenditures. Included within accrued liabilities at December 31, 2023 and 2022 is $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="smmt:AccruedResearchAndDevelopmentCurrent" format="ixt:num-dot-decimal" scale="3" id="f-697">7,289</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="smmt:AccruedResearchAndDevelopmentCurrent" format="ixt:num-dot-decimal" scale="3" id="f-698">8,911</ix:nonFraction>, respectively, relating to research and development expenditures.</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-694-2">These amounts are determined based on the estimated costs to complete each study or activity, the estimation of the current stage of completion and the invoices received, as well as predetermined milestones which are not reflective of the current stage of development for prepaid expenses. However, prepaid expenses decrease and accrued liabilities increase as the activities progress, and if actual costs incurred exceed the prepaid expense, an accrual will be recorded for the liability. The key sensitivity is the estimated current stage of completion of each study or activity, which is based on information received from the supplier and the Company&#8217;s operational knowledge of the work completed under those contracts.</ix:continuation> </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><div style="margin-bottom:6pt"><span><br/></span></div><div id="if355807d1b914743a4dab03fe6913e8f_175"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17. <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-699" continuedAt="f-699-1" escape="true">Leases</ix:nonNumeric></span><ix:continuation id="f-699-1" continuedAt="f-699-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></ix:continuation></div><div><span><br/></span></div><ix:continuation id="f-699-2" continuedAt="f-699-3"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for real estate. The Company does not have any finance leases. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-700">4,245</ix:nonFraction> of additional right-of-use assets related to a new lease for additional office space which commenced in May 2023 at its Menlo Park, California location. The Company will make total lease payments of $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-701">4,701</ix:nonFraction> over the <ix:nonNumeric contextRef="c-135" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth" id="f-702">36</ix:nonNumeric> month term of the new lease, which expires in May 2026. In addition, during the year ended December 31, 2023, the Company terminated the Company&#8217;s Cambridge, U.K. laboratory and office space lease as a result of the Company re-prioritizing its investments and financial resources towards the development of ivonescimab. This resulted in disposing the carrying value of the right-of use asset of $<ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="smmt:OperatingLeaseRightOfUseAssetDisposals" scale="3" id="f-703">788</ix:nonFraction>, removing the related lease liability of $<ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-704">809</ix:nonFraction>, and there were no penalties charged for early termination of this lease. The Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-705">2,860</ix:nonFraction> of right-of-use assets during the year ended December 31, 2022 related to its Menlo Park, California location.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the right-of-use assets as of December 31, 2023 and 2022 is $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-706">5,859</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-707">4,175</ix:nonFraction>, respectively.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-708" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The elements of lease expense were as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease Cost:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Fixed lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-709">2,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-710">1,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Variable lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="f-711">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="f-712">137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Short-term lease</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShortTermLeaseCost" format="ixt:fixed-zero" scale="3" id="f-713">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="f-714">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-715">2,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-716">1,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Short-term lease costs relate to the Company&#8217;s Cambridge, Massachusetts, United States office lease which the Company exited during fiscal year 2022.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average discount rate and the weighted average remaining lease term were <ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-717">6.6</ix:nonFraction>% and <ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-718">2.4</ix:nonNumeric> years, respectively, as of December 31, 2023. The weighted average discount rate and the weighted average remaining lease term were <ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-719">5.7</ix:nonFraction>% and <ix:nonNumeric contextRef="c-5" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-720">3.4</ix:nonNumeric> years, respectively, as of December 31, 2022. The Company made cash payments related to lease liabilities of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-721">2,208</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-722">1,092</ix:nonFraction> for the years ending December 31, 2023 and 2022 respectively. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-723" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future lease payments under non-cancelable leases as of December 31, 2023 are detailed as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:83.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.843%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.357%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-724">2,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-725">2,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="f-726">893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:fixed-zero" scale="3" id="f-727">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-728">6,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="f-729">490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-730">6,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities balance sheet presentation:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-731">2,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-732">3,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-733">6,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company signed a lease agreement on January 8, 2024 for executive office space for its new headquarters in Miami, Florida. The office space is approximately <ix:nonFraction unitRef="sqft" contextRef="c-138" decimals="-3" name="smmt:LesseeOperatingLeaseAreaOfPremisesLeased" format="ixt:num-dot-decimal" scale="0" id="f-734">9,000</ix:nonFraction> square feet. The term of the lease is <ix:nonNumeric contextRef="c-138" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth" id="f-735">64</ix:nonNumeric> months. Total payments for this office </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">133</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-699-3">space is approximately $<ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-736">5,100</ix:nonFraction> over the term of the lease. The table above excludes payments related to the lease signed in January 2024.</ix:continuation> </span></div><div><span><br/></span></div><div id="if355807d1b914743a4dab03fe6913e8f_178"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18. <ix:nonNumeric contextRef="c-1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-737" continuedAt="f-737-1" escape="true">Promissory Notes Payable to Related Parties</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-737-1" continuedAt="f-737-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="f-738" continuedAt="f-738-1" escape="true">Non-current and current debt consisted of the following:</ix:nonNumeric></span></div><ix:continuation id="f-738-1"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:41.288%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.183%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.526%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.079%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.484%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current notes</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal amounts</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="smmt:NotesPayableGrossCurrent" format="ixt:fixed-zero" scale="3" id="f-739">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="smmt:NotesPayableGrossCurrent" format="ixt:num-dot-decimal" scale="3" id="f-740">20,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="smmt:NotesPayableGrossNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-741">100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="smmt:NotesPayableGrossNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-742">500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountCurrent" format="ixt:fixed-zero" scale="3" id="f-743">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountCurrent" scale="3" id="f-744">230</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent" format="ixt:fixed-zero" scale="3" id="f-745">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-746">5,460</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total promissory notes payable to related parties</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:NotesPayableCurrent" format="ixt:fixed-zero" scale="3" id="f-747">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:NotesPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-748">19,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:LongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-749">100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:LongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-750">494,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">March 2022 Promissory Note</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 10, 2022, Mr. Duggan, entered into a Note Purchase Agreement (the &#8220;March 2022 Note&#8221;), pursuant to which he loaned the Company $<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:ProceedsFromRelatedPartyDebt" format="ixt:num-dot-decimal" scale="3" id="f-751">25,000</ix:nonFraction> in exchange for the issuance by the Company of an unsecured promissory note in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-752">25,000</ix:nonFraction>. The March 2022 Note accrued interest at a rate per annum equal to the prime rate as reported in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wall Street Journal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The March 2022 Note, including all accrued interest, became due upon the earlier of (i) the consummation of a registered public offering with net proceeds of no less than $<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="smmt:NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold" format="ixt:num-dot-decimal" scale="3" id="f-753">25,000</ix:nonFraction> or (ii) <ix:nonNumeric contextRef="c-141" name="smmt:NotesPayableRelatedPartiesMaximumTerm" format="ixt-sec:durmonth" id="f-754">18</ix:nonNumeric> months from the date of issuance of the March 2022 Note. Debt issuance costs associated with the March 2022 Note were immaterial and expensed as incurred. The March 2022 Note of $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-3" name="us-gaap:RepaymentsOfRelatedPartyDebt" format="ixt:num-dot-decimal" scale="3" id="f-755">25,000</ix:nonFraction>, plus accrued interest of $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-3" name="smmt:PaymentOfAccruedInterestToRelatedParties" scale="3" id="f-756">434</ix:nonFraction> has been repaid to Mr. Duggan on August 10, 2022 in connection with the completion of the rights offering with aggregate gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-757">100,000</ix:nonFraction>.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred interest expense related to the March 2022 Note of $<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-758">1,296</ix:nonFraction> for the year ended December 31, 2022, which included amortized imputed interest of $<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="f-759">861</ix:nonFraction>. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">December 2022 Promissory Notes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 6, 2022, the Company entered into a Note Purchase Agreement (the &#8220;Note Purchase Agreement&#8221;), with Mr. Duggan and Dr. Zanganeh, pursuant to which the Company agreed to sell to each of Mr. Duggan and Dr. Zanganeh unsecured promissory notes in the aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-760">520,000</ix:nonFraction>. Pursuant to the Note Purchase Agreement, the Company issued to Mr. Duggan and Dr. Zanganeh unsecured promissory notes in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-761">400,000</ix:nonFraction> (the &#8220;Duggan February Note&#8221;) and $<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-762">20,000</ix:nonFraction> (the &#8220;Zanganeh Note&#8221;), respectively, which matured and become due on February 15, 2023 and an unsecured promissory note to Mr. Duggan in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-763">100,000</ix:nonFraction> (the &#8220;Duggan September Note&#8221; and together with the Duggan February Note and the Zanganeh Note, the &#8220;December 2022 Notes&#8221;), which was originally due on September 15, 2023. The maturity dates of the December 2022 Notes could have been extended one or more times at the Company&#8217;s election, but in no event to a date later than September 6, 2024. In addition, if the Company consummates a public offering, then upon the later to occur of (i) <span style="-sec-ix-hidden:f-764">five</span> business days after the Company receives the net cash proceeds therefrom or (ii) May 15, 2023, the Duggan February Note and the Zanganeh Note shall be prepaid by an amount equal to the lesser of (a) <ix:nonFraction unitRef="number" contextRef="c-148" decimals="2" name="smmt:NotesPayableRelatedPartiesPotentialPrepaymentMaximumAmountPercentageOfNetProceedsFromPublicOffering" scale="-2" id="f-765">100</ix:nonFraction>% of the amount of the net proceeds of such offering and (b) the outstanding principal amount on such Notes.</span></div></ix:continuation><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-737-2" continuedAt="f-737-3"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 19, 2023, the Company provided notice to extend the term of the Duggan February Note and Duggan September Note to a maturity date of September 6, 2024. Furthermore, on January 19, 2023, the Company and Mr. Duggan rectified the Duggan February Note and Duggan September Note in order to correctly reflect the parties&#8217; intent that the Company may only prepay (i) the Duggan February Note following the completion of a public rights offering to be conducted by Summit in the approximate amount of $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="smmt:NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold" format="ixt:num-dot-decimal" scale="3" id="f-766">500,000</ix:nonFraction> (the &#8220;Rights Offering&#8221;), or a similar capital raise, in an amount equal to the lesser of (x) the net proceeds of the Rights Offering or such capital raise or (y) the full amount outstanding of the Duggan February Note, and (ii) the Duggan September Note following the completion of a capital raising transaction subsequent to the Rights Offering in an amount equal to the lesser of (A) the net proceeds of such capital raise or (B) the full amount outstanding of the Duggan September Note. Following the issuance of the <ix:nonFraction unitRef="promissory_note" contextRef="c-149" decimals="INF" name="smmt:NotesPayableRelatedPartiesNewIssuances" format="ixt-sec:numwordsen" scale="0" id="f-767">two</ix:nonFraction> new Promissory Notes (the &#8220;Duggan Promissory Notes&#8221;), the Duggan February Note and Duggan September Note were marked as &#8220;cancelled&#8221; on their face and replaced in their entirety by the Duggan Promissory Notes (together with the Zanganeh Note, the &#8220;Notes&#8221;).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 15, 2023, the $<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:RepaymentsOfRelatedPartyDebt" format="ixt:num-dot-decimal" scale="3" id="f-768">20,000</ix:nonFraction> Zanganeh Note matured and the Company repaid the outstanding principal balance. In connection with the closing of the rights offering, the $<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-3" name="us-gaap:RepaymentsOfRelatedPartyDebt" format="ixt:num-dot-decimal" scale="3" id="f-769">400,000</ix:nonFraction> Duggan Promissory Note matured and became due, and the Company repaid all principal and accrued interest thereunder using a portion of the proceeds from this rights offering.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes accrued interest at an initial rate of <ix:nonFraction unitRef="number" contextRef="c-151" decimals="3" name="us-gaap:RelatedPartyTransactionRate" scale="-2" id="f-770">7.5</ix:nonFraction>%. All interest on the Notes was paid on the date of signing for the period through February 15, 2023. Such prepaid interest was paid in a number of shares of the Company&#8217;s common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-152" decimals="2" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-771">0.01</ix:nonFraction> (&#8220;Common Stock&#8221;) equal to the dollar amount of such prepaid interest, divided by $<ix:nonFraction unitRef="usdPerShare" contextRef="c-151" decimals="4" name="smmt:NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominator" scale="0" id="f-772">0.7913</ix:nonFraction> (the consolidated closing bid price immediately preceding the time the Company entered into the Note Purchase Agreement, plus $<ix:nonFraction unitRef="usdPerShare" contextRef="c-151" decimals="2" name="smmt:NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominatorBaseAmountAddedToClosingBidPrice" scale="0" id="f-773">0.01</ix:nonFraction>), which was <ix:nonFraction unitRef="shares" contextRef="c-151" decimals="INF" name="smmt:StockIssuedDuringPeriodSharesRelatedPartyPrepaidInterest" format="ixt:num-dot-decimal" scale="0" id="f-774">9,720,291</ix:nonFraction> shares. For all applicable periods following February 15, 2023, interest shall accrue on the outstanding principal balance of the Notes at the US prime interest rate, as reported in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wall Street Journal,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plus <ix:nonFraction unitRef="number" contextRef="c-153" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-4" id="f-775">50</ix:nonFraction> basis points, as adjusted monthly, for three months immediately following February 15, 2023, and thereafter at the US prime rate plus <ix:nonFraction unitRef="number" contextRef="c-154" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-4" id="f-776">300</ix:nonFraction> basis points, as adjusted monthly.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt issuance costs associated with the Notes were $<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:DeferredFinanceCostsGross" scale="3" id="f-777">44</ix:nonFraction> and were capitalized as part of the carrying value of the promissory notes payable to related parties. During the year ended December 31, 2023, the Company incurred interest expense of $<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-778">16,461</ix:nonFraction> for the year ended December 31, 2023, which included amortized imputed interest of $<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="f-779">761</ix:nonFraction>. The Company incurred interest expense of $<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-780">3,105</ix:nonFraction> for the year ended December 31, 2022 related to the December 2022 Notes, which included amortized imputed interest of $<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="f-781">395</ix:nonFraction>.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023 and 2022 there was $<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:InterestPayableCurrentAndNoncurrent" scale="3" id="f-782"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:InterestPayableCurrentAndNoncurrent" scale="3" id="f-783">120</ix:nonFraction></ix:nonFraction> of accrued interest payable included within accrued expenses in the consolidated balance sheet. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Imputed interest is calculated as the difference between the expected interest payable and the deemed market rate of interest and is recorded as a debt discount at inception of the note payable with a credit to additional paid-in capital for notes payable to related parties. The debt discount is amortized to interest expense using an effective interest rate method. The effective interest rate of the Duggan February Note and Zanganeh Note was <ix:nonFraction unitRef="number" contextRef="c-159" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-784"><ix:nonFraction unitRef="number" contextRef="c-160" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-785">8.9</ix:nonFraction></ix:nonFraction>% and the effective interest rate of the Duggan September Note was <ix:nonFraction unitRef="number" contextRef="c-161" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-786">11.3</ix:nonFraction>%. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2024 the Duggan February Note was amended to extend the maturity date from September 6, 2024 to April 1, 2025. For all applicable periods commencing  February 17, 2024, interest shall accrue on the outstanding principal balance at the greater of <ix:nonFraction unitRef="number" contextRef="c-53" decimals="2" name="us-gaap:RelatedPartyTransactionRate" scale="-2" id="f-787">12</ix:nonFraction>% or the US prime interest rate, as reported in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wall Street Journal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plus <ix:nonFraction unitRef="number" contextRef="c-54" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-4" id="f-788">350</ix:nonFraction> basis points, as adjusted monthly, compounded quarterly.Interest shall be paid upon maturity of the loan.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the applicable accounting standards, a short-term debt obligation should be excluded from current liabilities if the entity has both the intent and ability to refinance the obligation on a long-term basis. The intent and ability can be demonstrated by the issuance of a long-term obligation to refinance the short-term obligation on a long-term basis after the date of an entity&#8217;s balance sheet but before that balance sheet is issued. As a result of the amendment entered into on February 17, 2024, to extend the maturity date to April 1, 2025, the Company classified $<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:LongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-789">100,000</ix:nonFraction> of notes payable to related party outstanding as of December 31, 2023 as long-term notes payable</span></div></ix:continuation><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-737-3" continuedAt="f-737-4"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future principal payments are $<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="f-790">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-791">100,000</ix:nonFraction> for 2024 and 2025, respectively, as the note matures on April 1, 2025.</span></div></ix:continuation><div><span><br/></span></div><div id="if355807d1b914743a4dab03fe6913e8f_181"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19. <ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock" id="f-792" continuedAt="f-792-1" escape="true">Other Non-Current Liabilities</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-792-1"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included within other non-current liabilities at December 31, 2023 and 2022 is $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="smmt:BusinessCombinationAssumedContingentLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-793">1,356</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="smmt:BusinessCombinationAssumedContingentLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-794">1,209</ix:nonFraction>, respectively, relating to assumed contingent liabilities. As part of the acquisition of Discuva Limited in December 2017, the Company assumed certain contingent liabilities as certain employees, former employees and former directors of Discuva Limited are eligible for payments from Discuva Limited based on specified development and clinical milestones related to proprietary product candidates developed under the Discuva Platform. The timing of these potential payments is uncertain.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the significant change in the Company&#8217;s strategy and shift in focus to the therapeutic area of oncology, the Company determined that it will cease further investment in the Discuva platform and evaluate further options for the use of the Discuva Platform. As a result, management has revised the estimated presented value of these payments and remeasured the contingent liabilities. This resulted in recording a gain on remeasurement of liabilities of $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="smmt:BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-795">1,265</ix:nonFraction> during the year ended December 31, 2022, which is included net as part of the research and development expenses in the consolidated statement of operations and comprehensive loss.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="smmt:BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss" format="ixt:fixed-zero" scale="0" id="f-796">no</ix:nonFraction> remeasurement losses or gains recognized during the year ended December 31, 2023.</span></div></ix:continuation><div><span><br/></span></div><div id="if355807d1b914743a4dab03fe6913e8f_184"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">20. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-797" continuedAt="f-797-1" escape="true">Stockholders' Equity </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-797-1" continuedAt="f-797-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Common Stock</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Company announced the closing of its 2022 rights offering (&#8220;2022 Rights Offering&#8221;). The rights offering commenced on July 18, 2022, and the associated subscription rights expired on August 8, 2022. The 2022 Rights Offering received aggregate gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-798">100,000</ix:nonFraction> from the sale of <ix:nonFraction unitRef="shares" contextRef="c-144" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-799">103,092,783</ix:nonFraction> shares of common stock. Mr. Duggan and Dr. Zanganeh fully subscribed to their respective basic subscription rights and oversubscribed, at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-162" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-800">0.97</ix:nonFraction>. Offering costs of $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="f-801">111</ix:nonFraction> were incurred. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 6, 2022, the Company announced a rights offering for its existing shareholders to participate in the purchase of additional shares of its Common Stock for $<ix:nonFraction unitRef="usdPerShare" contextRef="c-42" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-802">1.05</ix:nonFraction> per share (the &#8220;2023 Rights Offering&#8221;). The 2023 Rights Offering commenced on February 7, 2023 and the associated subscription rights expired on March 1, 2023. Aggregate gross proceeds from the 2023 Rights Offering were $<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-803">500,000</ix:nonFraction> from the sale of <ix:nonFraction unitRef="shares" contextRef="c-41" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-804">476,190,471</ix:nonFraction> shares of the Company&#8217;s common stock and issuance costs were $<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="f-805">619</ix:nonFraction>. Mr. Duggan and Dr. Zanganeh fully subscribed to their respective basic subscription rights at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-42" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-806">1.05</ix:nonFraction> per share. To satisfy the $<ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="3" id="f-807">395,314</ix:nonFraction> subscription price for the shares subscribed by Mr. Duggan in the 2023 Rights Offering, Mr. Duggan agreed with the Company to extinguish a portion of the amount due and payable to him by the Company at the closing of the 2023 Rights Offering pursuant to the $<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-808">400,000</ix:nonFraction> Duggan Promissory Note in an amount equal to the subscription price (see also Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January&#160;19, 2023, the Company filed Amendment No. 2 to the Restated Certificate of Incorporation (the &#8220;Amendment No. 2&#8221;) with the Secretary of State of the State of Delaware to increase the number of authorized shares of its common stock by <ix:nonFraction unitRef="shares" contextRef="c-38" decimals="INF" name="smmt:CommonStockSharesAuthorizedIncreaseDecrease" format="ixt:num-dot-decimal" scale="0" id="f-809">650,000,000</ix:nonFraction> (from <ix:nonFraction unitRef="shares" contextRef="c-39" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-810">350,000,000</ix:nonFraction> to <ix:nonFraction unitRef="shares" contextRef="c-40" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-811">1,000,000,000</ix:nonFraction>), which became effective on such date. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><div><span><br/></span></div><ix:continuation id="f-797-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2023, the Company filed a registration statement on Form S-3 to register for resale the following shares of the Company&#8217;s common stock at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-45" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-812">0.01</ix:nonFraction> par value: (i) <ix:nonFraction unitRef="shares" contextRef="c-46" decimals="INF" name="smmt:SaleOfStockNumberOfSharesRegisteredForResale" format="ixt:num-dot-decimal" scale="0" id="f-813">10,000,000</ix:nonFraction> shares of Common Stock issued on January 17, 2023 in connection with the License Agreement (as defined in Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) with Akeso pursuant to which the Company issued Akeso such shares; and (ii) the <ix:nonFraction unitRef="shares" contextRef="c-47" decimals="INF" name="smmt:SaleOfStockNumberOfSharesRegisteredForResale" format="ixt:num-dot-decimal" scale="0" id="f-814">9,346,434</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-48" decimals="INF" name="smmt:SaleOfStockNumberOfSharesRegisteredForResale" format="ixt:num-dot-decimal" scale="0" id="f-815">373,857</ix:nonFraction> shares of Common Stock issued in December 2022 to Mr. Duggan and Dr. Zanganeh, respectively, as payment of prepaid interest in connection with the Note Purchase Agreement dated December 6, 2022 between Mr. Duggan, Dr. Zanganeh and the Company. On April 27, 2023, the SEC issued the Company a Notice of Effectiveness for the registration statement on Form S-3.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Soni entered into a share purchase agreement with the Company to purchase $<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="3" id="f-816">5,000</ix:nonFraction> of its common stock via a private placement. The transaction was effective October 13, 2023 with a closing price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-51" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-817">1.68</ix:nonFraction>, resulting in the purchase of <ix:nonFraction unitRef="shares" contextRef="c-52" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-818">2,976,190</ix:nonFraction> shares of the Company&#8217;s common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Warrants</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the private placement on December 24, 2019, the participating investors were granted warrants with the right to subscribe for <ix:nonFraction unitRef="shares" contextRef="c-164" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-819">5,261,350</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-164" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-820">1.58</ix:nonFraction>, exercisable any time in the period commencing on the date falling six months following December 24, 2019 and ending on the tenth anniversary of admission. Each warrant entitles the warrant holder to subscribe in cash for <ix:nonFraction unitRef="shares" contextRef="c-164" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="f-821">one</ix:nonFraction> share. Shares of common stock allotted pursuant to the exercise of the warrant will rank in full for all dividends and other distributions with a record date after the exercise date with the shares of common stock in issue at that date. The Company has the option to require the warrant holder to exercise some or all of the outstanding warrants after the third anniversary date if the ten-day volume weighted average price of the shares of common stock as reported on Nasdaq represents a premium of at least <ix:nonFraction unitRef="number" contextRef="c-165" decimals="INF" name="smmt:ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage" format="ixt:num-dot-decimal" scale="-2" id="f-822">50</ix:nonFraction> percent to the exercise price. The warrants are classified within stockholders&#8217; equity as they are indexed to the Company&#8217;s shares of common stock and require settlement in its shares of common stock with no provision for any cash settlement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, as part of the private placement on December 24, 2019, certain consultants were granted warrants with the right to subscribe for <ix:nonFraction unitRef="shares" contextRef="c-166" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-823">3,358,732</ix:nonFraction> shares of common stock in exchange for certain services. The warrants have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-166" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-824">1.44</ix:nonFraction> and vest quarterly over <ix:nonNumeric contextRef="c-167" name="smmt:ClassOfWarrantOrRightQuarterlyVestingPeriod" format="ixt-sec:durwordsen" id="f-825">three years</ix:nonNumeric>. If the consulting agreement terminated prior to <ix:nonNumeric contextRef="c-167" name="smmt:ClassOfWarrantOrRightQuarterlyVestingPeriod" format="ixt-sec:durwordsen" id="f-826">three years</ix:nonNumeric> after the date of the grant, all unvested warrants will be deemed cancelled. On June 30, 2020, the consulting agreement was terminated and <ix:nonFraction unitRef="shares" contextRef="c-168" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" format="ixt:num-dot-decimal" scale="0" id="f-827">2,798,945</ix:nonFraction> warrants cancelled immediately. The remaining <ix:nonFraction unitRef="shares" contextRef="c-169" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-828">559,787</ix:nonFraction> of outstanding warrants are held by Dr. Zanganeh and Dr. Elaine Stracker.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants granted over shares of common stock to consultants in exchange of certain services are similar to stock-based compensation (see Note 21).</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="f-829" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The following table summarizes the Company&#8217;s warrants activity for the year ended December 31, 2023</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.655%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.306%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.306%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.306%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.313%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of share warrants</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate intrinsic value </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-830">5,821,137</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="smmt:ClassOfWarrantOrRightWeightedAverageExercisePrice" scale="0" id="f-831">1.56</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-6" name="smmt:ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="f-832">6.99</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="smmt:ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-833">15,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Exercised</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="smmt:ClassOfWarrantOrRightExercisesInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-834">805,495</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="smmt:ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod" scale="0" id="f-835">1.49</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-836">5,015,642</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="smmt:ClassOfWarrantOrRightWeightedAverageExercisePrice" scale="0" id="f-837">1.57</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="smmt:ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="f-838">5.92</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="smmt:ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-839">5,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="if355807d1b914743a4dab03fe6913e8f_187"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">21. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-840" continuedAt="f-840-1" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-840-1" continuedAt="f-840-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2016 Long Term Incentive Plan</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the effectiveness of the 2020 Stock Incentive Plan, no additional grants will be made under the 2016 Long Term Incentive Plan, (the &#8220;2016 Plan&#8221;) and any outstanding awards continue with their original terms. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">137</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><div><span><br/></span></div><ix:continuation id="f-840-2" continuedAt="f-840-3"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 Stock Award Plan</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company&#8217;s Board of Directors approved the 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;), which became effective on September 21, 2020. The 2020 plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A total of <ix:nonFraction unitRef="shares" contextRef="c-170" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-841">8,000,000</ix:nonFraction> shares of common stock were initially reserved for issuance under the 2020 Plan. Additionally, up to <ix:nonFraction unitRef="shares" contextRef="c-170" decimals="INF" name="smmt:CommonStockAdditionalCapitalSharesAllowableForForFutureIssuanceUponOptionExpiration" format="ixt:num-dot-decimal" scale="0" id="f-842">5,000,000</ix:nonFraction> shares of common stock, including RSUs can be added to the 2020 Plan for future issuance from options that expire, lapse or are terminated from the 2016 Plan or any other predecessor plans. The number of shares of common stock that may be issued under the 2020 Plan will automatically increase on each January 1, beginning in 2021 and continuing for each fiscal year until, and including, the fiscal year ending December 31, 2030, equal to the lesser of (i) <ix:nonFraction unitRef="shares" contextRef="c-170" decimals="INF" name="smmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardPotentialNumberOfAdditionalSharesAllowableUnderThePlan" format="ixt:num-dot-decimal" scale="0" id="f-843">6,400,000</ix:nonFraction> shares of common stock, (ii) <ix:nonFraction unitRef="number" contextRef="c-171" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="f-844">4</ix:nonFraction>% of the common shares outstanding on the final day of the immediately preceding calendar year and (iii) an amount as determined by the Company&#8217;s Board of Directors. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;27, 2022, the Company held a Special Meeting of Stockholders (the &#8220;Special Meeting&#8221;) whereby the following matters were submitted to a vote of the Company&#8217;s stockholders at the Special Meeting and the Board of Directors resolved the following: (i) an amendment to the Company&#8217;s Restated Certificate of Incorporation, dated September 18, 2020, to increase the number of authorized shares of common stock by <ix:nonFraction unitRef="shares" contextRef="c-172" decimals="INF" name="smmt:CommonStockSharesAuthorizedIncreaseDecrease" format="ixt:num-dot-decimal" scale="0" id="f-845">100,000,000</ix:nonFraction> (from <ix:nonFraction unitRef="shares" contextRef="c-173" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-846">250,000,000</ix:nonFraction> to <ix:nonFraction unitRef="shares" contextRef="c-174" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-847">350,000,000</ix:nonFraction>); and (ii) an amendment to the Summit Therapeutics Inc. 2020 Stock Incentive Plan (the &#8220;Plan&#8221;) to increase the number of shares of the Company&#8217;s common stock issuable under the Plan by <ix:nonFraction unitRef="shares" contextRef="c-175" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-848">8,000,000</ix:nonFraction> shares.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 12, 2023, the Company held a Special Meeting of Stockholders (the &#8220;October Special Meeting&#8221;) whereby the following matter was submitted to a vote of the Company&#8217;s stockholders at the Special Meeting and the Board of Directors resolved the following: an amendment to the Summit Therapeutics Inc. 2020 Stock Incentive Plan to increase the number of shares of the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s common stock issuable under the Plan by <ix:nonFraction unitRef="shares" contextRef="c-49" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-849">70,000,000</ix:nonFraction> shares.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, there are <ix:nonFraction unitRef="shares" contextRef="c-176" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-850">3,261,496</ix:nonFraction> shares available to be issued under the 2020 Plan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 Employee Stock Purchase Plan</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Employee Stock Purchase Plan (the &#8220;2020 ESPP&#8221;) was adopted by the Board of Directors and approved by the Company&#8217;s shareholders on July 17, 2020 and approved by the predecessor company shareholders on August 19, 2020 and is qualified under Section 423 of the Internal Revenue Code. The 2020 ESPP initially authorized the issuance of up to <ix:nonFraction unitRef="shares" contextRef="c-177" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-851">1,000,000</ix:nonFraction> shares of common stock to participating employees. The number of common shares that may be issued under the 2020 ESPP automatically increases on each fiscal year commencing January 1, 2021 and continuing for each fiscal year until, and including the fiscal year commencing on, January 1, 2030 equal to the lesser of (i) <ix:nonFraction unitRef="shares" contextRef="c-177" decimals="INF" name="smmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardPotentialNumberOfAdditionalSharesAllowableUnderThePlan" format="ixt:num-dot-decimal" scale="0" id="f-852">1,600,000</ix:nonFraction> shares of common stock, (ii) <ix:nonFraction unitRef="number" contextRef="c-178" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="f-853">1</ix:nonFraction>% of the common shares outstanding on such date and (iii) an amount as determined by the Company&#8217;s Board of Directors. As of December 31, 2022, there were <ix:nonFraction unitRef="shares" contextRef="c-179" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-854">2,628,893</ix:nonFraction> shares available to be issued under the 2020 ESPP.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first offering period of the 2020 ESPP plan consisted of <ix:nonNumeric contextRef="c-180" name="smmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" format="ixt-sec:durwordsen" id="f-855">seven months</ix:nonNumeric>, commencing on August 2, 2021 and completed on February 28, 2022. The second offering period commenced on March 1, 2022 and was completed on August 31, 2022. Offering periods thereafter will be <ix:nonNumeric contextRef="c-181" name="smmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod" format="ixt-sec:durwordsen" id="f-856">six months</ix:nonNumeric> in duration and will commence immediately proceeding the end of the previous offering period, unless otherwise determined by the Board of Directors or Compensation Committee. Under the 2020 ESPP, eligible employees can purchase shares of common stock through payroll deductions of up to <ix:nonFraction unitRef="number" contextRef="c-177" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="f-857">15</ix:nonFraction>% of their compensation received during the plan period or such shorter period during which deductions from payroll are made, up to a defined maximum amount. The option price is determined based on the lesser of the closing price of common stock on (i) the first business day of the plan period or (ii) the exercise date, or shall be based solely on the closing price of the common stock on the exercise date; provided that such option price shall be at least <ix:nonFraction unitRef="number" contextRef="c-182" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-858">85</ix:nonFraction>% of the applicable closing price. In the absence of a determination by the Board of Directors or the Compensation Committee, the option price is <ix:nonFraction unitRef="number" contextRef="c-178" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-859">85</ix:nonFraction>% of the lesser of the closing price of the common stock on (i) the first business day of the plan period or (ii) the exercise date. </span></div></ix:continuation><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-840-3" continuedAt="f-840-4"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The closing price is the (a) the closing price (for the primary trading session) on the Nasdaq Global Select Market or (b) the average of the closing bid and asked prices in the over-the-counter-market, whichever is applicable, as published in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wall Street Journal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or another source selected by the Board or the Committee. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal year ended December 31, 2023 and 2022, <ix:nonFraction unitRef="shares" contextRef="c-183" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-860">392,175</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-184" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-861">176,857</ix:nonFraction> shares, respectively, were issued under the 2020 ESPP Plan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Time-based Stock Options</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of stock options granted to employees and directors using the Black-Scholes valuation model. Stock options granted under the 2016 and 2020 Plans generally vest over <span style="-sec-ix-hidden:f-862">three</span> or <ix:nonNumeric contextRef="c-186" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-863">four years</ix:nonNumeric> and expire after <ix:nonNumeric contextRef="c-187" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-864">ten years</ix:nonNumeric>. This valuation methodology utilizes several key assumptions as highlighted below.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-865" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used in the Company&#8217;s valuation are summarized as follows, presented on a weighted average basis: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"/><td style="width:66.392%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.379%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.383%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-188" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-866">4.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-189" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-867">3.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-188" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-868">4.8</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-189" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-869">5.9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-188" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="f-870">98.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-189" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="f-871">91.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual dividends per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-188" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-872">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-189" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-873">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-874" continuedAt="f-874-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The following table summarizes the Company&#8217;s time-based stock option activity for the year ended December 31, 2023:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"/><td style="width:40.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.396%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.396%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.396%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.783%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of share options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate intrinsic value </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-190" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-875">12,712,359</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-190" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-876">4.83</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-191" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-877">8.4</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-878">8,702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-187" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-879">44,135,170</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-187" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-880">1.72</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-187" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-881">2,433,943</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-187" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-882">5.56</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Exercised</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-187" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-883">204,297</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-187" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-884">2.20</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-192" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-885">54,209,289</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-192" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-886">2.28</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-187" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-887">9.3</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-888">42,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2023 - vested and expected to vest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-192" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-889">49,407,492</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-192" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-890">2.31</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-187" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-891">9.3</ix:nonNumeric> years</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-892">38,406</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-192" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-893">5,716,319</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-192" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-894">4.89</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-187" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-895">7.2</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="f-896">892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><div><span><br/></span></div><ix:continuation id="f-840-4" continuedAt="f-840-5"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance and Market-based Stock Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee of the Company&#8217;s Board of Directors and management approved <ix:nonFraction unitRef="shares" contextRef="c-193" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-897">40,835,220</ix:nonFraction> option grants to its executives and certain employees of the Company during the year ended December 31, 2023, which will vest based upon certain revenue and market-based performance conditions. The fair value of performance and market-based stock options that include a market condition is determined using a Monte Carlo valuation model, which utilizes multiple input variables to estimate the probability that the market condition will be achieved.</span></div><div><span><br/></span></div><ix:continuation id="f-874-1"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s performance and market-based stock option activity for the year ended December 31, 2023:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"/><td style="width:40.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.396%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.396%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.396%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.783%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of share options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate intrinsic value </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-194" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-898">6,764,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-194" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-899">1.15</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-195" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-900">9.6</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-901">20,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-193" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-902">40,835,220</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-193" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-903">1.69</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-193" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-904">945,000</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-193" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-905">1.20</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Exercised</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-193" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="f-906">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-193" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-907">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-196" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-908">46,654,220</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-196" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-909">1.62</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-193" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-910">9.6</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-911">46,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2023 - vested and expected to vest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-196" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-912">8,397,760</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-196" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-913">1.62</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-193" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-914">9.6</ix:nonNumeric> years</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-915">8,323</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-196" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:fixed-zero" scale="0" id="f-916">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-196" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-917">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:fixed-zero" scale="3" id="f-918">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of stock options granted during the years ended December 31, 2023 and 2022 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-919">1.41</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-920">0.87</ix:nonFraction>, per share, respectively. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2023 and 2022 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="f-921">474</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="f-922">142</ix:nonFraction>, respectively. The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, total unrecognized compensation cost related to unvested stock option grants was approximately $<ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="3" id="f-923">61,162</ix:nonFraction>. This amount is expected to be recognized over a weighted average period of approximately <ix:nonNumeric contextRef="c-188" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-924">2.2</ix:nonNumeric> years. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of warrants is estimated on the date of grant using the Black-Scholes valuation methodology. Expected volatilities are based on historical share price performance, weighted to exclude periods of unusually high volatility. The Company assumed the warrants to be exercised immediately on vesting. The risk-free rate is equal to the prevailing U.K. Gilts rate at grant date that most closely matches the expected term of the grant, as the warrants were issued when the Company was domiciled in the U.K.. Expected dividend yield is <ix:nonFraction unitRef="number" contextRef="c-198" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-925">zero</ix:nonFraction>, and consistent with the Board of Directors&#8217; view that the Company&#8217;s business model is to generate value through capital growth rather than the payment of dividends.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each warrant entitles the warrant holder to subscribe in cash for <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="f-926">one</ix:nonFraction> share. Shares of common stock allotted pursuant to the exercise of the warrant will rank in full for all dividends and other distributions with a record date after the exercise date with the shares of common stock in issue at that date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 20 for the Company&#8217;s warrants activity for the year ended December 31, 2023.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-840-5"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2023, there was <ix:nonFraction unitRef="usd" contextRef="c-199" decimals="INF" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:fixed-zero" scale="3" id="f-927">no</ix:nonFraction> unrecognized compensation expense related to warrants. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-928" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock&#8209;based compensation expense related to stock options is recorded within the consolidated statements of operations and comprehensive loss as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.485%"><tr><td style="width:1.0%"/><td style="width:59.277%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.743%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.767%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.743%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.770%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Research and development</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-929">4,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-930">4,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-931">9,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-932">7,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Total stock-based compensation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-933">14,108</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-934">11,948</ix:nonFraction></span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense associated with each of our share-based compensation arrangements:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.485%"><tr><td style="width:1.0%"/><td style="width:59.277%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.743%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.767%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.743%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.770%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Time-based stock options</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-935">12,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-936">11,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Performance and market-based stock options </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-937">1,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-938">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Employee stock purchase plan</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-939">184</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-940">234</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Total stock-based compensation</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-941">14,108</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-942">11,948</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="if355807d1b914743a4dab03fe6913e8f_190"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 22. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-943" continuedAt="f-943-1" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><ix:continuation id="f-943-1" continuedAt="f-943-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fixed asset purchase commitments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2023 and 2022, the Company had <ix:nonFraction unitRef="usd" contextRef="c-4" decimals="INF" name="us-gaap:PurchaseObligation" format="ixt:fixed-zero" scale="0" id="f-944"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="INF" name="us-gaap:PurchaseObligation" format="ixt:fixed-zero" scale="0" id="f-945">no</ix:nonFraction></ix:nonFraction> capital commitments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease commitments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17 for a discussion of the Company&#8217;s lease commitments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt commitments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 18 for discussion of promissory notes payable to related parties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other commitments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into contracts in the normal course of business with various third parties for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes. Most contracts provide for termination upon notice, and therefore are cancellable contracts. As of December 31, 2023, total contractual commitments, excluding leases commitments and debt commitments, are estimated to be approximately $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherCommitment" format="ixt:num-dot-decimal" scale="3" id="f-946">37,700</ix:nonFraction> and the majority of these commitments are due within <ix:nonNumeric contextRef="c-4" name="smmt:OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid" format="ixt-sec:durwordsen" id="f-947">one year</ix:nonNumeric>.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to December 31, 2023, through February 9, 2024 the Company entered into additional contractual commitments of approximately $<ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3" name="smmt:OtherCommitmentIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="f-948">23,000</ix:nonFraction> with various third parties related to its clinical trials.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has certain commitments under its agreements with the Akeso, Wellcome Trust, the University College London and certain employees, former employees and former directors of Discuva, pursuant to which it will be required to pay royalties or make milestone payments. The License Agreement with Akeso also contains certain manufacturing and purchase commitments. As of December 31, 2023, the Company is unable to estimate the amount, timing or likelihood of achieving the </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">141</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-943-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">milestones, making future product sales or assessing estimated forecasts for manufacturing and supplied materials which these contingent payment obligations relate to. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indemnifications</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s certificate of incorporation provides that it will indemnify the directors and officers to the fullest extent permitted by Delaware law. In addition, the Company has entered into indemnification agreements with all of the directors and executive officers. These indemnification agreements may require the Company, among other things, to indemnify each such director or executive officer for some expenses, including attorneys&#8217; fees, judgments, fines, and settlement amounts incurred by him or her in any action or proceeding arising out of his or her service as one of the Company&#8217;s directors or executive officers. The Company believes the fair value for these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations as of December 31, 2023.</span></div><div style="margin-top:6pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not currently subject to any material legal proceedings.</span></div></ix:continuation><div><span><br/></span></div><div id="if355807d1b914743a4dab03fe6913e8f_193"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">23. <ix:continuation id="f-737-4" continuedAt="f-737-5">Related Party Transactions</ix:continuation></span></div><div><span><br/></span></div><ix:continuation id="f-737-5" continuedAt="f-737-6"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">July 25, 2022 First Amendment to Sublease Agreement with Maky Zanganeh and Associates, Inc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 25, 2022 the Company entered into a first amendment, dated July 19, 2022, to its existing sublease agreement with MZA, described above. The existing sublease term, which was set to expire on September 30, 2022, was extended for a period of <ix:nonNumeric contextRef="c-205" name="smmt:RelatedPartyTransactionSubleaseExtensionTerm" format="ixt-sec:durwordsen" id="f-949">thirty-nine months</ix:nonNumeric> from October 1, 2022 through December 31, 2025. The rent payable under the terms of the sublease is equivalent to the proportionate share of the net payable by MZA to the third-party landlord, based on the square footage of office space sublet by the Company, and no mark-up has been applied. During the year ended December 31, 2023, payments of $<ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-3" name="smmt:RelatedPartyTransactionPaymentsToRelatedParty" scale="3" id="f-950">762</ix:nonFraction>, were made pursuant to the first amendment to the Sublease Agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">July 29, 2022 Second Amendment to Sublease Agreement with Maky Zanganeh and Associates, Inc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 29, 2022, the Company entered into a second amendment, dated August 1, 2022, to its existing sublease agreement with MZA, described above. The second amendment was effective as of August 1, 2022 and expires on December 31, 2025. The second amendment includes an additional <ix:nonFraction unitRef="sqft" contextRef="c-207" decimals="0" name="smmt:AreaOfPremisesSubleased" format="ixt:num-dot-decimal" scale="0" id="f-951">1,277</ix:nonFraction> square feet (the &#8220;Expansion Premises&#8221;) of office space at 2882 Sand Hill Road, Menlo Park, California. The rent payable under the terms of the sublease is equivalent to the proportionate share of the net payable by MZA to the third-party landlord, based on the square footage of office space sublet by the Company, and no mark-up has been applied. During the year ended December 31, 2023 payments of $<ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-3" name="smmt:RelatedPartyTransactionPaymentsToRelatedParty" scale="3" id="f-952">218</ix:nonFraction>, were made pursuant to the secondment amendment to the sublease.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">March 10, 2022 Note Purchase Agreement</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 10, 2022, the Company entered into a Note Purchase Agreement (the &#8220;March 2022 Note&#8221;), with Mr. Duggan, pursuant to which Mr. Duggan loaned the Company $<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:ProceedsFromRelatedPartyDebt" format="ixt:num-dot-decimal" scale="3" id="f-953">25,000</ix:nonFraction> in exchange for the issuance by the Company of an unsecured promissory note in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-954">25,000</ix:nonFraction>. The March 2022 Note accrued interest at a rate per annum equal to the prime rate as reported in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wall Street Journal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was <ix:nonFraction unitRef="number" contextRef="c-141" decimals="4" name="us-gaap:RelatedPartyTransactionRate" scale="-2" id="f-955">3.25</ix:nonFraction>% as of the effective date and <ix:nonFraction unitRef="number" contextRef="c-209" decimals="4" name="us-gaap:RelatedPartyTransactionRate" scale="-2" id="f-956">4.75</ix:nonFraction>% as of June 30, 2022. The March 2022 Note, including accrued interest, became due upon the earlier of (i) the consummation of a registered public offering with net proceeds of no less than $<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="smmt:NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold" format="ixt:num-dot-decimal" scale="3" id="f-957">25,000</ix:nonFraction> or (ii) <ix:nonNumeric contextRef="c-141" name="smmt:NotesPayableRelatedPartiesMaximumTerm" format="ixt-sec:durmonth" id="f-958">18</ix:nonNumeric> months from the date of issuance of the March 2022 Note, and was repaid on August 10, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022 Rights Offering</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Rights Offering commenced on July 18, 2022, and the associated subscription rights expired on August 8, 2022. Aggregate gross proceeds received from the rights offering were $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-959">100,000</ix:nonFraction> from the sale of <ix:nonFraction unitRef="shares" contextRef="c-144" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-960">103,092,783</ix:nonFraction> shares of common stock. Mr. Duggan and Dr. Zanganeh fully subscribed to their respective basic subscription rights and oversubscribed, at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-162" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-961">0.97</ix:nonFraction> per share. Issuance costs were $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="f-962">111</ix:nonFraction>. In connection with the closing of the 2022 Rights Offering, the March 2022 Note </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">142</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-737-6" continuedAt="f-737-7"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">matured and became due, and the Company repaid all principal and accrued interest thereunder using a portion of the proceeds from the 2022 Rights Offering on August 10, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">December 6, 2022 Note Purchase Agreement</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 6, 2022, the Company entered into a Note Purchase Agreement (the &#8220;Note Purchase Agreement&#8221;), with Mr. Duggan and Dr. Zanganeh, pursuant to which the Company agreed to sell to each of Mr. Duggan and Dr. Zanganeh unsecured promissory notes in the aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-963">520,000</ix:nonFraction>. Pursuant to the Note Purchase Agreement, the Company issued to Mr. Duggan and Dr. Zanganeh unsecured promissory notes in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-964">400,000</ix:nonFraction> (the &#8220;Duggan February Note&#8221;) and $<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-965">20,000</ix:nonFraction> (the &#8220;Zanganeh Note&#8221;), respectively, which would mature and become due on February 15, 2023 and an unsecured promissory note to Mr. Duggan in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-966">100,000</ix:nonFraction> (the &#8220;Duggan September Note&#8221; and together with the Duggan February Note and the Zanganeh Note, the &#8220;December 2022 Notes&#8221;), which matured and became due on September 15, 2023. The maturity dates of the December 2022 Notes could have been extended one or more times at the Company&#8217;s election, but in no event to a date later than September 6, 2024. In addition, if the Company consummates a public offering, then upon the later to occur of (i) <span style="-sec-ix-hidden:f-967">five</span> business days after the Company receives the net cash proceeds therefrom or (ii) May 15, 2023, the Duggan February Note and the Zanganeh Note shall be prepaid by an amount equal to the lesser of (a) <ix:nonFraction unitRef="number" contextRef="c-148" decimals="2" name="smmt:NotesPayableRelatedPartiesPotentialPrepaymentMaximumAmountPercentageOfNetProceedsFromPublicOffering" scale="-2" id="f-968">100</ix:nonFraction>% of the amount of the net proceeds of such offering and (b) the outstanding principal amount on such notes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 19, 2023, the Company provided notice to extend the term of the Duggan February Note and Duggan September Note to a maturity date of September 6, 2024. Furthermore, on January 19, 2023, the Company and Mr. Duggan rectified the Duggan February Note and Duggan September Note in order to correctly reflect the parties&#8217; intent that the Company may only prepay (i) the Duggan February Note following the completion of a public rights offering to be conducted by Summit in the approximate amount of $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="smmt:NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold" format="ixt:num-dot-decimal" scale="3" id="f-969">500,000</ix:nonFraction> (the &#8220;Rights Offering&#8221;), or a similar capital raise, in an amount equal to the lesser of (x) the net proceeds of the Rights Offering or such capital raise or (y) the full amount outstanding of the Duggan February Note, and (ii) Duggan September Note following the completion of a capital raising transaction subsequent to the Rights Offering in an amount equal to the lesser of (i) the net proceeds of such capital raise or (ii) the full amount outstanding of the Duggan September Note. Following the issuance of the <ix:nonFraction unitRef="promissory_note" contextRef="c-149" decimals="INF" name="smmt:NotesPayableRelatedPartiesNewIssuances" format="ixt-sec:numwordsen" scale="0" id="f-970">two</ix:nonFraction> new Promissory Notes (the &#8220;Duggan Promissory Notes&#8221;), the Duggan February Note and Duggan September Note were marked as &#8220;cancelled&#8221; on their face and replaced in their entirety by the Duggan Promissory Notes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 15, 2023, the $<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:RepaymentsOfRelatedPartyDebt" format="ixt:num-dot-decimal" scale="3" id="f-971">20,000</ix:nonFraction> Zanganeh Note, matured and the Company repaid the outstanding principal balance. In connection with the closing of the 2023 Rights Offering, the $<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-972">400,000</ix:nonFraction> Duggan Promissory Note, matured and became due, and the Company satisfied all principal and accrued interest thereunder using a combination of a portion of the cash proceeds from the 2023 Rights Offering and the extinguishment of a portion of the amount due equal to the subscription price for shares subscribed by Mr. Duggan in the 2023 Rights Offering (as defined above).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes accrue interest at an initial rate of <ix:nonFraction unitRef="number" contextRef="c-151" decimals="3" name="us-gaap:RelatedPartyTransactionRate" scale="-2" id="f-973">7.5</ix:nonFraction>%. All interest on the Notes shall be paid on the date of signing for the period through February 15, 2023. Such prepaid interest shall be paid in a number of shares of the Company&#8217;s common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-152" decimals="2" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-974">0.01</ix:nonFraction> (&#8220;Common Stock&#8221;) equal to the dollar amount of such prepaid interest, divided by $<ix:nonFraction unitRef="usdPerShare" contextRef="c-151" decimals="4" name="smmt:NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominator" scale="0" id="f-975">0.7913</ix:nonFraction> (the consolidated closing bid price immediately preceding the time the Company entered into the Note Purchase Agreement, plus $<ix:nonFraction unitRef="usdPerShare" contextRef="c-151" decimals="2" name="smmt:NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominatorBaseAmountAddedToClosingBidPrice" scale="0" id="f-976">0.01</ix:nonFraction>), which was <ix:nonFraction unitRef="shares" contextRef="c-151" decimals="INF" name="smmt:StockIssuedDuringPeriodSharesRelatedPartyPrepaidInterest" format="ixt:num-dot-decimal" scale="0" id="f-977">9,720,291</ix:nonFraction> shares. For all applicable periods following February 15, 2023, interest shall accrue on the outstanding principal balance of the Notes at the United States prime interest rate, as reported in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wall Street Journal,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plus <ix:nonFraction unitRef="number" contextRef="c-153" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-4" id="f-978">50</ix:nonFraction> basis points, as adjusted monthly, for three months immediately following February 15, 2023, and thereafter at the United States prime rate plus <ix:nonFraction unitRef="number" contextRef="c-154" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-4" id="f-979">300</ix:nonFraction> basis points, as adjusted monthly. During the year ended December 31, 2023, the Company made payments for interest of $<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-980">10,650</ix:nonFraction>.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2024 the Duggan February Note was amended to extend the maturity date from September 6, 2024 to April 1, 2025. For all applicable periods commencing  February 17, 2024, interest shall accrue on the outstanding principal balance at the greater of <ix:nonFraction unitRef="number" contextRef="c-53" decimals="2" name="us-gaap:RelatedPartyTransactionRate" scale="-2" id="f-981">12</ix:nonFraction>% or the US prime interest rate, as reported in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wall Street Journal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plus <ix:nonFraction unitRef="number" contextRef="c-54" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-4" id="f-982">350</ix:nonFraction> basis points, as adjusted monthly, compounded quarterly. Interest shall be paid upon maturity of the loan.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Akeso License Agreement</span></div></ix:continuation><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summit Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-737-7"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the closing of the License Agreement, the Board of Directors (the &#8220;Board&#8221;) of the Company appointed Dr. Yu (Michelle) Xia to serve as a member of the Board pursuant to the terms of the License Agreement. Dr. Xia is the founder of Akeso, Inc., and has been the chairwoman, president and CEO of the Company since its inception in 2012. For details on the License Agreement, see Note 6. Furthermore, in connection with the License Agreement, the Company also entered into a Supply Agreement with Akeso, pursuant to which Summit agreed to purchase a certain portion of drug substance for clinical and commercial supply (the &#8220;Supply Agreement&#8221;). All transactions pursuant to the Supply Agreement, which occurred during 2023, were in the ordinary course of business. The Company paid approximately $<ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="smmt:RelatedPartyTransactionPaymentsToRelatedParty" format="ixt:num-dot-decimal" scale="3" id="f-983">2,500</ix:nonFraction> to Akeso during year ended December 31, 2023. As of December 31, 2023, the Company included in accrued expenses approximately $<ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-984">3,619</ix:nonFraction> due to Akeso.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2023 Rights Offering</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 6, 2022, the Company announced a rights offering for its existing shareholders to participate in the purchase of additional shares of its Common Stock for $<ix:nonFraction unitRef="usdPerShare" contextRef="c-42" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-985">1.05</ix:nonFraction> per share. The 2023 Rights Offering commenced on February 7, 2023 and the associated subscription rights expired on March 1, 2023. Aggregate gross proceeds from the 2023 Rights Offering were $<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-986">500,000</ix:nonFraction> from the sale of <ix:nonFraction unitRef="shares" contextRef="c-41" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-987">476,190,471</ix:nonFraction> shares of the Company&#8217;s common stock and issuance costs were $<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="f-988">619</ix:nonFraction>. Mr. Duggan and Dr. Zanganeh fully subscribed to their respective basic subscription rights at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-42" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-989">1.05</ix:nonFraction> per share. To satisfy the $<ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="3" id="f-990">395,314</ix:nonFraction> subscription price for the shares subscribed by Mr. Duggan in the 2023 Rights Offering, Mr. Duggan agreed with the Company to extinguish a portion of the amount due and payable to him by the Company at the closing of the 2023 Rights Offering pursuant to the $<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-991">400,000</ix:nonFraction> Duggan Promissory Note in an amount equal to the subscription price.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Registration of Shares</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2023, the Company filed a registration statement on Form S-3 to register for resale the following shares of the Company&#8217;s common stock at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-45" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-992">0.01</ix:nonFraction> par value: (i) <ix:nonFraction unitRef="shares" contextRef="c-46" decimals="INF" name="smmt:SaleOfStockNumberOfSharesRegisteredForResale" format="ixt:num-dot-decimal" scale="0" id="f-993">10,000,000</ix:nonFraction> shares of Common Stock issued on January 17, 2023 in connection with the License Agreement with Akeso pursuant to which the Company issued Akeso such shares; and (ii) the <ix:nonFraction unitRef="shares" contextRef="c-47" decimals="INF" name="smmt:SaleOfStockNumberOfSharesRegisteredForResale" format="ixt:num-dot-decimal" scale="0" id="f-994">9,346,434</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-48" decimals="INF" name="smmt:SaleOfStockNumberOfSharesRegisteredForResale" format="ixt:num-dot-decimal" scale="0" id="f-995">373,857</ix:nonFraction> shares of Common Stock issued in December 2022 to the Company&#8217;s Chief Executive Officers, Mr. Duggan and Dr. Zanganeh, respectively, as payment of prepaid interest in connection with the Note Purchase Agreement dated December 6, 2022 between Mr. Duggan, Dr. Zanganeh and the Company. On April 27, 2023, the SEC issued the Company a Notice of Effectiveness for the registration statement on Form S-3.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Private Placement</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 16, 2023, the Company announced the appointment of Mr. Manmeet Soni as its Chief Operating Officer, effective immediately. Mr. Soni has been a part of the Company&#8217;s Board of Directors since 2019. He will remain a member of the Board of Directors. In conjunction with his appointment, Mr. Soni entered into a share purchase agreement with the Company to purchase $<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="3" id="f-996">5,000</ix:nonFraction> of its common stock via a private placement. The transaction was effective October 13, 2023 with a closing price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-51" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-997">1.68</ix:nonFraction>, resulting in the purchase of <ix:nonFraction unitRef="shares" contextRef="c-52" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-998">2,976,190</ix:nonFraction> shares of the Company&#8217;s common stock.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Warrants Exercise</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, Dr. Zanganeh exercised <ix:nonFraction unitRef="shares" contextRef="c-212" decimals="INF" name="smmt:ClassOfWarrantOrRightExercisesInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-999">805,495</ix:nonFraction> shares of warrants. Refer to Note 20 for the warrants exercise activity for the year ended December 31, 2023.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">144</span></div><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.51
<SEQUENCE>2
<FILENAME>exhibit1051loanagreement.htm
<DESCRIPTION>EX-10.51
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ief5e3be63506452480ec1d48af84c5f0_35"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Exhibit 10.51</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">THIS NOTE HAS NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES ACT&#8221;), OR ANY STATE SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD, PLEDGED, ASSIGNED, OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT HERETO IS EFFECTIVE UNDER THE SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES LAWS OR (2) THE COMPANY RECEIVES AN OPINION OF COUNSEL TO THE HOLDER OF THIS NOTE, WHICH COUNSEL AND OPINION ARE REASONABLY SATISFACTORY TO THE COMPANY, THAT THIS NOTE MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED, OR OTHERWISE TRANSFERRED IN THE MANNER CONTEMPLATED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR APPLICABLE STATE SECURITIES LAWS.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">AMENDED AND RESTATED PROMISSORY NOTE</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">February 17, 2024</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                                                          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">U.S. $100,000,000</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">WHEREAS, the parties hereto entered into that certain Promissory Note, dated as of January 19, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Original Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;), pursuant to which Summit Therapeutics Inc., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;), promised to pay to Robert Duggan or his successors or assigns (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;), $100,000,000 and any interest, fees, charges and late fees on the Maturity Date (as defined therein), subject to, and in accordance with, the terms set forth therein&#59;</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">WHEREAS, this Amended and Restated Promissory Note (hereinafter, this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;) amends and restates (as well as supersedes and replaces) the Original Note.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This Note represents a renewal of, and is issued in substitution and exchange for, and not in satisfaction, repayment or as a novation of, the indebtedness outstanding under the Original Note (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Existing Debt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Nothing herein contained shall be construed to deem such Existing Debt paid.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Payment in full of, and the satisfaction of all obligations under, this Note shall also be deemed to be payment in full and satisfaction of the Existing Debt.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Should there be any conflict between any of the terms of the Original Note and the terms of this Note, the terms of this Note shall control&#59; and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">WHEREAS, following the execution of this Note, the Original Note shall be marked &#8220;cancelled&#8221; on its face and replaced in its entirety by this Note.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">NOW, THEREFORE, the Original Note is amended and restated by this Note as follows&#58;</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">FOR VALUE RECEIVED, Borrower, promises to pay to Lender, $100,000,000 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Principal Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">and any interest, fees, charges and late fees on April 1, 2025 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Maturity Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;), subject to, and in accordance with, the terms set forth herein, and to pay interest on the Outstanding Balance (as defined below) at the rate equal to the Interest Rate (as defined below) per annum (subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Section 2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">) from the Effective Date until the Outstanding Balance is paid in full. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This Note is issued and made effective as of February 17, 2024 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;). </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This Note is issued pursuant to, and subject to the terms of, that certain Note Purchase Agreement, dated as of December 6, 2022 (as the same may be amended, restated, amended and restated, supplemented, modified or replaced from time to time, the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;&#59; capitalized terms used, but not otherwise defined, herein shall have the meanings ascribed to such terms in the Purchase Agreement), by and between Borrower, Lender and the other lenders party thereto from time to time. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">All interest calculations hereunder shall be computed on the basis of a 365-day year, and shall be payable in accordance with the terms of this Note. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:8pt;text-decoration:underline">Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.1        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Payment of Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Section 2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, from and including the date hereof to, but excluding, the Maturity Date, interest on this Note shall accrue daily and compound quarterly in arrears, commencing with the Effective Date, on the Outstanding Balance of this Note outstanding at a rate of interest per annum (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Interest Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;) equal to the greater of (x) 12% and (y) the prime rate announced to be then in effect as published as the average rate in the Wall Street Journal (Northeast Edition) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Prime Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> 350 basis points, to be determined on the first day of each calendar month for the succeeding calendar month.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Default Interest shall be paid as provided for in the Purchase Agreement. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">All accrued and unpaid interest from and including January 1, 2024 to, but excluding, the Effective Date shall be payable on the date that is five Business Days following the Effective Date.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">All accrued and unpaid interest from and including the date hereof to, but excluding, the Maturity Date shall be payable on the Maturity Date, or if such day is not a Business Day, on the immediately succeeding Business Day.  Interest shall be calculated on the basis of a 365-day year and actual days elapsed.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.2     </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Payment of Principal and Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">On the Maturity Date, the Outstanding Balance, including all principal under this Note, together with all accrued and unpaid interest thereon and all other sums evidenced by this Note, shall be due and payable in cash.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Upon payment in full of the Outstanding Balance of this Note and all accrued and unpaid interest thereon, this Note will be automatically cancelled, whether or not this Note has been surrendered. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">As used herein, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Outstanding Balance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221; means, as of any date of determination, the outstanding principal amount of this Note, as reduced or increased, as the case may be, pursuant to the terms hereof for payment, offset or otherwise, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> accrued, but unpaid, interest, collection and enforcements costs (including attorneys&#8217; fees) incurred by Lender, transfer, stamp, issuance and similar taxes and any other fees or charges incurred under this Note.</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> 2.          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Defaults and Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.1       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Defaults</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">As used herein, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Event of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221; has the meaning given such term in the Purchase Agreement. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.2    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">At any time and from time to time after Lender becomes aware of the occurrence of any Event of Default that is continuing, Lender may exercise all of its rights and remedies provided for in the Purchase Agreement or otherwise available under applicable law or equity, including, subject to the Purchase Agreement, the right to accelerate this Note by written notice to Borrower, with the Outstanding Balance becoming immediately due and payable in cash. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Notwithstanding the foregoing, upon the occurrence of any Event of Default described in clause (b), (c), (d), (e) or (f) of Section 9.1 of the Purchase Agreement, the Outstanding Balance, as of the date of acceleration, shall become immediately and automatically due and payable in cash, without any written notice required by Lender or any other person. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Upon the occurrence of an Event of Default, interest shall accrue on the Outstanding Balance at an interest rate equal to the Default Interest (as defined in the Purchase Agreement) rate. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In connection with acceleration described herein, Lender need not provide, and Borrower hereby waives, any presentment, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">demand, protest or other notice of any kind, and Lender may immediately and without expiration of any grace period enforce any and all of its rights and remedies hereunder and all other remedies available to it under applicable law. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Such acceleration may be rescinded and annulled by Lender in accordance with the Purchase Agreement at any time prior to payment hereunder and Lender shall have all rights as a holder of the Note until such time, if any, as Lender receives full payment pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Section 2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">No such rescission or annulment shall affect any subsequent Event of Default or impair any right consequent thereon. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Nothing herein shall limit Lender&#8217;s right to pursue in one or more arbitrations any other remedies available to it at law or in equity including, without limitation, a decree of specific performance and&#47;or injunctive relief. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In the event the Lender accelerates, and receives any payment (including any payment in full) of the Outstanding Balance and other monetary obligations of the Borrower under the Transaction Documents, the Borrower shall not be entitled to any refund of the Prepaid Interest.</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">3.             </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Unconditional Obligation&#59; No Offset</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Borrower acknowledges that this Note is an unconditional, valid, binding and enforceable obligation of Borrower not subject to offset, deduction or counterclaim of any kind. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Borrower hereby waives any rights of offset it now has or may have hereafter against Lender, its successors and assigns, and agrees to make the payments called for herein in accordance with the terms of this Note.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">4.            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">No waiver of any provision of this Note shall be effective unless it is in the form of a writing signed by the party granting the waiver. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">No waiver of any provision or consent to any prohibited action shall constitute a waiver of any other provision or consent to any other prohibited action, whether or not similar. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">No waiver or consent shall constitute a continuing waiver or consent or commit a party to provide a waiver or consent in the future except to the extent specifically set forth in writing.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">5.         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Borrower Prepayment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Borrower shall have the right, exercisable at any time following its completion of a capital raise, in its sole and absolute discretion without penalty or fee, to prepay an amount of this Note equal to the lesser of (i) the net proceeds of the capital raise or (ii) the full amount outstanding of this Note (such amount, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Prepayment Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;), in either case by providing written notice to Lender at least two Business Days in advance of such prepayment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">On the prepayment date Borrower shall pay the Prepayment Amount in cash to Lender. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">6.         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Payment of Collection Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If this Note is placed in the hands of an attorney for collection or enforcement prior to commencing arbitration or legal proceedings, or is collected or enforced through any arbitration or legal proceeding, or Lender otherwise takes action to collect amounts due under this Note or to enforce the provisions of this Note, then Borrower shall pay the costs incurred by Lender for such collection, enforcement or action including, without limitation, attorneys&#8217; fees and disbursements.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">7.         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Opinion of Counsel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In the event that an opinion of counsel is needed for any matter related to this Note, Lender has the right to have any such opinion provided by its counsel&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> that such opinion shall be reasonably acceptable to Borrower.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">8.         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Governing Law&#59; Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This Note shall be construed and enforced in accordance with, and all questions concerning the construction, validity, interpretation and performance of this Note shall be governed by, the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of New York. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The provisions set forth in the Purchase Agreement to determine the proper venue for any disputes are incorporated herein by this reference.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">9.             </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Cancellation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">After repayment of the entire Outstanding Balance, this Note shall be deemed paid in full, shall automatically be deemed canceled and shall not be reissued.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">10.         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The prior written consent of both parties hereto shall be required for any change or amendment to this Note.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">11.        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Assignments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Borrower may not assign this Note without the prior written consent of Lender. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> This Note may be offered, sold, assigned or transferred by Lender without the consent of Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">12.         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Time is of the Essence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Time is expressly made of the essence with respect to each and every provision of this Note and the documents and instruments entered into in connection herewith.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">13.         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Whenever notice is required to be given under this Note, unless otherwise provided herein, such notice shall be given in accordance with the subsection of the Purchase Agreement titled &#8220;Notices.&#8221;</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">14.        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Liquidated Damages</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Lender and Borrower agree that in the event Borrower fails to comply with any of the terms or provisions of this Note, Lender&#8217;s damages would be uncertain and difficult (if not impossible) to accurately estimate because of the parties&#8217; inability to predict future interest rates, future share prices, future trading volumes and other relevant factors. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Accordingly, Lender and Borrower agree that any fees, balance adjustments, Default Interest or other charges assessed under this Note are not penalties but instead are intended by the parties to be, and shall be deemed, liquidated damages (under Lender&#8217;s and Borrower&#8217;s expectations that any such liquidated damages will, if allowed under applicable law, tack back to the Effective Date for purposes of determining the holding period under Rule 144).</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">15.        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Waiver of Jury Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">EACH OF LENDER AND BORROWER IRREVOCABLY WAIVES ANY AND ALL RIGHTS SUCH PARTY MAY HAVE TO DEMAND THAT ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR IN ANY WAY RELATED TO THIS NOTE OR THE RELATIONSHIPS OF THE PARTIES HERETO BE TRIED BY JURY. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">THIS WAIVER EXTENDS TO ANY AND ALL RIGHTS TO DEMAND A TRIAL BY JURY ARISING UNDER COMMON LAW OR ANY APPLICABLE STATUTE, LAW, RULE OR REGULATION. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">FURTHER, EACH PARTY HERETO ACKNOWLEDGES THAT SUCH PARTY IS KNOWINGLY AND VOLUNTARILY WAIVING SUCH PARTY&#8217;S RIGHT TO DEMAND TRIAL BY JURY.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">16.        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Voluntary Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Borrower has carefully read this Note and has asked any questions needed for Borrower to understand the terms, consequences and binding effect of this Note and fully understand them. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Borrower has had the opportunity to seek the advice of an attorney of Borrower&#8217;s choosing, or has waived the right to do so, and is executing this Note voluntarily and without any duress or undue influence by Lender or anyone else.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">17.        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If any part of this Note is construed to be in violation of any law, such part shall be modified to achieve the objective of Borrower and Lender to the fullest extent permitted by law and the balance of this Note shall remain in full force and effect.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#91;Remainder of page intentionally left blank&#59; signature page follows&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">IN WITNESS WHEREOF, Borrower has caused this Note to be duly executed as of the Effective Date.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:49.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.819%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.821%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">BORROWER&#58;</font></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:41pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">SUMMIT THERAPEUTICS INC.</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">By&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Ankur Dhingra</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Name&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Ankur Dhingra</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Title&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Chief Financial Officer</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">ACKNOWLEDGED, ACCEPTED AND AGREED&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.839%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">LENDER&#58;</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#47;S&#47; ROBERT DUGGAN</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Robert Duggan</font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>sum-ex211_20231231xxsubsid.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i99abfed0c7804e35918849fdabaf54c8_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1 </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUBSIDIARIES OF THE REGISTRANT </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.608%"><tr><td style="width:1.0%"></td><td style="width:66.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.670%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.192%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Subsidiary</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jurisdiction&#160;of&#160;incorporation <br>or organization</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Summit (Oxford) Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">England and Wales</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discuva Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">England and Wales</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Summit Therapeutics Sub Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware, USA</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Summit Therapeutics Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">England and Wales</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Summit International Holdings Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Summit Therapeutics Global LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware, USA</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>sum-ex231_20231231xxuscons.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ib4e134855915418a8e9740a06c06f203_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-251958, 333-268932, and 333-270656) and Form S-8 (Nos. 333-249313, 333-238582, and 333-264163) of Summit Therapeutics Inc. of our report dated February 20, 2024 relating to the financial statements, which appears in this Form 10-K.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; PricewaterhouseCoopers LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston, Massachusetts</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 20, 2024</font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>sum-ex311_20231231xduggan.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="icc05db85152d47af9c897570ff6383de_1"></div><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">I, Robert W. Duggan, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Summit Therapeutics Inc.&#59;  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Date&#58; February 20, 2024                                                                             </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.071%"><tr><td style="width:1.0%"></td><td style="width:41.357%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.290%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Robert W. Duggan</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert W. Duggan</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Executive Chairman&#59; (Principal Executive Officer)</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>sum-ex312_20231231xzanganeh.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i7f90612e8cbf4c0db7e9fb425604e7a3_1"></div><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">CERTIFICATION OF CO-CHIEF EXECUTIVE OFFICER PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">I, Dr. Mahkam Zanganeh, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Summit Therapeutics Inc.&#59;  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the Company's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Date&#58; February 20, 2024                                                                            </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.168%"><tr><td style="width:1.0%"></td><td style="width:39.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.755%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.360%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Maky Zanganeh</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Maky Zanganeh</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Director, Chief Executive Officer, President and member of the Board<br>(Principal Executive Officer)</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.3
<SEQUENCE>7
<FILENAME>sum-ex313_20231231xdhingra.htm
<DESCRIPTION>EX-31.3
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i2dd770a11ec9447db8daf286735500a4_1"></div><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Exhibit 31.3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">I, Ankur Dhingra, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Summit Therapeutics Inc.&#59;  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Date&#58; February 20, 2024                                                                             </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.436%"><tr><td style="width:1.0%"></td><td style="width:39.890%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.806%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.004%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Ankur Dhingra</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ankur Dhingra</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer<br>(Principal Financial Officer)</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>sum-ex321_20231231xx404906.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ib31f559a3f884388b19b92f6b999a0ad_1"></div><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Exhibit 32.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">CERTIFICATION OF CO-CHIEF EXECUTIVE OFFICER(S) AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div style="text-indent:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In connection with the Annual Report on Form 10-K of Summit Therapeutics Inc. (the &#8220;Company&#8221;) for the year ended December 31, 2023, as filed with the U.S. Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned officers of the Company does hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his or her knowledge&#58; </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.269%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.02pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Dated&#58; February 20, 2024</font></div></td><td colspan="6" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Robert W. Duggan</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert W. Duggan</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Executive Chairman<br>(Principal Executive Officer) </font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.923%"><tr><td style="width:1.0%"></td><td style="width:44.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.193%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.02pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Dated&#58; February 20, 2024</font></div></td><td colspan="6" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Maky Zanganeh</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Maky Zanganeh</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Director, Chief Executive Officer, President and member of the Board<br>(Principal Executive Officer)</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.269%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.02pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Dated&#58; February 20, 2024</font></div></td><td colspan="6" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Ankur Dhingra</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ankur Dhingra</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer<br>(Principal Financial Officer)</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>9
<FILENAME>ex971summitclawbackpolicy.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ic85f0d9c10bc4bb3903e693f0cc8c40d_35"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 97.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SUMMIT THERAEUTICS, INC.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INCENTIVE-BASED COMPENSATION CLAWBACK POLICY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Summit Therapeutics Inc. (&#8220;Company&#8221;) has adopted this clawback policy (the &#8220;Policy&#8221;) as a supplement to any other clawback policies in effect now or in the future at the Company.  To the extent this Policy applies to compensation payable to a covered person, it shall be the only clawback policy applicable to such compensation and no other clawback policy shall apply. However, notwithstanding the last sentence, if another Company policy provides that a greater amount of compensation shall be subject to clawback, such other policy shall apply, but only, to the amount in excess of the amount subject to clawback under this Policy.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">This Policy shall be interpreted to comply with the clawback rules found in 229 C.F.R. &#167;240.10D and Nasdaq Listing Rule 5608, which will take effect on October 2, 2023 (collectively, the &#8220;Rule&#8221;). To the extent this Policy is in any manner deemed inconsistent with the Rule, this Policy shall be treated as retroactively amended to be compliant with the Rule.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">1.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Definitions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">  As used in the Policy, the following capitalized terms shall have the meanings set forth in this Section 1. Terms used herein shall at all times be interpreted in accordance with 229 C.F.R. &#167;240.10D-1(d) and any other guidance that may be issued under the Rule. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">(a)  &#8220;Executive Officer&#8221; shall mean the Company&#8217;s president, principal financial officer, principal accounting officer, any vice-president of the Company in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a policy-making function, or any other person who performs similar policy-making functions for the Company. Executive Officers of the Company&#8217;s subsidiaries are deemed Executive Officers of the Company if they perform such policy making functions for the Company. Identification of an Executive Officer for purposes of this Policy includes, at a minimum, Executive Officers identified pursuant to 17 C.F.R. &#167;229.401(b). </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">(b)  &#8220;Financial Reporting Measure&#8221; means measures, including but not limited to stock price and total shareholder return, that are determined and presented in accordance with the accounting principles used in preparing the Company&#8217;s financial statements, and any measures that are derived wholly or in part from such measures. A Financial Reporting Measure need not be presented within the financial statements or included in a filing with the Securities Exchange Commission.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">(c)  &#8220;Incentive-Based Compensation&#8221; means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of one or more Financial Reporting Measures.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">2.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Application of the Policy.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">  This Policy shall only apply in the event that the Company is required to prepare an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct one or more errors in a previously issued financial statements that is or are material to such financial statements, or that would result in a material misstatement if the error or errors were corrected in the current period or left uncorrected in the current period. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">3.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Recovery Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  The Incentive-Based Compensation subject to clawback is the Incentive-Based Compensation Received during the three completed fiscal years immediately preceding the date that the Company is required to prepare an accounting restatement as described in Section 2, provided that the person served as an Executive Officer at any time during the performance period applicable to the Incentive-Based Compensation in question. The date that the Company is required to prepare an accounting restatement shall be determined pursuant to 229 C.F.R. &#167;240.10D-1(b)(1)(ii).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">(a)  For purposes of this Policy, Incentive-Based Compensation is deemed &#8220;Received&#8221; in the Company&#8217;s fiscal period during which the Financial Reporting Measure specified in the Incentive-Based Compensation award is attained, even if the payment or grant of the Incentive-Based Compensation occurs after the end of such period.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">(b)  Notwithstanding anything to the contrary, this Policy shall only apply if the Incentive-Based Compensation is Received on or after October 2, 2023.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">(c) To the extent applicable, 229 C.F.R. &#167;240.10D-1(b)(1)(i) shall govern certain circumstances under which the Policy will apply to Incentive-Based Compensation Received during a transition period arising due to a change in the Company&#8217;s fiscal year. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">4.    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Erroneously Awarded Compensation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">  The amount of Incentive-Based Compensation subject to clawback pursuant to this Policy (&#8220;Erroneously Awarded Compensation&#8221;) is the amount of Incentive-Based Compensation Received that exceeds the amount of Incentive Based-Compensation that otherwise would have been Received had it been determined based on the restated amounts and shall be computed without regard to any taxes paid. For Incentive-Based Compensation based on stock price or total shareholder return, where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in an accounting restatement&#58; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">(a)  the amount shall be based on a reasonable estimate of the effect of the accounting restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation was received&#59; and </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">(b)  the Company must maintain documentation of the determination of that reasonable estimate and provide such documentation to the exchange on which the Company&#8217;s shares are listed.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">5.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Recovery of Erroneously Awarded Compensation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">  The Company shall recover reasonably promptly any Erroneously Awarded Compensation except to the extent that the conditions of paragraphs (a), (b), or (c) below apply.  The Compensation Committee of the Company&#8217;s Board of Directors (the &#8220;Committee&#8221;) shall determine the repayment schedule for each amount of Erroneously Awarded Compensation in a manner that complies with the Rule&#8217;s &#8220;reasonably promptly&#8221; requirement.  Such determination shall be consistent with any applicable legal guidance, by the SEC, judicial opinion, or otherwise.  The determination of &#8220;reasonably promptly&#8221; may vary from case to case and the Committee is authorized to adopt additional rules to further describe what repayment schedules satisfy this requirement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">(a)  Erroneously Awarded Compensation need not be recovered if the direct expense paid to a third party to assist in enforcing the Policy (e.g., reasonable legal expenses and consulting fees) would exceed the amount to be recovered and the Committee makes a determination that recovery would be impracticable. However, before concluding that it would be impracticable to recover any amount of Erroneously Awarded Compensation based on expense of enforcement, the Company shall make a reasonable attempt to recover such Erroneously Awarded Compensation, establish that the direct costs of recovery exceed the recovery amounts, document such reasonable attempt(s) to recover, and provide such documentation to the exchange on which the Company&#8217;s shares are listed.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">(b)  Erroneously Awarded Compensation need not be recovered if recovery would violate home country law, provided such law was adopted prior to November 28, 2022.  Before concluding that it would be impracticable to recover any amount of Erroneously Awarded Compensation based on violation of home country law, the Company shall obtain an opinion of home country counsel, acceptable to the exchange on which the Company&#8217;s shares are listed, that recovery would result in such a violation and shall provide such opinion to such exchange. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">(c)  Erroneously Awarded Compensation need not be recovered if recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company or its subsidiaries, to fail to meet the requirements of Sections 401(a)(13) or 411(a) of the Internal Revenue Code of 1986, as amended, and regulations thereunder. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">6.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Committee decisions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Decisions of the Committee with respect to this Policy shall be final, conclusive, and binding on all Executive Officers subject to this Policy, unless determined to be an abuse of discretion.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">7.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">No Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary in any other policy of the Company or any agreement between the Company and an Executive Officer, no Executive Officer shall be indemnified by the Company against the loss of any Erroneously Awarded Compensation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">8.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement to Policy by Executive Officers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  The Committee shall take reasonable steps to inform Executive Officers of this Policy and obtain their acknowledgement of this Policy, which steps may include the inclusion of this Policy as an attachment to any award that is or has been accepted by the Executive Officer.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>smmt-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:cfc19273-6e1b-408d-b97d-a861bea67b02,g:5505fdd7-331f-4f8b-bf29-88d8f3b5e402-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:smmt="http://www.summitplc.com/20231231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.summitplc.com/20231231">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="smmt-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="smmt-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="smmt-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="smmt-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.summitplc.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.summitplc.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.summitplc.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.summitplc.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>0000005 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000006 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquityParenthetical" roleURI="http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical">
        <link:definition>0000007 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000008 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessandOperationsandRecentEvents" roleURI="http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEvents">
        <link:definition>0000009 - Disclosure - Nature of Business and Operations and Recent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationUseofEstimatesandRisksandUncertainties" roleURI="http://www.summitplc.com/role/BasisofPresentationUseofEstimatesandRisksandUncertainties">
        <link:definition>0000010 - Disclosure - Basis of Presentation, Use of Estimates, and Risks and Uncertainties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiquidityandCapitalResources" roleURI="http://www.summitplc.com/role/LiquidityandCapitalResources">
        <link:definition>0000011 - Disclosure - Liquidity and Capital Resources</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.summitplc.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000012 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentlyIssuedorAdoptedAccountingPronouncements" roleURI="http://www.summitplc.com/role/RecentlyIssuedorAdoptedAccountingPronouncements">
        <link:definition>0000013 - Disclosure - Recently Issued or Adopted Accounting Pronouncements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AkesoLicenseandCollaborationAgreement" roleURI="http://www.summitplc.com/role/AkesoLicenseandCollaborationAgreement">
        <link:definition>0000014 - Disclosure - Akeso License and Collaboration Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://www.summitplc.com/role/SegmentReporting">
        <link:definition>0000015 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://www.summitplc.com/role/Revenue">
        <link:definition>0000016 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherOperatingIncomenet" roleURI="http://www.summitplc.com/role/OtherOperatingIncomenet">
        <link:definition>0000017 - Disclosure - Other Operating Income, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherExpenseIncomenet" roleURI="http://www.summitplc.com/role/OtherExpenseIncomenet">
        <link:definition>0000018 - Disclosure - Other (Expense) Income, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTax" roleURI="http://www.summitplc.com/role/IncomeTax">
        <link:definition>0000019 - Disclosure - Income Tax</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShare" roleURI="http://www.summitplc.com/role/NetLossperShare">
        <link:definition>0000020 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://www.summitplc.com/role/GoodwillandIntangibleAssets">
        <link:definition>0000021 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandShortTermInvestments" roleURI="http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestments">
        <link:definition>0000022 - Disclosure - Fair Value Measurements and Short-Term Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.summitplc.com/role/PropertyandEquipment">
        <link:definition>0000023 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchandDevelopmentPrepaidExpensesandAccruedLiabilities" roleURI="http://www.summitplc.com/role/ResearchandDevelopmentPrepaidExpensesandAccruedLiabilities">
        <link:definition>0000024 - Disclosure - Research and Development Prepaid Expenses and Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.summitplc.com/role/Leases">
        <link:definition>0000025 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PromissoryNotesPayabletoRelatedParties" roleURI="http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedParties">
        <link:definition>0000026 - Disclosure - Promissory Notes Payable to Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNonCurrentLiabilities" roleURI="http://www.summitplc.com/role/OtherNonCurrentLiabilities">
        <link:definition>0000027 - Disclosure - Other Non-Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.summitplc.com/role/StockholdersEquity">
        <link:definition>0000028 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.summitplc.com/role/StockBasedCompensation">
        <link:definition>0000029 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.summitplc.com/role/CommitmentsandContingencies">
        <link:definition>0000030 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.summitplc.com/role/RelatedPartyTransactions">
        <link:definition>0000031 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://www.summitplc.com/role/SegmentReportingTables">
        <link:definition>9954473 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueTables" roleURI="http://www.summitplc.com/role/RevenueTables">
        <link:definition>9954474 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherOperatingIncomenetTables" roleURI="http://www.summitplc.com/role/OtherOperatingIncomenetTables">
        <link:definition>9954475 - Disclosure - Other Operating Income, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherExpenseIncomenetTables" roleURI="http://www.summitplc.com/role/OtherExpenseIncomenetTables">
        <link:definition>9954476 - Disclosure - Other (Expense) Income, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxTables" roleURI="http://www.summitplc.com/role/IncomeTaxTables">
        <link:definition>9954477 - Disclosure - Income Tax (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareTables" roleURI="http://www.summitplc.com/role/NetLossperShareTables">
        <link:definition>9954478 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsTables" roleURI="http://www.summitplc.com/role/GoodwillandIntangibleAssetsTables">
        <link:definition>9954479 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandShortTermInvestmentsTables" roleURI="http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsTables">
        <link:definition>9954480 - Disclosure - Fair Value Measurements and Short-Term Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.summitplc.com/role/PropertyandEquipmentTables">
        <link:definition>9954481 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.summitplc.com/role/LeasesTables">
        <link:definition>9954482 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PromissoryNotesPayabletoRelatedPartiesTables" roleURI="http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesTables">
        <link:definition>9954483 - Disclosure - Promissory Notes Payable to Related Parties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.summitplc.com/role/StockholdersEquityTables">
        <link:definition>9954484 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.summitplc.com/role/StockBasedCompensationTables">
        <link:definition>9954485 - Disclosure - Stock Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessandOperationsandRecentEventsDetails" roleURI="http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails">
        <link:definition>9954486 - Disclosure - Nature of Business and Operations and Recent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiquidityandCapitalResourcesDetails" roleURI="http://www.summitplc.com/role/LiquidityandCapitalResourcesDetails">
        <link:definition>9954487 - Disclosure - Liquidity and Capital Resources (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>9954488 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AkesoLicenseandCollaborationAgreementDetails" roleURI="http://www.summitplc.com/role/AkesoLicenseandCollaborationAgreementDetails">
        <link:definition>9954489 - Disclosure - Akeso License and Collaboration Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingNarrativeDetails" roleURI="http://www.summitplc.com/role/SegmentReportingNarrativeDetails">
        <link:definition>9954490 - Disclosure - Segment Reporting - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingLonglivedassetsbygeographyDetails" roleURI="http://www.summitplc.com/role/SegmentReportingLonglivedassetsbygeographyDetails">
        <link:definition>9954491 - Disclosure - Segment Reporting - Long-lived assets by geography (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueNarrativeDetails" roleURI="http://www.summitplc.com/role/RevenueNarrativeDetails">
        <link:definition>9954492 - Disclosure - Revenue - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueDeferredrevenueandotherincomeDetails" roleURI="http://www.summitplc.com/role/RevenueDeferredrevenueandotherincomeDetails">
        <link:definition>9954493 - Disclosure - Revenue - Deferred revenue and other income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherOperatingIncomenetSummarybycategoryDetails" roleURI="http://www.summitplc.com/role/OtherOperatingIncomenetSummarybycategoryDetails">
        <link:definition>9954494 - Disclosure - Other Operating Income, net - Summary by category (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherOperatingIncomenetNarrativeDetails" roleURI="http://www.summitplc.com/role/OtherOperatingIncomenetNarrativeDetails">
        <link:definition>9954495 - Disclosure - Other Operating Income, net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherExpenseIncomenetComponentsDetails" roleURI="http://www.summitplc.com/role/OtherExpenseIncomenetComponentsDetails">
        <link:definition>9954496 - Disclosure - Other (Expense) Income, net - Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxComponentsoflossbeforeincometaxesDetails" roleURI="http://www.summitplc.com/role/IncomeTaxComponentsoflossbeforeincometaxesDetails">
        <link:definition>9954497 - Disclosure - Income Tax - Components of loss before income taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxNarrativeDetails" roleURI="http://www.summitplc.com/role/IncomeTaxNarrativeDetails">
        <link:definition>9954498 - Disclosure - Income Tax - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails" roleURI="http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails">
        <link:definition>9954499 - Disclosure - Income Tax - Major components of deferred tax assets and liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxValuationAllowanceDetails" roleURI="http://www.summitplc.com/role/IncomeTaxValuationAllowanceDetails">
        <link:definition>9954500 - Disclosure - Income Tax - Valuation Allowance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails" roleURI="http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails">
        <link:definition>9954501 - Disclosure - Income Tax - Reconciliation of the effective income tax rate to statutory rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxReconciliationofunrecognizedtaxbenefitsDetails" roleURI="http://www.summitplc.com/role/IncomeTaxReconciliationofunrecognizedtaxbenefitsDetails">
        <link:definition>9954502 - Disclosure - Income Tax - Reconciliation of unrecognized tax benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareComputationofnetlosspershareDetails" roleURI="http://www.summitplc.com/role/NetLossperShareComputationofnetlosspershareDetails">
        <link:definition>9954503 - Disclosure - Net Loss per Share - Computation of net loss per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareNarrativeDetails" roleURI="http://www.summitplc.com/role/NetLossperShareNarrativeDetails">
        <link:definition>9954504 - Disclosure - Net Loss per Share - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperSharePotentiallydilutivesecuritiesexcludedfromthecomputationoflosspershareDetails" roleURI="http://www.summitplc.com/role/NetLossperSharePotentiallydilutivesecuritiesexcludedfromthecomputationoflosspershareDetails">
        <link:definition>9954505 - Disclosure - Net Loss per Share - Potentially dilutive securities excluded from the computation of loss per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNarrativeDetails" roleURI="http://www.summitplc.com/role/GoodwillandIntangibleAssetsNarrativeDetails">
        <link:definition>9954506 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails" roleURI="http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails">
        <link:definition>9954507 - Disclosure - Goodwill and Intangible Assets - Schedule of acquired intangible assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>9954508 - Disclosure - Fair Value Measurements and Short-Term Investments - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandShortTermInvestmentsNarrativeDetails" roleURI="http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails">
        <link:definition>9954509 - Disclosure - Fair Value Measurements and Short-Term Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandShortTermInvestmentsShortterminvestmentswithcontractualmaturityoflessthanonyearDetails" roleURI="http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsShortterminvestmentswithcontractualmaturityoflessthanonyearDetails">
        <link:definition>9954510 - Disclosure - Fair Value Measurements and Short-Term Investments - Short-term investments with contractual maturity of less than on year (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentComponentsofpropertyandequipmentDetails" roleURI="http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails">
        <link:definition>9954511 - Disclosure - Property and Equipment - Components of property and equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNarrativeDetails" roleURI="http://www.summitplc.com/role/PropertyandEquipmentNarrativeDetails">
        <link:definition>9954512 - Disclosure - Property and Equipment - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchandDevelopmentPrepaidExpensesandAccruedLiabilitiesDetails" roleURI="http://www.summitplc.com/role/ResearchandDevelopmentPrepaidExpensesandAccruedLiabilitiesDetails">
        <link:definition>9954513 - Disclosure - Research and Development Prepaid Expenses and Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.summitplc.com/role/LeasesNarrativeDetails">
        <link:definition>9954514 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseexpenseDetails" roleURI="http://www.summitplc.com/role/LeasesLeaseexpenseDetails">
        <link:definition>9954515 - Disclosure - Leases - Lease expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureleasepaymentsDetails" roleURI="http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails">
        <link:definition>9954516 - Disclosure - Leases - Future lease payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureleasepaymentsDetails_1" roleURI="http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails_1">
        <link:definition>9954516 - Disclosure - Leases - Future lease payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PromissoryNotesPayabletoRelatedPartiesSummaryofrelatedpartydebtDetails" roleURI="http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesSummaryofrelatedpartydebtDetails">
        <link:definition>9954517 - Disclosure - Promissory Notes Payable to Related Parties - Summary of related party debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PromissoryNotesPayabletoRelatedPartiesNarrativeDetails" roleURI="http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails">
        <link:definition>9954518 - Disclosure - Promissory Notes Payable to Related Parties - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNonCurrentLiabilitiesDetails" roleURI="http://www.summitplc.com/role/OtherNonCurrentLiabilitiesDetails">
        <link:definition>9954519 - Disclosure - Other Non-Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.summitplc.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>9954520 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityWarrantactivityDetails" roleURI="http://www.summitplc.com/role/StockholdersEquityWarrantactivityDetails">
        <link:definition>9954521 - Disclosure - Stockholders' Equity - Warrant activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>9954522 - Disclosure - Stock Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationWeightedaverageassumptionsusedforstockoptionawardsDetails" roleURI="http://www.summitplc.com/role/StockBasedCompensationWeightedaverageassumptionsusedforstockoptionawardsDetails">
        <link:definition>9954523 - Disclosure - Stock Based Compensation - Weighted-average assumptions used for stock option awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockoptionactivityDetails" roleURI="http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails">
        <link:definition>9954524 - Disclosure - Stock Based Compensation - Stock option activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofstockbasedcompensationexpenseDetails" roleURI="http://www.summitplc.com/role/StockBasedCompensationSummaryofstockbasedcompensationexpenseDetails">
        <link:definition>9954525 - Disclosure - Stock-Based Compensation - Summary of stock-based compensation expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.summitplc.com/role/CommitmentsandContingenciesDetails">
        <link:definition>9954526 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.summitplc.com/role/RelatedPartyTransactionsDetails">
        <link:definition>9954527 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="smmt_CambridgeUKLaboratoryAndOfficeSpaceMember" abstract="true" name="CambridgeUKLaboratoryAndOfficeSpaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="smmt_ChiefExecutiveOfficerAndPresidentMember" abstract="true" name="ChiefExecutiveOfficerAndPresidentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="smmt_AreaOfPremisesSubleased" abstract="false" name="AreaOfPremisesSubleased" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:areaItemType"/>
  <xs:element id="smmt_NotesPayableRelatedPartiesPotentialPrepaymentMaximumAmountPercentageOfNetProceedsFromPublicOffering" abstract="false" name="NotesPayableRelatedPartiesPotentialPrepaymentMaximumAmountPercentageOfNetProceedsFromPublicOffering" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="smmt_BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss" abstract="false" name="BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_OperatingLeaseRightOfUseAssetDisposals" abstract="false" name="OperatingLeaseRightOfUseAssetDisposals" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome" abstract="false" name="CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_ClassOfWarrantOrRightOutstandingRollForward" abstract="true" name="ClassOfWarrantOrRightOutstandingRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="smmt_VariableRatePeriodDomain" abstract="true" name="VariableRatePeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentSharesOfCommonStockIssuedInLieuOfCash" abstract="false" name="CollaborativeArrangementRightsAndObligationsUpfrontPaymentSharesOfCommonStockIssuedInLieuOfCash" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm" abstract="false" name="ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="smmt_OtherCommitmentIncreaseDecrease" abstract="false" name="OtherCommitmentIncreaseDecrease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_WarrantsPolicyPolicyTextBlock" abstract="false" name="WarrantsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod" abstract="false" name="ClassOfWarrantOrRightQuarterlyVestingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="smmt_NotesPayableRelatedPartiesPotentialPrepaymentPeriodPostReceiptOfCashProceedsFromPublicOffering" abstract="false" name="NotesPayableRelatedPartiesPotentialPrepaymentPeriodPostReceiptOfCashProceedsFromPublicOffering" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="smmt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid" abstract="false" name="OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="smmt_GrantFundingArrangementMaximumFundingValue" abstract="false" name="GrantFundingArrangementMaximumFundingValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_March2022NoteMember" abstract="true" name="March2022NoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="smmt_CashPaymentForCollaborativeArrangementUpfrontPayment" abstract="false" name="CashPaymentForCollaborativeArrangementUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_DugganSeptemberNoteMember" abstract="true" name="DugganSeptemberNoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="smmt_DeferredTaxAssetsLiabilities" abstract="false" name="DeferredTaxAssetsLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage" abstract="false" name="ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="smmt_OtherOperatingIncomeOther" abstract="false" name="OtherOperatingIncomeOther" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_StockIssuedDuringPeriodSharesIssuedForRelatedPartyInterest" abstract="false" name="StockIssuedDuringPeriodSharesIssuedForRelatedPartyInterest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominator" abstract="false" name="NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominator" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="smmt_NotesPayableGrossCurrent" abstract="false" name="NotesPayableGrossCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent" abstract="false" name="ResearchAndDevelopmentTaxCreditReceivableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_OtherPatentsAndLicensesMember" abstract="true" name="OtherPatentsAndLicensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="smmt_RelatedPartyTransactionSubleaseExtensionTerm" abstract="false" name="RelatedPartyTransactionSubleaseExtensionTerm" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="smmt_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod" abstract="false" name="ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="smmt_NotesPayableRelatedPartiesMaximumTerm" abstract="false" name="NotesPayableRelatedPartiesMaximumTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="smmt_PromissoryNotesMember" abstract="true" name="PromissoryNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="smmt_LiquidityAndCapitalResourcesTextBlock" abstract="false" name="LiquidityAndCapitalResourcesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="smmt_StockIssuedDuringPeriodSharesRelatedPartyPrepaidInterest" abstract="false" name="StockIssuedDuringPeriodSharesRelatedPartyPrepaidInterest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="smmt_ScheduleOfOtherOperatingIncomeExpenseNetTableTextBlock" abstract="false" name="ScheduleOfOtherOperatingIncomeExpenseNetTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="smmt_NotePurchaseAgreementMember" abstract="true" name="NotePurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="smmt_DeferredTaxAssetsLeasingArrangements" abstract="false" name="DeferredTaxAssetsLeasingArrangements" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_VariableRatePeriodOneMember" abstract="true" name="VariableRatePeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="smmt_S3RegistrationStatementMember" abstract="true" name="S3RegistrationStatementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="smmt_ConsultingAgreementMember" abstract="true" name="ConsultingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="smmt_PaymentOfAccruedInterestToRelatedParties" abstract="false" name="PaymentOfAccruedInterestToRelatedParties" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_CollaborativeArrangementRightsAndObligationsDirectTransactionCosts" abstract="false" name="CollaborativeArrangementRightsAndObligationsDirectTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentPaidInShares" abstract="false" name="CollaborativeArrangementRightsAndObligationsUpfrontPaymentPaidInShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="smmt_CashEquivalentsFairValueDisclosure" abstract="false" name="CashEquivalentsFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_SignificantAccountingPoliciesLineItems" abstract="true" name="SignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="smmt_DugganPromissoryNotesMember" abstract="true" name="DugganPromissoryNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="smmt_MenloParkCaliforniaExpirationMay2026Member" abstract="true" name="MenloParkCaliforniaExpirationMay2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="smmt_NotesPayableRelatedPartiesNewIssuances" abstract="false" name="NotesPayableRelatedPartiesNewIssuances" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" abstract="true" name="BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="smmt_DeferredTaxAssetsValuationAllowanceRollForward" abstract="true" name="DeferredTaxAssetsValuationAllowanceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="smmt_EmployeeStockOptionPerformanceAndMarketBasedMember" abstract="true" name="EmployeeStockOptionPerformanceAndMarketBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="smmt_RelatedPartyTransactionPaymentsToRelatedParty" abstract="false" name="RelatedPartyTransactionPaymentsToRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_DiscuvaPlatformMember" abstract="true" name="DiscuvaPlatformMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentTwoMember" abstract="true" name="CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="smmt_DugganFebruaryNoteAndZanganehNoteMember" abstract="true" name="DugganFebruaryNoteAndZanganehNoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="smmt_LesseeOperatingLeaseAreaOfPremisesLeased" abstract="false" name="LesseeOperatingLeaseAreaOfPremisesLeased" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="smmt_GrantFundingArrangementIncomeEarned" abstract="false" name="GrantFundingArrangementIncomeEarned" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_StockIssuedDuringPeriodSharesWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="smmt_SaleOfStockNumberOfSharesRegisteredForResale" abstract="false" name="SaleOfStockNumberOfSharesRegisteredForResale" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember" abstract="true" name="FurnitureAndFixturesOfficeEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="smmt_ContractWithCustomerLiabilityAdditions" abstract="false" name="ContractWithCustomerLiabilityAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_VariableRatePeriodAxis" abstract="true" name="VariableRatePeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="smmt_ResearchAndDevelopmentPrepaidExpensesCurrent" abstract="false" name="ResearchAndDevelopmentPrepaidExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_CommonStockAdditionalCapitalSharesAllowableForForFutureIssuanceUponOptionExpiration" abstract="false" name="CommonStockAdditionalCapitalSharesAllowableForForFutureIssuanceUponOptionExpiration" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember" abstract="true" name="CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="smmt_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding" abstract="false" name="ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward" abstract="true" name="ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="smmt_SignificantAccountingPoliciesTable" abstract="true" name="SignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="smmt_EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="smmt_EmployeeStockOptionTimeBasedMember" abstract="true" name="EmployeeStockOptionTimeBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="smmt_NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold" abstract="false" name="NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_OptionOverNonFinancialAssetsMember" abstract="true" name="OptionOverNonFinancialAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="smmt_ResearchAndDevelopmentExpenseAmortizableAmount" abstract="false" name="ResearchAndDevelopmentExpenseAmortizableAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_CollaborativeArrangementRightsAndObligationsUpfrontPayment" abstract="false" name="CollaborativeArrangementRightsAndObligationsUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_NotesPayableGrossNoncurrent" abstract="false" name="NotesPayableGrossNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_BusinessCombinationAssumedContingentLiabilityMeasurementInput" abstract="false" name="BusinessCombinationAssumedContingentLiabilityMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="smmt_InProcessResearchAndDevelopmentExpense" abstract="false" name="InProcessResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_StockIssuedDuringPeriodValueWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance" abstract="false" name="ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_ResearchAndDevelopmentExpenseCapitalizedAmount" abstract="false" name="ResearchAndDevelopmentExpenseCapitalizedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_AkesoLicenseAgreementMember" abstract="true" name="AkesoLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="smmt_UtrophinProgramMember" abstract="true" name="UtrophinProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="smmt_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable" abstract="false" name="IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_A2020StockIncentivePlanMember" abstract="true" name="A2020StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="smmt_DeferredTransactionCostsIncurredDuringNoncashOrPartialNoncashTransaction" abstract="false" name="DeferredTransactionCostsIncurredDuringNoncashOrPartialNoncashTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_ZanganehNoteMember" abstract="true" name="ZanganehNoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="smmt_ClassOfWarrantOrRightExercisesInPeriod" abstract="false" name="ClassOfWarrantOrRightExercisesInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="smmt_CommonStockSharesAuthorizedIncreaseDecrease" abstract="false" name="CommonStockSharesAuthorizedIncreaseDecrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="smmt_ResearchAndDevelopmentTaxCreditReceivableNoncurrent" abstract="false" name="ResearchAndDevelopmentTaxCreditReceivableNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_DebtIssuanceCostsIncurredButNotYetPaid" abstract="false" name="DebtIssuanceCostsIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment" abstract="false" name="FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="smmt_StockIssuedDuringPeriodValueIssuedForRelatedPartyInterest" abstract="false" name="StockIssuedDuringPeriodValueIssuedForRelatedPartyInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominatorBaseAmountAddedToClosingBidPrice" abstract="false" name="NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominatorBaseAmountAddedToClosingBidPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="smmt_CollaborativeArrangementRightsAndObligationsPotentialRegulatoryMilestonePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsPotentialRegulatoryMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentOneMember" abstract="true" name="CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="smmt_StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement" abstract="false" name="StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_EarningsPerShareBasicAndDilutedEPSAbstract" abstract="true" name="EarningsPerShareBasicAndDilutedEPSAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="smmt_ClassOfWarrantOrRightWeightedAverageExercisePrice" abstract="false" name="ClassOfWarrantOrRightWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="smmt_AkesoSupplyAgreementMember" abstract="true" name="AkesoSupplyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="smmt_RightsOfferingMember" abstract="true" name="RightsOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="smmt_GrantFundingArrangementCommittedFundingTotal" abstract="false" name="GrantFundingArrangementCommittedFundingTotal" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_OtherOperatingIncomePolicyPolicyTextBlock" abstract="false" name="OtherOperatingIncomePolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="smmt_ContractWithCustomerLiabilityForeignCurrencyTranslation" abstract="false" name="ContractWithCustomerLiabilityForeignCurrencyTranslation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_SubleaseAgreementSecondAmendmentMember" abstract="true" name="SubleaseAgreementSecondAmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="smmt_ResearchAndDevelopmentTaxCreditReceivable" abstract="false" name="ResearchAndDevelopmentTaxCreditReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_AssumedContingentLiabilitiesPolicyPolicyTextBlock" abstract="false" name="AssumedContingentLiabilitiesPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="smmt_GrantFundingArrangementMilestoneFundingIncrease" abstract="false" name="GrantFundingArrangementMilestoneFundingIncrease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="smmt_ResearchAndDevelopmentTaxCredit" abstract="false" name="ResearchAndDevelopmentTaxCredit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember" abstract="true" name="ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="smmt_StockIssuedDuringPeriodSharesInLieuOfCashForCollaborativeArrangement" abstract="false" name="StockIssuedDuringPeriodSharesInLieuOfCashForCollaborativeArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward" abstract="true" name="ChangeInContractWithCustomerAssetAndLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="smmt_BusinessCombinationAssumedContingentLiabilityNoncurrent" abstract="false" name="BusinessCombinationAssumedContingentLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_PaymentsForCollaborativeArrangement" abstract="false" name="PaymentsForCollaborativeArrangement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPotentialNumberOfAdditionalSharesAllowableUnderThePlan" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPotentialNumberOfAdditionalSharesAllowableUnderThePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="smmt_AccruedResearchAndDevelopmentCurrent" abstract="false" name="AccruedResearchAndDevelopmentCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_DeferredTaxAssetsCapitalizedResearchAndDevelopment" abstract="false" name="DeferredTaxAssetsCapitalizedResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_DugganFebruaryNoteMember" abstract="true" name="DugganFebruaryNoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="smmt_SubleaseAgreementFirstAmendmentMember" abstract="true" name="SubleaseAgreementFirstAmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="smmt_InterestExpenseIncomeNoncash" abstract="false" name="InterestExpenseIncomeNoncash" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="smmt_VariableRatePeriodTwoMember" abstract="true" name="VariableRatePeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="smmt_CollaborativeArrangementRightsAndObligationsPotentialCommercialMilestonePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsPotentialCommercialMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>smmt-20231231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:cfc19273-6e1b-408d-b97d-a861bea67b02,g:5505fdd7-331f-4f8b-bf29-88d8f3b5e402-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.summitplc.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="smmt-20231231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.summitplc.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_35fed882-cf66-4639-9c92-ddc945a8da05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ff400b66-4a5f-4bc3-ba25-ef817b651f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_35fed882-cf66-4639-9c92-ddc945a8da05" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ff400b66-4a5f-4bc3-ba25-ef817b651f1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_15350fab-c9b8-425f-bea9-eb5f5e01c73c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_35fed882-cf66-4639-9c92-ddc945a8da05" xlink:to="loc_us-gaap_RestrictedCashCurrent_15350fab-c9b8-425f-bea9-eb5f5e01c73c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4661a1fb-eba9-439c-8c8b-e4b0af83c09d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_35fed882-cf66-4639-9c92-ddc945a8da05" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4661a1fb-eba9-439c-8c8b-e4b0af83c09d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_9ea4bde8-e0fb-48a5-bb39-7b0c5550bcb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_35fed882-cf66-4639-9c92-ddc945a8da05" xlink:to="loc_us-gaap_ShortTermInvestments_9ea4bde8-e0fb-48a5-bb39-7b0c5550bcb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_d5a9b2b2-18c3-4369-b373-91172385a6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_35fed882-cf66-4639-9c92-ddc945a8da05" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_d5a9b2b2-18c3-4369-b373-91172385a6d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_d91c0729-f148-4bdd-9ee0-f7b65dfe05ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_35fed882-cf66-4639-9c92-ddc945a8da05" xlink:to="loc_us-gaap_OtherAssetsCurrent_d91c0729-f148-4bdd-9ee0-f7b65dfe05ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent_9bd0ed00-3f2b-4323-987b-7841ceb8dfc2" xlink:href="smmt-20231231.xsd#smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_35fed882-cf66-4639-9c92-ddc945a8da05" xlink:to="loc_smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent_9bd0ed00-3f2b-4323-987b-7841ceb8dfc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_89696dde-54c8-46aa-94b6-77811eab29bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_4bc78073-d775-4ab0-9fd1-7ae78812a4a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_89696dde-54c8-46aa-94b6-77811eab29bd" xlink:to="loc_us-gaap_CommonStockValue_4bc78073-d775-4ab0-9fd1-7ae78812a4a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_3023a474-2272-4ea5-88ee-b64e6a654094" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_89696dde-54c8-46aa-94b6-77811eab29bd" xlink:to="loc_us-gaap_AdditionalPaidInCapital_3023a474-2272-4ea5-88ee-b64e6a654094" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_46f9a77e-2471-416f-9578-2760d89be3e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_89696dde-54c8-46aa-94b6-77811eab29bd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_46f9a77e-2471-416f-9578-2760d89be3e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_101cc8e0-eaf8-4a25-befa-d7a8cb5def5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_89696dde-54c8-46aa-94b6-77811eab29bd" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_101cc8e0-eaf8-4a25-befa-d7a8cb5def5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_6269ef2b-9c71-4aa4-ad6e-eea553f09260" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_89696dde-54c8-46aa-94b6-77811eab29bd" xlink:to="loc_us-gaap_PreferredStockValue_6269ef2b-9c71-4aa4-ad6e-eea553f09260" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_4b84adad-e2a8-4c28-8672-3e05185623ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ea572665-ab10-4981-8e4d-f8b0817330df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4b84adad-e2a8-4c28-8672-3e05185623ba" xlink:to="loc_us-gaap_AssetsCurrent_ea572665-ab10-4981-8e4d-f8b0817330df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_048ea119-c695-47a2-b67c-26a705134e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4b84adad-e2a8-4c28-8672-3e05185623ba" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_048ea119-c695-47a2-b67c-26a705134e4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b570229b-4fb6-43af-99cb-54bdb732e9c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4b84adad-e2a8-4c28-8672-3e05185623ba" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b570229b-4fb6-43af-99cb-54bdb732e9c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_49e52105-2e23-4f26-aeda-83db123d093e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4b84adad-e2a8-4c28-8672-3e05185623ba" xlink:to="loc_us-gaap_Goodwill_49e52105-2e23-4f26-aeda-83db123d093e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ResearchAndDevelopmentTaxCreditReceivableNoncurrent_76787243-3f93-41ba-8ae9-fa1135e3162d" xlink:href="smmt-20231231.xsd#smmt_ResearchAndDevelopmentTaxCreditReceivableNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4b84adad-e2a8-4c28-8672-3e05185623ba" xlink:to="loc_smmt_ResearchAndDevelopmentTaxCreditReceivableNoncurrent_76787243-3f93-41ba-8ae9-fa1135e3162d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_d79b8b71-f47b-44f1-b1d9-a52c8ae33d01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4b84adad-e2a8-4c28-8672-3e05185623ba" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_d79b8b71-f47b-44f1-b1d9-a52c8ae33d01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_18e4be7f-6a0f-4f1a-b3bd-b2cd197c6cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_04d1578e-87c8-4380-82da-36ed5545fb00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_18e4be7f-6a0f-4f1a-b3bd-b2cd197c6cd3" xlink:to="loc_us-gaap_LiabilitiesCurrent_04d1578e-87c8-4380-82da-36ed5545fb00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_22ba79cb-f9f3-44eb-abe6-0c7a44f034c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_18e4be7f-6a0f-4f1a-b3bd-b2cd197c6cd3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_22ba79cb-f9f3-44eb-abe6-0c7a44f034c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_bc60cca7-830e-4d30-8bad-592522ed74b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_18e4be7f-6a0f-4f1a-b3bd-b2cd197c6cd3" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_bc60cca7-830e-4d30-8bad-592522ed74b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_83b90cf9-a90f-45f6-90cc-b68bc300261d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_18e4be7f-6a0f-4f1a-b3bd-b2cd197c6cd3" xlink:to="loc_us-gaap_LongTermNotesPayable_83b90cf9-a90f-45f6-90cc-b68bc300261d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_cea728e9-5b5c-4ef9-9c14-d0efd67885a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_953774b1-5358-4e1a-91d0-5c68dc2b9f99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cea728e9-5b5c-4ef9-9c14-d0efd67885a4" xlink:to="loc_us-gaap_Liabilities_953774b1-5358-4e1a-91d0-5c68dc2b9f99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_79e2e3e3-81f7-4a79-b8c0-cd7de2bb05b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cea728e9-5b5c-4ef9-9c14-d0efd67885a4" xlink:to="loc_us-gaap_CommitmentsAndContingencies_79e2e3e3-81f7-4a79-b8c0-cd7de2bb05b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_25cf84f8-f9e0-4549-b4b1-02c61bc24c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cea728e9-5b5c-4ef9-9c14-d0efd67885a4" xlink:to="loc_us-gaap_StockholdersEquity_25cf84f8-f9e0-4549-b4b1-02c61bc24c7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f97c2a0c-4de7-4302-bda4-cb357ef59f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_149b1380-8f1d-4ade-883e-e89f2372aaf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f97c2a0c-4de7-4302-bda4-cb357ef59f3c" xlink:to="loc_us-gaap_AccountsPayableCurrent_149b1380-8f1d-4ade-883e-e89f2372aaf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7a2bdc67-a696-4270-9cf1-4dfb8a53db10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f97c2a0c-4de7-4302-bda4-cb357ef59f3c" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7a2bdc67-a696-4270-9cf1-4dfb8a53db10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_46ee9f43-51ed-494b-946f-f1a887f99a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f97c2a0c-4de7-4302-bda4-cb357ef59f3c" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_46ee9f43-51ed-494b-946f-f1a887f99a4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_82bf8778-9910-44ef-b821-0a6034f72f86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f97c2a0c-4de7-4302-bda4-cb357ef59f3c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_82bf8778-9910-44ef-b821-0a6034f72f86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_e29a8d44-8394-4b00-b769-e2f014716fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f97c2a0c-4de7-4302-bda4-cb357ef59f3c" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_e29a8d44-8394-4b00-b769-e2f014716fc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_21b9640d-5c40-4de0-b801-048bb0da16e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f97c2a0c-4de7-4302-bda4-cb357ef59f3c" xlink:to="loc_us-gaap_NotesPayableCurrent_21b9640d-5c40-4de0-b801-048bb0da16e6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="smmt-20231231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a65ed132-2780-4630-b414-4b8f0c4710ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ade2fe96-d43e-4798-8d20-2ae0cfae6f16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_a65ed132-2780-4630-b414-4b8f0c4710ea" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ade2fe96-d43e-4798-8d20-2ae0cfae6f16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_8b7b56b6-4ad9-4546-be18-7cbd5f1b2350" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_a65ed132-2780-4630-b414-4b8f0c4710ea" xlink:to="loc_us-gaap_OperatingExpenses_8b7b56b6-4ad9-4546-be18-7cbd5f1b2350" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_f4a9c0f8-4a3c-4874-b3c1-dfba6dc58f49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_a65ed132-2780-4630-b414-4b8f0c4710ea" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_f4a9c0f8-4a3c-4874-b3c1-dfba6dc58f49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_3285ae79-c5b6-428c-ade0-e823aa755957" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_20509755-5786-4108-935f-ed24960de464" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_3285ae79-c5b6-428c-ade0-e823aa755957" xlink:to="loc_us-gaap_NetIncomeLoss_20509755-5786-4108-935f-ed24960de464" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_ff7419b0-e260-4f7a-8572-a3505af82ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_3285ae79-c5b6-428c-ade0-e823aa755957" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_ff7419b0-e260-4f7a-8572-a3505af82ce9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_0bc8861d-6af1-405b-9854-c94bcbbb73f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_3285ae79-c5b6-428c-ade0-e823aa755957" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_0bc8861d-6af1-405b-9854-c94bcbbb73f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_4120030f-8361-4a39-92e1-58e36c8b86fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_3285ae79-c5b6-428c-ade0-e823aa755957" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_4120030f-8361-4a39-92e1-58e36c8b86fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9e45ab9b-de62-4965-8b54-f6a61a62f0c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b7c13381-5194-437a-8020-f27608a272df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_9e45ab9b-de62-4965-8b54-f6a61a62f0c3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b7c13381-5194-437a-8020-f27608a272df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_b242003b-e48c-4e41-a063-539d2830f459" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_c3ecfaa6-12a2-4ea4-90b7-90b6e128ed3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_b242003b-e48c-4e41-a063-539d2830f459" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_c3ecfaa6-12a2-4ea4-90b7-90b6e128ed3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_InProcessResearchAndDevelopmentExpense_f474e7f8-aeb6-43e7-b9cb-46bdb0446b73" xlink:href="smmt-20231231.xsd#smmt_InProcessResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_b242003b-e48c-4e41-a063-539d2830f459" xlink:to="loc_smmt_InProcessResearchAndDevelopmentExpense_f474e7f8-aeb6-43e7-b9cb-46bdb0446b73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_a9497cff-c8c0-4147-826b-0aff128f86ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_b242003b-e48c-4e41-a063-539d2830f459" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_a9497cff-c8c0-4147-826b-0aff128f86ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_99b4ee72-3f78-4a1a-aa89-ae8c9a9f6110" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_b242003b-e48c-4e41-a063-539d2830f459" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_99b4ee72-3f78-4a1a-aa89-ae8c9a9f6110" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f78f861b-9cb7-43a8-a544-ae3d7b6a8145" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_fd1326ae-0dc5-4f4a-92d2-8ee9f8664e17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f78f861b-9cb7-43a8-a544-ae3d7b6a8145" xlink:to="loc_us-gaap_OperatingIncomeLoss_fd1326ae-0dc5-4f4a-92d2-8ee9f8664e17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_83a267d1-5305-4d91-9bf5-106054f53ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f78f861b-9cb7-43a8-a544-ae3d7b6a8145" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_83a267d1-5305-4d91-9bf5-106054f53ef3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="smmt-20231231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d03b187d-c3df-4c4a-ba0d-1cf23db60fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e0d1fd69-ae1d-4750-8752-2533317638e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d03b187d-c3df-4c4a-ba0d-1cf23db60fc0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e0d1fd69-ae1d-4750-8752-2533317638e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_5875a701-c0e7-47e5-9d54-c0202fc9a627" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d03b187d-c3df-4c4a-ba0d-1cf23db60fc0" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_5875a701-c0e7-47e5-9d54-c0202fc9a627" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_41f96f0c-214b-4266-9f57-67c32e9fa479" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d03b187d-c3df-4c4a-ba0d-1cf23db60fc0" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_41f96f0c-214b-4266-9f57-67c32e9fa479" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_78f004a7-c01c-48c2-9042-e533b3a2b088" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d03b187d-c3df-4c4a-ba0d-1cf23db60fc0" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_78f004a7-c01c-48c2-9042-e533b3a2b088" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_PaymentsForCollaborativeArrangement_ac0b3d16-b959-49c6-8ba2-1aba37bb6079" xlink:href="smmt-20231231.xsd#smmt_PaymentsForCollaborativeArrangement"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d03b187d-c3df-4c4a-ba0d-1cf23db60fc0" xlink:to="loc_smmt_PaymentsForCollaborativeArrangement_ac0b3d16-b959-49c6-8ba2-1aba37bb6079" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8cee12a5-ca45-4252-ad58-3da12bfb9f07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8ed4e1c5-c8c4-4811-8846-d97b9b4cb8ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8cee12a5-ca45-4252-ad58-3da12bfb9f07" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8ed4e1c5-c8c4-4811-8846-d97b9b4cb8ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_31251062-a862-42db-99df-422b00e2ac4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8cee12a5-ca45-4252-ad58-3da12bfb9f07" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_31251062-a862-42db-99df-422b00e2ac4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_0881a542-eafa-4b9b-a85f-3820c85273de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8cee12a5-ca45-4252-ad58-3da12bfb9f07" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_0881a542-eafa-4b9b-a85f-3820c85273de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_417f1f67-3d32-42ea-b74f-eefc37e6848c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8cee12a5-ca45-4252-ad58-3da12bfb9f07" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_417f1f67-3d32-42ea-b74f-eefc37e6848c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_79085c87-5069-42c1-985f-85036956bfcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8cee12a5-ca45-4252-ad58-3da12bfb9f07" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_79085c87-5069-42c1-985f-85036956bfcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_13df7cb7-6db6-45d6-8a8f-5def2eb65ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8cee12a5-ca45-4252-ad58-3da12bfb9f07" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_13df7cb7-6db6-45d6-8a8f-5def2eb65ccd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_fad46875-5af9-49ff-a114-74485c50c041" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8cee12a5-ca45-4252-ad58-3da12bfb9f07" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_fad46875-5af9-49ff-a114-74485c50c041" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_097e0667-a0a2-4db5-9648-08e0edd9a530" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8cee12a5-ca45-4252-ad58-3da12bfb9f07" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_097e0667-a0a2-4db5-9648-08e0edd9a530" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8bfc8ec7-3fb9-4456-b7de-7852f107f8c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_53e27e46-9e54-4c22-8eb5-05ed2a70d3d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8bfc8ec7-3fb9-4456-b7de-7852f107f8c1" xlink:to="loc_us-gaap_NetIncomeLoss_53e27e46-9e54-4c22-8eb5-05ed2a70d3d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss_0bc42318-3e1a-48d3-8af4-6f3cad2edd62" xlink:href="smmt-20231231.xsd#smmt_BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8bfc8ec7-3fb9-4456-b7de-7852f107f8c1" xlink:to="loc_smmt_BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss_0bc42318-3e1a-48d3-8af4-6f3cad2edd62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_InterestExpenseIncomeNoncash_a1f162e1-eabb-4fad-8408-14351773210c" xlink:href="smmt-20231231.xsd#smmt_InterestExpenseIncomeNoncash"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8bfc8ec7-3fb9-4456-b7de-7852f107f8c1" xlink:to="loc_smmt_InterestExpenseIncomeNoncash_a1f162e1-eabb-4fad-8408-14351773210c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_55246d22-54b3-45e2-a6b7-a0a94064c5bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8bfc8ec7-3fb9-4456-b7de-7852f107f8c1" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_55246d22-54b3-45e2-a6b7-a0a94064c5bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_235694a2-e468-4c7b-86c2-e67ce1f38353" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8bfc8ec7-3fb9-4456-b7de-7852f107f8c1" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_235694a2-e468-4c7b-86c2-e67ce1f38353" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome_2147b5e9-410c-446a-951c-d74cfe9807a3" xlink:href="smmt-20231231.xsd#smmt_CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8bfc8ec7-3fb9-4456-b7de-7852f107f8c1" xlink:to="loc_smmt_CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome_2147b5e9-410c-446a-951c-d74cfe9807a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_a5ed014c-7ff6-4bbc-9f1a-ecdf165f69ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8bfc8ec7-3fb9-4456-b7de-7852f107f8c1" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_a5ed014c-7ff6-4bbc-9f1a-ecdf165f69ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_7489212f-2a92-412d-a32f-2e1e15abe3fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8bfc8ec7-3fb9-4456-b7de-7852f107f8c1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_7489212f-2a92-412d-a32f-2e1e15abe3fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_16283b20-1a01-428b-92c4-123483eceeee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8bfc8ec7-3fb9-4456-b7de-7852f107f8c1" xlink:to="loc_us-gaap_Depreciation_16283b20-1a01-428b-92c4-123483eceeee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_e39da70b-62fc-4687-aee2-7373fd75f02b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8bfc8ec7-3fb9-4456-b7de-7852f107f8c1" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_e39da70b-62fc-4687-aee2-7373fd75f02b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_866198c6-28cd-466f-ad07-1d5271499b09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8bfc8ec7-3fb9-4456-b7de-7852f107f8c1" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_866198c6-28cd-466f-ad07-1d5271499b09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_0cbf732f-347c-4910-9fb8-1a4236ebf628" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8bfc8ec7-3fb9-4456-b7de-7852f107f8c1" xlink:to="loc_us-gaap_ShareBasedCompensation_0cbf732f-347c-4910-9fb8-1a4236ebf628" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_26674057-05eb-4a15-907d-0248b913ab01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8bfc8ec7-3fb9-4456-b7de-7852f107f8c1" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_26674057-05eb-4a15-907d-0248b913ab01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_InProcessResearchAndDevelopmentExpense_c22af9f2-93b8-4ada-ab84-6cb0988eb1f3" xlink:href="smmt-20231231.xsd#smmt_InProcessResearchAndDevelopmentExpense"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8bfc8ec7-3fb9-4456-b7de-7852f107f8c1" xlink:to="loc_smmt_InProcessResearchAndDevelopmentExpense_c22af9f2-93b8-4ada-ab84-6cb0988eb1f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_be5439a0-5a7b-47c2-9a93-11134bd1c7ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8bfc8ec7-3fb9-4456-b7de-7852f107f8c1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_be5439a0-5a7b-47c2-9a93-11134bd1c7ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_ee873e94-942d-4bfe-b479-a48110fcbbc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8bfc8ec7-3fb9-4456-b7de-7852f107f8c1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_ee873e94-942d-4bfe-b479-a48110fcbbc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_2a48ec2e-c7c8-4a00-8794-d1cda092fd03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8bfc8ec7-3fb9-4456-b7de-7852f107f8c1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_2a48ec2e-c7c8-4a00-8794-d1cda092fd03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable_63f99c32-1374-4c06-854f-9e2ccf22d9e7" xlink:href="smmt-20231231.xsd#smmt_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable"/>
    <link:calculationArc order="18" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8bfc8ec7-3fb9-4456-b7de-7852f107f8c1" xlink:to="loc_smmt_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable_63f99c32-1374-4c06-854f-9e2ccf22d9e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c44b9925-66d1-4f5f-9042-52fa6453a3d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8bfc8ec7-3fb9-4456-b7de-7852f107f8c1" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c44b9925-66d1-4f5f-9042-52fa6453a3d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_75e8211c-925e-4d3b-bd61-ce7cfd53ab0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="20" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8bfc8ec7-3fb9-4456-b7de-7852f107f8c1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_75e8211c-925e-4d3b-bd61-ce7cfd53ab0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6ebcb0b5-aaeb-41fb-954e-6d875a943648" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="21" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8bfc8ec7-3fb9-4456-b7de-7852f107f8c1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6ebcb0b5-aaeb-41fb-954e-6d875a943648" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_e6f9937a-1373-4d40-9d25-b9c22a2517f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="22" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8bfc8ec7-3fb9-4456-b7de-7852f107f8c1" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_e6f9937a-1373-4d40-9d25-b9c22a2517f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_794bf936-ebae-4830-8065-2c869864b8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="23" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8bfc8ec7-3fb9-4456-b7de-7852f107f8c1" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_794bf936-ebae-4830-8065-2c869864b8fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_214b456e-f592-4c03-9b93-2eb567d0bb63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_60087e64-0fbd-4396-97d9-bb1e54e6a6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_214b456e-f592-4c03-9b93-2eb567d0bb63" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_60087e64-0fbd-4396-97d9-bb1e54e6a6ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_01c6d17f-820f-4372-a809-5bb7eb596379" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_214b456e-f592-4c03-9b93-2eb567d0bb63" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_01c6d17f-820f-4372-a809-5bb7eb596379" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_97986a21-d24d-46f5-a0b0-e9e7ee97cdda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_214b456e-f592-4c03-9b93-2eb567d0bb63" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_97986a21-d24d-46f5-a0b0-e9e7ee97cdda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_36cb982c-b0b8-42f4-946e-24226f3a749d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_214b456e-f592-4c03-9b93-2eb567d0bb63" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_36cb982c-b0b8-42f4-946e-24226f3a749d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/AkesoLicenseandCollaborationAgreementDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#AkesoLicenseandCollaborationAgreementDetails"/>
  <link:calculationLink xlink:role="http://www.summitplc.com/role/AkesoLicenseandCollaborationAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments_bfe9f01e-d069-4bf8-84c1-b08087f89491" xlink:href="smmt-20231231.xsd#smmt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CollaborativeArrangementRightsAndObligationsPotentialCommercialMilestonePayments_2dbf48bf-4512-479b-a410-bd5cc35ca8b5" xlink:href="smmt-20231231.xsd#smmt_CollaborativeArrangementRightsAndObligationsPotentialCommercialMilestonePayments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_smmt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments_bfe9f01e-d069-4bf8-84c1-b08087f89491" xlink:to="loc_smmt_CollaborativeArrangementRightsAndObligationsPotentialCommercialMilestonePayments_2dbf48bf-4512-479b-a410-bd5cc35ca8b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CollaborativeArrangementRightsAndObligationsPotentialRegulatoryMilestonePayments_a3fd34fe-4d55-477d-aed0-07e4f71f0dfb" xlink:href="smmt-20231231.xsd#smmt_CollaborativeArrangementRightsAndObligationsPotentialRegulatoryMilestonePayments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_smmt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments_bfe9f01e-d069-4bf8-84c1-b08087f89491" xlink:to="loc_smmt_CollaborativeArrangementRightsAndObligationsPotentialRegulatoryMilestonePayments_a3fd34fe-4d55-477d-aed0-07e4f71f0dfb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/OtherOperatingIncomenetSummarybycategoryDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#OtherOperatingIncomenetSummarybycategoryDetails"/>
  <link:calculationLink xlink:role="http://www.summitplc.com/role/OtherOperatingIncomenetSummarybycategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome_d7c7a1ef-78a4-4458-9991-e0ba1de4edbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GrantFundingArrangementIncomeEarned_069d9acf-eac4-4a6b-b0ff-8d0b5b517d1f" xlink:href="smmt-20231231.xsd#smmt_GrantFundingArrangementIncomeEarned"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncome_d7c7a1ef-78a4-4458-9991-e0ba1de4edbe" xlink:to="loc_smmt_GrantFundingArrangementIncomeEarned_069d9acf-eac4-4a6b-b0ff-8d0b5b517d1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ResearchAndDevelopmentTaxCredit_2140f4a9-3a9c-4a6a-a957-964435cb575a" xlink:href="smmt-20231231.xsd#smmt_ResearchAndDevelopmentTaxCredit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncome_d7c7a1ef-78a4-4458-9991-e0ba1de4edbe" xlink:to="loc_smmt_ResearchAndDevelopmentTaxCredit_2140f4a9-3a9c-4a6a-a957-964435cb575a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_OtherOperatingIncomeOther_20926295-3158-4b2b-b1a3-e65c50444fa6" xlink:href="smmt-20231231.xsd#smmt_OtherOperatingIncomeOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncome_d7c7a1ef-78a4-4458-9991-e0ba1de4edbe" xlink:to="loc_smmt_OtherOperatingIncomeOther_20926295-3158-4b2b-b1a3-e65c50444fa6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/OtherExpenseIncomenetComponentsDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#OtherExpenseIncomenetComponentsDetails"/>
  <link:calculationLink xlink:role="http://www.summitplc.com/role/OtherExpenseIncomenetComponentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_baef625c-6b79-415d-81df-c0a46653c35e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_54faa71e-df72-49e2-9701-86b87fdae8b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_baef625c-6b79-415d-81df-c0a46653c35e" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_54faa71e-df72-49e2-9701-86b87fdae8b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_5b6648be-b61f-4605-a528-a8b50ad7bf4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_baef625c-6b79-415d-81df-c0a46653c35e" xlink:to="loc_us-gaap_InterestExpenseDebt_5b6648be-b61f-4605-a528-a8b50ad7bf4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating_3849f80c-cc65-4f15-a118-00677379d6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNonoperating"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_baef625c-6b79-415d-81df-c0a46653c35e" xlink:to="loc_us-gaap_InvestmentIncomeNonoperating_3849f80c-cc65-4f15-a118-00677379d6fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome_3ab38e6b-c343-44fd-9e7e-cd670d2e87a5" xlink:href="smmt-20231231.xsd#smmt_CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_baef625c-6b79-415d-81df-c0a46653c35e" xlink:to="loc_smmt_CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome_3ab38e6b-c343-44fd-9e7e-cd670d2e87a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_3cbeb824-fe6b-4804-85f3-c5e5475bf665" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_baef625c-6b79-415d-81df-c0a46653c35e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_3cbeb824-fe6b-4804-85f3-c5e5475bf665" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/IncomeTaxComponentsoflossbeforeincometaxesDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#IncomeTaxComponentsoflossbeforeincometaxesDetails"/>
  <link:calculationLink xlink:role="http://www.summitplc.com/role/IncomeTaxComponentsoflossbeforeincometaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_81f905a0-6306-44ce-9120-f658e3136823" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_3a1442e3-f103-476d-a5c2-413e13a2a1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_81f905a0-6306-44ce-9120-f658e3136823" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_3a1442e3-f103-476d-a5c2-413e13a2a1f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_06442178-82bb-4029-8f2d-12d07e2a5cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_81f905a0-6306-44ce-9120-f658e3136823" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_06442178-82bb-4029-8f2d-12d07e2a5cfd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_0da4f06a-9472-474f-8f2c-b5c7677d836d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_d911ce8f-97f2-4b03-8a67-c0f6d7be609a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_0da4f06a-9472-474f-8f2c-b5c7677d836d" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_d911ce8f-97f2-4b03-8a67-c0f6d7be609a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_72d27abc-8763-41c9-baaa-670bd88cd2d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_0da4f06a-9472-474f-8f2c-b5c7677d836d" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_72d27abc-8763-41c9-baaa-670bd88cd2d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_dc3b181c-0fd4-4bf7-8b27-866c2f3b56ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DeferredTaxAssetsLiabilities_2fecb957-af31-40e8-810f-b2aff5af11a5" xlink:href="smmt-20231231.xsd#smmt_DeferredTaxAssetsLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_dc3b181c-0fd4-4bf7-8b27-866c2f3b56ec" xlink:to="loc_smmt_DeferredTaxAssetsLiabilities_2fecb957-af31-40e8-810f-b2aff5af11a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_33711fc4-a0f8-4736-b732-9c647bac6bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_dc3b181c-0fd4-4bf7-8b27-866c2f3b56ec" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_33711fc4-a0f8-4736-b732-9c647bac6bc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_367a8944-6ebf-4d2b-8d2a-79f5bcd003e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_ed7e5da9-a932-4117-91de-cfff883e1733" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_367a8944-6ebf-4d2b-8d2a-79f5bcd003e6" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_ed7e5da9-a932-4117-91de-cfff883e1733" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_bd26cd8d-3dfd-4e95-b141-bb9eb025cd46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_367a8944-6ebf-4d2b-8d2a-79f5bcd003e6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_bd26cd8d-3dfd-4e95-b141-bb9eb025cd46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9d85d423-c67a-4d16-b95b-9f2ccc7ba888" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_367a8944-6ebf-4d2b-8d2a-79f5bcd003e6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9d85d423-c67a-4d16-b95b-9f2ccc7ba888" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DeferredTaxAssetsCapitalizedResearchAndDevelopment_0d3fdf98-e469-46f1-82a6-c249095645fc" xlink:href="smmt-20231231.xsd#smmt_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_367a8944-6ebf-4d2b-8d2a-79f5bcd003e6" xlink:to="loc_smmt_DeferredTaxAssetsCapitalizedResearchAndDevelopment_0d3fdf98-e469-46f1-82a6-c249095645fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DeferredTaxAssetsLeasingArrangements_9939e797-3969-4f5a-8c9c-b84f63f7319b" xlink:href="smmt-20231231.xsd#smmt_DeferredTaxAssetsLeasingArrangements"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_367a8944-6ebf-4d2b-8d2a-79f5bcd003e6" xlink:to="loc_smmt_DeferredTaxAssetsLeasingArrangements_9939e797-3969-4f5a-8c9c-b84f63f7319b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_da280aa3-932d-4026-8596-4d01ca8b91d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_367a8944-6ebf-4d2b-8d2a-79f5bcd003e6" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_da280aa3-932d-4026-8596-4d01ca8b91d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DeferredTaxAssetsLiabilities_897bc199-abf5-41df-902f-f725883f4f98" xlink:href="smmt-20231231.xsd#smmt_DeferredTaxAssetsLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_b1bbfcb8-44ad-4644-8751-f5b47f6eb34c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_smmt_DeferredTaxAssetsLiabilities_897bc199-abf5-41df-902f-f725883f4f98" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_b1bbfcb8-44ad-4644-8751-f5b47f6eb34c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_1bd188a8-8ce3-427f-8b89-fecdb40bab88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_smmt_DeferredTaxAssetsLiabilities_897bc199-abf5-41df-902f-f725883f4f98" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_1bd188a8-8ce3-427f-8b89-fecdb40bab88" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails"/>
  <link:calculationLink xlink:role="http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e97ebe10-07f9-42c6-971c-6f9b21c6d3b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_e880449a-4b34-4ad5-9911-1f8bcf0a8900" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e97ebe10-07f9-42c6-971c-6f9b21c6d3b1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_e880449a-4b34-4ad5-9911-1f8bcf0a8900" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_75a05984-ca6e-4081-ba9c-fd4afe81f8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e97ebe10-07f9-42c6-971c-6f9b21c6d3b1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_75a05984-ca6e-4081-ba9c-fd4afe81f8b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent_1ab24eb3-c461-401b-be1c-7ac43e58e9f7" xlink:href="smmt-20231231.xsd#smmt_EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e97ebe10-07f9-42c6-971c-6f9b21c6d3b1" xlink:to="loc_smmt_EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent_1ab24eb3-c461-401b-be1c-7ac43e58e9f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_6976a1e0-6900-4d01-a3d1-b52428e04883" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e97ebe10-07f9-42c6-971c-6f9b21c6d3b1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_6976a1e0-6900-4d01-a3d1-b52428e04883" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_ce23ff2f-599c-4c65-9128-1f93df56f622" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e97ebe10-07f9-42c6-971c-6f9b21c6d3b1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_ce23ff2f-599c-4c65-9128-1f93df56f622" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_081cb044-b3c0-48fa-aea9-d960db658a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e97ebe10-07f9-42c6-971c-6f9b21c6d3b1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_081cb044-b3c0-48fa-aea9-d960db658a1a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails"/>
  <link:calculationLink xlink:role="http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e75d60d0-e7d2-4537-94d2-756574c6029f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_afba8bfd-6684-43b1-9e64-181061519fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e75d60d0-e7d2-4537-94d2-756574c6029f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_afba8bfd-6684-43b1-9e64-181061519fb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment_e1584100-6aaa-4721-a9fb-a6148bc5aa97" xlink:href="smmt-20231231.xsd#smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e75d60d0-e7d2-4537-94d2-756574c6029f" xlink:to="loc_smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment_e1584100-6aaa-4721-a9fb-a6148bc5aa97" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_4916d71f-11be-40c3-969e-f39c41af5438" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CashEquivalentsFairValueDisclosure_6192adbd-fad6-4c1c-85b0-68b5c22bf121" xlink:href="smmt-20231231.xsd#smmt_CashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4916d71f-11be-40c3-969e-f39c41af5438" xlink:to="loc_smmt_CashEquivalentsFairValueDisclosure_6192adbd-fad6-4c1c-85b0-68b5c22bf121" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_61279bbe-f408-411c-94a7-3e926b1f98f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4916d71f-11be-40c3-969e-f39c41af5438" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_61279bbe-f408-411c-94a7-3e926b1f98f4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#PropertyandEquipmentComponentsofpropertyandequipmentDetails"/>
  <link:calculationLink xlink:role="http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e4fa4113-86a5-42d6-bed7-079dbc3076d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_ea87384a-c5fa-4363-bfb7-57ae125a569b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_e4fa4113-86a5-42d6-bed7-079dbc3076d3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_ea87384a-c5fa-4363-bfb7-57ae125a569b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0fc2dd32-5d55-41cb-8a32-1f6da8ab12b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_e4fa4113-86a5-42d6-bed7-079dbc3076d3" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0fc2dd32-5d55-41cb-8a32-1f6da8ab12b7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/LeasesLeaseexpenseDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#LeasesLeaseexpenseDetails"/>
  <link:calculationLink xlink:role="http://www.summitplc.com/role/LeasesLeaseexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_4b971ef8-49c6-4fc4-ba9e-36f2e9f68fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_47b5eba1-bc82-45b0-82a0-4eb0d33d7cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_4b971ef8-49c6-4fc4-ba9e-36f2e9f68fdb" xlink:to="loc_us-gaap_OperatingLeaseCost_47b5eba1-bc82-45b0-82a0-4eb0d33d7cfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_fcd77059-7056-4fc1-bb53-dc0aa352f664" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_4b971ef8-49c6-4fc4-ba9e-36f2e9f68fdb" xlink:to="loc_us-gaap_VariableLeaseCost_fcd77059-7056-4fc1-bb53-dc0aa352f664" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_9069d7c3-1772-45b5-a19d-eaef88a26512" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_4b971ef8-49c6-4fc4-ba9e-36f2e9f68fdb" xlink:to="loc_us-gaap_ShortTermLeaseCost_9069d7c3-1772-45b5-a19d-eaef88a26512" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#LeasesFutureleasepaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4a1a24d4-83b7-46c2-b46a-be3e34ff1fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_08ba7090-caef-4fe2-b3bf-b23582e20264" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4a1a24d4-83b7-46c2-b46a-be3e34ff1fcd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_08ba7090-caef-4fe2-b3bf-b23582e20264" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1622199c-b592-4687-b89b-3d4b707c18df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4a1a24d4-83b7-46c2-b46a-be3e34ff1fcd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1622199c-b592-4687-b89b-3d4b707c18df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_42727862-32f3-42d4-aee6-977fe8ff6582" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4a1a24d4-83b7-46c2-b46a-be3e34ff1fcd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_42727862-32f3-42d4-aee6-977fe8ff6582" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6c68b546-7b8f-4f62-9b2f-9e1ae3ee0aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4a1a24d4-83b7-46c2-b46a-be3e34ff1fcd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6c68b546-7b8f-4f62-9b2f-9e1ae3ee0aeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_0b7252b2-0daa-4e9f-a5e5-bc7eac336a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c3f2e0d2-8e01-4edb-8303-d2d5648e57c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_0b7252b2-0daa-4e9f-a5e5-bc7eac336a4f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c3f2e0d2-8e01-4edb-8303-d2d5648e57c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d13b8bb9-b37f-4ecf-a295-dc68f710bc78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_0b7252b2-0daa-4e9f-a5e5-bc7eac336a4f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d13b8bb9-b37f-4ecf-a295-dc68f710bc78" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails_1" xlink:type="simple" xlink:href="smmt-20231231.xsd#LeasesFutureleasepaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a412511f-6023-4228-8065-bdf89e8534ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_961158ab-37e6-4031-a678-442b124fef2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a412511f-6023-4228-8065-bdf89e8534ea" xlink:to="loc_us-gaap_OperatingLeaseLiability_961158ab-37e6-4031-a678-442b124fef2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8a32745e-ba96-4cd0-acb8-498da8a070b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a412511f-6023-4228-8065-bdf89e8534ea" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8a32745e-ba96-4cd0-acb8-498da8a070b9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesSummaryofrelatedpartydebtDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#PromissoryNotesPayabletoRelatedPartiesSummaryofrelatedpartydebtDetails"/>
  <link:calculationLink xlink:role="http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesSummaryofrelatedpartydebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_5c5b2fd7-f35f-485f-99fa-30fcea8155f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableGrossCurrent_bef1a3c7-b671-4b1f-8d11-cf6b074cf9aa" xlink:href="smmt-20231231.xsd#smmt_NotesPayableGrossCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NotesPayableCurrent_5c5b2fd7-f35f-485f-99fa-30fcea8155f7" xlink:to="loc_smmt_NotesPayableGrossCurrent_bef1a3c7-b671-4b1f-8d11-cf6b074cf9aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_8beec75f-0d8e-4eba-9b49-27f1b535bea2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NotesPayableCurrent_5c5b2fd7-f35f-485f-99fa-30fcea8155f7" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_8beec75f-0d8e-4eba-9b49-27f1b535bea2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_8c880cfe-4986-45f8-9391-44d6caccb4da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableGrossNoncurrent_aeede45c-f8c3-471a-9a5f-0963c74898ef" xlink:href="smmt-20231231.xsd#smmt_NotesPayableGrossNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable_8c880cfe-4986-45f8-9391-44d6caccb4da" xlink:to="loc_smmt_NotesPayableGrossNoncurrent_aeede45c-f8c3-471a-9a5f-0963c74898ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_a8efd4cd-6cb1-4897-8a1b-a3b9cbada914" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable_8c880cfe-4986-45f8-9391-44d6caccb4da" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_a8efd4cd-6cb1-4897-8a1b-a3b9cbada914" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>smmt-20231231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:cfc19273-6e1b-408d-b97d-a861bea67b02,g:5505fdd7-331f-4f8b-bf29-88d8f3b5e402-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="smmt-20231231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_93f54f82-0e0c-4011-834e-164e5b9ad13b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_71905684-dd14-4004-bab9-e47321bae5d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_93f54f82-0e0c-4011-834e-164e5b9ad13b" xlink:to="loc_us-gaap_StatementTable_71905684-dd14-4004-bab9-e47321bae5d0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_32f213d2-cbe8-4674-a69b-c8ee98a12c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_71905684-dd14-4004-bab9-e47321bae5d0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_32f213d2-cbe8-4674-a69b-c8ee98a12c5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_32f213d2-cbe8-4674-a69b-c8ee98a12c5a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_32f213d2-cbe8-4674-a69b-c8ee98a12c5a" xlink:to="loc_us-gaap_EquityComponentDomain_32f213d2-cbe8-4674-a69b-c8ee98a12c5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_52ca475f-9488-43d4-b30f-b33ac1896cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_32f213d2-cbe8-4674-a69b-c8ee98a12c5a" xlink:to="loc_us-gaap_EquityComponentDomain_52ca475f-9488-43d4-b30f-b33ac1896cd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_96b394ba-c3c4-46e0-bc9a-b7f1504df6c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_52ca475f-9488-43d4-b30f-b33ac1896cd6" xlink:to="loc_us-gaap_CommonStockMember_96b394ba-c3c4-46e0-bc9a-b7f1504df6c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_fa0f1350-6065-4563-aa90-f513a05daf34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_52ca475f-9488-43d4-b30f-b33ac1896cd6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_fa0f1350-6065-4563-aa90-f513a05daf34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ca511a50-2262-4ed5-bee6-e800cf89db9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_52ca475f-9488-43d4-b30f-b33ac1896cd6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ca511a50-2262-4ed5-bee6-e800cf89db9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_40260202-2964-41fd-a077-8b4bf0f2db8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_52ca475f-9488-43d4-b30f-b33ac1896cd6" xlink:to="loc_us-gaap_RetainedEarningsMember_40260202-2964-41fd-a077-8b4bf0f2db8c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ce66c420-f43b-4ae2-8aa2-9bd40155eb39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_71905684-dd14-4004-bab9-e47321bae5d0" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ce66c420-f43b-4ae2-8aa2-9bd40155eb39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ce66c420-f43b-4ae2-8aa2-9bd40155eb39_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ce66c420-f43b-4ae2-8aa2-9bd40155eb39" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ce66c420-f43b-4ae2-8aa2-9bd40155eb39_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bf20d326-6d76-4c0b-8d93-7ee99860b114" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ce66c420-f43b-4ae2-8aa2-9bd40155eb39" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bf20d326-6d76-4c0b-8d93-7ee99860b114" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RightsOfferingMember_b636885b-76d4-44f5-b3bc-35538fb0330c" xlink:href="smmt-20231231.xsd#smmt_RightsOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bf20d326-6d76-4c0b-8d93-7ee99860b114" xlink:to="loc_smmt_RightsOfferingMember_b636885b-76d4-44f5-b3bc-35538fb0330c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_fab0ca2b-0923-426a-82c4-97cc2e6af0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bf20d326-6d76-4c0b-8d93-7ee99860b114" xlink:to="loc_us-gaap_PrivatePlacementMember_fab0ca2b-0923-426a-82c4-97cc2e6af0e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5b8a5a4-886f-4665-a96c-07d7eed74cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_93f54f82-0e0c-4011-834e-164e5b9ad13b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5b8a5a4-886f-4665-a96c-07d7eed74cb9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_46fa1f73-0665-4af0-bc37-44f9848100e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5b8a5a4-886f-4665-a96c-07d7eed74cb9" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_46fa1f73-0665-4af0-bc37-44f9848100e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e0f65c44-0582-461f-a2a5-bf58809c0692" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5b8a5a4-886f-4665-a96c-07d7eed74cb9" xlink:to="loc_us-gaap_StockholdersEquity_e0f65c44-0582-461f-a2a5-bf58809c0692" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ad36c40c-95d0-4f0e-ae5e-63a31c2cc992" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5b8a5a4-886f-4665-a96c-07d7eed74cb9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ad36c40c-95d0-4f0e-ae5e-63a31c2cc992" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a0003d08-70dd-404c-8caa-4f88186a1eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5b8a5a4-886f-4665-a96c-07d7eed74cb9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a0003d08-70dd-404c-8caa-4f88186a1eb9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_StockIssuedDuringPeriodSharesWarrantsExercised_98359527-8ad1-474f-9044-c761debae023" xlink:href="smmt-20231231.xsd#smmt_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5b8a5a4-886f-4665-a96c-07d7eed74cb9" xlink:to="loc_smmt_StockIssuedDuringPeriodSharesWarrantsExercised_98359527-8ad1-474f-9044-c761debae023" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_StockIssuedDuringPeriodValueWarrantsExercised_2a745830-d992-42e2-9634-3850db1cee69" xlink:href="smmt-20231231.xsd#smmt_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5b8a5a4-886f-4665-a96c-07d7eed74cb9" xlink:to="loc_smmt_StockIssuedDuringPeriodValueWarrantsExercised_2a745830-d992-42e2-9634-3850db1cee69" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_StockIssuedDuringPeriodSharesIssuedForRelatedPartyInterest_c56dae97-fe20-4351-a05b-5e151c188272" xlink:href="smmt-20231231.xsd#smmt_StockIssuedDuringPeriodSharesIssuedForRelatedPartyInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5b8a5a4-886f-4665-a96c-07d7eed74cb9" xlink:to="loc_smmt_StockIssuedDuringPeriodSharesIssuedForRelatedPartyInterest_c56dae97-fe20-4351-a05b-5e151c188272" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_StockIssuedDuringPeriodValueIssuedForRelatedPartyInterest_e88716d9-e418-4630-8360-be7ea25b2bc8" xlink:href="smmt-20231231.xsd#smmt_StockIssuedDuringPeriodValueIssuedForRelatedPartyInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5b8a5a4-886f-4665-a96c-07d7eed74cb9" xlink:to="loc_smmt_StockIssuedDuringPeriodValueIssuedForRelatedPartyInterest_e88716d9-e418-4630-8360-be7ea25b2bc8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d5f0f5a7-657d-4e0c-9484-d3447f921466" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5b8a5a4-886f-4665-a96c-07d7eed74cb9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d5f0f5a7-657d-4e0c-9484-d3447f921466" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_8ef576ca-f216-4c90-aa53-ac81b91fe679" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5b8a5a4-886f-4665-a96c-07d7eed74cb9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_8ef576ca-f216-4c90-aa53-ac81b91fe679" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_StockIssuedDuringPeriodSharesInLieuOfCashForCollaborativeArrangement_bb392620-2f14-4c3b-bdce-cfb5bf5a3101" xlink:href="smmt-20231231.xsd#smmt_StockIssuedDuringPeriodSharesInLieuOfCashForCollaborativeArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5b8a5a4-886f-4665-a96c-07d7eed74cb9" xlink:to="loc_smmt_StockIssuedDuringPeriodSharesInLieuOfCashForCollaborativeArrangement_bb392620-2f14-4c3b-bdce-cfb5bf5a3101" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement_fbaeca20-fcb7-4cbd-a1e5-48a89a712451" xlink:href="smmt-20231231.xsd#smmt_StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5b8a5a4-886f-4665-a96c-07d7eed74cb9" xlink:to="loc_smmt_StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement_fbaeca20-fcb7-4cbd-a1e5-48a89a712451" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_020f9a81-e682-461e-9e55-bc8020ccfe6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5b8a5a4-886f-4665-a96c-07d7eed74cb9" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_020f9a81-e682-461e-9e55-bc8020ccfe6d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty_468aaee5-6af0-48bd-8227-93219889fa36" xlink:href="smmt-20231231.xsd#smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5b8a5a4-886f-4665-a96c-07d7eed74cb9" xlink:to="loc_smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty_468aaee5-6af0-48bd-8227-93219889fa36" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2ef00393-f3f3-4a0a-b25b-88ec8c3e64a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5b8a5a4-886f-4665-a96c-07d7eed74cb9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2ef00393-f3f3-4a0a-b25b-88ec8c3e64a0" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_3e4353a9-0330-4107-b8a6-2d2200eebb2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5b8a5a4-886f-4665-a96c-07d7eed74cb9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_3e4353a9-0330-4107-b8a6-2d2200eebb2f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_6c9caefd-e96a-46fc-9b99-42fc5fb0eb61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5b8a5a4-886f-4665-a96c-07d7eed74cb9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_6c9caefd-e96a-46fc-9b99-42fc5fb0eb61" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8b9e6c17-ebc7-43a3-870a-75438915f21a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5b8a5a4-886f-4665-a96c-07d7eed74cb9" xlink:to="loc_us-gaap_NetIncomeLoss_8b9e6c17-ebc7-43a3-870a-75438915f21a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_fbfd336f-bfff-4d84-8ce2-d999c70d6e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8710ee37-5599-4445-980e-e2e9d8a391d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="smmt-20231231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e91e3074-8796-45e2-90a1-d573f9cde0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_db021a23-3983-4b26-9fe9-cb4de315fafb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e91e3074-8796-45e2-90a1-d573f9cde0ca" xlink:to="loc_us-gaap_StatementTable_db021a23-3983-4b26-9fe9-cb4de315fafb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_59cfda61-6ce0-4477-a926-1c438b7003da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_db021a23-3983-4b26-9fe9-cb4de315fafb" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_59cfda61-6ce0-4477-a926-1c438b7003da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_59cfda61-6ce0-4477-a926-1c438b7003da_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_59cfda61-6ce0-4477-a926-1c438b7003da" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_59cfda61-6ce0-4477-a926-1c438b7003da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1ae4a5e1-73e3-4894-98f3-1204da7e5e42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_59cfda61-6ce0-4477-a926-1c438b7003da" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1ae4a5e1-73e3-4894-98f3-1204da7e5e42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_AkesoLicenseAgreementMember_b18c19b9-9c1b-4a6b-ba4f-81c06d8f61b1" xlink:href="smmt-20231231.xsd#smmt_AkesoLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1ae4a5e1-73e3-4894-98f3-1204da7e5e42" xlink:to="loc_smmt_AkesoLicenseAgreementMember_b18c19b9-9c1b-4a6b-ba4f-81c06d8f61b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RightsOfferingMember_0699210f-eab6-4c62-abb3-456e01d5727a" xlink:href="smmt-20231231.xsd#smmt_RightsOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1ae4a5e1-73e3-4894-98f3-1204da7e5e42" xlink:to="loc_smmt_RightsOfferingMember_0699210f-eab6-4c62-abb3-456e01d5727a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_dd7f74af-cecb-4b54-a56c-2e6a5bc7df2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e91e3074-8796-45e2-90a1-d573f9cde0ca" xlink:to="loc_us-gaap_InterestPaidNet_dd7f74af-cecb-4b54-a56c-2e6a5bc7df2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_02f0984c-08ca-4de7-9b63-70a26de9ef6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e91e3074-8796-45e2-90a1-d573f9cde0ca" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_02f0984c-08ca-4de7-9b63-70a26de9ef6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DebtIssuanceCostsIncurredButNotYetPaid_65df1492-05eb-4b3b-8a46-5b74082e5345" xlink:href="smmt-20231231.xsd#smmt_DebtIssuanceCostsIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e91e3074-8796-45e2-90a1-d573f9cde0ca" xlink:to="loc_smmt_DebtIssuanceCostsIncurredButNotYetPaid_65df1492-05eb-4b3b-8a46-5b74082e5345" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_9025dcdc-8bf4-4ba8-9d34-01059237c944" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e91e3074-8796-45e2-90a1-d573f9cde0ca" xlink:to="loc_us-gaap_StockIssued1_9025dcdc-8bf4-4ba8-9d34-01059237c944" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DeferredTransactionCostsIncurredDuringNoncashOrPartialNoncashTransaction_3048e026-9da9-4c35-af24-cb9534adb146" xlink:href="smmt-20231231.xsd#smmt_DeferredTransactionCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e91e3074-8796-45e2-90a1-d573f9cde0ca" xlink:to="loc_smmt_DeferredTransactionCostsIncurredDuringNoncashOrPartialNoncashTransaction_3048e026-9da9-4c35-af24-cb9534adb146" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b008ecfe-025e-43c5-962d-58ddc4f10847" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e91e3074-8796-45e2-90a1-d573f9cde0ca" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b008ecfe-025e-43c5-962d-58ddc4f10847" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#NatureofBusinessandOperationsandRecentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_186c04e3-a9b3-4266-92d3-193c976ed8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_815618d9-e950-4669-9ee6-9b51660477d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_186c04e3-a9b3-4266-92d3-193c976ed8cb" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_815618d9-e950-4669-9ee6-9b51660477d6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_ccadb535-7c25-40f4-934e-1a79a4e1f731" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_815618d9-e950-4669-9ee6-9b51660477d6" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_ccadb535-7c25-40f4-934e-1a79a4e1f731" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_ccadb535-7c25-40f4-934e-1a79a4e1f731_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_ccadb535-7c25-40f4-934e-1a79a4e1f731" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_ccadb535-7c25-40f4-934e-1a79a4e1f731_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_14b1962d-3fc3-4f56-97aa-fe28b6d1c88c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_ccadb535-7c25-40f4-934e-1a79a4e1f731" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_14b1962d-3fc3-4f56-97aa-fe28b6d1c88c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotePurchaseAgreementMember_5a1499cc-500c-41d3-9e89-c4003d87996b" xlink:href="smmt-20231231.xsd#smmt_NotePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_14b1962d-3fc3-4f56-97aa-fe28b6d1c88c" xlink:to="loc_smmt_NotePurchaseAgreementMember_5a1499cc-500c-41d3-9e89-c4003d87996b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DugganFebruaryNoteMember_d6eb1592-b0fc-422e-b6d0-8c37b384eac6" xlink:href="smmt-20231231.xsd#smmt_DugganFebruaryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_14b1962d-3fc3-4f56-97aa-fe28b6d1c88c" xlink:to="loc_smmt_DugganFebruaryNoteMember_d6eb1592-b0fc-422e-b6d0-8c37b384eac6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ZanganehNoteMember_44dee35c-89f3-4d9d-aec6-426f2389fb92" xlink:href="smmt-20231231.xsd#smmt_ZanganehNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_14b1962d-3fc3-4f56-97aa-fe28b6d1c88c" xlink:to="loc_smmt_ZanganehNoteMember_44dee35c-89f3-4d9d-aec6-426f2389fb92" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_18bb5f01-503b-4209-86ea-01995057063e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_815618d9-e950-4669-9ee6-9b51660477d6" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_18bb5f01-503b-4209-86ea-01995057063e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_18bb5f01-503b-4209-86ea-01995057063e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_18bb5f01-503b-4209-86ea-01995057063e" xlink:to="loc_us-gaap_RelatedPartyDomain_18bb5f01-503b-4209-86ea-01995057063e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ff36d1e5-b20e-4448-a51f-b95cc7b56e84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_18bb5f01-503b-4209-86ea-01995057063e" xlink:to="loc_us-gaap_RelatedPartyDomain_ff36d1e5-b20e-4448-a51f-b95cc7b56e84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember_877e29de-0aea-4b61-80a5-01e4031d6461" xlink:href="smmt-20231231.xsd#smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_ff36d1e5-b20e-4448-a51f-b95cc7b56e84" xlink:to="loc_smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember_877e29de-0aea-4b61-80a5-01e4031d6461" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_1df728b5-00f7-416b-87af-4086aaccbe9d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember_877e29de-0aea-4b61-80a5-01e4031d6461" xlink:to="loc_srt_ChiefExecutiveOfficerMember_1df728b5-00f7-416b-87af-4086aaccbe9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ChiefExecutiveOfficerAndPresidentMember_139143ba-5e60-4dd0-9b46-fa4c78e4df46" xlink:href="smmt-20231231.xsd#smmt_ChiefExecutiveOfficerAndPresidentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember_877e29de-0aea-4b61-80a5-01e4031d6461" xlink:to="loc_smmt_ChiefExecutiveOfficerAndPresidentMember_139143ba-5e60-4dd0-9b46-fa4c78e4df46" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_d9c085fe-ff51-413b-b59d-c15a7b773e28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_ff36d1e5-b20e-4448-a51f-b95cc7b56e84" xlink:to="loc_us-gaap_RelatedPartyMember_d9c085fe-ff51-413b-b59d-c15a7b773e28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefOperatingOfficerMember_3cce8e57-d52c-4807-80be-ca5382a50142" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefOperatingOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_ff36d1e5-b20e-4448-a51f-b95cc7b56e84" xlink:to="loc_srt_ChiefOperatingOfficerMember_3cce8e57-d52c-4807-80be-ca5382a50142" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4be9303f-c0a1-4f31-85a9-1baa505a2575" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_815618d9-e950-4669-9ee6-9b51660477d6" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4be9303f-c0a1-4f31-85a9-1baa505a2575" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4be9303f-c0a1-4f31-85a9-1baa505a2575_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4be9303f-c0a1-4f31-85a9-1baa505a2575" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4be9303f-c0a1-4f31-85a9-1baa505a2575_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7e1908dd-225f-4741-ba4d-035bea08c917" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4be9303f-c0a1-4f31-85a9-1baa505a2575" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7e1908dd-225f-4741-ba4d-035bea08c917" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RightsOfferingMember_0d01ac95-fdf7-40b1-900a-6b2bcfd9c81d" xlink:href="smmt-20231231.xsd#smmt_RightsOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7e1908dd-225f-4741-ba4d-035bea08c917" xlink:to="loc_smmt_RightsOfferingMember_0d01ac95-fdf7-40b1-900a-6b2bcfd9c81d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_S3RegistrationStatementMember_f1f8e307-770f-4fe5-a98f-7779e99678c6" xlink:href="smmt-20231231.xsd#smmt_S3RegistrationStatementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7e1908dd-225f-4741-ba4d-035bea08c917" xlink:to="loc_smmt_S3RegistrationStatementMember_f1f8e307-770f-4fe5-a98f-7779e99678c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_57b0369c-1195-49fb-9371-43e5377fa1c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7e1908dd-225f-4741-ba4d-035bea08c917" xlink:to="loc_us-gaap_PrivatePlacementMember_57b0369c-1195-49fb-9371-43e5377fa1c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_527ff7aa-7081-4a34-9419-2e9bb1c4117e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_815618d9-e950-4669-9ee6-9b51660477d6" xlink:to="loc_us-gaap_PlanNameAxis_527ff7aa-7081-4a34-9419-2e9bb1c4117e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_527ff7aa-7081-4a34-9419-2e9bb1c4117e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_527ff7aa-7081-4a34-9419-2e9bb1c4117e" xlink:to="loc_us-gaap_PlanNameDomain_527ff7aa-7081-4a34-9419-2e9bb1c4117e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7de05ece-43e6-48a2-a286-2f6529c00bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_527ff7aa-7081-4a34-9419-2e9bb1c4117e" xlink:to="loc_us-gaap_PlanNameDomain_7de05ece-43e6-48a2-a286-2f6529c00bdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_A2020StockIncentivePlanMember_9f087a87-7e08-40b5-974f-e70428755bf6" xlink:href="smmt-20231231.xsd#smmt_A2020StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7de05ece-43e6-48a2-a286-2f6529c00bdf" xlink:to="loc_smmt_A2020StockIncentivePlanMember_9f087a87-7e08-40b5-974f-e70428755bf6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3038f1f0-fd1e-4c49-b6e7-4fdf07f88dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_815618d9-e950-4669-9ee6-9b51660477d6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3038f1f0-fd1e-4c49-b6e7-4fdf07f88dd9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3038f1f0-fd1e-4c49-b6e7-4fdf07f88dd9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3038f1f0-fd1e-4c49-b6e7-4fdf07f88dd9" xlink:to="loc_us-gaap_EquityComponentDomain_3038f1f0-fd1e-4c49-b6e7-4fdf07f88dd9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e85539ff-aed1-4726-8308-b8d08eb3c80e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3038f1f0-fd1e-4c49-b6e7-4fdf07f88dd9" xlink:to="loc_us-gaap_EquityComponentDomain_e85539ff-aed1-4726-8308-b8d08eb3c80e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_33d597eb-890b-480f-ba82-b72fdde68633" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e85539ff-aed1-4726-8308-b8d08eb3c80e" xlink:to="loc_us-gaap_CommonStockMember_33d597eb-890b-480f-ba82-b72fdde68633" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2114163c-1e6f-4eb0-a513-cae371944834" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_815618d9-e950-4669-9ee6-9b51660477d6" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2114163c-1e6f-4eb0-a513-cae371944834" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2114163c-1e6f-4eb0-a513-cae371944834_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2114163c-1e6f-4eb0-a513-cae371944834" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2114163c-1e6f-4eb0-a513-cae371944834_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6c619ad2-9d06-4da5-8bdd-739043040e35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2114163c-1e6f-4eb0-a513-cae371944834" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6c619ad2-9d06-4da5-8bdd-739043040e35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_29c0d69b-0f3d-4c69-9b73-7df8e98987ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6c619ad2-9d06-4da5-8bdd-739043040e35" xlink:to="loc_us-gaap_SubsequentEventMember_29c0d69b-0f3d-4c69-9b73-7df8e98987ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_56149fea-151b-45c6-b059-af9e98671794" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_815618d9-e950-4669-9ee6-9b51660477d6" xlink:to="loc_us-gaap_VariableRateAxis_56149fea-151b-45c6-b059-af9e98671794" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_56149fea-151b-45c6-b059-af9e98671794_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_56149fea-151b-45c6-b059-af9e98671794" xlink:to="loc_us-gaap_VariableRateDomain_56149fea-151b-45c6-b059-af9e98671794_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_f7908ef7-ac3d-4470-b6a2-4dae28592884" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_56149fea-151b-45c6-b059-af9e98671794" xlink:to="loc_us-gaap_VariableRateDomain_f7908ef7-ac3d-4470-b6a2-4dae28592884" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_f8f6727d-b030-42c6-a46d-80fa4647c6d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_f7908ef7-ac3d-4470-b6a2-4dae28592884" xlink:to="loc_us-gaap_PrimeRateMember_f8f6727d-b030-42c6-a46d-80fa4647c6d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_6ec49c44-b6d3-4ee2-a779-9337d9a543f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_186c04e3-a9b3-4266-92d3-193c976ed8cb" xlink:to="loc_us-gaap_NotesPayable_6ec49c44-b6d3-4ee2-a779-9337d9a543f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CommonStockSharesAuthorizedIncreaseDecrease_63370ae1-0fd2-4548-b86e-17a34d51a83c" xlink:href="smmt-20231231.xsd#smmt_CommonStockSharesAuthorizedIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_186c04e3-a9b3-4266-92d3-193c976ed8cb" xlink:to="loc_smmt_CommonStockSharesAuthorizedIncreaseDecrease_63370ae1-0fd2-4548-b86e-17a34d51a83c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_28de5812-9b78-46db-b84d-61943afc5868" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_186c04e3-a9b3-4266-92d3-193c976ed8cb" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_28de5812-9b78-46db-b84d-61943afc5868" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8988199d-a345-4511-99af-4a3bce5bdcad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_186c04e3-a9b3-4266-92d3-193c976ed8cb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8988199d-a345-4511-99af-4a3bce5bdcad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f8769f92-8129-4142-9aa5-3e23e4bf0319" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_186c04e3-a9b3-4266-92d3-193c976ed8cb" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f8769f92-8129-4142-9aa5-3e23e4bf0319" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_bb28e3dd-02ae-43af-8caa-2b97ccc77d02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_186c04e3-a9b3-4266-92d3-193c976ed8cb" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_bb28e3dd-02ae-43af-8caa-2b97ccc77d02" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_5e560bf3-e4a2-49ef-942c-4f8179fbeeca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_186c04e3-a9b3-4266-92d3-193c976ed8cb" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_5e560bf3-e4a2-49ef-942c-4f8179fbeeca" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_f6631746-e6e3-46e1-9eca-d7935cdb27ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_186c04e3-a9b3-4266-92d3-193c976ed8cb" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_f6631746-e6e3-46e1-9eca-d7935cdb27ae" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_e250ba00-94fd-4a4e-bcf5-f0096dde86cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_186c04e3-a9b3-4266-92d3-193c976ed8cb" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_e250ba00-94fd-4a4e-bcf5-f0096dde86cf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_SaleOfStockNumberOfSharesRegisteredForResale_449d069f-37eb-4ef2-a1c2-a78d9da4209e" xlink:href="smmt-20231231.xsd#smmt_SaleOfStockNumberOfSharesRegisteredForResale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_186c04e3-a9b3-4266-92d3-193c976ed8cb" xlink:to="loc_smmt_SaleOfStockNumberOfSharesRegisteredForResale_449d069f-37eb-4ef2-a1c2-a78d9da4209e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_d280ec54-bd71-443e-b97f-0125f8ba84ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_186c04e3-a9b3-4266-92d3-193c976ed8cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_d280ec54-bd71-443e-b97f-0125f8ba84ea" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_956b7867-b6bc-49b5-a1df-c31d15e417de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_186c04e3-a9b3-4266-92d3-193c976ed8cb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_956b7867-b6bc-49b5-a1df-c31d15e417de" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionRate_c90b9a5a-7ed9-43a7-8d04-66d1186d7cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_186c04e3-a9b3-4266-92d3-193c976ed8cb" xlink:to="loc_us-gaap_RelatedPartyTransactionRate_c90b9a5a-7ed9-43a7-8d04-66d1186d7cbe" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_4661ef47-a655-4ddb-811c-02f1b5e18778" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_186c04e3-a9b3-4266-92d3-193c976ed8cb" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_4661ef47-a655-4ddb-811c-02f1b5e18778" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_smmt_SignificantAccountingPoliciesLineItems_709852bf-e90d-49b4-bf25-5aa7fd015600" xlink:href="smmt-20231231.xsd#smmt_SignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_SignificantAccountingPoliciesTable_a8011364-509b-47ab-b163-5a0c55136dec" xlink:href="smmt-20231231.xsd#smmt_SignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_smmt_SignificantAccountingPoliciesLineItems_709852bf-e90d-49b4-bf25-5aa7fd015600" xlink:to="loc_smmt_SignificantAccountingPoliciesTable_a8011364-509b-47ab-b163-5a0c55136dec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_321603f6-32f3-4800-97ca-034d975e22e0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_smmt_SignificantAccountingPoliciesTable_a8011364-509b-47ab-b163-5a0c55136dec" xlink:to="loc_srt_RangeAxis_321603f6-32f3-4800-97ca-034d975e22e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_321603f6-32f3-4800-97ca-034d975e22e0_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_321603f6-32f3-4800-97ca-034d975e22e0" xlink:to="loc_srt_RangeMember_321603f6-32f3-4800-97ca-034d975e22e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_24349d05-e01b-4770-b1f9-e2e716d20788" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_321603f6-32f3-4800-97ca-034d975e22e0" xlink:to="loc_srt_RangeMember_24349d05-e01b-4770-b1f9-e2e716d20788" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d6e9977e-8570-4df4-b983-b9d6021b1ca2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_24349d05-e01b-4770-b1f9-e2e716d20788" xlink:to="loc_srt_MinimumMember_d6e9977e-8570-4df4-b983-b9d6021b1ca2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_989c318d-5d6d-44fb-9d54-9ed26354e114" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_24349d05-e01b-4770-b1f9-e2e716d20788" xlink:to="loc_srt_MaximumMember_989c318d-5d6d-44fb-9d54-9ed26354e114" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fd8f7aa6-c14d-4994-953e-ac96a60de8e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_smmt_SignificantAccountingPoliciesTable_a8011364-509b-47ab-b163-5a0c55136dec" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fd8f7aa6-c14d-4994-953e-ac96a60de8e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fd8f7aa6-c14d-4994-953e-ac96a60de8e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fd8f7aa6-c14d-4994-953e-ac96a60de8e8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fd8f7aa6-c14d-4994-953e-ac96a60de8e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0682fe8f-4c63-4b6f-92f6-dabcbd554834" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fd8f7aa6-c14d-4994-953e-ac96a60de8e8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0682fe8f-4c63-4b6f-92f6-dabcbd554834" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_LaboratoryEquipmentMember_45808603-c317-4639-9a42-524903176f04" xlink:href="smmt-20231231.xsd#smmt_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0682fe8f-4c63-4b6f-92f6-dabcbd554834" xlink:to="loc_smmt_LaboratoryEquipmentMember_45808603-c317-4639-9a42-524903176f04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember_76e4fae9-24fd-419d-b8e4-792f2be996dd" xlink:href="smmt-20231231.xsd#smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0682fe8f-4c63-4b6f-92f6-dabcbd554834" xlink:to="loc_smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember_76e4fae9-24fd-419d-b8e4-792f2be996dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_ad85ad36-ff02-4529-87ae-e5c06b03eb70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0682fe8f-4c63-4b6f-92f6-dabcbd554834" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_ad85ad36-ff02-4529-87ae-e5c06b03eb70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_701c4dc8-ca6d-4931-b0fa-2f08c4932008" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_smmt_SignificantAccountingPoliciesTable_a8011364-509b-47ab-b163-5a0c55136dec" xlink:to="loc_us-gaap_TypeOfArrangementAxis_701c4dc8-ca6d-4931-b0fa-2f08c4932008" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_701c4dc8-ca6d-4931-b0fa-2f08c4932008_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_701c4dc8-ca6d-4931-b0fa-2f08c4932008" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_701c4dc8-ca6d-4931-b0fa-2f08c4932008_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_545700db-4ad6-4ae8-a94c-5db6da6a7f19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_701c4dc8-ca6d-4931-b0fa-2f08c4932008" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_545700db-4ad6-4ae8-a94c-5db6da6a7f19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentOneMember_6d8888c1-9bfc-4855-9d37-92a35e8002a0" xlink:href="smmt-20231231.xsd#smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_545700db-4ad6-4ae8-a94c-5db6da6a7f19" xlink:to="loc_smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentOneMember_6d8888c1-9bfc-4855-9d37-92a35e8002a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_0f7d98b0-34fa-4227-a936-d0801566fe5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_smmt_SignificantAccountingPoliciesTable_a8011364-509b-47ab-b163-5a0c55136dec" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_0f7d98b0-34fa-4227-a936-d0801566fe5a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_0f7d98b0-34fa-4227-a936-d0801566fe5a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_0f7d98b0-34fa-4227-a936-d0801566fe5a" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_0f7d98b0-34fa-4227-a936-d0801566fe5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1709c330-4f06-4ab2-b9b6-8e03ce345401" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_0f7d98b0-34fa-4227-a936-d0801566fe5a" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1709c330-4f06-4ab2-b9b6-8e03ce345401" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_4e208856-70b9-4519-8666-bfddba45020f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1709c330-4f06-4ab2-b9b6-8e03ce345401" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_4e208856-70b9-4519-8666-bfddba45020f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_00b25fa1-4b77-4f7e-8498-9a868a39a103" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_smmt_SignificantAccountingPoliciesLineItems_709852bf-e90d-49b4-bf25-5aa7fd015600" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_00b25fa1-4b77-4f7e-8498-9a868a39a103" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_9337eb37-1ae9-4a88-a774-b283e83d6227" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_smmt_SignificantAccountingPoliciesLineItems_709852bf-e90d-49b4-bf25-5aa7fd015600" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_9337eb37-1ae9-4a88-a774-b283e83d6227" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_888cf6fb-ab24-4a1b-b63f-f6e7497de8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_smmt_SignificantAccountingPoliciesLineItems_709852bf-e90d-49b4-bf25-5aa7fd015600" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_888cf6fb-ab24-4a1b-b63f-f6e7497de8a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_52c5f81c-ec4e-4621-8f9a-efe7b1085346" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_smmt_SignificantAccountingPoliciesLineItems_709852bf-e90d-49b4-bf25-5aa7fd015600" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_52c5f81c-ec4e-4621-8f9a-efe7b1085346" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_f20ed06d-6fb0-45fb-9011-379477082b49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_smmt_SignificantAccountingPoliciesLineItems_709852bf-e90d-49b4-bf25-5aa7fd015600" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_f20ed06d-6fb0-45fb-9011-379477082b49" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_a2dffdad-ab51-46a8-8aea-6a988c308b03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_smmt_SignificantAccountingPoliciesLineItems_709852bf-e90d-49b4-bf25-5aa7fd015600" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_a2dffdad-ab51-46a8-8aea-6a988c308b03" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_fe1e1556-6999-4c5f-9841-18977cb50a39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_smmt_SignificantAccountingPoliciesLineItems_709852bf-e90d-49b4-bf25-5aa7fd015600" xlink:to="loc_us-gaap_RestrictedCashCurrent_fe1e1556-6999-4c5f-9841-18977cb50a39" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentSharesOfCommonStockIssuedInLieuOfCash_b5ac8bab-9a26-4cac-b79b-8c91d32d9dec" xlink:href="smmt-20231231.xsd#smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentSharesOfCommonStockIssuedInLieuOfCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_smmt_SignificantAccountingPoliciesLineItems_709852bf-e90d-49b4-bf25-5aa7fd015600" xlink:to="loc_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentSharesOfCommonStockIssuedInLieuOfCash_b5ac8bab-9a26-4cac-b79b-8c91d32d9dec" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CashPaymentForCollaborativeArrangementUpfrontPayment_3544fa40-0c32-4205-b6e1-57f1d1332c81" xlink:href="smmt-20231231.xsd#smmt_CashPaymentForCollaborativeArrangementUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_smmt_SignificantAccountingPoliciesLineItems_709852bf-e90d-49b4-bf25-5aa7fd015600" xlink:to="loc_smmt_CashPaymentForCollaborativeArrangementUpfrontPayment_3544fa40-0c32-4205-b6e1-57f1d1332c81" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_BusinessCombinationAssumedContingentLiabilityMeasurementInput_c5d273f7-6de1-4bf6-a188-be9942216ee8" xlink:href="smmt-20231231.xsd#smmt_BusinessCombinationAssumedContingentLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_smmt_SignificantAccountingPoliciesLineItems_709852bf-e90d-49b4-bf25-5aa7fd015600" xlink:to="loc_smmt_BusinessCombinationAssumedContingentLiabilityMeasurementInput_c5d273f7-6de1-4bf6-a188-be9942216ee8" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/AkesoLicenseandCollaborationAgreementDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#AkesoLicenseandCollaborationAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/AkesoLicenseandCollaborationAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_188ef3bc-5fa0-47b4-aae4-f193c72aa21f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39d0af37-9f2c-4350-b8bf-53388844163e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_188ef3bc-5fa0-47b4-aae4-f193c72aa21f" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39d0af37-9f2c-4350-b8bf-53388844163e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c91b6aa7-451f-4f96-b03a-19c8e5547de1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39d0af37-9f2c-4350-b8bf-53388844163e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c91b6aa7-451f-4f96-b03a-19c8e5547de1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c91b6aa7-451f-4f96-b03a-19c8e5547de1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c91b6aa7-451f-4f96-b03a-19c8e5547de1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c91b6aa7-451f-4f96-b03a-19c8e5547de1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b7316939-b663-4437-b59f-7682dc965b55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c91b6aa7-451f-4f96-b03a-19c8e5547de1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b7316939-b663-4437-b59f-7682dc965b55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_9fd0b8a5-0e93-4a4e-9f57-0291fd25c8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b7316939-b663-4437-b59f-7682dc965b55" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_9fd0b8a5-0e93-4a4e-9f57-0291fd25c8a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentOneMember_c57b3a8d-e608-49be-b6ed-72c1bc26c9d9" xlink:href="smmt-20231231.xsd#smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_9fd0b8a5-0e93-4a4e-9f57-0291fd25c8a8" xlink:to="loc_smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentOneMember_c57b3a8d-e608-49be-b6ed-72c1bc26c9d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentTwoMember_a9efa6c8-8e77-403d-a469-89d160e9b758" xlink:href="smmt-20231231.xsd#smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_9fd0b8a5-0e93-4a4e-9f57-0291fd25c8a8" xlink:to="loc_smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentTwoMember_a9efa6c8-8e77-403d-a469-89d160e9b758" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPayment_dcbab8f5-eb71-48df-a16d-4cca906b8f13" xlink:href="smmt-20231231.xsd#smmt_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_188ef3bc-5fa0-47b4-aae4-f193c72aa21f" xlink:to="loc_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPayment_dcbab8f5-eb71-48df-a16d-4cca906b8f13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CashPaymentForCollaborativeArrangementUpfrontPayment_38c34051-f979-491f-8d91-769c161f60e4" xlink:href="smmt-20231231.xsd#smmt_CashPaymentForCollaborativeArrangementUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_188ef3bc-5fa0-47b4-aae4-f193c72aa21f" xlink:to="loc_smmt_CashPaymentForCollaborativeArrangementUpfrontPayment_38c34051-f979-491f-8d91-769c161f60e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentSharesOfCommonStockIssuedInLieuOfCash_f3787da7-156a-45bc-ba06-34cae7eafcb0" xlink:href="smmt-20231231.xsd#smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentSharesOfCommonStockIssuedInLieuOfCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_188ef3bc-5fa0-47b4-aae4-f193c72aa21f" xlink:to="loc_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentSharesOfCommonStockIssuedInLieuOfCash_f3787da7-156a-45bc-ba06-34cae7eafcb0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentPaidInShares_335e052e-7b40-4cce-9303-93d50e73a1ba" xlink:href="smmt-20231231.xsd#smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentPaidInShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_188ef3bc-5fa0-47b4-aae4-f193c72aa21f" xlink:to="loc_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentPaidInShares_335e052e-7b40-4cce-9303-93d50e73a1ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_InProcessResearchAndDevelopmentExpense_d9368b87-1681-467b-be68-5d0ba74214e2" xlink:href="smmt-20231231.xsd#smmt_InProcessResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_188ef3bc-5fa0-47b4-aae4-f193c72aa21f" xlink:to="loc_smmt_InProcessResearchAndDevelopmentExpense_d9368b87-1681-467b-be68-5d0ba74214e2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement_b1d6f269-33c2-41aa-80b2-774c2583c875" xlink:href="smmt-20231231.xsd#smmt_StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_188ef3bc-5fa0-47b4-aae4-f193c72aa21f" xlink:to="loc_smmt_StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement_b1d6f269-33c2-41aa-80b2-774c2583c875" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CollaborativeArrangementRightsAndObligationsDirectTransactionCosts_c1059b77-688e-4178-872e-61c40773a805" xlink:href="smmt-20231231.xsd#smmt_CollaborativeArrangementRightsAndObligationsDirectTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_188ef3bc-5fa0-47b4-aae4-f193c72aa21f" xlink:to="loc_smmt_CollaborativeArrangementRightsAndObligationsDirectTransactionCosts_c1059b77-688e-4178-872e-61c40773a805" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments_0a7cebae-f80a-4b29-8635-9aadbca150b2" xlink:href="smmt-20231231.xsd#smmt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_188ef3bc-5fa0-47b4-aae4-f193c72aa21f" xlink:to="loc_smmt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments_0a7cebae-f80a-4b29-8635-9aadbca150b2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CollaborativeArrangementRightsAndObligationsPotentialRegulatoryMilestonePayments_13d62f6b-29e6-4d5f-ae56-690e8fd2cd8c" xlink:href="smmt-20231231.xsd#smmt_CollaborativeArrangementRightsAndObligationsPotentialRegulatoryMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_188ef3bc-5fa0-47b4-aae4-f193c72aa21f" xlink:to="loc_smmt_CollaborativeArrangementRightsAndObligationsPotentialRegulatoryMilestonePayments_13d62f6b-29e6-4d5f-ae56-690e8fd2cd8c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CollaborativeArrangementRightsAndObligationsPotentialCommercialMilestonePayments_3b102cc0-bc03-43d9-bfc2-59b7e87d4240" xlink:href="smmt-20231231.xsd#smmt_CollaborativeArrangementRightsAndObligationsPotentialCommercialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_188ef3bc-5fa0-47b4-aae4-f193c72aa21f" xlink:to="loc_smmt_CollaborativeArrangementRightsAndObligationsPotentialCommercialMilestonePayments_3b102cc0-bc03-43d9-bfc2-59b7e87d4240" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/SegmentReportingLonglivedassetsbygeographyDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#SegmentReportingLonglivedassetsbygeographyDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/SegmentReportingLonglivedassetsbygeographyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_2e86e170-e2af-43d3-984d-17e9752939c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_47933b64-ec09-4565-adf1-cdfc4fc248f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_2e86e170-e2af-43d3-984d-17e9752939c3" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_47933b64-ec09-4565-adf1-cdfc4fc248f6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_fe16d230-28d9-486b-b99b-2c81157615aa" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_47933b64-ec09-4565-adf1-cdfc4fc248f6" xlink:to="loc_srt_StatementGeographicalAxis_fe16d230-28d9-486b-b99b-2c81157615aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_fe16d230-28d9-486b-b99b-2c81157615aa_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_fe16d230-28d9-486b-b99b-2c81157615aa" xlink:to="loc_srt_SegmentGeographicalDomain_fe16d230-28d9-486b-b99b-2c81157615aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_891223d0-0fb8-4142-879b-ebe0c9ac4ceb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_fe16d230-28d9-486b-b99b-2c81157615aa" xlink:to="loc_srt_SegmentGeographicalDomain_891223d0-0fb8-4142-879b-ebe0c9ac4ceb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_47e5d7d4-e9c3-4bd2-9099-f9e1028e51f2" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_891223d0-0fb8-4142-879b-ebe0c9ac4ceb" xlink:to="loc_country_GB_47e5d7d4-e9c3-4bd2-9099-f9e1028e51f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_1211bdc6-619e-4660-8bb2-f8468d643bea" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_891223d0-0fb8-4142-879b-ebe0c9ac4ceb" xlink:to="loc_country_US_1211bdc6-619e-4660-8bb2-f8468d643bea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_e3c077fa-a924-4c7c-87e4-89c1cd8cd55a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_2e86e170-e2af-43d3-984d-17e9752939c3" xlink:to="loc_us-gaap_NoncurrentAssets_e3c077fa-a924-4c7c-87e4-89c1cd8cd55a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/OtherOperatingIncomenetSummarybycategoryDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#OtherOperatingIncomenetSummarybycategoryDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/OtherOperatingIncomenetSummarybycategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_89874462-861a-4d2c-bf98-d654f90cbda5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_200a79ff-e7c4-4033-bcbc-bb0ff4265f71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_89874462-861a-4d2c-bf98-d654f90cbda5" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_200a79ff-e7c4-4033-bcbc-bb0ff4265f71" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_76f593a4-920c-4117-9ad9-9663d3839060" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_200a79ff-e7c4-4033-bcbc-bb0ff4265f71" xlink:to="loc_srt_CounterpartyNameAxis_76f593a4-920c-4117-9ad9-9663d3839060" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_76f593a4-920c-4117-9ad9-9663d3839060_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_76f593a4-920c-4117-9ad9-9663d3839060" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_76f593a4-920c-4117-9ad9-9663d3839060_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0bf2314a-ed21-4948-b487-97b95848d246" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_76f593a4-920c-4117-9ad9-9663d3839060" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0bf2314a-ed21-4948-b487-97b95848d246" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_8205074c-2347-4ad4-9592-bd3f436739f9" xlink:href="smmt-20231231.xsd#smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0bf2314a-ed21-4948-b487-97b95848d246" xlink:to="loc_smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_8205074c-2347-4ad4-9592-bd3f436739f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember_0aa2b5c7-3ffa-4ab6-8bbe-01183b45f7cd" xlink:href="smmt-20231231.xsd#smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0bf2314a-ed21-4948-b487-97b95848d246" xlink:to="loc_smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember_0aa2b5c7-3ffa-4ab6-8bbe-01183b45f7cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GrantFundingArrangementIncomeEarned_02c5f3bb-21a1-40fb-a82a-6cc7a029990a" xlink:href="smmt-20231231.xsd#smmt_GrantFundingArrangementIncomeEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_89874462-861a-4d2c-bf98-d654f90cbda5" xlink:to="loc_smmt_GrantFundingArrangementIncomeEarned_02c5f3bb-21a1-40fb-a82a-6cc7a029990a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ResearchAndDevelopmentTaxCredit_c919edc0-aac2-4d82-acb6-2647b8de3a16" xlink:href="smmt-20231231.xsd#smmt_ResearchAndDevelopmentTaxCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_89874462-861a-4d2c-bf98-d654f90cbda5" xlink:to="loc_smmt_ResearchAndDevelopmentTaxCredit_c919edc0-aac2-4d82-acb6-2647b8de3a16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_OtherOperatingIncomeOther_fee24314-1c47-480f-b28f-4ddc26c6f39a" xlink:href="smmt-20231231.xsd#smmt_OtherOperatingIncomeOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_89874462-861a-4d2c-bf98-d654f90cbda5" xlink:to="loc_smmt_OtherOperatingIncomeOther_fee24314-1c47-480f-b28f-4ddc26c6f39a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome_5f39163b-6a77-4248-891d-bed735cb81eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_89874462-861a-4d2c-bf98-d654f90cbda5" xlink:to="loc_us-gaap_OtherOperatingIncome_5f39163b-6a77-4248-891d-bed735cb81eb" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/OtherOperatingIncomenetNarrativeDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#OtherOperatingIncomenetNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/OtherOperatingIncomenetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ac5592c3-6540-486e-85a8-bac5c5fbd642" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_14924cd2-ae55-44be-aae2-7669de4adf4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ac5592c3-6540-486e-85a8-bac5c5fbd642" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_14924cd2-ae55-44be-aae2-7669de4adf4d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ad428fdc-0f3f-4dee-9725-9b7e2976655a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_14924cd2-ae55-44be-aae2-7669de4adf4d" xlink:to="loc_srt_CounterpartyNameAxis_ad428fdc-0f3f-4dee-9725-9b7e2976655a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ad428fdc-0f3f-4dee-9725-9b7e2976655a_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_ad428fdc-0f3f-4dee-9725-9b7e2976655a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ad428fdc-0f3f-4dee-9725-9b7e2976655a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6568af55-ea07-4afe-b983-68268b2b8b08" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_ad428fdc-0f3f-4dee-9725-9b7e2976655a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6568af55-ea07-4afe-b983-68268b2b8b08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_6fbf092b-c983-45fc-9000-6dac07d2fe59" xlink:href="smmt-20231231.xsd#smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6568af55-ea07-4afe-b983-68268b2b8b08" xlink:to="loc_smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_6fbf092b-c983-45fc-9000-6dac07d2fe59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember_a2b1a64d-7b5d-4bfc-9a3d-b32e8fd9386e" xlink:href="smmt-20231231.xsd#smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6568af55-ea07-4afe-b983-68268b2b8b08" xlink:to="loc_smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember_a2b1a64d-7b5d-4bfc-9a3d-b32e8fd9386e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GrantFundingArrangementMaximumFundingValue_af502976-a395-4f46-adb1-9e90621ce3d0" xlink:href="smmt-20231231.xsd#smmt_GrantFundingArrangementMaximumFundingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ac5592c3-6540-486e-85a8-bac5c5fbd642" xlink:to="loc_smmt_GrantFundingArrangementMaximumFundingValue_af502976-a395-4f46-adb1-9e90621ce3d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GrantFundingArrangementCommittedFundingTotal_98439e49-6a98-44ec-abb8-9b7a184d7cb1" xlink:href="smmt-20231231.xsd#smmt_GrantFundingArrangementCommittedFundingTotal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ac5592c3-6540-486e-85a8-bac5c5fbd642" xlink:to="loc_smmt_GrantFundingArrangementCommittedFundingTotal_98439e49-6a98-44ec-abb8-9b7a184d7cb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GrantFundingArrangementIncomeEarned_f8ccd8bc-9092-43f0-8c2d-73ce72f14478" xlink:href="smmt-20231231.xsd#smmt_GrantFundingArrangementIncomeEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ac5592c3-6540-486e-85a8-bac5c5fbd642" xlink:to="loc_smmt_GrantFundingArrangementIncomeEarned_f8ccd8bc-9092-43f0-8c2d-73ce72f14478" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ResearchAndDevelopmentTaxCreditReceivable_8f8f5a35-5ef1-4165-802d-01a991dabe60" xlink:href="smmt-20231231.xsd#smmt_ResearchAndDevelopmentTaxCreditReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ac5592c3-6540-486e-85a8-bac5c5fbd642" xlink:to="loc_smmt_ResearchAndDevelopmentTaxCreditReceivable_8f8f5a35-5ef1-4165-802d-01a991dabe60" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GrantFundingArrangementMilestoneFundingIncrease_df112d18-7212-4c25-873d-00b9ea07fa9e" xlink:href="smmt-20231231.xsd#smmt_GrantFundingArrangementMilestoneFundingIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ac5592c3-6540-486e-85a8-bac5c5fbd642" xlink:to="loc_smmt_GrantFundingArrangementMilestoneFundingIncrease_df112d18-7212-4c25-873d-00b9ea07fa9e" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/IncomeTaxNarrativeDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#IncomeTaxNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/IncomeTaxNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_73eb83ef-c97b-44b5-8830-b4c4d9e9a301" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_26091416-ab25-453d-9104-b4c430d20856" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_73eb83ef-c97b-44b5-8830-b4c4d9e9a301" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_26091416-ab25-453d-9104-b4c430d20856" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_31837be2-6ab4-4ef3-8a32-913c45b606f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_26091416-ab25-453d-9104-b4c430d20856" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_31837be2-6ab4-4ef3-8a32-913c45b606f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_31837be2-6ab4-4ef3-8a32-913c45b606f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_31837be2-6ab4-4ef3-8a32-913c45b606f2" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_31837be2-6ab4-4ef3-8a32-913c45b606f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_d877d4ae-b86a-46f3-b10f-815d8c0d1804" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_31837be2-6ab4-4ef3-8a32-913c45b606f2" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_d877d4ae-b86a-46f3-b10f-815d8c0d1804" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_7306c45a-5740-45e0-b169-d574846222ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d877d4ae-b86a-46f3-b10f-815d8c0d1804" xlink:to="loc_us-gaap_DomesticCountryMember_7306c45a-5740-45e0-b169-d574846222ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_69a07cb5-9f3c-4875-a1e2-9286f00c10d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d877d4ae-b86a-46f3-b10f-815d8c0d1804" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_69a07cb5-9f3c-4875-a1e2-9286f00c10d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_d1c43320-411b-4460-9927-f1751f5b1191" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d877d4ae-b86a-46f3-b10f-815d8c0d1804" xlink:to="loc_us-gaap_ForeignCountryMember_d1c43320-411b-4460-9927-f1751f5b1191" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_e0790235-20b9-4444-906c-cee256d6c45b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_73eb83ef-c97b-44b5-8830-b4c4d9e9a301" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_e0790235-20b9-4444-906c-cee256d6c45b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_70de2312-7c13-45fb-b589-a470a339c9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_73eb83ef-c97b-44b5-8830-b4c4d9e9a301" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_70de2312-7c13-45fb-b589-a470a339c9ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_bc3d8d78-2fef-4ece-8ec5-492933f74ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_73eb83ef-c97b-44b5-8830-b4c4d9e9a301" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_bc3d8d78-2fef-4ece-8ec5-492933f74ffb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_c05f7204-f899-4efe-b537-e42e3c3cefa9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_73eb83ef-c97b-44b5-8830-b4c4d9e9a301" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_c05f7204-f899-4efe-b537-e42e3c3cefa9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1c8934d6-752a-41d1-a8cf-0dd11535b452" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_73eb83ef-c97b-44b5-8830-b4c4d9e9a301" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1c8934d6-752a-41d1-a8cf-0dd11535b452" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_807cecec-c089-49e2-b8c4-ac3a8c7922b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_73eb83ef-c97b-44b5-8830-b4c4d9e9a301" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_807cecec-c089-49e2-b8c4-ac3a8c7922b6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_c1efdb8a-b2dd-44e2-b96d-328bbed11a36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_73eb83ef-c97b-44b5-8830-b4c4d9e9a301" xlink:to="loc_us-gaap_OperatingLossCarryforwards_c1efdb8a-b2dd-44e2-b96d-328bbed11a36" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_22100a30-cd70-493f-b6c2-6b23922fc178" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_73eb83ef-c97b-44b5-8830-b4c4d9e9a301" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_22100a30-cd70-493f-b6c2-6b23922fc178" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ResearchAndDevelopmentExpenseCapitalizedAmount_4b080562-8213-4342-9c2d-b346228ab9f9" xlink:href="smmt-20231231.xsd#smmt_ResearchAndDevelopmentExpenseCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_73eb83ef-c97b-44b5-8830-b4c4d9e9a301" xlink:to="loc_smmt_ResearchAndDevelopmentExpenseCapitalizedAmount_4b080562-8213-4342-9c2d-b346228ab9f9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ResearchAndDevelopmentExpenseAmortizableAmount_243aa51d-65ea-4fa4-bd93-eb3ea984d595" xlink:href="smmt-20231231.xsd#smmt_ResearchAndDevelopmentExpenseAmortizableAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_73eb83ef-c97b-44b5-8830-b4c4d9e9a301" xlink:to="loc_smmt_ResearchAndDevelopmentExpenseAmortizableAmount_243aa51d-65ea-4fa4-bd93-eb3ea984d595" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ResearchAndDevelopmentTaxCredit_582dd37b-ace6-4d75-b6b7-1315474b5acf" xlink:href="smmt-20231231.xsd#smmt_ResearchAndDevelopmentTaxCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_73eb83ef-c97b-44b5-8830-b4c4d9e9a301" xlink:to="loc_smmt_ResearchAndDevelopmentTaxCredit_582dd37b-ace6-4d75-b6b7-1315474b5acf" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_19e9a5a4-465f-4f45-b724-be1eb5295be4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_73eb83ef-c97b-44b5-8830-b4c4d9e9a301" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_19e9a5a4-465f-4f45-b724-be1eb5295be4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_1028e976-412f-44d1-b07a-aa8789615d98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_73eb83ef-c97b-44b5-8830-b4c4d9e9a301" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_1028e976-412f-44d1-b07a-aa8789615d98" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/NetLossperShareNarrativeDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#NetLossperShareNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/NetLossperShareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_789ed010-34de-444b-b492-934eef426ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_3d5d6221-2ff9-464d-9110-8f29a58dbcca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_789ed010-34de-444b-b492-934eef426ba8" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_3d5d6221-2ff9-464d-9110-8f29a58dbcca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ee39fe93-4ae7-417b-9ada-26f144059ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_3d5d6221-2ff9-464d-9110-8f29a58dbcca" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ee39fe93-4ae7-417b-9ada-26f144059ea9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ee39fe93-4ae7-417b-9ada-26f144059ea9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ee39fe93-4ae7-417b-9ada-26f144059ea9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ee39fe93-4ae7-417b-9ada-26f144059ea9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_58630e3a-dadf-4b53-afd7-82bfd2df54fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ee39fe93-4ae7-417b-9ada-26f144059ea9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_58630e3a-dadf-4b53-afd7-82bfd2df54fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RightsOfferingMember_c58eb4c6-3074-4569-9d94-0e539e288ea2" xlink:href="smmt-20231231.xsd#smmt_RightsOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_58630e3a-dadf-4b53-afd7-82bfd2df54fa" xlink:to="loc_smmt_RightsOfferingMember_c58eb4c6-3074-4569-9d94-0e539e288ea2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_c7ed9a56-4119-42a2-882c-4c134c60c530" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_789ed010-34de-444b-b492-934eef426ba8" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_c7ed9a56-4119-42a2-882c-4c134c60c530" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_491166a9-475a-4fc1-a9f8-a805f7baa057" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_789ed010-34de-444b-b492-934eef426ba8" xlink:to="loc_us-gaap_SharePrice_491166a9-475a-4fc1-a9f8-a805f7baa057" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/NetLossperSharePotentiallydilutivesecuritiesexcludedfromthecomputationoflosspershareDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#NetLossperSharePotentiallydilutivesecuritiesexcludedfromthecomputationoflosspershareDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/NetLossperSharePotentiallydilutivesecuritiesexcludedfromthecomputationoflosspershareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e437ee8c-0a5d-44ad-988d-c4671808e4ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e63b3981-7584-4bbd-b72b-18a6b120e335" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e437ee8c-0a5d-44ad-988d-c4671808e4ca" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e63b3981-7584-4bbd-b72b-18a6b120e335" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d62bd617-5d04-4c58-a779-095d097ae83d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e63b3981-7584-4bbd-b72b-18a6b120e335" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d62bd617-5d04-4c58-a779-095d097ae83d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d62bd617-5d04-4c58-a779-095d097ae83d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d62bd617-5d04-4c58-a779-095d097ae83d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d62bd617-5d04-4c58-a779-095d097ae83d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0b7c65db-c6b7-4c24-9346-3f8d1764007e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d62bd617-5d04-4c58-a779-095d097ae83d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0b7c65db-c6b7-4c24-9346-3f8d1764007e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_be43683b-e2f1-43b4-8e74-2e1fb62d2ded" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0b7c65db-c6b7-4c24-9346-3f8d1764007e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_be43683b-e2f1-43b4-8e74-2e1fb62d2ded" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_8a617ce1-597b-40fc-88de-1025fd51b639" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0b7c65db-c6b7-4c24-9346-3f8d1764007e" xlink:to="loc_us-gaap_WarrantMember_8a617ce1-597b-40fc-88de-1025fd51b639" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_1e052cd2-7771-4851-b03d-5a3476bba2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0b7c65db-c6b7-4c24-9346-3f8d1764007e" xlink:to="loc_us-gaap_EmployeeStockMember_1e052cd2-7771-4851-b03d-5a3476bba2c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_819e7634-10c9-4e2a-b03e-61052f417095" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e437ee8c-0a5d-44ad-988d-c4671808e4ca" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_819e7634-10c9-4e2a-b03e-61052f417095" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_098cb1b9-aa65-486d-ab54-a32b959dbd32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_066cec70-5cca-4e1f-a8b9-f6b6c4d60de3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_098cb1b9-aa65-486d-ab54-a32b959dbd32" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_066cec70-5cca-4e1f-a8b9-f6b6c4d60de3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a1e66928-2050-40a4-804b-d48b76eed5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_066cec70-5cca-4e1f-a8b9-f6b6c4d60de3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a1e66928-2050-40a4-804b-d48b76eed5d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a1e66928-2050-40a4-804b-d48b76eed5d4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a1e66928-2050-40a4-804b-d48b76eed5d4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a1e66928-2050-40a4-804b-d48b76eed5d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a33a7e87-c192-4cd8-88df-a308266c24fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a1e66928-2050-40a4-804b-d48b76eed5d4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a33a7e87-c192-4cd8-88df-a308266c24fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_fed51be3-0966-496d-9ccd-a57a3673503c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a33a7e87-c192-4cd8-88df-a308266c24fe" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_fed51be3-0966-496d-9ccd-a57a3673503c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_OptionOverNonFinancialAssetsMember_ffe3052f-d003-41a9-8428-aeeeadb56942" xlink:href="smmt-20231231.xsd#smmt_OptionOverNonFinancialAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a33a7e87-c192-4cd8-88df-a308266c24fe" xlink:to="loc_smmt_OptionOverNonFinancialAssetsMember_ffe3052f-d003-41a9-8428-aeeeadb56942" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_OtherPatentsAndLicensesMember_71d3cdb5-66f8-442f-85d4-85eb84a44e8a" xlink:href="smmt-20231231.xsd#smmt_OtherPatentsAndLicensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a33a7e87-c192-4cd8-88df-a308266c24fe" xlink:to="loc_smmt_OtherPatentsAndLicensesMember_71d3cdb5-66f8-442f-85d4-85eb84a44e8a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bbc57b48-8881-4012-9b41-d82ac569ce7a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_066cec70-5cca-4e1f-a8b9-f6b6c4d60de3" xlink:to="loc_srt_ProductOrServiceAxis_bbc57b48-8881-4012-9b41-d82ac569ce7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bbc57b48-8881-4012-9b41-d82ac569ce7a_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_bbc57b48-8881-4012-9b41-d82ac569ce7a" xlink:to="loc_srt_ProductsAndServicesDomain_bbc57b48-8881-4012-9b41-d82ac569ce7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_27c12d8a-267d-4909-b75c-ea40c0569452" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_bbc57b48-8881-4012-9b41-d82ac569ce7a" xlink:to="loc_srt_ProductsAndServicesDomain_27c12d8a-267d-4909-b75c-ea40c0569452" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_UtrophinProgramMember_6f3f8ce1-08b5-446e-8f46-cd355bc5f780" xlink:href="smmt-20231231.xsd#smmt_UtrophinProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_27c12d8a-267d-4909-b75c-ea40c0569452" xlink:to="loc_smmt_UtrophinProgramMember_6f3f8ce1-08b5-446e-8f46-cd355bc5f780" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DiscuvaPlatformMember_6f9ffad1-d11a-4cf3-aaec-9f74682f192e" xlink:href="smmt-20231231.xsd#smmt_DiscuvaPlatformMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_27c12d8a-267d-4909-b75c-ea40c0569452" xlink:to="loc_smmt_DiscuvaPlatformMember_6f9ffad1-d11a-4cf3-aaec-9f74682f192e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_fe841d28-ca51-4455-88e9-887345b3ca5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_098cb1b9-aa65-486d-ab54-a32b959dbd32" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_fe841d28-ca51-4455-88e9-887345b3ca5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment_02f905bf-8353-40bb-9dea-6a9521cc197b" xlink:href="smmt-20231231.xsd#smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_098cb1b9-aa65-486d-ab54-a32b959dbd32" xlink:to="loc_smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment_02f905bf-8353-40bb-9dea-6a9521cc197b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a997d11e-caa7-4b34-8ea8-9f350f65e105" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_098cb1b9-aa65-486d-ab54-a32b959dbd32" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a997d11e-caa7-4b34-8ea8-9f350f65e105" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_7d87e759-c0f4-4d56-b499-a34d676c2517" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_098cb1b9-aa65-486d-ab54-a32b959dbd32" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_7d87e759-c0f4-4d56-b499-a34d676c2517" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_98c08ff5-d21e-4170-ab09-d8eef729d656" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_098cb1b9-aa65-486d-ab54-a32b959dbd32" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_98c08ff5-d21e-4170-ab09-d8eef729d656" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e7e95c31-1a84-47b6-beaf-d22f5d5c975d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4aeb9ea3-9d36-40c1-bb50-a9b2f2110175" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e7e95c31-1a84-47b6-beaf-d22f5d5c975d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4aeb9ea3-9d36-40c1-bb50-a9b2f2110175" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_220fcff9-4d83-4a26-bdd2-e2c32bdecfc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4aeb9ea3-9d36-40c1-bb50-a9b2f2110175" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_220fcff9-4d83-4a26-bdd2-e2c32bdecfc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_220fcff9-4d83-4a26-bdd2-e2c32bdecfc5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_220fcff9-4d83-4a26-bdd2-e2c32bdecfc5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_220fcff9-4d83-4a26-bdd2-e2c32bdecfc5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dd73615f-6973-45a9-9866-aaf35ba4a26c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_220fcff9-4d83-4a26-bdd2-e2c32bdecfc5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dd73615f-6973-45a9-9866-aaf35ba4a26c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_dfc8527a-5348-4039-9e82-74c83dbdead8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dd73615f-6973-45a9-9866-aaf35ba4a26c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_dfc8527a-5348-4039-9e82-74c83dbdead8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2d4111b9-b45a-4ffd-9ec8-33c036c040cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dd73615f-6973-45a9-9866-aaf35ba4a26c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2d4111b9-b45a-4ffd-9ec8-33c036c040cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_66be36cc-1a70-48f4-a155-4f70884488cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dd73615f-6973-45a9-9866-aaf35ba4a26c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_66be36cc-1a70-48f4-a155-4f70884488cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_daf2a33f-e0d9-4caa-acc3-5d8e8674509c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4aeb9ea3-9d36-40c1-bb50-a9b2f2110175" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_daf2a33f-e0d9-4caa-acc3-5d8e8674509c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_daf2a33f-e0d9-4caa-acc3-5d8e8674509c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_daf2a33f-e0d9-4caa-acc3-5d8e8674509c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_daf2a33f-e0d9-4caa-acc3-5d8e8674509c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_756157ed-3efe-45b2-979e-77d84719b6f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_daf2a33f-e0d9-4caa-acc3-5d8e8674509c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_756157ed-3efe-45b2-979e-77d84719b6f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_ec152bed-9eae-41ba-9533-495e0a20ba35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_756157ed-3efe-45b2-979e-77d84719b6f0" xlink:to="loc_us-gaap_MoneyMarketFundsMember_ec152bed-9eae-41ba-9533-495e0a20ba35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_de49863a-6490-43c7-9ec9-0ad31b344700" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_756157ed-3efe-45b2-979e-77d84719b6f0" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_de49863a-6490-43c7-9ec9-0ad31b344700" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_36e53633-4389-424f-8068-d9051128619e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4aeb9ea3-9d36-40c1-bb50-a9b2f2110175" xlink:to="loc_us-gaap_FinancialInstrumentAxis_36e53633-4389-424f-8068-d9051128619e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_36e53633-4389-424f-8068-d9051128619e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_36e53633-4389-424f-8068-d9051128619e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_36e53633-4389-424f-8068-d9051128619e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2b54ec52-16a0-4f06-89c1-5e966fc0befe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_36e53633-4389-424f-8068-d9051128619e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2b54ec52-16a0-4f06-89c1-5e966fc0befe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_80798b48-d12e-4a66-8b65-fcebaa0f29b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2b54ec52-16a0-4f06-89c1-5e966fc0befe" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_80798b48-d12e-4a66-8b65-fcebaa0f29b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CashEquivalentsFairValueDisclosure_2098d95c-fdff-4340-a310-ccdb12ba0714" xlink:href="smmt-20231231.xsd#smmt_CashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e7e95c31-1a84-47b6-beaf-d22f5d5c975d" xlink:to="loc_smmt_CashEquivalentsFairValueDisclosure_2098d95c-fdff-4340-a310-ccdb12ba0714" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_a5166186-7dab-4358-8440-2fdb44df781f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e7e95c31-1a84-47b6-beaf-d22f5d5c975d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_a5166186-7dab-4358-8440-2fdb44df781f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_ab9558d0-808b-41b2-b175-b0b83de80f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e7e95c31-1a84-47b6-beaf-d22f5d5c975d" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_ab9558d0-808b-41b2-b175-b0b83de80f6a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsShortterminvestmentswithcontractualmaturityoflessthanonyearDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#FairValueMeasurementsandShortTermInvestmentsShortterminvestmentswithcontractualmaturityoflessthanonyearDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsShortterminvestmentswithcontractualmaturityoflessthanonyearDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_baeaa320-c842-4282-bb15-625940bbe1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_e3da910c-361a-4f9a-a6ee-3ad5fbcf8321" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_baeaa320-c842-4282-bb15-625940bbe1d2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_e3da910c-361a-4f9a-a6ee-3ad5fbcf8321" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b67b9177-6178-4ab4-946d-db89ef990f48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_e3da910c-361a-4f9a-a6ee-3ad5fbcf8321" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b67b9177-6178-4ab4-946d-db89ef990f48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b67b9177-6178-4ab4-946d-db89ef990f48_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b67b9177-6178-4ab4-946d-db89ef990f48" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b67b9177-6178-4ab4-946d-db89ef990f48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ba2f6667-55dd-4e67-8554-33aa0ba6a6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b67b9177-6178-4ab4-946d-db89ef990f48" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ba2f6667-55dd-4e67-8554-33aa0ba6a6c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_912cae4e-1a57-45b6-901a-b4eb0619cb8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ba2f6667-55dd-4e67-8554-33aa0ba6a6c6" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_912cae4e-1a57-45b6-901a-b4eb0619cb8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_556e6f56-88fa-45c9-94b7-2750328157db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_baeaa320-c842-4282-bb15-625940bbe1d2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_556e6f56-88fa-45c9-94b7-2750328157db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_445866e2-c730-477b-b24f-aef3388f6702" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_baeaa320-c842-4282-bb15-625940bbe1d2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_445866e2-c730-477b-b24f-aef3388f6702" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0ccc9b6a-14ac-4afc-aab2-283cd93226c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_baeaa320-c842-4282-bb15-625940bbe1d2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0ccc9b6a-14ac-4afc-aab2-283cd93226c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_69ec64b9-434d-4649-8215-23d1f3755346" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_baeaa320-c842-4282-bb15-625940bbe1d2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_69ec64b9-434d-4649-8215-23d1f3755346" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_9a9ff9c1-defb-4388-812b-8654777fb602" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_baeaa320-c842-4282-bb15-625940bbe1d2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_9a9ff9c1-defb-4388-812b-8654777fb602" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#PropertyandEquipmentComponentsofpropertyandequipmentDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3498ab0e-17a2-4c6d-8993-104180e2ce97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_246a198b-fe36-4710-8b27-93d60c3ce2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3498ab0e-17a2-4c6d-8993-104180e2ce97" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_246a198b-fe36-4710-8b27-93d60c3ce2e0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0035822a-560f-4e7d-a686-870ed4e6a70b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_246a198b-fe36-4710-8b27-93d60c3ce2e0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0035822a-560f-4e7d-a686-870ed4e6a70b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0035822a-560f-4e7d-a686-870ed4e6a70b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0035822a-560f-4e7d-a686-870ed4e6a70b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0035822a-560f-4e7d-a686-870ed4e6a70b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d1098bd5-c9b0-4cb8-81fe-e5d71bf4b70b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0035822a-560f-4e7d-a686-870ed4e6a70b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d1098bd5-c9b0-4cb8-81fe-e5d71bf4b70b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_LaboratoryEquipmentMember_f91b27fa-62cd-4ce6-89ed-63011848ad78" xlink:href="smmt-20231231.xsd#smmt_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d1098bd5-c9b0-4cb8-81fe-e5d71bf4b70b" xlink:to="loc_smmt_LaboratoryEquipmentMember_f91b27fa-62cd-4ce6-89ed-63011848ad78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember_2159d552-89ac-453a-9a84-a1c94e539ac9" xlink:href="smmt-20231231.xsd#smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d1098bd5-c9b0-4cb8-81fe-e5d71bf4b70b" xlink:to="loc_smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember_2159d552-89ac-453a-9a84-a1c94e539ac9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_2b5f6176-4e1a-4b50-a4bb-5360f0b7ff12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d1098bd5-c9b0-4cb8-81fe-e5d71bf4b70b" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_2b5f6176-4e1a-4b50-a4bb-5360f0b7ff12" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_66526b3f-eef6-454c-85f3-40a7c294f77e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3498ab0e-17a2-4c6d-8993-104180e2ce97" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_66526b3f-eef6-454c-85f3-40a7c294f77e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_29c99d70-0499-42ae-93d9-a5bd57cea15b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3498ab0e-17a2-4c6d-8993-104180e2ce97" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_29c99d70-0499-42ae-93d9-a5bd57cea15b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_49cda640-925b-4cc1-807f-908de278a7ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3498ab0e-17a2-4c6d-8993-104180e2ce97" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_49cda640-925b-4cc1-807f-908de278a7ab" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_71f92e3f-f825-4466-bb1b-1454596147cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_285e2ecc-22c8-4aa4-ad85-44c0da5c2bce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_71f92e3f-f825-4466-bb1b-1454596147cc" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_285e2ecc-22c8-4aa4-ad85-44c0da5c2bce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_f99375b7-48dc-41af-a13b-63c5517f97fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_285e2ecc-22c8-4aa4-ad85-44c0da5c2bce" xlink:to="loc_us-gaap_LeaseContractualTermAxis_f99375b7-48dc-41af-a13b-63c5517f97fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_f99375b7-48dc-41af-a13b-63c5517f97fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_f99375b7-48dc-41af-a13b-63c5517f97fc" xlink:to="loc_us-gaap_LeaseContractualTermDomain_f99375b7-48dc-41af-a13b-63c5517f97fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_5548749f-6e80-49bb-b6f4-1a7bc5a8abd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_f99375b7-48dc-41af-a13b-63c5517f97fc" xlink:to="loc_us-gaap_LeaseContractualTermDomain_5548749f-6e80-49bb-b6f4-1a7bc5a8abd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_MenloParkCaliforniaExpirationMay2026Member_85d68fa0-2206-42f3-a093-9409921db8b1" xlink:href="smmt-20231231.xsd#smmt_MenloParkCaliforniaExpirationMay2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_5548749f-6e80-49bb-b6f4-1a7bc5a8abd5" xlink:to="loc_smmt_MenloParkCaliforniaExpirationMay2026Member_85d68fa0-2206-42f3-a093-9409921db8b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CambridgeUKLaboratoryAndOfficeSpaceMember_2686b604-6743-49ac-a291-0aa2fe64aeff" xlink:href="smmt-20231231.xsd#smmt_CambridgeUKLaboratoryAndOfficeSpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_5548749f-6e80-49bb-b6f4-1a7bc5a8abd5" xlink:to="loc_smmt_CambridgeUKLaboratoryAndOfficeSpaceMember_2686b604-6743-49ac-a291-0aa2fe64aeff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b61425e0-f996-4a0e-b090-fbfe072f3dce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_285e2ecc-22c8-4aa4-ad85-44c0da5c2bce" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b61425e0-f996-4a0e-b090-fbfe072f3dce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b61425e0-f996-4a0e-b090-fbfe072f3dce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b61425e0-f996-4a0e-b090-fbfe072f3dce" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b61425e0-f996-4a0e-b090-fbfe072f3dce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a9193067-0263-496b-8f49-6000b7e09f11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b61425e0-f996-4a0e-b090-fbfe072f3dce" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a9193067-0263-496b-8f49-6000b7e09f11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_9d6965fb-416c-4e98-aadd-02cad34e53fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a9193067-0263-496b-8f49-6000b7e09f11" xlink:to="loc_us-gaap_SubsequentEventMember_9d6965fb-416c-4e98-aadd-02cad34e53fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_e640a69e-1e94-4089-8dbd-ed5680e76348" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_71f92e3f-f825-4466-bb1b-1454596147cc" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_e640a69e-1e94-4089-8dbd-ed5680e76348" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_eae14c33-b3ba-4836-833f-ff91742a97e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_71f92e3f-f825-4466-bb1b-1454596147cc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_eae14c33-b3ba-4836-833f-ff91742a97e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_bf78f117-1a81-4f8a-82fd-f1993350e944" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_71f92e3f-f825-4466-bb1b-1454596147cc" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_bf78f117-1a81-4f8a-82fd-f1993350e944" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_OperatingLeaseRightOfUseAssetDisposals_233d6ae0-064a-4a73-b771-1144bff2fdd4" xlink:href="smmt-20231231.xsd#smmt_OperatingLeaseRightOfUseAssetDisposals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_71f92e3f-f825-4466-bb1b-1454596147cc" xlink:to="loc_smmt_OperatingLeaseRightOfUseAssetDisposals_233d6ae0-064a-4a73-b771-1144bff2fdd4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_3acb6f64-0fc2-4ed7-9107-ae1747c5115e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_71f92e3f-f825-4466-bb1b-1454596147cc" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_3acb6f64-0fc2-4ed7-9107-ae1747c5115e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7a8c4e01-3072-4f40-8a8f-cf2e7f46f737" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_71f92e3f-f825-4466-bb1b-1454596147cc" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7a8c4e01-3072-4f40-8a8f-cf2e7f46f737" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_e3bf2b67-c058-4320-bae0-7bb7020d58ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_71f92e3f-f825-4466-bb1b-1454596147cc" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_e3bf2b67-c058-4320-bae0-7bb7020d58ff" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8948d72d-2084-491a-b5c7-18d5711ae207" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_71f92e3f-f825-4466-bb1b-1454596147cc" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8948d72d-2084-491a-b5c7-18d5711ae207" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_dd8477be-e700-4298-ba50-59b00be25291" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_71f92e3f-f825-4466-bb1b-1454596147cc" xlink:to="loc_us-gaap_OperatingLeasePayments_dd8477be-e700-4298-ba50-59b00be25291" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_LesseeOperatingLeaseAreaOfPremisesLeased_4f3ee932-276c-43df-8d3a-7f9bb73743df" xlink:href="smmt-20231231.xsd#smmt_LesseeOperatingLeaseAreaOfPremisesLeased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_71f92e3f-f825-4466-bb1b-1454596147cc" xlink:to="loc_smmt_LesseeOperatingLeaseAreaOfPremisesLeased_4f3ee932-276c-43df-8d3a-7f9bb73743df" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesSummaryofrelatedpartydebtDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#PromissoryNotesPayabletoRelatedPartiesSummaryofrelatedpartydebtDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesSummaryofrelatedpartydebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_ebe129f0-bcae-4098-8611-4a2f7561e055" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_605774f8-4d9f-4698-8f78-e98ecfa2b8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ebe129f0-bcae-4098-8611-4a2f7561e055" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_605774f8-4d9f-4698-8f78-e98ecfa2b8f0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_11678c64-ae66-4330-b7e3-40ad1a1e3b26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_605774f8-4d9f-4698-8f78-e98ecfa2b8f0" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_11678c64-ae66-4330-b7e3-40ad1a1e3b26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_11678c64-ae66-4330-b7e3-40ad1a1e3b26_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_11678c64-ae66-4330-b7e3-40ad1a1e3b26" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_11678c64-ae66-4330-b7e3-40ad1a1e3b26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_3d6281fd-3387-4af7-bc8d-8522a2a6852c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_11678c64-ae66-4330-b7e3-40ad1a1e3b26" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_3d6281fd-3387-4af7-bc8d-8522a2a6852c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_PromissoryNotesMember_7c1bb765-d99b-4807-aef1-75223d4e69b8" xlink:href="smmt-20231231.xsd#smmt_PromissoryNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_3d6281fd-3387-4af7-bc8d-8522a2a6852c" xlink:to="loc_smmt_PromissoryNotesMember_7c1bb765-d99b-4807-aef1-75223d4e69b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7159330e-7728-46c5-a221-115cfc15b608" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_605774f8-4d9f-4698-8f78-e98ecfa2b8f0" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7159330e-7728-46c5-a221-115cfc15b608" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7159330e-7728-46c5-a221-115cfc15b608_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7159330e-7728-46c5-a221-115cfc15b608" xlink:to="loc_us-gaap_RelatedPartyDomain_7159330e-7728-46c5-a221-115cfc15b608_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_624fac53-f2c0-4a9a-8b54-6f8b908572fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7159330e-7728-46c5-a221-115cfc15b608" xlink:to="loc_us-gaap_RelatedPartyDomain_624fac53-f2c0-4a9a-8b54-6f8b908572fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_9cc9b296-2d7a-43c0-8c6a-7c06ff47802f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_624fac53-f2c0-4a9a-8b54-6f8b908572fa" xlink:to="loc_us-gaap_RelatedPartyMember_9cc9b296-2d7a-43c0-8c6a-7c06ff47802f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrentAbstract_4a47ef90-f8af-4b7d-88b4-425ff8cea967" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ebe129f0-bcae-4098-8611-4a2f7561e055" xlink:to="loc_us-gaap_NotesPayableCurrentAbstract_4a47ef90-f8af-4b7d-88b4-425ff8cea967" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableGrossCurrent_37d4241a-e779-49a6-99d5-281226b12ae9" xlink:href="smmt-20231231.xsd#smmt_NotesPayableGrossCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NotesPayableCurrentAbstract_4a47ef90-f8af-4b7d-88b4-425ff8cea967" xlink:to="loc_smmt_NotesPayableGrossCurrent_37d4241a-e779-49a6-99d5-281226b12ae9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_9f4681c2-7563-43e3-970e-5794f80c67f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NotesPayableCurrentAbstract_4a47ef90-f8af-4b7d-88b4-425ff8cea967" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_9f4681c2-7563-43e3-970e-5794f80c67f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_81142700-9cf3-4679-9918-0641a05c9480" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NotesPayableCurrentAbstract_4a47ef90-f8af-4b7d-88b4-425ff8cea967" xlink:to="loc_us-gaap_NotesPayableCurrent_81142700-9cf3-4679-9918-0641a05c9480" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayableAbstract_51b66fa0-5b32-40b3-b31b-490d408c9e98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayableAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ebe129f0-bcae-4098-8611-4a2f7561e055" xlink:to="loc_us-gaap_LongTermNotesPayableAbstract_51b66fa0-5b32-40b3-b31b-490d408c9e98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableGrossNoncurrent_f661a070-b99a-4160-81c0-599f5b73346f" xlink:href="smmt-20231231.xsd#smmt_NotesPayableGrossNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermNotesPayableAbstract_51b66fa0-5b32-40b3-b31b-490d408c9e98" xlink:to="loc_smmt_NotesPayableGrossNoncurrent_f661a070-b99a-4160-81c0-599f5b73346f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_38e1ed67-e39a-4233-a755-9243328739e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermNotesPayableAbstract_51b66fa0-5b32-40b3-b31b-490d408c9e98" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_38e1ed67-e39a-4233-a755-9243328739e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_de024b75-7c7f-4265-ab66-128d4b5d88f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermNotesPayableAbstract_51b66fa0-5b32-40b3-b31b-490d408c9e98" xlink:to="loc_us-gaap_LongTermNotesPayable_de024b75-7c7f-4265-ab66-128d4b5d88f4" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#PromissoryNotesPayabletoRelatedPartiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_cb64dcc7-ccdb-4022-9f3f-586ab7a98792" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_cb64dcc7-ccdb-4022-9f3f-586ab7a98792" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_2cc298a3-b59e-46cd-8a84-9c75da7e18bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_cb64dcc7-ccdb-4022-9f3f-586ab7a98792" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_2cc298a3-b59e-46cd-8a84-9c75da7e18bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_2cc298a3-b59e-46cd-8a84-9c75da7e18bf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_2cc298a3-b59e-46cd-8a84-9c75da7e18bf" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_2cc298a3-b59e-46cd-8a84-9c75da7e18bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_4abce440-f4a4-4468-9ff7-db37157edc5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_2cc298a3-b59e-46cd-8a84-9c75da7e18bf" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_4abce440-f4a4-4468-9ff7-db37157edc5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_March2022NoteMember_1d9f6fc5-397f-425b-b57a-a33e9fd4d8d3" xlink:href="smmt-20231231.xsd#smmt_March2022NoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_4abce440-f4a4-4468-9ff7-db37157edc5a" xlink:to="loc_smmt_March2022NoteMember_1d9f6fc5-397f-425b-b57a-a33e9fd4d8d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotePurchaseAgreementMember_579d4aeb-dc79-407f-aa91-e9df0f29df99" xlink:href="smmt-20231231.xsd#smmt_NotePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_4abce440-f4a4-4468-9ff7-db37157edc5a" xlink:to="loc_smmt_NotePurchaseAgreementMember_579d4aeb-dc79-407f-aa91-e9df0f29df99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DugganPromissoryNotesMember_e52efcc9-1a47-4478-b7fe-2f7ce0158741" xlink:href="smmt-20231231.xsd#smmt_DugganPromissoryNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_smmt_NotePurchaseAgreementMember_579d4aeb-dc79-407f-aa91-e9df0f29df99" xlink:to="loc_smmt_DugganPromissoryNotesMember_e52efcc9-1a47-4478-b7fe-2f7ce0158741" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DugganSeptemberNoteMember_96c0c169-80f9-497a-b8c1-1e06e7999a18" xlink:href="smmt-20231231.xsd#smmt_DugganSeptemberNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_smmt_DugganPromissoryNotesMember_e52efcc9-1a47-4478-b7fe-2f7ce0158741" xlink:to="loc_smmt_DugganSeptemberNoteMember_96c0c169-80f9-497a-b8c1-1e06e7999a18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DugganFebruaryNoteMember_29a9825d-0fa6-4a01-aa18-37e2891ddbd5" xlink:href="smmt-20231231.xsd#smmt_DugganFebruaryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_smmt_DugganPromissoryNotesMember_e52efcc9-1a47-4478-b7fe-2f7ce0158741" xlink:to="loc_smmt_DugganFebruaryNoteMember_29a9825d-0fa6-4a01-aa18-37e2891ddbd5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ZanganehNoteMember_d3dff11a-6137-4675-8dc1-cc02a376befb" xlink:href="smmt-20231231.xsd#smmt_ZanganehNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_smmt_NotePurchaseAgreementMember_579d4aeb-dc79-407f-aa91-e9df0f29df99" xlink:to="loc_smmt_ZanganehNoteMember_d3dff11a-6137-4675-8dc1-cc02a376befb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DugganFebruaryNoteAndZanganehNoteMember_d73fe862-f61a-472f-bd6d-a7240048eff9" xlink:href="smmt-20231231.xsd#smmt_DugganFebruaryNoteAndZanganehNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_smmt_NotePurchaseAgreementMember_579d4aeb-dc79-407f-aa91-e9df0f29df99" xlink:to="loc_smmt_DugganFebruaryNoteAndZanganehNoteMember_d73fe862-f61a-472f-bd6d-a7240048eff9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_PromissoryNotesMember_fde60138-f4d3-4a19-92dc-4976954c40cd" xlink:href="smmt-20231231.xsd#smmt_PromissoryNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_4abce440-f4a4-4468-9ff7-db37157edc5a" xlink:to="loc_smmt_PromissoryNotesMember_fde60138-f4d3-4a19-92dc-4976954c40cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_238bf51d-3748-49fb-9d2d-dd67d26bc99a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_cb64dcc7-ccdb-4022-9f3f-586ab7a98792" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_238bf51d-3748-49fb-9d2d-dd67d26bc99a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_238bf51d-3748-49fb-9d2d-dd67d26bc99a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_238bf51d-3748-49fb-9d2d-dd67d26bc99a" xlink:to="loc_us-gaap_RelatedPartyDomain_238bf51d-3748-49fb-9d2d-dd67d26bc99a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_4dded9d1-dda0-4bd4-82ac-f48bec0abec1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_238bf51d-3748-49fb-9d2d-dd67d26bc99a" xlink:to="loc_us-gaap_RelatedPartyDomain_4dded9d1-dda0-4bd4-82ac-f48bec0abec1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember_f13369df-ac05-4cbe-8f4b-8aaa5fe038be" xlink:href="smmt-20231231.xsd#smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_4dded9d1-dda0-4bd4-82ac-f48bec0abec1" xlink:to="loc_smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember_f13369df-ac05-4cbe-8f4b-8aaa5fe038be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_bcdbd984-7588-40b4-8827-09fe1740f477" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember_f13369df-ac05-4cbe-8f4b-8aaa5fe038be" xlink:to="loc_srt_ChiefExecutiveOfficerMember_bcdbd984-7588-40b4-8827-09fe1740f477" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ChiefExecutiveOfficerAndPresidentMember_88812e2f-f3d4-40c5-b879-49ff3d57b9be" xlink:href="smmt-20231231.xsd#smmt_ChiefExecutiveOfficerAndPresidentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember_f13369df-ac05-4cbe-8f4b-8aaa5fe038be" xlink:to="loc_smmt_ChiefExecutiveOfficerAndPresidentMember_88812e2f-f3d4-40c5-b879-49ff3d57b9be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_57fe9db1-100c-4c2e-9a47-6292f0c3c7b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_4dded9d1-dda0-4bd4-82ac-f48bec0abec1" xlink:to="loc_us-gaap_RelatedPartyMember_57fe9db1-100c-4c2e-9a47-6292f0c3c7b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_cec5c52c-f4b0-4304-9a32-00722cb64e04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_cb64dcc7-ccdb-4022-9f3f-586ab7a98792" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_cec5c52c-f4b0-4304-9a32-00722cb64e04" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cec5c52c-f4b0-4304-9a32-00722cb64e04_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_cec5c52c-f4b0-4304-9a32-00722cb64e04" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cec5c52c-f4b0-4304-9a32-00722cb64e04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7c12732d-d1e1-4dc2-b037-4e19d9b80d70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_cec5c52c-f4b0-4304-9a32-00722cb64e04" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7c12732d-d1e1-4dc2-b037-4e19d9b80d70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RightsOfferingMember_d5a83ff7-b184-4459-a38f-ff1c4c086c08" xlink:href="smmt-20231231.xsd#smmt_RightsOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7c12732d-d1e1-4dc2-b037-4e19d9b80d70" xlink:to="loc_smmt_RightsOfferingMember_d5a83ff7-b184-4459-a38f-ff1c4c086c08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_057309a2-b789-4e09-9f99-18d3bf2a3aab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_cb64dcc7-ccdb-4022-9f3f-586ab7a98792" xlink:to="loc_us-gaap_VariableRateAxis_057309a2-b789-4e09-9f99-18d3bf2a3aab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_057309a2-b789-4e09-9f99-18d3bf2a3aab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_057309a2-b789-4e09-9f99-18d3bf2a3aab" xlink:to="loc_us-gaap_VariableRateDomain_057309a2-b789-4e09-9f99-18d3bf2a3aab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_6344ea55-2958-4fa0-821b-bceb47589314" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_057309a2-b789-4e09-9f99-18d3bf2a3aab" xlink:to="loc_us-gaap_VariableRateDomain_6344ea55-2958-4fa0-821b-bceb47589314" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_e6515228-0098-4a0c-a30d-c461f87321fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_6344ea55-2958-4fa0-821b-bceb47589314" xlink:to="loc_us-gaap_PrimeRateMember_e6515228-0098-4a0c-a30d-c461f87321fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_VariableRatePeriodAxis_e525adba-9d10-459d-8aeb-76be3a5a56e7" xlink:href="smmt-20231231.xsd#smmt_VariableRatePeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_cb64dcc7-ccdb-4022-9f3f-586ab7a98792" xlink:to="loc_smmt_VariableRatePeriodAxis_e525adba-9d10-459d-8aeb-76be3a5a56e7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_VariableRatePeriodDomain_e525adba-9d10-459d-8aeb-76be3a5a56e7_default" xlink:href="smmt-20231231.xsd#smmt_VariableRatePeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_smmt_VariableRatePeriodAxis_e525adba-9d10-459d-8aeb-76be3a5a56e7" xlink:to="loc_smmt_VariableRatePeriodDomain_e525adba-9d10-459d-8aeb-76be3a5a56e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_VariableRatePeriodDomain_b6cedcfb-9853-46e7-b17b-c0be8b2a83e7" xlink:href="smmt-20231231.xsd#smmt_VariableRatePeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_smmt_VariableRatePeriodAxis_e525adba-9d10-459d-8aeb-76be3a5a56e7" xlink:to="loc_smmt_VariableRatePeriodDomain_b6cedcfb-9853-46e7-b17b-c0be8b2a83e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_VariableRatePeriodOneMember_c80801bb-21df-437e-b0d1-bd23c60aeef1" xlink:href="smmt-20231231.xsd#smmt_VariableRatePeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_smmt_VariableRatePeriodDomain_b6cedcfb-9853-46e7-b17b-c0be8b2a83e7" xlink:to="loc_smmt_VariableRatePeriodOneMember_c80801bb-21df-437e-b0d1-bd23c60aeef1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_VariableRatePeriodTwoMember_277e1fde-a84a-41ac-8564-5be02dec914f" xlink:href="smmt-20231231.xsd#smmt_VariableRatePeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_smmt_VariableRatePeriodDomain_b6cedcfb-9853-46e7-b17b-c0be8b2a83e7" xlink:to="loc_smmt_VariableRatePeriodTwoMember_277e1fde-a84a-41ac-8564-5be02dec914f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_176874f6-4408-4a59-9a68-e96164b1e0b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_cb64dcc7-ccdb-4022-9f3f-586ab7a98792" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_176874f6-4408-4a59-9a68-e96164b1e0b9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_176874f6-4408-4a59-9a68-e96164b1e0b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_176874f6-4408-4a59-9a68-e96164b1e0b9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_176874f6-4408-4a59-9a68-e96164b1e0b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_589ef023-2550-471b-bf5f-8318e864e0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_176874f6-4408-4a59-9a68-e96164b1e0b9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_589ef023-2550-471b-bf5f-8318e864e0f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_34cb85bc-8c57-4566-9f6d-af8a1b07d8da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_589ef023-2550-471b-bf5f-8318e864e0f7" xlink:to="loc_us-gaap_SubsequentEventMember_34cb85bc-8c57-4566-9f6d-af8a1b07d8da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_4f098ee7-7433-4372-8819-cc4010cd69c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_4f098ee7-7433-4372-8819-cc4010cd69c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_de014bbf-9bf4-4005-b746-2b8496c13962" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_us-gaap_NotesPayable_de014bbf-9bf4-4005-b746-2b8496c13962" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold_89fe6c48-8d52-4821-a549-417d6ba84e82" xlink:href="smmt-20231231.xsd#smmt_NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_smmt_NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold_89fe6c48-8d52-4821-a549-417d6ba84e82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartiesMaximumTerm_ae6279ca-0409-4de3-8450-d88330c33621" xlink:href="smmt-20231231.xsd#smmt_NotesPayableRelatedPartiesMaximumTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_smmt_NotesPayableRelatedPartiesMaximumTerm_ae6279ca-0409-4de3-8450-d88330c33621" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_12eac5ee-5e92-4d64-a2e8-9f0541cf0f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_12eac5ee-5e92-4d64-a2e8-9f0541cf0f7d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_PaymentOfAccruedInterestToRelatedParties_bdce042b-9259-4212-8e13-55ba4b5ebb37" xlink:href="smmt-20231231.xsd#smmt_PaymentOfAccruedInterestToRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_smmt_PaymentOfAccruedInterestToRelatedParties_bdce042b-9259-4212-8e13-55ba4b5ebb37" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e1bf7925-34ef-4154-a001-d602a06af04d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e1bf7925-34ef-4154-a001-d602a06af04d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_26426a79-273f-426b-8805-9af2a642a695" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_us-gaap_InterestExpenseDebt_26426a79-273f-426b-8805-9af2a642a695" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_fc3acb62-bb23-4af3-b17e-b335b156caf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_fc3acb62-bb23-4af3-b17e-b335b156caf8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartiesPotentialPrepaymentPeriodPostReceiptOfCashProceedsFromPublicOffering_913f207e-e215-43cb-9607-7ce8285bde15" xlink:href="smmt-20231231.xsd#smmt_NotesPayableRelatedPartiesPotentialPrepaymentPeriodPostReceiptOfCashProceedsFromPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_smmt_NotesPayableRelatedPartiesPotentialPrepaymentPeriodPostReceiptOfCashProceedsFromPublicOffering_913f207e-e215-43cb-9607-7ce8285bde15" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartiesPotentialPrepaymentMaximumAmountPercentageOfNetProceedsFromPublicOffering_85b1d73f-103d-4fb0-81c8-f7737266be0c" xlink:href="smmt-20231231.xsd#smmt_NotesPayableRelatedPartiesPotentialPrepaymentMaximumAmountPercentageOfNetProceedsFromPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_smmt_NotesPayableRelatedPartiesPotentialPrepaymentMaximumAmountPercentageOfNetProceedsFromPublicOffering_85b1d73f-103d-4fb0-81c8-f7737266be0c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartiesNewIssuances_f92bead8-3835-4759-b95d-db80b9d2bd2a" xlink:href="smmt-20231231.xsd#smmt_NotesPayableRelatedPartiesNewIssuances"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_smmt_NotesPayableRelatedPartiesNewIssuances_f92bead8-3835-4759-b95d-db80b9d2bd2a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionRate_dbfe1cc9-a5b7-43bf-9c90-b0c186c5d495" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_us-gaap_RelatedPartyTransactionRate_dbfe1cc9-a5b7-43bf-9c90-b0c186c5d495" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_41590755-b322-475e-b5b2-ce54f5a98ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_41590755-b322-475e-b5b2-ce54f5a98ef9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominator_1e781e52-d452-4a6e-9a4c-d4641f6ca48d" xlink:href="smmt-20231231.xsd#smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominator"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominator_1e781e52-d452-4a6e-9a4c-d4641f6ca48d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominatorBaseAmountAddedToClosingBidPrice_b5813d2d-8530-4665-a150-a0b7a086404e" xlink:href="smmt-20231231.xsd#smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominatorBaseAmountAddedToClosingBidPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominatorBaseAmountAddedToClosingBidPrice_b5813d2d-8530-4665-a150-a0b7a086404e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_StockIssuedDuringPeriodSharesRelatedPartyPrepaidInterest_279d5667-2705-4a8c-90e7-260d0e45de74" xlink:href="smmt-20231231.xsd#smmt_StockIssuedDuringPeriodSharesRelatedPartyPrepaidInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_smmt_StockIssuedDuringPeriodSharesRelatedPartyPrepaidInterest_279d5667-2705-4a8c-90e7-260d0e45de74" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_f8d1dd87-e43c-45db-8d2f-9b74725ea4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_f8d1dd87-e43c-45db-8d2f-9b74725ea4ee" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_daeb8298-7991-4e6f-9e51-d72acdd6f624" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_daeb8298-7991-4e6f-9e51-d72acdd6f624" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_43ab2d42-3888-4fc2-a388-7db2357006ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_43ab2d42-3888-4fc2-a388-7db2357006ad" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_2ba77b02-8517-4a4d-a873-a0aedc9582b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_2ba77b02-8517-4a4d-a873-a0aedc9582b2" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_919e19f0-310b-4ed0-99ca-5aaf3b492a95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_us-gaap_LongTermNotesPayable_919e19f0-310b-4ed0-99ca-5aaf3b492a95" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_b868cd52-dc65-4f6d-81e2-b2d0993cba26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_b868cd52-dc65-4f6d-81e2-b2d0993cba26" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_8e111fdc-9df9-45de-bf09-38ca2b6e415e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_8e111fdc-9df9-45de-bf09-38ca2b6e415e" xlink:type="arc" order="23"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_fa937aa0-7421-469d-86df-f3498f2f971f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_43954884-e1bd-442e-be9c-6c4859a5a287" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fa937aa0-7421-469d-86df-f3498f2f971f" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_43954884-e1bd-442e-be9c-6c4859a5a287" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1ee962e3-ed4f-44cd-9002-58643ad18143" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_43954884-e1bd-442e-be9c-6c4859a5a287" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1ee962e3-ed4f-44cd-9002-58643ad18143" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1ee962e3-ed4f-44cd-9002-58643ad18143_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1ee962e3-ed4f-44cd-9002-58643ad18143" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1ee962e3-ed4f-44cd-9002-58643ad18143_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2e1265da-ffaa-4ba0-a8ce-280d7fbcee5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1ee962e3-ed4f-44cd-9002-58643ad18143" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2e1265da-ffaa-4ba0-a8ce-280d7fbcee5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RightsOfferingMember_d8afc25a-1ace-4942-9755-3ca347ca75d7" xlink:href="smmt-20231231.xsd#smmt_RightsOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2e1265da-ffaa-4ba0-a8ce-280d7fbcee5a" xlink:to="loc_smmt_RightsOfferingMember_d8afc25a-1ace-4942-9755-3ca347ca75d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_e78ccbec-2cdf-454a-bb1f-48072fed23d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2e1265da-ffaa-4ba0-a8ce-280d7fbcee5a" xlink:to="loc_us-gaap_PrivatePlacementMember_e78ccbec-2cdf-454a-bb1f-48072fed23d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_S3RegistrationStatementMember_e59f8f39-7987-44dd-8274-a7ad69c953c8" xlink:href="smmt-20231231.xsd#smmt_S3RegistrationStatementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2e1265da-ffaa-4ba0-a8ce-280d7fbcee5a" xlink:to="loc_smmt_S3RegistrationStatementMember_e59f8f39-7987-44dd-8274-a7ad69c953c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_4e6fa613-f2e7-4914-a91b-88a585e4dc7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_43954884-e1bd-442e-be9c-6c4859a5a287" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_4e6fa613-f2e7-4914-a91b-88a585e4dc7f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_4e6fa613-f2e7-4914-a91b-88a585e4dc7f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_4e6fa613-f2e7-4914-a91b-88a585e4dc7f" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_4e6fa613-f2e7-4914-a91b-88a585e4dc7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_961bd804-fea4-4494-8c85-a18fea4c0b09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_4e6fa613-f2e7-4914-a91b-88a585e4dc7f" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_961bd804-fea4-4494-8c85-a18fea4c0b09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DugganFebruaryNoteMember_f760645d-9678-44cf-b014-b7111f6f421e" xlink:href="smmt-20231231.xsd#smmt_DugganFebruaryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_961bd804-fea4-4494-8c85-a18fea4c0b09" xlink:to="loc_smmt_DugganFebruaryNoteMember_f760645d-9678-44cf-b014-b7111f6f421e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ConsultingAgreementMember_5a472057-d03d-47ae-bff3-1ec7f77e0399" xlink:href="smmt-20231231.xsd#smmt_ConsultingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_961bd804-fea4-4494-8c85-a18fea4c0b09" xlink:to="loc_smmt_ConsultingAgreementMember_5a472057-d03d-47ae-bff3-1ec7f77e0399" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fd72ba80-80c4-47aa-8efa-b7da7f65e649" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_43954884-e1bd-442e-be9c-6c4859a5a287" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fd72ba80-80c4-47aa-8efa-b7da7f65e649" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_fd72ba80-80c4-47aa-8efa-b7da7f65e649_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fd72ba80-80c4-47aa-8efa-b7da7f65e649" xlink:to="loc_us-gaap_RelatedPartyDomain_fd72ba80-80c4-47aa-8efa-b7da7f65e649_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_118320a0-12ed-4ce5-a6c4-194237943b23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fd72ba80-80c4-47aa-8efa-b7da7f65e649" xlink:to="loc_us-gaap_RelatedPartyDomain_118320a0-12ed-4ce5-a6c4-194237943b23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_7aaf2f79-fe2a-4d9a-ae6b-376805c1a977" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_118320a0-12ed-4ce5-a6c4-194237943b23" xlink:to="loc_srt_ChiefExecutiveOfficerMember_7aaf2f79-fe2a-4d9a-ae6b-376805c1a977" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_c61a0659-b0b0-46d0-86e5-a765f3359cca" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_118320a0-12ed-4ce5-a6c4-194237943b23" xlink:to="loc_srt_AffiliatedEntityMember_c61a0659-b0b0-46d0-86e5-a765f3359cca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_0a66bfc4-7130-4575-a427-d3f596cc5f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_118320a0-12ed-4ce5-a6c4-194237943b23" xlink:to="loc_us-gaap_RelatedPartyMember_0a66bfc4-7130-4575-a427-d3f596cc5f4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ChiefExecutiveOfficerAndPresidentMember_c8f96795-5547-4312-9073-69b898b7527c" xlink:href="smmt-20231231.xsd#smmt_ChiefExecutiveOfficerAndPresidentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_118320a0-12ed-4ce5-a6c4-194237943b23" xlink:to="loc_smmt_ChiefExecutiveOfficerAndPresidentMember_c8f96795-5547-4312-9073-69b898b7527c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefOperatingOfficerMember_f32eb2d9-d7a7-46cc-9af9-f0562f1060c1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefOperatingOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_118320a0-12ed-4ce5-a6c4-194237943b23" xlink:to="loc_srt_ChiefOperatingOfficerMember_f32eb2d9-d7a7-46cc-9af9-f0562f1060c1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0ea4ba14-4e6c-4374-9db5-983d4835ab41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_43954884-e1bd-442e-be9c-6c4859a5a287" xlink:to="loc_us-gaap_AwardTypeAxis_0ea4ba14-4e6c-4374-9db5-983d4835ab41" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ea4ba14-4e6c-4374-9db5-983d4835ab41_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0ea4ba14-4e6c-4374-9db5-983d4835ab41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ea4ba14-4e6c-4374-9db5-983d4835ab41_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a24c8c92-a595-4a62-ae6b-dd31e16dd9e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0ea4ba14-4e6c-4374-9db5-983d4835ab41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a24c8c92-a595-4a62-ae6b-dd31e16dd9e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_e630c691-e336-4728-af6f-5fcd44bf73cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a24c8c92-a595-4a62-ae6b-dd31e16dd9e2" xlink:to="loc_us-gaap_WarrantMember_e630c691-e336-4728-af6f-5fcd44bf73cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0d0772c5-6409-42b6-95a8-d2ce3aa416b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fa937aa0-7421-469d-86df-f3498f2f971f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0d0772c5-6409-42b6-95a8-d2ce3aa416b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2b4ea438-2186-4719-b5f2-4cb3601ee31f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fa937aa0-7421-469d-86df-f3498f2f971f" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2b4ea438-2186-4719-b5f2-4cb3601ee31f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_dbb5a908-12ed-44de-9e58-3b5fe30a970b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fa937aa0-7421-469d-86df-f3498f2f971f" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_dbb5a908-12ed-44de-9e58-3b5fe30a970b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_bb3e9c26-e457-44c9-afdc-0c03abd24808" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fa937aa0-7421-469d-86df-f3498f2f971f" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_bb3e9c26-e457-44c9-afdc-0c03abd24808" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_2f58c980-e702-4df9-9b01-3803eb88830d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fa937aa0-7421-469d-86df-f3498f2f971f" xlink:to="loc_us-gaap_StockIssued1_2f58c980-e702-4df9-9b01-3803eb88830d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_fa2cc620-692a-4690-bf0e-bf62dd4fd21e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fa937aa0-7421-469d-86df-f3498f2f971f" xlink:to="loc_us-gaap_NotesPayable_fa2cc620-692a-4690-bf0e-bf62dd4fd21e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CommonStockSharesAuthorizedIncreaseDecrease_78a36b2a-86c3-48f2-88e8-fefa849409cc" xlink:href="smmt-20231231.xsd#smmt_CommonStockSharesAuthorizedIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fa937aa0-7421-469d-86df-f3498f2f971f" xlink:to="loc_smmt_CommonStockSharesAuthorizedIncreaseDecrease_78a36b2a-86c3-48f2-88e8-fefa849409cc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_98ab315a-97fc-4ad3-ac3d-e0a408068af7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fa937aa0-7421-469d-86df-f3498f2f971f" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_98ab315a-97fc-4ad3-ac3d-e0a408068af7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_53462265-74af-43d7-8259-3d4a8557ff0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fa937aa0-7421-469d-86df-f3498f2f971f" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_53462265-74af-43d7-8259-3d4a8557ff0c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_SaleOfStockNumberOfSharesRegisteredForResale_f11a000d-bfa6-4004-bc07-f9e64ce12f1e" xlink:href="smmt-20231231.xsd#smmt_SaleOfStockNumberOfSharesRegisteredForResale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fa937aa0-7421-469d-86df-f3498f2f971f" xlink:to="loc_smmt_SaleOfStockNumberOfSharesRegisteredForResale_f11a000d-bfa6-4004-bc07-f9e64ce12f1e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_5a5f38c5-7ccc-456c-be47-8a624a953d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fa937aa0-7421-469d-86df-f3498f2f971f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_5a5f38c5-7ccc-456c-be47-8a624a953d9c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2b5087fc-8fb6-4f30-8eef-6506d1ef1745" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fa937aa0-7421-469d-86df-f3498f2f971f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2b5087fc-8fb6-4f30-8eef-6506d1ef1745" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_72606658-3a02-4c3b-a40f-f89f2183867e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fa937aa0-7421-469d-86df-f3498f2f971f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_72606658-3a02-4c3b-a40f-f89f2183867e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_8e78bb02-0000-445d-9eec-d463e3b0d9e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fa937aa0-7421-469d-86df-f3498f2f971f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_8e78bb02-0000-445d-9eec-d463e3b0d9e1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage_381f5c85-04dc-4099-a428-5b9709694fed" xlink:href="smmt-20231231.xsd#smmt_ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fa937aa0-7421-469d-86df-f3498f2f971f" xlink:to="loc_smmt_ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage_381f5c85-04dc-4099-a428-5b9709694fed" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod_cfea7576-27cc-4788-b114-6a67dc82b125" xlink:href="smmt-20231231.xsd#smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fa937aa0-7421-469d-86df-f3498f2f971f" xlink:to="loc_smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod_cfea7576-27cc-4788-b114-6a67dc82b125" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_7d2389ab-69cc-41f6-a204-44b31c91f4f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fa937aa0-7421-469d-86df-f3498f2f971f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_7d2389ab-69cc-41f6-a204-44b31c91f4f9" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6982b4e6-d99c-42cb-bfa2-17153deb7e51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fa937aa0-7421-469d-86df-f3498f2f971f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6982b4e6-d99c-42cb-bfa2-17153deb7e51" xlink:type="arc" order="17"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/StockholdersEquityWarrantactivityDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#StockholdersEquityWarrantactivityDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/StockholdersEquityWarrantactivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_28d9dc18-7a48-4dbc-9a18-5c2f4fa272dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_9ac6e456-af63-4060-b8e7-f7da7d1ed19c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_28d9dc18-7a48-4dbc-9a18-5c2f4fa272dc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_9ac6e456-af63-4060-b8e7-f7da7d1ed19c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9f9fdb2f-67d7-4d0d-a199-bc00bcbe62da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_9ac6e456-af63-4060-b8e7-f7da7d1ed19c" xlink:to="loc_us-gaap_AwardTypeAxis_9f9fdb2f-67d7-4d0d-a199-bc00bcbe62da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f9fdb2f-67d7-4d0d-a199-bc00bcbe62da_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9f9fdb2f-67d7-4d0d-a199-bc00bcbe62da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f9fdb2f-67d7-4d0d-a199-bc00bcbe62da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e1e35014-63a8-47f2-ad0e-c7d4fa8f6979" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9f9fdb2f-67d7-4d0d-a199-bc00bcbe62da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e1e35014-63a8-47f2-ad0e-c7d4fa8f6979" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_b1871e4e-370a-4cd9-afea-f44408e3b830" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e1e35014-63a8-47f2-ad0e-c7d4fa8f6979" xlink:to="loc_us-gaap_WarrantMember_b1871e4e-370a-4cd9-afea-f44408e3b830" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ClassOfWarrantOrRightOutstandingRollForward_cd29138e-73fc-4e94-aa16-d6f036ead293" xlink:href="smmt-20231231.xsd#smmt_ClassOfWarrantOrRightOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_28d9dc18-7a48-4dbc-9a18-5c2f4fa272dc" xlink:to="loc_smmt_ClassOfWarrantOrRightOutstandingRollForward_cd29138e-73fc-4e94-aa16-d6f036ead293" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_cfe5cbb3-8d41-46f3-9a74-05d8784ca6ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_smmt_ClassOfWarrantOrRightOutstandingRollForward_cd29138e-73fc-4e94-aa16-d6f036ead293" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_cfe5cbb3-8d41-46f3-9a74-05d8784ca6ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ClassOfWarrantOrRightExercisesInPeriod_b2e51864-9bbc-425a-8d71-0b2e81d33eba" xlink:href="smmt-20231231.xsd#smmt_ClassOfWarrantOrRightExercisesInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_smmt_ClassOfWarrantOrRightOutstandingRollForward_cd29138e-73fc-4e94-aa16-d6f036ead293" xlink:to="loc_smmt_ClassOfWarrantOrRightExercisesInPeriod_b2e51864-9bbc-425a-8d71-0b2e81d33eba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7906a9f0-290f-4e14-a6da-5f1bd3ce1f75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward_e2e31f70-7ea5-4524-87c8-8c1656997b9b" xlink:href="smmt-20231231.xsd#smmt_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_28d9dc18-7a48-4dbc-9a18-5c2f4fa272dc" xlink:to="loc_smmt_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward_e2e31f70-7ea5-4524-87c8-8c1656997b9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ClassOfWarrantOrRightWeightedAverageExercisePrice_daddb55d-5aea-4fdb-a401-6703b2e6f9d3" xlink:href="smmt-20231231.xsd#smmt_ClassOfWarrantOrRightWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_smmt_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward_e2e31f70-7ea5-4524-87c8-8c1656997b9b" xlink:to="loc_smmt_ClassOfWarrantOrRightWeightedAverageExercisePrice_daddb55d-5aea-4fdb-a401-6703b2e6f9d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod_106441a5-96db-4610-969f-6b0d78dc124e" xlink:href="smmt-20231231.xsd#smmt_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_smmt_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward_e2e31f70-7ea5-4524-87c8-8c1656997b9b" xlink:to="loc_smmt_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod_106441a5-96db-4610-969f-6b0d78dc124e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ClassOfWarrantOrRightWeightedAverageExercisePrice_2eea5639-411a-457a-8ee1-213160d3fd1d" xlink:href="smmt-20231231.xsd#smmt_ClassOfWarrantOrRightWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm_8ec579e1-7dde-49db-bfef-4281d77ddbf4" xlink:href="smmt-20231231.xsd#smmt_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_28d9dc18-7a48-4dbc-9a18-5c2f4fa272dc" xlink:to="loc_smmt_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm_8ec579e1-7dde-49db-bfef-4281d77ddbf4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding_c4999fe8-5cf5-4058-8cde-d0f902e006bf" xlink:href="smmt-20231231.xsd#smmt_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_28d9dc18-7a48-4dbc-9a18-5c2f4fa272dc" xlink:to="loc_smmt_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding_c4999fe8-5cf5-4058-8cde-d0f902e006bf" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e2d1276-1fe7-431d-bf6c-3f1e86c8c58e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e2d1276-1fe7-431d-bf6c-3f1e86c8c58e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_df6f3f75-6aae-4a75-95ba-c23df08b6552" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e2d1276-1fe7-431d-bf6c-3f1e86c8c58e" xlink:to="loc_us-gaap_PlanNameAxis_df6f3f75-6aae-4a75-95ba-c23df08b6552" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_df6f3f75-6aae-4a75-95ba-c23df08b6552_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_df6f3f75-6aae-4a75-95ba-c23df08b6552" xlink:to="loc_us-gaap_PlanNameDomain_df6f3f75-6aae-4a75-95ba-c23df08b6552_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_cf2e033d-07c0-4f46-804a-da102cccf644" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_df6f3f75-6aae-4a75-95ba-c23df08b6552" xlink:to="loc_us-gaap_PlanNameDomain_cf2e033d-07c0-4f46-804a-da102cccf644" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_A2020StockIncentivePlanMember_6d693beb-76e4-4a88-884e-bae45a667a7f" xlink:href="smmt-20231231.xsd#smmt_A2020StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_cf2e033d-07c0-4f46-804a-da102cccf644" xlink:to="loc_smmt_A2020StockIncentivePlanMember_6d693beb-76e4-4a88-884e-bae45a667a7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3e21baa4-a486-4ec2-bf58-0a0510532d83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e2d1276-1fe7-431d-bf6c-3f1e86c8c58e" xlink:to="loc_us-gaap_AwardTypeAxis_3e21baa4-a486-4ec2-bf58-0a0510532d83" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3e21baa4-a486-4ec2-bf58-0a0510532d83_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_3e21baa4-a486-4ec2-bf58-0a0510532d83" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3e21baa4-a486-4ec2-bf58-0a0510532d83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9990887-dfc0-4a91-96d8-929ad21d71b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_3e21baa4-a486-4ec2-bf58-0a0510532d83" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9990887-dfc0-4a91-96d8-929ad21d71b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_462b4418-8227-421a-ac69-52691705b46c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9990887-dfc0-4a91-96d8-929ad21d71b6" xlink:to="loc_us-gaap_EmployeeStockMember_462b4418-8227-421a-ac69-52691705b46c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_fd3654e8-0202-4483-a867-5a30fc6ed591" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9990887-dfc0-4a91-96d8-929ad21d71b6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_fd3654e8-0202-4483-a867-5a30fc6ed591" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_EmployeeStockOptionTimeBasedMember_7a4949a4-408e-43f5-85d9-749b8e4ba8e6" xlink:href="smmt-20231231.xsd#smmt_EmployeeStockOptionTimeBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOptionMember_fd3654e8-0202-4483-a867-5a30fc6ed591" xlink:to="loc_smmt_EmployeeStockOptionTimeBasedMember_7a4949a4-408e-43f5-85d9-749b8e4ba8e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_EmployeeStockOptionPerformanceAndMarketBasedMember_dfbb86cf-6d0a-469b-a2c9-8556f6bd9207" xlink:href="smmt-20231231.xsd#smmt_EmployeeStockOptionPerformanceAndMarketBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOptionMember_fd3654e8-0202-4483-a867-5a30fc6ed591" xlink:to="loc_smmt_EmployeeStockOptionPerformanceAndMarketBasedMember_dfbb86cf-6d0a-469b-a2c9-8556f6bd9207" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_e5ffd55b-3de7-4c8e-b328-9a80ebd5196d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9990887-dfc0-4a91-96d8-929ad21d71b6" xlink:to="loc_us-gaap_WarrantMember_e5ffd55b-3de7-4c8e-b328-9a80ebd5196d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9b2329e4-2b29-471c-a97d-459735fb06c6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e2d1276-1fe7-431d-bf6c-3f1e86c8c58e" xlink:to="loc_srt_RangeAxis_9b2329e4-2b29-471c-a97d-459735fb06c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9b2329e4-2b29-471c-a97d-459735fb06c6_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9b2329e4-2b29-471c-a97d-459735fb06c6" xlink:to="loc_srt_RangeMember_9b2329e4-2b29-471c-a97d-459735fb06c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7a4c4d8c-7062-44c6-a576-056114d493f9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9b2329e4-2b29-471c-a97d-459735fb06c6" xlink:to="loc_srt_RangeMember_7a4c4d8c-7062-44c6-a576-056114d493f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_89d95d61-b34c-40e8-96bf-8de3018f1395" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7a4c4d8c-7062-44c6-a576-056114d493f9" xlink:to="loc_srt_MinimumMember_89d95d61-b34c-40e8-96bf-8de3018f1395" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3a2a829b-64ba-41d5-a5a3-af0fe6061821" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7a4c4d8c-7062-44c6-a576-056114d493f9" xlink:to="loc_srt_MaximumMember_3a2a829b-64ba-41d5-a5a3-af0fe6061821" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_27f631c9-0722-4baf-a25b-2ba84337d268" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e2d1276-1fe7-431d-bf6c-3f1e86c8c58e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_27f631c9-0722-4baf-a25b-2ba84337d268" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_27f631c9-0722-4baf-a25b-2ba84337d268_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_27f631c9-0722-4baf-a25b-2ba84337d268" xlink:to="loc_us-gaap_EquityComponentDomain_27f631c9-0722-4baf-a25b-2ba84337d268_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_512277a8-d248-4b75-91b6-5dfa0af1933e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_27f631c9-0722-4baf-a25b-2ba84337d268" xlink:to="loc_us-gaap_EquityComponentDomain_512277a8-d248-4b75-91b6-5dfa0af1933e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_90e4429f-fc64-441d-802e-eea197874ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_512277a8-d248-4b75-91b6-5dfa0af1933e" xlink:to="loc_us-gaap_CommonStockMember_90e4429f-fc64-441d-802e-eea197874ab8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8fab405a-644e-4f6c-8cdc-06db4daa70c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8fab405a-644e-4f6c-8cdc-06db4daa70c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CommonStockAdditionalCapitalSharesAllowableForForFutureIssuanceUponOptionExpiration_3acd5275-1f07-4a4a-9509-954efeac7631" xlink:href="smmt-20231231.xsd#smmt_CommonStockAdditionalCapitalSharesAllowableForForFutureIssuanceUponOptionExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_smmt_CommonStockAdditionalCapitalSharesAllowableForForFutureIssuanceUponOptionExpiration_3acd5275-1f07-4a4a-9509-954efeac7631" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPotentialNumberOfAdditionalSharesAllowableUnderThePlan_0dda2462-290d-42ab-93b9-e4c0bebcea70" xlink:href="smmt-20231231.xsd#smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPotentialNumberOfAdditionalSharesAllowableUnderThePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPotentialNumberOfAdditionalSharesAllowableUnderThePlan_0dda2462-290d-42ab-93b9-e4c0bebcea70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_d6320fe6-95a7-4c5b-be33-5e74cc0fc53a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_d6320fe6-95a7-4c5b-be33-5e74cc0fc53a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CommonStockSharesAuthorizedIncreaseDecrease_8be43519-97ff-4517-9823-c516730ae546" xlink:href="smmt-20231231.xsd#smmt_CommonStockSharesAuthorizedIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_smmt_CommonStockSharesAuthorizedIncreaseDecrease_8be43519-97ff-4517-9823-c516730ae546" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_3248d181-9aff-45bb-b862-885be6b2acc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_3248d181-9aff-45bb-b862-885be6b2acc6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c7330c90-5168-479b-94ba-d7a1a2e4a82a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c7330c90-5168-479b-94ba-d7a1a2e4a82a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e678d783-5578-47d6-8946-afcb58de23be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e678d783-5578-47d6-8946-afcb58de23be" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_b67d0234-5047-478c-addc-ce878ec8232b" xlink:href="smmt-20231231.xsd#smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_b67d0234-5047-478c-addc-ce878ec8232b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod_d05a610a-58dd-4bcd-b73d-5b6d4a295f5e" xlink:href="smmt-20231231.xsd#smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod_d05a610a-58dd-4bcd-b73d-5b6d4a295f5e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_ceecba1b-1762-4be2-997a-a0de8cd6236e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_ceecba1b-1762-4be2-997a-a0de8cd6236e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_f228afc8-2e74-4501-8c39-3489a09084b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_f228afc8-2e74-4501-8c39-3489a09084b9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_f906f012-8f05-45fb-b300-f8ac2e57036a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_f906f012-8f05-45fb-b300-f8ac2e57036a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_98447f15-5f46-4362-af4d-7f32b8b97241" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_98447f15-5f46-4362-af4d-7f32b8b97241" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_999cf2e4-76b3-4891-b596-54f21c43dc2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_999cf2e4-76b3-4891-b596-54f21c43dc2e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e6bb6f33-15b5-4ee4-9772-85b152a22f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e6bb6f33-15b5-4ee4-9772-85b152a22f5c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_25445981-0f29-4d3f-95ac-a17e159ba6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_25445981-0f29-4d3f-95ac-a17e159ba6fe" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_08a160ac-aa6a-4686-9f1a-5324c7d860e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_08a160ac-aa6a-4686-9f1a-5324c7d860e1" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_115e3dfb-6b17-45be-b584-19a576c6bffd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_115e3dfb-6b17-45be-b584-19a576c6bffd" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_12f3fc7a-4e02-459b-82e3-67278d683377" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_12f3fc7a-4e02-459b-82e3-67278d683377" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_518ed610-2df1-450d-90f0-bca5a8fd055d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_518ed610-2df1-450d-90f0-bca5a8fd055d" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_2e1f9ebc-3512-43ce-8c15-8d6084f9d787" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_2e1f9ebc-3512-43ce-8c15-8d6084f9d787" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_84975a80-5013-4732-a32a-9c2cf9f61ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_84975a80-5013-4732-a32a-9c2cf9f61ee0" xlink:type="arc" order="22"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/StockBasedCompensationWeightedaverageassumptionsusedforstockoptionawardsDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#StockBasedCompensationWeightedaverageassumptionsusedforstockoptionawardsDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/StockBasedCompensationWeightedaverageassumptionsusedforstockoptionawardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a8b153a-7eff-4ae6-a411-ae16df1aba97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4c8a4cb3-7cfa-4457-8ed5-a2fe567c1848" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a8b153a-7eff-4ae6-a411-ae16df1aba97" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4c8a4cb3-7cfa-4457-8ed5-a2fe567c1848" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3794b771-1528-49db-93d3-dc94bff09d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4c8a4cb3-7cfa-4457-8ed5-a2fe567c1848" xlink:to="loc_us-gaap_AwardTypeAxis_3794b771-1528-49db-93d3-dc94bff09d3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3794b771-1528-49db-93d3-dc94bff09d3c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_3794b771-1528-49db-93d3-dc94bff09d3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3794b771-1528-49db-93d3-dc94bff09d3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44d5eb5c-771b-4998-b027-7469e3e163b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_3794b771-1528-49db-93d3-dc94bff09d3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44d5eb5c-771b-4998-b027-7469e3e163b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_173d5442-199d-4f63-9d89-02105b872a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44d5eb5c-771b-4998-b027-7469e3e163b7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_173d5442-199d-4f63-9d89-02105b872a6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_74713bb5-42c0-44e7-a2b8-4285796099db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a8b153a-7eff-4ae6-a411-ae16df1aba97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_74713bb5-42c0-44e7-a2b8-4285796099db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0764554a-9a66-4338-97a1-85f0531b38e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a8b153a-7eff-4ae6-a411-ae16df1aba97" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0764554a-9a66-4338-97a1-85f0531b38e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_55176573-2beb-4525-a14e-531778b445cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a8b153a-7eff-4ae6-a411-ae16df1aba97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_55176573-2beb-4525-a14e-531778b445cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_16d53a87-d37a-4682-9125-7126d6b5978d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a8b153a-7eff-4ae6-a411-ae16df1aba97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_16d53a87-d37a-4682-9125-7126d6b5978d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#StockBasedCompensationStockoptionactivityDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d1133e95-6c5c-4189-beb0-56303a8830cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f7fd239e-de12-4731-aff5-77e97bc68550" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d1133e95-6c5c-4189-beb0-56303a8830cb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f7fd239e-de12-4731-aff5-77e97bc68550" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a854f90a-fe7c-4d24-bfdd-d016cb57015e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f7fd239e-de12-4731-aff5-77e97bc68550" xlink:to="loc_us-gaap_AwardTypeAxis_a854f90a-fe7c-4d24-bfdd-d016cb57015e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a854f90a-fe7c-4d24-bfdd-d016cb57015e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a854f90a-fe7c-4d24-bfdd-d016cb57015e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a854f90a-fe7c-4d24-bfdd-d016cb57015e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db12dd6e-d529-4ec6-93ec-ffe8dfbe5100" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a854f90a-fe7c-4d24-bfdd-d016cb57015e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db12dd6e-d529-4ec6-93ec-ffe8dfbe5100" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_EmployeeStockOptionTimeBasedMember_aff78e10-f8cd-4fc6-bb43-6a24a2ad80d2" xlink:href="smmt-20231231.xsd#smmt_EmployeeStockOptionTimeBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db12dd6e-d529-4ec6-93ec-ffe8dfbe5100" xlink:to="loc_smmt_EmployeeStockOptionTimeBasedMember_aff78e10-f8cd-4fc6-bb43-6a24a2ad80d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_EmployeeStockOptionPerformanceAndMarketBasedMember_7e079d93-0420-49a6-bc4c-727155df92c8" xlink:href="smmt-20231231.xsd#smmt_EmployeeStockOptionPerformanceAndMarketBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db12dd6e-d529-4ec6-93ec-ffe8dfbe5100" xlink:to="loc_smmt_EmployeeStockOptionPerformanceAndMarketBasedMember_7e079d93-0420-49a6-bc4c-727155df92c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2df1ab3e-5d8e-4c36-91fb-1b769c34c6db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d1133e95-6c5c-4189-beb0-56303a8830cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2df1ab3e-5d8e-4c36-91fb-1b769c34c6db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f4bf5d5e-9334-4144-9fb5-25bdd2474fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2df1ab3e-5d8e-4c36-91fb-1b769c34c6db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f4bf5d5e-9334-4144-9fb5-25bdd2474fc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c18e230b-e3e9-4719-b51d-2cb86b6ce8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2df1ab3e-5d8e-4c36-91fb-1b769c34c6db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c18e230b-e3e9-4719-b51d-2cb86b6ce8b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_43918df9-b5a5-43aa-a28a-b65d76a804c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2df1ab3e-5d8e-4c36-91fb-1b769c34c6db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_43918df9-b5a5-43aa-a28a-b65d76a804c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ae9b2d9b-f314-4b4a-b871-39d9942f072d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2df1ab3e-5d8e-4c36-91fb-1b769c34c6db" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ae9b2d9b-f314-4b4a-b871-39d9942f072d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_923ee1b5-0dff-4373-92bf-b2f6f74a6622" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e2f68ba2-80fc-4dfb-81d2-6ab33b83c1fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d1133e95-6c5c-4189-beb0-56303a8830cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e2f68ba2-80fc-4dfb-81d2-6ab33b83c1fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_31d89632-35a7-44ae-b9db-c1eb8ddd2f20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e2f68ba2-80fc-4dfb-81d2-6ab33b83c1fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_31d89632-35a7-44ae-b9db-c1eb8ddd2f20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_14a81e5a-a39d-421e-89bd-39dfaa2ec6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e2f68ba2-80fc-4dfb-81d2-6ab33b83c1fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_14a81e5a-a39d-421e-89bd-39dfaa2ec6e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8ddc1b6b-8342-43f0-8208-4d4ef18619da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e2f68ba2-80fc-4dfb-81d2-6ab33b83c1fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8ddc1b6b-8342-43f0-8208-4d4ef18619da" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9fb32f59-1312-4f58-b6e3-1013aa7ccfc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e2f68ba2-80fc-4dfb-81d2-6ab33b83c1fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9fb32f59-1312-4f58-b6e3-1013aa7ccfc6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7fa100b0-1126-46d1-8c26-ea8049f705be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4d38d3b0-e5a2-4689-8b5a-3ea7e2784480" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d1133e95-6c5c-4189-beb0-56303a8830cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4d38d3b0-e5a2-4689-8b5a-3ea7e2784480" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1b20e69c-39d9-43db-b3e6-60e299232c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4d38d3b0-e5a2-4689-8b5a-3ea7e2784480" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1b20e69c-39d9-43db-b3e6-60e299232c1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_fc3dee6c-964b-4012-a08d-e535ce9a2c69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4d38d3b0-e5a2-4689-8b5a-3ea7e2784480" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_fc3dee6c-964b-4012-a08d-e535ce9a2c69" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1bfd6b2c-1858-4ae2-aa6b-2fbbd2089ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4d38d3b0-e5a2-4689-8b5a-3ea7e2784480" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1bfd6b2c-1858-4ae2-aa6b-2fbbd2089ca4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_f411e55c-7470-45c9-8285-45fa5641b905" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4d38d3b0-e5a2-4689-8b5a-3ea7e2784480" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_f411e55c-7470-45c9-8285-45fa5641b905" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6cebc349-a9e3-4819-aa80-31c12f5fa3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4d38d3b0-e5a2-4689-8b5a-3ea7e2784480" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6cebc349-a9e3-4819-aa80-31c12f5fa3ab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_4fb44a63-8e4c-444f-9d1d-00794b5c2b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4d38d3b0-e5a2-4689-8b5a-3ea7e2784480" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_4fb44a63-8e4c-444f-9d1d-00794b5c2b5f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_32bb224d-f826-44a6-b320-88d4717b4458" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4d38d3b0-e5a2-4689-8b5a-3ea7e2784480" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_32bb224d-f826-44a6-b320-88d4717b4458" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_03a7226c-9038-43bc-87f1-5a9ee25dd964" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4d38d3b0-e5a2-4689-8b5a-3ea7e2784480" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_03a7226c-9038-43bc-87f1-5a9ee25dd964" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_cb48dd42-adaa-47a6-aa25-87bdad65d6a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4d38d3b0-e5a2-4689-8b5a-3ea7e2784480" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_cb48dd42-adaa-47a6-aa25-87bdad65d6a1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6c110218-9443-479e-a832-182bdac28405" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4d38d3b0-e5a2-4689-8b5a-3ea7e2784480" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6c110218-9443-479e-a832-182bdac28405" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/StockBasedCompensationSummaryofstockbasedcompensationexpenseDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#StockBasedCompensationSummaryofstockbasedcompensationexpenseDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/StockBasedCompensationSummaryofstockbasedcompensationexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_01d14cc6-dce2-4746-802b-6b199f4c8080" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1d5581ad-91dd-4d62-b056-94b608352236" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_01d14cc6-dce2-4746-802b-6b199f4c8080" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1d5581ad-91dd-4d62-b056-94b608352236" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2ff8fd63-50cf-43a5-9079-6980d4a7872f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1d5581ad-91dd-4d62-b056-94b608352236" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2ff8fd63-50cf-43a5-9079-6980d4a7872f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2ff8fd63-50cf-43a5-9079-6980d4a7872f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2ff8fd63-50cf-43a5-9079-6980d4a7872f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2ff8fd63-50cf-43a5-9079-6980d4a7872f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e7960a2f-c6e1-4c11-b25c-24aee8960b53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2ff8fd63-50cf-43a5-9079-6980d4a7872f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e7960a2f-c6e1-4c11-b25c-24aee8960b53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a4a9f5df-3c7a-464e-8000-9d11f78f4ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e7960a2f-c6e1-4c11-b25c-24aee8960b53" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a4a9f5df-3c7a-464e-8000-9d11f78f4ea0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_917cfb0b-7e5b-4e1f-b08a-9c4ce05eda75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e7960a2f-c6e1-4c11-b25c-24aee8960b53" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_917cfb0b-7e5b-4e1f-b08a-9c4ce05eda75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4a88460a-965e-4e99-92c0-0d148c5edf43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1d5581ad-91dd-4d62-b056-94b608352236" xlink:to="loc_us-gaap_AwardTypeAxis_4a88460a-965e-4e99-92c0-0d148c5edf43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a88460a-965e-4e99-92c0-0d148c5edf43_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4a88460a-965e-4e99-92c0-0d148c5edf43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a88460a-965e-4e99-92c0-0d148c5edf43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac39ccfb-65d4-415f-ae4d-1b21bacc7cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4a88460a-965e-4e99-92c0-0d148c5edf43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac39ccfb-65d4-415f-ae4d-1b21bacc7cfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_EmployeeStockOptionTimeBasedMember_6b0efeae-b749-4de4-ab7c-644ec7e4c95b" xlink:href="smmt-20231231.xsd#smmt_EmployeeStockOptionTimeBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac39ccfb-65d4-415f-ae4d-1b21bacc7cfb" xlink:to="loc_smmt_EmployeeStockOptionTimeBasedMember_6b0efeae-b749-4de4-ab7c-644ec7e4c95b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_EmployeeStockOptionPerformanceAndMarketBasedMember_455768da-48b2-43a8-93de-ec3a0d728699" xlink:href="smmt-20231231.xsd#smmt_EmployeeStockOptionPerformanceAndMarketBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac39ccfb-65d4-415f-ae4d-1b21bacc7cfb" xlink:to="loc_smmt_EmployeeStockOptionPerformanceAndMarketBasedMember_455768da-48b2-43a8-93de-ec3a0d728699" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_4858e6d9-8945-4916-99b6-04787cfebce6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac39ccfb-65d4-415f-ae4d-1b21bacc7cfb" xlink:to="loc_us-gaap_EmployeeStockMember_4858e6d9-8945-4916-99b6-04787cfebce6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d59ec7b6-21f2-460c-a56c-6a8aa3311e76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_01d14cc6-dce2-4746-802b-6b199f4c8080" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d59ec7b6-21f2-460c-a56c-6a8aa3311e76" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_ead41b94-2383-4726-93af-faabdd966bda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_95bee6b9-8e99-48b1-9899-60338ae7e090" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_ead41b94-2383-4726-93af-faabdd966bda" xlink:to="loc_us-gaap_OtherCommitmentsTable_95bee6b9-8e99-48b1-9899-60338ae7e090" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_31650083-8dc8-4b18-955a-49f73edcd09c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_95bee6b9-8e99-48b1-9899-60338ae7e090" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_31650083-8dc8-4b18-955a-49f73edcd09c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_31650083-8dc8-4b18-955a-49f73edcd09c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_31650083-8dc8-4b18-955a-49f73edcd09c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_31650083-8dc8-4b18-955a-49f73edcd09c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e8e58204-1335-4117-892d-c64995c5bc22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_31650083-8dc8-4b18-955a-49f73edcd09c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e8e58204-1335-4117-892d-c64995c5bc22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_456a6970-f14d-4056-bb21-c6f07eb701f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e8e58204-1335-4117-892d-c64995c5bc22" xlink:to="loc_us-gaap_SubsequentEventMember_456a6970-f14d-4056-bb21-c6f07eb701f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_OtherCommitmentIncreaseDecrease_09c49096-761e-4b31-a5ee-0851f95c2e10" xlink:href="smmt-20231231.xsd#smmt_OtherCommitmentIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_ead41b94-2383-4726-93af-faabdd966bda" xlink:to="loc_smmt_OtherCommitmentIncreaseDecrease_09c49096-761e-4b31-a5ee-0851f95c2e10" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.summitplc.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_df3c1b12-ac70-4a3d-b6b5-f22c8b86eb95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_df3c1b12-ac70-4a3d-b6b5-f22c8b86eb95" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b48accee-f415-4c83-8cc2-97cacaa41db2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_df3c1b12-ac70-4a3d-b6b5-f22c8b86eb95" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b48accee-f415-4c83-8cc2-97cacaa41db2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_b48accee-f415-4c83-8cc2-97cacaa41db2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b48accee-f415-4c83-8cc2-97cacaa41db2" xlink:to="loc_us-gaap_RelatedPartyDomain_b48accee-f415-4c83-8cc2-97cacaa41db2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9209b7dd-9938-423d-856a-128514d24afb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b48accee-f415-4c83-8cc2-97cacaa41db2" xlink:to="loc_us-gaap_RelatedPartyDomain_9209b7dd-9938-423d-856a-128514d24afb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_17f65313-1e20-47b3-9059-9743ce582c85" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_9209b7dd-9938-423d-856a-128514d24afb" xlink:to="loc_srt_AffiliatedEntityMember_17f65313-1e20-47b3-9059-9743ce582c85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember_9a62a25f-cd61-46d1-9803-98b0ac97baf9" xlink:href="smmt-20231231.xsd#smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_9209b7dd-9938-423d-856a-128514d24afb" xlink:to="loc_smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember_9a62a25f-cd61-46d1-9803-98b0ac97baf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_13432840-b35c-4ea5-a0d3-5d74b133ec13" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember_9a62a25f-cd61-46d1-9803-98b0ac97baf9" xlink:to="loc_srt_ChiefExecutiveOfficerMember_13432840-b35c-4ea5-a0d3-5d74b133ec13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ChiefExecutiveOfficerAndPresidentMember_15eefcdc-d064-4014-990d-2e2c245135d3" xlink:href="smmt-20231231.xsd#smmt_ChiefExecutiveOfficerAndPresidentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember_9a62a25f-cd61-46d1-9803-98b0ac97baf9" xlink:to="loc_smmt_ChiefExecutiveOfficerAndPresidentMember_15eefcdc-d064-4014-990d-2e2c245135d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_1d4db5d8-8d41-4d66-92f9-98f386e893d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_9209b7dd-9938-423d-856a-128514d24afb" xlink:to="loc_us-gaap_RelatedPartyMember_1d4db5d8-8d41-4d66-92f9-98f386e893d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefOperatingOfficerMember_6136fc50-1681-4e2e-93b5-6601ffb0fb3b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefOperatingOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_9209b7dd-9938-423d-856a-128514d24afb" xlink:to="loc_srt_ChiefOperatingOfficerMember_6136fc50-1681-4e2e-93b5-6601ffb0fb3b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_7daf2a65-9f80-43e3-a434-0a71ad8534a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_df3c1b12-ac70-4a3d-b6b5-f22c8b86eb95" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_7daf2a65-9f80-43e3-a434-0a71ad8534a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_7daf2a65-9f80-43e3-a434-0a71ad8534a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_7daf2a65-9f80-43e3-a434-0a71ad8534a9" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_7daf2a65-9f80-43e3-a434-0a71ad8534a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_690c6c99-4584-4919-bba1-aa7d4a937261" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_7daf2a65-9f80-43e3-a434-0a71ad8534a9" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_690c6c99-4584-4919-bba1-aa7d4a937261" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_SubleaseAgreementFirstAmendmentMember_0de0411e-a819-4dec-b4ce-1a4726dd9e32" xlink:href="smmt-20231231.xsd#smmt_SubleaseAgreementFirstAmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_690c6c99-4584-4919-bba1-aa7d4a937261" xlink:to="loc_smmt_SubleaseAgreementFirstAmendmentMember_0de0411e-a819-4dec-b4ce-1a4726dd9e32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_SubleaseAgreementSecondAmendmentMember_90ce7007-e735-46cf-b132-4bc28888755e" xlink:href="smmt-20231231.xsd#smmt_SubleaseAgreementSecondAmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_690c6c99-4584-4919-bba1-aa7d4a937261" xlink:to="loc_smmt_SubleaseAgreementSecondAmendmentMember_90ce7007-e735-46cf-b132-4bc28888755e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_March2022NoteMember_77777c0e-6f90-4183-9e5c-a9e4ae2b217b" xlink:href="smmt-20231231.xsd#smmt_March2022NoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_690c6c99-4584-4919-bba1-aa7d4a937261" xlink:to="loc_smmt_March2022NoteMember_77777c0e-6f90-4183-9e5c-a9e4ae2b217b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotePurchaseAgreementMember_dd7264b7-3c30-4bbe-843f-63df12b206e0" xlink:href="smmt-20231231.xsd#smmt_NotePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_690c6c99-4584-4919-bba1-aa7d4a937261" xlink:to="loc_smmt_NotePurchaseAgreementMember_dd7264b7-3c30-4bbe-843f-63df12b206e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DugganPromissoryNotesMember_0dcde12d-e45a-4c2d-81cd-45d71464eed9" xlink:href="smmt-20231231.xsd#smmt_DugganPromissoryNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_smmt_NotePurchaseAgreementMember_dd7264b7-3c30-4bbe-843f-63df12b206e0" xlink:to="loc_smmt_DugganPromissoryNotesMember_0dcde12d-e45a-4c2d-81cd-45d71464eed9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DugganFebruaryNoteMember_0549dc3c-e80e-4073-808c-7cd2d785f77c" xlink:href="smmt-20231231.xsd#smmt_DugganFebruaryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_smmt_DugganPromissoryNotesMember_0dcde12d-e45a-4c2d-81cd-45d71464eed9" xlink:to="loc_smmt_DugganFebruaryNoteMember_0549dc3c-e80e-4073-808c-7cd2d785f77c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DugganSeptemberNoteMember_543430df-bb12-48ce-9d91-d059615557df" xlink:href="smmt-20231231.xsd#smmt_DugganSeptemberNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_smmt_DugganPromissoryNotesMember_0dcde12d-e45a-4c2d-81cd-45d71464eed9" xlink:to="loc_smmt_DugganSeptemberNoteMember_543430df-bb12-48ce-9d91-d059615557df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ZanganehNoteMember_103752b0-ac9f-44ca-a9d8-89fa4542c578" xlink:href="smmt-20231231.xsd#smmt_ZanganehNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_smmt_NotePurchaseAgreementMember_dd7264b7-3c30-4bbe-843f-63df12b206e0" xlink:to="loc_smmt_ZanganehNoteMember_103752b0-ac9f-44ca-a9d8-89fa4542c578" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DugganFebruaryNoteAndZanganehNoteMember_5ce47ea2-d90f-41a8-850a-7a59670e236a" xlink:href="smmt-20231231.xsd#smmt_DugganFebruaryNoteAndZanganehNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_smmt_NotePurchaseAgreementMember_dd7264b7-3c30-4bbe-843f-63df12b206e0" xlink:to="loc_smmt_DugganFebruaryNoteAndZanganehNoteMember_5ce47ea2-d90f-41a8-850a-7a59670e236a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_AkesoSupplyAgreementMember_22fdb237-aec8-4416-bd91-ac5dc71add16" xlink:href="smmt-20231231.xsd#smmt_AkesoSupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_690c6c99-4584-4919-bba1-aa7d4a937261" xlink:to="loc_smmt_AkesoSupplyAgreementMember_22fdb237-aec8-4416-bd91-ac5dc71add16" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ConsultingAgreementMember_8100e7a8-360d-4f82-b3ba-9475d6e42506" xlink:href="smmt-20231231.xsd#smmt_ConsultingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_690c6c99-4584-4919-bba1-aa7d4a937261" xlink:to="loc_smmt_ConsultingAgreementMember_8100e7a8-360d-4f82-b3ba-9475d6e42506" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_94376cc6-fff5-4b83-9c88-235ad9c356d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_df3c1b12-ac70-4a3d-b6b5-f22c8b86eb95" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_94376cc6-fff5-4b83-9c88-235ad9c356d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_94376cc6-fff5-4b83-9c88-235ad9c356d1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_94376cc6-fff5-4b83-9c88-235ad9c356d1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_94376cc6-fff5-4b83-9c88-235ad9c356d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cc80f537-9b82-466a-8124-bcc6f79e3f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_94376cc6-fff5-4b83-9c88-235ad9c356d1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cc80f537-9b82-466a-8124-bcc6f79e3f4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RightsOfferingMember_c89bb943-068b-41b3-b9c4-c031cabff0e4" xlink:href="smmt-20231231.xsd#smmt_RightsOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cc80f537-9b82-466a-8124-bcc6f79e3f4e" xlink:to="loc_smmt_RightsOfferingMember_c89bb943-068b-41b3-b9c4-c031cabff0e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_S3RegistrationStatementMember_6a53c69b-669d-4e6d-ad4d-9a6dd0879c3c" xlink:href="smmt-20231231.xsd#smmt_S3RegistrationStatementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cc80f537-9b82-466a-8124-bcc6f79e3f4e" xlink:to="loc_smmt_S3RegistrationStatementMember_6a53c69b-669d-4e6d-ad4d-9a6dd0879c3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_c338c7ed-598e-4235-87d4-faaff4c6578d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cc80f537-9b82-466a-8124-bcc6f79e3f4e" xlink:to="loc_us-gaap_PrivatePlacementMember_c338c7ed-598e-4235-87d4-faaff4c6578d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_a963ea3b-55ba-4e05-8173-4022f6a31b33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_df3c1b12-ac70-4a3d-b6b5-f22c8b86eb95" xlink:to="loc_us-gaap_VariableRateAxis_a963ea3b-55ba-4e05-8173-4022f6a31b33" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_a963ea3b-55ba-4e05-8173-4022f6a31b33_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_a963ea3b-55ba-4e05-8173-4022f6a31b33" xlink:to="loc_us-gaap_VariableRateDomain_a963ea3b-55ba-4e05-8173-4022f6a31b33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_3698f3e8-1109-4cc1-ae62-245d4b45a148" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_a963ea3b-55ba-4e05-8173-4022f6a31b33" xlink:to="loc_us-gaap_VariableRateDomain_3698f3e8-1109-4cc1-ae62-245d4b45a148" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_60e7d09d-3c5d-49ff-b1db-c33b2149d402" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_3698f3e8-1109-4cc1-ae62-245d4b45a148" xlink:to="loc_us-gaap_PrimeRateMember_60e7d09d-3c5d-49ff-b1db-c33b2149d402" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_VariableRatePeriodAxis_0de8c107-1c6b-4e5d-a999-65470d2f99b4" xlink:href="smmt-20231231.xsd#smmt_VariableRatePeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_df3c1b12-ac70-4a3d-b6b5-f22c8b86eb95" xlink:to="loc_smmt_VariableRatePeriodAxis_0de8c107-1c6b-4e5d-a999-65470d2f99b4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_VariableRatePeriodDomain_0de8c107-1c6b-4e5d-a999-65470d2f99b4_default" xlink:href="smmt-20231231.xsd#smmt_VariableRatePeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_smmt_VariableRatePeriodAxis_0de8c107-1c6b-4e5d-a999-65470d2f99b4" xlink:to="loc_smmt_VariableRatePeriodDomain_0de8c107-1c6b-4e5d-a999-65470d2f99b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_VariableRatePeriodDomain_e8d89ab3-bcf8-4815-b1e4-ff01f9decf3b" xlink:href="smmt-20231231.xsd#smmt_VariableRatePeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_smmt_VariableRatePeriodAxis_0de8c107-1c6b-4e5d-a999-65470d2f99b4" xlink:to="loc_smmt_VariableRatePeriodDomain_e8d89ab3-bcf8-4815-b1e4-ff01f9decf3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_VariableRatePeriodOneMember_987ff005-237d-4541-8c9f-4ad792085cde" xlink:href="smmt-20231231.xsd#smmt_VariableRatePeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_smmt_VariableRatePeriodDomain_e8d89ab3-bcf8-4815-b1e4-ff01f9decf3b" xlink:to="loc_smmt_VariableRatePeriodOneMember_987ff005-237d-4541-8c9f-4ad792085cde" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_VariableRatePeriodTwoMember_55d88c52-7830-4446-ae80-d478f86fa879" xlink:href="smmt-20231231.xsd#smmt_VariableRatePeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_smmt_VariableRatePeriodDomain_e8d89ab3-bcf8-4815-b1e4-ff01f9decf3b" xlink:to="loc_smmt_VariableRatePeriodTwoMember_55d88c52-7830-4446-ae80-d478f86fa879" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a5056223-16a7-4418-b9ea-879ac8f40d64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_df3c1b12-ac70-4a3d-b6b5-f22c8b86eb95" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a5056223-16a7-4418-b9ea-879ac8f40d64" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a5056223-16a7-4418-b9ea-879ac8f40d64_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a5056223-16a7-4418-b9ea-879ac8f40d64" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a5056223-16a7-4418-b9ea-879ac8f40d64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_35dfe010-0b3b-47b5-8ae1-04ef545a9179" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a5056223-16a7-4418-b9ea-879ac8f40d64" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_35dfe010-0b3b-47b5-8ae1-04ef545a9179" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_6abd89c1-b639-41fe-a3d5-0f8f8305c1e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_35dfe010-0b3b-47b5-8ae1-04ef545a9179" xlink:to="loc_us-gaap_SubsequentEventMember_6abd89c1-b639-41fe-a3d5-0f8f8305c1e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RelatedPartyTransactionSubleaseExtensionTerm_7835b2d2-426e-4cf9-97ab-b28c01d0bd0e" xlink:href="smmt-20231231.xsd#smmt_RelatedPartyTransactionSubleaseExtensionTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_smmt_RelatedPartyTransactionSubleaseExtensionTerm_7835b2d2-426e-4cf9-97ab-b28c01d0bd0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RelatedPartyTransactionPaymentsToRelatedParty_fe0da8f1-739e-400d-b505-fcd291cb5095" xlink:href="smmt-20231231.xsd#smmt_RelatedPartyTransactionPaymentsToRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_smmt_RelatedPartyTransactionPaymentsToRelatedParty_fe0da8f1-739e-400d-b505-fcd291cb5095" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_AreaOfPremisesSubleased_db661fd4-b9ed-4ac1-bece-dc127691d5af" xlink:href="smmt-20231231.xsd#smmt_AreaOfPremisesSubleased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_smmt_AreaOfPremisesSubleased_db661fd4-b9ed-4ac1-bece-dc127691d5af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_9a87840c-13ca-4045-aa8a-399731405353" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_9a87840c-13ca-4045-aa8a-399731405353" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_640a03b2-53e9-4e5a-94e0-ee62a69254ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_us-gaap_NotesPayable_640a03b2-53e9-4e5a-94e0-ee62a69254ea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionRate_5b36bf23-857f-43c5-b0d5-09973a918bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_us-gaap_RelatedPartyTransactionRate_5b36bf23-857f-43c5-b0d5-09973a918bcb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold_2a6f3ad6-a0b3-44ba-8936-94bf2a98c8b4" xlink:href="smmt-20231231.xsd#smmt_NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_smmt_NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold_2a6f3ad6-a0b3-44ba-8936-94bf2a98c8b4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartiesMaximumTerm_a331cebc-3339-4790-bd72-37a347c01dc9" xlink:href="smmt-20231231.xsd#smmt_NotesPayableRelatedPartiesMaximumTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_smmt_NotesPayableRelatedPartiesMaximumTerm_a331cebc-3339-4790-bd72-37a347c01dc9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2080ef88-a18f-4ab6-8993-7a6d4586795a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2080ef88-a18f-4ab6-8993-7a6d4586795a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_587f4cee-b4ec-418e-8c0b-712bf0c9c4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_587f4cee-b4ec-418e-8c0b-712bf0c9c4dc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_ade22345-c7b0-44aa-8224-25c48870178a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_ade22345-c7b0-44aa-8224-25c48870178a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_6d5c4a5e-fe77-4c23-a777-ea676fdf0da0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_6d5c4a5e-fe77-4c23-a777-ea676fdf0da0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartiesPotentialPrepaymentPeriodPostReceiptOfCashProceedsFromPublicOffering_0f076aec-0605-4a26-b0fa-6e62051e8aa2" xlink:href="smmt-20231231.xsd#smmt_NotesPayableRelatedPartiesPotentialPrepaymentPeriodPostReceiptOfCashProceedsFromPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_smmt_NotesPayableRelatedPartiesPotentialPrepaymentPeriodPostReceiptOfCashProceedsFromPublicOffering_0f076aec-0605-4a26-b0fa-6e62051e8aa2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartiesPotentialPrepaymentMaximumAmountPercentageOfNetProceedsFromPublicOffering_d575af5f-8c24-41e6-ad4f-3f6a304f8cd4" xlink:href="smmt-20231231.xsd#smmt_NotesPayableRelatedPartiesPotentialPrepaymentMaximumAmountPercentageOfNetProceedsFromPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_smmt_NotesPayableRelatedPartiesPotentialPrepaymentMaximumAmountPercentageOfNetProceedsFromPublicOffering_d575af5f-8c24-41e6-ad4f-3f6a304f8cd4" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartiesNewIssuances_0169f7a6-7c03-4c40-8dd5-b427ce8f7ce8" xlink:href="smmt-20231231.xsd#smmt_NotesPayableRelatedPartiesNewIssuances"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_smmt_NotesPayableRelatedPartiesNewIssuances_0169f7a6-7c03-4c40-8dd5-b427ce8f7ce8" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_e1f3dc22-6304-41ea-aef5-0b798d434a20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_e1f3dc22-6304-41ea-aef5-0b798d434a20" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_4bc0c8ff-5c4a-4e3b-ba3b-abb45f250e10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_4bc0c8ff-5c4a-4e3b-ba3b-abb45f250e10" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominator_05bce360-2346-42ae-8306-e4b988744e71" xlink:href="smmt-20231231.xsd#smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominator"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominator_05bce360-2346-42ae-8306-e4b988744e71" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominatorBaseAmountAddedToClosingBidPrice_5d280ce2-fbef-4ed0-b2a2-202b2ce9a50d" xlink:href="smmt-20231231.xsd#smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominatorBaseAmountAddedToClosingBidPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominatorBaseAmountAddedToClosingBidPrice_5d280ce2-fbef-4ed0-b2a2-202b2ce9a50d" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_StockIssuedDuringPeriodSharesRelatedPartyPrepaidInterest_03ef791a-90cb-4c40-8e05-9f3a7e7cf7bb" xlink:href="smmt-20231231.xsd#smmt_StockIssuedDuringPeriodSharesRelatedPartyPrepaidInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_smmt_StockIssuedDuringPeriodSharesRelatedPartyPrepaidInterest_03ef791a-90cb-4c40-8e05-9f3a7e7cf7bb" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_49341ac2-d338-46c9-8dd7-f565e55e626e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_49341ac2-d338-46c9-8dd7-f565e55e626e" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_a1ac554e-e85f-4e79-9e21-2cc13a513564" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_us-gaap_InterestPaidNet_a1ac554e-e85f-4e79-9e21-2cc13a513564" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_505f0fa6-5688-4b63-8b7b-aa8c1a339d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_505f0fa6-5688-4b63-8b7b-aa8c1a339d9b" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_dab99564-dcdf-465b-9752-1b646197848e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_us-gaap_StockIssued1_dab99564-dcdf-465b-9752-1b646197848e" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_SaleOfStockNumberOfSharesRegisteredForResale_2defc91e-d94f-438a-992b-2aa7ba12416a" xlink:href="smmt-20231231.xsd#smmt_SaleOfStockNumberOfSharesRegisteredForResale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_smmt_SaleOfStockNumberOfSharesRegisteredForResale_2defc91e-d94f-438a-992b-2aa7ba12416a" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_c14e4f9b-bf78-4bd8-9348-bd20d93d7fef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_c14e4f9b-bf78-4bd8-9348-bd20d93d7fef" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ClassOfWarrantOrRightExercisesInPeriod_70bb7f45-b6d0-4d95-9f6b-3ee930ba3607" xlink:href="smmt-20231231.xsd#smmt_ClassOfWarrantOrRightExercisesInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_smmt_ClassOfWarrantOrRightExercisesInPeriod_70bb7f45-b6d0-4d95-9f6b-3ee930ba3607" xlink:type="arc" order="26"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="loc_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>smmt-20231231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:cfc19273-6e1b-408d-b97d-a861bea67b02,g:5505fdd7-331f-4f8b-bf29-88d8f3b5e402-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_smmt_ClassOfWarrantOrRightOutstandingRollForward_7fcca654-ef35-4fb5-a2c1-0483e8f11adc_terseLabel_en-US" xlink:label="lab_smmt_ClassOfWarrantOrRightOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share warrants</link:label>
    <link:label id="lab_smmt_ClassOfWarrantOrRightOutstandingRollForward_label_en-US" xlink:label="lab_smmt_ClassOfWarrantOrRightOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_smmt_ClassOfWarrantOrRightOutstandingRollForward_documentation_en-US" xlink:label="lab_smmt_ClassOfWarrantOrRightOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ClassOfWarrantOrRightOutstandingRollForward" xlink:href="smmt-20231231.xsd#smmt_ClassOfWarrantOrRightOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ClassOfWarrantOrRightOutstandingRollForward" xlink:to="lab_smmt_ClassOfWarrantOrRightOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_cf383b39-537a-4ad8-9bbe-ca1292f95499_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_047bb997-207f-4104-bebf-41a47ac67547_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_1baf7a91-522e-4e97-9c2d-8d722f8b227e_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_ff671a34-d395-4bba-85b3-ccb1bed24ecc_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_97975988-11b2-45e1-9ca7-13f48b724635_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_AkesoSupplyAgreementMember_793df940-12a1-4380-bd3a-6b244a4182fc_terseLabel_en-US" xlink:label="lab_smmt_AkesoSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Akeso Supply Agreement</link:label>
    <link:label id="lab_smmt_AkesoSupplyAgreementMember_label_en-US" xlink:label="lab_smmt_AkesoSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Akeso Supply Agreement [Member]</link:label>
    <link:label id="lab_smmt_AkesoSupplyAgreementMember_documentation_en-US" xlink:label="lab_smmt_AkesoSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Akeso Supply Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_AkesoSupplyAgreementMember" xlink:href="smmt-20231231.xsd#smmt_AkesoSupplyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_AkesoSupplyAgreementMember" xlink:to="lab_smmt_AkesoSupplyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6f180b1b-6475-47a9-a119-e32f0eeb559c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_f1bb69c4-1be4-4032-bf96-7c589bf44935_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_fb33c7fe-385e-489d-b150-d769f824848d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f51c78a-0d25-449a-b595-65fe8daa3744_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_PromissoryNotesMember_c685cb24-e3e7-429a-915a-888b48212439_terseLabel_en-US" xlink:label="lab_smmt_PromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promissory Notes</link:label>
    <link:label id="lab_smmt_PromissoryNotesMember_label_en-US" xlink:label="lab_smmt_PromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promissory Notes [Member]</link:label>
    <link:label id="lab_smmt_PromissoryNotesMember_documentation_en-US" xlink:label="lab_smmt_PromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promissory Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_PromissoryNotesMember" xlink:href="smmt-20231231.xsd#smmt_PromissoryNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_PromissoryNotesMember" xlink:to="lab_smmt_PromissoryNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_3c166891-6a54-44db-8550-b7d615571293_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_b172f231-f82c-490a-a462-dd8ac8a6c540_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, transaction with party to collaborative arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_d733671e-819b-4757-b5b2-75743c63724b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_d6d8daf9-1aeb-44fb-b07b-a0c6c565ac54_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfCountriesInWhichEntityOperates_c60a0af0-b0ff-4f8b-91cc-95bd8aed5c42_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of geographic regions in which the Company operates</link:label>
    <link:label id="lab_us-gaap_NumberOfCountriesInWhichEntityOperates_label_en-US" xlink:label="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Countries in which Entity Operates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:to="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_ca5b947d-056a-4e07-8b07-e64778229ecd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of short-term investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_8ff648b4-d201-483f-a0bc-970c3551dfec_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment charge</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Finite-Lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_a5189fa1-c1a9-4e29-9017-da3a872c5163_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4b880253-85a0-413b-b571-08ebbff4ba41_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod_b427cbd2-5a3a-4e2d-885e-f785296f343c_terseLabel_en-US" xlink:label="lab_smmt_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_smmt_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod_label_en-US" xlink:label="lab_smmt_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Weighted Average Exercise Price, Exercises In Period</link:label>
    <link:label id="lab_smmt_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod_documentation_en-US" xlink:label="lab_smmt_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Weighted Average Exercise Price, Exercises In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod" xlink:href="smmt-20231231.xsd#smmt_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod" xlink:to="lab_smmt_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_NotesPayableGrossCurrent_5be63351-0cb8-4796-be26-1c387eabe0ea_terseLabel_en-US" xlink:label="lab_smmt_NotesPayableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amounts</link:label>
    <link:label id="lab_smmt_NotesPayableGrossCurrent_label_en-US" xlink:label="lab_smmt_NotesPayableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Gross, Current</link:label>
    <link:label id="lab_smmt_NotesPayableGrossCurrent_documentation_en-US" xlink:label="lab_smmt_NotesPayableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Gross, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableGrossCurrent" xlink:href="smmt-20231231.xsd#smmt_NotesPayableGrossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_NotesPayableGrossCurrent" xlink:to="lab_smmt_NotesPayableGrossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_e36a8602-1a00-4a8c-993d-cd69afcb42b4_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_3b6fb570-a60a-48ef-94da-9e01c82356d8_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_55378bad-fc9c-4b46-b470-b93d25d65e8c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. federal income tax statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_March2022NoteMember_4c657b82-5e4e-4c3f-872b-283b0a2c5272_terseLabel_en-US" xlink:label="lab_smmt_March2022NoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2022 Note</link:label>
    <link:label id="lab_smmt_March2022NoteMember_label_en-US" xlink:label="lab_smmt_March2022NoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2022 Note [Member]</link:label>
    <link:label id="lab_smmt_March2022NoteMember_documentation_en-US" xlink:label="lab_smmt_March2022NoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2022 Note</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_March2022NoteMember" xlink:href="smmt-20231231.xsd#smmt_March2022NoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_March2022NoteMember" xlink:to="lab_smmt_March2022NoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_c14f7cf4-3512-4aea-b910-98b0662cd939_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 22)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2b854f24-b1d4-4f06-ac98-6b50db03db18_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options, exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominatorBaseAmountAddedToClosingBidPrice_8df9f54b-084e-4925-b7d3-ac1b5388c475_terseLabel_en-US" xlink:label="lab_smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominatorBaseAmountAddedToClosingBidPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid interest, conversion amount base (in dollars per share)</link:label>
    <link:label id="lab_smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominatorBaseAmountAddedToClosingBidPrice_label_en-US" xlink:label="lab_smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominatorBaseAmountAddedToClosingBidPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Related Party, Prepaid Interest, Equity Interests Issuable Calculation, Denominator, Base Amount Added To Closing Bid Price</link:label>
    <link:label id="lab_smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominatorBaseAmountAddedToClosingBidPrice_documentation_en-US" xlink:label="lab_smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominatorBaseAmountAddedToClosingBidPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Related Party, Prepaid Interest, Equity Interests Issuable Calculation, Denominator, Base Amount Added To Closing Bid Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominatorBaseAmountAddedToClosingBidPrice" xlink:href="smmt-20231231.xsd#smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominatorBaseAmountAddedToClosingBidPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominatorBaseAmountAddedToClosingBidPrice" xlink:to="lab_smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominatorBaseAmountAddedToClosingBidPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_5af20c3f-7b4f-4679-981e-d20af26c7ef0_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_EarningsPerShareBasicAndDilutedEPSAbstract_078955f2-10ae-4e86-b8cf-77de6e02b655_terseLabel_en-US" xlink:label="lab_smmt_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share:</link:label>
    <link:label id="lab_smmt_EarningsPerShareBasicAndDilutedEPSAbstract_label_en-US" xlink:label="lab_smmt_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted EPS [Abstract]</link:label>
    <link:label id="lab_smmt_EarningsPerShareBasicAndDilutedEPSAbstract_documentation_en-US" xlink:label="lab_smmt_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted EPS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:href="smmt-20231231.xsd#smmt_EarningsPerShareBasicAndDilutedEPSAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:to="lab_smmt_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_83f87bc4-d24f-43a4-b5df-4d97617fbb42_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_389ff6c2-fc75-4f32-8555-cc6e5109aef1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the issuance of common stock for rights offering</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_d818fbd7-92a3-4de9-9c3b-0151be4f9905_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross proceeds from the sale of stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_0ed9355c-eb13-4eee-af4b-3ad8e768d36d_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_29095a48-9c42-475f-8570-5977b6f3eaff_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_7338e5e1-04d8-492b-802f-1fcec8f9f095_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_9533b145-6d08-4013-9ff7-6b955c482923_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue and other income</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d87cdbbc-bfc7-4dec-aaec-8a514a651954_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4356aef5-2c62-4824-967d-71eb1ec28921_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected annual dividends per share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_43a09082-9695-4c3b-b564-e9fcd2f294d0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_e9bb2de4-e40c-4480-8249-cafe429de871_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_0eb46522-19f4-4e5d-a7f5-b2ac5dcdbb48_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred provision for federal income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_e5cffad1-0a39-40ed-9232-a6c305e0110b_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative goodwill impairment charges</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_DugganFebruaryNoteAndZanganehNoteMember_1ef98cbe-6a15-4fb1-8000-fca1c466b13e_terseLabel_en-US" xlink:label="lab_smmt_DugganFebruaryNoteAndZanganehNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duggan February Note and Zanganeh Note</link:label>
    <link:label id="lab_smmt_DugganFebruaryNoteAndZanganehNoteMember_label_en-US" xlink:label="lab_smmt_DugganFebruaryNoteAndZanganehNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duggan February Note And Zanganeh Note [Member]</link:label>
    <link:label id="lab_smmt_DugganFebruaryNoteAndZanganehNoteMember_documentation_en-US" xlink:label="lab_smmt_DugganFebruaryNoteAndZanganehNoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duggan February Note And Zanganeh Note</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DugganFebruaryNoteAndZanganehNoteMember" xlink:href="smmt-20231231.xsd#smmt_DugganFebruaryNoteAndZanganehNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_DugganFebruaryNoteAndZanganehNoteMember" xlink:to="lab_smmt_DugganFebruaryNoteAndZanganehNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_45abed78-4311-44bc-9794-95be5e32c38c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_fc94b0e2-ce0d-4bfd-8a0d-1d35a52e460a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.01 par value, 20,000,000 shares authorized; none issued and outstanding at December 31, 2023 and 2022, respectively</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_78c28d97-a523-4692-aabf-44f7a6924145_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_64e71b3a-13ec-4411-91cd-e8e8d071ebf8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm_29aa6b70-2c59-453b-bd2f-087a8d9b170d_terseLabel_en-US" xlink:label="lab_smmt_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term</link:label>
    <link:label id="lab_smmt_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_smmt_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_smmt_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_smmt_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm" xlink:href="smmt-20231231.xsd#smmt_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm" xlink:to="lab_smmt_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_e43397e6-c5cc-4ce8-91da-8cb809d39cc0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_c51da6d5-ff01-41f7-bc64-471ac16a9ec3_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_869d94cb-cd90-40b0-a95c-166490ea83e8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c9799c28-4cc8-4f5f-b05d-48a32201791f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_a46ae753-f2fd-4074-804c-493dd51ab8bc_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_5df3518f-aab4-4a65-8703-95d5bf4eadae_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_2b202e57-66d8-4b74-b3f0-16864b046abc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent_69c3c345-a173-4275-9c31-37bce1f9aaa0_terseLabel_en-US" xlink:label="lab_smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credit receivable</link:label>
    <link:label id="lab_smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent_label_en-US" xlink:label="lab_smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Credit Receivable, Current</link:label>
    <link:label id="lab_smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent_documentation_en-US" xlink:label="lab_smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Credit Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:href="smmt-20231231.xsd#smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:to="lab_smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0374965d-cedc-4891-a946-16604d5620b0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c4176024-f48d-49a8-82f8-bb6661869b71_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_08a54766-5736-429c-b3c2-049562cd297e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_7138e085-5e02-44cd-a19a-5e759ae3e970_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_8bb7a240-3fd0-4c42-a95b-147cff53515d_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_6609f33c-6544-4dcb-96a6-cb70be251e96_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Prepaid Expenses and Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research, Development, and Computer Software Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_f8e44bba-2f10-44ae-bb78-d7892201e6c8_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentOneMember_1200df6f-5d75-49bf-9c6f-7cb8c1753375_terseLabel_en-US" xlink:label="lab_smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, transaction with party to collaborative arrangement, upfront payment one</link:label>
    <link:label id="lab_smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentOneMember_label_en-US" xlink:label="lab_smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement, Upfront Payment One [Member]</link:label>
    <link:label id="lab_smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentOneMember_documentation_en-US" xlink:label="lab_smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement, Upfront Payment One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentOneMember" xlink:href="smmt-20231231.xsd#smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentOneMember" xlink:to="lab_smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c7e32f6a-a0c6-4f52-885a-e2183bf8884f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dee3003c-5d74-435f-a10a-40f61e1ba1f6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value of stock options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d34a2c54-4355-4eec-85e8-ecfc2364c652_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_a9ecf8fc-2cdf-4278-9870-b8919e6b82ff_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f22a2df5-53cc-48ec-9eab-e4219cf105d2_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_c16d2440-8fef-456f-b1d0-0ab5c6c1dad2_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a3b6a535-0b90-4bfb-91a1-7610e50b0444_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_b1c54007-116c-494d-a693-eac7fc3dee9f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_DebtIssuanceCostsIncurredButNotYetPaid_2ce06534-9dd6-4122-8c1c-c8b5c9fb93c3_terseLabel_en-US" xlink:label="lab_smmt_DebtIssuanceCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs in accrued expenses</link:label>
    <link:label id="lab_smmt_DebtIssuanceCostsIncurredButNotYetPaid_label_en-US" xlink:label="lab_smmt_DebtIssuanceCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs Incurred But Not Yet Paid</link:label>
    <link:label id="lab_smmt_DebtIssuanceCostsIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_smmt_DebtIssuanceCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs Incurred But Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DebtIssuanceCostsIncurredButNotYetPaid" xlink:href="smmt-20231231.xsd#smmt_DebtIssuanceCostsIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_DebtIssuanceCostsIncurredButNotYetPaid" xlink:to="lab_smmt_DebtIssuanceCostsIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember_0b99f78e-7ffa-4de1-a86c-42bb6bdb9b8d_terseLabel_en-US" xlink:label="lab_smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures, office equipment and software</link:label>
    <link:label id="lab_smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures, Office Equipment and Software [Member]</link:label>
    <link:label id="lab_smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures, Office Equipment and Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember" xlink:href="smmt-20231231.xsd#smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember" xlink:to="lab_smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_a31d3ffc-5147-4728-877d-42577fdeecdb_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_50931ea5-bb0b-4837-bff3-78f4305b1bb4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ResearchAndDevelopmentExpenseCapitalizedAmount_73c97346-df27-4b7d-94de-1f5ee68e4923_terseLabel_en-US" xlink:label="lab_smmt_ResearchAndDevelopmentExpenseCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and experimental expenditures capitalized</link:label>
    <link:label id="lab_smmt_ResearchAndDevelopmentExpenseCapitalizedAmount_label_en-US" xlink:label="lab_smmt_ResearchAndDevelopmentExpenseCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Capitalized Amount</link:label>
    <link:label id="lab_smmt_ResearchAndDevelopmentExpenseCapitalizedAmount_documentation_en-US" xlink:label="lab_smmt_ResearchAndDevelopmentExpenseCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Capitalized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ResearchAndDevelopmentExpenseCapitalizedAmount" xlink:href="smmt-20231231.xsd#smmt_ResearchAndDevelopmentExpenseCapitalizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ResearchAndDevelopmentExpenseCapitalizedAmount" xlink:to="lab_smmt_ResearchAndDevelopmentExpenseCapitalizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0a390de7-56f9-4e89-b8b1-b42c80d0d81e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_a79834ef-cf52-48dc-ad35-121a32b3fb3f_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized imputed interest</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_84826de8-4012-4a6f-a7ea-b82440d5a5c9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_OptionOverNonFinancialAssetsMember_862882b0-a181-414f-b938-1570e300dae2_terseLabel_en-US" xlink:label="lab_smmt_OptionOverNonFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option over non-financial asset</link:label>
    <link:label id="lab_smmt_OptionOverNonFinancialAssetsMember_label_en-US" xlink:label="lab_smmt_OptionOverNonFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Over Non-Financial Assets [Member]</link:label>
    <link:label id="lab_smmt_OptionOverNonFinancialAssetsMember_documentation_en-US" xlink:label="lab_smmt_OptionOverNonFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Over Non-Financial Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_OptionOverNonFinancialAssetsMember" xlink:href="smmt-20231231.xsd#smmt_OptionOverNonFinancialAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_OptionOverNonFinancialAssetsMember" xlink:to="lab_smmt_OptionOverNonFinancialAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_GrantFundingArrangementMilestoneFundingIncrease_eb08e866-e0a2-44e1-a074-e2e08a7a7644_terseLabel_en-US" xlink:label="lab_smmt_GrantFundingArrangementMilestoneFundingIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding increase based on achievement of future milestones</link:label>
    <link:label id="lab_smmt_GrantFundingArrangementMilestoneFundingIncrease_label_en-US" xlink:label="lab_smmt_GrantFundingArrangementMilestoneFundingIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Funding Arrangement, Milestone, Funding Increase</link:label>
    <link:label id="lab_smmt_GrantFundingArrangementMilestoneFundingIncrease_documentation_en-US" xlink:label="lab_smmt_GrantFundingArrangementMilestoneFundingIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Funding Arrangement, Milestone, Funding Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GrantFundingArrangementMilestoneFundingIncrease" xlink:href="smmt-20231231.xsd#smmt_GrantFundingArrangementMilestoneFundingIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_GrantFundingArrangementMilestoneFundingIncrease" xlink:to="lab_smmt_GrantFundingArrangementMilestoneFundingIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_8cbe6f8e-f5d7-4989-af97-3b629dae74fd_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares expected to be purchased under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_f09cddef-7285-4d98-a765-a8e2f3e9496d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_5ef44256-18ec-45e7-b0d2-b2ac1a0bb164_netLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_e41f501d-5034-4af2-936c-5f253f56e979_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of cumulative currency translation gain to other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_8f0c633f-974d-4a43-bf07-2bb8bc9952f7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of cumulative translation gain (Note 10)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_cbe7724c-9b02-45db-bf05-2e2fb17d3ff2_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_661bc0d0-3d94-42ee-a0ea-9ab8add70717_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_SubleaseAgreementSecondAmendmentMember_ac887e08-a127-4728-8944-0369d47306c3_terseLabel_en-US" xlink:label="lab_smmt_SubleaseAgreementSecondAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second amendment to sublease</link:label>
    <link:label id="lab_smmt_SubleaseAgreementSecondAmendmentMember_label_en-US" xlink:label="lab_smmt_SubleaseAgreementSecondAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Agreement, Second Amendment [Member]</link:label>
    <link:label id="lab_smmt_SubleaseAgreementSecondAmendmentMember_documentation_en-US" xlink:label="lab_smmt_SubleaseAgreementSecondAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Agreement, Second Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_SubleaseAgreementSecondAmendmentMember" xlink:href="smmt-20231231.xsd#smmt_SubleaseAgreementSecondAmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_SubleaseAgreementSecondAmendmentMember" xlink:to="lab_smmt_SubleaseAgreementSecondAmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6ddb0c57-8094-4beb-b427-4a906875109c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_cffffc31-dba2-4cf7-95c4-e4a133a66105_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5ca7c467-f0b7-4281-8d94-f129c0a89ade_negatedNetLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_b5330bfa-d848-4fa2-9c8d-6736a3336106_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning deferred revenue and other income</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_a3c3d1d1-08e2-4324-9f95-6c6d17e5c548_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending deferred revenue and other income</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_9e45a8ee-b2fc-4d2d-8f0c-dcbb7067a66d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_01f2952a-a321-4dc1-8c1a-7890090789c6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of net loss per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e7bd4824-000d-4bc5-94a6-15533f52a8d6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity award, vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_30036208-d34c-41ff-9a97-e3ffd52fd9b4_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rates on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermNotesPayable_8f5dc19c-d369-4cb9-876f-d987208bb6c2_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promissory notes payable to related parties</link:label>
    <link:label id="lab_us-gaap_LongTermNotesPayable_edaef46f-4291-49fb-b4e4-4048e0e421fe_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total promissory notes payable to related parties</link:label>
    <link:label id="lab_us-gaap_LongTermNotesPayable_5d6501e0-4298-4f6e-af23-100892215fef_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable classified as long-term</link:label>
    <link:label id="lab_us-gaap_LongTermNotesPayable_label_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable" xlink:to="lab_us-gaap_LongTermNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_cf0d5fb9-67a8-44ae-a301-880e31a6ce8f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_69272952-dae9-4dcc-8143-007dc906c99a_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_SubleaseAgreementFirstAmendmentMember_3cc094a8-a07e-4a4a-aecd-49a3b1ffd7b7_terseLabel_en-US" xlink:label="lab_smmt_SubleaseAgreementFirstAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First amendment to sublease</link:label>
    <link:label id="lab_smmt_SubleaseAgreementFirstAmendmentMember_label_en-US" xlink:label="lab_smmt_SubleaseAgreementFirstAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Agreement, First Amendment [Member]</link:label>
    <link:label id="lab_smmt_SubleaseAgreementFirstAmendmentMember_documentation_en-US" xlink:label="lab_smmt_SubleaseAgreementFirstAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Agreement, First Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_SubleaseAgreementFirstAmendmentMember" xlink:href="smmt-20231231.xsd#smmt_SubleaseAgreementFirstAmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_SubleaseAgreementFirstAmendmentMember" xlink:to="lab_smmt_SubleaseAgreementFirstAmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5700301a-5573-4762-8b18-eff9e3558e15_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_c4e382d5-72a7-44d0-a118-8f69b8384a98_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_ba91a60a-7c74-42ab-ae21-9a0f93cf698d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ClassOfWarrantOrRightWeightedAverageExercisePrice_fb51c39b-a263-45e0-94c3-4b67a7cd3152_periodStartLabel_en-US" xlink:label="lab_smmt_ClassOfWarrantOrRightWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_smmt_ClassOfWarrantOrRightWeightedAverageExercisePrice_33f764d0-c18f-4e84-917e-4a3931534e54_periodEndLabel_en-US" xlink:label="lab_smmt_ClassOfWarrantOrRightWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_smmt_ClassOfWarrantOrRightWeightedAverageExercisePrice_label_en-US" xlink:label="lab_smmt_ClassOfWarrantOrRightWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Weighted Average Exercise Price</link:label>
    <link:label id="lab_smmt_ClassOfWarrantOrRightWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_smmt_ClassOfWarrantOrRightWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ClassOfWarrantOrRightWeightedAverageExercisePrice" xlink:href="smmt-20231231.xsd#smmt_ClassOfWarrantOrRightWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ClassOfWarrantOrRightWeightedAverageExercisePrice" xlink:to="lab_smmt_ClassOfWarrantOrRightWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_1213f909-47fa-49b8-992e-7a90ba22136e_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_fbd93e78-11dd-466c-835e-687212f400e4_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases related to prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_2b3e37f5-6d12-4f13-87db-f526df57eecc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of property and equipment useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_576cce38-9741-4e35-9588-c827112d3a54_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_ad8630a0-6758-482e-95eb-ea73c6b3ce1a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e395dac4-d4cd-45be-9357-1e385a856271_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of warrants (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5fdf1ede-eace-4b10-863c-e8fdb5c18747_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments_29786d84-4d76-4ca5-8106-67f2d8852b1f_totalLabel_en-US" xlink:label="lab_smmt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, additional potential milestone payments</link:label>
    <link:label id="lab_smmt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments_label_en-US" xlink:label="lab_smmt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Milestone Payments</link:label>
    <link:label id="lab_smmt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments_documentation_en-US" xlink:label="lab_smmt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" xlink:href="smmt-20231231.xsd#smmt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" xlink:to="lab_smmt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_2e3237d2-8cd2-4d35-b2e2-ede3b849acbf_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_CommonStockSharesAuthorizedIncreaseDecrease_f4681f06-3966-4464-a2e0-fad431994cb7_terseLabel_en-US" xlink:label="lab_smmt_CommonStockSharesAuthorizedIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_smmt_CommonStockSharesAuthorizedIncreaseDecrease_label_en-US" xlink:label="lab_smmt_CommonStockSharesAuthorizedIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized, Increase (Decrease)</link:label>
    <link:label id="lab_smmt_CommonStockSharesAuthorizedIncreaseDecrease_documentation_en-US" xlink:label="lab_smmt_CommonStockSharesAuthorizedIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CommonStockSharesAuthorizedIncreaseDecrease" xlink:href="smmt-20231231.xsd#smmt_CommonStockSharesAuthorizedIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_CommonStockSharesAuthorizedIncreaseDecrease" xlink:to="lab_smmt_CommonStockSharesAuthorizedIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ScheduleOfOtherOperatingIncomeExpenseNetTableTextBlock_622ef793-1acb-4940-8cfa-83e4d4efb1d0_terseLabel_en-US" xlink:label="lab_smmt_ScheduleOfOtherOperatingIncomeExpenseNetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of other operating income</link:label>
    <link:label id="lab_smmt_ScheduleOfOtherOperatingIncomeExpenseNetTableTextBlock_label_en-US" xlink:label="lab_smmt_ScheduleOfOtherOperatingIncomeExpenseNetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Operating Income (Expense), Net [Table Text Block]</link:label>
    <link:label id="lab_smmt_ScheduleOfOtherOperatingIncomeExpenseNetTableTextBlock_documentation_en-US" xlink:label="lab_smmt_ScheduleOfOtherOperatingIncomeExpenseNetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ScheduleOfOtherOperatingIncomeExpenseNetTableTextBlock" xlink:href="smmt-20231231.xsd#smmt_ScheduleOfOtherOperatingIncomeExpenseNetTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ScheduleOfOtherOperatingIncomeExpenseNetTableTextBlock" xlink:to="lab_smmt_ScheduleOfOtherOperatingIncomeExpenseNetTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_InterestExpenseIncomeNoncash_1bf5997c-e566-4516-a18b-9dd01ebf2b0a_terseLabel_en-US" xlink:label="lab_smmt_InterestExpenseIncomeNoncash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_smmt_InterestExpenseIncomeNoncash_label_en-US" xlink:label="lab_smmt_InterestExpenseIncomeNoncash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense (Income), Noncash</link:label>
    <link:label id="lab_smmt_InterestExpenseIncomeNoncash_documentation_en-US" xlink:label="lab_smmt_InterestExpenseIncomeNoncash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense (Income), Noncash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_InterestExpenseIncomeNoncash" xlink:href="smmt-20231231.xsd#smmt_InterestExpenseIncomeNoncash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_InterestExpenseIncomeNoncash" xlink:to="lab_smmt_InterestExpenseIncomeNoncash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_00707bda-7a51-4713-9908-fe3d3c698115_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_5d2fab51-47bb-4061-9fc2-47db6b3a85df_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_e30dab21-9861-4c06-9364-021646b5536a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future principal payments for 2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d82071ef-76a2-4b12-9893-a0c276617a51_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_62ae5668-2459-48d8-ae2c-24bee0600b28_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_e3fcf4c0-ffa1-44b7-ba31-2d5e83b4bcdb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_fc608091-407c-4703-aec8-b8e0cb0eeb12_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_RelatedPartyTransactionSubleaseExtensionTerm_781b86de-81cc-4791-b76d-a9cbecea713c_terseLabel_en-US" xlink:label="lab_smmt_RelatedPartyTransactionSubleaseExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease extension term</link:label>
    <link:label id="lab_smmt_RelatedPartyTransactionSubleaseExtensionTerm_label_en-US" xlink:label="lab_smmt_RelatedPartyTransactionSubleaseExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Sublease Extension Term</link:label>
    <link:label id="lab_smmt_RelatedPartyTransactionSubleaseExtensionTerm_documentation_en-US" xlink:label="lab_smmt_RelatedPartyTransactionSubleaseExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Sublease Extension Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RelatedPartyTransactionSubleaseExtensionTerm" xlink:href="smmt-20231231.xsd#smmt_RelatedPartyTransactionSubleaseExtensionTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_RelatedPartyTransactionSubleaseExtensionTerm" xlink:to="lab_smmt_RelatedPartyTransactionSubleaseExtensionTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_3ef6efb9-78dc-4047-8f00-75cfaf4d9295_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_cff7eb88-1320-4b31-ad03-c7acd7458b63_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized foreign currency (gain) loss</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_SaleOfStockNumberOfSharesRegisteredForResale_14d6adc4-9624-4f3e-8dd2-a6deeefbfa12_terseLabel_en-US" xlink:label="lab_smmt_SaleOfStockNumberOfSharesRegisteredForResale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares registered for resale (in shares)</link:label>
    <link:label id="lab_smmt_SaleOfStockNumberOfSharesRegisteredForResale_label_en-US" xlink:label="lab_smmt_SaleOfStockNumberOfSharesRegisteredForResale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Number Of Shares Registered For Resale</link:label>
    <link:label id="lab_smmt_SaleOfStockNumberOfSharesRegisteredForResale_documentation_en-US" xlink:label="lab_smmt_SaleOfStockNumberOfSharesRegisteredForResale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Number Of Shares Registered For Resale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_SaleOfStockNumberOfSharesRegisteredForResale" xlink:href="smmt-20231231.xsd#smmt_SaleOfStockNumberOfSharesRegisteredForResale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_SaleOfStockNumberOfSharesRegisteredForResale" xlink:to="lab_smmt_SaleOfStockNumberOfSharesRegisteredForResale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_f7605c7b-6b56-4baa-b4e3-e61c8f08cd28_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_a66bdfcf-d365-49f1-9007-f59ecda06e6c_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_9ffa5f91-94a7-4d85-b746-01c3e362593a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_799ad02e-1e2d-4fb6-a3e3-509dbdff874f_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_258a0dac-6293-452c-bd40-40bc63e101c8_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_4cf2e86e-ed92-4591-b4fd-b5da25209629_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities and sales of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_9632cc91-3d08-4e70-9492-d36a5997b0d6_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_0e1c5d06-d1d6-47da-9590-58dc12c7d796_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs from the issuance of common stock for rights offering</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_90799935-b7c2-4554-aed9-0cd490acede6_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_3988d4e3-7cd9-483b-a765-2d8eaf6b096a_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_9c5c6c11-5cdb-47cb-ae73-ed836500a0d3_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_250b8c96-aec8-4fc2-887a-18395f374bda_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent_1687f437-a65a-4df6-b697-e3a161b3c6f0_negatedLabel_en-US" xlink:label="lab_smmt_EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refundable research and development tax credit</link:label>
    <link:label id="lab_smmt_EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent_label_en-US" xlink:label="lab_smmt_EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit Refundable, Research, Percent</link:label>
    <link:label id="lab_smmt_EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent_documentation_en-US" xlink:label="lab_smmt_EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit Refundable, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent" xlink:href="smmt-20231231.xsd#smmt_EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent" xlink:to="lab_smmt_EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_64c55bdb-3d94-4de5-b5d0-b70d5b650e20_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of related party promissory notes issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_2cb61d2a-bc2f-4c60-ba8e-43da621485ca_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_7fcca221-02c4-4027-9620-8a35eae103ca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of related party debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6f04542d-80f6-4a72-af3d-4cc4325a94a9_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfRelatedPartyDebt_85adda51-a181-4ffe-a582-905230026172_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Re-payment of related party promissory notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfRelatedPartyDebt_8377ccd2-c019-443b-a819-2d2b6dc80187_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of related party notes payable</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfRelatedPartyDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Related Party Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_WarrantsPolicyPolicyTextBlock_72d9c4ad-6712-4ecf-ae9a-8fd147f0dc2d_terseLabel_en-US" xlink:label="lab_smmt_WarrantsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_smmt_WarrantsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_smmt_WarrantsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Policy [Policy Text Block]</link:label>
    <link:label id="lab_smmt_WarrantsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_smmt_WarrantsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_WarrantsPolicyPolicyTextBlock" xlink:href="smmt-20231231.xsd#smmt_WarrantsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_WarrantsPolicyPolicyTextBlock" xlink:to="lab_smmt_WarrantsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2144fcc2-b8fb-459f-a487-a70e1cf3604a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of future lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold_6592b124-894d-49e8-afb2-e97266b5d30e_terseLabel_en-US" xlink:label="lab_smmt_NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable, maturity triggering event, public offering proceeds threshold</link:label>
    <link:label id="lab_smmt_NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold_label_en-US" xlink:label="lab_smmt_NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Related Parties, Potential Prepayment, Triggering Event, Public Offering Net Proceeds Threshold</link:label>
    <link:label id="lab_smmt_NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold_documentation_en-US" xlink:label="lab_smmt_NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Related Parties, Potential Prepayment, Triggering Event, Public Offering Net Proceeds Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold" xlink:href="smmt-20231231.xsd#smmt_NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold" xlink:to="lab_smmt_NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPayment_da33160c-f497-4f83-bc08-46ecd3ba65db_terseLabel_en-US" xlink:label="lab_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, upfront payment</link:label>
    <link:label id="lab_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPayment_label_en-US" xlink:label="lab_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Upfront Payment</link:label>
    <link:label id="lab_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPayment_documentation_en-US" xlink:label="lab_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:href="smmt-20231231.xsd#smmt_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:to="lab_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_27778f2a-f1c1-4b9e-ad2f-3d190c4084b1_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering cots</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b54b8e8a-4941-40cb-b43d-3242834a8fcb_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrentAbstract_ba483ac5-ade9-405d-816a-31a02ce925d2_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current notes</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrentAbstract" xlink:to="lab_us-gaap_NotesPayableCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_57e51b0d-2915-4736-a777-462b5c8c4781_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_b5d837bb-e028-462e-8be5-0f2574d2c254_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of potentially dilutive securities excluded from the computation of loss per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_47c8f60f-e3b9-42bc-808a-ff5a006c3ce3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense on promissory notes payable to related parties</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_4666a86e-1cb4-41fb-9d52-27bac5f6555c_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_b166ba9a-0d9a-48ba-8521-fcdbaa8b74c2_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of lease expense</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_a581d041-403a-4d76-be4d-ec10d8a700c8_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3c777f2e-7e66-4505-9361-bf780910dc58_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows used in investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage_3c264bad-9187-4a67-9326-ac457206af66_terseLabel_en-US" xlink:label="lab_smmt_ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum volume weighted average common stock price to warrant exercise price, premium, percentage</link:label>
    <link:label id="lab_smmt_ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage_label_en-US" xlink:label="lab_smmt_ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Minimum Ten Day Volume Weighted Average Common Stock Price to Warrant Exercise Price, Premium, Percentage</link:label>
    <link:label id="lab_smmt_ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage_documentation_en-US" xlink:label="lab_smmt_ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Minimum Ten Day Volume Weighted Average Common Stock Price to Warrant Exercise Price, Premium, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage" xlink:href="smmt-20231231.xsd#smmt_ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage" xlink:to="lab_smmt_ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_93b34744-bcf3-449e-9ee3-29c610c15c64_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8294f10e-810d-4874-922e-25a70aef8fac_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potentially dilutive securities excluded from the computation of diluted loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_75d61508-dbdf-4f2c-bc05-c514e71d75bc_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_AuditInformationAbstract_label_en-US" xlink:label="lab_smmt_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_smmt_AuditInformationAbstract_documentation_en-US" xlink:label="lab_smmt_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_AuditInformationAbstract" xlink:href="smmt-20231231.xsd#smmt_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_AuditInformationAbstract" xlink:to="lab_smmt_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_1732ce15-af4a-42e6-97ac-e2a75ed08023_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1a624a67-a7e3-453f-9c1a-f2cbb0d6da34_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_52964044-0a6f-4245-b879-8611198b5792_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_32bf633d-05b1-40ad-8c7d-e21977ec0831_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_c8aae85f-d090-4c33-8f92-11f02813811a_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_ae8d39ef-1a93-4753-8159-98d8b7b73eee_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f7e6da85-87f1-453b-bde6-cb28cd4f791f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term, options outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_0b555e90-e189-42f5-bc87-306599de6808_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leased assets obtained in exchange for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_8804dd24-9d82-4b08-9b1a-93927abe204b_verboseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional right-of-use assets recorded</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_00ca9b43-6840-4dc7-80e2-93883a5645b7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_e21f7913-a004-4d88-809c-2c8f4d238e5a_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promissory Notes Payable to Related Parties</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_c58c7b0d-816b-4670-a36f-3d27cacd038f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ef563297-0f7d-4968-a8d3-0b2a44047d67_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_OtherOperatingIncomePolicyPolicyTextBlock_c3a236ce-267a-477d-a783-89de0f1a6dbe_terseLabel_en-US" xlink:label="lab_smmt_OtherOperatingIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income</link:label>
    <link:label id="lab_smmt_OtherOperatingIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_smmt_OtherOperatingIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income, Policy [Policy Text Block]</link:label>
    <link:label id="lab_smmt_OtherOperatingIncomePolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_smmt_OtherOperatingIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_OtherOperatingIncomePolicyPolicyTextBlock" xlink:href="smmt-20231231.xsd#smmt_OtherOperatingIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_OtherOperatingIncomePolicyPolicyTextBlock" xlink:to="lab_smmt_OtherOperatingIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_1287f12a-be0c-4b1d-ba47-7857defbe3fd_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPotentialNumberOfAdditionalSharesAllowableUnderThePlan_34caa52a-3dfa-4af6-98c9-0d3e02bb46bf_terseLabel_en-US" xlink:label="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPotentialNumberOfAdditionalSharesAllowableUnderThePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential number of additional shares that can be added to the plan for future issuance (in shares)</link:label>
    <link:label id="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPotentialNumberOfAdditionalSharesAllowableUnderThePlan_label_en-US" xlink:label="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPotentialNumberOfAdditionalSharesAllowableUnderThePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Potential Number of Additional Shares Allowable Under The Plan</link:label>
    <link:label id="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPotentialNumberOfAdditionalSharesAllowableUnderThePlan_documentation_en-US" xlink:label="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPotentialNumberOfAdditionalSharesAllowableUnderThePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Potential Number of Additional Shares Allowable Under The Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPotentialNumberOfAdditionalSharesAllowableUnderThePlan" xlink:href="smmt-20231231.xsd#smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPotentialNumberOfAdditionalSharesAllowableUnderThePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPotentialNumberOfAdditionalSharesAllowableUnderThePlan" xlink:to="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPotentialNumberOfAdditionalSharesAllowableUnderThePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_11c4a922-44e9-4929-b8c6-cd2f6a194425_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d64a9581-4bd6-4726-9720-81e3db71fc3d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_6d9d7d67-7e23-45b9-9c71-a170a0f24629_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_5f97855a-64d4-4161-a71f-a967e5c4f6c8_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_248ea994-2908-4818-8a4a-f14ecb090d7a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_ba6284c3-b765-4151-a412-620f1733a981_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_3ae5b8e3-dc16-4ef1-92a4-00870e7d62ec_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_OperatingLeaseRightOfUseAssetDisposals_41d8aa05-242a-4964-8101-969e5bdfd05b_terseLabel_en-US" xlink:label="lab_smmt_OperatingLeaseRightOfUseAssetDisposals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal of right-of-use asset</link:label>
    <link:label id="lab_smmt_OperatingLeaseRightOfUseAssetDisposals_label_en-US" xlink:label="lab_smmt_OperatingLeaseRightOfUseAssetDisposals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Disposals</link:label>
    <link:label id="lab_smmt_OperatingLeaseRightOfUseAssetDisposals_documentation_en-US" xlink:label="lab_smmt_OperatingLeaseRightOfUseAssetDisposals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Disposals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_OperatingLeaseRightOfUseAssetDisposals" xlink:href="smmt-20231231.xsd#smmt_OperatingLeaseRightOfUseAssetDisposals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_OperatingLeaseRightOfUseAssetDisposals" xlink:to="lab_smmt_OperatingLeaseRightOfUseAssetDisposals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_855ad2f4-74ff-4be4-b8a9-1e3923f1149e_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_label_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Software, Intangible Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_17b2b756-7e42-41a5-908e-f8c21cd54601_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decreases related to prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_d99a4561-1ed6-4b26-8a02-a85bdb53ff76_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_8dab45f9-7e83-4514-b57a-fcf2a2b755d7_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_94b41db3-5848-4b37-8b8f-e93b8979c96f_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_88ac8488-b737-4499-9aaf-e8aec35116ad_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6007d60d-2f99-4ae0-a1b6-7d9926dbd3d5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentPaidInShares_8eca55d9-3e35-4835-a438-057853260ca8_terseLabel_en-US" xlink:label="lab_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentPaidInShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, upfront payment, paid in shares</link:label>
    <link:label id="lab_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentPaidInShares_label_en-US" xlink:label="lab_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentPaidInShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Upfront Payment, Paid In Shares</link:label>
    <link:label id="lab_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentPaidInShares_documentation_en-US" xlink:label="lab_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentPaidInShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Upfront Payment, Paid In Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentPaidInShares" xlink:href="smmt-20231231.xsd#smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentPaidInShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentPaidInShares" xlink:to="lab_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentPaidInShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_16b8bfa0-e165-4300-94bd-11de122d7ade_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_b110d5d4-5a64-4333-a309-92ea45ac0635_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ae1354cc-c5f9-474a-a3b2-a844e92bb310_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Issued or Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_dbdd590d-cbe3-4c37-a872-e0f2c793b9f7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_842c53d1-3ae9-4a0e-876d-f02614fc0a59_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_17cf3e79-3ea4-49d8-8b07-de457ab63f71_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases related to current year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_cf5788d0-81aa-4007-a246-680f8e7195ea_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4f45172e-493e-43aa-a471-acb56df02541_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6b1e8c6c-8c19-4286-9263-2347e2090b38_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3963e15d-3b1c-41dd-9301-ae7bae55e313_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_SignificantAccountingPoliciesTable_ebf2fd1f-841d-45ee-8496-8f4efea39dbb_terseLabel_en-US" xlink:label="lab_smmt_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_smmt_SignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_smmt_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_smmt_SignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_smmt_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_SignificantAccountingPoliciesTable" xlink:href="smmt-20231231.xsd#smmt_SignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_SignificantAccountingPoliciesTable" xlink:to="lab_smmt_SignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_4b9396f5-3156-4384-9099-93a7a1e3e01a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of loss before income taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_bb348077-2d1b-4d95-9855-da5aefcc70a1_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_e42b83c4-784b-48be-91b9-2e93b62ddae6_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_9c02b16d-31e0-44b9-9ee4-256248c810be_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease costs</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_8629e245-37ae-4aa6-965a-fa898193c724_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_25d617d6-f843-4b21-a0a7-9c5db92917c0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_a70240a7-e8b5-4ccb-a1d5-e3ace168b848_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod_e07f0c43-9ee1-41f3-8b35-5b0119221c71_terseLabel_en-US" xlink:label="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consecutive offering period</link:label>
    <link:label id="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod_label_en-US" xlink:label="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Consecutive Offering Period</link:label>
    <link:label id="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod_documentation_en-US" xlink:label="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Consecutive Offering Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod" xlink:href="smmt-20231231.xsd#smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod" xlink:to="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_c6d41894-da08-4f08-99ab-0e23ba1dfb8d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f959d1c1-3a6f-4749-8efc-d20d42ed7899_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of weighted-average assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_2ff7459a-6d80-48b5-a4bd-ae08f5c58994_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_6b75485a-792d-4cc6-8211-391decc76685_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_d5f8467e-01d9-4942-9340-eeb40ddbfa22_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_76bc06f6-b95a-4943-bde4-ac5055df83a1_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_36584108-bc17-4871-8176-036fa3eae0b3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock_d7233b06-c925-4e12-a901-97861cff07de_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Non-Current Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Noncurrent [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_2d975821-dd3a-4f4e-a317-5cc3ee60ed9e_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Akeso License and Collaboration Agreement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_f88a587d-3d11-4c91-801c-efb539cf0a2d_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_3964597e-6dfb-4d20-8785-4137eccbd879_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b1059a48-ca25-4967-999f-1b51413f272e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense for options, period of recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_e7386303-1152-477b-b9b0-1e941b140d86_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_5f7a8e5b-4b0b-4087-98a5-d2ff5f4b56ba_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_9b22ded3-7bd1-4fcd-8661-6e1bc087d2d6_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_3bb6d144-226c-4893-83c3-c193c59e3216_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_StockIssuedDuringPeriodValueIssuedForRelatedPartyInterest_7de76cff-e1ab-4a66-b04b-af4b1199ff5f_terseLabel_en-US" xlink:label="lab_smmt_StockIssuedDuringPeriodValueIssuedForRelatedPartyInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in lieu of interest to related parties</link:label>
    <link:label id="lab_smmt_StockIssuedDuringPeriodValueIssuedForRelatedPartyInterest_label_en-US" xlink:label="lab_smmt_StockIssuedDuringPeriodValueIssuedForRelatedPartyInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Issued For Related Party Interest</link:label>
    <link:label id="lab_smmt_StockIssuedDuringPeriodValueIssuedForRelatedPartyInterest_documentation_en-US" xlink:label="lab_smmt_StockIssuedDuringPeriodValueIssuedForRelatedPartyInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Issued For Related Party Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_StockIssuedDuringPeriodValueIssuedForRelatedPartyInterest" xlink:href="smmt-20231231.xsd#smmt_StockIssuedDuringPeriodValueIssuedForRelatedPartyInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_StockIssuedDuringPeriodValueIssuedForRelatedPartyInterest" xlink:to="lab_smmt_StockIssuedDuringPeriodValueIssuedForRelatedPartyInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_c4d344c7-d486-4563-aa8e-8c6c898999b8_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_21f150c6-ef38-4f95-8812-61c80d82a0c4_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_c10818f6-d036-424e-80c0-6f60e5f8eb58_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominator_1793a697-0314-4470-8599-ac1876eedefe_terseLabel_en-US" xlink:label="lab_smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominator" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid interest, conversion amount (in dollars per share)</link:label>
    <link:label id="lab_smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominator_label_en-US" xlink:label="lab_smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominator" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Related Party, Prepaid Interest, Equity Interests Issuable Calculation, Denominator</link:label>
    <link:label id="lab_smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominator_documentation_en-US" xlink:label="lab_smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominator" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Related Party, Prepaid Interest, Equity Interests Issuable Calculation, Denominator</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominator" xlink:href="smmt-20231231.xsd#smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominator" xlink:to="lab_smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominator" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_74743e92-cf81-4714-916f-ca6b77794b91_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_43f62fae-8571-4fd2-a597-bb2f85628af8_terseLabel_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer</link:label>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember" xlink:to="lab_srt_ChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_59648a40-1c30-4eb2-b7fa-a8cb6702674e_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_ddd422ce-f78a-4c0c-8139-7f295ee7e482_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current provision for federal income taxes</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c5e88458-ecb2-4c51-9ef7-6f04f7b57fe9_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_652c0cc4-233e-4831-a803-f1cd9b3b495a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_EmployeeStockOptionTimeBasedMember_14995ccb-1c62-4eb8-8054-073abf1f40cd_terseLabel_en-US" xlink:label="lab_smmt_EmployeeStockOptionTimeBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-based stock options</link:label>
    <link:label id="lab_smmt_EmployeeStockOptionTimeBasedMember_label_en-US" xlink:label="lab_smmt_EmployeeStockOptionTimeBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option, Time-Based [Member]</link:label>
    <link:label id="lab_smmt_EmployeeStockOptionTimeBasedMember_documentation_en-US" xlink:label="lab_smmt_EmployeeStockOptionTimeBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option, Time-Based</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_EmployeeStockOptionTimeBasedMember" xlink:href="smmt-20231231.xsd#smmt_EmployeeStockOptionTimeBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_EmployeeStockOptionTimeBasedMember" xlink:to="lab_smmt_EmployeeStockOptionTimeBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentSharesOfCommonStockIssuedInLieuOfCash_c0d492c6-81ec-45ce-85b8-4b41abaa10ed_terseLabel_en-US" xlink:label="lab_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentSharesOfCommonStockIssuedInLieuOfCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, common stock issued in lieu of cash upfront payment (in shares)</link:label>
    <link:label id="lab_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentSharesOfCommonStockIssuedInLieuOfCash_label_en-US" xlink:label="lab_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentSharesOfCommonStockIssuedInLieuOfCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Upfront Payment, Shares Of Common Stock Issued In Lieu Of Cash</link:label>
    <link:label id="lab_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentSharesOfCommonStockIssuedInLieuOfCash_documentation_en-US" xlink:label="lab_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentSharesOfCommonStockIssuedInLieuOfCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Upfront Payment, Shares Of Common Stock Issued In Lieu Of Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentSharesOfCommonStockIssuedInLieuOfCash" xlink:href="smmt-20231231.xsd#smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentSharesOfCommonStockIssuedInLieuOfCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentSharesOfCommonStockIssuedInLieuOfCash" xlink:to="lab_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentSharesOfCommonStockIssuedInLieuOfCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionRate_2989d883-7588-47b3-8960-66d5fc2a7f57_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionRate_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionRate" xlink:to="lab_us-gaap_RelatedPartyTransactionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_fd8d16c6-90f9-40f2-8f85-41ab7f202b47_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_7c3e08fe-606d-4bb0-a4fb-6116bd8bb47a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum common stock purchase allowable as a percentage of compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_d972d084-89eb-48bf-a02d-557c87e7b5a8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_0a3bae4f-90c5-40e2-9376-3e62f08acb88_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for interest and penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_DugganPromissoryNotesMember_79179f6d-32b7-4ce7-bb1d-8e9acc6f2134_terseLabel_en-US" xlink:label="lab_smmt_DugganPromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duggan Promissory Notes</link:label>
    <link:label id="lab_smmt_DugganPromissoryNotesMember_label_en-US" xlink:label="lab_smmt_DugganPromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duggan Promissory Notes [Member]</link:label>
    <link:label id="lab_smmt_DugganPromissoryNotesMember_documentation_en-US" xlink:label="lab_smmt_DugganPromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duggan Promissory Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DugganPromissoryNotesMember" xlink:href="smmt-20231231.xsd#smmt_DugganPromissoryNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_DugganPromissoryNotesMember" xlink:to="lab_smmt_DugganPromissoryNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_fb2367de-e0f1-472d-ad78-2c66c4128b98_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred provision for state income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_GrantFundingArrangementIncomeEarned_31934762-0e22-4623-99a6-6be66d95408f_terseLabel_en-US" xlink:label="lab_smmt_GrantFundingArrangementIncomeEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding/Grant income</link:label>
    <link:label id="lab_smmt_GrantFundingArrangementIncomeEarned_label_en-US" xlink:label="lab_smmt_GrantFundingArrangementIncomeEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Funding Arrangement, Income Earned</link:label>
    <link:label id="lab_smmt_GrantFundingArrangementIncomeEarned_documentation_en-US" xlink:label="lab_smmt_GrantFundingArrangementIncomeEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Funding Arrangement, Income Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GrantFundingArrangementIncomeEarned" xlink:href="smmt-20231231.xsd#smmt_GrantFundingArrangementIncomeEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_GrantFundingArrangementIncomeEarned" xlink:to="lab_smmt_GrantFundingArrangementIncomeEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_4b8d2a2f-a540-4319-9a54-2cd3625889bf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_ee97a6c3-7217-4e99-bfe8-e148bf56fe2e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_741997f3-666d-44a6-a368-cbe6631a7465_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_PaymentsForCollaborativeArrangement_1893122b-cf8b-4105-82af-6b004680074e_negatedTerseLabel_en-US" xlink:label="lab_smmt_PaymentsForCollaborativeArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Akeso for upfront milestone payments and associated direct transaction costs</link:label>
    <link:label id="lab_smmt_PaymentsForCollaborativeArrangement_label_en-US" xlink:label="lab_smmt_PaymentsForCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Collaborative Arrangement</link:label>
    <link:label id="lab_smmt_PaymentsForCollaborativeArrangement_documentation_en-US" xlink:label="lab_smmt_PaymentsForCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Collaborative Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_PaymentsForCollaborativeArrangement" xlink:href="smmt-20231231.xsd#smmt_PaymentsForCollaborativeArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_PaymentsForCollaborativeArrangement" xlink:to="lab_smmt_PaymentsForCollaborativeArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable_701dc8e3-f53f-483c-9acc-87bb849368af_negatedTerseLabel_en-US" xlink:label="lab_smmt_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credit receivable</link:label>
    <link:label id="lab_smmt_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable_label_en-US" xlink:label="lab_smmt_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Research And Development Tax Credit Receivable</link:label>
    <link:label id="lab_smmt_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable_documentation_en-US" xlink:label="lab_smmt_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Research And Development Tax Credit Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable" xlink:href="smmt-20231231.xsd#smmt_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable" xlink:to="lab_smmt_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_7fa0cd50-6db1-4e2a-8367-df898c1c4e3f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2ae2c535-9e07-4351-8d92-5c735476d7d6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rights Offering of common stock, net of offering costs/ Private placement of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0e3dd438-3dc2-403e-a742-122c576a437d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_0d0b0f9a-8bf4-42ab-a016-86413f77e8fc_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_8195b73d-52be-4562-baaa-9f24f08e83f3_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_18d941df-3049-47b6-b55f-9f11b654c5fe_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common stock shares into which each warrant converts (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_GrantFundingArrangementCommittedFundingTotal_34caa565-0f55-4f3b-bf3b-81264d1b81ce_terseLabel_en-US" xlink:label="lab_smmt_GrantFundingArrangementCommittedFundingTotal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total committed funding</link:label>
    <link:label id="lab_smmt_GrantFundingArrangementCommittedFundingTotal_label_en-US" xlink:label="lab_smmt_GrantFundingArrangementCommittedFundingTotal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Funding Arrangement, Committed Funding, Total</link:label>
    <link:label id="lab_smmt_GrantFundingArrangementCommittedFundingTotal_documentation_en-US" xlink:label="lab_smmt_GrantFundingArrangementCommittedFundingTotal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Funding Arrangement, Committed Funding, Total</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GrantFundingArrangementCommittedFundingTotal" xlink:href="smmt-20231231.xsd#smmt_GrantFundingArrangementCommittedFundingTotal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_GrantFundingArrangementCommittedFundingTotal" xlink:to="lab_smmt_GrantFundingArrangementCommittedFundingTotal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e723669e-0681-4820-a307-259653371b30_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under stock purchase plans and exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_4603017f-a95d-4f5b-ba4a-9165fb970e66_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_b95ae91f-e029-4224-9382-18573b477cbc_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_LiquidityAndCapitalResourcesTextBlock_aecec1b6-43bf-4dcf-b363-cdfc490473d4_terseLabel_en-US" xlink:label="lab_smmt_LiquidityAndCapitalResourcesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity and Capital Resources</link:label>
    <link:label id="lab_smmt_LiquidityAndCapitalResourcesTextBlock_label_en-US" xlink:label="lab_smmt_LiquidityAndCapitalResourcesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity and Capital Resources [Text Block]</link:label>
    <link:label id="lab_smmt_LiquidityAndCapitalResourcesTextBlock_documentation_en-US" xlink:label="lab_smmt_LiquidityAndCapitalResourcesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity and Capital Resources</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_LiquidityAndCapitalResourcesTextBlock" xlink:href="smmt-20231231.xsd#smmt_LiquidityAndCapitalResourcesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_LiquidityAndCapitalResourcesTextBlock" xlink:to="lab_smmt_LiquidityAndCapitalResourcesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_DeferredTransactionCostsIncurredDuringNoncashOrPartialNoncashTransaction_c838090c-a7bc-4532-ab23-bfd0dc75ef24_terseLabel_en-US" xlink:label="lab_smmt_DeferredTransactionCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred transaction costs included in other non-current assets</link:label>
    <link:label id="lab_smmt_DeferredTransactionCostsIncurredDuringNoncashOrPartialNoncashTransaction_label_en-US" xlink:label="lab_smmt_DeferredTransactionCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Transaction Costs Incurred During Noncash Or Partial Noncash Transaction</link:label>
    <link:label id="lab_smmt_DeferredTransactionCostsIncurredDuringNoncashOrPartialNoncashTransaction_documentation_en-US" xlink:label="lab_smmt_DeferredTransactionCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Transaction Costs Incurred During Noncash Or Partial Noncash Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DeferredTransactionCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:href="smmt-20231231.xsd#smmt_DeferredTransactionCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_DeferredTransactionCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="lab_smmt_DeferredTransactionCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_StockIssuedDuringPeriodValueWarrantsExercised_2d95f250-b37b-4a47-ac92-c2a73cf0aef2_terseLabel_en-US" xlink:label="lab_smmt_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of warrants</link:label>
    <link:label id="lab_smmt_StockIssuedDuringPeriodValueWarrantsExercised_label_en-US" xlink:label="lab_smmt_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised</link:label>
    <link:label id="lab_smmt_StockIssuedDuringPeriodValueWarrantsExercised_documentation_en-US" xlink:label="lab_smmt_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_StockIssuedDuringPeriodValueWarrantsExercised" xlink:href="smmt-20231231.xsd#smmt_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="lab_smmt_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment_5a0c5936-e487-4648-8010-870ae1ec2910_negatedTerseLabel_en-US" xlink:label="lab_smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated amortization and impairment charges</link:label>
    <link:label id="lab_smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment_label_en-US" xlink:label="lab_smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization And Impairment</link:label>
    <link:label id="lab_smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment_documentation_en-US" xlink:label="lab_smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization And Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment" xlink:href="smmt-20231231.xsd#smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment" xlink:to="lab_smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_7931deb2-6786-4f85-a1c9-ada38881ce7b_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements and Short-Term Investments</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_a8e2e284-dabc-445e-9d9a-ca417c9fb65a_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_ae095918-a7b2-4fb4-9f9a-701407448dde_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_df97d69b-d3a8-4a5e-9aa5-ed4739f9af5f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the issuance of common stock via private placement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_StockIssuedDuringPeriodSharesIssuedForRelatedPartyInterest_805bad48-50c4-4c22-af34-87aabe89fedc_terseLabel_en-US" xlink:label="lab_smmt_StockIssuedDuringPeriodSharesIssuedForRelatedPartyInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in lieu of interest to related parties (in shares)</link:label>
    <link:label id="lab_smmt_StockIssuedDuringPeriodSharesIssuedForRelatedPartyInterest_label_en-US" xlink:label="lab_smmt_StockIssuedDuringPeriodSharesIssuedForRelatedPartyInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Issued For Related Party Interest</link:label>
    <link:label id="lab_smmt_StockIssuedDuringPeriodSharesIssuedForRelatedPartyInterest_documentation_en-US" xlink:label="lab_smmt_StockIssuedDuringPeriodSharesIssuedForRelatedPartyInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Issued For Related Party Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_StockIssuedDuringPeriodSharesIssuedForRelatedPartyInterest" xlink:href="smmt-20231231.xsd#smmt_StockIssuedDuringPeriodSharesIssuedForRelatedPartyInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_StockIssuedDuringPeriodSharesIssuedForRelatedPartyInterest" xlink:to="lab_smmt_StockIssuedDuringPeriodSharesIssuedForRelatedPartyInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_e5ec3fb6-7e23-49b2-9ede-73a1b44270b5_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement_bac57710-f38c-450e-b293-13fde73934b5_terseLabel_en-US" xlink:label="lab_smmt_StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in lieu of cash for Akeso upfront payment</link:label>
    <link:label id="lab_smmt_StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement_label_en-US" xlink:label="lab_smmt_StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, In Lieu Of Cash For Collaborative Arrangement</link:label>
    <link:label id="lab_smmt_StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement_documentation_en-US" xlink:label="lab_smmt_StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, In Lieu Of Cash For Collaborative Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement" xlink:href="smmt-20231231.xsd#smmt_StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement" xlink:to="lab_smmt_StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_7e4b25eb-95fa-40ea-b9dc-4b8c1bf606a6_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_87cac50e-4966-4ec8-b9ac-69a341c2586e_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_StockIssuedDuringPeriodSharesWarrantsExercised_d2f94cf6-16a7-41b3-af88-dfc6de10b04d_terseLabel_en-US" xlink:label="lab_smmt_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of warrants (in shares)</link:label>
    <link:label id="lab_smmt_StockIssuedDuringPeriodSharesWarrantsExercised_label_en-US" xlink:label="lab_smmt_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:label id="lab_smmt_StockIssuedDuringPeriodSharesWarrantsExercised_documentation_en-US" xlink:label="lab_smmt_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:href="smmt-20231231.xsd#smmt_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="lab_smmt_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_CollaborativeArrangementRightsAndObligationsDirectTransactionCosts_4912e8dd-6491-42b7-abeb-abbbe8716cad_terseLabel_en-US" xlink:label="lab_smmt_CollaborativeArrangementRightsAndObligationsDirectTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, direct transaction costs</link:label>
    <link:label id="lab_smmt_CollaborativeArrangementRightsAndObligationsDirectTransactionCosts_label_en-US" xlink:label="lab_smmt_CollaborativeArrangementRightsAndObligationsDirectTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Direct Transaction Costs</link:label>
    <link:label id="lab_smmt_CollaborativeArrangementRightsAndObligationsDirectTransactionCosts_documentation_en-US" xlink:label="lab_smmt_CollaborativeArrangementRightsAndObligationsDirectTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Direct Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CollaborativeArrangementRightsAndObligationsDirectTransactionCosts" xlink:href="smmt-20231231.xsd#smmt_CollaborativeArrangementRightsAndObligationsDirectTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_CollaborativeArrangementRightsAndObligationsDirectTransactionCosts" xlink:to="lab_smmt_CollaborativeArrangementRightsAndObligationsDirectTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_3ea6f21e-2709-4e23-af4b-92624a1e4888_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember_0fd576e4-4f7e-4675-ae46-4a403ac49b5f_terseLabel_en-US" xlink:label="lab_smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARB-X</link:label>
    <link:label id="lab_smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember_label_en-US" xlink:label="lab_smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator Program [Member]</link:label>
    <link:label id="lab_smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember_documentation_en-US" xlink:label="lab_smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember" xlink:href="smmt-20231231.xsd#smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember" xlink:to="lab_smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ContractWithCustomerLiabilityAdditions_d7d760f3-2b9f-4fff-a593-1cbcbfa6f4a3_terseLabel_en-US" xlink:label="lab_smmt_ContractWithCustomerLiabilityAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_smmt_ContractWithCustomerLiabilityAdditions_label_en-US" xlink:label="lab_smmt_ContractWithCustomerLiabilityAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Additions</link:label>
    <link:label id="lab_smmt_ContractWithCustomerLiabilityAdditions_documentation_en-US" xlink:label="lab_smmt_ContractWithCustomerLiabilityAdditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ContractWithCustomerLiabilityAdditions" xlink:href="smmt-20231231.xsd#smmt_ContractWithCustomerLiabilityAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ContractWithCustomerLiabilityAdditions" xlink:to="lab_smmt_ContractWithCustomerLiabilityAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_RightsOfferingMember_291899dc-0a43-41d8-a3be-eb5dc1447aac_terseLabel_en-US" xlink:label="lab_smmt_RightsOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rights Offering</link:label>
    <link:label id="lab_smmt_RightsOfferingMember_label_en-US" xlink:label="lab_smmt_RightsOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rights Offering [Member]</link:label>
    <link:label id="lab_smmt_RightsOfferingMember_documentation_en-US" xlink:label="lab_smmt_RightsOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rights Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RightsOfferingMember" xlink:href="smmt-20231231.xsd#smmt_RightsOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_RightsOfferingMember" xlink:to="lab_smmt_RightsOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_32193cec-decb-4573-8e7d-618ec9c30eb2_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance_f072cf73-e067-4e7b-b24d-a3d5914e9b20_negatedTerseLabel_en-US" xlink:label="lab_smmt_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of deferred revenue and other income recognized in the statement of operations</link:label>
    <link:label id="lab_smmt_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance_label_en-US" xlink:label="lab_smmt_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized, Including Opening Balance</link:label>
    <link:label id="lab_smmt_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance_documentation_en-US" xlink:label="lab_smmt_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized, Including Opening Balance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance" xlink:href="smmt-20231231.xsd#smmt_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance" xlink:to="lab_smmt_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward_75c7e53e-fcae-4c2c-929a-658d7c2bc731_terseLabel_en-US" xlink:label="lab_smmt_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:label id="lab_smmt_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward_label_en-US" xlink:label="lab_smmt_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant Or Right, Outstanding, Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_smmt_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward_documentation_en-US" xlink:label="lab_smmt_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant Or Right, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward" xlink:href="smmt-20231231.xsd#smmt_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward" xlink:to="lab_smmt_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_0ea9ba62-e0ae-44c2-a4ab-e5547d45ffa3_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_949723f4-4f09-4dd9-a829-3142d7c74638_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred provision for non-United States income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_UtrophinProgramMember_a87516c2-d238-4c17-a793-64b12526d45d_terseLabel_en-US" xlink:label="lab_smmt_UtrophinProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Utrophin program</link:label>
    <link:label id="lab_smmt_UtrophinProgramMember_label_en-US" xlink:label="lab_smmt_UtrophinProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Utrophin Program [Member]</link:label>
    <link:label id="lab_smmt_UtrophinProgramMember_documentation_en-US" xlink:label="lab_smmt_UtrophinProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Utrophin Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_UtrophinProgramMember" xlink:href="smmt-20231231.xsd#smmt_UtrophinProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_UtrophinProgramMember" xlink:to="lab_smmt_UtrophinProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9414e917-4571-44c9-8f94-06794d11ea9c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_8861cf51-91ee-4a74-ae63-0cdaadecebcf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_39bf4f80-c182-40aa-b629-d5030b604ea2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of other (expense) income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_DeferredTaxAssetsValuationAllowanceRollForward_bd8cbf6b-9fb0-4105-82de-ef4692ccdc41_terseLabel_en-US" xlink:label="lab_smmt_DeferredTaxAssetsValuationAllowanceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance [Roll Forward]</link:label>
    <link:label id="lab_smmt_DeferredTaxAssetsValuationAllowanceRollForward_label_en-US" xlink:label="lab_smmt_DeferredTaxAssetsValuationAllowanceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance [Roll Forward]</link:label>
    <link:label id="lab_smmt_DeferredTaxAssetsValuationAllowanceRollForward_documentation_en-US" xlink:label="lab_smmt_DeferredTaxAssetsValuationAllowanceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DeferredTaxAssetsValuationAllowanceRollForward" xlink:href="smmt-20231231.xsd#smmt_DeferredTaxAssetsValuationAllowanceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_DeferredTaxAssetsValuationAllowanceRollForward" xlink:to="lab_smmt_DeferredTaxAssetsValuationAllowanceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_257cad8c-c231-404e-99c8-d3766bb3c9e9_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_eb1ee8e7-8611-4649-8e6a-e8f67f61e32d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember_94187ae0-6953-451f-ba51-efd2d1f04bfe_terseLabel_en-US" xlink:label="lab_smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer and Chief Executive Officer and President</link:label>
    <link:label id="lab_smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember_label_en-US" xlink:label="lab_smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer And Chief Executive Officer And President [Member]</link:label>
    <link:label id="lab_smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember_documentation_en-US" xlink:label="lab_smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer And Chief Executive Officer And President</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember" xlink:href="smmt-20231231.xsd#smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember" xlink:to="lab_smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_caa09b7f-a51c-4273-ad06-d2b87b8200cf_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_SignificantAccountingPoliciesLineItems_01c07b62-0a00-4bc0-bcaf-f19751ce6511_terseLabel_en-US" xlink:label="lab_smmt_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_smmt_SignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_smmt_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_smmt_SignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_smmt_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_SignificantAccountingPoliciesLineItems" xlink:href="smmt-20231231.xsd#smmt_SignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_SignificantAccountingPoliciesLineItems" xlink:to="lab_smmt_SignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_886652ae-8539-4c60-9d19-a9c0ba58bbed_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_f7ee2d10-0d01-4a4a-84f1-aa75475b9669_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_96cd3174-ef55-4727-ad70-48559abe6488_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_a67fd468-441c-4bcc-99ac-712ed074f0c2_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0abe9ce1-93fe-481a-b3f9-bb91d61ba5ba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major components of deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_ef30dd75-1ef9-4c7c-a172-bf76751cdc87_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_59c1c0e0-3cb9-4845-b279-8276c08dd921_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty_9a35c9a8-d903-4321-b53c-89c25a9e140d_terseLabel_en-US" xlink:label="lab_smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imputed interest expense on promissory note payable to a related party</link:label>
    <link:label id="lab_smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty_label_en-US" xlink:label="lab_smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Imputed Interest Expense, Related Party</link:label>
    <link:label id="lab_smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty_documentation_en-US" xlink:label="lab_smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Imputed Interest Expense, Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty" xlink:href="smmt-20231231.xsd#smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty" xlink:to="lab_smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_71db410f-5747-4087-ba72-73aafe002241_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_88304447-3212-483c-b5aa-c71312f4eb0e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows used in operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_008fd74e-8ebe-44ff-a52d-9dc2b2e4a50e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_64481f2b-d12b-4925-bc1f-c56f71f8d16d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_82650715-48c4-4ab5-9a26-1853da3b245e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments related to lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5c585b6b-f932-471a-8576-fbb0a59143e3_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on short-term investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_4ac66c2c-c04d-488c-bf19-eb14a87fd531_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on short-term investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_20024c59-cab2-4821-82ab-54a3d256e9d8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ac157278-ae86-43ed-9fef-81acaeea44df_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_62a1d75f-8eb2-40a2-83f8-e71f44ab9976_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_DugganFebruaryNoteMember_a1e85f40-57c1-4560-8952-c990fe5b5239_terseLabel_en-US" xlink:label="lab_smmt_DugganFebruaryNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duggan February Note</link:label>
    <link:label id="lab_smmt_DugganFebruaryNoteMember_label_en-US" xlink:label="lab_smmt_DugganFebruaryNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duggan February Note [Member]</link:label>
    <link:label id="lab_smmt_DugganFebruaryNoteMember_documentation_en-US" xlink:label="lab_smmt_DugganFebruaryNoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duggan February Note</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DugganFebruaryNoteMember" xlink:href="smmt-20231231.xsd#smmt_DugganFebruaryNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_DugganFebruaryNoteMember" xlink:to="lab_smmt_DugganFebruaryNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_01921208-1ef9-4c52-87d4-eed83ca6f79c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk and of Significant Supplier</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_bdea87b7-0b7e-408d-be31-0666e754a9f9_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayable_8f025aa6-7826-4fa7-a224-6f86e52f5e90_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promissory note</link:label>
    <link:label id="lab_us-gaap_NotesPayable_label_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable" xlink:to="lab_us-gaap_NotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_DeferredTaxAssetsLiabilities_2e5ff4e8-45ff-49e4-949a-775cbafa3f56_totalLabel_en-US" xlink:label="lab_smmt_DeferredTaxAssetsLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets before valuation allowance</link:label>
    <link:label id="lab_smmt_DeferredTaxAssetsLiabilities_label_en-US" xlink:label="lab_smmt_DeferredTaxAssetsLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets (Liabilities)</link:label>
    <link:label id="lab_smmt_DeferredTaxAssetsLiabilities_documentation_en-US" xlink:label="lab_smmt_DeferredTaxAssetsLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets (Liabilities)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DeferredTaxAssetsLiabilities" xlink:href="smmt-20231231.xsd#smmt_DeferredTaxAssetsLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_DeferredTaxAssetsLiabilities" xlink:to="lab_smmt_DeferredTaxAssetsLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_2e9caa1c-fd95-4236-80de-bd18b15d35b1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_65273b09-c20b-433f-8901-decf945b0ff8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_7819e01c-1cac-4435-bb20-292f069ee243_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_24a19362-ffd4-4850-9693-ae92cbfd59ac_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_OtherCommitmentIncreaseDecrease_b8c135b7-76f7-40ca-94ec-4dd8581d9c33_terseLabel_en-US" xlink:label="lab_smmt_OtherCommitmentIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional contractual commitments</link:label>
    <link:label id="lab_smmt_OtherCommitmentIncreaseDecrease_label_en-US" xlink:label="lab_smmt_OtherCommitmentIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment, Increase (Decrease)</link:label>
    <link:label id="lab_smmt_OtherCommitmentIncreaseDecrease_documentation_en-US" xlink:label="lab_smmt_OtherCommitmentIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_OtherCommitmentIncreaseDecrease" xlink:href="smmt-20231231.xsd#smmt_OtherCommitmentIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_OtherCommitmentIncreaseDecrease" xlink:to="lab_smmt_OtherCommitmentIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9ce159ef-7264-45db-8f8e-c9f95239835b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_f6183842-fa91-4f24-8e8d-3f6ad0c92773_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a42bc2bb-aa70-4c60-a2ff-ce9ef9345131_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_549e1a3d-1078-4ad9-bfe2-4fe9a99af7a1_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_585a27f7-e95a-412b-8971-e852bd5c32b7_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_BusinessCombinationAssumedContingentLiabilityNoncurrent_24dc390a-6eaf-4da2-813a-dc2d8b2ec008_terseLabel_en-US" xlink:label="lab_smmt_BusinessCombinationAssumedContingentLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed contingent liabilities, non-current</link:label>
    <link:label id="lab_smmt_BusinessCombinationAssumedContingentLiabilityNoncurrent_label_en-US" xlink:label="lab_smmt_BusinessCombinationAssumedContingentLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Assumed Contingent Liability, Noncurrent</link:label>
    <link:label id="lab_smmt_BusinessCombinationAssumedContingentLiabilityNoncurrent_documentation_en-US" xlink:label="lab_smmt_BusinessCombinationAssumedContingentLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Assumed Contingent Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_BusinessCombinationAssumedContingentLiabilityNoncurrent" xlink:href="smmt-20231231.xsd#smmt_BusinessCombinationAssumedContingentLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_BusinessCombinationAssumedContingentLiabilityNoncurrent" xlink:to="lab_smmt_BusinessCombinationAssumedContingentLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_68977c8f-e452-4c6c-8c29-89e3fdad6204_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e02aa7a1-c11f-4a89-b894-6dd25c00a1c8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_12cd84cb-17f2-4ad3-93a6-0e145dcf46a2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ResearchAndDevelopmentPrepaidExpensesCurrent_c697ab45-2371-40e5-8784-4ed4412a4268_terseLabel_en-US" xlink:label="lab_smmt_ResearchAndDevelopmentPrepaidExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid research and development expenditures</link:label>
    <link:label id="lab_smmt_ResearchAndDevelopmentPrepaidExpensesCurrent_label_en-US" xlink:label="lab_smmt_ResearchAndDevelopmentPrepaidExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Prepaid Expenses, Current</link:label>
    <link:label id="lab_smmt_ResearchAndDevelopmentPrepaidExpensesCurrent_documentation_en-US" xlink:label="lab_smmt_ResearchAndDevelopmentPrepaidExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Prepaid Expenses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ResearchAndDevelopmentPrepaidExpensesCurrent" xlink:href="smmt-20231231.xsd#smmt_ResearchAndDevelopmentPrepaidExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ResearchAndDevelopmentPrepaidExpensesCurrent" xlink:to="lab_smmt_ResearchAndDevelopmentPrepaidExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_667ac0b6-2a21-42ba-8294-5fd30c9e68ca_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ec0c18eb-d93e-43a1-b459-4c1d5efc6500_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares initially reserve for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_02c0c0f6-d8ca-439c-8075-f86a2bdc3fdf_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss_91060478-9abb-449b-bf69-0ffe25fd8a00_negatedTerseLabel_en-US" xlink:label="lab_smmt_BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on remeasurement of liabilities</link:label>
    <link:label id="lab_smmt_BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss_d49532f3-128f-4672-b7eb-1e9c2d27d02e_terseLabel_en-US" xlink:label="lab_smmt_BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement gains (losses)</link:label>
    <link:label id="lab_smmt_BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss_label_en-US" xlink:label="lab_smmt_BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Assumed Contingent Liability, Remeasurement Gain (Loss)</link:label>
    <link:label id="lab_smmt_BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss_documentation_en-US" xlink:label="lab_smmt_BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Assumed Contingent Liability, Remeasurement Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss" xlink:href="smmt-20231231.xsd#smmt_BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss" xlink:to="lab_smmt_BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_0c61685a-fdae-47ec-b95e-c9b07ac23ee2_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_f62b2fa0-e0b8-4e3c-bb4b-ce3e0c974946_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_1c95191b-0e2a-427c-b1c0-541c21dc33c7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_560f2387-20e4-4860-9217-309002fd7751_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccounting_c222ba2c-0c11-44ff-941e-0e99ec824ad5_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccounting" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation, Use of Estimates, and Risks and Uncertainties</link:label>
    <link:label id="lab_us-gaap_BasisOfAccounting_label_en-US" xlink:label="lab_us-gaap_BasisOfAccounting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccounting" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccounting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccounting" xlink:to="lab_us-gaap_BasisOfAccounting" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_VariableRatePeriodAxis_81c2a068-dd5e-45d1-b0c5-80502aef79ad_terseLabel_en-US" xlink:label="lab_smmt_VariableRatePeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Period [Axis]</link:label>
    <link:label id="lab_smmt_VariableRatePeriodAxis_label_en-US" xlink:label="lab_smmt_VariableRatePeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Period [Axis]</link:label>
    <link:label id="lab_smmt_VariableRatePeriodAxis_documentation_en-US" xlink:label="lab_smmt_VariableRatePeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_VariableRatePeriodAxis" xlink:href="smmt-20231231.xsd#smmt_VariableRatePeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_VariableRatePeriodAxis" xlink:to="lab_smmt_VariableRatePeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_0de08367-9695-4ada-8e8e-e54392b77e48_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_10a85781-882f-4bde-9ceb-5e069168a6a9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value: 1,000,000,000 shares authorized; 701,660,053 and 211,091,425 shares issued and outstanding at December 31, 2023 and 2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_58330f05-d667-499d-830d-20bfbf2373ff_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_ca4b047c-10bd-4be2-9c3a-fd6f43b62f55_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward_1125464f-0039-4d00-8079-af732d9703bf_terseLabel_en-US" xlink:label="lab_smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract with Customer, Asset and Liability [Roll Forward]</link:label>
    <link:label id="lab_smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward_label_en-US" xlink:label="lab_smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract with Customer, Asset and Liability [Roll Forward]</link:label>
    <link:label id="lab_smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward_documentation_en-US" xlink:label="lab_smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract with Customer, Asset and Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward" xlink:href="smmt-20231231.xsd#smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward" xlink:to="lab_smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_018e4e47-0a2b-4534-b0db-a04bfe6ea004_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of operating right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_fd7035a2-42f8-4953-95d2-57f16228f176_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current provision for state income taxes</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_715f8df1-bbb5-436f-aa81-50c43b3af340_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrentAndNoncurrent_399df5d3-2e77-4623-be5c-854269485b27_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest payable</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_591c497f-4091-4d07-9bdb-7de6a4a5adab_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosure of Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_620c74f7-6023-4d41-b233-6b17cf6d926d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_aaf7aa38-c597-4d01-b923-dc443408fb4e_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_c4921feb-55e0-4206-8be3-23262bc59184_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital commitments</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ChiefExecutiveOfficerAndPresidentMember_cd626387-3896-46e2-b5d0-ccf55327c593_terseLabel_en-US" xlink:label="lab_smmt_ChiefExecutiveOfficerAndPresidentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer and President</link:label>
    <link:label id="lab_smmt_ChiefExecutiveOfficerAndPresidentMember_label_en-US" xlink:label="lab_smmt_ChiefExecutiveOfficerAndPresidentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer And President [Member]</link:label>
    <link:label id="lab_smmt_ChiefExecutiveOfficerAndPresidentMember_documentation_en-US" xlink:label="lab_smmt_ChiefExecutiveOfficerAndPresidentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer And President</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ChiefExecutiveOfficerAndPresidentMember" xlink:href="smmt-20231231.xsd#smmt_ChiefExecutiveOfficerAndPresidentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ChiefExecutiveOfficerAndPresidentMember" xlink:to="lab_smmt_ChiefExecutiveOfficerAndPresidentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ResearchAndDevelopmentTaxCredit_ee9fc120-2626-429e-85d7-5e78c3fbc2b9_terseLabel_en-US" xlink:label="lab_smmt_ResearchAndDevelopmentTaxCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credits</link:label>
    <link:label id="lab_smmt_ResearchAndDevelopmentTaxCredit_516ebb08-4357-4e11-8314-c38fbc55750b_verboseLabel_en-US" xlink:label="lab_smmt_ResearchAndDevelopmentTaxCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax relief</link:label>
    <link:label id="lab_smmt_ResearchAndDevelopmentTaxCredit_label_en-US" xlink:label="lab_smmt_ResearchAndDevelopmentTaxCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development, Tax Credit</link:label>
    <link:label id="lab_smmt_ResearchAndDevelopmentTaxCredit_documentation_en-US" xlink:label="lab_smmt_ResearchAndDevelopmentTaxCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development, Tax Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ResearchAndDevelopmentTaxCredit" xlink:href="smmt-20231231.xsd#smmt_ResearchAndDevelopmentTaxCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ResearchAndDevelopmentTaxCredit" xlink:to="lab_smmt_ResearchAndDevelopmentTaxCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_c0edcf42-86b1-4e5f-ace0-3bf0198f8c0e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_2ade91a8-bccf-4e93-bcf7-494a2cb93f15_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_f6fbf88b-399d-41a4-a7b7-2a6d98dcdd2d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_73e980ef-e632-48d3-97f9-79dedf9872e9_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_f45f9b0a-c628-486a-bacd-02cc83d44414_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Issued or Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_c4c07ff3-4960-4c03-98cb-8d8b93fc4253_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of the effective income tax rate to the statutory rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_c9283c38-fca5-48e7-8995-479e9c08674b_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_d0b3baba-d2d7-4bfa-bf6a-5768d02e026e_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, beginning of year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_8c353200-b400-4d0e-b756-3ca21b889549_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, end of year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_20c345e2-de64-4d6e-bcb7-f8f5ff7d03f8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_4f3b668b-9d07-481e-9aa1-d445a01a2591_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_12c098a4-934c-45fa-84ab-6bf12669c9bd_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_b99387dd-917e-4a3c-a511-fbd16668d28d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_NotesPayableRelatedPartiesMaximumTerm_dd54a4b6-d5db-45bd-b86c-516198be2c8f_terseLabel_en-US" xlink:label="lab_smmt_NotesPayableRelatedPartiesMaximumTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable, maximum term</link:label>
    <link:label id="lab_smmt_NotesPayableRelatedPartiesMaximumTerm_label_en-US" xlink:label="lab_smmt_NotesPayableRelatedPartiesMaximumTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Related Parties, Maximum Term</link:label>
    <link:label id="lab_smmt_NotesPayableRelatedPartiesMaximumTerm_documentation_en-US" xlink:label="lab_smmt_NotesPayableRelatedPartiesMaximumTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Related Parties, Maximum Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartiesMaximumTerm" xlink:href="smmt-20231231.xsd#smmt_NotesPayableRelatedPartiesMaximumTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_NotesPayableRelatedPartiesMaximumTerm" xlink:to="lab_smmt_NotesPayableRelatedPartiesMaximumTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_ea2804e1-7331-4bae-bad9-2106ae8a1bf0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_0b048d2d-482f-4ef1-8eba-7321053052ea_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_69a02ade-0cef-466c-859a-034dd69a15f9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_d8efea33-a407-4281-84aa-d5862c3e3a6b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (Expense) Income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income and Expense [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:to="lab_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_8c772e09-86ba-47ba-ae11-f6080667efc2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_9c34e0c5-db34-4665-a486-d3bf2d10bba8_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3f1d4f4a-40f9-4dfe-8541-c6ef0ad45775_negatedLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5ed6c07e-48c1-4c1a-b316-d97b36c78aaf_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_CambridgeUKLaboratoryAndOfficeSpaceMember_d22698d5-0094-4a45-8a25-9d95e1cd8361_terseLabel_en-US" xlink:label="lab_smmt_CambridgeUKLaboratoryAndOfficeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cambridge UK, Laboratory and Office Space</link:label>
    <link:label id="lab_smmt_CambridgeUKLaboratoryAndOfficeSpaceMember_label_en-US" xlink:label="lab_smmt_CambridgeUKLaboratoryAndOfficeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cambridge UK, Laboratory And Office Space [Member]</link:label>
    <link:label id="lab_smmt_CambridgeUKLaboratoryAndOfficeSpaceMember_documentation_en-US" xlink:label="lab_smmt_CambridgeUKLaboratoryAndOfficeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cambridge UK, Laboratory And Office Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CambridgeUKLaboratoryAndOfficeSpaceMember" xlink:href="smmt-20231231.xsd#smmt_CambridgeUKLaboratoryAndOfficeSpaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_CambridgeUKLaboratoryAndOfficeSpaceMember" xlink:to="lab_smmt_CambridgeUKLaboratoryAndOfficeSpaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ResearchAndDevelopmentTaxCreditReceivable_53ed27a3-0fb4-4638-abaf-b2c730a46658_terseLabel_en-US" xlink:label="lab_smmt_ResearchAndDevelopmentTaxCreditReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current and long-term research and development tax credit receivable</link:label>
    <link:label id="lab_smmt_ResearchAndDevelopmentTaxCreditReceivable_label_en-US" xlink:label="lab_smmt_ResearchAndDevelopmentTaxCreditReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Credit Receivable</link:label>
    <link:label id="lab_smmt_ResearchAndDevelopmentTaxCreditReceivable_documentation_en-US" xlink:label="lab_smmt_ResearchAndDevelopmentTaxCreditReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Credit Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ResearchAndDevelopmentTaxCreditReceivable" xlink:href="smmt-20231231.xsd#smmt_ResearchAndDevelopmentTaxCreditReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ResearchAndDevelopmentTaxCreditReceivable" xlink:to="lab_smmt_ResearchAndDevelopmentTaxCreditReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_a0c9eb80-8ace-44b7-ac7a-d213f1a4771a_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Business and Operations and Recent Events</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_c4b6171c-6e89-4a0e-9c37-71e263196301_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating income</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_2c7b48b5-9f49-41b8-8fe2-4d52e5ba60d6_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_93d7a705-fe1b-4673-8c38-d86581789ac9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_9bd94610-f723-481a-9abb-92e34e381b12_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_6bae3b5d-1a3b-476e-9ffb-4d436746fa58_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net receipts related to the exercise of warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_2723829e-4afd-4195-8e27-a63c9069d58b_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_1ce1191a-988d-46c3-9040-60c83a6037c7_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_5dbbc3db-dcf1-4495-a173-4e4b57471b7f_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_89e37949-eb7c-485e-99b7-02d53d74f066_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_CommonStockAdditionalCapitalSharesAllowableForForFutureIssuanceUponOptionExpiration_d0593b44-a6da-4527-812b-4822fc7b96a5_terseLabel_en-US" xlink:label="lab_smmt_CommonStockAdditionalCapitalSharesAllowableForForFutureIssuanceUponOptionExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares that can be added to the plan upon option expiration (in shares)</link:label>
    <link:label id="lab_smmt_CommonStockAdditionalCapitalSharesAllowableForForFutureIssuanceUponOptionExpiration_label_en-US" xlink:label="lab_smmt_CommonStockAdditionalCapitalSharesAllowableForForFutureIssuanceUponOptionExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Additional Capital Shares Allowable For For Future Issuance Upon Option Expiration</link:label>
    <link:label id="lab_smmt_CommonStockAdditionalCapitalSharesAllowableForForFutureIssuanceUponOptionExpiration_documentation_en-US" xlink:label="lab_smmt_CommonStockAdditionalCapitalSharesAllowableForForFutureIssuanceUponOptionExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Additional Capital Shares Allowable For For Future Issuance Upon Option Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CommonStockAdditionalCapitalSharesAllowableForForFutureIssuanceUponOptionExpiration" xlink:href="smmt-20231231.xsd#smmt_CommonStockAdditionalCapitalSharesAllowableForForFutureIssuanceUponOptionExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_CommonStockAdditionalCapitalSharesAllowableForForFutureIssuanceUponOptionExpiration" xlink:to="lab_smmt_CommonStockAdditionalCapitalSharesAllowableForForFutureIssuanceUponOptionExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncurrentAssets_2e5cfdb5-a60d-4c5b-8316-abcb0610ba11_terseLabel_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-lived assets</link:label>
    <link:label id="lab_us-gaap_NoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncurrentAssets" xlink:to="lab_us-gaap_NoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_b33f75ea-cd57-45f7-a7a6-c5a77572c451_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1bde8a5c-71e7-49a7-99a4-8a8f6898dca1_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance as of beginning of year</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_6ad73050-e12e-4c4b-8da5-7114cb85cd61_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance as of end of year</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ad859170-ed52-4698-bf4b-2fdef78d44f2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7f88ff8c-77ad-4d1c-aa02-5dbab01acae8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0be8f468-368f-4c1d-851c-e1d83dc530af_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7b97dbf6-08b1-41b0-ad2a-e4bdaf85d72d_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_AkesoLicenseAgreementMember_62c67187-9d96-4ccc-b8ce-0fca65adb506_terseLabel_en-US" xlink:label="lab_smmt_AkesoLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Akeso License Agreement</link:label>
    <link:label id="lab_smmt_AkesoLicenseAgreementMember_label_en-US" xlink:label="lab_smmt_AkesoLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Akeso License Agreement [Member]</link:label>
    <link:label id="lab_smmt_AkesoLicenseAgreementMember_documentation_en-US" xlink:label="lab_smmt_AkesoLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Akeso License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_AkesoLicenseAgreementMember" xlink:href="smmt-20231231.xsd#smmt_AkesoLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_AkesoLicenseAgreementMember" xlink:to="lab_smmt_AkesoLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_484adc1b-96a1-4fc4-8b94-2f291d771254_terseLabel_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of fixed assets</link:label>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tangible Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:to="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a46b1415-9737-47a4-b884-425069246f93_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ChiefOperatingOfficerMember_f5bc9fc7-b63c-4602-b6e8-ff49dd44764b_terseLabel_en-US" xlink:label="lab_srt_ChiefOperatingOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Operations Officer</link:label>
    <link:label id="lab_srt_ChiefOperatingOfficerMember_label_en-US" xlink:label="lab_srt_ChiefOperatingOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Operating Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefOperatingOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefOperatingOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefOperatingOfficerMember" xlink:to="lab_srt_ChiefOperatingOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_b133fc83-278c-40ae-b62f-361f7eb98757_terseLabel_en-US" xlink:label="lab_smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BARDA</link:label>
    <link:label id="lab_smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_label_en-US" xlink:label="lab_smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biomedical Advanced Research And Development Authority [Member]</link:label>
    <link:label id="lab_smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_documentation_en-US" xlink:label="lab_smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biomedical Advanced Research And Development Authority</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:href="smmt-20231231.xsd#smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:to="lab_smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_06d9f50d-11d4-4393-a9cd-53cbe96faba9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_de6bdd42-2efe-40a0-b62a-5a661f569b47_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_e2d67cc1-4380-4bd1-ba11-4e33fb336f4c_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_country_GB_6aed107f-428a-4a7e-a340-8d49ddb8cb09_terseLabel_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom</link:label>
    <link:label id="lab_country_GB_label_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED KINGDOM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_GB" xlink:to="lab_country_GB" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_b62ef0c4-a3a5-4bc2-8ba8-25436444a4ba_terseLabel_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of long-lived assets by geography</link:label>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_80c505fb-97bc-426d-bb02-9c4414b3d211_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_c82bc647-10da-4ec8-805b-9ebafa6e15f6_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_InProcessResearchAndDevelopmentExpense_1e4e248f-c8b6-4a2d-8b26-967e8fde691c_terseLabel_en-US" xlink:label="lab_smmt_InProcessResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_smmt_InProcessResearchAndDevelopmentExpense_55f2a9eb-b85d-4303-8526-cb69af5b1912_verboseLabel_en-US" xlink:label="lab_smmt_InProcessResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development expense</link:label>
    <link:label id="lab_smmt_InProcessResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_smmt_InProcessResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-Process Research And Development Expense</link:label>
    <link:label id="lab_smmt_InProcessResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_smmt_InProcessResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-Process Research And Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_InProcessResearchAndDevelopmentExpense" xlink:href="smmt-20231231.xsd#smmt_InProcessResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_InProcessResearchAndDevelopmentExpense" xlink:to="lab_smmt_InProcessResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_7ada2db1-bcea-4126-af8d-d74fda236372_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ResearchAndDevelopmentTaxCreditReceivableNoncurrent_74a8f363-e1e2-4e22-b7df-99cf8df839f9_terseLabel_en-US" xlink:label="lab_smmt_ResearchAndDevelopmentTaxCreditReceivableNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credit receivable</link:label>
    <link:label id="lab_smmt_ResearchAndDevelopmentTaxCreditReceivableNoncurrent_label_en-US" xlink:label="lab_smmt_ResearchAndDevelopmentTaxCreditReceivableNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Credit Receivable, Noncurrent</link:label>
    <link:label id="lab_smmt_ResearchAndDevelopmentTaxCreditReceivableNoncurrent_documentation_en-US" xlink:label="lab_smmt_ResearchAndDevelopmentTaxCreditReceivableNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Credit Receivable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ResearchAndDevelopmentTaxCreditReceivableNoncurrent" xlink:href="smmt-20231231.xsd#smmt_ResearchAndDevelopmentTaxCreditReceivableNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ResearchAndDevelopmentTaxCreditReceivableNoncurrent" xlink:to="lab_smmt_ResearchAndDevelopmentTaxCreditReceivableNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b9bf291a-c586-4346-904b-2efb4f1ea3d1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableNoncurrentRelatedPartyTypeExtensibleEnumeration_9a5dd52d-3b46-4c21-b0cb-acd14fc5105f_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableNoncurrentRelatedPartyTypeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Noncurrent, Related Party, Type [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_NotesPayableNoncurrentRelatedPartyTypeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_NotesPayableNoncurrentRelatedPartyTypeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Noncurrent, Related Party, Type [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableNoncurrentRelatedPartyTypeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableNoncurrentRelatedPartyTypeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableNoncurrentRelatedPartyTypeExtensibleEnumeration" xlink:to="lab_us-gaap_NotesPayableNoncurrentRelatedPartyTypeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_22851580-2c4d-4a51-8c40-3d04836036a9_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_NotesPayableRelatedPartiesPotentialPrepaymentPeriodPostReceiptOfCashProceedsFromPublicOffering_3397b0d4-9293-4e71-a74a-9eb184404147_terseLabel_en-US" xlink:label="lab_smmt_NotesPayableRelatedPartiesPotentialPrepaymentPeriodPostReceiptOfCashProceedsFromPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period from public offering</link:label>
    <link:label id="lab_smmt_NotesPayableRelatedPartiesPotentialPrepaymentPeriodPostReceiptOfCashProceedsFromPublicOffering_label_en-US" xlink:label="lab_smmt_NotesPayableRelatedPartiesPotentialPrepaymentPeriodPostReceiptOfCashProceedsFromPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Related Parties, Potential Prepayment, Period Post Receipt Of Cash Proceeds From Public Offering</link:label>
    <link:label id="lab_smmt_NotesPayableRelatedPartiesPotentialPrepaymentPeriodPostReceiptOfCashProceedsFromPublicOffering_documentation_en-US" xlink:label="lab_smmt_NotesPayableRelatedPartiesPotentialPrepaymentPeriodPostReceiptOfCashProceedsFromPublicOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Related Parties, Potential Prepayment, Period Post Receipt Of Cash Proceeds From Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartiesPotentialPrepaymentPeriodPostReceiptOfCashProceedsFromPublicOffering" xlink:href="smmt-20231231.xsd#smmt_NotesPayableRelatedPartiesPotentialPrepaymentPeriodPostReceiptOfCashProceedsFromPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_NotesPayableRelatedPartiesPotentialPrepaymentPeriodPostReceiptOfCashProceedsFromPublicOffering" xlink:to="lab_smmt_NotesPayableRelatedPartiesPotentialPrepaymentPeriodPostReceiptOfCashProceedsFromPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermNotesPayableAbstract_f3bae60e-1ab1-40d0-b7fc-e101384703c0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermNotesPayableAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current notes</link:label>
    <link:label id="lab_us-gaap_LongTermNotesPayableAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermNotesPayableAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayableAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayableAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayableAbstract" xlink:to="lab_us-gaap_LongTermNotesPayableAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ClassOfWarrantOrRightExercisesInPeriod_b2d56dff-33fd-4bef-b794-5aa7c1d9962e_negatedTerseLabel_en-US" xlink:label="lab_smmt_ClassOfWarrantOrRightExercisesInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_smmt_ClassOfWarrantOrRightExercisesInPeriod_7bf90bd2-e479-479b-8fc3-f76474a74113_terseLabel_en-US" xlink:label="lab_smmt_ClassOfWarrantOrRightExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_smmt_ClassOfWarrantOrRightExercisesInPeriod_label_en-US" xlink:label="lab_smmt_ClassOfWarrantOrRightExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Exercises In Period</link:label>
    <link:label id="lab_smmt_ClassOfWarrantOrRightExercisesInPeriod_documentation_en-US" xlink:label="lab_smmt_ClassOfWarrantOrRightExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Exercises In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ClassOfWarrantOrRightExercisesInPeriod" xlink:href="smmt-20231231.xsd#smmt_ClassOfWarrantOrRightExercisesInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ClassOfWarrantOrRightExercisesInPeriod" xlink:to="lab_smmt_ClassOfWarrantOrRightExercisesInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5b9628cc-6528-4fdf-8bca-b4bcfa1c37cf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_96ba7189-3df6-4a17-ad7f-c8040e7c15a1_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_7e738d8e-e61b-4c87-9f56-c6d5756de546_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0e0b2782-fd2f-4354-8bb9-2a74778dd402_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6087590c-60c1-454b-bf36-bd56cd1243f8_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_0405bf22-664e-408b-8e27-afe8bc87b09c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_aab37a96-aae9-483d-96ad-1d61ceeb51c8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_b4079eac-d4eb-48bf-b74f-83c21deb7b38_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.K.</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_b7d0acd5-61c5-43da-8e30-0ebc47e5cc51_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_abb9133d-7493-47cf-b768-5acc04347ba1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_cbb0ffa5-78f1-411f-a837-9f6014b34c0f_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_d447c6c0-bc2a-4139-bcd0-6fdb987be0df_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_6f69735b-95e4-43dd-adcc-02d29a56dfe4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_2b539d92-5a6a-44f4-a788-3fc95a954fc9_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_feb4e338-e763-4bd4-ac3d-572209378a39_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_b6e1cd09-b9ca-4220-af51-208e3c975136_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_62eb0113-5c41-461d-9208-c154b59fbb2b_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_1fdfea89-3286-4fb1-946f-e253db1bfdd8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_aa0b413f-709f-4cb2-9e07-82ba8291787b_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1ffe0adc-b011-4d27-8918-ed4e6c82a3c8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of stock option activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_296208fa-0998-461e-85d3-0a65acc3ade6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Cash_977cbfc8-d7c0-48c8-89de-fa30d5031ff4_terseLabel_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_Cash_label_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_6fb97bcf-9898-4f0b-81de-336bb8886d06_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of warrant activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_ce4ae322-8ebd-4726-aaaf-97bcfc6e61ac_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_6219717d-cb17-4fb2-ab8f-5b660a270010_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency transaction gains (losses)</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_dfdc42a2-78fe-459d-bb27-91cab5f89830_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency gains (losses)</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_8af55a34-0dfe-4e2a-98a7-e75238dba480_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_3a58a513-ace3-4357-abf2-fd1099a54c14_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Removal of lease liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncome_c0f6be35-5dfa-424a-8895-2cf1a414cb1d_totalLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating income</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncome_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncome" xlink:to="lab_us-gaap_OtherOperatingIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_62370c4c-140c-4e96-92c9-7b945f2f835c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_ce4c2ff2-7cfb-4df1-ac26-9c4725de73ca_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_8e99745f-fc64-4a81-b74f-426d7b02dd77_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Government treasury bills</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_7dc3fdb8-8dac-414b-8a6f-9191d0e5928f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_72b36630-69eb-454a-8e52-cdef14f0d857_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_04590a79-dc50-44bd-a47e-737726ca3948_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of assets and liabilities measured at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_1f911411-b0b1-49b0-a4c3-bcbf3aea5255_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4a8de553-c384-4d52-9451-ab1b755651af_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_a0e4acef-9246-4048-8b1c-1963602415a0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_99f9641c-785a-4cc3-b1fb-65b513510465_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_f270b47e-c1a1-426c-a8c1-d1561c7cd13f_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_NotesPayableRelatedPartiesPotentialPrepaymentMaximumAmountPercentageOfNetProceedsFromPublicOffering_9381990f-a821-45fa-b925-b45158954a74_terseLabel_en-US" xlink:label="lab_smmt_NotesPayableRelatedPartiesPotentialPrepaymentMaximumAmountPercentageOfNetProceedsFromPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public offering proceeds threshold percentage</link:label>
    <link:label id="lab_smmt_NotesPayableRelatedPartiesPotentialPrepaymentMaximumAmountPercentageOfNetProceedsFromPublicOffering_label_en-US" xlink:label="lab_smmt_NotesPayableRelatedPartiesPotentialPrepaymentMaximumAmountPercentageOfNetProceedsFromPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Related Parties, Potential Prepayment, Maximum Amount, Percentage Of Net Proceeds From Public Offering</link:label>
    <link:label id="lab_smmt_NotesPayableRelatedPartiesPotentialPrepaymentMaximumAmountPercentageOfNetProceedsFromPublicOffering_documentation_en-US" xlink:label="lab_smmt_NotesPayableRelatedPartiesPotentialPrepaymentMaximumAmountPercentageOfNetProceedsFromPublicOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Related Parties, Potential Prepayment, Maximum Amount, Percentage Of Net Proceeds From Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartiesPotentialPrepaymentMaximumAmountPercentageOfNetProceedsFromPublicOffering" xlink:href="smmt-20231231.xsd#smmt_NotesPayableRelatedPartiesPotentialPrepaymentMaximumAmountPercentageOfNetProceedsFromPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_NotesPayableRelatedPartiesPotentialPrepaymentMaximumAmountPercentageOfNetProceedsFromPublicOffering" xlink:to="lab_smmt_NotesPayableRelatedPartiesPotentialPrepaymentMaximumAmountPercentageOfNetProceedsFromPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_c9718890-2728-496f-9bb3-3749004d8ba8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_AssumedContingentLiabilitiesPolicyPolicyTextBlock_cf4a99c2-1b91-4a6f-b836-42ddc10ba5bf_terseLabel_en-US" xlink:label="lab_smmt_AssumedContingentLiabilitiesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed Contingent Liabilities</link:label>
    <link:label id="lab_smmt_AssumedContingentLiabilitiesPolicyPolicyTextBlock_label_en-US" xlink:label="lab_smmt_AssumedContingentLiabilitiesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed Contingent Liabilities, Policy [Policy Text Block]</link:label>
    <link:label id="lab_smmt_AssumedContingentLiabilitiesPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_smmt_AssumedContingentLiabilitiesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed Contingent Liabilities, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_AssumedContingentLiabilitiesPolicyPolicyTextBlock" xlink:href="smmt-20231231.xsd#smmt_AssumedContingentLiabilitiesPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_AssumedContingentLiabilitiesPolicyPolicyTextBlock" xlink:to="lab_smmt_AssumedContingentLiabilitiesPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_EmployeeStockOptionPerformanceAndMarketBasedMember_7de338a9-6c1c-4287-a095-082b772ad16d_terseLabel_en-US" xlink:label="lab_smmt_EmployeeStockOptionPerformanceAndMarketBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance and market-based stock options</link:label>
    <link:label id="lab_smmt_EmployeeStockOptionPerformanceAndMarketBasedMember_label_en-US" xlink:label="lab_smmt_EmployeeStockOptionPerformanceAndMarketBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option, Performance And Market-Based [Member]</link:label>
    <link:label id="lab_smmt_EmployeeStockOptionPerformanceAndMarketBasedMember_documentation_en-US" xlink:label="lab_smmt_EmployeeStockOptionPerformanceAndMarketBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option, Performance And Market-Based</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_EmployeeStockOptionPerformanceAndMarketBasedMember" xlink:href="smmt-20231231.xsd#smmt_EmployeeStockOptionPerformanceAndMarketBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_EmployeeStockOptionPerformanceAndMarketBasedMember" xlink:to="lab_smmt_EmployeeStockOptionPerformanceAndMarketBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_5e2dd588-3cdb-4dc2-bd0a-996913f96b4c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of discount on short-term investments</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_c7d2a2a1-f9b3-406a-ac85-fe11feeb0958_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_e384c99e-2dd4-42bc-8850-cc9fd573b60b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e6d35c1b-86ec-4660-9bc2-a12fb1078d5b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_9d85982d-5914-49b3-85d6-713dcb012a15_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_5a711272-24dc-4d41-bf77-40ebdf724110_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_1095da86-a764-467b-811c-30daa91858e0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_87ef714e-6754-4eaf-a7b3-6d985cc8748b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense for options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_OtherPatentsAndLicensesMember_379229bd-6bef-4198-843b-3c10cc76fafa_terseLabel_en-US" xlink:label="lab_smmt_OtherPatentsAndLicensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangibles</link:label>
    <link:label id="lab_smmt_OtherPatentsAndLicensesMember_label_en-US" xlink:label="lab_smmt_OtherPatentsAndLicensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Patents and Licenses [Member]</link:label>
    <link:label id="lab_smmt_OtherPatentsAndLicensesMember_documentation_en-US" xlink:label="lab_smmt_OtherPatentsAndLicensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Patents and Licenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_OtherPatentsAndLicensesMember" xlink:href="smmt-20231231.xsd#smmt_OtherPatentsAndLicensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_OtherPatentsAndLicensesMember" xlink:to="lab_smmt_OtherPatentsAndLicensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_f70d3705-07de-493f-8ce9-48a768552ee1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_98d98172-e9e8-4ed2-9e94-8b5bb0a3bfef_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentTwoMember_83a4d8ab-b3ba-4fc9-8f84-e2ee1d6837a3_terseLabel_en-US" xlink:label="lab_smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, transaction with party to collaborative arrangement, upfront payment two</link:label>
    <link:label id="lab_smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentTwoMember_label_en-US" xlink:label="lab_smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement, Upfront Payment Two [Member]</link:label>
    <link:label id="lab_smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentTwoMember_documentation_en-US" xlink:label="lab_smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement, Upfront Payment Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentTwoMember" xlink:href="smmt-20231231.xsd#smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentTwoMember" xlink:to="lab_smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_be41fc60-c497-4d32-91e5-b9d909a16f5b_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current provision for non-United States income taxes</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_e35c7f40-54de-4ffe-a73f-b63480a64c83_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_4bf35e18-5021-4d11-98b6-9a59605c3fe5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2b22c119-0ebc-4041-80ed-54c4a4490a17_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common stock shares into which warrants may be converted (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_DeferredTaxAssetsLeasingArrangements_54bc920f-e9e6-4fbb-a65c-cabae98d1a72_terseLabel_en-US" xlink:label="lab_smmt_DeferredTaxAssetsLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_smmt_DeferredTaxAssetsLeasingArrangements_label_en-US" xlink:label="lab_smmt_DeferredTaxAssetsLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Leasing Arrangements</link:label>
    <link:label id="lab_smmt_DeferredTaxAssetsLeasingArrangements_documentation_en-US" xlink:label="lab_smmt_DeferredTaxAssetsLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DeferredTaxAssetsLeasingArrangements" xlink:href="smmt-20231231.xsd#smmt_DeferredTaxAssetsLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_DeferredTaxAssetsLeasingArrangements" xlink:to="lab_smmt_DeferredTaxAssetsLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_38ca6064-c13b-48f4-8aad-07d01a5c5bc2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_ee6eebae-730d-439c-a461-3261531f5e5a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_DiscuvaPlatformMember_8f934a20-7106-414b-a234-91a697134d23_terseLabel_en-US" xlink:label="lab_smmt_DiscuvaPlatformMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discuva platform</link:label>
    <link:label id="lab_smmt_DiscuvaPlatformMember_label_en-US" xlink:label="lab_smmt_DiscuvaPlatformMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discuva Platform [Member]</link:label>
    <link:label id="lab_smmt_DiscuvaPlatformMember_documentation_en-US" xlink:label="lab_smmt_DiscuvaPlatformMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discuva Platform</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DiscuvaPlatformMember" xlink:href="smmt-20231231.xsd#smmt_DiscuvaPlatformMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_DiscuvaPlatformMember" xlink:to="lab_smmt_DiscuvaPlatformMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_b5564faf-400d-4930-9a72-3b1cdd746c8f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_4d1a34c1-5533-4dda-9ca8-6ff0a9a50eaf_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term, vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_5c1e73a0-0a66-4203-9a0e-0baa74113a6f_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_8d6d5142-3459-4dde-82f0-977f742e4e9c_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_559aea44-cc0b-4088-bdd8-ebd6db6f4af1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_88060cee-f6f3-4abd-817a-4446fcbd18b0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_6188e45a-7846-4426-bf08-9cb6db74672e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_CollaborativeArrangementRightsAndObligationsPotentialCommercialMilestonePayments_74a37ebc-0b53-452f-87ec-1fa11c99b4c9_terseLabel_en-US" xlink:label="lab_smmt_CollaborativeArrangementRightsAndObligationsPotentialCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, potential commercial milestone payments</link:label>
    <link:label id="lab_smmt_CollaborativeArrangementRightsAndObligationsPotentialCommercialMilestonePayments_label_en-US" xlink:label="lab_smmt_CollaborativeArrangementRightsAndObligationsPotentialCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Potential Commercial Milestone Payments</link:label>
    <link:label id="lab_smmt_CollaborativeArrangementRightsAndObligationsPotentialCommercialMilestonePayments_documentation_en-US" xlink:label="lab_smmt_CollaborativeArrangementRightsAndObligationsPotentialCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Potential Commercial Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CollaborativeArrangementRightsAndObligationsPotentialCommercialMilestonePayments" xlink:href="smmt-20231231.xsd#smmt_CollaborativeArrangementRightsAndObligationsPotentialCommercialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_CollaborativeArrangementRightsAndObligationsPotentialCommercialMilestonePayments" xlink:to="lab_smmt_CollaborativeArrangementRightsAndObligationsPotentialCommercialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_AreaOfPremisesSubleased_37fbb23b-c6ec-4053-b1c9-c98428581b97_terseLabel_en-US" xlink:label="lab_smmt_AreaOfPremisesSubleased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of premises subleased</link:label>
    <link:label id="lab_smmt_AreaOfPremisesSubleased_label_en-US" xlink:label="lab_smmt_AreaOfPremisesSubleased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area Of Premises Subleased</link:label>
    <link:label id="lab_smmt_AreaOfPremisesSubleased_documentation_en-US" xlink:label="lab_smmt_AreaOfPremisesSubleased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area Of Premises Subleased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_AreaOfPremisesSubleased" xlink:href="smmt-20231231.xsd#smmt_AreaOfPremisesSubleased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_AreaOfPremisesSubleased" xlink:to="lab_smmt_AreaOfPremisesSubleased" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ZanganehNoteMember_e58ceb39-06ea-4654-bfee-c1a01cc23b82_terseLabel_en-US" xlink:label="lab_smmt_ZanganehNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zanganeh Note</link:label>
    <link:label id="lab_smmt_ZanganehNoteMember_label_en-US" xlink:label="lab_smmt_ZanganehNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zanganeh Note [Member]</link:label>
    <link:label id="lab_smmt_ZanganehNoteMember_documentation_en-US" xlink:label="lab_smmt_ZanganehNoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zanganeh Note</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ZanganehNoteMember" xlink:href="smmt-20231231.xsd#smmt_ZanganehNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ZanganehNoteMember" xlink:to="lab_smmt_ZanganehNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_1bcba37f-f2b6-4fdf-a6a6-f096e106510e_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2888fec6-a98a-4966-88c5-17f438ae20e6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_696b5b7a-a59e-4f84-84b6-dc02fd90ecef_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeAndExpenseTextBlock_6e0744d5-544b-4ee9-b755-d71e6aff8434_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeAndExpenseTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeAndExpenseTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeAndExpenseTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income and Expense [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeAndExpenseTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeAndExpenseTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeAndExpenseTextBlock" xlink:to="lab_us-gaap_OtherOperatingIncomeAndExpenseTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_VariableRatePeriodOneMember_066662b5-c10a-41a5-8dc6-993288d0a89f_terseLabel_en-US" xlink:label="lab_smmt_VariableRatePeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable rate, three months immediately following February 15, 2023</link:label>
    <link:label id="lab_smmt_VariableRatePeriodOneMember_label_en-US" xlink:label="lab_smmt_VariableRatePeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate, Period One [Member]</link:label>
    <link:label id="lab_smmt_VariableRatePeriodOneMember_documentation_en-US" xlink:label="lab_smmt_VariableRatePeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate, Period One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_VariableRatePeriodOneMember" xlink:href="smmt-20231231.xsd#smmt_VariableRatePeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_VariableRatePeriodOneMember" xlink:to="lab_smmt_VariableRatePeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_21374b1c-c2a7-45e6-9042-30ddde7d72df_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c1cd47d6-bc88-4ed6-8a19-4b9c7b1e23a3_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_d5cf7df9-c76f-4ae9-8fb6-fe913bd1cec6_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrent_9ea61ce5-abf6-4222-af81-72d77965066f_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promissory note payable to related parties</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_fe62e0b8-ab19-464e-b6c4-4a053014d19f_totalLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total promissory notes payable to related parties</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_6054b28a-a755-4415-9bfd-e9aa5a14037e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_128f3387-fca8-474d-a434-2c69da4daa04_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage of outstanding shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_OtherOperatingIncomeOther_dd015a73-ae34-4838-8887-06e3f004aa36_terseLabel_en-US" xlink:label="lab_smmt_OtherOperatingIncomeOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_smmt_OtherOperatingIncomeOther_label_en-US" xlink:label="lab_smmt_OtherOperatingIncomeOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income, Other</link:label>
    <link:label id="lab_smmt_OtherOperatingIncomeOther_documentation_en-US" xlink:label="lab_smmt_OtherOperatingIncomeOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_OtherOperatingIncomeOther" xlink:href="smmt-20231231.xsd#smmt_OtherOperatingIncomeOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_OtherOperatingIncomeOther" xlink:to="lab_smmt_OtherOperatingIncomeOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_1685d375-31e9-4190-a01c-3d9a1542de63_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_577520ce-cd97-4ed0-a2dd-97479df0d5d0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome_9dd36153-6821-4d9a-92cd-888d4d1aeda8_negatedTerseLabel_en-US" xlink:label="lab_smmt_CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of currency translation gain</link:label>
    <link:label id="lab_smmt_CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome_4a73403f-0700-4741-80fe-37d9e55027db_terseLabel_en-US" xlink:label="lab_smmt_CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of cumulative currency translation gain</link:label>
    <link:label id="lab_smmt_CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome_label_en-US" xlink:label="lab_smmt_CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Currency Translation Gains (Losses), Realized upon Sale or Liquidation, Reclassified From Other Comprehensive Income</link:label>
    <link:label id="lab_smmt_CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome_documentation_en-US" xlink:label="lab_smmt_CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Currency Translation Gains (Losses), Realized upon Sale or Liquidation, Reclassified From Other Comprehensive Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome" xlink:href="smmt-20231231.xsd#smmt_CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome" xlink:to="lab_smmt_CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_2e5bf35c-9610-441a-86d2-22916dccb388_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_dffdebc0-e9ab-406f-81e3-9df3bd95dda0_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_4facad47-3615-47db-8adc-51cde5231e1b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_VariableRatePeriodTwoMember_a43d0ac2-b3aa-4ae0-8612-8d53560318eb_terseLabel_en-US" xlink:label="lab_smmt_VariableRatePeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable rate, thereafter</link:label>
    <link:label id="lab_smmt_VariableRatePeriodTwoMember_label_en-US" xlink:label="lab_smmt_VariableRatePeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate, Period Two [Member]</link:label>
    <link:label id="lab_smmt_VariableRatePeriodTwoMember_documentation_en-US" xlink:label="lab_smmt_VariableRatePeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate, Period Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_VariableRatePeriodTwoMember" xlink:href="smmt-20231231.xsd#smmt_VariableRatePeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_VariableRatePeriodTwoMember" xlink:to="lab_smmt_VariableRatePeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_be18409a-ecd0-4b72-b319-38218a4fbe27_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e151fc32-1eb2-412e-89ce-92cb596d99aa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_1865e7a0-42a6-4475-b09c-b294e9e24718_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_18dcf7ba-3f5d-4e22-9bb9-3271e7a684f6_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_CashPaymentForCollaborativeArrangementUpfrontPayment_780e92a1-d4c9-4dae-9ba9-af03017bb442_terseLabel_en-US" xlink:label="lab_smmt_CashPaymentForCollaborativeArrangementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment for collaborative arrangement, upfront payment</link:label>
    <link:label id="lab_smmt_CashPaymentForCollaborativeArrangementUpfrontPayment_label_en-US" xlink:label="lab_smmt_CashPaymentForCollaborativeArrangementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment For Collaborative Arrangement, Upfront Payment</link:label>
    <link:label id="lab_smmt_CashPaymentForCollaborativeArrangementUpfrontPayment_documentation_en-US" xlink:label="lab_smmt_CashPaymentForCollaborativeArrangementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment For Collaborative Arrangement, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CashPaymentForCollaborativeArrangementUpfrontPayment" xlink:href="smmt-20231231.xsd#smmt_CashPaymentForCollaborativeArrangementUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_CashPaymentForCollaborativeArrangementUpfrontPayment" xlink:to="lab_smmt_CashPaymentForCollaborativeArrangementUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_NotePurchaseAgreementMember_7932145c-71e2-4808-9272-a437ccf11c96_terseLabel_en-US" xlink:label="lab_smmt_NotePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note Purchase Agreement</link:label>
    <link:label id="lab_smmt_NotePurchaseAgreementMember_label_en-US" xlink:label="lab_smmt_NotePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note Purchase Agreement [Member]</link:label>
    <link:label id="lab_smmt_NotePurchaseAgreementMember_documentation_en-US" xlink:label="lab_smmt_NotePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotePurchaseAgreementMember" xlink:href="smmt-20231231.xsd#smmt_NotePurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_NotePurchaseAgreementMember" xlink:to="lab_smmt_NotePurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_1cd0b64a-0302-47f6-9fb4-1d28feff3bef_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future principal payments for 2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_7080e40a-f0d3-4812-a2d9-38f0c5605bd4_verboseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7c267c0c-1daa-410a-9cfd-cfcde7c9b069_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_86d76079-cd8f-4d0c-aafe-e052256a8f27_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_819b89c8-0e11-428b-bb26-1cc16235f3b8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under stock purchase plans and exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_3abdf89b-fece-43de-bbcb-e3525da40800_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_b9edc465-92f5-42c6-9c83-bcd458a89711_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current and long-term assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_7443544e-071f-43be-a830-b7dcefa0a237_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of foreign operations taxed at various rates</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_cb5d890e-0cac-477b-806d-4af19f40948e_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired In-Process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_DugganSeptemberNoteMember_a5e8536c-694d-4f4e-b7b9-547273ebecd6_terseLabel_en-US" xlink:label="lab_smmt_DugganSeptemberNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duggan September Note</link:label>
    <link:label id="lab_smmt_DugganSeptemberNoteMember_label_en-US" xlink:label="lab_smmt_DugganSeptemberNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duggan September Note [Member]</link:label>
    <link:label id="lab_smmt_DugganSeptemberNoteMember_documentation_en-US" xlink:label="lab_smmt_DugganSeptemberNoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duggan September Note</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DugganSeptemberNoteMember" xlink:href="smmt-20231231.xsd#smmt_DugganSeptemberNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_DugganSeptemberNoteMember" xlink:to="lab_smmt_DugganSeptemberNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_d5832f0b-6f3d-449e-93f6-edba62e1f9dc_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of property. plant and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_cece02f1-fd3a-415c-afcd-4df526a939a7_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_f92f1f9a-141a-4958-9b54-11f7b343e197_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRelatedPartyDebt_2effac11-698f-4c10-b417-5fc124866e40_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from related party promissory notes</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRelatedPartyDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Related Party Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="lab_us-gaap_ProceedsFromRelatedPartyDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_8182be42-7d66-4187-a28d-7741485f6fe4_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_94027698-404f-4e30-b90e-d4f90dedd8a8_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9ee7d5ca-d15e-4cfc-b5a6-0f93c555344e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d5a54d2b-fb59-40db-90b4-a0e9ba5c3359_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_LesseeOperatingLeaseAreaOfPremisesLeased_562ab044-56a1-4153-8f2c-108270838289_terseLabel_en-US" xlink:label="lab_smmt_LesseeOperatingLeaseAreaOfPremisesLeased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of premises leased</link:label>
    <link:label id="lab_smmt_LesseeOperatingLeaseAreaOfPremisesLeased_label_en-US" xlink:label="lab_smmt_LesseeOperatingLeaseAreaOfPremisesLeased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Area Of Premises Leased</link:label>
    <link:label id="lab_smmt_LesseeOperatingLeaseAreaOfPremisesLeased_documentation_en-US" xlink:label="lab_smmt_LesseeOperatingLeaseAreaOfPremisesLeased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Area Of Premises Leased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_LesseeOperatingLeaseAreaOfPremisesLeased" xlink:href="smmt-20231231.xsd#smmt_LesseeOperatingLeaseAreaOfPremisesLeased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_LesseeOperatingLeaseAreaOfPremisesLeased" xlink:to="lab_smmt_LesseeOperatingLeaseAreaOfPremisesLeased" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_9b740e8b-0151-4471-a2f3-11c62883ced9_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_ee9f9502-c0c4-4cd1-9d0f-da160e46d813_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_c972ab6a-8780-4821-8218-2476f6f02ae2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_38ca1c0b-ae66-4f4f-9622-97ce465961ef_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_851ee2bd-2e64-4433-ab18-71b0827e94ff_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_BusinessCombinationAssumedContingentLiabilityMeasurementInput_7eb2667a-bfea-4e45-a6b7-87c797f653f6_terseLabel_en-US" xlink:label="lab_smmt_BusinessCombinationAssumedContingentLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed contingent liability, measurement input</link:label>
    <link:label id="lab_smmt_BusinessCombinationAssumedContingentLiabilityMeasurementInput_label_en-US" xlink:label="lab_smmt_BusinessCombinationAssumedContingentLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Assumed Contingent Liability, Measurement Input</link:label>
    <link:label id="lab_smmt_BusinessCombinationAssumedContingentLiabilityMeasurementInput_documentation_en-US" xlink:label="lab_smmt_BusinessCombinationAssumedContingentLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Assumed Contingent Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_BusinessCombinationAssumedContingentLiabilityMeasurementInput" xlink:href="smmt-20231231.xsd#smmt_BusinessCombinationAssumedContingentLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_BusinessCombinationAssumedContingentLiabilityMeasurementInput" xlink:to="lab_smmt_BusinessCombinationAssumedContingentLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_29647fd4-699f-4c73-8b00-5a211df81464_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_744482f2-fef7-4b7d-bc78-12a1391af15d_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_DeferredTaxAssetsCapitalizedResearchAndDevelopment_95a30b6b-5881-4104-bce1-8287b75c4f16_terseLabel_en-US" xlink:label="lab_smmt_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Section 174 Research and Development Capitalization</link:label>
    <link:label id="lab_smmt_DeferredTaxAssetsCapitalizedResearchAndDevelopment_label_en-US" xlink:label="lab_smmt_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Capitalized Research And Development</link:label>
    <link:label id="lab_smmt_DeferredTaxAssetsCapitalizedResearchAndDevelopment_documentation_en-US" xlink:label="lab_smmt_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Capitalized Research And Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:href="smmt-20231231.xsd#smmt_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:to="lab_smmt_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_319bf366-f9be-4b1e-80ca-fdafd258683a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rights Offering of common stock, net of offering costs/ Private placement of common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_18e94962-94c5-4c87-bfd8-255d8050a7e9_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f5ed2207-4c5c-403c-bffe-a9340de2d11f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_15e0ff4b-7b19-4e1e-8af0-e148b957315c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_017a6703-cc3f-4694-91fa-2244ba03d401_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_A2020StockIncentivePlanMember_46856731-011b-42b9-ac02-07f9e2933523_terseLabel_en-US" xlink:label="lab_smmt_A2020StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Plan</link:label>
    <link:label id="lab_smmt_A2020StockIncentivePlanMember_label_en-US" xlink:label="lab_smmt_A2020StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_smmt_A2020StockIncentivePlanMember_documentation_en-US" xlink:label="lab_smmt_A2020StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Stock Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_A2020StockIncentivePlanMember" xlink:href="smmt-20231231.xsd#smmt_A2020StockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_A2020StockIncentivePlanMember" xlink:to="lab_smmt_A2020StockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_796a5bf7-49d3-4712-93b7-971e7dc264f9_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_9b8ff423-275a-4e29-9153-198e60a7291d_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_64db49c5-1931-46f6-b55b-4684e0eec76e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_36694906-baed-4eca-9e42-59e3d9cfa86d_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7147530e-02ef-41fd-91c1-309e78735e36_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_08a433ab-cae8-4ccb-9fc1-cf59b297204b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_124b3161-dc1e-4771-a53c-440c9d2d7c7a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest on related party promissory note</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_6471b659-27cc-4105-b980-91948a171f42_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_fb141182-b6a3-4924-9373-5444ba64e143_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_19640c18-35d5-4865-80f8-fbcf9f68125b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, estimated useful Lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5d9cd2cb-4fc7-4350-92a9-7bc82dbe7e7d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate margin</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_6f31f3a0-b094-4077-ac52-aabc4f1658a3_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_2bcfc71d-589a-4690-8446-dc344fffbb8d_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d1c32a91-829f-480f-ad58-4df84539286c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_88bea6e1-6ff7-4173-a532-cb123730cdab_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted weighted average number of shares of common stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_83063455-d0d7-4d37-80d7-09e00ce4051e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_f64ea990-49cd-4052-9804-eb510e513653_terseLabel_en-US" xlink:label="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering period</link:label>
    <link:label id="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_label_en-US" xlink:label="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period</link:label>
    <link:label id="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_documentation_en-US" xlink:label="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:href="smmt-20231231.xsd#smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:to="lab_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_e7959a80-6ebe-4c13-af0b-604503bd38b5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_d4a29d74-4084-4f34-a66e-4282d63cba16_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitment_0bb421cc-727c-4aff-82ea-1f8270eafe94_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual commitments</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_label_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment" xlink:to="lab_us-gaap_OtherCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_a78f7ee5-1c4a-46b1-9eaa-069bf8571382_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of deferred revenue and other income</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid_1e6b6128-f36c-432b-b62f-74db72911eb0_terseLabel_en-US" xlink:label="lab_smmt_OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for which the majority of contractual commitments are to be paid</link:label>
    <link:label id="lab_smmt_OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid_label_en-US" xlink:label="lab_smmt_OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment, Period for Which the Majority of Commitments are To Be Paid</link:label>
    <link:label id="lab_smmt_OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid_documentation_en-US" xlink:label="lab_smmt_OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment, Period for Which the Majority of Commitments are To Be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid" xlink:href="smmt-20231231.xsd#smmt_OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid" xlink:to="lab_smmt_OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1abf9548-100d-4b88-b8a7-0eb4010d7b80_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase to number of shares of common stock issuable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_fcca45b9-54e2-4c6a-8c6c-60e6dd75e635_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_ee91b252-1e11-4c70-bef6-405c0ecdaf4e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8e7a38eb-f318-455c-ae92-c446a9fcf8b6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_LaboratoryEquipmentMember_ed07d91a-1736-4e8d-9315-a52546d42b0d_terseLabel_en-US" xlink:label="lab_smmt_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_smmt_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_smmt_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_smmt_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_smmt_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_LaboratoryEquipmentMember" xlink:href="smmt-20231231.xsd#smmt_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_LaboratoryEquipmentMember" xlink:to="lab_smmt_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_398811c7-388f-4bd9-9ca8-3109cf9d4d05_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_9c3649d7-7b2d-485f-a451-af5ef4ba9bbd_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod_d1d1d5e3-10a0-4296-b97e-90e80f6e2662_terseLabel_en-US" xlink:label="lab_smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants quarterly vesting period</link:label>
    <link:label id="lab_smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod_label_en-US" xlink:label="lab_smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Quarterly Vesting Period</link:label>
    <link:label id="lab_smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod_documentation_en-US" xlink:label="lab_smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Quarterly Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod" xlink:href="smmt-20231231.xsd#smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod" xlink:to="lab_smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_835a467e-5978-421a-aada-f735ebbe3edb_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Cost:</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_b3e7737d-e4de-4015-9fc9-40d33036189a_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_S3RegistrationStatementMember_c03453e9-fc77-4354-921a-74655f969560_terseLabel_en-US" xlink:label="lab_smmt_S3RegistrationStatementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">S-3 Registration Statement</link:label>
    <link:label id="lab_smmt_S3RegistrationStatementMember_label_en-US" xlink:label="lab_smmt_S3RegistrationStatementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">S-3 Registration Statement [Member]</link:label>
    <link:label id="lab_smmt_S3RegistrationStatementMember_documentation_en-US" xlink:label="lab_smmt_S3RegistrationStatementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">S-3 Registration Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_S3RegistrationStatementMember" xlink:href="smmt-20231231.xsd#smmt_S3RegistrationStatementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_S3RegistrationStatementMember" xlink:to="lab_smmt_S3RegistrationStatementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNonoperating_c245949d-5e87-4248-83ad-8f5eecc57dd3_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNonoperating_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNonoperating" xlink:to="lab_us-gaap_InvestmentIncomeNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f0cf1e5f-6b9b-40bb-9977-8b9d44f81a20_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_0023097c-7697-4459-8592-11892f0030ac_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_AccruedResearchAndDevelopmentCurrent_964e3c22-9097-42ce-87bd-700cf5832733_terseLabel_en-US" xlink:label="lab_smmt_AccruedResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development expenditure</link:label>
    <link:label id="lab_smmt_AccruedResearchAndDevelopmentCurrent_label_en-US" xlink:label="lab_smmt_AccruedResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development, Current</link:label>
    <link:label id="lab_smmt_AccruedResearchAndDevelopmentCurrent_documentation_en-US" xlink:label="lab_smmt_AccruedResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_AccruedResearchAndDevelopmentCurrent" xlink:href="smmt-20231231.xsd#smmt_AccruedResearchAndDevelopmentCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_AccruedResearchAndDevelopmentCurrent" xlink:to="lab_smmt_AccruedResearchAndDevelopmentCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_b5bea5b6-a027-43e8-8d30-45f74008a2f8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ContractWithCustomerLiabilityForeignCurrencyTranslation_fc7df159-c5bb-40a4-ba6a-5d6e7e577a41_terseLabel_en-US" xlink:label="lab_smmt_ContractWithCustomerLiabilityForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency adjustment</link:label>
    <link:label id="lab_smmt_ContractWithCustomerLiabilityForeignCurrencyTranslation_label_en-US" xlink:label="lab_smmt_ContractWithCustomerLiabilityForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Foreign Currency Translation</link:label>
    <link:label id="lab_smmt_ContractWithCustomerLiabilityForeignCurrencyTranslation_documentation_en-US" xlink:label="lab_smmt_ContractWithCustomerLiabilityForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Foreign Currency Translation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ContractWithCustomerLiabilityForeignCurrencyTranslation" xlink:href="smmt-20231231.xsd#smmt_ContractWithCustomerLiabilityForeignCurrencyTranslation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ContractWithCustomerLiabilityForeignCurrencyTranslation" xlink:to="lab_smmt_ContractWithCustomerLiabilityForeignCurrencyTranslation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_f7c1becb-9481-49ec-b476-72013acba9b6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_RelatedPartyTransactionPaymentsToRelatedParty_367e02a6-bba9-4033-a6e6-05cfe66641be_terseLabel_en-US" xlink:label="lab_smmt_RelatedPartyTransactionPaymentsToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to related party</link:label>
    <link:label id="lab_smmt_RelatedPartyTransactionPaymentsToRelatedParty_label_en-US" xlink:label="lab_smmt_RelatedPartyTransactionPaymentsToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Payments To Related Party</link:label>
    <link:label id="lab_smmt_RelatedPartyTransactionPaymentsToRelatedParty_documentation_en-US" xlink:label="lab_smmt_RelatedPartyTransactionPaymentsToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Payments To Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RelatedPartyTransactionPaymentsToRelatedParty" xlink:href="smmt-20231231.xsd#smmt_RelatedPartyTransactionPaymentsToRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_RelatedPartyTransactionPaymentsToRelatedParty" xlink:to="lab_smmt_RelatedPartyTransactionPaymentsToRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_718add2c-f737-4bc8-9dcc-f7a727d3ca13_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2bdac52c-8826-4b77-97e3-53eefa863e4d_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_4f795dfe-e301-4515-8665-76276ec0c29c_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ConsultingAgreementMember_20ad22e3-eb0b-4648-adf1-842243fcd084_terseLabel_en-US" xlink:label="lab_smmt_ConsultingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting Agreement</link:label>
    <link:label id="lab_smmt_ConsultingAgreementMember_label_en-US" xlink:label="lab_smmt_ConsultingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting Agreement [Member]</link:label>
    <link:label id="lab_smmt_ConsultingAgreementMember_documentation_en-US" xlink:label="lab_smmt_ConsultingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ConsultingAgreementMember" xlink:href="smmt-20231231.xsd#smmt_ConsultingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ConsultingAgreementMember" xlink:to="lab_smmt_ConsultingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_4f38090f-9da2-4986-a0d6-711e91f01d26_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities balance sheet presentation:</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_NotesPayableRelatedPartiesNewIssuances_7977d922-088c-4f02-b9cf-21b8c645af28_terseLabel_en-US" xlink:label="lab_smmt_NotesPayableRelatedPartiesNewIssuances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New note issuances</link:label>
    <link:label id="lab_smmt_NotesPayableRelatedPartiesNewIssuances_label_en-US" xlink:label="lab_smmt_NotesPayableRelatedPartiesNewIssuances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Related Parties, New Issuances</link:label>
    <link:label id="lab_smmt_NotesPayableRelatedPartiesNewIssuances_documentation_en-US" xlink:label="lab_smmt_NotesPayableRelatedPartiesNewIssuances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Related Parties, New Issuances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartiesNewIssuances" xlink:href="smmt-20231231.xsd#smmt_NotesPayableRelatedPartiesNewIssuances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_NotesPayableRelatedPartiesNewIssuances" xlink:to="lab_smmt_NotesPayableRelatedPartiesNewIssuances" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_MenloParkCaliforniaExpirationMay2026Member_4761dad7-6c99-45ee-b80a-7f318eae964c_terseLabel_en-US" xlink:label="lab_smmt_MenloParkCaliforniaExpirationMay2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Menlo Park, California, Expiration May 2026</link:label>
    <link:label id="lab_smmt_MenloParkCaliforniaExpirationMay2026Member_label_en-US" xlink:label="lab_smmt_MenloParkCaliforniaExpirationMay2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Menlo Park, California, Expiration May 2026 [Member]</link:label>
    <link:label id="lab_smmt_MenloParkCaliforniaExpirationMay2026Member_documentation_en-US" xlink:label="lab_smmt_MenloParkCaliforniaExpirationMay2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Menlo Park, California, Expiration May 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_MenloParkCaliforniaExpirationMay2026Member" xlink:href="smmt-20231231.xsd#smmt_MenloParkCaliforniaExpirationMay2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_MenloParkCaliforniaExpirationMay2026Member" xlink:to="lab_smmt_MenloParkCaliforniaExpirationMay2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_0cd36f6d-9d8f-4789-9ae2-023a66a6839c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_ade571bb-70f2-4a91-9258-632ebddc42b5_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrimeRateMember_783467c1-7c33-4eed-9096-d67ca60b0f04_terseLabel_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate</link:label>
    <link:label id="lab_us-gaap_PrimeRateMember_label_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember" xlink:to="lab_us-gaap_PrimeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_caf73f11-2d17-4d2b-a7f9-b7d59427c94f_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fd051924-ab37-4cb7-b911-0059dbb0a8b4_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Decrease) Increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7b135260-4250-4b79-bf1d-04c088e9efc7_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows provided by financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_6cb51131-62bd-4c1e-8f60-f37888d2bbb7_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration_02d501d4-5288-45cd-aeb5-c87f966bb539_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current, Related Party, Type [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current, Related Party, Type [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration" xlink:to="lab_us-gaap_NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_CollaborativeArrangementRightsAndObligationsPotentialRegulatoryMilestonePayments_28c56759-58e7-4bd8-8d67-4408346283df_terseLabel_en-US" xlink:label="lab_smmt_CollaborativeArrangementRightsAndObligationsPotentialRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, potential regulatory milestone payments</link:label>
    <link:label id="lab_smmt_CollaborativeArrangementRightsAndObligationsPotentialRegulatoryMilestonePayments_label_en-US" xlink:label="lab_smmt_CollaborativeArrangementRightsAndObligationsPotentialRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Potential Regulatory Milestone Payments</link:label>
    <link:label id="lab_smmt_CollaborativeArrangementRightsAndObligationsPotentialRegulatoryMilestonePayments_documentation_en-US" xlink:label="lab_smmt_CollaborativeArrangementRightsAndObligationsPotentialRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Potential Regulatory Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CollaborativeArrangementRightsAndObligationsPotentialRegulatoryMilestonePayments" xlink:href="smmt-20231231.xsd#smmt_CollaborativeArrangementRightsAndObligationsPotentialRegulatoryMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_CollaborativeArrangementRightsAndObligationsPotentialRegulatoryMilestonePayments" xlink:to="lab_smmt_CollaborativeArrangementRightsAndObligationsPotentialRegulatoryMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_dd9191f9-56af-48d9-bf27-d1c218dffd7e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of common stock as a percentage of closing price</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_53deecdb-cf37-46ca-a45f-7c843f86f400_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_bc70b3c6-b487-423b-9c2a-7f282489f8f7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credit carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_CashEquivalentsFairValueDisclosure_bedf4f9d-9de8-4252-a691-9318bedacf18_terseLabel_en-US" xlink:label="lab_smmt_CashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_smmt_CashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_smmt_CashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label id="lab_smmt_CashEquivalentsFairValueDisclosure_documentation_en-US" xlink:label="lab_smmt_CashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CashEquivalentsFairValueDisclosure" xlink:href="smmt-20231231.xsd#smmt_CashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_CashEquivalentsFairValueDisclosure" xlink:to="lab_smmt_CashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_d21fd53c-8d7f-4967-8611-79b838f5bcca_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_6b19f733-53bd-4597-bdfd-96641d68816f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c824855e-adbe-4484-9719-6b1812fd7a50_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d0356d9d-5127-4254-a5a7-900efc9f7011_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic weighted average number of shares of common stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_45407cb8-6689-456d-87de-22c78f6a625f_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_PaymentOfAccruedInterestToRelatedParties_6a1fa238-3aba-4c10-b665-903ce543aad1_terseLabel_en-US" xlink:label="lab_smmt_PaymentOfAccruedInterestToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of related party interest</link:label>
    <link:label id="lab_smmt_PaymentOfAccruedInterestToRelatedParties_label_en-US" xlink:label="lab_smmt_PaymentOfAccruedInterestToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Accrued Interest To Related Parties</link:label>
    <link:label id="lab_smmt_PaymentOfAccruedInterestToRelatedParties_documentation_en-US" xlink:label="lab_smmt_PaymentOfAccruedInterestToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Accrued Interest To Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_PaymentOfAccruedInterestToRelatedParties" xlink:href="smmt-20231231.xsd#smmt_PaymentOfAccruedInterestToRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_PaymentOfAccruedInterestToRelatedParties" xlink:to="lab_smmt_PaymentOfAccruedInterestToRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ResearchAndDevelopmentExpenseAmortizableAmount_647875c8-92bc-47f6-86d0-c26a31be3689_terseLabel_en-US" xlink:label="lab_smmt_ResearchAndDevelopmentExpenseAmortizableAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net adjustment for research and experimental expenditures</link:label>
    <link:label id="lab_smmt_ResearchAndDevelopmentExpenseAmortizableAmount_label_en-US" xlink:label="lab_smmt_ResearchAndDevelopmentExpenseAmortizableAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Amortizable Amount</link:label>
    <link:label id="lab_smmt_ResearchAndDevelopmentExpenseAmortizableAmount_documentation_en-US" xlink:label="lab_smmt_ResearchAndDevelopmentExpenseAmortizableAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Amortizable Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ResearchAndDevelopmentExpenseAmortizableAmount" xlink:href="smmt-20231231.xsd#smmt_ResearchAndDevelopmentExpenseAmortizableAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ResearchAndDevelopmentExpenseAmortizableAmount" xlink:to="lab_smmt_ResearchAndDevelopmentExpenseAmortizableAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_e0b45cda-e5e8-4d72-9321-a06764ee4a78_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding_40a7c0ed-02cd-40a4-9471-8bf2cdbb6a4c_terseLabel_en-US" xlink:label="lab_smmt_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value</link:label>
    <link:label id="lab_smmt_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding_label_en-US" xlink:label="lab_smmt_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:label id="lab_smmt_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding_documentation_en-US" xlink:label="lab_smmt_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding" xlink:href="smmt-20231231.xsd#smmt_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding" xlink:to="lab_smmt_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_StockIssuedDuringPeriodSharesInLieuOfCashForCollaborativeArrangement_3fff0e59-8ad0-4cf4-8752-324f920fa029_terseLabel_en-US" xlink:label="lab_smmt_StockIssuedDuringPeriodSharesInLieuOfCashForCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in lieu of cash for Akeso upfront payment (in shares)</link:label>
    <link:label id="lab_smmt_StockIssuedDuringPeriodSharesInLieuOfCashForCollaborativeArrangement_label_en-US" xlink:label="lab_smmt_StockIssuedDuringPeriodSharesInLieuOfCashForCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, In Lieu Of Cash For Collaborative Arrangement</link:label>
    <link:label id="lab_smmt_StockIssuedDuringPeriodSharesInLieuOfCashForCollaborativeArrangement_documentation_en-US" xlink:label="lab_smmt_StockIssuedDuringPeriodSharesInLieuOfCashForCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, In Lieu Of Cash For Collaborative Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_StockIssuedDuringPeriodSharesInLieuOfCashForCollaborativeArrangement" xlink:href="smmt-20231231.xsd#smmt_StockIssuedDuringPeriodSharesInLieuOfCashForCollaborativeArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_StockIssuedDuringPeriodSharesInLieuOfCashForCollaborativeArrangement" xlink:to="lab_smmt_StockIssuedDuringPeriodSharesInLieuOfCashForCollaborativeArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_NotesPayableGrossNoncurrent_23f31eda-9b07-4ae3-980b-de7528064d32_terseLabel_en-US" xlink:label="lab_smmt_NotesPayableGrossNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amounts</link:label>
    <link:label id="lab_smmt_NotesPayableGrossNoncurrent_label_en-US" xlink:label="lab_smmt_NotesPayableGrossNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Gross, Noncurrent</link:label>
    <link:label id="lab_smmt_NotesPayableGrossNoncurrent_documentation_en-US" xlink:label="lab_smmt_NotesPayableGrossNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Gross, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableGrossNoncurrent" xlink:href="smmt-20231231.xsd#smmt_NotesPayableGrossNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_NotesPayableGrossNoncurrent" xlink:to="lab_smmt_NotesPayableGrossNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_82d140ba-3ab0-49d6-9847-80da52016f3f_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_StockIssuedDuringPeriodSharesRelatedPartyPrepaidInterest_4744bf4f-7cf3-4403-97e9-a07de93230ce_terseLabel_en-US" xlink:label="lab_smmt_StockIssuedDuringPeriodSharesRelatedPartyPrepaidInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued for prepaid interest (in shares)</link:label>
    <link:label id="lab_smmt_StockIssuedDuringPeriodSharesRelatedPartyPrepaidInterest_label_en-US" xlink:label="lab_smmt_StockIssuedDuringPeriodSharesRelatedPartyPrepaidInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Related Party Prepaid Interest</link:label>
    <link:label id="lab_smmt_StockIssuedDuringPeriodSharesRelatedPartyPrepaidInterest_documentation_en-US" xlink:label="lab_smmt_StockIssuedDuringPeriodSharesRelatedPartyPrepaidInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Related Party Prepaid Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_StockIssuedDuringPeriodSharesRelatedPartyPrepaidInterest" xlink:href="smmt-20231231.xsd#smmt_StockIssuedDuringPeriodSharesRelatedPartyPrepaidInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_StockIssuedDuringPeriodSharesRelatedPartyPrepaidInterest" xlink:to="lab_smmt_StockIssuedDuringPeriodSharesRelatedPartyPrepaidInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_VariableRatePeriodDomain_309a1939-fe46-4b36-8ef6-8f2f51ff6ed6_terseLabel_en-US" xlink:label="lab_smmt_VariableRatePeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Period [Domain]</link:label>
    <link:label id="lab_smmt_VariableRatePeriodDomain_label_en-US" xlink:label="lab_smmt_VariableRatePeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Period [Domain]</link:label>
    <link:label id="lab_smmt_VariableRatePeriodDomain_documentation_en-US" xlink:label="lab_smmt_VariableRatePeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_VariableRatePeriodDomain" xlink:href="smmt-20231231.xsd#smmt_VariableRatePeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_VariableRatePeriodDomain" xlink:to="lab_smmt_VariableRatePeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_f6eb59c9-0110-4e0a-a664-c47042557453_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_12f0bcf1-806e-4364-9003-da7c5246bf81_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds received related to employee stock purchase plan and exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ca94f971-07e5-401c-8b8b-f2d0597613da_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_0f58ebef-a417-4e03-af3b-5aa0be377075_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_smmt_GrantFundingArrangementMaximumFundingValue_7889b260-6ba9-404d-a56c-4b71647a3669_terseLabel_en-US" xlink:label="lab_smmt_GrantFundingArrangementMaximumFundingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum funding value</link:label>
    <link:label id="lab_smmt_GrantFundingArrangementMaximumFundingValue_label_en-US" xlink:label="lab_smmt_GrantFundingArrangementMaximumFundingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Funding Arrangement, Maximum Funding Value</link:label>
    <link:label id="lab_smmt_GrantFundingArrangementMaximumFundingValue_documentation_en-US" xlink:label="lab_smmt_GrantFundingArrangementMaximumFundingValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Funding Arrangement, Maximum Funding Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GrantFundingArrangementMaximumFundingValue" xlink:href="smmt-20231231.xsd#smmt_GrantFundingArrangementMaximumFundingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_smmt_GrantFundingArrangementMaximumFundingValue" xlink:to="lab_smmt_GrantFundingArrangementMaximumFundingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_90ffcb49-fc9c-4e6c-82e0-15f73a8a58e4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_fe00d8ca-ad2b-47bf-93fd-03a9b44fe918_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_cf0dd80c-1f68-443f-a665-a7012ea74ade_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options, vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c5a6fca0-8063-41de-ba39-722e41d466fe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option activity, additional disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember_label_en-US" xlink:label="lab_us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful Life, Shorter of Lease Term or Asset Utility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember" xlink:to="lab_us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>smmt-20231231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:cfc19273-6e1b-408d-b97d-a861bea67b02,g:5505fdd7-331f-4f8b-bf29-88d8f3b5e402-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.summitplc.com/role/Cover" xlink:type="simple" xlink:href="smmt-20231231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_423c15b5-f438-456d-83a7-d1ed80b24fed" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_5ca04ade-419b-49e6-84c5-9d0f27c3e2ac" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_423c15b5-f438-456d-83a7-d1ed80b24fed" xlink:to="loc_dei_DocumentType_5ca04ade-419b-49e6-84c5-9d0f27c3e2ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_cdd093fd-f7b7-4638-a719-d437af7d81e4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_423c15b5-f438-456d-83a7-d1ed80b24fed" xlink:to="loc_dei_DocumentAnnualReport_cdd093fd-f7b7-4638-a719-d437af7d81e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c95857e5-7083-45e8-b1d1-fad54d7bf4c0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_423c15b5-f438-456d-83a7-d1ed80b24fed" xlink:to="loc_dei_DocumentPeriodEndDate_c95857e5-7083-45e8-b1d1-fad54d7bf4c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_574b5374-581c-4917-a2a6-e706d19ad867" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_423c15b5-f438-456d-83a7-d1ed80b24fed" xlink:to="loc_dei_CurrentFiscalYearEndDate_574b5374-581c-4917-a2a6-e706d19ad867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_c5431993-3531-47e6-9dab-cce4aa878012" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_423c15b5-f438-456d-83a7-d1ed80b24fed" xlink:to="loc_dei_DocumentTransitionReport_c5431993-3531-47e6-9dab-cce4aa878012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_a00e0301-f915-4c0e-a5c3-794e7a78da9a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_423c15b5-f438-456d-83a7-d1ed80b24fed" xlink:to="loc_dei_EntityFileNumber_a00e0301-f915-4c0e-a5c3-794e7a78da9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_6c53dec6-f2e8-405d-a92f-d48ffde72002" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_423c15b5-f438-456d-83a7-d1ed80b24fed" xlink:to="loc_dei_EntityRegistrantName_6c53dec6-f2e8-405d-a92f-d48ffde72002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_93df2647-8bac-422b-9b87-b6b9c7d16d38" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_423c15b5-f438-456d-83a7-d1ed80b24fed" xlink:to="loc_dei_EntityIncorporationStateCountryCode_93df2647-8bac-422b-9b87-b6b9c7d16d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_a0977b9a-de3f-4359-9f69-b4df94774c0e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_423c15b5-f438-456d-83a7-d1ed80b24fed" xlink:to="loc_dei_EntityTaxIdentificationNumber_a0977b9a-de3f-4359-9f69-b4df94774c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_3c53ee18-6fd9-42eb-a2dc-c2f59975e67d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_423c15b5-f438-456d-83a7-d1ed80b24fed" xlink:to="loc_dei_EntityAddressAddressLine1_3c53ee18-6fd9-42eb-a2dc-c2f59975e67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_ca224e76-62a5-4510-b893-1e038d1dc250" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_423c15b5-f438-456d-83a7-d1ed80b24fed" xlink:to="loc_dei_EntityAddressCityOrTown_ca224e76-62a5-4510-b893-1e038d1dc250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_6b82f353-3dbf-4e62-8c19-ad53c920daed" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_423c15b5-f438-456d-83a7-d1ed80b24fed" xlink:to="loc_dei_EntityAddressStateOrProvince_6b82f353-3dbf-4e62-8c19-ad53c920daed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_931b49af-cc28-4380-95bb-d641b95f37f2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_423c15b5-f438-456d-83a7-d1ed80b24fed" xlink:to="loc_dei_EntityAddressPostalZipCode_931b49af-cc28-4380-95bb-d641b95f37f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_92d51eb7-a647-48fc-98a0-99dd30175aaa" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_423c15b5-f438-456d-83a7-d1ed80b24fed" xlink:to="loc_dei_CityAreaCode_92d51eb7-a647-48fc-98a0-99dd30175aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_3cc361d2-a5f0-4a39-8d46-2122c5184036" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_423c15b5-f438-456d-83a7-d1ed80b24fed" xlink:to="loc_dei_LocalPhoneNumber_3cc361d2-a5f0-4a39-8d46-2122c5184036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_52a9a4ee-2bf0-4c12-870b-c4586f2f2ede" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_423c15b5-f438-456d-83a7-d1ed80b24fed" xlink:to="loc_dei_Security12bTitle_52a9a4ee-2bf0-4c12-870b-c4586f2f2ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_03f56911-bca2-4781-aa2c-b00a5bd03563" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_423c15b5-f438-456d-83a7-d1ed80b24fed" xlink:to="loc_dei_TradingSymbol_03f56911-bca2-4781-aa2c-b00a5bd03563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_35b82cf2-0761-4489-b79c-a70410a5d78a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_423c15b5-f438-456d-83a7-d1ed80b24fed" xlink:to="loc_dei_SecurityExchangeName_35b82cf2-0761-4489-b79c-a70410a5d78a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_0eee2998-1867-4063-a8e2-389aa3171346" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_423c15b5-f438-456d-83a7-d1ed80b24fed" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_0eee2998-1867-4063-a8e2-389aa3171346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_d4d30fbb-ec43-4013-ab2e-e2333e7870de" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_423c15b5-f438-456d-83a7-d1ed80b24fed" xlink:to="loc_dei_EntityVoluntaryFilers_d4d30fbb-ec43-4013-ab2e-e2333e7870de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_0d5f1d39-d08e-4bdd-bb37-017cf1e77ec6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_423c15b5-f438-456d-83a7-d1ed80b24fed" xlink:to="loc_dei_EntityCurrentReportingStatus_0d5f1d39-d08e-4bdd-bb37-017cf1e77ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_ea37aa64-1b57-4b50-9eb1-47f733f5ff59" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_423c15b5-f438-456d-83a7-d1ed80b24fed" xlink:to="loc_dei_EntityInteractiveDataCurrent_ea37aa64-1b57-4b50-9eb1-47f733f5ff59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_4b999f16-c48d-473f-9e22-6548b9970d73" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_423c15b5-f438-456d-83a7-d1ed80b24fed" xlink:to="loc_dei_EntityFilerCategory_4b999f16-c48d-473f-9e22-6548b9970d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_1c23a3d5-6c2c-49f0-88d2-3114d92d575f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_423c15b5-f438-456d-83a7-d1ed80b24fed" xlink:to="loc_dei_EntitySmallBusiness_1c23a3d5-6c2c-49f0-88d2-3114d92d575f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_4adbd0a9-43cd-4bb7-9634-1182c998fe45" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_423c15b5-f438-456d-83a7-d1ed80b24fed" xlink:to="loc_dei_EntityEmergingGrowthCompany_4adbd0a9-43cd-4bb7-9634-1182c998fe45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_f9d8f6eb-c69a-4ab0-bcc0-ea7596be1cc8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_423c15b5-f438-456d-83a7-d1ed80b24fed" xlink:to="loc_dei_IcfrAuditorAttestationFlag_f9d8f6eb-c69a-4ab0-bcc0-ea7596be1cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_a8777e70-2220-4528-acfa-3a7ebb885e59" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_423c15b5-f438-456d-83a7-d1ed80b24fed" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_a8777e70-2220-4528-acfa-3a7ebb885e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_435d1fe8-b754-4c22-b33f-f399cf1a366d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_423c15b5-f438-456d-83a7-d1ed80b24fed" xlink:to="loc_dei_EntityShellCompany_435d1fe8-b754-4c22-b33f-f399cf1a366d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_9bf8b92c-f2fa-4be3-b2b7-c1bc854af9d1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_423c15b5-f438-456d-83a7-d1ed80b24fed" xlink:to="loc_dei_EntityPublicFloat_9bf8b92c-f2fa-4be3-b2b7-c1bc854af9d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_3246c996-96e3-4d45-a6ba-005e83a81c08" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_423c15b5-f438-456d-83a7-d1ed80b24fed" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_3246c996-96e3-4d45-a6ba-005e83a81c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_29a061ca-b6d1-4688-86bc-1d2d0a11a117" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_423c15b5-f438-456d-83a7-d1ed80b24fed" xlink:to="loc_dei_AmendmentFlag_29a061ca-b6d1-4688-86bc-1d2d0a11a117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_08e47233-b90a-4b80-aa27-a2788122e80a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_423c15b5-f438-456d-83a7-d1ed80b24fed" xlink:to="loc_dei_EntityCentralIndexKey_08e47233-b90a-4b80-aa27-a2788122e80a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_e4334f16-9fb9-46ea-b3c3-c05073ba0d45" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_423c15b5-f438-456d-83a7-d1ed80b24fed" xlink:to="loc_dei_DocumentFiscalYearFocus_e4334f16-9fb9-46ea-b3c3-c05073ba0d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_3445c88e-0b40-4d05-9121-b6f7d5fb220e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_423c15b5-f438-456d-83a7-d1ed80b24fed" xlink:to="loc_dei_DocumentFiscalPeriodFocus_3445c88e-0b40-4d05-9121-b6f7d5fb220e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/AuditInformation" xlink:type="simple" xlink:href="smmt-20231231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_smmt_AuditInformationAbstract_106ef271-5de7-4943-8818-c15a55659b13" xlink:href="smmt-20231231.xsd#smmt_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_39dc56e1-ce96-4c71-ba25-b4c8488bdc91" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_AuditInformationAbstract_106ef271-5de7-4943-8818-c15a55659b13" xlink:to="loc_dei_AuditorFirmId_39dc56e1-ce96-4c71-ba25-b4c8488bdc91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_9a097fd4-ab1d-40da-99dc-36fa54fc8cb6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_AuditInformationAbstract_106ef271-5de7-4943-8818-c15a55659b13" xlink:to="loc_dei_AuditorName_9a097fd4-ab1d-40da-99dc-36fa54fc8cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_d105cbad-f4b6-40a1-8cc3-f1bfdcd615e1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_AuditInformationAbstract_106ef271-5de7-4943-8818-c15a55659b13" xlink:to="loc_dei_AuditorLocation_d105cbad-f4b6-40a1-8cc3-f1bfdcd615e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="smmt-20231231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_7c31aeb5-9fe6-4c56-b40d-ca83034c1994" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_d44825da-8b40-4eca-974d-81f89420ce84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7c31aeb5-9fe6-4c56-b40d-ca83034c1994" xlink:to="loc_us-gaap_AssetsAbstract_d44825da-8b40-4eca-974d-81f89420ce84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_d071a0b7-4362-4f2a-b904-e52880fd0f12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d44825da-8b40-4eca-974d-81f89420ce84" xlink:to="loc_us-gaap_AssetsCurrentAbstract_d071a0b7-4362-4f2a-b904-e52880fd0f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cdc59797-2c42-4a99-b3c6-a9053d67783e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d071a0b7-4362-4f2a-b904-e52880fd0f12" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cdc59797-2c42-4a99-b3c6-a9053d67783e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_12631ddf-e22d-4b9f-93b0-e57fddc17605" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d071a0b7-4362-4f2a-b904-e52880fd0f12" xlink:to="loc_us-gaap_RestrictedCashCurrent_12631ddf-e22d-4b9f-93b0-e57fddc17605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a8015c2e-9676-47dc-b5ee-f298bfb76862" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d071a0b7-4362-4f2a-b904-e52880fd0f12" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a8015c2e-9676-47dc-b5ee-f298bfb76862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_3490d4eb-5a6d-486b-bd89-45065193fa43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d071a0b7-4362-4f2a-b904-e52880fd0f12" xlink:to="loc_us-gaap_ShortTermInvestments_3490d4eb-5a6d-486b-bd89-45065193fa43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_40643114-e875-48fd-b4b4-a8652ba6d582" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d071a0b7-4362-4f2a-b904-e52880fd0f12" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_40643114-e875-48fd-b4b4-a8652ba6d582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_ebdbd1f6-8e92-4f7e-96d9-772e39cee175" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d071a0b7-4362-4f2a-b904-e52880fd0f12" xlink:to="loc_us-gaap_OtherAssetsCurrent_ebdbd1f6-8e92-4f7e-96d9-772e39cee175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent_a0c1b736-e794-45d9-bf5c-b5b1fd02e8c0" xlink:href="smmt-20231231.xsd#smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d071a0b7-4362-4f2a-b904-e52880fd0f12" xlink:to="loc_smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent_a0c1b736-e794-45d9-bf5c-b5b1fd02e8c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3a1a2ff6-4781-4559-8d8c-66a177fdae20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d071a0b7-4362-4f2a-b904-e52880fd0f12" xlink:to="loc_us-gaap_AssetsCurrent_3a1a2ff6-4781-4559-8d8c-66a177fdae20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_99e712c7-1ee3-4de2-8604-d80c982fbf3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d44825da-8b40-4eca-974d-81f89420ce84" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_99e712c7-1ee3-4de2-8604-d80c982fbf3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_61380407-fc99-46d6-925d-1edf41569d24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_99e712c7-1ee3-4de2-8604-d80c982fbf3b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_61380407-fc99-46d6-925d-1edf41569d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_a9871135-d61a-4a56-9ff2-7a53be991427" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_99e712c7-1ee3-4de2-8604-d80c982fbf3b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_a9871135-d61a-4a56-9ff2-7a53be991427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ec1b360b-af2b-49b9-a5b4-6c24ac413950" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_99e712c7-1ee3-4de2-8604-d80c982fbf3b" xlink:to="loc_us-gaap_Goodwill_ec1b360b-af2b-49b9-a5b4-6c24ac413950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ResearchAndDevelopmentTaxCreditReceivableNoncurrent_7d52233d-5b97-4260-819d-633e2efff3d6" xlink:href="smmt-20231231.xsd#smmt_ResearchAndDevelopmentTaxCreditReceivableNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_99e712c7-1ee3-4de2-8604-d80c982fbf3b" xlink:to="loc_smmt_ResearchAndDevelopmentTaxCreditReceivableNoncurrent_7d52233d-5b97-4260-819d-633e2efff3d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_69af8e14-86d8-48af-87d3-65e13243f492" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_99e712c7-1ee3-4de2-8604-d80c982fbf3b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_69af8e14-86d8-48af-87d3-65e13243f492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1644b51b-7aee-4dbc-93d1-fdda4885e1cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d44825da-8b40-4eca-974d-81f89420ce84" xlink:to="loc_us-gaap_Assets_1644b51b-7aee-4dbc-93d1-fdda4885e1cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3a53a6bf-9938-4a91-bc7a-af087213e437" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7c31aeb5-9fe6-4c56-b40d-ca83034c1994" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3a53a6bf-9938-4a91-bc7a-af087213e437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_9f5282e4-5068-4c86-af3e-f4c67095b918" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3a53a6bf-9938-4a91-bc7a-af087213e437" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_9f5282e4-5068-4c86-af3e-f4c67095b918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_cbb5bf7d-a48a-4a0e-94a3-a0bbfafec7ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9f5282e4-5068-4c86-af3e-f4c67095b918" xlink:to="loc_us-gaap_AccountsPayableCurrent_cbb5bf7d-a48a-4a0e-94a3-a0bbfafec7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_bcadd109-fdd3-4a40-84fb-30d063bb7378" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9f5282e4-5068-4c86-af3e-f4c67095b918" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_bcadd109-fdd3-4a40-84fb-30d063bb7378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_433bf97c-4dea-4d2e-b12f-a823d15621a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9f5282e4-5068-4c86-af3e-f4c67095b918" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_433bf97c-4dea-4d2e-b12f-a823d15621a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b5e76d40-de67-470a-9d10-d9620bbdcd6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9f5282e4-5068-4c86-af3e-f4c67095b918" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b5e76d40-de67-470a-9d10-d9620bbdcd6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_e267fce7-410b-4667-84f4-861bb0d44e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9f5282e4-5068-4c86-af3e-f4c67095b918" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_e267fce7-410b-4667-84f4-861bb0d44e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_d427a661-669c-43a0-a584-76bbcf11ea68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9f5282e4-5068-4c86-af3e-f4c67095b918" xlink:to="loc_us-gaap_NotesPayableCurrent_d427a661-669c-43a0-a584-76bbcf11ea68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d1c1ac3e-6670-48e5-a697-4ee4fe0fa04e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9f5282e4-5068-4c86-af3e-f4c67095b918" xlink:to="loc_us-gaap_LiabilitiesCurrent_d1c1ac3e-6670-48e5-a697-4ee4fe0fa04e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration_4d02a636-4139-4cc0-a490-2b490bc360f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9f5282e4-5068-4c86-af3e-f4c67095b918" xlink:to="loc_us-gaap_NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration_4d02a636-4139-4cc0-a490-2b490bc360f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_779e30ac-39d5-4028-bbde-2343e1dcb32c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3a53a6bf-9938-4a91-bc7a-af087213e437" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_779e30ac-39d5-4028-bbde-2343e1dcb32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0196abc8-ab20-4835-bb6d-da6a68b616d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_779e30ac-39d5-4028-bbde-2343e1dcb32c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0196abc8-ab20-4835-bb6d-da6a68b616d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f7d24ee2-64be-4971-b70c-44ed42d9ffee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_779e30ac-39d5-4028-bbde-2343e1dcb32c" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f7d24ee2-64be-4971-b70c-44ed42d9ffee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_908c4a7f-4bc4-4d2a-9946-17f44b525dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_779e30ac-39d5-4028-bbde-2343e1dcb32c" xlink:to="loc_us-gaap_LongTermNotesPayable_908c4a7f-4bc4-4d2a-9946-17f44b525dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableNoncurrentRelatedPartyTypeExtensibleEnumeration_bea93494-a3ec-4002-a54b-431096380357" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableNoncurrentRelatedPartyTypeExtensibleEnumeration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_779e30ac-39d5-4028-bbde-2343e1dcb32c" xlink:to="loc_us-gaap_NotesPayableNoncurrentRelatedPartyTypeExtensibleEnumeration_bea93494-a3ec-4002-a54b-431096380357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a2049c70-65d6-4450-a086-456899d8b860" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3a53a6bf-9938-4a91-bc7a-af087213e437" xlink:to="loc_us-gaap_Liabilities_a2049c70-65d6-4450-a086-456899d8b860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_8bc98f29-c421-4c1f-874a-8701612f9324" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3a53a6bf-9938-4a91-bc7a-af087213e437" xlink:to="loc_us-gaap_CommitmentsAndContingencies_8bc98f29-c421-4c1f-874a-8701612f9324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_3b1253ef-1786-436e-a671-707fc1b662cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3a53a6bf-9938-4a91-bc7a-af087213e437" xlink:to="loc_us-gaap_StockholdersEquityAbstract_3b1253ef-1786-436e-a671-707fc1b662cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_748e192c-7673-4940-923b-ec3fcdc68bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3b1253ef-1786-436e-a671-707fc1b662cd" xlink:to="loc_us-gaap_PreferredStockValue_748e192c-7673-4940-923b-ec3fcdc68bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_8ab07509-f04a-489b-9cad-3455559a51b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3b1253ef-1786-436e-a671-707fc1b662cd" xlink:to="loc_us-gaap_CommonStockValue_8ab07509-f04a-489b-9cad-3455559a51b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_932945f6-bdd5-44e5-9d43-0015a7adf6ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3b1253ef-1786-436e-a671-707fc1b662cd" xlink:to="loc_us-gaap_AdditionalPaidInCapital_932945f6-bdd5-44e5-9d43-0015a7adf6ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_72532710-f0c8-49c9-b986-1a0c3c775d84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3b1253ef-1786-436e-a671-707fc1b662cd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_72532710-f0c8-49c9-b986-1a0c3c775d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_40327ab4-893a-4d62-8b7c-27f572a50986" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3b1253ef-1786-436e-a671-707fc1b662cd" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_40327ab4-893a-4d62-8b7c-27f572a50986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fa825c4f-2526-4be0-b084-ae95f7286631" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3b1253ef-1786-436e-a671-707fc1b662cd" xlink:to="loc_us-gaap_StockholdersEquity_fa825c4f-2526-4be0-b084-ae95f7286631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ad781552-1b74-473e-a8f6-3f32cce2f31a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3a53a6bf-9938-4a91-bc7a-af087213e437" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_ad781552-1b74-473e-a8f6-3f32cce2f31a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="smmt-20231231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_9e62efcc-f4cb-449e-af99-f10e47e4a9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_76840067-7991-40e1-83fe-7c516cbe9592" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9e62efcc-f4cb-449e-af99-f10e47e4a9b2" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_76840067-7991-40e1-83fe-7c516cbe9592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_bca7b86d-c8cc-40ef-ae72-6a8e36eb3572" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9e62efcc-f4cb-449e-af99-f10e47e4a9b2" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_bca7b86d-c8cc-40ef-ae72-6a8e36eb3572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_534f0efa-a4e9-4c71-99f5-c311df517550" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9e62efcc-f4cb-449e-af99-f10e47e4a9b2" xlink:to="loc_us-gaap_PreferredStockSharesIssued_534f0efa-a4e9-4c71-99f5-c311df517550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_94710196-27a8-404e-9680-84fe33a19e47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9e62efcc-f4cb-449e-af99-f10e47e4a9b2" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_94710196-27a8-404e-9680-84fe33a19e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_bed72da5-6d9d-4c6a-bd6e-188353911372" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9e62efcc-f4cb-449e-af99-f10e47e4a9b2" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_bed72da5-6d9d-4c6a-bd6e-188353911372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_5890a6e8-00fa-493a-be03-0fc54c79f5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9e62efcc-f4cb-449e-af99-f10e47e4a9b2" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_5890a6e8-00fa-493a-be03-0fc54c79f5ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f8ec1454-6678-456c-b14d-09503af3ce00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9e62efcc-f4cb-449e-af99-f10e47e4a9b2" xlink:to="loc_us-gaap_CommonStockSharesIssued_f8ec1454-6678-456c-b14d-09503af3ce00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b430c01f-abc8-49a7-af83-f5d84a1effd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9e62efcc-f4cb-449e-af99-f10e47e4a9b2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b430c01f-abc8-49a7-af83-f5d84a1effd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="smmt-20231231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_9b7a8a02-99e2-476f-bbc1-c9e769ff08b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4c1de005-4fcd-48fd-97ed-ba0cd8bf526b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9b7a8a02-99e2-476f-bbc1-c9e769ff08b6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4c1de005-4fcd-48fd-97ed-ba0cd8bf526b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_d65cd9fd-c219-480d-9b5d-732c3bd337b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9b7a8a02-99e2-476f-bbc1-c9e769ff08b6" xlink:to="loc_us-gaap_OperatingExpensesAbstract_d65cd9fd-c219-480d-9b5d-732c3bd337b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f3852826-d862-495f-9d2d-fa43e795fdb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d65cd9fd-c219-480d-9b5d-732c3bd337b1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f3852826-d862-495f-9d2d-fa43e795fdb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_56736e26-bc67-4f9a-9d51-8d8a44f9cbd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d65cd9fd-c219-480d-9b5d-732c3bd337b1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_56736e26-bc67-4f9a-9d51-8d8a44f9cbd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_InProcessResearchAndDevelopmentExpense_03e5da66-fe8d-4ace-8eb2-f014722cf184" xlink:href="smmt-20231231.xsd#smmt_InProcessResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d65cd9fd-c219-480d-9b5d-732c3bd337b1" xlink:to="loc_smmt_InProcessResearchAndDevelopmentExpense_03e5da66-fe8d-4ace-8eb2-f014722cf184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_10560ea4-0ee2-4d3f-a091-527c8f827cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d65cd9fd-c219-480d-9b5d-732c3bd337b1" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_10560ea4-0ee2-4d3f-a091-527c8f827cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_1c423efe-bf48-4703-8ab0-715c24702e78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d65cd9fd-c219-480d-9b5d-732c3bd337b1" xlink:to="loc_us-gaap_OperatingExpenses_1c423efe-bf48-4703-8ab0-715c24702e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_5161f84e-f8e7-4819-8697-2b7e738e4bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9b7a8a02-99e2-476f-bbc1-c9e769ff08b6" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_5161f84e-f8e7-4819-8697-2b7e738e4bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6c3c7368-b9df-4ded-8876-ae811fdf952c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9b7a8a02-99e2-476f-bbc1-c9e769ff08b6" xlink:to="loc_us-gaap_OperatingIncomeLoss_6c3c7368-b9df-4ded-8876-ae811fdf952c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9be508aa-638e-4398-9515-90a341007cee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9b7a8a02-99e2-476f-bbc1-c9e769ff08b6" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9be508aa-638e-4398-9515-90a341007cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0e0e65a6-9184-49b9-a875-d5c20501bfd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9b7a8a02-99e2-476f-bbc1-c9e769ff08b6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0e0e65a6-9184-49b9-a875-d5c20501bfd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_580dc890-f93f-4408-b302-14a17e2b7f47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9b7a8a02-99e2-476f-bbc1-c9e769ff08b6" xlink:to="loc_us-gaap_NetIncomeLoss_580dc890-f93f-4408-b302-14a17e2b7f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_EarningsPerShareBasicAndDilutedEPSAbstract_b312812d-dc86-4ee0-8631-453c5edf99ab" xlink:href="smmt-20231231.xsd#smmt_EarningsPerShareBasicAndDilutedEPSAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9b7a8a02-99e2-476f-bbc1-c9e769ff08b6" xlink:to="loc_smmt_EarningsPerShareBasicAndDilutedEPSAbstract_b312812d-dc86-4ee0-8631-453c5edf99ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_35937840-252d-4455-a64a-ab7b512d8c64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_EarningsPerShareBasicAndDilutedEPSAbstract_b312812d-dc86-4ee0-8631-453c5edf99ab" xlink:to="loc_us-gaap_EarningsPerShareBasic_35937840-252d-4455-a64a-ab7b512d8c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_e894a8d7-66d9-40c9-97da-0c06d3f94327" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_EarningsPerShareBasicAndDilutedEPSAbstract_b312812d-dc86-4ee0-8631-453c5edf99ab" xlink:to="loc_us-gaap_EarningsPerShareDiluted_e894a8d7-66d9-40c9-97da-0c06d3f94327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_6c0363ff-d4fa-4d97-af7d-fad64634c0c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9b7a8a02-99e2-476f-bbc1-c9e769ff08b6" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_6c0363ff-d4fa-4d97-af7d-fad64634c0c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_221eae83-a338-41fa-a2f2-531a394605c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_6c0363ff-d4fa-4d97-af7d-fad64634c0c1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_221eae83-a338-41fa-a2f2-531a394605c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_201777c0-a575-46a4-a66f-cff5277ac402" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_6c0363ff-d4fa-4d97-af7d-fad64634c0c1" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_201777c0-a575-46a4-a66f-cff5277ac402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c62451d8-1d92-4917-8ce4-7a3571f5bda3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9b7a8a02-99e2-476f-bbc1-c9e769ff08b6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c62451d8-1d92-4917-8ce4-7a3571f5bda3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_a86d8472-5017-4e1a-b013-98da9d549ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c62451d8-1d92-4917-8ce4-7a3571f5bda3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_a86d8472-5017-4e1a-b013-98da9d549ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_8515a534-9bea-49e0-990d-98b068b448ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c62451d8-1d92-4917-8ce4-7a3571f5bda3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_8515a534-9bea-49e0-990d-98b068b448ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_e41c32b8-a3a1-4b42-9a4c-c842cf7b0873" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c62451d8-1d92-4917-8ce4-7a3571f5bda3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_e41c32b8-a3a1-4b42-9a4c-c842cf7b0873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_9fe94774-928f-49b8-b533-87061496010d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9b7a8a02-99e2-476f-bbc1-c9e769ff08b6" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_9fe94774-928f-49b8-b533-87061496010d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="smmt-20231231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_68b1f6ad-bf33-4304-8483-30002565daec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_71905684-dd14-4004-bab9-e47321bae5d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_68b1f6ad-bf33-4304-8483-30002565daec" xlink:to="loc_us-gaap_StatementTable_71905684-dd14-4004-bab9-e47321bae5d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_32f213d2-cbe8-4674-a69b-c8ee98a12c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_71905684-dd14-4004-bab9-e47321bae5d0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_32f213d2-cbe8-4674-a69b-c8ee98a12c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_52ca475f-9488-43d4-b30f-b33ac1896cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_32f213d2-cbe8-4674-a69b-c8ee98a12c5a" xlink:to="loc_us-gaap_EquityComponentDomain_52ca475f-9488-43d4-b30f-b33ac1896cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_96b394ba-c3c4-46e0-bc9a-b7f1504df6c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_52ca475f-9488-43d4-b30f-b33ac1896cd6" xlink:to="loc_us-gaap_CommonStockMember_96b394ba-c3c4-46e0-bc9a-b7f1504df6c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_fa0f1350-6065-4563-aa90-f513a05daf34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_52ca475f-9488-43d4-b30f-b33ac1896cd6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_fa0f1350-6065-4563-aa90-f513a05daf34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ca511a50-2262-4ed5-bee6-e800cf89db9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_52ca475f-9488-43d4-b30f-b33ac1896cd6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ca511a50-2262-4ed5-bee6-e800cf89db9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_40260202-2964-41fd-a077-8b4bf0f2db8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_52ca475f-9488-43d4-b30f-b33ac1896cd6" xlink:to="loc_us-gaap_RetainedEarningsMember_40260202-2964-41fd-a077-8b4bf0f2db8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ce66c420-f43b-4ae2-8aa2-9bd40155eb39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_71905684-dd14-4004-bab9-e47321bae5d0" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ce66c420-f43b-4ae2-8aa2-9bd40155eb39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bf20d326-6d76-4c0b-8d93-7ee99860b114" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ce66c420-f43b-4ae2-8aa2-9bd40155eb39" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bf20d326-6d76-4c0b-8d93-7ee99860b114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RightsOfferingMember_b636885b-76d4-44f5-b3bc-35538fb0330c" xlink:href="smmt-20231231.xsd#smmt_RightsOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bf20d326-6d76-4c0b-8d93-7ee99860b114" xlink:to="loc_smmt_RightsOfferingMember_b636885b-76d4-44f5-b3bc-35538fb0330c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_fab0ca2b-0923-426a-82c4-97cc2e6af0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bf20d326-6d76-4c0b-8d93-7ee99860b114" xlink:to="loc_us-gaap_PrivatePlacementMember_fab0ca2b-0923-426a-82c4-97cc2e6af0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_93f54f82-0e0c-4011-834e-164e5b9ad13b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_71905684-dd14-4004-bab9-e47321bae5d0" xlink:to="loc_us-gaap_StatementLineItems_93f54f82-0e0c-4011-834e-164e5b9ad13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5b8a5a4-886f-4665-a96c-07d7eed74cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_93f54f82-0e0c-4011-834e-164e5b9ad13b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5b8a5a4-886f-4665-a96c-07d7eed74cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_46fa1f73-0665-4af0-bc37-44f9848100e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5b8a5a4-886f-4665-a96c-07d7eed74cb9" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_46fa1f73-0665-4af0-bc37-44f9848100e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e0f65c44-0582-461f-a2a5-bf58809c0692" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5b8a5a4-886f-4665-a96c-07d7eed74cb9" xlink:to="loc_us-gaap_StockholdersEquity_e0f65c44-0582-461f-a2a5-bf58809c0692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ad36c40c-95d0-4f0e-ae5e-63a31c2cc992" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5b8a5a4-886f-4665-a96c-07d7eed74cb9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ad36c40c-95d0-4f0e-ae5e-63a31c2cc992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a0003d08-70dd-404c-8caa-4f88186a1eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5b8a5a4-886f-4665-a96c-07d7eed74cb9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a0003d08-70dd-404c-8caa-4f88186a1eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_StockIssuedDuringPeriodSharesWarrantsExercised_98359527-8ad1-474f-9044-c761debae023" xlink:href="smmt-20231231.xsd#smmt_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5b8a5a4-886f-4665-a96c-07d7eed74cb9" xlink:to="loc_smmt_StockIssuedDuringPeriodSharesWarrantsExercised_98359527-8ad1-474f-9044-c761debae023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_StockIssuedDuringPeriodValueWarrantsExercised_2a745830-d992-42e2-9634-3850db1cee69" xlink:href="smmt-20231231.xsd#smmt_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5b8a5a4-886f-4665-a96c-07d7eed74cb9" xlink:to="loc_smmt_StockIssuedDuringPeriodValueWarrantsExercised_2a745830-d992-42e2-9634-3850db1cee69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_StockIssuedDuringPeriodSharesIssuedForRelatedPartyInterest_c56dae97-fe20-4351-a05b-5e151c188272" xlink:href="smmt-20231231.xsd#smmt_StockIssuedDuringPeriodSharesIssuedForRelatedPartyInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5b8a5a4-886f-4665-a96c-07d7eed74cb9" xlink:to="loc_smmt_StockIssuedDuringPeriodSharesIssuedForRelatedPartyInterest_c56dae97-fe20-4351-a05b-5e151c188272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_StockIssuedDuringPeriodValueIssuedForRelatedPartyInterest_e88716d9-e418-4630-8360-be7ea25b2bc8" xlink:href="smmt-20231231.xsd#smmt_StockIssuedDuringPeriodValueIssuedForRelatedPartyInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5b8a5a4-886f-4665-a96c-07d7eed74cb9" xlink:to="loc_smmt_StockIssuedDuringPeriodValueIssuedForRelatedPartyInterest_e88716d9-e418-4630-8360-be7ea25b2bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d5f0f5a7-657d-4e0c-9484-d3447f921466" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5b8a5a4-886f-4665-a96c-07d7eed74cb9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d5f0f5a7-657d-4e0c-9484-d3447f921466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_8ef576ca-f216-4c90-aa53-ac81b91fe679" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5b8a5a4-886f-4665-a96c-07d7eed74cb9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_8ef576ca-f216-4c90-aa53-ac81b91fe679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_StockIssuedDuringPeriodSharesInLieuOfCashForCollaborativeArrangement_bb392620-2f14-4c3b-bdce-cfb5bf5a3101" xlink:href="smmt-20231231.xsd#smmt_StockIssuedDuringPeriodSharesInLieuOfCashForCollaborativeArrangement"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5b8a5a4-886f-4665-a96c-07d7eed74cb9" xlink:to="loc_smmt_StockIssuedDuringPeriodSharesInLieuOfCashForCollaborativeArrangement_bb392620-2f14-4c3b-bdce-cfb5bf5a3101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement_fbaeca20-fcb7-4cbd-a1e5-48a89a712451" xlink:href="smmt-20231231.xsd#smmt_StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5b8a5a4-886f-4665-a96c-07d7eed74cb9" xlink:to="loc_smmt_StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement_fbaeca20-fcb7-4cbd-a1e5-48a89a712451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_020f9a81-e682-461e-9e55-bc8020ccfe6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5b8a5a4-886f-4665-a96c-07d7eed74cb9" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_020f9a81-e682-461e-9e55-bc8020ccfe6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty_468aaee5-6af0-48bd-8227-93219889fa36" xlink:href="smmt-20231231.xsd#smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5b8a5a4-886f-4665-a96c-07d7eed74cb9" xlink:to="loc_smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty_468aaee5-6af0-48bd-8227-93219889fa36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2ef00393-f3f3-4a0a-b25b-88ec8c3e64a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5b8a5a4-886f-4665-a96c-07d7eed74cb9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2ef00393-f3f3-4a0a-b25b-88ec8c3e64a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_3e4353a9-0330-4107-b8a6-2d2200eebb2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5b8a5a4-886f-4665-a96c-07d7eed74cb9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_3e4353a9-0330-4107-b8a6-2d2200eebb2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_6c9caefd-e96a-46fc-9b99-42fc5fb0eb61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5b8a5a4-886f-4665-a96c-07d7eed74cb9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_6c9caefd-e96a-46fc-9b99-42fc5fb0eb61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8b9e6c17-ebc7-43a3-870a-75438915f21a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5b8a5a4-886f-4665-a96c-07d7eed74cb9" xlink:to="loc_us-gaap_NetIncomeLoss_8b9e6c17-ebc7-43a3-870a-75438915f21a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_fbfd336f-bfff-4d84-8ce2-d999c70d6e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5b8a5a4-886f-4665-a96c-07d7eed74cb9" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_fbfd336f-bfff-4d84-8ce2-d999c70d6e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8710ee37-5599-4445-980e-e2e9d8a391d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5b8a5a4-886f-4665-a96c-07d7eed74cb9" xlink:to="loc_us-gaap_StockholdersEquity_8710ee37-5599-4445-980e-e2e9d8a391d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="smmt-20231231.xsd#ConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_681e8738-bf3a-40ff-bd60-8a6f45b924e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_e9f97a1f-ff5f-4833-a4b4-f51874c53b53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_681e8738-bf3a-40ff-bd60-8a6f45b924e6" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_e9f97a1f-ff5f-4833-a4b4-f51874c53b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="smmt-20231231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_28354cc4-9544-43b9-8850-9e5b790090cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c816c720-dd80-4614-8209-403dbe40beb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_28354cc4-9544-43b9-8850-9e5b790090cb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c816c720-dd80-4614-8209-403dbe40beb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_52179915-36ad-4ea7-87e6-dbaa90977262" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c816c720-dd80-4614-8209-403dbe40beb8" xlink:to="loc_us-gaap_NetIncomeLoss_52179915-36ad-4ea7-87e6-dbaa90977262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_766746a8-eff4-4e06-aac2-f2a2ef8e66df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c816c720-dd80-4614-8209-403dbe40beb8" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_766746a8-eff4-4e06-aac2-f2a2ef8e66df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss_e29e5ec4-e509-4779-a100-27540350a00b" xlink:href="smmt-20231231.xsd#smmt_BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_766746a8-eff4-4e06-aac2-f2a2ef8e66df" xlink:to="loc_smmt_BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss_e29e5ec4-e509-4779-a100-27540350a00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_InterestExpenseIncomeNoncash_72fba59d-6e06-497d-8248-8e0a73f41578" xlink:href="smmt-20231231.xsd#smmt_InterestExpenseIncomeNoncash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_766746a8-eff4-4e06-aac2-f2a2ef8e66df" xlink:to="loc_smmt_InterestExpenseIncomeNoncash_72fba59d-6e06-497d-8248-8e0a73f41578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_cceef2a8-93ad-494d-8d03-844ff9239a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_766746a8-eff4-4e06-aac2-f2a2ef8e66df" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_cceef2a8-93ad-494d-8d03-844ff9239a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_59a30bf6-0425-4fe7-a566-54aaa66138e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_766746a8-eff4-4e06-aac2-f2a2ef8e66df" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_59a30bf6-0425-4fe7-a566-54aaa66138e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome_a8f8032c-61c2-4847-84e2-ceb9908b6131" xlink:href="smmt-20231231.xsd#smmt_CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_766746a8-eff4-4e06-aac2-f2a2ef8e66df" xlink:to="loc_smmt_CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome_a8f8032c-61c2-4847-84e2-ceb9908b6131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_1fc37ec7-c906-4b22-9382-5cf26fc54ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_766746a8-eff4-4e06-aac2-f2a2ef8e66df" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_1fc37ec7-c906-4b22-9382-5cf26fc54ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_2bd272c5-2119-4a90-9b7e-143bffc114b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_766746a8-eff4-4e06-aac2-f2a2ef8e66df" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_2bd272c5-2119-4a90-9b7e-143bffc114b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_4c3de097-29c5-43c1-86d5-477e6bee27b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_766746a8-eff4-4e06-aac2-f2a2ef8e66df" xlink:to="loc_us-gaap_Depreciation_4c3de097-29c5-43c1-86d5-477e6bee27b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_4334d793-7b18-4a5f-be23-48a16b50e6d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_766746a8-eff4-4e06-aac2-f2a2ef8e66df" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_4334d793-7b18-4a5f-be23-48a16b50e6d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_f087c3f2-e82d-4faf-ba70-82663df80b08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_766746a8-eff4-4e06-aac2-f2a2ef8e66df" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_f087c3f2-e82d-4faf-ba70-82663df80b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_15042987-e1e9-4997-afd9-8b5d112b36e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_766746a8-eff4-4e06-aac2-f2a2ef8e66df" xlink:to="loc_us-gaap_ShareBasedCompensation_15042987-e1e9-4997-afd9-8b5d112b36e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_b20e78cd-2e62-4935-aa10-310b6cf962bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_766746a8-eff4-4e06-aac2-f2a2ef8e66df" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_b20e78cd-2e62-4935-aa10-310b6cf962bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_InProcessResearchAndDevelopmentExpense_2d13d290-7acf-43b2-8c46-98b9e343f5f8" xlink:href="smmt-20231231.xsd#smmt_InProcessResearchAndDevelopmentExpense"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_766746a8-eff4-4e06-aac2-f2a2ef8e66df" xlink:to="loc_smmt_InProcessResearchAndDevelopmentExpense_2d13d290-7acf-43b2-8c46-98b9e343f5f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d3e59c2a-758e-4553-8862-7060e28b34d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_766746a8-eff4-4e06-aac2-f2a2ef8e66df" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d3e59c2a-758e-4553-8862-7060e28b34d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9c643da3-c083-4fab-bc0f-003c72ede81a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d3e59c2a-758e-4553-8862-7060e28b34d9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9c643da3-c083-4fab-bc0f-003c72ede81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_d1e1ed6d-6cc3-48a0-a31b-65d25c62594e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d3e59c2a-758e-4553-8862-7060e28b34d9" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_d1e1ed6d-6cc3-48a0-a31b-65d25c62594e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_3a89b1ea-ad46-464c-9835-80b8dfe89a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d3e59c2a-758e-4553-8862-7060e28b34d9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_3a89b1ea-ad46-464c-9835-80b8dfe89a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable_719fabb1-6eba-452a-adc3-f4355fad6bb1" xlink:href="smmt-20231231.xsd#smmt_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d3e59c2a-758e-4553-8862-7060e28b34d9" xlink:to="loc_smmt_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable_719fabb1-6eba-452a-adc3-f4355fad6bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_459b62ba-ef8b-4a4f-b65f-ede6e23dfb16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d3e59c2a-758e-4553-8862-7060e28b34d9" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_459b62ba-ef8b-4a4f-b65f-ede6e23dfb16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b624c4a0-28bd-443f-9abc-b19b63f1eaa6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d3e59c2a-758e-4553-8862-7060e28b34d9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b624c4a0-28bd-443f-9abc-b19b63f1eaa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_57c36998-e3e2-4dd4-a037-d211faa5720d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d3e59c2a-758e-4553-8862-7060e28b34d9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_57c36998-e3e2-4dd4-a037-d211faa5720d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_c2c43741-6eb4-49a0-befc-66afa47e5089" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d3e59c2a-758e-4553-8862-7060e28b34d9" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_c2c43741-6eb4-49a0-befc-66afa47e5089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_e6aa5d23-ad4c-41dc-ad9f-3bce58fe82a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d3e59c2a-758e-4553-8862-7060e28b34d9" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_e6aa5d23-ad4c-41dc-ad9f-3bce58fe82a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a8098852-b6b8-4d30-b0fb-1bf6fdf52106" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c816c720-dd80-4614-8209-403dbe40beb8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a8098852-b6b8-4d30-b0fb-1bf6fdf52106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1b290eea-3d25-48bc-891a-f5e32eef044f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_28354cc4-9544-43b9-8850-9e5b790090cb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1b290eea-3d25-48bc-891a-f5e32eef044f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_db595f86-0293-478e-9eae-eeb567968c12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1b290eea-3d25-48bc-891a-f5e32eef044f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_db595f86-0293-478e-9eae-eeb567968c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_15c4e4ee-3b43-48a5-a853-f3f18903fb8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1b290eea-3d25-48bc-891a-f5e32eef044f" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_15c4e4ee-3b43-48a5-a853-f3f18903fb8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_9088c907-7bca-4516-89a3-1fd8989f1406" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1b290eea-3d25-48bc-891a-f5e32eef044f" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_9088c907-7bca-4516-89a3-1fd8989f1406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_e4d20430-44de-4ee4-8a71-c506f9eae55e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1b290eea-3d25-48bc-891a-f5e32eef044f" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_e4d20430-44de-4ee4-8a71-c506f9eae55e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_PaymentsForCollaborativeArrangement_701040f3-577a-40b5-a592-8faf33dafd95" xlink:href="smmt-20231231.xsd#smmt_PaymentsForCollaborativeArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1b290eea-3d25-48bc-891a-f5e32eef044f" xlink:to="loc_smmt_PaymentsForCollaborativeArrangement_701040f3-577a-40b5-a592-8faf33dafd95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_629a6357-b3c5-4f6d-8634-d1012dce7856" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1b290eea-3d25-48bc-891a-f5e32eef044f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_629a6357-b3c5-4f6d-8634-d1012dce7856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a2c01e9f-fa4c-4660-8fda-168c2f2b1e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_28354cc4-9544-43b9-8850-9e5b790090cb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a2c01e9f-fa4c-4660-8fda-168c2f2b1e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8baf1e6c-8e3d-45b8-ac25-c517408caf5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a2c01e9f-fa4c-4660-8fda-168c2f2b1e3f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8baf1e6c-8e3d-45b8-ac25-c517408caf5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_8b2f82c9-b385-4dde-874e-23396757a5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a2c01e9f-fa4c-4660-8fda-168c2f2b1e3f" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_8b2f82c9-b385-4dde-874e-23396757a5a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_60681317-d0d3-4bca-be97-b72312c99965" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a2c01e9f-fa4c-4660-8fda-168c2f2b1e3f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_60681317-d0d3-4bca-be97-b72312c99965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_4b93a43c-cc2b-4734-91f0-3a4230c100b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a2c01e9f-fa4c-4660-8fda-168c2f2b1e3f" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_4b93a43c-cc2b-4734-91f0-3a4230c100b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_1eb8988c-9cfe-44ec-998b-f80bd6ec95f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a2c01e9f-fa4c-4660-8fda-168c2f2b1e3f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_1eb8988c-9cfe-44ec-998b-f80bd6ec95f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_2e1a24f4-29f6-4acc-817b-ffd00bd0adff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a2c01e9f-fa4c-4660-8fda-168c2f2b1e3f" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_2e1a24f4-29f6-4acc-817b-ffd00bd0adff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_baab49e6-a8c8-4967-8265-bd2d379c6307" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a2c01e9f-fa4c-4660-8fda-168c2f2b1e3f" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_baab49e6-a8c8-4967-8265-bd2d379c6307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_66298397-4d9c-4f4a-8f7a-a90768f6fb55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a2c01e9f-fa4c-4660-8fda-168c2f2b1e3f" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_66298397-4d9c-4f4a-8f7a-a90768f6fb55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9ab7ed64-cc88-4acf-9cc0-ed7f4f19c943" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a2c01e9f-fa4c-4660-8fda-168c2f2b1e3f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9ab7ed64-cc88-4acf-9cc0-ed7f4f19c943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_db639a7a-d34f-406a-bc6c-2ad655e39260" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_28354cc4-9544-43b9-8850-9e5b790090cb" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_db639a7a-d34f-406a-bc6c-2ad655e39260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9da290be-309d-4d18-8a27-ee6b838b5e34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_28354cc4-9544-43b9-8850-9e5b790090cb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9da290be-309d-4d18-8a27-ee6b838b5e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ddda4081-f548-4465-92d5-a50c36ea4681" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_28354cc4-9544-43b9-8850-9e5b790090cb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ddda4081-f548-4465-92d5-a50c36ea4681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b0cecbf6-a12c-46e2-b428-88e3c1241e67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_28354cc4-9544-43b9-8850-9e5b790090cb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b0cecbf6-a12c-46e2-b428-88e3c1241e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_a691cdd8-a610-4814-8d86-e7f5ba7cdb27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_28354cc4-9544-43b9-8850-9e5b790090cb" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_a691cdd8-a610-4814-8d86-e7f5ba7cdb27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_db021a23-3983-4b26-9fe9-cb4de315fafb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_a691cdd8-a610-4814-8d86-e7f5ba7cdb27" xlink:to="loc_us-gaap_StatementTable_db021a23-3983-4b26-9fe9-cb4de315fafb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_59cfda61-6ce0-4477-a926-1c438b7003da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_db021a23-3983-4b26-9fe9-cb4de315fafb" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_59cfda61-6ce0-4477-a926-1c438b7003da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1ae4a5e1-73e3-4894-98f3-1204da7e5e42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_59cfda61-6ce0-4477-a926-1c438b7003da" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1ae4a5e1-73e3-4894-98f3-1204da7e5e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_AkesoLicenseAgreementMember_b18c19b9-9c1b-4a6b-ba4f-81c06d8f61b1" xlink:href="smmt-20231231.xsd#smmt_AkesoLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1ae4a5e1-73e3-4894-98f3-1204da7e5e42" xlink:to="loc_smmt_AkesoLicenseAgreementMember_b18c19b9-9c1b-4a6b-ba4f-81c06d8f61b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RightsOfferingMember_0699210f-eab6-4c62-abb3-456e01d5727a" xlink:href="smmt-20231231.xsd#smmt_RightsOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1ae4a5e1-73e3-4894-98f3-1204da7e5e42" xlink:to="loc_smmt_RightsOfferingMember_0699210f-eab6-4c62-abb3-456e01d5727a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e91e3074-8796-45e2-90a1-d573f9cde0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_db021a23-3983-4b26-9fe9-cb4de315fafb" xlink:to="loc_us-gaap_StatementLineItems_e91e3074-8796-45e2-90a1-d573f9cde0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_dd7f74af-cecb-4b54-a56c-2e6a5bc7df2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e91e3074-8796-45e2-90a1-d573f9cde0ca" xlink:to="loc_us-gaap_InterestPaidNet_dd7f74af-cecb-4b54-a56c-2e6a5bc7df2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_02f0984c-08ca-4de7-9b63-70a26de9ef6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e91e3074-8796-45e2-90a1-d573f9cde0ca" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_02f0984c-08ca-4de7-9b63-70a26de9ef6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DebtIssuanceCostsIncurredButNotYetPaid_65df1492-05eb-4b3b-8a46-5b74082e5345" xlink:href="smmt-20231231.xsd#smmt_DebtIssuanceCostsIncurredButNotYetPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e91e3074-8796-45e2-90a1-d573f9cde0ca" xlink:to="loc_smmt_DebtIssuanceCostsIncurredButNotYetPaid_65df1492-05eb-4b3b-8a46-5b74082e5345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_9025dcdc-8bf4-4ba8-9d34-01059237c944" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e91e3074-8796-45e2-90a1-d573f9cde0ca" xlink:to="loc_us-gaap_StockIssued1_9025dcdc-8bf4-4ba8-9d34-01059237c944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DeferredTransactionCostsIncurredDuringNoncashOrPartialNoncashTransaction_3048e026-9da9-4c35-af24-cb9534adb146" xlink:href="smmt-20231231.xsd#smmt_DeferredTransactionCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e91e3074-8796-45e2-90a1-d573f9cde0ca" xlink:to="loc_smmt_DeferredTransactionCostsIncurredDuringNoncashOrPartialNoncashTransaction_3048e026-9da9-4c35-af24-cb9534adb146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b008ecfe-025e-43c5-962d-58ddc4f10847" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e91e3074-8796-45e2-90a1-d573f9cde0ca" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b008ecfe-025e-43c5-962d-58ddc4f10847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEvents" xlink:type="simple" xlink:href="smmt-20231231.xsd#NatureofBusinessandOperationsandRecentEvents"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ef5bc637-b1b3-4537-ad5c-9b147456bc0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_401b6622-4306-48ab-99ee-1500d90869e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ef5bc637-b1b3-4537-ad5c-9b147456bc0c" xlink:to="loc_us-gaap_NatureOfOperations_401b6622-4306-48ab-99ee-1500d90869e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/BasisofPresentationUseofEstimatesandRisksandUncertainties" xlink:type="simple" xlink:href="smmt-20231231.xsd#BasisofPresentationUseofEstimatesandRisksandUncertainties"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/BasisofPresentationUseofEstimatesandRisksandUncertainties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_028d519d-581b-4b1b-8c32-b932c9853f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccounting_988e5e40-99b7-4eee-a7fc-f323f17441e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccounting"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_028d519d-581b-4b1b-8c32-b932c9853f5d" xlink:to="loc_us-gaap_BasisOfAccounting_988e5e40-99b7-4eee-a7fc-f323f17441e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/LiquidityandCapitalResources" xlink:type="simple" xlink:href="smmt-20231231.xsd#LiquidityandCapitalResources"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/LiquidityandCapitalResources" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_492f3ccb-f427-48c7-9e14-92e095683851" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_LiquidityAndCapitalResourcesTextBlock_9a04ff78-6cd7-45bd-869d-5bb29ff658af" xlink:href="smmt-20231231.xsd#smmt_LiquidityAndCapitalResourcesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_492f3ccb-f427-48c7-9e14-92e095683851" xlink:to="loc_smmt_LiquidityAndCapitalResourcesTextBlock_9a04ff78-6cd7-45bd-869d-5bb29ff658af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="smmt-20231231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f049bf62-e972-4558-a57b-6775c31eeee0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_a77bec9e-eb26-4492-93ef-fa77420679b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f049bf62-e972-4558-a57b-6775c31eeee0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_a77bec9e-eb26-4492-93ef-fa77420679b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/RecentlyIssuedorAdoptedAccountingPronouncements" xlink:type="simple" xlink:href="smmt-20231231.xsd#RecentlyIssuedorAdoptedAccountingPronouncements"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/RecentlyIssuedorAdoptedAccountingPronouncements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_bb480977-dacb-4c8f-a16a-5d5330df851e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_4acf56d2-9628-408b-9d5d-3eb54cb3f5fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_bb480977-dacb-4c8f-a16a-5d5330df851e" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_4acf56d2-9628-408b-9d5d-3eb54cb3f5fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/AkesoLicenseandCollaborationAgreement" xlink:type="simple" xlink:href="smmt-20231231.xsd#AkesoLicenseandCollaborationAgreement"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/AkesoLicenseandCollaborationAgreement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b0326e6c-bef5-4069-aeb9-5816c9769749" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_9b0d8bac-4b4a-4413-a449-95e7c04a6544" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b0326e6c-bef5-4069-aeb9-5816c9769749" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_9b0d8bac-4b4a-4413-a449-95e7c04a6544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/SegmentReporting" xlink:type="simple" xlink:href="smmt-20231231.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_fa92182a-fcab-4a33-915d-67d509dbd287" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_bd4f653c-1ff2-45d0-af31-d708d24b2574" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_fa92182a-fcab-4a33-915d-67d509dbd287" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_bd4f653c-1ff2-45d0-af31-d708d24b2574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/Revenue" xlink:type="simple" xlink:href="smmt-20231231.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_56735ce4-296a-45eb-b3f9-4f1e752dd97b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_a85e6764-e467-4fa1-975c-f923ddfd818b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_56735ce4-296a-45eb-b3f9-4f1e752dd97b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_a85e6764-e467-4fa1-975c-f923ddfd818b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/OtherOperatingIncomenet" xlink:type="simple" xlink:href="smmt-20231231.xsd#OtherOperatingIncomenet"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/OtherOperatingIncomenet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_34424bb6-ac5b-49d0-aeca-9debd56f2bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeAndExpenseTextBlock_9f04abca-244e-471e-93aa-ce74de33d17f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeAndExpenseTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_34424bb6-ac5b-49d0-aeca-9debd56f2bfd" xlink:to="loc_us-gaap_OtherOperatingIncomeAndExpenseTextBlock_9f04abca-244e-471e-93aa-ce74de33d17f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/OtherExpenseIncomenet" xlink:type="simple" xlink:href="smmt-20231231.xsd#OtherExpenseIncomenet"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/OtherExpenseIncomenet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_cf33e22a-9275-440e-8382-e165be1b3027" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_cdf3c73f-b751-446a-9535-7964968d087e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_cf33e22a-9275-440e-8382-e165be1b3027" xlink:to="loc_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_cdf3c73f-b751-446a-9535-7964968d087e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/IncomeTax" xlink:type="simple" xlink:href="smmt-20231231.xsd#IncomeTax"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/IncomeTax" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7cb8c1e4-e5a3-4e25-a227-893703fc3b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_07465e42-50db-445d-b2d2-e525384e111c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7cb8c1e4-e5a3-4e25-a227-893703fc3b6e" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_07465e42-50db-445d-b2d2-e525384e111c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/NetLossperShare" xlink:type="simple" xlink:href="smmt-20231231.xsd#NetLossperShare"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/NetLossperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6bb5951b-1519-4afc-ad6d-5af2f29124fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_aa9575bc-b58c-4724-a339-b53b2e8e1a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6bb5951b-1519-4afc-ad6d-5af2f29124fe" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_aa9575bc-b58c-4724-a339-b53b2e8e1a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="smmt-20231231.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6651f290-28d9-49c2-8ca6-bf3c912b72c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_34992f0b-4cb6-4d47-bcf3-cf3a5c04c205" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6651f290-28d9-49c2-8ca6-bf3c912b72c2" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_34992f0b-4cb6-4d47-bcf3-cf3a5c04c205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestments" xlink:type="simple" xlink:href="smmt-20231231.xsd#FairValueMeasurementsandShortTermInvestments"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_701ebb70-ab86-4321-8d0a-a9db7268704f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_20455309-c56f-4b55-b656-9dd96b983128" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_701ebb70-ab86-4321-8d0a-a9db7268704f" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_20455309-c56f-4b55-b656-9dd96b983128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="smmt-20231231.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c821b55f-fb93-4f84-9347-6a1e7dea281b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_467a797f-0bdd-4604-8532-192bdb76b1fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c821b55f-fb93-4f84-9347-6a1e7dea281b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_467a797f-0bdd-4604-8532-192bdb76b1fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/ResearchandDevelopmentPrepaidExpensesandAccruedLiabilities" xlink:type="simple" xlink:href="smmt-20231231.xsd#ResearchandDevelopmentPrepaidExpensesandAccruedLiabilities"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/ResearchandDevelopmentPrepaidExpensesandAccruedLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_28c4dc1c-4cc7-43c9-9f98-ab6ca815ca71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_6b22e339-8359-42f4-a2d1-ee2e5f52931d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_28c4dc1c-4cc7-43c9-9f98-ab6ca815ca71" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_6b22e339-8359-42f4-a2d1-ee2e5f52931d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/Leases" xlink:type="simple" xlink:href="smmt-20231231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a791c579-5636-469b-b650-75b77e27b939" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_627cd48b-8d32-40d0-a6a3-466a1e1cd6d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a791c579-5636-469b-b650-75b77e27b939" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_627cd48b-8d32-40d0-a6a3-466a1e1cd6d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedParties" xlink:type="simple" xlink:href="smmt-20231231.xsd#PromissoryNotesPayabletoRelatedParties"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedParties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_bc8f2526-0ef0-46bc-b5e8-476ef0501acf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_a94e901c-5baf-4fd3-891d-6e41c621eb44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_bc8f2526-0ef0-46bc-b5e8-476ef0501acf" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_a94e901c-5baf-4fd3-891d-6e41c621eb44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/OtherNonCurrentLiabilities" xlink:type="simple" xlink:href="smmt-20231231.xsd#OtherNonCurrentLiabilities"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/OtherNonCurrentLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_676de26a-991e-4cdd-a295-39a2fb5b3563" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock_0289a9bc-7103-487d-b248-93a480c6bf2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_676de26a-991e-4cdd-a295-39a2fb5b3563" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock_0289a9bc-7103-487d-b248-93a480c6bf2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/StockholdersEquity" xlink:type="simple" xlink:href="smmt-20231231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c3b559d9-9576-41a5-9d48-47c0072296dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3c2a5b1b-f4fa-45b2-b8af-5ecc24454e46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c3b559d9-9576-41a5-9d48-47c0072296dc" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3c2a5b1b-f4fa-45b2-b8af-5ecc24454e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="smmt-20231231.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fcbb6147-63aa-4f20-8030-a7381eca2bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_fe03c2db-8a76-45c8-b96b-fdf29da4a1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fcbb6147-63aa-4f20-8030-a7381eca2bc6" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_fe03c2db-8a76-45c8-b96b-fdf29da4a1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="smmt-20231231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bf29c86e-66ad-4fec-b2f5-d62ffbc6e424" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_d4b0e70f-a384-4bd7-a470-250cb064a118" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bf29c86e-66ad-4fec-b2f5-d62ffbc6e424" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_d4b0e70f-a384-4bd7-a470-250cb064a118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="smmt-20231231.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_ed2d4bab-1ba8-4fad-997e-f688ffbf78ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_9fc61342-77ab-4d04-bca3-57c03f0f209d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_ed2d4bab-1ba8-4fad-997e-f688ffbf78ed" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_9fc61342-77ab-4d04-bca3-57c03f0f209d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="smmt-20231231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_448d23e1-ad82-4320-944e-ca04b241c906" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_852cbcfd-825c-4975-b096-8632c1c0840a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_448d23e1-ad82-4320-944e-ca04b241c906" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_852cbcfd-825c-4975-b096-8632c1c0840a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_2e3a7b9d-e719-44f2-a488-b4efd4c3f692" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_448d23e1-ad82-4320-944e-ca04b241c906" xlink:to="loc_us-gaap_UseOfEstimates_2e3a7b9d-e719-44f2-a488-b4efd4c3f692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_ce30c56b-a154-46af-b439-e1ad7112f78b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_448d23e1-ad82-4320-944e-ca04b241c906" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_ce30c56b-a154-46af-b439-e1ad7112f78b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_78314988-7ad0-4c24-930e-45303d05b9b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_448d23e1-ad82-4320-944e-ca04b241c906" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_78314988-7ad0-4c24-930e-45303d05b9b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_OtherOperatingIncomePolicyPolicyTextBlock_749b6664-6e62-47aa-8f57-b7bc7d41fca1" xlink:href="smmt-20231231.xsd#smmt_OtherOperatingIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_448d23e1-ad82-4320-944e-ca04b241c906" xlink:to="loc_smmt_OtherOperatingIncomePolicyPolicyTextBlock_749b6664-6e62-47aa-8f57-b7bc7d41fca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_39bee739-47e5-425a-b1d7-96674bbdb95f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_448d23e1-ad82-4320-944e-ca04b241c906" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_39bee739-47e5-425a-b1d7-96674bbdb95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_ab3a71b5-a287-4368-939c-970c49c4b747" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_448d23e1-ad82-4320-944e-ca04b241c906" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_ab3a71b5-a287-4368-939c-970c49c4b747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_f9482e79-6841-48fe-af2c-bc0f3ca3b75a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_448d23e1-ad82-4320-944e-ca04b241c906" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_f9482e79-6841-48fe-af2c-bc0f3ca3b75a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_9e273dc4-9777-4380-80c0-86c8759f2d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_448d23e1-ad82-4320-944e-ca04b241c906" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_9e273dc4-9777-4380-80c0-86c8759f2d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_ddb8ed71-2437-4062-943e-1036a2d06004" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_448d23e1-ad82-4320-944e-ca04b241c906" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_ddb8ed71-2437-4062-943e-1036a2d06004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_1af14d0a-474f-427b-beae-700ea94f8850" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_448d23e1-ad82-4320-944e-ca04b241c906" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_1af14d0a-474f-427b-beae-700ea94f8850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_26af15bb-5265-4168-9846-3a8eb07c6d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_448d23e1-ad82-4320-944e-ca04b241c906" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_26af15bb-5265-4168-9846-3a8eb07c6d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_d5d14557-016f-4e59-9ace-ca820725f036" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_448d23e1-ad82-4320-944e-ca04b241c906" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_d5d14557-016f-4e59-9ace-ca820725f036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_813b6aa3-4442-40e6-b085-1b8255ec249a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_448d23e1-ad82-4320-944e-ca04b241c906" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_813b6aa3-4442-40e6-b085-1b8255ec249a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_32984b70-7d5b-41fb-bbd9-f50d5fce4433" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_448d23e1-ad82-4320-944e-ca04b241c906" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_32984b70-7d5b-41fb-bbd9-f50d5fce4433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_17945ebd-ea66-457b-9b4d-47a10b21fac7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_448d23e1-ad82-4320-944e-ca04b241c906" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_17945ebd-ea66-457b-9b4d-47a10b21fac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_345e90b9-af5a-437a-83c8-92320edb758e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_448d23e1-ad82-4320-944e-ca04b241c906" xlink:to="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_345e90b9-af5a-437a-83c8-92320edb758e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_2bb4bc1c-1a22-4893-af79-9ad067ddbaf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_448d23e1-ad82-4320-944e-ca04b241c906" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_2bb4bc1c-1a22-4893-af79-9ad067ddbaf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_AssumedContingentLiabilitiesPolicyPolicyTextBlock_ad669d33-8bd6-464d-a0f5-79d9e84d65b5" xlink:href="smmt-20231231.xsd#smmt_AssumedContingentLiabilitiesPolicyPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_448d23e1-ad82-4320-944e-ca04b241c906" xlink:to="loc_smmt_AssumedContingentLiabilitiesPolicyPolicyTextBlock_ad669d33-8bd6-464d-a0f5-79d9e84d65b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_WarrantsPolicyPolicyTextBlock_37b6a3ee-fde3-40e7-b4dd-500cd3f6ee5d" xlink:href="smmt-20231231.xsd#smmt_WarrantsPolicyPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_448d23e1-ad82-4320-944e-ca04b241c906" xlink:to="loc_smmt_WarrantsPolicyPolicyTextBlock_37b6a3ee-fde3-40e7-b4dd-500cd3f6ee5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_af8e569a-eeaa-4bd3-85b2-0a520976de80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_448d23e1-ad82-4320-944e-ca04b241c906" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_af8e569a-eeaa-4bd3-85b2-0a520976de80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="smmt-20231231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e5757c25-1134-42eb-ba59-891adece35ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_59be5302-eef0-40b0-8f47-6676af6647df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e5757c25-1134-42eb-ba59-891adece35ff" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_59be5302-eef0-40b0-8f47-6676af6647df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="smmt-20231231.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_6a0d9ddd-a56a-4cae-b0de-b1bb7ed4f941" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_977aa74b-abd9-4e79-95a3-ccff0c6057b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6a0d9ddd-a56a-4cae-b0de-b1bb7ed4f941" xlink:to="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_977aa74b-abd9-4e79-95a3-ccff0c6057b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/RevenueTables" xlink:type="simple" xlink:href="smmt-20231231.xsd#RevenueTables"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/RevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d47d4588-671f-4a5d-9638-39e05f99a74f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_c73f3020-1daf-4bfc-8563-7a0e457ed9ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d47d4588-671f-4a5d-9638-39e05f99a74f" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_c73f3020-1daf-4bfc-8563-7a0e457ed9ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/OtherOperatingIncomenetTables" xlink:type="simple" xlink:href="smmt-20231231.xsd#OtherOperatingIncomenetTables"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/OtherOperatingIncomenetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_09dafe56-7df9-482b-b6df-d54b50dd885c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ScheduleOfOtherOperatingIncomeExpenseNetTableTextBlock_ee4070e8-0535-4922-a4ac-950491d32a13" xlink:href="smmt-20231231.xsd#smmt_ScheduleOfOtherOperatingIncomeExpenseNetTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_09dafe56-7df9-482b-b6df-d54b50dd885c" xlink:to="loc_smmt_ScheduleOfOtherOperatingIncomeExpenseNetTableTextBlock_ee4070e8-0535-4922-a4ac-950491d32a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/OtherExpenseIncomenetTables" xlink:type="simple" xlink:href="smmt-20231231.xsd#OtherExpenseIncomenetTables"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/OtherExpenseIncomenetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_3a546915-8bf8-4f87-91cc-fdb1573f1691" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_099ce4d9-2cc1-4e3d-821b-82e7279a2e49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_3a546915-8bf8-4f87-91cc-fdb1573f1691" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_099ce4d9-2cc1-4e3d-821b-82e7279a2e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/IncomeTaxTables" xlink:type="simple" xlink:href="smmt-20231231.xsd#IncomeTaxTables"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/IncomeTaxTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d0ee4225-2c8a-46ec-a193-15f5a17dbbfa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_341988e8-37b6-4e26-b1a3-a92cd77dcf97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d0ee4225-2c8a-46ec-a193-15f5a17dbbfa" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_341988e8-37b6-4e26-b1a3-a92cd77dcf97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_b0ac4779-b3b0-41dc-ae28-ab974258ef08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d0ee4225-2c8a-46ec-a193-15f5a17dbbfa" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_b0ac4779-b3b0-41dc-ae28-ab974258ef08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_8c85c919-a9b5-4502-972f-e66195466106" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d0ee4225-2c8a-46ec-a193-15f5a17dbbfa" xlink:to="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_8c85c919-a9b5-4502-972f-e66195466106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_9a3728cf-141d-4b03-b860-28199230ff7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d0ee4225-2c8a-46ec-a193-15f5a17dbbfa" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_9a3728cf-141d-4b03-b860-28199230ff7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_2d070c38-629d-4fc7-89db-092cd6c84e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d0ee4225-2c8a-46ec-a193-15f5a17dbbfa" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_2d070c38-629d-4fc7-89db-092cd6c84e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/NetLossperShareTables" xlink:type="simple" xlink:href="smmt-20231231.xsd#NetLossperShareTables"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/NetLossperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c67e1cb7-bf68-4819-8652-07207c7615a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_002ebde0-63bc-46b4-9011-5f6896a558a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c67e1cb7-bf68-4819-8652-07207c7615a6" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_002ebde0-63bc-46b4-9011-5f6896a558a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_87c11cfa-656a-43e0-a22e-6383e2e90dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c67e1cb7-bf68-4819-8652-07207c7615a6" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_87c11cfa-656a-43e0-a22e-6383e2e90dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="smmt-20231231.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2b4770bd-a839-494f-9cd0-cd52614bb629" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1406da74-189d-4099-809f-e920cf7c3ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2b4770bd-a839-494f-9cd0-cd52614bb629" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1406da74-189d-4099-809f-e920cf7c3ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsTables" xlink:type="simple" xlink:href="smmt-20231231.xsd#FairValueMeasurementsandShortTermInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_199bbbc8-2d55-487b-8f09-59b4ca6cfdee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_2805a210-d557-4d81-8ce1-255b983a2364" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_199bbbc8-2d55-487b-8f09-59b4ca6cfdee" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_2805a210-d557-4d81-8ce1-255b983a2364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_fbf379ea-5278-48e9-a93a-6b3c37c9cd1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_199bbbc8-2d55-487b-8f09-59b4ca6cfdee" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_fbf379ea-5278-48e9-a93a-6b3c37c9cd1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="smmt-20231231.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2c71a84f-851a-4654-9af6-29ee09ff6c57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_745ca6d5-b1b1-4fc1-80b8-53d44aa641f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2c71a84f-851a-4654-9af6-29ee09ff6c57" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_745ca6d5-b1b1-4fc1-80b8-53d44aa641f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/LeasesTables" xlink:type="simple" xlink:href="smmt-20231231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_44a55c2e-ce3d-4a9c-9a3a-4dc3032f8d74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_6d104083-efab-4bb3-a124-bea9cfca29e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_44a55c2e-ce3d-4a9c-9a3a-4dc3032f8d74" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_6d104083-efab-4bb3-a124-bea9cfca29e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_c324f039-a0c7-4440-8c97-347776f99e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_44a55c2e-ce3d-4a9c-9a3a-4dc3032f8d74" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_c324f039-a0c7-4440-8c97-347776f99e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesTables" xlink:type="simple" xlink:href="smmt-20231231.xsd#PromissoryNotesPayabletoRelatedPartiesTables"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_bc1c4d97-84e8-4d48-bc22-13bac85301cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_6232c366-ff0a-4b05-90fb-f501b538e099" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_bc1c4d97-84e8-4d48-bc22-13bac85301cc" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_6232c366-ff0a-4b05-90fb-f501b538e099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="smmt-20231231.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_28375801-c5a2-4bf4-a35b-323ff8138884" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_b3aa32a1-df31-48d3-a3b5-ba9c1bdb34a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_28375801-c5a2-4bf4-a35b-323ff8138884" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_b3aa32a1-df31-48d3-a3b5-ba9c1bdb34a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="smmt-20231231.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7f4bbca2-40e1-4d5e-a3ba-1998d4201205" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_bb066850-77ed-47f6-9aad-7f74591f5b79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7f4bbca2-40e1-4d5e-a3ba-1998d4201205" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_bb066850-77ed-47f6-9aad-7f74591f5b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_77296911-b97f-4d66-87e4-ad722458e88a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7f4bbca2-40e1-4d5e-a3ba-1998d4201205" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_77296911-b97f-4d66-87e4-ad722458e88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_6a890ce4-cbd1-47ce-b634-e53cfbad9c67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7f4bbca2-40e1-4d5e-a3ba-1998d4201205" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_6a890ce4-cbd1-47ce-b634-e53cfbad9c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#NatureofBusinessandOperationsandRecentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_07fb46cc-8f63-4682-92fc-7e861f454345" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_815618d9-e950-4669-9ee6-9b51660477d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_07fb46cc-8f63-4682-92fc-7e861f454345" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_815618d9-e950-4669-9ee6-9b51660477d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_ccadb535-7c25-40f4-934e-1a79a4e1f731" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_815618d9-e950-4669-9ee6-9b51660477d6" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_ccadb535-7c25-40f4-934e-1a79a4e1f731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_14b1962d-3fc3-4f56-97aa-fe28b6d1c88c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_ccadb535-7c25-40f4-934e-1a79a4e1f731" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_14b1962d-3fc3-4f56-97aa-fe28b6d1c88c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotePurchaseAgreementMember_5a1499cc-500c-41d3-9e89-c4003d87996b" xlink:href="smmt-20231231.xsd#smmt_NotePurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_14b1962d-3fc3-4f56-97aa-fe28b6d1c88c" xlink:to="loc_smmt_NotePurchaseAgreementMember_5a1499cc-500c-41d3-9e89-c4003d87996b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DugganFebruaryNoteMember_d6eb1592-b0fc-422e-b6d0-8c37b384eac6" xlink:href="smmt-20231231.xsd#smmt_DugganFebruaryNoteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_14b1962d-3fc3-4f56-97aa-fe28b6d1c88c" xlink:to="loc_smmt_DugganFebruaryNoteMember_d6eb1592-b0fc-422e-b6d0-8c37b384eac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ZanganehNoteMember_44dee35c-89f3-4d9d-aec6-426f2389fb92" xlink:href="smmt-20231231.xsd#smmt_ZanganehNoteMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_14b1962d-3fc3-4f56-97aa-fe28b6d1c88c" xlink:to="loc_smmt_ZanganehNoteMember_44dee35c-89f3-4d9d-aec6-426f2389fb92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_18bb5f01-503b-4209-86ea-01995057063e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_815618d9-e950-4669-9ee6-9b51660477d6" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_18bb5f01-503b-4209-86ea-01995057063e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ff36d1e5-b20e-4448-a51f-b95cc7b56e84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_18bb5f01-503b-4209-86ea-01995057063e" xlink:to="loc_us-gaap_RelatedPartyDomain_ff36d1e5-b20e-4448-a51f-b95cc7b56e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember_877e29de-0aea-4b61-80a5-01e4031d6461" xlink:href="smmt-20231231.xsd#smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_ff36d1e5-b20e-4448-a51f-b95cc7b56e84" xlink:to="loc_smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember_877e29de-0aea-4b61-80a5-01e4031d6461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_1df728b5-00f7-416b-87af-4086aaccbe9d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember_877e29de-0aea-4b61-80a5-01e4031d6461" xlink:to="loc_srt_ChiefExecutiveOfficerMember_1df728b5-00f7-416b-87af-4086aaccbe9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ChiefExecutiveOfficerAndPresidentMember_139143ba-5e60-4dd0-9b46-fa4c78e4df46" xlink:href="smmt-20231231.xsd#smmt_ChiefExecutiveOfficerAndPresidentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember_877e29de-0aea-4b61-80a5-01e4031d6461" xlink:to="loc_smmt_ChiefExecutiveOfficerAndPresidentMember_139143ba-5e60-4dd0-9b46-fa4c78e4df46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_d9c085fe-ff51-413b-b59d-c15a7b773e28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_ff36d1e5-b20e-4448-a51f-b95cc7b56e84" xlink:to="loc_us-gaap_RelatedPartyMember_d9c085fe-ff51-413b-b59d-c15a7b773e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefOperatingOfficerMember_3cce8e57-d52c-4807-80be-ca5382a50142" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefOperatingOfficerMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_ff36d1e5-b20e-4448-a51f-b95cc7b56e84" xlink:to="loc_srt_ChiefOperatingOfficerMember_3cce8e57-d52c-4807-80be-ca5382a50142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4be9303f-c0a1-4f31-85a9-1baa505a2575" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_815618d9-e950-4669-9ee6-9b51660477d6" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4be9303f-c0a1-4f31-85a9-1baa505a2575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7e1908dd-225f-4741-ba4d-035bea08c917" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4be9303f-c0a1-4f31-85a9-1baa505a2575" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7e1908dd-225f-4741-ba4d-035bea08c917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RightsOfferingMember_0d01ac95-fdf7-40b1-900a-6b2bcfd9c81d" xlink:href="smmt-20231231.xsd#smmt_RightsOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7e1908dd-225f-4741-ba4d-035bea08c917" xlink:to="loc_smmt_RightsOfferingMember_0d01ac95-fdf7-40b1-900a-6b2bcfd9c81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_S3RegistrationStatementMember_f1f8e307-770f-4fe5-a98f-7779e99678c6" xlink:href="smmt-20231231.xsd#smmt_S3RegistrationStatementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7e1908dd-225f-4741-ba4d-035bea08c917" xlink:to="loc_smmt_S3RegistrationStatementMember_f1f8e307-770f-4fe5-a98f-7779e99678c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_57b0369c-1195-49fb-9371-43e5377fa1c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7e1908dd-225f-4741-ba4d-035bea08c917" xlink:to="loc_us-gaap_PrivatePlacementMember_57b0369c-1195-49fb-9371-43e5377fa1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_527ff7aa-7081-4a34-9419-2e9bb1c4117e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_815618d9-e950-4669-9ee6-9b51660477d6" xlink:to="loc_us-gaap_PlanNameAxis_527ff7aa-7081-4a34-9419-2e9bb1c4117e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7de05ece-43e6-48a2-a286-2f6529c00bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_527ff7aa-7081-4a34-9419-2e9bb1c4117e" xlink:to="loc_us-gaap_PlanNameDomain_7de05ece-43e6-48a2-a286-2f6529c00bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_A2020StockIncentivePlanMember_9f087a87-7e08-40b5-974f-e70428755bf6" xlink:href="smmt-20231231.xsd#smmt_A2020StockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7de05ece-43e6-48a2-a286-2f6529c00bdf" xlink:to="loc_smmt_A2020StockIncentivePlanMember_9f087a87-7e08-40b5-974f-e70428755bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3038f1f0-fd1e-4c49-b6e7-4fdf07f88dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_815618d9-e950-4669-9ee6-9b51660477d6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3038f1f0-fd1e-4c49-b6e7-4fdf07f88dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e85539ff-aed1-4726-8308-b8d08eb3c80e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3038f1f0-fd1e-4c49-b6e7-4fdf07f88dd9" xlink:to="loc_us-gaap_EquityComponentDomain_e85539ff-aed1-4726-8308-b8d08eb3c80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_33d597eb-890b-480f-ba82-b72fdde68633" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e85539ff-aed1-4726-8308-b8d08eb3c80e" xlink:to="loc_us-gaap_CommonStockMember_33d597eb-890b-480f-ba82-b72fdde68633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2114163c-1e6f-4eb0-a513-cae371944834" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_815618d9-e950-4669-9ee6-9b51660477d6" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2114163c-1e6f-4eb0-a513-cae371944834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6c619ad2-9d06-4da5-8bdd-739043040e35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2114163c-1e6f-4eb0-a513-cae371944834" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6c619ad2-9d06-4da5-8bdd-739043040e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_29c0d69b-0f3d-4c69-9b73-7df8e98987ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6c619ad2-9d06-4da5-8bdd-739043040e35" xlink:to="loc_us-gaap_SubsequentEventMember_29c0d69b-0f3d-4c69-9b73-7df8e98987ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_56149fea-151b-45c6-b059-af9e98671794" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_815618d9-e950-4669-9ee6-9b51660477d6" xlink:to="loc_us-gaap_VariableRateAxis_56149fea-151b-45c6-b059-af9e98671794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_f7908ef7-ac3d-4470-b6a2-4dae28592884" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_56149fea-151b-45c6-b059-af9e98671794" xlink:to="loc_us-gaap_VariableRateDomain_f7908ef7-ac3d-4470-b6a2-4dae28592884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_f8f6727d-b030-42c6-a46d-80fa4647c6d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_f7908ef7-ac3d-4470-b6a2-4dae28592884" xlink:to="loc_us-gaap_PrimeRateMember_f8f6727d-b030-42c6-a46d-80fa4647c6d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_186c04e3-a9b3-4266-92d3-193c976ed8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_815618d9-e950-4669-9ee6-9b51660477d6" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_186c04e3-a9b3-4266-92d3-193c976ed8cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_6ec49c44-b6d3-4ee2-a779-9337d9a543f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_186c04e3-a9b3-4266-92d3-193c976ed8cb" xlink:to="loc_us-gaap_NotesPayable_6ec49c44-b6d3-4ee2-a779-9337d9a543f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CommonStockSharesAuthorizedIncreaseDecrease_63370ae1-0fd2-4548-b86e-17a34d51a83c" xlink:href="smmt-20231231.xsd#smmt_CommonStockSharesAuthorizedIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_186c04e3-a9b3-4266-92d3-193c976ed8cb" xlink:to="loc_smmt_CommonStockSharesAuthorizedIncreaseDecrease_63370ae1-0fd2-4548-b86e-17a34d51a83c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_28de5812-9b78-46db-b84d-61943afc5868" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_186c04e3-a9b3-4266-92d3-193c976ed8cb" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_28de5812-9b78-46db-b84d-61943afc5868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8988199d-a345-4511-99af-4a3bce5bdcad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_186c04e3-a9b3-4266-92d3-193c976ed8cb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8988199d-a345-4511-99af-4a3bce5bdcad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f8769f92-8129-4142-9aa5-3e23e4bf0319" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_186c04e3-a9b3-4266-92d3-193c976ed8cb" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f8769f92-8129-4142-9aa5-3e23e4bf0319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_bb28e3dd-02ae-43af-8caa-2b97ccc77d02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_186c04e3-a9b3-4266-92d3-193c976ed8cb" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_bb28e3dd-02ae-43af-8caa-2b97ccc77d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_5e560bf3-e4a2-49ef-942c-4f8179fbeeca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_186c04e3-a9b3-4266-92d3-193c976ed8cb" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_5e560bf3-e4a2-49ef-942c-4f8179fbeeca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_f6631746-e6e3-46e1-9eca-d7935cdb27ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_186c04e3-a9b3-4266-92d3-193c976ed8cb" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_f6631746-e6e3-46e1-9eca-d7935cdb27ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_e250ba00-94fd-4a4e-bcf5-f0096dde86cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_186c04e3-a9b3-4266-92d3-193c976ed8cb" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_e250ba00-94fd-4a4e-bcf5-f0096dde86cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_SaleOfStockNumberOfSharesRegisteredForResale_449d069f-37eb-4ef2-a1c2-a78d9da4209e" xlink:href="smmt-20231231.xsd#smmt_SaleOfStockNumberOfSharesRegisteredForResale"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_186c04e3-a9b3-4266-92d3-193c976ed8cb" xlink:to="loc_smmt_SaleOfStockNumberOfSharesRegisteredForResale_449d069f-37eb-4ef2-a1c2-a78d9da4209e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_d280ec54-bd71-443e-b97f-0125f8ba84ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_186c04e3-a9b3-4266-92d3-193c976ed8cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_d280ec54-bd71-443e-b97f-0125f8ba84ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_956b7867-b6bc-49b5-a1df-c31d15e417de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_186c04e3-a9b3-4266-92d3-193c976ed8cb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_956b7867-b6bc-49b5-a1df-c31d15e417de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionRate_c90b9a5a-7ed9-43a7-8d04-66d1186d7cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionRate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_186c04e3-a9b3-4266-92d3-193c976ed8cb" xlink:to="loc_us-gaap_RelatedPartyTransactionRate_c90b9a5a-7ed9-43a7-8d04-66d1186d7cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_4661ef47-a655-4ddb-811c-02f1b5e18778" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_186c04e3-a9b3-4266-92d3-193c976ed8cb" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_4661ef47-a655-4ddb-811c-02f1b5e18778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/LiquidityandCapitalResourcesDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#LiquidityandCapitalResourcesDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/LiquidityandCapitalResourcesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9771056d-167a-451a-803e-e038cb9ca5b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_49a92c13-b4bb-42cd-8932-79d8dc93c3bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9771056d-167a-451a-803e-e038cb9ca5b6" xlink:to="loc_us-gaap_NetIncomeLoss_49a92c13-b4bb-42cd-8932-79d8dc93c3bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ca414564-46cf-4628-9ace-c2f6178728ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9771056d-167a-451a-803e-e038cb9ca5b6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ca414564-46cf-4628-9ace-c2f6178728ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_15b5dca7-2220-46b8-9fab-50db0686a5eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9771056d-167a-451a-803e-e038cb9ca5b6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_15b5dca7-2220-46b8-9fab-50db0686a5eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_87bc9f0d-c4d9-41fa-a4a1-4eaa81d3e0f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9771056d-167a-451a-803e-e038cb9ca5b6" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_87bc9f0d-c4d9-41fa-a4a1-4eaa81d3e0f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_e9519734-e5e6-41f5-9abc-34f49184223e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9771056d-167a-451a-803e-e038cb9ca5b6" xlink:to="loc_us-gaap_LongTermNotesPayable_e9519734-e5e6-41f5-9abc-34f49184223e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c4056e25-5267-44bd-8bb2-bc035fbb7d72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_SignificantAccountingPoliciesTable_a8011364-509b-47ab-b163-5a0c55136dec" xlink:href="smmt-20231231.xsd#smmt_SignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c4056e25-5267-44bd-8bb2-bc035fbb7d72" xlink:to="loc_smmt_SignificantAccountingPoliciesTable_a8011364-509b-47ab-b163-5a0c55136dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_321603f6-32f3-4800-97ca-034d975e22e0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_SignificantAccountingPoliciesTable_a8011364-509b-47ab-b163-5a0c55136dec" xlink:to="loc_srt_RangeAxis_321603f6-32f3-4800-97ca-034d975e22e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_24349d05-e01b-4770-b1f9-e2e716d20788" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_321603f6-32f3-4800-97ca-034d975e22e0" xlink:to="loc_srt_RangeMember_24349d05-e01b-4770-b1f9-e2e716d20788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d6e9977e-8570-4df4-b983-b9d6021b1ca2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_24349d05-e01b-4770-b1f9-e2e716d20788" xlink:to="loc_srt_MinimumMember_d6e9977e-8570-4df4-b983-b9d6021b1ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_989c318d-5d6d-44fb-9d54-9ed26354e114" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_24349d05-e01b-4770-b1f9-e2e716d20788" xlink:to="loc_srt_MaximumMember_989c318d-5d6d-44fb-9d54-9ed26354e114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fd8f7aa6-c14d-4994-953e-ac96a60de8e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_SignificantAccountingPoliciesTable_a8011364-509b-47ab-b163-5a0c55136dec" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fd8f7aa6-c14d-4994-953e-ac96a60de8e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0682fe8f-4c63-4b6f-92f6-dabcbd554834" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fd8f7aa6-c14d-4994-953e-ac96a60de8e8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0682fe8f-4c63-4b6f-92f6-dabcbd554834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_LaboratoryEquipmentMember_45808603-c317-4639-9a42-524903176f04" xlink:href="smmt-20231231.xsd#smmt_LaboratoryEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0682fe8f-4c63-4b6f-92f6-dabcbd554834" xlink:to="loc_smmt_LaboratoryEquipmentMember_45808603-c317-4639-9a42-524903176f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember_76e4fae9-24fd-419d-b8e4-792f2be996dd" xlink:href="smmt-20231231.xsd#smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0682fe8f-4c63-4b6f-92f6-dabcbd554834" xlink:to="loc_smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember_76e4fae9-24fd-419d-b8e4-792f2be996dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_ad85ad36-ff02-4529-87ae-e5c06b03eb70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0682fe8f-4c63-4b6f-92f6-dabcbd554834" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_ad85ad36-ff02-4529-87ae-e5c06b03eb70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_701c4dc8-ca6d-4931-b0fa-2f08c4932008" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_SignificantAccountingPoliciesTable_a8011364-509b-47ab-b163-5a0c55136dec" xlink:to="loc_us-gaap_TypeOfArrangementAxis_701c4dc8-ca6d-4931-b0fa-2f08c4932008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_545700db-4ad6-4ae8-a94c-5db6da6a7f19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_701c4dc8-ca6d-4931-b0fa-2f08c4932008" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_545700db-4ad6-4ae8-a94c-5db6da6a7f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentOneMember_6d8888c1-9bfc-4855-9d37-92a35e8002a0" xlink:href="smmt-20231231.xsd#smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_545700db-4ad6-4ae8-a94c-5db6da6a7f19" xlink:to="loc_smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentOneMember_6d8888c1-9bfc-4855-9d37-92a35e8002a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_0f7d98b0-34fa-4227-a936-d0801566fe5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_SignificantAccountingPoliciesTable_a8011364-509b-47ab-b163-5a0c55136dec" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_0f7d98b0-34fa-4227-a936-d0801566fe5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1709c330-4f06-4ab2-b9b6-8e03ce345401" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_0f7d98b0-34fa-4227-a936-d0801566fe5a" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1709c330-4f06-4ab2-b9b6-8e03ce345401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_4e208856-70b9-4519-8666-bfddba45020f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1709c330-4f06-4ab2-b9b6-8e03ce345401" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_4e208856-70b9-4519-8666-bfddba45020f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_SignificantAccountingPoliciesLineItems_709852bf-e90d-49b4-bf25-5aa7fd015600" xlink:href="smmt-20231231.xsd#smmt_SignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_SignificantAccountingPoliciesTable_a8011364-509b-47ab-b163-5a0c55136dec" xlink:to="loc_smmt_SignificantAccountingPoliciesLineItems_709852bf-e90d-49b4-bf25-5aa7fd015600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_00b25fa1-4b77-4f7e-8498-9a868a39a103" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_SignificantAccountingPoliciesLineItems_709852bf-e90d-49b4-bf25-5aa7fd015600" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_00b25fa1-4b77-4f7e-8498-9a868a39a103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_9337eb37-1ae9-4a88-a774-b283e83d6227" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_SignificantAccountingPoliciesLineItems_709852bf-e90d-49b4-bf25-5aa7fd015600" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_9337eb37-1ae9-4a88-a774-b283e83d6227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_888cf6fb-ab24-4a1b-b63f-f6e7497de8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_SignificantAccountingPoliciesLineItems_709852bf-e90d-49b4-bf25-5aa7fd015600" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_888cf6fb-ab24-4a1b-b63f-f6e7497de8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_52c5f81c-ec4e-4621-8f9a-efe7b1085346" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_SignificantAccountingPoliciesLineItems_709852bf-e90d-49b4-bf25-5aa7fd015600" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_52c5f81c-ec4e-4621-8f9a-efe7b1085346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_f20ed06d-6fb0-45fb-9011-379477082b49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_SignificantAccountingPoliciesLineItems_709852bf-e90d-49b4-bf25-5aa7fd015600" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_f20ed06d-6fb0-45fb-9011-379477082b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_a2dffdad-ab51-46a8-8aea-6a988c308b03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_SignificantAccountingPoliciesLineItems_709852bf-e90d-49b4-bf25-5aa7fd015600" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_a2dffdad-ab51-46a8-8aea-6a988c308b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_fe1e1556-6999-4c5f-9841-18977cb50a39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_SignificantAccountingPoliciesLineItems_709852bf-e90d-49b4-bf25-5aa7fd015600" xlink:to="loc_us-gaap_RestrictedCashCurrent_fe1e1556-6999-4c5f-9841-18977cb50a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentSharesOfCommonStockIssuedInLieuOfCash_b5ac8bab-9a26-4cac-b79b-8c91d32d9dec" xlink:href="smmt-20231231.xsd#smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentSharesOfCommonStockIssuedInLieuOfCash"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_SignificantAccountingPoliciesLineItems_709852bf-e90d-49b4-bf25-5aa7fd015600" xlink:to="loc_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentSharesOfCommonStockIssuedInLieuOfCash_b5ac8bab-9a26-4cac-b79b-8c91d32d9dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CashPaymentForCollaborativeArrangementUpfrontPayment_3544fa40-0c32-4205-b6e1-57f1d1332c81" xlink:href="smmt-20231231.xsd#smmt_CashPaymentForCollaborativeArrangementUpfrontPayment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_SignificantAccountingPoliciesLineItems_709852bf-e90d-49b4-bf25-5aa7fd015600" xlink:to="loc_smmt_CashPaymentForCollaborativeArrangementUpfrontPayment_3544fa40-0c32-4205-b6e1-57f1d1332c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_BusinessCombinationAssumedContingentLiabilityMeasurementInput_c5d273f7-6de1-4bf6-a188-be9942216ee8" xlink:href="smmt-20231231.xsd#smmt_BusinessCombinationAssumedContingentLiabilityMeasurementInput"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_SignificantAccountingPoliciesLineItems_709852bf-e90d-49b4-bf25-5aa7fd015600" xlink:to="loc_smmt_BusinessCombinationAssumedContingentLiabilityMeasurementInput_c5d273f7-6de1-4bf6-a188-be9942216ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/AkesoLicenseandCollaborationAgreementDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#AkesoLicenseandCollaborationAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/AkesoLicenseandCollaborationAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5cfa7081-2799-4aff-a81c-94b76cae8412" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39d0af37-9f2c-4350-b8bf-53388844163e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5cfa7081-2799-4aff-a81c-94b76cae8412" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39d0af37-9f2c-4350-b8bf-53388844163e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c91b6aa7-451f-4f96-b03a-19c8e5547de1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39d0af37-9f2c-4350-b8bf-53388844163e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c91b6aa7-451f-4f96-b03a-19c8e5547de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b7316939-b663-4437-b59f-7682dc965b55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c91b6aa7-451f-4f96-b03a-19c8e5547de1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b7316939-b663-4437-b59f-7682dc965b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_9fd0b8a5-0e93-4a4e-9f57-0291fd25c8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b7316939-b663-4437-b59f-7682dc965b55" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_9fd0b8a5-0e93-4a4e-9f57-0291fd25c8a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentOneMember_c57b3a8d-e608-49be-b6ed-72c1bc26c9d9" xlink:href="smmt-20231231.xsd#smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_9fd0b8a5-0e93-4a4e-9f57-0291fd25c8a8" xlink:to="loc_smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentOneMember_c57b3a8d-e608-49be-b6ed-72c1bc26c9d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentTwoMember_a9efa6c8-8e77-403d-a469-89d160e9b758" xlink:href="smmt-20231231.xsd#smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_9fd0b8a5-0e93-4a4e-9f57-0291fd25c8a8" xlink:to="loc_smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentTwoMember_a9efa6c8-8e77-403d-a469-89d160e9b758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_188ef3bc-5fa0-47b4-aae4-f193c72aa21f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39d0af37-9f2c-4350-b8bf-53388844163e" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_188ef3bc-5fa0-47b4-aae4-f193c72aa21f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPayment_dcbab8f5-eb71-48df-a16d-4cca906b8f13" xlink:href="smmt-20231231.xsd#smmt_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_188ef3bc-5fa0-47b4-aae4-f193c72aa21f" xlink:to="loc_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPayment_dcbab8f5-eb71-48df-a16d-4cca906b8f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CashPaymentForCollaborativeArrangementUpfrontPayment_38c34051-f979-491f-8d91-769c161f60e4" xlink:href="smmt-20231231.xsd#smmt_CashPaymentForCollaborativeArrangementUpfrontPayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_188ef3bc-5fa0-47b4-aae4-f193c72aa21f" xlink:to="loc_smmt_CashPaymentForCollaborativeArrangementUpfrontPayment_38c34051-f979-491f-8d91-769c161f60e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentSharesOfCommonStockIssuedInLieuOfCash_f3787da7-156a-45bc-ba06-34cae7eafcb0" xlink:href="smmt-20231231.xsd#smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentSharesOfCommonStockIssuedInLieuOfCash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_188ef3bc-5fa0-47b4-aae4-f193c72aa21f" xlink:to="loc_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentSharesOfCommonStockIssuedInLieuOfCash_f3787da7-156a-45bc-ba06-34cae7eafcb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentPaidInShares_335e052e-7b40-4cce-9303-93d50e73a1ba" xlink:href="smmt-20231231.xsd#smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentPaidInShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_188ef3bc-5fa0-47b4-aae4-f193c72aa21f" xlink:to="loc_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentPaidInShares_335e052e-7b40-4cce-9303-93d50e73a1ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_InProcessResearchAndDevelopmentExpense_d9368b87-1681-467b-be68-5d0ba74214e2" xlink:href="smmt-20231231.xsd#smmt_InProcessResearchAndDevelopmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_188ef3bc-5fa0-47b4-aae4-f193c72aa21f" xlink:to="loc_smmt_InProcessResearchAndDevelopmentExpense_d9368b87-1681-467b-be68-5d0ba74214e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement_b1d6f269-33c2-41aa-80b2-774c2583c875" xlink:href="smmt-20231231.xsd#smmt_StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_188ef3bc-5fa0-47b4-aae4-f193c72aa21f" xlink:to="loc_smmt_StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement_b1d6f269-33c2-41aa-80b2-774c2583c875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CollaborativeArrangementRightsAndObligationsDirectTransactionCosts_c1059b77-688e-4178-872e-61c40773a805" xlink:href="smmt-20231231.xsd#smmt_CollaborativeArrangementRightsAndObligationsDirectTransactionCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_188ef3bc-5fa0-47b4-aae4-f193c72aa21f" xlink:to="loc_smmt_CollaborativeArrangementRightsAndObligationsDirectTransactionCosts_c1059b77-688e-4178-872e-61c40773a805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments_0a7cebae-f80a-4b29-8635-9aadbca150b2" xlink:href="smmt-20231231.xsd#smmt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_188ef3bc-5fa0-47b4-aae4-f193c72aa21f" xlink:to="loc_smmt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments_0a7cebae-f80a-4b29-8635-9aadbca150b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CollaborativeArrangementRightsAndObligationsPotentialRegulatoryMilestonePayments_13d62f6b-29e6-4d5f-ae56-690e8fd2cd8c" xlink:href="smmt-20231231.xsd#smmt_CollaborativeArrangementRightsAndObligationsPotentialRegulatoryMilestonePayments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_188ef3bc-5fa0-47b4-aae4-f193c72aa21f" xlink:to="loc_smmt_CollaborativeArrangementRightsAndObligationsPotentialRegulatoryMilestonePayments_13d62f6b-29e6-4d5f-ae56-690e8fd2cd8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CollaborativeArrangementRightsAndObligationsPotentialCommercialMilestonePayments_3b102cc0-bc03-43d9-bfc2-59b7e87d4240" xlink:href="smmt-20231231.xsd#smmt_CollaborativeArrangementRightsAndObligationsPotentialCommercialMilestonePayments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_188ef3bc-5fa0-47b4-aae4-f193c72aa21f" xlink:to="loc_smmt_CollaborativeArrangementRightsAndObligationsPotentialCommercialMilestonePayments_3b102cc0-bc03-43d9-bfc2-59b7e87d4240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/SegmentReportingNarrativeDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#SegmentReportingNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/SegmentReportingNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_84d49395-58e0-4c78-b276-872fa82c2a88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_64f42d4b-dea4-414f-a585-d31d145223f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_84d49395-58e0-4c78-b276-872fa82c2a88" xlink:to="loc_us-gaap_NumberOfOperatingSegments_64f42d4b-dea4-414f-a585-d31d145223f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_e4b211ec-7b47-41e9-bb15-e49b8492ac1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_84d49395-58e0-4c78-b276-872fa82c2a88" xlink:to="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_e4b211ec-7b47-41e9-bb15-e49b8492ac1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/SegmentReportingLonglivedassetsbygeographyDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#SegmentReportingLonglivedassetsbygeographyDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/SegmentReportingLonglivedassetsbygeographyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_b584229e-8695-4d67-be38-2252f3aaeea4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_47933b64-ec09-4565-adf1-cdfc4fc248f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b584229e-8695-4d67-be38-2252f3aaeea4" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_47933b64-ec09-4565-adf1-cdfc4fc248f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_fe16d230-28d9-486b-b99b-2c81157615aa" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_47933b64-ec09-4565-adf1-cdfc4fc248f6" xlink:to="loc_srt_StatementGeographicalAxis_fe16d230-28d9-486b-b99b-2c81157615aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_891223d0-0fb8-4142-879b-ebe0c9ac4ceb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_fe16d230-28d9-486b-b99b-2c81157615aa" xlink:to="loc_srt_SegmentGeographicalDomain_891223d0-0fb8-4142-879b-ebe0c9ac4ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_47e5d7d4-e9c3-4bd2-9099-f9e1028e51f2" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_891223d0-0fb8-4142-879b-ebe0c9ac4ceb" xlink:to="loc_country_GB_47e5d7d4-e9c3-4bd2-9099-f9e1028e51f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_1211bdc6-619e-4660-8bb2-f8468d643bea" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_891223d0-0fb8-4142-879b-ebe0c9ac4ceb" xlink:to="loc_country_US_1211bdc6-619e-4660-8bb2-f8468d643bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_2e86e170-e2af-43d3-984d-17e9752939c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_47933b64-ec09-4565-adf1-cdfc4fc248f6" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_2e86e170-e2af-43d3-984d-17e9752939c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_e3c077fa-a924-4c7c-87e4-89c1cd8cd55a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncurrentAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_2e86e170-e2af-43d3-984d-17e9752939c3" xlink:to="loc_us-gaap_NoncurrentAssets_e3c077fa-a924-4c7c-87e4-89c1cd8cd55a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/RevenueNarrativeDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#RevenueNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/RevenueNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_86a126e1-6885-46f1-9670-46b635d36b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d25d7aab-c0a7-41ae-a8d0-468dfe46269f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_86a126e1-6885-46f1-9670-46b635d36b8f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d25d7aab-c0a7-41ae-a8d0-468dfe46269f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/RevenueDeferredrevenueandotherincomeDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#RevenueDeferredrevenueandotherincomeDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/RevenueDeferredrevenueandotherincomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1d07914c-47d2-462a-88e4-04aed72077e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward_9d47b451-d60c-4a96-b420-a8aa77fbf843" xlink:href="smmt-20231231.xsd#smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1d07914c-47d2-462a-88e4-04aed72077e3" xlink:to="loc_smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward_9d47b451-d60c-4a96-b420-a8aa77fbf843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_8e26c223-c7fa-421e-ac17-dfe873014376" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward_9d47b451-d60c-4a96-b420-a8aa77fbf843" xlink:to="loc_us-gaap_ContractWithCustomerLiability_8e26c223-c7fa-421e-ac17-dfe873014376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ContractWithCustomerLiabilityAdditions_c94038ce-d8cb-4dc0-b94f-73c6cc8fb515" xlink:href="smmt-20231231.xsd#smmt_ContractWithCustomerLiabilityAdditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward_9d47b451-d60c-4a96-b420-a8aa77fbf843" xlink:to="loc_smmt_ContractWithCustomerLiabilityAdditions_c94038ce-d8cb-4dc0-b94f-73c6cc8fb515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance_7729db87-97d6-4999-a076-56ee6549b511" xlink:href="smmt-20231231.xsd#smmt_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward_9d47b451-d60c-4a96-b420-a8aa77fbf843" xlink:to="loc_smmt_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance_7729db87-97d6-4999-a076-56ee6549b511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ContractWithCustomerLiabilityForeignCurrencyTranslation_3f58ca24-4f04-4bb0-821d-7b25912a4449" xlink:href="smmt-20231231.xsd#smmt_ContractWithCustomerLiabilityForeignCurrencyTranslation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward_9d47b451-d60c-4a96-b420-a8aa77fbf843" xlink:to="loc_smmt_ContractWithCustomerLiabilityForeignCurrencyTranslation_3f58ca24-4f04-4bb0-821d-7b25912a4449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_39d3dc56-b8e5-49c4-949b-9b4cfc4f673f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward_9d47b451-d60c-4a96-b420-a8aa77fbf843" xlink:to="loc_us-gaap_ContractWithCustomerLiability_39d3dc56-b8e5-49c4-949b-9b4cfc4f673f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/OtherOperatingIncomenetSummarybycategoryDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#OtherOperatingIncomenetSummarybycategoryDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/OtherOperatingIncomenetSummarybycategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_55893695-2639-4342-b577-adfd5ba62768" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_200a79ff-e7c4-4033-bcbc-bb0ff4265f71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_55893695-2639-4342-b577-adfd5ba62768" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_200a79ff-e7c4-4033-bcbc-bb0ff4265f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_76f593a4-920c-4117-9ad9-9663d3839060" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_200a79ff-e7c4-4033-bcbc-bb0ff4265f71" xlink:to="loc_srt_CounterpartyNameAxis_76f593a4-920c-4117-9ad9-9663d3839060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0bf2314a-ed21-4948-b487-97b95848d246" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_76f593a4-920c-4117-9ad9-9663d3839060" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0bf2314a-ed21-4948-b487-97b95848d246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_8205074c-2347-4ad4-9592-bd3f436739f9" xlink:href="smmt-20231231.xsd#smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0bf2314a-ed21-4948-b487-97b95848d246" xlink:to="loc_smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_8205074c-2347-4ad4-9592-bd3f436739f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember_0aa2b5c7-3ffa-4ab6-8bbe-01183b45f7cd" xlink:href="smmt-20231231.xsd#smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0bf2314a-ed21-4948-b487-97b95848d246" xlink:to="loc_smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember_0aa2b5c7-3ffa-4ab6-8bbe-01183b45f7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_89874462-861a-4d2c-bf98-d654f90cbda5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_200a79ff-e7c4-4033-bcbc-bb0ff4265f71" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_89874462-861a-4d2c-bf98-d654f90cbda5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GrantFundingArrangementIncomeEarned_02c5f3bb-21a1-40fb-a82a-6cc7a029990a" xlink:href="smmt-20231231.xsd#smmt_GrantFundingArrangementIncomeEarned"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_89874462-861a-4d2c-bf98-d654f90cbda5" xlink:to="loc_smmt_GrantFundingArrangementIncomeEarned_02c5f3bb-21a1-40fb-a82a-6cc7a029990a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ResearchAndDevelopmentTaxCredit_c919edc0-aac2-4d82-acb6-2647b8de3a16" xlink:href="smmt-20231231.xsd#smmt_ResearchAndDevelopmentTaxCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_89874462-861a-4d2c-bf98-d654f90cbda5" xlink:to="loc_smmt_ResearchAndDevelopmentTaxCredit_c919edc0-aac2-4d82-acb6-2647b8de3a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_OtherOperatingIncomeOther_fee24314-1c47-480f-b28f-4ddc26c6f39a" xlink:href="smmt-20231231.xsd#smmt_OtherOperatingIncomeOther"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_89874462-861a-4d2c-bf98-d654f90cbda5" xlink:to="loc_smmt_OtherOperatingIncomeOther_fee24314-1c47-480f-b28f-4ddc26c6f39a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome_5f39163b-6a77-4248-891d-bed735cb81eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_89874462-861a-4d2c-bf98-d654f90cbda5" xlink:to="loc_us-gaap_OtherOperatingIncome_5f39163b-6a77-4248-891d-bed735cb81eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/OtherOperatingIncomenetNarrativeDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#OtherOperatingIncomenetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/OtherOperatingIncomenetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_92519c8a-3a93-413c-bfdb-80e017e7487a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_14924cd2-ae55-44be-aae2-7669de4adf4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_92519c8a-3a93-413c-bfdb-80e017e7487a" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_14924cd2-ae55-44be-aae2-7669de4adf4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ad428fdc-0f3f-4dee-9725-9b7e2976655a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_14924cd2-ae55-44be-aae2-7669de4adf4d" xlink:to="loc_srt_CounterpartyNameAxis_ad428fdc-0f3f-4dee-9725-9b7e2976655a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6568af55-ea07-4afe-b983-68268b2b8b08" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_ad428fdc-0f3f-4dee-9725-9b7e2976655a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6568af55-ea07-4afe-b983-68268b2b8b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_6fbf092b-c983-45fc-9000-6dac07d2fe59" xlink:href="smmt-20231231.xsd#smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6568af55-ea07-4afe-b983-68268b2b8b08" xlink:to="loc_smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_6fbf092b-c983-45fc-9000-6dac07d2fe59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember_a2b1a64d-7b5d-4bfc-9a3d-b32e8fd9386e" xlink:href="smmt-20231231.xsd#smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6568af55-ea07-4afe-b983-68268b2b8b08" xlink:to="loc_smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember_a2b1a64d-7b5d-4bfc-9a3d-b32e8fd9386e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ac5592c3-6540-486e-85a8-bac5c5fbd642" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_14924cd2-ae55-44be-aae2-7669de4adf4d" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ac5592c3-6540-486e-85a8-bac5c5fbd642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GrantFundingArrangementMaximumFundingValue_af502976-a395-4f46-adb1-9e90621ce3d0" xlink:href="smmt-20231231.xsd#smmt_GrantFundingArrangementMaximumFundingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ac5592c3-6540-486e-85a8-bac5c5fbd642" xlink:to="loc_smmt_GrantFundingArrangementMaximumFundingValue_af502976-a395-4f46-adb1-9e90621ce3d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GrantFundingArrangementCommittedFundingTotal_98439e49-6a98-44ec-abb8-9b7a184d7cb1" xlink:href="smmt-20231231.xsd#smmt_GrantFundingArrangementCommittedFundingTotal"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ac5592c3-6540-486e-85a8-bac5c5fbd642" xlink:to="loc_smmt_GrantFundingArrangementCommittedFundingTotal_98439e49-6a98-44ec-abb8-9b7a184d7cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GrantFundingArrangementIncomeEarned_f8ccd8bc-9092-43f0-8c2d-73ce72f14478" xlink:href="smmt-20231231.xsd#smmt_GrantFundingArrangementIncomeEarned"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ac5592c3-6540-486e-85a8-bac5c5fbd642" xlink:to="loc_smmt_GrantFundingArrangementIncomeEarned_f8ccd8bc-9092-43f0-8c2d-73ce72f14478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ResearchAndDevelopmentTaxCreditReceivable_8f8f5a35-5ef1-4165-802d-01a991dabe60" xlink:href="smmt-20231231.xsd#smmt_ResearchAndDevelopmentTaxCreditReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ac5592c3-6540-486e-85a8-bac5c5fbd642" xlink:to="loc_smmt_ResearchAndDevelopmentTaxCreditReceivable_8f8f5a35-5ef1-4165-802d-01a991dabe60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_GrantFundingArrangementMilestoneFundingIncrease_df112d18-7212-4c25-873d-00b9ea07fa9e" xlink:href="smmt-20231231.xsd#smmt_GrantFundingArrangementMilestoneFundingIncrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ac5592c3-6540-486e-85a8-bac5c5fbd642" xlink:to="loc_smmt_GrantFundingArrangementMilestoneFundingIncrease_df112d18-7212-4c25-873d-00b9ea07fa9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/OtherExpenseIncomenetComponentsDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#OtherExpenseIncomenetComponentsDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/OtherExpenseIncomenetComponentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_21cb68d3-3eb7-41df-a5cb-cdec5956b086" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_3dfed5cf-088b-4038-8361-1b02ee7424a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_21cb68d3-3eb7-41df-a5cb-cdec5956b086" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_3dfed5cf-088b-4038-8361-1b02ee7424a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_f35e8882-2a19-4f0f-9884-1cd71a40ac66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_21cb68d3-3eb7-41df-a5cb-cdec5956b086" xlink:to="loc_us-gaap_InterestExpenseDebt_f35e8882-2a19-4f0f-9884-1cd71a40ac66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating_09479b8b-508f-4922-9f0c-fe2719712726" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNonoperating"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_21cb68d3-3eb7-41df-a5cb-cdec5956b086" xlink:to="loc_us-gaap_InvestmentIncomeNonoperating_09479b8b-508f-4922-9f0c-fe2719712726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome_a6f7e776-c9d8-4bdd-9c94-9cb406b120da" xlink:href="smmt-20231231.xsd#smmt_CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_21cb68d3-3eb7-41df-a5cb-cdec5956b086" xlink:to="loc_smmt_CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome_a6f7e776-c9d8-4bdd-9c94-9cb406b120da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_b977ec53-d735-4cb2-baea-0eba693243fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_21cb68d3-3eb7-41df-a5cb-cdec5956b086" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_b977ec53-d735-4cb2-baea-0eba693243fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_e99fa661-2fb1-4fb5-a820-fdb2459a9ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_21cb68d3-3eb7-41df-a5cb-cdec5956b086" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_e99fa661-2fb1-4fb5-a820-fdb2459a9ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/IncomeTaxComponentsoflossbeforeincometaxesDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#IncomeTaxComponentsoflossbeforeincometaxesDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/IncomeTaxComponentsoflossbeforeincometaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b1d60619-10f0-4888-81e7-30d8a066657e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_33a59f7d-d354-4072-84f8-dadbd6b6c4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b1d60619-10f0-4888-81e7-30d8a066657e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_33a59f7d-d354-4072-84f8-dadbd6b6c4fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_7422b727-d21e-470a-9e66-52139ac21cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b1d60619-10f0-4888-81e7-30d8a066657e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_7422b727-d21e-470a-9e66-52139ac21cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3256b63e-d97b-4ea5-850b-bb43806762a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b1d60619-10f0-4888-81e7-30d8a066657e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3256b63e-d97b-4ea5-850b-bb43806762a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/IncomeTaxNarrativeDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#IncomeTaxNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/IncomeTaxNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_79a1929d-ffcf-4bec-a2bc-d0ce93a0adfe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_26091416-ab25-453d-9104-b4c430d20856" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_79a1929d-ffcf-4bec-a2bc-d0ce93a0adfe" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_26091416-ab25-453d-9104-b4c430d20856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_31837be2-6ab4-4ef3-8a32-913c45b606f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_26091416-ab25-453d-9104-b4c430d20856" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_31837be2-6ab4-4ef3-8a32-913c45b606f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_d877d4ae-b86a-46f3-b10f-815d8c0d1804" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_31837be2-6ab4-4ef3-8a32-913c45b606f2" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_d877d4ae-b86a-46f3-b10f-815d8c0d1804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_7306c45a-5740-45e0-b169-d574846222ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d877d4ae-b86a-46f3-b10f-815d8c0d1804" xlink:to="loc_us-gaap_DomesticCountryMember_7306c45a-5740-45e0-b169-d574846222ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_69a07cb5-9f3c-4875-a1e2-9286f00c10d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d877d4ae-b86a-46f3-b10f-815d8c0d1804" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_69a07cb5-9f3c-4875-a1e2-9286f00c10d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_d1c43320-411b-4460-9927-f1751f5b1191" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d877d4ae-b86a-46f3-b10f-815d8c0d1804" xlink:to="loc_us-gaap_ForeignCountryMember_d1c43320-411b-4460-9927-f1751f5b1191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_73eb83ef-c97b-44b5-8830-b4c4d9e9a301" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_26091416-ab25-453d-9104-b4c430d20856" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_73eb83ef-c97b-44b5-8830-b4c4d9e9a301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_e0790235-20b9-4444-906c-cee256d6c45b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_73eb83ef-c97b-44b5-8830-b4c4d9e9a301" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_e0790235-20b9-4444-906c-cee256d6c45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_70de2312-7c13-45fb-b589-a470a339c9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_73eb83ef-c97b-44b5-8830-b4c4d9e9a301" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_70de2312-7c13-45fb-b589-a470a339c9ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_bc3d8d78-2fef-4ece-8ec5-492933f74ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_73eb83ef-c97b-44b5-8830-b4c4d9e9a301" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_bc3d8d78-2fef-4ece-8ec5-492933f74ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_c05f7204-f899-4efe-b537-e42e3c3cefa9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_73eb83ef-c97b-44b5-8830-b4c4d9e9a301" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_c05f7204-f899-4efe-b537-e42e3c3cefa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1c8934d6-752a-41d1-a8cf-0dd11535b452" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_73eb83ef-c97b-44b5-8830-b4c4d9e9a301" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1c8934d6-752a-41d1-a8cf-0dd11535b452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_807cecec-c089-49e2-b8c4-ac3a8c7922b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_73eb83ef-c97b-44b5-8830-b4c4d9e9a301" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_807cecec-c089-49e2-b8c4-ac3a8c7922b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_c1efdb8a-b2dd-44e2-b96d-328bbed11a36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_73eb83ef-c97b-44b5-8830-b4c4d9e9a301" xlink:to="loc_us-gaap_OperatingLossCarryforwards_c1efdb8a-b2dd-44e2-b96d-328bbed11a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_22100a30-cd70-493f-b6c2-6b23922fc178" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_73eb83ef-c97b-44b5-8830-b4c4d9e9a301" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_22100a30-cd70-493f-b6c2-6b23922fc178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ResearchAndDevelopmentExpenseCapitalizedAmount_4b080562-8213-4342-9c2d-b346228ab9f9" xlink:href="smmt-20231231.xsd#smmt_ResearchAndDevelopmentExpenseCapitalizedAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_73eb83ef-c97b-44b5-8830-b4c4d9e9a301" xlink:to="loc_smmt_ResearchAndDevelopmentExpenseCapitalizedAmount_4b080562-8213-4342-9c2d-b346228ab9f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ResearchAndDevelopmentExpenseAmortizableAmount_243aa51d-65ea-4fa4-bd93-eb3ea984d595" xlink:href="smmt-20231231.xsd#smmt_ResearchAndDevelopmentExpenseAmortizableAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_73eb83ef-c97b-44b5-8830-b4c4d9e9a301" xlink:to="loc_smmt_ResearchAndDevelopmentExpenseAmortizableAmount_243aa51d-65ea-4fa4-bd93-eb3ea984d595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ResearchAndDevelopmentTaxCredit_582dd37b-ace6-4d75-b6b7-1315474b5acf" xlink:href="smmt-20231231.xsd#smmt_ResearchAndDevelopmentTaxCredit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_73eb83ef-c97b-44b5-8830-b4c4d9e9a301" xlink:to="loc_smmt_ResearchAndDevelopmentTaxCredit_582dd37b-ace6-4d75-b6b7-1315474b5acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_19e9a5a4-465f-4f45-b724-be1eb5295be4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_73eb83ef-c97b-44b5-8830-b4c4d9e9a301" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_19e9a5a4-465f-4f45-b724-be1eb5295be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_1028e976-412f-44d1-b07a-aa8789615d98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_73eb83ef-c97b-44b5-8830-b4c4d9e9a301" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_1028e976-412f-44d1-b07a-aa8789615d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1baa81ae-9a13-4373-9578-d1d2a735e11c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_a811f70f-a142-461b-99d1-3d55257b876c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1baa81ae-9a13-4373-9578-d1d2a735e11c" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_a811f70f-a142-461b-99d1-3d55257b876c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_a789986f-4a81-4509-9989-0b1aa0ac20bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_a811f70f-a142-461b-99d1-3d55257b876c" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_a789986f-4a81-4509-9989-0b1aa0ac20bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2dae053f-7cee-4227-bd01-6585b766a0ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_a811f70f-a142-461b-99d1-3d55257b876c" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2dae053f-7cee-4227-bd01-6585b766a0ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_92545ee0-a8ad-4b80-9315-e281ee42a4de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_a811f70f-a142-461b-99d1-3d55257b876c" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_92545ee0-a8ad-4b80-9315-e281ee42a4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DeferredTaxAssetsCapitalizedResearchAndDevelopment_e34a90dc-bbd8-4572-bfe6-21c3e3d3e329" xlink:href="smmt-20231231.xsd#smmt_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_a811f70f-a142-461b-99d1-3d55257b876c" xlink:to="loc_smmt_DeferredTaxAssetsCapitalizedResearchAndDevelopment_e34a90dc-bbd8-4572-bfe6-21c3e3d3e329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DeferredTaxAssetsLeasingArrangements_070f735d-3591-4599-a690-13dca0f7ec04" xlink:href="smmt-20231231.xsd#smmt_DeferredTaxAssetsLeasingArrangements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_a811f70f-a142-461b-99d1-3d55257b876c" xlink:to="loc_smmt_DeferredTaxAssetsLeasingArrangements_070f735d-3591-4599-a690-13dca0f7ec04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_35b0495d-5b9d-42fc-b71c-42f88134a297" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_a811f70f-a142-461b-99d1-3d55257b876c" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_35b0495d-5b9d-42fc-b71c-42f88134a297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_22c47016-dd16-47a5-8c8a-b16f0f59f819" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_a811f70f-a142-461b-99d1-3d55257b876c" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_22c47016-dd16-47a5-8c8a-b16f0f59f819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_20483637-7bda-4027-8560-9ba9e9c80ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1baa81ae-9a13-4373-9578-d1d2a735e11c" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_20483637-7bda-4027-8560-9ba9e9c80ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_bc866082-716b-45c5-9f54-84b673759075" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_20483637-7bda-4027-8560-9ba9e9c80ecc" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_bc866082-716b-45c5-9f54-84b673759075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_9ac879bc-e33a-40b7-903d-fe9db3b47eae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_20483637-7bda-4027-8560-9ba9e9c80ecc" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_9ac879bc-e33a-40b7-903d-fe9db3b47eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_501ace11-0c46-4756-a1e5-f0a1addfcd7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_20483637-7bda-4027-8560-9ba9e9c80ecc" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_501ace11-0c46-4756-a1e5-f0a1addfcd7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DeferredTaxAssetsLiabilities_352f79c7-02e4-4e76-9735-f24e6509df36" xlink:href="smmt-20231231.xsd#smmt_DeferredTaxAssetsLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1baa81ae-9a13-4373-9578-d1d2a735e11c" xlink:to="loc_smmt_DeferredTaxAssetsLiabilities_352f79c7-02e4-4e76-9735-f24e6509df36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_47a23bbb-1a23-4c42-870c-1ecc2406ee38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1baa81ae-9a13-4373-9578-d1d2a735e11c" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_47a23bbb-1a23-4c42-870c-1ecc2406ee38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_5b5ee3c9-3944-4ad2-8d2b-a7807a83ec0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1baa81ae-9a13-4373-9578-d1d2a735e11c" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_5b5ee3c9-3944-4ad2-8d2b-a7807a83ec0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/IncomeTaxValuationAllowanceDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#IncomeTaxValuationAllowanceDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/IncomeTaxValuationAllowanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_15701116-d291-47c8-bbd5-719f2c82f737" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DeferredTaxAssetsValuationAllowanceRollForward_6fd66785-962d-4be3-8574-ae8464964103" xlink:href="smmt-20231231.xsd#smmt_DeferredTaxAssetsValuationAllowanceRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_15701116-d291-47c8-bbd5-719f2c82f737" xlink:to="loc_smmt_DeferredTaxAssetsValuationAllowanceRollForward_6fd66785-962d-4be3-8574-ae8464964103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_ace9a11f-9884-41fc-9054-0fd3a5d5de02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_DeferredTaxAssetsValuationAllowanceRollForward_6fd66785-962d-4be3-8574-ae8464964103" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_ace9a11f-9884-41fc-9054-0fd3a5d5de02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_fefe0aff-2576-4ef8-9a20-576e45ebbdc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_DeferredTaxAssetsValuationAllowanceRollForward_6fd66785-962d-4be3-8574-ae8464964103" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_fefe0aff-2576-4ef8-9a20-576e45ebbdc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c53bc2bc-7266-412e-9f04-4694f7135502" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_DeferredTaxAssetsValuationAllowanceRollForward_6fd66785-962d-4be3-8574-ae8464964103" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c53bc2bc-7266-412e-9f04-4694f7135502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c91e6d4e-4b45-466e-87fa-8bb80d3e10f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_f2ba43d3-399d-4a8e-97a3-75346f1e58e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c91e6d4e-4b45-466e-87fa-8bb80d3e10f2" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_f2ba43d3-399d-4a8e-97a3-75346f1e58e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1d40bcc7-217b-4f85-9efe-aac32d5c2e10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c91e6d4e-4b45-466e-87fa-8bb80d3e10f2" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1d40bcc7-217b-4f85-9efe-aac32d5c2e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent_3ed7ebcf-6e2c-4b21-9ba8-b1016c786db1" xlink:href="smmt-20231231.xsd#smmt_EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c91e6d4e-4b45-466e-87fa-8bb80d3e10f2" xlink:to="loc_smmt_EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent_3ed7ebcf-6e2c-4b21-9ba8-b1016c786db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_6b42c32e-8667-4b8d-a313-af56a016c41b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c91e6d4e-4b45-466e-87fa-8bb80d3e10f2" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_6b42c32e-8667-4b8d-a313-af56a016c41b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_588b7718-6c7a-4659-87ee-e0dec81ba17a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c91e6d4e-4b45-466e-87fa-8bb80d3e10f2" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_588b7718-6c7a-4659-87ee-e0dec81ba17a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_f044cfb2-d041-4c8c-8412-2d419931dfcb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c91e6d4e-4b45-466e-87fa-8bb80d3e10f2" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_f044cfb2-d041-4c8c-8412-2d419931dfcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_13766d50-4944-4edd-9a5d-19f7e4c0bb69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c91e6d4e-4b45-466e-87fa-8bb80d3e10f2" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_13766d50-4944-4edd-9a5d-19f7e4c0bb69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/IncomeTaxReconciliationofunrecognizedtaxbenefitsDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#IncomeTaxReconciliationofunrecognizedtaxbenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/IncomeTaxReconciliationofunrecognizedtaxbenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b171ab02-884d-4753-823e-caf9252aa07d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ebef34ec-1652-4450-8fce-7042e98e9e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b171ab02-884d-4753-823e-caf9252aa07d" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ebef34ec-1652-4450-8fce-7042e98e9e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_c015e968-301a-427a-a3bc-2cb917953a65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ebef34ec-1652-4450-8fce-7042e98e9e0f" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_c015e968-301a-427a-a3bc-2cb917953a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_f17f1ebf-cc8d-420e-b247-d1a4f8bd8ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ebef34ec-1652-4450-8fce-7042e98e9e0f" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_f17f1ebf-cc8d-420e-b247-d1a4f8bd8ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_f4d45fa2-6d8c-4ab2-91cc-ca6c5e444e97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ebef34ec-1652-4450-8fce-7042e98e9e0f" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_f4d45fa2-6d8c-4ab2-91cc-ca6c5e444e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_db8132e8-b3a6-42ed-ad65-8f4aed9cc2f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ebef34ec-1652-4450-8fce-7042e98e9e0f" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_db8132e8-b3a6-42ed-ad65-8f4aed9cc2f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_c8ab7861-f013-4b18-b055-9724bb59c5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ebef34ec-1652-4450-8fce-7042e98e9e0f" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_c8ab7861-f013-4b18-b055-9724bb59c5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/NetLossperShareComputationofnetlosspershareDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#NetLossperShareComputationofnetlosspershareDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/NetLossperShareComputationofnetlosspershareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0000e03f-81a8-4efc-8fd7-759e4b5a004a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_805308d8-fd93-48f4-b009-aab55ffabf9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0000e03f-81a8-4efc-8fd7-759e4b5a004a" xlink:to="loc_us-gaap_NetIncomeLoss_805308d8-fd93-48f4-b009-aab55ffabf9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_67fbf813-baab-42b7-8dcf-74fe22277466" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0000e03f-81a8-4efc-8fd7-759e4b5a004a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_67fbf813-baab-42b7-8dcf-74fe22277466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b050661b-a78c-48cf-b7cb-5c02b8a00858" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0000e03f-81a8-4efc-8fd7-759e4b5a004a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b050661b-a78c-48cf-b7cb-5c02b8a00858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f5deff60-8cd7-46ee-9a8a-bb02d114fb38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0000e03f-81a8-4efc-8fd7-759e4b5a004a" xlink:to="loc_us-gaap_EarningsPerShareBasic_f5deff60-8cd7-46ee-9a8a-bb02d114fb38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_917c6f37-fbc0-4ece-9545-82c72d11f021" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0000e03f-81a8-4efc-8fd7-759e4b5a004a" xlink:to="loc_us-gaap_EarningsPerShareDiluted_917c6f37-fbc0-4ece-9545-82c72d11f021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/NetLossperShareNarrativeDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#NetLossperShareNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/NetLossperShareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b32ca472-ee58-4f41-ae49-e6840e9bc89f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_3d5d6221-2ff9-464d-9110-8f29a58dbcca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b32ca472-ee58-4f41-ae49-e6840e9bc89f" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_3d5d6221-2ff9-464d-9110-8f29a58dbcca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ee39fe93-4ae7-417b-9ada-26f144059ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_3d5d6221-2ff9-464d-9110-8f29a58dbcca" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ee39fe93-4ae7-417b-9ada-26f144059ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_58630e3a-dadf-4b53-afd7-82bfd2df54fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ee39fe93-4ae7-417b-9ada-26f144059ea9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_58630e3a-dadf-4b53-afd7-82bfd2df54fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RightsOfferingMember_c58eb4c6-3074-4569-9d94-0e539e288ea2" xlink:href="smmt-20231231.xsd#smmt_RightsOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_58630e3a-dadf-4b53-afd7-82bfd2df54fa" xlink:to="loc_smmt_RightsOfferingMember_c58eb4c6-3074-4569-9d94-0e539e288ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_789ed010-34de-444b-b492-934eef426ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_3d5d6221-2ff9-464d-9110-8f29a58dbcca" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_789ed010-34de-444b-b492-934eef426ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_c7ed9a56-4119-42a2-882c-4c134c60c530" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_789ed010-34de-444b-b492-934eef426ba8" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_c7ed9a56-4119-42a2-882c-4c134c60c530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_491166a9-475a-4fc1-a9f8-a805f7baa057" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_789ed010-34de-444b-b492-934eef426ba8" xlink:to="loc_us-gaap_SharePrice_491166a9-475a-4fc1-a9f8-a805f7baa057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/NetLossperSharePotentiallydilutivesecuritiesexcludedfromthecomputationoflosspershareDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#NetLossperSharePotentiallydilutivesecuritiesexcludedfromthecomputationoflosspershareDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/NetLossperSharePotentiallydilutivesecuritiesexcludedfromthecomputationoflosspershareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d1161984-c646-46bb-87b9-c68ffd7cecb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e63b3981-7584-4bbd-b72b-18a6b120e335" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d1161984-c646-46bb-87b9-c68ffd7cecb6" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e63b3981-7584-4bbd-b72b-18a6b120e335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d62bd617-5d04-4c58-a779-095d097ae83d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e63b3981-7584-4bbd-b72b-18a6b120e335" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d62bd617-5d04-4c58-a779-095d097ae83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0b7c65db-c6b7-4c24-9346-3f8d1764007e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d62bd617-5d04-4c58-a779-095d097ae83d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0b7c65db-c6b7-4c24-9346-3f8d1764007e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_be43683b-e2f1-43b4-8e74-2e1fb62d2ded" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0b7c65db-c6b7-4c24-9346-3f8d1764007e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_be43683b-e2f1-43b4-8e74-2e1fb62d2ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_8a617ce1-597b-40fc-88de-1025fd51b639" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0b7c65db-c6b7-4c24-9346-3f8d1764007e" xlink:to="loc_us-gaap_WarrantMember_8a617ce1-597b-40fc-88de-1025fd51b639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_1e052cd2-7771-4851-b03d-5a3476bba2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0b7c65db-c6b7-4c24-9346-3f8d1764007e" xlink:to="loc_us-gaap_EmployeeStockMember_1e052cd2-7771-4851-b03d-5a3476bba2c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e437ee8c-0a5d-44ad-988d-c4671808e4ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e63b3981-7584-4bbd-b72b-18a6b120e335" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e437ee8c-0a5d-44ad-988d-c4671808e4ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_819e7634-10c9-4e2a-b03e-61052f417095" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e437ee8c-0a5d-44ad-988d-c4671808e4ca" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_819e7634-10c9-4e2a-b03e-61052f417095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bac5c39f-f013-435a-be89-e0243ac01ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_69162c1f-c97d-44f9-a99d-450dc62afdb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bac5c39f-f013-435a-be89-e0243ac01ad2" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_69162c1f-c97d-44f9-a99d-450dc62afdb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_c794f17e-96a9-4bd0-b111-d02ea559c2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bac5c39f-f013-435a-be89-e0243ac01ad2" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_c794f17e-96a9-4bd0-b111-d02ea559c2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1a184ee3-909a-4dc5-a239-9f7f3e76fdfa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bac5c39f-f013-435a-be89-e0243ac01ad2" xlink:to="loc_us-gaap_Goodwill_1a184ee3-909a-4dc5-a239-9f7f3e76fdfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_6710196c-659a-443d-9596-117e4d83130d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bac5c39f-f013-435a-be89-e0243ac01ad2" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_6710196c-659a-443d-9596-117e4d83130d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f3f59996-672f-4018-8d65-4cae169857f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_066cec70-5cca-4e1f-a8b9-f6b6c4d60de3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f3f59996-672f-4018-8d65-4cae169857f5" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_066cec70-5cca-4e1f-a8b9-f6b6c4d60de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a1e66928-2050-40a4-804b-d48b76eed5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_066cec70-5cca-4e1f-a8b9-f6b6c4d60de3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a1e66928-2050-40a4-804b-d48b76eed5d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a33a7e87-c192-4cd8-88df-a308266c24fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a1e66928-2050-40a4-804b-d48b76eed5d4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a33a7e87-c192-4cd8-88df-a308266c24fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_fed51be3-0966-496d-9ccd-a57a3673503c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a33a7e87-c192-4cd8-88df-a308266c24fe" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_fed51be3-0966-496d-9ccd-a57a3673503c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_OptionOverNonFinancialAssetsMember_ffe3052f-d003-41a9-8428-aeeeadb56942" xlink:href="smmt-20231231.xsd#smmt_OptionOverNonFinancialAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a33a7e87-c192-4cd8-88df-a308266c24fe" xlink:to="loc_smmt_OptionOverNonFinancialAssetsMember_ffe3052f-d003-41a9-8428-aeeeadb56942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_OtherPatentsAndLicensesMember_71d3cdb5-66f8-442f-85d4-85eb84a44e8a" xlink:href="smmt-20231231.xsd#smmt_OtherPatentsAndLicensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a33a7e87-c192-4cd8-88df-a308266c24fe" xlink:to="loc_smmt_OtherPatentsAndLicensesMember_71d3cdb5-66f8-442f-85d4-85eb84a44e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bbc57b48-8881-4012-9b41-d82ac569ce7a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_066cec70-5cca-4e1f-a8b9-f6b6c4d60de3" xlink:to="loc_srt_ProductOrServiceAxis_bbc57b48-8881-4012-9b41-d82ac569ce7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_27c12d8a-267d-4909-b75c-ea40c0569452" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_bbc57b48-8881-4012-9b41-d82ac569ce7a" xlink:to="loc_srt_ProductsAndServicesDomain_27c12d8a-267d-4909-b75c-ea40c0569452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_UtrophinProgramMember_6f3f8ce1-08b5-446e-8f46-cd355bc5f780" xlink:href="smmt-20231231.xsd#smmt_UtrophinProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_27c12d8a-267d-4909-b75c-ea40c0569452" xlink:to="loc_smmt_UtrophinProgramMember_6f3f8ce1-08b5-446e-8f46-cd355bc5f780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DiscuvaPlatformMember_6f9ffad1-d11a-4cf3-aaec-9f74682f192e" xlink:href="smmt-20231231.xsd#smmt_DiscuvaPlatformMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_27c12d8a-267d-4909-b75c-ea40c0569452" xlink:to="loc_smmt_DiscuvaPlatformMember_6f9ffad1-d11a-4cf3-aaec-9f74682f192e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_098cb1b9-aa65-486d-ab54-a32b959dbd32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_066cec70-5cca-4e1f-a8b9-f6b6c4d60de3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_098cb1b9-aa65-486d-ab54-a32b959dbd32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_fe841d28-ca51-4455-88e9-887345b3ca5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_098cb1b9-aa65-486d-ab54-a32b959dbd32" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_fe841d28-ca51-4455-88e9-887345b3ca5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment_02f905bf-8353-40bb-9dea-6a9521cc197b" xlink:href="smmt-20231231.xsd#smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_098cb1b9-aa65-486d-ab54-a32b959dbd32" xlink:to="loc_smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment_02f905bf-8353-40bb-9dea-6a9521cc197b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a997d11e-caa7-4b34-8ea8-9f350f65e105" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_098cb1b9-aa65-486d-ab54-a32b959dbd32" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a997d11e-caa7-4b34-8ea8-9f350f65e105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_7d87e759-c0f4-4d56-b499-a34d676c2517" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_098cb1b9-aa65-486d-ab54-a32b959dbd32" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_7d87e759-c0f4-4d56-b499-a34d676c2517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_98c08ff5-d21e-4170-ab09-d8eef729d656" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_098cb1b9-aa65-486d-ab54-a32b959dbd32" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_98c08ff5-d21e-4170-ab09-d8eef729d656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5f3bd75c-60d9-4dab-a56c-197f317e641d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4aeb9ea3-9d36-40c1-bb50-a9b2f2110175" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5f3bd75c-60d9-4dab-a56c-197f317e641d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4aeb9ea3-9d36-40c1-bb50-a9b2f2110175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_220fcff9-4d83-4a26-bdd2-e2c32bdecfc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4aeb9ea3-9d36-40c1-bb50-a9b2f2110175" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_220fcff9-4d83-4a26-bdd2-e2c32bdecfc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dd73615f-6973-45a9-9866-aaf35ba4a26c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_220fcff9-4d83-4a26-bdd2-e2c32bdecfc5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dd73615f-6973-45a9-9866-aaf35ba4a26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_dfc8527a-5348-4039-9e82-74c83dbdead8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dd73615f-6973-45a9-9866-aaf35ba4a26c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_dfc8527a-5348-4039-9e82-74c83dbdead8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2d4111b9-b45a-4ffd-9ec8-33c036c040cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dd73615f-6973-45a9-9866-aaf35ba4a26c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2d4111b9-b45a-4ffd-9ec8-33c036c040cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_66be36cc-1a70-48f4-a155-4f70884488cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dd73615f-6973-45a9-9866-aaf35ba4a26c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_66be36cc-1a70-48f4-a155-4f70884488cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_daf2a33f-e0d9-4caa-acc3-5d8e8674509c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4aeb9ea3-9d36-40c1-bb50-a9b2f2110175" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_daf2a33f-e0d9-4caa-acc3-5d8e8674509c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_756157ed-3efe-45b2-979e-77d84719b6f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_daf2a33f-e0d9-4caa-acc3-5d8e8674509c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_756157ed-3efe-45b2-979e-77d84719b6f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_ec152bed-9eae-41ba-9533-495e0a20ba35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_756157ed-3efe-45b2-979e-77d84719b6f0" xlink:to="loc_us-gaap_MoneyMarketFundsMember_ec152bed-9eae-41ba-9533-495e0a20ba35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_de49863a-6490-43c7-9ec9-0ad31b344700" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_756157ed-3efe-45b2-979e-77d84719b6f0" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_de49863a-6490-43c7-9ec9-0ad31b344700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_36e53633-4389-424f-8068-d9051128619e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4aeb9ea3-9d36-40c1-bb50-a9b2f2110175" xlink:to="loc_us-gaap_FinancialInstrumentAxis_36e53633-4389-424f-8068-d9051128619e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2b54ec52-16a0-4f06-89c1-5e966fc0befe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_36e53633-4389-424f-8068-d9051128619e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2b54ec52-16a0-4f06-89c1-5e966fc0befe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_80798b48-d12e-4a66-8b65-fcebaa0f29b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2b54ec52-16a0-4f06-89c1-5e966fc0befe" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_80798b48-d12e-4a66-8b65-fcebaa0f29b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e7e95c31-1a84-47b6-beaf-d22f5d5c975d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4aeb9ea3-9d36-40c1-bb50-a9b2f2110175" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e7e95c31-1a84-47b6-beaf-d22f5d5c975d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CashEquivalentsFairValueDisclosure_2098d95c-fdff-4340-a310-ccdb12ba0714" xlink:href="smmt-20231231.xsd#smmt_CashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e7e95c31-1a84-47b6-beaf-d22f5d5c975d" xlink:to="loc_smmt_CashEquivalentsFairValueDisclosure_2098d95c-fdff-4340-a310-ccdb12ba0714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_a5166186-7dab-4358-8440-2fdb44df781f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e7e95c31-1a84-47b6-beaf-d22f5d5c975d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_a5166186-7dab-4358-8440-2fdb44df781f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_ab9558d0-808b-41b2-b175-b0b83de80f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e7e95c31-1a84-47b6-beaf-d22f5d5c975d" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_ab9558d0-808b-41b2-b175-b0b83de80f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#FairValueMeasurementsandShortTermInvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9418fa56-206b-4dd1-be2c-9bac7b4cbecc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_c1f55d0e-b79d-461f-8897-54df738a5709" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9418fa56-206b-4dd1-be2c-9bac7b4cbecc" xlink:to="loc_us-gaap_Cash_c1f55d0e-b79d-461f-8897-54df738a5709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_6870a3d9-5c10-4604-8236-509eb14c7141" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9418fa56-206b-4dd1-be2c-9bac7b4cbecc" xlink:to="loc_us-gaap_ShortTermInvestments_6870a3d9-5c10-4604-8236-509eb14c7141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsShortterminvestmentswithcontractualmaturityoflessthanonyearDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#FairValueMeasurementsandShortTermInvestmentsShortterminvestmentswithcontractualmaturityoflessthanonyearDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsShortterminvestmentswithcontractualmaturityoflessthanonyearDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4832687c-7c02-4eeb-ba91-8ae51bf23178" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_e3da910c-361a-4f9a-a6ee-3ad5fbcf8321" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4832687c-7c02-4eeb-ba91-8ae51bf23178" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_e3da910c-361a-4f9a-a6ee-3ad5fbcf8321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b67b9177-6178-4ab4-946d-db89ef990f48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_e3da910c-361a-4f9a-a6ee-3ad5fbcf8321" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b67b9177-6178-4ab4-946d-db89ef990f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ba2f6667-55dd-4e67-8554-33aa0ba6a6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b67b9177-6178-4ab4-946d-db89ef990f48" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ba2f6667-55dd-4e67-8554-33aa0ba6a6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_912cae4e-1a57-45b6-901a-b4eb0619cb8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ba2f6667-55dd-4e67-8554-33aa0ba6a6c6" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_912cae4e-1a57-45b6-901a-b4eb0619cb8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_baeaa320-c842-4282-bb15-625940bbe1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_e3da910c-361a-4f9a-a6ee-3ad5fbcf8321" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_baeaa320-c842-4282-bb15-625940bbe1d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_556e6f56-88fa-45c9-94b7-2750328157db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_baeaa320-c842-4282-bb15-625940bbe1d2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_556e6f56-88fa-45c9-94b7-2750328157db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_445866e2-c730-477b-b24f-aef3388f6702" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_baeaa320-c842-4282-bb15-625940bbe1d2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_445866e2-c730-477b-b24f-aef3388f6702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0ccc9b6a-14ac-4afc-aab2-283cd93226c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_baeaa320-c842-4282-bb15-625940bbe1d2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0ccc9b6a-14ac-4afc-aab2-283cd93226c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_69ec64b9-434d-4649-8215-23d1f3755346" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_baeaa320-c842-4282-bb15-625940bbe1d2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_69ec64b9-434d-4649-8215-23d1f3755346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_9a9ff9c1-defb-4388-812b-8654777fb602" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_baeaa320-c842-4282-bb15-625940bbe1d2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_9a9ff9c1-defb-4388-812b-8654777fb602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#PropertyandEquipmentComponentsofpropertyandequipmentDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_fcc779de-d51a-4d07-ad56-9dacf798ace1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_246a198b-fe36-4710-8b27-93d60c3ce2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_fcc779de-d51a-4d07-ad56-9dacf798ace1" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_246a198b-fe36-4710-8b27-93d60c3ce2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0035822a-560f-4e7d-a686-870ed4e6a70b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_246a198b-fe36-4710-8b27-93d60c3ce2e0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0035822a-560f-4e7d-a686-870ed4e6a70b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d1098bd5-c9b0-4cb8-81fe-e5d71bf4b70b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0035822a-560f-4e7d-a686-870ed4e6a70b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d1098bd5-c9b0-4cb8-81fe-e5d71bf4b70b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_LaboratoryEquipmentMember_f91b27fa-62cd-4ce6-89ed-63011848ad78" xlink:href="smmt-20231231.xsd#smmt_LaboratoryEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d1098bd5-c9b0-4cb8-81fe-e5d71bf4b70b" xlink:to="loc_smmt_LaboratoryEquipmentMember_f91b27fa-62cd-4ce6-89ed-63011848ad78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember_2159d552-89ac-453a-9a84-a1c94e539ac9" xlink:href="smmt-20231231.xsd#smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d1098bd5-c9b0-4cb8-81fe-e5d71bf4b70b" xlink:to="loc_smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember_2159d552-89ac-453a-9a84-a1c94e539ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_2b5f6176-4e1a-4b50-a4bb-5360f0b7ff12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d1098bd5-c9b0-4cb8-81fe-e5d71bf4b70b" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_2b5f6176-4e1a-4b50-a4bb-5360f0b7ff12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3498ab0e-17a2-4c6d-8993-104180e2ce97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_246a198b-fe36-4710-8b27-93d60c3ce2e0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3498ab0e-17a2-4c6d-8993-104180e2ce97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_66526b3f-eef6-454c-85f3-40a7c294f77e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3498ab0e-17a2-4c6d-8993-104180e2ce97" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_66526b3f-eef6-454c-85f3-40a7c294f77e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_29c99d70-0499-42ae-93d9-a5bd57cea15b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3498ab0e-17a2-4c6d-8993-104180e2ce97" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_29c99d70-0499-42ae-93d9-a5bd57cea15b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_49cda640-925b-4cc1-807f-908de278a7ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3498ab0e-17a2-4c6d-8993-104180e2ce97" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_49cda640-925b-4cc1-807f-908de278a7ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#PropertyandEquipmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e4e6e8c9-7650-4870-90f8-7ca27f37d0ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_416df14a-9ad3-433f-9338-28b28a162606" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e4e6e8c9-7650-4870-90f8-7ca27f37d0ea" xlink:to="loc_us-gaap_Depreciation_416df14a-9ad3-433f-9338-28b28a162606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_380c1cbc-b501-4992-9a08-5e9848a2ae56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e4e6e8c9-7650-4870-90f8-7ca27f37d0ea" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_380c1cbc-b501-4992-9a08-5e9848a2ae56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/ResearchandDevelopmentPrepaidExpensesandAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#ResearchandDevelopmentPrepaidExpensesandAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/ResearchandDevelopmentPrepaidExpensesandAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_564aa27c-6364-4625-9184-e4bc6ab45d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ResearchAndDevelopmentPrepaidExpensesCurrent_1f468d41-6545-4d9a-8466-0591e866efc5" xlink:href="smmt-20231231.xsd#smmt_ResearchAndDevelopmentPrepaidExpensesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_564aa27c-6364-4625-9184-e4bc6ab45d3d" xlink:to="loc_smmt_ResearchAndDevelopmentPrepaidExpensesCurrent_1f468d41-6545-4d9a-8466-0591e866efc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_AccruedResearchAndDevelopmentCurrent_2adfc75e-bf84-4eb4-ba0e-b79dc0eb21e4" xlink:href="smmt-20231231.xsd#smmt_AccruedResearchAndDevelopmentCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_564aa27c-6364-4625-9184-e4bc6ab45d3d" xlink:to="loc_smmt_AccruedResearchAndDevelopmentCurrent_2adfc75e-bf84-4eb4-ba0e-b79dc0eb21e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_38988f2d-718d-4417-a913-4665a6e48933" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_285e2ecc-22c8-4aa4-ad85-44c0da5c2bce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_38988f2d-718d-4417-a913-4665a6e48933" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_285e2ecc-22c8-4aa4-ad85-44c0da5c2bce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_f99375b7-48dc-41af-a13b-63c5517f97fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_285e2ecc-22c8-4aa4-ad85-44c0da5c2bce" xlink:to="loc_us-gaap_LeaseContractualTermAxis_f99375b7-48dc-41af-a13b-63c5517f97fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_5548749f-6e80-49bb-b6f4-1a7bc5a8abd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_f99375b7-48dc-41af-a13b-63c5517f97fc" xlink:to="loc_us-gaap_LeaseContractualTermDomain_5548749f-6e80-49bb-b6f4-1a7bc5a8abd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_MenloParkCaliforniaExpirationMay2026Member_85d68fa0-2206-42f3-a093-9409921db8b1" xlink:href="smmt-20231231.xsd#smmt_MenloParkCaliforniaExpirationMay2026Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_5548749f-6e80-49bb-b6f4-1a7bc5a8abd5" xlink:to="loc_smmt_MenloParkCaliforniaExpirationMay2026Member_85d68fa0-2206-42f3-a093-9409921db8b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CambridgeUKLaboratoryAndOfficeSpaceMember_2686b604-6743-49ac-a291-0aa2fe64aeff" xlink:href="smmt-20231231.xsd#smmt_CambridgeUKLaboratoryAndOfficeSpaceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_5548749f-6e80-49bb-b6f4-1a7bc5a8abd5" xlink:to="loc_smmt_CambridgeUKLaboratoryAndOfficeSpaceMember_2686b604-6743-49ac-a291-0aa2fe64aeff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b61425e0-f996-4a0e-b090-fbfe072f3dce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_285e2ecc-22c8-4aa4-ad85-44c0da5c2bce" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b61425e0-f996-4a0e-b090-fbfe072f3dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a9193067-0263-496b-8f49-6000b7e09f11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b61425e0-f996-4a0e-b090-fbfe072f3dce" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a9193067-0263-496b-8f49-6000b7e09f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_9d6965fb-416c-4e98-aadd-02cad34e53fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a9193067-0263-496b-8f49-6000b7e09f11" xlink:to="loc_us-gaap_SubsequentEventMember_9d6965fb-416c-4e98-aadd-02cad34e53fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_71f92e3f-f825-4466-bb1b-1454596147cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_285e2ecc-22c8-4aa4-ad85-44c0da5c2bce" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_71f92e3f-f825-4466-bb1b-1454596147cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_e640a69e-1e94-4089-8dbd-ed5680e76348" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_71f92e3f-f825-4466-bb1b-1454596147cc" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_e640a69e-1e94-4089-8dbd-ed5680e76348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_eae14c33-b3ba-4836-833f-ff91742a97e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_71f92e3f-f825-4466-bb1b-1454596147cc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_eae14c33-b3ba-4836-833f-ff91742a97e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_bf78f117-1a81-4f8a-82fd-f1993350e944" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_71f92e3f-f825-4466-bb1b-1454596147cc" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_bf78f117-1a81-4f8a-82fd-f1993350e944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_OperatingLeaseRightOfUseAssetDisposals_233d6ae0-064a-4a73-b771-1144bff2fdd4" xlink:href="smmt-20231231.xsd#smmt_OperatingLeaseRightOfUseAssetDisposals"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_71f92e3f-f825-4466-bb1b-1454596147cc" xlink:to="loc_smmt_OperatingLeaseRightOfUseAssetDisposals_233d6ae0-064a-4a73-b771-1144bff2fdd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_3acb6f64-0fc2-4ed7-9107-ae1747c5115e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_71f92e3f-f825-4466-bb1b-1454596147cc" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_3acb6f64-0fc2-4ed7-9107-ae1747c5115e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7a8c4e01-3072-4f40-8a8f-cf2e7f46f737" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_71f92e3f-f825-4466-bb1b-1454596147cc" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7a8c4e01-3072-4f40-8a8f-cf2e7f46f737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_e3bf2b67-c058-4320-bae0-7bb7020d58ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_71f92e3f-f825-4466-bb1b-1454596147cc" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_e3bf2b67-c058-4320-bae0-7bb7020d58ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8948d72d-2084-491a-b5c7-18d5711ae207" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_71f92e3f-f825-4466-bb1b-1454596147cc" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8948d72d-2084-491a-b5c7-18d5711ae207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_dd8477be-e700-4298-ba50-59b00be25291" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_71f92e3f-f825-4466-bb1b-1454596147cc" xlink:to="loc_us-gaap_OperatingLeasePayments_dd8477be-e700-4298-ba50-59b00be25291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_LesseeOperatingLeaseAreaOfPremisesLeased_4f3ee932-276c-43df-8d3a-7f9bb73743df" xlink:href="smmt-20231231.xsd#smmt_LesseeOperatingLeaseAreaOfPremisesLeased"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_71f92e3f-f825-4466-bb1b-1454596147cc" xlink:to="loc_smmt_LesseeOperatingLeaseAreaOfPremisesLeased_4f3ee932-276c-43df-8d3a-7f9bb73743df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/LeasesLeaseexpenseDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#LeasesLeaseexpenseDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/LeasesLeaseexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_91b0ec74-f640-4ae8-bc7b-a60d6989c653" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_6b08a48b-bfce-4de4-95d4-0f1a3c8a5fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_91b0ec74-f640-4ae8-bc7b-a60d6989c653" xlink:to="loc_us-gaap_LeaseCostAbstract_6b08a48b-bfce-4de4-95d4-0f1a3c8a5fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_ed98143c-0ecc-4941-8af5-ef06a41809f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_6b08a48b-bfce-4de4-95d4-0f1a3c8a5fa9" xlink:to="loc_us-gaap_OperatingLeaseCost_ed98143c-0ecc-4941-8af5-ef06a41809f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_fd5fccc8-24d4-413a-9e41-9d09e6c79aae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_6b08a48b-bfce-4de4-95d4-0f1a3c8a5fa9" xlink:to="loc_us-gaap_VariableLeaseCost_fd5fccc8-24d4-413a-9e41-9d09e6c79aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_4c765c7e-dc19-4e53-9268-be96f2b6b8ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_6b08a48b-bfce-4de4-95d4-0f1a3c8a5fa9" xlink:to="loc_us-gaap_ShortTermLeaseCost_4c765c7e-dc19-4e53-9268-be96f2b6b8ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_2b528d55-a942-4fc3-aae6-9b94bfb8e966" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_6b08a48b-bfce-4de4-95d4-0f1a3c8a5fa9" xlink:to="loc_us-gaap_LeaseCost_2b528d55-a942-4fc3-aae6-9b94bfb8e966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#LeasesFutureleasepaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_38713e0f-aba3-4006-8562-2adff17f21c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2c6d725f-0761-4528-8861-4c44b27d2d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_38713e0f-aba3-4006-8562-2adff17f21c6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2c6d725f-0761-4528-8861-4c44b27d2d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5f21eb49-2ed1-4300-8055-238c4216c8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_38713e0f-aba3-4006-8562-2adff17f21c6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5f21eb49-2ed1-4300-8055-238c4216c8d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f5313954-3cc6-4261-a036-65072462d93a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_38713e0f-aba3-4006-8562-2adff17f21c6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f5313954-3cc6-4261-a036-65072462d93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_90152504-7e85-42fe-a83b-17597023a8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_38713e0f-aba3-4006-8562-2adff17f21c6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_90152504-7e85-42fe-a83b-17597023a8cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8923fee0-dc3f-49e9-a7ad-12955f644e23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_38713e0f-aba3-4006-8562-2adff17f21c6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8923fee0-dc3f-49e9-a7ad-12955f644e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_da1a9338-735e-42d1-a404-7a39fcf3f822" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_38713e0f-aba3-4006-8562-2adff17f21c6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_da1a9338-735e-42d1-a404-7a39fcf3f822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_46eecb1d-7122-4098-830f-4d6fc2753f59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_38713e0f-aba3-4006-8562-2adff17f21c6" xlink:to="loc_us-gaap_OperatingLeaseLiability_46eecb1d-7122-4098-830f-4d6fc2753f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract_2fa90b85-d291-43d0-8e8e-75b86a6c1b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_38713e0f-aba3-4006-8562-2adff17f21c6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityAbstract_2fa90b85-d291-43d0-8e8e-75b86a6c1b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_39598906-945f-4614-bb97-40f9e2511314" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_2fa90b85-d291-43d0-8e8e-75b86a6c1b4c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_39598906-945f-4614-bb97-40f9e2511314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_41ad1c08-14a1-4fdd-a617-c0c7b1d28f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_2fa90b85-d291-43d0-8e8e-75b86a6c1b4c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_41ad1c08-14a1-4fdd-a617-c0c7b1d28f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_3a740229-cf73-489d-be6a-09008484d745" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_2fa90b85-d291-43d0-8e8e-75b86a6c1b4c" xlink:to="loc_us-gaap_OperatingLeaseLiability_3a740229-cf73-489d-be6a-09008484d745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails_1" xlink:type="simple" xlink:href="smmt-20231231.xsd#LeasesFutureleasepaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesSummaryofrelatedpartydebtDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#PromissoryNotesPayabletoRelatedPartiesSummaryofrelatedpartydebtDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesSummaryofrelatedpartydebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_94461d9f-2f50-4234-8207-727d4e72a923" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_605774f8-4d9f-4698-8f78-e98ecfa2b8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_94461d9f-2f50-4234-8207-727d4e72a923" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_605774f8-4d9f-4698-8f78-e98ecfa2b8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_11678c64-ae66-4330-b7e3-40ad1a1e3b26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_605774f8-4d9f-4698-8f78-e98ecfa2b8f0" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_11678c64-ae66-4330-b7e3-40ad1a1e3b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_3d6281fd-3387-4af7-bc8d-8522a2a6852c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_11678c64-ae66-4330-b7e3-40ad1a1e3b26" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_3d6281fd-3387-4af7-bc8d-8522a2a6852c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_PromissoryNotesMember_7c1bb765-d99b-4807-aef1-75223d4e69b8" xlink:href="smmt-20231231.xsd#smmt_PromissoryNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_3d6281fd-3387-4af7-bc8d-8522a2a6852c" xlink:to="loc_smmt_PromissoryNotesMember_7c1bb765-d99b-4807-aef1-75223d4e69b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7159330e-7728-46c5-a221-115cfc15b608" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_605774f8-4d9f-4698-8f78-e98ecfa2b8f0" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7159330e-7728-46c5-a221-115cfc15b608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_624fac53-f2c0-4a9a-8b54-6f8b908572fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7159330e-7728-46c5-a221-115cfc15b608" xlink:to="loc_us-gaap_RelatedPartyDomain_624fac53-f2c0-4a9a-8b54-6f8b908572fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_9cc9b296-2d7a-43c0-8c6a-7c06ff47802f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_624fac53-f2c0-4a9a-8b54-6f8b908572fa" xlink:to="loc_us-gaap_RelatedPartyMember_9cc9b296-2d7a-43c0-8c6a-7c06ff47802f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_ebe129f0-bcae-4098-8611-4a2f7561e055" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_605774f8-4d9f-4698-8f78-e98ecfa2b8f0" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_ebe129f0-bcae-4098-8611-4a2f7561e055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrentAbstract_4a47ef90-f8af-4b7d-88b4-425ff8cea967" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ebe129f0-bcae-4098-8611-4a2f7561e055" xlink:to="loc_us-gaap_NotesPayableCurrentAbstract_4a47ef90-f8af-4b7d-88b4-425ff8cea967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableGrossCurrent_37d4241a-e779-49a6-99d5-281226b12ae9" xlink:href="smmt-20231231.xsd#smmt_NotesPayableGrossCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NotesPayableCurrentAbstract_4a47ef90-f8af-4b7d-88b4-425ff8cea967" xlink:to="loc_smmt_NotesPayableGrossCurrent_37d4241a-e779-49a6-99d5-281226b12ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_9f4681c2-7563-43e3-970e-5794f80c67f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NotesPayableCurrentAbstract_4a47ef90-f8af-4b7d-88b4-425ff8cea967" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_9f4681c2-7563-43e3-970e-5794f80c67f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_81142700-9cf3-4679-9918-0641a05c9480" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NotesPayableCurrentAbstract_4a47ef90-f8af-4b7d-88b4-425ff8cea967" xlink:to="loc_us-gaap_NotesPayableCurrent_81142700-9cf3-4679-9918-0641a05c9480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayableAbstract_51b66fa0-5b32-40b3-b31b-490d408c9e98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayableAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ebe129f0-bcae-4098-8611-4a2f7561e055" xlink:to="loc_us-gaap_LongTermNotesPayableAbstract_51b66fa0-5b32-40b3-b31b-490d408c9e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableGrossNoncurrent_f661a070-b99a-4160-81c0-599f5b73346f" xlink:href="smmt-20231231.xsd#smmt_NotesPayableGrossNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermNotesPayableAbstract_51b66fa0-5b32-40b3-b31b-490d408c9e98" xlink:to="loc_smmt_NotesPayableGrossNoncurrent_f661a070-b99a-4160-81c0-599f5b73346f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_38e1ed67-e39a-4233-a755-9243328739e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermNotesPayableAbstract_51b66fa0-5b32-40b3-b31b-490d408c9e98" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_38e1ed67-e39a-4233-a755-9243328739e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_de024b75-7c7f-4265-ab66-128d4b5d88f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermNotesPayableAbstract_51b66fa0-5b32-40b3-b31b-490d408c9e98" xlink:to="loc_us-gaap_LongTermNotesPayable_de024b75-7c7f-4265-ab66-128d4b5d88f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#PromissoryNotesPayabletoRelatedPartiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_1dfb5115-6a77-4a4e-ba4b-51c7a1b9cb67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_cb64dcc7-ccdb-4022-9f3f-586ab7a98792" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_1dfb5115-6a77-4a4e-ba4b-51c7a1b9cb67" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_cb64dcc7-ccdb-4022-9f3f-586ab7a98792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_2cc298a3-b59e-46cd-8a84-9c75da7e18bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_cb64dcc7-ccdb-4022-9f3f-586ab7a98792" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_2cc298a3-b59e-46cd-8a84-9c75da7e18bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_4abce440-f4a4-4468-9ff7-db37157edc5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_2cc298a3-b59e-46cd-8a84-9c75da7e18bf" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_4abce440-f4a4-4468-9ff7-db37157edc5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_March2022NoteMember_1d9f6fc5-397f-425b-b57a-a33e9fd4d8d3" xlink:href="smmt-20231231.xsd#smmt_March2022NoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_4abce440-f4a4-4468-9ff7-db37157edc5a" xlink:to="loc_smmt_March2022NoteMember_1d9f6fc5-397f-425b-b57a-a33e9fd4d8d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotePurchaseAgreementMember_579d4aeb-dc79-407f-aa91-e9df0f29df99" xlink:href="smmt-20231231.xsd#smmt_NotePurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_4abce440-f4a4-4468-9ff7-db37157edc5a" xlink:to="loc_smmt_NotePurchaseAgreementMember_579d4aeb-dc79-407f-aa91-e9df0f29df99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DugganPromissoryNotesMember_e52efcc9-1a47-4478-b7fe-2f7ce0158741" xlink:href="smmt-20231231.xsd#smmt_DugganPromissoryNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_NotePurchaseAgreementMember_579d4aeb-dc79-407f-aa91-e9df0f29df99" xlink:to="loc_smmt_DugganPromissoryNotesMember_e52efcc9-1a47-4478-b7fe-2f7ce0158741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DugganSeptemberNoteMember_96c0c169-80f9-497a-b8c1-1e06e7999a18" xlink:href="smmt-20231231.xsd#smmt_DugganSeptemberNoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_DugganPromissoryNotesMember_e52efcc9-1a47-4478-b7fe-2f7ce0158741" xlink:to="loc_smmt_DugganSeptemberNoteMember_96c0c169-80f9-497a-b8c1-1e06e7999a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DugganFebruaryNoteMember_29a9825d-0fa6-4a01-aa18-37e2891ddbd5" xlink:href="smmt-20231231.xsd#smmt_DugganFebruaryNoteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_DugganPromissoryNotesMember_e52efcc9-1a47-4478-b7fe-2f7ce0158741" xlink:to="loc_smmt_DugganFebruaryNoteMember_29a9825d-0fa6-4a01-aa18-37e2891ddbd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ZanganehNoteMember_d3dff11a-6137-4675-8dc1-cc02a376befb" xlink:href="smmt-20231231.xsd#smmt_ZanganehNoteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_NotePurchaseAgreementMember_579d4aeb-dc79-407f-aa91-e9df0f29df99" xlink:to="loc_smmt_ZanganehNoteMember_d3dff11a-6137-4675-8dc1-cc02a376befb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DugganFebruaryNoteAndZanganehNoteMember_d73fe862-f61a-472f-bd6d-a7240048eff9" xlink:href="smmt-20231231.xsd#smmt_DugganFebruaryNoteAndZanganehNoteMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_NotePurchaseAgreementMember_579d4aeb-dc79-407f-aa91-e9df0f29df99" xlink:to="loc_smmt_DugganFebruaryNoteAndZanganehNoteMember_d73fe862-f61a-472f-bd6d-a7240048eff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_PromissoryNotesMember_fde60138-f4d3-4a19-92dc-4976954c40cd" xlink:href="smmt-20231231.xsd#smmt_PromissoryNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_4abce440-f4a4-4468-9ff7-db37157edc5a" xlink:to="loc_smmt_PromissoryNotesMember_fde60138-f4d3-4a19-92dc-4976954c40cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_238bf51d-3748-49fb-9d2d-dd67d26bc99a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_cb64dcc7-ccdb-4022-9f3f-586ab7a98792" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_238bf51d-3748-49fb-9d2d-dd67d26bc99a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_4dded9d1-dda0-4bd4-82ac-f48bec0abec1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_238bf51d-3748-49fb-9d2d-dd67d26bc99a" xlink:to="loc_us-gaap_RelatedPartyDomain_4dded9d1-dda0-4bd4-82ac-f48bec0abec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember_f13369df-ac05-4cbe-8f4b-8aaa5fe038be" xlink:href="smmt-20231231.xsd#smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_4dded9d1-dda0-4bd4-82ac-f48bec0abec1" xlink:to="loc_smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember_f13369df-ac05-4cbe-8f4b-8aaa5fe038be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_bcdbd984-7588-40b4-8827-09fe1740f477" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember_f13369df-ac05-4cbe-8f4b-8aaa5fe038be" xlink:to="loc_srt_ChiefExecutiveOfficerMember_bcdbd984-7588-40b4-8827-09fe1740f477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ChiefExecutiveOfficerAndPresidentMember_88812e2f-f3d4-40c5-b879-49ff3d57b9be" xlink:href="smmt-20231231.xsd#smmt_ChiefExecutiveOfficerAndPresidentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember_f13369df-ac05-4cbe-8f4b-8aaa5fe038be" xlink:to="loc_smmt_ChiefExecutiveOfficerAndPresidentMember_88812e2f-f3d4-40c5-b879-49ff3d57b9be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_57fe9db1-100c-4c2e-9a47-6292f0c3c7b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_4dded9d1-dda0-4bd4-82ac-f48bec0abec1" xlink:to="loc_us-gaap_RelatedPartyMember_57fe9db1-100c-4c2e-9a47-6292f0c3c7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_cec5c52c-f4b0-4304-9a32-00722cb64e04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_cb64dcc7-ccdb-4022-9f3f-586ab7a98792" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_cec5c52c-f4b0-4304-9a32-00722cb64e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7c12732d-d1e1-4dc2-b037-4e19d9b80d70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_cec5c52c-f4b0-4304-9a32-00722cb64e04" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7c12732d-d1e1-4dc2-b037-4e19d9b80d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RightsOfferingMember_d5a83ff7-b184-4459-a38f-ff1c4c086c08" xlink:href="smmt-20231231.xsd#smmt_RightsOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7c12732d-d1e1-4dc2-b037-4e19d9b80d70" xlink:to="loc_smmt_RightsOfferingMember_d5a83ff7-b184-4459-a38f-ff1c4c086c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_057309a2-b789-4e09-9f99-18d3bf2a3aab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_cb64dcc7-ccdb-4022-9f3f-586ab7a98792" xlink:to="loc_us-gaap_VariableRateAxis_057309a2-b789-4e09-9f99-18d3bf2a3aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_6344ea55-2958-4fa0-821b-bceb47589314" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_057309a2-b789-4e09-9f99-18d3bf2a3aab" xlink:to="loc_us-gaap_VariableRateDomain_6344ea55-2958-4fa0-821b-bceb47589314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_e6515228-0098-4a0c-a30d-c461f87321fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_6344ea55-2958-4fa0-821b-bceb47589314" xlink:to="loc_us-gaap_PrimeRateMember_e6515228-0098-4a0c-a30d-c461f87321fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_VariableRatePeriodAxis_e525adba-9d10-459d-8aeb-76be3a5a56e7" xlink:href="smmt-20231231.xsd#smmt_VariableRatePeriodAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_cb64dcc7-ccdb-4022-9f3f-586ab7a98792" xlink:to="loc_smmt_VariableRatePeriodAxis_e525adba-9d10-459d-8aeb-76be3a5a56e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_VariableRatePeriodDomain_b6cedcfb-9853-46e7-b17b-c0be8b2a83e7" xlink:href="smmt-20231231.xsd#smmt_VariableRatePeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_VariableRatePeriodAxis_e525adba-9d10-459d-8aeb-76be3a5a56e7" xlink:to="loc_smmt_VariableRatePeriodDomain_b6cedcfb-9853-46e7-b17b-c0be8b2a83e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_VariableRatePeriodOneMember_c80801bb-21df-437e-b0d1-bd23c60aeef1" xlink:href="smmt-20231231.xsd#smmt_VariableRatePeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_VariableRatePeriodDomain_b6cedcfb-9853-46e7-b17b-c0be8b2a83e7" xlink:to="loc_smmt_VariableRatePeriodOneMember_c80801bb-21df-437e-b0d1-bd23c60aeef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_VariableRatePeriodTwoMember_277e1fde-a84a-41ac-8564-5be02dec914f" xlink:href="smmt-20231231.xsd#smmt_VariableRatePeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_VariableRatePeriodDomain_b6cedcfb-9853-46e7-b17b-c0be8b2a83e7" xlink:to="loc_smmt_VariableRatePeriodTwoMember_277e1fde-a84a-41ac-8564-5be02dec914f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_176874f6-4408-4a59-9a68-e96164b1e0b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_cb64dcc7-ccdb-4022-9f3f-586ab7a98792" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_176874f6-4408-4a59-9a68-e96164b1e0b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_589ef023-2550-471b-bf5f-8318e864e0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_176874f6-4408-4a59-9a68-e96164b1e0b9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_589ef023-2550-471b-bf5f-8318e864e0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_34cb85bc-8c57-4566-9f6d-af8a1b07d8da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_589ef023-2550-471b-bf5f-8318e864e0f7" xlink:to="loc_us-gaap_SubsequentEventMember_34cb85bc-8c57-4566-9f6d-af8a1b07d8da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_cb64dcc7-ccdb-4022-9f3f-586ab7a98792" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_4f098ee7-7433-4372-8819-cc4010cd69c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_4f098ee7-7433-4372-8819-cc4010cd69c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_de014bbf-9bf4-4005-b746-2b8496c13962" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_us-gaap_NotesPayable_de014bbf-9bf4-4005-b746-2b8496c13962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold_89fe6c48-8d52-4821-a549-417d6ba84e82" xlink:href="smmt-20231231.xsd#smmt_NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_smmt_NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold_89fe6c48-8d52-4821-a549-417d6ba84e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartiesMaximumTerm_ae6279ca-0409-4de3-8450-d88330c33621" xlink:href="smmt-20231231.xsd#smmt_NotesPayableRelatedPartiesMaximumTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_smmt_NotesPayableRelatedPartiesMaximumTerm_ae6279ca-0409-4de3-8450-d88330c33621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_12eac5ee-5e92-4d64-a2e8-9f0541cf0f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_12eac5ee-5e92-4d64-a2e8-9f0541cf0f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_PaymentOfAccruedInterestToRelatedParties_bdce042b-9259-4212-8e13-55ba4b5ebb37" xlink:href="smmt-20231231.xsd#smmt_PaymentOfAccruedInterestToRelatedParties"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_smmt_PaymentOfAccruedInterestToRelatedParties_bdce042b-9259-4212-8e13-55ba4b5ebb37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e1bf7925-34ef-4154-a001-d602a06af04d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e1bf7925-34ef-4154-a001-d602a06af04d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_26426a79-273f-426b-8805-9af2a642a695" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_us-gaap_InterestExpenseDebt_26426a79-273f-426b-8805-9af2a642a695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_fc3acb62-bb23-4af3-b17e-b335b156caf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_fc3acb62-bb23-4af3-b17e-b335b156caf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartiesPotentialPrepaymentPeriodPostReceiptOfCashProceedsFromPublicOffering_913f207e-e215-43cb-9607-7ce8285bde15" xlink:href="smmt-20231231.xsd#smmt_NotesPayableRelatedPartiesPotentialPrepaymentPeriodPostReceiptOfCashProceedsFromPublicOffering"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_smmt_NotesPayableRelatedPartiesPotentialPrepaymentPeriodPostReceiptOfCashProceedsFromPublicOffering_913f207e-e215-43cb-9607-7ce8285bde15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartiesPotentialPrepaymentMaximumAmountPercentageOfNetProceedsFromPublicOffering_85b1d73f-103d-4fb0-81c8-f7737266be0c" xlink:href="smmt-20231231.xsd#smmt_NotesPayableRelatedPartiesPotentialPrepaymentMaximumAmountPercentageOfNetProceedsFromPublicOffering"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_smmt_NotesPayableRelatedPartiesPotentialPrepaymentMaximumAmountPercentageOfNetProceedsFromPublicOffering_85b1d73f-103d-4fb0-81c8-f7737266be0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartiesNewIssuances_f92bead8-3835-4759-b95d-db80b9d2bd2a" xlink:href="smmt-20231231.xsd#smmt_NotesPayableRelatedPartiesNewIssuances"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_smmt_NotesPayableRelatedPartiesNewIssuances_f92bead8-3835-4759-b95d-db80b9d2bd2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionRate_dbfe1cc9-a5b7-43bf-9c90-b0c186c5d495" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionRate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_us-gaap_RelatedPartyTransactionRate_dbfe1cc9-a5b7-43bf-9c90-b0c186c5d495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_41590755-b322-475e-b5b2-ce54f5a98ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_41590755-b322-475e-b5b2-ce54f5a98ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominator_1e781e52-d452-4a6e-9a4c-d4641f6ca48d" xlink:href="smmt-20231231.xsd#smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominator"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominator_1e781e52-d452-4a6e-9a4c-d4641f6ca48d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominatorBaseAmountAddedToClosingBidPrice_b5813d2d-8530-4665-a150-a0b7a086404e" xlink:href="smmt-20231231.xsd#smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominatorBaseAmountAddedToClosingBidPrice"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominatorBaseAmountAddedToClosingBidPrice_b5813d2d-8530-4665-a150-a0b7a086404e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_StockIssuedDuringPeriodSharesRelatedPartyPrepaidInterest_279d5667-2705-4a8c-90e7-260d0e45de74" xlink:href="smmt-20231231.xsd#smmt_StockIssuedDuringPeriodSharesRelatedPartyPrepaidInterest"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_smmt_StockIssuedDuringPeriodSharesRelatedPartyPrepaidInterest_279d5667-2705-4a8c-90e7-260d0e45de74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_f8d1dd87-e43c-45db-8d2f-9b74725ea4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_f8d1dd87-e43c-45db-8d2f-9b74725ea4ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_daeb8298-7991-4e6f-9e51-d72acdd6f624" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_daeb8298-7991-4e6f-9e51-d72acdd6f624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_43ab2d42-3888-4fc2-a388-7db2357006ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_43ab2d42-3888-4fc2-a388-7db2357006ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_2ba77b02-8517-4a4d-a873-a0aedc9582b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_2ba77b02-8517-4a4d-a873-a0aedc9582b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_919e19f0-310b-4ed0-99ca-5aaf3b492a95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_us-gaap_LongTermNotesPayable_919e19f0-310b-4ed0-99ca-5aaf3b492a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_b868cd52-dc65-4f6d-81e2-b2d0993cba26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_b868cd52-dc65-4f6d-81e2-b2d0993cba26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_8e111fdc-9df9-45de-bf09-38ca2b6e415e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9579e4d-a00f-4466-a407-7f565de7c5ba" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_8e111fdc-9df9-45de-bf09-38ca2b6e415e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/OtherNonCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#OtherNonCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/OtherNonCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_4144e305-c651-46f9-9c1e-d3628e2a85e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_BusinessCombinationAssumedContingentLiabilityNoncurrent_5bc7da55-364e-4957-be52-bae2f2e95df0" xlink:href="smmt-20231231.xsd#smmt_BusinessCombinationAssumedContingentLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4144e305-c651-46f9-9c1e-d3628e2a85e9" xlink:to="loc_smmt_BusinessCombinationAssumedContingentLiabilityNoncurrent_5bc7da55-364e-4957-be52-bae2f2e95df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss_e9cff8ed-5540-4bf9-a5ee-c9a800187630" xlink:href="smmt-20231231.xsd#smmt_BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4144e305-c651-46f9-9c1e-d3628e2a85e9" xlink:to="loc_smmt_BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss_e9cff8ed-5540-4bf9-a5ee-c9a800187630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_939b159e-a433-4b47-88be-22d0de157460" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_43954884-e1bd-442e-be9c-6c4859a5a287" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_939b159e-a433-4b47-88be-22d0de157460" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_43954884-e1bd-442e-be9c-6c4859a5a287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1ee962e3-ed4f-44cd-9002-58643ad18143" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_43954884-e1bd-442e-be9c-6c4859a5a287" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1ee962e3-ed4f-44cd-9002-58643ad18143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2e1265da-ffaa-4ba0-a8ce-280d7fbcee5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1ee962e3-ed4f-44cd-9002-58643ad18143" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2e1265da-ffaa-4ba0-a8ce-280d7fbcee5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RightsOfferingMember_d8afc25a-1ace-4942-9755-3ca347ca75d7" xlink:href="smmt-20231231.xsd#smmt_RightsOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2e1265da-ffaa-4ba0-a8ce-280d7fbcee5a" xlink:to="loc_smmt_RightsOfferingMember_d8afc25a-1ace-4942-9755-3ca347ca75d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_e78ccbec-2cdf-454a-bb1f-48072fed23d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2e1265da-ffaa-4ba0-a8ce-280d7fbcee5a" xlink:to="loc_us-gaap_PrivatePlacementMember_e78ccbec-2cdf-454a-bb1f-48072fed23d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_S3RegistrationStatementMember_e59f8f39-7987-44dd-8274-a7ad69c953c8" xlink:href="smmt-20231231.xsd#smmt_S3RegistrationStatementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2e1265da-ffaa-4ba0-a8ce-280d7fbcee5a" xlink:to="loc_smmt_S3RegistrationStatementMember_e59f8f39-7987-44dd-8274-a7ad69c953c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_4e6fa613-f2e7-4914-a91b-88a585e4dc7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_43954884-e1bd-442e-be9c-6c4859a5a287" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_4e6fa613-f2e7-4914-a91b-88a585e4dc7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_961bd804-fea4-4494-8c85-a18fea4c0b09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_4e6fa613-f2e7-4914-a91b-88a585e4dc7f" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_961bd804-fea4-4494-8c85-a18fea4c0b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DugganFebruaryNoteMember_f760645d-9678-44cf-b014-b7111f6f421e" xlink:href="smmt-20231231.xsd#smmt_DugganFebruaryNoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_961bd804-fea4-4494-8c85-a18fea4c0b09" xlink:to="loc_smmt_DugganFebruaryNoteMember_f760645d-9678-44cf-b014-b7111f6f421e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ConsultingAgreementMember_5a472057-d03d-47ae-bff3-1ec7f77e0399" xlink:href="smmt-20231231.xsd#smmt_ConsultingAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_961bd804-fea4-4494-8c85-a18fea4c0b09" xlink:to="loc_smmt_ConsultingAgreementMember_5a472057-d03d-47ae-bff3-1ec7f77e0399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fd72ba80-80c4-47aa-8efa-b7da7f65e649" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_43954884-e1bd-442e-be9c-6c4859a5a287" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fd72ba80-80c4-47aa-8efa-b7da7f65e649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_118320a0-12ed-4ce5-a6c4-194237943b23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fd72ba80-80c4-47aa-8efa-b7da7f65e649" xlink:to="loc_us-gaap_RelatedPartyDomain_118320a0-12ed-4ce5-a6c4-194237943b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_7aaf2f79-fe2a-4d9a-ae6b-376805c1a977" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_118320a0-12ed-4ce5-a6c4-194237943b23" xlink:to="loc_srt_ChiefExecutiveOfficerMember_7aaf2f79-fe2a-4d9a-ae6b-376805c1a977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_c61a0659-b0b0-46d0-86e5-a765f3359cca" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_118320a0-12ed-4ce5-a6c4-194237943b23" xlink:to="loc_srt_AffiliatedEntityMember_c61a0659-b0b0-46d0-86e5-a765f3359cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_0a66bfc4-7130-4575-a427-d3f596cc5f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_118320a0-12ed-4ce5-a6c4-194237943b23" xlink:to="loc_us-gaap_RelatedPartyMember_0a66bfc4-7130-4575-a427-d3f596cc5f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ChiefExecutiveOfficerAndPresidentMember_c8f96795-5547-4312-9073-69b898b7527c" xlink:href="smmt-20231231.xsd#smmt_ChiefExecutiveOfficerAndPresidentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_118320a0-12ed-4ce5-a6c4-194237943b23" xlink:to="loc_smmt_ChiefExecutiveOfficerAndPresidentMember_c8f96795-5547-4312-9073-69b898b7527c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefOperatingOfficerMember_f32eb2d9-d7a7-46cc-9af9-f0562f1060c1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefOperatingOfficerMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_118320a0-12ed-4ce5-a6c4-194237943b23" xlink:to="loc_srt_ChiefOperatingOfficerMember_f32eb2d9-d7a7-46cc-9af9-f0562f1060c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0ea4ba14-4e6c-4374-9db5-983d4835ab41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_43954884-e1bd-442e-be9c-6c4859a5a287" xlink:to="loc_us-gaap_AwardTypeAxis_0ea4ba14-4e6c-4374-9db5-983d4835ab41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a24c8c92-a595-4a62-ae6b-dd31e16dd9e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0ea4ba14-4e6c-4374-9db5-983d4835ab41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a24c8c92-a595-4a62-ae6b-dd31e16dd9e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_e630c691-e336-4728-af6f-5fcd44bf73cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a24c8c92-a595-4a62-ae6b-dd31e16dd9e2" xlink:to="loc_us-gaap_WarrantMember_e630c691-e336-4728-af6f-5fcd44bf73cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_fa937aa0-7421-469d-86df-f3498f2f971f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_43954884-e1bd-442e-be9c-6c4859a5a287" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_fa937aa0-7421-469d-86df-f3498f2f971f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0d0772c5-6409-42b6-95a8-d2ce3aa416b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fa937aa0-7421-469d-86df-f3498f2f971f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0d0772c5-6409-42b6-95a8-d2ce3aa416b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2b4ea438-2186-4719-b5f2-4cb3601ee31f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fa937aa0-7421-469d-86df-f3498f2f971f" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2b4ea438-2186-4719-b5f2-4cb3601ee31f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_dbb5a908-12ed-44de-9e58-3b5fe30a970b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fa937aa0-7421-469d-86df-f3498f2f971f" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_dbb5a908-12ed-44de-9e58-3b5fe30a970b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_bb3e9c26-e457-44c9-afdc-0c03abd24808" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fa937aa0-7421-469d-86df-f3498f2f971f" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_bb3e9c26-e457-44c9-afdc-0c03abd24808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_2f58c980-e702-4df9-9b01-3803eb88830d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fa937aa0-7421-469d-86df-f3498f2f971f" xlink:to="loc_us-gaap_StockIssued1_2f58c980-e702-4df9-9b01-3803eb88830d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_fa2cc620-692a-4690-bf0e-bf62dd4fd21e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fa937aa0-7421-469d-86df-f3498f2f971f" xlink:to="loc_us-gaap_NotesPayable_fa2cc620-692a-4690-bf0e-bf62dd4fd21e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CommonStockSharesAuthorizedIncreaseDecrease_78a36b2a-86c3-48f2-88e8-fefa849409cc" xlink:href="smmt-20231231.xsd#smmt_CommonStockSharesAuthorizedIncreaseDecrease"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fa937aa0-7421-469d-86df-f3498f2f971f" xlink:to="loc_smmt_CommonStockSharesAuthorizedIncreaseDecrease_78a36b2a-86c3-48f2-88e8-fefa849409cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_98ab315a-97fc-4ad3-ac3d-e0a408068af7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fa937aa0-7421-469d-86df-f3498f2f971f" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_98ab315a-97fc-4ad3-ac3d-e0a408068af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_53462265-74af-43d7-8259-3d4a8557ff0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fa937aa0-7421-469d-86df-f3498f2f971f" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_53462265-74af-43d7-8259-3d4a8557ff0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_SaleOfStockNumberOfSharesRegisteredForResale_f11a000d-bfa6-4004-bc07-f9e64ce12f1e" xlink:href="smmt-20231231.xsd#smmt_SaleOfStockNumberOfSharesRegisteredForResale"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fa937aa0-7421-469d-86df-f3498f2f971f" xlink:to="loc_smmt_SaleOfStockNumberOfSharesRegisteredForResale_f11a000d-bfa6-4004-bc07-f9e64ce12f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_5a5f38c5-7ccc-456c-be47-8a624a953d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fa937aa0-7421-469d-86df-f3498f2f971f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_5a5f38c5-7ccc-456c-be47-8a624a953d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2b5087fc-8fb6-4f30-8eef-6506d1ef1745" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fa937aa0-7421-469d-86df-f3498f2f971f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2b5087fc-8fb6-4f30-8eef-6506d1ef1745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_72606658-3a02-4c3b-a40f-f89f2183867e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fa937aa0-7421-469d-86df-f3498f2f971f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_72606658-3a02-4c3b-a40f-f89f2183867e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_8e78bb02-0000-445d-9eec-d463e3b0d9e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fa937aa0-7421-469d-86df-f3498f2f971f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_8e78bb02-0000-445d-9eec-d463e3b0d9e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage_381f5c85-04dc-4099-a428-5b9709694fed" xlink:href="smmt-20231231.xsd#smmt_ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fa937aa0-7421-469d-86df-f3498f2f971f" xlink:to="loc_smmt_ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage_381f5c85-04dc-4099-a428-5b9709694fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod_cfea7576-27cc-4788-b114-6a67dc82b125" xlink:href="smmt-20231231.xsd#smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fa937aa0-7421-469d-86df-f3498f2f971f" xlink:to="loc_smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod_cfea7576-27cc-4788-b114-6a67dc82b125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_7d2389ab-69cc-41f6-a204-44b31c91f4f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fa937aa0-7421-469d-86df-f3498f2f971f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_7d2389ab-69cc-41f6-a204-44b31c91f4f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6982b4e6-d99c-42cb-bfa2-17153deb7e51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fa937aa0-7421-469d-86df-f3498f2f971f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6982b4e6-d99c-42cb-bfa2-17153deb7e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/StockholdersEquityWarrantactivityDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#StockholdersEquityWarrantactivityDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/StockholdersEquityWarrantactivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e1a76854-3ff1-45a6-8349-1aaeecde519d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_9ac6e456-af63-4060-b8e7-f7da7d1ed19c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e1a76854-3ff1-45a6-8349-1aaeecde519d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_9ac6e456-af63-4060-b8e7-f7da7d1ed19c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9f9fdb2f-67d7-4d0d-a199-bc00bcbe62da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_9ac6e456-af63-4060-b8e7-f7da7d1ed19c" xlink:to="loc_us-gaap_AwardTypeAxis_9f9fdb2f-67d7-4d0d-a199-bc00bcbe62da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e1e35014-63a8-47f2-ad0e-c7d4fa8f6979" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9f9fdb2f-67d7-4d0d-a199-bc00bcbe62da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e1e35014-63a8-47f2-ad0e-c7d4fa8f6979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_b1871e4e-370a-4cd9-afea-f44408e3b830" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e1e35014-63a8-47f2-ad0e-c7d4fa8f6979" xlink:to="loc_us-gaap_WarrantMember_b1871e4e-370a-4cd9-afea-f44408e3b830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_28d9dc18-7a48-4dbc-9a18-5c2f4fa272dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_9ac6e456-af63-4060-b8e7-f7da7d1ed19c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_28d9dc18-7a48-4dbc-9a18-5c2f4fa272dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ClassOfWarrantOrRightOutstandingRollForward_cd29138e-73fc-4e94-aa16-d6f036ead293" xlink:href="smmt-20231231.xsd#smmt_ClassOfWarrantOrRightOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_28d9dc18-7a48-4dbc-9a18-5c2f4fa272dc" xlink:to="loc_smmt_ClassOfWarrantOrRightOutstandingRollForward_cd29138e-73fc-4e94-aa16-d6f036ead293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_cfe5cbb3-8d41-46f3-9a74-05d8784ca6ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_ClassOfWarrantOrRightOutstandingRollForward_cd29138e-73fc-4e94-aa16-d6f036ead293" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_cfe5cbb3-8d41-46f3-9a74-05d8784ca6ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ClassOfWarrantOrRightExercisesInPeriod_b2e51864-9bbc-425a-8d71-0b2e81d33eba" xlink:href="smmt-20231231.xsd#smmt_ClassOfWarrantOrRightExercisesInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_ClassOfWarrantOrRightOutstandingRollForward_cd29138e-73fc-4e94-aa16-d6f036ead293" xlink:to="loc_smmt_ClassOfWarrantOrRightExercisesInPeriod_b2e51864-9bbc-425a-8d71-0b2e81d33eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7906a9f0-290f-4e14-a6da-5f1bd3ce1f75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_ClassOfWarrantOrRightOutstandingRollForward_cd29138e-73fc-4e94-aa16-d6f036ead293" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7906a9f0-290f-4e14-a6da-5f1bd3ce1f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward_e2e31f70-7ea5-4524-87c8-8c1656997b9b" xlink:href="smmt-20231231.xsd#smmt_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_28d9dc18-7a48-4dbc-9a18-5c2f4fa272dc" xlink:to="loc_smmt_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward_e2e31f70-7ea5-4524-87c8-8c1656997b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ClassOfWarrantOrRightWeightedAverageExercisePrice_daddb55d-5aea-4fdb-a401-6703b2e6f9d3" xlink:href="smmt-20231231.xsd#smmt_ClassOfWarrantOrRightWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward_e2e31f70-7ea5-4524-87c8-8c1656997b9b" xlink:to="loc_smmt_ClassOfWarrantOrRightWeightedAverageExercisePrice_daddb55d-5aea-4fdb-a401-6703b2e6f9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod_106441a5-96db-4610-969f-6b0d78dc124e" xlink:href="smmt-20231231.xsd#smmt_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward_e2e31f70-7ea5-4524-87c8-8c1656997b9b" xlink:to="loc_smmt_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod_106441a5-96db-4610-969f-6b0d78dc124e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ClassOfWarrantOrRightWeightedAverageExercisePrice_2eea5639-411a-457a-8ee1-213160d3fd1d" xlink:href="smmt-20231231.xsd#smmt_ClassOfWarrantOrRightWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward_e2e31f70-7ea5-4524-87c8-8c1656997b9b" xlink:to="loc_smmt_ClassOfWarrantOrRightWeightedAverageExercisePrice_2eea5639-411a-457a-8ee1-213160d3fd1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm_8ec579e1-7dde-49db-bfef-4281d77ddbf4" xlink:href="smmt-20231231.xsd#smmt_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_28d9dc18-7a48-4dbc-9a18-5c2f4fa272dc" xlink:to="loc_smmt_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm_8ec579e1-7dde-49db-bfef-4281d77ddbf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding_c4999fe8-5cf5-4058-8cde-d0f902e006bf" xlink:href="smmt-20231231.xsd#smmt_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_28d9dc18-7a48-4dbc-9a18-5c2f4fa272dc" xlink:to="loc_smmt_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding_c4999fe8-5cf5-4058-8cde-d0f902e006bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ef43c2f3-6a17-4632-ba4f-98ea8d647301" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e2d1276-1fe7-431d-bf6c-3f1e86c8c58e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ef43c2f3-6a17-4632-ba4f-98ea8d647301" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e2d1276-1fe7-431d-bf6c-3f1e86c8c58e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_df6f3f75-6aae-4a75-95ba-c23df08b6552" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e2d1276-1fe7-431d-bf6c-3f1e86c8c58e" xlink:to="loc_us-gaap_PlanNameAxis_df6f3f75-6aae-4a75-95ba-c23df08b6552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_cf2e033d-07c0-4f46-804a-da102cccf644" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_df6f3f75-6aae-4a75-95ba-c23df08b6552" xlink:to="loc_us-gaap_PlanNameDomain_cf2e033d-07c0-4f46-804a-da102cccf644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_A2020StockIncentivePlanMember_6d693beb-76e4-4a88-884e-bae45a667a7f" xlink:href="smmt-20231231.xsd#smmt_A2020StockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_cf2e033d-07c0-4f46-804a-da102cccf644" xlink:to="loc_smmt_A2020StockIncentivePlanMember_6d693beb-76e4-4a88-884e-bae45a667a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3e21baa4-a486-4ec2-bf58-0a0510532d83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e2d1276-1fe7-431d-bf6c-3f1e86c8c58e" xlink:to="loc_us-gaap_AwardTypeAxis_3e21baa4-a486-4ec2-bf58-0a0510532d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9990887-dfc0-4a91-96d8-929ad21d71b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3e21baa4-a486-4ec2-bf58-0a0510532d83" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9990887-dfc0-4a91-96d8-929ad21d71b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_462b4418-8227-421a-ac69-52691705b46c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9990887-dfc0-4a91-96d8-929ad21d71b6" xlink:to="loc_us-gaap_EmployeeStockMember_462b4418-8227-421a-ac69-52691705b46c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_fd3654e8-0202-4483-a867-5a30fc6ed591" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9990887-dfc0-4a91-96d8-929ad21d71b6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_fd3654e8-0202-4483-a867-5a30fc6ed591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_EmployeeStockOptionTimeBasedMember_7a4949a4-408e-43f5-85d9-749b8e4ba8e6" xlink:href="smmt-20231231.xsd#smmt_EmployeeStockOptionTimeBasedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOptionMember_fd3654e8-0202-4483-a867-5a30fc6ed591" xlink:to="loc_smmt_EmployeeStockOptionTimeBasedMember_7a4949a4-408e-43f5-85d9-749b8e4ba8e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_EmployeeStockOptionPerformanceAndMarketBasedMember_dfbb86cf-6d0a-469b-a2c9-8556f6bd9207" xlink:href="smmt-20231231.xsd#smmt_EmployeeStockOptionPerformanceAndMarketBasedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOptionMember_fd3654e8-0202-4483-a867-5a30fc6ed591" xlink:to="loc_smmt_EmployeeStockOptionPerformanceAndMarketBasedMember_dfbb86cf-6d0a-469b-a2c9-8556f6bd9207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_e5ffd55b-3de7-4c8e-b328-9a80ebd5196d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9990887-dfc0-4a91-96d8-929ad21d71b6" xlink:to="loc_us-gaap_WarrantMember_e5ffd55b-3de7-4c8e-b328-9a80ebd5196d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9b2329e4-2b29-471c-a97d-459735fb06c6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e2d1276-1fe7-431d-bf6c-3f1e86c8c58e" xlink:to="loc_srt_RangeAxis_9b2329e4-2b29-471c-a97d-459735fb06c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7a4c4d8c-7062-44c6-a576-056114d493f9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9b2329e4-2b29-471c-a97d-459735fb06c6" xlink:to="loc_srt_RangeMember_7a4c4d8c-7062-44c6-a576-056114d493f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_89d95d61-b34c-40e8-96bf-8de3018f1395" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7a4c4d8c-7062-44c6-a576-056114d493f9" xlink:to="loc_srt_MinimumMember_89d95d61-b34c-40e8-96bf-8de3018f1395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3a2a829b-64ba-41d5-a5a3-af0fe6061821" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7a4c4d8c-7062-44c6-a576-056114d493f9" xlink:to="loc_srt_MaximumMember_3a2a829b-64ba-41d5-a5a3-af0fe6061821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_27f631c9-0722-4baf-a25b-2ba84337d268" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e2d1276-1fe7-431d-bf6c-3f1e86c8c58e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_27f631c9-0722-4baf-a25b-2ba84337d268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_512277a8-d248-4b75-91b6-5dfa0af1933e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_27f631c9-0722-4baf-a25b-2ba84337d268" xlink:to="loc_us-gaap_EquityComponentDomain_512277a8-d248-4b75-91b6-5dfa0af1933e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_90e4429f-fc64-441d-802e-eea197874ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_512277a8-d248-4b75-91b6-5dfa0af1933e" xlink:to="loc_us-gaap_CommonStockMember_90e4429f-fc64-441d-802e-eea197874ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e2d1276-1fe7-431d-bf6c-3f1e86c8c58e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8fab405a-644e-4f6c-8cdc-06db4daa70c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8fab405a-644e-4f6c-8cdc-06db4daa70c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CommonStockAdditionalCapitalSharesAllowableForForFutureIssuanceUponOptionExpiration_3acd5275-1f07-4a4a-9509-954efeac7631" xlink:href="smmt-20231231.xsd#smmt_CommonStockAdditionalCapitalSharesAllowableForForFutureIssuanceUponOptionExpiration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_smmt_CommonStockAdditionalCapitalSharesAllowableForForFutureIssuanceUponOptionExpiration_3acd5275-1f07-4a4a-9509-954efeac7631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPotentialNumberOfAdditionalSharesAllowableUnderThePlan_0dda2462-290d-42ab-93b9-e4c0bebcea70" xlink:href="smmt-20231231.xsd#smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPotentialNumberOfAdditionalSharesAllowableUnderThePlan"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPotentialNumberOfAdditionalSharesAllowableUnderThePlan_0dda2462-290d-42ab-93b9-e4c0bebcea70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_d6320fe6-95a7-4c5b-be33-5e74cc0fc53a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_d6320fe6-95a7-4c5b-be33-5e74cc0fc53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_CommonStockSharesAuthorizedIncreaseDecrease_8be43519-97ff-4517-9823-c516730ae546" xlink:href="smmt-20231231.xsd#smmt_CommonStockSharesAuthorizedIncreaseDecrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_smmt_CommonStockSharesAuthorizedIncreaseDecrease_8be43519-97ff-4517-9823-c516730ae546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_3248d181-9aff-45bb-b862-885be6b2acc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_3248d181-9aff-45bb-b862-885be6b2acc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c7330c90-5168-479b-94ba-d7a1a2e4a82a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c7330c90-5168-479b-94ba-d7a1a2e4a82a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e678d783-5578-47d6-8946-afcb58de23be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e678d783-5578-47d6-8946-afcb58de23be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_b67d0234-5047-478c-addc-ce878ec8232b" xlink:href="smmt-20231231.xsd#smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_b67d0234-5047-478c-addc-ce878ec8232b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod_d05a610a-58dd-4bcd-b73d-5b6d4a295f5e" xlink:href="smmt-20231231.xsd#smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod_d05a610a-58dd-4bcd-b73d-5b6d4a295f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_ceecba1b-1762-4be2-997a-a0de8cd6236e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_ceecba1b-1762-4be2-997a-a0de8cd6236e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_f228afc8-2e74-4501-8c39-3489a09084b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_f228afc8-2e74-4501-8c39-3489a09084b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_f906f012-8f05-45fb-b300-f8ac2e57036a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_f906f012-8f05-45fb-b300-f8ac2e57036a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_98447f15-5f46-4362-af4d-7f32b8b97241" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_98447f15-5f46-4362-af4d-7f32b8b97241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_999cf2e4-76b3-4891-b596-54f21c43dc2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_999cf2e4-76b3-4891-b596-54f21c43dc2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e6bb6f33-15b5-4ee4-9772-85b152a22f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e6bb6f33-15b5-4ee4-9772-85b152a22f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_25445981-0f29-4d3f-95ac-a17e159ba6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_25445981-0f29-4d3f-95ac-a17e159ba6fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_08a160ac-aa6a-4686-9f1a-5324c7d860e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_08a160ac-aa6a-4686-9f1a-5324c7d860e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_115e3dfb-6b17-45be-b584-19a576c6bffd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_115e3dfb-6b17-45be-b584-19a576c6bffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_12f3fc7a-4e02-459b-82e3-67278d683377" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_12f3fc7a-4e02-459b-82e3-67278d683377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_518ed610-2df1-450d-90f0-bca5a8fd055d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_518ed610-2df1-450d-90f0-bca5a8fd055d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_2e1f9ebc-3512-43ce-8c15-8d6084f9d787" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_2e1f9ebc-3512-43ce-8c15-8d6084f9d787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_84975a80-5013-4732-a32a-9c2cf9f61ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b3869-fe01-437e-be46-c285054b48a9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_84975a80-5013-4732-a32a-9c2cf9f61ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/StockBasedCompensationWeightedaverageassumptionsusedforstockoptionawardsDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#StockBasedCompensationWeightedaverageassumptionsusedforstockoptionawardsDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/StockBasedCompensationWeightedaverageassumptionsusedforstockoptionawardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_383b7893-316c-4424-8698-42f966c70def" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4c8a4cb3-7cfa-4457-8ed5-a2fe567c1848" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_383b7893-316c-4424-8698-42f966c70def" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4c8a4cb3-7cfa-4457-8ed5-a2fe567c1848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3794b771-1528-49db-93d3-dc94bff09d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4c8a4cb3-7cfa-4457-8ed5-a2fe567c1848" xlink:to="loc_us-gaap_AwardTypeAxis_3794b771-1528-49db-93d3-dc94bff09d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44d5eb5c-771b-4998-b027-7469e3e163b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3794b771-1528-49db-93d3-dc94bff09d3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44d5eb5c-771b-4998-b027-7469e3e163b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_173d5442-199d-4f63-9d89-02105b872a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44d5eb5c-771b-4998-b027-7469e3e163b7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_173d5442-199d-4f63-9d89-02105b872a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a8b153a-7eff-4ae6-a411-ae16df1aba97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4c8a4cb3-7cfa-4457-8ed5-a2fe567c1848" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a8b153a-7eff-4ae6-a411-ae16df1aba97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_74713bb5-42c0-44e7-a2b8-4285796099db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a8b153a-7eff-4ae6-a411-ae16df1aba97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_74713bb5-42c0-44e7-a2b8-4285796099db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0764554a-9a66-4338-97a1-85f0531b38e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a8b153a-7eff-4ae6-a411-ae16df1aba97" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0764554a-9a66-4338-97a1-85f0531b38e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_55176573-2beb-4525-a14e-531778b445cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a8b153a-7eff-4ae6-a411-ae16df1aba97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_55176573-2beb-4525-a14e-531778b445cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_16d53a87-d37a-4682-9125-7126d6b5978d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a8b153a-7eff-4ae6-a411-ae16df1aba97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_16d53a87-d37a-4682-9125-7126d6b5978d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#StockBasedCompensationStockoptionactivityDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e23d099a-c4b8-42ff-ad8a-7eef49f930e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f7fd239e-de12-4731-aff5-77e97bc68550" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e23d099a-c4b8-42ff-ad8a-7eef49f930e5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f7fd239e-de12-4731-aff5-77e97bc68550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a854f90a-fe7c-4d24-bfdd-d016cb57015e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f7fd239e-de12-4731-aff5-77e97bc68550" xlink:to="loc_us-gaap_AwardTypeAxis_a854f90a-fe7c-4d24-bfdd-d016cb57015e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db12dd6e-d529-4ec6-93ec-ffe8dfbe5100" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a854f90a-fe7c-4d24-bfdd-d016cb57015e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db12dd6e-d529-4ec6-93ec-ffe8dfbe5100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_EmployeeStockOptionTimeBasedMember_aff78e10-f8cd-4fc6-bb43-6a24a2ad80d2" xlink:href="smmt-20231231.xsd#smmt_EmployeeStockOptionTimeBasedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db12dd6e-d529-4ec6-93ec-ffe8dfbe5100" xlink:to="loc_smmt_EmployeeStockOptionTimeBasedMember_aff78e10-f8cd-4fc6-bb43-6a24a2ad80d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_EmployeeStockOptionPerformanceAndMarketBasedMember_7e079d93-0420-49a6-bc4c-727155df92c8" xlink:href="smmt-20231231.xsd#smmt_EmployeeStockOptionPerformanceAndMarketBasedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db12dd6e-d529-4ec6-93ec-ffe8dfbe5100" xlink:to="loc_smmt_EmployeeStockOptionPerformanceAndMarketBasedMember_7e079d93-0420-49a6-bc4c-727155df92c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d1133e95-6c5c-4189-beb0-56303a8830cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f7fd239e-de12-4731-aff5-77e97bc68550" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d1133e95-6c5c-4189-beb0-56303a8830cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2df1ab3e-5d8e-4c36-91fb-1b769c34c6db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d1133e95-6c5c-4189-beb0-56303a8830cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2df1ab3e-5d8e-4c36-91fb-1b769c34c6db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f4bf5d5e-9334-4144-9fb5-25bdd2474fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2df1ab3e-5d8e-4c36-91fb-1b769c34c6db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f4bf5d5e-9334-4144-9fb5-25bdd2474fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c18e230b-e3e9-4719-b51d-2cb86b6ce8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2df1ab3e-5d8e-4c36-91fb-1b769c34c6db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c18e230b-e3e9-4719-b51d-2cb86b6ce8b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_43918df9-b5a5-43aa-a28a-b65d76a804c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2df1ab3e-5d8e-4c36-91fb-1b769c34c6db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_43918df9-b5a5-43aa-a28a-b65d76a804c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ae9b2d9b-f314-4b4a-b871-39d9942f072d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2df1ab3e-5d8e-4c36-91fb-1b769c34c6db" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ae9b2d9b-f314-4b4a-b871-39d9942f072d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_923ee1b5-0dff-4373-92bf-b2f6f74a6622" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2df1ab3e-5d8e-4c36-91fb-1b769c34c6db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_923ee1b5-0dff-4373-92bf-b2f6f74a6622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e2f68ba2-80fc-4dfb-81d2-6ab33b83c1fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d1133e95-6c5c-4189-beb0-56303a8830cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e2f68ba2-80fc-4dfb-81d2-6ab33b83c1fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_31d89632-35a7-44ae-b9db-c1eb8ddd2f20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e2f68ba2-80fc-4dfb-81d2-6ab33b83c1fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_31d89632-35a7-44ae-b9db-c1eb8ddd2f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_14a81e5a-a39d-421e-89bd-39dfaa2ec6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e2f68ba2-80fc-4dfb-81d2-6ab33b83c1fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_14a81e5a-a39d-421e-89bd-39dfaa2ec6e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8ddc1b6b-8342-43f0-8208-4d4ef18619da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e2f68ba2-80fc-4dfb-81d2-6ab33b83c1fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8ddc1b6b-8342-43f0-8208-4d4ef18619da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9fb32f59-1312-4f58-b6e3-1013aa7ccfc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e2f68ba2-80fc-4dfb-81d2-6ab33b83c1fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9fb32f59-1312-4f58-b6e3-1013aa7ccfc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7fa100b0-1126-46d1-8c26-ea8049f705be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e2f68ba2-80fc-4dfb-81d2-6ab33b83c1fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7fa100b0-1126-46d1-8c26-ea8049f705be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4d38d3b0-e5a2-4689-8b5a-3ea7e2784480" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d1133e95-6c5c-4189-beb0-56303a8830cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4d38d3b0-e5a2-4689-8b5a-3ea7e2784480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1b20e69c-39d9-43db-b3e6-60e299232c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4d38d3b0-e5a2-4689-8b5a-3ea7e2784480" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1b20e69c-39d9-43db-b3e6-60e299232c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_fc3dee6c-964b-4012-a08d-e535ce9a2c69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4d38d3b0-e5a2-4689-8b5a-3ea7e2784480" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_fc3dee6c-964b-4012-a08d-e535ce9a2c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1bfd6b2c-1858-4ae2-aa6b-2fbbd2089ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4d38d3b0-e5a2-4689-8b5a-3ea7e2784480" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1bfd6b2c-1858-4ae2-aa6b-2fbbd2089ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_f411e55c-7470-45c9-8285-45fa5641b905" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4d38d3b0-e5a2-4689-8b5a-3ea7e2784480" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_f411e55c-7470-45c9-8285-45fa5641b905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6cebc349-a9e3-4819-aa80-31c12f5fa3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4d38d3b0-e5a2-4689-8b5a-3ea7e2784480" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6cebc349-a9e3-4819-aa80-31c12f5fa3ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_4fb44a63-8e4c-444f-9d1d-00794b5c2b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4d38d3b0-e5a2-4689-8b5a-3ea7e2784480" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_4fb44a63-8e4c-444f-9d1d-00794b5c2b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_32bb224d-f826-44a6-b320-88d4717b4458" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4d38d3b0-e5a2-4689-8b5a-3ea7e2784480" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_32bb224d-f826-44a6-b320-88d4717b4458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_03a7226c-9038-43bc-87f1-5a9ee25dd964" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4d38d3b0-e5a2-4689-8b5a-3ea7e2784480" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_03a7226c-9038-43bc-87f1-5a9ee25dd964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_cb48dd42-adaa-47a6-aa25-87bdad65d6a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4d38d3b0-e5a2-4689-8b5a-3ea7e2784480" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_cb48dd42-adaa-47a6-aa25-87bdad65d6a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6c110218-9443-479e-a832-182bdac28405" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4d38d3b0-e5a2-4689-8b5a-3ea7e2784480" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6c110218-9443-479e-a832-182bdac28405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/StockBasedCompensationSummaryofstockbasedcompensationexpenseDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#StockBasedCompensationSummaryofstockbasedcompensationexpenseDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/StockBasedCompensationSummaryofstockbasedcompensationexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_469f09d9-7f50-4060-87e9-37fee134ca58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1d5581ad-91dd-4d62-b056-94b608352236" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_469f09d9-7f50-4060-87e9-37fee134ca58" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1d5581ad-91dd-4d62-b056-94b608352236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2ff8fd63-50cf-43a5-9079-6980d4a7872f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1d5581ad-91dd-4d62-b056-94b608352236" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2ff8fd63-50cf-43a5-9079-6980d4a7872f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e7960a2f-c6e1-4c11-b25c-24aee8960b53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2ff8fd63-50cf-43a5-9079-6980d4a7872f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e7960a2f-c6e1-4c11-b25c-24aee8960b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a4a9f5df-3c7a-464e-8000-9d11f78f4ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e7960a2f-c6e1-4c11-b25c-24aee8960b53" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a4a9f5df-3c7a-464e-8000-9d11f78f4ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_917cfb0b-7e5b-4e1f-b08a-9c4ce05eda75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e7960a2f-c6e1-4c11-b25c-24aee8960b53" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_917cfb0b-7e5b-4e1f-b08a-9c4ce05eda75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4a88460a-965e-4e99-92c0-0d148c5edf43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1d5581ad-91dd-4d62-b056-94b608352236" xlink:to="loc_us-gaap_AwardTypeAxis_4a88460a-965e-4e99-92c0-0d148c5edf43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac39ccfb-65d4-415f-ae4d-1b21bacc7cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4a88460a-965e-4e99-92c0-0d148c5edf43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac39ccfb-65d4-415f-ae4d-1b21bacc7cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_EmployeeStockOptionTimeBasedMember_6b0efeae-b749-4de4-ab7c-644ec7e4c95b" xlink:href="smmt-20231231.xsd#smmt_EmployeeStockOptionTimeBasedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac39ccfb-65d4-415f-ae4d-1b21bacc7cfb" xlink:to="loc_smmt_EmployeeStockOptionTimeBasedMember_6b0efeae-b749-4de4-ab7c-644ec7e4c95b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_EmployeeStockOptionPerformanceAndMarketBasedMember_455768da-48b2-43a8-93de-ec3a0d728699" xlink:href="smmt-20231231.xsd#smmt_EmployeeStockOptionPerformanceAndMarketBasedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac39ccfb-65d4-415f-ae4d-1b21bacc7cfb" xlink:to="loc_smmt_EmployeeStockOptionPerformanceAndMarketBasedMember_455768da-48b2-43a8-93de-ec3a0d728699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_4858e6d9-8945-4916-99b6-04787cfebce6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac39ccfb-65d4-415f-ae4d-1b21bacc7cfb" xlink:to="loc_us-gaap_EmployeeStockMember_4858e6d9-8945-4916-99b6-04787cfebce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_01d14cc6-dce2-4746-802b-6b199f4c8080" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1d5581ad-91dd-4d62-b056-94b608352236" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_01d14cc6-dce2-4746-802b-6b199f4c8080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d59ec7b6-21f2-460c-a56c-6a8aa3311e76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_01d14cc6-dce2-4746-802b-6b199f4c8080" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d59ec7b6-21f2-460c-a56c-6a8aa3311e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0f00451e-e952-4384-9923-24e52cd7b58b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_b21596f0-c045-4a35-9550-3e1cb2eac81a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0f00451e-e952-4384-9923-24e52cd7b58b" xlink:to="loc_us-gaap_PurchaseObligation_b21596f0-c045-4a35-9550-3e1cb2eac81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_6436127b-c169-47fd-a3c6-74c11b5fca80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0f00451e-e952-4384-9923-24e52cd7b58b" xlink:to="loc_us-gaap_OtherCommitment_6436127b-c169-47fd-a3c6-74c11b5fca80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid_fcfe11e3-9380-4a60-8121-5b18427ad39f" xlink:href="smmt-20231231.xsd#smmt_OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0f00451e-e952-4384-9923-24e52cd7b58b" xlink:to="loc_smmt_OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid_fcfe11e3-9380-4a60-8121-5b18427ad39f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_95bee6b9-8e99-48b1-9899-60338ae7e090" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0f00451e-e952-4384-9923-24e52cd7b58b" xlink:to="loc_us-gaap_OtherCommitmentsTable_95bee6b9-8e99-48b1-9899-60338ae7e090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_31650083-8dc8-4b18-955a-49f73edcd09c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_95bee6b9-8e99-48b1-9899-60338ae7e090" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_31650083-8dc8-4b18-955a-49f73edcd09c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e8e58204-1335-4117-892d-c64995c5bc22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_31650083-8dc8-4b18-955a-49f73edcd09c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e8e58204-1335-4117-892d-c64995c5bc22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_456a6970-f14d-4056-bb21-c6f07eb701f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e8e58204-1335-4117-892d-c64995c5bc22" xlink:to="loc_us-gaap_SubsequentEventMember_456a6970-f14d-4056-bb21-c6f07eb701f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_ead41b94-2383-4726-93af-faabdd966bda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_95bee6b9-8e99-48b1-9899-60338ae7e090" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_ead41b94-2383-4726-93af-faabdd966bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_OtherCommitmentIncreaseDecrease_09c49096-761e-4b31-a5ee-0851f95c2e10" xlink:href="smmt-20231231.xsd#smmt_OtherCommitmentIncreaseDecrease"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_ead41b94-2383-4726-93af-faabdd966bda" xlink:to="loc_smmt_OtherCommitmentIncreaseDecrease_09c49096-761e-4b31-a5ee-0851f95c2e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.summitplc.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="smmt-20231231.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.summitplc.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_3ffb0dbe-3b37-46df-9425-7e8f15275bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_df3c1b12-ac70-4a3d-b6b5-f22c8b86eb95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_3ffb0dbe-3b37-46df-9425-7e8f15275bf7" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_df3c1b12-ac70-4a3d-b6b5-f22c8b86eb95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b48accee-f415-4c83-8cc2-97cacaa41db2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_df3c1b12-ac70-4a3d-b6b5-f22c8b86eb95" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b48accee-f415-4c83-8cc2-97cacaa41db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9209b7dd-9938-423d-856a-128514d24afb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b48accee-f415-4c83-8cc2-97cacaa41db2" xlink:to="loc_us-gaap_RelatedPartyDomain_9209b7dd-9938-423d-856a-128514d24afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_17f65313-1e20-47b3-9059-9743ce582c85" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_9209b7dd-9938-423d-856a-128514d24afb" xlink:to="loc_srt_AffiliatedEntityMember_17f65313-1e20-47b3-9059-9743ce582c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember_9a62a25f-cd61-46d1-9803-98b0ac97baf9" xlink:href="smmt-20231231.xsd#smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_9209b7dd-9938-423d-856a-128514d24afb" xlink:to="loc_smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember_9a62a25f-cd61-46d1-9803-98b0ac97baf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_13432840-b35c-4ea5-a0d3-5d74b133ec13" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember_9a62a25f-cd61-46d1-9803-98b0ac97baf9" xlink:to="loc_srt_ChiefExecutiveOfficerMember_13432840-b35c-4ea5-a0d3-5d74b133ec13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ChiefExecutiveOfficerAndPresidentMember_15eefcdc-d064-4014-990d-2e2c245135d3" xlink:href="smmt-20231231.xsd#smmt_ChiefExecutiveOfficerAndPresidentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember_9a62a25f-cd61-46d1-9803-98b0ac97baf9" xlink:to="loc_smmt_ChiefExecutiveOfficerAndPresidentMember_15eefcdc-d064-4014-990d-2e2c245135d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_1d4db5d8-8d41-4d66-92f9-98f386e893d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_9209b7dd-9938-423d-856a-128514d24afb" xlink:to="loc_us-gaap_RelatedPartyMember_1d4db5d8-8d41-4d66-92f9-98f386e893d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefOperatingOfficerMember_6136fc50-1681-4e2e-93b5-6601ffb0fb3b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefOperatingOfficerMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_9209b7dd-9938-423d-856a-128514d24afb" xlink:to="loc_srt_ChiefOperatingOfficerMember_6136fc50-1681-4e2e-93b5-6601ffb0fb3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_7daf2a65-9f80-43e3-a434-0a71ad8534a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_df3c1b12-ac70-4a3d-b6b5-f22c8b86eb95" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_7daf2a65-9f80-43e3-a434-0a71ad8534a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_690c6c99-4584-4919-bba1-aa7d4a937261" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_7daf2a65-9f80-43e3-a434-0a71ad8534a9" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_690c6c99-4584-4919-bba1-aa7d4a937261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_SubleaseAgreementFirstAmendmentMember_0de0411e-a819-4dec-b4ce-1a4726dd9e32" xlink:href="smmt-20231231.xsd#smmt_SubleaseAgreementFirstAmendmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_690c6c99-4584-4919-bba1-aa7d4a937261" xlink:to="loc_smmt_SubleaseAgreementFirstAmendmentMember_0de0411e-a819-4dec-b4ce-1a4726dd9e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_SubleaseAgreementSecondAmendmentMember_90ce7007-e735-46cf-b132-4bc28888755e" xlink:href="smmt-20231231.xsd#smmt_SubleaseAgreementSecondAmendmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_690c6c99-4584-4919-bba1-aa7d4a937261" xlink:to="loc_smmt_SubleaseAgreementSecondAmendmentMember_90ce7007-e735-46cf-b132-4bc28888755e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_March2022NoteMember_77777c0e-6f90-4183-9e5c-a9e4ae2b217b" xlink:href="smmt-20231231.xsd#smmt_March2022NoteMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_690c6c99-4584-4919-bba1-aa7d4a937261" xlink:to="loc_smmt_March2022NoteMember_77777c0e-6f90-4183-9e5c-a9e4ae2b217b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotePurchaseAgreementMember_dd7264b7-3c30-4bbe-843f-63df12b206e0" xlink:href="smmt-20231231.xsd#smmt_NotePurchaseAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_690c6c99-4584-4919-bba1-aa7d4a937261" xlink:to="loc_smmt_NotePurchaseAgreementMember_dd7264b7-3c30-4bbe-843f-63df12b206e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DugganPromissoryNotesMember_0dcde12d-e45a-4c2d-81cd-45d71464eed9" xlink:href="smmt-20231231.xsd#smmt_DugganPromissoryNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_NotePurchaseAgreementMember_dd7264b7-3c30-4bbe-843f-63df12b206e0" xlink:to="loc_smmt_DugganPromissoryNotesMember_0dcde12d-e45a-4c2d-81cd-45d71464eed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DugganFebruaryNoteMember_0549dc3c-e80e-4073-808c-7cd2d785f77c" xlink:href="smmt-20231231.xsd#smmt_DugganFebruaryNoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_DugganPromissoryNotesMember_0dcde12d-e45a-4c2d-81cd-45d71464eed9" xlink:to="loc_smmt_DugganFebruaryNoteMember_0549dc3c-e80e-4073-808c-7cd2d785f77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DugganSeptemberNoteMember_543430df-bb12-48ce-9d91-d059615557df" xlink:href="smmt-20231231.xsd#smmt_DugganSeptemberNoteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_DugganPromissoryNotesMember_0dcde12d-e45a-4c2d-81cd-45d71464eed9" xlink:to="loc_smmt_DugganSeptemberNoteMember_543430df-bb12-48ce-9d91-d059615557df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ZanganehNoteMember_103752b0-ac9f-44ca-a9d8-89fa4542c578" xlink:href="smmt-20231231.xsd#smmt_ZanganehNoteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_NotePurchaseAgreementMember_dd7264b7-3c30-4bbe-843f-63df12b206e0" xlink:to="loc_smmt_ZanganehNoteMember_103752b0-ac9f-44ca-a9d8-89fa4542c578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_DugganFebruaryNoteAndZanganehNoteMember_5ce47ea2-d90f-41a8-850a-7a59670e236a" xlink:href="smmt-20231231.xsd#smmt_DugganFebruaryNoteAndZanganehNoteMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_NotePurchaseAgreementMember_dd7264b7-3c30-4bbe-843f-63df12b206e0" xlink:to="loc_smmt_DugganFebruaryNoteAndZanganehNoteMember_5ce47ea2-d90f-41a8-850a-7a59670e236a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_AkesoSupplyAgreementMember_22fdb237-aec8-4416-bd91-ac5dc71add16" xlink:href="smmt-20231231.xsd#smmt_AkesoSupplyAgreementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_690c6c99-4584-4919-bba1-aa7d4a937261" xlink:to="loc_smmt_AkesoSupplyAgreementMember_22fdb237-aec8-4416-bd91-ac5dc71add16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ConsultingAgreementMember_8100e7a8-360d-4f82-b3ba-9475d6e42506" xlink:href="smmt-20231231.xsd#smmt_ConsultingAgreementMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_690c6c99-4584-4919-bba1-aa7d4a937261" xlink:to="loc_smmt_ConsultingAgreementMember_8100e7a8-360d-4f82-b3ba-9475d6e42506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_94376cc6-fff5-4b83-9c88-235ad9c356d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_df3c1b12-ac70-4a3d-b6b5-f22c8b86eb95" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_94376cc6-fff5-4b83-9c88-235ad9c356d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cc80f537-9b82-466a-8124-bcc6f79e3f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_94376cc6-fff5-4b83-9c88-235ad9c356d1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cc80f537-9b82-466a-8124-bcc6f79e3f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RightsOfferingMember_c89bb943-068b-41b3-b9c4-c031cabff0e4" xlink:href="smmt-20231231.xsd#smmt_RightsOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cc80f537-9b82-466a-8124-bcc6f79e3f4e" xlink:to="loc_smmt_RightsOfferingMember_c89bb943-068b-41b3-b9c4-c031cabff0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_S3RegistrationStatementMember_6a53c69b-669d-4e6d-ad4d-9a6dd0879c3c" xlink:href="smmt-20231231.xsd#smmt_S3RegistrationStatementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cc80f537-9b82-466a-8124-bcc6f79e3f4e" xlink:to="loc_smmt_S3RegistrationStatementMember_6a53c69b-669d-4e6d-ad4d-9a6dd0879c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_c338c7ed-598e-4235-87d4-faaff4c6578d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cc80f537-9b82-466a-8124-bcc6f79e3f4e" xlink:to="loc_us-gaap_PrivatePlacementMember_c338c7ed-598e-4235-87d4-faaff4c6578d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_a963ea3b-55ba-4e05-8173-4022f6a31b33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_df3c1b12-ac70-4a3d-b6b5-f22c8b86eb95" xlink:to="loc_us-gaap_VariableRateAxis_a963ea3b-55ba-4e05-8173-4022f6a31b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_3698f3e8-1109-4cc1-ae62-245d4b45a148" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_a963ea3b-55ba-4e05-8173-4022f6a31b33" xlink:to="loc_us-gaap_VariableRateDomain_3698f3e8-1109-4cc1-ae62-245d4b45a148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_60e7d09d-3c5d-49ff-b1db-c33b2149d402" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_3698f3e8-1109-4cc1-ae62-245d4b45a148" xlink:to="loc_us-gaap_PrimeRateMember_60e7d09d-3c5d-49ff-b1db-c33b2149d402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_VariableRatePeriodAxis_0de8c107-1c6b-4e5d-a999-65470d2f99b4" xlink:href="smmt-20231231.xsd#smmt_VariableRatePeriodAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_df3c1b12-ac70-4a3d-b6b5-f22c8b86eb95" xlink:to="loc_smmt_VariableRatePeriodAxis_0de8c107-1c6b-4e5d-a999-65470d2f99b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_VariableRatePeriodDomain_e8d89ab3-bcf8-4815-b1e4-ff01f9decf3b" xlink:href="smmt-20231231.xsd#smmt_VariableRatePeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_VariableRatePeriodAxis_0de8c107-1c6b-4e5d-a999-65470d2f99b4" xlink:to="loc_smmt_VariableRatePeriodDomain_e8d89ab3-bcf8-4815-b1e4-ff01f9decf3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_VariableRatePeriodOneMember_987ff005-237d-4541-8c9f-4ad792085cde" xlink:href="smmt-20231231.xsd#smmt_VariableRatePeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_VariableRatePeriodDomain_e8d89ab3-bcf8-4815-b1e4-ff01f9decf3b" xlink:to="loc_smmt_VariableRatePeriodOneMember_987ff005-237d-4541-8c9f-4ad792085cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_VariableRatePeriodTwoMember_55d88c52-7830-4446-ae80-d478f86fa879" xlink:href="smmt-20231231.xsd#smmt_VariableRatePeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_smmt_VariableRatePeriodDomain_e8d89ab3-bcf8-4815-b1e4-ff01f9decf3b" xlink:to="loc_smmt_VariableRatePeriodTwoMember_55d88c52-7830-4446-ae80-d478f86fa879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a5056223-16a7-4418-b9ea-879ac8f40d64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_df3c1b12-ac70-4a3d-b6b5-f22c8b86eb95" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a5056223-16a7-4418-b9ea-879ac8f40d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_35dfe010-0b3b-47b5-8ae1-04ef545a9179" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a5056223-16a7-4418-b9ea-879ac8f40d64" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_35dfe010-0b3b-47b5-8ae1-04ef545a9179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_6abd89c1-b639-41fe-a3d5-0f8f8305c1e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_35dfe010-0b3b-47b5-8ae1-04ef545a9179" xlink:to="loc_us-gaap_SubsequentEventMember_6abd89c1-b639-41fe-a3d5-0f8f8305c1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_df3c1b12-ac70-4a3d-b6b5-f22c8b86eb95" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RelatedPartyTransactionSubleaseExtensionTerm_7835b2d2-426e-4cf9-97ab-b28c01d0bd0e" xlink:href="smmt-20231231.xsd#smmt_RelatedPartyTransactionSubleaseExtensionTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_smmt_RelatedPartyTransactionSubleaseExtensionTerm_7835b2d2-426e-4cf9-97ab-b28c01d0bd0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_RelatedPartyTransactionPaymentsToRelatedParty_fe0da8f1-739e-400d-b505-fcd291cb5095" xlink:href="smmt-20231231.xsd#smmt_RelatedPartyTransactionPaymentsToRelatedParty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_smmt_RelatedPartyTransactionPaymentsToRelatedParty_fe0da8f1-739e-400d-b505-fcd291cb5095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_AreaOfPremisesSubleased_db661fd4-b9ed-4ac1-bece-dc127691d5af" xlink:href="smmt-20231231.xsd#smmt_AreaOfPremisesSubleased"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_smmt_AreaOfPremisesSubleased_db661fd4-b9ed-4ac1-bece-dc127691d5af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_9a87840c-13ca-4045-aa8a-399731405353" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_9a87840c-13ca-4045-aa8a-399731405353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_640a03b2-53e9-4e5a-94e0-ee62a69254ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_us-gaap_NotesPayable_640a03b2-53e9-4e5a-94e0-ee62a69254ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionRate_5b36bf23-857f-43c5-b0d5-09973a918bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_us-gaap_RelatedPartyTransactionRate_5b36bf23-857f-43c5-b0d5-09973a918bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold_2a6f3ad6-a0b3-44ba-8936-94bf2a98c8b4" xlink:href="smmt-20231231.xsd#smmt_NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_smmt_NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold_2a6f3ad6-a0b3-44ba-8936-94bf2a98c8b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartiesMaximumTerm_a331cebc-3339-4790-bd72-37a347c01dc9" xlink:href="smmt-20231231.xsd#smmt_NotesPayableRelatedPartiesMaximumTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_smmt_NotesPayableRelatedPartiesMaximumTerm_a331cebc-3339-4790-bd72-37a347c01dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2080ef88-a18f-4ab6-8993-7a6d4586795a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2080ef88-a18f-4ab6-8993-7a6d4586795a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_587f4cee-b4ec-418e-8c0b-712bf0c9c4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_587f4cee-b4ec-418e-8c0b-712bf0c9c4dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_ade22345-c7b0-44aa-8224-25c48870178a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_ade22345-c7b0-44aa-8224-25c48870178a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_6d5c4a5e-fe77-4c23-a777-ea676fdf0da0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_6d5c4a5e-fe77-4c23-a777-ea676fdf0da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartiesPotentialPrepaymentPeriodPostReceiptOfCashProceedsFromPublicOffering_0f076aec-0605-4a26-b0fa-6e62051e8aa2" xlink:href="smmt-20231231.xsd#smmt_NotesPayableRelatedPartiesPotentialPrepaymentPeriodPostReceiptOfCashProceedsFromPublicOffering"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_smmt_NotesPayableRelatedPartiesPotentialPrepaymentPeriodPostReceiptOfCashProceedsFromPublicOffering_0f076aec-0605-4a26-b0fa-6e62051e8aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartiesPotentialPrepaymentMaximumAmountPercentageOfNetProceedsFromPublicOffering_d575af5f-8c24-41e6-ad4f-3f6a304f8cd4" xlink:href="smmt-20231231.xsd#smmt_NotesPayableRelatedPartiesPotentialPrepaymentMaximumAmountPercentageOfNetProceedsFromPublicOffering"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_smmt_NotesPayableRelatedPartiesPotentialPrepaymentMaximumAmountPercentageOfNetProceedsFromPublicOffering_d575af5f-8c24-41e6-ad4f-3f6a304f8cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartiesNewIssuances_0169f7a6-7c03-4c40-8dd5-b427ce8f7ce8" xlink:href="smmt-20231231.xsd#smmt_NotesPayableRelatedPartiesNewIssuances"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_smmt_NotesPayableRelatedPartiesNewIssuances_0169f7a6-7c03-4c40-8dd5-b427ce8f7ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_e1f3dc22-6304-41ea-aef5-0b798d434a20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_e1f3dc22-6304-41ea-aef5-0b798d434a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_4bc0c8ff-5c4a-4e3b-ba3b-abb45f250e10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_4bc0c8ff-5c4a-4e3b-ba3b-abb45f250e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominator_05bce360-2346-42ae-8306-e4b988744e71" xlink:href="smmt-20231231.xsd#smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominator"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominator_05bce360-2346-42ae-8306-e4b988744e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominatorBaseAmountAddedToClosingBidPrice_5d280ce2-fbef-4ed0-b2a2-202b2ce9a50d" xlink:href="smmt-20231231.xsd#smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominatorBaseAmountAddedToClosingBidPrice"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominatorBaseAmountAddedToClosingBidPrice_5d280ce2-fbef-4ed0-b2a2-202b2ce9a50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_StockIssuedDuringPeriodSharesRelatedPartyPrepaidInterest_03ef791a-90cb-4c40-8e05-9f3a7e7cf7bb" xlink:href="smmt-20231231.xsd#smmt_StockIssuedDuringPeriodSharesRelatedPartyPrepaidInterest"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_smmt_StockIssuedDuringPeriodSharesRelatedPartyPrepaidInterest_03ef791a-90cb-4c40-8e05-9f3a7e7cf7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_49341ac2-d338-46c9-8dd7-f565e55e626e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_49341ac2-d338-46c9-8dd7-f565e55e626e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_a1ac554e-e85f-4e79-9e21-2cc13a513564" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_us-gaap_InterestPaidNet_a1ac554e-e85f-4e79-9e21-2cc13a513564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_505f0fa6-5688-4b63-8b7b-aa8c1a339d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_505f0fa6-5688-4b63-8b7b-aa8c1a339d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_dab99564-dcdf-465b-9752-1b646197848e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_us-gaap_StockIssued1_dab99564-dcdf-465b-9752-1b646197848e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_SaleOfStockNumberOfSharesRegisteredForResale_2defc91e-d94f-438a-992b-2aa7ba12416a" xlink:href="smmt-20231231.xsd#smmt_SaleOfStockNumberOfSharesRegisteredForResale"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_smmt_SaleOfStockNumberOfSharesRegisteredForResale_2defc91e-d94f-438a-992b-2aa7ba12416a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_c14e4f9b-bf78-4bd8-9348-bd20d93d7fef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_c14e4f9b-bf78-4bd8-9348-bd20d93d7fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_smmt_ClassOfWarrantOrRightExercisesInPeriod_70bb7f45-b6d0-4d95-9f6b-3ee930ba3607" xlink:href="smmt-20231231.xsd#smmt_ClassOfWarrantOrRightExercisesInPeriod"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_fdc287c9-ba12-441d-8116-b7386a996b05" xlink:to="loc_smmt_ClassOfWarrantOrRightExercisesInPeriod_70bb7f45-b6d0-4d95-9f6b-3ee930ba3607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>smmt-20231231_g1.jpg
<TEXT>
begin 644 smmt-20231231_g1.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_X2A@17AI9@  34T *@    @ !@ +  (
M   F   (8@$2  ,    !  $   $Q  (    F   (B $R  (    4   (KH=I
M  0    !   (PNH<  <   @,    5@  $48<Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                     %=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P
M,3$N,38S.#0 5VEN9&]W<R!0:&]T;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X
M-  R,#(S.C S.C Q(#$Q.C4V.C,X   &D ,  @   !0  !$<D 0  @   !0
M !$PDI$  @    ,P,   DI(  @    ,P,   H $  P    $  0  ZAP !P
M" P   D0     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M,C R,SHP,SHP,2 Q,3HU-#HU-  R,#(S.C S.C Q(#$Q.C4T.C4T      8!
M P #     0 &   !&@ %     0  $90!&P %     0  $9P!*  #     0 "
M   " 0 $     0  $:0" @ $     0  %K,         8     $   !@
M ?_8_]L 0P (!@8'!@4(!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N
M)R B+",<'"@W*2PP,30T-!\G.3TX,CPN,S0R_]L 0P$)"0D,"PP8#0T8,B$<
M(3(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R_\  $0@ RP$  P$A  (1 0,1 ?_$ !\   $% 0$! 0$!
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M]/7V]_CY^O_:  P# 0 "$0,1 #\ ]_HH ** "B@ HH ** "B@ HH ** "B@
MHH ** "B@ HH ** "B@ HH ** "L#Q7K5UH-G:WMO!Y\0G"W$>.3'@]#V.<5
M<(J4DF5%7=C4TW4[35[&.\LIA+"XX(Z@^A'8CTJW4M-.S$U9V"BD(** "B@
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M=_6@".^O8M/LI+N?=Y<8!;:,GKC^M<]-XDL-0NM/,'F_N;CS'W)CC8Z_S84
M='#=1SNRIG*@$Y'K575=9M-'2)KKS,2DA=BYZ4 4K#7;.]U&62+S-KQ(@W+C
MD%R?_0A6S!,EQ%YB9VDD<CTH <Z+(I5AD&H8[54;U4=* +%% !10 44 %% !
M10 44 %% !10 44 %% !10 44 8WBO\ Y%B]_P!U?_0A7G^D_P"O7ZT >C:9
M_P ?$W^XG]:P?'__ ![6/_71OY"@#+\-_P#'RE=SI?\ QXK_ +S?S- %RB@
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M%!04%!3_P  1" 4?!G # 2(  A$! Q$!_\0 'P   04! 0$! 0$
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI/2
MDH =124M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%(:2@!U%-I10 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% $<S[!G. !DU\[? O]M3PG\:?&NH^%S:W'AW4XVSI\.H.NZ]0*
M-X&#@.K;OEYRN""?F ^BI.4/TK\0O$&FW.E:X][92R6MW;S^;%-"VUT8-D,"
M.00<<U[F6X*&-52,MUL>AA:$:ZDGN?M[&<YYS3Z^2OV.OVPH?BM:P>$?%MQ'
M:^,[=-L,[85-251R5_Z: <LHZX)'<#ZR4]>2:\O$4)X:HZ=1:G)4IRI2Y9#Z
M*:/O&G5SF04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME8_>Z'YN3]K1N6S_ (YKX'$X:>%G[.:/G*M*5&7+(EHI!2URF(4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% #9/NGZ&OQ4_M+;J$_/\ &W\Z_:J3[I^AK\+Y-0_X
MF5QS_P M&_F:^LR&-_:_+]3VLN5^;Y'I.E:Q]WFNSTO6/N_-7CNGZEM*\UU>
MEZQ]WFOHZE,].43VK2=:Y7YOUKN-'UO;MPU>'Z7K'W?FKL])UK;M^;]:\JI3
M..<#WO0?$'W<O@_6M^^T^VUZU) 42^GK7CFCZW@K\WZUWFA>("-OS8_&O*J4
MW%W1Q2@UJCB/&O@7#2$1X/..*\;\1>'6A9E9*^Q9K>VU^V(8*)2.OK7EGC7P
M)]_$?Z5U8?$6=F;TJMMSY/UK1/O?+SV_S^?ZU]*?LG_M9/X+FM?!7C>\/]B,
M1'I^JS-G[)V$<C?\\_1C]W(SQR/,?$7AE[=W5H^*\_UG0QAOE^M>K4A#&4W"
MIJ=LXQK0Y9'["PR"10RD,K#((J2O@?\ 9._:NF\%R6O@GQM>,^B$B+3]4F/-
MGZ12$_\ +// )Y3('W<%?O.&198PZ.'1N59>00??O7P^*PL\+/EE\CYZM1E1
ME9DM%(.IYI:XS **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *2@]*Q_%7BG3/!>@W>LZQ>1V.GVD9DEFE.  .P]2>@ Y--)R=D
M-)MV1F?$SXE:%\*/"EUX@\0W@M;*W&%48,DTA!*QQK_$QP>/8DX )'Y:_&#X
MH:M\?/B!+XCU*!;.!%$%E9(<B"$$D G^)CG);N3Q@  7?C5\8M=^/GC1]1U&
M8II%L[)IUA$3Y4,>?O8[NV!ECZ#IC%96AZ'M"_+^E?<8# K!Q]I/XG^!]!AL
M/&@N=_$.T/1?N_+^E>E^$_";W4D9*<4>$_"C74D>4.*]W\%^#$AB1W3:JCDT
M\1B.56N.M42'>"_!L<$:/(H50,DUTVJ:M%9V_E1':@&*75-4BL;?R80%0#\Z
M\^US7-V[YJ\91=5WD>?9S=PUS7"Q?YJX+6-9Y;YJ76=9^]\U<-JVL?>YKU*5
M$[80#5M7SN^:N*U;5_F;FC5M8^]\U<=J6IEF;FO7ITSMA$-2U(L6YK]!/^"=
M_B2[UKX-ZE:7#JT&FZI)!;A4 (5D20Y]?F<U^:NH:AUYK]"_^"9,WG?"3Q21
M_P!!UO\ TGAKASB%L(WV:.?'1_<,^R**0=Z6O@3YL**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M26:5@J(H&223T %&K=D&^B*GBOQ3I?@O0;S6=9O8]/TVSC,LUQ*>% [>Y)P
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !124ULXX- "2,5P1R._-?(/[6G[4D6GP7W@3PG/'<7DR
M-;ZE? ;DB4\-"OJQ&0WH,CKTW?VP/VC&\&Z8?!_A;4MGB2ZP+Z6$;FLX&4G
M;/R2-E<<$A3G@E37Q+I&DF9_,;+LQRS'DD_YQ7TF6X%2_?UEIT/5PN'_ .7D
MQ-&T8[E)'(XY_P _Y_6O2?"_A5[N5/D^6CPMX5:ZDC'E_+]*]W\$^"UA1&9<
M*.237KXC$**W.ZK5LA?!/@M8E1F3:JC)-=AJ6I1:?;^3%PH%&I:E%I]OY,.
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M;R;K6RD!5]5<'](0>"?XB"!W-?J]I]E;Z?9PVMK#';VT"+''#$H5$4# 4 =
M!7Q^:Y@G%T*?S/#QF)5O9Q+*\TZH;BXCM87EE=8HD!9G8X  [DUYZW[0G@19
MGB_MO<RG:2EK,PR/<)BOE8PE/X5<\=1;V/2**\_B^.G@N;[FK,?^W6;_ .(J
M[%\7O"LV-FI,?^W:7_XFJ]E-;H.5G9T5RT7Q*\/S?=O6/_;"3_XFKD?C72).
M5NF/_;%_\*GEEV%9F[17/R>.M&ASNNR/^V3_ .%5)/B?X<B^]?D?]L)#_P"R
MT<DNP69U=%<5)\8?"D?WM3(_[=Y?_B:KR?&_P;'DMJS#_MVE_P#B:KV4^P^5
MG>T5REO\4O",\*2CQ'IL:L,A9KI$8?56((_$4YOBEX.7[WBG1Q_V_1__ !5+
MV<^P<K['4T5R+?%KP4O7Q;HH^NH1?_%5&WQB\"K][QCH8^NHQ?\ Q5'LZG\K
M#EEV.RHKB3\:_ "?>\:Z /KJ4/\ \53?^%X?#S_H=_#_ /X,X?\ XJG[&I_*
M_N#EEV.XHKA6^.'P]XQXX\/_ /@SA_\ BJW?#'C;P_XR6X.@ZW8:R+?:)FL;
ME)A'NSM#%2<9P?RJ90G%7:8<K6K1NT4E+4$A1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "$9KE?B1\2-(^
M%N@)K.MFX6Q:=;<M;PF0JS!B"0.WRXS[BNJJO?6<%_;O;W,,=Q!(,-'*@96^
MH/6FFD[RV&O,\-'[:OPSY_TZ^QTS]D;_ !JIJW[<'P\L=/DFM&U"_G7&VW6#
M86Y&>2<<#)_"O#OVH?V79? MQ<>*?"]NTGAZ1MUS:(,FR8]QZQG\QD=J^9OT
M(]Z^JP^7X3$14X-_>>A&C3FKH^ZX_P!OGPO)C_BGM37ZR1_XTM]^W1HSV,C:
M?X?NVNAC:MQ*JIU&<D9[9KX35BO(J_:WA4CG!KK_ ++PJU29?U>!]FP?MMWL
MG7PU /I<-_A5BY_;$U*ZM76UT6WM9SC;(\I<#D9XX[9KY$L[SIS6[9WQ7!!P
M:CZA0C]D7L8KH?2EO^U-XKEQF+3S[B%O\:N2?M'>*+ZW:,&UMV8<211$,.?<
MD5\\V=Y]WFMNSO.G-8RPM%?9)]G'L>T6_P :/%4GWM68_P#;-/\ "M.+XL>(
M+R,QRZE)ANZ@*?S %>/6MZ>.:VK*\QCFL)4(+9$.*/6M/\9:D^-VH7!^LI/]
M:WX?$5U=Q;'NYCD?WS_C7DMCJ)&.?UKIM.U3[O-<LJ2[&;B;6HZ>S%F^]GO7
M+:EIO!R*[2TO$N$"N15?4--# E>12BU%["1Y3J6FMSUKE=2TTX/4#^M>KZEI
M?7Y:Y?4=+QD[:[Z<S:,AWP?^,%Y\,]16RO?,N= F;+Q=3"3_ !I_4=Z^P=+U
M*UUFP@O;*=+FUF0/'*AR&!KX2U+2QSA?IQ77_!_XN7GPSU);*[,ESH$S8EB[
MPM_?3^H[\>V.3%8555[2&Y%2GS*Z/=/C[^S9X*_:'\/M8^)M.7^T8H7CL=6@
M^6YM&;!RI_B&0#M;(//UK\9_CQ\"?$_[/'CJ?PWXDM\H<R6>H0J?(OH<G#QG
M'TRN<J00<\$_O%I>IVFM6$%[93I<VLZAXY$.0P-<)\=?@3X5^/\ X(F\->*+
M,R1$[[:]@PMQ:2XXDC8@X/8@@@C@BN? YA/!RY)_"]_(>'Q$J,K/8_!>.3L>
MM6%DKU_]J+]EGQ%^S/XR-G=^9J7AJ\8MIFL*G$J_W) /NR+QD'@\$>WB\<G3
MZ5][1KQJ14X/0^DIU%-7B:$<E7K:Z,;#'2LE)*L))7H1D="9U5AJ'3FNDT_4
M.G->>6]P8V!!XK<L=0/'-$HW!JYZ5IVJ%6'-==I.L<CFO*;#43QS72:=J17'
M-<%2F<\HGLFDZQG;\WZUVFD:U]WYOUKQ32M8(9>:[+2M8/R\BO.J4T<LH'N6
MC:Y@K\WZUWVA^(!P"V1WYKP/1]:.Y?FKM]'ULC;S7DU:)Q3IGJNM:';ZW:F2
M( OCE:\6\:>!C&78(1M.>GZ5ZGH/B#[N6Y^M=;9^#U\=,$B4(?XWQP!ZUR0J
MN@_>>ABINGN?)OA+X+ZQ\2O$T6D:;!MYW37+@^7 G0LQ_'IWZ5]_?"GX8Z3\
M)?!]MX?T@.T49,LTTARTTI #.?3.!P.@ K2\&^"]-\$Z9]CTZ!8PWS228&^1
MO4G\_P ZW\#TKSL9C)XGW?LHY:]=U=.B!:6BBO-.4**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#,\RY;T:3UZOL>+B\4E[D'J&GV-OIUG#:VL$=O;0(L<4,*!4C51A551T &
M.F*G/R\X_*A\XXX..U?-WQV^.[733^&O#4_[OF.[OHF^]V,<9]/5OJ!QR?EZ
M-*=:?+$\:,7-F9^T+\89M=OY/#.A7BMID?%W<0G_ %K9Y0'NHX^I/H!7D&EZ
M9PN5YI=-TTM@D9)Z^_X5UFEZ9TXKZ6$8T(<D#N24%9":;IO3Y:ZS3-,Z?+1I
MFF?=XKJ]-TT!02,"N6I,R<@TW30,97BK]S<I:QE5I+JZ6UCVIBN:U+4^O-<]
MG)D;BZEJ77G%<KJ&H;F//2C4-0+$\U@7MYC/-=<(&D4+>7G7FL.\O.O-)>7G
M7FL2\O.O-=L8FJ0MY?'GYOUK#O+XC/S?K3;V\Z\UAWEYUYKKA$T2%O+X\_-^
MM8=Y?=?F_6F7E[UYK&N+@R-[5V1B:*(MQ=-(QP34&X\<G/UH_P __7KT3X)_
M!;6?C1XF2QL$:WTZ$AKV_=<I A/3CJY&<*.OL,FBI4C3BY2V0VU%78[X*_!7
M6OC-XD2RL0;?382&O+]E)2%?3W8]@/Y9K])/A_X T;X:^&[?0]$M1;VD/)8\
MR3.>KNV.6/\ @!@8%'P]\ Z/\-_#-MHNBVH@M81\S$?/*W=W/<G_ /5Q72U\
M3CL;+%2LOA6QY=6JYO38 ,4M%%>88!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MDM_!-N^^TLI,JVJ,#W[B$="?XL8'<U^KVGV=OIUI#:6L,=M;6Z+%'#"@5(U
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7TE&E'#PLMSMC%00FEZ8>.*ZO2]+Z<4NFZ6>.*ZO3=-V@9&*RJ5"9,--TT*
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MR]^0>1ZT^.3\/>OU[_;4_8KT_P#: T>7Q'X<BAT_Q]9P_NY.%3444<12GIN
MX5^W )QC'YG?"/\ 9Q\;?%SXHR>!;#2IK#4K24IJ<E[&533D4X9I>_4$ =23
MBONL)F%.M3YV[6W/HJ.*C./,W83X%?!'Q+\?/'%MX<\-V^XG#W=[("8;.'(S
M)(1TXZ#J2<"OV9^!/P*\-_ 'P/!X>\/P OP]YJ$JCSKR7'+N?Y*. .E'P$^
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M :U&NGZB^W4$&%E/ F'OZ-ZBN]I +1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV6P@I:**\DY@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^Q9KY&_X*%?ML:I^Q_X6\+)X;T:QUCQ-XCGG%M_:@D:V@A@$?F,RQLK,Q,R
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M(?\ [91_PT&?^B:_$/\ \$/_ -LKUJB@#R7_ (:#/_1-?B'_ ."'_P"V4?\
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MYTRXF8-A9(8]R,.QR.F??TKU/X9>"Y?#-K/<7@"WMQC]VIR(TZ@'CKZ\GH*
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M+_\ A4'_  AO@WP_X2^W?VQ]K_L/2X++[1L^Q;/,\I%W;=[XSG&YL=37D/\
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M+_P;XFT?7],E^SZEI5Y#?6LW]R6)PZ-^#**_J)O+6+4+2:VN8EGMYT:.2*0
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M^W__ "/7[!?\$<V\5M\ ?%(\1'4S9+K[#3_[2W\+Y$7F>7O_ (=V.G&=W?-
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M2?\ @CU_R9\G_8P7W\HJ /"O^"YW_-$_^XW_ .V%>*?\$;O^3M[SW\,W@_\
M(MO7T1_P7 \-3WG@GX5:^D3-;6&H7]B\G96GCA=1^(MF_*O@[]AW]H;3OV8O
MVA-'\9:S:W-WH36\]AJ"60!F$,J_?120&*NJ-@D9 /?% ']$Z]*_-;_@MY_R
M2SX:_P#89N/_ $0*^@_@M_P4<^$_Q\^+.E?#_P (KKL^J:A;S3Q7EU8K!; Q
M(7:,YDW[BJL1A2..M?/?_!;H_P#%J_AK_P!AFX_]$"@#Y!_X)0_\GM>$/^O+
M4?\ TDEK[\_X*H_LM_$;]I/P[\/6^'>C)KUUHEU>_:[,WD%LP298=K@S.BD
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M33OA;H%M?V4\=S;S"!F,<B,&5@"Q'! /->Z"EH :N><TZDI: "BBB@ HHHH
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M6TF]6ZKD;E/H12 O44@I:0!1110 4444 %%%% !1110 4444 %%%% !1110
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M\(?\% /^"?\ XW_:Y^)'A[Q%X>\7:/I>G:9I(L#I^K+,-LGG2.TJM&C [@Z
M@@?ZL>M?>-)@>E 'Q'_P3]_X)\ZA^R/XB\2>)_$^NZ;KVOZE:)IUJ-,BD$=M
M!OWR?.X!8NRQ=%&-AY.>/MM>..E+2T -;M7QK_P4$_8-O?VOF\)ZMX=UK3]!
M\1:*LUM+)J2.8[FW<JRJ60$@HP8@8(/F-TK[+HH _-']D/\ X)>_$/\ 9U_:
M \,^/M4\;^'Y]/TH7'G6VF+.\MPLD#Q&/#HJ@?/G))/RCBO4O^"@W[!7B/\
M:]\1>$M:\-^)M+T>?1[6:SEM]5CEV2*[APRO&K<CD8(].>U?;F/:EH ^%O\
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M7$:%SP%&2:X?Q1XF:X=K6!ML:G#'U.: '>)_%!NMUK:GY/XFZ5RO?-'MUHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%CE<X()^H^+/A+\6/%_[#_Q(?X=_$99KKP3<R;[6]3+I"K-@3Q'NG/SIU!Y
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MR3U/I3?FD<*O))Q70:7IHM8P7'S]<4 /TW3ULX_5O7O5T44M !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% "5FZWHL6L6Q4@+*/NOBM.B@#RG4M*N-+F,<R
M$#L:I5ZMJFF0ZI;F.503V;'(KSG6=(FT>X9).4_A;'^?\_E0!GT444 %.5L4
MVB@"PDE6$DJ@K%:F22@#2CDJS')68DE6(Y.E &G')4Z/6='-5E)* +RL&%(R
M>E1+)4\>9&"@9)H A2UDN) D:Y/\JZ?3K=[>W"NVYO6F:?9"WCYZ]:NT %%%
M% !1110 4444 %%%% !7+?$KX<:!\5O"-[X<\1V2WNG72XP>'C;LZ-_"P/0U
MU-% 'XN>"?C]X^_9_P!0UW1O!7B*;3].>[?=!-#%<(2I*A]KJP5B."1C.T>@
MKK/^&^_CA@?\5='_ ."NT_\ C5>)>-/^1PUO_K]F_P#0S6+5(#Z'_P"&^_CA
M_P!#='_X*[3_ .-4?\-]_'#_ *&Z/_P5VG_QJOGBBF!]#_\ #??QP_Z&Z/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %4M4TZ'4K<Q2@>S8Z5=I
M* /,=<T&;1YL-EXB?E<#K677K5]8Q7UNT,J@J?TKSS7M ETB8G!> ]&'^?\
M/ZT 9%%%% !2YI** )DDJ=9.E4P:E62@#0CDJRDE9L<E68Y"64#G)Z>OM0!J
M0$R,%49)KI-+TPP@22?>]*K>']+,,8EE7YR>_;VK=H .*6BB@ HHHH ****
M"BBB@ HHHH ***:QQSG'XT ?@[XT_P"1PUO_ *_9O_0S6+7LMK^SQXP^(_QR
M\7>"='@M6UW3IKF>XCEN51 BRA6PQZ\R+7<C_@G1\8VZ6.E?^#&.J ^8:*^G
M_P#AW/\ &/\ Y\=*_P#!@E'_  [G^,?_ #XZ5_X,$H ^8**^G_\ AW/\8_\
MGQTK_P &"4?\.Y_C'_SXZ5_X,$H ^8**^G_^'<_QC_Y\=*_\&"4?\.Y_C'_S
MXZ5_X,$H ^8**^G_ /AW/\8_^?'2O_!@E'_#N?XQ_P#/CI7_ (,$H ^8**^G
M_P#AW/\ &/\ Y\=*_P#!@E'_  [G^,?_ #XZ5_X,$H ^8**^G_\ AW/\8_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4W_I/;U]@5\?_P#!,3_DAWB'_L8IO_2>WK[ IL HHHI %%%% !1110 4444
M%%%% !1110 4AI:* ,O5='CO%+K\L@[US[6[0N4==K"NTJE>Z?'<J#C##H:
M.=1:D9MHJ2:%K9MK#FGV5B]Z=QX3- !8V+74@W#"=:Z&.-8U 48%-MX%MXPJ
MC'K4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4UE##! (],4ZB@".&&.WC"1H
M$7T Q4E%% !1110 4444 %%%% !1110 4E+24 >3_'+XR7OPGFT=+2Q@O!?+
M,6\\M\NPIC&"/[WZ5YC'^U]K#_\ ,%L?S?\ ^*JU^V5_Q\^$_P#KG=?SBKYS
MBH ^B%_:XU<]=&LOS?\ ^*J9?VL=6;_F#V?YM_\ %5\]QU;CH ^@8OVJ-4DZ
MZ39C_OK_ .*J_!^TMJ,W72[4'V#?_%5\^VOWJVK/M0!H_#O1;?P1\=/$WQ-M
M[F:XU'74N(Y+&9%$,?FRI(2N#NS^[ _&OH'3_C1<W?WK.)<GC"G_ .*KPNR[
M5U&C<,N*=@/<=/\ 'S7F-T.W/HG_ -E6Q)XD5+<2 ,<_],__ +*O-M$/W:ZJ
M;FQ% ":A\2)+/.V!6^J__95:\&^.IO%&I2VSP)&D<32;@".0RC'4^M>?ZX,%
MJU_A!_R,%W_U[M_Z$E%@/6QWI:2EI %%%% !2&EHH ^>OB5^TMJG@;QQJFA0
M:5:W$5HR*LDA?<<HK>O^U7/+^UYK!_Y@MC^;_P#Q5>=_M!?\ED\1_P#72+_T
M3'7!QT ?0Z_M;:N<?\2:R_\ 'O\ XJIE_:OU5O\ F#V?_CW_ ,57SY'5R/I0
M!] V_P"U)J<W72;0?]]?_%4SQ'\<KSQAX7U?1)[&"&+4K.:S>2/=N421LA(^
M;J-U>(V/:MVSZ"@#I/V;_*_9[\&WOAW39)-5@NK][]I[Q KAF1$VX4@8'E_K
M7M^G_%V>\(W6L2Y]%/\ \57A5C]X5V.AGIFF![5I_C+[9C<FW/I'_P#95/?>
M*OL:DA2WUC_^RKCM$_@J_KB_(?I0 V^^*4UJ2%MHV^JG_P"*KJ/!GB*3Q-I<
MEW)&L1$OEA5S_=4^O^U^E>-ZN/F.?6O3?A)_R*[_ /7P?_0$HL!VU%%%( HH
MHH **** "BBB@ HHHH *0TM% %:ZL8[I=K<<YR.M200+;QA%&!4M% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DI:2@#YB_;,_X^O"7^
MY=?SBKYRBKZ-_;,_X^O"7^Y=?SBKYRBH MQU:BJK'5J*@"Y;_>%;5GVK%M_O
M"MJQ[4 ;UGVKI='^\*YFS[5TNC_>7ZU2 [_0_P"&NTB_X\C7%:)]Y:[2'_CQ
M-)@<CKG\7XUI?"7_ )&"[_Z]V_\ 0DK-US^+\:TOA-_R'KO_ *]V_P#0DHZ
M>KTM)2T@"BBB@ HHHH ^%OVAO^2R>(_^ND7_ *)CK@8Z[W]H;_DL?B/_ *Z1
M?^B8ZX*.@"U'VJW'TJI'VJW'0!>M>HK=L>U85KU%;MCVIW W;/M77:&?NUR-
MIVKKM$_AI@>@:)_#6[JG_'N/I6!HO\-=!JG_ ![+]*74#@=9^^?K7I/PI_Y%
MJ3_KX/\ Z E>;:U]XUZ3\*?^1:D_Z^#_ .@)38'9T445(!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DI:2@#YB_;,
M_P"/KPE_N77\XJ^<HJ^C/VS?^/GPG_N77\XJ^<X>U %J.K4=58ZM1T 7(?O5
MLV=8L/WA6U9]: -VS[5T6D_ZP5SMGVKH=)_U@JD!WVA_P5W5A_QZM]*X31/X
M:[G3_P#CV/TI,#FM<_BJ]\*/^0_=_P#7NW_H252US^*KWPI_Y#UU_P!<&_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *2EI* /F+]LS_CX\)_[EU_.*
MOG"*OH[]LW_CY\)_[EU_.*OG"&@"Y'5J&JL=6HJ +D745KV7:L>'J*U[/JM
M&[9]JZ#3/]8OUKG[/M70Z7_K%JD!WFA_PUWFD_ZG\*X#0S]VN^TG_5_A28&+
MKHX>K/PK_P"0]=_]<&_]"2H-<_CJQ\+?^0]=?]<&_P#0DHZ >H4M%%( HHHH
M *2EI* /A7]H?_DLGB/_ *Z1?^B8ZX".N_\ VA_^2R>(_P#KI%_Z)CK@(Z +
M<=6HNU5(ZMQ4 7;?[PK;LNU8EM]X5M6704 ;MGT%=1HWWUKE[/M73:+]X52
M] T/HE=@PS8UQVB=$KL?^7&DP.+UP<FN_P#A?_R+DG_7<_\ H"5P6N=37>_"
M_P#Y%V3_ *[G_P! 2CH!V%%%%( HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %)2T4 8'B?P+H/C)K=M:TZ._-ON$7F,
MPV[L9Z$>@_*L,? _P,O3P]!_W\D_^*KNZ2@#AQ\$_! Z>'X/^_DG_P 53U^#
M'@I>F@0_]_)/_BJ[:B@#BQ\'?!HZ:%"/^VDG_P 54B_"7PE']W1(1_VTD_\
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M2,+MPVWTWM_C5BB@#-FT&QG_ -9"7/N[?XU8L-/M]-B:.WC$2$[B,YYJU10
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4E+24 ?!_P"SE_RD.^*__7#4?_2J"OO"O@_]G+_E(=\5_P#KAJ/_ *505]X4
M +1110 4444 %%%% !1110 4444 %%%% !1110 5Q_QB_P"21>./^P'??^D[
MUV%<?\8O^21>./\ L!WW_I.] 'S?_P $Q/\ DAWB'_L8IO\ TGMZ^P*^/_\
M@F)_R0[Q#_V,4W_I/;U]@4V 4444@"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO_2>2ORDK]6_^"O_ /R1[P1_V'6_])Y*_*.@I#&JQ9?>%5VJQ8_>H$SI-/\
MX?K7HGAC^"O/-/[5Z+X9_P"6= CU?PQ_!7J_A_\ U0^E>5^&/X*]6T'_ %(H
M VUJ:.H(ZG3K0!R?BK^.OKO]AW_DCEW_ -A>?_T7%7R%XJ_CKZ]_8=_Y(Y=_
M]A>;_P!%0T ?0M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M <3XJ_CK["_88_Y(S=?]A>;_ -%0U\=^*OX_QK[#_86_Y(S=_P#87F_]%0T
M?1-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'RS_P4Q_Y
M- \5_P#7U8_^E45?BE7[6_\ !3'_ )- \5_]?5C_ .E45?BCZT%(8U3V?^LJ
M!JL67WA0)G1Z=_#7H?AC^'\*\\T_M7HOAG^"@1ZQX9_@KU;P_P#ZD?2O*O#/
M5*]7\/\ ^I_"@#<C_I4RU#']VIUH Y7Q5T;_ #VKZ"_X)^?ZGQY_UTLOY3U\
M^>*C]ZOH+_@GW_J?'G_72R_E/0!]>T444 %%%% !1110!\#_ /!7_P#Y(]X(
M_P"PZW_I/)7Y1]J_5S_@K_\ \D>\$?\ 8=;_ -)Y*_*,]*"D,:KECU%4VJ[I
M_6@&=+IOWE^M>E^&?^6=>:Z9]Y:]+\,KRE!)ZSX8_@KU+1_^/<5Y;X84_)7J
M>C_\>PH TXZF7[IJ&.IA]T_2@#A?%1Y;ZU]B_L*_\D9N_P#L+S?^BH:^./%G
M\=?8W["G_)%[O_L+S?\ HJ&@#Z*HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !13
M6S^%-W>_ H DHIJ_K3J "BBB@!#7#_&+XL:/\&/ >I>)=9N(HUMXF%M;2/M:
M[N-I\N%, G+,,9P<#)/ )KJ=>UJS\.Z/>:IJ$RV]E9Q---([!0%4$GD\=J_.
M6\;Q+_P4'^.=K);Z?+IGP\T*14EED9E @W MEAD>=(!@  [0!DD#- &K^S?\
M+_$7[8'Q4G^,'Q!N89] TZ[6*VL/+5HYVCPZ6Z(V0L";P22"6)89+%F'Z"KH
MFFMD_P!GVIYY_<+_ (5%X7\-Z9X/T"QT71K*'3M+L8Q#;VL"[4C4?S/4D]22
M3WK5H H_V%IO_0.M?^_"_P"%']AZ=_T#[7_ORO\ A5ZB@"E_8NG_ //A;?\
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M&J:.LI<6<^(9E/.TX9"3@8.",]LY^H^D_P!G']I :U]F\+>)[D)?X$=E?2'
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'Q$,3#G@SZZC7AB(<\22BD6EKI.@**** "BBB@ HHHH **** "BBB@ HHHH
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M7GEG?'C/'>M^ROSQS7QD*MW<^>A4;U9Z'97X.,FMNUN^G-<!8W^<<UT%C?<
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-)_*G4Q_3M2]
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M#NWH/Q.<8/MS=J^6?VBOV=]1U35[GQ1X=CDOVN"TEY9@Y=2!DLH[@XZ#)SC
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MW&)X@W7+$C=CVSV%=4*>$J/2\6=D:=">VA[W8Z>553M.&^8''4>H]JZ&QLL
M<<U\FM\"/C/X 6ZE\*>)I-3MRL8V6UV4EGQ_"L<N0,9/\0R/7@5I1_M$?&3X
M?R7Z>*_!(OHK5E>>X-A)#';H!EB)(\H<@CD]"/R[HX-?8E<ZXT$MG<^OK2WZ
M<5K6UKTXKYM\(_MS>!-4D$>L:;JGAYVG6-695N8PAQ\[LN-H!/3!..:]T\%_
M&#P'XV1#HOBS2[UWE\A(?/$4KR #A8WP[=>N,=:Z%1E'='0H-':11+"NYSA1
M7.^(?$ 1&56PH[5/X@UP0JR*< 9&,_A7F.O:V9F8;C7+7JJ"L85:G*K$.N:T
MTS, >*Y&^ON>N>WZ4[4;\'<,_EUKUCX'_!&3Q1+#XAU^%DTD'=;VS=;D_P!X
MC^YT^N...3Y<(SQ53V<=SS(J5::C$N_L]_""?4;Z'Q-K5NGV)1NM(9E)\QNT
MF#V';/>OII1T[#M20QQQ1JD:JJ*-H51@#':G<5]?AL/'#0Y(GOT**HQM$&P.
M:XKXB?$:W\&69CBVS:E(/W<)Y"_[38/3V[^W6K7Q!\:Q>#]':92KWDG$43'G
MTS7S/J6I7.M7TMW=R&6:4Y+-SWKY[.,V6$7L:+]]_@88G$>S7+'<^A? WQ6L
M?%,,=O<E;740!N0\*Y[E>>G3@^O?K7?)SS7QW#F-PZG:PY!%>A^%OBUJVC;(
MKM_MML" ?,/S 9YP<YSC_P#57%E^?.WL\5]YE1Q?29]"45R&@_$[1=:PIG^R
M3$ E9R ,G/ ;IV/H:ZN*19%#*VY2,@@U]C2Q%*LKTY7/2C*,M4R2BFTO3K70
M4+12;J-U "T4FZEH **:U96J>)M/T=6-Q<H''_+-3EOR_P :SE4C35YNPG)+
M<UF.,5C>(/%&G^&[1I[V<1@=%'+'Z"O-?%GQFD*O!I2^4""/.;EA]X<=A_">
M]97@;P;?^/M0&K:O)(UBK[AOS^\8$\#/8=,_US7S]7-E4G[#"+FEWZ(Y)8CF
M?+3U9ZEX+\27GBB"XO9;9+:Q9L6_S$NP'4G^E=-4-G;Q6<"0PQK'$BA551P
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M9X)5."",@J1@J5/XBOUI_8?_ &LF_:'\*W.D^(&CC\;Z.@:[,2!$O("=HN%
MX!!^5PO 8@C ;  /J*BFJVX9IU @HHKD_BQX^B^%OPW\1^+9[5KV+1[&6\^S
M(^PRE%R$W8.,GC.#CK@T ;FO:YI_AO2;G5-5OK?3--M4,D]W=2B.*-1W9CP*
M^1?%7_!4;X6Z#KEQ8Z;IFO\ B"UA;8-1M(8HX9CZH))%8KTY*CZ=,_"'QD_:
M'^)?[5GBJ"QO6NKJVEGQI_AC2(W,*GG;B-<F1_\ ;;)ZXVCBO(=8TF]T#5K[
M3-1MWM-0LYY+:YMY,;HY$8JZ'W# B@=C]U?@3\:M&^/WP^M_%VA6M]96,TTE
MN8-11%E5T.&X1F&,]#G\!7H5?*?_  3/_P"37;'_ +"EY_Z$*^K*!!1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %(5!I:* &LO'J*\6^+'PIR)M:T:++??GMHQS
M[LM>U=>M-;'3M7G8W TL=3]G47H^QC5I1K1Y9'R#I?B#4=%F9K.\FMY#P3&S
M+GIVSST'4'I7H.A_';6+-0M]!#J"^O\ JW_$@8_2M3XK?"<MYVL:/%\WWI[5
M!P?5E']*\:5BI(/!STK\TJ2QF45?9\[7Y,\27M,/*USZ(TGXY:)?;1=)-9/M
MR2P#IN] 5R3^5=)9_$+P_?1>8FIPJN<8D;8?R.#7RTLOO4\<E>K1XAQ,=)I,
MZ%C)GU?9^(]+U#=]GOK>;;C=LD!QGI_*IY-4LX5+O<Q*HZDN*^4X[AH_NN5^
MAQ5I+N5A@R,1Z%C7H1XBFUK#7U-5C'U1]*GQ;H_.-1M^/]L5ES?$S1(XRR3/
M,1QM1#G_  KP:.;IS5J.;I0\\K35E%(?UJ3V/6;CXI&8XM;4(N?ORMDX^@_Q
MJE_PE-Y>-^\F9N,$9Q^@Q_*O/X9RI&#6I9WG09J(X^K4?OR#VTGN=S;7@D'S
M'.:6XM@RY%8-G>=.:V[6[W  C.> ,XKTJ<U-69JG<R;ZRW*1BN6U32>I"YKM
M]?U#3M"T_P"VZI?VNFV>X)]HOIT@CW') +.0 >#@>U>&>./VLOA/X1:>&;Q,
MNK74,YMYK?2(&N'0@'+$\*4R,;@W<8KGK8-U?A5R9TW+8])\$^-I_"-U]GN2
MTFG2'D=T/]X5[?:7D5];1W$$@EBD 964\$'O7YI>(/VYK;6)C9>%?!%[?ZE)
M/LMQ>2EA/'D\B.(%PQ&"!GBH]&^*G[37C2UCMM#M6\)Z1<7330S/$EL(=H<&
M-GDR^WMRN20*[,#[?"+EQ+2ATNRZ//3]V>Q^EMYJ-II\8ENKJ&UC)P&FD" G
M'N:\.^*/[5'P1L=+ETKQ!XJL-6MKL/%);:>K794J1][RP=AR>"<'(X/%>!:'
M^P-XV^)B6NI?$3XGS7L4YDN'M[25[K9(Q.&5G(7N"<* .G:O9?!'[ /PD\("
M&2[TJX\17(A\EVU*X)C9N,N$7 #<'OT)KZ+W:D==4=C2DK,^$O$_QTTQM3NS
MX4T34KK35W/&^H!4D1>VX1[P?S&>O!-8C:]\4/$S"*UL6TQ&B.66(1*X/<.Y
M.#@@C!%?K;;?"GP=IFARZ18>'--L+&6W6U9+6V2-C&N-H+ 9;! ().<CUKX]
M^-'P;OOA;K!>,/=:).Q^SW(&2.^QO]K!./7MZ5\]BJ,<&N>C33]>AX>(I1PJ
MYZ<$SY7@^"7B#Q#()]>\0_,T2[>7N) >H1@2 0.>Y%=EH?P'\)V&3<QW&H[E
M (GFPJL.I&S&,^ASTKL8Y/YX..GT_E^=6XYO>O$ECZ\M%*R/-^NU9=36\.Z-
MHVA*PTW2[.P\S;O\B%5+8X&<=>_7UKL['43Q\Y/XUP5O<E6&*V;&^Z<UE&M)
MOWF5&HWN[GH=E?=#GMC\/2M^SO=W4UYY9W_3FN@L=0Z<UVTYG="9W=M<]#FM
M2UNNG-<A9W^0.:V+6ZZ<UZ$)]3LC+J=4KK<1[7&X5A:MX6:^DV01[V<\ "KE
MC*\TB)&"S,< +S7JWA?P_P#V;;K).-TY&<?W:[84_;Z,V4%4T9RWPW^$EGX7
MD74KQ%GU,CY"PXASZ#U]Z]( _"G45ZE.G&G'EB=4(*"M$/6EHHK4L**** "B
MBB@ HHHH **** $/:HV QR!BI:3 ]* /G3X^?L]KK7VGQ+X<MP+_ )DO+&-?
M]=SRZ ?Q^H'7DCGK\PK;M%(4<;64\@U^E# 5X1\9OV?U\373ZSH$<<-^Q+7%
MOT64XSD?[1.!CWZU\UF&7*7[ZBM>J/$Q>"4G[2F?+=K:EB..*W["SY'%.CT>
M6QN'MYXFAFB;8\;@A@PZ@@]/Y\5O:?8].*\&%-W/.A#74?86/08XKH]/L>1Q
M[4RQL>G%;]G:XQQ7I4X6.^G$?:VNW Q6O;V^]0C?,F,;6Y!]L4EK:].*U[6U
MP,G@5WPB=D8G'^)O@GX&\?+<MK_A?3;VXG15DNA"([C"XVXE7#+CIP?;H:\(
M^(7[$O@&XFN+GP]J&I>'+IG0Q()!<00@8#85L/D\G)?@GBOIK6]72UA**W;F
MO-/$&O%G8*WZU<\0Z2T"I5Y%H?+5U\'_ (I?#AMOA7Q@VHV$$[-!9_:'C!#
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M>./'%IX*TTSS'S;F3Y8+<'!=OKV'/7\.I%?!FM?LL_'#X!6L5_X1^(\<UK!
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M -#IX>_\&L'_ ,72_P#"H? G_0E>'?\ P50?_$4?\*A\"?\ 0E>'?_!5!_\
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M'_Q=+_PJ'P)_T)7AW_P50?\ Q%'_  J'P)_T)7AW_P %4'_Q% "?\+=\"_\
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M_P &L'_Q='_"W? O_0Z>'O\ P:P?_%TO_"H? G_0E>'?_!5!_P#$4?\ "H?
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M^AFOM3]FS_@H5X>^!GP5\.^"+[PGJFIW>E_:/,N;>XC5'\VYEF& >>!*!^%
M^A]G?MM+8M^RS\0QJ"*\/]G@HK8_UHE0Q8]]^T_A7XF'OG'3G@@8Z5].?M6?
MMPZ_^T?IL/AZSTQ?#?A**59WM!.9IKN12=K2N% V#.0@&,@$DD#'%?LH_L^Z
ME^T'\5-.TM+>4>'+&5+G6;X+\L4(.3'D?QR8*J!DC);&%- ;'['?"..>'X5^
M#8[G<;E=%LQ+NZ[_ "$W9]\YK\&_$G_(Q:K_ -?4O_H9K^@Z-%C7:J[548
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS$G@<UT>!Z44""OY[O$G_(Q:K_U]R_\ H9K^A$U_/=XD_P"1AU7_ *^Y>?\
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MD9[YRIX'<$>L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MVV;1B.LK/H<5NV5GTXIEE9].*W;6U"J">*]JA1[G3"(MM;B-0QZ4VZNL*<'
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "D(S2T4@$P*3\*=13 04M%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 (:0^XIU% #=M+C%+10 E+110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
..1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>smmt-20231231_g2.jpg
<TEXT>
begin 644 smmt-20231231_g2.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "9 ^\# 2(  A$! Q$!_\0
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MOX/S^\/[>Q?E]Q^J'_#S3X6_\^6M_P#@.O\ \51_P\T^%O\ SY:W_P" Z_\
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MU-T"@9QG^]7Y1UT_PS_Y'S1O^NW_ +*:B>0X2,6U?[RXYYBY22=ON/TNNO\
M@I9\,+.ZFMY+'6O,B=HVQ;KC(.#_ !5%_P /-/A;_P ^6M_^ Z__ !5?E_XB
M_P"1@U/_ *^I?_0S6?3608-J^OWDO/<7?I]Q^J'_  \T^%O_ #Y:W_X#K_\
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MO-)YYBHRLK?<?JA_P\T^%O\ SY:W_P" Z_\ Q5'_  \T^%O_ #Y:W_X#K_\
M%5^5]%:?ZOX/S^\S_M[%^7W'ZH?\/-/A;_SY:W_X#K_\51_P\T^%O_/EK?\
MX#K_ /%5^5]%'^K^#\_O#^WL7Y?<?JA_P\T^%O\ SY:W_P" Z_\ Q5'_  \T
M^%O_ #Y:W_X#K_\ %5^5]*5*X)! /2E_J_@_/[P_M[%^7W'ZG_\ #S3X6_\
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M ,^6M_\ @.O_ ,57Y7T4?ZOX/S^\/[>Q?E]Q^J'_  \T^%O_ #Y:W_X#K_\
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M_BJ_*^BG_J_@_/[P_M[%^7W'ZH?\/-/A;_SY:W_X#K_\51_P\T^%O_/EK?\
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M1TX/!HITK!Y'8="2:;7M'D!1110 4444 %%%% !1110 4444 %%%% !1110
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M4**** "BBB@ HHHH **** "OUD_X)O\ _)N-G_U_7'_HPU^3=?K)_P $W_\
MDW&S_P"OZX_]&&OF.(?]T7^)?DSZ3(/]Z?H_S1YQ_P %4E+>%/!&!G_3)O\
MT 5^<GEM_=/Y5^[7C#P3H'C;6-/M]?T>RUF"%&>..]@6558]P&'!K._X9_\
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M-'^LE/\ Y]O[P_U>J?\ /Q?<?AMY;?W3^5'EM_=/Y5^Y/_#/_P -?^A%\/\
M_@NB_P#B:/\ AG_X:_\ 0B^'_P#P71?_ !-'^LE/_GV_O#_5ZI_S\7W'X;>6
MW]T_E1Y;?W3^5?N3_P ,_P#PU_Z$7P__ ."Z+_XFC_AG_P"&O_0B^'__  71
M?_$T?ZR4_P#GV_O#_5ZI_P _%]Q^&WEM_=/Y4>6W]T_E7[D_\,__  U_Z$7P
M_P#^"Z+_ .)H_P"&?_AK_P!"+X?_ /!=%_\ $T?ZR4_^?;^\/]7JG_/Q?<?A
MMY;?W3^5'EM_=/Y5^Y/_  S_ /#7_H1?#_\ X+HO_B:/^&?_ (:_]"+X?_\
M!=%_\31_K)3_ .?;^\/]7JG_ #\7W'X;>6W]T_E1Y;?W3^5?N3_PS_\ #7_H
M1?#_ /X+HO\ XFC_ (9_^&O_ $(OA_\ \%T7_P 31_K)3_Y]O[P_U>J?\_%]
MQ^&WEM_=/Y5TWPT5E\=:.2"!YWI_LFOVC_X9_P#AK_T(OA__ ,%T7_Q-.C^
M?PWA<.G@?04=>0RZ?$"/_':F7$5.46O9O[RH\/U(M/VB^X_$3Q"C?V_J?RG_
M (^I>W^V:S_+;^Z?RK]RF^ /PV9BS>!M +$Y).GQ?_$TG_#/_P -?^A%\/\
M_@NB_P#B::XCII6]F_O$^'JE_P"(ON/PV\MO[I_*CRV_NG\J_<G_ (9_^&O_
M $(OA_\ \%T7_P 31_PS_P##7_H1?#__ (+HO_B:?^LE/_GV_O%_J]4_Y^+[
MC\-O+;^Z?RH\MO[I_*OW)_X9_P#AK_T(OA__ ,%T7_Q-'_#/_P -?^A%\/\
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M4>6W]T_E7[D_\,__  U_Z$7P_P#^"Z+_ .)H_P"&?_AK_P!"+X?_ /!=%_\
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M)I?ZQTKW]F_O'_J]4V]HON/PV\MO[I_*CRV_NG\J_<G_ (9_^&O_ $(OA_\
M\%T7_P 31_PS_P##7_H1?#__ (+HO_B:?^LE/_GV_O%_J]4_Y^+[C\-O+;^Z
M?RH\MO[I_*OW)_X9_P#AK_T(OA__ ,%T7_Q-'_#/_P -?^A%\/\ _@NB_P#B
M:/\ 62G_ ,^W]X?ZO5/^?B^X_#;RV_NG\J/+;^Z?RK]R?^&?_AK_ -"+X?\
M_!=%_P#$T?\ #/\ \-?^A%\/_P#@NB_^)H_UDI_\^W]X?ZO5/^?B^X_#;RV_
MNG\J/+;^Z?RK]R?^&?\ X:_]"+X?_P#!=%_\31_PS_\ #7_H1?#_ /X+HO\
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MWJ_F?AMY;?W3^5'EM_=/Y5^Y/_#/_P -?^A%\/\ _@NB_P#B:/\ AG_X:_\
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MN3_PS_\ #7_H1?#_ /X+HO\ XFC_ (9_^&O_ $(OA_\ \%T7_P 35_ZR4_\
MGV_O(_U>J?\ /Q?<?AMY;?W3^5'EM_=/Y5^Y/_#/_P -?^A%\/\ _@NB_P#B
M:/\ AG_X:_\ 0B^'_P#P71?_ !-'^LE/_GV_O#_5ZI_S\7W'X;>6W]T_E1Y;
M?W3^5?N3_P ,_P#PU_Z$7P__ ."Z+_XFC_AG_P"&O_0B^'__  71?_$T?ZR4
M_P#GV_O#_5ZI_P _%]Q^&WEM_=/Y4>6W]T_E7[D_\,__  U_Z$7P_P#^"Z+_
M .)H_P"&?_AK_P!"+X?_ /!=%_\ $T?ZR4_^?;^\/]7JG_/Q?<?AMY;?W3^5
M'EM_=/Y5^Y/_  S_ /#7_H1?#_\ X+HO_B:/^&?_ (:_]"+X?_\ !=%_\31_
MK)3_ .?;^\/]7JG_ #\7W'X;>6W]T_E1Y;?W3^5?N3_PS_\ #7_H1?#_ /X+
MHO\ XFC_ (9_^&O_ $(OA_\ \%T7_P 31_K)3_Y]O[P_U>J?\_%]Q^&WEM_=
M/Y4>6W]T_E7[D_\ #/\ \-?^A%\/_P#@NB_^)H_X9_\ AK_T(OA__P %T7_Q
M-'^LE/\ Y]O[P_U>J?\ /Q?<?AMY;?W3^5'EM_=/Y5^Y/_#/_P -?^A%\/\
M_@NB_P#B:/\ AG_X:_\ 0B^'_P#P71?_ !-'^LE/_GV_O#_5ZI_S\7W'X;>6
MW]T_E1Y;?W3^5?N3_P ,_P#PU_Z$7P__ ."Z+_XFC_AG_P"&O_0B^'__  71
M?_$T?ZR4_P#GV_O#_5ZI_P _%]Q^&WEM_=/Y4>6W]T_E7[D_\,__  U_Z$7P
M_P#^"Z+_ .)H_P"&?_AK_P!"+X?_ /!=%_\ $T?ZR4_^?;^\/]7JG_/Q?<?A
MMY;?W3^5'EM_=/Y5^Y/_  S_ /#7_H1?#_\ X+HO_B:/^&?_ (:_]"+X?_\
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M9_'BU^%4H=-;N=..H17!/[IL-M,0_P!L<''H17H.O7UQI>DW-W:6@OIX4+B
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M/N[B,]1T]:^5]0^$OAD_$+]H&#_A&K7[%!HD7V*W$&((7>R#.T*?=1RQ)W(
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M/_&C_A+=#_Z#.G_^!4?^-?F[17S'^MU3_GROO_X!P_VD_P"4_2+_ (2W0_\
MH,Z?_P"!4?\ C1_PENA_]!G3_P#P*C_QK\W:*/\ 6ZI_SY7W_P# #^TG_*?I
M%_PENA_]!G3_ /P*C_QH_P"$MT/_ *#.G_\ @5'_ (U^;M%'^MU3_GROO_X
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M?^-?F[11_K=4_P"?*^__ ( ?VD_Y3](O^$MT/_H,Z?\ ^!4?^-'_  ENA_\
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M?<UZI?\ [-_A:;Q+JNMZ==ZSX>NM6P;^+1KXV\5T1_$Z@')/<U%=?LT^%_\
MA,KOQ/I>HZ]X;U2ZM8K.5M%U VZ-%& %7&#Z#\JYY8JG-S]YI25DK;;?Y&\<
M+4@H>ZKQ=V[[[_YGD7P3\*Z3\=OBU\6M5\>:=;^(+C2[^/3M/L=03SH]/A8.
M6\M&SM+%5.X<_+7U3H>C6WA[2;73;/S!:VR>7$)9&D8*.@W,2<#H/8 5YSJ?
M[./AF^\33^(+2_UO1=7NH!!>7.E7Y@:\7UEP/F/O7HVB:/;>'])M=.LT*6UN
M@1 QR3ZDGN2<D_6N+%5HUFG!NVFG165CLPM&5)-26NNO>[+U%%%<!W!1110
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M\_1_[Y-'_"PM$_Y^C_WR: .DHKF_^%A:)_S]'_ODT?\ "PM$_P"?H_\ ?)H
MZ2BN;_X6%HG_ #]'_ODT?\+"T3_GZ/\ WR: .DKQ.Z_9)\&7=U-.]WK >5R[
M;;B/&2<_\\Z](_X6%HG_ #]'_ODT?\+"T3_GZ/\ WR:X\1@\/B[*O!2MM<RG
M3A4^-7/,_P#AD'P5_P _FL?^!$?_ ,;H_P"&0?!7_/YK'_@1'_\ &Z],_P"%
MA:)_S]'_ +Y-'_"PM$_Y^C_WR:XO[&R__GRC/ZK1_E1YG_PR#X*_Y_-8_P#
MB/\ ^-T?\,@^"O\ G\UC_P "(_\ XW7IG_"PM$_Y^C_WR:/^%A:)_P _1_[Y
M-']C9?\ \^4'U6C_ "H\S_X9!\%?\_FL?^!$?_QNC_AD'P5_S^:Q_P"!$?\
M\;KTS_A86B?\_1_[Y-'_  L+1/\ GZ/_ 'R:/[&R_P#Y\H/JM'^5'F?_  R#
MX*_Y_-8_\"(__C='_#(/@K_G\UC_ ,"(_P#XW7IG_"PM$_Y^C_WR:/\ A86B
M?\_1_P"^31_8V7_\^4'U6C_*CS/_ (9!\%?\_FL?^!$?_P ;H_X9!\%?\_FL
M?^!$?_QNO3/^%A:)_P _1_[Y-'_"PM$_Y^C_ -\FC^QLO_Y\H/JM'^5'F?\
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M_P!\FC^QLO\ ^?*#ZK1_E1YG_P ,@^"O^?S6/_ B/_XW1_PR#X*_Y_-8_P#
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M\S4\I/[B_E1Y2?W%_*N!_P"%G:Q_T(/B#_OB+_XNC_A9VL?]"#X@_P"^(O\
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M^$O\C#Z[0_F_,^FO*3^XOY4>4G]Q?RKYE_X;2_ZE+_R?_P#M='_#:7_4I?\
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MR#Z[0_F_,^FO*3^XOY4>4G]Q?RKYE_X;2_ZE+_R?_P#M='_#:7_4I?\ D_\
M_:Z/]8<L_P"?OX2_R#Z[0_F_,^FO*3^XOY4>4G]Q?RKYE_X;2_ZE+_R?_P#M
M='_#:7_4I?\ D_\ _:Z/]8<L_P"?OX2_R#Z[0_F_,^FO*3^XOY5FZ0H74-3
M&!YHZ?2IM U3^W-"T[4?+\G[9;1W'EYSMWJ&QGOC-0Z3_P A#4_^NH_E7T49
M*2YELSL3OJ+<?\C!:_\ 7)OZUJ5EW'_(P6O_ %R;^M:E4,\1_;8_Y-5^)/\
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M6J:UX:UO1WTJ_L9KK3G78UO);N5*^AKG)/"?PTF\+IX;?PPCZ"C;UT\VLGE
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MG;VKTO0?@=X*\-V>DVMAH[K!I-Q]JL4GO;B?[/)@+\OF2-QA0-OW1CI2:/\
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MK6M%^+7COP%>Z[?>*=*TJ"SOK34M2<27,+3><'@D< !L>4I' QN-=KK'P/\
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MQYIGB_5+-]-\4R!-(@*K9RQM+&CK(O)8D/UR.@XKZFNO@3X&O/&$GB>31/\
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M]3_&M6B@#*_M2]_Z!,O_ ']3_&C^U+W_ *!,O_?U/\:U:* ,K^U+W_H$R_\
M?U/\:/[4O?\ H$R_]_4_QK5HH RO[4O?^@3+_P!_4_QH_M2]_P"@3+_W]3_&
MM6B@#*_M2]_Z!,O_ ']3_&C^U+W_ *!,O_?U/\:U:* ,K^U+W_H$R_\ ?U/\
M:/[4O?\ H$R_]_4_QK5HH RO[4O?^@3+_P!_4_QH_M2]_P"@3+_W]3_&M6B@
M#*_M2]_Z!,O_ ']3_&C^U+W_ *!,O_?U/\:U:* ,K^U+W_H$R_\ ?U/\:/[4
MO?\ H$R_]_4_QK5HH RO[4O?^@3+_P!_4_QH_M2]_P"@3+_W]3_&M6B@#*_M
M2]_Z!,O_ ']3_&C^U+W_ *!,O_?U/\:U:* ,K^U+W_H$R_\ ?U/\:/[4O?\
MH$R_]_4_QK5HH RO[4O?^@3+_P!_4_QH_M2]_P"@3+_W]3_&M6B@#*_M2]_Z
M!,O_ ']3_&C^U+W_ *!,O_?U/\:U:* ,K^U+W_H$R_\ ?U/\:/[4O?\ H$R_
M]_4_QK5HH RO[4O?^@3+_P!_4_QH_M2]_P"@3+_W]3_&M6B@#*_M2]_Z!,O_
M ']3_&C^U+W_ *!,O_?U/\:U:* ,K^U+W_H$R_\ ?U/\:/[4O?\ H$R_]_4_
MQK5HH RO[4O?^@3+_P!_4_QH_M2]_P"@3+_W]3_&M6B@#*_M2]_Z!,O_ ']3
M_&C^U+W_ *!,O_?U/\:U:* ,K^U+W_H$R_\ ?U/\:/[4O?\ H$R_]_4_QK5H
MH RO[4O?^@3+_P!_4_QH_M2]_P"@3+_W]3_&M6B@#*_M2]_Z!,O_ ']3_&C^
MU+W_ *!,O_?U/\:U:* ,K^U+W_H$R_\ ?U/\:/[4O?\ H$R_]_4_QK5HH RO
M[4O?^@3+_P!_4_QH_M2]_P"@3+_W]3_&M6B@#*_M2]_Z!,O_ ']3_&C^U+W_
M *!,O_?U/\:U:* ,K^U+W_H$R_\ ?U/\:/[4O?\ H$R_]_4_QK5HH RO[4O?
M^@3+_P!_4_QH_M2]_P"@3+_W]3_&M6B@#*_M2]_Z!,O_ ']3_&C^U+W_ *!,
MO_?U/\:U:* ,K^U+W_H$R_\ ?U/\:/[4O?\ H$R_]_4_QK5HH RO[4O?^@3+
M_P!_4_QH_M2]_P"@3+_W]3_&M6B@#*_M2]_Z!,O_ ']3_&C^U+W_ *!,O_?U
M/\:U:* ,K^U+W_H$R_\ ?U/\:/[4O?\ H$R_]_4_QK5HH RO[4O?^@3+_P!_
M4_QH_M2]_P"@3+_W]3_&M6B@#*_M2]_Z!,O_ ']3_&ET6*X$UY-/ ;?SG!5"
*P8XQ[5J44@/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996810031488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 09, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Summit Therapeutics Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">37-1979717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">601 Brickell Key Drive, Suite 1000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Miami<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">460-8308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SMMT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 108.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">701,697,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001599298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996809901744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PricewaterhouseCoopers LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996809596336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 71,425<span></span>
</td>
<td class="nump">$ 348,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">114,817<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">2,441<span></span>
</td>
<td class="nump">1,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">181<span></span>
</td>
<td class="nump">486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent', window );">Research and development tax credit receivable</a></td>
<td class="nump">848<span></span>
</td>
<td class="nump">5,766<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">189,712<span></span>
</td>
<td class="nump">656,712<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">204<span></span>
</td>
<td class="nump">906<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">5,859<span></span>
</td>
<td class="nump">4,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">1,893<span></span>
</td>
<td class="nump">1,798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ResearchAndDevelopmentTaxCreditReceivableNoncurrent', window );">Research and development tax credit receivable</a></td>
<td class="nump">959<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">4,322<span></span>
</td>
<td class="nump">577<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">202,949<span></span>
</td>
<td class="nump">664,168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,667<span></span>
</td>
<td class="nump">355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">8,783<span></span>
</td>
<td class="nump">10,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">5,429<span></span>
</td>
<td class="nump">5,641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">2,809<span></span>
</td>
<td class="nump">1,690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">717<span></span>
</td>
<td class="nump">662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Promissory note payable to related parties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,770<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">$ 20,405<span></span>
</td>
<td class="nump">$ 38,782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration', window );">Notes Payable, Current, Related Party, Type [Extensible Enumeration]</a></td>
<td class="text">Related party<span></span>
</td>
<td class="text">Related party<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">$ 3,290<span></span>
</td>
<td class="nump">$ 2,763<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">1,562<span></span>
</td>
<td class="nump">1,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Promissory notes payable to related parties</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 494,540<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableNoncurrentRelatedPartyTypeExtensibleEnumeration', window );">Notes Payable, Noncurrent, Related Party, Type [Extensible Enumeration]</a></td>
<td class="text">Related party<span></span>
</td>
<td class="text">Related party<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">$ 125,257<span></span>
</td>
<td class="nump">$ 537,514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 22)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value, 20,000,000 shares authorized; none issued and outstanding at December 31, 2023 and 2022, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value: 1,000,000,000 shares authorized; 701,660,053 and 211,091,425 shares issued and outstanding at December 31, 2023 and 2022, respectively</a></td>
<td class="nump">7,017<span></span>
</td>
<td class="nump">2,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,066,381<span></span>
</td>
<td class="nump">504,767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(2,448)<span></span>
</td>
<td class="num">(1,893)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(993,258)<span></span>
</td>
<td class="num">(378,330)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">77,692<span></span>
</td>
<td class="nump">126,654<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 202,949<span></span>
</td>
<td class="nump">$ 664,168<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Tax Credit Receivable, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ResearchAndDevelopmentTaxCreditReceivableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Tax Credit Receivable, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ResearchAndDevelopmentTaxCreditReceivableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of related party for notes payable classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableNoncurrentRelatedPartyTypeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of related party for notes payable classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableNoncurrentRelatedPartyTypeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996809920768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">701,660,053<span></span>
</td>
<td class="nump">211,091,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">701,660,053<span></span>
</td>
<td class="nump">211,091,425<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996810273824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">59,471<span></span>
</td>
<td class="nump">51,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">30,265<span></span>
</td>
<td class="nump">26,743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_InProcessResearchAndDevelopmentExpense', window );">In-process research and development</a></td>
<td class="nump">520,915<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,468<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">610,651<span></span>
</td>
<td class="nump">87,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other operating income</a></td>
<td class="nump">1,001<span></span>
</td>
<td class="nump">14,416<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(609,650)<span></span>
</td>
<td class="num">(72,089)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(5,278)<span></span>
</td>
<td class="num">(6,693)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax</a></td>
<td class="num">(614,928)<span></span>
</td>
<td class="num">(78,782)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (614,928)<span></span>
</td>
<td class="num">$ (78,782)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_EarningsPerShareBasicAndDilutedEPSAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.99)<span></span>
</td>
<td class="num">$ (0.41)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.99)<span></span>
</td>
<td class="num">$ (0.41)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">619,646,180<span></span>
</td>
<td class="nump">193,336,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">619,646,180<span></span>
</td>
<td class="nump">193,336,063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive (loss) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">$ (172)<span></span>
</td>
<td class="nump">$ 304<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax', window );">Reclassification of cumulative currency translation gain to other expense, net</a></td>
<td class="num">(419)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain on short-term investments</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (615,483)<span></span>
</td>
<td class="num">$ (78,478)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_EarningsPerShareBasicAndDilutedEPSAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share, Basic and Diluted EPS</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_EarningsPerShareBasicAndDilutedEPSAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_InProcessResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In-Process Research And Development Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_InProcessResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481839/830-10-45-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482014/830-20-35-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 40<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481724/830-30-40-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-17A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996806393216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Rights Offering</div></th>
<th class="th"><div>Private placement</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Rights Offering</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Private placement</div>
</th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Rights Offering</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Private placement</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Total Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,039,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 83,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 384,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,197)<span></span>
</td>
<td class="num">$ (299,548)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Rights Offering of common stock, net of offering costs/ Private placement of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,092,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Rights Offering of common stock, net of offering costs/ Private placement of common stock</a></td>
<td class="nump">99,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_StockIssuedDuringPeriodSharesIssuedForRelatedPartyInterest', window );">Issuance of common stock in lieu of interest to related parties (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,720,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_StockIssuedDuringPeriodValueIssuedForRelatedPartyInterest', window );">Issuance of common stock in lieu of interest to related parties</a></td>
<td class="nump">7,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under stock purchase plans and exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under stock purchase plans and exercise of stock options</a></td>
<td class="nump">399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">11,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty', window );">Imputed interest expense on promissory note payable to a related party</a></td>
<td class="nump">2,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain on short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax', window );">Reclassification of cumulative translation gain (Note 10)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (78,782)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(78,782)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">211,091,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211,091,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 126,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">504,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,893)<span></span>
</td>
<td class="num">(378,330)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Rights Offering of common stock, net of offering costs/ Private placement of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">476,190,471<span></span>
</td>
<td class="nump">2,976,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Rights Offering of common stock, net of offering costs/ Private placement of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 499,381<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,762<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 494,619<span></span>
</td>
<td class="nump">$ 4,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">805,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_StockIssuedDuringPeriodValueWarrantsExercised', window );">Exercise of warrants</a></td>
<td class="nump">1,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under stock purchase plans and exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">596,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under stock purchase plans and exercise of stock options</a></td>
<td class="nump">929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_StockIssuedDuringPeriodSharesInLieuOfCashForCollaborativeArrangement', window );">Issuance of common stock in lieu of cash for Akeso upfront payment (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement', window );">Issuance of common stock in lieu of cash for Akeso upfront payment</a></td>
<td class="nump">45,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">14,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain on short-term investments</a></td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax', window );">Reclassification of cumulative translation gain (Note 10)</a></td>
<td class="num">(419)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(419)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(172)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(172)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (614,928)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(614,928)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">701,660,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">701,660,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">$ 77,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,066,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,448)<span></span>
</td>
<td class="num">$ (993,258)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Imputed Interest Expense, Related Party</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_StockIssuedDuringPeriodSharesInLieuOfCashForCollaborativeArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, In Lieu Of Cash For Collaborative Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_StockIssuedDuringPeriodSharesInLieuOfCashForCollaborativeArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_StockIssuedDuringPeriodSharesIssuedForRelatedPartyInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Issued For Related Party Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_StockIssuedDuringPeriodSharesIssuedForRelatedPartyInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, In Lieu Of Cash For Collaborative Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_StockIssuedDuringPeriodValueIssuedForRelatedPartyInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Issued For Related Party Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_StockIssuedDuringPeriodValueIssuedForRelatedPartyInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481839/830-10-45-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482014/830-20-35-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 40<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481724/830-30-40-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-17A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996811592400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Offering cots</a></td>
<td class="nump">$ 619<span></span>
</td>
<td class="nump">$ 111<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996807501632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (614,928)<span></span>
</td>
<td class="num">$ (78,782)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss', window );">Gain on remeasurement of liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,265)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_InterestExpenseIncomeNoncash', window );">Non-cash interest expense</a></td>
<td class="nump">6,253<span></span>
</td>
<td class="nump">4,303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of discount on short-term investments</a></td>
<td class="num">(1,924)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized foreign currency (gain) loss</a></td>
<td class="num">(812)<span></span>
</td>
<td class="nump">2,616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome', window );">Reclassification of currency translation gain</a></td>
<td class="num">(419)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Impairment of fixed assets</a></td>
<td class="nump">474<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating right-of-use assets</a></td>
<td class="nump">1,852<span></span>
</td>
<td class="nump">1,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">198<span></span>
</td>
<td class="nump">349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">14,108<span></span>
</td>
<td class="nump">11,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposal of assets</a></td>
<td class="num">(109)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_InProcessResearchAndDevelopmentExpense', window );">In-process research and development expense</a></td>
<td class="nump">520,915<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">359<span></span>
</td>
<td class="nump">975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(914)<span></span>
</td>
<td class="nump">5,107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other current and long-term assets</a></td>
<td class="num">(3,421)<span></span>
</td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable', window );">Research and development tax credit receivable</a></td>
<td class="nump">4,168<span></span>
</td>
<td class="nump">8,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue and other income</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,278)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">2,263<span></span>
</td>
<td class="num">(4,132)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="num">(2,377)<span></span>
</td>
<td class="nump">4,782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
<td class="num">(235)<span></span>
</td>
<td class="nump">1,609<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(2,211)<span></span>
</td>
<td class="num">(1,099)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(76,760)<span></span>
</td>
<td class="num">(41,582)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows used in investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(128)<span></span>
</td>
<td class="num">(624)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property. plant and equipment</a></td>
<td class="nump">226<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchase of short-term investments</a></td>
<td class="num">(321,022)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments', window );">Maturities and sales of short-term investments</a></td>
<td class="nump">208,165<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_PaymentsForCollaborativeArrangement', window );">Payments to Akeso for upfront milestone payments and associated direct transaction costs</a></td>
<td class="num">(475,015)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(587,774)<span></span>
</td>
<td class="num">(624)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows provided by financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock for rights offering</a></td>
<td class="nump">104,686<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Transaction costs from the issuance of common stock for rights offering</a></td>
<td class="num">(619)<span></span>
</td>
<td class="num">(111)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from the issuance of common stock via private placement</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Net receipts related to the exercise of warrants</a></td>
<td class="nump">1,203<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds received related to employee stock purchase plan and exercise of stock options</a></td>
<td class="nump">929<span></span>
</td>
<td class="nump">399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from related party promissory notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">545,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Re-payment of related party promissory notes</a></td>
<td class="num">(24,686)<span></span>
</td>
<td class="num">(25,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of related party promissory notes issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">86,513<span></span>
</td>
<td class="nump">620,244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rates on cash and cash equivalents</a></td>
<td class="nump">839<span></span>
</td>
<td class="num">(1,222)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">(Decrease) Increase in cash, cash equivalents and restricted cash</a></td>
<td class="num">(577,182)<span></span>
</td>
<td class="nump">576,816<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">648,607<span></span>
</td>
<td class="nump">71,791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">71,425<span></span>
</td>
<td class="nump">648,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest on related party promissory note</a></td>
<td class="nump">10,650<span></span>
</td>
<td class="nump">434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_DebtIssuanceCostsIncurredButNotYetPaid', window );">Debt issuance costs in accrued expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_DeferredTransactionCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Deferred transaction costs included in other non-current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Leased assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">4,245<span></span>
</td>
<td class="nump">2,860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=smmt_AkesoLicenseAgreementMember', window );">Akeso License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common stock</a></td>
<td class="nump">45,900<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=smmt_RightsOfferingMember', window );">Rights Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common stock</a></td>
<td class="nump">$ 395,314<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Assumed Contingent Liability, Remeasurement Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cumulative Currency Translation Gains (Losses), Realized upon Sale or Liquidation, Reclassified From Other Comprehensive Income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_DebtIssuanceCostsIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Issuance Costs Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_DebtIssuanceCostsIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_DeferredTransactionCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Transaction Costs Incurred During Noncash Or Partial Noncash Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_DeferredTransactionCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_InProcessResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In-Process Research And Development Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_InProcessResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Research And Development Tax Credit Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_InterestExpenseIncomeNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Expense (Income), Noncash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_InterestExpenseIncomeNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_PaymentsForCollaborativeArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Collaborative Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_PaymentsForCollaborativeArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=smmt_AkesoLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=smmt_AkesoLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=smmt_RightsOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=smmt_RightsOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996812103872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Operations and Recent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Business and Operations and Recent Events</a></td>
<td class="text">Nature of Business and Operations and Recent Events<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Nature of Business and Operations</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summit Therapeutics Inc. (</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we&#8221;, </span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summit&#8221; or the </span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company&#8221;) is a biopharmaceutical company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s pipeline of product candidates is designed with the goal to become the patient-friendly, new-era standard-of-care medicines, in the therapeutic area of oncology.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s current lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. On December 5, 2022, the Company entered into a Collaboration and License Agreement (the &#8220;License Agreement&#8221;) with Akeso, Inc. and its affiliates (&#8220;Akeso&#8221;) pursuant to which the Company has in-licensed ivonescimab. Through the License Agreement (as defined in Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company obtained the rights to develop and commercialize ivonescimab in the United States, Canada, Europe, and Japan (the &#8220;Licensed Territory&#8221;). The License Agreement and transaction closed in January 2023 following customary waiting periods. The Company&#8217;s operations will be focused on the development of ivonescimab and other future activities, as the Company determines.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has begun its development for ivonescimab in non-small cell lung cancer (</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NSCLC&#8221;), specifically launching Phase III clinical trials in the following indications:</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)  ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EGFR&#8221;)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TKI&#8221;) (&#8220;HARMONi&#8221;); and</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)  ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (&#8220;HARMONi-3&#8221;)</span></div><div style="padding-left:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of these financial statements, both studies are enrolling patients.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The entry into the License Agreement with Akeso represents a significant change in the Company&#8217;s strategy and its future operations will be focused on the development of ivonescimab and other future activities as the Company determines. The Company&#8217;s portfolio includes ridinilazole, a product candidate for treating patients suffering from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clostridioides difficile </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">infection, also known as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C. difficile </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">infection, or CDI. All prior development and marketing activities related to ridinilazole have been terminated. The Company&#8217;s anti-infectives portfolio includes SMT-738, the first of a novel class of precision antibiotics for combating multidrug resistant infections, specifically carbapenem-resistant Enterobacteriaceae (&#8220;CRE&#8221;) infections. The Company will continue to pursue partnerships for further development of SMT-738. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Recent Events</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the events detailed in the Company Overview section above, the following other recent developments have occurred. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, on December 5, 2022, the Company entered into a Collaboration and License Agreement (the &#8220;License Agreement&#8221;) with Akeso  pursuant to which the Company is in-licensing breakthrough bispecific antibody, ivonescimab (Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;6, 2022, the Company entered into a Note Purchase Agreement (the &#8220;Note Purchase Agreement&#8221;), with Mr. Robert Duggan and Dr. Maky Zanganeh, pursuant to which the Company agreed to sell to each of Mr. Duggan and Dr. Zanganeh unsecured promissory notes in the aggregate amount of $520,000 (Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January&#160;19, 2023, the Company filed Amendment No. 2 to the Restated Certificate of Incorporation (the &#8220;Amendment No. 2&#8221;) with the Secretary of State of the State of Delaware to increase the number of authorized shares of its common stock by 650,000,000 (from 350,000,000 to 1,000,000,000), which became effective on such date. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;7, 2023, the Company commenced its previously announced rights offering (&#8220;2023 Rights Offering&#8221;). On March 1, 2023, the Company closed the 2023 Rights Offering, which was fully subscribed. The Company received aggregate gross proceeds from the 2023 Rights Offering of $500,000 from the sale of&#8239;476,190,471&#8239;shares of its common stock at a price per share of $1.05. Issuance costs associated with the 2023 Rights Offering were approximately $619. In connection with the closing of the 2023 Rights Offering, $400,000 of the unsecured promissory notes, issued by the Company to Mr. Duggan,&#8239;matured and became due and the Company repaid the principal amount and all outstanding accrued interest thereunder using a portion of the proceeds from this 2023 Rights Offering (Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;15, 2023, $20,000 of the unsecured promissory notes, issued by us to Dr. Zanganeh, matured and the Company repaid the outstanding principal balance.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2023, the Company filed a registration statement on Form S-3 to register for resale the following shares of its common stock at $0.01 par value: (i) 10,000,000 shares of Common Stock issued on January 17, 2023 in connection with the License Agreement with Akeso pursuant to which the Company issued Akeso such shares; and (ii) the 9,346,434 and 373,857 shares of common stock issued in December 2022 to its Chief Executive Officers, Mr. Robert Duggan and Dr. Mahkam Zanganeh, respectively, as payment of prepaid interest in connection with the Note Purchase Agreement dated December 6, 2022 between Mr. Duggan, Dr. Zanganeh and the Company (Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). On April 27, 2023, the SEC issued a Notice of Effectiveness for the registration statement on Form S-3 filed with the SEC.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 12, 2023, the Company held a Special Meeting of Stockholders (the &#8220;October Special Meeting&#8221;) whereby an amendment to the Summit Therapeutics Inc. 2020 Stock Incentive Plan (the &#8220;Plan&#8221;) to increase the number of shares of the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s common stock issuable under the Plan by 70,000,000 shares was approved by a vote of the Company&#8217;s stockholders at the Special Meeting and subsequently ratified by the Board of Directors.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 16, 2023, the Company announced the appointment of Mr. Manmeet Soni as its Chief Operating Officer, effective immediately. Mr. Soni has been a part of the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s Board of Directors since 2019. He will remain a member of the Board of Directors. In conjunction with his appointment, Mr. Soni entered into a share purchase agreement with the Company to purchase $5,000 of its common stock via a private placement. The transaction was effective October 13, 2023 with a closing price of $1.68, resulting in the purchase of 2,976,190 shares of the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2024 the Duggan February Note was amended to extend the maturity date from September 6, 2024 to April 1, 2025. For all applicable periods commencing  February 17, 2024, interest shall accrue on the outstanding principal balance at the greater of 12% or the US prime interest rate, as reported in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wall Street Journal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plus 350 basis points, as adjusted monthly, compounded quarterly (Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Interest shall be paid upon maturity of the loan.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996815740704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Use of Estimates, and Risks and Uncertainties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">Basis of Presentation, Use of Estimates, and Risks and Uncertainties</a></td>
<td class="text">Basis of Presentation, Use of Estimates, and Risks and Uncertainties <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. Any reference in these notes to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and as amended by Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments, including those related to revenue recognition, accrued research and development expenses, stock-based compensation, intangible assets, goodwill, other long-lived assets and income taxes. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996814777568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Capital Resources<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_LiquidityAndCapitalResourcesTextBlock', window );">Liquidity and Capital Resources</a></td>
<td class="text">Liquidity and Capital Resources<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company incurred a net loss of $614,928 and cash flows used in operating activities was $76,760. As of December 31, 2023, the Company had an accumulated deficit of $993,258, and cash and cash equivalents and short term investments in U.S. treasury securities of $186,242. The Company expects to continue to generate operating losses for the foreseeable future. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated whether its cash, cash equivalents, short-term investments and U.K. research and development tax credits provide sufficient cash to fund its operating cash needs for the next twelve months from the date of issuance of these annual financials. The Company is investing in the clinical development of ivonescimab, including its ongoing clinical trials. In addition, the Company has a $100,000 promissory note payable to a related party (refer to Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details) that matures on April 1, 2025. Based upon the Company's cash and cash equivalents and short-term investments as of December 31, 2023, the Company expects to be able to operate into the first quarter of 2025. In order to further fund the Company's operating cash needs and repay this promissory note, the Company intends to raise additional capital. As of the date of the issuance of these financial statements the additional capital has not been secured. As a result, these conditions raise substantial doubt about the Company's ability to continue as a going concern.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until the Company can generate substantial revenue and achieve profitability, the Company will need to raise additional capital to fund its ongoing operations and capital needs. The Company continues to evaluate options to further finance its operating cash needs for its product candidates through a combination of some, or all, of the following: equity and debt offerings, collaborations, strategic alliances, grants and clinical trial support from government entities, philanthropic, non-government and not-for-profit organizations, and marketing, distribution or licensing arrangements. There is no assurance, however, that additional financing will be available when needed or that management of the Company will be able to obtain financing on terms acceptable to the Company. If the Company is unable to obtain funding when required in the future, the Company could be required to delay, reduce, or eliminate research and development programs, product portfolio expansion, or future commercialization efforts, which could adversely affect its business prospects.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements are prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of the business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classifications of liabilities that might result from the outcome of this uncertainty.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_LiquidityAndCapitalResourcesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity and Capital Resources</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_LiquidityAndCapitalResourcesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996814777568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant accounting policies adopted by the Company in the preparation of these consolidated financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. The consolidated financial statements reflect the accounts of Summit Therapeutics Inc. and its wholly owned subsidiaries. Intercompany balances and transactions are eliminated in consolidation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements of the Company&#8217;s subsidiaries with functional currencies other than the United States (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) dollar are translated into U.S. dollars using period-end exchange rates for assets and liabilities, historical exchange rates for stockholders&#8217; equity and weighted average exchange rates for operating results. Translation gains and losses are included in </span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accumulated other comprehensive (loss) income in shareholders&#8217; equity. Foreign currency transaction gains and losses are included in other expen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">se, net in the results of operations. The Company recorded realized and unrealized foreign currency transaction gains (losses) of $613 and ($4,109) for the years ended December 31, 2023 and 2022, respectively, which is included in other expense, net in the statements of operations and comprehensive loss.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Operating Income</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates income from government contracts that reimburse the Company for certain allowable costs for funded projects. For contracts with government agencies where the funding arrangement is considered central to the Company&#8217;s ongoing operations, the Company classifies the recognized funding received as other operating income.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income from government grants is recognized as the qualifying expenses related to the contracts are incurred, provided that there is reasonable assurance of recoverability. If the government agency approves the project proposed by the Company, the government agency funds the project upon receipt of the support for the costs incurred up to the contract limit. Income recognized upon incurring qualifying expenses in advance of billing is recorded as unbilled receivable, a component of other current assets, in the consolidated balance sheet.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant income is not recognized as deductions of research and development costs because the Company acts as the principal in conducting the research and development activities and these contracts are central to its ongoing operations. The funds received through these means are held as deferred income in the consolidated balance sheets and are released to the consolidated statement of operations and comprehensive loss, classified as other operating income, as the underlying expenditure is incurred and to the extent the conditions of the grant are met. The related costs incurred by the Company are included in research and development expense in the Company&#8217;s consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company benefits from two U.K. research and development (&#8220;R&amp;D&#8221;) tax credit cash rebate regimes: Small and Medium Enterprise (&#8220;SME&#8221;) Program and the Research and Development Expenditure Credit (&#8220;RDEC&#8221;) Program. Each reporting period, management evaluates which tax relief programs the Company is expected to be eligible for and records as other operating income the portion of the expense that it expects to qualify under the programs, that it plans to submit a claim for, and it has reasonable assurance that the amount will ultimately be realized. Based on criteria established by HM Revenue and Customs (&#8220;HMRC&#8221;), management of the Company expects a proportion of expenditures being undertaken in relation to its pipeline research, clinical trials management and manufacturing development activities to be eligible for the research and development tax relief programs for the year ended December 31, 2023. Qualifying expenditures largely comprise of employment costs for research staff, consumables, a proportion of relevant, permitted sub-contract costs and certain internal overhead costs incurred as part of research projects for which the Company does not receive commercial or other funding income. Credits related to the SME and RDEC Programs are recorded as other operating income in the consolidated statements of operations and other comprehensive (loss)/income. Under the SME scheme, the Company receives cash rebate payments of up to 33.3% up to March 31, 2023 and 18.6% from April 1, 2023 of eligible research and development expenditures, and under the RDEC scheme the Company receives cash rebate payments of up to 10.53% up to March 31, 2023 and 15% from April 1, 2023 of eligible research and development expenditure, and these payments are not dependent on the Company&#8217;s pre-tax net income levels. The Company has qualified under the more favorable SME regime and expects such elements of expenditures will also continue to be eligible for the SME regime for future periods.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the diluted net loss by the weighted-average number of common shares outstanding for the period, including potentially dilutive common shares. The dilutive effect of share options and warrants are determined under the treasury stock method using the average market price for the period.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the assumed proceeds under the treasury stock method include the average unrecognized compensation expense of stock options and warrants that are in-the-money.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Combinations </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for under the acquisition method. Acquired assets and assumed liabilities are measured at their fair values at the acquisition date. The excess of the consideration transferred over the net fair value of assets acquired and liabilities assumed is recorded as goodwill. The accounting for an acquisition involves a considerable amount of judgement and estimation. Cost, income, market or a combination of approaches may be used to establish the fair value of consideration exchanged, assets acquired, and liabilities assumed, depending on the nature of those items. The valuation approach is determined in accordance with generally accepted valuation methods. Key areas of estimation and judgment may include the selection of valuation approaches, cost of capital, market characteristics, cost structure, impacts of synergies, and estimates of terminal value, among other factors.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Company uses estimates and assumptions as part of the purchase price allocation process to estimate the value of assets acquired and liabilities assumed, estimates are inherently uncertain and subject to refinement. During the measurement period, which maybe up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with a corresponding offset to goodwill, to the extent that adjustments are identified to the preliminary purchase price allocation. Upon conclusion of the measurement period, or final determination of the value of the assets acquired and liabilities assumed, whichever comes first, any subsequent adjustments are recorded to results of operations. Results of operations related to business combinations are included prospectively beginning with the date of acquisition and transaction costs related to business combinations are recorded within general and administrative expenses. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the consideration transferred over the fair value of net assets acquired. Goodwill is assigned to reporting units at the time of acquisition or when there is a change in the reporting structure and bases that allocation on which reporting units will benefit from the acquired assets and liabilities. Reporting units are defined as operating segments or one level below an operating segment, referred to as a component. Typically acquisitions related to a single reporting unit do not require the allocation of goodwill to multiple reporting units. If the products obtained in an acquisition are assigned to multiple reporting units, the goodwill is distributed to the respective reporting units as part of the purchase price allocation process.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses goodwill for impairment on an annual basis or more frequently when events and circumstances occur indicating that the recorded goodwill may be impaired. The Company regularly monitors current business conditions and other factors including, but not limited to, adverse industry or economic trends and lower projections of profitability that may impact future operating results. The process of evaluating the potential impairment of goodwill requires significant judgment. In performing the Company&#8217;s annual goodwill impairment test, the Company is permitted to first assess qualitative factors to determine whether it is more likely than not that the fair value of the Company&#8217;s reporting unit is less than its carrying amount, including goodwill. In performing the qualitative assessment, the Company considers certain events and circumstances specific to the reporting unit and to the entity as a whole, such as macroeconomic conditions, industry and market considerations, overall financial performance and cost factors when evaluating whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. The Company is also permitted to bypass the qualitative assessment and proceed directly to the quantitative test. If the Company chooses to undertake the qualitative assessment and concludes that it is more likely than not that the fair value of the reporting unit is less than its carrying amount, the Company would then proceed to the quantitative impairment test. In the quantitative assessment, the Company compares the fair value of the reporting unit to its carrying amount, which includes goodwill. If the fair value exceeds the carrying value, no impairment loss exists. If the fair value is less than the carrying amount, a goodwill impairment loss is measured and recorded.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses goodwill for impairment on an annual basis as of December 31 or more frequently when events and circumstances occur indicating that recorded goodwill may be impaired.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment </span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation. Cost is comprised of the purchase price plus any incidental costs of acquisition and commissioning. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is calculated based on cost, less residual value, in equal annual installments over the estimated useful lives of the assets. The residual value, if significant, is reassessed annually.</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 - 10 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures, office equipment and software</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="-sec-ix-hidden:f-377"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Over the shorter of the asset</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">s useful life or the remaining lease term</span></span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is recognized as part of the general and administrative and research and development expense lines shown on the face of the consolidated statement of operations and comprehensive loss depending on the nature of the underlying assets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenditures for repairs and maintenance are expensed as incurred. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in loss from operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for real estate. The Company does not have any finance leases. Under ASC 842, a contract is or contains a lease when the lessee has the right to control the use of an identified asset. The Company determines if an arrangement is a lease at inception of the contract, which is the date on which the terms of the contract are agreed to and the agreement creates enforceable rights and obligations. The lease term used to calculate the lease liability include options to extend or terminate the lease when it is reasonably certain that the option will be exercised.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the lease commencement date, the Company measures and recognizes a lease liability and a right-of-use asset in the financial statements. Lease liabilities are recognized based on the present value of the future lease payments over the lease term at commencement date. The right-of use asset is measured by taking the present value of future lease payments, plus any incremental direct costs incurred, less any lease incentives received. As most of the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s leases do not provide an implicit rate, the Company uses an estimated incremental borrowing rate based on the lease term and the economic environment of the lease at the lease commencement date, which is then utilized to determine the present value of future lease payments. Lease expense for minimum lease payments are recognized on a straight-line basis over the lease term, with variable lease payments recognized in the periods in which they are incurred.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has existing lease agreements with lease and non-lease components, has elected to account for the lease and non-lease components as a single lease component, and has allocated all of the contract consideration to the lease component only. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial lease term of 12 months or less are not recorded on the balance sheet. The Company recognizes lease expense for its short-term leases on a straight-line basis over the lease term.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquired In-Process Research and Development</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company  may enter into agreements with collaboration partners for the development and commercialization of its products. These arrangements may include payments contingent on the occurrence of certain events such as development, regulatory or sales-based milestones. The Company considers the unique nature, terms and facts and circumstances of each transaction. The Company considers whether or not the assets acquired have a future alternative use. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value associated with acquired in-process research and development which does not have an alternative future use is expensed and is recorded as research and development expense. Any development or commercial milestone payments are recognized when the achievement of the associated milestone becomes probable and will either be expensed or capitalized depending upon whether or not regulatory approval has been obtained. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Costs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred to discover, research and develop product candidates, including personnel expenses, stock-based compensation expense, allocated facility-related and depreciation expenses, third-party license fees and external costs of outside vendors engaged to conduct </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preclinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are recorded as prepaid expenses. Such amounts are recognized as an expense as the goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered. Milestone and other payments made to third-parties with respect to in-process research and development, in accordance with the Company&#8217;s license, acquisition and other similar agreements are expensed when determined to be probable and estimable.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various research and development contracts with other companies. These agreements are generally cancellable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research and development costs or prepaid expenses where the payments made exceeds the estimated costs. When evaluating the adequacy of these balances, the Company analyzes progress of the studies, including the estimated costs to complete each study or activity, the estimation of the current stage of completion and the invoices received, as well as predetermined milestones which are not reflective of the current stage of development for prepaid expenses. Actual results could differ from the Company&#8217;s estimates. In all cases, the full cost of each study or activity is expensed by the time the final report or where applicable, product, has been received. The Company&#8217;s historical estimates have not been materially different from the actual costs.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and recognizes compensation expense for all stock option and restricted stock unit awards based on the estimated fair value of the award on the grant date. The Company uses the Black-Scholes option pricing model to estimate the fair value of stock option awards. Additionally, the Company uses a Monte Carlo simulation model to calculate the estimated fair value on the date of grant related to awards with market-based service conditions. The fair value is recognized as expense, over the requisite service period, which is generally the vesting period of the respective award, on a straight-line basis for each separately vesting portion of the award when the only condition to vesting is continued service.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If vesting is subject to a market or performance condition, recognition is based on the derived service period of the award. Expense for awards with performance conditions is estimated and adjusted on a quarterly basis based upon the assessment of the probability that the performance condition will be met. Use of the Black-Scholes option-pricing model requires management to apply judgment under highly subjective assumptions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These assumptions include:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expected term&#8212;The expected term of stock options represents the weighted-average period the stock options are expected to be outstanding. The Company uses the simplified method for estimating the expected term as provided by the Securities and Exchange Commission. The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life of the options.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expected volatility&#8212;The expected volatility is calculated based on historical volatility of the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s share price.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk-free interest rate&#8212;The risk-free rate assumption is based on the U.S. Treasury instruments, the terms of which were consistent with the expected term of the Company&#8217;s stock options.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expected dividend&#8212;The expected dividend assumption is based on the Company&#8217;s history and expectation of dividend payouts. The Company has not paid and does not intend to pay dividends. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates expected forfeitures at the time of grant instead of accounting for forfeitures as they occur. Stock option and restricted stock unit awards have been granted at fair value to non-employees in connection with research and consulting services provided to the Company. Equity awards generally vest over terms of 3 or 4 years. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies stock-based compensation expense in the consolidated statements of operations in the same manner in which the award recipient&#8217;s payroll costs are classified.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is determined using the asset and liability approach. Tax laws may require items to be included in tax filings at different times than the items are reflected in the financial statements. A current asset or liability is recognized for the estimated taxes receivable or payable for the current year. Deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. Deferred taxes are initially recognized at enacted tax rates in force at the time of initial recognition and are subsequently adjusted for any enacted changes in tax rates </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and tax laws. Subsequent changes to deferred taxes originally recognized in equity are recognized in income. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The Company has recorded a full valuation allowance against the deferred tax assets in excess of its deferred tax liabilities, as the deferred tax liability represents future reversals of existing taxable temporary differences. The Company records interest and penalties related to income tax matters as part of income tax expense.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertainty in income taxes by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed as the amount of benefit to recognize in the consolidated financial statements. The amount of benefits that may be used is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate, as well as the related net interest and penalties. At December 31, 2023 and 2022, the Company had unrecognized tax positions of $1,064 and $0, respectively. Due to the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s full valuation allowance, the unrecognized tax benefits would not materially impact the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s effective tax rate when recognized.  The Company does not anticipate the total amount of unrecognized tax benefits to significantly increase or decrease in the next 12 months. The Company&#8217;s policy is to recognize interest and penalties related to uncertain tax positions as part of its income tax provision. For the years ended December 31, 2023and 2022, the Company had no interest or penalties related to unrecognized tax benefits.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk and of Significant Supplier</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of short-term cash deposits and accounts and other receivables. The Company&#8217;s cash is comprised of short-term cash deposits at a variety of financial institutions with strong credit ratings in amounts that may exceed federally insured limits and has not experienced any losses on such accounts. Cash balances maintained during the year have been principally held with reputable U.K.-based and U.S.-based banks. The Company does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The credit risk with respect to customers and funding bodies is limited as the Company has only a small number of these arrangements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies, and expects to continue to rely, on a number of vendors to conduct its clinical trials and preclinical studies, manufacture drug product and supply clinical trial and preclinical study materials for its development programs. These programs could be adversely affected by a significant interruption in these services or the availability of materials.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the provisions of fair value accounting, a fair value measurement assumes that the transaction to sell an asset or transfer a liability occurs in the principal market for the asset or liability or, in the absence of a principal market, the most advantageous market for the asset or liability and defines fair value based on the exit price model.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurement guidance establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The guidance describes three levels of inputs that may be used to measure fair value:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quoted prices in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 2 assets and liabilities include debt securities with quoted prices that are traded less frequently than exchange-traded instruments or securities or derivative contracts that are valued using a pricing model with inputs that are observable in the market or can be derived principally from or corroborated by observable market data.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the Company categorizes such assets and liabilities based on the lowest level input that is significant to the fair value measurement in its entirety. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers only those investments that are highly liquid, readily convertible to cash and that mature within 90 days or less from date of purchase to be cash equivalents. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2023 and 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, cash equivalents were comprised of a money market funds and U.S. treasury securities with maturities less than 90 days from the date of purchase. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Cash</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash of $300,000 as of December 31, 2022, represents amounts which are legally restricted to withdrawal or usage and is presented in the Consolidated Balance Sheet as restricted cash. On December 15, 2022, the Company transferred $300,000 into an escrow fund reserved for the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s initial upfront payment to Akeso in connection with the License Agreement, as described further in Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Following the Antitrust Clearance Date, on January 17, 2023, the License Agreement closed and Akeso was issued 10,000,000 shares of Company common stock pursuant to the Common Stock Issuance Agreement and was paid $274,900 in cash as initial upfront payment. The remaining amounts in escrow were returned to the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s operating cash accounts. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assumed Contingent Liabilities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the acquisition of Discuva Limited in December 2017, the Company assumed certain contingent liabilities as certain employees, former employees and former directors of Discuva Limited are eligible for payments from Discuva Limited based on specified development and clinical milestones related to proprietary product candidates developed under the Discuva Platform. The timing of these potential payments is uncertain. The fair value of the assumed contingent liability was estimated using the expected value of the payments. The assumed contingent liabilities are subsequently measured at amortized cost using discounted cash flow models which calculate the risk adjusted net present values of estimated potential future cash flows of the payments. The assumed contingent liabilities are remeasured when there is a specific significant event that provides evidence of a significant change in the probability of successful development and clinical milestones being achieved. The models will be updated for changes in the probability of successful development and clinical milestones being achieved and other associated assumptions with the discount factor remaining unchanged within the model. A discount factor of 13% has been used to discount the contingent liabilities back to net present value. This discount factor has been calculated using appropriate measures and rates which could have been obtained in the period that the contingent liabilities were assumed. Accretion of the discount </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">factor and gains or losses upon remeasurement are recognized as part of operating expenses in the consolidated statements of operations and comprehensive loss.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants issued by the Company are recognized and classified as equity when, upon exercise, the Company would issue a fixed amount of its own equity instruments (common stock) in exchange for a fixed amount of cash or another financial asset.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration received, net of incremental costs directly attributable to the issue of such new warrants, is shown in equity. Such warrants are not remeasured at fair value in subsequent reporting periods.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants issued in which external services are received as consideration for equity instruments of the company should be measured at the fair value of the goods or services received. Only if the fair value of the services cannot be measured reliably would the fair value of the equity instruments granted be used. The fair value for the warrants is calculated using the Black-Scholes formula and recorded in the consolidated statement of operations and comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on a straight-line basis over the period of the consulting services. If the services are terminated prior to the end of the consultancy agreement, the warrants cease vesting and any unvested portion of the warrants will lapse immediately.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The warrants in issue are classified within stockholders&#8217; equity as they are indexed to the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span>s own shares of common stock and require settlement in its shares of common stocks with no provision for any cash settlement.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996812703408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recently Issued or Adopted Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Recently Issued or Adopted Accounting Pronouncements</a></td>
<td class="text">Recently Issued or Adopted Accounting Pronouncements <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards update &#8220;ASU&#8221; No. 2023-09, &#8220;Improvements to Income Tax Disclosures&#8221;, which requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. ASU No. 2023-09 is effective for fiscal years beginning after December 15, 2024 and allows for adoption on a prospective basis, with a retrospective option. Early adoption is permitted. The Company is currently evaluating the impact of the ASU on the income tax disclosures within the consolidated financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU No. 2023-07, &#8220;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&#8221;, which provides updates to qualitative and quantitative reportable segment disclosure requirements, including enhanced disclosures about significant segment expenses and increased interim disclosure requirements, among others. ASU No. 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. Early adoption is permitted, and the amendments should be applied retrospectively. The Company is currently evaluating the impact of the ASU on the consolidated financial statement disclosures. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, &#8220;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#8221;, which has subsequently been amended by ASU 2019-04 and ASU 2019-10 (collectively &#8220;ASU 2016-03&#8221;). ASU 2016-13 amends the guidance on the impairment of financial instruments. This update adds an impairment model (known as the current expected credit losses model) that is based on expected losses rather than incurred losses. Under the new guidance, an entity recognizes, as an allowance, its estimate of expected credit losses. The Company adopted this standard on January 1, 2023, and it did not have a material impact on the consolidated financial statements or related disclosures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other recent authoritative guidance issued by the FASB (including technical corrections to the FASB ASC), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not expected to have a material impact on the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -Publisher FASB<br> -URI https://asc.fasb.org//250/tableOfContent<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -SubTopic 20<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -SubTopic 20<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996813439712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Akeso License and Collaboration Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Akeso License and Collaboration Agreement</a></td>
<td class="text">Akeso License and Collaboration Agreement<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 5, 2022, the Company entered into a Collaboration and License Agreement (the &#8220;License Agreement&#8221;) with Akeso pursuant to which the Company is in-licensing its breakthrough bispecific antibody, ivonescimab. The License Agreement and transaction closed in January 2023 following customary waiting periods.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ivonescimab, known as AK112 in China and Australia, and also as SMT112 in the United States, Canada, Europe, and Japan, is a novel, potential first-in-class bispecific antibody intending to combine the benefits of immunotherapy via a blockade of PD-1 with the anti-angiogenesis benefits of an anti-VEGF into a single molecule. Ivonescimab was engineered to bring two well established oncology targeted mechanisms together. Ivonescimab is currently in clinical development and, pursuant to the terms of the License Agreement, Summit will design and conduct the clinical trial activities to support regulatory filings in the Licensed Territory that Summit will submit. Pursuant to the terms of the License Agreement, Summit will have final decision making authority with respect to commercial strategy, pricing and reimbursement and other commercialization matters in the Licensed Territory. In connection with the License Agreement, the Company has also entered into a Supply Agreement with Akeso, pursuant to which Summit agrees to purchase a certain portion of drug substance for clinical and commercial supply. Summit is not assuming any liabilities (including contingent liabilities), acquiring any physical assets or trade names, or hiring or acquiring any employees from Akeso in connection with the License Agreement. Through the License Agreement, the Company obtained the rights to develop and commercialize SMT112 in the United States, Canada, Europe, and Japan (the &#8220;Licensed Territory&#8221;).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In exchange for the rights obtained, an upfront payment of $500,000 was made to Akeso, of which $274,900 was paid in cash and, pursuant to the License Agreement and Issuance Agreement, Akeso elected to receive 10,000,000 shares of our common stock in lieu of $25,100 cash. The remaining $200,000 amount of the upfront payment was paid on March 6, 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has accounted for the License Agreement to acquire the rights to develop and commercialize SMT112 as the acquisition of an asset. All of the consideration relates to SMT112 and technological feasibility of the asset has not yet been established since SMT112 is in clinical development. As such, the Company has expensed the consideration as in-process research and development upon closing of the transaction in the consolidated statement of comprehensive loss. In-process research and development expense for the year ended December 31, 2023 was $520,915, which is comprised of the $474,900 paid in cash, the fair value of the 10,000,000 shares of common stock on the date of closing the transaction of $45,900, and $115 of direct transactions costs incurred.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the payments already made to Akeso, under the License Agreement, there are additional potential milestone payments of up to $4,500,000, as Akeso will be eligible to receive regulatory milestones of up to $1,050,000 and commercial milestones of up to $3,450,000. In addition, Akeso will be eligible to receive low double-digit royalties on net sales.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996811441952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment Reporting <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s chief operating decision makers (the &#8220;CODM function&#8221;), which are the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s Chief Executive Officers, Mr. Duggan and Dr. Zanganeh, utilize consolidated financial information to make decisions about allocating resources and assessing performance for the entire Company. The CODM function approves of key operating and strategic decisions, including key decisions in clinical development and clinical operating activities, entering into significant contracts, such as revenue contracts and collaboration agreements and approves the Company&#8217;s consolidated operating budget. The CODM function views the Company&#8217;s operations and manages its business as a single reportable operating segment. The Company&#8217;s single operating segment covers the Company&#8217;s research and development activities, primarily comprising of oncology product research activities (including ivonescimab), antibiotic pipeline research activities, and CDI program activities. As the Company operates in one operating segment, all required financial segment information can be found in the consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in two geographic regions: the U.K. and the U.S. The following table summarizes the Company&#8217;s long-lived assets, which include the Company&#8217;s property and equipment, net and right-of-use assets by geography: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">808&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,517&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,062&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,081&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The decrease of long-lived assets in the United Kingdom is primarily attributed to the Company exiting its lease for its Sawston, United Kingdom location.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The increase of long-lived assets in the United States is primarily attributed to additional right-of-use assets recorded related to the Company&#8217;s amendment to its sublease agreement during the period for its Menlo Park, California, U.S. location.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For details of revenue from external customers by geography refer to Note 8.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//280/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996813436192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text">Revenue<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized no revenue and $705 during the year ended December 31, 2023 and 2022, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized during the year ended December 31, 2022 consists of amounts received from the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s license and commercialization agreement with Eurofarma Laborat&#243;rios S.A. Revenue recognized during the year ended December 31, 2022 was from Latin America. The analysis of revenue by geography has been identified on the basis of the geographical location of each collaboration partner.</span></div><div style="margin-top:5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the deferred revenue relating to Eurofarma Laborat&#243;rios S.A. and deferred other income relating to BARDA (as defined in Note 9):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:69.653%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.080%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.344%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning deferred revenue and other income, January 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,939&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of deferred revenue and other income recognized in the statement of operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,790)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(546)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending deferred revenue and other income, December 31</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 9 below for further details regarding other income recognized under the BARDA contract.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996811845168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Operating Income, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeAndExpenseTextBlock', window );">Other Operating Income, net</a></td>
<td class="text">Other Operating Income, net<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of other operating income by category:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Funding income from BARDA (as defined below)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,085&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grant income from CARB-X (as defined below)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,808&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,001&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,416&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BARDA (as defined below)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, the Company was awarded a funding contract from the Biomedical Advanced Research and Development Authority (&#8220;BARDA&#8221;), part of the Office of the Assistant Secretary for Preparedness and Response at the United States Department of Health and Human Services, in support of the Company&#8217;s Ri-CoDIFy clinical trials and clinical development of ridinilazole. The awarded contract was originally worth up to $62,000. In June 2019 and again in January 2020, BARDA increased the value of the contract such that it is now worth up to $72,500 and brought the total amount of committed funding to $62,400. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining federal government funding is dependent on BARDA in its sole discretion exercising the final independent option work segment, upon the achievement by the Company of certain agreed-upon milestones for ridinilazole. This option work segment was never exercised by BARDA. The contract ran through April 2022 and was extended through December 2022 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as a no cost contract, solely to close out open activities. As of December 31, 2022, based on translation of historical foreign currency amounts in the period of recognition, the Company has recognized $59,203 of cumulative income since contract inception. As a result of the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s decision, on September 28, 2022, to not pursue further internal clinical development of ridinilazole and seek partners or a divestiture related to ridinilazole as a path forward for the clinical development of the asset, the Company recorded expenses for the remaining clinical trial costs associated with the close out activities of ridinilazole and recognized the remainder of the deferred income that had been received from BARDA prior to the expenses being recognized during the third quarter of 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and development credits</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income from tax credits, consist of R&amp;D tax credits received in the U.K. The Company benefits from two U.K. research and development tax credit cash rebate regimes: Small and Medium Enterprise Program (&#8220;SME, Program&#8221;) and the Research and Development Expenditure Credit Program (&#8220;RDEC Program&#8221;). Qualifying expenditures largely comprise of employment costs for research staff, consumables, a proportion of relevant, permitted sub-contract costs and certain internal overhead costs incurred as part of research projects for which the Company does not receive income. Tax credits related to the SME Program and RDEC Program are recorded as other operating income in the consolidated statements of operations and other comprehensive loss. Under both schemes, the Company receives cash payments that are not dependent on the Company&#8217;s pre-tax net income levels.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on criteria established by His Majesty&#8217;s Revenue and Customs (&#8220;HMRC&#8221;), a portion of expenditures being carried out in relation to the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s pipeline research and development, clinical trials management and third-party manufacturing development activities are eligible for the SME regime and the Company expects such elements of research and development expenditure incurred in its UK entities will also continue to be eligible for the SME regime for future periods.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023 and 2022, the current and long-term research and development tax credit receivable was $1,807 and $5,766, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARB-X (as defined below)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company announced the selection of a new preclinical candidate, SMT-738, from the DDS-04 series for development in the fight against multi-drug resistant infections, specifically Carbapenem-resistant Enterobacteriaceae (&#8220;CRE&#8221;) infections. Simultaneously, the Company announced it had received an award from the Trustees of Boston University under the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator program (&#8220;CARB-X&#8221;) to progress this candidate through preclinical development and Phase Ia clinical trials. The award commits initial funding of up to $4,100, with the possibility of up to another $3,700 based on the achievement of future milestones. As of December 31, 2023, based on translation of historical foreign currency amounts in the period that the amounts were recognized, the Company has recognized $2,920 of cumulative income since contract inception. During the quarter ended September 30, 2022, CARB-X announced changes to its funding arrangements and terms and conditions. As a result, the current arrangement concluded as of June 30, 2022, however the Company has the ability to recognize reimbursements for any milestone payments related to work incurred subsequent to this date in accordance with this agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeAndExpenseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other operating income and other operating expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeAndExpenseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996814660432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Expense) Income, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock', window );">Other (Expense) Income, net</a></td>
<td class="text">Other (Expense) Income, net<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of other (expense) income:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency gains (losses)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,109)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense on promissory notes payable to related parties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,461)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,401)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,513&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of cumulative currency translation gain</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(252)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,278)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,693)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 17, 2023, the Company dissolved the following dormant entities; Summit (Cambridge) Limited, Summit (Wales) Limited, Summit Corporation Employee Benefit Trust Company Limited, Summit Corporation Limited, Summit Discovery 1 Limited and Summit Infectious Diseases Limited. As a result, the Company reclassified $419 of cumulative foreign currency translation adjustments from accumulated other comprehensive loss relating to these entities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2023, other expense, net primarily consisted of loan interest expense incurred related to the promissory notes described in Note 18. These amounts are partially offset in the year ended December 31, 2023 by interest income related to the Company&#8217;s money market funds and the Company&#8217;s short-term investments in U.S. treasury securities and favorable changes in foreign currency.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2022, other expense, net primarily consisted of unfavorable changes in foreign currency, loan interest expense incurred related to the promissory notes described in Note 18, partially offset by investment income related to the Company&#8217;s money market funds and investments in highly liquid U.S. treasury securities, which are classified as cash equivalents as of December&#160;31, 2022.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996814609712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax</a></td>
<td class="text">Income Tax&#160;<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is primarily subject to corporation taxes in the U.S. and the U.K.. The calculation of the Company&#8217;s tax provision involves the application of both U.S. and U.K. tax law and requires judgment and estimates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is determined using the asset and liability approach. Tax laws may require items to be included in tax filings at different times than the items are reflected in the financial statements. A current asset or liability is recognized for the estimated taxes receivable or payable for the current year. Deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. Deferred taxes are initially recognized at enacted tax rates in force at the time of initial recognition and are subsequently adjusted for any enacted changes in tax rates and tax laws. Subsequent changes to deferred taxes originally recognized in equity are recognized in income. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The Company has recorded a full valuation allowance against the deferred tax assets in excess of its deferred tax liabilities, as the deferred tax liability represents future reversals of existing taxable temporary differences. The Company records interest and penalties related to income tax matters as part of income tax expense.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertainty in income taxes by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed as the amount of benefit to recognize in the consolidated financial statements. The amount of benefits that may be used is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate, as well as the related net interest and penalties. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company&#8217;s loss before income taxes are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(499,810)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,868)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115,118)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,914)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(614,928)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,782)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not recognized a current or deferred provision for federal, state or non-United States income taxes in either of the years ending December 31, 2023 or 2022, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of deferred tax assets and liabilities are as follows:</span></div><div style="padding-left:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.468%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss carryforward</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development credit carryforward</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Section 174 Research and Development Capitalization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liability</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,010&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,893&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,085)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(651)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(174)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,259)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(877)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax assets before valuation allowance </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,751</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,016</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84,751)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,016)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated the positive and negative evidence bearing upon its ability to realize its deferred tax assets, which are comprised primarily of net operating loss carryforwards and research and development costs capitalized for tax purposes. Management has considered the Company&#8217;s history of cumulative net losses in the United States (&#8220;U.S.&#8221;) and the United Kingdom (&#8220;U.K.&#8221;), estimated future taxable income, as well as prudent and feasible tax planning strategies, and has concluded that it is more likely than not that the Company will not realize the benefits of its U.S. federal and state deferred tax assets and U.K. deferred tax assets. Accordingly, a full valuation allowance has been established against these net deferred tax assets as of December 31, 2023 and 2022, respectively. The Company reevaluates the positive and negative evidence at each reporting period. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the valuation allowance was as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.468%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance as of beginning of year</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,016)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,746)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase recorded to the income tax provision</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,735)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,270)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance as of end of year</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84,751)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,016)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023 and 2022, the Company had U.S. Federal gross operating loss carryforwards of approximately $48,184 and $11,620, respectively, which may be available to offset future income tax liabilities. The 2017 Tax Cuts and Jobs Act (&#8220;TCJA&#8221;) will generally allow losses incurred after 2017 to be carried over indefinitely, but will generally limit the net operating loss deduction to the lesser of the net operating loss carryover or 80% of a corporation&#8217;s taxable income (subject to Section 382 of the Internal Revenue Code of 1986, as amended). In addition, the Company has approximately $3,705 in U.S. State gross loss carryforwards which expire through various dates through 2043 and as of December 31, 2023, the Company had an estimated U.S. federal and state research and development tax credit carryforwards of $2,900 and $900, respectively, which may be available to offset future tax liabilities, and each begin to expire in 2041 and 2037, respectively. The Company also had approximately $194,454 in U.K. gross loss carryforwards available to use against future taxable profits on a year-by-year basis. To the extent that U.K. taxable profits exceed &#163;5,000 in each year, the loss available to utilize against profits in excess of &#163;5,000 will be restricted to 50%. The U.K. loss carryforwards do not lapse and therefore, the full amount will be relieved over time provided there are sufficient profits against which the losses can be utilized. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilization of the U.S. net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986 due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has not completed a study to assess whether a change of ownership has occurred, or whether there have been multiple ownership changes since its formation. Any limitation may result in the loss of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.K. tax losses are subject to additional restrictions where there is a change in ownership in the business and certain other conditions are met. An ownership change of a UK tax resident company would occur where (directly or indirectly) a single person acquires more than half of the ordinary share capital of a company, or two or more persons each acquire a holding of at least 5% of the ordinary share capital of a company and these holdings together amount to more than half the ordinary share capital of a company. Where a change in ownership has occurred, and within three years prior to that change in ownership and five years afterwards, there is a major change in the nature and conduct of trade of that company or the trade of that business becomes small or negligible, any losses carried forward will be extinguished from the point of the change in ownership. In addition, losses accrued subsequent to April 1, 2017 will be extinguished on a change of ownership when there is a major change in the nature or conduct of a company&#8217;s business, or where there is a major change in the scale of that business, or a company ceases to carry on a particular trade or business. The Company has not completed a study to assess whether a change of ownership has occurred since its formation, or whether there has been a major change in the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s business that would restrict the U.K. tax losses. Any limitation may result in the loss of a portion of the net operating loss carryforwards before utilization.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2017 Tax Cuts and Jobs Act (&#8220;TCJA&#8221;) created a requirement that US corporations include in income earnings of certain controlled foreign corporations (&#8220;CFC&#8221;) under the global intangible low taxed income (&#8220;GILTI&#8221;) regime. The Company is allowed to make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as period expense only. The Company has elected to account for GILTI in the year the tax is incurred and include the current tax impact of GILTI in the effective tax rate. Given the Company&#8217;s loss position in the U.S. and the valuation allowance recorded against </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">its U.S. net deferred tax assets, these provisions have not had a material impact on the Company&#8217;s consolidated financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IRC Section 174 generally permitted taxpayers that incurred research expenses to deduct them in the current year. For tax years beginning before January 1, 2022, taxpayers were able to make an election with respect to research and experimental (&#8220;R&amp;E&#8221;) expenditures incurred in connection with a trade or business to either currently deduct or defer and amortize such expenditures.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The TCJA amended this provision to require that R&amp;E expenditures be capitalized and amortized, but delayed the effective date of this amendment, which applies to tax years beginning January 1, 2022 or later. As such, the changes to IRC Section 174 pursuant to the TCJA are currently applicable to the Company for the 2022 tax year. R&amp;E expenditures attributable to U.S. based research must be amortized over a period of five years and R&amp;E expenditures attributable to research conducted outside of the U.S. must be amortized over a period of 15 years. As such, the Company is capitalizing $73,129 R&amp;E expenditures with a net adjustment of $65,816</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to account for the capitalization and amortization of R&amp;D expenses incurred in the U.S.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the Company&#8217;s effective tax rate to the U.S. federal statutory rate is as follows: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. federal income tax statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Refundable research and development tax credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of foreign operations taxed at various rates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.K., the Company is entitled to a research and development tax relief for small and medium-sized enterprises which allows the Company an enhanced deduction rate of 230% (up to March 31, 2023) and 186% (from April 1, 2023) on qualifying research and development expenditure (the tax relief). If the Company incurs tax losses, it is entitled to surrender the lesser of unrelieved tax loss sustained and the tax relief. As the realization of the tax relief does not depend on generation of future taxable income or the Company&#8217;s ongoing tax status or tax position, the Company does not consider the tax relief as an element of income tax accounting under ASC 740. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2023 and 2022, the Company recognized research and development tax relief of $946 and $4,523 respectively, which is included in other operating income in the consolidated statements of operations and other comprehensive loss.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the intention of the Company to reinvest the earnings of its non-U.S. subsidiaries in those operations and not to repatriate the earnings to the U.S. Accordingly, the Company does not provide for deferred taxes on differences between financial reporting and tax basis in its investments in foreign subsidiaries as they are considered permanent in duration or are not expected to reverse in the foreseeable future. As of December 31, 2023, there are no unremitted earnings of the Company&#8217;s foreign subsidiaries.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records unrecognized tax benefits in accordance with ASC 740-10, Income Taxes. ASC 740-10 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in the Company&#8217;s income tax return and also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. As of December 31, 2023 and 2022, the Company had total unrecognized tax benefits of $1,064 and $0, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Company&#8217;s full valuation allowance, the unrecognized tax benefits would not materially impact the Company&#8217;s effective tax rate when recognized.  The Company does not anticipate the total amounts of unrecognized tax benefits will significantly increase or decrease in the next 12 months. The Company&#8217;s policy is to recognize interest and penalties related to uncertain tax positions as part of its income tax provision. For the years ended December 31, 2023 and 2022, the Company had no interest or penalties related to unrecognized tax benefits.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of unrecognized tax benefits from continuing operations is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:67.972%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.629%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized tax benefits, beginning of year</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases related to prior year tax positions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decreases related to prior year tax positions</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases related to current year tax positions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized tax benefits, end of year</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,064&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal, state, and foreign jurisdictions, where applicable. the U.S. In the U.S., tax years from 2020 remain subject to examination by the U.S. Internal Revenue Service and state tax authorities. The Company is not currently under examination by the Internal Revenue Service or any other jurisdiction for years 2020 through present. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may be adjusted upon examination by the Internal Revenue Service or state tax authorities to the extent utilized in a future period. In the U.K., tax returns for the year ended December 31, 2022 remains subject to examination by HMRC.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996814600752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text">Net Loss per Share <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net loss per share: </span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(614,928)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,782)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average number of shares of common stock outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619,646,180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,336,063&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average number of shares of common stock outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619,646,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,336,063&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net loss per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net loss per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.99)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the diluted net loss by the weighted-average number of common shares outstanding for the period, including potentially dilutive common shares. Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share for all periods, as the inclusion of all potential common share equivalents outstanding would have been anti-dilutive. </span></div><div style="margin-top:1pt"><span><br/></span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because the 2023 Rights Offering (as defined in Note 20) exercise price of $1.05 per share was less than the closing price of $1.82 per share on March 1, 2023, the expiration of the , the Company has retroactively adjusted earnings per share and weighted average number of shares outstanding for the bonus element for all periods presented.</span></div><div style="margin-top:1pt"><span><br/></span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities were excluded from the computation of the diluted net loss per share of common stock for the periods presented because their effect would have been anti-dilutive: </span></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,209,289</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,476,359</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,015,642</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,821,137</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares expected to be purchased under employee stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,163</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,475</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,380,094</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,526,971</span></td></tr></table></div><div style="margin-top:1pt"><span><br/></span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options that are outstanding and contain performance-based or market-based vesting criteria for which the performance or market conditions have not been met are excluded from the presentation of common stock equivalents outstanding in the chart above. Refer to Note 21 for further information on market-based awards.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996814667792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill and Intangible Assets<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Company expanded its activities in the field of infectious diseases with the acquisition of Discuva Limited, a privately held United Kingdom-based company. Through this acquisition, the Company obtained a bacterial genetics platform and a suite of software-based technologies (the &#8220;Discuva Platform&#8221;), which facilitates the discovery and development of new mechanism antibiotics. This resulted in the recognition of goodwill of &#163;1.5&#160;million, which is translated into U.S. dollars at each reporting period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses goodwill for impairment on an annual basis as of December 31 or more frequently when events and circumstances occur indicating that recorded goodwill may be impaired.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the Company performed its annual impairment assessment of goodwill and determined that it is more likely than not that the fair value of the reporting unit exceeds its carrying amount. There have been no cumulative goodwill impairment charges recognized to date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023 and 2022, goodwill was $1,893 and $1,798, respectively. Changes year over year are the result of changes in foreign currency.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Intangible Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of the Company&#8217;s acquired intangible assets are comprised of the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:25.301%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.961%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.681%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.717%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.961%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.681%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.724%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated amortization and impairment charges</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated amortization and impairment charges</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Utrophin program acquired</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,015&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,015)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discuva platform acquired</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,583&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,583)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,900&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,900)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Option over non-financial asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(859)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(816)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other intangibles</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,582&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,582)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,864&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,864)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company dissolved the wholly-owned subsidiary, Muox Limited, a dormant entity. The Utrophin program intangible assets, which arose from the Muox Limited acquisition were fully impaired and have been removed from the Company&#8217;s accounting records.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the significant change in the Company&#8217;s strategy and shift in focus to the therapeutic area of oncology, the Company determined that it would cease further investment in the Discuva Platform. Management concluded that the carrying amount of the acquired Discuva Platform intangible asset may not be recoverable and performed an assessment to calculate the fair value of the asset using a probability-weighted approach which was compared to the carrying value of the asset. An impairment charge of $8,468 which represented the carrying value of the Discuva Platform was recognized during the year ended December 31, 2022. This impairment charge is presented as <span style="-sec-ix-hidden:f-630">impairment of intangible assets</span> in the consolidated statements of operations and comprehensive loss.</span></div>Changes year over year in the gross and accumulation amortization amounts of intangible assets are the result of changes in foreign currency. Amortization expense was $0 and $914 for the years ended December 31, 2023 and 2022, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996814573568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Short-Term Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Fair Value Measurements and Short-Term Investments</a></td>
<td class="text">Fair Value Measurements and Short-Term Investments<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Fair Value Measurements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables sets forth the Company&#8217;s fair value hierarchy for its assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2023 and 2022: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:37.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.486%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements as of December 31, 2023</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government treasury bills</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government treasury bills</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,817&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,817&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,016&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,158&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,174&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:37.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.486%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements as of December 31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,783&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,783&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government treasury bills</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,783&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,730&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,513&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table above does not include cash at December 31, 2023 and 2022 of $11,068 and $62,094, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that the carrying amounts of prepaid expenses, other current assets, accounts payable, and accrued expenses approximates their fair values due to the short-term nature of those instruments. The carrying value of the Company&#8217;s promissory note approximates its fair value due to the recent issuance of the notes in December 2022 and the current interest rate of the note outstanding when compared to market interest rates (which represents a Level 2 measurement). Refer to Note 18 for further details.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Short-Term Investments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Company&#8217;s short-term investments as of December 31, 2023, which have a contractual maturity of less than one year:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:35.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Credit Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,781&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,817&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any short-term investments as of December 31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996814720832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:60.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.826%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.829%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures, office equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,203&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">906&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the years ended December 31, 2023 and 2022 was $198 and $349, respectively. The Company recognized a fixed asset impairment charge of $474 for the year ended December 31, 2023. There were no impairment charges related to fixed assets for the year ended December 31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996814640832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Prepaid Expenses and Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">Research and Development Prepaid Expenses and Accrued Liabilities</a></td>
<td class="text">Research and Development Prepaid Expenses and Accrued Liabilities<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included within prepaid expenses at December 31, 2023 and 2022 is $1,466 and $442, respectively, of prepayments relating to research and development expenditures. Included within accrued liabilities at December 31, 2023 and 2022 is $7,289 and $8,911, respectively, relating to research and development expenditures.</span></div>These amounts are determined based on the estimated costs to complete each study or activity, the estimation of the current stage of completion and the invoices received, as well as predetermined milestones which are not reflective of the current stage of development for prepaid expenses. However, prepaid expenses decrease and accrued liabilities increase as the activities progress, and if actual costs incurred exceed the prepaid expense, an accrual will be recorded for the liability. The key sensitivity is the estimated current stage of completion of each study or activity, which is based on information received from the supplier and the Company&#8217;s operational knowledge of the work completed under those contracts.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 985<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//985-730/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996814673952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for real estate. The Company does not have any finance leases. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company recorded $4,245 of additional right-of-use assets related to a new lease for additional office space which commenced in May 2023 at its Menlo Park, California location. The Company will make total lease payments of $4,701 over the 36 month term of the new lease, which expires in May 2026. In addition, during the year ended December 31, 2023, the Company terminated the Company&#8217;s Cambridge, U.K. laboratory and office space lease as a result of the Company re-prioritizing its investments and financial resources towards the development of ivonescimab. This resulted in disposing the carrying value of the right-of use asset of $788, removing the related lease liability of $809, and there were no penalties charged for early termination of this lease. The Company recorded $2,860 of right-of-use assets during the year ended December 31, 2022 related to its Menlo Park, California location.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the right-of-use assets as of December 31, 2023 and 2022 is $5,859 and $4,175, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The elements of lease expense were as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease Cost:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Fixed lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,214&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,384&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Variable lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Short-term lease</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,297&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,552&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Short-term lease costs relate to the Company&#8217;s Cambridge, Massachusetts, United States office lease which the Company exited during fiscal year 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average discount rate and the weighted average remaining lease term were 6.6% and 2.4 years, respectively, as of December 31, 2023. The weighted average discount rate and the weighted average remaining lease term were 5.7% and 3.4 years, respectively, as of December 31, 2022. The Company made cash payments related to lease liabilities of $2,208 and $1,092 for the years ending December 31, 2023 and 2022 respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future lease payments under non-cancelable leases as of December 31, 2023 are detailed as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:83.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.357%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,810&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,099&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities balance sheet presentation:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,099&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company signed a lease agreement on January 8, 2024 for executive office space for its new headquarters in Miami, Florida. The office space is approximately 9,000 square feet. The term of the lease is 64 months. Total payments for this office </span></div>space is approximately $5,100 over the term of the lease. The table above excludes payments related to the lease signed in January 2024.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996811845168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Promissory Notes Payable to Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Promissory Notes Payable to Related Parties</a></td>
<td class="text">Promissory Notes Payable to Related Parties<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Non-current and current debt consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"></td><td style="width:41.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.484%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current notes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current notes</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal amounts</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(230)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,460)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total promissory notes payable to related parties</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,770&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494,540&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">March 2022 Promissory Note</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 10, 2022, Mr. Duggan, entered into a Note Purchase Agreement (the &#8220;March 2022 Note&#8221;), pursuant to which he loaned the Company $25,000 in exchange for the issuance by the Company of an unsecured promissory note in the amount of $25,000. The March 2022 Note accrued interest at a rate per annum equal to the prime rate as reported in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wall Street Journal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The March 2022 Note, including all accrued interest, became due upon the earlier of (i) the consummation of a registered public offering with net proceeds of no less than $25,000 or (ii) 18 months from the date of issuance of the March 2022 Note. Debt issuance costs associated with the March 2022 Note were immaterial and expensed as incurred. The March 2022 Note of $25,000, plus accrued interest of $434 has been repaid to Mr. Duggan on August 10, 2022 in connection with the completion of the rights offering with aggregate gross proceeds of $100,000.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred interest expense related to the March 2022 Note of $1,296 for the year ended December 31, 2022, which included amortized imputed interest of $861. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">December 2022 Promissory Notes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 6, 2022, the Company entered into a Note Purchase Agreement (the &#8220;Note Purchase Agreement&#8221;), with Mr. Duggan and Dr. Zanganeh, pursuant to which the Company agreed to sell to each of Mr. Duggan and Dr. Zanganeh unsecured promissory notes in the aggregate amount of $520,000. Pursuant to the Note Purchase Agreement, the Company issued to Mr. Duggan and Dr. Zanganeh unsecured promissory notes in the amount of $400,000 (the &#8220;Duggan February Note&#8221;) and $20,000 (the &#8220;Zanganeh Note&#8221;), respectively, which matured and become due on February 15, 2023 and an unsecured promissory note to Mr. Duggan in the amount of $100,000 (the &#8220;Duggan September Note&#8221; and together with the Duggan February Note and the Zanganeh Note, the &#8220;December 2022 Notes&#8221;), which was originally due on September 15, 2023. The maturity dates of the December 2022 Notes could have been extended one or more times at the Company&#8217;s election, but in no event to a date later than September 6, 2024. In addition, if the Company consummates a public offering, then upon the later to occur of (i) <span style="-sec-ix-hidden:f-764">five</span> business days after the Company receives the net cash proceeds therefrom or (ii) May 15, 2023, the Duggan February Note and the Zanganeh Note shall be prepaid by an amount equal to the lesser of (a) 100% of the amount of the net proceeds of such offering and (b) the outstanding principal amount on such Notes.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 19, 2023, the Company provided notice to extend the term of the Duggan February Note and Duggan September Note to a maturity date of September 6, 2024. Furthermore, on January 19, 2023, the Company and Mr. Duggan rectified the Duggan February Note and Duggan September Note in order to correctly reflect the parties&#8217; intent that the Company may only prepay (i) the Duggan February Note following the completion of a public rights offering to be conducted by Summit in the approximate amount of $500,000 (the &#8220;Rights Offering&#8221;), or a similar capital raise, in an amount equal to the lesser of (x) the net proceeds of the Rights Offering or such capital raise or (y) the full amount outstanding of the Duggan February Note, and (ii) the Duggan September Note following the completion of a capital raising transaction subsequent to the Rights Offering in an amount equal to the lesser of (A) the net proceeds of such capital raise or (B) the full amount outstanding of the Duggan September Note. Following the issuance of the two new Promissory Notes (the &#8220;Duggan Promissory Notes&#8221;), the Duggan February Note and Duggan September Note were marked as &#8220;cancelled&#8221; on their face and replaced in their entirety by the Duggan Promissory Notes (together with the Zanganeh Note, the &#8220;Notes&#8221;).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 15, 2023, the $20,000 Zanganeh Note matured and the Company repaid the outstanding principal balance. In connection with the closing of the rights offering, the $400,000 Duggan Promissory Note matured and became due, and the Company repaid all principal and accrued interest thereunder using a portion of the proceeds from this rights offering.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes accrued interest at an initial rate of 7.5%. All interest on the Notes was paid on the date of signing for the period through February 15, 2023. Such prepaid interest was paid in a number of shares of the Company&#8217;s common stock, par value $0.01 (&#8220;Common Stock&#8221;) equal to the dollar amount of such prepaid interest, divided by $0.7913 (the consolidated closing bid price immediately preceding the time the Company entered into the Note Purchase Agreement, plus $0.01), which was 9,720,291 shares. For all applicable periods following February 15, 2023, interest shall accrue on the outstanding principal balance of the Notes at the US prime interest rate, as reported in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wall Street Journal,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plus 50 basis points, as adjusted monthly, for three months immediately following February 15, 2023, and thereafter at the US prime rate plus 300 basis points, as adjusted monthly.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt issuance costs associated with the Notes were $44 and were capitalized as part of the carrying value of the promissory notes payable to related parties. During the year ended December 31, 2023, the Company incurred interest expense of $16,461 for the year ended December 31, 2023, which included amortized imputed interest of $761. The Company incurred interest expense of $3,105 for the year ended December 31, 2022 related to the December 2022 Notes, which included amortized imputed interest of $395.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023 and 2022 there was $120 of accrued interest payable included within accrued expenses in the consolidated balance sheet. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Imputed interest is calculated as the difference between the expected interest payable and the deemed market rate of interest and is recorded as a debt discount at inception of the note payable with a credit to additional paid-in capital for notes payable to related parties. The debt discount is amortized to interest expense using an effective interest rate method. The effective interest rate of the Duggan February Note and Zanganeh Note was 8.9% and the effective interest rate of the Duggan September Note was 11.3%. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2024 the Duggan February Note was amended to extend the maturity date from September 6, 2024 to April 1, 2025. For all applicable periods commencing  February 17, 2024, interest shall accrue on the outstanding principal balance at the greater of 12% or the US prime interest rate, as reported in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wall Street Journal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plus 350 basis points, as adjusted monthly, compounded quarterly.Interest shall be paid upon maturity of the loan.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the applicable accounting standards, a short-term debt obligation should be excluded from current liabilities if the entity has both the intent and ability to refinance the obligation on a long-term basis. The intent and ability can be demonstrated by the issuance of a long-term obligation to refinance the short-term obligation on a long-term basis after the date of an entity&#8217;s balance sheet but before that balance sheet is issued. As a result of the amendment entered into on February 17, 2024, to extend the maturity date to April 1, 2025, the Company classified $100,000 of notes payable to related party outstanding as of December 31, 2023 as long-term notes payable</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future principal payments are $0 and $100,000 for 2024 and 2025, respectively, as the note matures on April 1, 2025.</span></div>Related Party Transactions<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">July 25, 2022 First Amendment to Sublease Agreement with Maky Zanganeh and Associates, Inc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 25, 2022 the Company entered into a first amendment, dated July 19, 2022, to its existing sublease agreement with MZA, described above. The existing sublease term, which was set to expire on September 30, 2022, was extended for a period of thirty-nine months from October 1, 2022 through December 31, 2025. The rent payable under the terms of the sublease is equivalent to the proportionate share of the net payable by MZA to the third-party landlord, based on the square footage of office space sublet by the Company, and no mark-up has been applied. During the year ended December 31, 2023, payments of $762, were made pursuant to the first amendment to the Sublease Agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">July 29, 2022 Second Amendment to Sublease Agreement with Maky Zanganeh and Associates, Inc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 29, 2022, the Company entered into a second amendment, dated August 1, 2022, to its existing sublease agreement with MZA, described above. The second amendment was effective as of August 1, 2022 and expires on December 31, 2025. The second amendment includes an additional 1,277 square feet (the &#8220;Expansion Premises&#8221;) of office space at 2882 Sand Hill Road, Menlo Park, California. The rent payable under the terms of the sublease is equivalent to the proportionate share of the net payable by MZA to the third-party landlord, based on the square footage of office space sublet by the Company, and no mark-up has been applied. During the year ended December 31, 2023 payments of $218, were made pursuant to the secondment amendment to the sublease.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">March 10, 2022 Note Purchase Agreement</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 10, 2022, the Company entered into a Note Purchase Agreement (the &#8220;March 2022 Note&#8221;), with Mr. Duggan, pursuant to which Mr. Duggan loaned the Company $25,000 in exchange for the issuance by the Company of an unsecured promissory note in the amount of $25,000. The March 2022 Note accrued interest at a rate per annum equal to the prime rate as reported in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wall Street Journal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was 3.25% as of the effective date and 4.75% as of June 30, 2022. The March 2022 Note, including accrued interest, became due upon the earlier of (i) the consummation of a registered public offering with net proceeds of no less than $25,000 or (ii) 18 months from the date of issuance of the March 2022 Note, and was repaid on August 10, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022 Rights Offering</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Rights Offering commenced on July 18, 2022, and the associated subscription rights expired on August 8, 2022. Aggregate gross proceeds received from the rights offering were $100,000 from the sale of 103,092,783 shares of common stock. Mr. Duggan and Dr. Zanganeh fully subscribed to their respective basic subscription rights and oversubscribed, at a price of $0.97 per share. Issuance costs were $111. In connection with the closing of the 2022 Rights Offering, the March 2022 Note </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">matured and became due, and the Company repaid all principal and accrued interest thereunder using a portion of the proceeds from the 2022 Rights Offering on August 10, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">December 6, 2022 Note Purchase Agreement</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 6, 2022, the Company entered into a Note Purchase Agreement (the &#8220;Note Purchase Agreement&#8221;), with Mr. Duggan and Dr. Zanganeh, pursuant to which the Company agreed to sell to each of Mr. Duggan and Dr. Zanganeh unsecured promissory notes in the aggregate amount of $520,000. Pursuant to the Note Purchase Agreement, the Company issued to Mr. Duggan and Dr. Zanganeh unsecured promissory notes in the amount of $400,000 (the &#8220;Duggan February Note&#8221;) and $20,000 (the &#8220;Zanganeh Note&#8221;), respectively, which would mature and become due on February 15, 2023 and an unsecured promissory note to Mr. Duggan in the amount of $100,000 (the &#8220;Duggan September Note&#8221; and together with the Duggan February Note and the Zanganeh Note, the &#8220;December 2022 Notes&#8221;), which matured and became due on September 15, 2023. The maturity dates of the December 2022 Notes could have been extended one or more times at the Company&#8217;s election, but in no event to a date later than September 6, 2024. In addition, if the Company consummates a public offering, then upon the later to occur of (i) <span style="-sec-ix-hidden:f-967">five</span> business days after the Company receives the net cash proceeds therefrom or (ii) May 15, 2023, the Duggan February Note and the Zanganeh Note shall be prepaid by an amount equal to the lesser of (a) 100% of the amount of the net proceeds of such offering and (b) the outstanding principal amount on such notes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 19, 2023, the Company provided notice to extend the term of the Duggan February Note and Duggan September Note to a maturity date of September 6, 2024. Furthermore, on January 19, 2023, the Company and Mr. Duggan rectified the Duggan February Note and Duggan September Note in order to correctly reflect the parties&#8217; intent that the Company may only prepay (i) the Duggan February Note following the completion of a public rights offering to be conducted by Summit in the approximate amount of $500,000 (the &#8220;Rights Offering&#8221;), or a similar capital raise, in an amount equal to the lesser of (x) the net proceeds of the Rights Offering or such capital raise or (y) the full amount outstanding of the Duggan February Note, and (ii) Duggan September Note following the completion of a capital raising transaction subsequent to the Rights Offering in an amount equal to the lesser of (i) the net proceeds of such capital raise or (ii) the full amount outstanding of the Duggan September Note. Following the issuance of the two new Promissory Notes (the &#8220;Duggan Promissory Notes&#8221;), the Duggan February Note and Duggan September Note were marked as &#8220;cancelled&#8221; on their face and replaced in their entirety by the Duggan Promissory Notes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 15, 2023, the $20,000 Zanganeh Note, matured and the Company repaid the outstanding principal balance. In connection with the closing of the 2023 Rights Offering, the $400,000 Duggan Promissory Note, matured and became due, and the Company satisfied all principal and accrued interest thereunder using a combination of a portion of the cash proceeds from the 2023 Rights Offering and the extinguishment of a portion of the amount due equal to the subscription price for shares subscribed by Mr. Duggan in the 2023 Rights Offering (as defined above).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes accrue interest at an initial rate of 7.5%. All interest on the Notes shall be paid on the date of signing for the period through February 15, 2023. Such prepaid interest shall be paid in a number of shares of the Company&#8217;s common stock, par value $0.01 (&#8220;Common Stock&#8221;) equal to the dollar amount of such prepaid interest, divided by $0.7913 (the consolidated closing bid price immediately preceding the time the Company entered into the Note Purchase Agreement, plus $0.01), which was 9,720,291 shares. For all applicable periods following February 15, 2023, interest shall accrue on the outstanding principal balance of the Notes at the United States prime interest rate, as reported in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wall Street Journal,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plus 50 basis points, as adjusted monthly, for three months immediately following February 15, 2023, and thereafter at the United States prime rate plus 300 basis points, as adjusted monthly. During the year ended December 31, 2023, the Company made payments for interest of $10,650.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2024 the Duggan February Note was amended to extend the maturity date from September 6, 2024 to April 1, 2025. For all applicable periods commencing  February 17, 2024, interest shall accrue on the outstanding principal balance at the greater of 12% or the US prime interest rate, as reported in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wall Street Journal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plus 350 basis points, as adjusted monthly, compounded quarterly. Interest shall be paid upon maturity of the loan.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Akeso License Agreement</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the closing of the License Agreement, the Board of Directors (the &#8220;Board&#8221;) of the Company appointed Dr. Yu (Michelle) Xia to serve as a member of the Board pursuant to the terms of the License Agreement. Dr. Xia is the founder of Akeso, Inc., and has been the chairwoman, president and CEO of the Company since its inception in 2012. For details on the License Agreement, see Note 6. Furthermore, in connection with the License Agreement, the Company also entered into a Supply Agreement with Akeso, pursuant to which Summit agreed to purchase a certain portion of drug substance for clinical and commercial supply (the &#8220;Supply Agreement&#8221;). All transactions pursuant to the Supply Agreement, which occurred during 2023, were in the ordinary course of business. The Company paid approximately $2,500 to Akeso during year ended December 31, 2023. As of December 31, 2023, the Company included in accrued expenses approximately $3,619 due to Akeso.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2023 Rights Offering</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 6, 2022, the Company announced a rights offering for its existing shareholders to participate in the purchase of additional shares of its Common Stock for $1.05 per share. The 2023 Rights Offering commenced on February 7, 2023 and the associated subscription rights expired on March 1, 2023. Aggregate gross proceeds from the 2023 Rights Offering were $500,000 from the sale of 476,190,471 shares of the Company&#8217;s common stock and issuance costs were $619. Mr. Duggan and Dr. Zanganeh fully subscribed to their respective basic subscription rights at a price of $1.05 per share. To satisfy the $395,314 subscription price for the shares subscribed by Mr. Duggan in the 2023 Rights Offering, Mr. Duggan agreed with the Company to extinguish a portion of the amount due and payable to him by the Company at the closing of the 2023 Rights Offering pursuant to the $400,000 Duggan Promissory Note in an amount equal to the subscription price.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Registration of Shares</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2023, the Company filed a registration statement on Form S-3 to register for resale the following shares of the Company&#8217;s common stock at $0.01 par value: (i) 10,000,000 shares of Common Stock issued on January 17, 2023 in connection with the License Agreement with Akeso pursuant to which the Company issued Akeso such shares; and (ii) the 9,346,434 and 373,857 shares of Common Stock issued in December 2022 to the Company&#8217;s Chief Executive Officers, Mr. Duggan and Dr. Zanganeh, respectively, as payment of prepaid interest in connection with the Note Purchase Agreement dated December 6, 2022 between Mr. Duggan, Dr. Zanganeh and the Company. On April 27, 2023, the SEC issued the Company a Notice of Effectiveness for the registration statement on Form S-3.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Private Placement</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 16, 2023, the Company announced the appointment of Mr. Manmeet Soni as its Chief Operating Officer, effective immediately. Mr. Soni has been a part of the Company&#8217;s Board of Directors since 2019. He will remain a member of the Board of Directors. In conjunction with his appointment, Mr. Soni entered into a share purchase agreement with the Company to purchase $5,000 of its common stock via a private placement. The transaction was effective October 13, 2023 with a closing price of $1.68, resulting in the purchase of 2,976,190 shares of the Company&#8217;s common stock.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Warrants Exercise</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, Dr. Zanganeh exercised 805,495 shares of warrants. Refer to Note 20 for the warrants exercise activity for the year ended December 31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996809688000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Non-Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock', window );">Other Non-Current Liabilities</a></td>
<td class="text">Other Non-Current Liabilities<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included within other non-current liabilities at December 31, 2023 and 2022 is $1,356 and $1,209, respectively, relating to assumed contingent liabilities. As part of the acquisition of Discuva Limited in December 2017, the Company assumed certain contingent liabilities as certain employees, former employees and former directors of Discuva Limited are eligible for payments from Discuva Limited based on specified development and clinical milestones related to proprietary product candidates developed under the Discuva Platform. The timing of these potential payments is uncertain.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the significant change in the Company&#8217;s strategy and shift in focus to the therapeutic area of oncology, the Company determined that it will cease further investment in the Discuva platform and evaluate further options for the use of the Discuva Platform. As a result, management has revised the estimated presented value of these payments and remeasured the contingent liabilities. This resulted in recording a gain on remeasurement of liabilities of $1,265 during the year ended December 31, 2022, which is included net as part of the research and development expenses in the consolidated statement of operations and comprehensive loss.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no remeasurement losses or gains recognized during the year ended December 31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as noncurrent at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996814642064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Common Stock</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Company announced the closing of its 2022 rights offering (&#8220;2022 Rights Offering&#8221;). The rights offering commenced on July 18, 2022, and the associated subscription rights expired on August 8, 2022. The 2022 Rights Offering received aggregate gross proceeds of $100,000 from the sale of 103,092,783 shares of common stock. Mr. Duggan and Dr. Zanganeh fully subscribed to their respective basic subscription rights and oversubscribed, at a price per share of $0.97. Offering costs of $111 were incurred. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 6, 2022, the Company announced a rights offering for its existing shareholders to participate in the purchase of additional shares of its Common Stock for $1.05 per share (the &#8220;2023 Rights Offering&#8221;). The 2023 Rights Offering commenced on February 7, 2023 and the associated subscription rights expired on March 1, 2023. Aggregate gross proceeds from the 2023 Rights Offering were $500,000 from the sale of 476,190,471 shares of the Company&#8217;s common stock and issuance costs were $619. Mr. Duggan and Dr. Zanganeh fully subscribed to their respective basic subscription rights at a price of $1.05 per share. To satisfy the $395,314 subscription price for the shares subscribed by Mr. Duggan in the 2023 Rights Offering, Mr. Duggan agreed with the Company to extinguish a portion of the amount due and payable to him by the Company at the closing of the 2023 Rights Offering pursuant to the $400,000 Duggan Promissory Note in an amount equal to the subscription price (see also Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January&#160;19, 2023, the Company filed Amendment No. 2 to the Restated Certificate of Incorporation (the &#8220;Amendment No. 2&#8221;) with the Secretary of State of the State of Delaware to increase the number of authorized shares of its common stock by 650,000,000 (from 350,000,000 to 1,000,000,000), which became effective on such date. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2023, the Company filed a registration statement on Form S-3 to register for resale the following shares of the Company&#8217;s common stock at $0.01 par value: (i) 10,000,000 shares of Common Stock issued on January 17, 2023 in connection with the License Agreement (as defined in Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) with Akeso pursuant to which the Company issued Akeso such shares; and (ii) the 9,346,434 and 373,857 shares of Common Stock issued in December 2022 to Mr. Duggan and Dr. Zanganeh, respectively, as payment of prepaid interest in connection with the Note Purchase Agreement dated December 6, 2022 between Mr. Duggan, Dr. Zanganeh and the Company. On April 27, 2023, the SEC issued the Company a Notice of Effectiveness for the registration statement on Form S-3.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Soni entered into a share purchase agreement with the Company to purchase $5,000 of its common stock via a private placement. The transaction was effective October 13, 2023 with a closing price of $1.68, resulting in the purchase of 2,976,190 shares of the Company&#8217;s common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Warrants</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the private placement on December 24, 2019, the participating investors were granted warrants with the right to subscribe for 5,261,350 shares of common stock at an exercise price of $1.58, exercisable any time in the period commencing on the date falling six months following December 24, 2019 and ending on the tenth anniversary of admission. Each warrant entitles the warrant holder to subscribe in cash for one share. Shares of common stock allotted pursuant to the exercise of the warrant will rank in full for all dividends and other distributions with a record date after the exercise date with the shares of common stock in issue at that date. The Company has the option to require the warrant holder to exercise some or all of the outstanding warrants after the third anniversary date if the ten-day volume weighted average price of the shares of common stock as reported on Nasdaq represents a premium of at least 50 percent to the exercise price. The warrants are classified within stockholders&#8217; equity as they are indexed to the Company&#8217;s shares of common stock and require settlement in its shares of common stock with no provision for any cash settlement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, as part of the private placement on December 24, 2019, certain consultants were granted warrants with the right to subscribe for 3,358,732 shares of common stock in exchange for certain services. The warrants have an exercise price of $1.44 and vest quarterly over three years. If the consulting agreement terminated prior to three years after the date of the grant, all unvested warrants will be deemed cancelled. On June 30, 2020, the consulting agreement was terminated and 2,798,945 warrants cancelled immediately. The remaining 559,787 of outstanding warrants are held by Dr. Zanganeh and Dr. Elaine Stracker.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants granted over shares of common stock to consultants in exchange of certain services are similar to stock-based compensation (see Note 21).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The following table summarizes the Company&#8217;s warrants activity for the year ended December 31, 2023</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.306%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.306%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.306%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.313%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of share warrants</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate intrinsic value </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,821,137</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.56</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.99 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,640&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Exercised</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(805,495)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.49</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,015,642</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.57</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.92 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996811606960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2016 Long Term Incentive Plan</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the effectiveness of the 2020 Stock Incentive Plan, no additional grants will be made under the 2016 Long Term Incentive Plan, (the &#8220;2016 Plan&#8221;) and any outstanding awards continue with their original terms. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 Stock Award Plan</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company&#8217;s Board of Directors approved the 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;), which became effective on September 21, 2020. The 2020 plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A total of 8,000,000 shares of common stock were initially reserved for issuance under the 2020 Plan. Additionally, up to 5,000,000 shares of common stock, including RSUs can be added to the 2020 Plan for future issuance from options that expire, lapse or are terminated from the 2016 Plan or any other predecessor plans. The number of shares of common stock that may be issued under the 2020 Plan will automatically increase on each January 1, beginning in 2021 and continuing for each fiscal year until, and including, the fiscal year ending December 31, 2030, equal to the lesser of (i) 6,400,000 shares of common stock, (ii) 4% of the common shares outstanding on the final day of the immediately preceding calendar year and (iii) an amount as determined by the Company&#8217;s Board of Directors. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;27, 2022, the Company held a Special Meeting of Stockholders (the &#8220;Special Meeting&#8221;) whereby the following matters were submitted to a vote of the Company&#8217;s stockholders at the Special Meeting and the Board of Directors resolved the following: (i) an amendment to the Company&#8217;s Restated Certificate of Incorporation, dated September 18, 2020, to increase the number of authorized shares of common stock by 100,000,000 (from 250,000,000 to 350,000,000); and (ii) an amendment to the Summit Therapeutics Inc. 2020 Stock Incentive Plan (the &#8220;Plan&#8221;) to increase the number of shares of the Company&#8217;s common stock issuable under the Plan by 8,000,000 shares.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 12, 2023, the Company held a Special Meeting of Stockholders (the &#8220;October Special Meeting&#8221;) whereby the following matter was submitted to a vote of the Company&#8217;s stockholders at the Special Meeting and the Board of Directors resolved the following: an amendment to the Summit Therapeutics Inc. 2020 Stock Incentive Plan to increase the number of shares of the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s common stock issuable under the Plan by 70,000,000 shares.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, there are 3,261,496 shares available to be issued under the 2020 Plan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 Employee Stock Purchase Plan</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Employee Stock Purchase Plan (the &#8220;2020 ESPP&#8221;) was adopted by the Board of Directors and approved by the Company&#8217;s shareholders on July 17, 2020 and approved by the predecessor company shareholders on August 19, 2020 and is qualified under Section 423 of the Internal Revenue Code. The 2020 ESPP initially authorized the issuance of up to 1,000,000 shares of common stock to participating employees. The number of common shares that may be issued under the 2020 ESPP automatically increases on each fiscal year commencing January 1, 2021 and continuing for each fiscal year until, and including the fiscal year commencing on, January 1, 2030 equal to the lesser of (i) 1,600,000 shares of common stock, (ii) 1% of the common shares outstanding on such date and (iii) an amount as determined by the Company&#8217;s Board of Directors. As of December 31, 2022, there were 2,628,893 shares available to be issued under the 2020 ESPP.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first offering period of the 2020 ESPP plan consisted of seven months, commencing on August 2, 2021 and completed on February 28, 2022. The second offering period commenced on March 1, 2022 and was completed on August 31, 2022. Offering periods thereafter will be six months in duration and will commence immediately proceeding the end of the previous offering period, unless otherwise determined by the Board of Directors or Compensation Committee. Under the 2020 ESPP, eligible employees can purchase shares of common stock through payroll deductions of up to 15% of their compensation received during the plan period or such shorter period during which deductions from payroll are made, up to a defined maximum amount. The option price is determined based on the lesser of the closing price of common stock on (i) the first business day of the plan period or (ii) the exercise date, or shall be based solely on the closing price of the common stock on the exercise date; provided that such option price shall be at least 85% of the applicable closing price. In the absence of a determination by the Board of Directors or the Compensation Committee, the option price is 85% of the lesser of the closing price of the common stock on (i) the first business day of the plan period or (ii) the exercise date. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The closing price is the (a) the closing price (for the primary trading session) on the Nasdaq Global Select Market or (b) the average of the closing bid and asked prices in the over-the-counter-market, whichever is applicable, as published in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wall Street Journal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or another source selected by the Board or the Committee. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal year ended December 31, 2023 and 2022, 392,175 and 176,857 shares, respectively, were issued under the 2020 ESPP Plan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Time-based Stock Options</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of stock options granted to employees and directors using the Black-Scholes valuation model. Stock options granted under the 2016 and 2020 Plans generally vest over <span style="-sec-ix-hidden:f-862">three</span> or four years and expire after ten years. This valuation methodology utilizes several key assumptions as highlighted below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used in the Company&#8217;s valuation are summarized as follows, presented on a weighted average basis: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"></td><td style="width:66.392%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual dividends per share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The following table summarizes the Company&#8217;s time-based stock option activity for the year ended December 31, 2023:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:40.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.783%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of share options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate intrinsic value </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,712,359</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.83</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,702&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,135,170</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.72</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,433,943)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.56</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Exercised</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204,297)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,209,289</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2023 - vested and expected to vest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,407,492</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3 years</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,406&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,716,319</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.89</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance and Market-based Stock Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee of the Company&#8217;s Board of Directors and management approved 40,835,220 option grants to its executives and certain employees of the Company during the year ended December 31, 2023, which will vest based upon certain revenue and market-based performance conditions. The fair value of performance and market-based stock options that include a market condition is determined using a Monte Carlo valuation model, which utilizes multiple input variables to estimate the probability that the market condition will be achieved.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s performance and market-based stock option activity for the year ended December 31, 2023:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:40.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.783%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of share options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate intrinsic value </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,764,000</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,955&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,835,220</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.69</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(945,000)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Exercised</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,654,220</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.62</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2023 - vested and expected to vest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,397,760</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.62</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6 years</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,323&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of stock options granted during the years ended December 31, 2023 and 2022 was $1.41 and $0.87, per share, respectively. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2023 and 2022 was $474 and $142, respectively. The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, total unrecognized compensation cost related to unvested stock option grants was approximately $61,162. This amount is expected to be recognized over a weighted average period of approximately 2.2 years. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of warrants is estimated on the date of grant using the Black-Scholes valuation methodology. Expected volatilities are based on historical share price performance, weighted to exclude periods of unusually high volatility. The Company assumed the warrants to be exercised immediately on vesting. The risk-free rate is equal to the prevailing U.K. Gilts rate at grant date that most closely matches the expected term of the grant, as the warrants were issued when the Company was domiciled in the U.K.. Expected dividend yield is zero, and consistent with the Board of Directors&#8217; view that the Company&#8217;s business model is to generate value through capital growth rather than the payment of dividends.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each warrant entitles the warrant holder to subscribe in cash for one share. Shares of common stock allotted pursuant to the exercise of the warrant will rank in full for all dividends and other distributions with a record date after the exercise date with the shares of common stock in issue at that date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 20 for the Company&#8217;s warrants activity for the year ended December 31, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2023, there was no unrecognized compensation expense related to warrants. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock&#8209;based compensation expense related to stock options is recorded within the consolidated statements of operations and comprehensive loss as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.485%"><tr><td style="width:1.0%"></td><td style="width:59.277%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.767%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.770%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Research and development</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,408&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,645&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Total stock-based compensation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,108</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,948</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense associated with each of our share-based compensation arrangements:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.485%"><tr><td style="width:1.0%"></td><td style="width:59.277%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.767%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.770%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Time-based stock options</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,606&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,630&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Performance and market-based stock options </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Employee stock purchase plan</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Total stock-based compensation</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,108</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,948</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996814720832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fixed asset purchase commitments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2023 and 2022, the Company had no capital commitments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease commitments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17 for a discussion of the Company&#8217;s lease commitments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt commitments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 18 for discussion of promissory notes payable to related parties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other commitments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into contracts in the normal course of business with various third parties for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes. Most contracts provide for termination upon notice, and therefore are cancellable contracts. As of December 31, 2023, total contractual commitments, excluding leases commitments and debt commitments, are estimated to be approximately $37,700 and the majority of these commitments are due within one year.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to December 31, 2023, through February 9, 2024 the Company entered into additional contractual commitments of approximately $23,000 with various third parties related to its clinical trials.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has certain commitments under its agreements with the Akeso, Wellcome Trust, the University College London and certain employees, former employees and former directors of Discuva, pursuant to which it will be required to pay royalties or make milestone payments. The License Agreement with Akeso also contains certain manufacturing and purchase commitments. As of December 31, 2023, the Company is unable to estimate the amount, timing or likelihood of achieving the </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">milestones, making future product sales or assessing estimated forecasts for manufacturing and supplied materials which these contingent payment obligations relate to. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indemnifications</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s certificate of incorporation provides that it will indemnify the directors and officers to the fullest extent permitted by Delaware law. In addition, the Company has entered into indemnification agreements with all of the directors and executive officers. These indemnification agreements may require the Company, among other things, to indemnify each such director or executive officer for some expenses, including attorneys&#8217; fees, judgments, fines, and settlement amounts incurred by him or her in any action or proceeding arising out of his or her service as one of the Company&#8217;s directors or executive officers. The Company believes the fair value for these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations as of December 31, 2023.</span></div><div style="margin-top:6pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not currently subject to any material legal proceedings.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996809688000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Promissory Notes Payable to Related Parties<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Non-current and current debt consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"></td><td style="width:41.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.484%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current notes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current notes</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal amounts</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(230)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,460)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total promissory notes payable to related parties</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,770&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494,540&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">March 2022 Promissory Note</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 10, 2022, Mr. Duggan, entered into a Note Purchase Agreement (the &#8220;March 2022 Note&#8221;), pursuant to which he loaned the Company $25,000 in exchange for the issuance by the Company of an unsecured promissory note in the amount of $25,000. The March 2022 Note accrued interest at a rate per annum equal to the prime rate as reported in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wall Street Journal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The March 2022 Note, including all accrued interest, became due upon the earlier of (i) the consummation of a registered public offering with net proceeds of no less than $25,000 or (ii) 18 months from the date of issuance of the March 2022 Note. Debt issuance costs associated with the March 2022 Note were immaterial and expensed as incurred. The March 2022 Note of $25,000, plus accrued interest of $434 has been repaid to Mr. Duggan on August 10, 2022 in connection with the completion of the rights offering with aggregate gross proceeds of $100,000.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred interest expense related to the March 2022 Note of $1,296 for the year ended December 31, 2022, which included amortized imputed interest of $861. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">December 2022 Promissory Notes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 6, 2022, the Company entered into a Note Purchase Agreement (the &#8220;Note Purchase Agreement&#8221;), with Mr. Duggan and Dr. Zanganeh, pursuant to which the Company agreed to sell to each of Mr. Duggan and Dr. Zanganeh unsecured promissory notes in the aggregate amount of $520,000. Pursuant to the Note Purchase Agreement, the Company issued to Mr. Duggan and Dr. Zanganeh unsecured promissory notes in the amount of $400,000 (the &#8220;Duggan February Note&#8221;) and $20,000 (the &#8220;Zanganeh Note&#8221;), respectively, which matured and become due on February 15, 2023 and an unsecured promissory note to Mr. Duggan in the amount of $100,000 (the &#8220;Duggan September Note&#8221; and together with the Duggan February Note and the Zanganeh Note, the &#8220;December 2022 Notes&#8221;), which was originally due on September 15, 2023. The maturity dates of the December 2022 Notes could have been extended one or more times at the Company&#8217;s election, but in no event to a date later than September 6, 2024. In addition, if the Company consummates a public offering, then upon the later to occur of (i) <span style="-sec-ix-hidden:f-764">five</span> business days after the Company receives the net cash proceeds therefrom or (ii) May 15, 2023, the Duggan February Note and the Zanganeh Note shall be prepaid by an amount equal to the lesser of (a) 100% of the amount of the net proceeds of such offering and (b) the outstanding principal amount on such Notes.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 19, 2023, the Company provided notice to extend the term of the Duggan February Note and Duggan September Note to a maturity date of September 6, 2024. Furthermore, on January 19, 2023, the Company and Mr. Duggan rectified the Duggan February Note and Duggan September Note in order to correctly reflect the parties&#8217; intent that the Company may only prepay (i) the Duggan February Note following the completion of a public rights offering to be conducted by Summit in the approximate amount of $500,000 (the &#8220;Rights Offering&#8221;), or a similar capital raise, in an amount equal to the lesser of (x) the net proceeds of the Rights Offering or such capital raise or (y) the full amount outstanding of the Duggan February Note, and (ii) the Duggan September Note following the completion of a capital raising transaction subsequent to the Rights Offering in an amount equal to the lesser of (A) the net proceeds of such capital raise or (B) the full amount outstanding of the Duggan September Note. Following the issuance of the two new Promissory Notes (the &#8220;Duggan Promissory Notes&#8221;), the Duggan February Note and Duggan September Note were marked as &#8220;cancelled&#8221; on their face and replaced in their entirety by the Duggan Promissory Notes (together with the Zanganeh Note, the &#8220;Notes&#8221;).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 15, 2023, the $20,000 Zanganeh Note matured and the Company repaid the outstanding principal balance. In connection with the closing of the rights offering, the $400,000 Duggan Promissory Note matured and became due, and the Company repaid all principal and accrued interest thereunder using a portion of the proceeds from this rights offering.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes accrued interest at an initial rate of 7.5%. All interest on the Notes was paid on the date of signing for the period through February 15, 2023. Such prepaid interest was paid in a number of shares of the Company&#8217;s common stock, par value $0.01 (&#8220;Common Stock&#8221;) equal to the dollar amount of such prepaid interest, divided by $0.7913 (the consolidated closing bid price immediately preceding the time the Company entered into the Note Purchase Agreement, plus $0.01), which was 9,720,291 shares. For all applicable periods following February 15, 2023, interest shall accrue on the outstanding principal balance of the Notes at the US prime interest rate, as reported in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wall Street Journal,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plus 50 basis points, as adjusted monthly, for three months immediately following February 15, 2023, and thereafter at the US prime rate plus 300 basis points, as adjusted monthly.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt issuance costs associated with the Notes were $44 and were capitalized as part of the carrying value of the promissory notes payable to related parties. During the year ended December 31, 2023, the Company incurred interest expense of $16,461 for the year ended December 31, 2023, which included amortized imputed interest of $761. The Company incurred interest expense of $3,105 for the year ended December 31, 2022 related to the December 2022 Notes, which included amortized imputed interest of $395.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023 and 2022 there was $120 of accrued interest payable included within accrued expenses in the consolidated balance sheet. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Imputed interest is calculated as the difference between the expected interest payable and the deemed market rate of interest and is recorded as a debt discount at inception of the note payable with a credit to additional paid-in capital for notes payable to related parties. The debt discount is amortized to interest expense using an effective interest rate method. The effective interest rate of the Duggan February Note and Zanganeh Note was 8.9% and the effective interest rate of the Duggan September Note was 11.3%. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2024 the Duggan February Note was amended to extend the maturity date from September 6, 2024 to April 1, 2025. For all applicable periods commencing  February 17, 2024, interest shall accrue on the outstanding principal balance at the greater of 12% or the US prime interest rate, as reported in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wall Street Journal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plus 350 basis points, as adjusted monthly, compounded quarterly.Interest shall be paid upon maturity of the loan.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the applicable accounting standards, a short-term debt obligation should be excluded from current liabilities if the entity has both the intent and ability to refinance the obligation on a long-term basis. The intent and ability can be demonstrated by the issuance of a long-term obligation to refinance the short-term obligation on a long-term basis after the date of an entity&#8217;s balance sheet but before that balance sheet is issued. As a result of the amendment entered into on February 17, 2024, to extend the maturity date to April 1, 2025, the Company classified $100,000 of notes payable to related party outstanding as of December 31, 2023 as long-term notes payable</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future principal payments are $0 and $100,000 for 2024 and 2025, respectively, as the note matures on April 1, 2025.</span></div>Related Party Transactions<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">July 25, 2022 First Amendment to Sublease Agreement with Maky Zanganeh and Associates, Inc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 25, 2022 the Company entered into a first amendment, dated July 19, 2022, to its existing sublease agreement with MZA, described above. The existing sublease term, which was set to expire on September 30, 2022, was extended for a period of thirty-nine months from October 1, 2022 through December 31, 2025. The rent payable under the terms of the sublease is equivalent to the proportionate share of the net payable by MZA to the third-party landlord, based on the square footage of office space sublet by the Company, and no mark-up has been applied. During the year ended December 31, 2023, payments of $762, were made pursuant to the first amendment to the Sublease Agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">July 29, 2022 Second Amendment to Sublease Agreement with Maky Zanganeh and Associates, Inc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 29, 2022, the Company entered into a second amendment, dated August 1, 2022, to its existing sublease agreement with MZA, described above. The second amendment was effective as of August 1, 2022 and expires on December 31, 2025. The second amendment includes an additional 1,277 square feet (the &#8220;Expansion Premises&#8221;) of office space at 2882 Sand Hill Road, Menlo Park, California. The rent payable under the terms of the sublease is equivalent to the proportionate share of the net payable by MZA to the third-party landlord, based on the square footage of office space sublet by the Company, and no mark-up has been applied. During the year ended December 31, 2023 payments of $218, were made pursuant to the secondment amendment to the sublease.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">March 10, 2022 Note Purchase Agreement</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 10, 2022, the Company entered into a Note Purchase Agreement (the &#8220;March 2022 Note&#8221;), with Mr. Duggan, pursuant to which Mr. Duggan loaned the Company $25,000 in exchange for the issuance by the Company of an unsecured promissory note in the amount of $25,000. The March 2022 Note accrued interest at a rate per annum equal to the prime rate as reported in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wall Street Journal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was 3.25% as of the effective date and 4.75% as of June 30, 2022. The March 2022 Note, including accrued interest, became due upon the earlier of (i) the consummation of a registered public offering with net proceeds of no less than $25,000 or (ii) 18 months from the date of issuance of the March 2022 Note, and was repaid on August 10, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022 Rights Offering</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Rights Offering commenced on July 18, 2022, and the associated subscription rights expired on August 8, 2022. Aggregate gross proceeds received from the rights offering were $100,000 from the sale of 103,092,783 shares of common stock. Mr. Duggan and Dr. Zanganeh fully subscribed to their respective basic subscription rights and oversubscribed, at a price of $0.97 per share. Issuance costs were $111. In connection with the closing of the 2022 Rights Offering, the March 2022 Note </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">matured and became due, and the Company repaid all principal and accrued interest thereunder using a portion of the proceeds from the 2022 Rights Offering on August 10, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">December 6, 2022 Note Purchase Agreement</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 6, 2022, the Company entered into a Note Purchase Agreement (the &#8220;Note Purchase Agreement&#8221;), with Mr. Duggan and Dr. Zanganeh, pursuant to which the Company agreed to sell to each of Mr. Duggan and Dr. Zanganeh unsecured promissory notes in the aggregate amount of $520,000. Pursuant to the Note Purchase Agreement, the Company issued to Mr. Duggan and Dr. Zanganeh unsecured promissory notes in the amount of $400,000 (the &#8220;Duggan February Note&#8221;) and $20,000 (the &#8220;Zanganeh Note&#8221;), respectively, which would mature and become due on February 15, 2023 and an unsecured promissory note to Mr. Duggan in the amount of $100,000 (the &#8220;Duggan September Note&#8221; and together with the Duggan February Note and the Zanganeh Note, the &#8220;December 2022 Notes&#8221;), which matured and became due on September 15, 2023. The maturity dates of the December 2022 Notes could have been extended one or more times at the Company&#8217;s election, but in no event to a date later than September 6, 2024. In addition, if the Company consummates a public offering, then upon the later to occur of (i) <span style="-sec-ix-hidden:f-967">five</span> business days after the Company receives the net cash proceeds therefrom or (ii) May 15, 2023, the Duggan February Note and the Zanganeh Note shall be prepaid by an amount equal to the lesser of (a) 100% of the amount of the net proceeds of such offering and (b) the outstanding principal amount on such notes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 19, 2023, the Company provided notice to extend the term of the Duggan February Note and Duggan September Note to a maturity date of September 6, 2024. Furthermore, on January 19, 2023, the Company and Mr. Duggan rectified the Duggan February Note and Duggan September Note in order to correctly reflect the parties&#8217; intent that the Company may only prepay (i) the Duggan February Note following the completion of a public rights offering to be conducted by Summit in the approximate amount of $500,000 (the &#8220;Rights Offering&#8221;), or a similar capital raise, in an amount equal to the lesser of (x) the net proceeds of the Rights Offering or such capital raise or (y) the full amount outstanding of the Duggan February Note, and (ii) Duggan September Note following the completion of a capital raising transaction subsequent to the Rights Offering in an amount equal to the lesser of (i) the net proceeds of such capital raise or (ii) the full amount outstanding of the Duggan September Note. Following the issuance of the two new Promissory Notes (the &#8220;Duggan Promissory Notes&#8221;), the Duggan February Note and Duggan September Note were marked as &#8220;cancelled&#8221; on their face and replaced in their entirety by the Duggan Promissory Notes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 15, 2023, the $20,000 Zanganeh Note, matured and the Company repaid the outstanding principal balance. In connection with the closing of the 2023 Rights Offering, the $400,000 Duggan Promissory Note, matured and became due, and the Company satisfied all principal and accrued interest thereunder using a combination of a portion of the cash proceeds from the 2023 Rights Offering and the extinguishment of a portion of the amount due equal to the subscription price for shares subscribed by Mr. Duggan in the 2023 Rights Offering (as defined above).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes accrue interest at an initial rate of 7.5%. All interest on the Notes shall be paid on the date of signing for the period through February 15, 2023. Such prepaid interest shall be paid in a number of shares of the Company&#8217;s common stock, par value $0.01 (&#8220;Common Stock&#8221;) equal to the dollar amount of such prepaid interest, divided by $0.7913 (the consolidated closing bid price immediately preceding the time the Company entered into the Note Purchase Agreement, plus $0.01), which was 9,720,291 shares. For all applicable periods following February 15, 2023, interest shall accrue on the outstanding principal balance of the Notes at the United States prime interest rate, as reported in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wall Street Journal,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plus 50 basis points, as adjusted monthly, for three months immediately following February 15, 2023, and thereafter at the United States prime rate plus 300 basis points, as adjusted monthly. During the year ended December 31, 2023, the Company made payments for interest of $10,650.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2024 the Duggan February Note was amended to extend the maturity date from September 6, 2024 to April 1, 2025. For all applicable periods commencing  February 17, 2024, interest shall accrue on the outstanding principal balance at the greater of 12% or the US prime interest rate, as reported in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wall Street Journal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plus 350 basis points, as adjusted monthly, compounded quarterly. Interest shall be paid upon maturity of the loan.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Akeso License Agreement</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the closing of the License Agreement, the Board of Directors (the &#8220;Board&#8221;) of the Company appointed Dr. Yu (Michelle) Xia to serve as a member of the Board pursuant to the terms of the License Agreement. Dr. Xia is the founder of Akeso, Inc., and has been the chairwoman, president and CEO of the Company since its inception in 2012. For details on the License Agreement, see Note 6. Furthermore, in connection with the License Agreement, the Company also entered into a Supply Agreement with Akeso, pursuant to which Summit agreed to purchase a certain portion of drug substance for clinical and commercial supply (the &#8220;Supply Agreement&#8221;). All transactions pursuant to the Supply Agreement, which occurred during 2023, were in the ordinary course of business. The Company paid approximately $2,500 to Akeso during year ended December 31, 2023. As of December 31, 2023, the Company included in accrued expenses approximately $3,619 due to Akeso.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2023 Rights Offering</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 6, 2022, the Company announced a rights offering for its existing shareholders to participate in the purchase of additional shares of its Common Stock for $1.05 per share. The 2023 Rights Offering commenced on February 7, 2023 and the associated subscription rights expired on March 1, 2023. Aggregate gross proceeds from the 2023 Rights Offering were $500,000 from the sale of 476,190,471 shares of the Company&#8217;s common stock and issuance costs were $619. Mr. Duggan and Dr. Zanganeh fully subscribed to their respective basic subscription rights at a price of $1.05 per share. To satisfy the $395,314 subscription price for the shares subscribed by Mr. Duggan in the 2023 Rights Offering, Mr. Duggan agreed with the Company to extinguish a portion of the amount due and payable to him by the Company at the closing of the 2023 Rights Offering pursuant to the $400,000 Duggan Promissory Note in an amount equal to the subscription price.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Registration of Shares</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2023, the Company filed a registration statement on Form S-3 to register for resale the following shares of the Company&#8217;s common stock at $0.01 par value: (i) 10,000,000 shares of Common Stock issued on January 17, 2023 in connection with the License Agreement with Akeso pursuant to which the Company issued Akeso such shares; and (ii) the 9,346,434 and 373,857 shares of Common Stock issued in December 2022 to the Company&#8217;s Chief Executive Officers, Mr. Duggan and Dr. Zanganeh, respectively, as payment of prepaid interest in connection with the Note Purchase Agreement dated December 6, 2022 between Mr. Duggan, Dr. Zanganeh and the Company. On April 27, 2023, the SEC issued the Company a Notice of Effectiveness for the registration statement on Form S-3.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Private Placement</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 16, 2023, the Company announced the appointment of Mr. Manmeet Soni as its Chief Operating Officer, effective immediately. Mr. Soni has been a part of the Company&#8217;s Board of Directors since 2019. He will remain a member of the Board of Directors. In conjunction with his appointment, Mr. Soni entered into a share purchase agreement with the Company to purchase $5,000 of its common stock via a private placement. The transaction was effective October 13, 2023 with a closing price of $1.68, resulting in the purchase of 2,976,190 shares of the Company&#8217;s common stock.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Warrants Exercise</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, Dr. Zanganeh exercised 805,495 shares of warrants. Refer to Note 20 for the warrants exercise activity for the year ended December 31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996810100000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments, including those related to revenue recognition, accrued research and development expenses, stock-based compensation, intangible assets, goodwill, other long-lived assets and income taxes. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation </span></div>The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. The consolidated financial statements reflect the accounts of Summit Therapeutics Inc. and its wholly owned subsidiaries. Intercompany balances and transactions are eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements of the Company&#8217;s subsidiaries with functional currencies other than the United States (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) dollar are translated into U.S. dollars using period-end exchange rates for assets and liabilities, historical exchange rates for stockholders&#8217; equity and weighted average exchange rates for operating results. Translation gains and losses are included in </span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accumulated other comprehensive (loss) income in shareholders&#8217; equity. Foreign currency transaction gains and losses are included in other expen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">se, net in the results of operations. The Company recorded realized and unrealized foreign currency transaction gains (losses) of $613 and ($4,109) for the years ended December 31, 2023 and 2022, respectively, which is included in other expense, net in the statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_OtherOperatingIncomePolicyPolicyTextBlock', window );">Other Operating Income</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Operating Income</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates income from government contracts that reimburse the Company for certain allowable costs for funded projects. For contracts with government agencies where the funding arrangement is considered central to the Company&#8217;s ongoing operations, the Company classifies the recognized funding received as other operating income.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income from government grants is recognized as the qualifying expenses related to the contracts are incurred, provided that there is reasonable assurance of recoverability. If the government agency approves the project proposed by the Company, the government agency funds the project upon receipt of the support for the costs incurred up to the contract limit. Income recognized upon incurring qualifying expenses in advance of billing is recorded as unbilled receivable, a component of other current assets, in the consolidated balance sheet.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant income is not recognized as deductions of research and development costs because the Company acts as the principal in conducting the research and development activities and these contracts are central to its ongoing operations. The funds received through these means are held as deferred income in the consolidated balance sheets and are released to the consolidated statement of operations and comprehensive loss, classified as other operating income, as the underlying expenditure is incurred and to the extent the conditions of the grant are met. The related costs incurred by the Company are included in research and development expense in the Company&#8217;s consolidated statements of operations and comprehensive loss.</span></div>The Company benefits from two U.K. research and development (&#8220;R&amp;D&#8221;) tax credit cash rebate regimes: Small and Medium Enterprise (&#8220;SME&#8221;) Program and the Research and Development Expenditure Credit (&#8220;RDEC&#8221;) Program. Each reporting period, management evaluates which tax relief programs the Company is expected to be eligible for and records as other operating income the portion of the expense that it expects to qualify under the programs, that it plans to submit a claim for, and it has reasonable assurance that the amount will ultimately be realized. Based on criteria established by HM Revenue and Customs (&#8220;HMRC&#8221;), management of the Company expects a proportion of expenditures being undertaken in relation to its pipeline research, clinical trials management and manufacturing development activities to be eligible for the research and development tax relief programs for the year ended December 31, 2023. Qualifying expenditures largely comprise of employment costs for research staff, consumables, a proportion of relevant, permitted sub-contract costs and certain internal overhead costs incurred as part of research projects for which the Company does not receive commercial or other funding income. Credits related to the SME and RDEC Programs are recorded as other operating income in the consolidated statements of operations and other comprehensive (loss)/income. Under the SME scheme, the Company receives cash rebate payments of up to 33.3% up to March 31, 2023 and 18.6% from April 1, 2023 of eligible research and development expenditures, and under the RDEC scheme the Company receives cash rebate payments of up to 10.53% up to March 31, 2023 and 15% from April 1, 2023 of eligible research and development expenditure, and these payments are not dependent on the Company&#8217;s pre-tax net income levels.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the diluted net loss by the weighted-average number of common shares outstanding for the period, including potentially dilutive common shares. The dilutive effect of share options and warrants are determined under the treasury stock method using the average market price for the period.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the assumed proceeds under the treasury stock method include the average unrecognized compensation expense of stock options and warrants that are in-the-money.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Combinations </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for under the acquisition method. Acquired assets and assumed liabilities are measured at their fair values at the acquisition date. The excess of the consideration transferred over the net fair value of assets acquired and liabilities assumed is recorded as goodwill. The accounting for an acquisition involves a considerable amount of judgement and estimation. Cost, income, market or a combination of approaches may be used to establish the fair value of consideration exchanged, assets acquired, and liabilities assumed, depending on the nature of those items. The valuation approach is determined in accordance with generally accepted valuation methods. Key areas of estimation and judgment may include the selection of valuation approaches, cost of capital, market characteristics, cost structure, impacts of synergies, and estimates of terminal value, among other factors.</span></div>While the Company uses estimates and assumptions as part of the purchase price allocation process to estimate the value of assets acquired and liabilities assumed, estimates are inherently uncertain and subject to refinement. During the measurement period, which maybe up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with a corresponding offset to goodwill, to the extent that adjustments are identified to the preliminary purchase price allocation. Upon conclusion of the measurement period, or final determination of the value of the assets acquired and liabilities assumed, whichever comes first, any subsequent adjustments are recorded to results of operations. Results of operations related to business combinations are included prospectively beginning with the date of acquisition and transaction costs related to business combinations are recorded within general and administrative expenses.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the consideration transferred over the fair value of net assets acquired. Goodwill is assigned to reporting units at the time of acquisition or when there is a change in the reporting structure and bases that allocation on which reporting units will benefit from the acquired assets and liabilities. Reporting units are defined as operating segments or one level below an operating segment, referred to as a component. Typically acquisitions related to a single reporting unit do not require the allocation of goodwill to multiple reporting units. If the products obtained in an acquisition are assigned to multiple reporting units, the goodwill is distributed to the respective reporting units as part of the purchase price allocation process.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses goodwill for impairment on an annual basis or more frequently when events and circumstances occur indicating that the recorded goodwill may be impaired. The Company regularly monitors current business conditions and other factors including, but not limited to, adverse industry or economic trends and lower projections of profitability that may impact future operating results. The process of evaluating the potential impairment of goodwill requires significant judgment. In performing the Company&#8217;s annual goodwill impairment test, the Company is permitted to first assess qualitative factors to determine whether it is more likely than not that the fair value of the Company&#8217;s reporting unit is less than its carrying amount, including goodwill. In performing the qualitative assessment, the Company considers certain events and circumstances specific to the reporting unit and to the entity as a whole, such as macroeconomic conditions, industry and market considerations, overall financial performance and cost factors when evaluating whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. The Company is also permitted to bypass the qualitative assessment and proceed directly to the quantitative test. If the Company chooses to undertake the qualitative assessment and concludes that it is more likely than not that the fair value of the reporting unit is less than its carrying amount, the Company would then proceed to the quantitative impairment test. In the quantitative assessment, the Company compares the fair value of the reporting unit to its carrying amount, which includes goodwill. If the fair value exceeds the carrying value, no impairment loss exists. If the fair value is less than the carrying amount, a goodwill impairment loss is measured and recorded.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses goodwill for impairment on an annual basis as of December 31 or more frequently when events and circumstances occur indicating that recorded goodwill may be impaired.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment </span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation. Cost is comprised of the purchase price plus any incidental costs of acquisition and commissioning. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is calculated based on cost, less residual value, in equal annual installments over the estimated useful lives of the assets. The residual value, if significant, is reassessed annually.</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 - 10 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures, office equipment and software</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="-sec-ix-hidden:f-377"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Over the shorter of the asset</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">s useful life or the remaining lease term</span></span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is recognized as part of the general and administrative and research and development expense lines shown on the face of the consolidated statement of operations and comprehensive loss depending on the nature of the underlying assets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenditures for repairs and maintenance are expensed as incurred. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in loss from operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for real estate. The Company does not have any finance leases. Under ASC 842, a contract is or contains a lease when the lessee has the right to control the use of an identified asset. The Company determines if an arrangement is a lease at inception of the contract, which is the date on which the terms of the contract are agreed to and the agreement creates enforceable rights and obligations. The lease term used to calculate the lease liability include options to extend or terminate the lease when it is reasonably certain that the option will be exercised.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the lease commencement date, the Company measures and recognizes a lease liability and a right-of-use asset in the financial statements. Lease liabilities are recognized based on the present value of the future lease payments over the lease term at commencement date. The right-of use asset is measured by taking the present value of future lease payments, plus any incremental direct costs incurred, less any lease incentives received. As most of the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s leases do not provide an implicit rate, the Company uses an estimated incremental borrowing rate based on the lease term and the economic environment of the lease at the lease commencement date, which is then utilized to determine the present value of future lease payments. Lease expense for minimum lease payments are recognized on a straight-line basis over the lease term, with variable lease payments recognized in the periods in which they are incurred.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has existing lease agreements with lease and non-lease components, has elected to account for the lease and non-lease components as a single lease component, and has allocated all of the contract consideration to the lease component only. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial lease term of 12 months or less are not recorded on the balance sheet. The Company recognizes lease expense for its short-term leases on a straight-line basis over the lease term.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">Acquired In-Process Research and Development</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquired In-Process Research and Development</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company  may enter into agreements with collaboration partners for the development and commercialization of its products. These arrangements may include payments contingent on the occurrence of certain events such as development, regulatory or sales-based milestones. The Company considers the unique nature, terms and facts and circumstances of each transaction. The Company considers whether or not the assets acquired have a future alternative use. </span></div>The fair value associated with acquired in-process research and development which does not have an alternative future use is expensed and is recorded as research and development expense. Any development or commercial milestone payments are recognized when the achievement of the associated milestone becomes probable and will either be expensed or capitalized depending upon whether or not regulatory approval has been obtained.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Costs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred to discover, research and develop product candidates, including personnel expenses, stock-based compensation expense, allocated facility-related and depreciation expenses, third-party license fees and external costs of outside vendors engaged to conduct </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preclinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are recorded as prepaid expenses. Such amounts are recognized as an expense as the goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered. Milestone and other payments made to third-parties with respect to in-process research and development, in accordance with the Company&#8217;s license, acquisition and other similar agreements are expensed when determined to be probable and estimable.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various research and development contracts with other companies. These agreements are generally cancellable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research and development costs or prepaid expenses where the payments made exceeds the estimated costs. When evaluating the adequacy of these balances, the Company analyzes progress of the studies, including the estimated costs to complete each study or activity, the estimation of the current stage of completion and the invoices received, as well as predetermined milestones which are not reflective of the current stage of development for prepaid expenses. Actual results could differ from the Company&#8217;s estimates. In all cases, the full cost of each study or activity is expensed by the time the final report or where applicable, product, has been received. The Company&#8217;s historical estimates have not been materially different from the actual costs.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and recognizes compensation expense for all stock option and restricted stock unit awards based on the estimated fair value of the award on the grant date. The Company uses the Black-Scholes option pricing model to estimate the fair value of stock option awards. Additionally, the Company uses a Monte Carlo simulation model to calculate the estimated fair value on the date of grant related to awards with market-based service conditions. The fair value is recognized as expense, over the requisite service period, which is generally the vesting period of the respective award, on a straight-line basis for each separately vesting portion of the award when the only condition to vesting is continued service.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If vesting is subject to a market or performance condition, recognition is based on the derived service period of the award. Expense for awards with performance conditions is estimated and adjusted on a quarterly basis based upon the assessment of the probability that the performance condition will be met. Use of the Black-Scholes option-pricing model requires management to apply judgment under highly subjective assumptions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These assumptions include:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expected term&#8212;The expected term of stock options represents the weighted-average period the stock options are expected to be outstanding. The Company uses the simplified method for estimating the expected term as provided by the Securities and Exchange Commission. The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life of the options.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expected volatility&#8212;The expected volatility is calculated based on historical volatility of the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s share price.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk-free interest rate&#8212;The risk-free rate assumption is based on the U.S. Treasury instruments, the terms of which were consistent with the expected term of the Company&#8217;s stock options.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expected dividend&#8212;The expected dividend assumption is based on the Company&#8217;s history and expectation of dividend payouts. The Company has not paid and does not intend to pay dividends. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates expected forfeitures at the time of grant instead of accounting for forfeitures as they occur. Stock option and restricted stock unit awards have been granted at fair value to non-employees in connection with research and consulting services provided to the Company. Equity awards generally vest over terms of 3 or 4 years. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies stock-based compensation expense in the consolidated statements of operations in the same manner in which the award recipient&#8217;s payroll costs are classified.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is determined using the asset and liability approach. Tax laws may require items to be included in tax filings at different times than the items are reflected in the financial statements. A current asset or liability is recognized for the estimated taxes receivable or payable for the current year. Deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. Deferred taxes are initially recognized at enacted tax rates in force at the time of initial recognition and are subsequently adjusted for any enacted changes in tax rates </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and tax laws. Subsequent changes to deferred taxes originally recognized in equity are recognized in income. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The Company has recorded a full valuation allowance against the deferred tax assets in excess of its deferred tax liabilities, as the deferred tax liability represents future reversals of existing taxable temporary differences. The Company records interest and penalties related to income tax matters as part of income tax expense.</span></div>The Company accounts for uncertainty in income taxes by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed as the amount of benefit to recognize in the consolidated financial statements. The amount of benefits that may be used is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate, as well as the related net interest and penalties. The Company&#8217;s policy is to recognize interest and penalties related to uncertain tax positions as part of its income tax provision.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and of Significant Supplier</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk and of Significant Supplier</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of short-term cash deposits and accounts and other receivables. The Company&#8217;s cash is comprised of short-term cash deposits at a variety of financial institutions with strong credit ratings in amounts that may exceed federally insured limits and has not experienced any losses on such accounts. Cash balances maintained during the year have been principally held with reputable U.K.-based and U.S.-based banks. The Company does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The credit risk with respect to customers and funding bodies is limited as the Company has only a small number of these arrangements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies, and expects to continue to rely, on a number of vendors to conduct its clinical trials and preclinical studies, manufacture drug product and supply clinical trial and preclinical study materials for its development programs. These programs could be adversely affected by a significant interruption in these services or the availability of materials.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the provisions of fair value accounting, a fair value measurement assumes that the transaction to sell an asset or transfer a liability occurs in the principal market for the asset or liability or, in the absence of a principal market, the most advantageous market for the asset or liability and defines fair value based on the exit price model.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurement guidance establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The guidance describes three levels of inputs that may be used to measure fair value:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quoted prices in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 2 assets and liabilities include debt securities with quoted prices that are traded less frequently than exchange-traded instruments or securities or derivative contracts that are valued using a pricing model with inputs that are observable in the market or can be derived principally from or corroborated by observable market data.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the Company categorizes such assets and liabilities based on the lowest level input that is significant to the fair value measurement in its entirety. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div>The Company considers only those investments that are highly liquid, readily convertible to cash and that mature within 90 days or less from date of purchase to be cash equivalents.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Cash</span></div>Restricted cash of $300,000 as of December 31, 2022, represents amounts which are legally restricted to withdrawal or usage and is presented in the Consolidated Balance Sheet as restricted cash.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_AssumedContingentLiabilitiesPolicyPolicyTextBlock', window );">Assumed Contingent Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assumed Contingent Liabilities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the acquisition of Discuva Limited in December 2017, the Company assumed certain contingent liabilities as certain employees, former employees and former directors of Discuva Limited are eligible for payments from Discuva Limited based on specified development and clinical milestones related to proprietary product candidates developed under the Discuva Platform. The timing of these potential payments is uncertain. The fair value of the assumed contingent liability was estimated using the expected value of the payments. The assumed contingent liabilities are subsequently measured at amortized cost using discounted cash flow models which calculate the risk adjusted net present values of estimated potential future cash flows of the payments. The assumed contingent liabilities are remeasured when there is a specific significant event that provides evidence of a significant change in the probability of successful development and clinical milestones being achieved. The models will be updated for changes in the probability of successful development and clinical milestones being achieved and other associated assumptions with the discount factor remaining unchanged within the model. A discount factor of 13% has been used to discount the contingent liabilities back to net present value. This discount factor has been calculated using appropriate measures and rates which could have been obtained in the period that the contingent liabilities were assumed. Accretion of the discount </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">factor and gains or losses upon remeasurement are recognized as part of operating expenses in the consolidated statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_WarrantsPolicyPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants issued by the Company are recognized and classified as equity when, upon exercise, the Company would issue a fixed amount of its own equity instruments (common stock) in exchange for a fixed amount of cash or another financial asset.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration received, net of incremental costs directly attributable to the issue of such new warrants, is shown in equity. Such warrants are not remeasured at fair value in subsequent reporting periods.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants issued in which external services are received as consideration for equity instruments of the company should be measured at the fair value of the goods or services received. Only if the fair value of the services cannot be measured reliably would the fair value of the equity instruments granted be used. The fair value for the warrants is calculated using the Black-Scholes formula and recorded in the consolidated statement of operations and comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on a straight-line basis over the period of the consulting services. If the services are terminated prior to the end of the consultancy agreement, the warrants cease vesting and any unvested portion of the warrants will lapse immediately.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The warrants in issue are classified within stockholders&#8217; equity as they are indexed to the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span>s own shares of common stock and require settlement in its shares of common stocks with no provision for any cash settlement.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued or Adopted Accounting Pronouncements</a></td>
<td class="text">Recently Issued or Adopted Accounting Pronouncements <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards update &#8220;ASU&#8221; No. 2023-09, &#8220;Improvements to Income Tax Disclosures&#8221;, which requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. ASU No. 2023-09 is effective for fiscal years beginning after December 15, 2024 and allows for adoption on a prospective basis, with a retrospective option. Early adoption is permitted. The Company is currently evaluating the impact of the ASU on the income tax disclosures within the consolidated financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU No. 2023-07, &#8220;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&#8221;, which provides updates to qualitative and quantitative reportable segment disclosure requirements, including enhanced disclosures about significant segment expenses and increased interim disclosure requirements, among others. ASU No. 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. Early adoption is permitted, and the amendments should be applied retrospectively. The Company is currently evaluating the impact of the ASU on the consolidated financial statement disclosures. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, &#8220;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#8221;, which has subsequently been amended by ASU 2019-04 and ASU 2019-10 (collectively &#8220;ASU 2016-03&#8221;). ASU 2016-13 amends the guidance on the impairment of financial instruments. This update adds an impairment model (known as the current expected credit losses model) that is based on expected losses rather than incurred losses. Under the new guidance, an entity recognizes, as an allowance, its estimate of expected credit losses. The Company adopted this standard on January 1, 2023, and it did not have a material impact on the consolidated financial statements or related disclosures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other recent authoritative guidance issued by the FASB (including technical corrections to the FASB ASC), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not expected to have a material impact on the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_AssumedContingentLiabilitiesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assumed Contingent Liabilities, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_AssumedContingentLiabilitiesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_OtherOperatingIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Operating Income, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_OtherOperatingIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_WarrantsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_WarrantsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479515/805-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996814709776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment useful lives</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is calculated based on cost, less residual value, in equal annual installments over the estimated useful lives of the assets. The residual value, if significant, is reassessed annually.</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 - 10 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures, office equipment and software</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="-sec-ix-hidden:f-377"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Over the shorter of the asset</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">s useful life or the remaining lease term</span></span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:60.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.826%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.829%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures, office equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,203&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">906&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996810302656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock', window );">Summary of long-lived assets by geography</a></td>
<td class="text">The following table summarizes the Company&#8217;s long-lived assets, which include the Company&#8217;s property and equipment, net and right-of-use assets by geography: <div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">808&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,517&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,062&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,081&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The decrease of long-lived assets in the United Kingdom is primarily attributed to the Company exiting its lease for its Sawston, United Kingdom location.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The increase of long-lived assets in the United States is primarily attributed to additional right-of-use assets recorded related to the Company&#8217;s amendment to its sublease agreement during the period for its Menlo Park, California, U.S. location.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph b<br> -SubTopic 10<br> -Topic 280<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996814700224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Summary of deferred revenue and other income</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the deferred revenue relating to Eurofarma Laborat&#243;rios S.A. and deferred other income relating to BARDA (as defined in Note 9):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:69.653%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.080%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.344%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning deferred revenue and other income, January 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,939&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of deferred revenue and other income recognized in the statement of operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,790)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(546)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending deferred revenue and other income, December 31</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996814836960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Operating Income, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ScheduleOfOtherOperatingIncomeExpenseNetTableTextBlock', window );">Schedule of other operating income</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of other operating income by category:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Funding income from BARDA (as defined below)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,085&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grant income from CARB-X (as defined below)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,808&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,001&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,416&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ScheduleOfOtherOperatingIncomeExpenseNetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Other Operating Income (Expense), Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ScheduleOfOtherOperatingIncomeExpenseNetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996814782992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Expense) Income, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of other (expense) income</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of other (expense) income:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency gains (losses)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,109)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense on promissory notes payable to related parties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,461)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,401)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,513&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of cumulative currency translation gain</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(252)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,278)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,693)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 17, 2023, the Company dissolved the following dormant entities; Summit (Cambridge) Limited, Summit (Wales) Limited, Summit Corporation Employee Benefit Trust Company Limited, Summit Corporation Limited, Summit Discovery 1 Limited and Summit Infectious Diseases Limited. As a result, the Company reclassified $419 of cumulative foreign currency translation adjustments from accumulated other comprehensive loss relating to these entities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996810001488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Components of loss before income taxes</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company&#8217;s loss before income taxes are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(499,810)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,868)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115,118)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,914)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(614,928)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,782)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Major components of deferred tax assets and liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of deferred tax assets and liabilities are as follows:</span></div><div style="padding-left:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.468%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss carryforward</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development credit carryforward</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Section 174 Research and Development Capitalization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liability</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,010&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,893&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,085)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(651)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(174)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,259)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(877)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax assets before valuation allowance </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,751</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,016</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84,751)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,016)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Change in valuation allowance</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the valuation allowance was as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.468%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance as of beginning of year</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,016)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,746)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase recorded to the income tax provision</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,735)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,270)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance as of end of year</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84,751)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,016)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of the effective income tax rate to the statutory rate</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the Company&#8217;s effective tax rate to the U.S. federal statutory rate is as follows: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. federal income tax statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Refundable research and development tax credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of foreign operations taxed at various rates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Reconciliation of unrecognized tax benefits</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of unrecognized tax benefits from continuing operations is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:67.972%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.629%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized tax benefits, beginning of year</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases related to prior year tax positions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decreases related to prior year tax positions</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases related to current year tax positions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized tax benefits, end of year</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,064&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996810138496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of net loss per share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net loss per share: </span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(614,928)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,782)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average number of shares of common stock outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619,646,180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,336,063&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average number of shares of common stock outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619,646,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,336,063&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net loss per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net loss per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.99)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potentially dilutive securities excluded from the computation of loss per share</a></td>
<td class="text"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities were excluded from the computation of the diluted net loss per share of common stock for the periods presented because their effect would have been anti-dilutive: </span></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,209,289</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,476,359</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,015,642</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,821,137</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares expected to be purchased under employee stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,163</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,475</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,380,094</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,526,971</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996814885024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of acquired intangible assets</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of the Company&#8217;s acquired intangible assets are comprised of the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:25.301%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.961%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.681%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.717%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.961%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.681%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.724%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated amortization and impairment charges</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated amortization and impairment charges</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Utrophin program acquired</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,015&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,015)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discuva platform acquired</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,583&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,583)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,900&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,900)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Option over non-financial asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(859)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(816)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other intangibles</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,582&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,582)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,864&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,864)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company dissolved the wholly-owned subsidiary, Muox Limited, a dormant entity. The Utrophin program intangible assets, which arose from the Muox Limited acquisition were fully impaired and have been removed from the Company&#8217;s accounting records.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the significant change in the Company&#8217;s strategy and shift in focus to the therapeutic area of oncology, the Company determined that it would cease further investment in the Discuva Platform. Management concluded that the carrying amount of the acquired Discuva Platform intangible asset may not be recoverable and performed an assessment to calculate the fair value of the asset using a probability-weighted approach which was compared to the carrying value of the asset. An impairment charge of $8,468 which represented the carrying value of the Discuva Platform was recognized during the year ended December 31, 2022. This impairment charge is presented as <span style="-sec-ix-hidden:f-630">impairment of intangible assets</span> in the consolidated statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996810004240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Short-Term Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of assets and liabilities measured at fair value on a recurring basis</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables sets forth the Company&#8217;s fair value hierarchy for its assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2023 and 2022: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:37.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.486%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements as of December 31, 2023</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government treasury bills</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government treasury bills</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,817&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,817&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,016&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,158&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,174&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:37.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.486%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements as of December 31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,783&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,783&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government treasury bills</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,783&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,730&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,513&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of short-term investments</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Company&#8217;s short-term investments as of December 31, 2023, which have a contractual maturity of less than one year:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:35.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Credit Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,781&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,817&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996814809728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is calculated based on cost, less residual value, in equal annual installments over the estimated useful lives of the assets. The residual value, if significant, is reassessed annually.</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 - 10 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures, office equipment and software</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="-sec-ix-hidden:f-377"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Over the shorter of the asset</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">s useful life or the remaining lease term</span></span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:60.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.826%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.829%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures, office equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,203&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">906&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996815670016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of lease expense</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The elements of lease expense were as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease Cost:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Fixed lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,214&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,384&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Variable lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Short-term lease</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,297&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,552&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Short-term lease costs relate to the Company&#8217;s Cambridge, Massachusetts, United States office lease which the Company exited during fiscal year 2022.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of future lease payments</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future lease payments under non-cancelable leases as of December 31, 2023 are detailed as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:83.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.357%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,810&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,099&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities balance sheet presentation:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,099&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996814778096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Promissory Notes Payable to Related Parties (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of related party debt</a></td>
<td class="text">Non-current and current debt consisted of the following:<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"></td><td style="width:41.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.484%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current notes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current notes</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal amounts</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(230)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,460)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total promissory notes payable to related parties</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,770&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494,540&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996814748656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrant activity</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The following table summarizes the Company&#8217;s warrants activity for the year ended December 31, 2023</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.306%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.306%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.306%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.313%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of share warrants</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate intrinsic value </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,821,137</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.56</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.99 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,640&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Exercised</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(805,495)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.49</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,015,642</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.57</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.92 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996814657904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted-average assumptions</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used in the Company&#8217;s valuation are summarized as follows, presented on a weighted average basis: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"></td><td style="width:66.392%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual dividends per share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The following table summarizes the Company&#8217;s time-based stock option activity for the year ended December 31, 2023:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:40.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.783%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of share options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate intrinsic value </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,712,359</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.83</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,702&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,135,170</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.72</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,433,943)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.56</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Exercised</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204,297)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,209,289</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2023 - vested and expected to vest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,407,492</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3 years</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,406&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,716,319</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.89</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s performance and market-based stock option activity for the year ended December 31, 2023:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:40.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.783%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of share options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate intrinsic value </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,764,000</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,955&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,835,220</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.69</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(945,000)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Exercised</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,654,220</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.62</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2023 - vested and expected to vest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,397,760</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.62</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6 years</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,323&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock-based compensation expense</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock&#8209;based compensation expense related to stock options is recorded within the consolidated statements of operations and comprehensive loss as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.485%"><tr><td style="width:1.0%"></td><td style="width:59.277%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.767%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.770%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Research and development</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,408&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,645&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Total stock-based compensation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,108</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,948</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense associated with each of our share-based compensation arrangements:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.485%"><tr><td style="width:1.0%"></td><td style="width:59.277%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.767%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.770%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Time-based stock options</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,606&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,630&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Performance and market-based stock options </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Employee stock purchase plan</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Total stock-based compensation</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,108</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,948</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996806733856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Operations and Recent Events (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 17, 2024</div></th>
<th class="th"><div>Oct. 13, 2023</div></th>
<th class="th"><div>Oct. 12, 2023</div></th>
<th class="th"><div>Mar. 01, 2023</div></th>
<th class="th"><div>Feb. 15, 2023</div></th>
<th class="th"><div>Jan. 19, 2023</div></th>
<th class="th"><div>Dec. 06, 2022</div></th>
<th class="th"><div>Aug. 08, 2022</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Apr. 27, 2023</div></th>
<th class="th"><div>Jan. 18, 2023</div></th>
<th class="th"><div>Jul. 26, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_CommonStockSharesAuthorizedIncreaseDecrease', window );">Increase in common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from the sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,686<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">619<span></span>
</td>
<td class="nump">111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment of related party notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,686<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from the issuance of common stock via private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=smmt_A2020StockIncentivePlanMember', window );">2020 Plan | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase to number of shares of common stock issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=smmt_RightsOfferingMember', window );">Rights Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from the sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">476,190,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,092,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer | S-3 Registration Statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_SaleOfStockNumberOfSharesRegisteredForResale', window );">Number of shares registered for resale (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,346,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=smmt_ChiefExecutiveOfficerAndPresidentMember', window );">Chief Executive Officer and President | S-3 Registration Statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_SaleOfStockNumberOfSharesRegisteredForResale', window );">Number of shares registered for resale (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">373,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | S-3 Registration Statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_SaleOfStockNumberOfSharesRegisteredForResale', window );">Number of shares registered for resale (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefOperatingOfficerMember', window );">Chief Operations Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from the issuance of common stock via private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefOperatingOfficerMember', window );">Chief Operations Officer | Private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,976,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=smmt_NotePurchaseAgreementMember', window );">Note Purchase Agreement | Chief Executive Officer and Chief Executive Officer and President</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 520,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=smmt_DugganFebruaryNoteMember', window );">Duggan February Note | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment of related party notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=smmt_DugganFebruaryNoteMember', window );">Duggan February Note | Chief Executive Officer | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Interest rate</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=smmt_DugganFebruaryNoteMember', window );">Duggan February Note | Chief Executive Officer | Subsequent event | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate margin</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=smmt_ZanganehNoteMember', window );">Zanganeh Note | Chief Executive Officer and President</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment of related party notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_CommonStockSharesAuthorizedIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Shares Authorized, Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_CommonStockSharesAuthorizedIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_SaleOfStockNumberOfSharesRegisteredForResale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Number Of Shares Registered For Resale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_SaleOfStockNumberOfSharesRegisteredForResale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=smmt_A2020StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=smmt_A2020StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=smmt_RightsOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=smmt_RightsOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=smmt_S3RegistrationStatementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=smmt_S3RegistrationStatementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=smmt_ChiefExecutiveOfficerAndPresidentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=smmt_ChiefExecutiveOfficerAndPresidentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefOperatingOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefOperatingOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=smmt_NotePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=smmt_NotePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=smmt_DugganFebruaryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=smmt_DugganFebruaryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=smmt_ZanganehNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=smmt_ZanganehNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996807954032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Capital Resources (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 614,928<span></span>
</td>
<td class="nump">$ 78,782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="nump">76,760<span></span>
</td>
<td class="nump">41,582<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">993,258<span></span>
</td>
<td class="nump">378,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash and cash equivalents and short-term investments</a></td>
<td class="nump">186,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Promissory notes payable to related parties</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 494,540<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996801504416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 17, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 15, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency transaction gains (losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 613<span></span>
</td>
<td class="num">$ (4,109)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,064<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Liability for interest and penalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_BusinessCombinationAssumedContingentLiabilityMeasurementInput', window );">Assumed contingent liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentOneMember', window );">Collaborative arrangement, transaction with party to collaborative arrangement, upfront payment one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentSharesOfCommonStockIssuedInLieuOfCash', window );">Collaborative arrangement, common stock issued in lieu of cash upfront payment (in shares) | shares</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_CashPaymentForCollaborativeArrangementUpfrontPayment', window );">Cash payment for collaborative arrangement, upfront payment</a></td>
<td class="nump">$ 274,900<span></span>
</td>
<td class="nump">$ 274,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration', window );">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Useful Life, Shorter of Lease Term or Asset Utility [Member]<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Equity award, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Furniture and fixtures, office equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Equity award, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Furniture and fixtures, office equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_BusinessCombinationAssumedContingentLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Assumed Contingent Liability, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_BusinessCombinationAssumedContingentLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_CashPaymentForCollaborativeArrangementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payment For Collaborative Arrangement, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_CashPaymentForCollaborativeArrangementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentSharesOfCommonStockIssuedInLieuOfCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Upfront Payment, Shares Of Common Stock Issued In Lieu Of Cash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentSharesOfCommonStockIssuedInLieuOfCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant Accounting Policies</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482190/360-10-35-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=smmt_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=smmt_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996808060240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Akeso License and Collaboration Agreement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 06, 2023</div></th>
<th class="th"><div>Jan. 17, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Mar. 06, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_InProcessResearchAndDevelopmentExpense', window );">In-process research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 520,915<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement', window );">Issuance of common stock in lieu of cash for Akeso upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Collaborative arrangement, transaction with party to collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPayment', window );">Collaborative arrangement, upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_CashPaymentForCollaborativeArrangementUpfrontPayment', window );">Cash payment for collaborative arrangement, upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">474,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_CollaborativeArrangementRightsAndObligationsDirectTransactionCosts', window );">Collaborative arrangement, direct transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments', window );">Collaborative arrangement, additional potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_CollaborativeArrangementRightsAndObligationsPotentialRegulatoryMilestonePayments', window );">Collaborative arrangement, potential regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_CollaborativeArrangementRightsAndObligationsPotentialCommercialMilestonePayments', window );">Collaborative arrangement, potential commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentOneMember', window );">Collaborative arrangement, transaction with party to collaborative arrangement, upfront payment one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_CashPaymentForCollaborativeArrangementUpfrontPayment', window );">Cash payment for collaborative arrangement, upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 274,900<span></span>
</td>
<td class="nump">$ 274,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentSharesOfCommonStockIssuedInLieuOfCash', window );">Collaborative arrangement, common stock issued in lieu of cash upfront payment (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentPaidInShares', window );">Collaborative arrangement, upfront payment, paid in shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement', window );">Issuance of common stock in lieu of cash for Akeso upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentTwoMember', window );">Collaborative arrangement, transaction with party to collaborative arrangement, upfront payment two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_CashPaymentForCollaborativeArrangementUpfrontPayment', window );">Cash payment for collaborative arrangement, upfront payment</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_CashPaymentForCollaborativeArrangementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payment For Collaborative Arrangement, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_CashPaymentForCollaborativeArrangementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_CollaborativeArrangementRightsAndObligationsDirectTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Direct Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_CollaborativeArrangementRightsAndObligationsDirectTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_CollaborativeArrangementRightsAndObligationsPotentialCommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Potential Commercial Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_CollaborativeArrangementRightsAndObligationsPotentialCommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_CollaborativeArrangementRightsAndObligationsPotentialRegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Potential Regulatory Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_CollaborativeArrangementRightsAndObligationsPotentialRegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_CollaborativeArrangementRightsAndObligationsUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentPaidInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Upfront Payment, Paid In Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentPaidInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentSharesOfCommonStockIssuedInLieuOfCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Upfront Payment, Shares Of Common Stock Issued In Lieu Of Cash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentSharesOfCommonStockIssuedInLieuOfCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_InProcessResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In-Process Research And Development Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_InProcessResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, In Lieu Of Cash For Collaborative Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996815675024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>country </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfCountriesInWhichEntityOperates', window );">Number of geographic regions in which the Company operates | country</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfCountriesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of countries in which the entity operates as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfCountriesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996801494176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment Reporting - Long-lived assets by geography (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">$ 6,062<span></span>
</td>
<td class="nump">$ 5,081<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_GB', window );">United Kingdom</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">808<span></span>
</td>
<td class="nump">2,517<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">$ 5,254<span></span>
</td>
<td class="nump">$ 2,564<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996900383200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 705<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996811793392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Deferred revenue and other income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward', window );"><strong>Change in Contract with Customer, Asset and Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning deferred revenue and other income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 7,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ContractWithCustomerLiabilityAdditions', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance', window );">Amount of deferred revenue and other income recognized in the statement of operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,790)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ContractWithCustomerLiabilityForeignCurrencyTranslation', window );">Foreign currency adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(546)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending deferred revenue and other income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in Contract with Customer, Asset and Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ContractWithCustomerLiabilityAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Additions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ContractWithCustomerLiabilityAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ContractWithCustomerLiabilityForeignCurrencyTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Foreign Currency Translation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ContractWithCustomerLiabilityForeignCurrencyTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Revenue Recognized, Including Opening Balance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996801534096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Operating Income, net - Summary by category (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">32 Months Ended</th>
<th class="th" colspan="1">64 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ResearchAndDevelopmentTaxCredit', window );">Research and development tax credits</a></td>
<td class="nump">$ 946<span></span>
</td>
<td class="nump">$ 4,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_OtherOperatingIncomeOther', window );">Other income</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">1,001<span></span>
</td>
<td class="nump">14,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember', window );">BARDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_GrantFundingArrangementIncomeEarned', window );">Funding/Grant income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember', window );">CARB-X</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_GrantFundingArrangementIncomeEarned', window );">Funding/Grant income</a></td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 1,808<span></span>
</td>
<td class="nump">$ 2,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_GrantFundingArrangementIncomeEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant Funding Arrangement, Income Earned</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_GrantFundingArrangementIncomeEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_OtherOperatingIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Operating Income, Other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_OtherOperatingIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ResearchAndDevelopmentTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development, Tax Credit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ResearchAndDevelopmentTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996807890336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Operating Income, net - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">32 Months Ended</th>
<th class="th" colspan="1">64 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ResearchAndDevelopmentTaxCreditReceivable', window );">Current and long-term research and development tax credit receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,807<span></span>
</td>
<td class="nump">$ 5,766<span></span>
</td>
<td class="nump">$ 1,807<span></span>
</td>
<td class="nump">$ 5,766<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember', window );">BARDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_GrantFundingArrangementMaximumFundingValue', window );">Maximum funding value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,000<span></span>
</td>
<td class="nump">72,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_GrantFundingArrangementCommittedFundingTotal', window );">Total committed funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_GrantFundingArrangementIncomeEarned', window );">Funding/Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember', window );">CARB-X</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_GrantFundingArrangementMaximumFundingValue', window );">Maximum funding value</a></td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_GrantFundingArrangementIncomeEarned', window );">Funding/Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 1,808<span></span>
</td>
<td class="nump">$ 2,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_GrantFundingArrangementMilestoneFundingIncrease', window );">Funding increase based on achievement of future milestones</a></td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_GrantFundingArrangementCommittedFundingTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant Funding Arrangement, Committed Funding, Total</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_GrantFundingArrangementCommittedFundingTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_GrantFundingArrangementIncomeEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant Funding Arrangement, Income Earned</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_GrantFundingArrangementIncomeEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_GrantFundingArrangementMaximumFundingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant Funding Arrangement, Maximum Funding Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_GrantFundingArrangementMaximumFundingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_GrantFundingArrangementMilestoneFundingIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant Funding Arrangement, Milestone, Funding Increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_GrantFundingArrangementMilestoneFundingIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ResearchAndDevelopmentTaxCreditReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Tax Credit Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ResearchAndDevelopmentTaxCreditReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996810123792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Expense) Income, net - Components (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 17, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency gains (losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 613<span></span>
</td>
<td class="num">$ (4,109)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense on promissory notes payable to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,461)<span></span>
</td>
<td class="num">(4,401)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNonoperating', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,403<span></span>
</td>
<td class="nump">1,513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome', window );">Reclassification of cumulative currency translation gain</a></td>
<td class="nump">$ 419<span></span>
</td>
<td class="nump">419<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(252)<span></span>
</td>
<td class="nump">304<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other (expense) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,278)<span></span>
</td>
<td class="num">$ (6,693)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cumulative Currency Translation Gains (Losses), Realized upon Sale or Liquidation, Reclassified From Other Comprehensive Income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996809972000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax - Components of loss before income taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">$ (499,810)<span></span>
</td>
<td class="num">$ (46,868)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="num">(115,118)<span></span>
</td>
<td class="num">(31,914)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax</a></td>
<td class="num">$ (614,928)<span></span>
</td>
<td class="num">$ (78,782)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996805919760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Current provision for federal income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Current provision for state income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Current provision for non-United States income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Deferred provision for federal income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">Deferred provision for state income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Deferred provision for non-United States income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ResearchAndDevelopmentExpenseCapitalizedAmount', window );">Research and experimental expenditures capitalized</a></td>
<td class="nump">73,129,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ResearchAndDevelopmentExpenseAmortizableAmount', window );">Net adjustment for research and experimental expenditures</a></td>
<td class="nump">65,816,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ResearchAndDevelopmentTaxCredit', window );">Research and development tax relief</a></td>
<td class="nump">946,000<span></span>
</td>
<td class="nump">4,523,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">1,064,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Liability for interest and penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">48,184,000<span></span>
</td>
<td class="nump">$ 11,620,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">U.S. State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">3,705,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">U.K.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 194,454,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ResearchAndDevelopmentExpenseAmortizableAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Amortizable Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ResearchAndDevelopmentExpenseAmortizableAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ResearchAndDevelopmentExpenseCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Capitalized Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ResearchAndDevelopmentExpenseCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ResearchAndDevelopmentTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development, Tax Credit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ResearchAndDevelopmentTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996806394512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Tax - Major components of deferred tax assets and liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 58,975<span></span>
</td>
<td class="nump">$ 52,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforward</a></td>
<td class="nump">4,522<span></span>
</td>
<td class="nump">1,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">4,128<span></span>
</td>
<td class="nump">3,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_DeferredTaxAssetsCapitalizedResearchAndDevelopment', window );">Section 174 Research and Development Capitalization</a></td>
<td class="nump">15,982<span></span>
</td>
<td class="nump">3,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_DeferredTaxAssetsLeasingArrangements', window );">Lease liability</a></td>
<td class="nump">1,143<span></span>
</td>
<td class="nump">737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">1,260<span></span>
</td>
<td class="nump">2,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">86,010<span></span>
</td>
<td class="nump">64,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right-of-use assets</a></td>
<td class="num">(1,085)<span></span>
</td>
<td class="num">(651)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(174)<span></span>
</td>
<td class="num">(226)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(1,259)<span></span>
</td>
<td class="num">(877)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_DeferredTaxAssetsLiabilities', window );">Net deferred tax assets before valuation allowance</a></td>
<td class="nump">84,751<span></span>
</td>
<td class="nump">64,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(84,751)<span></span>
</td>
<td class="num">(64,016)<span></span>
</td>
<td class="num">$ (51,746)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_DeferredTaxAssetsCapitalizedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Capitalized Research And Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_DeferredTaxAssetsCapitalizedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_DeferredTaxAssetsLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Leasing Arrangements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_DeferredTaxAssetsLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_DeferredTaxAssetsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets (Liabilities)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_DeferredTaxAssetsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996806180336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax - Valuation Allowance (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_DeferredTaxAssetsValuationAllowanceRollForward', window );"><strong>Deferred Tax Assets, Valuation Allowance [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance as of beginning of year</a></td>
<td class="num">$ (64,016)<span></span>
</td>
<td class="num">$ (51,746)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="num">(20,735)<span></span>
</td>
<td class="num">(12,270)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance as of end of year</a></td>
<td class="num">$ (84,751)<span></span>
</td>
<td class="num">$ (64,016)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_DeferredTaxAssetsValuationAllowanceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_DeferredTaxAssetsValuationAllowanceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996805635712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax - Reconciliation of the effective income tax rate to statutory rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal income tax statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(3.40%)<span></span>
</td>
<td class="num">(16.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent', window );">Refundable research and development tax credit</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="num">(3.60%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Effect of foreign operations taxed at various rates</a></td>
<td class="num">(17.00%)<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Stock-based compensation</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(2.20%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.80%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Tax Credit Refundable, Research, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -SubTopic 740<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480887/718-740-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996903588912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax - Reconciliation of unrecognized tax benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits, beginning of year</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increases related to prior year tax positions</a></td>
<td class="nump">610<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decreases related to prior year tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases related to current year tax positions</a></td>
<td class="nump">454<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits, end of year</a></td>
<td class="nump">$ 1,064<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996816046848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Computation of net loss per share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (614,928)<span></span>
</td>
<td class="num">$ (78,782)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average number of shares of common stock outstanding (in shares)</a></td>
<td class="nump">619,646,180<span></span>
</td>
<td class="nump">193,336,063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average number of shares of common stock outstanding (in shares)</a></td>
<td class="nump">619,646,180<span></span>
</td>
<td class="nump">193,336,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share (in dollars per share)</a></td>
<td class="num">$ (0.99)<span></span>
</td>
<td class="num">$ (0.41)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share (in dollars per share)</a></td>
<td class="num">$ (0.99)<span></span>
</td>
<td class="num">$ (0.41)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996808103984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Net Loss per Share - Narrative (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 01, 2023</div></th>
<th class="th"><div>Aug. 08, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 1.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=smmt_RightsOfferingMember', window );">Rights Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price (in dollars per share)</a></td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="nump">$ 0.97<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=smmt_RightsOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=smmt_RightsOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996805852368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Potentially dilutive securities excluded from the computation of loss per share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from the computation of diluted loss per share (in shares)</a></td>
<td class="nump">59,380,094<span></span>
</td>
<td class="nump">25,526,971<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from the computation of diluted loss per share (in shares)</a></td>
<td class="nump">54,209,289<span></span>
</td>
<td class="nump">19,476,359<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from the computation of diluted loss per share (in shares)</a></td>
<td class="nump">5,015,642<span></span>
</td>
<td class="nump">5,821,137<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Shares expected to be purchased under employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from the computation of diluted loss per share (in shares)</a></td>
<td class="nump">155,163<span></span>
</td>
<td class="nump">229,475<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996806194736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Narrative (Details)<br> $ in Thousands, &#163; in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Recognition of goodwill | &#163;</a></td>
<td class="nump">&#163; 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Cumulative goodwill impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,893<span></span>
</td>
<td class="nump">$ 1,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 914<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996808086224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule of acquired intangible assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross</a></td>
<td class="nump">$ 17,864<span></span>
</td>
<td class="nump">$ 14,582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment', window );">Accumulated amortization and impairment charges</a></td>
<td class="num">(17,864)<span></span>
</td>
<td class="num">(14,582)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Impairment of intangible assets<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Software | Utrophin program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross</a></td>
<td class="nump">$ 4,015<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment', window );">Accumulated amortization and impairment charges</a></td>
<td class="num">(4,015)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Software | Discuva platform</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross</a></td>
<td class="nump">12,900<span></span>
</td>
<td class="nump">13,583<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment', window );">Accumulated amortization and impairment charges</a></td>
<td class="num">(12,900)<span></span>
</td>
<td class="num">(13,583)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment charge</a></td>
<td class="nump">8,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=smmt_OptionOverNonFinancialAssetsMember', window );">Option over non-financial asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross</a></td>
<td class="nump">816<span></span>
</td>
<td class="nump">859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment', window );">Accumulated amortization and impairment charges</a></td>
<td class="num">(816)<span></span>
</td>
<td class="num">(859)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=smmt_OtherPatentsAndLicensesMember', window );">Other intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross</a></td>
<td class="nump">133<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment', window );">Accumulated amortization and impairment charges</a></td>
<td class="num">(133)<span></span>
</td>
<td class="num">(140)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Accumulated Amortization And Impairment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes impairment of finite-lived intangible asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=smmt_UtrophinProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=smmt_UtrophinProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=smmt_DiscuvaPlatformMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=smmt_DiscuvaPlatformMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=smmt_OptionOverNonFinancialAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=smmt_OptionOverNonFinancialAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=smmt_OtherPatentsAndLicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=smmt_OtherPatentsAndLicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996810204384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Short-Term Investments - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Short-term investments</a></td>
<td class="nump">$ 114,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">175,174<span></span>
</td>
<td class="nump">$ 286,513<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Government treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Short-term investments</a></td>
<td class="nump">114,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_CashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">21,016<span></span>
</td>
<td class="nump">60,783<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Government treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_CashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">39,341<span></span>
</td>
<td class="nump">225,730<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">21,016<span></span>
</td>
<td class="nump">60,783<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. Government treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_CashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">21,016<span></span>
</td>
<td class="nump">60,783<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. Government treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_CashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">154,158<span></span>
</td>
<td class="nump">225,730<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. Government treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Short-term investments</a></td>
<td class="nump">114,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_CashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. Government treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_CashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">39,341<span></span>
</td>
<td class="nump">225,730<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | U.S. Government treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_CashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | U.S. Government treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_CashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_CashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_CashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996809750192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Short-Term Investments - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 11,068<span></span>
</td>
<td class="nump">$ 62,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">$ 114,817<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996810252976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Short-Term Investments - Short-term investments with contractual maturity of less than on year (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">$ 114,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest', window );">Credit Loss</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">114,817<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Government treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">114,781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest', window );">Credit Loss</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">$ 114,817<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, before allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996805677360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Components of property and equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 1,246<span></span>
</td>
<td class="nump">$ 2,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="nump">1,042<span></span>
</td>
<td class="nump">1,297<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">204<span></span>
</td>
<td class="nump">906<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=smmt_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">505<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember', window );">Furniture and fixtures, office equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">896<span></span>
</td>
<td class="nump">889<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 328<span></span>
</td>
<td class="nump">$ 809<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=smmt_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=smmt_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996809750064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 198<span></span>
</td>
<td class="nump">$ 349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Impairment of fixed assets</a></td>
<td class="nump">$ 474<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996814543696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Research and Development Prepaid Expenses and Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ResearchAndDevelopmentPrepaidExpensesCurrent', window );">Prepaid research and development expenditures</a></td>
<td class="nump">$ 1,466<span></span>
</td>
<td class="nump">$ 442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_AccruedResearchAndDevelopmentCurrent', window );">Accrued research and development expenditure</a></td>
<td class="nump">$ 7,289<span></span>
</td>
<td class="nump">$ 8,911<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_AccruedResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research And Development, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_AccruedResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ResearchAndDevelopmentPrepaidExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Prepaid Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ResearchAndDevelopmentPrepaidExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996805579632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> ft&#178; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 08, 2024 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Additional right-of-use assets recorded</a></td>
<td class="nump">$ 4,245<span></span>
</td>
<td class="nump">$ 2,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">6,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Removal of lease liability</a></td>
<td class="nump">2,211<span></span>
</td>
<td class="nump">1,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 5,859<span></span>
</td>
<td class="nump">$ 4,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">6.60%<span></span>
</td>
<td class="nump">5.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash payments related to lease liabilities</a></td>
<td class="nump">$ 2,208<span></span>
</td>
<td class="nump">$ 1,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">64 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_LesseeOperatingLeaseAreaOfPremisesLeased', window );">Area of premises leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=smmt_MenloParkCaliforniaExpirationMay2026Member', window );">Menlo Park, California, Expiration May 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Additional right-of-use assets recorded</a></td>
<td class="nump">4,245<span></span>
</td>
<td class="nump">$ 2,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">$ 4,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=smmt_CambridgeUKLaboratoryAndOfficeSpaceMember', window );">Cambridge UK, Laboratory and Office Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_OperatingLeaseRightOfUseAssetDisposals', window );">Disposal of right-of-use asset</a></td>
<td class="nump">$ 788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Removal of lease liability</a></td>
<td class="nump">$ 809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_LesseeOperatingLeaseAreaOfPremisesLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Area Of Premises Leased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_LesseeOperatingLeaseAreaOfPremisesLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_OperatingLeaseRightOfUseAssetDisposals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Right-of-Use Asset, Disposals</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_OperatingLeaseRightOfUseAssetDisposals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=smmt_MenloParkCaliforniaExpirationMay2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=smmt_MenloParkCaliforniaExpirationMay2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=smmt_CambridgeUKLaboratoryAndOfficeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=smmt_CambridgeUKLaboratoryAndOfficeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996807930368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Lease expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Fixed lease costs</a></td>
<td class="nump">$ 2,214<span></span>
</td>
<td class="nump">$ 1,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 2,297<span></span>
</td>
<td class="nump">$ 1,552<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996808071456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Future lease payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 2,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">2,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">6,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">6,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Total operating lease liabilities balance sheet presentation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current lease liabilities</a></td>
<td class="nump">2,809<span></span>
</td>
<td class="nump">$ 1,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current lease liabilities</a></td>
<td class="nump">3,290<span></span>
</td>
<td class="nump">$ 2,763<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 6,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996805701184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Promissory Notes Payable to Related Parties - Summary of related party debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrentAbstract', window );"><strong>Current notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Total promissory notes payable to related parties</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 19,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayableAbstract', window );"><strong>Non-current notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Total promissory notes payable to related parties</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">494,540<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=smmt_PromissoryNotesMember', window );">Promissory Notes | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrentAbstract', window );"><strong>Current notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_NotesPayableGrossCurrent', window );">Principal amounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent', window );">Debt discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(230)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Total promissory notes payable to related parties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,770<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayableAbstract', window );"><strong>Non-current notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_NotesPayableGrossNoncurrent', window );">Principal amounts</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent', window );">Debt discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,460)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Total promissory notes payable to related parties</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 494,540<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_NotesPayableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes Payable, Gross, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_NotesPayableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_NotesPayableGrossNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes Payable, Gross, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_NotesPayableGrossNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount to be amortized after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=smmt_PromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=smmt_PromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996800886960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Promissory Notes Payable to Related Parties - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 17, 2024</div></th>
<th class="th">
<div>Mar. 01, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 15, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 19, 2023 </div>
<div>USD ($) </div>
<div>promissory_note</div>
</th>
<th class="th">
<div>Dec. 06, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 10, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 08, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th">
<div>Mar. 10, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 27, 2023 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from related party promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 545,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment of related party notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,686<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from the sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,686<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,461<span></span>
</td>
<td class="nump">$ 4,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable classified as long-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 494,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=smmt_RightsOfferingMember', window );">Rights Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from the sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=smmt_March2022NoteMember', window );">March 2022 Note | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from related party promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold', window );">Notes payable, maturity triggering event, public offering proceeds threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_NotesPayableRelatedPartiesMaximumTerm', window );">Notes payable, maximum term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment of related party notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_PaymentOfAccruedInterestToRelatedParties', window );">Payment of related party interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortized imputed interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=smmt_NotePurchaseAgreementMember', window );">Note Purchase Agreement | Chief Executive Officer and Chief Executive Officer and President</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 520,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,461<span></span>
</td>
<td class="nump">3,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortized imputed interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">761<span></span>
</td>
<td class="nump">395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominator', window );">Prepaid interest, conversion amount (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominatorBaseAmountAddedToClosingBidPrice', window );">Prepaid interest, conversion amount base (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_StockIssuedDuringPeriodSharesRelatedPartyPrepaidInterest', window );">Common stock issued for prepaid interest (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,720,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=smmt_NotePurchaseAgreementMember', window );">Note Purchase Agreement | Chief Executive Officer and Chief Executive Officer and President | Prime Rate | Variable rate, three months immediately following February 15, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate margin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=smmt_NotePurchaseAgreementMember', window );">Note Purchase Agreement | Chief Executive Officer and Chief Executive Officer and President | Prime Rate | Variable rate, thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate margin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=smmt_DugganPromissoryNotesMember', window );">Duggan Promissory Notes | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold', window );">Notes payable, maturity triggering event, public offering proceeds threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_NotesPayableRelatedPartiesNewIssuances', window );">New note issuances | promissory_note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=smmt_DugganSeptemberNoteMember', window );">Duggan September Note | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=smmt_DugganFebruaryNoteMember', window );">Duggan February Note | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment of related party notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">Future principal payments for 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">Future principal payments for 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=smmt_DugganFebruaryNoteMember', window );">Duggan February Note | Chief Executive Officer | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Interest rate</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=smmt_DugganFebruaryNoteMember', window );">Duggan February Note | Chief Executive Officer | Prime Rate | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate margin</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=smmt_ZanganehNoteMember', window );">Zanganeh Note | Chief Executive Officer and President</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment of related party notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=smmt_DugganFebruaryNoteAndZanganehNoteMember', window );">Duggan February Note and Zanganeh Note | Chief Executive Officer and Chief Executive Officer and President</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_NotesPayableRelatedPartiesPotentialPrepaymentPeriodPostReceiptOfCashProceedsFromPublicOffering', window );">Period from public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_NotesPayableRelatedPartiesPotentialPrepaymentMaximumAmountPercentageOfNetProceedsFromPublicOffering', window );">Public offering proceeds threshold percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=smmt_PromissoryNotesMember', window );">Promissory Notes | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable classified as long-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 494,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_NotesPayableRelatedPartiesMaximumTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes Payable, Related Parties, Maximum Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_NotesPayableRelatedPartiesMaximumTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_NotesPayableRelatedPartiesNewIssuances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes Payable, Related Parties, New Issuances</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_NotesPayableRelatedPartiesNewIssuances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_NotesPayableRelatedPartiesPotentialPrepaymentMaximumAmountPercentageOfNetProceedsFromPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes Payable, Related Parties, Potential Prepayment, Maximum Amount, Percentage Of Net Proceeds From Public Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_NotesPayableRelatedPartiesPotentialPrepaymentMaximumAmountPercentageOfNetProceedsFromPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_NotesPayableRelatedPartiesPotentialPrepaymentPeriodPostReceiptOfCashProceedsFromPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes Payable, Related Parties, Potential Prepayment, Period Post Receipt Of Cash Proceeds From Public Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_NotesPayableRelatedPartiesPotentialPrepaymentPeriodPostReceiptOfCashProceedsFromPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes Payable, Related Parties, Potential Prepayment, Triggering Event, Public Offering Net Proceeds Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominator">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes Payable, Related Party, Prepaid Interest, Equity Interests Issuable Calculation, Denominator</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominator</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominatorBaseAmountAddedToClosingBidPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes Payable, Related Party, Prepaid Interest, Equity Interests Issuable Calculation, Denominator, Base Amount Added To Closing Bid Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominatorBaseAmountAddedToClosingBidPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_PaymentOfAccruedInterestToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment Of Accrued Interest To Related Parties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_PaymentOfAccruedInterestToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_StockIssuedDuringPeriodSharesRelatedPartyPrepaidInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Related Party Prepaid Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_StockIssuedDuringPeriodSharesRelatedPartyPrepaidInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=smmt_RightsOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=smmt_RightsOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=smmt_March2022NoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=smmt_March2022NoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=smmt_NotePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=smmt_NotePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_VariableRatePeriodAxis=smmt_VariableRatePeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_VariableRatePeriodAxis=smmt_VariableRatePeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_VariableRatePeriodAxis=smmt_VariableRatePeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_VariableRatePeriodAxis=smmt_VariableRatePeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=smmt_DugganPromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=smmt_DugganPromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=smmt_DugganSeptemberNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=smmt_DugganSeptemberNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=smmt_DugganFebruaryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=smmt_DugganFebruaryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=smmt_ZanganehNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=smmt_ZanganehNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=smmt_ChiefExecutiveOfficerAndPresidentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=smmt_ChiefExecutiveOfficerAndPresidentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=smmt_DugganFebruaryNoteAndZanganehNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=smmt_DugganFebruaryNoteAndZanganehNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=smmt_PromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=smmt_PromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996812753456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Non-Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_BusinessCombinationAssumedContingentLiabilityNoncurrent', window );">Assumed contingent liabilities, non-current</a></td>
<td class="nump">$ 1,356<span></span>
</td>
<td class="nump">$ 1,209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss', window );">Remeasurement gains (losses)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,265<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_BusinessCombinationAssumedContingentLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Assumed Contingent Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_BusinessCombinationAssumedContingentLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Assumed Contingent Liability, Remeasurement Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996805013008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 13, 2023</div></th>
<th class="th"><div>Mar. 01, 2023</div></th>
<th class="th"><div>Jan. 19, 2023</div></th>
<th class="th"><div>Aug. 08, 2022</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 24, 2019</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Apr. 27, 2023</div></th>
<th class="th"><div>Jan. 18, 2023</div></th>
<th class="th"><div>Dec. 06, 2022</div></th>
<th class="th"><div>Jul. 26, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from the sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,686<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 619<span></span>
</td>
<td class="nump">$ 111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_CommonStockSharesAuthorizedIncreaseDecrease', window );">Increase in common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from the issuance of common stock via private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of common stock shares into which each warrant converts (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,015,642<span></span>
</td>
<td class="nump">5,821,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefOperatingOfficerMember', window );">Chief Operations Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from the issuance of common stock via private placement</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=smmt_DugganFebruaryNoteMember', window );">Duggan February Note | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=smmt_ConsultingAgreementMember', window );">Consulting Agreement | Affiliated entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common stock shares into which warrants may be converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,358,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod', window );">Warrants quarterly vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=smmt_ConsultingAgreementMember', window );">Consulting Agreement | Affiliated entity | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations', window );">Warrants cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,798,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">559,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=smmt_RightsOfferingMember', window );">Rights Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from the sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">476,190,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,092,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 395,314<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=smmt_RightsOfferingMember', window );">Rights Offering | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 395,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common stock shares into which warrants may be converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,261,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of common stock shares into which each warrant converts (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage', window );">Minimum volume weighted average common stock price to warrant exercise price, premium, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private placement | Chief Operations Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued (in shares)</a></td>
<td class="nump">2,976,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price (in dollars per share)</a></td>
<td class="nump">$ 1.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=smmt_S3RegistrationStatementMember', window );">S-3 Registration Statement | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_SaleOfStockNumberOfSharesRegisteredForResale', window );">Number of shares registered for resale (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,346,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=smmt_S3RegistrationStatementMember', window );">S-3 Registration Statement | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_SaleOfStockNumberOfSharesRegisteredForResale', window );">Number of shares registered for resale (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=smmt_S3RegistrationStatementMember', window );">S-3 Registration Statement | Chief Executive Officer and President</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_SaleOfStockNumberOfSharesRegisteredForResale', window );">Number of shares registered for resale (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">373,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Minimum Ten Day Volume Weighted Average Common Stock Price to Warrant Exercise Price, Premium, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Quarterly Vesting Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_CommonStockSharesAuthorizedIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Shares Authorized, Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_CommonStockSharesAuthorizedIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_SaleOfStockNumberOfSharesRegisteredForResale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Number Of Shares Registered For Resale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_SaleOfStockNumberOfSharesRegisteredForResale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were either cancelled or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefOperatingOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefOperatingOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=smmt_DugganFebruaryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=smmt_DugganFebruaryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=smmt_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=smmt_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=smmt_RightsOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=smmt_RightsOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=smmt_S3RegistrationStatementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=smmt_S3RegistrationStatementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=smmt_ChiefExecutiveOfficerAndPresidentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=smmt_ChiefExecutiveOfficerAndPresidentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996805778640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Warrant activity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ClassOfWarrantOrRightOutstandingRollForward', window );"><strong>Number of share warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, beginning balance (in shares) | shares</a></td>
<td class="nump">5,821,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ClassOfWarrantOrRightExercisesInPeriod', window );">Exercised (in shares) | shares</a></td>
<td class="num">(805,495)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, ending balance (in shares) | shares</a></td>
<td class="nump">5,015,642<span></span>
</td>
<td class="nump">5,821,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ClassOfWarrantOrRightWeightedAverageExercisePrice', window );">Outstanding, beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">1.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ClassOfWarrantOrRightWeightedAverageExercisePrice', window );">Outstanding, ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.57<span></span>
</td>
<td class="nump">$ 1.56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm', window );">Weighted average remaining contractual term</a></td>
<td class="text">5 years 11 months 1 day<span></span>
</td>
<td class="text">6 years 11 months 26 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding', window );">Aggregate intrinsic value | $</a></td>
<td class="nump">$ 5,194<span></span>
</td>
<td class="nump">$ 15,640<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Aggregate Intrinsic Value, Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ClassOfWarrantOrRightExercisesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Exercises In Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ClassOfWarrantOrRightExercisesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ClassOfWarrantOrRightOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ClassOfWarrantOrRightOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant Or Right, Outstanding, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Outstanding, Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ClassOfWarrantOrRightWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ClassOfWarrantOrRightWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Weighted Average Exercise Price, Exercises In Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996801013840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 12, 2023</div></th>
<th class="th"><div>Jan. 19, 2023</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Mar. 01, 2022</div></th>
<th class="th"><div>Sep. 21, 2020</div></th>
<th class="th"><div>Aug. 19, 2020</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 18, 2023</div></th>
<th class="th"><div>Jul. 26, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_CommonStockSharesAuthorizedIncreaseDecrease', window );">Increase in common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of stock options granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.41<span></span>
</td>
<td class="nump">$ 0.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value, options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 474,000<span></span>
</td>
<td class="nump">$ 142,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of common stock shares into which each warrant converts (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Equity award, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Equity award, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares initially reserve for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPotentialNumberOfAdditionalSharesAllowableUnderThePlan', window );">Potential number of additional shares that can be added to the plan for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Maximum percentage of outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,628,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod', window );">Offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod', window );">Consecutive offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum common stock purchase allowable as a percentage of compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock as a percentage of closing price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">392,175<span></span>
</td>
<td class="nump">176,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock as a percentage of closing price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense for options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,162,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense for options, period of recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=smmt_EmployeeStockOptionTimeBasedMember', window );">Time-based stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,135,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=smmt_EmployeeStockOptionTimeBasedMember', window );">Time-based stock options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Equity award, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=smmt_EmployeeStockOptionTimeBasedMember', window );">Time-based stock options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Equity award, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=smmt_EmployeeStockOptionPerformanceAndMarketBasedMember', window );">Performance and market-based stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,835,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=smmt_A2020StockIncentivePlanMember', window );">2020 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares initially reserve for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_CommonStockAdditionalCapitalSharesAllowableForForFutureIssuanceUponOptionExpiration', window );">Number of shares that can be added to the plan upon option expiration (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPotentialNumberOfAdditionalSharesAllowableUnderThePlan', window );">Potential number of additional shares that can be added to the plan for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Maximum percentage of outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,261,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=smmt_A2020StockIncentivePlanMember', window );">2020 Plan | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase to number of shares of common stock issuable (in shares)</a></td>
<td class="nump">70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_CommonStockAdditionalCapitalSharesAllowableForForFutureIssuanceUponOptionExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Additional Capital Shares Allowable For For Future Issuance Upon Option Expiration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_CommonStockAdditionalCapitalSharesAllowableForForFutureIssuanceUponOptionExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_CommonStockSharesAuthorizedIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Shares Authorized, Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_CommonStockSharesAuthorizedIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Consecutive Offering Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPotentialNumberOfAdditionalSharesAllowableUnderThePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Potential Number of Additional Shares Allowable Under The Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPotentialNumberOfAdditionalSharesAllowableUnderThePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=smmt_EmployeeStockOptionTimeBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=smmt_EmployeeStockOptionTimeBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=smmt_EmployeeStockOptionPerformanceAndMarketBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=smmt_EmployeeStockOptionPerformanceAndMarketBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=smmt_A2020StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=smmt_A2020StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996809784768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Weighted-average assumptions used for stock option awards (Details) - Stock options<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.59%<span></span>
</td>
<td class="nump">3.11%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">98.10%<span></span>
</td>
<td class="nump">91.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected annual dividends per share</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996809671536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Stock option activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=smmt_EmployeeStockOptionTimeBasedMember', window );">Time-based stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of share options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">12,712,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">44,135,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(2,433,943)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(204,297)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">54,209,289<span></span>
</td>
<td class="nump">12,712,359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 4.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">1.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">5.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">2.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">$ 2.28<span></span>
</td>
<td class="nump">$ 4.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock option activity, additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term, options outstanding</a></td>
<td class="text">9 years 3 months 18 days<span></span>
</td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, options outstanding</a></td>
<td class="nump">$ 42,574<span></span>
</td>
<td class="nump">$ 8,702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of share options, vested and expected to vest (in shares)</a></td>
<td class="nump">49,407,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, vested and expected to vest (in dollars per share)</a></td>
<td class="nump">$ 2.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, vested and expected to vest</a></td>
<td class="text">9 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, vested and expected to vest</a></td>
<td class="nump">$ 38,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of share options, exercisable (in shares)</a></td>
<td class="nump">5,716,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable (in dollars per share)</a></td>
<td class="nump">$ 4.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, exercisable</a></td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable</a></td>
<td class="nump">$ 892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=smmt_EmployeeStockOptionPerformanceAndMarketBasedMember', window );">Performance and market-based stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of share options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">6,764,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">40,835,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(945,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">46,654,220<span></span>
</td>
<td class="nump">6,764,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">1.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">1.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">$ 1.62<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock option activity, additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term, options outstanding</a></td>
<td class="text">9 years 7 months 6 days<span></span>
</td>
<td class="text">9 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, options outstanding</a></td>
<td class="nump">$ 46,237<span></span>
</td>
<td class="nump">$ 20,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of share options, vested and expected to vest (in shares)</a></td>
<td class="nump">8,397,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, vested and expected to vest (in dollars per share)</a></td>
<td class="nump">$ 1.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, vested and expected to vest</a></td>
<td class="text">9 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, vested and expected to vest</a></td>
<td class="nump">$ 8,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of share options, exercisable (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=smmt_EmployeeStockOptionTimeBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=smmt_EmployeeStockOptionTimeBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=smmt_EmployeeStockOptionPerformanceAndMarketBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=smmt_EmployeeStockOptionPerformanceAndMarketBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996806199072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of stock-based compensation expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 14,108<span></span>
</td>
<td class="nump">$ 11,948<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=smmt_EmployeeStockOptionTimeBasedMember', window );">Time-based stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">12,606<span></span>
</td>
<td class="nump">11,630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=smmt_EmployeeStockOptionPerformanceAndMarketBasedMember', window );">Performance and market-based stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">1,318<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">184<span></span>
</td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">4,408<span></span>
</td>
<td class="nump">4,303<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 9,700<span></span>
</td>
<td class="nump">$ 7,645<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=smmt_EmployeeStockOptionTimeBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=smmt_EmployeeStockOptionTimeBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=smmt_EmployeeStockOptionPerformanceAndMarketBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=smmt_EmployeeStockOptionPerformanceAndMarketBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996815785968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 09, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Capital commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Contractual commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid', window );">Period for which the majority of contractual commitments are to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_OtherCommitmentIncreaseDecrease', window );">Additional contractual commitments</a></td>
<td class="nump">$ 23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_OtherCommitmentIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Commitment, Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_OtherCommitmentIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Commitment, Period for Which the Majority of Commitments are To Be Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139996797569680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 17, 2024</div></th>
<th class="th">
<div>Oct. 13, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 01, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 15, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 19, 2023 </div>
<div>USD ($) </div>
<div>promissory_note</div>
</th>
<th class="th">
<div>Dec. 06, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 10, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 08, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th">
<div>Mar. 10, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 27, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 29, 2022 </div>
<div>ft&#178;</div>
</th>
<th class="th"><div>Jul. 25, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from related party promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 545,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from the sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,686<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">619<span></span>
</td>
<td class="nump">111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment of related party notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,686<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest on related party promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,650<span></span>
</td>
<td class="nump">$ 434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,783<span></span>
</td>
<td class="nump">8,783<span></span>
</td>
<td class="nump">10,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from the issuance of common stock via private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ClassOfWarrantOrRightExercisesInPeriod', window );">Exercised (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">805,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=smmt_RightsOfferingMember', window );">Rights Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from the sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">476,190,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,092,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 395,314<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated entity | First amendment to sublease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_RelatedPartyTransactionSubleaseExtensionTerm', window );">Sublease extension term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">39 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_RelatedPartyTransactionPaymentsToRelatedParty', window );">Payments to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated entity | Second amendment to sublease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_RelatedPartyTransactionPaymentsToRelatedParty', window );">Payments to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_AreaOfPremisesSubleased', window );">Area of premises subleased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated entity | Consulting Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_ClassOfWarrantOrRightExercisesInPeriod', window );">Exercised (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">805,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember', window );">Chief Executive Officer and Chief Executive Officer and President | Note Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 520,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominator', window );">Prepaid interest, conversion amount (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominatorBaseAmountAddedToClosingBidPrice', window );">Prepaid interest, conversion amount base (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_StockIssuedDuringPeriodSharesRelatedPartyPrepaidInterest', window );">Common stock issued for prepaid interest (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,720,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest on related party promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember', window );">Chief Executive Officer and Chief Executive Officer and President | Note Purchase Agreement | Prime Rate | Variable rate, three months immediately following February 15, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate margin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember', window );">Chief Executive Officer and Chief Executive Officer and President | Note Purchase Agreement | Prime Rate | Variable rate, thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate margin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember', window );">Chief Executive Officer and Chief Executive Officer and President | Duggan February Note and Zanganeh Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_NotesPayableRelatedPartiesPotentialPrepaymentPeriodPostReceiptOfCashProceedsFromPublicOffering', window );">Period from public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_NotesPayableRelatedPartiesPotentialPrepaymentMaximumAmountPercentageOfNetProceedsFromPublicOffering', window );">Public offering proceeds threshold percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer | Rights Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">395,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer | S-3 Registration Statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_SaleOfStockNumberOfSharesRegisteredForResale', window );">Number of shares registered for resale (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,346,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer | March 2022 Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from related party promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold', window );">Notes payable, maturity triggering event, public offering proceeds threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_NotesPayableRelatedPartiesMaximumTerm', window );">Notes payable, maximum term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment of related party notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer | Duggan Promissory Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold', window );">Notes payable, maturity triggering event, public offering proceeds threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_NotesPayableRelatedPartiesNewIssuances', window );">New note issuances | promissory_note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer | Duggan February Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment of related party notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer | Duggan February Note | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Interest rate</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer | Duggan February Note | Prime Rate | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate margin</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer | Duggan September Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=smmt_ChiefExecutiveOfficerAndPresidentMember', window );">Chief Executive Officer and President | S-3 Registration Statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_SaleOfStockNumberOfSharesRegisteredForResale', window );">Number of shares registered for resale (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">373,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=smmt_ChiefExecutiveOfficerAndPresidentMember', window );">Chief Executive Officer and President | Zanganeh Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment of related party notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | S-3 Registration Statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_SaleOfStockNumberOfSharesRegisteredForResale', window );">Number of shares registered for resale (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Akeso Supply Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_smmt_RelatedPartyTransactionPaymentsToRelatedParty', window );">Payments to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,619<span></span>
</td>
<td class="nump">$ 3,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefOperatingOfficerMember', window );">Chief Operations Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from the issuance of common stock via private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefOperatingOfficerMember', window );">Chief Operations Officer | Private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,976,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_AreaOfPremisesSubleased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area Of Premises Subleased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_AreaOfPremisesSubleased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_ClassOfWarrantOrRightExercisesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Exercises In Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_ClassOfWarrantOrRightExercisesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_NotesPayableRelatedPartiesMaximumTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes Payable, Related Parties, Maximum Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_NotesPayableRelatedPartiesMaximumTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_NotesPayableRelatedPartiesNewIssuances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes Payable, Related Parties, New Issuances</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_NotesPayableRelatedPartiesNewIssuances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_NotesPayableRelatedPartiesPotentialPrepaymentMaximumAmountPercentageOfNetProceedsFromPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes Payable, Related Parties, Potential Prepayment, Maximum Amount, Percentage Of Net Proceeds From Public Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_NotesPayableRelatedPartiesPotentialPrepaymentMaximumAmountPercentageOfNetProceedsFromPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_NotesPayableRelatedPartiesPotentialPrepaymentPeriodPostReceiptOfCashProceedsFromPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes Payable, Related Parties, Potential Prepayment, Period Post Receipt Of Cash Proceeds From Public Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_NotesPayableRelatedPartiesPotentialPrepaymentPeriodPostReceiptOfCashProceedsFromPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes Payable, Related Parties, Potential Prepayment, Triggering Event, Public Offering Net Proceeds Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominator">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes Payable, Related Party, Prepaid Interest, Equity Interests Issuable Calculation, Denominator</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominator</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominatorBaseAmountAddedToClosingBidPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes Payable, Related Party, Prepaid Interest, Equity Interests Issuable Calculation, Denominator, Base Amount Added To Closing Bid Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominatorBaseAmountAddedToClosingBidPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_RelatedPartyTransactionPaymentsToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Payments To Related Party</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_RelatedPartyTransactionPaymentsToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_RelatedPartyTransactionSubleaseExtensionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Sublease Extension Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_RelatedPartyTransactionSubleaseExtensionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_SaleOfStockNumberOfSharesRegisteredForResale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Number Of Shares Registered For Resale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_SaleOfStockNumberOfSharesRegisteredForResale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_StockIssuedDuringPeriodSharesRelatedPartyPrepaidInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Related Party Prepaid Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_StockIssuedDuringPeriodSharesRelatedPartyPrepaidInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>smmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=smmt_RightsOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=smmt_RightsOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=smmt_SubleaseAgreementFirstAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=smmt_SubleaseAgreementFirstAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=smmt_SubleaseAgreementSecondAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=smmt_SubleaseAgreementSecondAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=smmt_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=smmt_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=smmt_NotePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=smmt_NotePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_VariableRatePeriodAxis=smmt_VariableRatePeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_VariableRatePeriodAxis=smmt_VariableRatePeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_smmt_VariableRatePeriodAxis=smmt_VariableRatePeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">smmt_VariableRatePeriodAxis=smmt_VariableRatePeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=smmt_DugganFebruaryNoteAndZanganehNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=smmt_DugganFebruaryNoteAndZanganehNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=smmt_S3RegistrationStatementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=smmt_S3RegistrationStatementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=smmt_March2022NoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=smmt_March2022NoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=smmt_DugganPromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=smmt_DugganPromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=smmt_DugganFebruaryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=smmt_DugganFebruaryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=smmt_DugganSeptemberNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=smmt_DugganSeptemberNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=smmt_ChiefExecutiveOfficerAndPresidentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=smmt_ChiefExecutiveOfficerAndPresidentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=smmt_ZanganehNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=smmt_ZanganehNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=smmt_AkesoSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=smmt_AkesoSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefOperatingOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefOperatingOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>106
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M>-O>-E0=F-"DA+V1!J-;<X.J;1GM!&7ERG0GT12]&Q:FRX*R 69_+R4>)_:
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M/;C8">Y7M>4U)-KCA& #&)MSQU-\I@R$A1U>TL-+3@4%9W7:1G#&#T"[.[W
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MXX,V.7XBJ*9\6"D?ME9^08(/]W;2P[@YQ5N%UCR,*@^C\SVTR_#1GJ@!]H(
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M]D1SEM@\*+XSQW&W7"E>F=LMT!Q$;:#_7W.N'A[J#W0GNLO_ 5!+ P04
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MJ#]6RD([@=IIV+K%SR+E!>VK2RC-/M!.NTV-$R4TH0.EN<+]S_>;T)0^E!9
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MTQ:4#<#S0DJS->P%_?Q.?P-02P,$%     @ &#Q46'X!!,0 "@  >2\  !@
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MXN-4:1&9)SAQ!'6LR1+[R7+<9)OLV6E0D_HPCJ=EBD4*TM/(425CS9#8SY"
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M%?HNA5R*E0+,# UUV@\.%_#:D)7:"];LZO/@;/(\U"8.=R[^0:&(H$98CX'
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MB\V^J]U%];V(E7%&W$6,22-X77AP=B]?J>YRM5D%)I-B93K]<__LW8-0^H#
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MY^&V&@<G5=Z%Z_ON=Q#H*^@Y"$MHQ\-XF-++A.P@XQ$.-$P87!&D$9LY76F
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M5FF74L^*\Y!.SHU+:=/JW_$^ DJ?5#\OR(8(BT[0EI4(V8-<?=N%M6*IBV0
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MKQ%;,AYQ;+^I5"!7K+U[_>T&H0<==DUBUZ:R(WVJCY7DXS%U. +:<=,5BES
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M9>D ?E\8X[LOI*#_-X>S_P!02P,$%     @ &#Q46 XL?N><!   E L  !D
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M++G64JU 2$/45FSE8C&2QDC!#%FNF#*<MCK1*!R.H@,+..Q'&X ^%HCZM#Z
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M=!B \G= _V%DY>Y=,VGH%N=><[HVH[("M)])RG[S80VT%_'IWU!+ P04
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M@]!.[*P&+]3% ?QQ^3OXB*B,R(S=&2O)7RKYH)S0\ (6?AY\' A9YO[-^\&
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MG+#%G@&A4R.6910>SL#LV1!);;G3#(_V?@*9X7#(M@TO_EW#/NV]8!\608^
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M:!_B\BJ1_CM.(7"15ZV[::1!83BKJB>ODCK_-M (;NDY.OD/Q):))U@S31C
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MT:ZQ9KPQ==:H[MQL;7M_*XP?0(?387R_\%/K\W,_^U/QWW%AV\:*1*/121:
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M?Y'@Y&4('O>CR71P@.!F\R>Y2))1-!GT?YA_QT5K\7%_)Z33<32*!Z%60H6
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M1X<56+&@Q;;#L(-B,[%06?)$NDGWZR?)CIMM;88=>K'U03Z^1TK4>*?-/>8
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MYMKAM<@_4JBX(0'\OM#:M2^T07>SO?H;4$L#!!0    ( !@\5%BILNL#AA(
M .Q.   9    >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;.T\:6_;2)9_I>!Q
M!@G R*(.R\X%.$>CT]ALC#B]LSN#^5 B2U)-*%)31?K87[_OJ"H>HF0YZ5GT
MS!AH="2JZM6K=U_FJYO"?+,KI4IQN\YR^_IH59:;%R<G-EFIM;2#8J-R^&51
MF+4LX:M9GMB-43*E3>OL9#0<GIZLI<Z/WKRB9Y?FS:NB*C.=JTLC;+5>2W/W
M5F7%S>NC^,@_^**7JQ(?G+QYM9%+=:7*7S>7!KZ=!"BI7JO<ZB(71BU>'UW$
M+]Y.<#TM^"^M;FSCL\";S(OB&W[YF+X^&B)"*E-)B1 D_'.MWJDL0T" QM\=
MS*-P)&YL?O;0?Z*[PUWFTJIW1?8GG9:KUT=G1R)5"UEEY9?BYF?E[C-%>$F1
M6?J_N.&UD\F12"I;%FNW&3!8ZYS_E;>.#HT-9\,=&T9NPXCPYH,(R_>RE&]>
MF>)&&%P-T/ #795V W(Z1Z9<E09^U;"O?'-IBK6VMC!WXC^+4EEQ*>_D/%.B
M+,07E<E2I?#(E%K95R<E'(C;3A('_"T#'^T 'H_$IR(O5U9\R%.5M@&< *8!
MW9%']^UH+\3W*AF(<1R)T7 TW@-O'*X_)GCC'?":5[P37XW,K21QL>(O%W-;
M&OCVU[Z+,]A)/UC4I!=V(Q/U^@A4Q2ISK8[>_/$/\>GPY1ZD)P'IR3[H/\JS
MWPPX+,B?)Y4Q*B^%S%/A/Z=J7HH$B*@M+B\6HEPIL2@R, $Z7[X0[]S"G$YH
M@N$GP&:UGBL36+WU9'30FDNC\T1O9";DNJCRTHIC\<<_G(WBT4OX-!I&P^$0
M/L1#_VGJ/KW'&Z3:)K@K;'DZ&@^?U=^FT>04OG\M2CA@4].-[["IZ68<W3:.
M;DTDXO-H-FLC,3F?1-/)4'R2)EGYB[2X(C[G[M=XR%>-Q"<S$.^KY5+FD0!*
M*@,'ZAQ.E[SELH+U8+_$Q=(HM49B/T6V("JCX<O&8;B<GL8OGT5B4QE;25@-
MH&Y6&A;!IJR0.<#'_>^*]4;F=^)X-"7\=2[4+9R4+Y'EAM8 Z@ B46)^U]H#
MDB%S4>56 ?^10&TB(BQ<SLS#U>Z0@?@*CSLH@X5/3,6WAMM;D$GX3Q@@O=B
M5,@\K]9"_;T";L%=$/#&@(/A%=("FS:%*0D _?HGF64"= -]XR]%97+8V'MR
M!#N2K$I!M@7NZ2(2B;E*))R45DI4FX+!*VDR#7C!M9[J9_0(=0:](SDL) [@
MM$0E(N)4\TPG\'BA#)YTH\N5R $WH%JB5&IQ1UZ(3%D+T("PGB7 A:<:CHC/
MQ)KM\0((32>F>'?8%SCDE+5SPP%K1%B5%!:420*K$DVB3<CT;!0W@+O0>"?
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MP($'6FJ(RC.U@*W#P6QZQ-&#_U(6&WJ?V;PHRV)-'U=*0N2("^!W'&?S7_"
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M5;G4F PHZ6 -V,280A8A;9QMG** :<OKHLV#R*&G"DCX 0VR+9K5Q0@-).X
MPCY-Q4><!E!"EKK0>Q*-#:"@8'AT >EN31^M*0J)8_H73F*"N)PBO%=; U=
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MG@^BZ6PH[%H"=QI-/<"6 .Z+CU5?O*M7*UFR(>_P^2]9XE.MQ;+.86DP9D%
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M^4EFC8D,.C*J(1%,3V.*3*I6FIH41HF19&0H$Z$/%7<OAZ2!7P6[B/PPA9(
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MG-\7MQ+Y(P!!G-0NAWVTLQGT3>PA*!3)$DT!@6-*U30Q=R?0@<*. ']<VEO
M@H>;([<ZSP5^^T8'4=_%!T&,R/2]SF!AN =@4X4Q!*->U,1FV_ 5EQQ391Y$
MN:3*<7 @C[=N/^%5',[YP7<OTH7"]ELG&,%TEF!\D\&5"C?.2IV L%7 &E @
M&!6L-[5#,O'>:ZFYU]VM-0SJ>I*-T,O&SR\SN1/W)J\A><OO,U1@L5BN.I1\
MQE[8@I2-+L^7N$_29O([#='=FI6AG%[HNF 2.9&CZW "80$2I^J(7_E4C]C>
MHHKZ0-PFT"N%ME,'#<)]*>0%:N;H[NXAWO%&7680WO3>3Q+)*</ E<8O5CE0
MG-,'^=>=W,3L* U=5^XUO\HQ">%TIOY>#I(]&LI0_?Y\NDK1-DI?&BF5^H3T
ME]+4$"EJ%DV'@V<(K1Z0G<N5W] <32\G<)1]Y*DUR',RKXU\7T&)5:#I!FDJ
M7(_H9@X54;S$3LD*$M][-()UQ.U];<.>0I=<YB':5-ZM[>8.^;-.#\RX1!PY
M-2?V0XPP##PR.@)IE>YY>1[N]Q]JY*IAS)4MCD[K126QHQO9.8BF\UDT'XWW
M1[6RA4;NSNAJG._"2X^B%V(2.A[/H^EL2KH?CV\X>JUROKL]Z6)HX#:')&K\
M*YE^4U6G/#;\8,Q/>!R =GG5)0 M?>1_UL;J0N?2)WR2\9*>@;E ;=#)AML,
M7:.XI1DDX65A7Y8<USG_[HW;AST:J7L J.^@,&^Z*W(]%;%N[]<\C8I/[>W&
M-TRMF-\?)[Q'I'TROW<1 .)'4KXYPNN=!PLT9[B3TI6>KPGB<\>%TOI[V*&*
M S0+,#%*AE-Q)E#^)V+2G\\#H3$RCB:C6-P&[="OS^)Q-)J/7_#RT?P'SACB
MC)@%#?P94S'NSP?M&6.T7"-Q[)7VHO-T7JAJQ7\@H/X+=V?_BMZ.MG^#N/%/
M[_OE_@\8N-NM  UJP!);X_YTW/-YJ?EP9L,/\0O4?E/PKVLED=]I >:7!OP)
M'W1 ^Y>9Z_\!4$L#!!0    ( !@\5%A).XJ\+ \  - N   9    >&PO=V]R
M:W-H965T<R]S:&5E=#(Y+GAM;-U::X_;1K+]*XU9[\(&.!J1>OL%C!,G-[F;
M9."Q-[A8[(<6V9(:)MD,FYS'_OH]5=U\21K-V ZPP/U@CT@VZUVGJZKY^M:4
MG^U.J4K<96ENWYSMJJIX>7%AXYW*I!V90N5XLC%E)BM<EML+6Y1*)OQ2EEY$
MX_'\(I,Z/WO[FN]=E6]?F[I*=:ZN2F'K+)/E_3N5FMLW9^%9<^.#WNXJNG'Q
M]G4AM^I:59^*JQ)7%RV51&<JM]KDHE2;-V>7X<MW4UK/"_ZAU:WM_1:DR=J8
MSW3Q4_+F;$P"J53%%5&0^'.COE-I2H0@QA^>YEG+DE[L_VZH_\"Z0Y>UM.H[
MD_ZNDVKWYFQY)A*UD75:?3"W_Z.\/C.B%YO4\O_BUJV=3LY$7-O*9/YE2)#I
MW/V5=]X.O1>6XP=>B/P+$<OM&+&4W\M*OGU=FEM1TFI0HQ^L*K\-X71.3KFN
M2CS5>*]Z>UV9^//Y.^B5B.],!E];2>9Z?5&!.JVYB#VE=XY2] "E,!*_F+S:
M6?$^3U0R)' !L5K9HD:V=]%)BM^K>"0F82"B<30Y06_2ZCIA>I.'=-W)4GE=
MK^0]0JL2EV4I\ZWBW_^\7-NJ1)S\ZYCVCO;T.&W*G9>VD+%Z<X;DL*J\46=O
M__:7<#Y^=4+R:2OY]!3U+_+2UU&"C<.Y^+O)M^*C*C/Q4Q[#)$@8<97*7'PJ
ML*3:*:$V&\6)E"MKA=GP3?AG+)CRWGN!R(V02:*)A4S%%L:N+$(\3<5:(8X3
M)6I$2^G)G! A$,]IS=_^LHRB\2M>2K?Y.GSU0L@\P;][ >"Q%2XTR,A;6296
MQ A+G=<*?*L=<=*E,*7>:A*I BL[ZJMP26\YM7_*Q;4J*I6M(2(M"5A0,AQX
M$>]P\<J*=X;>@#&^UR6L8THK9%&4Y@9&/FF?/9VPJJ]3(&YW.M[!4K',>J87
M9B"62Y#Q2'QL6!5$FOCK1%D!Y&8IV/@DI6YEL"R3*<@]EIR5G_]1RU1O-"3?
M>^@N22\5:Q<S)4$>'B'@JU+'5?/2X1UX6</QY"0#64IW]WS-<>C<-!*7HC(5
M7 (1E\%X/*9_PE+2<J3%)LO U-&[5:6"(@@LF:;WPJ=<PLIJ:VL)'0>AY6T+
M+FTXIO>!J LP%;-'V 5DL[3FH/IP_0DA!0,C@!':Y&(SY,%";.JJ)A$;63:E
MR1IC8KFLA+HK$"Z!2&5AX=-2@#.'(^*2#,=OM'G!A&D1Q3B;$(Y(5(PTQ%WR
MN'41D-<<%M#@ =,Q\TS>DP(D'E@=,91+4EEC X*S8[8RC("-WW( *HG(_%GF
M-;9R@1!<*^133@;2!"91R,[VJ4>WR2C\TD9;D!/W2I9@7.DTX*6MA5V.]5<I
ME\[8#US(NSUA@FQ4%*Z- U+8PFG^7+\0\V#ZB$^?:RR;_K5!L>:A7]W#$8]]
M&P:,!);S;^@L4PER0<$VE!:*5T-L" RQ6792#8PT(920F8'&0EH4#L[3,/[Z
M_HF@,A*_Y>+G&LRB!>=\-( CL5,IDDE<%Y2@J?@%-0%+OW'8LS,IO&P'F+.W
MMD736P28\H)M3(K2C2@A$BJBP,EGZW6FJ\K%OQ0WIE*-7?95L7WV"#Y:LR\E
MV8GN'\%2N,.D#9:VTKQD+[-186[>P'T<[+/_ ##BC/I.E16P+99.5&"Q*0M3
M,I@%<"RMZ8 U7 8-YILN]*M!BB$_=MA*_DTX=SS;8,30Q2''XG/.ZFC6W0'Q
M27?YXE43,<=UNT;QK"M*]%(6JD9F6M)C],0]9K!E/JQ6I\LQ>P[T8X!;IWVP
M9:[0>Q_$.7Y_@T_9NI&KZ[XYA!N"7Q/*XA:I^-\/Y#_)T5_H3^'5$D_WZ&)\
MX-)+)KL'S=ZM0 G:TR9!- ^#Z6K>R"%OI$Z9!40^N0MY==]G16KNE?)Z7]5E
MO",M6:ZV[#FYZJ#2>G]]==4%">) )MB>.SP^5M11C=D4=@_ -JO8A(CQ>!TZ
MO!X?I=#?QV/OFGTJE_46O: (5STZVHJN6'.VN_:][C2:-,[^*4><T[[U0:%H
MKTG@1/5J13)#KY#J 1KO<$WY FJN5 H?J\RPII# V5@7DA-">;<<U"?##??Q
MLH1%/5Z1V+8DZ=<-Q$#E,0G1JU2^J3@YJ$UZ/&@3&?"9C$\5*&$P?TJ!$CZM
M0+$UI*<M[,^M.(ZG=]2D-U<"43"/EL%R-?FR_"9WNI#8Z-)29[)1)6E3X(])
M!LTENY[;&CC-:DMY2KA&,2TR'CL$0U<T*1,-'(Y05/QN+GY0ZY)=%;E]/G*R
M6 4.R8$PGK9[]1<)9/&A%#%EPH\!=<^]L1>VOB%!ZPPH-[P+^7[8ZCNO#!71
M2>TJ$\> EC1"[!6>)E:JC4V5MY8#L-QH4]M]9=#UY"FW[R3#K09$'@;'$?A#
MC@Q&!KC@C1-P\NG0M2C.4_38% 4M G#?5#2X_&!_4IIZNP.*W)?8(R%;4L>N
M;^I0:-9DA7:@V0I%9;@F=(7Y&INX?MA'5>E2Q0+FR/;^ME_M&NX>1R[7&DEH
M,Z.91=,V2IK_L=$R>:>S.O/IYB+)-7OP@B:/#1.0^U[?5G2HP$F>&LNNXM?V
M;8,?!!U5FS3K&JO)E[VV9$]=1A$.C3M5QNQM1$[ EMA)%WE.(%0G%%%>K@-)
M^AC42'- ]U4S>$@<HK.Q!Z9HF>)I"O"NQ++U)FV.*;"=HF; ?T2S&%ZPMLIO
M2+(UJ7/]R<AM .\P>ET%NN^MGDR/..B86?XD)[E &G+4#!WBN7QQ1)SGS; '
MES1D%U4I&1JP1=(<_47CLU^E3>0?XL?4K+$_7?.4G'#MLZI8G+6C+F]0?F[5
MONYKG;A2QGZ&GYDU0Q8;$J^<X\=Y3*F WQE3]<,L #8-:'I^#FAS*NIUJNU.
M)0V5WRE&KJN2SB5^-C57,#S]\.,CW*)08KD/0*OU=@-/WW=8L#=7P+L'M2NK
MYG:YR2H*PL6,[X2+>;"<+3QL\8RK< ,Y&B2Y@=3#=8NK9EUE^IL? WW4F?(S
ML+T'O2H=S2M<62GG]HT$X-W(M&:?#$9T;L#GVI@.<4GRI$V$VC9V>)?*^//Y
M=8PB$ZN(HDN+#.5AV@BZ3WEO5NOMY$IUK%(YHH7*LAM%^_D-KX4+61\)VV2>
M7FT[3^]7(9THDJ<,=%C$]:BTOF>"[7G&GON]5L+X-(FD-3Y>851M7XK_(R^_
M?\#+)QY&XH.VG\\W)+NF("9]2BJNIJ/92OQ53$9AB#_O[PH7?P1#R.&<X\J^
MP+*EF(U6W8(;DT*I5%?W8K4<T;NK<!3U2<@\IU(QT02>.0J$0I4NUERC%KW"
MZN[7QT$[6S%BML:R1RU;=>'6#QQW,D:2->!Q*CE>BE^';64;)+_O.Z&%,H=-
M!\]+1:>&/#)#T4,'+[4?R(O+[;946S(XS(_<M3KV4?];?[Y_O#BEV<("_R9P
MU3-RQ40L1U/G&MQ8!HMQ)'[T(3V=!N%DAB0?XU$X6D3B!U-NE*9GSZ-@.ID$
MJ^GD!1[.1K,YW.5THH?C:1"M%O0H&B$)'I=L(F9X9;P*HN7*O;44J]&DE6P:
M!;/%]$F$SCG'E(-AU8:A<:DW7073\0(M=\1L)N& S62)IZTJ'#G8BH\("RO.
M@TGHK;@2"T1L:T70OE(E'PO3?DQRN/WC)*(=;K\/S5H>Z+_!3?KSNK:1GHZ#
M)7R(UKX):7_01!,1_$$@QC4!M2,1J[)"X/5 <F\PTBL=3Z5"<S[#M3G;W6E>
MTV%9PZ3T;;>3O6>?HF<\:CGX4,+WR$.4+_;,/" SW *XY'+-*M;ZE1WYO3+4
M[0:2SVVAO2Q3L[\3-#K6!%X$+%F=5AI]#K@4=87EI:8(8ELW6Y6O0%!:K!WD
ML5AT\T"@IO5![ZUAJ63T-<#V9 /]_X.Z>;"83WF(0.@5SI#H\S9'HW&PFLTZ
MJ.O2A!;/5WVH6TWY$.P%/Z*BI06Z9L]YUOYZ"D!-Y\&<T*YA%@TDP]-HLO@3
MD&X93%8+V. H%SP$@4=Q[E#!PSL4E4V5<=YXE5'FG(<N3ZG+]F#%/EI_\ECA
M63B:NO'%L_%HN0BZNF!8@KK,D0]&TX%8JO7P5PHVQ5[%<H78N+Y-%DVC@32N
M4SZ#D2[-$TUS"^[VUJJZ56JOW1QT8$-ZS1!^Z)9'#S,<*AB[3X[Q:R>3/=Y6
M *6XR)7Y5[ [-3SG@_ ZQ\YGMCF7OX,I1VRH(%7.7,B%.O=),D"[YG,+Z;]'
MN&-T1GW^;!X&X9PG7M2+N1FAMH/T6A-JM=RYF#]2:'>SNB&'J"D51FCE2B?'
MX<YVVSPBWG[S:.<BB3^F<]\M/*%S47!=8E*S1?P=%MZ:=O]2=;,7J(ZJ@@;)
M'MU=//4VDZ#3EW:W.[>M-@,\&D;EM:VYX]EA7:_('PU:.&Y]_$2]5=F9N$O"
M_DP/TI$_H;$C5+;="#<A9*W^7)D&?1)\8:!/H_\=B1]U"@:\%''K[)>X?9EF
M[!0[U,D3)U@<3;GUB=7O9GP \]M!DY*M]/UV]W:G!JT<!UQB,AWKM.OS2+*>
M7YH^1]QK.O.#2O]6I0F:P3S/>"%V\\G.D7*P.;ZZH6__V@IC/^':V0N7,SP]
M,;Y3A4%<)#83QU@6NN+/E,PMV&+%KI_=A?]F#$*T71HTHF,#;Q=!QW%5J@;&
M$NX<A_C:>FWC4M-('#DL[8X1Q^1^%HJV^_A(%"%F^(2RJ$LZD&E/"5L\\MYJ
M6')9A5^?B=&FQ@4QHIE*UU]V'^,DFK[66=<.[-CDDI,?%G='"CRF/AA/==YY
M8)2K<Q<C[JQ45GZH]4%MG#U^I;-65 B;WH"N[[PVW+ZH;@.N'MGFVR,+!&=N
M3F KI4%N51]>&SG\7.38]W/\@ 0?KUXYB'F,Z,$.Z"Q."06S^JRA5#"I=M\F
M\&<,%()L:5,H=T!@V\.-4NWH>]D;A8T)(=]-3+YI%**LX@,/'B6A2$]-P7F
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M,3H:=0N?U++TO#"]/&_DDCZ3_]K<6;Q->RV%JJAVRM3"TN)B='7TYOJ$Y:/
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M)B0>6XA[.Y>NI8ZG$;K0-%I!D,4CHMHB=+W43B#?I5>83*MEI),.FXAP(CX
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M -\7!H>^]H4-]/?DRW\ 4$L#!!0    ( !@\5%@RVG'(A!(  ,I.   9
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MKU>NM1'@HNY%!S8Y'+W3(7:S0>,W!8"Q]+1,_U913X_Z")CZLS+"X[ZUT!3
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MY7,&$PO/P% 3&\$T8%*RZF^U/P%AQ(?HE\5[3G=U("IXIVWA%%HD/L^5Q)_
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MT7@'LF^T=H>)WV!X=5?_ 5!+ P04    "  8/%18/?M.:_("  "X!@  &0
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M&@/:3P4=]V9B C2/5?@74$L#!!0    ( !@\5%A']!^HR0(  "D&   9
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MI[!'R7F%TG E06,Q#V[BJ^78\7N&WSENS<$W.$_62GUSA_M\'D3.(!2868?
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MG4\"T.VV:@]6U7Y#K)6E?>,_2UKPJ!T#T0M%/=4=G(+^+\/B/U!+ P04
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MK 'M%Y*4,DQL@/$;9O,-4$L#!!0    ( !@\5%BFQ/+/M 0  !\+   9
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M,Z#S4BE[6K@+^C\4ZW\!4$L#!!0    ( !@\5%C^_T;SN (  #H&   9
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M*VEHZ;AC3EL>E74@^UI*LQ5L@NY_8_X;4$L#!!0    ( !@\5%B?YVJ)7P4
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MRG[VW/[SG<A$NDH;!02UGJ$T"J4%4%H(I44H6ET?E0'MG=:!]J 6-)1&H;0
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MT26*:5'(B5'.S/&=FO[RC&RJXYBG2*X-43VE;M9+)J<6M,8/RH0^ XPYAQH
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M$I7ELVTJ\GVR\FJY[?I1;S:^NGX-KQ;YYFDED^_E?L9\1=,,Q&0I)=W^2!;
M\^W1_$2PC=XP?&1"L$0?K@F6KVAJ@/Q\R9AX.5$3E)O4\_\!4$L#!!0    (
M !@\5%AIE<'6.00  .H2   9    >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM
M;+58:V_;-A3]*X16#"U01Z+>SFP#JX6A!=8U2-+N,RW1-A=)U$C:3O;K1\J*
M+$LTZQKN%UN/>X_N.20OCS394?;$UQ@+\%SD)9]::R&J6]OFZ1H7B-_0"I?R
MSI*R @EYRE8VKQA&69U4Y+;K.*%=(%):LTE][8[-)G0C<E+B.P;XIB@0>_F
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M0!)MJ.F,5%_[E8M[,)1Q_?L\,LC.GA$5.R9W/9/T!),D)1^E,+4F[T0)Y3%
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MWY=]I&K-\&EPJ! R#F>8>53?ZO03(UO7+:RDP=[##6ML#T'9#?B]DM+L)_:
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M$X8(#8#Y%>=JU]$+-!]%T2]02P,$%     @ &#Q46)].).>  @  X@<  !D
M  !X;"]W;W)K<VAE971S+W-H965T-C4N>&ULM55M;],P$/XKIX 0DT:3IB\K
MI8VT=4),&J-:!7Q ?'"32V/-B8/MMN/?<W:RJ(6T8JA\2?QRSW-^[L[GR5:J
M!YTA&GC,1:&G7F9,.?9]'6>8,]V1)1:TDTJ5,T-3M?)UJ9 E#I0+/PR"H9\S
M7GC1Q*W-5321:R-X@7,%>IWG3/V\0B&W4Z_K/2W<\U5F[((?34JVP@6:S^5<
MT<QO6!*>8Z&Y+$!A.O4NN^/9T-H[@R\<MWIG#%;)4LH'.[E)IEY@#X0"8V,9
M&/TV.$,A+!$=XT?-Z34N+7!W_,3^WFDG+4NF<2;%5YZ8;.J-/$@P96MA[N7V
M ]9Z!I8OED*[+VPKVT'?@WBMC<QK,)T@YT7U9X]U''8 W4. L :$?POHU8">
M$UJ=S,FZ9H9%$R6WH*PUL=F!BXU#DQI>V"PNC*)=3C@3W5&AW$JMH40%BXPI
MA#=PQY1B-KSP^AH-XT*?T>I+\$%;"SWQ#;FV!'Y<N[FJW(0'W'QDJ@-!]QS"
M(.RUP&?'X9?K%<%'#A[NPWT2W*@.&]6AX^L=X%NLEYHGG,KV'!9,(,@4%D;&
M#_#MEDSAQF"NO[?)K'C[[;SVRHUUR6*<>G2G-*H->M&K%]UA\*Y-](G(]D+0
M:T+0.\8>5;DN%8\IR[R 1 K!5%4'+LMG;?(KSI'CM UB$W4[(\K(9E?64<?_
M**O?R.H?E>7:D(9/:8J*%ZLV#4<)GIO"$Y'M:1TT6@?_J8H'IPS!B<CV0C!L
M0C \7L6U;.UD/[>:ARW5' Q^J^8_C8+.VXO&J#JVO].![>M'_6[%"PT"4X(%
MG0L*DJI>E&IB9.F:\E(::O%NF-$CC,H:T'XJI7F:V#[?/.O1+U!+ P04
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MI0L_^YCIVAR$&:#?;[CVNFF8#[35_O)?4$L#!!0    ( !@\5%C>X,K$%0,
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M6BB!&<ZINN6K3U#ETS-\,:>R^$6KRM:Q4)Q+Q;,*K"/(""O_\6.EPP; \UX
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MLY<KP9="I@.2S^_B6#]=I,_SE]_?F/\/4$L#!!0    ( !@\5%CE#PJ45@(
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M@, :;9596W.B2!()WB!ALC6;6=C:6+1V0TOS%Y=*Z%.J<2JY(E2@!\)J0#=
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M]=D]G;E=[9!;_&"PD94QT:'<<7ZO)Y>+B>5H1A!!H#0$Q;\US""*-!+R>"A
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M%/TK&G>GLSM#8EN @2PPD^#M=-NDS22;[D.G#P*+H(EML9* ,-,?7\DV-OY
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M$"9 [R\Y5_N)2=!>K.D?4$L#!!0    ( !@\5%B[&8)%-@,  /8,   9
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MI9MO4!KJ*[Z01CS_19MBK><9*,RXH'$)E@IBDA3_^*G<B!K [KT!<$J <RC
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M55('GON&VM?Z;>L+>*?39#?+>\MQTD=^[Q-CUII2]47P [,E2;@4O)#TUME
M%C=6--G%1- T[U-G5,BN-Q^NY(<),+5 WE]0*EXFJO6M/G6"_U!+ P04
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MU3/M-BV*=+G]\D'$=R*K%BA_/T_+SE%_4PWPF&:_;S?[ZC]02P,$%     @
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MP>45"E--<VL61BY=?YA+@]W&34O\'X"R ?A^(:79+.P!W1\F_0M02P,$%
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M,RYX;6S%W5USVM@!QO&O<L;M=+8SV1B)%^/4\4P2O4O;]6RZW8M.+V0XQIJ
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M%HG9).:0F+O!KG:"-+@:'!['#N^F#?3#8QBY:0&$-1(WWB9NK$S<7U>+^^(
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M+_&E1CN'%:U H9J):A:JV:CFH)J+:AZJ^:@64%HSP'5-:J"_\:)Z@!:F4,U
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M0$,+9 K9+O3:7K<W'+F[NII&LX[O5V8G/'L5S]Y5GH]O.18IS!.2S,@-X^0
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M+*.CD=?!",M;',./7PWS!@PL#D3ZNUSCNXU7R/XZP/9T7X5@*\4K$5LIGFM
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MSE4CV%?!'<0,73 3H.>K>#1.T#R%6!J0"T,'/QCX$^AX'3X0TV&N2(A= :&
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M_J>L/\;Q\(_CEV?:FW9XSL^6OY/<_ )02P$"% ,4    "  8/%18!T%-8H$
M  "Q    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( !@\5%@QT>*3[0   "L"   1              "  :\   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( !@\5%B97)PC$ 8  )PG   3
M          "  <L!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
M&#Q46,M0'#T]!P  <2X  !@              ("!# @  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( !@\5%B)^^VG/@(  ,,%   8
M          " @7\/  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M    "  8/%18V9$0>E '  !W(0  &               @('S$0  >&PO=V]R
M:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ &#Q46/%OW!;W @  5PH
M !@              ("!>1D  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+
M 0(4 Q0    ( !@\5%AOO.]\8P4  -T5   8              " @:8<  !X
M;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  8/%183O;=-B@+
M   B>P  &               @($_(@  >&PO=V]R:W-H965T<R]S:&5E=#8N
M>&UL4$L! A0#%     @ &#Q46"&EM!QH @  RP4  !@              ("!
MG2T  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( !@\5%A^
M 03$  H  'DO   8              " @3LP  !X;"]W;W)K<VAE971S+W-H
M965T."YX;6Q02P$"% ,4    "  8/%18F6H(&04-  ![(@  &
M    @(%Q.@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @
M&#Q46!YQ!2/;!   <PL  !D              ("!K$<  'AL+W=O<FMS:&5E
M=',O<VAE970Q,"YX;6Q02P$"% ,4    "  8/%18_@6&CO &  #/$   &0
M            @(&^3   >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4
M Q0    ( !@\5%@SOQB(5B8  ,9\   9              " @>53  !X;"]W
M;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ &#Q46.0 =7_=!0
M]0X  !D              ("!<GH  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX
M;6Q02P$"% ,4    "  8/%18LW!B3D8'   ;$@  &0              @(&&
M@   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( !@\5%A\
MVJ5M.P4  (D,   9              " @0.(  !X;"]W;W)K<VAE971S+W-H
M965T,34N>&UL4$L! A0#%     @ &#Q46-E,@9/, P  XP@  !D
M     ("!=8T  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !@\5%@)H]A-B08  -(/   9              "
M@<*Y  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ &#Q4
M6&QF#*;*!   L P  !D              ("!@L   'AL+W=O<FMS:&5E=',O
M<VAE970R,BYX;6Q02P$"% ,4    "  8/%186M?E Q(#   S!P  &0
M        @(&#Q0  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0
M   ( !@\5%@CEP*^K0(  )H&   9              " @<S(  !X;"]W;W)K
M<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ &#Q46$"E.2_F!0  Y0X
M !D              ("!L,L  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q0
M2P$"% ,4    "  8/%18J;+K X82  #L3@  &0              @('-T0
M>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( !@\5%BUV'Z_
M9P0   @*   9              " @8KD  !X;"]W;W)K<VAE971S+W-H965T
M,C<N>&UL4$L! A0#%     @ &#Q46!T);%^8"0  I1D  !D
M ("!*.D  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    "  8
M/%1823N*O"P/  #0+@  &0              @('W\@  >&PO=V]R:W-H965T
M<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( !@\5%B)O@X!. 8  #,/   9
M          " @5H" 0!X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#
M%     @ &#Q46#+:<<B$$@  RDX  !D              ("!R0@! 'AL+W=O
M<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    "  8/%18<7XZR%\D   _
M?   &0              @(&$&P$ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM
M;%!+ 0(4 Q0    ( !@\5%A-SCKY9@,  ,<'   9              " @1I
M 0!X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ &#Q46!*U
M-HU# P  @0<  !D              ("!MT,! 'AL+W=O<FMS:&5E=',O<VAE
M970S-"YX;6Q02P$"% ,4    "  8/%18/?M.:_("  "X!@  &0
M    @($Q1P$ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    (
M !@\5%A']!^HR0(  "D&   9              " @5I* 0!X;"]W;W)K<VAE
M971S+W-H965T,S8N>&UL4$L! A0#%     @ &#Q46$'CYGRZ P  /@@  !D
M             ("!6DT! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"
M% ,4    "  8/%18)/Q/D%\%  #D#P  &0              @(%+40$ >&PO
M=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( !@\5%AF.4&EFP,
M ,\(   9              " @>%6 0!X;"]W;W)K<VAE971S+W-H965T,SDN
M>&UL4$L! A0#%     @ &#Q46*;$\L^T!   'PL  !D              ("!
MLUH! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    "  8/%18
MS \WM,4#  !O"@  &0              @(&>7P$ >&PO=V]R:W-H965T<R]S
M:&5E=#0Q+GAM;%!+ 0(4 Q0    ( !@\5%CX%H0&6P,  + '   9
M      " @9IC 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%
M  @ &#Q46%\!U_]\ P  7 @  !D              ("!+&<! 'AL+W=O<FMS
M:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    "  8/%18_O]&\[@"   Z!@
M&0              @('?:@$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+
M 0(4 Q0    ( !@\5%AYN6+4W0(  $,&   9              " @<YM 0!X
M;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ &#Q46)_G:HE?
M!0  2 \  !D              ("!XG ! 'AL+W=O<FMS:&5E=',O<VAE970T
M-BYX;6Q02P$"% ,4    "  8/%18%8)TQ!,/  #&\0  &0
M@(%X=@$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( !@\
M5%C$7<;/1@,  -<(   9              " @<*% 0!X;"]W;W)K<VAE971S
M+W-H965T-#@N>&UL4$L! A0#%     @ &#Q46'^8!'D-"   .DX  !D
M         ("!/XD! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4
M    "  8/%18=6&_Y_$%   >,P  &0              @(&#D0$ >&PO=V]R
M:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( !@\5%A\NTVO5P(  &$%
M   9              " @:N7 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL
M4$L! A0#%     @ &#Q46!XH^>30 @  D H  !D              ("!.9H!
M 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    "  8/%18E415
M#50"  "C!0  &0              @(% G0$ >&PO=V]R:W-H965T<R]S:&5E
M=#4S+GAM;%!+ 0(4 Q0    ( !@\5%C_(0RF"P,  +T(   9
M  " @<N? 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @
M&#Q46+O0U 3+ P  4A,  !D              ("!#:,! 'AL+W=O<FMS:&5E
M=',O<VAE970U-2YX;6Q02P$"% ,4    "  8/%18>[]^+MP$   V'P  &0
M            @($/IP$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4
M Q0    ( !@\5%CA1)76? ,  *4+   9              " @2*L 0!X;"]W
M;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ &#Q46'ZVJQBL @
M!0<  !D              ("!U:\! 'AL+W=O<FMS:&5E=',O<VAE970U."YX
M;6Q02P$"% ,4    "  8/%18D77+U0,%  "P'@  &0              @(&X
ML@$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( !@\5%AI
ME<'6.00  .H2   9              " @?*W 0!X;"]W;W)K<VAE971S+W-H
M965T-C N>&UL4$L! A0#%     @ &#Q46"-J(WNU @  2P<  !D
M     ("!8KP! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !@\5%C6UZ8EF@,  /D/   9              "
M@2K, 0!X;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @ &#Q4
M6-[@RL05 P  9PH  !D              ("!^\\! 'AL+W=O<FMS:&5E=',O
M<VAE970V-RYX;6Q02P$"% ,4    "  8/%18D=B/;]$$  #%&   &0
M        @(%'TP$ >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4 Q0
M   ( !@\5%C)C5)7WP4  ,LQ   9              " @4_8 0!X;"]W;W)K
M<VAE971S+W-H965T-CDN>&UL4$L! A0#%     @ &#Q46.4/"I16 @  P04
M !D              ("!9=X! 'AL+W=O<FMS:&5E=',O<VAE970W,"YX;6Q0
M2P$"% ,4    "  8/%18-:)Z6!\#   ^"@  &0              @('RX $
M>&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    ( !@\5%AVG>QY
M7@,  *8.   9              " @4CD 0!X;"]W;W)K<VAE971S+W-H965T
M-S(N>&UL4$L! A0#%     @ &#Q46%U 8#&* @  7@8  !D
M ("!W><! 'AL+W=O<FMS:&5E=',O<VAE970W,RYX;6Q02P$"% ,4    "  8
M/%18(_QOUH8"   L!@  &0              @(&>Z@$ >&PO=V]R:W-H965T
M<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    ( !@\5%A4(RJ)5 4  "(>   9
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M970W.2YX;6Q02P$"% ,4    "  8/%18M1P?+YP"  !M!@  &0
M    @(%.#P( >&PO=V]R:W-H965T<R]S:&5E=#@P+GAM;%!+ 0(4 Q0    (
M !@\5%BG:@IX<0\  '?J   9              " @2$2 @!X;"]W;W)K<VAE
M971S+W-H965T.#$N>&UL4$L! A0#%     @ &#Q46/KOY4:F P  , T  !D
M             ("!R2$" 'AL+W=O<FMS:&5E=',O<VAE970X,BYX;6Q02P$"
M% ,4    "  8/%18],.EX&,/   .WP  &0              @(&F)0( >&PO
M=V]R:W-H965T<R]S:&5E=#@S+GAM;%!+ 0(4 Q0    ( !@\5%BJ&"86" ,
M %$(   9              " @4 U @!X;"]W;W)K<VAE971S+W-H965T.#0N
M>&UL4$L! A0#%     @ &#Q46"&+2_0+!P  [2X  !D              ("!
M?S@" 'AL+W=O<FMS:&5E=',O<VAE970X-2YX;6Q02P$"% ,4    "  8/%18
MQ8C3U?L#   E%   &0              @('!/P( >&PO=V]R:W-H965T<R]S
M:&5E=#@V+GAM;%!+ 0(4 Q0    ( !@\5%C)U/Q]+@,  ,$,   9
M      " @?-# @!X;"]W;W)K<VAE971S+W-H965T.#<N>&UL4$L! A0#%
M  @ &#Q46!?!ZQN('   O@@" !D              ("!6$<" 'AL+W=O<FMS
M:&5E=',O<VAE970X."YX;6Q02P$"% ,4    "  8/%182=4SN%$#  #N%
M#0              @ $79 ( >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( !@\
M5%B7BKL<P    !,"   +              "  9-G @!?<F5L<R\N<F5L<U!+
M 0(4 Q0    ( !@\5%A73I9KJ 8  /@Y   /              "  7QH @!X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  8/%18PR792)0"  #?,P  &@
M            @ %1;P( >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    "  8/%18C9S+JS0"  !6,@  $P              @ $=<@( 6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     8 !@ %<:  ""= (    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>212</ContextCount>
  <ElementCount>416</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>70</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Nature of Business and Operations and Recent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEvents</Role>
      <ShortName>Nature of Business and Operations and Recent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Basis of Presentation, Use of Estimates, and Risks and Uncertainties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/BasisofPresentationUseofEstimatesandRisksandUncertainties</Role>
      <ShortName>Basis of Presentation, Use of Estimates, and Risks and Uncertainties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Liquidity and Capital Resources</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/LiquidityandCapitalResources</Role>
      <ShortName>Liquidity and Capital Resources</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Recently Issued or Adopted Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/RecentlyIssuedorAdoptedAccountingPronouncements</Role>
      <ShortName>Recently Issued or Adopted Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Akeso License and Collaboration Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/AkesoLicenseandCollaborationAgreement</Role>
      <ShortName>Akeso License and Collaboration Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Other Operating Income, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/OtherOperatingIncomenet</Role>
      <ShortName>Other Operating Income, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Other (Expense) Income, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/OtherExpenseIncomenet</Role>
      <ShortName>Other (Expense) Income, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Income Tax</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/IncomeTax</Role>
      <ShortName>Income Tax</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/NetLossperShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Fair Value Measurements and Short-Term Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestments</Role>
      <ShortName>Fair Value Measurements and Short-Term Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Research and Development Prepaid Expenses and Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/ResearchandDevelopmentPrepaidExpensesandAccruedLiabilities</Role>
      <ShortName>Research and Development Prepaid Expenses and Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Promissory Notes Payable to Related Parties</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedParties</Role>
      <ShortName>Promissory Notes Payable to Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Other Non-Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/OtherNonCurrentLiabilities</Role>
      <ShortName>Other Non-Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/SegmentReporting</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/Revenue</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Other Operating Income, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/OtherOperatingIncomenetTables</Role>
      <ShortName>Other Operating Income, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/OtherOperatingIncomenet</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Other (Expense) Income, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/OtherExpenseIncomenetTables</Role>
      <ShortName>Other (Expense) Income, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/OtherOperatingIncomenet</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Income Tax (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/IncomeTaxTables</Role>
      <ShortName>Income Tax (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/IncomeTax</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/NetLossperShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/NetLossperShare</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/GoodwillandIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/GoodwillandIntangibleAssets</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Fair Value Measurements and Short-Term Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsTables</Role>
      <ShortName>Fair Value Measurements and Short-Term Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestments</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/PropertyandEquipment</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/Leases</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Promissory Notes Payable to Related Parties (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesTables</Role>
      <ShortName>Promissory Notes Payable to Related Parties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedParties</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/StockholdersEquity</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Stock Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Nature of Business and Operations and Recent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails</Role>
      <ShortName>Nature of Business and Operations and Recent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEvents</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Liquidity and Capital Resources (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/LiquidityandCapitalResourcesDetails</Role>
      <ShortName>Liquidity and Capital Resources (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/LiquidityandCapitalResources</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Akeso License and Collaboration Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/AkesoLicenseandCollaborationAgreementDetails</Role>
      <ShortName>Akeso License and Collaboration Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/AkesoLicenseandCollaborationAgreement</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Segment Reporting - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/SegmentReportingNarrativeDetails</Role>
      <ShortName>Segment Reporting - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Segment Reporting - Long-lived assets by geography (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/SegmentReportingLonglivedassetsbygeographyDetails</Role>
      <ShortName>Segment Reporting - Long-lived assets by geography (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Revenue - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/RevenueNarrativeDetails</Role>
      <ShortName>Revenue - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Revenue - Deferred revenue and other income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/RevenueDeferredrevenueandotherincomeDetails</Role>
      <ShortName>Revenue - Deferred revenue and other income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Other Operating Income, net - Summary by category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/OtherOperatingIncomenetSummarybycategoryDetails</Role>
      <ShortName>Other Operating Income, net - Summary by category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Other Operating Income, net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/OtherOperatingIncomenetNarrativeDetails</Role>
      <ShortName>Other Operating Income, net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Other (Expense) Income, net - Components (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/OtherExpenseIncomenetComponentsDetails</Role>
      <ShortName>Other (Expense) Income, net - Components (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/OtherOperatingIncomenetTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Income Tax - Components of loss before income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/IncomeTaxComponentsoflossbeforeincometaxesDetails</Role>
      <ShortName>Income Tax - Components of loss before income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Income Tax - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/IncomeTaxNarrativeDetails</Role>
      <ShortName>Income Tax - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Income Tax - Major components of deferred tax assets and liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails</Role>
      <ShortName>Income Tax - Major components of deferred tax assets and liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Income Tax - Valuation Allowance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/IncomeTaxValuationAllowanceDetails</Role>
      <ShortName>Income Tax - Valuation Allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Income Tax - Reconciliation of the effective income tax rate to statutory rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails</Role>
      <ShortName>Income Tax - Reconciliation of the effective income tax rate to statutory rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Income Tax - Reconciliation of unrecognized tax benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/IncomeTaxReconciliationofunrecognizedtaxbenefitsDetails</Role>
      <ShortName>Income Tax - Reconciliation of unrecognized tax benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Net Loss per Share - Computation of net loss per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/NetLossperShareComputationofnetlosspershareDetails</Role>
      <ShortName>Net Loss per Share - Computation of net loss per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Net Loss per Share - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/NetLossperShareNarrativeDetails</Role>
      <ShortName>Net Loss per Share - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Net Loss per Share - Potentially dilutive securities excluded from the computation of loss per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/NetLossperSharePotentiallydilutivesecuritiesexcludedfromthecomputationoflosspershareDetails</Role>
      <ShortName>Net Loss per Share - Potentially dilutive securities excluded from the computation of loss per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/GoodwillandIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - Goodwill and Intangible Assets - Schedule of acquired intangible assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule of acquired intangible assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - Fair Value Measurements and Short-Term Investments - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements and Short-Term Investments - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - Fair Value Measurements and Short-Term Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements and Short-Term Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9954510 - Disclosure - Fair Value Measurements and Short-Term Investments - Short-term investments with contractual maturity of less than on year (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsShortterminvestmentswithcontractualmaturityoflessthanonyearDetails</Role>
      <ShortName>Fair Value Measurements and Short-Term Investments - Short-term investments with contractual maturity of less than on year (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9954511 - Disclosure - Property and Equipment - Components of property and equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails</Role>
      <ShortName>Property and Equipment - Components of property and equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9954512 - Disclosure - Property and Equipment - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/PropertyandEquipmentNarrativeDetails</Role>
      <ShortName>Property and Equipment - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9954513 - Disclosure - Research and Development Prepaid Expenses and Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/ResearchandDevelopmentPrepaidExpensesandAccruedLiabilitiesDetails</Role>
      <ShortName>Research and Development Prepaid Expenses and Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/ResearchandDevelopmentPrepaidExpensesandAccruedLiabilities</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9954514 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9954515 - Disclosure - Leases - Lease expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/LeasesLeaseexpenseDetails</Role>
      <ShortName>Leases - Lease expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9954516 - Disclosure - Leases - Future lease payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails</Role>
      <ShortName>Leases - Future lease payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9954517 - Disclosure - Promissory Notes Payable to Related Parties - Summary of related party debt (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesSummaryofrelatedpartydebtDetails</Role>
      <ShortName>Promissory Notes Payable to Related Parties - Summary of related party debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9954518 - Disclosure - Promissory Notes Payable to Related Parties - Narrative (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails</Role>
      <ShortName>Promissory Notes Payable to Related Parties - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9954519 - Disclosure - Other Non-Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/OtherNonCurrentLiabilitiesDetails</Role>
      <ShortName>Other Non-Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/OtherNonCurrentLiabilities</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9954520 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9954521 - Disclosure - Stockholders' Equity - Warrant activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/StockholdersEquityWarrantactivityDetails</Role>
      <ShortName>Stockholders' Equity - Warrant activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9954522 - Disclosure - Stock Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9954523 - Disclosure - Stock Based Compensation - Weighted-average assumptions used for stock option awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/StockBasedCompensationWeightedaverageassumptionsusedforstockoptionawardsDetails</Role>
      <ShortName>Stock Based Compensation - Weighted-average assumptions used for stock option awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>9954524 - Disclosure - Stock Based Compensation - Stock option activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails</Role>
      <ShortName>Stock Based Compensation - Stock option activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>9954525 - Disclosure - Stock-Based Compensation - Summary of stock-based compensation expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/StockBasedCompensationSummaryofstockbasedcompensationexpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of stock-based compensation expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>9954526 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/CommitmentsandContingencies</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="smmt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>9954527 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.summitplc.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.summitplc.com/role/RelatedPartyTransactions</ParentRole>
      <Position>88</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="smmt-20231231.htm">smmt-20231231.htm</File>
    <File>smmt-20231231.xsd</File>
    <File>smmt-20231231_cal.xml</File>
    <File>smmt-20231231_def.xml</File>
    <File>smmt-20231231_lab.xml</File>
    <File>smmt-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>smmt-20231231_g1.jpg</File>
    <File>smmt-20231231_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="772">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>113
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "smmt-20231231.htm": {
   "nsprefix": "smmt",
   "nsuri": "http://www.summitplc.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "smmt-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "smmt-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "smmt-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "smmt-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "smmt-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "smmt-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 333,
   "keyCustom": 83,
   "axisStandard": 23,
   "axisCustom": 1,
   "memberStandard": 32,
   "memberCustom": 34,
   "hidden": {
    "total": 13,
    "http://fasb.org/us-gaap/2023": 7,
    "http://www.summitplc.com/20231231": 2,
    "http://xbrl.sec.gov/dei/2023": 4
   },
   "contextCount": 212,
   "entityCount": 1,
   "segmentCount": 70,
   "elementCount": 624,
   "unitCount": 9,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 772,
    "http://xbrl.sec.gov/dei/2023": 37
   },
   "report": {
    "R1": {
     "role": "http://www.summitplc.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.summitplc.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.summitplc.com/role/ConsolidatedBalanceSheets",
     "longName": "0000003 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.summitplc.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "0000004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
     "longName": "0000005 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity",
     "longName": "0000006 - Statement - Consolidated Statements of Stockholders' Equity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
     "longName": "0000007 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "0000008 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "smmt:InterestExpenseIncomeNoncash",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEvents",
     "longName": "0000009 - Disclosure - Nature of Business and Operations and Recent Events",
     "shortName": "Nature of Business and Operations and Recent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.summitplc.com/role/BasisofPresentationUseofEstimatesandRisksandUncertainties",
     "longName": "0000010 - Disclosure - Basis of Presentation, Use of Estimates, and Risks and Uncertainties",
     "shortName": "Basis of Presentation, Use of Estimates, and Risks and Uncertainties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccounting",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccounting",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.summitplc.com/role/LiquidityandCapitalResources",
     "longName": "0000011 - Disclosure - Liquidity and Capital Resources",
     "shortName": "Liquidity and Capital Resources",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "smmt:LiquidityAndCapitalResourcesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "smmt:LiquidityAndCapitalResourcesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.summitplc.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "0000012 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.summitplc.com/role/RecentlyIssuedorAdoptedAccountingPronouncements",
     "longName": "0000013 - Disclosure - Recently Issued or Adopted Accounting Pronouncements",
     "shortName": "Recently Issued or Adopted Accounting Pronouncements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.summitplc.com/role/AkesoLicenseandCollaborationAgreement",
     "longName": "0000014 - Disclosure - Akeso License and Collaboration Agreement",
     "shortName": "Akeso License and Collaboration Agreement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.summitplc.com/role/SegmentReporting",
     "longName": "0000015 - Disclosure - Segment Reporting",
     "shortName": "Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.summitplc.com/role/Revenue",
     "longName": "0000016 - Disclosure - Revenue",
     "shortName": "Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.summitplc.com/role/OtherOperatingIncomenet",
     "longName": "0000017 - Disclosure - Other Operating Income, net",
     "shortName": "Other Operating Income, net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherOperatingIncomeAndExpenseTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherOperatingIncomeAndExpenseTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.summitplc.com/role/OtherExpenseIncomenet",
     "longName": "0000018 - Disclosure - Other (Expense) Income, net",
     "shortName": "Other (Expense) Income, net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.summitplc.com/role/IncomeTax",
     "longName": "0000019 - Disclosure - Income Tax",
     "shortName": "Income Tax",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.summitplc.com/role/NetLossperShare",
     "longName": "0000020 - Disclosure - Net Loss per Share",
     "shortName": "Net Loss per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.summitplc.com/role/GoodwillandIntangibleAssets",
     "longName": "0000021 - Disclosure - Goodwill and Intangible Assets",
     "shortName": "Goodwill and Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestments",
     "longName": "0000022 - Disclosure - Fair Value Measurements and Short-Term Investments",
     "shortName": "Fair Value Measurements and Short-Term Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.summitplc.com/role/PropertyandEquipment",
     "longName": "0000023 - Disclosure - Property and Equipment",
     "shortName": "Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.summitplc.com/role/ResearchandDevelopmentPrepaidExpensesandAccruedLiabilities",
     "longName": "0000024 - Disclosure - Research and Development Prepaid Expenses and Accrued Liabilities",
     "shortName": "Research and Development Prepaid Expenses and Accrued Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.summitplc.com/role/Leases",
     "longName": "0000025 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedParties",
     "longName": "0000026 - Disclosure - Promissory Notes Payable to Related Parties",
     "shortName": "Promissory Notes Payable to Related Parties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R27": {
     "role": "http://www.summitplc.com/role/OtherNonCurrentLiabilities",
     "longName": "0000027 - Disclosure - Other Non-Current Liabilities",
     "shortName": "Other Non-Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.summitplc.com/role/StockholdersEquity",
     "longName": "0000028 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.summitplc.com/role/StockBasedCompensation",
     "longName": "0000029 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.summitplc.com/role/CommitmentsandContingencies",
     "longName": "0000030 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.summitplc.com/role/RelatedPartyTransactions",
     "longName": "0000031 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R32": {
     "role": "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R34": {
     "role": "http://www.summitplc.com/role/SegmentReportingTables",
     "longName": "9954473 - Disclosure - Segment Reporting (Tables)",
     "shortName": "Segment Reporting (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.summitplc.com/role/RevenueTables",
     "longName": "9954474 - Disclosure - Revenue (Tables)",
     "shortName": "Revenue (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.summitplc.com/role/OtherOperatingIncomenetTables",
     "longName": "9954475 - Disclosure - Other Operating Income, net (Tables)",
     "shortName": "Other Operating Income, net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "smmt:ScheduleOfOtherOperatingIncomeExpenseNetTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "smmt:ScheduleOfOtherOperatingIncomeExpenseNetTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.summitplc.com/role/OtherExpenseIncomenetTables",
     "longName": "9954476 - Disclosure - Other (Expense) Income, net (Tables)",
     "shortName": "Other (Expense) Income, net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.summitplc.com/role/IncomeTaxTables",
     "longName": "9954477 - Disclosure - Income Tax (Tables)",
     "shortName": "Income Tax (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.summitplc.com/role/NetLossperShareTables",
     "longName": "9954478 - Disclosure - Net Loss per Share (Tables)",
     "shortName": "Net Loss per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.summitplc.com/role/GoodwillandIntangibleAssetsTables",
     "longName": "9954479 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsTables",
     "longName": "9954480 - Disclosure - Fair Value Measurements and Short-Term Investments (Tables)",
     "shortName": "Fair Value Measurements and Short-Term Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.summitplc.com/role/PropertyandEquipmentTables",
     "longName": "9954481 - Disclosure - Property and Equipment (Tables)",
     "shortName": "Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R43": {
     "role": "http://www.summitplc.com/role/LeasesTables",
     "longName": "9954482 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesTables",
     "longName": "9954483 - Disclosure - Promissory Notes Payable to Related Parties (Tables)",
     "shortName": "Promissory Notes Payable to Related Parties (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.summitplc.com/role/StockholdersEquityTables",
     "longName": "9954484 - Disclosure - Stockholders' Equity (Tables)",
     "shortName": "Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.summitplc.com/role/StockBasedCompensationTables",
     "longName": "9954485 - Disclosure - Stock Based Compensation (Tables)",
     "shortName": "Stock Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
     "longName": "9954486 - Disclosure - Nature of Business and Operations and Recent Events (Details)",
     "shortName": "Nature of Business and Operations and Recent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-38",
      "name": "smmt:CommonStockSharesAuthorizedIncreaseDecrease",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R48": {
     "role": "http://www.summitplc.com/role/LiquidityandCapitalResourcesDetails",
     "longName": "9954487 - Disclosure - Liquidity and Capital Resources (Details)",
     "shortName": "Liquidity and Capital Resources (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "longName": "9954488 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-62",
      "name": "us-gaap:RestrictedCashCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.summitplc.com/role/AkesoLicenseandCollaborationAgreementDetails",
     "longName": "9954489 - Disclosure - Akeso License and Collaboration Agreement (Details)",
     "shortName": "Akeso License and Collaboration Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "smmt:InProcessResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-65",
      "name": "smmt:CollaborativeArrangementRightsAndObligationsUpfrontPayment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.summitplc.com/role/SegmentReportingNarrativeDetails",
     "longName": "9954490 - Disclosure - Segment Reporting - Narrative (Details)",
     "shortName": "Segment Reporting - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.summitplc.com/role/SegmentReportingLonglivedassetsbygeographyDetails",
     "longName": "9954491 - Disclosure - Segment Reporting - Long-lived assets by geography (Details)",
     "shortName": "Segment Reporting - Long-lived assets by geography (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:NoncurrentAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:NoncurrentAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.summitplc.com/role/RevenueNarrativeDetails",
     "longName": "9954492 - Disclosure - Revenue - Narrative (Details)",
     "shortName": "Revenue - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R54": {
     "role": "http://www.summitplc.com/role/RevenueDeferredrevenueandotherincomeDetails",
     "longName": "9954493 - Disclosure - Revenue - Deferred revenue and other income (Details)",
     "shortName": "Revenue - Deferred revenue and other income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.summitplc.com/role/OtherOperatingIncomenetSummarybycategoryDetails",
     "longName": "9954494 - Disclosure - Other Operating Income, net - Summary by category (Details)",
     "shortName": "Other Operating Income, net - Summary by category (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "smmt:ResearchAndDevelopmentTaxCredit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "smmt:ScheduleOfOtherOperatingIncomeExpenseNetTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "smmt:OtherOperatingIncomeOther",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "smmt:ScheduleOfOtherOperatingIncomeExpenseNetTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.summitplc.com/role/OtherOperatingIncomenetNarrativeDetails",
     "longName": "9954495 - Disclosure - Other Operating Income, net - Narrative (Details)",
     "shortName": "Other Operating Income, net - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "smmt:ResearchAndDevelopmentTaxCreditReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-77",
      "name": "smmt:GrantFundingArrangementMaximumFundingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.summitplc.com/role/OtherExpenseIncomenetComponentsDetails",
     "longName": "9954496 - Disclosure - Other (Expense) Income, net - Components (Details)",
     "shortName": "Other (Expense) Income, net - Components (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentIncomeNonoperating",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.summitplc.com/role/IncomeTaxComponentsoflossbeforeincometaxesDetails",
     "longName": "9954497 - Disclosure - Income Tax - Components of loss before income taxes (Details)",
     "shortName": "Income Tax - Components of loss before income taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.summitplc.com/role/IncomeTaxNarrativeDetails",
     "longName": "9954498 - Disclosure - Income Tax - Narrative (Details)",
     "shortName": "Income Tax - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails",
     "longName": "9954499 - Disclosure - Income Tax - Major components of deferred tax assets and liabilities (Details)",
     "shortName": "Income Tax - Major components of deferred tax assets and liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.summitplc.com/role/IncomeTaxValuationAllowanceDetails",
     "longName": "9954500 - Disclosure - Income Tax - Valuation Allowance (Details)",
     "shortName": "Income Tax - Valuation Allowance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails",
     "longName": "9954501 - Disclosure - Income Tax - Reconciliation of the effective income tax rate to statutory rate (Details)",
     "shortName": "Income Tax - Reconciliation of the effective income tax rate to statutory rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.summitplc.com/role/IncomeTaxReconciliationofunrecognizedtaxbenefitsDetails",
     "longName": "9954502 - Disclosure - Income Tax - Reconciliation of unrecognized tax benefits (Details)",
     "shortName": "Income Tax - Reconciliation of unrecognized tax benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.summitplc.com/role/NetLossperShareComputationofnetlosspershareDetails",
     "longName": "9954503 - Disclosure - Net Loss per Share - Computation of net loss per share (Details)",
     "shortName": "Net Loss per Share - Computation of net loss per share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R65": {
     "role": "http://www.summitplc.com/role/NetLossperShareNarrativeDetails",
     "longName": "9954504 - Disclosure - Net Loss per Share - Narrative (Details)",
     "shortName": "Net Loss per Share - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-86",
      "name": "us-gaap:SharePrice",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-86",
      "name": "us-gaap:SharePrice",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.summitplc.com/role/NetLossperSharePotentiallydilutivesecuritiesexcludedfromthecomputationoflosspershareDetails",
     "longName": "9954505 - Disclosure - Net Loss per Share - Potentially dilutive securities excluded from the computation of loss per share (Details)",
     "shortName": "Net Loss per Share - Potentially dilutive securities excluded from the computation of loss per share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.summitplc.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
     "longName": "9954506 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)",
     "shortName": "Goodwill and Intangible Assets - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-93",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "unitRef": "gbp",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-93",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "unitRef": "gbp",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails",
     "longName": "9954507 - Disclosure - Goodwill and Intangible Assets - Schedule of acquired intangible assets (Details)",
     "shortName": "Goodwill and Intangible Assets - Schedule of acquired intangible assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
     "longName": "9954508 - Disclosure - Fair Value Measurements and Short-Term Investments - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "shortName": "Fair Value Measurements and Short-Term Investments - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails",
     "longName": "9954509 - Disclosure - Fair Value Measurements and Short-Term Investments - Narrative (Details)",
     "shortName": "Fair Value Measurements and Short-Term Investments - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:Cash",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:Cash",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsShortterminvestmentswithcontractualmaturityoflessthanonyearDetails",
     "longName": "9954510 - Disclosure - Fair Value Measurements and Short-Term Investments - Short-term investments with contractual maturity of less than on year (Details)",
     "shortName": "Fair Value Measurements and Short-Term Investments - Short-term investments with contractual maturity of less than on year (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails",
     "longName": "9954511 - Disclosure - Property and Equipment - Components of property and equipment (Details)",
     "shortName": "Property and Equipment - Components of property and equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.summitplc.com/role/PropertyandEquipmentNarrativeDetails",
     "longName": "9954512 - Disclosure - Property and Equipment - Narrative (Details)",
     "shortName": "Property and Equipment - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R74": {
     "role": "http://www.summitplc.com/role/ResearchandDevelopmentPrepaidExpensesandAccruedLiabilitiesDetails",
     "longName": "9954513 - Disclosure - Research and Development Prepaid Expenses and Accrued Liabilities (Details)",
     "shortName": "Research and Development Prepaid Expenses and Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "smmt:ResearchAndDevelopmentPrepaidExpensesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "smmt:ResearchAndDevelopmentPrepaidExpensesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.summitplc.com/role/LeasesNarrativeDetails",
     "longName": "9954514 - Disclosure - Leases - Narrative (Details)",
     "shortName": "Leases - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.summitplc.com/role/LeasesLeaseexpenseDetails",
     "longName": "9954515 - Disclosure - Leases - Lease expense (Details)",
     "shortName": "Leases - Lease expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails",
     "longName": "9954516 - Disclosure - Leases - Future lease payments (Details)",
     "shortName": "Leases - Future lease payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesSummaryofrelatedpartydebtDetails",
     "longName": "9954517 - Disclosure - Promissory Notes Payable to Related Parties - Summary of related party debt (Details)",
     "shortName": "Promissory Notes Payable to Related Parties - Summary of related party debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:NotesPayableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-139",
      "name": "smmt:NotesPayableGrossCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
     "longName": "9954518 - Disclosure - Promissory Notes Payable to Related Parties - Narrative (Details)",
     "shortName": "Promissory Notes Payable to Related Parties - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProceedsFromRelatedPartyDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-143",
      "name": "smmt:PaymentOfAccruedInterestToRelatedParties",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.summitplc.com/role/OtherNonCurrentLiabilitiesDetails",
     "longName": "9954519 - Disclosure - Other Non-Current Liabilities (Details)",
     "shortName": "Other Non-Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "smmt:BusinessCombinationAssumedContingentLiabilityNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "smmt:BusinessCombinationAssumedContingentLiabilityNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.summitplc.com/role/StockholdersEquityNarrativeDetails",
     "longName": "9954520 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-166",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.summitplc.com/role/StockholdersEquityWarrantactivityDetails",
     "longName": "9954521 - Disclosure - Stockholders' Equity - Warrant activity (Details)",
     "shortName": "Stockholders' Equity - Warrant activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "smmt:ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails",
     "longName": "9954522 - Disclosure - Stock Based Compensation - Narrative (Details)",
     "shortName": "Stock Based Compensation - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-38",
      "name": "smmt:CommonStockSharesAuthorizedIncreaseDecrease",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.summitplc.com/role/StockBasedCompensationWeightedaverageassumptionsusedforstockoptionawardsDetails",
     "longName": "9954523 - Disclosure - Stock Based Compensation - Weighted-average assumptions used for stock option awards (Details)",
     "shortName": "Stock Based Compensation - Weighted-average assumptions used for stock option awards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-188",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-188",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails",
     "longName": "9954524 - Disclosure - Stock Based Compensation - Stock option activity (Details)",
     "shortName": "Stock Based Compensation - Stock option activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c-190",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-187",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.summitplc.com/role/StockBasedCompensationSummaryofstockbasedcompensationexpenseDetails",
     "longName": "9954525 - Disclosure - Stock-Based Compensation - Summary of stock-based compensation expense (Details)",
     "shortName": "Stock-Based Compensation - Summary of stock-based compensation expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.summitplc.com/role/CommitmentsandContingenciesDetails",
     "longName": "9954526 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PurchaseObligation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PurchaseObligation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
     "longName": "9954527 - Disclosure - Related Party Transactions (Details)",
     "shortName": "Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProceedsFromRelatedPartyDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-205",
      "name": "smmt:RelatedPartyTransactionSubleaseExtensionTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "smmt-20231231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "smmt_A2020StockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "A2020StockIncentivePlanMember",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Plan",
        "label": "2020 Stock Incentive Plan [Member]",
        "documentation": "2020 Stock Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingChangesAndErrorCorrectionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Changes and Error Corrections [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/OtherNonCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Non-Current Liabilities",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Noncurrent [Text Block]",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as noncurrent at the end of the reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r760"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r263"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Amortization of discount on short-term investments",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "smmt_AccruedResearchAndDevelopmentCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "AccruedResearchAndDevelopmentCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/ResearchandDevelopmentPrepaidExpensesandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued research and development expenditure",
        "label": "Accrued Research And Development, Current",
        "documentation": "Accrued Research And Development, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r167",
      "r604"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r98",
      "r171",
      "r600",
      "r622",
      "r625"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r13",
      "r35",
      "r472",
      "r475",
      "r529",
      "r618",
      "r619",
      "r799",
      "r800",
      "r801",
      "r809",
      "r810",
      "r811"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r760",
      "r901"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r426",
      "r427",
      "r634",
      "r809",
      "r810",
      "r811",
      "r874",
      "r903"
     ]
    },
    "smmt_AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Imputed interest expense on promissory note payable to a related party",
        "label": "Adjustments to Additional Paid in Capital, Imputed Interest Expense, Related Party",
        "documentation": "Adjustments to Additional Paid in Capital, Imputed Interest Expense, Related Party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r69",
      "r388"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering cots",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r125"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_AffiliatedEntityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "AffiliatedEntityMember",
     "presentation": [
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Affiliated entity",
        "label": "Affiliated Entity [Member]"
       }
      }
     },
     "auth_ref": [
      "r670",
      "r726",
      "r766",
      "r837",
      "r883",
      "r884",
      "r886"
     ]
    },
    "smmt_AkesoLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "AkesoLicenseAgreementMember",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Akeso License Agreement",
        "label": "Akeso License Agreement [Member]",
        "documentation": "Akeso License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_AkesoSupplyAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "AkesoSupplyAgreementMember",
     "presentation": [
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Akeso Supply Agreement",
        "label": "Akeso Supply Agreement [Member]",
        "documentation": "Akeso Supply Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationSummaryofstockbasedcompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r420",
      "r432"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.summitplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "presentation": [
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized imputed interest",
        "label": "Amortization of Debt Discount (Premium)",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r77",
      "r106",
      "r342"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangible assets",
        "verboseLabel": "Amortization expense",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r55",
      "r58"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.summitplc.com/role/NetLossperSharePotentiallydilutivesecuritiesexcludedfromthecomputationoflosspershareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potentially dilutive securities excluded from the computation of diluted loss per share (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.summitplc.com/role/NetLossperSharePotentiallydilutivesecuritiesexcludedfromthecomputationoflosspershareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.summitplc.com/role/NetLossperSharePotentiallydilutivesecuritiesexcludedfromthecomputationoflosspershareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.summitplc.com/role/NetLossperSharePotentiallydilutivesecuritiesexcludedfromthecomputationoflosspershareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "smmt_AreaOfPremisesSubleased": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "AreaOfPremisesSubleased",
     "presentation": [
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Area of premises subleased",
        "label": "Area Of Premises Subleased",
        "documentation": "Area Of Premises Subleased"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.summitplc.com/role/AkesoLicenseandCollaborationAgreementDetails",
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r170",
      "r198",
      "r242",
      "r248",
      "r253",
      "r294",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r467",
      "r469",
      "r491",
      "r595",
      "r663",
      "r760",
      "r773",
      "r831",
      "r832",
      "r887"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r174",
      "r198",
      "r294",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r467",
      "r469",
      "r491",
      "r760",
      "r831",
      "r832",
      "r887"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current assets:",
        "label": "Assets, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_AssumedContingentLiabilitiesPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "AssumedContingentLiabilitiesPolicyPolicyTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assumed Contingent Liabilities",
        "label": "Assumed Contingent Liabilities, Policy [Policy Text Block]",
        "documentation": "Assumed Contingent Liabilities, Policy"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.summitplc.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r777",
      "r778",
      "r779"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.summitplc.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r777",
      "r778",
      "r779"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.summitplc.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r777",
      "r778",
      "r779"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsShortterminvestmentswithcontractualmaturityoflessthanonyearDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r268"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsShortterminvestmentswithcontractualmaturityoflessthanonyearDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gross Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails",
      "http://www.summitplc.com/role/StockBasedCompensationSummaryofstockbasedcompensationexpenseDetails",
      "http://www.summitplc.com/role/StockBasedCompensationWeightedaverageassumptionsusedforstockoptionawardsDetails",
      "http://www.summitplc.com/role/StockholdersEquityNarrativeDetails",
      "http://www.summitplc.com/role/StockholdersEquityWarrantactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r392",
      "r393",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419"
     ]
    },
    "us-gaap_BasisOfAccounting": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccounting",
     "presentation": [
      "http://www.summitplc.com/role/BasisofPresentationUseofEstimatesandRisksandUncertainties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation, Use of Estimates, and Risks and Uncertainties",
        "label": "Basis of Accounting [Text Block]",
        "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "smmt_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "BiomedicalAdvancedResearchAndDevelopmentAuthorityMember",
     "presentation": [
      "http://www.summitplc.com/role/OtherOperatingIncomenetNarrativeDetails",
      "http://www.summitplc.com/role/OtherOperatingIncomenetSummarybycategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BARDA",
        "label": "Biomedical Advanced Research And Development Authority [Member]",
        "documentation": "Biomedical Advanced Research And Development Authority"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_BusinessCombinationAssumedContingentLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "BusinessCombinationAssumedContingentLiabilityMeasurementInput",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assumed contingent liability, measurement input",
        "label": "Business Combination, Assumed Contingent Liability, Measurement Input",
        "documentation": "Business Combination, Assumed Contingent Liability, Measurement Input"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_BusinessCombinationAssumedContingentLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "BusinessCombinationAssumedContingentLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/OtherNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assumed contingent liabilities, non-current",
        "label": "Business Combination, Assumed Contingent Liability, Noncurrent",
        "documentation": "Business Combination, Assumed Contingent Liability, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.summitplc.com/role/OtherNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gain on remeasurement of liabilities",
        "terseLabel": "Remeasurement gains (losses)",
        "label": "Business Combination, Assumed Contingent Liability, Remeasurement Gain (Loss)",
        "documentation": "Business Combination, Assumed Contingent Liability, Remeasurement Gain (Loss)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsPolicy",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combinations",
        "label": "Business Combinations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "smmt_CambridgeUKLaboratoryAndOfficeSpaceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "CambridgeUKLaboratoryAndOfficeSpaceMember",
     "presentation": [
      "http://www.summitplc.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cambridge UK, Laboratory and Office Space",
        "label": "Cambridge UK, Laboratory And Office Space [Member]",
        "documentation": "Cambridge UK, Laboratory And Office Space"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r597",
      "r635",
      "r658",
      "r760",
      "r773",
      "r796"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r165",
      "r732"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Axis]",
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Cash",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r132"
     ]
    },
    "us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.summitplc.com/role/LiquidityandCapitalResourcesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents and short-term investments",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r111",
      "r195"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "(Decrease) Increase in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r111"
     ]
    },
    "smmt_CashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "CashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash Equivalents, Fair Value Disclosure",
        "documentation": "Cash Equivalents, Fair Value Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_CashPaymentForCollaborativeArrangementUpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "CashPaymentForCollaborativeArrangementUpfrontPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/AkesoLicenseandCollaborationAgreementDetails",
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash payment for collaborative arrangement, upfront payment",
        "label": "Cash payment For Collaborative Arrangement, Upfront Payment",
        "documentation": "Cash payment For Collaborative Arrangement, Upfront Payment"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_ChangeInContractWithCustomerAssetAndLiabilityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "ChangeInContractWithCustomerAssetAndLiabilityRollForward",
     "presentation": [
      "http://www.summitplc.com/role/RevenueDeferredrevenueandotherincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Contract with Customer, Asset and Liability [Roll Forward]",
        "label": "Change in Contract with Customer, Asset and Liability [Roll Forward]",
        "documentation": "Change in Contract with Customer, Asset and Liability"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chief Executive Officer and Chief Executive Officer and President",
        "label": "Chief Executive Officer And Chief Executive Officer And President [Member]",
        "documentation": "Chief Executive Officer And Chief Executive Officer And President"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_ChiefExecutiveOfficerAndPresidentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "ChiefExecutiveOfficerAndPresidentMember",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chief Executive Officer and President",
        "label": "Chief Executive Officer And President [Member]",
        "documentation": "Chief Executive Officer And President"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chief Executive Officer",
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "srt_ChiefOperatingOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ChiefOperatingOfficerMember",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chief Operations Officer",
        "label": "Chief Operating Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r814",
      "r885"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.summitplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://www.summitplc.com/role/StockholdersEquityWarrantactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value",
        "label": "Class Of Warrant Or Right, Aggregate Intrinsic Value, Outstanding",
        "documentation": "Class Of Warrant Or Right, Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.summitplc.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price of warrants (in dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "smmt_ClassOfWarrantOrRightExercisesInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "ClassOfWarrantOrRightExercisesInPeriod",
     "presentation": [
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/StockholdersEquityWarrantactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Exercised (in shares)",
        "terseLabel": "Exercised (in shares)",
        "label": "Class Of Warrant Or Right, Exercises In Period",
        "documentation": "Class Of Warrant Or Right, Exercises In Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://www.summitplc.com/role/StockholdersEquityWarrantactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Line Items]",
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "smmt_ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage",
     "presentation": [
      "http://www.summitplc.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum volume weighted average common stock price to warrant exercise price, premium, percentage",
        "label": "Class Of Warrant Or Right, Minimum Ten Day Volume Weighted Average Common Stock Price to Warrant Exercise Price, Premium, Percentage",
        "documentation": "Class Of Warrant Or Right, Minimum Ten Day Volume Weighted Average Common Stock Price to Warrant Exercise Price, Premium, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.summitplc.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of common stock shares into which each warrant converts (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.summitplc.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of common stock shares into which warrants may be converted (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.summitplc.com/role/StockholdersEquityNarrativeDetails",
      "http://www.summitplc.com/role/StockholdersEquityWarrantactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants outstanding (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "smmt_ClassOfWarrantOrRightOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "ClassOfWarrantOrRightOutstandingRollForward",
     "presentation": [
      "http://www.summitplc.com/role/StockholdersEquityWarrantactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of share warrants",
        "label": "Class Of Warrant Or Right, Outstanding [Roll Forward]",
        "documentation": "Class Of Warrant Or Right, Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "ClassOfWarrantOrRightOutstandingWeightedAverageExercisePriceRollForward",
     "presentation": [
      "http://www.summitplc.com/role/StockholdersEquityWarrantactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price",
        "label": "Class of Warrant Or Right, Outstanding, Weighted Average Exercise Price [Roll Forward]",
        "documentation": "Class of Warrant Or Right, Outstanding, Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.summitplc.com/role/StockholdersEquityWarrantactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term",
        "label": "Class Of Warrant Or Right, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Class Of Warrant Or Right, Outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_ClassOfWarrantOrRightQuarterlyVestingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "ClassOfWarrantOrRightQuarterlyVestingPeriod",
     "presentation": [
      "http://www.summitplc.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants quarterly vesting period",
        "label": "Class of Warrant or Right, Quarterly Vesting Period",
        "documentation": "Class of Warrant or Right, Quarterly Vesting Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://www.summitplc.com/role/StockholdersEquityWarrantactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Table]",
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "smmt_ClassOfWarrantOrRightWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePrice",
     "presentation": [
      "http://www.summitplc.com/role/StockholdersEquityWarrantactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning balance (in dollars per share)",
        "periodEndLabel": "Outstanding, ending balance (in dollars per share)",
        "label": "Class Of Warrant Or Right, Weighted Average Exercise Price",
        "documentation": "Class Of Warrant Or Right, Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod",
     "presentation": [
      "http://www.summitplc.com/role/StockholdersEquityWarrantactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Class Of Warrant Or Right, Weighted Average Exercise Price, Exercises In Period",
        "documentation": "Class Of Warrant Or Right, Weighted Average Exercise Price, Exercises In Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/AkesoLicenseandCollaborationAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Akeso License and Collaboration Agreement",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r146",
      "r159"
     ]
    },
    "smmt_CollaborativeArrangementRightsAndObligationsDirectTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "CollaborativeArrangementRightsAndObligationsDirectTransactionCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.summitplc.com/role/AkesoLicenseandCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, direct transaction costs",
        "label": "Collaborative Arrangement, Rights And Obligations, Direct Transaction Costs",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Direct Transaction Costs"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/AkesoLicenseandCollaborationAgreementDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/AkesoLicenseandCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Collaborative arrangement, additional potential milestone payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Milestone Payments",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_CollaborativeArrangementRightsAndObligationsPotentialCommercialMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "CollaborativeArrangementRightsAndObligationsPotentialCommercialMilestonePayments",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/AkesoLicenseandCollaborationAgreementDetails": {
       "parentTag": "smmt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/AkesoLicenseandCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, potential commercial milestone payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Potential Commercial Milestone Payments",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Potential Commercial Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_CollaborativeArrangementRightsAndObligationsPotentialRegulatoryMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "CollaborativeArrangementRightsAndObligationsPotentialRegulatoryMilestonePayments",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/AkesoLicenseandCollaborationAgreementDetails": {
       "parentTag": "smmt_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/AkesoLicenseandCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, potential regulatory milestone payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Potential Regulatory Milestone Payments",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Potential Regulatory Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_CollaborativeArrangementRightsAndObligationsUpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "CollaborativeArrangementRightsAndObligationsUpfrontPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/AkesoLicenseandCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, upfront payment",
        "label": "Collaborative Arrangement, Rights And Obligations, Upfront Payment",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Upfront Payment"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentPaidInShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "CollaborativeArrangementRightsAndObligationsUpfrontPaymentPaidInShares",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/AkesoLicenseandCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, upfront payment, paid in shares",
        "label": "Collaborative Arrangement, Rights And Obligations, Upfront Payment, Paid In Shares",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Upfront Payment, Paid In Shares"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_CollaborativeArrangementRightsAndObligationsUpfrontPaymentSharesOfCommonStockIssuedInLieuOfCash": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "CollaborativeArrangementRightsAndObligationsUpfrontPaymentSharesOfCommonStockIssuedInLieuOfCash",
     "presentation": [
      "http://www.summitplc.com/role/AkesoLicenseandCollaborationAgreementDetails",
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, common stock issued in lieu of cash upfront payment (in shares)",
        "label": "Collaborative Arrangement, Rights And Obligations, Upfront Payment, Shares Of Common Stock Issued In Lieu Of Cash",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Upfront Payment, Shares Of Common Stock Issued In Lieu Of Cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "presentation": [
      "http://www.summitplc.com/role/AkesoLicenseandCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, transaction with party to collaborative arrangement",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement."
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentOneMember",
     "presentation": [
      "http://www.summitplc.com/role/AkesoLicenseandCollaborationAgreementDetails",
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, transaction with party to collaborative arrangement, upfront payment one",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement, Upfront Payment One [Member]",
        "documentation": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement, Upfront Payment One"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentTwoMember",
     "presentation": [
      "http://www.summitplc.com/role/AkesoLicenseandCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, transaction with party to collaborative arrangement, upfront payment two",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement, Upfront Payment Two [Member]",
        "documentation": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement, Upfront Payment Two"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.summitplc.com/role/AkesoLicenseandCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "smmt_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember",
     "presentation": [
      "http://www.summitplc.com/role/OtherOperatingIncomenetNarrativeDetails",
      "http://www.summitplc.com/role/OtherOperatingIncomenetSummarybycategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CARB-X",
        "label": "Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator Program [Member]",
        "documentation": "Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator Program"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 22)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r84",
      "r596",
      "r649"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r323",
      "r324",
      "r716",
      "r828"
     ]
    },
    "smmt_CommonStockAdditionalCapitalSharesAllowableForForFutureIssuanceUponOptionExpiration": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "CommonStockAdditionalCapitalSharesAllowableForForFutureIssuanceUponOptionExpiration",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares that can be added to the plan upon option expiration (in shares)",
        "label": "Common Stock, Additional Capital Shares Allowable For For Future Issuance Upon Option Expiration",
        "documentation": "Common Stock, Additional Capital Shares Allowable For For Future Issuance Upon Option Expiration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares initially reserve for future issuance (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r763",
      "r764",
      "r765",
      "r767",
      "r768",
      "r769",
      "r770",
      "r809",
      "r810",
      "r874",
      "r900",
      "r903"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.summitplc.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r650"
     ]
    },
    "smmt_CommonStockSharesAuthorizedIncreaseDecrease": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "CommonStockSharesAuthorizedIncreaseDecrease",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.summitplc.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized, Increase (Decrease)",
        "documentation": "Common Stock, Shares Authorized, Increase (Decrease)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r92",
      "r650",
      "r669",
      "r903",
      "r904"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.01 par value: 1,000,000,000 shares authorized; 701,660,053 and 211,091,425 shares issued and outstanding at December 31, 2023 and 2022, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r599",
      "r760"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Components of Deferred Tax Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Components of Deferred Tax Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r180",
      "r182",
      "r187",
      "r591",
      "r609"
     ]
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software",
        "label": "Computer Software, Intangible Asset [Member]",
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks."
       }
      }
     },
     "auth_ref": [
      "r731",
      "r823",
      "r824"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk and of Significant Supplier",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r148"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r737"
     ]
    },
    "smmt_ConsultingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "ConsultingAgreementMember",
     "presentation": [
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consulting Agreement",
        "label": "Consulting Agreement [Member]",
        "documentation": "Consulting Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/RevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of deferred revenue and other income",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability."
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/RevenueDeferredrevenueandotherincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning deferred revenue and other income",
        "periodEndLabel": "Ending deferred revenue and other income",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r364",
      "r375"
     ]
    },
    "smmt_ContractWithCustomerLiabilityAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "ContractWithCustomerLiabilityAdditions",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/RevenueDeferredrevenueandotherincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Contract with Customer, Liability, Additions",
        "documentation": "Contract with Customer, Liability, Additions"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_ContractWithCustomerLiabilityForeignCurrencyTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "ContractWithCustomerLiabilityForeignCurrencyTranslation",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/RevenueDeferredrevenueandotherincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency adjustment",
        "label": "Contract with Customer, Liability, Foreign Currency Translation",
        "documentation": "Contract with Customer, Liability, Foreign Currency Translation"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/RevenueDeferredrevenueandotherincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Amount of deferred revenue and other income recognized in the statement of operations",
        "label": "Contract with Customer, Liability, Revenue Recognized, Including Opening Balance",
        "documentation": "Contract with Customer, Liability, Revenue Recognized, Including Opening Balance"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.summitplc.com/role/OtherOperatingIncomenetNarrativeDetails",
      "http://www.summitplc.com/role/OtherOperatingIncomenetSummarybycategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r203",
      "r204",
      "r338",
      "r349",
      "r537",
      "r734",
      "r736"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "smmt_CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/OtherExpenseIncomenetComponentsDetails": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.summitplc.com/role/OtherExpenseIncomenetComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Reclassification of currency translation gain",
        "terseLabel": "Reclassification of cumulative currency translation gain",
        "label": "Cumulative Currency Translation Gains (Losses), Realized upon Sale or Liquidation, Reclassified From Other Comprehensive Income",
        "documentation": "Cumulative Currency Translation Gains (Losses), Realized upon Sale or Liquidation, Reclassified From Other Comprehensive Income"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current provision for federal income taxes",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r788",
      "r807",
      "r871"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.summitplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current provision for non-United States income taxes",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r788",
      "r807"
     ]
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current provision for state income taxes",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r788",
      "r807",
      "r871"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate margin",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective interest rate",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r78",
      "r344",
      "r511"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscountCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesSummaryofrelatedpartydebtDetails": {
       "parentTag": "us-gaap_NotesPayableCurrent",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesSummaryofrelatedpartydebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Debt discount",
        "label": "Debt Instrument, Unamortized Discount, Current",
        "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r80"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscountNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesSummaryofrelatedpartydebtDetails": {
       "parentTag": "us-gaap_LongTermNotesPayable",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesSummaryofrelatedpartydebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Debt discount",
        "label": "Debt Instrument, Unamortized Discount, Noncurrent",
        "documentation": "Amount of debt discount to be amortized after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r80"
     ]
    },
    "smmt_DebtIssuanceCostsIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "DebtIssuanceCostsIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance costs in accrued expenses",
        "label": "Debt Issuance Costs Incurred But Not Yet Paid",
        "documentation": "Debt Issuance Costs Incurred But Not Yet Paid"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsShortterminvestmentswithcontractualmaturityoflessthanonyearDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Credit Loss",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Excluding Accrued Interest",
        "documentation": "Amount excluding accrued interest, of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r304"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsShortterminvestmentswithcontractualmaturityoflessthanonyearDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss",
        "documentation": "Amortized cost excluding accrued interest, before allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r304"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsShortterminvestmentswithcontractualmaturityoflessthanonyearDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term investments",
        "verboseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest",
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsShortterminvestmentswithcontractualmaturityoflessthanonyearDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-Sale [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275"
     ]
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred provision for federal income taxes",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r807",
      "r870",
      "r871"
     ]
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance costs",
        "label": "Debt Issuance Costs, Gross",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred provision for non-United States income taxes",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r807",
      "r870"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails": {
       "parentTag": "smmt_DeferredTaxAssetsLiabilities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r90",
      "r134",
      "r449"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred provision for state income taxes",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r807",
      "r870",
      "r871"
     ]
    },
    "smmt_DeferredTaxAssetsCapitalizedResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Section 174 Research and Development Capitalization",
        "label": "Deferred Tax Assets, Capitalized Research And Development",
        "documentation": "Deferred Tax Assets, Capitalized Research And Development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails": {
       "parentTag": "smmt_DeferredTaxAssetsLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "smmt_DeferredTaxAssetsLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "DeferredTaxAssetsLeasingArrangements",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Deferred Tax Assets, Leasing Arrangements",
        "documentation": "Deferred Tax Assets, Leasing Arrangements"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_DeferredTaxAssetsLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "DeferredTaxAssetsLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets before valuation allowance",
        "label": "Deferred Tax Assets (Liabilities)",
        "documentation": "Deferred Tax Assets (Liabilities)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax, net",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforward",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r869"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r869"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development credit carryforward",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73",
      "r869"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r869"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails",
      "http://www.summitplc.com/role/IncomeTaxValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Valuation allowance",
        "negatedPeriodStartLabel": "Valuation allowance as of beginning of year",
        "negatedPeriodEndLabel": "Valuation allowance as of end of year",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "smmt_DeferredTaxAssetsValuationAllowanceRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "DeferredTaxAssetsValuationAllowanceRollForward",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Tax Assets, Valuation Allowance [Roll Forward]",
        "label": "Deferred Tax Assets, Valuation Allowance [Roll Forward]",
        "documentation": "Deferred Tax Assets, Valuation Allowance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Right-of-use assets",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r869"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxMajorcomponentsofdeferredtaxassetsandliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other",
        "label": "Deferred Tax Liabilities, Other",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r869"
     ]
    },
    "smmt_DeferredTransactionCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "DeferredTransactionCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred transaction costs included in other non-current assets",
        "label": "Deferred Transaction Costs Incurred During Noncash Or Partial Noncash Transaction",
        "documentation": "Deferred Transaction Costs Incurred During Noncash Or Partial Noncash Transaction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.summitplc.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "verboseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r59"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r390",
      "r421",
      "r422",
      "r424",
      "r756"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_DiscuvaPlatformMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "DiscuvaPlatformMember",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discuva platform",
        "label": "Discuva Platform [Member]",
        "documentation": "Discuva Platform"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.summitplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r777",
      "r778",
      "r779"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.summitplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r777",
      "r778",
      "r779",
      "r781"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.summitplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.summitplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.summitplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.summitplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.summitplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Federal",
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "smmt_DugganFebruaryNoteAndZanganehNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "DugganFebruaryNoteAndZanganehNoteMember",
     "presentation": [
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Duggan February Note and Zanganeh Note",
        "label": "Duggan February Note And Zanganeh Note [Member]",
        "documentation": "Duggan February Note And Zanganeh Note"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_DugganFebruaryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "DugganFebruaryNoteMember",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Duggan February Note",
        "label": "Duggan February Note [Member]",
        "documentation": "Duggan February Note"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_DugganPromissoryNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "DugganPromissoryNotesMember",
     "presentation": [
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Duggan Promissory Notes",
        "label": "Duggan Promissory Notes [Member]",
        "documentation": "Duggan Promissory Notes"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_DugganSeptemberNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "DugganSeptemberNoteMember",
     "presentation": [
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Duggan September Note",
        "label": "Duggan September Note [Member]",
        "documentation": "Duggan September Note"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.summitplc.com/role/NetLossperShareComputationofnetlosspershareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in dollars per share)",
        "verboseLabel": "Basic net loss per share (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r226",
      "r228",
      "r230",
      "r231",
      "r232",
      "r236",
      "r482",
      "r483",
      "r592",
      "r610",
      "r739"
     ]
    },
    "smmt_EarningsPerShareBasicAndDilutedEPSAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "EarningsPerShareBasicAndDilutedEPSAbstract",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share:",
        "label": "Earnings Per Share, Basic and Diluted EPS [Abstract]",
        "documentation": "Earnings Per Share, Basic and Diluted EPS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.summitplc.com/role/NetLossperShareComputationofnetlosspershareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in dollars per share)",
        "verboseLabel": "Diluted net loss per share (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r228",
      "r230",
      "r231",
      "r232",
      "r236",
      "r482",
      "r483",
      "r592",
      "r610",
      "r739"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/NetLossperShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r233",
      "r234",
      "r235"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rates on cash and cash equivalents",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. federal income tax statutory rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r440",
      "r462"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r866",
      "r872"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of foreign operations taxed at various rates",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r866",
      "r872"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r866",
      "r872"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r784",
      "r866"
     ]
    },
    "smmt_EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent",
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxReconciliationoftheeffectiveincometaxratetostatutoryrateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Refundable research and development tax credit",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit Refundable, Research, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Tax Credit Refundable, Research, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationSummaryofstockbasedcompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense for options, period of recognition",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense for options",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.summitplc.com/role/NetLossperSharePotentiallydilutivesecuritiesexcludedfromthecomputationoflosspershareDetails",
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.summitplc.com/role/StockBasedCompensationSummaryofstockbasedcompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares expected to be purchased under employee stock purchase plan",
        "terseLabel": "ESPP",
        "netLabel": "Employee stock purchase plan",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.summitplc.com/role/NetLossperSharePotentiallydilutivesecuritiesexcludedfromthecomputationoflosspershareDetails",
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.summitplc.com/role/StockBasedCompensationWeightedaverageassumptionsusedforstockoptionawardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options to purchase common stock",
        "terseLabel": "Stock options",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "smmt_EmployeeStockOptionPerformanceAndMarketBasedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "EmployeeStockOptionPerformanceAndMarketBasedMember",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails",
      "http://www.summitplc.com/role/StockBasedCompensationSummaryofstockbasedcompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance and market-based stock options",
        "label": "Employee Stock Option, Performance And Market-Based [Member]",
        "documentation": "Employee Stock Option, Performance And Market-Based"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_EmployeeStockOptionTimeBasedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "EmployeeStockOptionTimeBasedMember",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails",
      "http://www.summitplc.com/role/StockBasedCompensationSummaryofstockbasedcompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Time-based stock options",
        "label": "Employee Stock Option, Time-Based [Member]",
        "documentation": "Employee Stock Option, Time-Based"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.summitplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.summitplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.summitplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.summitplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.summitplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.summitplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.summitplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.summitplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.summitplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.summitplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.summitplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.summitplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.summitplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.summitplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.summitplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.summitplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.summitplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.summitplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "presentation": [
      "http://www.summitplc.com/role/OtherOperatingIncomenetSummarybycategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from External Customer [Line Items]",
        "label": "Revenue from External Customer [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r160",
      "r184",
      "r185",
      "r186",
      "r206",
      "r207",
      "r208",
      "r212",
      "r220",
      "r222",
      "r237",
      "r295",
      "r298",
      "r362",
      "r425",
      "r426",
      "r427",
      "r455",
      "r456",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r477",
      "r481",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r529",
      "r618",
      "r619",
      "r620",
      "r634",
      "r696"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r488",
      "r490"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r488",
      "r490"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of assets and liabilities measured at fair value on a recurring basis",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r131"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r488",
      "r543",
      "r544",
      "r545",
      "r745",
      "r746",
      "r752",
      "r753",
      "r754"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r378",
      "r383",
      "r488",
      "r543",
      "r752",
      "r753",
      "r754"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r378",
      "r383",
      "r488",
      "r544",
      "r745",
      "r746",
      "r752",
      "r753",
      "r754"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r488",
      "r545",
      "r745",
      "r746",
      "r752",
      "r753",
      "r754"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r543",
      "r544",
      "r545",
      "r745",
      "r746",
      "r752",
      "r753",
      "r754"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r21"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsShortterminvestmentswithcontractualmaturityoflessthanonyearDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r305",
      "r306",
      "r307",
      "r343",
      "r359",
      "r478",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r608",
      "r743",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r815",
      "r816",
      "r817",
      "r818"
     ]
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements and Short-Term Investments",
        "label": "Financial Instruments Disclosure [Text Block]",
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures."
       }
      }
     },
     "auth_ref": []
    },
    "smmt_FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accumulated amortization and impairment charges",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization And Impairment",
        "documentation": "Finite-Lived Intangible Assets, Accumulated Amortization And Impairment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317",
      "r318",
      "r319",
      "r573",
      "r577"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r577"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r573"
     ]
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.K.",
        "label": "Foreign Tax Authority [Member]",
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/OtherExpenseIncomenetComponentsDetails": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/OtherExpenseIncomenetComponentsDetails",
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign currency transaction gains (losses)",
        "terseLabel": "Foreign currency gains (losses)",
        "label": "Gain (Loss), Foreign Currency Transaction, before Tax",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r498",
      "r500",
      "r501",
      "r693"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized foreign currency (gain) loss",
        "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax",
        "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r671",
      "r771",
      "r877",
      "r878",
      "r902"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Translation",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "smmt_FurnitureAndFixturesOfficeEquipmentAndSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "FurnitureAndFixturesOfficeEquipmentAndSoftwareMember",
     "presentation": [
      "http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails",
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures, office equipment and software",
        "label": "Furniture and Fixtures, Office Equipment and Software [Member]",
        "documentation": "Furniture and Fixtures, Office Equipment and Software"
       }
      }
     },
     "auth_ref": []
    },
    "country_GB": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "GB",
     "presentation": [
      "http://www.summitplc.com/role/SegmentReportingLonglivedassetsbygeographyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United Kingdom",
        "label": "UNITED KINGDOM"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnDispositionOfAssets1",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on disposal of assets",
        "label": "Gain (Loss) on Disposition of Assets",
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r674"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationSummaryofstockbasedcompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets",
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r311",
      "r590",
      "r744",
      "r760",
      "r821",
      "r822"
     ]
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAcquiredDuringPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognition of goodwill",
        "label": "Goodwill, Acquired During Period",
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r744"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r315",
      "r744"
     ]
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative goodwill impairment charges",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r314",
      "r744"
     ]
    },
    "smmt_GrantFundingArrangementCommittedFundingTotal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "GrantFundingArrangementCommittedFundingTotal",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/OtherOperatingIncomenetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total committed funding",
        "label": "Grant Funding Arrangement, Committed Funding, Total",
        "documentation": "Grant Funding Arrangement, Committed Funding, Total"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_GrantFundingArrangementIncomeEarned": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "GrantFundingArrangementIncomeEarned",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/OtherOperatingIncomenetSummarybycategoryDetails": {
       "parentTag": "us-gaap_OtherOperatingIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/OtherOperatingIncomenetNarrativeDetails",
      "http://www.summitplc.com/role/OtherOperatingIncomenetSummarybycategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Funding/Grant income",
        "label": "Grant Funding Arrangement, Income Earned",
        "documentation": "Grant Funding Arrangement, Income Earned"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_GrantFundingArrangementMaximumFundingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "GrantFundingArrangementMaximumFundingValue",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/OtherOperatingIncomenetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum funding value",
        "label": "Grant Funding Arrangement, Maximum Funding Value",
        "documentation": "Grant Funding Arrangement, Maximum Funding Value"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_GrantFundingArrangementMilestoneFundingIncrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "GrantFundingArrangementMilestoneFundingIncrease",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/OtherOperatingIncomenetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Funding increase based on achievement of future milestones",
        "label": "Grant Funding Arrangement, Milestone, Funding Increase",
        "documentation": "Grant Funding Arrangement, Milestone, Funding Increase"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.summitplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r777",
      "r778",
      "r779"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes impairment of finite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of intangible assets",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r19"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment charge",
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "auth_ref": [
      "r804",
      "r825"
     ]
    },
    "smmt_InProcessResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "InProcessResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/AkesoLicenseandCollaborationAgreementDetails",
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In-process research and development",
        "verboseLabel": "In-process research and development expense",
        "label": "In-Process Research And Development Expense",
        "documentation": "In-Process Research And Development Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired In-Process Research and Development",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxComponentsoflossbeforeincometaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxComponentsoflossbeforeincometaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r461"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.summitplc.com/role/IncomeTaxComponentsoflossbeforeincometaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.summitplc.com/role/IncomeTaxComponentsoflossbeforeincometaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income tax",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r100",
      "r139",
      "r242",
      "r247",
      "r252",
      "r255",
      "r593",
      "r606",
      "r741"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/IncomeTaxComponentsoflossbeforeincometaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxComponentsoflossbeforeincometaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r461"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationSummaryofstockbasedcompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r322",
      "r680"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationSummaryofstockbasedcompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r680"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Axis]",
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Domain]",
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTax"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r436",
      "r441",
      "r446",
      "r453",
      "r460",
      "r463",
      "r464",
      "r465",
      "r630"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r438",
      "r439",
      "r446",
      "r447",
      "r452",
      "r454",
      "r627"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for income taxes",
        "label": "Income Taxes Paid, Net",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue and other income",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r571",
      "r803"
     ]
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.summitplc.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "negatedTerseLabel": "Removal of lease liability",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r786",
      "r803"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other current and long-term assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expense",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "smmt_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Research and development tax credit receivable",
        "label": "Increase (Decrease) In Research And Development Tax Credit Receivable",
        "documentation": "Increase (Decrease) In Research And Development Tax Credit Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/OtherExpenseIncomenetComponentsDetails": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/OtherExpenseIncomenetComponentsDetails",
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest expense on promissory notes payable to related parties",
        "terseLabel": "Interest expense",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r341",
      "r345",
      "r747",
      "r748"
     ]
    },
    "smmt_InterestExpenseIncomeNoncash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "InterestExpenseIncomeNoncash",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash interest expense",
        "label": "Interest Expense (Income), Noncash",
        "documentation": "Interest Expense (Income), Noncash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest on related party promissory note",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r193",
      "r194"
     ]
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest payable",
        "label": "Interest Payable",
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r897"
     ]
    },
    "us-gaap_InvestmentIncomeNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeNonoperating",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/OtherExpenseIncomenetComponentsDetails": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/OtherExpenseIncomenetComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Nonoperating",
        "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "smmt_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails",
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory equipment",
        "label": "Laboratory Equipment [Member]",
        "documentation": "Laboratory Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://www.summitplc.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Contractual Term [Axis]",
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://www.summitplc.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Contractual Term [Domain]",
        "label": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/LeasesLeaseexpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/LeasesLeaseexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r759"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostAbstract",
     "presentation": [
      "http://www.summitplc.com/role/LeasesLeaseexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Cost:",
        "label": "Lease, Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of lease expense",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails",
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.summitplc.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.summitplc.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "smmt_LesseeOperatingLeaseAreaOfPremisesLeased": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "LesseeOperatingLeaseAreaOfPremisesLeased",
     "presentation": [
      "http://www.summitplc.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Area of premises leased",
        "label": "Lessee, Operating Lease, Area Of Premises Leased",
        "documentation": "Lessee, Operating Lease, Area Of Premises Leased"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of future lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails",
      "http://www.summitplc.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total lease payments",
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.summitplc.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r198",
      "r294",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r468",
      "r469",
      "r470",
      "r491",
      "r648",
      "r740",
      "r773",
      "r831",
      "r887",
      "r888"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r136",
      "r602",
      "r760",
      "r806",
      "r819",
      "r876"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r164",
      "r198",
      "r294",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r468",
      "r469",
      "r470",
      "r491",
      "r760",
      "r831",
      "r887",
      "r888"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current liabilities",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_LiquidityAndCapitalResourcesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "LiquidityAndCapitalResourcesTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/LiquidityandCapitalResources"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liquidity and Capital Resources",
        "label": "Liquidity and Capital Resources [Text Block]",
        "documentation": "Liquidity and Capital Resources"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.summitplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongLivedAssetsByGeographicAreasTableTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/SegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of long-lived assets by geography",
        "label": "Long-Lived Assets by Geographic Areas [Table Text Block]",
        "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future principal payments for 2024",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r205",
      "r340"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future principal payments for 2025",
        "label": "Long-Term Debt, Maturity, Year Two",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r205",
      "r340"
     ]
    },
    "us-gaap_LongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesSummaryofrelatedpartydebtDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets",
      "http://www.summitplc.com/role/LiquidityandCapitalResourcesDetails",
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesSummaryofrelatedpartydebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Promissory notes payable to related parties",
        "totalLabel": "Total promissory notes payable to related parties",
        "verboseLabel": "Notes payable classified as long-term",
        "label": "Notes Payable, Noncurrent",
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_LongTermNotesPayableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermNotesPayableAbstract",
     "presentation": [
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesSummaryofrelatedpartydebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current notes",
        "label": "Notes Payable, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_March2022NoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "March2022NoteMember",
     "presentation": [
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "March 2022 Note",
        "label": "March 2022 Note [Member]",
        "documentation": "March 2022 Note"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r328",
      "r385",
      "r570",
      "r617",
      "r640",
      "r641",
      "r704",
      "r706",
      "r708",
      "r709",
      "r711",
      "r727",
      "r728",
      "r742",
      "r749",
      "r755",
      "r762",
      "r833",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate",
        "label": "Measurement Input, Discount Rate [Member]",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Axis]",
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Domain]",
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "smmt_MenloParkCaliforniaExpirationMay2026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "MenloParkCaliforniaExpirationMay2026Member",
     "presentation": [
      "http://www.summitplc.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Menlo Park, California, Expiration May 2026",
        "label": "Menlo Park, California, Expiration May 2026 [Member]",
        "documentation": "Menlo Park, California, Expiration May 2026"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r328",
      "r385",
      "r570",
      "r617",
      "r640",
      "r641",
      "r704",
      "r706",
      "r708",
      "r709",
      "r711",
      "r727",
      "r728",
      "r742",
      "r749",
      "r755",
      "r762",
      "r833",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nature of Business and Operations and Recent Events",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r157"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows provided by financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows used in investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.summitplc.com/role/LiquidityandCapitalResourcesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "negatedLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r112",
      "r113"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows used in operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.summitplc.com/role/LiquidityandCapitalResourcesDetails",
      "http://www.summitplc.com/role/NetLossperShareComputationofnetlosspershareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "negatedLabel": "Net loss",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r113",
      "r140",
      "r162",
      "r179",
      "r181",
      "r186",
      "r198",
      "r211",
      "r215",
      "r216",
      "r217",
      "r218",
      "r221",
      "r222",
      "r229",
      "r242",
      "r247",
      "r252",
      "r255",
      "r294",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r483",
      "r491",
      "r607",
      "r672",
      "r694",
      "r695",
      "r741",
      "r771",
      "r831"
     ]
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/RecentlyIssuedorAdoptedAccountingPronouncements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Issued or Adopted Accounting Pronouncements",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r161",
      "r209",
      "r210",
      "r213",
      "r214",
      "r223",
      "r224",
      "r296",
      "r297",
      "r457",
      "r458",
      "r459",
      "r476",
      "r480",
      "r484",
      "r485",
      "r486",
      "r492",
      "r493",
      "r494",
      "r512",
      "r513",
      "r530",
      "r574",
      "r575",
      "r576",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Issued or Adopted Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.summitplc.com/role/SegmentReportingLonglivedassetsbygeographyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-lived assets",
        "label": "Long-Lived Assets",
        "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r260"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.summitplc.com/role/OtherExpenseIncomenetComponentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.summitplc.com/role/OtherExpenseIncomenetComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other expense, net",
        "totalLabel": "Other (expense) income",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "smmt_NotePurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "NotePurchaseAgreementMember",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Note Purchase Agreement",
        "label": "Note Purchase Agreement [Member]",
        "documentation": "Note Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Promissory note",
        "label": "Notes Payable",
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r135",
      "r898"
     ]
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesSummaryofrelatedpartydebtDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets",
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesSummaryofrelatedpartydebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Promissory note payable to related parties",
        "totalLabel": "Total promissory notes payable to related parties",
        "label": "Notes Payable, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_NotesPayableCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayableCurrentAbstract",
     "presentation": [
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesSummaryofrelatedpartydebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current notes",
        "label": "Notes Payable, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes Payable, Current, Related Party, Type [Extensible Enumeration]",
        "label": "Notes Payable, Current, Related Party, Type [Extensible Enumeration]",
        "documentation": "Indicates type of related party for notes payable classified as current."
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "smmt_NotesPayableGrossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "NotesPayableGrossCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesSummaryofrelatedpartydebtDetails": {
       "parentTag": "us-gaap_NotesPayableCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesSummaryofrelatedpartydebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal amounts",
        "label": "Notes Payable, Gross, Current",
        "documentation": "Notes Payable, Gross, Current"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_NotesPayableGrossNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "NotesPayableGrossNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesSummaryofrelatedpartydebtDetails": {
       "parentTag": "us-gaap_LongTermNotesPayable",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesSummaryofrelatedpartydebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal amounts",
        "label": "Notes Payable, Gross, Noncurrent",
        "documentation": "Notes Payable, Gross, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayableNoncurrentRelatedPartyTypeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayableNoncurrentRelatedPartyTypeExtensibleEnumeration",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes Payable, Noncurrent, Related Party, Type [Extensible Enumeration]",
        "label": "Notes Payable, Noncurrent, Related Party, Type [Extensible Enumeration]",
        "documentation": "Indicates type of related party for notes payable classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "smmt_NotesPayableRelatedPartiesMaximumTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "NotesPayableRelatedPartiesMaximumTerm",
     "presentation": [
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes payable, maximum term",
        "label": "Notes Payable, Related Parties, Maximum Term",
        "documentation": "Notes Payable, Related Parties, Maximum Term"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_NotesPayableRelatedPartiesNewIssuances": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "NotesPayableRelatedPartiesNewIssuances",
     "presentation": [
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New note issuances",
        "label": "Notes Payable, Related Parties, New Issuances",
        "documentation": "Notes Payable, Related Parties, New Issuances"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_NotesPayableRelatedPartiesPotentialPrepaymentMaximumAmountPercentageOfNetProceedsFromPublicOffering": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "NotesPayableRelatedPartiesPotentialPrepaymentMaximumAmountPercentageOfNetProceedsFromPublicOffering",
     "presentation": [
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public offering proceeds threshold percentage",
        "label": "Notes Payable, Related Parties, Potential Prepayment, Maximum Amount, Percentage Of Net Proceeds From Public Offering",
        "documentation": "Notes Payable, Related Parties, Potential Prepayment, Maximum Amount, Percentage Of Net Proceeds From Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_NotesPayableRelatedPartiesPotentialPrepaymentPeriodPostReceiptOfCashProceedsFromPublicOffering": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "NotesPayableRelatedPartiesPotentialPrepaymentPeriodPostReceiptOfCashProceedsFromPublicOffering",
     "presentation": [
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period from public offering",
        "label": "Notes Payable, Related Parties, Potential Prepayment, Period Post Receipt Of Cash Proceeds From Public Offering",
        "documentation": "Notes Payable, Related Parties, Potential Prepayment, Period Post Receipt Of Cash Proceeds From Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold",
     "crdr": "debit",
     "presentation": [
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes payable, maturity triggering event, public offering proceeds threshold",
        "label": "Notes Payable, Related Parties, Potential Prepayment, Triggering Event, Public Offering Net Proceeds Threshold",
        "documentation": "Notes Payable, Related Parties, Potential Prepayment, Triggering Event, Public Offering Net Proceeds Threshold"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominator": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominator",
     "presentation": [
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid interest, conversion amount (in dollars per share)",
        "label": "Notes Payable, Related Party, Prepaid Interest, Equity Interests Issuable Calculation, Denominator",
        "documentation": "Notes Payable, Related Party, Prepaid Interest, Equity Interests Issuable Calculation, Denominator"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominatorBaseAmountAddedToClosingBidPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominatorBaseAmountAddedToClosingBidPrice",
     "presentation": [
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid interest, conversion amount base (in dollars per share)",
        "label": "Notes Payable, Related Party, Prepaid Interest, Equity Interests Issuable Calculation, Denominator, Base Amount Added To Closing Bid Price",
        "documentation": "Notes Payable, Related Party, Prepaid Interest, Equity Interests Issuable Calculation, Denominator, Base Amount Added To Closing Bid Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfCountriesInWhichEntityOperates": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfCountriesInWhichEntityOperates",
     "presentation": [
      "http://www.summitplc.com/role/SegmentReportingNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of geographic regions in which the Company operates",
        "label": "Number of Countries in which Entity Operates",
        "documentation": "The number of countries in which the entity operates as of balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.summitplc.com/role/SegmentReportingNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r247",
      "r252",
      "r255",
      "r741"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/LeasesLeaseexpenseDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/LeasesLeaseexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed lease costs",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r521",
      "r759"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityAbstract",
     "presentation": [
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total operating lease liabilities balance sheet presentation:",
        "label": "Operating Lease, Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets",
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "verboseLabel": "Current lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets",
      "http://www.summitplc.com/role/LeasesFutureleasepaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities, net of current portion",
        "verboseLabel": "Non-current lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash payments related to lease liabilities",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r517",
      "r524"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets",
      "http://www.summitplc.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of operating right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "smmt_OperatingLeaseRightOfUseAssetDisposals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "OperatingLeaseRightOfUseAssetDisposals",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal of right-of-use asset",
        "label": "Operating Lease, Right-of-Use Asset, Disposals",
        "documentation": "Operating Lease, Right-of-Use Asset, Disposals"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.summitplc.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r527",
      "r759"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.summitplc.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r526",
      "r759"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Line Items]",
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "smmt_OptionOverNonFinancialAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "OptionOverNonFinancialAssetsMember",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option over non-financial asset",
        "label": "Option Over Non-Financial Assets [Member]",
        "documentation": "Option Over Non-Financial Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r760"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "us-gaap_OtherCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitment",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual commitments",
        "label": "Other Commitment",
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions."
       }
      }
     },
     "auth_ref": []
    },
    "smmt_OtherCommitmentIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "OtherCommitmentIncreaseDecrease",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional contractual commitments",
        "label": "Other Commitment, Increase (Decrease)",
        "documentation": "Other Commitment, Increase (Decrease)"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid",
     "presentation": [
      "http://www.summitplc.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period for which the majority of contractual commitments are to be paid",
        "label": "Other Commitment, Period for Which the Majority of Commitments are To Be Paid",
        "documentation": "Other Commitment, Period for Which the Majority of Commitments are To Be Paid"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.summitplc.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Line Items]",
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://www.summitplc.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Table]",
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustments",
        "verboseLabel": "Foreign currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r98",
      "r497",
      "r499",
      "r503"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Unrealized gain on short-term investments",
        "terseLabel": "Unrealized gain on short-term investments",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r176",
      "r177"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Reclassification of cumulative currency translation gain to other expense, net",
        "negatedTerseLabel": "Reclassification of cumulative translation gain (Note 10)",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax",
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r6",
      "r98",
      "r178",
      "r502"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive (loss) income:",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherIncomeAndExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r760"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeAndExpenseTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/OtherExpenseIncomenet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other (Expense) Income, net",
        "label": "Other Nonoperating Income and Expense [Text Block]",
        "documentation": "The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r190"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/OtherExpenseIncomenetComponentsDetails": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/OtherExpenseIncomenetComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other (expense) income, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_OtherOperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherOperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/OtherOperatingIncomenetSummarybycategoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/OtherOperatingIncomenetSummarybycategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other operating income",
        "label": "Other Operating Income",
        "documentation": "The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_OtherOperatingIncomeAndExpenseTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherOperatingIncomeAndExpenseTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/OtherOperatingIncomenet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Operating Income, net",
        "label": "Other Operating Income and Expense [Text Block]",
        "documentation": "The entire disclosure for other operating income and other operating expense items."
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherOperatingIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other operating income",
        "label": "Other Operating Income (Expense), Net",
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations."
       }
      }
     },
     "auth_ref": []
    },
    "smmt_OtherOperatingIncomeOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "OtherOperatingIncomeOther",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/OtherOperatingIncomenetSummarybycategoryDetails": {
       "parentTag": "us-gaap_OtherOperatingIncome",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/OtherOperatingIncomenetSummarybycategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income",
        "label": "Other Operating Income, Other",
        "documentation": "Other Operating Income, Other"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_OtherOperatingIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "OtherOperatingIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Operating Income",
        "label": "Other Operating Income, Policy [Policy Text Block]",
        "documentation": "Other Operating Income, Policy"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_OtherPatentsAndLicensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "OtherPatentsAndLicensesMember",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other intangibles",
        "label": "Other Patents and Licenses [Member]",
        "documentation": "Other Patents and Licenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_PaymentOfAccruedInterestToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "PaymentOfAccruedInterestToRelatedParties",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment of related party interest",
        "label": "Payment Of Accrued Interest To Related Parties",
        "documentation": "Payment Of Accrued Interest To Related Parties"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_PaymentsForCollaborativeArrangement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "PaymentsForCollaborativeArrangement",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments to Akeso for upfront milestone payments and associated direct transaction costs",
        "label": "Payments For Collaborative Arrangement",
        "documentation": "Payments For Collaborative Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments of related party promissory notes issuance costs",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Transaction costs from the issuance of common stock for rights offering",
        "verboseLabel": "Issuance costs",
        "terseLabel": "Offering costs",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireShortTermInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of short-term investments",
        "label": "Payments to Acquire Short-Term Investments",
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r347"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r650"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r347"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r650",
      "r669",
      "r903",
      "r904"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.01 par value, 20,000,000 shares authorized; none issued and outstanding at December 31, 2023 and 2022, respectively",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r598",
      "r760"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r308",
      "r309",
      "r733"
     ]
    },
    "us-gaap_PrimeRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrimeRateMember",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prime Rate",
        "label": "Prime Rate [Member]",
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private placement",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the issuance of common stock for rights offering",
        "verboseLabel": "Gross proceeds from the sale of stock",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the issuance of common stock via private placement",
        "label": "Proceeds from Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds received related to employee stock purchase plan and exercise of stock options",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r18"
     ]
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromRelatedPartyDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from related party promissory notes",
        "label": "Proceeds from Related Party Debt",
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturities and sales of short-term investments",
        "label": "Proceeds from Sale, Maturity and Collection of Short-Term Investments",
        "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of property. plant and equipment",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net receipts related to the exercise of warrants",
        "label": "Proceeds from Warrant Exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r257",
      "r572",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r729",
      "r750",
      "r761",
      "r787",
      "r829",
      "r830",
      "r835",
      "r899"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r257",
      "r572",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r729",
      "r750",
      "r761",
      "r787",
      "r829",
      "r830",
      "r835",
      "r899"
     ]
    },
    "smmt_PromissoryNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "PromissoryNotesMember",
     "presentation": [
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesSummaryofrelatedpartydebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Promissory Notes",
        "label": "Promissory Notes [Member]",
        "documentation": "Promissory Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails",
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/PropertyandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r149",
      "r152",
      "r153"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r166",
      "r605"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets",
      "http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r594",
      "r605",
      "r760"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r149",
      "r152",
      "r603"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/PropertyandEquipmentTables",
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of property and equipment useful lives",
        "verboseLabel": "Schedule of property and equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails",
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, estimated useful Lives",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]",
        "label": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]",
        "documentation": "Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "us-gaap_PurchaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PurchaseObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital commitments",
        "label": "Purchase Obligation",
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r328",
      "r377",
      "r385",
      "r416",
      "r417",
      "r418",
      "r546",
      "r570",
      "r617",
      "r640",
      "r641",
      "r704",
      "r706",
      "r708",
      "r709",
      "r711",
      "r727",
      "r728",
      "r742",
      "r749",
      "r755",
      "r762",
      "r765",
      "r827",
      "r833",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r328",
      "r377",
      "r385",
      "r416",
      "r417",
      "r418",
      "r546",
      "r570",
      "r617",
      "r640",
      "r641",
      "r704",
      "r706",
      "r708",
      "r709",
      "r711",
      "r727",
      "r728",
      "r742",
      "r749",
      "r755",
      "r762",
      "r765",
      "r827",
      "r833",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894"
     ]
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxReconciliationofunrecognizedtaxbenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesSummaryofrelatedpartydebtDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Domain]",
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r534",
      "r535",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r668",
      "r670",
      "r703"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesSummaryofrelatedpartydebtDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r202",
      "r534",
      "r535",
      "r536",
      "r537",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r668",
      "r670",
      "r703"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesSummaryofrelatedpartydebtDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Axis]",
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r535",
      "r886"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesSummaryofrelatedpartydebtDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Domain]",
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesSummaryofrelatedpartydebtDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r675",
      "r676",
      "r680"
     ]
    },
    "smmt_RelatedPartyTransactionPaymentsToRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "RelatedPartyTransactionPaymentsToRelatedParty",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments to related party",
        "label": "Related Party Transaction, Payments To Related Party",
        "documentation": "Related Party Transaction, Payments To Related Party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionRate",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "label": "Related Party Transaction, Rate",
        "documentation": "Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties."
       }
      }
     },
     "auth_ref": []
    },
    "smmt_RelatedPartyTransactionSubleaseExtensionTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "RelatedPartyTransactionSubleaseExtensionTerm",
     "presentation": [
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublease extension term",
        "label": "Related Party Transaction, Sublease Extension Term",
        "documentation": "Related Party Transaction, Sublease Extension Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesSummaryofrelatedpartydebtDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Axis]",
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r534",
      "r535",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r668",
      "r670",
      "r703",
      "r886"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedParties",
      "http://www.summitplc.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Promissory Notes Payable to Related Parties",
        "terseLabel": "Related Party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r531",
      "r532",
      "r533",
      "r535",
      "r538",
      "r631",
      "r632",
      "r633",
      "r677",
      "r679",
      "r680",
      "r700",
      "r702"
     ]
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfRelatedPartyDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Re-payment of related party promissory notes",
        "terseLabel": "Repayment of related party notes payable",
        "label": "Repayments of Related Party Debt",
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.summitplc.com/role/OtherOperatingIncomenetNarrativeDetails",
      "http://www.summitplc.com/role/OtherOperatingIncomenetSummarybycategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r203",
      "r204",
      "r338",
      "r349",
      "r537",
      "r735",
      "r736"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "presentation": [
      "http://www.summitplc.com/role/OtherOperatingIncomenetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r865"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r434",
      "r895"
     ]
    },
    "smmt_ResearchAndDevelopmentExpenseAmortizableAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "ResearchAndDevelopmentExpenseAmortizableAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net adjustment for research and experimental expenditures",
        "label": "Research And Development Expense, Amortizable Amount",
        "documentation": "Research And Development Expense, Amortizable Amount"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_ResearchAndDevelopmentExpenseCapitalizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "ResearchAndDevelopmentExpenseCapitalizedAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and experimental expenditures capitalized",
        "label": "Research And Development Expense, Capitalized Amount",
        "documentation": "Research And Development Expense, Capitalized Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationSummaryofstockbasedcompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Costs",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "smmt_ResearchAndDevelopmentPrepaidExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "ResearchAndDevelopmentPrepaidExpensesCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.summitplc.com/role/ResearchandDevelopmentPrepaidExpensesandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid research and development expenditures",
        "label": "Research and Development Prepaid Expenses, Current",
        "documentation": "Research and Development Prepaid Expenses, Current"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_ResearchAndDevelopmentTaxCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "ResearchAndDevelopmentTaxCredit",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/OtherOperatingIncomenetSummarybycategoryDetails": {
       "parentTag": "us-gaap_OtherOperatingIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxNarrativeDetails",
      "http://www.summitplc.com/role/OtherOperatingIncomenetSummarybycategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development tax credits",
        "verboseLabel": "Research and development tax relief",
        "label": "Research And Development, Tax Credit",
        "documentation": "Research And Development, Tax Credit"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_ResearchAndDevelopmentTaxCreditReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "ResearchAndDevelopmentTaxCreditReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.summitplc.com/role/OtherOperatingIncomenetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current and long-term research and development tax credit receivable",
        "label": "Research And Development Tax Credit Receivable",
        "documentation": "Research And Development Tax Credit Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_ResearchAndDevelopmentTaxCreditReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "ResearchAndDevelopmentTaxCreditReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development tax credit receivable",
        "label": "Research And Development Tax Credit Receivable, Current",
        "documentation": "Research And Development Tax Credit Receivable, Current"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_ResearchAndDevelopmentTaxCreditReceivableNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "ResearchAndDevelopmentTaxCreditReceivableNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development tax credit receivable",
        "label": "Research And Development Tax Credit Receivable, Noncurrent",
        "documentation": "Research And Development Tax Credit Receivable, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/ResearchandDevelopmentPrepaidExpensesandAccruedLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Prepaid Expenses and Accrued Liabilities",
        "label": "Research, Development, and Computer Software Disclosure [Text Block]",
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r435"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Domain]",
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets",
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash, Current",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r796",
      "r805"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets",
      "http://www.summitplc.com/role/LiquidityandCapitalResourcesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "negatedTerseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r125",
      "r601",
      "r621",
      "r625",
      "r629",
      "r651",
      "r760"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r206",
      "r207",
      "r208",
      "r212",
      "r220",
      "r222",
      "r295",
      "r298",
      "r425",
      "r426",
      "r427",
      "r455",
      "r456",
      "r471",
      "r473",
      "r474",
      "r477",
      "r481",
      "r618",
      "r620",
      "r634",
      "r903"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.summitplc.com/role/RevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r244",
      "r246",
      "r250",
      "r251",
      "r257",
      "r259",
      "r261",
      "r373",
      "r374",
      "r572"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/Revenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r376"
     ]
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "presentation": [
      "http://www.summitplc.com/role/SegmentReportingLonglivedassetsbygeographyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.summitplc.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leased assets obtained in exchange for operating lease liabilities",
        "verboseLabel": "Additional right-of-use assets recorded",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r759"
     ]
    },
    "smmt_RightsOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "RightsOfferingMember",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/NetLossperShareNarrativeDetails",
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rights Offering",
        "label": "Rights Offering [Member]",
        "documentation": "Rights Offering"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_S3RegistrationStatementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "S3RegistrationStatementMember",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "S-3 Registration Statement",
        "label": "S-3 Registration Statement [Member]",
        "documentation": "S-3 Registration Statement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/NetLossperShareNarrativeDetails",
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "smmt_SaleOfStockNumberOfSharesRegisteredForResale": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "SaleOfStockNumberOfSharesRegisteredForResale",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares registered for resale (in shares)",
        "label": "Sale Of Stock, Number Of Shares Registered For Resale",
        "documentation": "Sale Of Stock, Number Of Shares Registered For Resale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/NetLossperShareNarrativeDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock price (in dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.summitplc.com/role/NetLossperSharePotentiallydilutivesecuritiesexcludedfromthecomputationoflosspershareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/NetLossperShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of potentially dilutive securities excluded from the computation of loss per share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsShortterminvestmentswithcontractualmaturityoflessthanonyearDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-Sale [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of short-term investments",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.summitplc.com/role/AkesoLicenseandCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of related party debt",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r61",
      "r62",
      "r77",
      "r78",
      "r80",
      "r85",
      "r123",
      "r124",
      "r745",
      "r747",
      "r808"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Major components of deferred tax assets and liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/NetLossperShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of net loss per share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of the effective income tax rate to the statutory rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationSummaryofstockbasedcompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "presentation": [
      "http://www.summitplc.com/role/OtherOperatingIncomenetSummarybycategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from External Customers by Products and Services [Table]",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57",
      "r573"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of acquired intangible assets",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of loss before income taxes",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/OtherExpenseIncomenetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of other (expense) income",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items."
       }
      }
     },
     "auth_ref": []
    },
    "smmt_ScheduleOfOtherOperatingIncomeExpenseNetTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "ScheduleOfOtherOperatingIncomeExpenseNetTableTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/OtherOperatingIncomenetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of other operating income",
        "label": "Schedule Of Other Operating Income (Expense), Net [Table Text Block]",
        "documentation": "Schedule Of Other Operating Income (Expense), Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.summitplc.com/role/PropertyandEquipmentComponentsofpropertyandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesSummaryofrelatedpartydebtDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82",
      "r675",
      "r676",
      "r680"
     ]
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "presentation": [
      "http://www.summitplc.com/role/OtherOperatingIncomenetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r865"
     ]
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "presentation": [
      "http://www.summitplc.com/role/SegmentReportingLonglivedassetsbygeographyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r99"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails",
      "http://www.summitplc.com/role/StockBasedCompensationWeightedaverageassumptionsusedforstockoptionawardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r389",
      "r391",
      "r392",
      "r393",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of stock option activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r65"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of weighted-average assumptions",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of warrant activity",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of unrecognized tax benefits",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r758",
      "r867"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.summitplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.summitplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.summitplc.com/role/SegmentReportingLonglivedassetsbygeographyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260",
      "r637",
      "r638",
      "r639",
      "r705",
      "r707",
      "r710",
      "r712",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r730",
      "r751",
      "r765",
      "r835",
      "r899"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/SegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r245",
      "r249",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r261"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity award, vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consecutive offering period",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Consecutive Offering Period",
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Consecutive Offering Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.summitplc.com/role/StockBasedCompensationWeightedaverageassumptionsusedforstockoptionawardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected dividend yield",
        "terseLabel": "Expected annual dividends per share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationWeightedaverageassumptionsusedforstockoptionawardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationWeightedaverageassumptionsusedforstockoptionawardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails",
      "http://www.summitplc.com/role/StockBasedCompensationWeightedaverageassumptionsusedforstockoptionawardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r389",
      "r391",
      "r392",
      "r393",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum common stock purchase allowable as a percentage of compensation",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations",
     "presentation": [
      "http://www.summitplc.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants cancelled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations",
        "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase to number of shares of common stock issuable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares available for grant (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering period",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period",
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock option activity, additional disclosures",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of share options, exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, exercisable (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average grant date fair value of stock options granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, options outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r396"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of share options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r396"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of share options, vested and expected to vest (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, vested and expected to vest (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum percentage of outstanding shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": []
    },
    "smmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPotentialNumberOfAdditionalSharesAllowableUnderThePlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPotentialNumberOfAdditionalSharesAllowableUnderThePlan",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential number of additional shares that can be added to the plan for future issuance (in shares)",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Potential Number of Additional Shares Allowable Under The Plan",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Potential Number of Additional Shares Allowable Under The Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issued (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails",
      "http://www.summitplc.com/role/StockBasedCompensationSummaryofstockbasedcompensationexpenseDetails",
      "http://www.summitplc.com/role/StockBasedCompensationWeightedaverageassumptionsusedforstockoptionawardsDetails",
      "http://www.summitplc.com/role/StockholdersEquityNarrativeDetails",
      "http://www.summitplc.com/role/StockholdersEquityWarrantactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r392",
      "r393",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r394",
      "r413",
      "r414",
      "r415",
      "r416",
      "r419",
      "r428",
      "r429",
      "r430",
      "r431"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://www.summitplc.com/role/NetLossperShareNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share price (in dollars per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationWeightedaverageassumptionsusedforstockoptionawardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term, exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term, options outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term, vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price of common stock as a percentage of closing price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets",
      "http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term investments",
        "label": "Short-Term Investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r138",
      "r797"
     ]
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/LeasesLeaseexpenseDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/LeasesLeaseexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term lease",
        "label": "Short-Term Lease, Cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r759"
     ]
    },
    "smmt_SignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "SignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Accounting Policies [Line Items]",
        "label": "Significant Accounting Policies [Line Items]",
        "documentation": "Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_SignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "SignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Accounting Policies [Table]",
        "label": "Significant Accounting Policies [Table]",
        "documentation": "Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r196"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. State",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r33",
      "r160",
      "r184",
      "r185",
      "r186",
      "r206",
      "r207",
      "r208",
      "r212",
      "r220",
      "r222",
      "r237",
      "r295",
      "r298",
      "r362",
      "r425",
      "r426",
      "r427",
      "r455",
      "r456",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r477",
      "r481",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r529",
      "r618",
      "r619",
      "r620",
      "r634",
      "r696"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.summitplc.com/role/SegmentReportingLonglivedassetsbygeographyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260",
      "r637",
      "r638",
      "r639",
      "r705",
      "r707",
      "r710",
      "r712",
      "r715",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r730",
      "r751",
      "r765",
      "r835",
      "r899"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r237",
      "r572",
      "r626",
      "r636",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r650",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r659",
      "r660",
      "r661",
      "r662",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r670",
      "r673",
      "r674",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r696",
      "r766"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r237",
      "r572",
      "r626",
      "r636",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r650",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r659",
      "r660",
      "r661",
      "r662",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r670",
      "r673",
      "r674",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r696",
      "r766"
     ]
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock",
        "label": "Stock Issued",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r47"
     ]
    },
    "smmt_StockIssuedDuringPeriodSharesInLieuOfCashForCollaborativeArrangement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesInLieuOfCashForCollaborativeArrangement",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in lieu of cash for Akeso upfront payment (in shares)",
        "label": "Stock Issued During Period, Shares, In Lieu Of Cash For Collaborative Arrangement",
        "documentation": "Stock Issued During Period, Shares, In Lieu Of Cash For Collaborative Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_StockIssuedDuringPeriodSharesIssuedForRelatedPartyInterest": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesIssuedForRelatedPartyInterest",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in lieu of interest to related parties (in shares)",
        "label": "Stock Issued During Period, Shares, Issued For Related Party Interest",
        "documentation": "Stock Issued During Period, Shares, Issued For Related Party Interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rights Offering of common stock, net of offering costs/ Private placement of common stock (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r91",
      "r92",
      "r125",
      "r628",
      "r696",
      "r713"
     ]
    },
    "smmt_StockIssuedDuringPeriodSharesRelatedPartyPrepaidInterest": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesRelatedPartyPrepaidInterest",
     "presentation": [
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued for prepaid interest (in shares)",
        "label": "Stock Issued During Period, Shares, Related Party Prepaid Interest",
        "documentation": "Stock Issued During Period, Shares, Related Party Prepaid Interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under stock purchase plans and exercise of stock options (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r91",
      "r92",
      "r125"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.summitplc.com/role/StockBasedCompensationStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedNetLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r91",
      "r92",
      "r125",
      "r400"
     ]
    },
    "smmt_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of warrants (in shares)",
        "label": "Stock Issued During Period, Shares, Warrants Exercised",
        "documentation": "Stock Issued During Period, Shares, Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/AkesoLicenseandCollaborationAgreementDetails",
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in lieu of cash for Akeso upfront payment",
        "label": "Stock Issued During Period, Value, In Lieu Of Cash For Collaborative Arrangement",
        "documentation": "Stock Issued During Period, Value, In Lieu Of Cash For Collaborative Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_StockIssuedDuringPeriodValueIssuedForRelatedPartyInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "StockIssuedDuringPeriodValueIssuedForRelatedPartyInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in lieu of interest to related parties",
        "label": "Stock Issued During Period, Value, Issued For Related Party Interest",
        "documentation": "Stock Issued During Period, Value, Issued For Related Party Interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rights Offering of common stock, net of offering costs/ Private placement of common stock",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r91",
      "r92",
      "r125",
      "r634",
      "r696",
      "r713",
      "r772"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under stock purchase plans and exercise of stock options",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r91",
      "r92",
      "r125"
     ]
    },
    "smmt_StockIssuedDuringPeriodValueWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of warrants",
        "label": "Stock Issued During Period, Value, Warrants Exercised",
        "documentation": "Stock Issued During Period, Value, Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets",
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r95",
      "r96",
      "r115",
      "r652",
      "r669",
      "r697",
      "r698",
      "r760",
      "r773",
      "r806",
      "r819",
      "r876",
      "r903"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r197",
      "r346",
      "r348",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r360",
      "r362",
      "r479",
      "r699",
      "r701",
      "r714"
     ]
    },
    "smmt_SubleaseAgreementFirstAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "SubleaseAgreementFirstAmendmentMember",
     "presentation": [
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First amendment to sublease",
        "label": "Sublease Agreement, First Amendment [Member]",
        "documentation": "Sublease Agreement, First Amendment"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_SubleaseAgreementSecondAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "SubleaseAgreementSecondAmendmentMember",
     "presentation": [
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Second amendment to sublease",
        "label": "Sublease Agreement, Second Amendment [Member]",
        "documentation": "Sublease Agreement, Second Amendment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.summitplc.com/role/CommitmentsandContingenciesDetails",
      "http://www.summitplc.com/role/LeasesNarrativeDetails",
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r539"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.summitplc.com/role/CommitmentsandContingenciesDetails",
      "http://www.summitplc.com/role/LeasesNarrativeDetails",
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r539"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.summitplc.com/role/CommitmentsandContingenciesDetails",
      "http://www.summitplc.com/role/LeasesNarrativeDetails",
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r539"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://www.summitplc.com/role/NetLossperShareNarrativeDetails",
      "http://www.summitplc.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "documentation": "Different names of stock transactions and the different attributes of each transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.summitplc.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/NetLossperShareNarrativeDetails",
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails",
      "http://www.summitplc.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://www.summitplc.com/role/NetLossperShareNarrativeDetails",
      "http://www.summitplc.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental Disclosure of Cash Flow Information",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TangibleAssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TangibleAssetImpairmentCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.summitplc.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of fixed assets",
        "label": "Tangible Asset Impairment Charges",
        "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r120"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforward",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.summitplc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsShortterminvestmentswithcontractualmaturityoflessthanonyearDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r343",
      "r359",
      "r478",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r608",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r815",
      "r816",
      "r817",
      "r818"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.summitplc.com/role/AkesoLicenseandCollaborationAgreementDetails",
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "US",
     "presentation": [
      "http://www.summitplc.com/role/SegmentReportingLonglivedassetsbygeographyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.summitplc.com/role/FairValueMeasurementsandShortTermInvestmentsShortterminvestmentswithcontractualmaturityoflessthanonyearDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Government treasury bills",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r738",
      "r752",
      "r754",
      "r896"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxNarrativeDetails",
      "http://www.summitplc.com/role/IncomeTaxReconciliationofunrecognizedtaxbenefitsDetails",
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits",
        "periodStartLabel": "Unrecognized tax benefits, beginning of year",
        "periodEndLabel": "Unrecognized tax benefits, end of year",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r443"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxReconciliationofunrecognizedtaxbenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Decreases related to prior year tax positions",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxNarrativeDetails",
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability for interest and penalties",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxReconciliationofunrecognizedtaxbenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increases related to current year tax positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxReconciliationofunrecognizedtaxbenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increases related to prior year tax positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r52",
      "r145",
      "r147",
      "r150",
      "r151"
     ]
    },
    "smmt_UtrophinProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "UtrophinProgramMember",
     "presentation": [
      "http://www.summitplc.com/role/GoodwillandIntangibleAssetsScheduleofacquiredintangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Utrophin program",
        "label": "Utrophin Program [Member]",
        "documentation": "Utrophin Program"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.summitplc.com/role/IncomeTaxValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Increase in valuation allowance",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.summitplc.com/role/LeasesLeaseexpenseDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.summitplc.com/role/LeasesLeaseexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease costs",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r759"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Axis]",
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Domain]",
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "smmt_VariableRatePeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "VariableRatePeriodAxis",
     "presentation": [
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate Period [Axis]",
        "label": "Variable Rate Period [Axis]",
        "documentation": "Variable Rate Period"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_VariableRatePeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "VariableRatePeriodDomain",
     "presentation": [
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate Period [Domain]",
        "label": "Variable Rate Period [Domain]",
        "documentation": "Variable Rate Period [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_VariableRatePeriodOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "VariableRatePeriodOneMember",
     "presentation": [
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable rate, three months immediately following February 15, 2023",
        "label": "Variable Rate, Period One [Member]",
        "documentation": "Variable Rate, Period One"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_VariableRatePeriodTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "VariableRatePeriodTwoMember",
     "presentation": [
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable rate, thereafter",
        "label": "Variable Rate, Period Two [Member]",
        "documentation": "Variable Rate, Period Two"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.summitplc.com/role/NetLossperSharePotentiallydilutivesecuritiesexcludedfromthecomputationoflosspershareDetails",
      "http://www.summitplc.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.summitplc.com/role/StockholdersEquityNarrativeDetails",
      "http://www.summitplc.com/role/StockholdersEquityWarrantactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r763",
      "r764",
      "r767",
      "r768",
      "r769",
      "r770"
     ]
    },
    "smmt_WarrantsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "WarrantsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.summitplc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Warrants, Policy [Policy Text Block]",
        "documentation": "Warrants, Policy"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.summitplc.com/role/NetLossperShareComputationofnetlosspershareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in shares)",
        "verboseLabel": "Diluted weighted average number of shares of common stock outstanding (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r232"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.summitplc.com/role/NetLossperShareComputationofnetlosspershareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic (in shares)",
        "terseLabel": "Basic weighted average number of shares of common stock outstanding (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r232"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "presentation": [
      "http://www.summitplc.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares outstanding:",
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "smmt_ZanganehNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.summitplc.com/20231231",
     "localname": "ZanganehNoteMember",
     "presentation": [
      "http://www.summitplc.com/role/NatureofBusinessandOperationsandRecentEventsDetails",
      "http://www.summitplc.com/role/PromissoryNotesPayabletoRelatedPartiesNarrativeDetails",
      "http://www.summitplc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Zanganeh Note",
        "label": "Zanganeh Note [Member]",
        "documentation": "Zanganeh Note"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a-c)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-16"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "b",
   "SubTopic": "10",
   "Topic": "280",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(a)-(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350/tableOfContent"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "985",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//985-730/tableOfContent"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "SubTopic": "20",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "SubTopic": "20",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//250/tableOfContent"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-17A"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-6"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//280/tableOfContent"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-20/tableOfContent"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-9"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-3"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "40",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481724/830-30-40-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-12"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-6"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(b)",
   "SubTopic": "20",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "SubTopic": "740",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480887/718-740-35-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482190/360-10-35-3"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>114
<FILENAME>0001599298-24-000031-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001599298-24-000031-xbrl.zip
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M1WUDG5Y.W%EV@4XF"Q'.UM_& YW?CF0L+3O<[_8#KP_DXU1+GGW;[NPAXDE
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M;U%F'-)!NY\<BT(,I'7V'&O%4RP"QEQFP3,@KF=J*L3"/":.+MG9@4[ZJL<
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M%D[R5#<2J_]&Q7H41J_=G_5X37].Y+]02P,$%     @ &#Q46$LKSD< &P
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M$N0S2/2\.,]B=Q-%#Z =4!T45X+Y!1<*+, 'AQSI"(1S/1CRB=2YV2K/DY?
MU"#DL(0,:^"[4EX+'#25=,;Z+4]';XRSQE7/!^6G2H]0"$).M7=SQ:RP'A!U
MYJHD,YP:"TZ)-QV$<-$#45GL:BMFD5W1=AJZ+IJSP80:C[&^"7[*$W?6CV:<
M7\W[UF),6;=*CEFEJCS8AZ]CH]3R$P" 7?(#$SB6P-^MDLI+TS .Q"Q!<FF\
M>DW%>]N(3Y1<I*!,A6@:PZ;'^ EH9!I95"1!PI82:Q(>%4S3E-_K6D"J;"?Y
MJ H"X[Q2,%]]3L5^0\6REDA?ED[[OFC9WZU#R_U#!JN.)R2ZF1&]%+%64GYR
M#LM^GF"K-P4\>R:UL%J,+JQ#Q-VYU;ZLII$ZV"X3;4SHVAQV+6_)J-9%.8^)
M>#X=R;)?7[%2"UVRP6(E)6.+BL=0M2^4DC$JF#35:"/ (=Y=S3O13G3HDDVF
M?6=<;EX@Y%%L["F404815;TD&OKB7L0N%MIQY9IC8QK-S3-=_8I&'IFSJ+@
MC-]RL"XQ%*),1AY%8*S3#SZ_PW/%/YE,9Z5HCC5?K+NL()>:'G"/>!+8U<(7
ML0K8&U<>#."[6*8IR!WP\:5+,"T*_/+D^K(@! $:?RA'A%?%=C:7? '.",8<
M?)0W#&-Q'1(:LTA'PQ]!HIXPQ9L(5I^#MF5;HVV+;;GXQ\,_8AOI96N\C1>:
M*I(3,-PT)ZRBDZ7!0YXW[!JW.J<B\JI-2 \YKD(&Y"%5 DLK"$/1&'CF],1S
MM!@CV5?\-)K8D'M>.%<C##:8MBY7$<\"[93J;RHE-P]4R6 Q3%!<MM@]M9#
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M,Y<2R_P,LB@F'\@M_0B.!(4";T,_F^I"'--F[XM;G*XQYFX:QLD&$YE-,AO
MY,\J;ZU=1G%(1EC29+&1:5GW4+KJ?O.%H5?Y3!XS_QG</+0'%^8_4]Z'QC=1
M,3A&C'#$-=IY@GLZ*Y2JUU^7.K>DZK@<B;E7O*J8K<7\0I(9*MY2=YZC\?(#
MYS^"/0N*2S??Y\]/&G#)POC. #7>!>OD\T>L3O.Q6,K=&X >_-$%['-O$Z*9
MZ%D,'"22\JQVD_'%&3,TI%V-)%(WZ6/6M'%XN/WD+-VCFNO*J[RS[:\,O)@A
MOJ;W65NNY=$=NWG&>N]9Q^FVG#ZSNRWVKM?O]Z[@2[O?=S[VFO:[SB=V9;<_
M.@,X_HG.L3L=UF]_.!L.V. 25KBP^\-/[-S^Q,[LCPX;]EC+.<<3AV?V4%W5
M'+9[78M=]'M-QVFUNQ]8K\^:O<ONT.DW.W;[G-G]]H!^OQSBEN!PNTO77L&Z
M?:=C#YT6+CT\:P]8MS=T\)3AF:..P>J#L_;% "_%'W%+;=CRF=-WX*)WL*M^
M&Q9X]XG]==G_M,$X)_@10OO,^=\A8'Z 8%V"VP*/-D+/[ACHY;BZ)+)I]L[/
M>UW6L:\0);30Q46GC:3CL,'0'EX.'0L/6ZQ_V2&\]9T/EPIK&XR)]Y=](-6^
MQ8@-%1-I>K6;_]/M776<U@>@8>*B$J,!_O H(*"C</:QUP%& J1H5D74%.=K
MY3Q0:"US9QFG3TX-OJRY&OP(%G9  XMRG_Y9"ZXW:83%T"['P4Y8R!"C&5T-
MJ^()/+D1ZGTM18EAJ? Z7PQL5<(V55<4;J15#(=SM7]E1MWH(L"%8*[:3G6Q
MZ3.^%+XF7 $WC*(P3K- N\")$#>JC-&[S4>;%DU I2Q8[KNXDS!,3!<.+DU-
M_%ZU/-Z#I4/E.E'X7KB9GH)A,':K^5K.#4JEFKTLIF A#2*C 7=CGPAA820U
MSKT3?O+T<OBO:BZ6!Q@%UK&49WF\KJ8^-08PGA.&ZG4*NA)<1>5EP&YEZ%<&
M$%/00'4]XQ)YB&,:>G(L]00_=R*%[N(/:6P8AA/*$\5*\VMUV 'E,(9H]+B.
M"(,,::K"*UB5;>3\:-EK%=4N8C'E:I85-=&;V<B>EOU?QNU?* E<2ONMB>]_
M_^VD\;I/3Z_G_6*-KXI0J<EO("YQ9#8; ?!N5!<&UC=P"DO2R6J<0@)+'2PF
M.#[WP%\'IH>OVM"RZ9\)ZB^=FKG&MVRVN^RJ/>PZ W"OT8WKO;?8G&E)[[,J
M9((285[FS[0E(;S2.S)6O-[\D:)!M97E)!<#U^U@LRZ^^_K4?'B-300^GYW*
M@)Z'+GH]Y?$U$(FFTR-X>%")5-ZK\48 5X<U^9R<[+Y\=8(4E,)N4L_<6!/7
M+A'7'ZFW>.SP9'?OY>K#>[N-E<<>6G;_8/>X<?)#EMU??6EYV3\($O&<K&@<
M$7W"A8"#).+!GR\.7C"@$?7YY8N"E^DU J=[K$%7F/OEERV>NA_=X\GE]PV@
M1%W 7AB5.?UGSV Q 480\<=S8OS+X/896"U?Y[#QB'5^#4 .+L_/VT.,=O;M
M"^=RV&X.6+O;W/T6F![4'A8K7,+9*G+ZCD_WDPUQTL@T;#RAO\P.;K*8M7"8
M>LSS1]T(_';Y5/P$#*_M^9:C=H,8>(C53$\9PTWP-\?LO0S -90XL!Q+0(H:
M['E<_T&FV'=P!+_MV$_G@R+OT;*8W6PZ%YCVHQS4A[[CM):0R!K,73!:CP^^
MRMP].=X]V7N<N:MY_E<C_^7&BLHP?[/-M_CXRVR^&FO]O4=&2T#?#Y36[_?>
M.?TA:UU^^&!WEVG]54^KN0">XA0>%IM&I,?,WNM*/<OAT0]'L!_6RJZO>?!=
M1&:]0CA_C$)O!O],TJG_]O\!4$L#!!0    ( !@\5%B>,[OWW><# (PT(@ 1
M    <VUM="TR,#(S,3(S,2YH=&WL?>M7VTBV[_?S5V@Q<\\D:]D.-N]T=^XB
MA/0PG00ND.DSY\NLLE2VJR-+;CT SU]_]Z.J5))E,,2 3'S7N3W!EJ52[5W[
MO7_[Y_][,PZ]*YFD*HY^^5NWL_DW3T9^'*AH^,O?#B^.3D[^]G_?_=?/HPPN
M@TNC]&TZ'F>_;(RR;/+VS9OKZ^M.FH_'*IN$?L>/QV]ZF[VM+OS?AKY<I?%V
MK[M7^L5-/PD[<3*$BS>WWN@KS _R+)E[\<$;^-9<F";%.@8B[=-%\"$MP5SD
MQWF4)5-[(=TME7YG&%^]T5^Z/R@]^GJ+[MD].#AX<X-;8%_J)JM?HXI"%<G_
M>7_^Z4V6B"@=Q,E89+"W^(S-]F:OW>TY-VG#2LI[J5=VVWVZ.^W-_7:QP_CP
M0)7?4._7[AO^TEZ:JKH7A"N[;_[G\Z<+?R3'HJVB-!.1+RU%TO90B,GL9NLO
M2AL.Z_YV"['QZ[Y(I;MX=1MS5-822%5/2_BBM YU,^^NW2UG>^TZ9M9=(CY^
M2Y>^#06<C T9M;]>;+S[>21%\.[GL<R$AS]MRS]S=?7+QE$<93+*VI?3":S<
MY[]^V<CD3?:&^.C-N__ZK__Z.5-9*-_A@6J;8_/S&_[PYS=\ZWX<3-_]'*@K
M+\VFH?QE(U#I)!33MU$<25B NGF+%\J$_ZF"0$;T3_C^2SZ6B?+Y^3?9N1S\
MLN&W@6\B,<8[2?7V<"RC /Y_]C$4PPV/V>R7#6#-MP-U(X/V0(1(+!7\LC%
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MCN+3BZ;O%5G?KW1*G'.GTBDN_3ZEL\+12&:R!L2E'BKHEI(QZAXLEC$J7?K
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M]YI045E-*^^U>WN+I95+EW[?1CQZY.G>435XM^64ENX]>JCD(>^VMYQW:VY
M(@-FQ-\@,&,V/8K'DSB2,UCO\/DXCDC>+$MS-T:H/==9;FP$I"&Z?:F&5&/#
M#7/,]>/Q)(RG4BYRY+[;A-IWNKR^;YM7S5%_Y&VN&D_["W;>52[]/CFS:I[J
MT['^,B7,?F-=M0:P?I>RK[T%56ROW5L.DLI^8SVZ!M"DMWA&M+?$C.A^8ZL5
MED"3.Y^%H;!S$0UE$1G[K"(USL<O4_GL-[94H@$G\)F:'O8;6Y/0 )H\4[_
M?N,"! ^65 ^E-OF9)5*?3C"4?PF_?"]2&;S0T]BX,$ =Y<7-FO)+I_RJQ"1^
M5/JL=#"#2?1"*;/2(8TGH<PSV3$'JQ(%>0:9]DCM@P>K$N1X;C7R7$=B50(>
MSWLDEAF+/5B5J,.\+3^3R2!.QB+R$0/SLTB^R>P%6UH'JQ*1: "]'DN+-"X
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M[X/(A/>114:)*XM[3.(TJV@]5[Z?RV$><K;PHGWIO<**LKV?>EN]CE4 (*6
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MB"21>+!!8+VEU(F 9.*M 4IGL:<"7.1@>@OM@+9A!D\=CKPHSN"/\):+S5G
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M?&E?)'%&#%+$KV7%"NEI.>(<3:2KP;@^O X;(>2"BH#K9;3!3?>2"94X."&
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MCD%.759J471:;B58:W[MJT9;:;>\R6B:*O@V:E.CJAQBLUB;8^ZQKV0FPO8
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MYD)5GMS#^LBA4[KC6VHP]!<@]Q$8.QF^68P15(W(B6'\YXOP;KQ3T<#6NX3
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M[%ADF2Q&G]?QIUXN,EPQQ)F'X)D6/CRZKXH: [8)J*7!N>)U"WZ?<$-\HF_
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MK-O&#5YSL*;I\F@ZD0DUQFM;3P1@+ILX 08PVMKIQDJ#^J-6$[ S,4>2PT6
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M6E&FA"J0":[-M>N=0S$>!X046W$M4 R$)7D-;UU =U6$"M> &^'DTIC\&#B
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MJV_WE%T%*9:?<5QSJ]1^=-S3Z?C:SDW=3U,@ 4IH@P0'("6S?_T]>^W'V0<
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MJ)Z^#B@\G)9?A7[7EB-:>5QI,1D@O-M)"3OV"EW-6'Q-PN)])'>W\'[[R3*
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MX^F'G]17/)[@/[$;C62(:+.47E<Y%-9-QG87^2(Q,Q).1_^'[4C9S=IJ*A]
MH_N2$Y[Q?[/FQF8?OYG^6B3GB:5L(="+W%QG( ;QUU]ROGCRDYN!*^XD<N!\
M <AN3$LB'PT+>0F9%-_HB?,WZ*7K^FWOZG]&3B;F/[,M0-2#+:>K<S0P]<Z9
M)*TD63:/9-*JP[H_Y?OUE7-/#J.<>UAW6GJ4YN4@#^E8_22+6%Q4'3$A1#P)
M4^K6=, OS[><XFNUG'C)(K40E0F'1OVQ;,>S8%W#1)0UL]\Z,3^6)_(.#OMO
MH&N/R?(.:2(0L=A71#B.W"RB512R#$M5*YED6[),66&<N.&==V6E@@-%M-U3
MEW]E2@"PH#&OM[I'T69I/S!U16L$F/YL9S6T_N2(1NS:+MI.YSK]/ET=T@U.
M()]%_HF#T!GXZ@XA#7K#.M(;XHWX2 S%V>3/GL/XHW(8O],TQ/LH ??>$QB?
M*F^Q?&7R*F:8N]L_8=<ZY%54W"J%CTA2-C'OI1&"\&0C0"DT0N$R\':@1N+2
M'ILER02SWU/#3=1X8 ?#>?B=:VD=Q,@>Y0OEV$XH88BI^HB9JEV!(!OEM4X_
MT4M3#>H+"=EUG^/:?_H #M?^DFPB6NLCF;A9\J3"YB8];A.6-M,]DL4(HI;X
MFS,*4U6QXMJ."\U-1![;,;N*)_^ZNTB47RDA$IQ.CJSZ*A5N0P]WLP* *$K>
ML4_?I),2WR'VD^="@W^&T;:,U12VF%@OZ$,[Q84'?,EG#3I-;F%*AC]MI1=_
M?;GR@2L;:FE%:/B545A^2_*KL<I711'EF&'*I/"3 !Y$@Z"GAI$R0/1DY>7:
M'GLCR_1&:@!?%XW]^G*Y]Z81?S8!T. QG)?%1HJ6PR(P7]$+"8@2<;04<\8/
M7N5;G6B0^DM9./@ WS>7(;AL[5C9N@#;QB0MJ#9@(#SG0I@29\"O8=&42B]R
M5BT%;48/K^E"[,HDU>96.7)NI"1)G(0=LZ$ZX;0WBS:_7/KLM=L%E(8H+WR6
MT3^$.:.#"2!5).&.X&7'1H#<$E6M#MV&EF0-,F<G9?9<B62GWL*8]10\Y2\V
MGB:*=G.#.8 NV=DMZ6!1AE1@%7[1_7L[2^MA7"IAQK:<DO+EYTJ9GD2"; )]
MPV&^-GBVGOXIS!)K?T9X@?^A>&4HZV,S#=- #KORACJ+%*G]TT3#FCC,+>/J
M334E;:4T.[*@59F$+.=-C?\O(%=G[=6(R->;C9Z?*.,C.?H78M8P5V'C4HHA
M! NSL@?9L4=&;)I_FA=/?R$\V1@:3747M@1==.M\/A^O?;Z@+ FM BS4K&VZ
M[BCLH%D5[!-V2O@<2M9UF4>DH'8<E/E"!)HX.E%.M'+51<\4W^AS8 GCJ^(!
M1"G\T&U&N&[;XGH.5]]7-8,1/\8'D?9]Y\Y\<JB!Y=;(-3AH"&:-PS$Y7_ZD
M4N5 &"7;E&TH'A?O"NP0\,OZJ55&B^GX(Z_6GJ%<LK0<"9YIGHYW42+^HV*&
M'W8\14QS5=<;-E*XC\RX(0G!Y'!]=J7QN,:YFF(TM8[L;5(8<2R$.>6_(R1C
MI1XG4\'&ACB49QOZ# UD>4X1B/ZJ)DE=V0H[@-X-IR\J1MHBZCVP62,5*LEE
M]]H[6:7H "(!GA Y'4].X\[L7?H^5F08L#&,YFNXW19F=<VFG46EW-1O9.N>
M5+N4B(JJ6:S1F7A6YDV)F5'*/GJ%1&@M)KR EHCH"7JX@1$.H@S_II(R*8X$
M2:ZBS,=.VKA"&EH.W']53F&-U=5>!J>-8WR70="2/HNKU,Q3V\8,2T*R%U9Y
M&J8?2?&89[A=A)<75?Y[=GZQ[\[EF"-7-$OG#LE8+?7\[=WI*R.8"W;@_#+?
MLB6FO^B_^"3G9EG]SX9*4[-@0ZIN85?S7AJUB#N+"UO""@P')X[@E4&TI!JR
MR.+MA%*=8.?D2"K4B90O!%;[+FP<2(C3-"PV_KPPG HF&-7S3=NB\U!M;R=!
MKS5FX"VIY9$O1ZC8X&VK9DU]-\Z78G+:<$N 97RZ9:U<!?$#B$IEL!$O,R:T
M;)CS8.A%=MUMB&QR'K;*$>I3?J+P-1ZAE%0[MS 8*CS0X%N%FP"BA#Q<X:X>
M/HS*5U%'4UH_U3E7I;<P6]AA_,L(MF\T027)>:H(4<)GV)6RBTQ\'O5 WK;3
MO,[E@K+"-G*2S9RJ%U3"E2*>_+N*E\N%HEMMN8%Q\[ML-+7)<=-1!*3 LB:2
MRLCDS"D5TT(2B=V:H?#SNZ$.&*:;Q6-8JQ%3ZK(M7;78U&''EF''!S???S0)
M^.;)K3=(W.H>.P O^886^]0NGH*TD?FZ><=6[_:_[+5K<]R%F+N7]0T0>92O
MW1_A.ZE<)D*76\$U-['+7&[H "/1O6:A@KCG>\&ZF4\YK](.KD% 'G]N?>XX
M:SF&8T06C3I8X^:,>>XYFN?O4!)2Q7^W#CT2CG6P0^MH4L4:I$$[S-*>N?.Y
M7!H80HJ[FKO5W!\>1LW]]Q.<U"AMN*.7B5"\2YLEVUNNVG#^",E3F/(K=R+X
M!U;!6Z';#?=G,/K3JA"H[(* ?(".J%/X]H<?'%)<E0FO.DK)SX5'1"&$_B'+
M-)R"QA 166^8P#@8GS#&BA1_VIS_/\.%+JBS9&912)I>1&6=8W;#_]:4@*:P
MP:N6.T_M%3P$'&V1*!P<;F3C*<_&(\L7I;3 4E$=V.R\55=T5ZQ+$ "XGOI+
MP1\V^+BI.![X1?-&^TPW+:5AN(XT,J/9N)U&Y@G!=.OZNR)D>:O;FY%X-(&J
MDS*I%L%X*"@.0-PSYEKGC2=?M/W+JM/K?1> @"2X+A*\P[*F!(L^R!>?[,;X
M,'@G%MILYI0'\,<3SA8YL?76?"]*,!7UEH_LX)BCE_LJ4\ S&"=)DD+N)BX5
M0L;SH  0>'A[CG22/W702;[NTFX\?_3C+4J&37UFP&FJTE#18WO$>>W[7[KC
MA:+G:P%![!0&%5<B2NRP&(%H[(Z=^-@I,#)WMHA2N?*SG^R5P81!=!QR+@B5
M1RR LO^W F"*GPXKI:E_\X%&!G>5;48$)(+&>U;TT"W11VGT&:RLYC'"/*$G
MEX^FBCMVY9J+*=72<<F'6ZE5&0\M;87O4_E1U$!BIY 47^EZHEIL99H++-]N
M9L@%A_O.%6&(M2P:#Q:7EM76-.U59@$Z-IT:& 86E)]SJM!GX]-D8A"8&>'K
MN"BYQM6O)O4S=!QT\Q9/4MJDY2$:4DRBT)MH)%GY9N<*IC^T,?5,[WY1"2JW
M*$5Q);HRZ@HD".YS$ZBT-91UE04*"UHNSTCC$ VJS:)<8T?6E,49$]3R]4AW
MV!$)R/CT9O@*3M.FVZCV)QTAZ?/(M708H2/:S]@C0</9"MYZK,1EOL,N!5^'
M[\TK D^P!R9$:PUE;2BK(;QIA"PO+5B,O .#>_LT"D3[8KOE5R(PLY&N7;;+
M:1M_B#*:E@)FC#46!5PQ)>5?J)Q%-QT>V:\BW?-_A\#SD9THTS%B)0:V(!S^
MX!_#!MGT1Q.5_I))H/'U@Y\8N=4*Z?M*WSKJITE>KVXN?:)? 2 QF+?V4D&T
M<_ 34U"8\[!8-;+^BT9[+P4?GW0F^=R8+1XC:OU&CI1XG5)(Z&JB!&4MTH91
M.8"C?,/$U\=>I>N5P'ME_O\]Q+Q_Y.-@6GK]\EY:'O0H)UQN,Z%0ZN&V^D>X
M1Z;B&M?D7]).R=@;F=;KJZ[;:*,7G\1@%]:L_)='T@+M\9._(C[H?\.*;$#D
M+<IV%EM&ANJ)4A=1^5'?G=/78+0/I6Q3.T?G+G+A@A;51.UH)@M>J6MCJ#GH
M];GN'%_Z=K>#=K<V*?ME1>7R0L@\G.TAG+OK,'-5V^/)V[DV;"TE8D^&&-O4
MI2J5T,W8?NI(4W,N16)<;L++D( !QUM-=RU_&DLIF+^(%36A!SI/?HMG];*!
M7Q*;X;D=@KNKU#D2D(*?/W1Y%<>3U^2'\N[HO06T3L?H*.);:;PAD1?U#Q2N
MKW 4B,@3J&T-IIIIJNI>=_0@BNEO([91+B2'L\D(> .0!47(.BM\:WE=+:7X
MZQ%Z978^UM(N@K:[(J(;+O-VB<"&LVBS?,,/),"*++)3&X0MB(1+R<-WN C1
M$)KG,N",FI9.N"[LVCE+!WH%LL11TV1:PGKHAN/HK<CC+L/A@9<5"Z&-=@0F
M;\8/C/90^F/AYY"48Z? Q]AWD_3I.V%Q.FK$M2:E9A-\1>]MOLS/!!ND-?+D
M0=3BI\Q)O[;3S[U?6KF@G"F<\58VE\YZ<@E$IS>IE;H+S;EW7G%T=.+#1=!;
MLP7X!X.)P;-H,LXB-L>V>NS@U712@8EB+@VWG=-[5!_'O %FBZR7&0IUD21,
M/3R="-U' PX"FL(1$,J_GPOXCM;6BI[OW3S<_E?=^V*<W/>\'M)FS >8MMRF
M#8$K1Z/1-BL;J8\'RO8B[]"U([0:U7+#VT9C"!<FN&,^3EB7;#;/E$>^25M,
M/I7E"E_FA%)PM)C[@/]-8;F4PE$3Z,U2QDWHX0K5OUK$)/ X>1;.OO:K6U;6
M@8G-I@Q.-&7/?N5!C@;SJK/*T=BN XE>NY*+M$HBRZN3C9#5I7.O^LQLVN+8
M.U SD*XZ_7_ 8%)..6W@4=U-SN)&G@PF-TDX]^X*PE80?G08!>'#,G?^WA='
M)O< I<1U2Z^[G2PDD>.OES?V$:NZ9+T<D-RLPTYKYQ0.O+>A8\BB[0,_;N G
M#HNNXX[> 5S@U^>/0>K,W7"M;V$W[C=NRHA.OOO"X/*(JR_\4MHB&^L83*+!
MX7/51O+J'NNSTJE3M3S\SAG'T.R?CHU[<./RS;=9!B/>;- IZRFX7.>8I/R[
MLO=;4CJ[@G'J>/(RO<A&&:UX?/#V:U/3D&9]+B/9,;#;RDZ1=$FR?+<1.5%H
MS9>:RT/2+:9/2OFEV?-HVYA48E60BTKC0TJAXO70G<HF(%[V6&D!_R?Z(+QN
M %SY#B*5NE]33\D1\>AN>TMF0;S7>=< ']0\P7. /GGX_3IE^E4]9+FM2Z6R
MHJ4,QX5<C&5IQYIJM;)YPSKDL&>1!8P^!$SC>ALISPA(6K'\->8D[H-#MP @
MX_09HLH@+*EA3K+LGKNF?R9<CF40!T6(2Z44')6R]#<0D0_/G88=W7&ET?&U
M^N:3<TGY\?UP//D;.I:ITXN @%M>T;"7&:&Z63*UDCV:D0(N8Q+IR1+")7H.
M68QU-:M6.:O6,Y8(=( @<%W.&%"$9^Z@KV/U!%\L"3.VW3M;F5R&$+JI6!6'
M<W!]!]GS; 5;SETP?(VY%-H+/L)V)^^(P4<J0G)SNL<"R?S"4ASVS-3R6P+#
MIS6D;L*41.)('T]^Q =C=H)2JCRWN&^$'VH8^WQWLVQ=] 410AS5Y7S]W3-2
MW_%']>CD6SNIUSB,IS11O^X( A?W],7OU^7Q(IF1D\=LJ])\U-(=.,F/I[N]
MSW[6;9AU*^:H8\1GJ7TU*B,2)/T27NLL $'>NQ=W"_SK%GC.[9"2T)72 ,P
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MTCR*)TA+JP*UPE(,Y[11S8NM>-H+2B3@>V4[+Z5O3+3=R2!4TKYE.ZV7=CN
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MZ8(#SICE91-',0S#^3=314P7,CI&'4<LGK@0?=F+TEJEPP69S)(F4DW0@*'
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MEELO[#*//50X !1?[%%3.PP', ?P]F,(JB:O55CB\-T]<RLL;A'."[RN"'\
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MVT1@F+%;9NF''*2BU..RM<@"W3CD)"F2!1>07#SZL*0K+&G.BP2F!]"7>FW
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M<!0BB"IIS<7I>!D"KMQ#UJG/G)NCD,-D$0\'CZ&(1FF[K\E^=K?$5R^Q.^@
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M@&L+7<T"*'&M?-*5IM>$W3"A.F$?@HZRA/3PP>1>'IM^I9"57&KSC%66/9[
MW(/[P&Z]BC,,#$>AF9,FF'LA.'<W>?Y*6[)P%R+W9!2'7SYRKE9O;^H=AG*9
M?Y(UEYP.3,;Z CPQ))-A* MG'*-8WXR?\$&3\E2\^0_HC&BB(+>:.&?2#9/0
M8,:V0U(B Y.-U,W)N^B4\59*9Y;X$X&V>%KR<E::0P+^3![CJ0SZ W&R::.^
M#N]T:,_MB:7IBKHL:ARCCG/77P<3^ _%?D5QY?)8^GZ4R>?VH&8C<&D(QH^C
MRY;J!9CIEU!E:+ BY)-Q+-6#T=%<K5X:_79VO4S/ 0XB'81G% CV"3M7-1LU
M ^4YHQU9JT<"%5&=.-(1Y_#ZP-?6[X%/_?62M!-4RVR$EP2UW;N&:Y#M'L1[
M2)G]ALI_<AU.B&T7_D'KN1=BA]$B1E(F">ND7ENR]EMT.Y>TDQ%D]]6>HUKY
M8,,L+U4[:",E*84)Y"-G>5"FQ,Z1QHU-B.VW43&%+ =S__D5*KR,3=EJSOG8
MA5ERQB:YS=4JYM"4LE?*>X,$K;[D1F'PMNQ)D93.B:X%I%NXY6E=#JL_4XGQ
ME=[DC547__R*BHN[2)X#JJ:^HI?2'%A?$8NN8@2%=2J!SLO8X%8#!]_4=$8[
M/%[ _!-V"S>$&:?Q1TY?Q,IC,IQ;+*BALD +['4OKI]=-3SPCA,=I2K^38F%
M(%]>AYTA]Z1Q!]$:8T*_&:F=-LS)=V1L8/Q?AKG;G%:??//=R]_@+F]2CXY^
M]9V8IJ\KAE26\ITW7].7N)#I"K2^*MNN1(4\+6"4@FY6!&EF; 6N;(_\MW:"
MC'"5WO\,/V])?)J>]B_!;6[?$^[^KU=L_=VEV+H\.D(V3XFT8NJO2096W0/U
M(NXS_>B];08IY&3(W=F[KJ2(4QC==*0]6%?3L%,UMV>'D3A"C\2O%^PA*DFC
M<Q4=YUCVK)@?#XMX#1ZNX8@64#L?%L5_.7[T\'ZM"7@J=,VKP))K6?N,AQ>5
M,-+;+=TG7"3RT!:3<4T$9<YU^^0\(0Y/\2A6:.,L<C8SKB4;=!HH#WSFW9^%
M6T4-*K0E="]EA48[8LL3[1YC%[+,N"329[M0XA:XQ%X&V? _TA13]D=U@.SB
MD?%KPOPW:2N<#_OYA/Z]^08E"\,E(^:=U'4JU4) .HQZ=QB,86PGD60)+,Q/
M9?X?&2:_SM9/7 ^"ZP)/VLN-Y%UU)1"B/%"$#R(H3V7$'HP6\>]E%*K:4AD7
MQF,(746MA]DC77M2VGT?YB$,,#%=PD:1X 3''^<5$HH(7]D L=>Y.8P]_"S9
M-G=&%^C<%T4"[AD!3JH\4]#0W\F0;5*29R/\$^*MJGIGI@GXXPG3Q]7J[R)5
M"V^F!$_7MMI!C,1W/2J7:<(XX+C<"^*DIR-)K7=['>9Z/$B[?DG&:V";.6<M
MM%:TM"L89]\1U1#5@M+Z9+N5-C*Y&KT> )43R0'="/,_N[M6P6B/CAHUPIN$
MN)?B)UHHRN,KW?%H6>151W,0)<ARX2*_ ZK>]0V%IPY[1WAA#Y=@K5YVQM)]
M+$EE7>X:065X8GF,K=S/DD/6FK\HB48_YCL+D7(*H\0IGO2QZ'4=1;$>9" 6
M_SF<J-KX.(;_]^2PB#ZQ%U>%^*JG@O(*@H+T")L,UTM$(4MBA&Z:JKU6$,V-
MNY!FVL/XEKTJ E!/8GVTU6/?!Z*>,H=C\ ).TNRFI3I=<I+OH)KXCU-R*W/P
MJ;170R$BE33*E?CU/:T+78)IH@3=E*X%4FN"QC8]L9ZRXE5]6FCWTBUA_9L
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MRDIH5*C/80G\'8A2R8A$>K8S#F'&ZE"&Z3X+JHY_:GA+I-UVY^Z'<U3O);P
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M]9651,IW5=2YT=9M+JI(RQ!'[():2:1O$:AK]I*+_WJER$%OK- .4A:3=@R
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M!R83ME"-CFY9Y29)A93<.UG^R9&'VV,17&A+UA0\"828P)W&5J3BPFN /A(
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M"1W3ZGJLR8$4E18Y^YKJ%KKUZ<?P#Z(3&)MKG*_B8LQ3'"S'LC5J8MXAM*/
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M/K%C3_I&@GV8V"TD22QIYF8J;BO26^):6#?3VF4TAN,0X.YU<Y!AD,B%/_?
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M-'OG=1EPP0B5=K3]%#E2>*M12_>:,*#+0S)$>&;2:[(LJX<K!RX8<M <%<+
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M>0,NHZ/N1X>_+G<6-H!JN66Z]#.E74UZ"D$CPT,^!])/P06',2/-X1$00#.
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MLK61#5>\K<@8)@I= 8\TP-=SZFT$J"T$E):3[ZL^3^<19$NQ(IK=9$*OD19
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M^/D8O6!.YH&9@#TK8UL;-Q7@.$6&-XMD8N +98C.E&<7.0$IO__OMZ_W#EZ
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M4Q&&X#-C*A0MW#;G3+X 6P4C^DS.3G!:2G D-P MBLR3N3O(\ATOMW2K[ 1
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MK5&O+@8-\'\)DQEAV8DI89Q2#\3$0:'\&I>3^%_13P1&JJ+@*NC*Y7R4IUI
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M#&'*)YY"92N2'@H/,V6%+8$<R)37/SGP85+>!O"2^P@PV7QP:3!UL=F3CT(
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MZVI)LI4U9MHZI*B@2<G8MH;:?T9UDE*)&D*!<J,63AH6-+[@EJC*Q/, HU3
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MK+WV&K]/GM'Q+NCQ=:QW<KZI!,RMR1HJL!VB.5>CG?=UAY$9$8W&#$O]JXC
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M9==D;9N(Y=;,Y7PRH9V+NLK?XJS.2C&JE3CP6I"#!(8#$T.Z;6 %Q"+.*!J
M$T07&F)N3W>,_G)T>MPY++\(*YSI)K90 !6>NY99S8HLG BY6Y1@V1A"1+<C
MWM D&'[!@DZX]4$-"!2ZC"C(\S2,&",IRJCV!QGNN);&J>O'LC::#8PL&PO
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M,5A4BB.4'<*R0T=K4G/IJ"48%C[VN-#Z>*D*)-X6[JNI#_&'E* <&5#8%%:
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M?JLD0/NG3A]L8"[(/U-'896[K>BI&/K'722<'>X<W7P?V5)AO2H%O>K=<K7
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M;_<:RJLR.C)(U^[ O'%%%YV>.?PN40N3V!N1XONS&([E^A]%B09YR]5\'@N
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M_\]?HE'_^/CL\'38'9QWCTZ/^L'1,!@<]D?JY+S;5V>C_S[J_V4;\Q$;"C:
M3#*1TNE%Q_M/Q%&*YMR(A(H._A#K_WYMVLU!7JE1^0.7L6!"8"?B5@AJ@+B;
MZ&" T2]SH58(F@CF+<@$B2/P_X;DP="?&((*'I6(QQ[R)]NBM)=N\7LS&=RH
M[1KQ<A2R$:-UHE)U H-YA#XL_A]37PC[%Y'WS%!P%.MQN :T-Z^Q]G)3'4!
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MH/D!N7,2Q@FN@RC66&\%X5<P.(E$0[(INTWH&<5QQT,%!L_1A76IT'1HTHZ
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M4 &+S%B8*^XZU6R+25INA^/J9DO!0U@.V/ZNAF.""(H")YD4+JPLR!1*RR7
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M4\1K%#4W!E/5/<Q('].!71BG:,<!>V5)"W3_/P:_#&1[5*9),/QJ:<D#(LI
M+)2,"$EG)^2EH@6I6UIW<Z^V2:VRPS?K5II8-0-KD_:57\;[JMZR@AN&?QYG
MY Z]S8*IPB)':N>Q\)[D7L[G++=7>)6E5"#]J=3D(J</X>6&-R"QUBGUGEU^
MNOKT'!:DV]<V=BK!=0MF[$OZMR0S9:M*RN?V@G+?@H(U)^9$[@HJ5J2K15S
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M1O1XQG8\)EI/O<]H[A+ZO&-*,\Q,I'%U8NH)*345(VVU^\Q8!4.JY,!."F]
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M'.% 7AIR,J.Y0:^FJP*UN9F:DV9%":%C@- Y!)#4PC)?NLRT7J+_P$=$<!O
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M 7)\@DG2",]1''MI$B^$S65! ,Z)1F1L I/6J(S1R. !I;,H<>#+2M!##E&
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ML@*FD%3M6N4\"2R#U?C.X4<E"Q^H[ZY"[[B3,Z$@/.$4AA[#V)!;I!06^D>
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MN<>LYMV=A7OC:+75%VY[:D2WI4IG7U]YVO?/UTYF[*OY'C(!TMO*+=EG-I]
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MJ^U5VZNV]\2V=R>RZDCMJE4%793JI#13M;UJ>]7V'JY=U9A,V$/__7'<8C3
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M2!X9(])N0T:_FX5N$*+4FW^1=L]##OL>:E_@5S@LF7;]MU'&28%?G$SV]?L
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M(;3TV>+>X"U># 3@RL@8''$Q"  .($]<,-+$A4UV.P\YJ#S&?.=A#O.;@8&
M.$P:<D>>)3CV2-ST:C)428R %W"H@95<'_A>X407H0JXG!L^BV74T4"$^>K%
MZ"(X79M-N8A<$S>9<CV<KEQO$@R)P!"DD,UX A@,\_3L[,[XF^?(9W*^ PH5
MT1BSP/7CTML8#(S)/>6?B>C+$:"8O/45VXB'5.03X4'C%(WF4"!C.5'K%OUL
MI;B/TJ^)>O$7=XSNP,L_SH)>BIF*VGRV7^HBS=Y .'4YQ?M8GAYZEJZ![ZV_
M_3PL,*]/\\O O)2KE7H]TT,!6KKT&(P+FX0WZ+!_N.48]9]X\"O[@2[S7;R?
MEVCGS$7"S3-(^GE&0L7!6)HJ(R 3 PX$ *0)#M,D1IC*GP,&^N_$%T>Z15#C
MTF3DNKM U_G+"W=L=;N#=M\Q1D.CT^]8K..P4=L:\][0L/A@_'O?>K%2O=E?
M3-$GP!?-L%K:!>AH<,)Y],;$G0FFI4]@VZ]8"!SW':-MF(A@:7RTW\7E]??S
M3U^UZ\O/Y]\_??MZ\[=/5S?:^=</XI/+#]K5^?7W?VG?K\^_WIQ?T"-/&2*V
MPP57<_JW2M%(027,"69XC/<A1LGY6=2)C-() )831$ED;(K!YW<N3 JCSH%[
MX_S8048@/,C@(7@Z+)!,'G)?Y'T*.)DQM )<^" 64DQJ'*Y_%WAW5##%YAS0
M_!=#Y!J(B/O YZD:417+F)53R?\(LA5U!4Z)V=T_%W,-0/T3RW-!3DY!F+D8
M(BV.0IN2J(U>%>,2@ZEVCWLQ%A*52K9(Z1E*OA"YJGJJ0])>R[G@!-(H6PWS
M%T(,;$NC[EO:IS%FVY;&P:,0&;WP.N(=?#X0NA%;^QS2/,'U)E\:-EV(((+2
M8U-,O@(A'H0R?UC,U9E_KC <OAC/3D3W768G^"VMB8-)S"%H1D 8GHQEHKP'
M\;T(H"9:?<#T82\GT#5?/DI)641&ZYH[3K.4R0,&+R<MM.@.PPF?)P[H3EE4
M:4O[;<)]3$^'%^/H%!.MRUW"':$85<DU%(M% \)22'4/;#L)\V@X.#*1?R&$
M86'.@BJ<.U))JX:3RN/"+.8F+%XK!M#ERD&)!:F.>28A%R2$Q0]"AI*PZKQ+
MTRH<!/.B )^9XG#$Z)A-D]H!\Q.!->;K6+7_ZQRKM*08YJ;"^<;W'/!L_JW8
MLPR.!+/>D]$?R( X#UPJ5A) XI#Q[O,_A)%Q63X@>CI(2SL'%%MC0H!,_FV
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M(G0UR[ :N6B1(4XN*D#.PN'I^7D)!5H2EZ2):KUVQ+PB"TNJ%#K,KS?XX+1
MGJ%(J(ID8EI^]_D;ON\FAKV)M?_&&OG,DQO4;6/G%(IG<.DB@#)&,4D:?@WD
M$4_0KA4$&F*4#7X4E4YLZ9JE!0&: QDM\U,/1:<:F(C57F,F9&U5=5Q,:4KN
M4Q5:"XXO.08J<:S:>L_C"7.;BX@?=[9@AXA:[&'""^P9Y]4\$IHE* &8-YC?
MCV>"(0MGJ%H!$FGFH:0*'L+87:C37%:\I\SAZ6VT<+CF,#5^FH)?:VI7OQ@
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MW2S&F/Q2B@$;BWI*13E\YS+<AQ"L(PJK!QLE%Z;SQ:?SG<W.TY(22Y0LSN2
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M,OQ>&)1:R%&)WCGNS1J\ !N'/&:B8C/=_\[;,>8&NAB,D:&(>&.Y"VL^=M;
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MA>V3ER.'D4*K[%^I*MX-%L>"QPPS+>V4H<RYO0H"\7&G_*XH?Y<=4+FGO,2
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MR?,KI]YAW FP.Y 3V FR8G3&ULE%/Y^%KJ<9=?=MR[U=_H\DU#Y,@%I"MN]
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M2/&!SI3_[H?UFX6??D>!!7OK>%:PO(G8/ 2^QJ<'ONL29T<L8&%E?[W7P41
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MGGI>5 NLHIF*VH"FB0\*>FV/T_5L'(7"@B?53^,B 34.0\UU0AK)^MDAX>&
MXDKMINKIQ"AKB[*G'5$60:&WQB<PVNO4_8>O+#)PMKP1(Q)6NKD2CNSQ^5I@
M1[;=Q ]L%IS#!KW#\P]]U[$-W)93Y^)-]0.<X#4<X+? ?W1L9G]8_H23U%CY
M2AUC938>G5T.!^9PT-K>H]CL&(_ UWBU]+BI5GE!>ASCO$BS7Q"<.B%Z%!I'
M7B@.K$OP6;NTD_9P_?I-?@4K.W4+ IG=F+G^4ZAL",=[9&'&AFA &8X6E.%8
MQGM^BX/I P8P_)FQ"-"0C9940LG^CAVJQ&W&31^V?>N;M<1C"'_X5U,XDX!]
M$\?TS;6\Z,JS/\F3*E#_HQ9XE9T3*&!K2*9">'L[DFF?70XZV[1_UX1D=F1$
MU!_BCW"^F!T:L\"?&R&<IR[-+XP%GGJ)4'_E><O]@?PIWA2'A5/8:4S[K!)S
M8M5*9W BJ:6&<*H(]2J$LW$KQ:C;(+N6JZMZBWW-= \?_"#B< O<D23]WV0B
M#P;0G3/![O"$?L !W23G4S68-T+,A4[;;'6VB>;5Q#P[?7IZ28M^/3FM%OO]
M4^N@>S76_E]6% <4'B23'LW]<,<JH+'77L#0%^>V!$/MVG==-N5@_,3(T99Z
M :M26B.S/=@:5J4F1EQ#:5MX!L^FM-4JHYD!L65"0-Y87'_H(3_2IC BW[CZ
MQ4(?:<&(%[, +C7@>4 DOL>P.9;_#M6-%88^#@MGMF&#&3*-C"B )0@BGOKA
M5L.!7J^MN O?@P!6Y*E^]@-D?FOB8PG!([L* @2#SX<'-E OH[/+WK!OM@I0
MNQJWHW:DM*L!$I4I:;7Z:*9''%F10J[,L:A$H2ESK$/&N%I9V8T\Q^>7E8U;
M9Y?]T= <#G> $UW?NK*&(/=2YUA(D'F:VSHQ77MZ:^H83VMEIVXB:'6,"\'3
MQF1IS!S/\J9-+6-3RWB0V2-Z-4STP PG#&.@1TJ43OWYW,<7\:>_*-Y!$AT#
MZ#-8HW??!"\."@2FAS)OQ+'=SJ[IT.[PS"H;JAV<>]PS!Z.MBV9JXG8VY/2\
MR/ANR*F+Y-0R80-.A)SV/>G^B#3)CVQD>^\JY0338X<KH+^=$<M+.7"-)UK$
MXCUP,]O;M&'7)+W5$,DS"FPV)1($>=D*!:(F1-(X$KMP)!X="QQ@Y]&*&%;;
M3UG3.%6O IS$^/O&C^F;/*7*%N  Y]F=COW7D-36_L1JDEJ9%1WOKJBF)O34
M^!.E?V)"E:9>+6@&.@'-8?$-JA;VFP53AQ?S/UF88=^JD.8$;<+#*I!_\C/Y
M)(ZI>L)TA/!.G58#2'^*A%1!;:PFI-7*8G<E-#6AHE=>@9GQ,_A$1!IEI70#
M$[BDPM%8R)XO[.GE+;V:XN"_\1=($4T99ATS&7</5L#"GY[-@AOXP*-Z.L^F
MCS_ N=K7&KHT]G6&\#,WQFVDN,0M/]N\<.BV6F>7X\[6H+,UL2(;2MO6*7E!
M2FN?778+<"J/D]).O41C%[$OJ8\6%J(#+> C)PS]8&EX?G38$M#39OP**D;@
MEG_#$_K()A5B$-U6Y]3,RH:(GJ<]5A/16B>WV^J>7?9[.XF.UH22&O#[XO'N
MYZ(I#+V.%] .K]8LW&7>^SM;J*3FUIR-4U**JZB:#K"C)J(UZF&G1-0'(BK6
M#D='1(W;4.@VR%;AM6HAR:6G>X8;'V+//H3B;N3H3-G+YB[$H'$ACHR&7J9X
MJH"(\L0R/+OL[:"-Z] D<NJ^@>K_7=?:<T@3_Y1:+G<HUDL:+3_+TWMVYV^W
M-3J[' W,?GOK3':E$SP"1^&UDN(:Y?""I#C&AN"6V2G0)J=&BZ^BK.K3;(:(
M0N \L-_3!P09,0(+G05LP$!-A EO^@L"63\".=2B2NJU,OX:'<1/\W;V29SE
M=SC*6P]E ?[O4W*"WUD8!<X4G$7\XLJSTQ]HOU0IRH].N/!#R_T3SF,!5\"_
M<6V.%S-;3$TJ3EZV6Z"^NKN:S7IX>=&0\'Z0*^I S-6T8[M-%8=;0077GLQ?
M1?O*&SEL]*TAQX\B'!,J0C.G#DE'!HKFZ/O#EX*]6OFR*5335I+D&[R';^='
MTPKYHLLL+L<JRY+.V65_.#3;6XT1K+V1_8J)>H<.7\U)&6L4A@-SU-X5($1]
MZ?E5.(W7&ZM!PXJ,";MW/ _CES@BB8CM\ [D:8N+_@N*B\K<C\W]O9$Y: V;
M1-7ID5I[34ABO[36/[L<MLWA. \3<)RD=NH)KVJ:A,''>1VR(]_J!4W/HBT_
M)'__V\O86QLS1NV%6J].,FU ,JW7V7K02.V-YX8+&RZLJQ4[W)D56WLVW),/
MNQ\R'!:2X5V\6+B$'&*Y!@;_73^, ^KH)8#=SZ[_9-QXG$;@C ^)I*L12A>H
MP?;CB<NV1$\^PJ7MR10^I' DTEM8( <0T] !68A&,*;B5U;V[ML2/GU->YKZ
M=(VG?B/H[1L0X%=6/<J+<"LM<] _(9BNAA-.DQ/6I%-RG) G]O'99:^[JQJX
M0U/ZO@V^0^8M=/TZ]>?,B*S?[(4JVK:.#.]/?&R(T+2Y_"AZQ=-!GUJK2I&T
M?B!EE<N0#@YTRB?WCS-0W5#["5/[6G69I_:-^]@Z[5/K8WL%CBKVG&7:2;$\
MSII.@Y@A0!K"'.V^2ZDQQ^L@8/;FF-)(U%Q[(TB;. B8_2&.OOK1_V5DI5<1
M.+O#WJF)^=YPQLERQJIAP9MR1IX#NF>7W:TK)&I"_*_&=_6]T+%%9P+YKU6'
MXO"API%O( !A.%L:EK'P [H=7&VMCC$;;[[BG^W1VU?O*N]:@-7(=]B]  -M
MN])W4*-?F-VN&G'N]! 5LV]VVUL'XFKB.C2,<+*,T%U34U3."*NMV7[C/A^A
M^PP:.4!EG!MWYU#;!7P%[K0/&CX [>N=DUWG1885ANR9R$V-\_#JG(?5;C4G
M06W@8LJ'^!BCR?C5][#V]C9  #K'<L6_M8NJB*K=(5;5Q/=H>.=D>6>UX[TK
MWLGS" )U[:S2]]#\<5*%A,4T]05[)6VAF U_$EGP$]+>"D\%77&?8PJ $^Y2
M+[GK6!/'?3Z45^- O#H'8AWT,-[V=O8S9%=(B[>"$F\\V;_[V0]N)142U7X1
M-+BL['>/0$B9G=[68JHF'D?#-"?+-.N@EO?(-..SRXXY&C0P_<<5=[\IB[ O
MX@"_B>0XR:M?+/2-+\X44]_&U7W J+] !,X'V\3-&__CU?D?W37-3]O$S;LM
MT-]]<WQ* Y4;/CA1/EBCP9\9-N_NKNJL)CQ ^OB/R)JX3.H8;?JFV/_N\*(U
M@C-:^*&#[_J.<K[.(WO_Y-C1@SP?[4*^P'>MY!)K$OIN')5?HKTS#L%CP?XK
M'#NXIA^@E*TIZ&QX]A)=;SX%P0K@8X^ZJ^X#RZ5T-RIWU.% >]2'27EP@;L-
M/PDC^(#@UB_26KR&;]UNMS.6AO8GKA<YP)EU^_U1:VBW)^-V;]CK6CW;FK2Z
M,S88M[ML-/OO-K;SB*L> OD2"^N>G4\"9OTZMV;PCN\L]\E:ADA_VE;,'4^N
M:=B!16<)A6_,Y?^:!$BWM=G/7*=HAW>*SN=.9  Q!=:"Q<"\(4("7ABU7_E7
M(G>P3J]UJOZLJ/I.477]W^6-XP&#^C'<PPY-C*TQ[)E^X,QL(R2(^!>\I96U
MM>5;'=\YK&:5#5D92ZP/O0EM8!BN9[_&<[C%-!_=RF"86U$<L-N9CL8JE7>'
M6PF$UGH5B<_P%@P4_0+)-H@9;#S= F7[ASB$%84<6":Y(_WS.T/*-CX]<F3K
MU"+S>UY^('"A6!0OT5*+Q845++?S(D[M1EJ"FR5@5OE\(][%.+,6?[7!IE6C
MT0V^W+>&+)7H;^0""U;5F>+_O>"JT!KM)&;G(3;FB=$BVN]-XY7O!"<1L1N&
MJ+5\Y7MRS0UIL2EO#0<$@S%Q_ 6HW;DU)48";2;L;7#%IE1OZGNT>38";(/S
MLS3!G7MDKK] C6?R\0+^'*0MZD+G7Y:L1UW W^ 7YZ:Q>%B&#GSKG2-26,#N
MP5\)SNG*T)\Z+ )O:A; CVUW:<R9#;_U8"$1\;>#<\] T7@VKWUUYCA:AQE_
MQQ9&<?%)KC-C)A;><)CG!:AK#Q.VAAT':CG\1P*7S'?A#KB-8)" ]SIG$7\N
M7./A8-<+%"Z&V+"B,RMUZ_9UF.3[#@]*3Z&Q<!8,/Z?C#GP[GN+T(\\F"PG'
MU0&I('8SG-R3$ST0'=W[>+2^,6&\>1<^DI0B:<"$0W@ZA\-'O\VSK< ^]V?G
M2#F2.EB(YTT71XD60,_0PK7X'N[!_3+O[-50FVF4)@XU-&2YF,LL6V>W9'=Q
M<YU''W8"0RL3H&SPCN%WID;^,R<(HW/PY::N!5; Q D7;.K,<*/@!Q/?7@K.
M0M\:C@0.9(*GB=O*""B8AA(Z\WGL^7R?E\:C8Z'8</WI+\NFD__V\;R=G"_>
M^MSR[AW_GL'J8)G:K6!WZ?M_?/KS,PD:Y"!<A _W!&/EWH4C]ETVC5UV8=QZ
MQD>P[>83\ WZIM%I=3HF/4-LET$.#5,WN/9=UYH(DXA8O2"8C]<+89S[5HE&
M>AO*!YC<LL";.8AK.)LYKD/4_4;<A7ZFKM23"D\/SO0AM> '"X79N<L?;.LG
MB"('!,H]OZ!@X19RTTP6)U!.8C_<7^P/)/F00S!-F@Y4U09^*)HF8/\%X^14
M%-/W7<J1GYZ#7AWY<B!=KBW/LBW3^!0'_D(HCO^T\$T+*,@V?K @<"(_4-J5
M:Y#\,>)]4D6CKA_R$_U/"QR/8(EDW@7EZ[K^$_(E*.$(]@N^>+(<*D#AZ)EI
M':4DAY_X1D^.ZX*8S2ER39P@=VM;@8OC-:NSF)R(9%X=[$"8VG.; >_-410?
MFY0E+IRP^]@CEM;W@U ETK2!U;OAW(*MG#+XPXWQ3#"?&+QZ=^/KW?67:TGP
MIB&U"^S5TG"MV)L^(+E^>T"C[.;F!FC=\<C&B@+@PU!R7D+KCH<V&%'ONXJ1
M%!7?I*CZ.2:#WG4'B^A 05SKK9$B)*%:A1TT?6!SI5!A%X0!%/)OV0+;Q(#D
M#+ PG^"#&; A=H,QC)GY#=V!\?!=DMWY/$:);9L&6"1$>9;]B.QIH]<'AKV%
ML7\P>8B/P6F8H\E/E OZV0=9 )X V*X@H$.J \2H.! HLR*2"'0B%M"I U8H
M6C3"NL U&-$R\#'$8OP"AX4&S#PX$Z<Y(A"W_W6C3")I*/W'U?>_;K\Z\O/W
MJ&Z.F\LGE;B<F^/D+VETF:%))0HRNW;>E?M6>5=JI8>O0IFJ(R^&_QU8IRA7
M9QH3V#_X(+8=D?=C7@#:@JP@L5%'8WW 8H,E=U6*+?S$Z0!1OP!YQ)'4:?H1
MZ57T_WA%LM"<6>,OC'#TX_U2N2O"C'LIHW"%35AHG&*W,FA[QY==4B%8ZT"S
MCFO]"[P^=&)S803>*8WR6#]U(XQE4_0L\.<O[0G1'=\Y$7@/TTTB;6#41_AF
MOH/O:#O@-4X==U\.6_&B' _=<" "V&87:.R7YS]Y>((UV[N+^NT74.#UQYL+
MXPIX9P'.5Y#B%V00<-!^,:)0C3MD/SYPO$[FW.:8, :L1^R"/RIF& J6B(4\
MLD(&NOOKQ_FP.^(.,:D8#@9 T2"#1WXH/ ?&><CC(A$8*3YE39"W4&EQYIK'
M;N3807R/(5('8V^1H78AS!CX4RN86 LPB.;GR:\_84#&G\ >P)Y;4V8QI<>N
MOW]*(L_JIJG7YL))9MIPVRB:PJC" RRO\,%9\#7/XH D4D9LB;TH2.W73B>L
MRN!E$IIU?Y6SRQN@*K ]R# 6ZHW1XE$C6,#(=D9C&;>/+'ATX.DA)P3#F@"]
MFAE_D*N=@&^'=M8A9R%_RMNUCN&\R?+!^B5;OJI?@^BFL29>Z6CA2CP0JAR*
M1)RR()YLIBR'-S4(4EX<4H4<!5UJ479>.#G8@!CI9+_%P92".\4$6/*;)&!$
M=/A7< %O 0^/C(_Q_;W%2?LC?/J7]6MI_']@[UH>>S#74*J%M^?@.!BF@_\R
M"WX"2@$?D+FSO*D1 X. #$',G#1:C@I.6?=PXWNT0]%+XVKFWRK5OPY7U[]2
M<=$W:XEUGY7KP'$N8Z=EM@H*P6O ?1K6T"$(.ZL6_L@4^!35UU*YXZLHKFVW
M.^5EIDW!:%,P>OP%H^4%?0<LW2.%*W)]7-^VQZ1PNVF%.R.S^0I.RR;-^M6_
M,#K2NL:I2'2VU]B-@"X9CZ4AD&^PD#:BKHPS-TK;@OB[.QP;'&&>$1VI* G.
M)?_X".+P"7<\\I-J&_P%:"JT8M'OC.', M@,FQ\.+R  >DMUWDV61JD*Y9?E
MM.A(UZ(W7S^G\!RNZ>;427)'EU^I962G(F^F8EN)BL7AIWU2L25JEL>?*K[.
MN.1UU&BL\C>J_ ;]L\ONJC> TZRX_%YKC\L?@*Z2BR]\ ;0DR1Z<L"FL0M2;
M..@@ L'%\ 7*P>-P$D$V?&:3(!$.PR+90,4,E.-"UEH$[!$+V3#WY7E@I.(7
M6>A(&8:AZH+O_,M;\652LP"/_\L"@]UH%SZ6URK@1T6WD<?P9&'@&6-$83P)
MIX$SR82WR*.'\[$UZ_H^\$-\%7^*]7<\J%OVH,HV>&\-],(W\=C/\%39+GP[
MTXBXLF$^!,.\C-_4NX5P%;P+;G]W_+XJ#[;7\. =W/UV1LO_2O(9_D%WXLUV
M-UXI"-0&3(D $L.!V1ZWS-ZP"(F67FF%"K B"O8[4Z9I\G7G^HT%] JYO4AA
M5'96[,0W?&)RF_R+C;'3H94'QK@P;M)HZ5:(M:NDA)4.+236)X86RP)(^S<L
M,&+ %[LE7FM))IUXPQ2@< %I@NR^'+3'12^($':>)P)RZJ60ZP73E7-^M3?J
MOIQ+#+MUV2OC//$*Y5Z_27B\\ 58*+KD Q69A!%,0=US:K2PR1H5JL>.N7$:
MI80=#:RA0E?8K*FS $M<!!/PMUA:Y,<1E;KR! +'X%?3XS (RB@\;,1T$BG8
M7W[?M-ATPF)2K$-(X) 1@;='D2S.V0#MOM3&U=AL#6#I=R!,*3J^\U05(ITM
M$9:\,MN!1U46B*K$=3'YKWJ0SC1T1BOA+)V!$BZ;6"Z*PF,Y=6%Z%9I\W!U$
MC.][A]+\#JE2X<^CI?L9#LRX.^]2NI%^A2E[JALC0R.=6EFMFI^GA?N;>P5
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M.;SU.3]">(U[RQ-3@41V5&%EFIAK@"=/8O[J@9$@S5E)33,_G("R5)Y/<8@
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MFLZ8H?I*YY9#)2>$$$ 5:XJHBIGI#[(,UT;X#FWFIW$C])SPBJ(7'BE> P^
MSPZ1])X\614YL]2@GVW %5:76Z;0%(1+<0S1[$]ZHR%O',9@<2C27S1CB6>U
M E5V1(<F&WU%#5G (D<4C"$PJ>6*HCE9Q2FJ,]"/\45 ,)D)SQV^LGBB*(Z:
M^PC$H=5]3)-!$#R7C?E?2D9B_A"GR(A<@XXO09_QJ;A)N=A6V%Z5W/HOZ#DR
MTA>E\-/#&K5)\I7N G/K<#&&;)NN-L^1WDZ0/4+LDD1(9TQ54SK!S!/BEACV
MQ*^6G=U7=]?&J-?A>$"B;=Z1$Y(CCKLHY+BLEJ*8!F.T*&($&E4BIGX%/I^C
M$/-6-<Q8)D6>Q$V9=<JB@!"C%IAT2L-UR8=;U-C,%GKQIERP!J*7U#=Z6J<^
MGW"4N8J7#]T'(D,JV9H^X:@$L+D86V0>[/24S\ND=Q45)1,P;G3LG43;J4IZ
M%1<2^V:1J)>U(;*R7)O,1=6R?+"3*%;5+Z43X!EAA8ZQ5*4'*J/,[Z=F/['?
M"$80%N4IZT;S5Y'VM@2C &=.AU%0S\Q3L:%*Q9)F3B@FV6<2M?SHSOW9.9(F
MG]$CYU,5(+=?&%]2=Y&])YH)H")]HG 9*Q[3B7!1[,/7DT +2$M3(QC*4&5>
M5\3VQ+(-;=E:'AH;D:U?JDHHNXK"%9BI#!97?U@@3142&4 ,$<'$W_*;(!=Z
M$44B)<P4#1&<"XVI'5'=K.;.X:UF#A,K);@HF91395%8SA<N37,.<O1.#0_P
MDR0LK!_>Q \"&K!'5Z9I4Z<S(>54#1'S'IW ]W18&R5P5[*B+G(](XX<CE>;
MJO/:G"0ENTE[&'4;6M'S>)YEGPP7HJ&%!;H6\0FAYXCRQ#R;B>Z%1RMP2)IG
M[JS=50XDXA 4^$^E398IR,(R:_G0U@*5P"0^F-)J CI3?$H##[US=<B\"A@!
M_/$6KL*.$E:K:OY??3DO71-5PIDO>4<3#0[F=;-H%H">RBKG3)FXGR9&B5OH
MN<OCF%W-#5+1/(,-?@[5<FJ<"1O0[LB9T.@%D-@5 #"J1D9P=!J#,8<H+32A
MFV,IK,/2)NP*,52%A;8IQJGD<MQXWW@QK(18N_)L#6 MV[-1T. [K%6#KVIP
MO?'.Q9N5HL<= T7K-$<56Y0XYW-$LM(F-=>5XB8>ULQ*:9*"+1,E,^D!G3BX
M/!E#&\KY;OJ4U52OIA+IG";N->@D*D)#?'#>SIHNVY5UMMJ*3#D!R^=UX!@C
M",^Y?H5M!6V, ]5S WA%63"/L#A_QS+L8LIQJYAVX.B>^3JYF<&PTU5KR"J[
MOZS)A87QHM)\%QMW *7:M5P"0*/(%%@4ZPJ2ZDE[I14+8XDCJ95\PG[X&)(1
M'6K)QH##(^OM2^-S7.MGG>G4+HJ-1?-<("[R6).7:P%?%P4$.YH\XN0+<L,5
MF)PBMU)C2+GH8A*U;M9I^Y#<:,)X!R-LQ(2WF".:##J.S"'"FFCA,UP-[VJF
MAR6!10(JSI"BQC4<?%E,(*>)=[*I9Y^-@,5ZY!-_N8PZ&;7RZF34JI,Z*04>
MQ2+&BI&OPS#Q]]5 R^6!V](+%2JV&/+)\0I2\([HGC@A@8:;A?Q8,.H\A= %
M0M?W/.:JAYD<CDEHA"+()E,S=4'D4TSB7$6/O4S4.+EO]. $]CEJRZ68+ ["
MAHF !P:*",A2%9XBQ!AZD:#);)\&4=Q;]R(,Q7&HF^+32L6GPZ;XM"D^;8I/
M=U)\VB\L/AV4FW*D;0^HG5 B2^AE/K-=_&,%;G\6JQFTUA-##%0BD02JF65^
M:6 XCRZY,+[Z'N@&1 LF<XQ& PM;#]TE[)&A\ "\UJ,SE7UF,M0?"S,-6U1I
MQ(D&I[K1]($,T# ]WK$3X ;CCCPD.<P^;7U:/#XIX@TB.\17S+O7L8 UX"O4
M,ZCJ72R.^HK5.HQ#=R!&DBM2'IYON#[X<H$&:RY3'OPI<AO4DTSY*/4(N3,7
MQE_*"$[Z@]5>SRV;\:B3U,%J4JMH%*>VMO4>A%F$4%34Q2HTO)EK(.$K"QT@
M<AS;F;C6*0N)+'\-%XDC[:;,>AXXAG]5S/#7+4F4"W6BT&1BA"G&=D&&K1KC
MD9HAE$!@6Y[#DLA">IL32*DIGB)&,UP!V2R)..>2;>KUA6GK-AO+(WC^Z32(
M4:(@.R?Q?SD$9,W($C_(\;$V)BE-\GJC9?(@NL^%\<],0S!YE396LD^7PLL,
M56PR,RS) EMU^2_N:<+>)G@@8026==K(+G@XMV+G"Q<HG ='\#H*R CQ)<;V
M:$A>,J0LD '"" %6.3(OWD?!WCPP EP3XH&GM$Q=>,/N:9R5!'U$=" )TM(<
M<XP)E#U:/YQ9P;D@#EZ$A?P2'VA*W;RV,YLQ#>@I*SL4\A2U\6(X?6J%\@1F
ML>NJ>I;BK4L%+@2T,4&FR.RH*WIZ!6@*6@0+3%1Q-A NDYGX]TEF\$?!<O7I
MP HSBT(KN(UT ZD1"0@97YYV+"FBH4WB9+FN"J92D( @M6ENQ+7FR=U20IT0
MA$3R$ZM-LR"3HYJUKI08V^2M\M$8^CN6Q5T.*=W+4OR%P,B$H^BZ*71D67P'
M9M:4E\[A=QQPX<E"T9I*E"9")]_43K^7/^1S@^Q<U4T<BJ;X#ZX%NWPW1?B&
M4"X&NT=1OLU],%!R@'/I1Z;?@M8*PD$ 3B-?%"6'C;^0NHUK*W!]M!AB,5Y$
M/3!=CU+\NIY61#,3;ZK#__!](^7)<29$Z$.86!HJA1A)E>J^3YN+*D*B,DT$
M8P+6CS+9,@AX<(M$&>,%CRS4!N8D$ 0*S8<6;)8GN4BGDE@$61SP,3+JING)
M-YP&5) 5TX_)Z^+FR.N<,'%WY(N\$%1Z9R.N.BQ4^DS?& W_T-+P274H$K6G
MIJ0768&;8E<PY&G*69I24H=U87S2Q8-&NX7/H[K+A"UX-2^B^,E" [!UL#@<
M@?6(>/AZ*/XM<R\"#<17.%:3%!:0*"O(/UMY+S2*[&>H)$^1+#E/RQ(%_J.-
M!\+]!26]3-!,.0+O YR,NY3'(& ^)&[FZR528?=K$*(BF?BN)HJQ/((DVC'.
ML??B77<@&S(<&AGS[KP].IBK1M.S!@<LMGJ?VIMV[X*Z5S^I^ $8]626=MZC
MJF+ZY_E)"QE<P]SP#R%_N%>3&M$0Z/<FSUP;"%)B0H14"T9ULV)@A.;]*3<I
MM6+R5<0 56'&WS%P0I(0U2<!V(R/$[ 4_/'YIRE;(2Q^$LD[\>9"4J'/<![Y
MYU+:2_=*^MQHM/-.D9E6J%K0<=!0]K:4_>BC[8=JIXB^DV_+NM<U'TW[<5/?
MN5E])X^3$UI,0]P[(^[O3OCK?!8PQL?X@9"A8E>-P /U"ZJ"3;1YSG;\>7$'
M@D_.Y4$ AB 6Q=&IC@'N=3QAR$-DE:DL1$9Q<QJC*#R34@8-/>Q>V-DXJXMY
M=I&HD]^M(H;B -52FW6G(HKJ=@MKB3K\(C=.CRJZ,:A'T5A9.40=::3\X4)U
ME_ XJE?U5TPB=FJ+P2Z9,=&+EP%<OA?3MX%M+-X]EQY\D;HTY.755*%W8=Q5
MBN-0^)!"A_1(#OJEA1XBGTJ5^=!1+*+@X[D],<Y!9G:2.#I-'G4%<+)('B73
MZ7V=;BX(/ T;3?A:D@ %&D(BMB$%RLIXY*"U64#R*BE\_+!,?O*-Q_*O<!GT
MQS^X(?:-#-/V^C[X4:>H)Q_.:?6J-PRCOMBJNV>7O>+N_>/C+S4*/5Q;6%1M
MX*OX<0@'A6$"CXIUM28Y'MS"0J2% Y<GLT6M9>"[LM"(9M&K:>U[K ;'.L4?
MUN^R[M-1 ;S5J%<W-*GBD#Q_.0/>KK1G]1 42=*.QFM0ZX"8!XZ+S,S@T29&
M4G^:CF6_5,-Q+O %#==Z"L4H$HX33\-^A%.L=SSC.-L9W,&[)Z629($B>D\%
MX,JOYTG7F>A86=G7=Z72<GRUV&N1M&2F(M2R0#V)"/+7Y^DM2JS[5#1@Z=-L
MY>U1 %T8'Q78OKA4-D1I#8(TI1YXE'!4IRP]MYVCIJJ@,T_$H7X311C:B)KL
MO!*1B59%%VB6Y%;$NYD<,794C\]'!O.LJ7AMLJA)BE W;%;1RXX6/5Y+X5-$
MX50S47"L@(RG\KE72_4,'I@(Y=GSQS45BU4J%D=-Q6)3L=A4+.ZD8G%06+$X
M7%&Q2-9&@0W2.60=(X5@A=[%ZCTUG4J*6VK832D$/W#N'2^K#3AF)2GT=-6?
MXPG;X,+X1S(1SW7])][-E!]]9<=3EGJH5& :OD$Y9KY%5\B!.I0TXV4C!(:!
M2\K[Y$D]%B^'><POU+ 0?R6,1&8QOSC'TR8983=:ZD>:WC5E=+SP!TL]C:!*
M,W'>"!9X88F.[-R%J\BN 'X$E8\3T:01-,TVG,E",147X^0/ATB&@):^3\PX
MK+&)L(=,@S+2OI4]21N S!3(!=3QSFRY6JK7JWF,.+6(?[L9\'R)X,.'FHH.
M0H+S2!O)DR5/P%(FQ(B>_'.P>Q;ZP,%TIWPRW5,G<&X9)_QV <(ZD.-8\(?2
M4#'FL.?4K\6INZ@9GQC*>?!]43KK)*7#(5S-!RU1-EOUE[#?EAJ:)TO#K-_T
M3C$(WT",JQ*C%E(+(B^!X2Q4Y.9SSLWGR,WGQ,U^ZKD%;R31!1+HVC"S4]HN
MJ2TJ=(N+?8$?13<3-=7Z4%2!+.."PTC<Q2^AGU$KNW%/6#$!%U7]UK_K.TUW
MYG6:HG..=AB#2U3\ ](E<L44R'5^5S)=!,X9A($8&)H&DB+SF6'4BB M@_14
M>8VX*-@M!L;+GE+<9?38%H%#. ]Z$;M6L^VQJ$3:H!&4E1)7D3XYPC0ZK4Z7
MKH*_=-*53 ^6G5^OI AZV7\3H8//@1A6B'% "AS$H7V6B23TSH &I[#1;OB_
MSW#B=#JN\%-[$KBG'\2^I&).[[QX?F[[T;FXT9D13BV46-TD^M '\]ML#504
M2J[MDMZRTHK[SURQ6%0K6=3@[+*56Y"IU48A>L+'F&7"F4U:KRRM5V8[F*+/
MNX3+Q$P>E'E:7:L8"-9L_ 8;ST4=36H2H0%N*^IJL1C^#*<939V%+'F,? 3+
M241^^9E%OHZA[@JH)(3! ($*#!H(-"2ZK0?LF\!W7!@K;(RT-9%$62FN28HF
MK<K6&73)<.&TH-2M.MX!*RT[I5^*NJ\_BR 61<\-;):Q\Z*[7'*_O*!+(L%R
M-_AD5]JF*VR48'8^90 B_ DM9.8EXG&H<(]?4)/L;KFCLTO/SXGSO,)1)$-%
ME8444T+SY:GIJI;]LZZKE!"X]JD4GR<WL##@&BP7.#SX6[)EX_KTZZ?6BTS)
MUVO@@GF;U\RXTR8WWL788,&";=)7!]<=25A)*[#@)J>:9PF2%5Q-/TQ/=^=-
MZ\F.D>$WY5N&11ZJQ1_,U+D5P-*I7"^!-II:X0,VUJ,\%&"K.O(J;_M*XOAA
M<:<*W24[$:K\*1B<P 8TQDNE9JG7=Z*8OPGEFF$[?##5Y2M111_%&&187_D@
MO"7+F#%;))7A9@3]1Q-+0X6GA=H.G79X/&P<!Y=%V%@.\,21;<067!C7N'#9
MJ<4!<[GS9R=CZ&FX?))7APWP4)/B$AZ8:\N<^2+FLT!^7OS7A4A6XI*PP$;\
M<V)YOS(!"Z6?)^ E,9Q'&(DF)%] 9U(MI!>'U.BC'?R$+7U15NBAU$Q_FP5[
MT=!3<!7<"^-=$>&#L]@.[/C@_)7JE1%G&";TR#M/:7=2'G"*&E-AK3(BRV*V
MR@=$DD6\LMO+,(,X9U&H@37H\MSX-,WE<^@X76)SS*2T3XK17S+;T3P%+0WV
MB@#2QC9T?,^)CRV:-#Q33$D6T8 4/C%VPUA&.,<F+#!@)@I#/X/4=7PU&0%2
M5FAJ]6"AQ#O&6"$WV;$EBWI$DG>74"P:! NQ3!8G@,;4)G@#JB56APRP@_A>
M@=/05)*8NCLR4 )%]UHF  ,*!5#O1*667&NNFI_EOT7WZ83)@=AXP.2)\?IR
M*S5KFNS.(!85=IXX>%4[)?P*Z]%R7!D)ARU*H _V54KRV7("3%2PVYFR3VX2
M\R33U#DN0((:UPH)"M^',B_,^(OW2Z;'>-28QVZ*H1&4@\IUD@;EIHH'$:]<
M^V*>O#BO\Y3 &.3S)S!ZY-53---+JC_H>^ROMK0D#55=J*(I9?O(AC59ZU%0
M0N('IKS,FH02:-#*W8,[SP2;#.P%'&3=,T0N6/\$WN8_(]!T;1/2K:R_G4B,
M*Z46L:/13B6G>A\[G$H0['[B.N$#-;QJOWX ;PFK-Y>R550UQ2$H"9^I3C L
MOT&'_8N[&P*EWI^@F"(KUO' GA5C)!!_.//+V,O_EB)1?*U4UJJ6Q*TFM7(;
M)$;@3(@TL43=11',LXG\1KFT RZ7[X%VU[)^M!J=)"]<MS$I2?;1.SYD!'Z%
M2+CPUD:[*>RI4M@S;@I[FL*>IK!G)X4]P\+"GE%Y8<#XP%!D_R?V"6 H(#N:
MG'I*A7!#09CT-&2%P,IXM8IF,#B\MT(A(Q"H 2@J#E]QE;Z91;! /D]MB.+P
MQ'X*5QH^5*CJH(^.4Q0=#MG":UJYT?((\G9.[I(<>2#;V!V/A\ I.(J5HPK<
MB/KLC\!Z6:_S.K58Y]GE;<Z"X=%0JET0ZEE0FZD0L?].$2%2@4(D*R*X]YD+
M'$]1F*HXH/0<4=][O)HO0C>%\$>:N47PPQX:1U,<=D%XXMP1U7XDK&>4"WR5
M\03[K$6D.9)X2'J[7N$+7(B=Z)055TNH<9M-0#0E7=;DQ:1?7KT,<!+FTPC:
M7W!&).O;F.C,/A<_TB/FA/>GGD#YQ\!YY/#3"9Z9>@R9B;(LW\K SM#Z5NRR
M<%T28 ZQYQ)L0P\#\X%DP8;G<1),W*W%.L\N?Q8X(NHX,33$FP0F"!V,Y44<
MEEL>AP+^XAWZ\C(MFB-*0@IPD%9Q2W<=M\P*,T)/I' 41E"NM21%P2"4",(Y
MIBX_"C_/7/])P!; ]M\[HNQ)2JB(31\(@S],E3/I*Y@1L)ELA9(+4,DZ;1N4
M5ZGOE@:[HM!6-+ &2K77G?8I'"-K"33\.$%<Y0XIN:PSC/H2 F/2J9,XN!E2
M4JXZX=61BM$>J#KA0)S<^P$A?@DU5$A;Z5E'_A/FONG1?.DB!1&N(6\]V("5
MG!$!2\))1\OBW& >ZR=Y@(KY(' H8BL$<BU5GIO0FB(JV9G*IS]@;!CCRQB^
MQP?+V_,Y>_L;#XG9Q"O/QO]@)RR\&#(55D3(CMWB7V1CK07U\^-VG6*ME#;%
M,Z"_:&]R2E,T:,O3/:F*XBC)(_T#[&[64OJH0@2XE O2UK&QU-"R'0Z21C.A
MJ9S=YT);J9XYGT>+A@DPP+@%QL(R&8%$-H9$HUO$(#5H%!'5#M-]6'(*105-
M5[SKNHZE=>4EL8>LMC-SVRKA+[0:" M+W=A2!:MA$T.5]@<[5^!J9.UB.FK^
M;SI<LGSEB2MXS^QI5TH8[D!P?:\HM@K:!L:=.HFMY(5(<)V4L,*-UE^0B+=J
ME?B:4L0T05SS_MZJ->+C[MEEM]4R89\*JL1)2F4%0L?4FX5D95"".NRR>]&F
MI5X?!"-RFAU83V!D8^U_B !=8AJ1N%?2(IT*%GX04^7N<*J<@*[6M[5(O-YZ
MR:K;?;.@+%2FU[":I-*A##K[.)7>BE/AP\QPY.8T  \#I9QLK$B:PYOB[37%
MV[(U/%Z A,=R X[W@:1Z]8N%?A$4"V[L%S'SYDIBL9M\-!O/HF%U2B!"1@8&
MO_>$'EDL80>'W.(+X[./K0BR<.\*DYT!=H-=N\P*B*<_4C,/;.]_6L"[H)K;
M0VYSF,5[;4Q=7Y;R\5-Z0I<Y##&R5,K%%)0/<XS<U1GYYNMGR<GA?!Z]NTZ&
M SXR#2+F.[XA5DO?)H.V?W(2$H@Q!"$3WLX0R]#W""_HAA9XXWUQ6 Q?@%S8
M3" D73-C;.4A>5 L$_@K4@6OLH[Q\0*3"&R6,-8\3+XV 6:$JZ/32+:9YJU1
MK;Y353QVB\4CWU1X<[%+G_V@;(O3VUE9= [.+CO#GCDN%IW"RB_E?S'>FF'A
M(@4JA7ISE+PELQ,<X3CP<IA+C;@M$[<"\@>+B^D 5,WOKHUH(K0KJK:QKWTY
M9_-+$IGA=G(98L^X(!$W'M;);!;O9B0O9VAO=PP1O:ND"8CB0MIH&30WG7 :
M/UKP4KRHT]%LN4X+%81NQUEB-U2(,-F53*91#5658&LF218<W*/@UZB\E'_(
MY\YC'*M@302="_+?D0@[R3@D=!>S/U>Q0!$28YE11_J4)FV0A]8=PUM?680Z
M,C\+4-X-0].$IHT[)!?Q#6Z"[\0E6P1+ B94);"JXR%Y!;#(5?M6#BP_B;?S
M;<]O]Y(T1P).E. P)4"O^JV28>L_5M]8@@>E@'M$H))P@4!6!Q'U#]%@$?[@
MXJ@\A>R%SY(>/\"KK"4<$#84IV;%<S $]7+)]@G0!/6,\-GOAV%7\5(27RF@
M#(25A%3UJ#%-"1;]*SR!#=M/2(XRX*O_6B MJQ+"! @>FTCB*1;=SV)W(P+E
M#>1BJJL N)!;*V=_+42G.R;D-"RE'3];:Y_1*N1UW'1EP$N"$'%J3=<#U=,*
M;1GUB^3[(#Y7]KH$-3%O&/%BZYQME&K6ZZ0TU@>D5GA]D&L3D>(I56)+K:+V
M!@/XR@Q"K BIR$9@,79S)M"_)^-P9.Y$O9B )RBB2S1B"*TRRP]XZ)@<RVR.
M>HB&XBPROTD;?V:2"DDRP9)4XIUT^<C)O(IT)*:YM7+59*H)CL.:DFG ],$9
M:M%-V5^%LK].JRG[:\K^FK*_G93]C0K+_L8K(LO#PY;]"?F.+T[(5)01XWUP
MA!^CC!>NO'.C.*7AG_B#:OI?)=Q8GG*>@RX"$RG$DB-<Q8OA0FWN>OZ3FLJB
M=6[FN,#-'*\&ABU=\+XY0K[BSAKS#T/*\C5D_%#@2"G/,D.[9(=*B&$:$\:!
MY]!&-R4\%;9BABSMHG*<%7H(]H8XOQ5,JH3!\)\4C)U>_O-&C^&]%3VQW'PG
MF-+<O7B6";F3F\))75-1[44]@P/7(JO/I5XR^1(M3XX%QV6+&C+/'75L HRB
MP)F(OF\1E^.[SKV+![C'$SBG_-1-*KYYP*U7(()BD+#\B39#4W<S]=%QGN:-
M:D7,W#X]A@+A/!NH"FL%MI::A"Q/A$(JJ;.B04!Y*I931P4WP):+]DU]3XNK
M^O)SI9,1GK=8\^'DBKADT9.\ 'Q>@<.H'H=]LT CDC&+;U#P(A+"7_1!Y4(C
M,O7VE&QHWOW!'Z1'IV%L!GZBIDD&=N+G%.O"C53A(?-.!QV95CI244US3$_D
M*QBIH( #4Y0OJR]YN3$>-I<QS,O>RZ+6@B1!F****4$TZ<.H.!( ?D(1I=1P
M1W49!51<:X$U3G/P9QV:";FF/[EB>=TJ8Y5;)P4V2Z?<6"53MLC ;;<..*4[
MX4]/:N74^  9_2&U"SR*)68BAZ+ 9L50$(Y2;K/?1YD)RE-'_I-:5=6L(S8D
M*VY-)?G05!Z4RU@.\9\ 7,H*U^*+1.C0\S,0F+P8.'S0D3(WV=)RC[=L\D-9
MN )?W)EU^_U1:VBW)^-V;]CK6CW;FK2Z,S88M[ML-/OO=G=PMD<CHU@C]"]6
M#VO)U<#!<Z]47_VWP/=\S$F0(L;2-QY)OO'TWU '"&C4G+?5:^4E%WQ6X&WM
M:HDKG3\@^H+E%* W?&=3GN3@]0-H"%W9_@*U1/)@(_UDHU 'I/Y=)=]:P&A\
MY\J_/7!?XDTJ72@K29+0D[9S=SCJDF8C??!QRLP;FBC6>O_YZNX#_;7]_JVT
MB@LOX\D-0UQV=?=37&5\]2_HX>>ML2F_OIFC_!"G!,HBF:]"J3JPV3 4+NZ0
M0PNPU4_XO*_0N@?[XM[B&5(-C!=+-DR*T8NV_E L5W4NL*1?$LU&W]/-] ),
M2S1*8>_ :.;#CPF%P+?Y-"#9'R=7<"Z3ELF"<;K)W4]]3P@)23V()FXYF,$0
M^(X3!F*05U]@##A7RM?C5I-+6382Q;88R$6V'VRS&K--EI_));B%51O:=_R:
M"^.3%= $$%^-85N@I1=%6<QVM.=Y/1_"PPG$56'3"]Q4L8OXOJ+U0X.XU+9$
MSS!M@ A]#'[D#1:\/>88#WA)\5"*"H:*,^X8;R/YKOSG-S_\!0C@SJCU]IV1
M91S^,_+RY97E#*0RHIQ7Z08<VXLW*B(E_8VE4?*#(+E[*.ZN\9[@1S&3D?>/
M41#3>[ (%TP_8VOBQU$J^2KOJ&*>5 $K(%QM#E;DS,L?:,T1GH]X+L=5PRVY
MJFN*U? UB! &!U&KPIPK&<I4TW=!E7HV/],D)& 1O*2=9E1WN0,V7,=D:7EU
M)/SVGS$XMYU6>U#,:_C->;NK^"Q1@AJRE'$N03^_\#"^X+UN9P"\IV6:-7C0
M+PKXKO"6&1;$7'"J9H-2NG3^/.HJUCH^;W')KO[=;F$,U'4E'6B:EK]<JROU
M](7^QOSF' Q. =U(>0P4X@3RA0H[/T5.6VAWRZ8F$OU"WK/\YI>'KH8 G9/S
MM521BP"T$\D1NN2MZOI3%4'JY^)WH'%5USL(AI@*U/EW%\9/5=R#D4SY9J8&
M):0"UKRIU$K!@5,7GRA=X3,]BI::9C9+&)P1[H@R)?2*W93P0#[BF.*4O+<4
MDIKBS UUGD&5&7E3XA@X\S:2,*Z8 A/S*+AV4=28SCD0Y[Y)U GO#9Y2C#L(
MF$"Y$!$&^O'5W?5;SO579-?#6]X(A$LZVVML;*-HQK=X FZ(-&!YZ%L*X?5S
MV-5YHIDEPN'Z'+C5QWQ$P9##E,6NM_W6932+<YP;A@9Z_4X^-G @7BII8;@P
M*D8.RLK*$QNQP"//-\O!9WF/G/<<R+8$:KE-G@8TKRKH7\#K[A3$7_'3@P[R
MTANM"ONLJ'*#F[8^R(GT=N$&YGL\WN#U0M/GOE5^.;ET_#ST[H8$+D$S%QWO
MW*4;$:@/*!>J,(H>0/S</Q@31Y55HA\P\>TEZ,I'K#+$6KT)5XCY=9(0U5 <
M16^*D^A&ZIZ=J2X8#F.+7SQ9SHH\85-PEBXX:V]2:'#0@K.FK*PI*]M_6=DS
MU<A!%<9-(E=-0SE05__5;G=0<EX_P&%R)S#&'*[K6*:(]H&@AU_>_?7C_V?O
MW9O;1I)\T:^"T#FSUQT!\9#@VQVA"+5L]VBFW?:UW3-WSS\;(%$4T08!-AZ2
M.9_^9F95X4$42( $G\+&[(PED4!55KXK\Y?BHZCC_W"IOX+.'8CX8+JF!5]X
M'_G>DO$O_L.$7>J\?-[U((K4TT7[.+3N%H2;;O]4EH#R(1QOG/"RL3J;-PK$
M,WFP*F6QB'C-C;E<:<\V;$&;H(=A6N2-?WYWVTDJT/'9M^"6V-X3/ .OIM//
MPI@-/_"O][]^D&83#1?"5GD0"D<.:VDI,O)V"WB:R\C2(@@%GY;PXG%4H02<
M%B,W/.DG"#MP:AP2;\'0Z;<#FG<-OX)-9)^?R;=@BXVLQE\KT]=S;89X8QYG
MEA6-LT(3T=6VQ3!1)J%DJ,&% L4U('$.$65S-2 0I2#4>L(B"P\LJQS.+1A$
MO-32OC$? AW\!(7@Z3<'T03^W8) :??54QB$_KM#%?X4.2W,[^F!A*L\K'V"
MW8^\'K*GE1ZC2O&K2GLQ@54E_@9/MR=?M/_#I5M.S2S<-F$:E>QG3GM/-$@0
M96_-D?O*<=X3;RCQQW2%0R9H1341='0Q9HH9-V:E*A\(5EZ Y$UY+C-F!%'N
M$E..%M*2;[#%@"TL^N=D7&5: E)!MKII *)J:DCSY;>7\U6PAF%)8'@4=G!(
MKSG_-(;(F:\FC674%E:MKQS=3NZ@ECBFN$&"MS!ACS*?LTD2ND8S1(_>38^J
M?/,4D\7)N$O(TCRNE5.F*">I29FU=8" JB@>@P(8CSW;S"OV1??:W9N[?E'[
M.)J0!?*T1#_0<9M<=*MM=G#:]N]>N[>A_3MN:8_[P%562QWIY;OD=2'0S(FS
M8:(\L3(4P>!RH AZ[=)0!%[D9\MO@.P.O+>Z"&WDJIW)\QE8X=']*HZD(I\A
MS$!?[Z@H0*@T:S@"U?8[/+44#6%WA:A R41H'$&PIAYC&8,]?D0X16W ;P@N
MPBA\6W=]IK)Y6)J(O'9 ?VC*:\HJ6E\Y.#K; "^G@+2T>_ L4Y6EZ;)X1UYF
MRT=A,@IO#0AJ%-V5&3,#.VFO#24"8SS.:L5"?A67C@\@TI@FWD%0Y.^W$,$.
M:^KSWJ*XV[84RR;8C5LY:AS;2(E!^.20)):@7@K,IB6=ZIE$V];B:$5C$+B_
MVU\LEAZ?-<V:*Y@V2HQ>2:H[&X3ZT?W,%_=%K WTUKMD9>_YPBJ+\0ALOM'6
MQYV^8N(R-^_K<P1QWS7Z-\=05N.;NUZ1R4^;>[V@UO^:K366Q):SUAE++>[O
M).:A%,9U2:S5D*=V_(Z&UGRF[#@-D4J38 ,C566=3@=8IZ_D'+WZC/3://UW
MU-+T+2'T W8ZJ=9OX!R6O'#S&D&?\@SI.0F\8TK6%5R$1<9I7)9ERSE9:40-
MS700RG6U'KHD&"CJJ-GG%?_RL8A]$F<$8X2)Y"TX8&F)CZ_&#*.:F.$CCH:*
M%O>RWO.C7*%0&Y5=UPY$@CV]*!:DNA&!K28P/&*DFU2$DTJYI4 Y3DRJS_(8
MO\2KVY]:$%!V]':_R!G.9J/.D!8/\>KVIP6$?EV]5T +2C%*H=)+\! B\5A>
M!+^]M>"OH>9[*S$8'*B$#9^!Z>1J?JKW-)5NE!B?OE%B6+510I3 QK6SF\H<
M.H-\!0$6S*V7.>0+<NNO9^#O5:SFI-=3J?BO*5HJ+%J:VRR-X)"^\<!+B'22
M^.'3NX\(44LJ0N:']11:<%,F5H+B#T3Q]S_8-*(RPD\XR@I(K6L?_9;V+GIZ
M,OG5V3OX\?^"63!=!N$.?)C2#0559NGQ5C2#\CN+SU)6KV/YZ)0?,\0)7N1/
M1:T@'S0ABECH.?*FAO?$XK (>;"BI#3-"AP'ZIG;R>]LE6(G&B/,[\- _<4+
M2I?;XQ>2E6ZXDTS^D'I^?(>H\ULM/NH+[Q/3.&F>F&"43)OR$6DM2@\WXM8_
M4](D/4U!);G+%)O'LSHRQY*L;Q)93RQ4T>S99B_J1ZVU@_/)+WP4^D0@BU$]
ML+Q)3G4Y)"\6W0GJP2+BB[E/PRYP"K-R586)EO01+'WP-GP^CX'R$"+K$]]4
M2[S#Y&G))7#J.B]5L85W>'A_;WLA<-#27C)J U<\@$=Y#^\>Y7CIU-\HQY6Y
M9*.]<Z2:XIP!)\O&Y$\J9Q W$Q)BW*?9)TE?88.S/AIHD"GZ:2^>;P7,5<7[
M0^R 9XJ(</W@=)1MV5^2*3X5!YM6#V+<U@P5L3+_5J)V]3SCRV]5#Y@2POYJ
M_8![)0_X@;YN8_/JO]$(OJ?"_4_BS55/>W1S%[YX^=-^8LC-2W@!1FJH%][R
MB][6/UMQ]3=-Q:CF;?[FN4^_(0#'/5V&_[+Z-7[1/38Q?4.5HG \\S  O8X"
M[H@0-1+4<-Z%%2U0/_RG0(DZL*);1R"2X)KBQ*88[J7Z$D(0,E],&D,)6'*)
MP)B#"B\(.\*;W>* 97'O/UG%5%V]/81#K )8P-_&#K&@AZSH]"WFWY+U60;L
MK?S'SY8=+!US]=9VB=GI2S]G6\O[(!DT^0;X2=3"45D<_W-2W=AJ\PK'T(?_
MM^2;Q9];\*?_D__]8-CJ#8;*/[5;G8J_[W?5+RGZ1M&B.MU6OS.^[D7U-W[C
M_] 9\G,$5D%^I,@^+H.UT(B^;6N=92B>L__'C.4/_.#/N9K+=>[CC'?\2DQB
M[__&6Y[WZEN>6')#JZ&)&/^R"TVVL%\^RIM.&8,H;P/5'#;+:S%O>:+L09N/
MOZ0RJG_"BBUO<9"0<=#JEUB*HC, 2//VMMM2J'[L1>3#1-]TUNN,BX]XZY&E
MY6';=X0QPS5VL H:W4H-J91A@+96D@V.)#IJ)OC?Z_)1T^;3FR;_Y*QV72G'
M/=X\0NEWSQ4%Q]S+5&2BC?;-W:@]RCF^__6_.H/VSX<Y ?Q3I9,HM 6-[#2R
MLZ/L#-M59:?:%8_1N;DS]'YG>/6B5=DE$8GGBW1)>&7W!7HDQCX>R=J)*3UT
MH]J)*_7HA:N4@L*TVE2*<7/7UXU^;U^5HA; @RF.AGM*<<^6>9A[<T^7#-+@
M6KAGWTAX2YKA$*ZER!IV@5J\7(,;\,;QW)<TUZ,%>@=6 KV;NX'>'ACU>J5[
MG=YYAX.-S#8RN]]X\;UEMH]N7WO4>>4R2P;__] U7%44I]<+^6+DBS@;R)<&
M\J6!?-FMTK88-C]38% K4?JMT=;$D+$I,=0I>U=5Z[+'I304E<B![2/@7JQ6
MRY6AK$$KB#M! L.-"][DQ*+<] C@#0X0A@5\#KT#*ROQIZ_F"];PZ^L/YF6:
MGEM4='4QYVJ<_%PE('.9<^6)U4W'FFHS4I45Q2-_4M.>525+,5XR?H"F5:#S
M0P@J<2>R%?FR2T_,N)%<\Y&YCJ=]-OWOB.[AV/![%Z&5J 2L@'5V&1YS"F_A
M ^S18J%I.U1,+*MT"7(EGF'%L?>P4#5=QP4?GC$:Y(-V1AL=K=6DI\#=/+8Y
M&E4M_OO"*?L!"/L@2J#_;8?S!T':?-F?H>@W,13])N+!FVOJ"NP7/>^$W,>#
MF?Q_GXEPI,M;4],,:^A;+\D5[W^( NU[:AA@UC?S1S:4I"F&M_]AOJ>*(H<W
M=ZZBP%5*>?4FW0/L)K_JT<W=L*WHRTUIZ(W@ K@M#J8J\,($#OXE5%0+$J;9
MK=RV#0X7$0@</((924;^<87>M N5:!=R4@#%>:PX,XO9AB!?,Q/$4?N-M['\
MU_\R>MV?P7T 9[-UW]+V.$_$R*!C^PU;#R14.6\P,<$LKV@N7V*S,[8YGB%O
M6]A.1&#F I= #/034R+C$G2P\]*7(7Q[DT;)I]MS</RPR_R\DQR'_;Q0&EW5
M_L8!7!4QJ?.JA+)J]Z[UF\">6Q74SAMCU5#@TUF3+?7Y%GI4?,RF9!M'S.?P
MMO,:;Q023\C,%DH_YI?[+^_NM3? '_!9@KVS7>[!C7]ZJ]""QRV<'X]:X^&@
M<MW\N#7H=VNJ!A]UJSUI0XEZ>U2MVKWX]]UQ377S1JO;ZUU$M?O&.Y/SRE!1
M8C-3\KZMWN95DL=0D.=(Q>UIRISF=NF7>/933LLGX+1<7^O)@)BFI+PIBSWQ
M7:;*_XK]K@K1:+<M/'SCYZNOCVUDK)&Q;%2S)1%40<BV5P]T.S=W0WW<'9^]
MG!VICORD;'(O[C""=;(WA;3UB==&X*\-HA4?3A5#9M1FR,ZDKK9AIA)9[IV9
MJ83"[B).7G>\=^-03?QT[*#L)&HY1N+>&H^EL[?B!CL#F9P ".VDXLL4J6^2
M2@7QKU J=U;Q(@7_)3[#1PE[]&G),"#_Q700?ZN*!>C5'<J<0<!RY;SVYB@F
M8#=F*V$A^C=W(WTXSB.'_G1L5GL-/OL'SV<X48L7<4]QE/.?<-1\.FGCQ9^;
MBA?']2!.B\"_';+(593ZH''K+XV[]E/J"%D)_ZJ'S_+\-+RYZ_<&>RCL"_7F
M3W;%\I[/FBQQOY*JMCCI#4O3:=9TFNW7'5K;[<SH0+<S%]=SUDAO([T7=[<Z
MOA;I+>CX3%>VGVOE;KH;8JQ-&([HP!Z26>23\R'[+' 4C4^>2E&2,1G"PZOU
M)&AZF1:+M6),<8#CC?6859HO^J=OOAA7;;[XA'2.T<$?B=[WKB4FP^7+1GOM
M?.]%KYWOO:#G:O&#M4?A7KHLK!_CF"] L2SCIF1%+9\4-ITS*W+8IYF**H(D
MO[.PH**VER/"F5748E\82)V8#(VP^)XK1U%Q>4O0W(7D35;:%"<F>/XJ7P%;
M6-S<($J?"7CS62ZJ091N$*4;1.EEW03;VHG,T_<1SP0)_4Y=-/F^!_+0<MFX
MINZOJ?NK$>&ON^%.XU??=$/!JZF)A,(3,WU@T@HQ8*^^LJ2FOO:\.*Z1LZUR
M5I FW4W.MM_'][IX']\>Y=N4KTW4C@KU? )?X4O1G+70_*%-?6;985.Y>YH[
M?WDT]Z[U+CF8;^:/!SH6E5CV;N[&BCO7YO[^\CEE4TW65DZIJ-W[-.4; \ZK
M8*1KC_?(P&>BO8?[+[_<_G]'"/>NO&JRD@]6<-E5W@?+"^( !+$N'^O4GE3#
M+1ENV:3/#^&Q#[''HKZY1Z?FI@L?P5).L7]*79 VLTQ.Z(JK[@KI=RI)&X&D
MY0O5+]-U:EBDK ^^@47*YS#KJV,Y$_YI1I8<-:%:SJR\JJJV<B2I$=12I0BJ
M>FO]-GIK[?9K'X#02&TCM8>UW;5*;0>DMJ?W.GMG8"]<;&NH8E77<0[B.LYC
M%UUNK9\X;?GMHZM]9<N0U\88[<Y0S\P$0#!5\\4DL'A3FXGZ$%E7F\#C_F(#
MVUN$AGIO/6.GKJ5E;HA2Z67M/@KGGF^'*^T-.JU&^V<B$OV[\_-/.B&F2J35
M3[.9/67RI_L L7HQ:_D5!R&$"/:&M<*??09?8I;+@H#>!R]?>H1'&RJ@\]_A
MIT.)0_!W9CHA7^;?(Z H/-M_AI<&.L(6!-%RZ27K6<?(_V+?/GCO'C^LM"E0
MER@0^C8H"XZ$*W^7OB%#\%D;"&D[YG\\APEH6D'EF+9(>J 2,+'I.' 25)L9
M+;%4NA+X]'!8/6'TT?QA+Z*%^,._3">JKM.,F[N! :Y(/J)M:<!U_XA<A@PW
M)CJ93R:0&OXC$?R,MM'61?&1G(U@T0$\XVKD:<34"J(I5J[":=LA3D9PO9<]
M2+9#]4D=).O>W T-O:\@&1%I CH4))<V'GHA<)49@W$@Y+(=(HM+(3W&IA_D
M6\6?ON&J*F^[1YS24W+*)8"/H_CZ; $<C'2?,3"N<#9/'IA)EP1>'HF-1F")
MP-5X:&[,WGRV!J@"S;(#5&MX5NP'0F@'ML"\GJ$>@,^F'K"DSP&7?]<"]H1O
MTH';!5RU.9W;H'/H_9-51JDCNX %1XDC7&[KEKX%E&$XYH51(7A.12'X=?Z-
MI*9<>)$O%XP6;L6WQC5;+*/ -K .8F+M?NG;#@?L1M;&I^#<#*K5E)^):S;I
M8Q5Z.%[A\+)NH2/4#"]KAI>]WN%EQ4U!AYE 5E)@T:T&'P5T8Q#&"E(G&P"^
M'IS>U/%P&%2$:IZ!GL9I'*"46- "'Q@U>*Z@7<<)!6)<00*P@!\%U1UZ/KFA
MLQQ BYAX(?"YQ @G&H] ;77XC&Q(@",24CUWU7R,T7$O+_LX#W2L&^U\10I9
MP6@1<:,@BR# W$Y3%@M_(IM'5#=Q,$KDK(<"S4R0HID@># !,9"7"3-'DF.!
MT5TOU):1'^#T+-'P:;MR@%:)Z(D40<#8=SEG Z,F."H0;?!F[##R67K,6?:K
M>*9+$X($8"N,O\CQH;BBX,WD6>$0C:Q,Q /5&.\##.(')7YA-CPDR0_P61ZH
M95P<#4;A[Y:BGTB]<M<I*4Q>A1VP8J$QH(=@;@J/YJ;%)YQD9]QP5Q2<,L^7
MT^#BO4P8KE\]BB6<VT"VOR!F"_F+\6"+Y@&>R&M7&Y?" M;UXM6SV$-1]B8I
MW4K5W>IRJ!$>R)?_,A?+G]^E_YZ<O1PLV/HG]]4E0T^8RV;X2?[H%X]_Q-]>
M]*M-S6 .'YP 4V/+-F[WK?85]+-#W_H('XH6VGN4<6 WX/3//L[26<3)H*\?
MW^ORES(G1%_%E18FE:@#U^+RSJL7<P_^\N[]P_J#6]K_&X&G,ULA0[/D&8'F
MF/X3&F-LA:5UXG2?Q=+Q5IQ+2'XI4))+"D)S-N.TCQ:8PX2# /WB>Y@_$K88
M5!%[-C%2 U,K(O8@FMS&)D?H!<P=B1@M5H<84,Z9:8G/V'Q6-@Z)C#-F\5K@
MK7^RJ5CAR]R>SC,*R_)80*I7<()0$< $&2[)3(>$<XE)2BFV%#DUTV>)%L3,
ME;IE6/#;-.V;!HE'F@$%3>$/T1FP.:@C7"OH1W"#_B!5!T$;$'XZAP<$.9V,
M.PLX0R[-%7\%*4%<+>X^$XVKLGOPUEOD;9?%=9(.,EUP9BI.K1Y^D0[AU+>!
MAVQ3 Y,(C&D'<QZE_QV"^H_FG_#;5$(SA?[$L36"6(+^_O'+0Y*F!=Y.&#LC
M.]QB3$W?IP%:$1)/3%-"0GN-^U3&?5K:2QI06ZAV]5S.&=YJ<K=9:$RPSK>H
M'%;XIV@&&H;;[K3R3KD9*!CPSB<;+XND#X."SS5YK(:3F<%+TC*4?@75%HMQ
MH:5(\4FBP40*[(]_:CAUC5;R8J/!< (OAFY OIEL7AZ'#:%G\TA&(:?;@#Z.
M?<[J<"X]CI$T)@5L_%1I/C#(\Z*4/>9ZD$ 7,,M6*5[;U!VVI7?@2_S:RD';
M@%><YE&]JT_>W%1:?;@-((*A/ASD;W/71FN>B2>\O>C_C&W<HPL6C.Z+.EG[
M;[HN&)"I"(X"4$Y3::M,L.<O:-MC]3D%SB)W1 =U\NUVV(40-;[<?/?NZVV[
MI^$"1627%C7ATLQP3?P>"_SN1>2$]JWE1Q@WR2M+VYWQ-8"G@EQ@S_#=X&(^
MF/[$!+7(%K?)I\E#]L 2DN6>,I/%9OCAR_O8,4X>VM*^VOA>TV5>%#BK(G+8
M/ B,8P X,Y,'OW+#WWRP^XQ'G;]X>"> ]Z?@?09X:9N@+,&S)]R]NP<5/;&]
MT)ZBARYV\(M8.]X.+^<X@G%*J52\))Y.X4# T0-B+M?<=,Z.\09!Z],G\&8W
MQ%N(^*SBBX+T268,&ZB+SW.<5_YHKIO*U*VKN#Q#CQIL#V;)Q'T-;'^7V\/Q
M:6X/1]A\U5'<HNE);F$)KK/-8=*2W9DN][(/OTMYPR3^]"@N=BMO=7QSU]6'
MJGO2) >Z=@<&NQ6>07+/591+[=:92Z6 @U8C_OS"_#1J67W9U5'[N-G50?OF
MSM#'AN(8*B97WR4))9E*XE>!2=*PVY9)0V&N$H4VG>-NZ-*#4A9">LUDESR6
M1)=)A-:>*T:.9!*[:ZY6\GW\ N+1B]AVQJL7DB7-O1>Z ET_23IV(6Z8?)0'
M"_^R%Y/(#\3JT*;@=V+63.+55!!.]ZZQSQQ$DX#]%9&WYW'-2$H1;W6G&(AC
M%8Z4?/AC/(+Y'-#P1J='P^NT=X+#^]USO?*(> ,%]-R@4X2(]T8\YZ?Z$/'*
M[VX-X"Z_3[E)-<#=P%#LU,COM.A&CE-%0:N3WM/M")7WALF#Y*KO[3:14U0Y
MON)BAEY3S- 4,S3%#&6+&4A)JE1G=X.Z1=5\DE'U#2+G92VJ0>1L$#D;1,[:
M$5IVG:A%"4;M#=Z!LN"4*)S&V;;%'0$=<-/FKZ=M?4O#JFJL$W_JK\"DOP&'
M_L(P2?;-_*'*'H%W,NCL#155Z6S.NQ6UD:J+E:I:!ZKM)%\54[<]?EF0'W5?
M>2[F^4K>Y4)PEN2Z1_3O6!#*4DV\KUCZWL(. L]?8843P]*P%<5WE'_FN60L
M"+%9 \]Y0!G?8CKER8F<ZCLVJ0RV..C?W'4&.L3YIQ^5V##/80U$_<R# (%Z
M3X$3<G&\<_4A8*SEU_#<&B3.(\<[CRZVE"2WYNDKLLH"B+"*;9# N@*@4SM;
M#2=5TN U<A+"!NK]VB+I4S/2A0-TEF2F+VSJF$% )8"RMBA5,1.G^]+E1YCZ
M.TA%^J#5+[%HQ>TS!GVWW9;BW@?KI_ !X/ETUN^RFG#CF!"D#S%7*>:O8R(A
M^(URR5\8;/H_S/ICZ;E?0<=\\G^S_XKPRA4^E[ KLSY A$DE(@_IKAR)?)77
M3V-P-3OY1,-EXE(V?%<6U_3(?%<:*W78;K!2]XB 3F8Q/RDKJT2)W,[VY?6Z
ML_NELPI2UIM+!U72V+FY,_K&_FGH4[NMU\\P=8-F5F(3X^:NV^XU(<YNX-8;
MOK_M.U< DUO[S66=I#EOF3^(D=@@^-52'\,N-EH:P_QLDLI9['-'S&TDN)'@
M\ZE,J$^"$?M3'XSSR<M7(\$*S.N3M;O\C^K_#MWH72+[:.R3?=0.DC,M2='W
MLQEO]X^1C1%BF_>89@!YL&;#>1;=ZDG+D87BA+ 9 A?C9TUT<[QY,!<3W[:>
M(!3^S5X@NK4>_^W?(&9!_O</GK_T.+J.]IZ@C!C3?N%03[SI.U[/IJ^N_^V=
M'4P1FPCV)O]&'0WBSX^B0ST*\)/8[QO(CRFZ+U/P/7'FIV(;[#EG0X=]=39T
M+?^?ZRU.WP.8UI\1OST2^%SF5'R5%0,F"?@=#@P-GPE8S%-E&D+/$/GA@\!_
M66%-.5/7V>N"'B)K1-DB1+E;F+Y-V%X$D\8(\=+Q3 &VE2ZIBOMMU]"P<G56
M%@NFOCWA:#;8N*1U1@0R$"2MW]C=0\57!/O@S68!BP$D-FT#L9KL;!G ^GK6
MD:L6GLL0],?_SC@ =; .WA-_-)A[?L@!9>SX8I+:V/]H?6T!ZX',1K#/@ $I
M!$X0/&IF/H-&0 LK&[#A&^N,6P-O%7<]=4_4H5B"\XPJG!>YI6BI'X)%]3Q#
M$K-)/MB/W=;X:0Y$A/<XI$H+N4L7@'4H+2DC8 HH-P9??@:U2@*5P6_@V2!Y
M @GKY9CN%/U_%:'LR[;2X^R8,P'H*>BS[U3ML^?&\YOY QT+L%V1K^@WQSFH
MZRV/PT&^WUQ 9,+39*YPGW9ZE2+B;U6LY>2=Z]*7LH.4Y@FB"2)#$LATRJD+
MS1\LABXAR93F I$_!9*_Z4RC! M%I0<0> STSC/A_J+XHU,K@#"62R=5[4#(
MC?&+"%X4O^R8+P+<%L0<L03_C*RG&,T'(7T7.,+E(O 7OW$E+(B!(!\2B9<3
M&S4RFEV"W(KB40\$,,R1WFR)'@+$\SUS.N<(G4 DQ/I;22IIX$PO @&09TNH
M$IM.59O!$]RG "?A6#:$(P1N$M(^P[G)#YQ_GX-XSA I*\&&G<7=U@E0)_CM
M"4P*K1;VEBS6SF#82)P^>7:6V'X*F Y1H$29>HS +!Z/-K8%&EY &<NO+A'Z
MSN7 .@+7AS#O<.8/@J),62# ";G-\L!%1B!4Y@JL9(2N1*,B/#-$!0L(V2%-
M=PF)B+N!  >M-:[4MG(K,@G.T!:&-+5[$V,W<RJVK?DT?X@;]VD\G0A/ Y<@
M :A2X.M\/ X\/<%[@1?P$$ 0EX 8Q3M2[D/R.I)DP38M",MBX)@4<HZ5W4]J
M\E!J,_!49#CDQPR&$0$X"@19!*\2<0H&L28=108>ECH1K&C*,B^5]*<SXD-\
M%N  P5E\)TQ\9%7$;.4 KO0-@5+,L2+Q;Q-\"P_<LGC&$E8I'F0%7WC.+S3&
M;\O 9Z<6AP3X,44H,CRM,,A^*,4VNB;@?Y0?6"4<'$CV]1%!*$ 03T)3!>>0
M0X[\X-T;;(&JVE_%,CQE07:/?']!XA]R5 $X1.+CE .7:"%0(F&(F.DI#.'4
M7X6'>3'*-@:[FTZY6*-X($@4(2FC9G*S*GA"FM4A]&<3<:YO0:J6J+3ID$DN
MA(9.87B1\4OQ']>[B3BTM ^V'XB$!EE$D;O2%IAC01!3SGS\.+*O('ZWYYZ$
M#I/\/4$5$. ^T%@L:4*0 (9F/X"@+N=E,>L'WDI[$J/6:'#$XRR_(+)!H-0M
M$K9;+FRW*&RW)&Q>YKV*'=G$YBX)2!!P-SU+J125$@ L%1"TVM)\4SU,X#BC
M"83U1?A>OA .VXW,S[\B,.\QR_0$JB$DD"Y@SG[[;VE*TY,YRCU7'YS"B.*(
M)@LQ?T*.;LL7E+7JS6BB36@^_;-'\SDWJ)@&L.<<]G(XP!Z*#5418_>4$6,V
M-N%!!->IC"XQN)-,C@:FZX5W0AC4_C-Z/&1KTT-)$A-)V/P">)]27Q9YTQ35
M0&A*P+LF0F,BZ'<@7'3NKW#H?95+4VDZX(Y8>#Q]P/NLD[P$_ ^X9]-[UQ(]
MV@6@>#A[<PW^[J3^41:K3A6_TU7!A+:;]92(ZP-Q,Q6\+91>@0B%=W-]@HML
MT*7.!,CI+!?5H$LUZ%(-NM1A"NO'51"F#E-#7P$\)%N6<^T%:)7W?T559F7K
M1+F_A?486&3QP-UE(,BG>$34FE_& L',E<O0$#M_/-9'G3R6^3Z .)O/]/S1
MJ!J9?"TR6;;R\X@RB7VC WTTV*>Z^W0B6=69J.@S'(:SRGD,?[A4XD>YG#(@
M4B5[I2ZP)>I<S)Y,2%25L5$;ZS/Z>J=37LB.)"ZODT<.J(9WYI'.S1T$4>-.
MOOONQ"QRN<A/Y?3L;P6YN!.!_C8-1 <BS17IKP/:N/<_0M\$@MJNZ:\>L5[I
M=\^E85*>XU ?$K\CJ*S?#,0A[NECHSY'\VR;D!HMT&B!B_9B#J8%NC=WPY$^
M'-4 17%>2J!,PZ%B_-295WAA2<_.ANGQ]P_KK,B[P<(/#,[&=(#51$.KZ([;
MBB_43CBIMP=VEV)ELM"4PNU[U_K-@S?&$K'[,OM[('IL(*"\#]]C98/#$%"<
M;0VD&QZ$=)D#WFM]HWK75S\!Q^?*>^/V>1_MN'.8HZU9N8R- W$@/^$:%M@]
MD(ZI;8$5K4A9$=G?OHW!<+A>F'.3+O@7F7Z-N/.$YKR+XOULO>^,4U'G=<KX
M07C:;28MOM;IXVK,IG9047:%72T!MHYB%5V^W1>>R'M(P95=<OP 9[V5]CQ]
M-$5;S'HKD*J309NP\(6)YIR)&=B;.G+H"/*UXJ+A-&Y>6$;^T@N.4R8HMPV"
M=4^+1EV:++F@/' \.*_RP(7YI^>O%0FJNF!4+5)E:@-%*'*+$?_;[F#;-.E+
MJ1ULMX8]HY[BNCK+$$=&M[Y%C8Y8IU<U1W1>M>/EJ_.V55HU9%,6\"5DNYXK
M]7=Y+?NVS#7/UEQ2/:6Q%=YSI$NY4Q[6[]CO+.'/>,7\U/3]%?@E+Z9O[8-&
M>J4)\@M*=%<)NGJ;46YS3N$GR328\GY(L4Q0-5T]'M[<]4?Z>-B_$DC<1DZN
M6$[ZIY.3$<B)H8][^;O=T\C)D:;;G-(\?F$!N'&(WP1AHL6>F>,M*3Z?PAG;
MX49;J2CY>JVS-:H:%_C' Q$X(S#R,"H+#E;?ZGTC?QUZF3,R&M[:1R'7REO]
M-E:=ZD-C[XEE-?'6*PA9OH;>]/LMPN):E-]C;D %%COIW]<QPF('_2M_)^Y6
M'E*$OG<M<=42?$7,@%_P*-(?>/ J%ZWTVQV:XJTH7+O8(*!AP'V4]-$9$,>R
MZ*/AWM/=&N^ZM"9GG',ZPYZ6\;3?I3SM!W-IAPADM+N2?QV.4(&2)ZCPG(#%
M5&66I#Q(58KNE<6G"XY07Q\KB@X;+_ORF:M @1^+N7JHF_O]U^IEGPI/X3><
M<) @/6ZY[6O<G$HJ&(D+M+CW?00N)2"QRG+1Q^BST[N6>=D--^VL<Y7<E&>8
MP<W=L#L\$W9Y!2XNC5-IG-;ZKAV1GI75Y!#5I#'( Z(TKNGELU#E&[F=6&AT
M<V?H[5?K@9Y =7[S((90U6SND^C=H[?SLJ6DJJ+]U?>"ZO[H^.9N--#;"NBI
MW3R,L^XR;OCN -IY)[[KM&_N!CU]I)B]>6Y\)Q2W7(&DJ\"7/2(T:-6/O0*+
M\ZY@ $:I\M6=-,<IOG_LJ.M4R:LO^.];;W8;!6S=<ZB>P+I<7[H2W$%Y-R'5
M$E1#)JO3P1"M/<K7@%8>GMQ$9V?%4>4=@&T<E6<:A+OI=T[/,J_ -NZ>R+K<
M9.WA-:?(1>0Y&V]3A^51ZBXBH[^?0%PX>^RD!@O9HW=S9QB#+>SQ"M+KBAQ1
MRF_?)^]^50'[(119C N1XM?*7A_=7QK]?,U591-^^DQ1&7^PQ/=+;^2*6*ZD
M<E2S7)ZK!C=WHV'^DE.I':LD8@YF]O;N?3V'E;T"<X/=LBH0"0%LJYK"NE/J
M:#MESD_@#U<GLX=]&8(FZ.E#18Q8Q[GLJN*O]ERK5:SL<:XCRO>W.WD7>#\/
M^/+B<L6(ZCJRU1?!F@>*SSE[QH2]EW2MS*7C0NV3<V^;(/NX079=9VRT"S71
MJPO&T]=G.LXZW3&&:V"Y#T2:\Y;T0RKSE*\!/OQ6A,B4?'=N[FB@K/%S395?
MYX6H7<G';>2WD=_35 7M+K_&M<COU4#=,YXF03\!_K+T ALQ8:GOTV5/)OW
MGFT+P52U"3-]1":+ECAR'O$Z>2N2%GJ:SZC'C'ZMR,KHVLO<QH92GP\+]^V
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MGTGQ"<J(#Y"2F<"Z/EMZ/C$Y<+OM6>LXPJA)4$/;+M]H!E%32//0 ''G[_-
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MS.FH$$Q7 QI4(\K2U= D"Z1T[ K\^G5S29BD(C6LI_!805VCP[<6?=14.'%
M<)BKF6E^V5/+CY%Q*^T;#]H'JO8XP"SR1KH:Z:I5NCH%U]@UBM>ABA(/(%['
M[J<XE8U_%*FF3&3/Y^#Q^3KI/- >1O[U%L[74$FR/4/$S_ +#1@#^GR ,/DS
M'N)GNOW#Y)$\0Y5<&C=W@\[>@&]G4D#?<%2)&J!Z.:J\!>C69@%JXK;7$LN]
M8\?1\Z^W#?;P>CX^P[JELE>W7W8&P4W#;7O:@(-Q6__<N.U5^_KI46&-MW\!
M5D#MFSWP8RSG[P]N[GK]? U<X^]?/D_5Z>]OX*GRVG[8>/QG=WM#?4MG<&]3
M?Y/KU>2=]R/-]>BSX]2%#T9%=>$7U.1[U$NA1G0;T3WY=>WX*IKSR_6V5V_Y
M.$T]WX::\T&V;6QF.RQ(M47Q,F/9\65IDU7<W.R8+W$+W9^1;P>6/155?ZYL
M*0U%,2"VD(F6>Q<YR0&VC+"O#[XO9T?G^O"#:/*GF&+-?@!97+YV6((8$Z;S
MYC'>.B6[]C)+P=Y6:@*,9P>WD@;*QV0TJ)X::TSEC$;;: ,)%EAV7;R.U*-"
MYKNPK2_LF;D1T[XR_]F>\IX 6B1O]H["N>?;6+2;*1+'W5(#>3SLF/>"*UY7
M^"9LH(0G\7;;-!&HYXYOC785SD'*GN9TJO R6 BO[P?!H)[K3 4XYX6D?V]J
M^OYJQ@M9Q8DEE(O/'7^=?.<%GB+:\8&#%N:*IAL3=!3\'"UAB14WJJ2H[%,0
M^XA"FX_ QCY'"0# &^]21_]/<?22VV?;&]H-P1>;&/3O'[\\M/+JH6)//XFI
M/>OV^Z/VT.I,QIW>L-<U>Y8Y:7=G;##N=-EH]C\=;/0^GHI1-\9TC)96K6;Z
MO6C#A5"6("/S)='#=JXA!GZ'3\H62O_.0NTWA)+ [AMZEI97U8<N_%[?SB]F
M8$^QD]_&EKRBJN]A;C,%NEIL7$$.XY25XM^H*1O+NSEB!E5SLY $*9P+J(#%
M,@KC.G)L(Y]RI =.&9K?[<CCH^8IQ53@N&V/5WV3O4<'^=@EY+L.!!ZU.N/1
M.4[,/<LQOKTCUI!??"%T4QS>3-DM'2S^+I3M@4HOKSJ)<-EI@F*PV#+78 50
ML<!.O!<2_:^J&;XAU;CU]+&Q#]IP4]5]7GS62%?U"\&#2%?WYFXXTH>C&I#T
MSU>XA,V67Y1GTN.A08W7V*_Q^Z_!(:(X7>,?00Q*6)OYQ#0.=XL!*T6DE.D$
M25QXN$"(X#4O"H,0PEC89Z&O^<K*W#BE-KH2[745]V]!^'M.]]^)[)]FE$()
M/B4TIF,JIP(3%*=A#QV,L3[H#?3.J*[IZ:=6>0V';3*G1^8P!"\;=_5N=Z"W
M!]<R,?6B!]>4Y#&1ESV!YK_"HK<:-;\XEYQX5I;,0:VZORFL/$\>VTGWU\9C
MPUJU_YGP6"TAU3$FX%SB]VLRK<04_59?863I9]NUF!N^O>VU%+=:9Q!OY>_\
M]I&2:TN,J;9XWEI[8_I+7HEO] ^,XG%DJIMUE38>X;BQ\?CRYXTU[/\:V']0
M,_O3W,;>/N-YSX3]:TH[7JZ-?%=8&;-/)N':U(1JBU>H)G:TDH*'%(IBU-[;
M3IY)GJH1@-<@ #O:R0T"T-G;4IZ) !3T*&1[$A03^535E!3>;ZI&SN8#7M.T
MBG$SK:)B.7@SK>(<]G*P:16INO.-JN38HEJ47,(&&UZ'SGN88-VV117K-+U!
M?%QTGL@;H=O\C9"\!Q(70TGF.&X<D1TFQ2[\QK7D:N+K6Y,NQOOA7Y8>3;.C
MT1OT2AROD7E02_MJX^RK=#L0-O)0-PW?D%#D]!J<?2JF6LG&(@9OG&PX#WQR
M !8<.\R*6P'6GZZ+L7)\,X%H*J /R#UE-J*QOR+[&1P FOF1(@X?0S('>FH3
M''V'PT)N)2TVZ*E=3.9YR :;FE' 3Y2F?GS!/P;:)QP#B!1Y@P?!9C2*%8X9
M%2%\\"=0&\R?VO#-I4_]5UNFB!6Y<3UCS8];ZZ0QL8OF*]ZP?L;W)(_)^V^@
M>CJM=C\_'R-A&^15G#L+VS7%R$I@+.+]O78Q6O=&UW:!WZ'UJ];=Q74KZO%2
MZX9E\!F_Z3&&.-K.]C/3;]='M2!^4.A[IIA-EO37Q=,.DW>@ZB]Q[:W0)!//
MC8)XDFVAX.>'C526GAV[L.Y!BJ40?V73B+<&OO_!YYH2@$K2CI1OVLHW:(UZ
MJK$<9R78V1XLI6H/8E+ P:-2% 3AS:Z*+BVE+4IQZ5I)1-;2I#@!=&NL=6Q?
MS'+:K'M+-G]==>_7Q35LU;<HH]O,#]FM'>HUMX*=:A[(2;-IGY9B JZG+2/P
M&7 B75HMEV"&@Q4^E.X8..^$9<5JI-%P8SG2GM[)/8TNK%JD-.K?W/5[NM$>
MZ\8HG_1OF.3H3#(Z0R898"6;WAL.]&Y_"Y,<J3KXI$?Z;]/WP2O-M<F>HAWG
M*F5@?(8R, 1%J;<[?7W0R\?H#2<<AA/&[3/DA!%RPLCHZ)WNL&9E>(%^)J^3
MQB04!.\<H7K"8I?3DF!5BZ7CK1@3*8'8(X70VSVEDW'5PK.YQ>(TPC,&5Z+?
MUSN*@OB&#P[$!\;Y\0$H]CO#0)\RGZBOU9\\5;MT3<"45\6(9ZB/0$?>]<=Z
M=]36V^,\F/ ^?MWV,VYXZUBM7J?A+0-T7%_O&P-]/,S7D^75W&8\V6NX9O[*
M>V1E:G)NAAK=&*5N$_'^$8\6P567S">2NU-V.R%OTO,UV,AW%HJ?GUF PP^T
M*9PH+,FDRZ8$9S3U@.2K^'B+ST7@UTR(KDI730O&UY._ 1-W5O$56.:"JZB*
MP!9WR\!"\-R)AZ4#P*[@#H.3S&_0.[3@6>03,JOM<@ZCE[C9G9J$JKIV>:K$
M&-Z)2\JBB0[/ $VT6Q5-]%?/LUYLQ[EWK4<X1/?)!CF[#Q"+\IT=X-U_I+K>
M'7?SF)KC;AYB5#Z>>#=Y@<;?L!_:J*J^BJ]!L;*3HGT^N@G0GM'N#+-%"! ?
MF@3&9X.04"$"OW$6,C*SF4,C+D $&.K'".M^ C[\Z,46:*'F%"1-%!;!9_'L
MHF=3^\U>V%119&+]QK,98HW#'!_XAXM_T/X)TFAY"R%)4[XD!%GF8,?AW [2
MS\ZNW)N@+D()U, BDY9Q"+*8ZA8A@ U1:.GL32V(X(54)^'-0I!8J;="-IV[
M<!!/N.<W^'C$03?:/\L]?!;/H5]W?OY)%UIL9DYMQ\:RPD#<NP=34"3^BJ.D
MLF?F>$LJN("7NG"2"WB3Z=K!@B[.)[:'R\2]VE@%@L-B> 4//DS@N4MZ/DD^
MAG]C=W+WYT(C_#19YL*,;@:XJE\HA$AHGUGO(BPLXK-JRIG602*9/2R6R8<.
MO*<:F-NA8Q1 XT Y'QB;3]"R75"^A,MM80F #R<?:LR$S_ELZ?ED342=7C5
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M':4X0'S0=N,9$WQ.PW1U 8S&,P 6:FIR,-]2LAX_A>Y<SH^MH03S@XT>V6]
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MG/#+9!GPZ(QL@ZQ.;^T?MW/;LIC[%G;5;=_<I8<:S_)*6"@)R>_3]"RX()D
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MQ@DDPZBSIV>S9-17PMU(1B,9AY>,@IZ'0WE4O3/SJ)K6H*8UJ(R8%#1N',"
M-*7S5\Y*QT7OZP]N[@RCKP^[^0$G#3]= S\=#>^N7Q^J5\-*9\E*=0+$E5!-
MHW-334W[3M.^TU0@UJY6CE7^WQ_7'%TV%<2-_#;R:]13_;]=?G$D8$T.02/
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M@B;-]GA<M4EST&YUV^H_56Z#&[9&QN9)N55Z\VJ:*8R+.F9OWA5,[RUNR,O
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M7XW[O:/[[;+R5Z=9V]F4F#8CL@X4H?S.0I7.P"O7=G[DQV4-P3H"[D,CH(V
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M_D[$[8]NH?K,;ZJG;G3090@K[W!<#WQ04'@4Y?.;$1Z. VL["=_&Z1 X>J)
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M*R4CPN,G"%-#GGZNR%79!$(N@UPQ43_"SBM#5;7H7UVVZ- KW+B>73(@!TV
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MQ& 1_HWM3A@_6S;O=A=/@\_R*F;*?HI%?(:'X)YX' XN0E(M'H"/(+N4DBV
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M*8YOQM'I^%WEN&?9 C-U!(WU61\'$-EF;U*&/]NVD;'UJDYK6R>I@B3';JV
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M!*+Y:(KG6E^:9!HKY!?@X(A-P_L GHCZ.0/ /@WCE4%C.7C)4A*(6J8<#+/
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M2^@Z.?' B6-@2*Y\U);YG4VM(V\!7_'X=835X<V!'?,'15[\_7(6,?@WTIQ
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M\Q3D+N8P,OS;P$QN@@O%EPGL$_@VF"[+, 8&,CX3&J?:#WP?8?,XPAN+%E[
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M' Q#3),HX@2?>PM< 2[80Q/RT1 >!'P(1SUEC+\R\NC^APG-5\#)/N)7(H"
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MS+Y$;(%3BR4[N9NE5-*2H@'6$9N]47D.MI)[#*3;*SP_=,!ZW;<??L(I4LF
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M^15?U=NT0+^V!KV"YJ.CT=S&NIB^/33MOD;CU2++5>QE?+2]('3>J&^.!SI
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MBVO>9FU[=&V/8VF)PJ(RX%&K>L%0K:PB?3"-603+LLS_:QH2],20^_L3[**
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MNZ;3I/239,0&RC\ZJ-^]LWU6]_KB<H%NU=JC>O6EK!!N.ELCJ:WW@.]I29O
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M$<CI465_>5?LVW7O[<MRPCTR]FV8C,^Z0W;V[1W+LJ'&-ZTNUVT+WXQA@3_
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M:C'%Y8<VXM_N+D8$1GF,E(2(7I44R9&0T6 IQP98DR27]0,^?9#]2=<C:/A
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M^FDI^W%"W;IQ#QI2>=?,T7D9H]MWE<:318E2S" NVG&)$L&7.%DD2$5\\W/
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MOB*\!\Z3L37K1,%J";YVY=]-7%U'IQ6XD3!)<LD\ 6-<*4/3Q+FD"!K<G.O
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M"@>AF *ZI*Q4+%:FUL[5 P).D/ES<IU.6RFDYT%=FYNJL\RL%4F#60[G$-&
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MO0JW=31KC<+?,4TG^3&)) "TC%E 6_-83"I GK  %9-P])_5^MFG_AW6.U\
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M2X;7+.SL[.2T/ +<K/Q,;.RL]P>!>_SX,3H:.@$&!@'K<Y+GK/_'<M<$8*,
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M@#R /( \@#R /( \@#R /( \@#R /( \@#R /( \@#R /( \@#R /( \@#R
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MVG:^GQ4G+Q$-SFK(X_>@BWD;(D[>50+;/N/L;%U3MH^I2%T\(LY54W6"^"U
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MJ5I[SMPLA4I5HJ=D&*'SF>I)VLA&KL)/740(H\6RF,-4BF&$MF5&CHB!I7Z
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MK<WEHWGK<^.:=WHG*A0A;8KQ2S$^,7N03#'RTQOR.P!/:K*_R+:A4U'$EO$
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MIOVNN@.LDM&Z0LXSRSDNN\C/A^;=9XG8)GY.>?C]GMHP,)^1S$D4M15U-6[
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M]12#A@=Z!$['W/X<#U&"3.<M>-V'ZL$Z*3#\5]5=&!&4OJ?CY?P33>AXKLE
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M=6V8B*R)>\/](46](^6/B21+_H:HK3E.7\*P //T'C7Z_G"+QC+@\T[BM:N
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M-."760H5YSE&2EE%Q:\R2E%N^LH\]-&(660N?"[CQ-^%G_B[\*1.*N8_>5(
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M*JS&IM4&^]S$PS58PL^_"U(%^(/6,41-1U"U]!O5W[DB$9$B#PKR\ZI"!BN
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M3C]!#TBD^ NX_/RIHR&XJH'\!;^X;*PD,+2$KN'VJ:O.T*R\=ZR>?8",A$E
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MY;F+,#!#B\W9EI< YJ*B@A)7SD*]JSG1B^0[?D>B8<V,)'7L^(;9O@A?E_E
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MG^\XJI<'!@0/&B,:H:7.(Q5)BN_O3BH<:AK9_7@+8H320I_#,.#O"^BY:Q\
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M,$O:@4Q+NN!SF: +%,#\<]B0G.(BWC\5'HX-LG%I1XB=-?'?V^$U7PYOUJ,
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M172#ZA,Z/_?/3F*L. 9[+S$A<G1P:B5C&M?G?\NTRL>),YW>+;O2"J\&=PP
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M#"'(X7[(<$T5)]:/U',FOX +-H2$&-_?@3ZFAEGE"HT>4JTT1".7WI&$6O'
M'[WIV$P>/97E #YZ7["P;HD.Z&?%DH&<JBRR#HHZ5CSA]W@)HU)27HJ:B*PX
MLAILQC_YV55;TR=^[@6$4CUG->-9VW6*OYW88B=;VD(4-TX7:FR"?U8(S2&N
M](K>WEC6P40>#7971CY!TYC=K&20]<I66_QE%P,X^6I/Y!M^(TN_H#1:M7@U
M"1;GPRYPPFR:LB6#P OX5G8\K1[SW-Z@D&KDMOV$U!029",<=,23R=6I0W'
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MI]8FK!YI3?2ZI_E/SO4IG=L K^ M2IV]3++5I"_MIW[A2/0$;!+-RT\$B-[
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M+3(P,C,Q,C,Q7V<R+FIP9^R\!U13[98_?! ! 041 :E1:2HB*$UI$9$FTD1
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MW^&#(?XQ^&94Y!292H![W2,W3F]K4D5<\554: 6*S *AGHLG/<YOGMS=0-,
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M&E2(U_$_4G&3<;5.;XL64T;;,C3D*"^63IWW;'I48XI)WP0)P+^.%,$Q731
M>17L+/-< -(<'_U+T>2=_9CU]$[/R%'5C+2'LJS"E.7TVE>?^HTG)K/ZM-HO
M1]6L^O2I>F'+!^'.%$U+ B3,=Y(YL%GXQIGR FGY[8'W]>%1QYP 1EE^3^_1
MFN#XD0#S")4Z)H)(G$QLL2\-6.6'2O&_&H]J9S\3DJGG9U-JO-N<*6>\".%?
MJ0"%660*$,Y7536>'/!*,L93]M]E?//XTBE8)JMB/;>]W-\@U0ZI8(J/:1PH
M'@[<:<T\/G3A065G]IB+.4;V8Q[;9^G.9)"#[X_OH<$8!'5 ?_SITOY87JV2
M!S7$<)WHEKF566F+1%/,ZZ"U0BQ/:(!CW3JO)>G!)*GJ.AZ=AY.YN#4N<\LZ
M3+4OJXG>GS5IG H]K*%BQ%-8"!6L'JQGG3)@^\;)6?PC"Q=<S*] NE[D_1!+
MI&[)WXUJ6IP<;9ANV<FT2\4/:'(\J->BQ,08W)/A5"RH;'=U<G)X3(Q*YOSP
M^L>D:3K!!2;K8L<,820%&&=NWD+AX7$7MH]H;TR(NZR=YN9J%*V;DRY_(\01
MA#9!VI6_K2@;HP$':,"3H8P;X6PF%OW+<#(+E?->.&8E&.Y9NX%\42\C3P6=
M7#[ZL8SQ7EJ3O[@L2=6>7>@ET-GV**AJ91&IB0.Q+>XI;,='?83J,]JX[N6E
M!4[=U]SOQYF97PT[N&8RZ*#0H-3>P]GI1\C4$"9.\H51WN[G[<+[<U)W$$I=
M&X6+F>Z09E1Y>\94%SS\B*.[G^J$4$5#V1!7LJFOSZ[#145#W5$CT4H5S+64
M2^?V449KDYN]\][->F..RY1EF-4;I6AU1H-<DK^!CR8]^^-6+XV27:L&%MTO
MQ>@9*JX=R^8US>17XN!4&"+E$,%H587'.-OS@64:@ZHZ[ZSTX3[9HVFQW5XG
MSMO>:3_Z-L=_?*R.*_/LY+%&.<NE4='A10A7O5[)'?U@H9Y<R (OVOOUT&=V
M/:&/EO2PN>\\6K$-&95JWD&4*[V >@A9O>RK*+Y$_#%R^)S$I'1=>P8&!OQL
M4<T\ZX-;]9L?Z.\<EU%[^<C>RWD6@UZU1$F/;.H8<C)'^WX4T;'O372M6!6Y
M:J)U'/AW%L,85) ^AF\,4&L,:$#V:'7Z:N,1&O!UUY4&V+RG 7T>-@:.()Q^
M'^P]DN2]#7]'C_+"E[\G9+'4GH!G:389)IT>E7EFQX_"=\^EWT>KZOC-ZBCD
M'&3294D12^IY8#&K%L*];P#K&X6W>:@T\3;RU@ZM<.L-I*.)5^(3/U\9B67R
MJ8;FETBU?Y?=+N7.9_/LLF[P'3!(WQ5I/-!P7O6<879=?Y?AWAKB^TZWTA0L
MF0 BNA.JPNM/?5RT<DKVF%X4"S,=DMB8NF,^<5*;#'_\23UY<WM^Q1KW5@87
MWA/FIP:_VM^JJ ^GE#[V=2@+-"(PBZII"*N8>\80RK0&X([!\9$>Q&W"P<:S
M!G>_1JF&>9[6.EFYLO8M\V)\T X/I53]Q!*(2W[5U&Q H6:+1);AB,:<]0*-
MGGSK4S-M?N\C1Q#B6W5B._;-D$KYV")2'YPV/,%Y-*LG1\]O>V#F,6<T^%[\
M"1*\C<K5NZK@P6<7V?J]R_&#:Y7XZJ,"F]DH_EVS>&#K ^P4Y:6J3B[Y6B]4
M\/WRGF14A8=Q=X/O+H+WFEI=^L-O;)QO[DZ_$=BF =&0BO@6B) -6:WB<S7!
M+SDRLF0F)7@8]U3E2^/-&,%3IN5OO]<(7FUW6RO<?Q@(TB.%3XV[:_=M2]LL
M$G=XTU.*"S2.\R5IG8J-/2AVD4D%]\:;/RYGS=UYH*22(G^\X.X%RNJ%VJU^
M&E"( YT WX<<)8OC@TEI4(UWI*(;3Z=7JAXM6$AX?>ZBC%P^ >YJ\ =]7F^9
M/$(JFI)I5[.PZ'M0(:Q_<R O\=L2[NB&]:=GG^Y+9O4H!!"?4[+)K-/(R*H]
MHS Z"L&*V>W1'G5$48=;BI:>>'6LY]?5)!OG+S(OJ,(D1WPDSCE"P<4+84P0
M?I5"]/ X5FZ??CKL\?E#_&I/BI$Q1<]V!N;F[ PQVGKVKO<:.M9&=HM&$#=(
M 5/PT!+UDV2FLM3F()N4T<KP8.^"Z^AOYDM:&Y7E8:"+@O&2Z$96TA-G9L1T
MSS$KZ^N?K#4*;=J.Z\H6%$D![X( IA"O;.J(R*$!LB,^S"P%8[&O%.X;4R1\
M5;J6]Y+>[.I&.PUX#8V\T@8-FQ:V$@YN&YW+?W#">F+2R.?$2_NG];$MHACF
M(IE\.V[/XE5/%"YU\=[%S9PS,H[ND_DDA[V?'?0Q>%S5F#X& W^[D&@CD@0-
M(&?$(2AP&_A""R3);Z^3!ARD%\\D[S(:@%R.IYQPG[L<2>F#/X?=W+L91EG<
M W>+>-, IENW)H[CM9GA W0*O4RP1X\]* .[%FN86%7N=X%C=P96MRDB799/
MCSN_4!GF-3-7^V+?]'']E_MS$:BMTR0XG4(?G*" <]S]+GN;AU^CSH98NJM*
M2!YW5+'KP%:E3(Z#DT6LX;Y4L_TD&G"8!N QU&<03AHP52M#E8C_ Z$%&O#Q
M%0V8']OO4:'8%=( ,-]/F."O0IG,5NT8S4)JP/@>&G $OJ"%IP%4]FP:@'.A
M$X&3W&G -9E(.@=;/AK K;/7:40-0=6#AY80FX20?T(6>?A?)&GYER#_-P3Q
MG3S"D]IA=>7DD_D@^&=W8CR5GP9@D91#C2 :T.0+(1LH@T/A1[ /%Z="F(0?
M'ZZ%7HTG^[^WT3(T<1]!U1?@*;KEE.S]^%:CHSEPKR7X61H07Q@,KW0'=WFM
M(;ZA'F5,<;8XW>N>\@!*KX@M$NAX$'^0U[5$]'UR0\9^*RDHCP9$-4[CQW[=
M'2^-JH6?HW3^&1RR' UH@>QQ0<$TX.D"BI0.7Q8'[Q*I!'C1$'@>MQ_?XO7K
M;M5*ZB*Y:$?R#[A ?Z8V2[K\/54[D7L-IE283#59<6-L/W\CYR]8X%@$58 >
ML3%8>N#S:=& UKX_,>!V(H*\#P_\EQQ_+D=[3U2T80+V\ $X[O;;HN>_$D3^
M[%0_0+Z2<1=^T$6FW,-V%*K#.+ V /X#_4'-J,)V1:+7^@4H^)8AM>^?"2B%
MOWC*QG^_F*PM*F(V_A+V4L=MH43]-*EYT\B=E6Q48G2O<[;B8_JS;BX;!]=;
MPQT5L %X"YBL0 .R^%IH .E"# UXGO,'B^KCSEV:2)VYA=TK'47.P41EHA3"
M^UZ\5)#"YI9Y*1X(V&!W5JFO7_T1C"LC_^->0>\X/_JF#"(F9+9A11/9_XQC
MN?Y;O6FC(F_3 $3,&ICC;F*P94XZ;^+9G+N+8O>+I!A?:@@?4E#,+YA<MABP
M6U)2XMLI$^KT]A/5$WWC</Z[GBH#IA_U\(\N\B<NF+K7<6.'[C0@NAM[N?PK
MO?P7RO$3+R!+Z(C4,Z4!IP1ADUM#[L2J/RTI'*<2[ALQ+IQ9TI2Z@#AZ\D7D
MVF!7U&(YI@S^V 2[]SQ_E1Y3$J3N.R2D^2D]&J 'F]B.^TMP&>!9L&47G?"*
MH7I_MZ2XQ',-Z,DX4?%0L$G=OM8.*&+BE_"^_9=.R^@/]OVC(PW]-<CI#F+Q
M =[3M@.*WH.WRO"Y*KLMHM7%T1^WMF\5N7K!Y;V!H- GI6%)HS7K_QF72FZ]
M[5 A23I.HL<1/3[_F0QB1OU,US3":UWR?W67\B]!_I<*HD 6OM6H6OY5=,?4
MGP:\]["Q^)4H;*X%SX?MKH\1LSO4ZY 0=&F1< !,&/UC<WH-=P[ZPZZ;,ML(
M*OR6L_I/0K/X:Q2)_O?3T+\$^9<@_Q+DGQ/$8AE$YG[&M7]Y]( L;-R;!N0<
M"5;Z0QD>P1M%;"%92[+R749#*E/MA<921OM/";D9ZIW2X9EULJR_.&AVIGGT
MY_:EE0^! C]R\T/.N_Z$?VVBP[#)V$/G.?[M!VCG5J3@]'K,! \)PM:#BS/:
MEQB)+JA.D739$9KR-%/%NWNUJ)\;(-N^?Y_U7G?32I=!3T#1X$NH!D/HY29D
M&G@JWZ",:%/[8+6]U+&'S%HT"1,*3-(SBLSD,RVT.BM@6W#R>SUL-F1I+/)"
MS*V&L<?)]0Z$@28(Y[:^ATJK\I?^]0NY1\<ZSA\#7>G\<ON4KN1H;2Z!YTVZ
MX-*7+J*"YBEU4\^._>J>10@?O$E#P5V%/C> RZ)';5L>3N+?6'ERZ0K&39>H
M6/PT@7\P>I=5;6FILHVA L&5YCH,-(!]K!FQB3&FIUZ/#AK I4.6\6*#]]AJ
MTJU0!2)K&==2LE25G DX#/9VUH!US<"++)XF<.T#Q8&C-.#!0^\%K2".AA#O
MO$4E)?^4IWN!QM6A7T7'7XQ]\MXUV[Q%M=BA 5_.X5=)]+?+DR2[B>,T(+,V
MDLKN"29%@['!@:;4H"402;J:[D=2W\J18]<$>\(4(3P7ZOD#7*<Z/<W98\+K
M+24JS1,<CLD',UOX'-[L;PS+L)0+]-FW, R%L$JW?>?B&YD[4!?Z@^-R3GKJ
M!@I%!>R$42 2B^A_",X!U@,N=XK<UW2I'?^1X2J16K"0'COJE)5OB)W@=U#S
M>9)\\BF'R@!5&M8K$-!, P1)<LWL^>I()"E[ILG=,^G0,S<&">U[G$(FW?J[
MD$D: ,AP3,:3&:VI?%7AX/F2++HSCL533\?_#O@  =%:+/=E_D9%PQ'%L@^=
M,W<64VB ?%GUK5;.NPQBQ!)P!XJ?K(_O,0CQL<$+]9,>@=*7U@T:^;BM)0-<
M*@\_F4R_4@B7VJ?'#A-VC$ #0CUI0#,1GT_>'@3CK>DQT6KR!_!Z.'"LHCGJ
MD!,I$EMG1C!_F2)I$B?MS)5FSUJ]>EEUNJI8$\\W744/81=.QC:<\%&UCQ\F
MS.8R'L+ASK++@O'&P;@7;I!O5/IHRA#H3X9/"68*DK*R LMN[7-D[GAX?VJ4
M*$L1_]+A;ZR"]GQ"R+E.X&L[XO,E!5T;[;9WW55LL]NK<CSLS%VNS<ZF+;HV
MF,A:@ZIFTYS'%JI$1$(N"?-JQ4Y4]"8XGV<5M'#I8$07CP2VZ-80S OM'?.Y
M/XQ=1WK+O.)ZXR]8FM3FH#QXMLY(?Z%B><<]B\/X!<5?1>#<^PSH:'A!VKO$
MGS/Q%S1ZF(L'W^>6/#MN8OQS0L,9E.8M_U#2H/^RR6[Z70.MJQCTXBQO]?/K
M]3JI(/  .H.2[^39V$VL5N][\UC]WGK/P)5\)ZGL;A[SZ=N?RU[J> <</"9R
MK?-<(?B)PCE;#;%5MF[!FSG2 I_.LQ0>MPSOD^:Q6C8M*W6TCJF6'JD]__E<
MTF[ZIX_"FF</Y][GZNV]Z)(=??6XB1;PU\7#M(US)5KPW9KO>JJ87+G=_-00
M?"ZS3/5F'EFIZ%QL:?EK /Q3GF%FDAWEI@**!3G5X">?J-IZ9W<'HIVM4MBO
M5\06O0KPVHK;UV"Y?"MPT?P"V+5;9*?5ZD<"UHN=E-1AE//5'E77*SWE'N@(
M"E+;-!#!R<+6=!J@W?LLRU:&8=@Z:1E34O('5X'6T>*?%TF*UY]XS :\;?8+
M[4SY"EY6&0)%*J_V?$&%PL[A.>IPQ=;8CE;I \O&@QY.%4\EJ*-.E@),S'=R
M)V+'@NYNS1BS#$R<I121U; -D*;1ZR)"!(F*CX$?6)T_#:Q(W[-\I7W5[Z7^
M>7LC]?PL8GY@$3%G@ SZ$ C1:<3KQ'!&U5]+5"N).<[[?O; 15,4Y>3)'Y=D
M.\(@$M8ZTZ!HNN.BG*0U;=#;<3*M :-J*ZFU0V_K];V%,E+?J!H() )+R0N3
M('61Y218'X1I2U?5&JFV91YP#JH_.Y;1T*Y]LO+41L0EEI]"#)/IP)XD-F"5
M&RL3;04KEC_6C=UOD#3VN$ #C# W_3?'?C[5;HET%"..=A3[M> DPP70UEFX
MD!-CUW%G)?:AUEQ?Q<YZ#!\,#20J[*;ANA7GNK _&J8HSC=3( (C@526H>T[
MM[1";BLTX^;#PK^*KMT]3$32&]!P]QS4*@,A^PLI"+0216;;,;9BAUI3<B6[
M3K]73&,V%.3G5W\?JKY5@Y%?5E/S6I-9O5MZEVU<[])''379UNGTRL]2VL*Z
MCJ*G4E]JP1X%/IW$7:B@ 0<I^)NX?0,/R:_A$I]K!_(3R5^K;H5">^3/&&<%
MGLU4QHR#V3SJ+9RQ@B:X,8H$=?E;[)=1K5>57Q-63I@?TS\EO79(9)"A:Q%>
MGA(?C(L3U6G ST>5JX0X!50-*'C<0)]9]1(V0[ _/QQ]HXBK@2_/'W: ]/P]
M^7JD=9)!])QXO]\5WT)J?W1-BH+VO6I)J>=\26&8Z%W,#=+X%.H%G%_>?=RT
ME7?4*1R[C+'ETT,\LIF$?))]_L8#>Z NW&;CCA A>H#$33!MMN-"D9YCB]U;
M91=J9W=B2B8F)JY>S[,[P2/\*%=$HSWPZSO.['<$NR0?7#"2HRTPOMAJM"-8
MX3WZY\NZ2T7S)YKNVV-4S2N@G5ED)D(<:O5(B5LB5).0N!B7;77.K5@X<D\S
MYGF,-3?Q@8>QYD-&*+ET&F30R_#[IZ;_=MW)O$1(29@"<8R[!\V.CKBBNU)?
M%MXS<C2^(D8\4+G<3@/<BAF-T52A.S9W[AC0.Y/[RXKI>6UOJ[NZ#]]L&^28
M9\D#O +9IY7($J/%#7&8,%4CK'EMV"IOF7M*[T>?V/L%%_4ET!V7'Z(0/!C7
MQDN]"C$C#U84NA7WUDY:Z0>[5\\D )?%"L1"I=KK0PA%-T@H/*HM7;+EB+D'
MI$U)6;QK+$[MA%K9ZPPGHNC,O6$3:A_/K.*M0*6VH*KFP$:>87'4<_FBR SK
M1#2CT"=+2N+]9,\Q1IBC2_6#MV-&;L >#B04^ BWZG&/P)PJ/G#6,5S&X<+M
M8ZSL=9</@KYB1 G@:?.,*43$7FJ,O.5YJ %/TD</X>*E5YUJ["4K0D*8;[7P
M%F$!KY'Y+ZG=V1Y#:U"7+F__Z,5']US7E,Z^/-ITR&Q7@WVULX@&B-1+>6#W
MXV.#)&*R,PQ$/,"&U;P"#\2Y9IJSSA0]J7-[\::79614,KH<SL5GH&16BDH_
M>;ATU":W&%3&) F*4[I)2'E2[';LSN+>7 8\Y,1Y(KK*N_-TZ$,],['88V!E
M>D=A%VE R'^.G"%)NA!W9 .UB9/&23=CFVJ=;FIQ>W\?:>>T4QY:/>#%1$+8
MD;186M@/K9(M\B98%6JD[U[49RH(1V,O9/"']+_N^6XD*L^P#8F"VGMA&RQT
M/U=7IF&,7?E6I<3TA!@ \=R)I>%YDJ;O/$^N7_%EZ]&?@OLF3",F7C)OZIRD
M=ZX)8<L28OV0?*3=G)(: @0KGMO+7^R(,'X!>97,D!/E8P?&Y[0TGD+7.]KC
M<7?6F*I:3@6AJ_A$N7Z">WB>= JM:C^G1/>R8$I)75<S[BA?#YI+W_M0JGFO
MRCNMA2%1T=G_*O%]][07QYB=>.XH,8UG#)7R26W&O@ON>_;!?&8RP3RS\<00
M3#!0LV64XTT?V;D"O9K;(,U^Y,99\P<_.^6K?QJWU0N]$6Z)'JHF!>>-DX5)
MTTB;A=(>W!E5+3DKB/P#I_@'_GDW=3[$EH5,-"PPKAA VM)!D6NGJX84WH(-
M,NU?X^IK7TAXO[G/?#(SY*R?%Z]+^F$T?BGH!R+?P/O[Q?%Q,0/)R[N:7)FZ
MBQ#.P VZ%7 Z,1;M5O/A\OJV[C<_4[OK"$[Q:LN[S&B%I)5^L:^BIR%RJL[^
MAN[!': 1.*=7O6A1?O06IPBI\LBY+J,D+8P\ND;Y:7D"SEH=[B/UI.E>2Z86
M$!+^&+?*;C1XZE,MNGS???&+2[%3;9SX2Y'PVV]>AA0I:9/"WR\]A!CX@TL=
M*NK=I4?C6MG$'3O.F6M/S8<.>]E#%$F0VWASQ#1*:)ALV)=6#X$7:7CGC?[\
M<K_&_5+AC'@9P/;,^X)_0N]<S95ZQ=H5\R _2FPJKP68Y[81ESD#[GQ:YXG+
M.^\X2U%8^T#KE81Q>+-^#B5%9R/1JZJM%+&?5747X595%%AVO?=(]>!V'-A0
M";0$P_@F/'ZKOH:3&_3=1B9O<SYKY <?1;F< &,%*O:/"XA![E4=O7?(=B5,
MY1K"3ZA4\A$PL3W?J$Y(^AEHUW5S\&.]BKTO5"R.-POGH8RC!B^>D.6R8DJ^
M?DN"V?I@8M?B59#5$DK@HSPX1@\K?77DSF)QKL1[A>",MKA+/Y:X#P,+:3_6
M*%*]*^O%VU)W2CPNG*ZM3 [0D;\@+"3RC*N)!]_^I" 0HD>8#%4 /U>$^2=F
MLCQEJ1Y\Y^HQ_;I+EOWD%<$HH?O<38MV._N2"SOT)O60S&E(A6NMP5Q104\V
M/<H_1K3K%UK]++C[L-'ZE+'/DR=711K<<6_/;;9:I!]7BI$H=CYFI%9@_C-J
MTN]Y^Y4]=#&T!PL)I<J6DK:12TGDZX148L"(M*4"J^BGML5;[%=GK!U<%C?"
M+Z]#] M&WW%7/QG<><?T^Z_I/[XGV$7%FE7$J=T1.NJ9)+I=;$4>Q(!G% K@
MF%;$'A?RS0\?5T>WC-@K-4CTF#7YAY#Y*>RJ8S B&X5/68!O\0_0I\]S8$(.
M]=@X)S5,&4YETJ$J[-9I03OVQDVI4"2*RM!"R:4!KRBG:<"S*OJ\\.X'@@8\
MH7?5<:#?D$!VCYZA =8?X#W)OXPZG*N2Y/Q%/K)X+8C"[$L#R&SQ9)<_D(!Y
M]NG\E1$ =P7/@G516.E>&K @ET_OZ6_#IW5^0\%]TS\:C*9/TK,A=*Z,^WHT
MX.R>%@U@]:1WZQIOZ3/O@1P:( #^+0U(1KD)M>J7;V*DUNDC FC4:->H7X:D
M[PO>.[Q([^)Y0*2^/] @CV?';]?FDW<A<#) [8=_@R7 FZWI@TROLQ$=7P$-
M:(__#0G,W.IQ>/$0>/[;+^,("S&):KH5\[=ZE?_]?I222P[%DUXYU2U^&9G
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MA,)>3.&U/!9:J#).=?36V9@&6#DW(4*I(-*)"?'(EN"L@>UBC0I0:<*&=1W
M;TK)E".E+ZQ 3Z!A\O4$EK&TB26%Y\7D3X"QK*R/S9UTG\)SGE*NMGN6:;=C
MDN)JY0JRHZ7*!Z5F>TAG>-_REN'K- 9*^-LJ)BH\#M=Q< R<#HO>>U&]_AS!
MY@N*479,CFA,Y?1R]DWU#LF$G-^-TN"_/'.?0PK):F:,9$L<D4OET4/GG/,>
M1[#JX%8MH0;X(FS'<[$Q'/@0*4[ZX+/9]Y6RWT1?.:_[=^Z4_,#HU5/>0/T>
M!Q-DFL+LXN\0&%+U":NQ=>L'7U3KSMZ%MMK<99J^["DKM8C@AW4WLA(P\5M>
M_&[^J:"QH%OA$;H2PR^ +Q/5N]4%?$1G_)OTE SOX("/2RE!'DVU9?U(Y/?*
MA[IZ5^Y\G3[XQF>B(?6U2>(-M(%;_=K$"PI5Y^4GA>RQAM$@L)3XARJO-!S=
MXN"G\E[Q?#3@&-E@>OF$JEY1!_*GJ_&%=T]-\YOX!1UB_&_>/V;4%=;] "I8
M:B!#Q)#>NG)WB3UT42PM,A+5G6&.=4Q[?CZD^Y>GIE8FL:[U^A^6@_PFRK#+
MQ=;,5&D!TEB;KPY!.?21D8^)+:Q;G<[IV;?UUCV['&2@U^W:BN@?YGU^C)YQ
MQ^\RV=S=X_Q6,QN=KP1^G"=^O[AR<L9+2%KW3/ '0H#G_CK5.0'*C2])(HSA
M,&W%%AWI?JBH"_)UI*U5]0YC(V4U=5X.ZR[M'_UMM]>$R!7;AI$YUH'!>A4#
M#\A-[@\R;:Y9"FBS*1_YKO=E02V49UX9L3*-S5CG-L*QZU.\M(;6WAVULUFT
MF&.NAU@^5'=8MXO+=B%.@/H]?)?ESWIX/CEZL5,]-W/F3=)VR7DS%[1K4YUK
MOI:C0QF[]NVD6U;+R.#/V\=-;%@>_O9Y9U%98[W+C(D&@#3/1ARR789+CY .
MYE,O5H9>1K0>P=XN"VBKG"HZA!@ NV[RJ<EFUT)B$'Q0VV)+LEX?611;)*VC
MTRL_DC7HM;:>SMI5?T&WZNJSBR:) 9>V<*'JS[,;74DR!"P4_&XLT,OV,V_"
M,,E<[=&WK6]WQK/+GB=$7+ZOKCM]9?/<9!3858;'M9&UWV^K5_5*'J7(4#FC
M#7?$U^IQ7QDJ5;CZT/>-Q_9W(LP8 X%,%\:%6JEYPKYV8'Q;^OR3+=1!DEW[
MGA%/H*NJ%D][*11-L#XE.I-T3^51_M-WY.$?+/+C2L14-%0_FV38I87O+B-A
M;*JK*Q/;-_!YR5E/?*3JOWUL>V2B?331YB&S+K#'%KU+[ZI Y1914'%O["3'
MQ$(Z1\*T@?:5^>IX*[169<9ADT\,*2%Y&3"829FJXM5I^7+P:)$QH3+^W7 @
MY-K -J> FU4<^@TQ"9)@SS>2]JPL)(LK1MM,_RQ[XJ&OS*'J<=F-,,IK/P,O
M,T)^6R2!*7&Q-MNM-Q?]Z8=3^!W1F?;6 \9$L;/;!_((+!V3)[Y/G!\BG\5*
MJYCB(R,D]Q5FY[)@>%N;KZ'R[1/B<<G)9JE,(Y=\KHKL:@7:O27LMZHKDN+<
ML9/,),]V8K/ML1[;$/U;C2X''_[D;4Z^[H-B_R+D7,CS=O^>6Z9L12]9U'[J
M[:-E372%L''3\11D5;<W]R5MZH<[9]0'&;:D>3;Y6KU>U"*B&YE)_F#6B:Y\
M$JI5(^N29BOZVJ%1_>>&WK&/[6&?BYT#G8EI0^5>ATB2+82?"Z.1T9Y;SQ6D
MNC7;TJN&3U[\V*^-J&?[OG$QKIK]Q95?[@WX\6R(5.Q?"YS'B93B8TSP\E8W
M%4<SLX(=0IQ]"K^][ DX\%E?4-[[LHOFJ?O>B3\=M0(F>6F B]=1\H6:3,LM
MU.&\N/B7GE.-F.M*&+:U#ZONAS3KSXC%S;*V <';/%AO,A0#U23<\&)?$/!\
MXNY^I*&\J5ZGL-/9S]_)PFO+)47R6.CQ^Q$_]*;?/^YY N9J%)^P@]ZL)1S)
M1'QT#3(L]A8R'ETRQ)SI$N").'7>5>2'1I?R5%(;$"*C!6U06A7'-3B!> (]
MI;Q8$5P=V+$XJ_9-#4SFQLB!PY<36C42M0XF"^J*<>A8Q;2@CM6[>^%[L-I9
MN"\1RU88Z14'A-Y0WO@E>;X+=M.^F@$7&3[=%YI7-689'+2(#01/\\5"0SYV
M%;C CI56XU6#<M/MZQ,IB93ZRK-BS<<R%%D.HY:5A'R1SN\.1)_YRY**)#41
M3I)E\(ENQG<4"PO&Q[7RARW7AC__O*&KY43EF9K9O"K<QK.1WV%TG*P1/=GD
M8(/OCJLL\\(5\90;B)JX>G@Q*A]5JA4%6%L<582<:KOB1^_1@*9:,+W""@BG
MI):0[EI=&EO$1+@'9_FVG3RM<_N<DH/WR;M"FU=%:( 6%)-+12M]ZBX>=N=5
M%ZX?\O!U^#B"C*A 5&F>+KJGF_<HV@0C-1Q6%];&"RIW;@TNMFX.<B>#^]'+
M[;Q@C[YD/Z?3)[F#!<MFR=''P_91LOM.H>JOLAN#*BCO*XI6)3ITJ_ 5]0@N
MS^V:+?%^V#"L-?&+<%YR_EBU]C&ED\]^/F2><*\B61!,+0@ZT:KZ6!#/(F^M
M3+0O6"(@WJC&/<8ZYG'5[B/MM8*1[YZ'SEWLL.EER3>QXRR$#7AE+Z"X#*CA
M,\M4GL%4HZH!WGNPR3DMH9?*E9>/S#D,%Q;9'26-X2!\4)-!5=E:2&1YM?Q(
MRL2<L.;M%#5M)ZZUA-6IC:A$69^(GY>N7%Z\*C*NQ;-YA5*@ZC8A@H9:@YZ<
M1V$Y^Q0D/Z'>5DCL6Y_KK,B+D VWU)[%IAGZ=/"?!-TT@5PD*;5C,D4('1T&
M$(,(X1M:@RNP[U55[AX>)X(%H7KG7\!T(P(N I5RX9+1%7E4S#'-7%*EL,7-
M?B14(Z?'V=45%+$M4SEBU^V+NPR\_K J.!)P_Z$<)@\($=<*-(II5 FLP\*?
M.342JB+DXU1,J^LJ/@^(8,RD[54'6 4?)'Z-ZEOA.M;AI.[8Y.D]"SK1J&Y+
M6L;RM4(X)R1>0#6S.[Q\Q?#MA<0QO:R7V!O?S YY?)LJ9'RGML"X,BK5M$:/
MR3B?+\JKJ\A6H\-C+FA1G6JTQP7YHLK:>R\+ Z*-O];='\U?2[&);]#+)?L3
M,E.+ Q6-^ -U#/M5K^ ZJ9V.?@X%JCN\ _)>Y]V]!;4_9"4JS?+C'ZK,A:K-
M16\@1OFF'>.;UAF7E" NZ<(N8VGGGRY6\5WD/<CY-D?;;)E\W4(37X2#)1$T
M6XPABV4_#<Y[:U^ 4M1QO:QLS"K7"^HBU2Q$)T)5K*3:5?D(8>TP=72J";UN
M.2H] 9>+E2HA85T%/#?CK]B?+7-:;;A_Y*FA7%L@?;R%Q#1>P(-:A'GW-EO0
M >I',EKY!!Y@^B%58RVJ&_?,8NPU1:XA+S'_@-GX ?LBT;N1;9!*N86]R.?(
M!RMD]0D!_#BAK$&?XJ+QX><#QN[@8(_<RP>3&=+TS@6VLPX0P/0$\G5[7:0)
MBV!UK2U)P++K;@MF+'=K3,E]N;N9YF B"-OD__+@;,=Y96.6/E^+'JHP);=B
M4:&'LPMGQ-J437)N-5?BJ_5H#6CTF'$2MQCQ%AF/OK$NZH :7TU_"AJ5:R/N
M:2=,']%O(O). $,R*6BIJ&UF#^TS(]\^]FO.1C4GYA).71:-)5P%:?;]]:^>
MYM[7T$>*8DUJHQ@-Z(V#)6-^_YO@MLDCG/O!6ZHV72[0;[=-M& / I_\>[?^
M_\YB6<"$PF>T\/.4, _4UJVAMY+4:P((BA_H6U$@"_4ZA ,^K#A&3RO2EOWP
MF5.%- !C0B[:XXW$YRS$?XYL#J^F 0E/,=0:I>WB&_,*JX\&-#'G<^N3NG3B
M0B_W%$N2STMS4V'QE WW1UVC^>%;X_>FC (8.R\HSCHE7-Z38C #8QEZ:<!\
MOQ&9+94&1+^'-S?W@><7:,"D1#SICI4DF0+:G\&H%MQ*JGOJU<?=)=)" WZ[
M)8=Z5)B3&D)7RY="..F#\[^Q=*%/=.'9\)X^&M!H(%/41]7:.3D;;T\#\*$+
M\,U%22J3_O_Y=TB'.")I@'HB?.HVBFPF1^7E?4X#P#K47?F_%>9?^_]\_VVB
M.F>_[]BKZJHJW^0KAYT34-=:S2#_9CJZ\MG9K], 1 X-@*:[A1]?>]<X(U2Z
MXOO*0NDWI\!8>Q?$YA9\/<GZU;]S\JJP.$\W#?@S+^EET=/R@>,_E1OM[H%W
M.G/^!@A#OXG-Y)\[!O!_EUDR B<H6&QZ#57VN<9:I2A*Y,R:,'M4UV'/T4,_
MY)8M_PY%;&WDBN14#/+9*O9UYIP,5PCB(69TR?\ B=P^_W53\?Y7_=4.6,.R
MYBW*&_(#,<)A*YU605OUCE:B.T?YYT4)2SO(^1P]QL?O=.HD3R7O84K_-,IZ
M6>(#IXE&](FKKAG&U/^.(.J*F1"&?/X)T?%("G;YCCQ_T',W0-Y[,RDN_X6;
M5S2H3)H&Q*J:/2YTL4(GY ]/NIJXFHZZ*VL,'JG5AKA;(10.2D< B<7]#5Y_
M[E.AJOM8Y I%J87B_B5@O3AO =_S;!K?I5W9IM[[56?]R4__L/BZ'O2G4_3^
M/(196-($OQ,CO0(UR7-+#4#O!%@%&[@1;  1?OMC4HJ';AWRF]7I;PC[>ZSR
MV^C3:PD*]UQ5#:F/LSV]W[[WP$=3;:XLF[U!/3#W[@UVKXN6_E,>ZO:BTF]F
M['=H  /43"$^?%L-W*HNU$OV>&?3?5Z)WG:,"BO?R6.R4ZK@7KMB&ON<H4=]
M:.GOF.T;E(^D_X&L4$_0SBH.? [5*B0]75+I>IZ(^:K[4XKY4%W&;-=#5K&@
M]%F%^)&=-N_)P!Q#_'S<^2TD4V#*U#AD,<#*VLB/NYI=9F2>^\S5;Q]DOY+F
MT0W6?P?C%:\#9)XJ/&>K?C>LG21\94M0FFWB2]OF]93O,U>@Y)'#S++*P>C4
M5E2$%X'1'!^"<V._)R]LXL>K'0-_<R#ADU!<0]"F%3V^_Q3,[ 0O)66E7H;
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M#JW+O04LW"O]0EO]9Y18J7.<9S$@5\?,66IS2\A8EZF?J?_TVT/M=WK8CRK
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M8A"Z]7'68\-4,>SR96Y%G4BC!=V=T;/^:7""0D.UI-U!=*U3'/_3*>5DWMY
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MT%T;HA-.^NKRUAW\BH'TP)>R5B6F[%#(G0S5"&L&,T:4\@1A& G'0HARM4^
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M'P)(T,%O;1>5W^3BF]TCI!15\J/XVY,HYDSSC 57K'Z 7!915KO7&9F2PLN
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M[XRZ*8""2Q1 >L^_U)HKW*9XGL36A2)J>Z(.:#$4P+0D!? *B(]<@6_3HRB
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M2J%N^G:[X&_%BYCGSWI"WGU_%HM2S-(D3:(48^C[-( H$KY:J$D"_5 B3),
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M,[7ELD,)GAN8UB4'#U%II@0N)VA@%;#BID4X3*7!$QRX*S-X:)"Q:PR>$/1
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MS*?!3%4-0N[ VJK#? ,ZU#=@ S=8 P<:N3M]94V6(Y5E/NZH6LN:CEW%9?^
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M10X4E"<+/[VK&30X'KG"O RLJVN)P+T$K4S@O@"U5#M5#E=3UXH&5K*!#>'
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M$84^2IB441CY$;>M,S[TE(R3N+%VDX\R$69*?WAR!UX2M !@+<$-6,D 95Y
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MDTY'6M!V]%%58D]J=O5CW\?T4Y:;G>@VBX9JW3S#$>%<]V<G/O8ADE) $N$
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M,H"B+4=1Y>!9BP!>!2E 1;Z#YTX&RQPD%S-JI@I'FZ"1\IV.]^+M1 (KD9H
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M19Q0=>"2%!FUPKHRS_PVV>:8U 16M*>EHJD8^6K?!\(R(.42QF:'( ?(>=X
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M7J((IS1/.$AC*@!,LQA00@C ,H8R1 (E,AE;UKB98FZOZG&IWC\;(2T]A&>
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MR3&=@MI2]+WNXV]T;I,Z2^BS<.L)^Z24)-6/^U*' !5DU?Z[]]"2H02%.&2
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M6J[),+/XP]DSS>P!;B4.&I'K+@NMT,&K5NS+:<4C(KAM<'(6Q&TTZ<1QW#9
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ML18_D*O-KRK854V[Z$/M2+(7W_+&>\32F)&K7\ ]$ZH2/JCQ[L37I=E?_='
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M-VCU=>F2]+H@KOR9?H2<UAGJ%>@33ZK?V<;M)9;UJ3_NBV+*+$()@C&0!$<
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MS9H&+'!P1 XF,TY*&180/"<2FT?')M#_%.N=>*^D/NLELKM!-!QM1M_\5N)
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MT)\^T0KY]KZW:M3M#_=+TD;KZUNUNH_5LR5L'/5^SNTN<'7EX;]%E&GO QR
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MC)P"=DNOD=YHL^DZ<JJA3?^1,T^/O+L@VUTI[F7KPE+'BB4)&184A<J:9P)
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MKX;56V'0[I(,7$/T:LB.RXU>WZ1[1-&'>H_T*2\XG57E"S_IWQ73*,))F.
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M;-L-([&9"%6@T8]*2,<R%Q9 VY&*7_CZ/@AR0\[=3\0:#%^.'I<['-93PQJ
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M"-LM<+YPZWG)V1.S4VEV=R<7"V1\>;"T=36L>XJ%TD>^)S;ON-]B?JC/B\H
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MD,1A FD2)2@5*&*!53:4]F[&9D)M!74EHPMP6MQ0>0&I9Y+9P6<CY.74)RY
M.=P1>0%LH,N?4\!YNL.Y"$/KY<SYMX>[=;FHP=YURN6GNUEVV_,M<^ER.Z^+
MK-3?94PP#D.>P1AC!1$3!!).,8S#@'!%!!*!TU%4:V]CH\6=<V@C+;R=-R5H
MW"RU=HCMC#-OP/5,E8>8Y1O,>L@5906*)YNKO:]!S2PKM0\M*[N7W#A$R'SZ
MH5Y);N;S-9U]E<^+Y6I*>)PB(C*8L4A A!,%*4I"2%4B%6*4,&9E1IWK8&Q,
MT<@(*B%!):4=2YP%L9T8?$#3,Q<XHF(]_2^I?F+&%Y+_]7'Q\A_ZU6JRZQ^V
M<_QL@X-,ZTOJ-#/YXG,==D+O9[0H[M0_J+D06]TMOYI$/O_?FB[UK)F]_MU4
M$-A&DX?Z_Q,9PS"@ 40122$CF80DD#A0J8S2U,H1V[7CL4WV6N8"_*L1%[Q4
M\KKG:'#!WV(SU1.J/?-$*;4Y%JOEUI\O*"6?@(WLH!;>/9F"TR=NOPWK">J!
M-F8^(7?;MW7 K74GY]+><'N[#EKN[?:ZO']%;N#WBV*UN2K'<4)1JHD](1G6
M/!]22*F@4&5Q(AF3L11.%76.>A@;H9<" B.AH[O!,79VF[FK$.G[K*NJ_FRD
MZ\6OX*SN/K/Z[K4_?"[?4^J=S.![\L&.YSAEZO IBV66Q9F $@D)41 FIF@\
MT3^). [B-,2$3E<+O?.S/+ IFW6:L9O&^_M('TP?@):R.9[%5#!9'KHX*]_W
MZ4J[QNX'*'L*^CHIJ1H=]DAD3Y&CLX_]?^V2\2[^*A]S,U&-7?9-FV=RY_2>
M!S%*8DF@XEE9[PE!8I;-#*5)HDA*DM0^L*JUJ[$MG=]@#';%!1MY7=*=M8)K
ML>WQ!EG/T_<\6EUND]IA<\G]Y@N^H3*ZN7]TCIG9; !IS[?6VL* 6=1L--G/
MC6;UAOLY\?O%BUQ:VLE'SX]H#I=R>;6,SVK;Z1QSOZ7!#C!/*K![<GGZ@6ZV
M[NW<'+B9S[(JK_-E,5\T[KA3'J&$(")@(K%>C".$(8ZI@%@E4G*>9$(X%2UK
MZVQLR_&FX&*7W ^MJ-H9S+ZPZGD.;\6LRX%-P*ZD_NQK&SP\6=VM70UJB]LH
M?6BA6[W3U<'AG^NJ:>-5=OH6M SM88=10E^-,U21K^0WN7S)N:S.VTP1K\=Y
MV8I)<R6G*N JE(F"*2-,;[09@X3H?0!F1""D<$@CIVC0O@4>&VE],[&>=>)=
MOJ.-JY-%S\-L>60PHL'K^S#B_O;]Y'1$YS:\;@(V$;\FX+\\5MS1R:<OR##
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M1DM-KIZ\NHCNL&@:$S/'4L@6+FV!HXO%"=E2<OK+P_KY_^00M5B1'_;2Y.+
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M%HS)GR]_^B\7/_[USL__(3<_S;WW/V^^>_6CJ^E]/T@?RW_^7W]_]3Y]PK,
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M7D>96&-E[6W)P M9!_7*DG(B3_9VV4&+UA&WR1B[6U\;"=_M'G$2NSM S,Y
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M CVIGNLZD(FI51[2.(@^E]IW.8-SUD! QWG)Q>OF+='N(6/<6VS08,"1O.Y
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MC==\=-M)^!.NR;Z>W=Q;ZTZD-Y=ZZK:D>S;ZQ#U*.3HK7>U+2984(XT5LV%
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MSRX*8"^#WS)K;S&"\RS6X'<AU\ )B%:4G-$X(V5CV-PAHH<F)B<)=M&2RQW
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MZF'CY7/X^Q41,EW566D>:Z(SA-H\,#L!(=$%((RRT664@9N]P/3$0N,>9R,
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M[[A]QCQ$?/:)I08.QQ["Z!FBKY%;'B(3X)S*M2I6@A,2(87BA18A,-MZ,,Z
MT=<[1W?9T36,#(Z+RUQ?.:P3<DLR.$CZ,_K&Y_F;O\.WZ6S]ZQ]Q=;F8+6\G
M:#!BD0H3<*,%*$7;T96$8)D2Z!UZ9*V[?0S-4[]QVT.P>?=@[0H)'9@!N_HY
M)L8U>N- ,DXVMJAM\61,(%+TW'HM@VG]"NNDAII#X; OO.S9C/,0Y1V-P>^-
M"UUV=W)<('F&M4_/Y45M)?66E/2!UEYL,LGTNQ_FR^G&&"K<%HZQ0$JNONEF
M"%$H"YD'55S,CH1]'M@>1/>XB83GB/'A8-'OH?P:#^)99:5+$& RN:(JQ#J$
M/26Z)4W2J)3"YNTE6M ];J[B.6Z%X6#13Y'90:? =N[? \SGZ+@4Z"#2%4CG
M &8(V6A2@0J8?4JBM)[8TX;R<5,?SW%7# F-?J^(27(A6F<X%%;?$$5.##&M
MP5NA8M2>]OB93OUQLQG/$;('*>]$NWW8^LL_<%4;OM)2Z\Q.3>I<KK:!KAFN
M+C8_6]:?G1#).V*5-D&\4]EK%+][$Q85J16T:SJN R2,_H=,%G \N%I(G@B;
MV8+5'NM0#\94\V3H#EI./>=(U)M04!7XQ#$MF<L.2IUJH^ALI@W"/(00M2XE
MQ.);MR3ZA8!Q8Q%-]'WW+#I>P!W<@O^)TR]?R=!\\0,7X0O^<?DMXN)]64MG
M^?YRM5R%63W=7X;E-$V,+;'0+0^1V*$K/EIP.16PJJ 0PEIE6EM_!Q$X;A1@
M$'0-IZ!^T?=Z>G%)W[W'XX3N<F9JS[E@J^M5A^U&FR+HQ$1T)$>G6W=<.)#$
M<9WO<R*PB9*Z&(EU5VJ;K51TQE(,&:6)!*4,UJX"M2UA9")SKDILWMWC04+&
M=5P'0=3I N\2-]L=,?'<)E.DA1(3(]&03^.U(D=8)%LY*4SP@9&S)65<#_(L
MV#E&Z W1,[#?]T=8U"J5'PV=O'L?.8A']SCA0[MO48H4E!6 J%V=I<<AH/*
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M4GWG5:=51:W %!<]<]J*YFU<[U/1Y1EVLKX?@=41PN\,/E<]:5/R47@#(MM
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M2 &,62&JHX.L=6'K3F*>X\OI4WS!-EKI 5XWY/\1OM%?[T=K;.+"RNK-<.1
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MYL-,2<\IB*N$!PU*A@!!N #1Z&Q-<$QU=[K<0\:)%J[TJRV'0F5W;?&7VK+
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M[Y&"D48LG1H9+Y>+]<79^6:X\&TJ'&<,+:%:&D8G;'$"HHP!O+(Z&U1"LV'
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M]9SZYC+>X:-6N4.MN%(\[]N_(&0E>5:JQY GNNMV-(W^L/[!^ %02P,$%
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M9F[OPK\-8MW'*-$%;QD$IJFNRBX[LA)I+R!"DYUE$)3*A'HA%<ZUOD&&E;K
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MYT&*<J>'R^HY6RXRKJ%4.ES5>76.C4;-QCRHP)RPQ>I41:Y[MU5@5:2D4>R
M\MG?Y8"<-566,[([B=:E;\>0VA(,0M_N)A42@ ZK5#*QPRUGQ#RS8X:O$Q;+
M&WP*B 7!O9A/D>/:+<1ML#FXK=GT+FS7YJ,E]*[/9&N#&, ?JXBQ*:W.)5.V
MM, UUY0,6&FB&7@ 9R4#E:IRRME\U;)\E!S.'(3\*;@CNE"3NLQP4SM45*8
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M4$L! A0#%     @ &#Q46)XSN_?=YP, C#0B !$              ( !Z"D
M '-M;70M,C R,S$R,S$N:'1M4$L! A0#%     @ &#Q46'9^T9$'&@  ]RL!
M !$              ( !]!$$ '-M;70M,C R,S$R,S$N>'-D4$L! A0#%
M  @ &#Q46#][MT'+)0  YVT! !4              ( !*BP$ '-M;70M,C R
M,S$R,S%?8V%L+GAM;%!+ 0(4 Q0    ( !@\5%B</M]DJ'H  "ET!0 5
M          "  2A2! !S;6UT+3(P,C,Q,C,Q7V1E9BYX;6Q02P$"% ,4
M"  8/%186[$2B^<J 0!_YP$ %               @ $#S00 <VUM="TR,#(S
M,3(S,5]G,2YJ<&=02P$"% ,4    "  8/%18]$D-=OAN  #DG0  %
M        @ $<^ 4 <VUM="TR,#(S,3(S,5]G,BYJ<&=02P$"% ,4    "  8
M/%18/2T^E-<N 0!,H0P %0              @ %&9P8 <VUM="TR,#(S,3(S
M,5]L86(N>&UL4$L! A0#%     @ &#Q46!5IPX+LS@  [SP) !4
M     ( !4)8' '-M;70M,C R,S$R,S%?<')E+GAM;%!+ 0(4 Q0    ( !@\
M5%B@Q5^P-@,  %<4   >              "  6]E" !S=6TM97@R,3%?,C R
M,S$R,S%X>'-U8G-I9"YH=&U02P$"% ,4    "  8/%18:RX2JZ0"  !G"
M'@              @ 'A: @ <W5M+65X,C,Q7S(P,C,Q,C,Q>'AU<V-O;G,N
M:'1M4$L! A0#%     @ &#Q46*8"#E%""   CBL  !T              ( !
MP6L( '-U;2UE>#,Q,5\R,#(S,3(S,7AD=6=G86XN:'1M4$L! A0#%     @
M&#Q46(@2D"5G"   K"L  !\              ( !/G0( '-U;2UE>#,Q,E\R
M,#(S,3(S,7AZ86YG86YE:"YH=&U02P$"% ,4    "  8/%18;IO G"X(  !L
M*P  '@              @ 'B? @ <W5M+65X,S$S7S(P,C,Q,C,Q>&1H:6YG
M<F$N:'1M4$L! A0#%     @ &#Q46(P#[EBI!0  F2@  !X
M ( !3(4( '-U;2UE>#,R,5\R,#(S,3(S,7AX-# T.3 V+FAT;5!+!08
..$  0 &L$   QBP@    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>smmt-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:smmt="http://www.summitplc.com/20231231"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="smmt-20231231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
        </entity>
        <period>
            <instant>2024-02-09</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">smmt:RightsOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">smmt:RightsOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">smmt:RightsOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">smmt:RightsOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">smmt:AkesoLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">smmt:AkesoLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:NotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">smmt:ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-06</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
        </entity>
        <period>
            <startDate>2023-01-19</startDate>
            <endDate>2023-01-19</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
        </entity>
        <period>
            <instant>2023-01-18</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
        </entity>
        <period>
            <instant>2023-01-19</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">smmt:RightsOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-01</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">smmt:RightsOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-01</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:DugganFebruaryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-06</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:ZanganehNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">smmt:ChiefExecutiveOfficerAndPresidentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-15</startDate>
            <endDate>2023-02-15</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
        </entity>
        <period>
            <instant>2023-04-27</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">smmt:S3RegistrationStatementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-27</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">smmt:S3RegistrationStatementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-27</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">smmt:ChiefExecutiveOfficerAndPresidentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">smmt:S3RegistrationStatementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-27</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">smmt:A2020StockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-12</startDate>
            <endDate>2023-10-12</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-13</startDate>
            <endDate>2023-10-13</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-13</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-13</startDate>
            <endDate>2023-10-13</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:DugganFebruaryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-17</startDate>
            <endDate>2024-02-17</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:DugganFebruaryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-17</startDate>
            <endDate>2024-02-17</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">smmt:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">smmt:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">smmt:FurnitureAndFixturesOfficeEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">smmt:FurnitureAndFixturesOfficeEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
        </entity>
        <period>
            <instant>2022-12-15</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">smmt:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-17</startDate>
            <endDate>2023-01-17</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-06</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">smmt:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">smmt:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementUpfrontPaymentTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-06</startDate>
            <endDate>2023-03-06</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">smmt:CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
        </entity>
        <period>
            <startDate>2023-01-17</startDate>
            <endDate>2023-01-17</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
        </entity>
        <period>
            <instant>2023-03-01</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">smmt:UtrophinProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">smmt:UtrophinProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">smmt:DiscuvaPlatformMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">smmt:DiscuvaPlatformMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">smmt:OptionOverNonFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">smmt:OptionOverNonFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">smmt:OtherPatentsAndLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">smmt:OtherPatentsAndLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">smmt:DiscuvaPlatformMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">smmt:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">smmt:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">smmt:FurnitureAndFixturesOfficeEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">smmt:FurnitureAndFixturesOfficeEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">smmt:MenloParkCaliforniaExpirationMay2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">smmt:MenloParkCaliforniaExpirationMay2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">smmt:CambridgeUKLaboratoryAndOfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">smmt:MenloParkCaliforniaExpirationMay2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-08</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:PromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:PromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:March2022NoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-10</startDate>
            <endDate>2022-03-10</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:March2022NoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-10</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:March2022NoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-10</startDate>
            <endDate>2022-08-10</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">smmt:RightsOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-08</startDate>
            <endDate>2022-08-08</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:March2022NoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:ZanganehNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">smmt:ChiefExecutiveOfficerAndPresidentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-06</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:DugganSeptemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-06</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:DugganFebruaryNoteAndZanganehNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">smmt:ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-06</startDate>
            <endDate>2022-12-06</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:DugganPromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-19</startDate>
            <endDate>2023-01-19</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:DugganFebruaryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-01</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:NotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">smmt:ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-06</startDate>
            <endDate>2022-12-06</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
        </entity>
        <period>
            <instant>2022-12-06</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:NotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">smmt:ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="smmt:VariableRatePeriodAxis">smmt:VariableRatePeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-06</startDate>
            <endDate>2022-12-06</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:NotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">smmt:ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="smmt:VariableRatePeriodAxis">smmt:VariableRatePeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-06</startDate>
            <endDate>2022-12-06</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:NotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">smmt:ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:NotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">smmt:ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:NotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">smmt:ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:NotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">smmt:ChiefExecutiveOfficerAndChiefExecutiveOfficerAndPresidentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:DugganFebruaryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:ZanganehNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">smmt:ChiefExecutiveOfficerAndPresidentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:DugganSeptemberNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">smmt:RightsOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-08</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">smmt:RightsOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-01</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-24</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-24</startDate>
            <endDate>2019-12-24</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-24</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-24</startDate>
            <endDate>2019-12-24</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-30</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">smmt:A2020StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-21</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">smmt:A2020StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-21</startDate>
            <endDate>2020-09-21</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
        </entity>
        <period>
            <startDate>2022-07-27</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
        </entity>
        <period>
            <instant>2022-07-27</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">smmt:A2020StockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-27</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">smmt:A2020StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-19</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-19</startDate>
            <endDate>2020-08-19</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-02</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-01</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-19</startDate>
            <endDate>2020-08-19</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">smmt:EmployeeStockOptionTimeBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">smmt:EmployeeStockOptionTimeBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">smmt:EmployeeStockOptionTimeBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">smmt:EmployeeStockOptionTimeBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">smmt:EmployeeStockOptionTimeBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">smmt:EmployeeStockOptionTimeBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">smmt:EmployeeStockOptionPerformanceAndMarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">smmt:EmployeeStockOptionPerformanceAndMarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">smmt:EmployeeStockOptionPerformanceAndMarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">smmt:EmployeeStockOptionPerformanceAndMarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-02-09</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:SubleaseAgreementFirstAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-25</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:SubleaseAgreementFirstAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:SubleaseAgreementSecondAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-29</instant>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:SubleaseAgreementSecondAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:March2022NoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:AkesoSupplyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:AkesoSupplyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001599298</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">smmt:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>smmt:segment</measure>
    </unit>
    <unit id="country">
        <measure>smmt:country</measure>
    </unit>
    <unit id="gbp">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="promissory_note">
        <measure>smmt:promissory_note</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-31">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-32">0001599298</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-33">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-34">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration contextRef="c-5" id="f-76">http://fasb.org/us-gaap/2023#RelatedPartyMember</us-gaap:NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration>
    <us-gaap:NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration contextRef="c-4" id="f-77">http://fasb.org/us-gaap/2023#RelatedPartyMember</us-gaap:NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration>
    <us-gaap:NotesPayableNoncurrentRelatedPartyTypeExtensibleEnumeration contextRef="c-4" id="f-86">http://fasb.org/us-gaap/2023#RelatedPartyMember</us-gaap:NotesPayableNoncurrentRelatedPartyTypeExtensibleEnumeration>
    <us-gaap:NotesPayableNoncurrentRelatedPartyTypeExtensibleEnumeration contextRef="c-5" id="f-87">http://fasb.org/us-gaap/2023#RelatedPartyMember</us-gaap:NotesPayableNoncurrentRelatedPartyTypeExtensibleEnumeration>
    <us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration contextRef="c-59" id="f-377">http://fasb.org/us-gaap/2023#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember</us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration>
    <us-gaap:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-6" id="f-630">http://fasb.org/us-gaap/2023#ImpairmentOfIntangibleAssetsExcludingGoodwill</us-gaap:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <smmt:NotesPayableRelatedPartiesPotentialPrepaymentPeriodPostReceiptOfCashProceedsFromPublicOffering contextRef="c-148" id="f-764">P5D</smmt:NotesPayableRelatedPartiesPotentialPrepaymentPeriodPostReceiptOfCashProceedsFromPublicOffering>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-185" id="f-862">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <smmt:NotesPayableRelatedPartiesPotentialPrepaymentPeriodPostReceiptOfCashProceedsFromPublicOffering contextRef="c-148" id="f-967">P5D</smmt:NotesPayableRelatedPartiesPotentialPrepaymentPeriodPostReceiptOfCashProceedsFromPublicOffering>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-36866</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">Summit Therapeutics Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">37-1979717</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">601 Brickell Key Drive, Suite 1000</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Miami</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">33131</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">460-8308</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">SMMT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-19">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-20">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-21">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-22">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-23">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-24">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-25">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-26">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-27">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-28">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="-5" id="f-29" unitRef="usd">108400000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-30" unitRef="shares">701697179</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId contextRef="c-1" id="f-35">238</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-36">PricewaterhouseCoopers LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-37">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-38" unitRef="usd">71425000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-3" id="f-39" unitRef="usd">348607000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent contextRef="c-4" decimals="-3" id="f-40" unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-5" decimals="-3" id="f-41" unitRef="usd">300000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-3" id="f-42" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-5" decimals="-3" id="f-43" unitRef="usd">349000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ShortTermInvestments contextRef="c-4" decimals="-3" id="f-44" unitRef="usd">114817000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c-5" decimals="-3" id="f-45" unitRef="usd">0</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-4" decimals="-3" id="f-46" unitRef="usd">2441000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-5" decimals="-3" id="f-47" unitRef="usd">1504000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-48" unitRef="usd">181000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-49" unitRef="usd">486000</us-gaap:OtherAssetsCurrent>
    <smmt:ResearchAndDevelopmentTaxCreditReceivableCurrent contextRef="c-4" decimals="-3" id="f-50" unitRef="usd">848000</smmt:ResearchAndDevelopmentTaxCreditReceivableCurrent>
    <smmt:ResearchAndDevelopmentTaxCreditReceivableCurrent contextRef="c-5" decimals="-3" id="f-51" unitRef="usd">5766000</smmt:ResearchAndDevelopmentTaxCreditReceivableCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-52" unitRef="usd">189712000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-5" decimals="-3" id="f-53" unitRef="usd">656712000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-54" unitRef="usd">204000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-55" unitRef="usd">906000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-56" unitRef="usd">5859000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-57" unitRef="usd">4175000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill contextRef="c-4" decimals="-3" id="f-58" unitRef="usd">1893000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-5" decimals="-3" id="f-59" unitRef="usd">1798000</us-gaap:Goodwill>
    <smmt:ResearchAndDevelopmentTaxCreditReceivableNoncurrent contextRef="c-4" decimals="-3" id="f-60" unitRef="usd">959000</smmt:ResearchAndDevelopmentTaxCreditReceivableNoncurrent>
    <smmt:ResearchAndDevelopmentTaxCreditReceivableNoncurrent contextRef="c-5" decimals="-3" id="f-61" unitRef="usd">0</smmt:ResearchAndDevelopmentTaxCreditReceivableNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-62" unitRef="usd">4322000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-5" decimals="-3" id="f-63" unitRef="usd">577000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-64" unitRef="usd">202949000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-5" decimals="-3" id="f-65" unitRef="usd">664168000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-66" unitRef="usd">2667000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-5" decimals="-3" id="f-67" unitRef="usd">355000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-68" unitRef="usd">8783000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-69" unitRef="usd">10664000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-70" unitRef="usd">5429000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-71" unitRef="usd">5641000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-72" unitRef="usd">2809000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-73" unitRef="usd">1690000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-74" unitRef="usd">717000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-75" unitRef="usd">662000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c-4" decimals="-3" id="f-78" unitRef="usd">0</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c-5" decimals="-3" id="f-79" unitRef="usd">19770000</us-gaap:NotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-80" unitRef="usd">20405000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-81" unitRef="usd">38782000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-82" unitRef="usd">3290000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-83" unitRef="usd">2763000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-84" unitRef="usd">1562000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-5" decimals="-3" id="f-85" unitRef="usd">1429000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LongTermNotesPayable contextRef="c-4" decimals="-3" id="f-88" unitRef="usd">100000000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable contextRef="c-5" decimals="-3" id="f-89" unitRef="usd">494540000</us-gaap:LongTermNotesPayable>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-90" unitRef="usd">125257000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-5" decimals="-3" id="f-91" unitRef="usd">537514000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-92" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-5" id="f-93" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-94"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-95"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-96" unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-97" unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-98" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-99" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="INF" id="f-100" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c-5" decimals="INF" id="f-101" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="-3" id="f-102" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-5" decimals="-3" id="f-103" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-104"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-105"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-106" unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-107" unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-108" unitRef="shares">701660053</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-109" unitRef="shares">701660053</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-110" unitRef="shares">211091425</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-5" decimals="INF" id="f-111" unitRef="shares">211091425</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-112" unitRef="usd">7017000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-5" decimals="-3" id="f-113" unitRef="usd">2110000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-3" id="f-114" unitRef="usd">1066381000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-5" decimals="-3" id="f-115" unitRef="usd">504767000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-116" unitRef="usd">-2448000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-5" decimals="-3" id="f-117" unitRef="usd">-1893000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-118" unitRef="usd">-993258000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-3" id="f-119" unitRef="usd">-378330000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-120" unitRef="usd">77692000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-121" unitRef="usd">126654000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-122" unitRef="usd">202949000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-5" decimals="-3" id="f-123" unitRef="usd">664168000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-124" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-3" id="f-125" unitRef="usd">705000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-126" unitRef="usd">59471000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-6" decimals="-3" id="f-127" unitRef="usd">51999000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-128" unitRef="usd">30265000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-6" decimals="-3" id="f-129" unitRef="usd">26743000</us-gaap:GeneralAndAdministrativeExpense>
    <smmt:InProcessResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-130" unitRef="usd">520915000</smmt:InProcessResearchAndDevelopmentExpense>
    <smmt:InProcessResearchAndDevelopmentExpense contextRef="c-6" decimals="-3" id="f-131" unitRef="usd">0</smmt:InProcessResearchAndDevelopmentExpense>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-1" decimals="-3" id="f-132" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-6" decimals="-3" id="f-133" unitRef="usd">8468000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-134" unitRef="usd">610651000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-6" decimals="-3" id="f-135" unitRef="usd">87210000</us-gaap:OperatingExpenses>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-1" decimals="-3" id="f-136" unitRef="usd">1001000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-6" decimals="-3" id="f-137" unitRef="usd">14416000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-138" unitRef="usd">-609650000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-6" decimals="-3" id="f-139" unitRef="usd">-72089000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-140" unitRef="usd">-5278000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-6" decimals="-3" id="f-141" unitRef="usd">-6693000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-142" unitRef="usd">-614928000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-6" decimals="-3" id="f-143" unitRef="usd">-78782000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-144" unitRef="usd">-614928000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-145" unitRef="usd">-78782000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-146"
      unitRef="usdPerShare">-0.99</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-147"
      unitRef="usdPerShare">-0.99</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-148"
      unitRef="usdPerShare">-0.41</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-149"
      unitRef="usdPerShare">-0.41</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-150" unitRef="shares">619646180</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-151" unitRef="shares">619646180</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="0" id="f-152" unitRef="shares">193336063</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="0" id="f-153" unitRef="shares">193336063</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c-1" decimals="-3" id="f-154" unitRef="usd">-172000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c-6" decimals="-3" id="f-155" unitRef="usd">304000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax contextRef="c-1" decimals="-3" id="f-156" unitRef="usd">419000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax contextRef="c-6" decimals="-3" id="f-157" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-158" unitRef="usd">36000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-6" decimals="-3" id="f-159" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-160" unitRef="usd">-615483000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-6" decimals="-3" id="f-161" unitRef="usd">-78478000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-7" decimals="INF" id="f-162" unitRef="shares">98039540</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-7" decimals="-3" id="f-163" unitRef="usd">980000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-164" unitRef="usd">384049000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="-3" id="f-165" unitRef="usd">-2197000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="-3" id="f-166" unitRef="usd">-299548000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-167" unitRef="usd">83284000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-6" decimals="-3" id="f-168" unitRef="usd">111000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-12"
      decimals="INF"
      id="f-169"
      unitRef="shares">103092783</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-12" decimals="-3" id="f-170" unitRef="usd">1031000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-13" decimals="-3" id="f-171" unitRef="usd">98858000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-6" decimals="-3" id="f-172" unitRef="usd">99889000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <smmt:StockIssuedDuringPeriodSharesIssuedForRelatedPartyInterest
      contextRef="c-12"
      decimals="INF"
      id="f-173"
      unitRef="shares">9720291</smmt:StockIssuedDuringPeriodSharesIssuedForRelatedPartyInterest>
    <smmt:StockIssuedDuringPeriodValueIssuedForRelatedPartyInterest contextRef="c-12" decimals="-3" id="f-174" unitRef="usd">97000</smmt:StockIssuedDuringPeriodValueIssuedForRelatedPartyInterest>
    <smmt:StockIssuedDuringPeriodValueIssuedForRelatedPartyInterest contextRef="c-13" decimals="-3" id="f-175" unitRef="usd">7497000</smmt:StockIssuedDuringPeriodValueIssuedForRelatedPartyInterest>
    <smmt:StockIssuedDuringPeriodValueIssuedForRelatedPartyInterest contextRef="c-6" decimals="-3" id="f-176" unitRef="usd">7594000</smmt:StockIssuedDuringPeriodValueIssuedForRelatedPartyInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-12"
      decimals="INF"
      id="f-177"
      unitRef="shares">238811</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-12" decimals="-3" id="f-178" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-13" decimals="-3" id="f-179" unitRef="usd">397000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-6" decimals="-3" id="f-180" unitRef="usd">399000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-13" decimals="-3" id="f-181" unitRef="usd">11948000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-6" decimals="-3" id="f-182" unitRef="usd">11948000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <smmt:AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty contextRef="c-13" decimals="-3" id="f-183" unitRef="usd">2018000</smmt:AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty>
    <smmt:AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty contextRef="c-6" decimals="-3" id="f-184" unitRef="usd">2018000</smmt:AdjustmentsToAdditionalPaidInCapitalImputedInterestExpenseRelatedParty>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c-14" decimals="-3" id="f-185" unitRef="usd">304000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c-6" decimals="-3" id="f-186" unitRef="usd">304000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-3" id="f-187" unitRef="usd">-78782000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-188" unitRef="usd">-78782000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-16"
      decimals="INF"
      id="f-189"
      unitRef="shares">211091425</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="-3" id="f-190" unitRef="usd">2110000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-191" unitRef="usd">504767000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-192" unitRef="usd">-1893000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-193" unitRef="usd">-378330000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-194" unitRef="usd">126654000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-1" decimals="-3" id="f-195" unitRef="usd">619000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-20"
      decimals="INF"
      id="f-196"
      unitRef="shares">476190471</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-20" decimals="-3" id="f-197" unitRef="usd">4762000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-21" decimals="-3" id="f-198" unitRef="usd">494619000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-22" decimals="-3" id="f-199" unitRef="usd">499381000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-23"
      decimals="INF"
      id="f-200"
      unitRef="shares">596472</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-23" decimals="-3" id="f-201" unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-24" decimals="-3" id="f-202" unitRef="usd">922000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-1" decimals="-3" id="f-203" unitRef="usd">929000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <smmt:StockIssuedDuringPeriodSharesInLieuOfCashForCollaborativeArrangement
      contextRef="c-23"
      decimals="INF"
      id="f-204"
      unitRef="shares">10000000</smmt:StockIssuedDuringPeriodSharesInLieuOfCashForCollaborativeArrangement>
    <smmt:StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement contextRef="c-23" decimals="-3" id="f-205" unitRef="usd">100000</smmt:StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement>
    <smmt:StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement contextRef="c-24" decimals="-3" id="f-206" unitRef="usd">45800000</smmt:StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement>
    <smmt:StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement contextRef="c-1" decimals="-3" id="f-207" unitRef="usd">45900000</smmt:StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-25"
      decimals="INF"
      id="f-208"
      unitRef="shares">2976190</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-25" decimals="-3" id="f-209" unitRef="usd">30000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-26" decimals="-3" id="f-210" unitRef="usd">4970000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-27" decimals="-3" id="f-211" unitRef="usd">5000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <smmt:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="c-23"
      decimals="INF"
      id="f-212"
      unitRef="shares">805495</smmt:StockIssuedDuringPeriodSharesWarrantsExercised>
    <smmt:StockIssuedDuringPeriodValueWarrantsExercised contextRef="c-23" decimals="-3" id="f-213" unitRef="usd">8000</smmt:StockIssuedDuringPeriodValueWarrantsExercised>
    <smmt:StockIssuedDuringPeriodValueWarrantsExercised contextRef="c-24" decimals="-3" id="f-214" unitRef="usd">1195000</smmt:StockIssuedDuringPeriodValueWarrantsExercised>
    <smmt:StockIssuedDuringPeriodValueWarrantsExercised contextRef="c-1" decimals="-3" id="f-215" unitRef="usd">1203000</smmt:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-24" decimals="-3" id="f-216" unitRef="usd">14108000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-217" unitRef="usd">14108000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-28" decimals="-3" id="f-218" unitRef="usd">36000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-219" unitRef="usd">36000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax contextRef="c-28" decimals="-3" id="f-220" unitRef="usd">419000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax contextRef="c-1" decimals="-3" id="f-221" unitRef="usd">419000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c-28" decimals="-3" id="f-222" unitRef="usd">-172000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c-1" decimals="-3" id="f-223" unitRef="usd">-172000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-29" decimals="-3" id="f-224" unitRef="usd">-614928000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-225" unitRef="usd">-614928000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-30"
      decimals="INF"
      id="f-226"
      unitRef="shares">701660053</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="-3" id="f-227" unitRef="usd">7017000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-228" unitRef="usd">1066381000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-3" id="f-229" unitRef="usd">-2448000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-3" id="f-230" unitRef="usd">-993258000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-231" unitRef="usd">77692000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-232" unitRef="usd">-614928000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-233" unitRef="usd">-78782000</us-gaap:NetIncomeLoss>
    <smmt:BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss contextRef="c-1" decimals="-3" id="f-234" unitRef="usd">0</smmt:BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss>
    <smmt:BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss contextRef="c-6" decimals="-3" id="f-235" unitRef="usd">1265000</smmt:BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss>
    <smmt:InterestExpenseIncomeNoncash contextRef="c-1" decimals="-3" id="f-236" unitRef="usd">6253000</smmt:InterestExpenseIncomeNoncash>
    <smmt:InterestExpenseIncomeNoncash contextRef="c-6" decimals="-3" id="f-237" unitRef="usd">4303000</smmt:InterestExpenseIncomeNoncash>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-1" decimals="-3" id="f-238" unitRef="usd">1924000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-6" decimals="-3" id="f-239" unitRef="usd">0</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="c-1" decimals="-3" id="f-240" unitRef="usd">812000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="c-6" decimals="-3" id="f-241" unitRef="usd">-2616000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <smmt:CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome contextRef="c-1" decimals="-3" id="f-242" unitRef="usd">419000</smmt:CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome>
    <smmt:CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome contextRef="c-6" decimals="-3" id="f-243" unitRef="usd">0</smmt:CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome>
    <us-gaap:TangibleAssetImpairmentCharges contextRef="c-1" decimals="-3" id="f-244" unitRef="usd">474000</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges contextRef="c-6" decimals="-3" id="f-245" unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="-3" id="f-246" unitRef="usd">1852000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-6" decimals="-3" id="f-247" unitRef="usd">1251000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-248" unitRef="usd">198000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-6" decimals="-3" id="f-249" unitRef="usd">349000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-3" id="f-250" unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-6" decimals="-3" id="f-251" unitRef="usd">914000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-1" decimals="-3" id="f-252" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-6" decimals="-3" id="f-253" unitRef="usd">8468000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-254" unitRef="usd">14108000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-6" decimals="-3" id="f-255" unitRef="usd">11948000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c-1" decimals="-3" id="f-256" unitRef="usd">109000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c-6" decimals="-3" id="f-257" unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets1>
    <smmt:InProcessResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-258" unitRef="usd">520915000</smmt:InProcessResearchAndDevelopmentExpense>
    <smmt:InProcessResearchAndDevelopmentExpense contextRef="c-6" decimals="-3" id="f-259" unitRef="usd">0</smmt:InProcessResearchAndDevelopmentExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-260" unitRef="usd">-359000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-6" decimals="-3" id="f-261" unitRef="usd">-975000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c-1" decimals="-3" id="f-262" unitRef="usd">914000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c-6" decimals="-3" id="f-263" unitRef="usd">-5107000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-1" decimals="-3" id="f-264" unitRef="usd">3421000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-6" decimals="-3" id="f-265" unitRef="usd">-215000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <smmt:IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable contextRef="c-1" decimals="-3" id="f-266" unitRef="usd">-4168000</smmt:IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable>
    <smmt:IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable contextRef="c-6" decimals="-3" id="f-267" unitRef="usd">-8437000</smmt:IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-3" id="f-268" unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-6" decimals="-3" id="f-269" unitRef="usd">-7278000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-270" unitRef="usd">2263000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-6" decimals="-3" id="f-271" unitRef="usd">-4132000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-3" id="f-272" unitRef="usd">-2377000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-6" decimals="-3" id="f-273" unitRef="usd">4782000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-1" decimals="-3" id="f-274" unitRef="usd">-235000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-6" decimals="-3" id="f-275" unitRef="usd">1609000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-276" unitRef="usd">-2211000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-6" decimals="-3" id="f-277" unitRef="usd">-1099000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-278" unitRef="usd">-76760000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-6" decimals="-3" id="f-279" unitRef="usd">-41582000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-280" unitRef="usd">128000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-6" decimals="-3" id="f-281" unitRef="usd">624000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-282" unitRef="usd">226000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-6" decimals="-3" id="f-283" unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="c-1" decimals="-3" id="f-284" unitRef="usd">321022000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="c-6" decimals="-3" id="f-285" unitRef="usd">0</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments contextRef="c-1" decimals="-3" id="f-286" unitRef="usd">208165000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments contextRef="c-6" decimals="-3" id="f-287" unitRef="usd">0</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <smmt:PaymentsForCollaborativeArrangement contextRef="c-1" decimals="-3" id="f-288" unitRef="usd">475015000</smmt:PaymentsForCollaborativeArrangement>
    <smmt:PaymentsForCollaborativeArrangement contextRef="c-6" decimals="-3" id="f-289" unitRef="usd">0</smmt:PaymentsForCollaborativeArrangement>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-290" unitRef="usd">-587774000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-6" decimals="-3" id="f-291" unitRef="usd">-624000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-292" unitRef="usd">104686000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-6" decimals="-3" id="f-293" unitRef="usd">100000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-1" decimals="-3" id="f-294" unitRef="usd">619000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-6" decimals="-3" id="f-295" unitRef="usd">111000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c-1" decimals="-3" id="f-296" unitRef="usd">5000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c-6" decimals="-3" id="f-297" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c-1" decimals="-3" id="f-298" unitRef="usd">1203000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c-6" decimals="-3" id="f-299" unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-1" decimals="-3" id="f-300" unitRef="usd">929000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-6" decimals="-3" id="f-301" unitRef="usd">399000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="c-1" decimals="-3" id="f-302" unitRef="usd">0</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="c-6" decimals="-3" id="f-303" unitRef="usd">545000000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="c-1" decimals="-3" id="f-304" unitRef="usd">24686000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="c-6" decimals="-3" id="f-305" unitRef="usd">25000000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-1" decimals="-3" id="f-306" unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-6" decimals="-3" id="f-307" unitRef="usd">44000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-308" unitRef="usd">86513000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-6" decimals="-3" id="f-309" unitRef="usd">620244000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-1" decimals="-3" id="f-310" unitRef="usd">839000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-6" decimals="-3" id="f-311" unitRef="usd">-1222000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-312" unitRef="usd">-577182000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-6" decimals="-3" id="f-313" unitRef="usd">576816000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-314" unitRef="usd">648607000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-11" decimals="-3" id="f-315" unitRef="usd">71791000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-316" unitRef="usd">71425000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-317" unitRef="usd">648607000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-318" unitRef="usd">10650000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-6" decimals="-3" id="f-319" unitRef="usd">434000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-1" decimals="-3" id="f-320" unitRef="usd">52000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-6" decimals="-3" id="f-321" unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <smmt:DebtIssuanceCostsIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-322" unitRef="usd">0</smmt:DebtIssuanceCostsIncurredButNotYetPaid>
    <smmt:DebtIssuanceCostsIncurredButNotYetPaid contextRef="c-6" decimals="-3" id="f-323" unitRef="usd">31000</smmt:DebtIssuanceCostsIncurredButNotYetPaid>
    <us-gaap:StockIssued1 contextRef="c-22" decimals="-3" id="f-324" unitRef="usd">395314000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="c-34" decimals="-3" id="f-325" unitRef="usd">0</us-gaap:StockIssued1>
    <smmt:DeferredTransactionCostsIncurredDuringNoncashOrPartialNoncashTransaction contextRef="c-1" decimals="-3" id="f-326" unitRef="usd">0</smmt:DeferredTransactionCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <smmt:DeferredTransactionCostsIncurredDuringNoncashOrPartialNoncashTransaction contextRef="c-6" decimals="-3" id="f-327" unitRef="usd">425000</smmt:DeferredTransactionCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-328" unitRef="usd">4245000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-6" decimals="-3" id="f-329" unitRef="usd">2860000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:StockIssued1 contextRef="c-35" decimals="-3" id="f-330" unitRef="usd">45900000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="c-36" decimals="-3" id="f-331" unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:NatureOfOperations contextRef="c-1" id="f-332">Nature of Business and Operations and Recent Events&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Nature of Business and Operations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summit Therapeutics Inc. (&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;we&#x201d;, &lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summit&#x201d; or the &lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company&#x201d;) is a biopharmaceutical company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The Company&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s pipeline of product candidates is designed with the goal to become the patient-friendly, new-era standard-of-care medicines, in the therapeutic area of oncology.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s current lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. On December 5, 2022, the Company entered into a Collaboration and License Agreement (the &#x201c;License Agreement&#x201d;) with Akeso, Inc. and its affiliates (&#x201c;Akeso&#x201d;) pursuant to which the Company has in-licensed ivonescimab. Through the License Agreement (as defined in Note &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company obtained the rights to develop and commercialize ivonescimab in the United States, Canada, Europe, and Japan (the &#x201c;Licensed Territory&#x201d;). The License Agreement and transaction closed in January 2023 following customary waiting periods. The Company&#x2019;s operations will be focused on the development of ivonescimab and other future activities, as the Company determines.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has begun its development for ivonescimab in non-small cell lung cancer (&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NSCLC&#x201d;), specifically launching Phase III clinical trials in the following indications:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a)  ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;EGFR&#x201d;)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;TKI&#x201d;) (&#x201c;HARMONi&#x201d;); and&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;b)  ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (&#x201c;HARMONi-3&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of the date of these financial statements, both studies are enrolling patients.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The entry into the License Agreement with Akeso represents a significant change in the Company&#x2019;s strategy and its future operations will be focused on the development of ivonescimab and other future activities as the Company determines. The Company&#x2019;s portfolio includes ridinilazole, a product candidate for treating patients suffering from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Clostridioides difficile &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;infection, also known as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C. difficile &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;infection, or CDI. All prior development and marketing activities related to ridinilazole have been terminated. The Company&#x2019;s anti-infectives portfolio includes SMT-738, the first of a novel class of precision antibiotics for combating multidrug resistant infections, specifically carbapenem-resistant Enterobacteriaceae (&#x201c;CRE&#x201d;) infections. The Company will continue to pursue partnerships for further development of SMT-738. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Recent Events&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the events detailed in the Company Overview section above, the following other recent developments have occurred. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As noted above, on December 5, 2022, the Company entered into a Collaboration and License Agreement (the &#x201c;License Agreement&#x201d;) with Akeso  pursuant to which the Company is in-licensing breakthrough bispecific antibody, ivonescimab (Note &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;6, 2022, the Company entered into a Note Purchase Agreement (the &#x201c;Note Purchase Agreement&#x201d;), with Mr. Robert Duggan and Dr. Maky Zanganeh, pursuant to which the Company agreed to sell to each of Mr. Duggan and Dr. Zanganeh unsecured promissory notes in the aggregate amount of $520,000 (Note &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;18)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January&#160;19, 2023, the Company filed Amendment No. 2 to the Restated Certificate of Incorporation (the &#x201c;Amendment No. 2&#x201d;) with the Secretary of State of the State of Delaware to increase the number of authorized shares of its common stock by 650,000,000 (from 350,000,000 to 1,000,000,000), which became effective on such date. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February&#160;7, 2023, the Company commenced its previously announced rights offering (&#x201c;2023 Rights Offering&#x201d;). On March 1, 2023, the Company closed the 2023 Rights Offering, which was fully subscribed. The Company received aggregate gross proceeds from the 2023 Rights Offering of $500,000 from the sale of&#x202f;476,190,471&#x202f;shares of its common stock at a price per share of $1.05. Issuance costs associated with the 2023 Rights Offering were approximately $619. In connection with the closing of the 2023 Rights Offering, $400,000 of the unsecured promissory notes, issued by the Company to Mr. Duggan,&#x202f;matured and became due and the Company repaid the principal amount and all outstanding accrued interest thereunder using a portion of the proceeds from this 2023 Rights Offering (Note &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February&#160;15, 2023, $20,000 of the unsecured promissory notes, issued by us to Dr. Zanganeh, matured and the Company repaid the outstanding principal balance.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 17, 2023, the Company filed a registration statement on Form S-3 to register for resale the following shares of its common stock at $0.01 par value: (i) 10,000,000 shares of Common Stock issued on January 17, 2023 in connection with the License Agreement with Akeso pursuant to which the Company issued Akeso such shares; and (ii) the 9,346,434 and 373,857 shares of common stock issued in December 2022 to its Chief Executive Officers, Mr. Robert Duggan and Dr. Mahkam Zanganeh, respectively, as payment of prepaid interest in connection with the Note Purchase Agreement dated December 6, 2022 between Mr. Duggan, Dr. Zanganeh and the Company (Note &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). On April 27, 2023, the SEC issued a Notice of Effectiveness for the registration statement on Form S-3 filed with the SEC.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 12, 2023, the Company held a Special Meeting of Stockholders (the &#x201c;October Special Meeting&#x201d;) whereby an amendment to the Summit Therapeutics Inc. 2020 Stock Incentive Plan (the &#x201c;Plan&#x201d;) to increase the number of shares of the Company&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s common stock issuable under the Plan by 70,000,000 shares was approved by a vote of the Company&#x2019;s stockholders at the Special Meeting and subsequently ratified by the Board of Directors.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 16, 2023, the Company announced the appointment of Mr. Manmeet Soni as its Chief Operating Officer, effective immediately. Mr. Soni has been a part of the Company&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s Board of Directors since 2019. He will remain a member of the Board of Directors. In conjunction with his appointment, Mr. Soni entered into a share purchase agreement with the Company to purchase $5,000 of its common stock via a private placement. The transaction was effective October 13, 2023 with a closing price of $1.68, resulting in the purchase of 2,976,190 shares of the Company&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 17, 2024 the Duggan February Note was amended to extend the maturity date from September 6, 2024 to April 1, 2025. For all applicable periods commencing  February 17, 2024, interest shall accrue on the outstanding principal balance at the greater of 12% or the US prime interest rate, as reported in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Wall Street Journal &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;plus 350 basis points, as adjusted monthly, compounded quarterly (Note &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). Interest shall be paid upon maturity of the loan.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:NotesPayable contextRef="c-37" decimals="-3" id="f-333" unitRef="usd">520000000</us-gaap:NotesPayable>
    <smmt:CommonStockSharesAuthorizedIncreaseDecrease
      contextRef="c-38"
      decimals="INF"
      id="f-334"
      unitRef="shares">650000000</smmt:CommonStockSharesAuthorizedIncreaseDecrease>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-39"
      decimals="INF"
      id="f-335"
      unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-40"
      decimals="INF"
      id="f-336"
      unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-41" decimals="-3" id="f-337" unitRef="usd">500000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-41"
      decimals="INF"
      id="f-338"
      unitRef="shares">476190471</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-42"
      decimals="2"
      id="f-339"
      unitRef="usdPerShare">1.05</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-41" decimals="-3" id="f-340" unitRef="usd">619000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NotesPayable contextRef="c-43" decimals="-3" id="f-341" unitRef="usd">400000000</us-gaap:NotesPayable>
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="c-44" decimals="-3" id="f-342" unitRef="usd">20000000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-45"
      decimals="INF"
      id="f-343"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <smmt:SaleOfStockNumberOfSharesRegisteredForResale
      contextRef="c-46"
      decimals="INF"
      id="f-344"
      unitRef="shares">10000000</smmt:SaleOfStockNumberOfSharesRegisteredForResale>
    <smmt:SaleOfStockNumberOfSharesRegisteredForResale
      contextRef="c-47"
      decimals="INF"
      id="f-345"
      unitRef="shares">9346434</smmt:SaleOfStockNumberOfSharesRegisteredForResale>
    <smmt:SaleOfStockNumberOfSharesRegisteredForResale
      contextRef="c-48"
      decimals="INF"
      id="f-346"
      unitRef="shares">373857</smmt:SaleOfStockNumberOfSharesRegisteredForResale>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-49"
      decimals="INF"
      id="f-347"
      unitRef="shares">70000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c-50" decimals="-3" id="f-348" unitRef="usd">5000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-51"
      decimals="2"
      id="f-349"
      unitRef="usdPerShare">1.68</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-52"
      decimals="INF"
      id="f-350"
      unitRef="shares">2976190</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:RelatedPartyTransactionRate contextRef="c-53" decimals="2" id="f-351" unitRef="number">0.12</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-54"
      decimals="INF"
      id="f-352"
      unitRef="number">0.0350</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:BasisOfAccounting contextRef="c-1" id="f-353">Basis of Presentation, Use of Estimates, and Risks and Uncertainties &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. Any reference in these notes to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and as amended by Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments, including those related to revenue recognition, accrued research and development expenses, stock-based compensation, intangible assets, goodwill, other long-lived assets and income taxes. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccounting>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-354">The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-355">The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments, including those related to revenue recognition, accrued research and development expenses, stock-based compensation, intangible assets, goodwill, other long-lived assets and income taxes. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <smmt:LiquidityAndCapitalResourcesTextBlock contextRef="c-1" id="f-356">Liquidity and Capital Resources&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2023, the Company incurred a net loss of $614,928 and cash flows used in operating activities was $76,760. As of December 31, 2023, the Company had an accumulated deficit of $993,258, and cash and cash equivalents and short term investments in U.S. treasury securities of $186,242. The Company expects to continue to generate operating losses for the foreseeable future. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated whether its cash, cash equivalents, short-term investments and U.K. research and development tax credits provide sufficient cash to fund its operating cash needs for the next twelve months from the date of issuance of these annual financials. The Company is investing in the clinical development of ivonescimab, including its ongoing clinical trials. In addition, the Company has a $100,000 promissory note payable to a related party (refer to Note &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further details) that matures on April 1, 2025. Based upon the Company's cash and cash equivalents and short-term investments as of December 31, 2023, the Company expects to be able to operate into the first quarter of 2025. In order to further fund the Company's operating cash needs and repay this promissory note, the Company intends to raise additional capital. As of the date of the issuance of these financial statements the additional capital has not been secured. As a result, these conditions raise substantial doubt about the Company's ability to continue as a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Until the Company can generate substantial revenue and achieve profitability, the Company will need to raise additional capital to fund its ongoing operations and capital needs. The Company continues to evaluate options to further finance its operating cash needs for its product candidates through a combination of some, or all, of the following: equity and debt offerings, collaborations, strategic alliances, grants and clinical trial support from government entities, philanthropic, non-government and not-for-profit organizations, and marketing, distribution or licensing arrangements. There is no assurance, however, that additional financing will be available when needed or that management of the Company will be able to obtain financing on terms acceptable to the Company. If the Company is unable to obtain funding when required in the future, the Company could be required to delay, reduce, or eliminate research and development programs, product portfolio expansion, or future commercialization efforts, which could adversely affect its business prospects.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements are prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of the business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classifications of liabilities that might result from the outcome of this uncertainty.&lt;/span&gt;&lt;/div&gt;</smmt:LiquidityAndCapitalResourcesTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-357" unitRef="usd">-614928000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-358" unitRef="usd">-76760000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-359" unitRef="usd">-993258000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-4" decimals="-3" id="f-360" unitRef="usd">186242000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:LongTermNotesPayable contextRef="c-4" decimals="-3" id="f-361" unitRef="usd">100000000</us-gaap:LongTermNotesPayable>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-362">Summary of Significant Accounting Policies&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant accounting policies adopted by the Company in the preparation of these consolidated financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. The consolidated financial statements reflect the accounts of Summit Therapeutics Inc. and its wholly owned subsidiaries. Intercompany balances and transactions are eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial statements of the Company&#x2019;s subsidiaries with functional currencies other than the United States (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) dollar are translated into U.S. dollars using period-end exchange rates for assets and liabilities, historical exchange rates for stockholders&#x2019; equity and weighted average exchange rates for operating results. Translation gains and losses are included in &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;accumulated other comprehensive (loss) income in shareholders&#x2019; equity. Foreign currency transaction gains and losses are included in other expen&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;se, net in the results of operations. The Company recorded realized and unrealized foreign currency transaction gains (losses) of $613 and ($4,109) for the years ended December 31, 2023 and 2022, respectively, which is included in other expense, net in the statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Operating Income&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generates income from government contracts that reimburse the Company for certain allowable costs for funded projects. For contracts with government agencies where the funding arrangement is considered central to the Company&#x2019;s ongoing operations, the Company classifies the recognized funding received as other operating income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income from government grants is recognized as the qualifying expenses related to the contracts are incurred, provided that there is reasonable assurance of recoverability. If the government agency approves the project proposed by the Company, the government agency funds the project upon receipt of the support for the costs incurred up to the contract limit. Income recognized upon incurring qualifying expenses in advance of billing is recorded as unbilled receivable, a component of other current assets, in the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Grant income is not recognized as deductions of research and development costs because the Company acts as the principal in conducting the research and development activities and these contracts are central to its ongoing operations. The funds received through these means are held as deferred income in the consolidated balance sheets and are released to the consolidated statement of operations and comprehensive loss, classified as other operating income, as the underlying expenditure is incurred and to the extent the conditions of the grant are met. The related costs incurred by the Company are included in research and development expense in the Company&#x2019;s consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company benefits from two U.K. research and development (&#x201c;R&amp;amp;D&#x201d;) tax credit cash rebate regimes: Small and Medium Enterprise (&#x201c;SME&#x201d;) Program and the Research and Development Expenditure Credit (&#x201c;RDEC&#x201d;) Program. Each reporting period, management evaluates which tax relief programs the Company is expected to be eligible for and records as other operating income the portion of the expense that it expects to qualify under the programs, that it plans to submit a claim for, and it has reasonable assurance that the amount will ultimately be realized. Based on criteria established by HM Revenue and Customs (&#x201c;HMRC&#x201d;), management of the Company expects a proportion of expenditures being undertaken in relation to its pipeline research, clinical trials management and manufacturing development activities to be eligible for the research and development tax relief programs for the year ended December 31, 2023. Qualifying expenditures largely comprise of employment costs for research staff, consumables, a proportion of relevant, permitted sub-contract costs and certain internal overhead costs incurred as part of research projects for which the Company does not receive commercial or other funding income. Credits related to the SME and RDEC Programs are recorded as other operating income in the consolidated statements of operations and other comprehensive (loss)/income. Under the SME scheme, the Company receives cash rebate payments of up to 33.3% up to March 31, 2023 and 18.6% from April 1, 2023 of eligible research and development expenditures, and under the RDEC scheme the Company receives cash rebate payments of up to 10.53% up to March 31, 2023 and 15% from April 1, 2023 of eligible research and development expenditure, and these payments are not dependent on the Company&#x2019;s pre-tax net income levels. The Company has qualified under the more favorable SME regime and expects such elements of expenditures will also continue to be eligible for the SME regime for future periods.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the diluted net loss by the weighted-average number of common shares outstanding for the period, including potentially dilutive common shares. The dilutive effect of share options and warrants are determined under the treasury stock method using the average market price for the period.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the assumed proceeds under the treasury stock method include the average unrecognized compensation expense of stock options and warrants that are in-the-money.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Business Combinations &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Business combinations are accounted for under the acquisition method. Acquired assets and assumed liabilities are measured at their fair values at the acquisition date. The excess of the consideration transferred over the net fair value of assets acquired and liabilities assumed is recorded as goodwill. The accounting for an acquisition involves a considerable amount of judgement and estimation. Cost, income, market or a combination of approaches may be used to establish the fair value of consideration exchanged, assets acquired, and liabilities assumed, depending on the nature of those items. The valuation approach is determined in accordance with generally accepted valuation methods. Key areas of estimation and judgment may include the selection of valuation approaches, cost of capital, market characteristics, cost structure, impacts of synergies, and estimates of terminal value, among other factors.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While the Company uses estimates and assumptions as part of the purchase price allocation process to estimate the value of assets acquired and liabilities assumed, estimates are inherently uncertain and subject to refinement. During the measurement period, which maybe up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with a corresponding offset to goodwill, to the extent that adjustments are identified to the preliminary purchase price allocation. Upon conclusion of the measurement period, or final determination of the value of the assets acquired and liabilities assumed, whichever comes first, any subsequent adjustments are recorded to results of operations. Results of operations related to business combinations are included prospectively beginning with the date of acquisition and transaction costs related to business combinations are recorded within general and administrative expenses. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of the consideration transferred over the fair value of net assets acquired. Goodwill is assigned to reporting units at the time of acquisition or when there is a change in the reporting structure and bases that allocation on which reporting units will benefit from the acquired assets and liabilities. Reporting units are defined as operating segments or one level below an operating segment, referred to as a component. Typically acquisitions related to a single reporting unit do not require the allocation of goodwill to multiple reporting units. If the products obtained in an acquisition are assigned to multiple reporting units, the goodwill is distributed to the respective reporting units as part of the purchase price allocation process.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses goodwill for impairment on an annual basis or more frequently when events and circumstances occur indicating that the recorded goodwill may be impaired. The Company regularly monitors current business conditions and other factors including, but not limited to, adverse industry or economic trends and lower projections of profitability that may impact future operating results. The process of evaluating the potential impairment of goodwill requires significant judgment. In performing the Company&#x2019;s annual goodwill impairment test, the Company is permitted to first assess qualitative factors to determine whether it is more likely than not that the fair value of the Company&#x2019;s reporting unit is less than its carrying amount, including goodwill. In performing the qualitative assessment, the Company considers certain events and circumstances specific to the reporting unit and to the entity as a whole, such as macroeconomic conditions, industry and market considerations, overall financial performance and cost factors when evaluating whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. The Company is also permitted to bypass the qualitative assessment and proceed directly to the quantitative test. If the Company chooses to undertake the qualitative assessment and concludes that it is more likely than not that the fair value of the reporting unit is less than its carrying amount, the Company would then proceed to the quantitative impairment test. In the quantitative assessment, the Company compares the fair value of the reporting unit to its carrying amount, which includes goodwill. If the fair value exceeds the carrying value, no impairment loss exists. If the fair value is less than the carrying amount, a goodwill impairment loss is measured and recorded.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses goodwill for impairment on an annual basis as of December 31 or more frequently when events and circumstances occur indicating that recorded goodwill may be impaired.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost less accumulated depreciation. Cost is comprised of the purchase price plus any incidental costs of acquisition and commissioning. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation is calculated based on cost, less residual value, in equal annual installments over the estimated useful lives of the assets. The residual value, if significant, is reassessed annually.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.736%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.064%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 - 10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures, office equipment and software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="-sec-ix-hidden:f-377"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Over the shorter of the asset&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;s useful life or the remaining lease term&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation is recognized as part of the general and administrative and research and development expense lines shown on the face of the consolidated statement of operations and comprehensive loss depending on the nature of the underlying assets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenditures for repairs and maintenance are expensed as incurred. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in loss from operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has operating leases for real estate. The Company does not have any finance leases. Under ASC 842, a contract is or contains a lease when the lessee has the right to control the use of an identified asset. The Company determines if an arrangement is a lease at inception of the contract, which is the date on which the terms of the contract are agreed to and the agreement creates enforceable rights and obligations. The lease term used to calculate the lease liability include options to extend or terminate the lease when it is reasonably certain that the option will be exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the lease commencement date, the Company measures and recognizes a lease liability and a right-of-use asset in the financial statements. Lease liabilities are recognized based on the present value of the future lease payments over the lease term at commencement date. The right-of use asset is measured by taking the present value of future lease payments, plus any incremental direct costs incurred, less any lease incentives received. As most of the Company&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s leases do not provide an implicit rate, the Company uses an estimated incremental borrowing rate based on the lease term and the economic environment of the lease at the lease commencement date, which is then utilized to determine the present value of future lease payments. Lease expense for minimum lease payments are recognized on a straight-line basis over the lease term, with variable lease payments recognized in the periods in which they are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has existing lease agreements with lease and non-lease components, has elected to account for the lease and non-lease components as a single lease component, and has allocated all of the contract consideration to the lease component only. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases with an initial lease term of 12 months or less are not recorded on the balance sheet. The Company recognizes lease expense for its short-term leases on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquired In-Process Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company  may enter into agreements with collaboration partners for the development and commercialization of its products. These arrangements may include payments contingent on the occurrence of certain events such as development, regulatory or sales-based milestones. The Company considers the unique nature, terms and facts and circumstances of each transaction. The Company considers whether or not the assets acquired have a future alternative use. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value associated with acquired in-process research and development which does not have an alternative future use is expensed and is recorded as research and development expense. Any development or commercial milestone payments are recognized when the achievement of the associated milestone becomes probable and will either be expensed or capitalized depending upon whether or not regulatory approval has been obtained. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred to discover, research and develop product candidates, including personnel expenses, stock-based compensation expense, allocated facility-related and depreciation expenses, third-party license fees and external costs of outside vendors engaged to conduct &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;preclinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are recorded as prepaid expenses. Such amounts are recognized as an expense as the goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered. Milestone and other payments made to third-parties with respect to in-process research and development, in accordance with the Company&#x2019;s license, acquisition and other similar agreements are expensed when determined to be probable and estimable.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into various research and development contracts with other companies. These agreements are generally cancellable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research and development costs or prepaid expenses where the payments made exceeds the estimated costs. When evaluating the adequacy of these balances, the Company analyzes progress of the studies, including the estimated costs to complete each study or activity, the estimation of the current stage of completion and the invoices received, as well as predetermined milestones which are not reflective of the current stage of development for prepaid expenses. Actual results could differ from the Company&#x2019;s estimates. In all cases, the full cost of each study or activity is expensed by the time the final report or where applicable, product, has been received. The Company&#x2019;s historical estimates have not been materially different from the actual costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures and recognizes compensation expense for all stock option and restricted stock unit awards based on the estimated fair value of the award on the grant date. The Company uses the Black-Scholes option pricing model to estimate the fair value of stock option awards. Additionally, the Company uses a Monte Carlo simulation model to calculate the estimated fair value on the date of grant related to awards with market-based service conditions. The fair value is recognized as expense, over the requisite service period, which is generally the vesting period of the respective award, on a straight-line basis for each separately vesting portion of the award when the only condition to vesting is continued service.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If vesting is subject to a market or performance condition, recognition is based on the derived service period of the award. Expense for awards with performance conditions is estimated and adjusted on a quarterly basis based upon the assessment of the probability that the performance condition will be met. Use of the Black-Scholes option-pricing model requires management to apply judgment under highly subjective assumptions.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These assumptions include:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Expected term&#x2014;The expected term of stock options represents the weighted-average period the stock options are expected to be outstanding. The Company uses the simplified method for estimating the expected term as provided by the Securities and Exchange Commission. The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life of the options.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Expected volatility&#x2014;The expected volatility is calculated based on historical volatility of the Company&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s share price.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Risk-free interest rate&#x2014;The risk-free rate assumption is based on the U.S. Treasury instruments, the terms of which were consistent with the expected term of the Company&#x2019;s stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Expected dividend&#x2014;The expected dividend assumption is based on the Company&#x2019;s history and expectation of dividend payouts. The Company has not paid and does not intend to pay dividends. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates expected forfeitures at the time of grant instead of accounting for forfeitures as they occur. Stock option and restricted stock unit awards have been granted at fair value to non-employees in connection with research and consulting services provided to the Company. Equity awards generally vest over terms of 3 or 4 years. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies stock-based compensation expense in the consolidated statements of operations in the same manner in which the award recipient&#x2019;s payroll costs are classified.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes is determined using the asset and liability approach. Tax laws may require items to be included in tax filings at different times than the items are reflected in the financial statements. A current asset or liability is recognized for the estimated taxes receivable or payable for the current year. Deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. Deferred taxes are initially recognized at enacted tax rates in force at the time of initial recognition and are subsequently adjusted for any enacted changes in tax rates &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and tax laws. Subsequent changes to deferred taxes originally recognized in equity are recognized in income. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The Company has recorded a full valuation allowance against the deferred tax assets in excess of its deferred tax liabilities, as the deferred tax liability represents future reversals of existing taxable temporary differences. The Company records interest and penalties related to income tax matters as part of income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for uncertainty in income taxes by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed as the amount of benefit to recognize in the consolidated financial statements. The amount of benefits that may be used is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate, as well as the related net interest and penalties. At December 31, 2023 and 2022, the Company had unrecognized tax positions of $1,064 and $0, respectively. Due to the Company&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s full valuation allowance, the unrecognized tax benefits would not materially impact the Company&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s effective tax rate when recognized.  The Company does not anticipate the total amount of unrecognized tax benefits to significantly increase or decrease in the next 12 months. The Company&#x2019;s policy is to recognize interest and penalties related to uncertain tax positions as part of its income tax provision. For the years ended December 31, 2023and 2022, the Company had no interest or penalties related to unrecognized tax benefits.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk and of Significant Supplier&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of short-term cash deposits and accounts and other receivables. The Company&#x2019;s cash is comprised of short-term cash deposits at a variety of financial institutions with strong credit ratings in amounts that may exceed federally insured limits and has not experienced any losses on such accounts. Cash balances maintained during the year have been principally held with reputable U.K.-based and U.S.-based banks. The Company does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The credit risk with respect to customers and funding bodies is limited as the Company has only a small number of these arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company relies, and expects to continue to rely, on a number of vendors to conduct its clinical trials and preclinical studies, manufacture drug product and supply clinical trial and preclinical study materials for its development programs. These programs could be adversely affected by a significant interruption in these services or the availability of materials.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the provisions of fair value accounting, a fair value measurement assumes that the transaction to sell an asset or transfer a liability occurs in the principal market for the asset or liability or, in the absence of a principal market, the most advantageous market for the asset or liability and defines fair value based on the exit price model.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value measurement guidance establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The guidance describes three levels of inputs that may be used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Quoted prices in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 2 assets and liabilities include debt securities with quoted prices that are traded less frequently than exchange-traded instruments or securities or derivative contracts that are valued using a pricing model with inputs that are observable in the market or can be derived principally from or corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the Company categorizes such assets and liabilities based on the lowest level input that is significant to the fair value measurement in its entirety. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers only those investments that are highly liquid, readily convertible to cash and that mature within 90 days or less from date of purchase to be cash equivalents. As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, cash equivalents were comprised of a money market funds and U.S. treasury securities with maturities less than 90 days from the date of purchase. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash of $300,000 as of December 31, 2022, represents amounts which are legally restricted to withdrawal or usage and is presented in the Consolidated Balance Sheet as restricted cash. On December 15, 2022, the Company transferred $300,000 into an escrow fund reserved for the Company&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s initial upfront payment to Akeso in connection with the License Agreement, as described further in Note &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Following the Antitrust Clearance Date, on January 17, 2023, the License Agreement closed and Akeso was issued 10,000,000 shares of Company common stock pursuant to the Common Stock Issuance Agreement and was paid $274,900 in cash as initial upfront payment. The remaining amounts in escrow were returned to the Company&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s operating cash accounts. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assumed Contingent Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the acquisition of Discuva Limited in December 2017, the Company assumed certain contingent liabilities as certain employees, former employees and former directors of Discuva Limited are eligible for payments from Discuva Limited based on specified development and clinical milestones related to proprietary product candidates developed under the Discuva Platform. The timing of these potential payments is uncertain. The fair value of the assumed contingent liability was estimated using the expected value of the payments. The assumed contingent liabilities are subsequently measured at amortized cost using discounted cash flow models which calculate the risk adjusted net present values of estimated potential future cash flows of the payments. The assumed contingent liabilities are remeasured when there is a specific significant event that provides evidence of a significant change in the probability of successful development and clinical milestones being achieved. The models will be updated for changes in the probability of successful development and clinical milestones being achieved and other associated assumptions with the discount factor remaining unchanged within the model. A discount factor of 13% has been used to discount the contingent liabilities back to net present value. This discount factor has been calculated using appropriate measures and rates which could have been obtained in the period that the contingent liabilities were assumed. Accretion of the discount &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;factor and gains or losses upon remeasurement are recognized as part of operating expenses in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants issued by the Company are recognized and classified as equity when, upon exercise, the Company would issue a fixed amount of its own equity instruments (common stock) in exchange for a fixed amount of cash or another financial asset.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consideration received, net of incremental costs directly attributable to the issue of such new warrants, is shown in equity. Such warrants are not remeasured at fair value in subsequent reporting periods.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants issued in which external services are received as consideration for equity instruments of the company should be measured at the fair value of the goods or services received. Only if the fair value of the services cannot be measured reliably would the fair value of the equity instruments granted be used. The fair value for the warrants is calculated using the Black-Scholes formula and recorded in the consolidated statement of operations and comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on a straight-line basis over the period of the consulting services. If the services are terminated prior to the end of the consultancy agreement, the warrants cease vesting and any unvested portion of the warrants will lapse immediately.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The warrants in issue are classified within stockholders&#x2019; equity as they are indexed to the Company&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;s own shares of common stock and require settlement in its shares of common stocks with no provision for any cash settlement.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-363">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation &lt;/span&gt;&lt;/div&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. The consolidated financial statements reflect the accounts of Summit Therapeutics Inc. and its wholly owned subsidiaries. Intercompany balances and transactions are eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c-1" id="f-364">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial statements of the Company&#x2019;s subsidiaries with functional currencies other than the United States (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) dollar are translated into U.S. dollars using period-end exchange rates for assets and liabilities, historical exchange rates for stockholders&#x2019; equity and weighted average exchange rates for operating results. Translation gains and losses are included in &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;accumulated other comprehensive (loss) income in shareholders&#x2019; equity. Foreign currency transaction gains and losses are included in other expen&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;se, net in the results of operations. The Company recorded realized and unrealized foreign currency transaction gains (losses) of $613 and ($4,109) for the years ended December 31, 2023 and 2022, respectively, which is included in other expense, net in the statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-1" decimals="-3" id="f-365" unitRef="usd">613000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-6" decimals="-3" id="f-366" unitRef="usd">-4109000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <smmt:OtherOperatingIncomePolicyPolicyTextBlock contextRef="c-1" id="f-367">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Operating Income&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generates income from government contracts that reimburse the Company for certain allowable costs for funded projects. For contracts with government agencies where the funding arrangement is considered central to the Company&#x2019;s ongoing operations, the Company classifies the recognized funding received as other operating income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income from government grants is recognized as the qualifying expenses related to the contracts are incurred, provided that there is reasonable assurance of recoverability. If the government agency approves the project proposed by the Company, the government agency funds the project upon receipt of the support for the costs incurred up to the contract limit. Income recognized upon incurring qualifying expenses in advance of billing is recorded as unbilled receivable, a component of other current assets, in the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Grant income is not recognized as deductions of research and development costs because the Company acts as the principal in conducting the research and development activities and these contracts are central to its ongoing operations. The funds received through these means are held as deferred income in the consolidated balance sheets and are released to the consolidated statement of operations and comprehensive loss, classified as other operating income, as the underlying expenditure is incurred and to the extent the conditions of the grant are met. The related costs incurred by the Company are included in research and development expense in the Company&#x2019;s consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;The Company benefits from two U.K. research and development (&#x201c;R&amp;amp;D&#x201d;) tax credit cash rebate regimes: Small and Medium Enterprise (&#x201c;SME&#x201d;) Program and the Research and Development Expenditure Credit (&#x201c;RDEC&#x201d;) Program. Each reporting period, management evaluates which tax relief programs the Company is expected to be eligible for and records as other operating income the portion of the expense that it expects to qualify under the programs, that it plans to submit a claim for, and it has reasonable assurance that the amount will ultimately be realized. Based on criteria established by HM Revenue and Customs (&#x201c;HMRC&#x201d;), management of the Company expects a proportion of expenditures being undertaken in relation to its pipeline research, clinical trials management and manufacturing development activities to be eligible for the research and development tax relief programs for the year ended December 31, 2023. Qualifying expenditures largely comprise of employment costs for research staff, consumables, a proportion of relevant, permitted sub-contract costs and certain internal overhead costs incurred as part of research projects for which the Company does not receive commercial or other funding income. Credits related to the SME and RDEC Programs are recorded as other operating income in the consolidated statements of operations and other comprehensive (loss)/income. Under the SME scheme, the Company receives cash rebate payments of up to 33.3% up to March 31, 2023 and 18.6% from April 1, 2023 of eligible research and development expenditures, and under the RDEC scheme the Company receives cash rebate payments of up to 10.53% up to March 31, 2023 and 15% from April 1, 2023 of eligible research and development expenditure, and these payments are not dependent on the Company&#x2019;s pre-tax net income levels.</smmt:OtherOperatingIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-368">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the diluted net loss by the weighted-average number of common shares outstanding for the period, including potentially dilutive common shares. The dilutive effect of share options and warrants are determined under the treasury stock method using the average market price for the period.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the assumed proceeds under the treasury stock method include the average unrecognized compensation expense of stock options and warrants that are in-the-money.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy contextRef="c-1" id="f-369">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Business Combinations &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Business combinations are accounted for under the acquisition method. Acquired assets and assumed liabilities are measured at their fair values at the acquisition date. The excess of the consideration transferred over the net fair value of assets acquired and liabilities assumed is recorded as goodwill. The accounting for an acquisition involves a considerable amount of judgement and estimation. Cost, income, market or a combination of approaches may be used to establish the fair value of consideration exchanged, assets acquired, and liabilities assumed, depending on the nature of those items. The valuation approach is determined in accordance with generally accepted valuation methods. Key areas of estimation and judgment may include the selection of valuation approaches, cost of capital, market characteristics, cost structure, impacts of synergies, and estimates of terminal value, among other factors.&lt;/span&gt;&lt;/div&gt;While the Company uses estimates and assumptions as part of the purchase price allocation process to estimate the value of assets acquired and liabilities assumed, estimates are inherently uncertain and subject to refinement. During the measurement period, which maybe up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with a corresponding offset to goodwill, to the extent that adjustments are identified to the preliminary purchase price allocation. Upon conclusion of the measurement period, or final determination of the value of the assets acquired and liabilities assumed, whichever comes first, any subsequent adjustments are recorded to results of operations. Results of operations related to business combinations are included prospectively beginning with the date of acquisition and transaction costs related to business combinations are recorded within general and administrative expenses.</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="c-1" id="f-370">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of the consideration transferred over the fair value of net assets acquired. Goodwill is assigned to reporting units at the time of acquisition or when there is a change in the reporting structure and bases that allocation on which reporting units will benefit from the acquired assets and liabilities. Reporting units are defined as operating segments or one level below an operating segment, referred to as a component. Typically acquisitions related to a single reporting unit do not require the allocation of goodwill to multiple reporting units. If the products obtained in an acquisition are assigned to multiple reporting units, the goodwill is distributed to the respective reporting units as part of the purchase price allocation process.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses goodwill for impairment on an annual basis or more frequently when events and circumstances occur indicating that the recorded goodwill may be impaired. The Company regularly monitors current business conditions and other factors including, but not limited to, adverse industry or economic trends and lower projections of profitability that may impact future operating results. The process of evaluating the potential impairment of goodwill requires significant judgment. In performing the Company&#x2019;s annual goodwill impairment test, the Company is permitted to first assess qualitative factors to determine whether it is more likely than not that the fair value of the Company&#x2019;s reporting unit is less than its carrying amount, including goodwill. In performing the qualitative assessment, the Company considers certain events and circumstances specific to the reporting unit and to the entity as a whole, such as macroeconomic conditions, industry and market considerations, overall financial performance and cost factors when evaluating whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. The Company is also permitted to bypass the qualitative assessment and proceed directly to the quantitative test. If the Company chooses to undertake the qualitative assessment and concludes that it is more likely than not that the fair value of the reporting unit is less than its carrying amount, the Company would then proceed to the quantitative impairment test. In the quantitative assessment, the Company compares the fair value of the reporting unit to its carrying amount, which includes goodwill. If the fair value exceeds the carrying value, no impairment loss exists. If the fair value is less than the carrying amount, a goodwill impairment loss is measured and recorded.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses goodwill for impairment on an annual basis as of December 31 or more frequently when events and circumstances occur indicating that recorded goodwill may be impaired.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-371">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost less accumulated depreciation. Cost is comprised of the purchase price plus any incidental costs of acquisition and commissioning. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation is calculated based on cost, less residual value, in equal annual installments over the estimated useful lives of the assets. The residual value, if significant, is reassessed annually.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.736%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.064%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 - 10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures, office equipment and software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="-sec-ix-hidden:f-377"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Over the shorter of the asset&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;s useful life or the remaining lease term&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation is recognized as part of the general and administrative and research and development expense lines shown on the face of the consolidated statement of operations and comprehensive loss depending on the nature of the underlying assets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenditures for repairs and maintenance are expensed as incurred. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in loss from operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-372">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation is calculated based on cost, less residual value, in equal annual installments over the estimated useful lives of the assets. The residual value, if significant, is reassessed annually.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.736%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.064%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 - 10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures, office equipment and software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="-sec-ix-hidden:f-377"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Over the shorter of the asset&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;s useful life or the remaining lease term&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.826%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.829%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures, office equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-55" id="f-373">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-56" id="f-374">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-57" id="f-375">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-58" id="f-376">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-378">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has operating leases for real estate. The Company does not have any finance leases. Under ASC 842, a contract is or contains a lease when the lessee has the right to control the use of an identified asset. The Company determines if an arrangement is a lease at inception of the contract, which is the date on which the terms of the contract are agreed to and the agreement creates enforceable rights and obligations. The lease term used to calculate the lease liability include options to extend or terminate the lease when it is reasonably certain that the option will be exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the lease commencement date, the Company measures and recognizes a lease liability and a right-of-use asset in the financial statements. Lease liabilities are recognized based on the present value of the future lease payments over the lease term at commencement date. The right-of use asset is measured by taking the present value of future lease payments, plus any incremental direct costs incurred, less any lease incentives received. As most of the Company&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s leases do not provide an implicit rate, the Company uses an estimated incremental borrowing rate based on the lease term and the economic environment of the lease at the lease commencement date, which is then utilized to determine the present value of future lease payments. Lease expense for minimum lease payments are recognized on a straight-line basis over the lease term, with variable lease payments recognized in the periods in which they are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has existing lease agreements with lease and non-lease components, has elected to account for the lease and non-lease components as a single lease component, and has allocated all of the contract consideration to the lease component only. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases with an initial lease term of 12 months or less are not recorded on the balance sheet. The Company recognizes lease expense for its short-term leases on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:InProcessResearchAndDevelopmentPolicy contextRef="c-1" id="f-379">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquired In-Process Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company  may enter into agreements with collaboration partners for the development and commercialization of its products. These arrangements may include payments contingent on the occurrence of certain events such as development, regulatory or sales-based milestones. The Company considers the unique nature, terms and facts and circumstances of each transaction. The Company considers whether or not the assets acquired have a future alternative use. &lt;/span&gt;&lt;/div&gt;The fair value associated with acquired in-process research and development which does not have an alternative future use is expensed and is recorded as research and development expense. Any development or commercial milestone payments are recognized when the achievement of the associated milestone becomes probable and will either be expensed or capitalized depending upon whether or not regulatory approval has been obtained.</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-380">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred to discover, research and develop product candidates, including personnel expenses, stock-based compensation expense, allocated facility-related and depreciation expenses, third-party license fees and external costs of outside vendors engaged to conduct &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;preclinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are recorded as prepaid expenses. Such amounts are recognized as an expense as the goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered. Milestone and other payments made to third-parties with respect to in-process research and development, in accordance with the Company&#x2019;s license, acquisition and other similar agreements are expensed when determined to be probable and estimable.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into various research and development contracts with other companies. These agreements are generally cancellable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research and development costs or prepaid expenses where the payments made exceeds the estimated costs. When evaluating the adequacy of these balances, the Company analyzes progress of the studies, including the estimated costs to complete each study or activity, the estimation of the current stage of completion and the invoices received, as well as predetermined milestones which are not reflective of the current stage of development for prepaid expenses. Actual results could differ from the Company&#x2019;s estimates. In all cases, the full cost of each study or activity is expensed by the time the final report or where applicable, product, has been received. The Company&#x2019;s historical estimates have not been materially different from the actual costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-381">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures and recognizes compensation expense for all stock option and restricted stock unit awards based on the estimated fair value of the award on the grant date. The Company uses the Black-Scholes option pricing model to estimate the fair value of stock option awards. Additionally, the Company uses a Monte Carlo simulation model to calculate the estimated fair value on the date of grant related to awards with market-based service conditions. The fair value is recognized as expense, over the requisite service period, which is generally the vesting period of the respective award, on a straight-line basis for each separately vesting portion of the award when the only condition to vesting is continued service.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If vesting is subject to a market or performance condition, recognition is based on the derived service period of the award. Expense for awards with performance conditions is estimated and adjusted on a quarterly basis based upon the assessment of the probability that the performance condition will be met. Use of the Black-Scholes option-pricing model requires management to apply judgment under highly subjective assumptions.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These assumptions include:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Expected term&#x2014;The expected term of stock options represents the weighted-average period the stock options are expected to be outstanding. The Company uses the simplified method for estimating the expected term as provided by the Securities and Exchange Commission. The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life of the options.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Expected volatility&#x2014;The expected volatility is calculated based on historical volatility of the Company&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s share price.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Risk-free interest rate&#x2014;The risk-free rate assumption is based on the U.S. Treasury instruments, the terms of which were consistent with the expected term of the Company&#x2019;s stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Expected dividend&#x2014;The expected dividend assumption is based on the Company&#x2019;s history and expectation of dividend payouts. The Company has not paid and does not intend to pay dividends. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates expected forfeitures at the time of grant instead of accounting for forfeitures as they occur. Stock option and restricted stock unit awards have been granted at fair value to non-employees in connection with research and consulting services provided to the Company. Equity awards generally vest over terms of 3 or 4 years. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies stock-based compensation expense in the consolidated statements of operations in the same manner in which the award recipient&#x2019;s payroll costs are classified.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-60" id="f-382">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-61" id="f-383">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-384">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes is determined using the asset and liability approach. Tax laws may require items to be included in tax filings at different times than the items are reflected in the financial statements. A current asset or liability is recognized for the estimated taxes receivable or payable for the current year. Deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. Deferred taxes are initially recognized at enacted tax rates in force at the time of initial recognition and are subsequently adjusted for any enacted changes in tax rates &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and tax laws. Subsequent changes to deferred taxes originally recognized in equity are recognized in income. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The Company has recorded a full valuation allowance against the deferred tax assets in excess of its deferred tax liabilities, as the deferred tax liability represents future reversals of existing taxable temporary differences. The Company records interest and penalties related to income tax matters as part of income tax expense.&lt;/span&gt;&lt;/div&gt;The Company accounts for uncertainty in income taxes by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed as the amount of benefit to recognize in the consolidated financial statements. The amount of benefits that may be used is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate, as well as the related net interest and penalties. The Company&#x2019;s policy is to recognize interest and penalties related to uncertain tax positions as part of its income tax provision.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-4" decimals="-3" id="f-385" unitRef="usd">1064000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-5" decimals="-3" id="f-386" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-5" decimals="-3" id="f-387" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-4" decimals="-3" id="f-388" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-389">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk and of Significant Supplier&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of short-term cash deposits and accounts and other receivables. The Company&#x2019;s cash is comprised of short-term cash deposits at a variety of financial institutions with strong credit ratings in amounts that may exceed federally insured limits and has not experienced any losses on such accounts. Cash balances maintained during the year have been principally held with reputable U.K.-based and U.S.-based banks. The Company does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The credit risk with respect to customers and funding bodies is limited as the Company has only a small number of these arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company relies, and expects to continue to rely, on a number of vendors to conduct its clinical trials and preclinical studies, manufacture drug product and supply clinical trial and preclinical study materials for its development programs. These programs could be adversely affected by a significant interruption in these services or the availability of materials.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c-1" id="f-390">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the provisions of fair value accounting, a fair value measurement assumes that the transaction to sell an asset or transfer a liability occurs in the principal market for the asset or liability or, in the absence of a principal market, the most advantageous market for the asset or liability and defines fair value based on the exit price model.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value measurement guidance establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The guidance describes three levels of inputs that may be used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Quoted prices in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 2 assets and liabilities include debt securities with quoted prices that are traded less frequently than exchange-traded instruments or securities or derivative contracts that are valued using a pricing model with inputs that are observable in the market or can be derived principally from or corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the Company categorizes such assets and liabilities based on the lowest level input that is significant to the fair value measurement in its entirety. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy contextRef="c-1" id="f-391">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;The Company considers only those investments that are highly liquid, readily convertible to cash and that mature within 90 days or less from date of purchase to be cash equivalents.</us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c-1" id="f-392">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;Restricted cash of $300,000 as of December 31, 2022, represents amounts which are legally restricted to withdrawal or usage and is presented in the Consolidated Balance Sheet as restricted cash.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCashCurrent contextRef="c-5" decimals="-3" id="f-393" unitRef="usd">300000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-62" decimals="-3" id="f-394" unitRef="usd">300000000</us-gaap:RestrictedCashCurrent>
    <smmt:CollaborativeArrangementRightsAndObligationsUpfrontPaymentSharesOfCommonStockIssuedInLieuOfCash
      contextRef="c-63"
      decimals="INF"
      id="f-395"
      unitRef="shares">10000000</smmt:CollaborativeArrangementRightsAndObligationsUpfrontPaymentSharesOfCommonStockIssuedInLieuOfCash>
    <smmt:CashPaymentForCollaborativeArrangementUpfrontPayment contextRef="c-63" decimals="-3" id="f-396" unitRef="usd">274900000</smmt:CashPaymentForCollaborativeArrangementUpfrontPayment>
    <smmt:AssumedContingentLiabilitiesPolicyPolicyTextBlock contextRef="c-1" id="f-397">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assumed Contingent Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the acquisition of Discuva Limited in December 2017, the Company assumed certain contingent liabilities as certain employees, former employees and former directors of Discuva Limited are eligible for payments from Discuva Limited based on specified development and clinical milestones related to proprietary product candidates developed under the Discuva Platform. The timing of these potential payments is uncertain. The fair value of the assumed contingent liability was estimated using the expected value of the payments. The assumed contingent liabilities are subsequently measured at amortized cost using discounted cash flow models which calculate the risk adjusted net present values of estimated potential future cash flows of the payments. The assumed contingent liabilities are remeasured when there is a specific significant event that provides evidence of a significant change in the probability of successful development and clinical milestones being achieved. The models will be updated for changes in the probability of successful development and clinical milestones being achieved and other associated assumptions with the discount factor remaining unchanged within the model. A discount factor of 13% has been used to discount the contingent liabilities back to net present value. This discount factor has been calculated using appropriate measures and rates which could have been obtained in the period that the contingent liabilities were assumed. Accretion of the discount &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;factor and gains or losses upon remeasurement are recognized as part of operating expenses in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</smmt:AssumedContingentLiabilitiesPolicyPolicyTextBlock>
    <smmt:BusinessCombinationAssumedContingentLiabilityMeasurementInput contextRef="c-64" decimals="2" id="f-398" unitRef="number">0.13</smmt:BusinessCombinationAssumedContingentLiabilityMeasurementInput>
    <smmt:WarrantsPolicyPolicyTextBlock contextRef="c-1" id="f-399">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants issued by the Company are recognized and classified as equity when, upon exercise, the Company would issue a fixed amount of its own equity instruments (common stock) in exchange for a fixed amount of cash or another financial asset.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consideration received, net of incremental costs directly attributable to the issue of such new warrants, is shown in equity. Such warrants are not remeasured at fair value in subsequent reporting periods.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants issued in which external services are received as consideration for equity instruments of the company should be measured at the fair value of the goods or services received. Only if the fair value of the services cannot be measured reliably would the fair value of the equity instruments granted be used. The fair value for the warrants is calculated using the Black-Scholes formula and recorded in the consolidated statement of operations and comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on a straight-line basis over the period of the consulting services. If the services are terminated prior to the end of the consultancy agreement, the warrants cease vesting and any unvested portion of the warrants will lapse immediately.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The warrants in issue are classified within stockholders&#x2019; equity as they are indexed to the Company&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;s own shares of common stock and require settlement in its shares of common stocks with no provision for any cash settlement.</smmt:WarrantsPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="c-1" id="f-401">Recently Issued or Adopted Accounting Pronouncements &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards update &#x201c;ASU&#x201d; No. 2023-09, &#x201c;Improvements to Income Tax Disclosures&#x201d;, which requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. ASU No. 2023-09 is effective for fiscal years beginning after December 15, 2024 and allows for adoption on a prospective basis, with a retrospective option. Early adoption is permitted. The Company is currently evaluating the impact of the ASU on the income tax disclosures within the consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued ASU No. 2023-07, &#x201c;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&#x201d;, which provides updates to qualitative and quantitative reportable segment disclosure requirements, including enhanced disclosures about significant segment expenses and increased interim disclosure requirements, among others. ASU No. 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. Early adoption is permitted, and the amendments should be applied retrospectively. The Company is currently evaluating the impact of the ASU on the consolidated financial statement disclosures. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU 2016-13, &#x201c;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#x201d;, which has subsequently been amended by ASU 2019-04 and ASU 2019-10 (collectively &#x201c;ASU 2016-03&#x201d;). ASU 2016-13 amends the guidance on the impairment of financial instruments. This update adds an impairment model (known as the current expected credit losses model) that is based on expected losses rather than incurred losses. Under the new guidance, an entity recognizes, as an allowance, its estimate of expected credit losses. The Company adopted this standard on January 1, 2023, and it did not have a material impact on the consolidated financial statements or related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other recent authoritative guidance issued by the FASB (including technical corrections to the FASB ASC), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not expected to have a material impact on the Company&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-400">Recently Issued or Adopted Accounting Pronouncements &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards update &#x201c;ASU&#x201d; No. 2023-09, &#x201c;Improvements to Income Tax Disclosures&#x201d;, which requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. ASU No. 2023-09 is effective for fiscal years beginning after December 15, 2024 and allows for adoption on a prospective basis, with a retrospective option. Early adoption is permitted. The Company is currently evaluating the impact of the ASU on the income tax disclosures within the consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued ASU No. 2023-07, &#x201c;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&#x201d;, which provides updates to qualitative and quantitative reportable segment disclosure requirements, including enhanced disclosures about significant segment expenses and increased interim disclosure requirements, among others. ASU No. 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. Early adoption is permitted, and the amendments should be applied retrospectively. The Company is currently evaluating the impact of the ASU on the consolidated financial statement disclosures. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU 2016-13, &#x201c;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#x201d;, which has subsequently been amended by ASU 2019-04 and ASU 2019-10 (collectively &#x201c;ASU 2016-03&#x201d;). ASU 2016-13 amends the guidance on the impairment of financial instruments. This update adds an impairment model (known as the current expected credit losses model) that is based on expected losses rather than incurred losses. Under the new guidance, an entity recognizes, as an allowance, its estimate of expected credit losses. The Company adopted this standard on January 1, 2023, and it did not have a material impact on the consolidated financial statements or related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other recent authoritative guidance issued by the FASB (including technical corrections to the FASB ASC), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not expected to have a material impact on the Company&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-402">Akeso License and Collaboration Agreement&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 5, 2022, the Company entered into a Collaboration and License Agreement (the &#x201c;License Agreement&#x201d;) with Akeso pursuant to which the Company is in-licensing its breakthrough bispecific antibody, ivonescimab. The License Agreement and transaction closed in January 2023 following customary waiting periods.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ivonescimab, known as AK112 in China and Australia, and also as SMT112 in the United States, Canada, Europe, and Japan, is a novel, potential first-in-class bispecific antibody intending to combine the benefits of immunotherapy via a blockade of PD-1 with the anti-angiogenesis benefits of an anti-VEGF into a single molecule. Ivonescimab was engineered to bring two well established oncology targeted mechanisms together. Ivonescimab is currently in clinical development and, pursuant to the terms of the License Agreement, Summit will design and conduct the clinical trial activities to support regulatory filings in the Licensed Territory that Summit will submit. Pursuant to the terms of the License Agreement, Summit will have final decision making authority with respect to commercial strategy, pricing and reimbursement and other commercialization matters in the Licensed Territory. In connection with the License Agreement, the Company has also entered into a Supply Agreement with Akeso, pursuant to which Summit agrees to purchase a certain portion of drug substance for clinical and commercial supply. Summit is not assuming any liabilities (including contingent liabilities), acquiring any physical assets or trade names, or hiring or acquiring any employees from Akeso in connection with the License Agreement. Through the License Agreement, the Company obtained the rights to develop and commercialize SMT112 in the United States, Canada, Europe, and Japan (the &#x201c;Licensed Territory&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In exchange for the rights obtained, an upfront payment of $500,000 was made to Akeso, of which $274,900 was paid in cash and, pursuant to the License Agreement and Issuance Agreement, Akeso elected to receive 10,000,000 shares of our common stock in lieu of $25,100 cash. The remaining $200,000 amount of the upfront payment was paid on March 6, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has accounted for the License Agreement to acquire the rights to develop and commercialize SMT112 as the acquisition of an asset. All of the consideration relates to SMT112 and technological feasibility of the asset has not yet been established since SMT112 is in clinical development. As such, the Company has expensed the consideration as in-process research and development upon closing of the transaction in the consolidated statement of comprehensive loss. In-process research and development expense for the year ended December 31, 2023 was $520,915, which is comprised of the $474,900 paid in cash, the fair value of the 10,000,000 shares of common stock on the date of closing the transaction of $45,900, and $115 of direct transactions costs incurred.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the payments already made to Akeso, under the License Agreement, there are additional potential milestone payments of up to $4,500,000, as Akeso will be eligible to receive regulatory milestones of up to $1,050,000 and commercial milestones of up to $3,450,000. In addition, Akeso will be eligible to receive low double-digit royalties on net sales.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <smmt:CollaborativeArrangementRightsAndObligationsUpfrontPayment contextRef="c-65" decimals="-3" id="f-403" unitRef="usd">500000000</smmt:CollaborativeArrangementRightsAndObligationsUpfrontPayment>
    <smmt:CashPaymentForCollaborativeArrangementUpfrontPayment contextRef="c-66" decimals="-3" id="f-404" unitRef="usd">274900000</smmt:CashPaymentForCollaborativeArrangementUpfrontPayment>
    <smmt:CollaborativeArrangementRightsAndObligationsUpfrontPaymentSharesOfCommonStockIssuedInLieuOfCash
      contextRef="c-66"
      decimals="INF"
      id="f-405"
      unitRef="shares">10000000</smmt:CollaborativeArrangementRightsAndObligationsUpfrontPaymentSharesOfCommonStockIssuedInLieuOfCash>
    <smmt:CollaborativeArrangementRightsAndObligationsUpfrontPaymentPaidInShares contextRef="c-66" decimals="-3" id="f-406" unitRef="usd">25100000</smmt:CollaborativeArrangementRightsAndObligationsUpfrontPaymentPaidInShares>
    <smmt:CashPaymentForCollaborativeArrangementUpfrontPayment contextRef="c-67" decimals="-3" id="f-407" unitRef="usd">200000000</smmt:CashPaymentForCollaborativeArrangementUpfrontPayment>
    <smmt:InProcessResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-408" unitRef="usd">520915000</smmt:InProcessResearchAndDevelopmentExpense>
    <smmt:CashPaymentForCollaborativeArrangementUpfrontPayment contextRef="c-65" decimals="-3" id="f-409" unitRef="usd">474900000</smmt:CashPaymentForCollaborativeArrangementUpfrontPayment>
    <smmt:CollaborativeArrangementRightsAndObligationsUpfrontPaymentSharesOfCommonStockIssuedInLieuOfCash
      contextRef="c-66"
      decimals="INF"
      id="f-410"
      unitRef="shares">10000000</smmt:CollaborativeArrangementRightsAndObligationsUpfrontPaymentSharesOfCommonStockIssuedInLieuOfCash>
    <smmt:StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement contextRef="c-66" decimals="-3" id="f-411" unitRef="usd">45900000</smmt:StockIssuedDuringPeriodValueInLieuOfCashForCollaborativeArrangement>
    <smmt:CollaborativeArrangementRightsAndObligationsDirectTransactionCosts contextRef="c-65" decimals="-3" id="f-412" unitRef="usd">115000</smmt:CollaborativeArrangementRightsAndObligationsDirectTransactionCosts>
    <smmt:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments contextRef="c-68" decimals="-3" id="f-413" unitRef="usd">4500000000</smmt:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments>
    <smmt:CollaborativeArrangementRightsAndObligationsPotentialRegulatoryMilestonePayments contextRef="c-68" decimals="-3" id="f-414" unitRef="usd">1050000000</smmt:CollaborativeArrangementRightsAndObligationsPotentialRegulatoryMilestonePayments>
    <smmt:CollaborativeArrangementRightsAndObligationsPotentialCommercialMilestonePayments contextRef="c-68" decimals="-3" id="f-415" unitRef="usd">3450000000</smmt:CollaborativeArrangementRightsAndObligationsPotentialCommercialMilestonePayments>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-416">Segment Reporting &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s chief operating decision makers (the &#x201c;CODM function&#x201d;), which are the Company&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s Chief Executive Officers, Mr. Duggan and Dr. Zanganeh, utilize consolidated financial information to make decisions about allocating resources and assessing performance for the entire Company. The CODM function approves of key operating and strategic decisions, including key decisions in clinical development and clinical operating activities, entering into significant contracts, such as revenue contracts and collaboration agreements and approves the Company&#x2019;s consolidated operating budget. The CODM function views the Company&#x2019;s operations and manages its business as a single reportable operating segment. The Company&#x2019;s single operating segment covers the Company&#x2019;s research and development activities, primarily comprising of oncology product research activities (including ivonescimab), antibiotic pipeline research activities, and CDI program activities. As the Company operates in one operating segment, all required financial segment information can be found in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates in two geographic regions: the U.K. and the U.S. The following table summarizes the Company&#x2019;s long-lived assets, which include the Company&#x2019;s property and equipment, net and right-of-use assets by geography: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; The decrease of long-lived assets in the United Kingdom is primarily attributed to the Company exiting its lease for its Sawston, United Kingdom location.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; The increase of long-lived assets in the United States is primarily attributed to additional right-of-use assets recorded related to the Company&#x2019;s amendment to its sublease agreement during the period for its Menlo Park, California, U.S. location.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For details of revenue from external customers by geography refer to Note 8.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-417"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfCountriesInWhichEntityOperates
      contextRef="c-4"
      decimals="INF"
      id="f-418"
      unitRef="country">2</us-gaap:NumberOfCountriesInWhichEntityOperates>
    <us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock contextRef="c-1" id="f-419">The following table summarizes the Company&#x2019;s long-lived assets, which include the Company&#x2019;s property and equipment, net and right-of-use assets by geography: &lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; The decrease of long-lived assets in the United Kingdom is primarily attributed to the Company exiting its lease for its Sawston, United Kingdom location.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; The increase of long-lived assets in the United States is primarily attributed to additional right-of-use assets recorded related to the Company&#x2019;s amendment to its sublease agreement during the period for its Menlo Park, California, U.S. location.&lt;/span&gt;&lt;/div&gt;</us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock>
    <us-gaap:NoncurrentAssets contextRef="c-69" decimals="-3" id="f-420" unitRef="usd">808000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-70" decimals="-3" id="f-421" unitRef="usd">2517000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-71" decimals="-3" id="f-422" unitRef="usd">5254000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-72" decimals="-3" id="f-423" unitRef="usd">2564000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-4" decimals="-3" id="f-424" unitRef="usd">6062000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-5" decimals="-3" id="f-425" unitRef="usd">5081000</us-gaap:NoncurrentAssets>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-426">Revenue&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized no revenue and $705 during the year ended December 31, 2023 and 2022, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognized during the year ended December 31, 2022 consists of amounts received from the Company&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s license and commercialization agreement with Eurofarma Laborat&#xf3;rios S.A. Revenue recognized during the year ended December 31, 2022 was from Latin America. The analysis of revenue by geography has been identified on the basis of the geographical location of each collaboration partner.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the deferred revenue relating to Eurofarma Laborat&#xf3;rios S.A. and deferred other income relating to BARDA (as defined in Note 9):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.653%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.833%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.080%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.390%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning deferred revenue and other income, January 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount of deferred revenue and other income recognized in the statement of operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,790)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(546)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending deferred revenue and other income, December 31&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 9 below for further details regarding other income recognized under the BARDA contract.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-427" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-3" id="f-428" unitRef="usd">705000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="c-1" id="f-429">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the deferred revenue relating to Eurofarma Laborat&#xf3;rios S.A. and deferred other income relating to BARDA (as defined in Note 9):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.653%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.833%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.080%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.390%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning deferred revenue and other income, January 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount of deferred revenue and other income recognized in the statement of operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,790)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(546)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending deferred revenue and other income, December 31&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability contextRef="c-5" decimals="-3" id="f-430" unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-11" decimals="-3" id="f-431" unitRef="usd">7939000</us-gaap:ContractWithCustomerLiability>
    <smmt:ContractWithCustomerLiabilityAdditions contextRef="c-1" decimals="-3" id="f-432" unitRef="usd">0</smmt:ContractWithCustomerLiabilityAdditions>
    <smmt:ContractWithCustomerLiabilityAdditions contextRef="c-6" decimals="-3" id="f-433" unitRef="usd">1397000</smmt:ContractWithCustomerLiabilityAdditions>
    <smmt:ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance contextRef="c-1" decimals="-3" id="f-434" unitRef="usd">0</smmt:ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance>
    <smmt:ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance contextRef="c-6" decimals="-3" id="f-435" unitRef="usd">8790000</smmt:ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance>
    <smmt:ContractWithCustomerLiabilityForeignCurrencyTranslation contextRef="c-1" decimals="-3" id="f-436" unitRef="usd">0</smmt:ContractWithCustomerLiabilityForeignCurrencyTranslation>
    <smmt:ContractWithCustomerLiabilityForeignCurrencyTranslation contextRef="c-6" decimals="-3" id="f-437" unitRef="usd">-546000</smmt:ContractWithCustomerLiabilityForeignCurrencyTranslation>
    <us-gaap:ContractWithCustomerLiability contextRef="c-4" decimals="-3" id="f-438" unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-5" decimals="-3" id="f-439" unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:OtherOperatingIncomeAndExpenseTextBlock contextRef="c-1" id="f-440">Other Operating Income, net&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the components of other operating income by category:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Funding income from BARDA (as defined below)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Grant income from CARB-X (as defined below)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;BARDA (as defined below)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2017, the Company was awarded a funding contract from the Biomedical Advanced Research and Development Authority (&#x201c;BARDA&#x201d;), part of the Office of the Assistant Secretary for Preparedness and Response at the United States Department of Health and Human Services, in support of the Company&#x2019;s Ri-CoDIFy clinical trials and clinical development of ridinilazole. The awarded contract was originally worth up to $62,000. In June 2019 and again in January 2020, BARDA increased the value of the contract such that it is now worth up to $72,500 and brought the total amount of committed funding to $62,400. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The remaining federal government funding is dependent on BARDA in its sole discretion exercising the final independent option work segment, upon the achievement by the Company of certain agreed-upon milestones for ridinilazole. This option work segment was never exercised by BARDA. The contract ran through April 2022 and was extended through December 2022 &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as a no cost contract, solely to close out open activities. As of December 31, 2022, based on translation of historical foreign currency amounts in the period of recognition, the Company has recognized $59,203 of cumulative income since contract inception. As a result of the Company&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s decision, on September 28, 2022, to not pursue further internal clinical development of ridinilazole and seek partners or a divestiture related to ridinilazole as a path forward for the clinical development of the asset, the Company recorded expenses for the remaining clinical trial costs associated with the close out activities of ridinilazole and recognized the remainder of the deferred income that had been received from BARDA prior to the expenses being recognized during the third quarter of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and development credits&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income from tax credits, consist of R&amp;amp;D tax credits received in the U.K. The Company benefits from two U.K. research and development tax credit cash rebate regimes: Small and Medium Enterprise Program (&#x201c;SME, Program&#x201d;) and the Research and Development Expenditure Credit Program (&#x201c;RDEC Program&#x201d;). Qualifying expenditures largely comprise of employment costs for research staff, consumables, a proportion of relevant, permitted sub-contract costs and certain internal overhead costs incurred as part of research projects for which the Company does not receive income. Tax credits related to the SME Program and RDEC Program are recorded as other operating income in the consolidated statements of operations and other comprehensive loss. Under both schemes, the Company receives cash payments that are not dependent on the Company&#x2019;s pre-tax net income levels.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on criteria established by His Majesty&#x2019;s Revenue and Customs (&#x201c;HMRC&#x201d;), a portion of expenditures being carried out in relation to the Company&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s pipeline research and development, clinical trials management and third-party manufacturing development activities are eligible for the SME regime and the Company expects such elements of research and development expenditure incurred in its UK entities will also continue to be eligible for the SME regime for future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2023 and 2022, the current and long-term research and development tax credit receivable was $1,807 and $5,766, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;CARB-X (as defined below)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the Company announced the selection of a new preclinical candidate, SMT-738, from the DDS-04 series for development in the fight against multi-drug resistant infections, specifically Carbapenem-resistant Enterobacteriaceae (&#x201c;CRE&#x201d;) infections. Simultaneously, the Company announced it had received an award from the Trustees of Boston University under the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator program (&#x201c;CARB-X&#x201d;) to progress this candidate through preclinical development and Phase Ia clinical trials. The award commits initial funding of up to $4,100, with the possibility of up to another $3,700 based on the achievement of future milestones. As of December 31, 2023, based on translation of historical foreign currency amounts in the period that the amounts were recognized, the Company has recognized $2,920 of cumulative income since contract inception. During the quarter ended September 30, 2022, CARB-X announced changes to its funding arrangements and terms and conditions. As a result, the current arrangement concluded as of June 30, 2022, however the Company has the ability to recognize reimbursements for any milestone payments related to work incurred subsequent to this date in accordance with this agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:OtherOperatingIncomeAndExpenseTextBlock>
    <smmt:ScheduleOfOtherOperatingIncomeExpenseNetTableTextBlock contextRef="c-1" id="f-441">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the components of other operating income by category:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Funding income from BARDA (as defined below)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Grant income from CARB-X (as defined below)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</smmt:ScheduleOfOtherOperatingIncomeExpenseNetTableTextBlock>
    <smmt:GrantFundingArrangementIncomeEarned contextRef="c-73" decimals="-3" id="f-442" unitRef="usd">0</smmt:GrantFundingArrangementIncomeEarned>
    <smmt:GrantFundingArrangementIncomeEarned contextRef="c-74" decimals="-3" id="f-443" unitRef="usd">8085000</smmt:GrantFundingArrangementIncomeEarned>
    <smmt:ResearchAndDevelopmentTaxCredit contextRef="c-1" decimals="-3" id="f-444" unitRef="usd">946000</smmt:ResearchAndDevelopmentTaxCredit>
    <smmt:ResearchAndDevelopmentTaxCredit contextRef="c-6" decimals="-3" id="f-445" unitRef="usd">4523000</smmt:ResearchAndDevelopmentTaxCredit>
    <smmt:GrantFundingArrangementIncomeEarned contextRef="c-75" decimals="-3" id="f-446" unitRef="usd">45000</smmt:GrantFundingArrangementIncomeEarned>
    <smmt:GrantFundingArrangementIncomeEarned contextRef="c-76" decimals="-3" id="f-447" unitRef="usd">1808000</smmt:GrantFundingArrangementIncomeEarned>
    <smmt:OtherOperatingIncomeOther contextRef="c-1" decimals="-3" id="f-448" unitRef="usd">10000</smmt:OtherOperatingIncomeOther>
    <smmt:OtherOperatingIncomeOther contextRef="c-6" decimals="-3" id="f-449" unitRef="usd">0</smmt:OtherOperatingIncomeOther>
    <us-gaap:OtherOperatingIncome contextRef="c-1" decimals="-3" id="f-450" unitRef="usd">1001000</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome contextRef="c-6" decimals="-3" id="f-451" unitRef="usd">14416000</us-gaap:OtherOperatingIncome>
    <smmt:GrantFundingArrangementMaximumFundingValue contextRef="c-77" decimals="-3" id="f-452" unitRef="usd">62000000</smmt:GrantFundingArrangementMaximumFundingValue>
    <smmt:GrantFundingArrangementMaximumFundingValue contextRef="c-73" decimals="-3" id="f-453" unitRef="usd">72500000</smmt:GrantFundingArrangementMaximumFundingValue>
    <smmt:GrantFundingArrangementCommittedFundingTotal contextRef="c-73" decimals="-3" id="f-454" unitRef="usd">62400000</smmt:GrantFundingArrangementCommittedFundingTotal>
    <smmt:GrantFundingArrangementIncomeEarned contextRef="c-78" decimals="-3" id="f-455" unitRef="usd">59203000</smmt:GrantFundingArrangementIncomeEarned>
    <smmt:ResearchAndDevelopmentTaxCreditReceivable contextRef="c-4" decimals="-3" id="f-456" unitRef="usd">1807000</smmt:ResearchAndDevelopmentTaxCreditReceivable>
    <smmt:ResearchAndDevelopmentTaxCreditReceivable contextRef="c-5" decimals="-3" id="f-457" unitRef="usd">5766000</smmt:ResearchAndDevelopmentTaxCreditReceivable>
    <smmt:GrantFundingArrangementMaximumFundingValue contextRef="c-79" decimals="-3" id="f-458" unitRef="usd">4100000</smmt:GrantFundingArrangementMaximumFundingValue>
    <smmt:GrantFundingArrangementMilestoneFundingIncrease contextRef="c-79" decimals="-3" id="f-459" unitRef="usd">3700000</smmt:GrantFundingArrangementMilestoneFundingIncrease>
    <smmt:GrantFundingArrangementIncomeEarned contextRef="c-80" decimals="-3" id="f-460" unitRef="usd">2920000</smmt:GrantFundingArrangementIncomeEarned>
    <us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock contextRef="c-1" id="f-461">Other (Expense) Income, net&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the components of other (expense) income:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense on promissory notes payable to related parties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,401)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification of cumulative currency translation gain&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (expense) income, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,278)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,693)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_____________________&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 17, 2023, the Company dissolved the following dormant entities; Summit (Cambridge) Limited, Summit (Wales) Limited, Summit Corporation Employee Benefit Trust Company Limited, Summit Corporation Limited, Summit Discovery 1 Limited and Summit Infectious Diseases Limited. As a result, the Company reclassified $419 of cumulative foreign currency translation adjustments from accumulated other comprehensive loss relating to these entities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December 31, 2023, other expense, net primarily consisted of loan interest expense incurred related to the promissory notes described in Note 18. These amounts are partially offset in the year ended December 31, 2023 by interest income related to the Company&#x2019;s money market funds and the Company&#x2019;s short-term investments in U.S. treasury securities and favorable changes in foreign currency.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December 31, 2022, other expense, net primarily consisted of unfavorable changes in foreign currency, loan interest expense incurred related to the promissory notes described in Note 18, partially offset by investment income related to the Company&#x2019;s money market funds and investments in highly liquid U.S. treasury securities, which are classified as cash equivalents as of December&#160;31, 2022.&lt;/span&gt;</us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="c-1" id="f-462">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the components of other (expense) income:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense on promissory notes payable to related parties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,401)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification of cumulative currency translation gain&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (expense) income, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,278)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,693)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_____________________&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 17, 2023, the Company dissolved the following dormant entities; Summit (Cambridge) Limited, Summit (Wales) Limited, Summit Corporation Employee Benefit Trust Company Limited, Summit Corporation Limited, Summit Discovery 1 Limited and Summit Infectious Diseases Limited. As a result, the Company reclassified $419 of cumulative foreign currency translation adjustments from accumulated other comprehensive loss relating to these entities.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-1" decimals="-3" id="f-463" unitRef="usd">613000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-6" decimals="-3" id="f-464" unitRef="usd">-4109000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:InterestExpenseDebt contextRef="c-1" decimals="-3" id="f-465" unitRef="usd">16461000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-6" decimals="-3" id="f-466" unitRef="usd">4401000</us-gaap:InterestExpenseDebt>
    <us-gaap:InvestmentIncomeNonoperating contextRef="c-1" decimals="-3" id="f-467" unitRef="usd">10403000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating contextRef="c-6" decimals="-3" id="f-468" unitRef="usd">1513000</us-gaap:InvestmentIncomeNonoperating>
    <smmt:CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome contextRef="c-1" decimals="-3" id="f-469" unitRef="usd">419000</smmt:CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome>
    <smmt:CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome contextRef="c-6" decimals="-3" id="f-470" unitRef="usd">0</smmt:CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-471" unitRef="usd">-252000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-6" decimals="-3" id="f-472" unitRef="usd">304000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-473" unitRef="usd">-5278000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-6" decimals="-3" id="f-474" unitRef="usd">-6693000</us-gaap:NonoperatingIncomeExpense>
    <smmt:CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome contextRef="c-81" decimals="-3" id="f-475" unitRef="usd">419000</smmt:CumulativeCurrencyTranslationGainsLossesRealizedUponSaleOrLiquidationReclassifiedFromOtherComprehensiveIncome>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-476">Income Tax&#160;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is primarily subject to corporation taxes in the U.S. and the U.K.. The calculation of the Company&#x2019;s tax provision involves the application of both U.S. and U.K. tax law and requires judgment and estimates.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes is determined using the asset and liability approach. Tax laws may require items to be included in tax filings at different times than the items are reflected in the financial statements. A current asset or liability is recognized for the estimated taxes receivable or payable for the current year. Deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. Deferred taxes are initially recognized at enacted tax rates in force at the time of initial recognition and are subsequently adjusted for any enacted changes in tax rates and tax laws. Subsequent changes to deferred taxes originally recognized in equity are recognized in income. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The Company has recorded a full valuation allowance against the deferred tax assets in excess of its deferred tax liabilities, as the deferred tax liability represents future reversals of existing taxable temporary differences. The Company records interest and penalties related to income tax matters as part of income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for uncertainty in income taxes by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed as the amount of benefit to recognize in the consolidated financial statements. The amount of benefits that may be used is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate, as well as the related net interest and penalties. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the Company&#x2019;s loss before income taxes are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(499,810)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46,868)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(115,118)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,914)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(614,928)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78,782)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has not recognized a current or deferred provision for federal, state or non-United States income taxes in either of the years ending December 31, 2023 or 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major components of deferred tax assets and liabilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.468%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development credit carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Section 174 Research and Development Capitalization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,085)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(226)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,259)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(877)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets before valuation allowance &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,751&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,016&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84,751)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64,016)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated the positive and negative evidence bearing upon its ability to realize its deferred tax assets, which are comprised primarily of net operating loss carryforwards and research and development costs capitalized for tax purposes. Management has considered the Company&#x2019;s history of cumulative net losses in the United States (&#x201c;U.S.&#x201d;) and the United Kingdom (&#x201c;U.K.&#x201d;), estimated future taxable income, as well as prudent and feasible tax planning strategies, and has concluded that it is more likely than not that the Company will not realize the benefits of its U.S. federal and state deferred tax assets and U.K. deferred tax assets. Accordingly, a full valuation allowance has been established against these net deferred tax assets as of December 31, 2023 and 2022, respectively. The Company reevaluates the positive and negative evidence at each reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in the valuation allowance was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.468%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Valuation allowance as of beginning of year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64,016)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51,746)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net increase recorded to the income tax provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,735)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Valuation allowance as of end of year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84,751)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64,016)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2023 and 2022, the Company had U.S. Federal gross operating loss carryforwards of approximately $48,184 and $11,620, respectively, which may be available to offset future income tax liabilities. The 2017 Tax Cuts and Jobs Act (&#x201c;TCJA&#x201d;) will generally allow losses incurred after 2017 to be carried over indefinitely, but will generally limit the net operating loss deduction to the lesser of the net operating loss carryover or 80% of a corporation&#x2019;s taxable income (subject to Section 382 of the Internal Revenue Code of 1986, as amended). In addition, the Company has approximately $3,705 in U.S. State gross loss carryforwards which expire through various dates through 2043 and as of December 31, 2023, the Company had an estimated U.S. federal and state research and development tax credit carryforwards of $2,900 and $900, respectively, which may be available to offset future tax liabilities, and each begin to expire in 2041 and 2037, respectively. The Company also had approximately $194,454 in U.K. gross loss carryforwards available to use against future taxable profits on a year-by-year basis. To the extent that U.K. taxable profits exceed &#xa3;5,000 in each year, the loss available to utilize against profits in excess of &#xa3;5,000 will be restricted to 50%. The U.K. loss carryforwards do not lapse and therefore, the full amount will be relieved over time provided there are sufficient profits against which the losses can be utilized. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Utilization of the U.S. net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986 due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has not completed a study to assess whether a change of ownership has occurred, or whether there have been multiple ownership changes since its formation. Any limitation may result in the loss of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.K. tax losses are subject to additional restrictions where there is a change in ownership in the business and certain other conditions are met. An ownership change of a UK tax resident company would occur where (directly or indirectly) a single person acquires more than half of the ordinary share capital of a company, or two or more persons each acquire a holding of at least 5% of the ordinary share capital of a company and these holdings together amount to more than half the ordinary share capital of a company. Where a change in ownership has occurred, and within three years prior to that change in ownership and five years afterwards, there is a major change in the nature and conduct of trade of that company or the trade of that business becomes small or negligible, any losses carried forward will be extinguished from the point of the change in ownership. In addition, losses accrued subsequent to April 1, 2017 will be extinguished on a change of ownership when there is a major change in the nature or conduct of a company&#x2019;s business, or where there is a major change in the scale of that business, or a company ceases to carry on a particular trade or business. The Company has not completed a study to assess whether a change of ownership has occurred since its formation, or whether there has been a major change in the Company&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s business that would restrict the U.K. tax losses. Any limitation may result in the loss of a portion of the net operating loss carryforwards before utilization.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2017 Tax Cuts and Jobs Act (&#x201c;TCJA&#x201d;) created a requirement that US corporations include in income earnings of certain controlled foreign corporations (&#x201c;CFC&#x201d;) under the global intangible low taxed income (&#x201c;GILTI&#x201d;) regime. The Company is allowed to make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as period expense only. The Company has elected to account for GILTI in the year the tax is incurred and include the current tax impact of GILTI in the effective tax rate. Given the Company&#x2019;s loss position in the U.S. and the valuation allowance recorded against &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;its U.S. net deferred tax assets, these provisions have not had a material impact on the Company&#x2019;s consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IRC Section 174 generally permitted taxpayers that incurred research expenses to deduct them in the current year. For tax years beginning before January 1, 2022, taxpayers were able to make an election with respect to research and experimental (&#x201c;R&amp;amp;E&#x201d;) expenditures incurred in connection with a trade or business to either currently deduct or defer and amortize such expenditures.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The TCJA amended this provision to require that R&amp;amp;E expenditures be capitalized and amortized, but delayed the effective date of this amendment, which applies to tax years beginning January 1, 2022 or later. As such, the changes to IRC Section 174 pursuant to the TCJA are currently applicable to the Company for the 2022 tax year. R&amp;amp;E expenditures attributable to U.S. based research must be amortized over a period of five years and R&amp;amp;E expenditures attributable to research conducted outside of the U.S. must be amortized over a period of 15 years. As such, the Company is capitalizing $73,129 R&amp;amp;E expenditures with a net adjustment of $65,816&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to account for the capitalization and amortization of R&amp;amp;D expenses incurred in the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the Company&#x2019;s effective tax rate to the U.S. federal statutory rate is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. federal income tax statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Refundable research and development tax credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of foreign operations taxed at various rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the U.K., the Company is entitled to a research and development tax relief for small and medium-sized enterprises which allows the Company an enhanced deduction rate of 230% (up to March 31, 2023) and 186% (from April 1, 2023) on qualifying research and development expenditure (the tax relief). If the Company incurs tax losses, it is entitled to surrender the lesser of unrelieved tax loss sustained and the tax relief. As the realization of the tax relief does not depend on generation of future taxable income or the Company&#x2019;s ongoing tax status or tax position, the Company does not consider the tax relief as an element of income tax accounting under ASC 740. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December 31, 2023 and 2022, the Company recognized research and development tax relief of $946 and $4,523 respectively, which is included in other operating income in the consolidated statements of operations and other comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is the intention of the Company to reinvest the earnings of its non-U.S. subsidiaries in those operations and not to repatriate the earnings to the U.S. Accordingly, the Company does not provide for deferred taxes on differences between financial reporting and tax basis in its investments in foreign subsidiaries as they are considered permanent in duration or are not expected to reverse in the foreseeable future. As of December 31, 2023, there are no unremitted earnings of the Company&#x2019;s foreign subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records unrecognized tax benefits in accordance with ASC 740-10, Income Taxes. ASC 740-10 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in the Company&#x2019;s income tax return and also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. As of December 31, 2023 and 2022, the Company had total unrecognized tax benefits of $1,064 and $0, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the Company&#x2019;s full valuation allowance, the unrecognized tax benefits would not materially impact the Company&#x2019;s effective tax rate when recognized.  The Company does not anticipate the total amounts of unrecognized tax benefits will significantly increase or decrease in the next 12 months. The Company&#x2019;s policy is to recognize interest and penalties related to uncertain tax positions as part of its income tax provision. For the years ended December 31, 2023 and 2022, the Company had no interest or penalties related to unrecognized tax benefits.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of unrecognized tax benefits from continuing operations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.972%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.627%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.629%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits, beginning of year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increases related to prior year tax positions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Decreases related to prior year tax positions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increases related to current year tax positions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits, end of year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal, state, and foreign jurisdictions, where applicable. the U.S. In the U.S., tax years from 2020 remain subject to examination by the U.S. Internal Revenue Service and state tax authorities. The Company is not currently under examination by the Internal Revenue Service or any other jurisdiction for years 2020 through present. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may be adjusted upon examination by the Internal Revenue Service or state tax authorities to the extent utilized in a future period. In the U.K., tax returns for the year ended December 31, 2022 remains subject to examination by HMRC.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c-1" id="f-477">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the Company&#x2019;s loss before income taxes are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(499,810)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46,868)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(115,118)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,914)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(614,928)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78,782)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-1" decimals="-3" id="f-478" unitRef="usd">-499810000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-6" decimals="-3" id="f-479" unitRef="usd">-46868000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-1" decimals="-3" id="f-480" unitRef="usd">-115118000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-6" decimals="-3" id="f-481" unitRef="usd">-31914000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-482" unitRef="usd">-614928000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-6" decimals="-3" id="f-483" unitRef="usd">-78782000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-1" decimals="INF" id="f-484" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-1" decimals="INF" id="f-485" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-6" decimals="INF" id="f-486" unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-1" decimals="INF" id="f-487" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-6" decimals="INF" id="f-488" unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-6" decimals="INF" id="f-489" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-6" decimals="INF" id="f-490" unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-6" decimals="INF" id="f-491" unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-6" decimals="INF" id="f-492" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-6" decimals="INF" id="f-493" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-1" decimals="INF" id="f-494" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-6" decimals="INF" id="f-495" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-496">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major components of deferred tax assets and liabilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.468%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development credit carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Section 174 Research and Development Capitalization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,085)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(226)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,259)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(877)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets before valuation allowance &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,751&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,016&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84,751)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64,016)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-4" decimals="-3" id="f-497" unitRef="usd">58975000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-5" decimals="-3" id="f-498" unitRef="usd">52948000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-4" decimals="-3" id="f-499" unitRef="usd">4522000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-5" decimals="-3" id="f-500" unitRef="usd">1723000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-4" decimals="-3" id="f-501" unitRef="usd">4128000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-5" decimals="-3" id="f-502" unitRef="usd">3879000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <smmt:DeferredTaxAssetsCapitalizedResearchAndDevelopment contextRef="c-4" decimals="-3" id="f-503" unitRef="usd">15982000</smmt:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <smmt:DeferredTaxAssetsCapitalizedResearchAndDevelopment contextRef="c-5" decimals="-3" id="f-504" unitRef="usd">3553000</smmt:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <smmt:DeferredTaxAssetsLeasingArrangements contextRef="c-4" decimals="-3" id="f-505" unitRef="usd">1143000</smmt:DeferredTaxAssetsLeasingArrangements>
    <smmt:DeferredTaxAssetsLeasingArrangements contextRef="c-5" decimals="-3" id="f-506" unitRef="usd">737000</smmt:DeferredTaxAssetsLeasingArrangements>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-4" decimals="-3" id="f-507" unitRef="usd">1260000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-5" decimals="-3" id="f-508" unitRef="usd">2053000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-4" decimals="-3" id="f-509" unitRef="usd">86010000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-5" decimals="-3" id="f-510" unitRef="usd">64893000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-4" decimals="-3" id="f-511" unitRef="usd">1085000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-5" decimals="-3" id="f-512" unitRef="usd">651000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="c-4" decimals="-3" id="f-513" unitRef="usd">174000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="c-5" decimals="-3" id="f-514" unitRef="usd">226000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-4" decimals="-3" id="f-515" unitRef="usd">1259000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-5" decimals="-3" id="f-516" unitRef="usd">877000</us-gaap:DeferredIncomeTaxLiabilities>
    <smmt:DeferredTaxAssetsLiabilities contextRef="c-4" decimals="-3" id="f-517" unitRef="usd">84751000</smmt:DeferredTaxAssetsLiabilities>
    <smmt:DeferredTaxAssetsLiabilities contextRef="c-5" decimals="-3" id="f-518" unitRef="usd">64016000</smmt:DeferredTaxAssetsLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-4" decimals="-3" id="f-519" unitRef="usd">84751000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-3" id="f-520" unitRef="usd">64016000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-4" decimals="-3" id="f-521" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-5" decimals="-3" id="f-522" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:SummaryOfValuationAllowanceTextBlock contextRef="c-1" id="f-523">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in the valuation allowance was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.468%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Valuation allowance as of beginning of year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64,016)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51,746)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net increase recorded to the income tax provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,735)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Valuation allowance as of end of year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84,751)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64,016)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-3" id="f-524" unitRef="usd">64016000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-11" decimals="-3" id="f-525" unitRef="usd">51746000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-1" decimals="-3" id="f-526" unitRef="usd">20735000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-6" decimals="-3" id="f-527" unitRef="usd">12270000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-4" decimals="-3" id="f-528" unitRef="usd">84751000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-3" id="f-529" unitRef="usd">64016000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards contextRef="c-82" decimals="-3" id="f-530" unitRef="usd">48184000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-83" decimals="-3" id="f-531" unitRef="usd">11620000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-84" decimals="-3" id="f-532" unitRef="usd">3705000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-82" decimals="-3" id="f-533" unitRef="usd">2900000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-84" decimals="-3" id="f-534" unitRef="usd">900000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards contextRef="c-85" decimals="-3" id="f-535" unitRef="usd">194454000</us-gaap:OperatingLossCarryforwards>
    <smmt:ResearchAndDevelopmentExpenseCapitalizedAmount contextRef="c-4" decimals="-3" id="f-536" unitRef="usd">73129000</smmt:ResearchAndDevelopmentExpenseCapitalizedAmount>
    <smmt:ResearchAndDevelopmentExpenseAmortizableAmount contextRef="c-4" decimals="-3" id="f-537" unitRef="usd">65816000</smmt:ResearchAndDevelopmentExpenseAmortizableAmount>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-538">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the Company&#x2019;s effective tax rate to the U.S. federal statutory rate is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. federal income tax statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Refundable research and development tax credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of foreign operations taxed at various rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="3" id="f-539" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-6" decimals="3" id="f-540" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="3" id="f-541" unitRef="number">-0.034</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-6" decimals="3" id="f-542" unitRef="number">-0.168</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <smmt:EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent contextRef="c-1" decimals="3" id="f-543" unitRef="number">-0.003</smmt:EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent>
    <smmt:EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent contextRef="c-6" decimals="3" id="f-544" unitRef="number">0.036</smmt:EffectiveIncomeTaxRateReconciliationTaxCreditRefundableResearchPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-1" decimals="3" id="f-545" unitRef="number">-0.170</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-6" decimals="3" id="f-546" unitRef="number">0.021</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent contextRef="c-1" decimals="3" id="f-547" unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent contextRef="c-6" decimals="3" id="f-548" unitRef="number">-0.022</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-1" decimals="3" id="f-549" unitRef="number">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-6" decimals="3" id="f-550" unitRef="number">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-551" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-6" decimals="3" id="f-552" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <smmt:ResearchAndDevelopmentTaxCredit contextRef="c-1" decimals="-3" id="f-553" unitRef="usd">946000</smmt:ResearchAndDevelopmentTaxCredit>
    <smmt:ResearchAndDevelopmentTaxCredit contextRef="c-6" decimals="-3" id="f-554" unitRef="usd">4523000</smmt:ResearchAndDevelopmentTaxCredit>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-4" decimals="-3" id="f-555" unitRef="usd">1064000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-5" decimals="-3" id="f-556" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-4" decimals="-3" id="f-557" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-5" decimals="-3" id="f-558" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="c-1" id="f-559">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of unrecognized tax benefits from continuing operations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.972%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.627%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.629%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits, beginning of year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increases related to prior year tax positions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Decreases related to prior year tax positions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increases related to current year tax positions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits, end of year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-5" decimals="-3" id="f-560" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-11" decimals="-3" id="f-561" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-562" unitRef="usd">610000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-6" decimals="-3" id="f-563" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-564" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-6" decimals="-3" id="f-565" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-566" unitRef="usd">454000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-6" decimals="-3" id="f-567" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-4" decimals="-3" id="f-568" unitRef="usd">1064000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-5" decimals="-3" id="f-569" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-570">Net Loss per Share &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted net loss per share: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.198%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(614,928)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78,782)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic weighted average number of shares of common stock outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;619,646,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,336,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted weighted average number of shares of common stock outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;619,646,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,336,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the diluted net loss by the weighted-average number of common shares outstanding for the period, including potentially dilutive common shares. Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share for all periods, as the inclusion of all potential common share equivalents outstanding would have been anti-dilutive. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because the 2023 Rights Offering (as defined in Note 20) exercise price of $1.05 per share was less than the closing price of $1.82 per share on March 1, 2023, the expiration of the , the Company has retroactively adjusted earnings per share and weighted average number of shares outstanding for the bonus element for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities were excluded from the computation of the diluted net loss per share of common stock for the periods presented because their effect would have been anti-dilutive: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.198%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.523%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,209,289&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,476,359&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,015,642&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,821,137&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares expected to be purchased under employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,163&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,475&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,380,094&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,526,971&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options that are outstanding and contain performance-based or market-based vesting criteria for which the performance or market conditions have not been met are excluded from the presentation of common stock equivalents outstanding in the chart above. Refer to Note 21 for further information on market-based awards.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-571">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted net loss per share: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.198%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(614,928)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78,782)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic weighted average number of shares of common stock outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;619,646,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,336,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted weighted average number of shares of common stock outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;619,646,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,336,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-572" unitRef="usd">-614928000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-573" unitRef="usd">-78782000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-574" unitRef="shares">619646180</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="0" id="f-575" unitRef="shares">193336063</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-576" unitRef="shares">619646180</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="0" id="f-577" unitRef="shares">193336063</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-578"
      unitRef="usdPerShare">-0.99</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-579"
      unitRef="usdPerShare">-0.41</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-580"
      unitRef="usdPerShare">-0.99</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-581"
      unitRef="usdPerShare">-0.41</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-42"
      decimals="2"
      id="f-582"
      unitRef="usdPerShare">1.05</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SharePrice
      contextRef="c-86"
      decimals="2"
      id="f-583"
      unitRef="usdPerShare">1.82</us-gaap:SharePrice>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-584">&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities were excluded from the computation of the diluted net loss per share of common stock for the periods presented because their effect would have been anti-dilutive: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.198%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.523%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,209,289&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,476,359&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,015,642&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,821,137&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares expected to be purchased under employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,163&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,475&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,380,094&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,526,971&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-87" decimals="0" id="f-585" unitRef="shares">54209289</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-88" decimals="0" id="f-586" unitRef="shares">19476359</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-89" decimals="0" id="f-587" unitRef="shares">5015642</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-90" decimals="0" id="f-588" unitRef="shares">5821137</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-91" decimals="0" id="f-589" unitRef="shares">155163</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-92" decimals="0" id="f-590" unitRef="shares">229475</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-591" unitRef="shares">59380094</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-6" decimals="0" id="f-592" unitRef="shares">25526971</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-593">Goodwill and Intangible Assets&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2017, the Company expanded its activities in the field of infectious diseases with the acquisition of Discuva Limited, a privately held United Kingdom-based company. Through this acquisition, the Company obtained a bacterial genetics platform and a suite of software-based technologies (the &#x201c;Discuva Platform&#x201d;), which facilitates the discovery and development of new mechanism antibiotics. This resulted in the recognition of goodwill of &#xa3;1.5&#160;million, which is translated into U.S. dollars at each reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses goodwill for impairment on an annual basis as of December 31 or more frequently when events and circumstances occur indicating that recorded goodwill may be impaired.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2023, the Company performed its annual impairment assessment of goodwill and determined that it is more likely than not that the fair value of the reporting unit exceeds its carrying amount. There have been no cumulative goodwill impairment charges recognized to date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2023 and 2022, goodwill was $1,893 and $1,798, respectively. Changes year over year are the result of changes in foreign currency.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of the Company&#x2019;s acquired intangible assets are comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.301%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.961%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.681%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.717%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.961%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.681%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.724%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated amortization and impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated amortization and impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Utrophin program acquired&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,015)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discuva platform acquired&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,583)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Option over non-financial asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(859)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(816)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(140)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(133)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,582)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,864)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2023, the Company dissolved the wholly-owned subsidiary, Muox Limited, a dormant entity. The Utrophin program intangible assets, which arose from the Muox Limited acquisition were fully impaired and have been removed from the Company&#x2019;s accounting records.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In conjunction with the significant change in the Company&#x2019;s strategy and shift in focus to the therapeutic area of oncology, the Company determined that it would cease further investment in the Discuva Platform. Management concluded that the carrying amount of the acquired Discuva Platform intangible asset may not be recoverable and performed an assessment to calculate the fair value of the asset using a probability-weighted approach which was compared to the carrying value of the asset. An impairment charge of $8,468 which represented the carrying value of the Discuva Platform was recognized during the year ended December 31, 2022. This impairment charge is presented as &lt;span style="-sec-ix-hidden:f-630"&gt;impairment of intangible assets&lt;/span&gt; in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;Changes year over year in the gross and accumulation amortization amounts of intangible assets are the result of changes in foreign currency. Amortization expense was $0 and $914 for the years ended December 31, 2023 and 2022, respectively.</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-93" decimals="-5" id="f-594" unitRef="gbp">1500000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss contextRef="c-4" decimals="-3" id="f-595" unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:Goodwill contextRef="c-4" decimals="-3" id="f-596" unitRef="usd">1893000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-5" decimals="-3" id="f-597" unitRef="usd">1798000</us-gaap:Goodwill>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c-1" id="f-598">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of the Company&#x2019;s acquired intangible assets are comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.301%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.961%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.681%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.717%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.961%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.681%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.724%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated amortization and impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated amortization and impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Utrophin program acquired&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,015)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discuva platform acquired&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,583)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Option over non-financial asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(859)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(816)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(140)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(133)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,582)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,864)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2023, the Company dissolved the wholly-owned subsidiary, Muox Limited, a dormant entity. The Utrophin program intangible assets, which arose from the Muox Limited acquisition were fully impaired and have been removed from the Company&#x2019;s accounting records.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In conjunction with the significant change in the Company&#x2019;s strategy and shift in focus to the therapeutic area of oncology, the Company determined that it would cease further investment in the Discuva Platform. Management concluded that the carrying amount of the acquired Discuva Platform intangible asset may not be recoverable and performed an assessment to calculate the fair value of the asset using a probability-weighted approach which was compared to the carrying value of the asset. An impairment charge of $8,468 which represented the carrying value of the Discuva Platform was recognized during the year ended December 31, 2022. This impairment charge is presented as &lt;span style="-sec-ix-hidden:f-630"&gt;impairment of intangible assets&lt;/span&gt; in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-94" decimals="-3" id="f-599" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsGross>
    <smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment contextRef="c-94" decimals="-3" id="f-600" unitRef="usd">0</smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-94" decimals="-3" id="f-601" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-95" decimals="-3" id="f-602" unitRef="usd">4015000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment contextRef="c-95" decimals="-3" id="f-603" unitRef="usd">4015000</smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-95" decimals="-3" id="f-604" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-96" decimals="-3" id="f-605" unitRef="usd">13583000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment contextRef="c-96" decimals="-3" id="f-606" unitRef="usd">13583000</smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-96" decimals="-3" id="f-607" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-97" decimals="-3" id="f-608" unitRef="usd">12900000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment contextRef="c-97" decimals="-3" id="f-609" unitRef="usd">12900000</smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-97" decimals="-3" id="f-610" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-98" decimals="-3" id="f-611" unitRef="usd">859000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment contextRef="c-98" decimals="-3" id="f-612" unitRef="usd">859000</smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-98" decimals="-3" id="f-613" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-99" decimals="-3" id="f-614" unitRef="usd">816000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment contextRef="c-99" decimals="-3" id="f-615" unitRef="usd">816000</smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-99" decimals="-3" id="f-616" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-100" decimals="-3" id="f-617" unitRef="usd">140000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment contextRef="c-100" decimals="-3" id="f-618" unitRef="usd">140000</smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-100" decimals="-3" id="f-619" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-101" decimals="-3" id="f-620" unitRef="usd">133000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment contextRef="c-101" decimals="-3" id="f-621" unitRef="usd">133000</smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-101" decimals="-3" id="f-622" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-4" decimals="-3" id="f-623" unitRef="usd">14582000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment contextRef="c-4" decimals="-3" id="f-624" unitRef="usd">14582000</smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-4" decimals="-3" id="f-625" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-5" decimals="-3" id="f-626" unitRef="usd">17864000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment contextRef="c-5" decimals="-3" id="f-627" unitRef="usd">17864000</smmt:FiniteLivedIntangibleAssetsAccumulatedAmortizationAndImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-5" decimals="-3" id="f-628" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-102" decimals="-3" id="f-629" unitRef="usd">8468000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-3" id="f-631" unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-6" decimals="-3" id="f-632" unitRef="usd">914000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="c-1" id="f-633">Fair Value Measurements and Short-Term Investments&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables sets forth the Company&#x2019;s fair value hierarchy for its assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2023 and 2022: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.888%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.486%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements as of December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Government treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Government treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.888%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.486%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements as of December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Government treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table above does not include cash at December 31, 2023 and 2022 of $11,068 and $62,094, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that the carrying amounts of prepaid expenses, other current assets, accounts payable, and accrued expenses approximates their fair values due to the short-term nature of those instruments. The carrying value of the Company&#x2019;s promissory note approximates its fair value due to the recent issuance of the notes in December 2022 and the current interest rate of the note outstanding when compared to market interest rates (which represents a Level 2 measurement). Refer to Note 18 for further details.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Short-Term Investments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the Company&#x2019;s short-term investments as of December 31, 2023, which have a contractual maturity of less than one year:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.655%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.804%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.804%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.804%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.804%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Credit Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Government treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not have any short-term investments as of December 31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="c-1" id="f-634">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables sets forth the Company&#x2019;s fair value hierarchy for its assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2023 and 2022: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.888%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.486%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements as of December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Government treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Government treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.888%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.486%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements as of December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Government treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <smmt:CashEquivalentsFairValueDisclosure contextRef="c-103" decimals="-3" id="f-635" unitRef="usd">21016000</smmt:CashEquivalentsFairValueDisclosure>
    <smmt:CashEquivalentsFairValueDisclosure contextRef="c-104" decimals="-3" id="f-636" unitRef="usd">0</smmt:CashEquivalentsFairValueDisclosure>
    <smmt:CashEquivalentsFairValueDisclosure contextRef="c-105" decimals="-3" id="f-637" unitRef="usd">0</smmt:CashEquivalentsFairValueDisclosure>
    <smmt:CashEquivalentsFairValueDisclosure contextRef="c-106" decimals="-3" id="f-638" unitRef="usd">21016000</smmt:CashEquivalentsFairValueDisclosure>
    <smmt:CashEquivalentsFairValueDisclosure contextRef="c-107" decimals="-3" id="f-639" unitRef="usd">0</smmt:CashEquivalentsFairValueDisclosure>
    <smmt:CashEquivalentsFairValueDisclosure contextRef="c-108" decimals="-3" id="f-640" unitRef="usd">39341000</smmt:CashEquivalentsFairValueDisclosure>
    <smmt:CashEquivalentsFairValueDisclosure contextRef="c-109" decimals="-3" id="f-641" unitRef="usd">0</smmt:CashEquivalentsFairValueDisclosure>
    <smmt:CashEquivalentsFairValueDisclosure contextRef="c-110" decimals="-3" id="f-642" unitRef="usd">39341000</smmt:CashEquivalentsFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-111" decimals="-3" id="f-643" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-112" decimals="-3" id="f-644" unitRef="usd">114817000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-113" decimals="-3" id="f-645" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-114" decimals="-3" id="f-646" unitRef="usd">114817000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-115" decimals="-3" id="f-647" unitRef="usd">21016000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-116" decimals="-3" id="f-648" unitRef="usd">154158000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-117" decimals="-3" id="f-649" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-4" decimals="-3" id="f-650" unitRef="usd">175174000</us-gaap:AssetsFairValueDisclosure>
    <smmt:CashEquivalentsFairValueDisclosure contextRef="c-118" decimals="-3" id="f-651" unitRef="usd">60783000</smmt:CashEquivalentsFairValueDisclosure>
    <smmt:CashEquivalentsFairValueDisclosure contextRef="c-119" decimals="-3" id="f-652" unitRef="usd">0</smmt:CashEquivalentsFairValueDisclosure>
    <smmt:CashEquivalentsFairValueDisclosure contextRef="c-120" decimals="-3" id="f-653" unitRef="usd">0</smmt:CashEquivalentsFairValueDisclosure>
    <smmt:CashEquivalentsFairValueDisclosure contextRef="c-121" decimals="-3" id="f-654" unitRef="usd">60783000</smmt:CashEquivalentsFairValueDisclosure>
    <smmt:CashEquivalentsFairValueDisclosure contextRef="c-122" decimals="-3" id="f-655" unitRef="usd">0</smmt:CashEquivalentsFairValueDisclosure>
    <smmt:CashEquivalentsFairValueDisclosure contextRef="c-123" decimals="-3" id="f-656" unitRef="usd">225730000</smmt:CashEquivalentsFairValueDisclosure>
    <smmt:CashEquivalentsFairValueDisclosure contextRef="c-124" decimals="-3" id="f-657" unitRef="usd">0</smmt:CashEquivalentsFairValueDisclosure>
    <smmt:CashEquivalentsFairValueDisclosure contextRef="c-125" decimals="-3" id="f-658" unitRef="usd">225730000</smmt:CashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-126" decimals="-3" id="f-659" unitRef="usd">60783000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-127" decimals="-3" id="f-660" unitRef="usd">225730000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-128" decimals="-3" id="f-661" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-5" decimals="-3" id="f-662" unitRef="usd">286513000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Cash contextRef="c-4" decimals="-3" id="f-663" unitRef="usd">11068000</us-gaap:Cash>
    <us-gaap:Cash contextRef="c-5" decimals="-3" id="f-664" unitRef="usd">62094000</us-gaap:Cash>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock contextRef="c-1" id="f-665">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the Company&#x2019;s short-term investments as of December 31, 2023, which have a contractual maturity of less than one year:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.655%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.804%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.804%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.804%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.804%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Credit Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Government treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss contextRef="c-114" decimals="-3" id="f-666" unitRef="usd">114781000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-114" decimals="-3" id="f-667" unitRef="usd">36000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-114" decimals="-3" id="f-668" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest contextRef="c-114" decimals="-3" id="f-669" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-114" decimals="-3" id="f-670" unitRef="usd">114817000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss contextRef="c-4" decimals="-3" id="f-671" unitRef="usd">114781000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-4" decimals="-3" id="f-672" unitRef="usd">36000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-4" decimals="-3" id="f-673" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest contextRef="c-4" decimals="-3" id="f-674" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-4" decimals="-3" id="f-675" unitRef="usd">114817000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:ShortTermInvestments contextRef="c-5" decimals="-3" id="f-676" unitRef="usd">0</us-gaap:ShortTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-677">Property and Equipment &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.826%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.829%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures, office equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense for the years ended December 31, 2023 and 2022 was $198 and $349, respectively. The Company recognized a fixed asset impairment charge of $474 for the year ended December 31, 2023. There were no impairment charges related to fixed assets for the year ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-129" decimals="-3" id="f-678" unitRef="usd">22000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-130" decimals="-3" id="f-679" unitRef="usd">505000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-131" decimals="-3" id="f-680" unitRef="usd">896000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-132" decimals="-3" id="f-681" unitRef="usd">889000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-59" decimals="-3" id="f-682" unitRef="usd">328000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-133" decimals="-3" id="f-683" unitRef="usd">809000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-4" decimals="-3" id="f-684" unitRef="usd">1246000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-5" decimals="-3" id="f-685" unitRef="usd">2203000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-686" unitRef="usd">1042000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-687" unitRef="usd">1297000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-688" unitRef="usd">204000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-689" unitRef="usd">906000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-690" unitRef="usd">198000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-6" decimals="-3" id="f-691" unitRef="usd">349000</us-gaap:Depreciation>
    <us-gaap:TangibleAssetImpairmentCharges contextRef="c-1" decimals="-3" id="f-692" unitRef="usd">474000</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges contextRef="c-6" decimals="-3" id="f-693" unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock contextRef="c-1" id="f-694">Research and Development Prepaid Expenses and Accrued Liabilities&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included within prepaid expenses at December 31, 2023 and 2022 is $1,466 and $442, respectively, of prepayments relating to research and development expenditures. Included within accrued liabilities at December 31, 2023 and 2022 is $7,289 and $8,911, respectively, relating to research and development expenditures.&lt;/span&gt;&lt;/div&gt;These amounts are determined based on the estimated costs to complete each study or activity, the estimation of the current stage of completion and the invoices received, as well as predetermined milestones which are not reflective of the current stage of development for prepaid expenses. However, prepaid expenses decrease and accrued liabilities increase as the activities progress, and if actual costs incurred exceed the prepaid expense, an accrual will be recorded for the liability. The key sensitivity is the estimated current stage of completion of each study or activity, which is based on information received from the supplier and the Company&#x2019;s operational knowledge of the work completed under those contracts.</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <smmt:ResearchAndDevelopmentPrepaidExpensesCurrent contextRef="c-4" decimals="-3" id="f-695" unitRef="usd">1466000</smmt:ResearchAndDevelopmentPrepaidExpensesCurrent>
    <smmt:ResearchAndDevelopmentPrepaidExpensesCurrent contextRef="c-5" decimals="-3" id="f-696" unitRef="usd">442000</smmt:ResearchAndDevelopmentPrepaidExpensesCurrent>
    <smmt:AccruedResearchAndDevelopmentCurrent contextRef="c-4" decimals="-3" id="f-697" unitRef="usd">7289000</smmt:AccruedResearchAndDevelopmentCurrent>
    <smmt:AccruedResearchAndDevelopmentCurrent contextRef="c-5" decimals="-3" id="f-698" unitRef="usd">8911000</smmt:AccruedResearchAndDevelopmentCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-699">Leases&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has operating leases for real estate. The Company does not have any finance leases. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2023, the Company recorded $4,245 of additional right-of-use assets related to a new lease for additional office space which commenced in May 2023 at its Menlo Park, California location. The Company will make total lease payments of $4,701 over the 36 month term of the new lease, which expires in May 2026. In addition, during the year ended December 31, 2023, the Company terminated the Company&#x2019;s Cambridge, U.K. laboratory and office space lease as a result of the Company re-prioritizing its investments and financial resources towards the development of ivonescimab. This resulted in disposing the carrying value of the right-of use asset of $788, removing the related lease liability of $809, and there were no penalties charged for early termination of this lease. The Company recorded $2,860 of right-of-use assets during the year ended December 31, 2022 related to its Menlo Park, California location.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of the right-of-use assets as of December 31, 2023 and 2022 is $5,859 and $4,175, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The elements of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lease Cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Fixed lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Short-term lease&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Short-term lease costs relate to the Company&#x2019;s Cambridge, Massachusetts, United States office lease which the Company exited during fiscal year 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average discount rate and the weighted average remaining lease term were 6.6% and 2.4 years, respectively, as of December 31, 2023. The weighted average discount rate and the weighted average remaining lease term were 5.7% and 3.4 years, respectively, as of December 31, 2022. The Company made cash payments related to lease liabilities of $2,208 and $1,092 for the years ending December 31, 2023 and 2022 respectively. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future lease payments under non-cancelable leases as of December 31, 2023 are detailed as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.843%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.357%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities balance sheet presentation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company signed a lease agreement on January 8, 2024 for executive office space for its new headquarters in Miami, Florida. The office space is approximately 9,000 square feet. The term of the lease is 64 months. Total payments for this office &lt;/span&gt;&lt;/div&gt;space is approximately $5,100 over the term of the lease. The table above excludes payments related to the lease signed in January 2024.</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-134" decimals="-3" id="f-700" unitRef="usd">4245000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-135" decimals="-3" id="f-701" unitRef="usd">4701000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-135" id="f-702">P36M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <smmt:OperatingLeaseRightOfUseAssetDisposals contextRef="c-136" decimals="-3" id="f-703" unitRef="usd">788000</smmt:OperatingLeaseRightOfUseAssetDisposals>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-136" decimals="-3" id="f-704" unitRef="usd">-809000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-137" decimals="-3" id="f-705" unitRef="usd">2860000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-706" unitRef="usd">5859000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-707" unitRef="usd">4175000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-708">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The elements of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lease Cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Fixed lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Short-term lease&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Short-term lease costs relate to the Company&#x2019;s Cambridge, Massachusetts, United States office lease which the Company exited during fiscal year 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-3" id="f-709" unitRef="usd">2214000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-6" decimals="-3" id="f-710" unitRef="usd">1384000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-1" decimals="-3" id="f-711" unitRef="usd">83000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-6" decimals="-3" id="f-712" unitRef="usd">137000</us-gaap:VariableLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-1" decimals="-3" id="f-713" unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-6" decimals="-3" id="f-714" unitRef="usd">31000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-3" id="f-715" unitRef="usd">2297000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-6" decimals="-3" id="f-716" unitRef="usd">1552000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-4" decimals="3" id="f-717" unitRef="number">0.066</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-4" id="f-718">P2Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-5" decimals="3" id="f-719" unitRef="number">0.057</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-5" id="f-720">P3Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-3" id="f-721" unitRef="usd">2208000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-6" decimals="-3" id="f-722" unitRef="usd">1092000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-723">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future lease payments under non-cancelable leases as of December 31, 2023 are detailed as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.843%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.357%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities balance sheet presentation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-4" decimals="-3" id="f-724" unitRef="usd">2810000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-4" decimals="-3" id="f-725" unitRef="usd">2886000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-4" decimals="-3" id="f-726" unitRef="usd">893000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-4" decimals="-3" id="f-727" unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-4" decimals="-3" id="f-728" unitRef="usd">6589000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-4" decimals="-3" id="f-729" unitRef="usd">490000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-4" decimals="-3" id="f-730" unitRef="usd">6099000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-731" unitRef="usd">2809000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-732" unitRef="usd">3290000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c-4" decimals="-3" id="f-733" unitRef="usd">6099000</us-gaap:OperatingLeaseLiability>
    <smmt:LesseeOperatingLeaseAreaOfPremisesLeased contextRef="c-138" decimals="-3" id="f-734" unitRef="sqft">9000</smmt:LesseeOperatingLeaseAreaOfPremisesLeased>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-138" id="f-735">P64M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-138" decimals="-3" id="f-736" unitRef="usd">5100000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c-1" id="f-737">Promissory Notes Payable to Related Parties&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Non-current and current debt consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.288%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.183%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.397%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.397%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.484%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-current notes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Principal amounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total promissory notes payable to related parties&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;March 2022 Promissory Note&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 10, 2022, Mr. Duggan, entered into a Note Purchase Agreement (the &#x201c;March 2022 Note&#x201d;), pursuant to which he loaned the Company $25,000 in exchange for the issuance by the Company of an unsecured promissory note in the amount of $25,000. The March 2022 Note accrued interest at a rate per annum equal to the prime rate as reported in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Wall Street Journal&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The March 2022 Note, including all accrued interest, became due upon the earlier of (i) the consummation of a registered public offering with net proceeds of no less than $25,000 or (ii) 18 months from the date of issuance of the March 2022 Note. Debt issuance costs associated with the March 2022 Note were immaterial and expensed as incurred. The March 2022 Note of $25,000, plus accrued interest of $434 has been repaid to Mr. Duggan on August 10, 2022 in connection with the completion of the rights offering with aggregate gross proceeds of $100,000.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred interest expense related to the March 2022 Note of $1,296 for the year ended December 31, 2022, which included amortized imputed interest of $861. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;December 2022 Promissory Notes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 6, 2022, the Company entered into a Note Purchase Agreement (the &#x201c;Note Purchase Agreement&#x201d;), with Mr. Duggan and Dr. Zanganeh, pursuant to which the Company agreed to sell to each of Mr. Duggan and Dr. Zanganeh unsecured promissory notes in the aggregate amount of $520,000. Pursuant to the Note Purchase Agreement, the Company issued to Mr. Duggan and Dr. Zanganeh unsecured promissory notes in the amount of $400,000 (the &#x201c;Duggan February Note&#x201d;) and $20,000 (the &#x201c;Zanganeh Note&#x201d;), respectively, which matured and become due on February 15, 2023 and an unsecured promissory note to Mr. Duggan in the amount of $100,000 (the &#x201c;Duggan September Note&#x201d; and together with the Duggan February Note and the Zanganeh Note, the &#x201c;December 2022 Notes&#x201d;), which was originally due on September 15, 2023. The maturity dates of the December 2022 Notes could have been extended one or more times at the Company&#x2019;s election, but in no event to a date later than September 6, 2024. In addition, if the Company consummates a public offering, then upon the later to occur of (i) &lt;span style="-sec-ix-hidden:f-764"&gt;five&lt;/span&gt; business days after the Company receives the net cash proceeds therefrom or (ii) May 15, 2023, the Duggan February Note and the Zanganeh Note shall be prepaid by an amount equal to the lesser of (a) 100% of the amount of the net proceeds of such offering and (b) the outstanding principal amount on such Notes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 19, 2023, the Company provided notice to extend the term of the Duggan February Note and Duggan September Note to a maturity date of September 6, 2024. Furthermore, on January 19, 2023, the Company and Mr. Duggan rectified the Duggan February Note and Duggan September Note in order to correctly reflect the parties&#x2019; intent that the Company may only prepay (i) the Duggan February Note following the completion of a public rights offering to be conducted by Summit in the approximate amount of $500,000 (the &#x201c;Rights Offering&#x201d;), or a similar capital raise, in an amount equal to the lesser of (x) the net proceeds of the Rights Offering or such capital raise or (y) the full amount outstanding of the Duggan February Note, and (ii) the Duggan September Note following the completion of a capital raising transaction subsequent to the Rights Offering in an amount equal to the lesser of (A) the net proceeds of such capital raise or (B) the full amount outstanding of the Duggan September Note. Following the issuance of the two new Promissory Notes (the &#x201c;Duggan Promissory Notes&#x201d;), the Duggan February Note and Duggan September Note were marked as &#x201c;cancelled&#x201d; on their face and replaced in their entirety by the Duggan Promissory Notes (together with the Zanganeh Note, the &#x201c;Notes&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 15, 2023, the $20,000 Zanganeh Note matured and the Company repaid the outstanding principal balance. In connection with the closing of the rights offering, the $400,000 Duggan Promissory Note matured and became due, and the Company repaid all principal and accrued interest thereunder using a portion of the proceeds from this rights offering.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Notes accrued interest at an initial rate of 7.5%. All interest on the Notes was paid on the date of signing for the period through February 15, 2023. Such prepaid interest was paid in a number of shares of the Company&#x2019;s common stock, par value $0.01 (&#x201c;Common Stock&#x201d;) equal to the dollar amount of such prepaid interest, divided by $0.7913 (the consolidated closing bid price immediately preceding the time the Company entered into the Note Purchase Agreement, plus $0.01), which was 9,720,291 shares. For all applicable periods following February 15, 2023, interest shall accrue on the outstanding principal balance of the Notes at the US prime interest rate, as reported in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Wall Street Journal,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; plus 50 basis points, as adjusted monthly, for three months immediately following February 15, 2023, and thereafter at the US prime rate plus 300 basis points, as adjusted monthly.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt issuance costs associated with the Notes were $44 and were capitalized as part of the carrying value of the promissory notes payable to related parties. During the year ended December 31, 2023, the Company incurred interest expense of $16,461 for the year ended December 31, 2023, which included amortized imputed interest of $761. The Company incurred interest expense of $3,105 for the year ended December 31, 2022 related to the December 2022 Notes, which included amortized imputed interest of $395.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2023 and 2022 there was $120 of accrued interest payable included within accrued expenses in the consolidated balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Imputed interest is calculated as the difference between the expected interest payable and the deemed market rate of interest and is recorded as a debt discount at inception of the note payable with a credit to additional paid-in capital for notes payable to related parties. The debt discount is amortized to interest expense using an effective interest rate method. The effective interest rate of the Duggan February Note and Zanganeh Note was 8.9% and the effective interest rate of the Duggan September Note was 11.3%. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 17, 2024 the Duggan February Note was amended to extend the maturity date from September 6, 2024 to April 1, 2025. For all applicable periods commencing  February 17, 2024, interest shall accrue on the outstanding principal balance at the greater of 12% or the US prime interest rate, as reported in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Wall Street Journal &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;plus 350 basis points, as adjusted monthly, compounded quarterly.Interest shall be paid upon maturity of the loan.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the applicable accounting standards, a short-term debt obligation should be excluded from current liabilities if the entity has both the intent and ability to refinance the obligation on a long-term basis. The intent and ability can be demonstrated by the issuance of a long-term obligation to refinance the short-term obligation on a long-term basis after the date of an entity&#x2019;s balance sheet but before that balance sheet is issued. As a result of the amendment entered into on February 17, 2024, to extend the maturity date to April 1, 2025, the Company classified $100,000 of notes payable to related party outstanding as of December 31, 2023 as long-term notes payable&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future principal payments are $0 and $100,000 for 2024 and 2025, respectively, as the note matures on April 1, 2025.&lt;/span&gt;&lt;/div&gt;Related Party Transactions&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;July 25, 2022 First Amendment to Sublease Agreement with Maky Zanganeh and Associates, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 25, 2022 the Company entered into a first amendment, dated July 19, 2022, to its existing sublease agreement with MZA, described above. The existing sublease term, which was set to expire on September 30, 2022, was extended for a period of thirty-nine months from October 1, 2022 through December 31, 2025. The rent payable under the terms of the sublease is equivalent to the proportionate share of the net payable by MZA to the third-party landlord, based on the square footage of office space sublet by the Company, and no mark-up has been applied. During the year ended December 31, 2023, payments of $762, were made pursuant to the first amendment to the Sublease Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;July 29, 2022 Second Amendment to Sublease Agreement with Maky Zanganeh and Associates, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 29, 2022, the Company entered into a second amendment, dated August 1, 2022, to its existing sublease agreement with MZA, described above. The second amendment was effective as of August 1, 2022 and expires on December 31, 2025. The second amendment includes an additional 1,277 square feet (the &#x201c;Expansion Premises&#x201d;) of office space at 2882 Sand Hill Road, Menlo Park, California. The rent payable under the terms of the sublease is equivalent to the proportionate share of the net payable by MZA to the third-party landlord, based on the square footage of office space sublet by the Company, and no mark-up has been applied. During the year ended December 31, 2023 payments of $218, were made pursuant to the secondment amendment to the sublease.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;March 10, 2022 Note Purchase Agreement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 10, 2022, the Company entered into a Note Purchase Agreement (the &#x201c;March 2022 Note&#x201d;), with Mr. Duggan, pursuant to which Mr. Duggan loaned the Company $25,000 in exchange for the issuance by the Company of an unsecured promissory note in the amount of $25,000. The March 2022 Note accrued interest at a rate per annum equal to the prime rate as reported in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Wall Street Journal&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which was 3.25% as of the effective date and 4.75% as of June 30, 2022. The March 2022 Note, including accrued interest, became due upon the earlier of (i) the consummation of a registered public offering with net proceeds of no less than $25,000 or (ii) 18 months from the date of issuance of the March 2022 Note, and was repaid on August 10, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;2022 Rights Offering&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2022 Rights Offering commenced on July 18, 2022, and the associated subscription rights expired on August 8, 2022. Aggregate gross proceeds received from the rights offering were $100,000 from the sale of 103,092,783 shares of common stock. Mr. Duggan and Dr. Zanganeh fully subscribed to their respective basic subscription rights and oversubscribed, at a price of $0.97 per share. Issuance costs were $111. In connection with the closing of the 2022 Rights Offering, the March 2022 Note &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;matured and became due, and the Company repaid all principal and accrued interest thereunder using a portion of the proceeds from the 2022 Rights Offering on August 10, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;December 6, 2022 Note Purchase Agreement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 6, 2022, the Company entered into a Note Purchase Agreement (the &#x201c;Note Purchase Agreement&#x201d;), with Mr. Duggan and Dr. Zanganeh, pursuant to which the Company agreed to sell to each of Mr. Duggan and Dr. Zanganeh unsecured promissory notes in the aggregate amount of $520,000. Pursuant to the Note Purchase Agreement, the Company issued to Mr. Duggan and Dr. Zanganeh unsecured promissory notes in the amount of $400,000 (the &#x201c;Duggan February Note&#x201d;) and $20,000 (the &#x201c;Zanganeh Note&#x201d;), respectively, which would mature and become due on February 15, 2023 and an unsecured promissory note to Mr. Duggan in the amount of $100,000 (the &#x201c;Duggan September Note&#x201d; and together with the Duggan February Note and the Zanganeh Note, the &#x201c;December 2022 Notes&#x201d;), which matured and became due on September 15, 2023. The maturity dates of the December 2022 Notes could have been extended one or more times at the Company&#x2019;s election, but in no event to a date later than September 6, 2024. In addition, if the Company consummates a public offering, then upon the later to occur of (i) &lt;span style="-sec-ix-hidden:f-967"&gt;five&lt;/span&gt; business days after the Company receives the net cash proceeds therefrom or (ii) May 15, 2023, the Duggan February Note and the Zanganeh Note shall be prepaid by an amount equal to the lesser of (a) 100% of the amount of the net proceeds of such offering and (b) the outstanding principal amount on such notes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 19, 2023, the Company provided notice to extend the term of the Duggan February Note and Duggan September Note to a maturity date of September 6, 2024. Furthermore, on January 19, 2023, the Company and Mr. Duggan rectified the Duggan February Note and Duggan September Note in order to correctly reflect the parties&#x2019; intent that the Company may only prepay (i) the Duggan February Note following the completion of a public rights offering to be conducted by Summit in the approximate amount of $500,000 (the &#x201c;Rights Offering&#x201d;), or a similar capital raise, in an amount equal to the lesser of (x) the net proceeds of the Rights Offering or such capital raise or (y) the full amount outstanding of the Duggan February Note, and (ii) Duggan September Note following the completion of a capital raising transaction subsequent to the Rights Offering in an amount equal to the lesser of (i) the net proceeds of such capital raise or (ii) the full amount outstanding of the Duggan September Note. Following the issuance of the two new Promissory Notes (the &#x201c;Duggan Promissory Notes&#x201d;), the Duggan February Note and Duggan September Note were marked as &#x201c;cancelled&#x201d; on their face and replaced in their entirety by the Duggan Promissory Notes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 15, 2023, the $20,000 Zanganeh Note, matured and the Company repaid the outstanding principal balance. In connection with the closing of the 2023 Rights Offering, the $400,000 Duggan Promissory Note, matured and became due, and the Company satisfied all principal and accrued interest thereunder using a combination of a portion of the cash proceeds from the 2023 Rights Offering and the extinguishment of a portion of the amount due equal to the subscription price for shares subscribed by Mr. Duggan in the 2023 Rights Offering (as defined above).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Notes accrue interest at an initial rate of 7.5%. All interest on the Notes shall be paid on the date of signing for the period through February 15, 2023. Such prepaid interest shall be paid in a number of shares of the Company&#x2019;s common stock, par value $0.01 (&#x201c;Common Stock&#x201d;) equal to the dollar amount of such prepaid interest, divided by $0.7913 (the consolidated closing bid price immediately preceding the time the Company entered into the Note Purchase Agreement, plus $0.01), which was 9,720,291 shares. For all applicable periods following February 15, 2023, interest shall accrue on the outstanding principal balance of the Notes at the United States prime interest rate, as reported in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Wall Street Journal,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; plus 50 basis points, as adjusted monthly, for three months immediately following February 15, 2023, and thereafter at the United States prime rate plus 300 basis points, as adjusted monthly. During the year ended December 31, 2023, the Company made payments for interest of $10,650.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 17, 2024 the Duggan February Note was amended to extend the maturity date from September 6, 2024 to April 1, 2025. For all applicable periods commencing  February 17, 2024, interest shall accrue on the outstanding principal balance at the greater of 12% or the US prime interest rate, as reported in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Wall Street Journal &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;plus 350 basis points, as adjusted monthly, compounded quarterly. Interest shall be paid upon maturity of the loan.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Akeso License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the closing of the License Agreement, the Board of Directors (the &#x201c;Board&#x201d;) of the Company appointed Dr. Yu (Michelle) Xia to serve as a member of the Board pursuant to the terms of the License Agreement. Dr. Xia is the founder of Akeso, Inc., and has been the chairwoman, president and CEO of the Company since its inception in 2012. For details on the License Agreement, see Note 6. Furthermore, in connection with the License Agreement, the Company also entered into a Supply Agreement with Akeso, pursuant to which Summit agreed to purchase a certain portion of drug substance for clinical and commercial supply (the &#x201c;Supply Agreement&#x201d;). All transactions pursuant to the Supply Agreement, which occurred during 2023, were in the ordinary course of business. The Company paid approximately $2,500 to Akeso during year ended December 31, 2023. As of December 31, 2023, the Company included in accrued expenses approximately $3,619 due to Akeso.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;2023 Rights Offering&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 6, 2022, the Company announced a rights offering for its existing shareholders to participate in the purchase of additional shares of its Common Stock for $1.05 per share. The 2023 Rights Offering commenced on February 7, 2023 and the associated subscription rights expired on March 1, 2023. Aggregate gross proceeds from the 2023 Rights Offering were $500,000 from the sale of 476,190,471 shares of the Company&#x2019;s common stock and issuance costs were $619. Mr. Duggan and Dr. Zanganeh fully subscribed to their respective basic subscription rights at a price of $1.05 per share. To satisfy the $395,314 subscription price for the shares subscribed by Mr. Duggan in the 2023 Rights Offering, Mr. Duggan agreed with the Company to extinguish a portion of the amount due and payable to him by the Company at the closing of the 2023 Rights Offering pursuant to the $400,000 Duggan Promissory Note in an amount equal to the subscription price.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Registration of Shares&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 17, 2023, the Company filed a registration statement on Form S-3 to register for resale the following shares of the Company&#x2019;s common stock at $0.01 par value: (i) 10,000,000 shares of Common Stock issued on January 17, 2023 in connection with the License Agreement with Akeso pursuant to which the Company issued Akeso such shares; and (ii) the 9,346,434 and 373,857 shares of Common Stock issued in December 2022 to the Company&#x2019;s Chief Executive Officers, Mr. Duggan and Dr. Zanganeh, respectively, as payment of prepaid interest in connection with the Note Purchase Agreement dated December 6, 2022 between Mr. Duggan, Dr. Zanganeh and the Company. On April 27, 2023, the SEC issued the Company a Notice of Effectiveness for the registration statement on Form S-3.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Private Placement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 16, 2023, the Company announced the appointment of Mr. Manmeet Soni as its Chief Operating Officer, effective immediately. Mr. Soni has been a part of the Company&#x2019;s Board of Directors since 2019. He will remain a member of the Board of Directors. In conjunction with his appointment, Mr. Soni entered into a share purchase agreement with the Company to purchase $5,000 of its common stock via a private placement. The transaction was effective October 13, 2023 with a closing price of $1.68, resulting in the purchase of 2,976,190 shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Warrants Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, Dr. Zanganeh exercised 805,495 shares of warrants. Refer to Note 20 for the warrants exercise activity for the year ended December 31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="c-1" id="f-738">Non-current and current debt consisted of the following:&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.288%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.183%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.397%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.397%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.484%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-current notes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Principal amounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total promissory notes payable to related parties&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <smmt:NotesPayableGrossCurrent contextRef="c-139" decimals="-3" id="f-739" unitRef="usd">0</smmt:NotesPayableGrossCurrent>
    <smmt:NotesPayableGrossCurrent contextRef="c-140" decimals="-3" id="f-740" unitRef="usd">20000000</smmt:NotesPayableGrossCurrent>
    <smmt:NotesPayableGrossNoncurrent contextRef="c-139" decimals="-3" id="f-741" unitRef="usd">100000000</smmt:NotesPayableGrossNoncurrent>
    <smmt:NotesPayableGrossNoncurrent contextRef="c-140" decimals="-3" id="f-742" unitRef="usd">500000000</smmt:NotesPayableGrossNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscountCurrent contextRef="c-139" decimals="-3" id="f-743" unitRef="usd">0</us-gaap:DebtInstrumentUnamortizedDiscountCurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscountCurrent contextRef="c-140" decimals="-3" id="f-744" unitRef="usd">230000</us-gaap:DebtInstrumentUnamortizedDiscountCurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent contextRef="c-139" decimals="-3" id="f-745" unitRef="usd">0</us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent contextRef="c-140" decimals="-3" id="f-746" unitRef="usd">5460000</us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent>
    <us-gaap:NotesPayableCurrent contextRef="c-139" decimals="-3" id="f-747" unitRef="usd">0</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c-140" decimals="-3" id="f-748" unitRef="usd">19770000</us-gaap:NotesPayableCurrent>
    <us-gaap:LongTermNotesPayable contextRef="c-139" decimals="-3" id="f-749" unitRef="usd">100000000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable contextRef="c-140" decimals="-3" id="f-750" unitRef="usd">494540000</us-gaap:LongTermNotesPayable>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="c-141" decimals="-3" id="f-751" unitRef="usd">25000000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:NotesPayable contextRef="c-142" decimals="-3" id="f-752" unitRef="usd">25000000</us-gaap:NotesPayable>
    <smmt:NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold contextRef="c-141" decimals="-3" id="f-753" unitRef="usd">25000000</smmt:NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold>
    <smmt:NotesPayableRelatedPartiesMaximumTerm contextRef="c-141" id="f-754">P18M</smmt:NotesPayableRelatedPartiesMaximumTerm>
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="c-143" decimals="-3" id="f-755" unitRef="usd">25000000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <smmt:PaymentOfAccruedInterestToRelatedParties contextRef="c-143" decimals="-3" id="f-756" unitRef="usd">434000</smmt:PaymentOfAccruedInterestToRelatedParties>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-144" decimals="-3" id="f-757" unitRef="usd">100000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:InterestExpenseDebt contextRef="c-145" decimals="-3" id="f-758" unitRef="usd">1296000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-145" decimals="-3" id="f-759" unitRef="usd">861000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:NotesPayable contextRef="c-37" decimals="-3" id="f-760" unitRef="usd">520000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayable contextRef="c-43" decimals="-3" id="f-761" unitRef="usd">400000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayable contextRef="c-146" decimals="-3" id="f-762" unitRef="usd">20000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayable contextRef="c-147" decimals="-3" id="f-763" unitRef="usd">100000000</us-gaap:NotesPayable>
    <smmt:NotesPayableRelatedPartiesPotentialPrepaymentMaximumAmountPercentageOfNetProceedsFromPublicOffering contextRef="c-148" decimals="2" id="f-765" unitRef="number">1</smmt:NotesPayableRelatedPartiesPotentialPrepaymentMaximumAmountPercentageOfNetProceedsFromPublicOffering>
    <smmt:NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold contextRef="c-149" decimals="-3" id="f-766" unitRef="usd">500000000</smmt:NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold>
    <smmt:NotesPayableRelatedPartiesNewIssuances
      contextRef="c-149"
      decimals="INF"
      id="f-767"
      unitRef="promissory_note">2</smmt:NotesPayableRelatedPartiesNewIssuances>
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="c-44" decimals="-3" id="f-768" unitRef="usd">20000000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="c-150" decimals="-3" id="f-769" unitRef="usd">400000000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RelatedPartyTransactionRate contextRef="c-151" decimals="3" id="f-770" unitRef="number">0.075</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-152"
      decimals="2"
      id="f-771"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <smmt:NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominator
      contextRef="c-151"
      decimals="4"
      id="f-772"
      unitRef="usdPerShare">0.7913</smmt:NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominator>
    <smmt:NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominatorBaseAmountAddedToClosingBidPrice
      contextRef="c-151"
      decimals="2"
      id="f-773"
      unitRef="usdPerShare">0.01</smmt:NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominatorBaseAmountAddedToClosingBidPrice>
    <smmt:StockIssuedDuringPeriodSharesRelatedPartyPrepaidInterest
      contextRef="c-151"
      decimals="INF"
      id="f-774"
      unitRef="shares">9720291</smmt:StockIssuedDuringPeriodSharesRelatedPartyPrepaidInterest>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-153"
      decimals="INF"
      id="f-775"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-154"
      decimals="INF"
      id="f-776"
      unitRef="number">0.0300</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DeferredFinanceCostsGross contextRef="c-37" decimals="-3" id="f-777" unitRef="usd">44000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:InterestExpenseDebt contextRef="c-155" decimals="-3" id="f-778" unitRef="usd">16461000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-155" decimals="-3" id="f-779" unitRef="usd">761000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestExpenseDebt contextRef="c-156" decimals="-3" id="f-780" unitRef="usd">3105000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-156" decimals="-3" id="f-781" unitRef="usd">395000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="c-157" decimals="-3" id="f-782" unitRef="usd">120000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="c-158" decimals="-3" id="f-783" unitRef="usd">120000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-159" decimals="3" id="f-784" unitRef="number">0.089</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-160" decimals="3" id="f-785" unitRef="number">0.089</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-161" decimals="3" id="f-786" unitRef="number">0.113</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:RelatedPartyTransactionRate contextRef="c-53" decimals="2" id="f-787" unitRef="number">0.12</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-54"
      decimals="INF"
      id="f-788"
      unitRef="number">0.0350</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LongTermNotesPayable contextRef="c-139" decimals="-3" id="f-789" unitRef="usd">100000000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c-159" decimals="-3" id="f-790" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c-159" decimals="-3" id="f-791" unitRef="usd">100000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock contextRef="c-1" id="f-792">Other Non-Current Liabilities&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included within other non-current liabilities at December 31, 2023 and 2022 is $1,356 and $1,209, respectively, relating to assumed contingent liabilities. As part of the acquisition of Discuva Limited in December 2017, the Company assumed certain contingent liabilities as certain employees, former employees and former directors of Discuva Limited are eligible for payments from Discuva Limited based on specified development and clinical milestones related to proprietary product candidates developed under the Discuva Platform. The timing of these potential payments is uncertain.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In conjunction with the significant change in the Company&#x2019;s strategy and shift in focus to the therapeutic area of oncology, the Company determined that it will cease further investment in the Discuva platform and evaluate further options for the use of the Discuva Platform. As a result, management has revised the estimated presented value of these payments and remeasured the contingent liabilities. This resulted in recording a gain on remeasurement of liabilities of $1,265 during the year ended December 31, 2022, which is included net as part of the research and development expenses in the consolidated statement of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no remeasurement losses or gains recognized during the year ended December 31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock>
    <smmt:BusinessCombinationAssumedContingentLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-793" unitRef="usd">1356000</smmt:BusinessCombinationAssumedContingentLiabilityNoncurrent>
    <smmt:BusinessCombinationAssumedContingentLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-794" unitRef="usd">1209000</smmt:BusinessCombinationAssumedContingentLiabilityNoncurrent>
    <smmt:BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss contextRef="c-6" decimals="-3" id="f-795" unitRef="usd">1265000</smmt:BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss>
    <smmt:BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss contextRef="c-1" decimals="-3" id="f-796" unitRef="usd">0</smmt:BusinessCombinationAssumedContingentLiabilityRemeasurementGainLoss>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-797">Stockholders' Equity &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, the Company announced the closing of its 2022 rights offering (&#x201c;2022 Rights Offering&#x201d;). The rights offering commenced on July 18, 2022, and the associated subscription rights expired on August 8, 2022. The 2022 Rights Offering received aggregate gross proceeds of $100,000 from the sale of 103,092,783 shares of common stock. Mr. Duggan and Dr. Zanganeh fully subscribed to their respective basic subscription rights and oversubscribed, at a price per share of $0.97. Offering costs of $111 were incurred. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 6, 2022, the Company announced a rights offering for its existing shareholders to participate in the purchase of additional shares of its Common Stock for $1.05 per share (the &#x201c;2023 Rights Offering&#x201d;). The 2023 Rights Offering commenced on February 7, 2023 and the associated subscription rights expired on March 1, 2023. Aggregate gross proceeds from the 2023 Rights Offering were $500,000 from the sale of 476,190,471 shares of the Company&#x2019;s common stock and issuance costs were $619. Mr. Duggan and Dr. Zanganeh fully subscribed to their respective basic subscription rights at a price of $1.05 per share. To satisfy the $395,314 subscription price for the shares subscribed by Mr. Duggan in the 2023 Rights Offering, Mr. Duggan agreed with the Company to extinguish a portion of the amount due and payable to him by the Company at the closing of the 2023 Rights Offering pursuant to the $400,000 Duggan Promissory Note in an amount equal to the subscription price (see also Note &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January&#160;19, 2023, the Company filed Amendment No. 2 to the Restated Certificate of Incorporation (the &#x201c;Amendment No. 2&#x201d;) with the Secretary of State of the State of Delaware to increase the number of authorized shares of its common stock by 650,000,000 (from 350,000,000 to 1,000,000,000), which became effective on such date. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 17, 2023, the Company filed a registration statement on Form S-3 to register for resale the following shares of the Company&#x2019;s common stock at $0.01 par value: (i) 10,000,000 shares of Common Stock issued on January 17, 2023 in connection with the License Agreement (as defined in Note &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) with Akeso pursuant to which the Company issued Akeso such shares; and (ii) the 9,346,434 and 373,857 shares of Common Stock issued in December 2022 to Mr. Duggan and Dr. Zanganeh, respectively, as payment of prepaid interest in connection with the Note Purchase Agreement dated December 6, 2022 between Mr. Duggan, Dr. Zanganeh and the Company. On April 27, 2023, the SEC issued the Company a Notice of Effectiveness for the registration statement on Form S-3.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As described in Note &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Mr. Soni entered into a share purchase agreement with the Company to purchase $5,000 of its common stock via a private placement. The transaction was effective October 13, 2023 with a closing price of $1.68, resulting in the purchase of 2,976,190 shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the private placement on December 24, 2019, the participating investors were granted warrants with the right to subscribe for 5,261,350 shares of common stock at an exercise price of $1.58, exercisable any time in the period commencing on the date falling six months following December 24, 2019 and ending on the tenth anniversary of admission. Each warrant entitles the warrant holder to subscribe in cash for one share. Shares of common stock allotted pursuant to the exercise of the warrant will rank in full for all dividends and other distributions with a record date after the exercise date with the shares of common stock in issue at that date. The Company has the option to require the warrant holder to exercise some or all of the outstanding warrants after the third anniversary date if the ten-day volume weighted average price of the shares of common stock as reported on Nasdaq represents a premium of at least 50 percent to the exercise price. The warrants are classified within stockholders&#x2019; equity as they are indexed to the Company&#x2019;s shares of common stock and require settlement in its shares of common stock with no provision for any cash settlement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also, as part of the private placement on December 24, 2019, certain consultants were granted warrants with the right to subscribe for 3,358,732 shares of common stock in exchange for certain services. The warrants have an exercise price of $1.44 and vest quarterly over three years. If the consulting agreement terminated prior to three years after the date of the grant, all unvested warrants will be deemed cancelled. On June 30, 2020, the consulting agreement was terminated and 2,798,945 warrants cancelled immediately. The remaining 559,787 of outstanding warrants are held by Dr. Zanganeh and Dr. Elaine Stracker.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants granted over shares of common stock to consultants in exchange of certain services are similar to stock-based compensation (see Note 21).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;The following table summarizes the Company&#x2019;s warrants activity for the year ended December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.655%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.306%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.306%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.306%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.313%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of share warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average remaining contractual term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate intrinsic value &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,821,137&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.56&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.99 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(805,495)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.49&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,015,642&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.57&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.92 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-144" decimals="-3" id="f-798" unitRef="usd">100000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-144"
      decimals="INF"
      id="f-799"
      unitRef="shares">103092783</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-162"
      decimals="2"
      id="f-800"
      unitRef="usdPerShare">0.97</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-144" decimals="-3" id="f-801" unitRef="usd">111000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-42"
      decimals="2"
      id="f-802"
      unitRef="usdPerShare">1.05</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-41" decimals="-3" id="f-803" unitRef="usd">500000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-41"
      decimals="INF"
      id="f-804"
      unitRef="shares">476190471</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-41" decimals="-3" id="f-805" unitRef="usd">619000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-42"
      decimals="2"
      id="f-806"
      unitRef="usdPerShare">1.05</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssued1 contextRef="c-163" decimals="-3" id="f-807" unitRef="usd">395314000</us-gaap:StockIssued1>
    <us-gaap:NotesPayable contextRef="c-43" decimals="-3" id="f-808" unitRef="usd">400000000</us-gaap:NotesPayable>
    <smmt:CommonStockSharesAuthorizedIncreaseDecrease
      contextRef="c-38"
      decimals="INF"
      id="f-809"
      unitRef="shares">650000000</smmt:CommonStockSharesAuthorizedIncreaseDecrease>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-39"
      decimals="INF"
      id="f-810"
      unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-40"
      decimals="INF"
      id="f-811"
      unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-45"
      decimals="INF"
      id="f-812"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <smmt:SaleOfStockNumberOfSharesRegisteredForResale
      contextRef="c-46"
      decimals="INF"
      id="f-813"
      unitRef="shares">10000000</smmt:SaleOfStockNumberOfSharesRegisteredForResale>
    <smmt:SaleOfStockNumberOfSharesRegisteredForResale
      contextRef="c-47"
      decimals="INF"
      id="f-814"
      unitRef="shares">9346434</smmt:SaleOfStockNumberOfSharesRegisteredForResale>
    <smmt:SaleOfStockNumberOfSharesRegisteredForResale
      contextRef="c-48"
      decimals="INF"
      id="f-815"
      unitRef="shares">373857</smmt:SaleOfStockNumberOfSharesRegisteredForResale>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c-50" decimals="-3" id="f-816" unitRef="usd">5000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-51"
      decimals="2"
      id="f-817"
      unitRef="usdPerShare">1.68</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-52"
      decimals="INF"
      id="f-818"
      unitRef="shares">2976190</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-164"
      decimals="INF"
      id="f-819"
      unitRef="shares">5261350</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-164"
      decimals="2"
      id="f-820"
      unitRef="usdPerShare">1.58</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-164"
      decimals="INF"
      id="f-821"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <smmt:ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage
      contextRef="c-165"
      decimals="INF"
      id="f-822"
      unitRef="number">0.50</smmt:ClassOfWarrantOrRightMinimumTenDayVolumeWeightedAverageCommonStockPriceToWarrantExercisePricePremiumPercentage>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-166"
      decimals="INF"
      id="f-823"
      unitRef="shares">3358732</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-166"
      decimals="2"
      id="f-824"
      unitRef="usdPerShare">1.44</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <smmt:ClassOfWarrantOrRightQuarterlyVestingPeriod contextRef="c-167" id="f-825">P3Y</smmt:ClassOfWarrantOrRightQuarterlyVestingPeriod>
    <smmt:ClassOfWarrantOrRightQuarterlyVestingPeriod contextRef="c-167" id="f-826">P3Y</smmt:ClassOfWarrantOrRightQuarterlyVestingPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="c-168"
      decimals="INF"
      id="f-827"
      unitRef="shares">2798945</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-169"
      decimals="INF"
      id="f-828"
      unitRef="shares">559787</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c-1" id="f-829">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;The following table summarizes the Company&#x2019;s warrants activity for the year ended December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.655%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.306%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.306%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.306%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.313%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of share warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average remaining contractual term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate intrinsic value &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,821,137&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.56&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.99 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(805,495)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.49&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,015,642&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.57&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.92 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c-5" decimals="INF" id="f-830" unitRef="shares">5821137</us-gaap:ClassOfWarrantOrRightOutstanding>
    <smmt:ClassOfWarrantOrRightWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-831"
      unitRef="usdPerShare">1.56</smmt:ClassOfWarrantOrRightWeightedAverageExercisePrice>
    <smmt:ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm contextRef="c-6" id="f-832">P6Y11M26D</smmt:ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm>
    <smmt:ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding contextRef="c-5" decimals="-3" id="f-833" unitRef="usd">15640000</smmt:ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding>
    <smmt:ClassOfWarrantOrRightExercisesInPeriod contextRef="c-1" decimals="INF" id="f-834" unitRef="shares">805495</smmt:ClassOfWarrantOrRightExercisesInPeriod>
    <smmt:ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod
      contextRef="c-1"
      decimals="2"
      id="f-835"
      unitRef="usdPerShare">1.49</smmt:ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c-4" decimals="INF" id="f-836" unitRef="shares">5015642</us-gaap:ClassOfWarrantOrRightOutstanding>
    <smmt:ClassOfWarrantOrRightWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-837"
      unitRef="usdPerShare">1.57</smmt:ClassOfWarrantOrRightWeightedAverageExercisePrice>
    <smmt:ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm contextRef="c-1" id="f-838">P5Y11M1D</smmt:ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm>
    <smmt:ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding contextRef="c-4" decimals="-3" id="f-839" unitRef="usd">5194000</smmt:ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-840">Stock-Based Compensation&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2016 Long Term Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the effectiveness of the 2020 Stock Incentive Plan, no additional grants will be made under the 2016 Long Term Incentive Plan, (the &#x201c;2016 Plan&#x201d;) and any outstanding awards continue with their original terms. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2020 Stock Award Plan&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, the Company&#x2019;s Board of Directors approved the 2020 Stock Incentive Plan (the &#x201c;2020 Plan&#x201d;), which became effective on September 21, 2020. The 2020 plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A total of 8,000,000 shares of common stock were initially reserved for issuance under the 2020 Plan. Additionally, up to 5,000,000 shares of common stock, including RSUs can be added to the 2020 Plan for future issuance from options that expire, lapse or are terminated from the 2016 Plan or any other predecessor plans. The number of shares of common stock that may be issued under the 2020 Plan will automatically increase on each January 1, beginning in 2021 and continuing for each fiscal year until, and including, the fiscal year ending December 31, 2030, equal to the lesser of (i) 6,400,000 shares of common stock, (ii) 4% of the common shares outstanding on the final day of the immediately preceding calendar year and (iii) an amount as determined by the Company&#x2019;s Board of Directors. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July&#160;27, 2022, the Company held a Special Meeting of Stockholders (the &#x201c;Special Meeting&#x201d;) whereby the following matters were submitted to a vote of the Company&#x2019;s stockholders at the Special Meeting and the Board of Directors resolved the following: (i) an amendment to the Company&#x2019;s Restated Certificate of Incorporation, dated September 18, 2020, to increase the number of authorized shares of common stock by 100,000,000 (from 250,000,000 to 350,000,000); and (ii) an amendment to the Summit Therapeutics Inc. 2020 Stock Incentive Plan (the &#x201c;Plan&#x201d;) to increase the number of shares of the Company&#x2019;s common stock issuable under the Plan by 8,000,000 shares.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 12, 2023, the Company held a Special Meeting of Stockholders (the &#x201c;October Special Meeting&#x201d;) whereby the following matter was submitted to a vote of the Company&#x2019;s stockholders at the Special Meeting and the Board of Directors resolved the following: an amendment to the Summit Therapeutics Inc. 2020 Stock Incentive Plan to increase the number of shares of the Company&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s common stock issuable under the Plan by 70,000,000 shares.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2023, there are 3,261,496 shares available to be issued under the 2020 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2020 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2020 Employee Stock Purchase Plan (the &#x201c;2020 ESPP&#x201d;) was adopted by the Board of Directors and approved by the Company&#x2019;s shareholders on July 17, 2020 and approved by the predecessor company shareholders on August 19, 2020 and is qualified under Section 423 of the Internal Revenue Code. The 2020 ESPP initially authorized the issuance of up to 1,000,000 shares of common stock to participating employees. The number of common shares that may be issued under the 2020 ESPP automatically increases on each fiscal year commencing January 1, 2021 and continuing for each fiscal year until, and including the fiscal year commencing on, January 1, 2030 equal to the lesser of (i) 1,600,000 shares of common stock, (ii) 1% of the common shares outstanding on such date and (iii) an amount as determined by the Company&#x2019;s Board of Directors. As of December 31, 2022, there were 2,628,893 shares available to be issued under the 2020 ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The first offering period of the 2020 ESPP plan consisted of seven months, commencing on August 2, 2021 and completed on February 28, 2022. The second offering period commenced on March 1, 2022 and was completed on August 31, 2022. Offering periods thereafter will be six months in duration and will commence immediately proceeding the end of the previous offering period, unless otherwise determined by the Board of Directors or Compensation Committee. Under the 2020 ESPP, eligible employees can purchase shares of common stock through payroll deductions of up to 15% of their compensation received during the plan period or such shorter period during which deductions from payroll are made, up to a defined maximum amount. The option price is determined based on the lesser of the closing price of common stock on (i) the first business day of the plan period or (ii) the exercise date, or shall be based solely on the closing price of the common stock on the exercise date; provided that such option price shall be at least 85% of the applicable closing price. In the absence of a determination by the Board of Directors or the Compensation Committee, the option price is 85% of the lesser of the closing price of the common stock on (i) the first business day of the plan period or (ii) the exercise date. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The closing price is the (a) the closing price (for the primary trading session) on the Nasdaq Global Select Market or (b) the average of the closing bid and asked prices in the over-the-counter-market, whichever is applicable, as published in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Wall Street Journal&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; or another source selected by the Board or the Committee. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the fiscal year ended December 31, 2023 and 2022, 392,175 and 176,857 shares, respectively, were issued under the 2020 ESPP Plan.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Time-based Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of stock options granted to employees and directors using the Black-Scholes valuation model. Stock options granted under the 2016 and 2020 Plans generally vest over &lt;span style="-sec-ix-hidden:f-862"&gt;three&lt;/span&gt; or four years and expire after ten years. This valuation methodology utilizes several key assumptions as highlighted below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assumptions used in the Company&#x2019;s valuation are summarized as follows, presented on a weighted average basis: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.392%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.573%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.379%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.573%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.383%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected annual dividends per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;The following table summarizes the Company&#x2019;s time-based stock option activity for the year ended December 31, 2023:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.413%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.413%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of share options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average remaining contractual term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate intrinsic value &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,712,359&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,135,170&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,433,943)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.56&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(204,297)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,209,289&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2023 - vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,407,492&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,716,319&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.89&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Performance and Market-based Stock Options&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Compensation Committee of the Company&#x2019;s Board of Directors and management approved 40,835,220 option grants to its executives and certain employees of the Company during the year ended December 31, 2023, which will vest based upon certain revenue and market-based performance conditions. The fair value of performance and market-based stock options that include a market condition is determined using a Monte Carlo valuation model, which utilizes multiple input variables to estimate the probability that the market condition will be achieved.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s performance and market-based stock option activity for the year ended December 31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.413%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.413%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of share options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average remaining contractual term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate intrinsic value &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,764,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,835,220&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(945,000)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,654,220&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.62&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2023 - vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,397,760&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.62&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant-date fair value of stock options granted during the years ended December 31, 2023 and 2022 was $1.41 and $0.87, per share, respectively. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2023 and 2022 was $474 and $142, respectively. The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#x2019;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2023, total unrecognized compensation cost related to unvested stock option grants was approximately $61,162. This amount is expected to be recognized over a weighted average period of approximately 2.2 years. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of warrants is estimated on the date of grant using the Black-Scholes valuation methodology. Expected volatilities are based on historical share price performance, weighted to exclude periods of unusually high volatility. The Company assumed the warrants to be exercised immediately on vesting. The risk-free rate is equal to the prevailing U.K. Gilts rate at grant date that most closely matches the expected term of the grant, as the warrants were issued when the Company was domiciled in the U.K.. Expected dividend yield is zero, and consistent with the Board of Directors&#x2019; view that the Company&#x2019;s business model is to generate value through capital growth rather than the payment of dividends.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each warrant entitles the warrant holder to subscribe in cash for one share. Shares of common stock allotted pursuant to the exercise of the warrant will rank in full for all dividends and other distributions with a record date after the exercise date with the shares of common stock in issue at that date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 20 for the Company&#x2019;s warrants activity for the year ended December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2023, there was no unrecognized compensation expense related to warrants. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock&#x2011;based compensation expense related to stock options is recorded within the consolidated statements of operations and comprehensive loss as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.485%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.277%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.743%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.767%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.743%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.770%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,108&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,948&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation arrangements:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.485%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.277%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.743%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.767%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.743%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.770%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;Time-based stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Performance and market-based stock options &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,108&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,948&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-170"
      decimals="INF"
      id="f-841"
      unitRef="shares">8000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <smmt:CommonStockAdditionalCapitalSharesAllowableForForFutureIssuanceUponOptionExpiration
      contextRef="c-170"
      decimals="INF"
      id="f-842"
      unitRef="shares">5000000</smmt:CommonStockAdditionalCapitalSharesAllowableForForFutureIssuanceUponOptionExpiration>
    <smmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardPotentialNumberOfAdditionalSharesAllowableUnderThePlan
      contextRef="c-170"
      decimals="INF"
      id="f-843"
      unitRef="shares">6400000</smmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardPotentialNumberOfAdditionalSharesAllowableUnderThePlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="c-171"
      decimals="INF"
      id="f-844"
      unitRef="number">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <smmt:CommonStockSharesAuthorizedIncreaseDecrease
      contextRef="c-172"
      decimals="INF"
      id="f-845"
      unitRef="shares">100000000</smmt:CommonStockSharesAuthorizedIncreaseDecrease>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-173"
      decimals="INF"
      id="f-846"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-174"
      decimals="INF"
      id="f-847"
      unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-175"
      decimals="INF"
      id="f-848"
      unitRef="shares">8000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-49"
      decimals="INF"
      id="f-849"
      unitRef="shares">70000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-176"
      decimals="INF"
      id="f-850"
      unitRef="shares">3261496</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-177"
      decimals="INF"
      id="f-851"
      unitRef="shares">1000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <smmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardPotentialNumberOfAdditionalSharesAllowableUnderThePlan
      contextRef="c-177"
      decimals="INF"
      id="f-852"
      unitRef="shares">1600000</smmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardPotentialNumberOfAdditionalSharesAllowableUnderThePlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="c-178"
      decimals="INF"
      id="f-853"
      unitRef="number">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-179"
      decimals="INF"
      id="f-854"
      unitRef="shares">2628893</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <smmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod contextRef="c-180" id="f-855">P7M</smmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod>
    <smmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod contextRef="c-181" id="f-856">P6M</smmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="c-177"
      decimals="INF"
      id="f-857"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c-182"
      decimals="INF"
      id="f-858"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c-178"
      decimals="INF"
      id="f-859"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c-183"
      decimals="INF"
      id="f-860"
      unitRef="shares">392175</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c-184"
      decimals="INF"
      id="f-861"
      unitRef="shares">176857</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-186" id="f-863">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-187" id="f-864">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-865">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assumptions used in the Company&#x2019;s valuation are summarized as follows, presented on a weighted average basis: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.392%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.573%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.379%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.573%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.383%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected annual dividends per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-188" decimals="4" id="f-866" unitRef="number">0.0459</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-189" decimals="4" id="f-867" unitRef="number">0.0311</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-188" id="f-868">P4Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-189" id="f-869">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="c-188" decimals="3" id="f-870" unitRef="number">0.981</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="c-189" decimals="3" id="f-871" unitRef="number">0.912</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-188"
      decimals="INF"
      id="f-872"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-189"
      decimals="INF"
      id="f-873"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-874">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;The following table summarizes the Company&#x2019;s time-based stock option activity for the year ended December 31, 2023:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.413%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.413%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of share options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average remaining contractual term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate intrinsic value &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,712,359&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,135,170&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,433,943)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.56&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(204,297)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,209,289&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2023 - vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,407,492&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,716,319&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.89&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s performance and market-based stock option activity for the year ended December 31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.413%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.413%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of share options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average remaining contractual term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate intrinsic value &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,764,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,835,220&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(945,000)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,654,220&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.62&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2023 - vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,397,760&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.62&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-190"
      decimals="INF"
      id="f-875"
      unitRef="shares">12712359</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-190"
      decimals="2"
      id="f-876"
      unitRef="usdPerShare">4.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-191" id="f-877">P8Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-190" decimals="-3" id="f-878" unitRef="usd">8702000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-187"
      decimals="INF"
      id="f-879"
      unitRef="shares">44135170</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-187"
      decimals="2"
      id="f-880"
      unitRef="usdPerShare">1.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-187"
      decimals="INF"
      id="f-881"
      unitRef="shares">2433943</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-187"
      decimals="2"
      id="f-882"
      unitRef="usdPerShare">5.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-187"
      decimals="INF"
      id="f-883"
      unitRef="shares">204297</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-187"
      decimals="2"
      id="f-884"
      unitRef="usdPerShare">2.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-192"
      decimals="INF"
      id="f-885"
      unitRef="shares">54209289</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-192"
      decimals="2"
      id="f-886"
      unitRef="usdPerShare">2.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-187" id="f-887">P9Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-192" decimals="-3" id="f-888" unitRef="usd">42574000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c-192"
      decimals="INF"
      id="f-889"
      unitRef="shares">49407492</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-192"
      decimals="2"
      id="f-890"
      unitRef="usdPerShare">2.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-187" id="f-891">P9Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-192" decimals="-3" id="f-892" unitRef="usd">38406000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-192"
      decimals="INF"
      id="f-893"
      unitRef="shares">5716319</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-192"
      decimals="2"
      id="f-894"
      unitRef="usdPerShare">4.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-187" id="f-895">P7Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-192" decimals="-3" id="f-896" unitRef="usd">892000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-193"
      decimals="INF"
      id="f-897"
      unitRef="shares">40835220</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-194"
      decimals="INF"
      id="f-898"
      unitRef="shares">6764000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-194"
      decimals="2"
      id="f-899"
      unitRef="usdPerShare">1.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-195" id="f-900">P9Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-194" decimals="-3" id="f-901" unitRef="usd">20955000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-193"
      decimals="INF"
      id="f-902"
      unitRef="shares">40835220</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-193"
      decimals="2"
      id="f-903"
      unitRef="usdPerShare">1.69</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-193"
      decimals="INF"
      id="f-904"
      unitRef="shares">945000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-193"
      decimals="2"
      id="f-905"
      unitRef="usdPerShare">1.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-193"
      decimals="INF"
      id="f-906"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-193"
      decimals="2"
      id="f-907"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-196"
      decimals="INF"
      id="f-908"
      unitRef="shares">46654220</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-196"
      decimals="2"
      id="f-909"
      unitRef="usdPerShare">1.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-193" id="f-910">P9Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-196" decimals="-3" id="f-911" unitRef="usd">46237000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c-196"
      decimals="INF"
      id="f-912"
      unitRef="shares">8397760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-196"
      decimals="2"
      id="f-913"
      unitRef="usdPerShare">1.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-193" id="f-914">P9Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-196" decimals="-3" id="f-915" unitRef="usd">8323000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-196"
      decimals="INF"
      id="f-916"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-196"
      decimals="2"
      id="f-917"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-196" decimals="-3" id="f-918" unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-919"
      unitRef="usdPerShare">1.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-6"
      decimals="2"
      id="f-920"
      unitRef="usdPerShare">0.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-1" decimals="-3" id="f-921" unitRef="usd">474000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-6" decimals="-3" id="f-922" unitRef="usd">142000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-197" decimals="-3" id="f-923" unitRef="usd">61162000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-188" id="f-924">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-198"
      decimals="INF"
      id="f-925"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="c-4" decimals="INF" id="f-926" unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-199" decimals="INF" id="f-927" unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-928">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock&#x2011;based compensation expense related to stock options is recorded within the consolidated statements of operations and comprehensive loss as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.485%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.277%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.743%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.767%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.743%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.770%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,108&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,948&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation arrangements:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.485%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.277%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.743%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.767%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.743%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.770%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%"&gt;Time-based stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Performance and market-based stock options &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,108&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,948&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-200" decimals="-3" id="f-929" unitRef="usd">4408000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-201" decimals="-3" id="f-930" unitRef="usd">4303000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-202" decimals="-3" id="f-931" unitRef="usd">9700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-203" decimals="-3" id="f-932" unitRef="usd">7645000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-933" unitRef="usd">14108000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-6" decimals="-3" id="f-934" unitRef="usd">11948000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-187" decimals="-3" id="f-935" unitRef="usd">12606000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-191" decimals="-3" id="f-936" unitRef="usd">11630000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-193" decimals="-3" id="f-937" unitRef="usd">1318000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-195" decimals="-3" id="f-938" unitRef="usd">84000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-183" decimals="-3" id="f-939" unitRef="usd">184000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-184" decimals="-3" id="f-940" unitRef="usd">234000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-941" unitRef="usd">14108000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-6" decimals="-3" id="f-942" unitRef="usd">11948000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-943">Commitments and Contingencies &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fixed asset purchase commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2023 and 2022, the Company had no capital commitments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lease commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17 for a discussion of the Company&#x2019;s lease commitments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 18 for discussion of promissory notes payable to related parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into contracts in the normal course of business with various third parties for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes. Most contracts provide for termination upon notice, and therefore are cancellable contracts. As of December 31, 2023, total contractual commitments, excluding leases commitments and debt commitments, are estimated to be approximately $37,700 and the majority of these commitments are due within one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to December 31, 2023, through February 9, 2024 the Company entered into additional contractual commitments of approximately $23,000 with various third parties related to its clinical trials.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has certain commitments under its agreements with the Akeso, Wellcome Trust, the University College London and certain employees, former employees and former directors of Discuva, pursuant to which it will be required to pay royalties or make milestone payments. The License Agreement with Akeso also contains certain manufacturing and purchase commitments. As of December 31, 2023, the Company is unable to estimate the amount, timing or likelihood of achieving the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;milestones, making future product sales or assessing estimated forecasts for manufacturing and supplied materials which these contingent payment obligations relate to. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indemnifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s certificate of incorporation provides that it will indemnify the directors and officers to the fullest extent permitted by Delaware law. In addition, the Company has entered into indemnification agreements with all of the directors and executive officers. These indemnification agreements may require the Company, among other things, to indemnify each such director or executive officer for some expenses, including attorneys&#x2019; fees, judgments, fines, and settlement amounts incurred by him or her in any action or proceeding arising out of his or her service as one of the Company&#x2019;s directors or executive officers. The Company believes the fair value for these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations as of December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is not currently subject to any material legal proceedings.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PurchaseObligation contextRef="c-4" decimals="INF" id="f-944" unitRef="usd">0</us-gaap:PurchaseObligation>
    <us-gaap:PurchaseObligation contextRef="c-5" decimals="INF" id="f-945" unitRef="usd">0</us-gaap:PurchaseObligation>
    <us-gaap:OtherCommitment contextRef="c-4" decimals="-3" id="f-946" unitRef="usd">37700000</us-gaap:OtherCommitment>
    <smmt:OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid contextRef="c-4" id="f-947">P1Y</smmt:OtherCommitmentPeriodForWhichTheMajorityOfCommitmentsAreToBePaid>
    <smmt:OtherCommitmentIncreaseDecrease contextRef="c-204" decimals="-3" id="f-948" unitRef="usd">23000000</smmt:OtherCommitmentIncreaseDecrease>
    <smmt:RelatedPartyTransactionSubleaseExtensionTerm contextRef="c-205" id="f-949">P39M</smmt:RelatedPartyTransactionSubleaseExtensionTerm>
    <smmt:RelatedPartyTransactionPaymentsToRelatedParty contextRef="c-206" decimals="-3" id="f-950" unitRef="usd">762000</smmt:RelatedPartyTransactionPaymentsToRelatedParty>
    <smmt:AreaOfPremisesSubleased contextRef="c-207" decimals="0" id="f-951" unitRef="sqft">1277</smmt:AreaOfPremisesSubleased>
    <smmt:RelatedPartyTransactionPaymentsToRelatedParty contextRef="c-208" decimals="-3" id="f-952" unitRef="usd">218000</smmt:RelatedPartyTransactionPaymentsToRelatedParty>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="c-141" decimals="-3" id="f-953" unitRef="usd">25000000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:NotesPayable contextRef="c-142" decimals="-3" id="f-954" unitRef="usd">25000000</us-gaap:NotesPayable>
    <us-gaap:RelatedPartyTransactionRate contextRef="c-141" decimals="4" id="f-955" unitRef="number">0.0325</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:RelatedPartyTransactionRate contextRef="c-209" decimals="4" id="f-956" unitRef="number">0.0475</us-gaap:RelatedPartyTransactionRate>
    <smmt:NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold contextRef="c-141" decimals="-3" id="f-957" unitRef="usd">25000000</smmt:NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold>
    <smmt:NotesPayableRelatedPartiesMaximumTerm contextRef="c-141" id="f-958">P18M</smmt:NotesPayableRelatedPartiesMaximumTerm>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-144" decimals="-3" id="f-959" unitRef="usd">100000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-144"
      decimals="INF"
      id="f-960"
      unitRef="shares">103092783</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-162"
      decimals="2"
      id="f-961"
      unitRef="usdPerShare">0.97</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-144" decimals="-3" id="f-962" unitRef="usd">111000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NotesPayable contextRef="c-37" decimals="-3" id="f-963" unitRef="usd">520000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayable contextRef="c-43" decimals="-3" id="f-964" unitRef="usd">400000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayable contextRef="c-146" decimals="-3" id="f-965" unitRef="usd">20000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayable contextRef="c-147" decimals="-3" id="f-966" unitRef="usd">100000000</us-gaap:NotesPayable>
    <smmt:NotesPayableRelatedPartiesPotentialPrepaymentMaximumAmountPercentageOfNetProceedsFromPublicOffering contextRef="c-148" decimals="2" id="f-968" unitRef="number">1</smmt:NotesPayableRelatedPartiesPotentialPrepaymentMaximumAmountPercentageOfNetProceedsFromPublicOffering>
    <smmt:NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold contextRef="c-149" decimals="-3" id="f-969" unitRef="usd">500000000</smmt:NotesPayableRelatedPartiesPotentialPrepaymentTriggeringEventPublicOfferingNetProceedsThreshold>
    <smmt:NotesPayableRelatedPartiesNewIssuances
      contextRef="c-149"
      decimals="INF"
      id="f-970"
      unitRef="promissory_note">2</smmt:NotesPayableRelatedPartiesNewIssuances>
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="c-44" decimals="-3" id="f-971" unitRef="usd">20000000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:NotesPayable contextRef="c-43" decimals="-3" id="f-972" unitRef="usd">400000000</us-gaap:NotesPayable>
    <us-gaap:RelatedPartyTransactionRate contextRef="c-151" decimals="3" id="f-973" unitRef="number">0.075</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-152"
      decimals="2"
      id="f-974"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <smmt:NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominator
      contextRef="c-151"
      decimals="4"
      id="f-975"
      unitRef="usdPerShare">0.7913</smmt:NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominator>
    <smmt:NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominatorBaseAmountAddedToClosingBidPrice
      contextRef="c-151"
      decimals="2"
      id="f-976"
      unitRef="usdPerShare">0.01</smmt:NotesPayableRelatedPartyPrepaidInterestEquityInterestsIssuableCalculationDenominatorBaseAmountAddedToClosingBidPrice>
    <smmt:StockIssuedDuringPeriodSharesRelatedPartyPrepaidInterest
      contextRef="c-151"
      decimals="INF"
      id="f-977"
      unitRef="shares">9720291</smmt:StockIssuedDuringPeriodSharesRelatedPartyPrepaidInterest>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-153"
      decimals="INF"
      id="f-978"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-154"
      decimals="INF"
      id="f-979"
      unitRef="number">0.0300</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:InterestPaidNet contextRef="c-155" decimals="-3" id="f-980" unitRef="usd">10650000</us-gaap:InterestPaidNet>
    <us-gaap:RelatedPartyTransactionRate contextRef="c-53" decimals="2" id="f-981" unitRef="number">0.12</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-54"
      decimals="INF"
      id="f-982"
      unitRef="number">0.0350</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <smmt:RelatedPartyTransactionPaymentsToRelatedParty contextRef="c-210" decimals="-3" id="f-983" unitRef="usd">2500000</smmt:RelatedPartyTransactionPaymentsToRelatedParty>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-211" decimals="-3" id="f-984" unitRef="usd">3619000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-42"
      decimals="2"
      id="f-985"
      unitRef="usdPerShare">1.05</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-41" decimals="-3" id="f-986" unitRef="usd">500000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-41"
      decimals="INF"
      id="f-987"
      unitRef="shares">476190471</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-41" decimals="-3" id="f-988" unitRef="usd">619000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-42"
      decimals="2"
      id="f-989"
      unitRef="usdPerShare">1.05</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssued1 contextRef="c-163" decimals="-3" id="f-990" unitRef="usd">395314000</us-gaap:StockIssued1>
    <us-gaap:NotesPayable contextRef="c-43" decimals="-3" id="f-991" unitRef="usd">400000000</us-gaap:NotesPayable>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-45"
      decimals="INF"
      id="f-992"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <smmt:SaleOfStockNumberOfSharesRegisteredForResale
      contextRef="c-46"
      decimals="INF"
      id="f-993"
      unitRef="shares">10000000</smmt:SaleOfStockNumberOfSharesRegisteredForResale>
    <smmt:SaleOfStockNumberOfSharesRegisteredForResale
      contextRef="c-47"
      decimals="INF"
      id="f-994"
      unitRef="shares">9346434</smmt:SaleOfStockNumberOfSharesRegisteredForResale>
    <smmt:SaleOfStockNumberOfSharesRegisteredForResale
      contextRef="c-48"
      decimals="INF"
      id="f-995"
      unitRef="shares">373857</smmt:SaleOfStockNumberOfSharesRegisteredForResale>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c-50" decimals="-3" id="f-996" unitRef="usd">5000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-51"
      decimals="2"
      id="f-997"
      unitRef="usdPerShare">1.68</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-52"
      decimals="INF"
      id="f-998"
      unitRef="shares">2976190</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <smmt:ClassOfWarrantOrRightExercisesInPeriod
      contextRef="c-212"
      decimals="INF"
      id="f-999"
      unitRef="shares">805495</smmt:ClassOfWarrantOrRightExercisesInPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
